<SUBMISSION>
<ACCESSION-NUMBER>0000950134-08-015833
<TYPE>S-1/A
<PUBLIC-DOCUMENT-COUNT>10
<FILING-DATE>20080827
<DATE-OF-FILING-DATE-CHANGE>20080827
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>FLUIDIGM CORP
<CIK>0001162194
<ASSIGNED-SIC>3826
<IRS-NUMBER>770513190
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>S-1/A
<ACT>33
<FILE-NUMBER>333-150227
<FILM-NUMBER>081040466
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>7000 SHORELINE COURT
<STREET2>SUITE 100
<CITY>SOUTH SAN FRANCISCO
<STATE>CA
<ZIP>94080
<PHONE>6502666000
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>7000 SHORELINE COURT
<STREET2>SUITE 100
<CITY>SOUTH SAN FRANCISCO
<STATE>CA
<ZIP>94080
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>f39432a6sv1za.htm
<DESCRIPTION>AMENDMENT TO FORM S-1
<TEXT>
<HTML>
<HEAD>
<TITLE>sv1za</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 94%; margin-left: 3%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B> As filed with the Securities and Exchange Commission on
    August 27, 2008</B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B> Registration
    <FONT style="white-space: nowrap">No.&#160;333-150227</FONT></B>
</DIV>

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 2pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=0 -->

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=0 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 14pt">UNITED STATES SECURITIES AND
    EXCHANGE COMMISSION</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">Washington,&#160;D.C.
    20549</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">AMENDMENT NO. 6 TO</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 18pt">
    <FONT style="white-space: nowrap">Form&#160;S-1</FONT></FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">REGISTRATION
    STATEMENT</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">UNDER</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">THE SECURITIES ACT OF
    1933</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 24pt">FLUIDIGM CORPORATION</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Exact name of Registrant as
    specified in its charter)</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="34%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="32%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="32%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom">
<TD nowrap align="center" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Delaware</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <B>3826</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <B>77-0513190</B>
</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">(State or other jurisdiction
    of<BR>
    incorporation or organization)</FONT></I>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">(Primary Standard Industrial<BR>
    Classification Code Number)<BR>
    </FONT></I>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">(I.R.S. Employer<BR>
    Identification Number)</FONT></I><FONT style="font-size: 8pt">
    </FONT>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>



<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>7000 Shoreline Court, Suite 100</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>South San&#160;Francisco, CA 94080</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>(650) 266-6000</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Address, including zip code,
    and telephone number,<BR>
    including area code, of Registrant&#146;s principal executive
    offices)</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Gajus V. Worthington</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>President and Chief Executive Officer</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>7000 Shoreline Court, Suite&#160;100</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>South San&#160;Francisco, CA 94080</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="white-space: nowrap">(650)&#160;266-6000</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Name, address, including zip
    code, and telephone number,<BR>
    including area code, of agent for service)</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Copies to:</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="34%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="32%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="32%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom">
<TD align="center" valign="top">
    <B>David J. Segre<BR>
    Robert F. Kornegay<BR>
    Asaf H. Kharal<BR>
    Wilson Sonsini Goodrich &#038; Rosati P.C.<BR>
    650 Page&#160;Mill Road<BR>
    Palo Alto, CA 94304<BR>
    Telephone:
    <FONT style="white-space: nowrap">(650)&#160;493-9300</FONT><BR>
    Telecopy:
    <FONT style="white-space: nowrap">(650)&#160;493-6811</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <B>William M. Smith<BR>
    Vice President, Legal Affairs<BR>
    and General Counsel<BR>
    7000 Shoreline Court, Suite 100<BR>
    South San&#160;Francisco, CA 94080<BR>
    Telephone: (650) 266-6000<BR>
    Telecopy: (650) 871-7152</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <B>Charles K. Ruck<BR>
    B. Shayne Kennedy<BR>
    Latham &#038; Watkins LLP<BR>
    650 Town Center Drive,
    20<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>&#160;Floor<BR>
    Costa Mesa, CA 92626<BR>
    Telephone: (714) 540-1235<BR>
    Telecopy: (714) 755-8290</B>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Approximate date of commencement of proposed sale to the
    public:</B>&#160;&#160;As soon as practicable after the
    effective date of this Registration Statement.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If any of the securities being registered on this Form are to be
    offered on a delayed or continuous basis pursuant to
    Rule&#160;415 under the Securities Act, as amended, check the
    following
    box.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If this Form is filed to register additional securities for an
    offering pursuant to Rule&#160;462(b) under the Securities Act,
    please check the following box and list the Securities Act
    registration statement number of the earlier effective
    registration statement for the same
    offering.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;<FONT style="word-spacing: 60pt; white-space: nowrap; font-size: 1pt"><U>&#173;
    &#173;</U></FONT><!-- callerid=128 iwidth=540 length=60 -->
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If this Form is a post-effective amendment filed pursuant to
    Rule&#160;462(c) under the Securities Act, check the following
    box and list the Securities Act registration statement number of
    the earlier effective registration statement for the same
    offering.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;<FONT style="word-spacing: 60pt; white-space: nowrap; font-size: 1pt"><U>&#173;
    &#173;</U></FONT><!-- callerid=128 iwidth=540 length=60 -->
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If this Form is a post-effective amendment filed pursuant to
    Rule&#160;462(d) under the Securities Act, check the following
    box and list the Securities Act registration statement number of
    the earlier effective registration statement for the same
    offering.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;<FONT style="word-spacing: 60pt; white-space: nowrap; font-size: 1pt"><U>&#173;
    &#173;</U></FONT><!-- callerid=128 iwidth=540 length=60 -->
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Indicate by check mark whether the registrant is a large
    accelerated filer, an accelerated filer, a non-accelerated
    filer, or a smaller reporting company. See the definitions of
    &#147;large accelerated filer,&#148; &#147;accelerated
    filer&#148; and &#147;smaller reporting company&#148; in Ruler
    <FONT style="white-space: nowrap">12b-2</FONT> of the
    Exchange Act. (Check one):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="24%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="22%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="24%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="24%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom">
<TD align="center" valign="top">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Large accelerated
    filer&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Accelerated
    filer&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Non-accelerated
    filer&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    Smaller reporting
    company&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="5" align="center" valign="top">
    (Do not check if a smaller reporting company)
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>The Registrant hereby amends this Registration Statement on
    such date or dates as may be necessary to delay its effective
    date until the Registrant shall file a further amendment that
    specifically states that this Registration Statement shall
    thereafter become effective in accordance with Section&#160;8(a)
    of the Securities Act of 1933, as amended, or until the
    Registration Statement shall become effective on such date as
    the Securities and Exchange Commission, acting pursuant to such
    Section&#160;8(a), may determine.</B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=0 -->

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 2pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=0 -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 94%; margin-left: 3%"><!-- BEGIN PAGE WIDTH -->

<TABLE style="color: #FF0000" width="100%" border="1" cellpadding="5"><TR><TD style=text-align:justify>
<FONT style="font-size: 9pt; font-family: Arial, Helvetica; color: #F93F26">The
information in this preliminary prospectus is not complete and
may be changed. We may not sell these securities until the
registration statement filed with the Securities and Exchange
Commission is declared effective. This preliminary prospectus is
not an offer to sell these securities and is not soliciting an
offer to buy these securities in any state where the offer or
sale is not permitted.<BR>
</FONT>
</TD></TR></TABLE>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 89%; margin-left: 5%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 12pt; color: #F93F26">PROSPECTUS
    (Subject to Completion)</FONT></I>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 11pt; color: #F93F26"> Issued
    August&#160;27, 2008</FONT></I>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 18pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Shares</FONT></I>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="f39432a6f3943216.gif" alt="(FLUIDIGM LOGO)"><FONT style="font-size: 18pt">
    </FONT>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 12pt">COMMON STOCK</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Fluidigm Corporation is
    offering&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of its common stock. This is our initial public offering, and no
    public market currently exists for our shares. We anticipate
    that the initial public offering price will be between
    $&#160;&#160;&#160;&#160;&#160; and
    $&#160;&#160;&#160;&#160;&#160; per share.</I></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We have applied to list our common stock on the NASDAQ
    Global Market under the symbol &#147;FLDM.&#148;</I></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 12pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Investing in our common stock involves risks. See
    &#147;Risk Factors&#148; beginning on page&#160;8.</I></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>PRICE
    <FONT style="font-size: 12pt">$&#160;&#160;&#160;&#160;&#160;</FONT>
    A SHARE</I>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="64%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><I>Underwriting<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><I>Proceeds to<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><I>Price to<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><I>Discounts and<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><I>Fluidigm<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><I>Public</I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><I>Commissions</I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><I>Corporation</I></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <I>Per Share</I>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><I>$&#160;&#160;&#160;&#160;&#160;</I></B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><I>$</I></B>&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><I>$</I></B>&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <I>Total</I>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><I>$</I></B>
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><I>$</I></B>
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><I>$</I></B>
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>We have granted the underwriters the right to purchase up to
    an
    additional&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock to cover over-allotments.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>The Securities and Exchange Commission and state securities
    regulators have not approved or disapproved these securities or
    determined if this prospectus is truthful or complete. Any
    representation to the contrary is a criminal offense.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Morgan Stanley&#160;&#038; Co. Incorporated expects to
    deliver the shares to purchasers
    on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    2008.</I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 16pt; font-variant: SMALL-CAPS">MORGAN
    STANLEY</FONT></I>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 16pt; font-variant: SMALL-CAPS"> UBS
    INVESTMENT BANK</FONT></I>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="50%"></TD>
    <TD width="50%"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">    <I><FONT style="font-size: 16pt; font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">
    LEERINK SWANN</FONT></I></TD>
    <TD nowrap align="right">    <I><FONT style="font-size: 16pt; font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">
    PACIFIC GROWTH EQUITIES, LLC</FONT></I></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    2008
    </FONT>
</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="f39432a6f3943218.gif" alt="(GRAPHIC)">
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 89%; margin-left: 5%"><!-- BEGIN PAGE WIDTH -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV align="left">
<!-- TOC -->
</DIV>

<DIV align="left">
<A name="tocpage"></A>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">TABLE OF
    CONTENTS</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>



<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="89%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Page</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#101'>Prospectus Summary</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#102'>Risk Factors</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#103'>Special Note Regarding Forward-Looking
    Statements</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#104'>Use of Proceeds</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#105'>Dividend Policy</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#106'>Capitalization</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#107'>Dilution</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#108'>Selected Consolidated Financial Data</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#109'>Management&#146;s Discussion and Analysis of
    Financial Condition and Results of Operations</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#110'>Business</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#111'>Management</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    77
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#112'>Certain Relationships and Related Party
    Transactions</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    104
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#113'>Principal Stockholders</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    108
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#114'>Description of Capital Stock</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    111
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#115'>Shares Eligible For Future Sale</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    115
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#120'>Material U.S. Federal Income and Estate Tax
    Consequences to Non-U.S. Holders</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    117
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#121'>Underwriters</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    120
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#116'>Legal Matters</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    124
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#117'>Experts</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    124
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#118'>Where You Can Find Additional Information</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    124
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#119'>Index to Consolidated Financial Statements</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-1
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432a6exv10w12.htm">EXHIBIT 10.12</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432a6exv10w12a.htm">EXHIBIT 10.12A</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432a6exv23w1.htm">EXHIBIT 23.1</A></FONT></TD></TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 21%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=455 length=96 -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You should rely only on the information contained in this
    prospectus and in any free writing prospectus prepared by or on
    behalf of us. We have not, and the underwriters have not,
    authorized anyone to provide you with information different
    from, or in addition to, that contained in this prospectus or
    any related free writing prospectus. This prospectus is an offer
    to sell only the shares offered hereby but only under
    circumstances and in jurisdictions where it is lawful to do so.
    The information contained in this prospectus is current only as
    of its date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Through and
    including,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    2008 (the 25th&#160;day after the date of this prospectus), all
    dealers effecting transactions in these securities, whether or
    not participating in this offering, may be required to deliver a
    prospectus. This is in addition to a dealer&#146;s obligation to
    deliver a prospectus when acting as an underwriter and with
    respect to an unsold allotment or subscription</B>.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For investors outside the United States: Neither we nor any of
    the underwriters have done anything that would permit this
    offering or possession or distribution of this prospectus in any
    jurisdiction where action for that purpose is required, other
    than the United States. You are required to inform yourselves
    about and to observe any restrictions relating to this offering
    and the distribution of this prospectus.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    i
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<A name='101'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PROSPECTUS
    SUMMARY</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>This summary highlights information contained in greater
    detail elsewhere in this prospectus. This summary may not
    contain all the information that you should consider before
    investing in our common stock. You should read the entire
    prospectus carefully, including &#147;Risk Factors&#148;
    beginning on page&#160;8 and our consolidated financial
    statements and related notes included elsewhere in this
    prospectus, before making an investment decision. Unless
    otherwise indicated, the terms &#147;Fluidigm,&#148;
    &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to
    Fluidigm Corporation.</I>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Overview</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We develop, manufacture and market proprietary Integrated
    Fluidic Circuit systems that significantly improve productivity
    in the life science industry. Our Integrated Fluidic Circuits,
    or IFCs, address critical industry needs by providing very
    large-scale integration of essential laboratory functions on a
    single microfabricated device. IFCs can measure, combine,
    diffuse, fold, mix, separate or pump nanoliter volumes of fluids
    with precise control and reproducibility. Based on their
    similarities to the integrated circuit that revolutionized the
    microelectronics industry, we often refer to our IFCs as
    &#147;integrated circuits for biology.&#148; These devices
    enable our customers to perform thousands of sophisticated
    biochemical reactions and measurements in parallel on samples
    smaller than the content of a single cell, while reducing the
    consumption of expensive laboratory chemicals. Particularly for
    large-scale experimentation, our IFC systems increase
    throughput, decrease costs and enhance sensitivity compared to
    conventional laboratory systems.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have commercialized IFC systems, consisting of
    instrumentation, software and single-use IFCs, for a wide range
    of life science applications. Researchers and clinicians have
    successfully employed our products in achieving breakthroughs
    across diverse scientific disciplines such as genetic variation,
    cellular function and structural biology. These advances include
    using our systems to help detect life-threatening mutations in
    patients&#146; cancer cells, discover indicators of
    susceptibility to cancer, manage some of the world&#146;s most
    valuable fisheries, analyze the genetic composition of
    individual stem cells, identify fetal chromosomal abnormalities
    from maternal blood samples, analyze the aggressiveness of the
    avian flu virus and assess the quality of agricultural seed
    products. We believe that the flexible architecture of our IFC
    technology will lead to the development of IFC systems for a
    wide variety of additional markets and applications, including
    high-throughput DNA sequencing and molecular diagnostics.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe our success and continued growth prospects are
    attributable to the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Disruptive Technology.</I>&#160;&#160;We believe we have
    achieved a level of miniaturization in microfluidics that allows
    us to integrate the components required to automate a broad
    range of life science applications in an area less than half the
    size of a credit card. Our IFCs deliver orders of magnitude
    improvements in cost and labor efficiencies, while being easily
    incorporated into existing laboratory workflows and allowing the
    use of broadly accepted chemistries.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Proven Customer Adoption.</I>&#160;&#160;We have sold our
    IFCs to over 100 customers. These customers include many leading
    biotechnology and pharmaceutical companies, academic
    institutions and life science laboratories worldwide.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Broad Application in the Life Science
    Market.</I>&#160;&#160;We have developed and commercialized IFCs
    for several significant life science research applications and
    believe that the inherent flexibility of our technology will
    enable the development of IFCs for a wide variety of additional
    markets and applications.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Strong Research and Development Capabilities and Intellectual
    Property Position.</I>&#160;&#160;We have and will continue to
    invest substantially in research and development to increase the
    density, throughput and functionality of our IFCs. We have
    developed an extensive portfolio of intellectual property,
    including more than 81 issued U.S.&#160;patents and 240 patent
    applications pending worldwide either owned by or licensed to us.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Efficient Manufacturing and Process
    Development.</I>&#160;&#160;Our sophisticated manufacturing
    process, which combines standard semiconductor methods with
    proprietary techniques, enables us to produce large
</TD>
</TR>

</TABLE>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>
</TD>
    <TD align="left">
    quantities of IFCs to stringent quality standards. We have
    established our manufacturing facility in Singapore because of
    the availability of a skilled workforce, an extensive supplier
    and partner network, lower operating costs and significant
    government support.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    Target Markets</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The life science industry is currently facing challenges similar
    to those faced by the information technology industry when
    computational power was constrained by the inherent limitations
    of the vacuum tube. Life science research efforts, ranging from
    large-scale initiatives, such as the Human Genome Project, to
    more traditional academic and commercial research projects, are
    continuing to reveal the complex biological and chemical
    processes that are fundamental to living organisms. Developing
    and applying this knowledge increasingly requires performing
    experimentation on a scale and with a precision that can be
    achieved only through automation. However, the most common forms
    of life science automation rely on cumbersome robotic systems
    that are slow, expensive and labor intensive and, we believe,
    fundamentally constrain life science research. In much the same
    way that integrated circuits overcame the limitations of early
    computers by placing an increasing number of transistors on a
    single silicon chip, our IFCs are designed to overcome many of
    the limitations of conventional laboratory systems by
    integrating an increasing number of fluidic components on a
    single microfabricated IFC.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Currently, researchers and clinicians use our IFCs to perform
    large-scale experimentation in the fields of genomics and
    proteomics. Genomics is the in-depth study of the genetic
    makeup, or genome, of microorganisms, plants, animals and
    people, including analyzing variations in genes and gene
    activity. Proteomics is the large-scale study of the structure
    and function of proteins. Our IFC systems support the following
    types of genomic and proteomic studies:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Genotyping: </I>determining the specific genetic traits of an
    individual or individuals.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Gene expression analysis: </I>measuring the activity of genes.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Protein crystallization:</I> determining the
    three-dimensional structure of proteins.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Digital PCR:</I> quantifying scarce genetic sequences in a
    biological sample.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    According to Strategic Directions International, in 2005 the
    principal segments of the genomic analysis market, gene
    expression and genotyping, accounted for $4.9&#160;billion
    worldwide in expenditures and are expected to grow annually by
    8% through 2010. We believe that our products may further be
    developed for use in high-throughput DNA sequencing and
    molecular diagnostics. High-throughput DNA sequencing is the
    large scale analysis of DNA sequences, including, for example,
    determining an organism&#146;s genome. Molecular diagnostics is
    a rapidly growing market that seeks to apply information learned
    from genomic and proteomic analysis to clinical practice in
    diagnosing, monitoring and treating disease.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">The
    Fluidigm Solution</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFC systems are designed to overcome many of the limitations
    of conventional laboratory systems by enabling researchers and
    clinicians to rapidly perform a large number of experiments at
    one time and in nanoliter volumes, significantly increasing
    throughput, reducing reagent costs, conserving patient samples
    and reducing workflow complexity.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We commercially introduced our Topaz IFC system in the first
    quarter of 2003 and our BioMark IFC system in the fourth quarter
    of 2006. Our first IFC, the 1.96 Dynamic Array for our Topaz
    system, was introduced in the first quarter of 2003 and allowed
    researchers to test a single sample against 96 different
    reagents. In May 2008, we introduced the 96.96 Dynamic Array IFC
    for our BioMark system. This IFC is based on a matrix
    architecture that allows a researcher to test each of 96
    different samples against each of 96 different reagents in
    parallel, and thus perform 9,216 individual experiments
    simultaneously.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The advantages of our IFC systems over conventional laboratory
    systems include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Reduced Complexity.</I>&#160;&#160;Loading our IFC requires
    orders of magnitude fewer liquid handling steps than
    conventional systems for the same experiment.
</TD>
</TR>

</TABLE>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Improved Throughput.</I>&#160;&#160;Our most advanced IFCs
    can conduct up to 24 times more experiments than a conventional
    system can perform in a single run.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Nanoliter Precision.</I>&#160;&#160;Our IFC systems allow
    researchers to dispense samples and reagents in nanoliter, or
    billionths of a liter, volumes, which supports high sensitivity
    techniques.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Reduced Reagent and Sample Requirements.</I>&#160;&#160;Our
    systems operate on volumes of reagents and samples that are
    typically less than 1% of the volumes required by conventional
    systems.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Decreased Capital Cost.</I>&#160;&#160;For high volume users,
    the cost of purchasing one BioMark system is much lower than the
    cost of purchasing the number of conventional systems required
    to provide the same throughput.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Ease of Adoption.</I>&#160;&#160;Our IFC systems support
    widely-used chemistries and are compatible with standard
    laboratory equipment, allowing researchers to easily incorporate
    our products into their laboratory workflow and processes.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that our IFC systems also offer significant
    advantages over other high-throughput methods for large scale
    experimentation. These alternative approaches have one or more
    limitations such as lack of flexibility, poor data quality,
    complex and slow workflows or high running costs. However, some
    of these methods are able to detect thousands of genetic markers
    in a single sample and may be more suitable for certain
    applications than our products. In addition, some of these
    alternative approaches are more widely adopted and better
    validated than our systems.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFC systems address the needs of researchers and clinicians
    who perform large-scale studies in the areas of genomics,
    proteomics and molecular diagnostics. Nevertheless, researchers
    and clinicians may be slow to adopt our IFC systems as they are
    based on technology that is not yet well-established in the
    industry. Moreover, many of the existing laboratories have
    already made substantial capital investments in their existing
    systems and may be hesitant to abandon that investment. In
    addition, our IFC systems are less well suited for smaller scale
    research initiatives where complexity and workflow issues may be
    less pressing and conventional systems may be more economical.
    As life science research continues to evolve and is
    commercialized, we believe that there will be increasing demand
    for life science automation solutions that enable
    experimentation on the scale supported by our IFC systems.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Affecting Us</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our business is subject to numerous risks, as more fully
    described in the section entitled &#147;Risk Factors&#148;
    immediately following this prospectus summary, including the
    following:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We have incurred significant losses since our inception, had an
    accumulated deficit of $149.1&#160;million as of June&#160;28,
    2008 and expect to incur losses for the foreseeable future.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    If our products fail to achieve and sustain market acceptance,
    our revenue will be adversely affected.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Our sales cycle for the BioMark and Topaz systems is lengthy and
    unpredictable, which makes it difficult for us to forecast
    revenue and could cause significant quarterly fluctuations in
    revenue and other operating results.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We receive a substantial portion of our revenues from a limited
    number of customers and other entities, and the loss of, or a
    significant reduction in, orders or grants from one or more of
    our major customers or grantors would adversely affect our
    operations and financial condition.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The life science industry is highly competitive and subject to
    rapid technological change, and we may not be able to
    successfully compete.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We have limited experience in producing our products, and we may
    experience development or manufacturing problems or delays that
    could limit the growth of our revenue or increase our losses.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We are dependent on single source suppliers for some of the
    components and materials used in our systems, and the loss of
    any of these suppliers could harm our business.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Our ability to protect our intellectual property and proprietary
    technology through patents and other means is uncertain, and we
    are dependent on certain licensed-in technology. In addition,
    our suit seeking declaratory judgments of non-infringement and
    invalidity against Applied BioSystems, Inc. and Applera
    Corporation, as well as future third-party claims of
    intellectual property infringement could adversely affect our
    operations and financial condition.
</TD>
</TR>

</TABLE>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Corporate
    History and Information</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We were incorporated in California in May 1999 as Mycometrix
    Corporation, changed our name to Fluidigm Corporation in April
    2001 and reincorporated in Delaware in July 2007. Our principal
    executive offices are located at 7000 Shoreline Court,
    Suite&#160;100, South San&#160;Francisco, California 94080. Our
    telephone number is
    <FONT style="white-space: nowrap">(650)&#160;266-6000.</FONT>
    Our website address is www.fluidigm.com. Information contained
    on our website is not incorporated by reference into this
    prospectus, and should not be considered to be part of this
    prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    &#147;Fluidigm,&#148; the Fluidigm logo, &#147;Topaz,&#148;
    &#147;BioMark,&#148; &#147;AutoInspeX,&#148; &#147;MSL&#148; and
    &#147;NanoFlex&#148; are trademarks or registered trademarks of
    Fluidigm. Other service marks, trademarks and trade names
    referred to in this prospectus are the property of their
    respective owners.
</DIV>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">THE
    OFFERING</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="36%"></TD>
    <TD width="1%"></TD>
    <TD width="63%"></TD>
</TR>

<TR>
    <TD valign="top">
    Common stock offered by us</TD>
    <TD></TD>
    <TD valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    shares</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    Common stock to be outstanding after this offering</TD>
    <TD></TD>
    <TD valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    shares</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    Use of proceeds</TD>
    <TD></TD>
    <TD valign="bottom">
    We intend to use the net proceeds from this offering to expand
    our sales force, support the commercialization of our products,
    continue research and development, expand our facilities and
    manufacturing operations and for working capital and other
    general corporate purposes. We may also use a portion of the net
    proceeds to acquire other businesses, products or technologies.
    However, we do not have agreements or commitments for any
    specific acquisitions at this time. See &#147;Use of
    Proceeds.&#148;</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    Proposed NASDAQ Global Market symbol</TD>
    <TD></TD>
    <TD valign="bottom">
    FLDM</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The number of shares of our common stock to be outstanding
    following this offering is based on 68,217,839&#160;shares of
    our common stock outstanding as of June&#160;28, 2008, which
    includes 23,750 shares of common stock subject to repurchase but
    excludes:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    8,309,725&#160;shares of common stock issuable upon exercise of
    options outstanding as of June&#160;28, 2008 at a weighted
    average exercise price of $1.56 per share;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    757,436&#160;shares of common stock issuable upon the exercise
    of warrants outstanding as of June&#160;28, 2008 at a weighted
    average exercise price of $3.26 per share, after conversion of
    our convertible preferred stock;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    9,105,546&#160;shares of common stock reserved for future
    issuance under our stock-based compensation plans, including
    7,000,000&#160;shares of common stock reserved for issuance
    under our 2008 Equity Incentive Plan, which will become
    effective on the date of this prospectus, and any future
    automatic increase in shares reserved for issuance under such
    plan; and
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless otherwise indicated, this prospectus reflects and assumes
    the following:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a&#160;&#160;-for-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    reverse split of our outstanding common stock and convertible
    preferred stock, to be effected prior to the completion of this
    offering;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the conversion of all outstanding shares of our convertible
    preferred stock into an aggregate of 58,191,261&#160;shares of
    common stock upon the closing of this offering;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the filing of our amended and restated certificate of
    incorporation immediately prior to the effectiveness of this
    offering; and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    no exercise by the underwriters of their over-allotment option.
</TD>
</TR>

</TABLE>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SUMMARY
    CONSOLIDATED FINANCIAL DATA</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have derived the summary consolidated statement of operations
    data for the years ended December&#160;31, 2005,
    December&#160;31, 2006 and December&#160;29, 2007 from our
    audited consolidated financial statements included elsewhere in
    this prospectus. We have derived the summary consolidated
    statement of operations data for the six months ended
    June&#160;30, 2007 and June&#160;28, 2008 and the consolidated
    balance sheet data as of June&#160;28, 2008 from our unaudited
    consolidated financial statements included elsewhere in this
    prospectus. Our historical results are not necessarily
    indicative of the results that may be expected in the future.
    The following summary consolidated financial data should be read
    in conjunction with &#147;Management&#146;s Discussion and
    Analysis of Financial Condition and Results of Operations&#148;
    and our consolidated financial statements and related notes
    included elsewhere in this prospectus.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="64%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Six Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom">
    <B>(in thousands, except per share amounts)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Consolidated Statement of Operations Data:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Revenue:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,076
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,959
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,489
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,382
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Collaboration revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,568
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,376
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    460
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    310
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Grant revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,063
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,364
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,198
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Total revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,674
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,997
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,520
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Cost and expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Cost of product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,764
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,773
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,514
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,490
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,988
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Research and development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,449
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,389
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,053
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,151
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Selling, general and administrative
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,955
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,898
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,183
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,843
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Total costs and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,168
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,801
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,726
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,982
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Loss from operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,494
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,663
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,526
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11,729
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,462
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (898
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,261
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,790
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,790
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,100
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,140
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Other income (expense), net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (194
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (170
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (37
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (214
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Loss before provision for income taxes and cumulative effect of
    change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,022
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,346
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,917
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,219
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Provision for income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (105
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (52
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (43
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Loss before cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,022
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,969
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,262
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    637
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (12,969
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (15,262
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Net loss per share of common stock, basic and
    diluted<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.82
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.53
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.35
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.54
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Shares used in computing net loss per share of common stock,
    basic and
    diluted<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,316
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,577
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,912
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Pro forma net loss per share of common stock, basic and
    diluted<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Shares used in computing pro forma net loss per share of common
    stock, basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Please see Note&#160;2 to our
    consolidated financial statements included elsewhere in this
    prospectus for an explanation of the method used to calculate
    basic and diluted net loss per share of common stock and pro
    forma net loss per share of common stock.
    </FONT></TD>
</TR>

</TABLE>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="63%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of June&#160;28, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Pro Forma<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Actual</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Pro
    Forma<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As
    Adjusted<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>(in thousands)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Consolidated Balance Sheet Data:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cash and cash equivalents and available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    32,469
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Working capital
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,644
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,768
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total long-term debt
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,558
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible preferred stock warrant liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,269
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible preferred stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    167,538
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total stockholders&#146; equity (deficit)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (144,908
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The pro forma balance sheet data in
    the table above reflects (i)&#160;the conversion of all
    outstanding shares of convertible preferred stock into common
    stock and (ii)&#160;the reclassification of the convertible
    preferred stock warrant liabilities to additional
    <FONT style="white-space: nowrap">paid-in</FONT>
    capital, each effective upon the closing of this offering.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The pro forma as adjusted balance
    sheet data in the table above also reflects the pro forma
    conversions and reclassifications described immediately above
    plus the sale
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of our common stock in this offering and the application of the
    net proceeds at an initial public offering price of
    $&#160;&#160;&#160;&#160;&#160; per share, the midpoint of the
    range set forth on the cover page of this prospectus, after
    deducting estimated underwriting discounts and commissions and
    estimated offering expenses payable by us.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">A $1.00 increase (decrease) in the
    assumed initial public offering price of
    $&#160;&#160;&#160;&#160;&#160; per share, the midpoint of the
    range set forth on the cover page of this prospectus, would
    increase (decrease) cash, cash equivalents and
    available-for-sale securities and each of working capital, total
    assets and total stockholders&#146; equity by
    $&#160;&#160;&#160;&#160;&#160;&#160;million, assuming that the
    number of shares offered by us, as set forth on the cover page
    of this prospectus, remains the same, and after deducting
    estimated underwriting discounts and commissions and estimated
    offering expenses payable by us. Each increase of
    1.0&#160;million shares in the number of shares offered by us
    would increase cash, cash equivalents, available-for-sale
    securities and each of working capital, total assets and total
    stockholders&#146; equity by approximately
    $&#160;&#160;&#160;&#160;&#160;&#160;million. Similarly, each
    decrease of 1.0&#160;million shares in the number of shares
    offered by us would decrease cash, cash equivalents and
    available-for-sale securities and each of working capital, total
    assets and total stockholders&#146; equity by approximately
    $&#160;&#160;&#160;&#160;&#160;&#160;million. The pro forma as
    adjusted information discussed above is illustrative only and
    will be adjusted based on the actual public offering price and
    other terms of this offering determined at pricing.
    </FONT></TD>
</TR>

</TABLE>
</DIV><!-- End box 1 -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='102'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">RISK
    FACTORS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Investing in our common stock involves a high degree of risk.
    You should consider carefully the risks and uncertainties
    described below, together with all of the other information in
    this prospectus, including our consolidated financial statements
    and related notes, before deciding whether to purchase shares of
    our common stock. If any of the following risks is realized, our
    business, financial condition, results of operations and
    prospects could be materially and adversely affected. In that
    event, the price of our common stock could decline and you could
    lose part or all of your investment.</I>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Related to our Business and Strategy</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We have incurred losses since inception, and we expect to
    continue to incur substantial losses for the foreseeable
    future.</I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have a limited operating history and have incurred
    significant losses in each fiscal year since our inception,
    including net losses of $16.4&#160;million, $23.6&#160;million,
    $25.5&#160;million and $15.3&#160;million during 2005, 2006,
    2007 and the six months ended June&#160;28, 2008. As of
    June&#160;28, 2008, we had an accumulated deficit of
    $149.1&#160;million. These losses have resulted principally from
    costs incurred in our research and development programs and from
    our selling, general and administrative expenses. We expect to
    continue to incur operating and net losses and negative cash
    flow from operations, which may increase, for the foreseeable
    future due in part to anticipated increases in expenses for
    research and product development and expansion of our sales and
    marketing capabilities. Additionally, following this offering,
    we expect that our selling, general and administrative expenses
    will increase due to the additional operational and reporting
    costs associated with being a public company. We anticipate that
    our business will generate operating losses until we
    successfully implement our commercial development strategy and
    generate significant additional revenues to support our level of
    operating expenses. Because of the numerous risks and
    uncertainties associated with our commercialization efforts and
    future product development, we are unable to predict when we
    will become profitable, and we may never become profitable. Even
    if we do achieve profitability, we may not be able to sustain or
    increase our profitability.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>If our products fail to achieve and sustain sufficient
    market acceptance, our revenue will be adversely
    affected.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our success depends, in part, on our ability to develop and
    market products that are recognized and accepted as reliable,
    enabling and cost effective. Most of our potential customers
    already use expensive research systems in their laboratories and
    may be reluctant to replace those systems. Market acceptance of
    our instrument systems will depend on many factors, including
    our ability to convince potential customers that our systems are
    an attractive alternative to existing technologies. Compared to
    other technologies, our Integrated Fluidic Circuit, or IFC,
    technology is new and unproven, and most potential customers
    have limited knowledge of, or experience with, our products.
    Prior to adopting our technology, potential customers generally
    need to devote significant effort to testing and validating our
    systems and benchmarking them against their current systems and
    performance requirements. Any failure of our systems to meet
    these customer benchmarks could result in customers choosing to
    retain their existing systems or to purchase systems other than
    ours.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, many customers intend to publish the results of
    their experiments in scientific and medical journals. Therefore,
    it is important that our systems be perceived as accurate and
    reliable by the scientific and medical research community as a
    whole. Many factors influence the perception of a system
    including its use by leading research groups and the publication
    of their results in well regarded journals. A significant part
    of our sales and marketing efforts have been directed at
    convincing industry leaders of the advantages of our systems and
    encouraging such leaders to publish or present the results of
    their evaluation of our system. If we are unable to induce
    leading researchers to use our system or if such researchers are
    unable to achieve and publish or present significant
    experimental results using our system, acceptance and adoption
    of our systems will be slowed.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our sales cycle is lengthy and unpredictable, which makes
    it difficult for us to forecast revenue and could cause
    significant quarterly fluctuations in revenue and other
    operating results.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The sales cycles for our instrument systems is lengthy, which
    makes it difficult for us to accurately forecast revenues in a
    given period, and may cause revenue and operating results to
    vary significantly from period to period.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Due in part to the high up-front cost associated with our
    systems, potential customers for our instrument systems
    typically need to commit significant time and resources to
    evaluate our technology and their decision to purchase our
    instruments may be further limited by budgetary constraints and
    several layers of internal review and approval, which are beyond
    our control. Even after initial approval by appropriate decision
    makers, the negotiation and documentation processes for a
    purchase can be lengthy. As a result of these factors, our sales
    cycle has varied widely and, in certain instances has been
    longer than 12&#160;months. The complexity and variability of
    our sales cycle has made it difficult for us to accurately
    project quarterly revenues, and we have frequently failed to
    meet our internal quarterly projections. Moreover, we do not
    recognize revenue on sales of our systems until the system has
    been delivered to the customer and, in many instances, installed
    and our other revenue recognition criteria have been met. This
    further complicates our ability to project quarterly revenue as
    we may have entered into a sale agreement with a customer for a
    system but cannot predict when that customer will take delivery
    of the system and when we will be able to recognize the revenue.
    We expect that our sales will continue to fluctuate on a
    quarterly basis and that our financial results for some periods
    may be below those projected by securities analysts. Such
    fluctuations could have a material adverse effect on our
    business and on the price of our common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our sales efforts require significant time and effort and
    could hinder our ability to increase sales.</I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Before purchasing one of our systems, customers typically
    require input from one or more scientific evaluators, as well as
    a review by personnel with finance or operational expertise. As
    a result, during our sales effort, we must identify all persons
    involved in the purchasing decision and devote a sufficient
    amount of time to presenting our systems to those individuals.
    The newness and complexity of our products often requires us to
    spend substantial time and effort assisting potential customers
    in evaluating our instruments, including providing
    demonstrations and benchmarking our products against other
    available technologies. This process can be costly and time
    consuming. We expect that our sales process will become less
    burdensome as our products become more widely known and used.
    However, if this change does not occur, we will not be able to
    expand our sales effort as quickly as anticipated and our sales
    will be adversely affected.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our future success is dependent upon our ability to expand
    our customer base and introduce new applications.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our customer base is primarily composed of pharmaceutical and
    biotechnology companies, academic institutions and life science
    laboratories that perform large-scale experimentation for life
    science research purposes. Our success will depend in part upon
    our ability to increase our market share amongst these
    customers, attract life science research customers who do not
    currently perform large-scale experimentation, attract customers
    outside the life science research market and market new
    applications to existing and new customers as we develop such
    applications. Attracting new customers and introducing new
    applications requires substantial time and expense. For example,
    it may be difficult to identify, engage and market to customers
    who do not currently perform large-scale experimentation or are
    unfamiliar with our current applications. In addition, certain
    new applications that we are considering developing are not
    practical to perform with conventional techniques. Any failure
    to expand our existing customer base or launch new applications
    would adversely affect our ability to increase our revenues.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our inability to develop new systems and enhance the
    capabilities of our IFC systems to keep pace with rapidly
    changing technology and customer requirements could adversely
    affect our business.</I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our success depends on our ability to develop new applications
    for our IFC technology in existing and new markets, while
    improving the performance and cost effectiveness of our systems.
    New technologies, techniques or products could emerge that might
    offer better combinations of price and performance than our
    current or future product lines and systems. Existing markets
    for our products, including gene expression analysis,
    genotyping, digital polymerase chain reaction, or PCR, and
    proteomics, as well as potential markets for our products such
    as high-throughput DNA sequencing and molecular diagnostics, are
    characterized by rapid technological change and innovation. It
    is critical to our success for us to anticipate changes in
    technology and customer requirements and to successfully
    introduce new, enhanced and competitive technology to meet our
    customers&#146; and prospective customers&#146; needs on a
    timely basis. While we have planned substantial improvements to
    the BioMark system, including enhancing the capabilities of our
    IFCs, we may not be able to successfully implement these
    improvements. Even if we successfully implement some or all of
    these planned improvements, we could incur substantial
    development costs in doing so. We may not have adequate
    resources available to develop new technologies or be
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    9
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    able to successfully introduce new applications of, or
    enhancements to, our systems. We cannot guarantee that we will
    be able to maintain technological advantages over emerging
    technologies in the future. If we fail to keep pace with
    emerging technologies, demand for our systems will not grow and
    may decline, and our business, revenue, financial condition and
    operating results could suffer materially.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We have limited resources for marketing, selling and
    distributing our products and we may not be able to develop a
    direct sales and marketing force or distribution capabilities
    that can meet our customers&#146; needs.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have limited marketing, sales and distribution resources and
    capabilities. We sell our products primarily through our own
    sales force and through distributors in certain territories. Our
    first product line, the Topaz system for protein
    crystallization, was introduced for commercial sale in 2002. Our
    BioMark system was introduced for commercial sale in 2006.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our future sales will depend in large part on our ability to
    develop and expand our direct sales force and to increase the
    scope of our marketing efforts. Our products are technically
    complex and used for highly specialized applications. As a
    result, we believe it is necessary to develop a direct sales
    force that includes people with specific scientific backgrounds
    and expertise and a marketing group with technical
    sophistication. Competition for such employees is intense. We
    may not be able to attract and retain personnel or be able to
    build an efficient and effective sales and marketing force,
    which could negatively impact sales of our products, and reduce
    our revenues and profitability.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, we may seek to enlist one or more additional
    parties to assist with sales, distribution and customer support
    globally or in certain regions of the world. If we do seek to
    enter into such arrangements, we may not be successful in
    attracting desirable sales and distribution partners, or we may
    not be able to enter into such arrangements on favorable terms.
    If our sales and marketing efforts, or those of any third-party
    sales and distribution partners, are not successful, our
    technologies and products may not gain market acceptance, which
    would materially impact our business operations.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>The life science industry is highly competitive and
    subject to rapid technological change, and we may not be able to
    successfully compete.</I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The markets for our products are characterized by rapidly
    changing technology, evolving industry standards, changes in
    customer needs, emerging competition, new product introductions
    and strong price competition. We compete with both established
    and development stage life science companies that design,
    manufacture and market instruments for gene expression analysis,
    genotyping, other nucleic acid detection and additional
    applications using well established laboratory techniques, as
    well as newer technologies such as bead encoded arrays,
    microfluidics, nanotechnology, high-throughput DNA sequencing
    and inkjet and photolithographic arrays. Most of our current
    competitors have significantly greater name recognition, greater
    financial and human resources, broader product lines and product
    packages, larger sales forces, large existing installed bases,
    substantial intellectual property portfolios and greater
    experience in research and development, manufacturing and
    marketing than we do. For example, companies such as Affymetrix,
    Applied Biosystems, BioTrove, Illumina, Roche Diagnostics and
    Sequenom have products that compete in certain segments of the
    market in which we sell our BioMark system.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Competitors may be able to respond more quickly and effectively
    than we can to new or changing opportunities, technologies,
    standards or customer requirements. In light of these
    advantages, even if our technology is more effective than the
    product or service offerings of our competitors, current or
    potential customers might accept competitive products and
    services in lieu of purchasing our technology. We anticipate
    that we will face increased competition in the future as
    existing companies and competitors develop new or improved
    products and as new companies enter the market with new
    technologies. We may not be able to compete effectively against
    these organizations. Increased competition is likely to result
    in pricing pressures, which could harm our sales, profitability
    or market share. Our failure to compete effectively could
    materially and adversely affect our business, financial
    condition and results of operations.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    10
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We receive a substantial portion of our revenue from a
    limited number of customers and other entities, and the loss of,
    or a significant reduction in, orders or grants from one or more
    of our major customers or grantors would adversely affect our
    operations and financial condition.</I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We receive a substantial portion of our revenue from a limited
    number of customers and grantors. We received an aggregate of
    approximately 37%, 44%, 38% and 27% of our total revenue from
    our top three customers in 2005, 2006, 2007 and the six months
    ended June&#160;28, 2008. Grant revenue from the Singapore
    Economic Development Board, or EDB, represented 0%, 14%, 24% and
    15% of our total revenue in 2005, 2006 and 2007 and the six
    months ended June&#160;28, 2008. We anticipate that we will
    continue to be dependent on a limited number of customers and
    grantors for a significant portion of our revenue in the near
    future and in some cases the portion of our revenue attributable
    to certain customers or grantors may increase in the future.
    However, we may not be able to maintain or increase sales to our
    top customers or grants from our top grantors for a variety of
    reasons, including the following:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our agreements with our customers and grantors do not require
    them to purchase a minimum quantity of our products or make a
    minimum amount of grants in any year;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our customers can stop using our products with limited notice to
    us and suffer little or no payment penalty;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our grants are subject to the achievement of milestones that we
    may not meet;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    many of our customers have pre-existing or concurrent
    relationships with our current or potential competitors that may
    affect the customers&#146; decisions to purchase our products.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the past, we have relied in significant part on our strategic
    relationships with customers that are technology leaders in our
    target markets. We intend to pursue the expansion of such
    relationships and the formation of new strategic relationships,
    but we cannot assure you that we will be able to do so. These
    relationships often require us to develop new products that may
    involve significant technological challenges. Our customers
    frequently place considerable pressure on us to meet their tight
    development schedules. Our grantors frequently condition their
    present and future grants on our compliance with certain
    development, hiring and local investment milestones.
    Accordingly, we may have to devote a substantial amount of our
    resources to our strategic relationships, which could detract
    from or delay our completion of other important development
    projects. Delays in development could impair our relationships
    with our strategic customers and grantors and negatively impact
    sales of the products under development or future grant
    activity. The loss of a key customer or grantor, a reduction in
    sales to any key customer, a reduction in grants from a key
    grantor, or our inability to attract new significant customers
    could seriously impact our revenue and materially and adversely
    affect our results of operations.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our business depends on research and development spending
    levels of pharmaceutical and biotechnology companies and
    academic, clinical and governmental research institutions and
    any reduction in such spending could limit our ability to sell
    our products.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We expect that our revenue in the foreseeable future will be
    derived primarily from sales of instruments and IFCs to academic
    institutions, biotechnology and pharmaceutical companies and
    life science laboratories worldwide. Our success will depend
    upon their demand for and use of our products. Accordingly, the
    spending policies of these customers could have a significant
    effect on the demand for our technology. These policies may be
    based on a wide variety of factors, including the resources
    available to make purchases, the spending priorities among
    various types of equipment, policies regarding spending during
    recessionary periods and changes in the political climate. In
    addition, academic, governmental and other research institutions
    that fund research and development activities may be subject to
    stringent budgetary constraints that could result in spending
    reductions, reduced allocations or budget cutbacks, which could
    jeopardize the ability of these customers to purchase our
    system. Our operating results may fluctuate substantially due to
    reductions and delays in research and development expenditures
    by these customers. For example, reductions in capital
    expenditures by these customers may result in lower than
    expected system sales and, similarly, reductions in operating
    expenditures by these customers could result in lower than
    expected sales of IFCs. These reductions and delays may result
    from factors that are not within our control, such as:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    changes in economic conditions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    changes in government programs that provide funding to research
    institutions and companies;
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    11
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    changes in the regulatory environment affecting life science
    companies and life science research;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    market-driven pressures on companies to consolidate operations
    and reduce costs;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    mergers and acquisitions in the life science industry;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    other factors affecting research and development spending.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Any decrease in our customers&#146; budgets or expenditures or
    in the size, scope or frequency of capital or operating
    expenditures as a result of the foregoing or other factors could
    materially adversely affect our operations or financial
    condition.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>If we cannot provide quality technical support, we could
    lose customers and our operating results could suffer.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The placement of our products at new customer sites, the
    introduction of our technology into our customers&#146; existing
    systems and ongoing customer support can be complex.
    Accordingly, we need highly trained technical support personnel.
    Hiring technical support personnel is very competitive in our
    industry due to the limited number of people available with the
    necessary biochemistry background and ability to understand our
    systems at a technical level. We are currently expanding our
    technical support staff and will need to increase it further to
    support expected new customers as well as the expanding needs of
    existing customers. If we are unable to attract, train or retain
    the number of highly qualified technical services personnel that
    our business needs, our business and prospects will suffer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>To use our products, customers typically need to purchase
    specialized reagents. Any interruption in the availability of
    these reagents for use in our products could limit our ability
    to market our products.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our products must be used in conjunction with one or more
    reagents designed to produce or facilitate the particular
    biological or chemical reaction desired by the user. Many of
    these reagents are highly specialized and available to the user
    only from a single supplier or a limited number of suppliers.
    Our customers typically purchase these reagents directly from
    the suppliers and we have no control over the supply of those
    materials. In addition, our products are designed to work with
    these reagents as they are currently formulated. We have no
    control of the formulation of these reagents and the performance
    of our products might be adversely affected if the formulation
    of these reagents was changed. If one or more of these reagents
    were to become unavailable or were reformulated, our ability to
    market and sell our products could be materially and adversely
    affected.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, the use of a reagent for a particular process may
    be covered by one or more patents relating to the reagent
    itself, the use of the reagent for the particular process, the
    performance of that process or the equipment required to perform
    the process. Typically, reagent suppliers, who are either the
    patent holders or their authorized licensees, sell the reagents
    along with a license or covenant not to sue with respect to such
    patents. The license accompanying the sale of a reagent often
    purports to restrict the purposes for which the reagent may be
    used. If a patent holder or authorized licensee were to assert
    against us or our customers that the license or covenant
    relating to a reagent precluded its use with our systems, our
    ability to sell and market our products could be materially and
    adversely affected. For example, the current applications of our
    BioMark system, which represented 43% of our product revenue in
    2007, involve real-time polymerase chain reaction, or PCR. The
    primary producers of reagents for PCR reactions are Applied
    Biosystems and Roche Diagnostics, who are our direct
    competitors, and their licensees. These PCR reagents are
    typically sold pursuant to limited licenses or covenants not to
    sue with respect to patents held by these companies. We do not
    have any contractual relationship with Roche Diagnostics or
    Applied Biosystems regarding these PCR reagents, and we cannot
    assure you that these reagents will continue to be available to
    our customers for use with our systems, or that these patent
    holders will not seek to enforce their patents against us, our
    customers, or suppliers.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    12
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We are dependent on single source suppliers for some of
    the components and materials used in our systems, and the loss
    of any of these suppliers could harm our business.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We rely on single source suppliers for certain components and
    materials used in our systems. Of these single source suppliers,
    the loss of any of the following would require significant time
    and effort to locate and qualify an alternative source of supply:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    An essential component of our BioMark system is a specialized
    thermal cycler that is available from a limited number of
    suppliers. We purchase this thermal cycler from one supplier,
    Eppendorf AG, which customizes it to our specifications pursuant
    to a supply agreement.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Our IFCs are fabricated using a specialized polymer that is
    available from a limited number of sources. In the past we have
    encountered quality issues that have reduced our manufacturing
    yield or required the use of additional manufacturing processes.
    We do not have a long term contract with our current sole
    supplier.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The plastic carriers that hold the core components of our IFCs
    need to be produced to specifications and tolerances that few
    manufacturers are able to meet. We have experienced quality
    issues in the past and, as a result, have recently switched
    suppliers. We do not have a long term contract with either of
    our current sole suppliers for particular carriers.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The reader for our BioMark system requires specialized high
    resolution camera lenses that are available from a limited
    number of sources. We do not have a long term contract with our
    current sole supplier.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our reliance on these suppliers also subjects us to other risks
    that could harm our business, including the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we may be subject to increased component costs;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we are not a major customer of many of our suppliers, and these
    suppliers may therefore give other customers&#146; needs higher
    priority than ours;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we may not be able to obtain adequate supply in a timely manner
    or on commercially reasonable terms;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our suppliers may make errors in manufacturing components that
    could negatively affect the efficacy of our systems or cause
    delays in shipment of our systems;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our suppliers may encounter financial hardships unrelated to our
    demand for components, which could inhibit their ability to
    fulfill our orders and meet our requirements.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have in the past experienced supply problems with some of our
    suppliers, such as manufacturing errors, and may again
    experience problems in the future. We may not be able to quickly
    establish additional or replacement suppliers, particularly for
    our single source components. Any interruption or delay in the
    supply of components or materials, or our inability to obtain
    components or materials from alternate sources at acceptable
    prices in a timely manner, could impair our ability to meet the
    demand of our customers and cause them to cancel orders or
    switch to competitive products.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We have limited experience in producing our products, and
    we may experience development or manufacturing problems or
    delays that could limit the growth of our revenue or increase
    our losses.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have limited experience manufacturing and assembling our
    products in commercial quantities and we may encounter
    unforeseen situations that would result in delays or shortfalls.
    In addition, our production processes and assembly methods may
    have to change to accommodate any significant future expansion
    of our manufacturing capacity. If we are unable to keep up with
    demand for our products, our revenue could be impaired, market
    acceptance for our products could be adversely affected and our
    customers might instead purchase our competitors&#146; products.
    Our inability to successfully manufacture our products would
    have a material adverse effect on our operating results.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We first produced the IFCs used in our current Topaz system in
    June 2002 at our facility in South San&#160;Francisco. We have
    since moved our commercial production of IFCs to our facility in
    Singapore, which first produced commercial IFCs for our Topaz
    systems in October 2006 and first produced commercial IFCs for
    our BioMark
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    13
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    system in December 2007. Production of the elastomeric block
    that is at the core of our IFCs is a complex process requiring
    advanced clean rooms, sophisticated equipment and strict
    adherence to procedures. Any contamination of the clean room,
    equipment malfunction or failure to strictly follow procedures
    can significantly reduce our yield in one or more batches. Such
    a drop in yield can greatly increase our cost to manufacture our
    IFCs or, in more severe cases, require us to halt the
    manufacture of IFCs until the problem is resolved. Identifying
    and resolving the cause of a drop in yield can require
    substantial time and resources. We have had significant yield
    problems in the past and cannot assure you that these types of
    yield issues will not occur again. Sustained yield problems
    would have a material adverse affect on our business, financial
    condition and results of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, developing an IFC for a new application typically
    requires developing a specific production process for that type
    of IFC. While all of our IFCs are produced using the same basic
    processes, significant variations are required to ensure
    adequate yield of any particular type of IFC. Developing such a
    process can be very time consuming, and any unexpected
    difficulty in doing so can delay the introduction of a product.
    For example, in the second quarter of 2006, our ability to
    conduct demonstrations for potential customers for our BioMark
    system was impaired because we were unable to produce sufficient
    quantities of that IFC. Though these production problems were
    resolved, the delay in conducting customer demonstrations
    resulted in the loss and delay of orders from potential
    customers. We cannot assure you that we will not face similar
    difficulties in developing new processes in the future.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>If we are unable to recruit and retain key executives and
    scientists, we may be unable to achieve our goals.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our performance is substantially dependent on the performance of
    our senior management and key scientific and technical
    personnel, particularly Gajus V. Worthington, our President and
    Chief Executive Officer. We do not maintain fixed term
    employment contracts with any of our employees. The loss of the
    services of any member of our senior management or our
    scientific or technical staff might significantly delay or
    prevent the development of our products or achievement of other
    business objectives by diverting management&#146;s attention to
    transition matters and identification of suitable replacements,
    if any, and could have a material adverse effect on our
    business. We do not maintain significant key man life insurance
    on any of our employees.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, our research and product development efforts could
    be delayed or curtailed if we are unable to attract, train and
    retain highly skilled employees, particularly, senior scientists
    and engineers. To expand our research and product development
    efforts, we need additional people skilled in areas such as
    molecular and cellular biology, assay development and
    manufacturing. Competition for these people is intense. Because
    of the complex and technical nature of our system and the
    dynamic market in which we compete, any failure to attract and
    retain a sufficient number of qualified employees could
    materially harm our ability to develop and commercialize our
    technology.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We may be unable to manage our anticipated growth
    effectively.</I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The rapid growth of our business has placed a significant strain
    on our managerial, operational and financial resources and
    systems. We have increased the number of our employees from 78
    at December&#160;31, 2005 to 143 at June&#160;28, 2008. In
    addition, since October 2006 we have commenced manufacturing
    operations in Singapore and opened sales offices in Europe and
    Japan. To execute our anticipated growth successfully, we must
    continue to attract and retain qualified personnel and manage
    and train them effectively. We must also upgrade our internal
    business processes and capabilities to create the scalability
    that a growing business demands.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe our primary commercial manufacturing facility located
    in Singapore is sufficient to meet our short-term manufacturing
    needs. The current lease for our manufacturing facility in
    Singapore expires in October&#160;2011. In order to meet the
    long-term demand for our IFC systems, we believe that we will
    need to add to our existing manufacturing space in Singapore or
    move all of our manufacturing facilities to a new location in
    Singapore. Such a move will involve significant expense in
    connection with the establishment of new clean rooms, the
    movement and installation of key manufacturing equipment and
    modifications to our manufacturing process and we cannot assure
    you that such a move would not delay or otherwise adversely
    affect our manufacturing activities.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    14
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Further, our anticipated growth will place additional strain on
    our suppliers and manufacturing facilities, resulting in an
    increased need for us to carefully monitor quality assurance.
    Any failure by us to manage our growth effectively could have an
    adverse effect on our ability to achieve our development and
    commercialization goals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our research and product development efforts may not
    result in commercially viable products within the timeline
    anticipated, if at all.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our business is dependent on the improvement of our existing
    products, our development of new products to serve existing
    markets and our development of new products to create new
    markets and applications that were previously not practical with
    existing systems. We intend to devote significant personnel and
    financial resources to research and development activities
    designed to advance the capabilities of our IFC technology. Our
    IFC technology is new and complex and the behavior of fluids and
    surrounding compounds in a nanoscale environment is difficult to
    predict in advance. Though we have developed design rules for
    the implementation of our IFC technology, these are frequently
    revised to reflect new insights we have gained about the
    technology. In addition, we have discovered that biological or
    chemical reactions sometimes behave differently when implemented
    on IFCs rather than in a standard laboratory environment. As a
    result, significant research and development efforts may be
    required to transfer even well-understood reactions to our
    technology. In the past, product development projects have been
    significantly delayed when we encountered unanticipated
    difficulties in implementing a process on our IFCs. We may have
    similar delays in the future, and we may not obtain any benefits
    from our research and development activities. Any delay or
    failure by us to develop new products or enhance existing
    products would have a substantial adverse effect on our business
    and results of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our products, although not currently regulated, could in
    the future be subject to regulation by the U.S. Food and Drug
    Administration or other regulatory agencies.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our products are currently labeled and sold for research
    purposes only and are not subject to U.S.&#160;Food and Drug
    Administration, or FDA, clearance or approval. However, in the
    future, certain of our products or related applications could be
    subject to the FDA&#146;s regulation, the FDA&#146;s regulatory
    jurisdiction could be expanded to include our products, or both.
    For example, if we wished to label and market our products for
    use in performing clinical diagnostics, FDA clearance or
    approval would be required. Even where a product is exempted
    from FDA clearance or approval, the FDA may impose restrictions
    on how and to whom we can market and sell our products.
    Obtaining FDA approval can be expensive and uncertain, generally
    takes several years to obtain and requires detailed and
    comprehensive scientific and clinical data. Notwithstanding the
    expense, these efforts may never result in FDA approval or
    clearance. Even if we were to obtain regulatory approval or
    clearance, it may not be for the uses we believe are important
    or commercially attractive. As a result, these regulations and
    restrictions could materially and adversely affect our business,
    financial condition and results of operations. Similar laws and
    regulations are also in effect in many foreign countries that
    could affect our ability to market certain products. The number
    and scope of these requirements are increasing. We may not be
    able to obtain regulatory approvals in such countries or may
    incur significant costs in obtaining or maintaining our foreign
    regulatory approvals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our future capital needs are uncertain and we may need to
    raise additional funds in the future.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that the net proceeds from this offering, together
    with our existing cash and cash equivalents, available for sale
    securities balances and cash receipts generated from sales of
    our products, will be sufficient to meet our anticipated cash
    requirements for at least the next 18&#160;months. However, we
    may need to raise substantial additional capital to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    expand the commercialization of our products;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    fund our operations;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    continue our research and development;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    defend, in litigation or otherwise, any claims that we infringe
    third-party patents or violate other intellectual property
    rights;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    commercialize new products;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    acquire companies and in-license products or intellectual
    property.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    15
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our future funding requirements will depend on many factors,
    including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    market acceptance of our products;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the cost of our research and development activities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the cost of filing and prosecuting patent applications;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the cost of defending, in litigation or otherwise, any claims
    that we infringe third-party patents or violate other
    intellectual property rights;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the cost and timing of regulatory clearances or approvals, if
    any;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the cost and timing of establishing additional sales, marketing
    and distribution capabilities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the cost and timing of establishing additional technical support
    capabilities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the effect of competing technological and market
    developments;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the extent to which we acquire or invest in businesses, products
    and technologies, although we currently have no commitments or
    agreements relating to any of these types of transactions.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>If we require additional funds in the future, such funds
    may not be available on acceptable terms, or at all.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We may require additional funds in the future and we may not be
    able to obtain such funds on acceptable terms, or at all. If we
    raise additional funds by issuing equity securities, our
    stockholders may experience dilution. Debt financing, if
    available, may involve covenants restricting our operations or
    our ability to incur additional debt. Any debt or additional
    equity financing that we raise may contain terms that are not
    favorable to us or our stockholders. If we raise additional
    funds through collaboration and licensing arrangements with
    third parties, it may be necessary to relinquish some rights to
    our technologies or our products, or grant licenses on terms
    that are not favorable to us. If we are unable to raise adequate
    funds, we may have to liquidate some or all of our assets, or
    delay, reduce the scope of or eliminate some or all of our
    development programs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If we do not have, or are not able to obtain, sufficient funds,
    we may have to delay development or commercialization of our
    products or license to third parties the rights to commercialize
    products or technologies that we would otherwise seek to
    commercialize. We also may have to reduce marketing, customer
    support or other resources devoted to our products or cease
    operations. Any of these factors could harm our operating
    results.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our products could have unknown defects or errors, which
    may give rise to claims against us and adversely affect market
    adoption of our systems.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFC systems utilize novel and complex technology applied on
    a nanoliter scale and such systems may develop or contain
    undetected defects or errors. We cannot assure you that material
    performance problems, defects or errors will not arise, and as
    we increase the density and integration of our IFCs, these risks
    may increase. While we do not provide express warranties that
    our IFCs will meet performance expectations or be free from
    defects, we have done so in the past, and expect to in the
    future in response to customer concerns in order to preserve
    customer relationships and help foster continued adoption and
    use of our systems. We typically do provide warranties relating
    to other parts of our IFC systems. The costs incurred in
    correcting any defects or errors may be substantial and could
    adversely affect our operating margins.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In manufacturing our products, we depend upon third parties for
    the supply of various components. Many of these components
    require a significant degree of technical expertise to produce.
    If our suppliers fail to produce components to specification, or
    if the suppliers, or we, use defective materials or workmanship
    in the manufacturing process, the reliability and performance of
    our products will be compromised.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If our products contain defects, we may experience:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a failure to achieve market acceptance or expansion of our
    product sales;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    loss of customer orders and delay in order fulfillment;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    damage to our brand reputation;
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    16
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    increased cost of our warranty program due to product repair or
    replacement;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    product recalls or replacements;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    inability to attract new customers;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    diversion of resources from our manufacturing and research and
    development departments into our service department;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    legal claims against us, including product liability claims,
    which could be costly and time consuming to defend and result in
    substantial damages.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The occurrence of any one or more of the foregoing could
    negatively affect our business, financial condition and results
    of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We generate a substantial portion of our revenues
    internationally and are subject to various risks relating to
    such international activities which could adversely affect our
    international sales and operating performance.</I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2005, 2006, 2007 and the six months ended June&#160;28,
    2008, approximately 28%, 40%, 52% and 54% of our total revenue
    was generated outside of North America. We believe that a
    significant percentage of our future revenue will come from
    international sources as we expand our overseas operations and
    develop opportunities in additional international areas. Our
    international business may be adversely affected by changing
    economic, political and regulatory conditions in foreign
    countries. Because the majority of our product sales are
    currently denominated in U.S.&#160;dollars, if the value of the
    U.S.&#160;dollar increases relative to foreign currencies, our
    products could become more costly to the international consumer
    and therefore less competitive in international markets, which
    could affect our financial performance. In addition, if the
    value of the U.S.&#160;dollar decreases relative to the
    Singapore dollar, it would become more costly in
    U.S.&#160;dollars for us to manufacture our products in
    Singapore. Furthermore, fluctuations in exchange rates could
    reduce our revenue, particularly with respect to grant revenue
    under agreements in Singapore, and affect demand for our
    products. Engaging in international business inherently involves
    a number of other difficulties and risks, including:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    required compliance with existing and changing foreign
    regulatory requirements and laws;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    export or import restrictions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    laws and business practices favoring local companies;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    longer payment cycles and difficulties in enforcing agreements
    and collecting receivables through certain foreign legal systems;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    political and economic instability;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    potentially adverse tax consequences, tariffs, customs charges,
    bureaucratic requirements and other trade barriers;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    difficulties and costs of staffing and managing foreign
    operations;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    difficulties protecting or procuring intellectual property
    rights.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If one or more of these risks occurs, it could require us to
    dedicate significant resources to remedy, and if we are
    unsuccessful in finding a solution, our financial results will
    suffer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We use hazardous chemicals and biological materials in our
    business. Any claims relating to improper handling, storage or
    disposal of these materials could be time consuming and
    costly.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our research and development and manufacturing processes involve
    the controlled use of hazardous materials, including flammables,
    toxics, corrosives and biologics. Our operations produce
    hazardous biological and chemical waste products. We cannot
    eliminate the risk of accidental contamination or discharge and
    any resultant injury from these materials. In addition, our IFC
    systems involve the use of pressurized systems and may involve
    the use of hazardous materials, which could result in injury. We
    may be sued for any injury or contamination that results from
    our use or the use by third parties of these materials. We do
    not currently maintain separate environmental liability coverage
    and any such contamination or discharge could result in
    significant cost to us in penalties, damages and suspension of
    our operations.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    17
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>If our facilities become inoperable, we will be unable to
    continue manufacturing our products and as a result, our
    business will be harmed until we are able to secure a new
    facility.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We manufacture and assemble our IFCs for commercial sale at our
    facility in Singapore and assemble our instrument platforms at
    our facilities in Singapore and South San&#160;Francisco,
    California. No other manufacturing or assembly facilities are
    currently available to us. Our facilities and the equipment we
    use to manufacture our products would be costly to replace and
    could require substantial lead time to repair or replace. The
    facilities may be harmed or rendered inoperable by natural or
    man-made disasters, including earthquakes, flooding and power
    outages, which may render it difficult or impossible for us to
    perform our research, development and manufacturing for some
    period of time. The inability to perform our research,
    development and manufacturing activities, combined with our
    limited inventory of reserve raw materials and manufactured
    supplies, may result in the loss of customers or harm our
    reputation, and we may be unable to reestablish relationships
    with those customers in the future. Although we possess
    insurance for damage to our property and the disruption of our
    business, this insurance may not be sufficient to cover all of
    our potential losses and may not continue to be available to us
    on acceptable terms, or at all.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>If we fail to maintain effective internal control over
    financial reporting in the future, the accuracy and timing of
    our financial reporting may be adversely affected.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In connection with the audit of our consolidated financial
    statements for the years ended December&#160;31, 2005 and 2006
    we, together with our independent registered public accounting
    firm identified material weaknesses in our internal control over
    financial reporting.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The material weaknesses related to our financial statement close
    process, revenue recognition and accrual processes and inventory
    costing, cost of sales, purchases cut-off and stock-based
    compensation. These material weaknesses resulted in the
    recording of numerous audit adjustments over the two year period
    ending December&#160;31, 2006. Since the date of our independent
    registered public accounting firm&#146;s reports on our
    consolidated financial statements for the years ended
    December&#160;31, 2005 and 2006 and through the date of this
    prospectus, we have taken steps intended to remediate these
    material weaknesses, primarily through the hiring of additional
    accounting and finance personnel with technical accounting and
    financial reporting experience. In addition, we have implemented
    procedures and controls in the financial statement close process
    designed to improve the accuracy and timeliness in financial
    accounting and reporting.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In April and May 2008, we reviewed our internal control over
    financial reporting and concluded that we had certain
    significant deficiencies. A significant deficiency is defined as
    a deficiency, or combination of deficiencies, in internal
    control over financial reporting that is less severe than a
    material weakness, yet important enough to merit attention by
    those responsible for oversight of a company&#146;s financial
    reporting. The significant deficiencies identified by us related
    to: our controls for the consolidation and elimination entries
    relating to intercompany transfer pricing and elimination of
    intercompany profits embedded in deferred costs of our Japanese
    subsidiary; our controls for applying SFAS&#160;123R to option
    grants with non-standard vesting terms and validation of stock
    compensation expenses calculated by our option tracking
    software; and our controls and procedures for the valuation of
    inventory.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not know the specific time frame that we will require to
    remediate the significant deficiencies identified. In addition,
    we expect to incur some incremental costs associated with this
    remediation. If we fail to enhance our internal control over
    financial reporting to meet the demands that will be placed upon
    us as a public company, including the requirements of the
    Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley Act, we may be
    unable to report our financial results accurately and prevent
    fraud. While we expect to remediate the significant
    deficiencies, we cannot assure you that we will be able to do so
    in a timely manner, which could impair our ability to accurately
    and timely report our financial position, results of operations
    or cash flows.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     No material weaknesses in internal control over financial
    reporting were identified in our April and May 2008 review.
    However, our management and independent registered public
    accounting firm did not perform an evaluation of our internal
    control over financial reporting as of any date in accordance
    with the provisions of Section&#160;404 of the Sarbanes-Oxley
    Act. Had we and our independent registered public accounting
    firm performed an evaluation of our internal control over
    financial reporting in accordance with the provisions of
    Section&#160;404 of the Sarbanes-Oxley Act, additional control
    deficiencies may have been identified by management or our
    independent registered public accounting firm.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    18
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We will incur significant increased costs as a result of
    operating as a public company, and our management will be
    required to devote substantial time to new compliance
    initiatives.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have never operated as a public company. As a public company,
    we will incur significant legal, accounting and other expenses
    that we did not incur as a private company. In addition, the
    Sarbanes-Oxley Act, as well as new rules subsequently
    implemented by the Securities and Exchange Commission and the
    NASDAQ Global Market, have imposed various new requirements on
    public companies, including requiring changes in corporate
    governance practices. Our management and other personnel will
    need to devote a substantial amount of time to these new
    compliance initiatives. Moreover, these rules and regulations
    will increase our legal and financial compliance costs and will
    make some activities more time-consuming and costly. For
    example, we expect these new rules and regulations to make it
    more difficult and more expensive for us to obtain director and
    officer liability insurance and we may be required to incur
    substantial costs to maintain the same or similar coverage.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, the Sarbanes-Oxley Act requires, among other
    things, that we maintain effective internal control over
    financial reporting and disclosure controls and procedures. In
    particular, commencing in 2009, we must perform system and
    process evaluation and testing of our internal control over
    financial reporting to allow management to report on the
    effectiveness of our internal control over financial reporting,
    as required by Section&#160;404 of the Sarbanes-Oxley Act. Our
    testing, or the subsequent testing by our independent registered
    public accounting firm, may reveal deficiencies in our internal
    control over financial reporting that are deemed to be material
    weaknesses. Our compliance with Section&#160;404 will require
    that we incur substantial accounting expense and expend
    significant management time on compliance-related issues. We
    currently do not have an internal audit group and we will
    evaluate the need to hire additional accounting and financial
    staff with appropriate public company experience and technical
    accounting knowledge. Moreover, if we are not able to comply
    with the requirements of Section&#160;404 in a timely manner, or
    if we or our independent registered public accounting firm
    identifies deficiencies in our internal control over financial
    reporting that are deemed to be material weaknesses, the market
    price of our stock could decline and we could be subject to
    sanctions or investigations by the NASDAQ Global Market, the
    Securities and Exchange Commission or other regulatory
    authorities, which would require additional financial and
    management resources.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Some of our programs are partially supported by government
    grants, which may be reduced, withdrawn, delayed or
    reclaimed.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have received and may continue to receive funds under
    research and economic development programs funded by the
    governments of Singapore and the United States. Funding by these
    governments may be significantly reduced or eliminated in the
    future for a number of reasons. For example, some
    U.S.&#160;programs are subject to a yearly appropriations
    process in Congress. Similarly, our grants from the Singapore
    government are part of an official policy to develop a life
    science industry in Singapore; that policy could change or the
    role of grants in it could be reduced or eliminated at any time.
    In addition, we may not receive funds under existing or future
    grants because of budgeting constraints of the agency
    administering the program. A restriction on the government
    funding available to us would reduce the resources that we would
    be able to devote to existing and future research and
    development efforts. Such a reduction could delay the
    introduction of new products and hurt our competitive position.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our agreements with the Singapore Economic Development Board, or
    EDB, provide that our continued eligibility for incentive grant
    payments from EDB is subject to our satisfaction of agreed upon
    targets for increasing levels of research, development and
    manufacturing activity in Singapore, including the use of local
    service providers, the hiring of personnel in Singapore, the
    incurrence of eligible expenses in Singapore, our receipt of new
    equity investment and our achievement of certain milestones
    relating to new product development or completion of specific
    manufacturing process objectives. These agreements further
    provide EDB with the right to demand repayment of a portion of
    past grants in the event that we did not meet our obligations
    under the applicable agreements. Based on correspondence with
    EDB, we believe that we have satisfied the conditions applicable
    to our EDB grant revenue through June&#160;28, 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our ability to use net operating losses to offset future
    taxable income may be subject to certain limitations.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, under Section&#160;382 of the Internal Revenue Code,
    a corporation that undergoes an &#147;ownership change&#148; is
    subject to limitations on its ability to utilize its pre-change
    net operating losses or NOLs to offset future
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    19
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    taxable income. Our existing NOLs may be subject to limitations
    arising from previous ownership changes, and if we undergo an
    ownership change in connection with or after this offering, our
    ability to utilize NOLs could be further limited by
    Section&#160;382 of the Internal Revenue Code. Future changes in
    our stock ownership, some of which are outside of our control,
    could result in an ownership change under Section&#160;382 of
    the Internal Revenue Code. We may not be able to utilize a
    material portion of the NOLs reflected on our balance sheet and
    for this reason, we have fully reserved against the value of our
    NOLs on our balance sheet.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Related to Intellectual Property</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our ability to protect our intellectual property and
    proprietary technology through patents and other means is
    uncertain.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our commercial success may depend in part on our ability to
    protect our intellectual property and proprietary technologies.
    We rely on patent protection, where appropriate and available,
    as well as a combination of copyright, trade secret and
    trademark laws, and nondisclosure, confidentiality and other
    contractual restrictions to protect our proprietary technology.
    However, these legal means afford only limited protection and
    may not adequately protect our rights or permit us to gain or
    keep any competitive advantage. Our pending U.S.&#160;and
    foreign patent applications may not issue as patents or may not
    issue in a form that will be advantageous to us. Any patents we
    have obtained or do obtain may be subject to re-examination,
    reissue, opposition or other administrative proceeding, or may
    be challenged in litigation, and such challenges could result in
    a determination that the patent is invalid or unenforceable. In
    addition, competitors may be able to design alternative methods
    or devices that avoid infringement of our patents. To the extent
    our intellectual property, including licensed intellectual
    property, offers inadequate protection, or is found to be
    invalid or unenforceable, we are exposed to a greater risk of
    direct competition. If our intellectual property does not
    provide adequate protection against our competitors&#146;
    products, our competitive position could be adversely affected,
    as could our business. Both the patent application process and
    the process of managing patent disputes can be time consuming
    and expensive. Furthermore, the laws of some foreign countries
    may not protect our intellectual property rights to the same
    extent as do the laws of the United States.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The patent positions of life science companies can be highly
    uncertain and involve complex legal and factual questions for
    which important legal principles remain unresolved. No
    consistent policy regarding the breadth of claims allowed in
    such companies&#146; patents has emerged to date in the United
    States. The laws of some
    <FONT style="white-space: nowrap">non-U.S.&#160;countries</FONT>
    do not protect intellectual property rights to the same extent
    as the laws of the United States, and many companies have
    encountered significant problems in protecting and defending
    such rights in foreign jurisdictions. The legal systems of
    certain countries, particularly certain developing countries, do
    not favor the enforcement of patents and other intellectual
    property protection, particularly those relating to
    biotechnology, which could make it difficult for us to stop the
    infringement of our patents. Proceedings to enforce our patent
    rights in foreign jurisdictions could result in substantial cost
    and divert our efforts and attention from other aspects of our
    business. Changes in either the patent laws or in
    interpretations of patent laws in the United States or other
    countries may diminish the value of our intellectual property.
    We cannot predict the breadth of claims that may be allowed or
    enforced in our patents or in third-party patents. For example:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We might not have been the first to make the inventions covered
    by each of our pending patent applications.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We might not have been the first to file patent applications for
    these inventions.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Others may independently develop similar or alternative products
    and technologies or duplicate any of our products and
    technologies.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    It is possible that none of our pending patent applications will
    result in issued patents, and even if they issue as patents,
    they may not provide a basis for commercially viable products,
    or may not provide us with any competitive advantages, or may be
    challenged and invalidated by third parties.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We may not develop additional proprietary products and
    technologies that are patentable.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The patents of others may have an adverse effect on our business.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We apply for patents covering our products and technologies and
    uses thereof, as we deem appropriate. However, we may fail to
    apply for patents on important products and technologies in a
    timely fashion or at all.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    20
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to pursuing patents on our technology, we take steps
    to protect our intellectual property and proprietary technology
    by entering into confidentiality agreements and intellectual
    property assignment agreements with our employees, consultants,
    corporate partners and, when needed, our advisors. Such
    agreements may not be enforceable or may not provide meaningful
    protection for our trade secrets or other proprietary
    information in the event of unauthorized use or disclosure or
    other breaches of the agreements, and we may not be able to
    prevent such unauthorized disclosure. Monitoring unauthorized
    disclosure is difficult, and we do not know whether the steps we
    have taken to prevent such disclosure are, or will be, adequate.
    If we were to enforce a claim that a third party had illegally
    obtained and was using our trade secrets, it would be expensive
    and time consuming, and the outcome would be unpredictable. In
    addition, courts outside the United States may be less willing
    to protect trade secrets.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We depend on certain technologies that are licensed to us.
    We do not control these technologies and any loss of our rights
    to them could prevent us from selling our products.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We rely on licenses in order to be able to use various
    proprietary technologies that are material to our business,
    including our core integrated fluidic circuit and multi-layer
    soft lithography technologies. We do not own the patents that
    underlie these licenses. Our rights to use these technologies
    and employ the inventions claimed in the licensed patents are
    subject to the negotiation of, continuation of and compliance
    with the terms of those licenses. In some cases, we do not
    control the prosecution, maintenance, or filing of the patents
    to which we hold licenses, or the enforcement of these patents
    against third parties. Some of our patents and patent
    applications were either acquired from another company who
    acquired those patents and patent applications from yet another
    company, or are licensed from a third party. Thus, these patents
    and patent applications are not written by us or our attorneys,
    and we did not have control over the drafting and prosecution.
    The former patent owners and our licensors might not have given
    the same attention to the drafting and prosecution of these
    patents and applications as we would have if we had been the
    owners of the patents and applications and had control over the
    drafting and prosecution. We cannot be certain that drafting
    <FONT style="white-space: nowrap">and/or</FONT>
    prosecution of the licensed patents and patent applications by
    the licensors have been or will be conducted in compliance with
    applicable laws and regulations or will result in valid and
    enforceable patents and other intellectual property rights.
    Enforcement of our licensed patents or defense or any claims
    asserting the invalidity of these patents is often subject to
    the control or cooperation of our licensors. Certain of our
    licenses contain provisions that allow the licensor to terminate
    the license upon specific conditions. Our rights under the
    licenses are subject to our continued compliance with the terms
    of the license, including the payment of royalties due under the
    license. Termination of these licenses could prevent us from
    marketing some or all of our products. Because of the complexity
    of our products and the patents we have licensed, determining
    the scope of the license and related royalty obligation can be
    difficult and can lead to disputes between us and the licensor.
    An unfavorable resolution of such a dispute could lead to an
    increase in the royalties payable pursuant to the license. If a
    licensor believed we were not paying the royalties due under the
    license or were otherwise not in compliance with the terms of
    the license, the licensor might attempt to revoke the license.
    If such an attempt were successful, we might be barred from
    producing and selling some or all of our products.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are subject to certain U.S.&#160;government regulations
    because we have licensed technologies that were developed with
    U.S.&#160;government grants. In accordance with these
    regulations, these licenses provide that products embodying the
    technologies will be manufactured substantially in the United
    States. If this domestic manufacturing requirement is not met,
    the government agency that funded the relevant grant is entitled
    to exercise specified rights, referred to as march-in rights,
    which if exercised would allow the government agency to require
    the licensors or us to grant a non-exclusive, partially
    exclusive or exclusive license in any field of use to a third
    party designated by such agency. As of June&#160;28, 2008, most
    of the instrumentation components of our IFC systems were
    manufactured in the United States and all commercial IFC
    components were manufactured in Singapore, though this division
    of manufacturing activities could change in the future. All of
    our IFC system revenue is dependent upon the availability of
    IFCs, which incorporate technology developed with U.S.
    government grants. As there is limited judicial or
    administrative guidance with respect to the interpretation or
    application of the U.S. manufacturing requirement, we are
    uncertain as to whether the current division of manufacturing
    for our IFC systems is in compliance with the requirement. The
    federal regulations allow the funding government agency to
    grant, at the request of the licensors of such technology, a
    waiver of the domestic manufacturing requirement. Waivers may be
    requested prior to any government notification. We are assisting
    the licensors of these technologies with the analysis of the
    domestic manufacturing requirement, and we believe that at least
    one of our licensors will be requesting a
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    21
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    waiver with our assistance. If it were to be determined that we
    are in violation of the domestic manufacturing requirement and a
    waiver of such requirement was either not requested or not
    granted, then the U.S.&#160;government could exercise its
    march-in rights. In addition, these licenses contain provisions
    relating to compliance with this domestic manufacturing
    requirement. If it were to be determined that we are not in
    compliance with these provisions and such non-compliance
    constituted a material breach of the licenses, the licenses
    could be terminated. Either the exercise of march-in rights or
    the termination of one or more of our licenses could materially
    adversely affect our business, operations and financial
    condition.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We may be involved in lawsuits to protect or enforce our
    patents and proprietary rights and to determine the scope,
    coverage and validity of others&#146; proprietary rights.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Litigation may be necessary to enforce our patent and
    proprietary rights
    <FONT style="white-space: nowrap">and/or</FONT> to
    determine the scope, coverage and validity of others&#146;
    proprietary rights. Litigation on these matters has been
    prevalent in our industry and we expect that this will continue.
    To determine the priority of inventions, we may have to initiate
    and participate in interference and re-examination proceedings
    declared by the U.S.&#160;Patent and Trademark Office that could
    result in substantial legal fees and could substantially affect
    the scope of our patent protection. Also, our intellectual
    property may be subject to significant administrative and
    litigation proceedings such as invalidity, unenforceability and
    opposition proceedings against our patents. The outcome of any
    litigation or interference proceeding might not be favorable to
    us, and we might not be able to obtain licenses to technology
    that we require. Even if such licenses are obtainable, they may
    not be available at a reasonable cost. In addition, if we resort
    to legal proceedings to enforce our intellectual property rights
    or to determine the validity, scope and coverage of the
    intellectual property or other proprietary rights of others, the
    proceedings could be burdensome and expensive, even if we were
    to prevail. Any litigation that may be necessary in the future
    could result in substantial costs and diversion of resources and
    could have a material adverse effect on our business, operating
    results or financial condition.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For example, on June&#160;4, 2008 we received a letter from
    Applied Biosystems, Inc., one of our competitors, asserting that
    our BioMark System for gene expression analysis infringes upon
    U.S.&#160;Patent No.&#160;6,814,934, or the &#146;934 patent,
    and its foreign counterparts in Europe and Canada, owned by
    Applied Biosystems&#146; parent company, Applera Corporation. In
    response to this letter, we filed suit against Applied
    Biosystems and Applera in federal district court in the Southern
    District of New York seeking declaratory judgments of
    non-infringement and invalidity of the &#146;934 patent.  In
    response to our action, Applied Biosystems and Applera may file
    suit against us in this and other jurisdictions asserting that
    our products infringe the &#146;934 patent or other proprietary
    rights held by them, or they may seek to dismiss or move our
    suit. Applied Biosystems has recently announced that it expects
    to be acquired by Invitrogen Corporation. This may make it more
    difficult for us to predict the direction of discussions and
    litigation among the parties.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Litigation, other proceedings or third party claims of
    intellectual property infringement could require us to spend
    significant time and money and could prevent us from selling our
    products or services or impact our stock price.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our commercial success may depend in part on our
    non-infringement of the patents or proprietary rights of third
    parties. Applied Biosystems, one of our competitors, has
    asserted that our BioMark System for gene expression analysis
    infringes upon Applera&#146;s &#146;934 patent, and we have
    filed suit against Applied Biosystems and Applera seeking
    declaratory judgments of non-infringement and invalidity of the
    Applera patent. Other third parties have asserted and may assert
    in the future that we are employing their proprietary technology
    without authorization. Competitors may assert that our products
    infringe their intellectual property rights as part of a
    business strategy to impede our successful entry into those
    markets. For example, numerous significant intellectual property
    issues have been litigated between existing and new participants
    in the PCR market, including litigation initiated by Applied
    Biosystems, Inc. In addition, our competitors and others may
    have patents or may in the future obtain patents and claim that
    use of our products infringes these patents. As we move into new
    markets and applications for our products, incumbent
    participants in such markets may assert their patents and other
    proprietary rights against us as a means of slowing our entry
    into such markets or as a means to extract substantial license
    and royalty payments from us.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Patent infringement suits can be expensive, lengthy and
    disruptive to business operations. We could incur substantial
    costs and divert the attention of our management and technical
    personnel in prosecuting or defending against any claims. There
    can be no assurance that we will prevail in our suit against
    Applied Biosystems and Applera in our defense of any claims
    brought against us by Applied Biosystems or Applera or in any
    other suit initiated against us by third parties. If we do not
    prevail in our suit against Applied Biosystems and Applera and
    we
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    22
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     are unable to secure any required licenses from such parties,
    we could be precluded from selling our BioMark products, which
    comprised 43% of our total product revenue in 2007 and 61% of
    our total product revenue for the six months ended June&#160;28,
    2008. Parties making claims against us may be able to obtain
    injunctive or other relief, which could block our ability to
    develop, commercialize and sell products, and could result in
    the award of substantial damages against us,&#160;including
    treble damages and attorneys&#146; fees and costs in the event
    that we are found to be a willful infringer of third party
    patents. In addition, our agreements with some of our suppliers,
    distributors, customers and other entities with whom we do
    business may require us to defend or indemnify these parties to
    the extent they become involved in infringement claims against
    us, including the claims described above. We could also
    voluntarily agree to defend or indemnify third parties in
    instances where we are not obligated to do so if we determine it
    would be important to our business relationships. If we are
    required or agree to defend or indemnify any of these third
    parties in connection with any infringement claims, we could
    incur significant costs and expenses that could adversely affect
    our business, operating results, or financial condition. In the
    event of a successful claim of infringement against us, we may
    be required to obtain one or more licenses from third parties,
    which we may not be able to obtain at a reasonable cost, if at
    all. In addition, we could encounter delays in product
    introductions while we attempt to develop alternative methods or
    products to avoid infringing third-party patents or proprietary
    rights. Defense of any lawsuit or failure to obtain any required
    licenses on favorable terms could prevent us from
    commercializing our products, and the risk of a prohibition on
    the sale of any of our products could adversely affect our
    ability to grow and gain market acceptance for our products.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Furthermore, because of the substantial amount of discovery
    required in connection with intellectual property litigation,
    there is a risk that some of our confidential information could
    be compromised by disclosure during this type of litigation. In
    addition, during the course of this kind of litigation, there
    could be public announcements of the results of hearings,
    motions or other interim proceedings or developments. If
    securities analysts or investors perceive these results to be
    negative, it could have a substantial adverse effect on the
    price of our common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We may be subject to damages resulting from claims that we
    or our employees have wrongfully used or disclosed alleged trade
    secrets of our employees&#146; former employers.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Many of our employees were previously employed at universities
    or other life science companies, including our competitors or
    potential competitors. Although no claims against us are
    currently pending, we may be subject to claims that these
    employees or we have inadvertently or otherwise used or
    disclosed trade secrets or other proprietary information of
    their former employers. Litigation may be necessary to defend
    against these claims. If we fail in defending such claims, in
    addition to paying monetary damages, we may lose valuable
    intellectual property rights or personnel. A loss of key
    research personnel or their work product could hamper or prevent
    our ability to commercialize certain potential products, which
    could severely harm our business. Even if we are successful in
    defending against these claims, litigation could result in
    substantial costs and be a distraction to management.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Related to Our Common Stock and this Offering</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We expect that our stock price will fluctuate
    significantly, and you may not be able to resell your shares at
    or above the initial public offering price.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to this offering, there has been no public market for
    shares of our common stock. We cannot predict the extent to
    which investor interest in our company will lead to the
    development of an active trading market on the NASDAQ Global
    Market or otherwise or how liquid that market might become. If
    an active trading market does not develop, you may have
    difficulty selling any of our shares of common stock that you
    buy. We and the underwriters will determine the initial public
    offering price of our common stock through negotiation. This
    price will not necessarily reflect the price at which investors
    in the market will be willing to buy and sell our shares
    following this offering. In addition, the trading price of our
    common stock following this offering may be highly volatile and
    could be subject to wide fluctuations in response to various
    factors, some of which are beyond our control. These factors
    include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    actual or anticipated quarterly variation in our results of
    operations or the results of our competitors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    announcements by us or our competitors of new commercial
    products, significant contracts, commercial relationships or
    capital commitments;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    issuance of new or changed securities analysts&#146; reports or
    recommendations for our stock;
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    23
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    developments or disputes concerning our intellectual property or
    other proprietary rights;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    commencement of, or our involvement in, litigation;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    market conditions in the life science sector;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any major change in our Board or management;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    general economic conditions and slow or negative growth of our
    markets.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The trading market for our common stock will rely in part on the
    research and reports that equity research analysts publish about
    us and our business. We do not control these analysts or the
    content and opinions included in their reports. Securities
    analysts may elect not to provide research coverage of our
    common stock after the completion of this offering, and such
    lack of research coverage may adversely affect the market price
    of our common stock. The price of our stock could decline if one
    or more equity research analysts downgrade our stock or if those
    analysts issue other unfavorable commentary or cease publishing
    reports about us or our business. If one or more equity research
    analysts ceases coverage of our company, we could lose
    visibility in the market, which in turn could cause our stock
    price to decline.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Purchasers in this offering will experience immediate and
    substantial dilution in the book value of their
    investment.</I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The initial public offering price of our common stock is
    substantially higher than the net tangible book value per share
    of our common stock immediately after this offering. Therefore,
    if you purchase our common stock in this offering, you will
    incur an immediate dilution of $&#160;&#160;&#160;&#160;&#160;
    in net tangible book value per share as of June&#160;28, 2008
    from the price you paid, based on an assumed initial public
    offering price of $&#160;&#160;&#160;&#160;&#160; per share, the
    mid-point of the range set forth on the cover page of this
    prospectus. In addition, new investors who purchase shares in
    this offering will contribute
    approximately&#160;&#160;&#160;&#160;&#160;% of the total amount
    of equity capital raised by us through the date of this
    offering, but will only own
    approximately&#160;&#160;&#160;&#160;&#160;% of the outstanding
    share capital and approximately&#160;&#160;&#160;&#160;&#160;%
    of the voting rights. The exercise of outstanding options and
    warrants will result in further dilution. For a further
    description of the dilution that you will experience immediately
    after this offering, see &#147;Dilution.&#148;
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Future sales of shares by existing stockholders could
    cause our stock price to decline.</I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If our existing stockholders sell, or indicate an intention to
    sell, substantial amounts of our common stock in the public
    market after the
    <FONT style="white-space: nowrap">lock-up</FONT> and
    other legal restrictions on resale discussed in this prospectus
    lapse, the trading price of our common stock could decline.
    Based on shares outstanding as of June&#160;28, 2008, upon
    completion of this offering, we will have outstanding a total
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock, assuming no exercise of the underwriters&#146;
    over-allotment option. Of these shares, only
    the&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock sold in this offering by us will be freely
    tradable, without restriction, in the public market immediately
    after the offering. Each of our directors and officers, and
    certain of our stockholders, have entered into
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements with the underwriters that restrict their ability to
    sell or transfer their shares. The
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements pertaining to this offering will expire 180&#160;days
    from the date of this prospectus, although they may be extended
    for up to an additional 34&#160;days under certain
    circumstances. Our underwriters, however, may, in their sole
    discretion, permit our officers, directors and other current
    stockholders who are subject to the contractual
    <FONT style="white-space: nowrap">lock-up</FONT> to
    sell shares prior to the expiration of the
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements. After the
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements expire, based on shares outstanding as of
    June&#160;28, 2008, up to an additional 68,101,494&#160;shares
    of common stock will be eligible for sale in the public
    market,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    of which are held by directors, executive officers and other
    affiliates and will be subject to volume limitations under
    Rule&#160;144 under the Securities Act and various vesting
    agreements. In
    addition,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock that are subject to outstanding options as of
    June&#160;28, 2008 will become eligible for sale in the public
    market to the extent permitted by the provisions of various
    vesting agreements, the
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements and Rules&#160;144 and 701 under the Securities Act.
    If these additional shares are sold, or if it is perceived that
    they will be sold, in the public market, the trading price of
    our common stock could decline.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our directors and executive officers will continue to have
    substantial control over us after this offering and could limit
    your ability to influence the outcome of key transactions,
    including changes of control.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our executive officers, directors and their affiliates will
    beneficially own or control
    approximately&#160;&#160;&#160;&#160;&#160;% of the outstanding
    shares of our common stock, following the completion of this
    offering. Accordingly, these executive
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    24
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    officers, directors and their affiliates, acting as a group,
    will have substantial influence over the outcome of corporate
    actions requiring stockholder approval, including the election
    of directors, any merger, consolidation or sale of all or
    substantially all of our assets or any other significant
    corporate transactions. These stockholders may also delay or
    prevent a change of control of us, even if such a change of
    control would benefit our other stockholders. The significant
    concentration of stock ownership may adversely affect the
    trading price of our common stock due to investors&#146;
    perception that conflicts of interest may exist or arise.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Anti-takeover provisions in our charter documents and
    under Delaware law could make an acquisition of us, which may be
    beneficial to our stockholders, more difficult and may prevent
    attempts by our stockholders to replace or remove our current
    management and limit the market price of our common
    stock.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Provisions in our certificate of incorporation and bylaws, as
    amended and restated upon the closing of this offering, may have
    the effect of delaying or preventing a change of control or
    changes in our management. Our amended and restated certificate
    of incorporation and amended and restated bylaws to become
    effective upon completion of this offering include provisions
    that:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    authorize our Board of Directors to issue, without further
    action by the stockholders, up to 20,000,000&#160;shares of
    undesignated preferred stock;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    require that any action to be taken by our stockholders be
    effected at a duly called annual or special meeting and not by
    written consent;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    specify that special meetings of our stockholders can be called
    only by our Board of Directors, the Chairman of the Board, the
    Chief Executive Officer or the President;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    establish an advance notice procedure for stockholder approvals
    to be brought before an annual meeting of our stockholders,
    including proposed nominations of persons for election to our
    Board of Directors;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    establish that our Board of Directors is divided into three
    classes, Class&#160;I, Class&#160;II and Class&#160;III, with
    each class serving staggered terms;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    provide that our directors may be removed only for cause;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    provide that vacancies on our Board of Directors may be filled
    only by a majority of directors then in office, even though less
    than a quorum;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    specify that no stockholder is permitted to cumulate votes at
    any election of directors;&#160;and
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    require a super-majority of votes to amend certain of the
    above-mentioned provisions.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    These provisions may frustrate or prevent any attempts by our
    stockholders to replace or remove our current management by
    making it more difficult for stockholders to replace members of
    our Board of Directors, which is responsible for appointing the
    members of our management. In addition, because we are
    incorporated in Delaware, we are governed by the provisions of
    Section&#160;203 of the Delaware General Corporation Law, which
    limits the ability of stockholders owning in excess of 15% of
    our outstanding voting stock to merge or combine with us.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We have broad discretion in the use of the net proceeds
    from this offering and may not use them effectively.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We will have broad discretion in the application of the net
    proceeds from this offering and could spend the proceeds in ways
    that do not improve our results of operations or enhance the
    value of our common stock. Our failure to apply these funds
    effectively could have a material adverse effect on our
    business, delay the development of our product candidates and
    cause the price of our common stock to decline.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We have never paid dividends on our capital stock, and we
    do not anticipate paying any cash dividends in the foreseeable
    future.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have paid no cash dividends on any of our classes of capital
    stock to date, have contractual restrictions against paying cash
    dividends and currently intend to retain our future earnings to
    fund the development and growth of our business. As a result,
    capital appreciation, if any, of our common stock will be your
    sole source of gain for the foreseeable future.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    25
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='103'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SPECIAL
    NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This prospectus includes forward-looking statements that relate
    to future events or our future financial performance and involve
    known and unknown risks, uncertainties and other factors that
    may cause our actual results, levels of activity, performance or
    achievements to differ materially from any future results,
    levels of activity, performance or achievements expressed or
    implied by these forward-looking statements. Words such as, but
    not limited to, &#147;believe,&#148; &#147;expect,&#148;
    &#147;anticipate,&#148; &#147;estimate,&#148;
    &#147;intend,&#148; &#147;plan,&#148; &#147;targets,&#148;
    &#147;likely,&#148; &#147;will,&#148; &#147;would,&#148;
    &#147;could,&#148; and similar expressions or phrases, or the
    negative of those expressions or phrases identify
    forward-looking statements. Although we believe that we have a
    reasonable basis for each forward-looking statement contained in
    this prospectus, we caution you that these statements are based
    on our projections of the future that are subject to known and
    unknown risks and uncertainties and other factors that may cause
    our actual results, level of activity, performance or
    achievements expressed or implied by these forward-looking
    statements, to differ. The sections in this prospectus entitled
    &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and
    Analysis of Financial Condition and Results of Operations&#148;
    and &#147;Business,&#148; as well as other sections in this
    prospectus, discuss some of the factors that could contribute to
    these differences.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Other unknown or unpredictable factors also could harm our
    results. Consequently, actual results or developments
    anticipated by us may not be realized or, even if substantially
    realized, may not have the expected consequences to, or effects
    on, us. Given these uncertainties, prospective investors are
    cautioned not to place undue reliance on such forward-looking
    statements. Except as required by law, we undertake no
    obligation to update or revise publicly any of the
    forward-looking statements after the date of this prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This prospectus contains market data that we obtained from
    industry sources. These sources do not guarantee the accuracy or
    completeness of the information. Although we believe that the
    industry sources are reliable, we have not independently
    verified the information. The market data include projections
    that are based on a number of other projections. While we
    believe these assumptions to be reasonable and sound as of the
    date of this prospectus, actual results may differ from the
    projections.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    26
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='104'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">USE OF
    PROCEEDS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We estimate that the net proceeds from the sale
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of our common stock that we are selling in this offering will be
    $&#160;&#160;&#160;&#160;&#160;&#160;million, based on an
    assumed initial public offering price of
    $&#160;&#160;&#160;&#160;&#160; per share, the midpoint of the
    range set forth on the cover page of this prospectus, after
    deducting estimated underwriting discounts and commissions and
    estimated offering expenses payable by us. A $1.00 increase
    (decrease) in the assumed initial public offering price of
    $&#160;&#160;&#160;&#160;&#160; per share would increase
    (decrease) the net proceeds to us by
    $&#160;&#160;&#160;&#160;&#160;&#160;million, after deducting
    estimated underwriting discounts and commissions and estimated
    offering expenses, assuming that the number of shares offered by
    us, as set forth on the cover page of this prospectus, remains
    the same. We may also increase or decrease the number of shares
    we are offering. An increase of 1.0&#160;million shares in the
    number of shares offered by us would increase the net proceeds
    to us by $&#160;&#160;&#160;&#160;&#160;&#160;million.
    Similarly, a decrease of 1.0&#160;million shares in the number
    of shares offered by us would decrease the net proceeds to us by
    $&#160;&#160;&#160;&#160;&#160;&#160;million. If the
    underwriters&#146; over-allotment option is exercised in full,
    we estimate that we will receive net proceeds of
    $&#160;&#160;&#160;&#160;&#160;&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Of the net proceeds that we will receive from this offering, we
    expect to use approximately:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    $&#160;&#160;&#160;&#160;&#160;&#160;million for sales and
    marketing initiatives, including significantly expanding our
    sales force, to support the ongoing commercialization of our
    products;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    $&#160;&#160;&#160;&#160;&#160;million for research and product
    development activities;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    $&#160;&#160;&#160;&#160;&#160;&#160;million to expand our
    facilities and manufacturing operations;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the balance for working capital and other general corporate
    purposes.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We may also use a portion of our net proceeds to acquire and
    invest in complementary products, technologies or businesses;
    however, we currently have no agreements or commitments to
    complete any such transaction and are not involved in
    negotiations to do so. Pending these uses, we intend to invest
    our net proceeds from this offering primarily in
    investment-grade, interest-bearing instruments.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of the date of this prospectus, we cannot specify with
    certainty all of the particular uses for the net proceeds to be
    received upon the completion of this offering. The amount and
    timing of our expenditures will depend on several factors,
    including cash flows from our operations and the anticipated
    growth of our business. Accordingly, our management will have
    broad discretion in the application of the net proceeds and
    investors will be relying on the judgment of our management
    regarding the application of the proceeds from this offering. We
    reserve the right to change the use of these proceeds as a
    result of certain contingencies such as the results of our
    commercialization efforts, competitive developments,
    opportunities to acquire products, technologies or businesses
    and other factors.
</DIV>
<A name='105'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">DIVIDEND
    POLICY</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have never declared or paid any cash dividends on our capital
    stock. We currently intend to retain all future earnings for the
    operation and expansion of our business and, therefore, we do
    not anticipate declaring or paying cash dividends in the
    foreseeable future. In addition, we are subject to several
    covenants under our debt arrangements that place restrictions on
    our ability to pay dividends. The payment of dividends will be
    at the discretion of our Board of Directors and will depend on
    our results of operations, capital requirements, financial
    condition, prospects, contractual arrangements, any limitations
    on payment of dividends present in our current and future debt
    agreements, and other factors that our Board of Directors may
    deem relevant.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    27
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='106'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CAPITALIZATION</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth our capitalization as of
    June&#160;28, 2008:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    on an actual basis;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    on a pro forma basis to give effect to (1) the conversion of all
    outstanding shares of convertible preferred stock into common
    stock and (2)&#160;the reclassification of the convertible
    preferred stock warrant liabilities to additional
    <FONT style="white-space: nowrap">paid-in</FONT>
    capital, each effective upon the closing of this
    offering;&#160;and
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    on a pro forma as adjusted basis to also give effect to the pro
    forma conversions and reclassifications described above and the
    sale
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of our common stock in this offering and the application of the
    net proceeds at the assumed initial public offering price of
    $&#160;&#160;&#160;&#160;&#160; per share, the midpoint of the
    range set forth on the cover page of this prospectus, after
    deducting estimated underwriting discounts and commissions and
    estimated offering expenses payable by us.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You should read this table together with &#147;Management&#146;s
    Discussion and Analysis of Financial Condition and Results of
    Operations&#148; and our consolidated financial statements and
    related notes included elsewhere in this prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="66%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of June&#160;28, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Pro Forma<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Actual</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Pro Forma</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>as
    Adjusted<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>(unaudited)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>(in thousands, except per share amounts)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Long-term debt, net of current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10,477
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible preferred stock warrant liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,269
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible preferred stock issuable in series, $0.001&#160;par
    value: 61,798&#160;shares authorized, 58,191&#160;shares issued
    and outstanding (actual); no shares authorized, issued or
    outstanding (pro forma and pro forma as adjusted)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    167,538
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Stockholders&#146; equity (deficit):
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Common stock, $0.001&#160;par value: 87,386&#160;shares
    authorized, 10,003&#160;shares issued and outstanding
    (actual);&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    authorized,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    issued and outstanding (pro
    forma);&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    authorized,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    issued and outstanding (pro forma as adjusted)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Preferred stock, $0.001 par value: no shares authorized, issued
    or outstanding
    (actual);&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    authorized, no shares issued or outstanding (pro forma and pro
    forma as adjusted)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Additional paid-in
    capital<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,383
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accumulated other comprehensive loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (241
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accumulated deficit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (149,060
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total stockholders&#146; equity
    (deficit)<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (144,908
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total
    capitalization<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    34,376
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">A $1.00 increase (decrease) in the
    assumed initial public offering price of
    $&#160;&#160;&#160;&#160;&#160; per share, the midpoint of the
    range set forth on the cover page of this prospectus, would
    increase (decrease) each of additional paid-in capital, total
    stockholders&#146; equity and total capitalization by
    $&#160;&#160;&#160;&#160;&#160;&#160;million, assuming that the
    number of shares offered by us, as set forth on the cover page
    of this prospectus, remains the same, and after deducting
    estimated underwriting discounts and commissions and estimated
    offering expenses payable by us. Each increase of
    1.0&#160;million shares in the number of shares offered by us,
    together with a $1.00 increase in the assumed offering price of
    $&#160;&#160;&#160;&#160;&#160; per share, would increase
    additional paid-in capital, total stockholders&#146; equity and
    total capitalization by approximately
    $&#160;&#160;&#160;&#160;&#160;&#160;million. Similarly, each
    decrease of 1.0&#160;million shares in the number of shares
    offered by us, together with a $1.00 decrease in the assumed
    offering price of $&#160;&#160;&#160;&#160;&#160; per share,
    would decrease additional paid-in capital, total
    stockholders&#146; equity and total capitalization by
    approximately $&#160;&#160;&#160;&#160;&#160;&#160;million. The
    pro forma
    </FONT></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    28
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">as adjusted information discussed
    above is illustrative only and will be adjusted based on the
    actual public offering price and terms of this offering
    determined at pricing.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The table above excludes the following shares:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    8,309,725&#160;shares of common stock issuable upon exercise of
    options outstanding as of June&#160;28, 2008 at a weighted
    average exercise price of $1.56&#160;per share;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    757,436&#160;shares of common stock issuable upon the exercise
    of warrants outstanding as of June&#160;28, 2008 at a weighted
    average exercise price of $3.26&#160;per share, after conversion
    of our convertible preferred stock;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    9,105,546&#160;shares of common stock reserved for future
    issuance under our stock-based compensation plans, including
    7,000,000&#160;shares of common stock reserved for issuance
    under our 2008 Equity Incentive Plan, and any future increase in
    shares reserved for issuance under such plan, each of which will
    become effective on the date of this prospectus; and
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    23,750&#160;shares of common stock that were legally issued and
    outstanding but were not included in stockholders&#146; deficit
    as of June&#160;28, 2008 pursuant to accounting principles
    generally accepted in the United States, as these shares were
    subject to a right of repurchase by us.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    29
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='107'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">DILUTION</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If you invest in our common stock, your interest will be diluted
    to the extent of the difference between the amount per share
    paid by purchasers of shares of common stock in this initial
    public offering and the pro forma as adjusted net tangible book
    value per share of common stock immediately after completion of
    this offering.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our pro forma net tangible book value as of June&#160;28, 2008,
    in the amount of $23.5&#160;million, or $0.34 per share, was
    based on the total number of shares of our common stock
    outstanding as of June&#160;28, 2008, after giving effect to
    (1)&#160;the conversion of all outstanding shares of our
    convertible preferred stock into common stock and (2)&#160;the
    reclassification of the convertible preferred stock warrant
    liabilities to additional
    <FONT style="white-space: nowrap">paid-in</FONT>
    capital, each effective upon the closing of this offering.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After giving effect to our sale
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock in this offering at an assumed initial public
    offering price of $&#160;&#160;&#160;&#160;&#160; per share, the
    midpoint of the range set forth on the cover page of this
    prospectus, and after deducting the estimated underwriting
    discounts and commissions and estimated offering expenses, our
    pro forma as adjusted net tangible book value as of
    June&#160;28, 2008 would have been
    $&#160;&#160;&#160;&#160;&#160;&#160;million, or
    $&#160;&#160;&#160;&#160;&#160; per share. This represents an
    immediate increase in net tangible book value of
    $&#160;&#160;&#160;&#160;&#160; per share to existing
    stockholders and an immediate dilution in net tangible book
    value of $&#160;&#160;&#160;&#160;&#160; per share to purchasers
    of common stock in this offering, as illustrated in the
    following table:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="84%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Assumed initial public offering price per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Pro forma net tangible book value per share as of June&#160;28,
    2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.34
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Increase in pro forma as adjusted net tangible book value per
    share attributable to new investors
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pro forma as adjusted net tangible book value per share after
    this offering
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pro forma dilution per share to new investors in this offering
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each $1.00 increase (decrease) in the assumed public offering
    price of $&#160;&#160;&#160;&#160;&#160; per share, the midpoint
    of the range set forth on the cover of this prospectus, would
    increase (decrease) our pro forma as adjusted net tangible book
    value by approximately
    $&#160;&#160;&#160;&#160;&#160;&#160;million, or approximately
    $&#160;&#160;&#160;&#160;&#160; per share, and the pro forma
    dilution per share to investors in this offering by
    approximately $&#160;&#160;&#160;&#160;&#160; per share,
    assuming that the number of shares offered by us, as set forth
    on the cover page of this prospectus, remains the same and after
    deducting estimated underwriting discounts and commissions and
    estimated offering expenses payable by us. We may also increase
    or decrease the number of shares we are offering. An increase of
    1.0&#160;million shares in the number of shares offered by us,
    together with a $1.00 increase in the assumed offering price of
    $&#160;&#160;&#160;&#160;&#160; per share, would result in a pro
    forma as adjusted net tangible book value of approximately
    $&#160;&#160;&#160;&#160;&#160;&#160;million, or
    $&#160;&#160;&#160;&#160;&#160; per share, and the pro forma
    dilution per share to investors in this offering would be
    $&#160;&#160;&#160;&#160;&#160; per share. Similarly, a decrease
    of 1.0&#160;million shares in the number of shares offered by
    us, together with a $1.00 decrease in the assumed public
    offering price of $&#160;&#160;&#160;&#160;&#160; per share,
    would result in an pro forma as adjusted net tangible book value
    of approximately $&#160;&#160;&#160;&#160;&#160;&#160;million,
    or $&#160;&#160;&#160;&#160;&#160; per share, and the pro forma
    dilution per share to investors in this offering would be
    $&#160;&#160;&#160;&#160;&#160; per share. The pro forma as
    adjusted information discussed above is illustrative only and
    will be adjusted based on the actual public offering price and
    other terms of this offering determined at pricing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If the underwriters&#146; over-allotment option is exercised in
    full, the pro forma as adjusted net tangible book value per
    share after this offering would be
    $&#160;&#160;&#160;&#160;&#160; per share, the increase in pro
    forma as adjusted net tangible book value per share to existing
    stockholders would be $&#160;&#160;&#160;&#160;&#160; per share
    and the dilution to new investors purchasing shares in this
    offering would be $&#160;&#160;&#160;&#160;&#160; per share.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    30
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table presents on a pro forma as adjusted basis as
    of June&#160;28, 2008, after giving effect to the automatic
    conversion of all outstanding shares of convertible preferred
    stock into common stock, the differences between the existing
    stockholders and the purchasers of shares in this offering with
    respect to the number of shares purchased from us, the total
    consideration paid, which includes net proceeds received from
    the issuance of common and convertible preferred stock, cash
    received from the exercise of stock options, the value of any
    stock issued for services and the proceeds from the issuance of
    convertible promissory notes which were subsequently converted
    to shares of convertible preferred stock, and the average price
    paid per share (in thousands, except per share amounts and
    percentages):
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="49%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares Purchased</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Total Consideration</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Average Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Number</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Percent</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Amount</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Percent</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Per Share</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Existing stockholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68,218
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    168,914
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.48
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    New investors
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Totals
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Each $1.00 increase (decrease) in
    the assumed initial public offering price of
    $&#160;&#160;&#160;&#160;&#160; per share, the midpoint of the
    range set forth on the cover page of this prospectus, would
    increase (decrease) the total consideration paid to us by new
    investors and total consideration paid to us by all stockholder
    by $&#160;&#160;&#160;&#160;&#160;&#160;million, assuming that
    the number of shares offered by us, as set forth on the cover
    page of this prospectus, remains the same, and after deducting
    estimated underwriting discounts and commissions and estimated
    offering expenses payable by us. An increase of 1.0&#160;million
    shares in the number of shares offered by us would increase the
    total consideration paid to us by new investors and total
    consideration paid to us by all stockholder by
    $&#160;&#160;&#160;&#160;&#160;&#160;million. Similarly, a
    decrease of 1.0&#160;million shares in the number of shares
    offered by us would decrease the total consideration paid to us
    by new investors and total consideration paid to us by all
    stockholder by $&#160;&#160;&#160;&#160;&#160;&#160;million.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If the underwriters exercise their over-allotment option in
    full, our existing stockholders would
    own&#160;&#160;&#160;&#160;&#160;% and our new investors would
    own&#160;&#160;&#160;&#160;&#160;% of the total number of shares
    of our common stock outstanding after this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The table above excludes the following shares:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    8,309,725&#160;shares of common stock issuable upon exercise of
    options outstanding as of June&#160;28, 2008 at a weighted
    average exercise price of $1.56 per share;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    757,436&#160;shares of common stock issuable upon the exercise
    of warrants outstanding as of June&#160;28, 2008 at a weighted
    average exercise price of $3.26 per share, after conversion of
    our convertible preferred stock;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    9,105,546&#160;shares of common stock reserved for future
    issuance under our stock-based compensation plans, including
    7,000,000&#160;shares of common stock reserved for issuance
    under our 2008 Equity Incentive Plan, and any future increase in
    shares reserved for issuance under such plan, each of which will
    become effective on the date of this prospectus; and
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    23,750&#160;shares of common stock that were legally issued and
    outstanding but were not included in stockholders&#146; deficit
    as of June&#160;28, 2008 pursuant to accounting principles
    generally accepted in the United States, as these shares were
    subject to a right of repurchase by us.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Assuming the exercise in full of the outstanding options and
    warrants, pro forma net tangible book value before this offering
    at June&#160;28, 2008 would be $&#160;&#160;&#160;&#160;&#160;
    per share, and after giving effect to the sale of shares in this
    offering, there would be immediate dilution of
    $&#160;&#160;&#160;&#160;&#160; per share to new investors in
    this offering.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Effective upon the closing of this offering, an aggregate
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of our common stock will be reserved for future issuance under
    our stock-based compensation plans. To the extent that any of
    these options or warrants are exercised, new options are issued
    under our stock-based compensation plans or we issue additional
    shares of common stock in the future, there will be further
    dilution to investors participating in this offering.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    31
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='108'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SELECTED
    CONSOLIDATED FINANCIAL DATA</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
</A>
<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have derived the selected consolidated statement of
    operations data for the years ended December&#160;31, 2005,
    December&#160;31, 2006 and December&#160;29, 2007 and the
    selected consolidated balance sheet data as of December&#160;31,
    2006 and December&#160;29, 2007 from our audited consolidated
    financial statements included elsewhere in this prospectus. We
    have derived the summary consolidated statement of operations
    data for the six months ended June&#160;30, 2007 and
    June&#160;28, 2008 and the consolidated balance sheet data as of
    June&#160;28, 2008 from our unaudited consolidated financial
    statements included elsewhere in this prospectus. We have
    derived the selected consolidated statement of operations data
    for the years ended December&#160;31, 2003 and 2004 and the
    selected consolidated balance sheet data as of December&#160;31,
    2003, 2004 and 2005 from our audited consolidated financial
    statements not included in this prospectus. Our historical
    results are not necessarily indicative of the results to be
    expected for any future period. The following selected
    consolidated financial data should be read in conjunction with
    &#147;Management&#146;s Discussion and Analysis of Financial
    Condition and Results of Operations&#148; and our consolidated
    financial statements and related notes included elsewhere in
    this prospectus.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="36%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Six Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2003</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2004</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="26" align="center" valign="bottom">
    <B>(in thousands, except per share amounts)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Consolidated Statement of Operations Data:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Revenue:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,133
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,603
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,076
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,959
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,489
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,382
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Collaboration revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    366
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,568
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,376
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    460
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    310
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Grant revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,063
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,364
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,198
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Total revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,133
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,039
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,674
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,997
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,520
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Costs and expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Cost of product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,918
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,362
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,764
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,773
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,514
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,490
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,988
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Research and development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,218
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,608
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,449
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,389
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,053
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,151
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Selling, general and administrative
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,263
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,690
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,955
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,898
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,183
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,843
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Total costs and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,399
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,660
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,168
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,801
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,726
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,982
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 32pt">
    Loss from operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,266
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,621
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,494
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,663
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,526
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11,729
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,462
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (305
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (508
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (898
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,261
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,790
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,790
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,100
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    267
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    291
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,140
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Other income (expense), net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (194
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (170
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (214
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Loss before provision for income taxes and cumulative of change
    in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,304
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,838
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,022
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,346
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,917
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,219
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Provision for income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (105
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (52
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (43
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Loss before cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,304
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,838
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,022
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,969
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,262
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    637
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (17,304
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,838
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (12,969
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (15,262
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net loss per share of common stock, basic and
    diluted<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.23
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.98
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.82
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.53
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.35
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.54
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Shares used in computing net loss per share of common stock,
    basic and
    diluted<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,775
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,505
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,316
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,577
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,912
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Please see Note&#160;2 to our
    consolidated financial statements for an explanation of the
    method used to calculate basic and diluted net loss per share of
    common stock.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    32
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="36%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="22" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2003</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2004</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="22" align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Consolidated Balance Sheet Data:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cash and cash equivalents and
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    28,874
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    12,520
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    19,659
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    25,518
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    40,363
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    32,469
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Working capital
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,689
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,710
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,764
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,939
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,754
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,644
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,908
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,493
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,776
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,678
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Long-term debt
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,261
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,111
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,838
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,362
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,558
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Convertible promissory notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,072
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,997
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Convertible preferred stock warrant liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    814
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    223
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    468
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,269
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Convertible preferred stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75,072
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,596
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,966
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    112,295
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    162,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    167,538
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total stockholder&#146;s deficit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (49,812
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (65,471
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (83,154
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (106,172
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (130,331
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (144,908
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    33
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='109'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">MANAGEMENT&#146;S
    DISCUSSION AND ANALYSIS OF<BR>
    FINANCIAL CONDITION AND RESULTS OF OPERATIONS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>The following discussion and analysis of the financial
    condition and results of our operations should be read in
    conjunction with the consolidated financial statements and
    related notes included elsewhere in this prospectus. This
    discussion contains forward-looking statements that involve
    risks and uncertainties. Our actual results could differ
    materially from those discussed below. Factors that could cause
    or contribute to such differences include, but are not limited
    to, those identified below, and those discussed in the section
    titled &#147;Risk Factors&#148; included elsewhere in this
    prospectus.</I>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Overview</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We develop, manufacture and market proprietary Integrated
    Fluidic Circuit systems that significantly improve productivity
    in the life science industry. Our Integrated Fluidic Circuits,
    or IFCs, enable the simultaneous performance of thousands of
    biochemical measurements in extremely minute volumes. We created
    this &#147;integrated circuit for biology&#148; by
    miniaturizing, integrating and automating sophisticated liquid
    handling processes on a single microfabricated device.
    Particularly in large-scale experimentation, our IFC systems,
    consisting of instrumentation, software and single-use IFCs,
    increase throughput, decrease costs and enhance sensitivity
    compared to conventional laboratory systems. We have sold our
    IFCs to over 100 customers, including many leading biotechnology
    and pharmaceutical companies, academic institutions, and life
    science laboratories worldwide.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have commercialized IFC systems for a wide range of life
    science applications, including our BioMark system for gene
    expression analysis, genotyping and digital PCR, and our Topaz
    system for protein crystallization. Researchers and clinicians
    have successfully employed our products to help achieve
    breakthroughs in the fields of genetic variation, cellular
    function and structural biology. We believe that the broad
    applicability of our IFC technology will lead to the development
    of IFC systems for a wide variety of additional markets and
    applications, including high-throughput DNA sequencing and
    molecular diagnostics.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We were founded in 1999. In the first quarter of 2003, we
    introduced our first product line, the Topaz system for protein
    crystallization based on our first generation Topaz IFC. In
    subsequent years, we enhanced the capability of the Topaz system
    by introducing IFCs with increased throughput. Prior to 2007,
    Topaz system products accounted for substantially all of our
    product revenue. In the fourth quarter of 2006, we announced the
    commercial availability of our BioMark system. We currently sell
    two types of single-use IFCs for use with the BioMark system,
    the Dynamic Array for gene expression and genotyping and the
    Digital Array for digital PCR.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have incurred significant losses since our inception,
    including net losses of $16.4&#160;million, $23.6&#160;million,
    $25.5&#160;million and $15.3&#160;million in 2005, 2006, 2007
    and the six months ended June&#160;28, 2008. As of June&#160;28,
    2008, we had an accumulated deficit of $149.1&#160;million. We
    sell our IFC systems around the world. For 2007 and the six
    months ended June&#160;28, 2008, customers in North America
    accounted for approximately 48% and 46% of our total revenue,
    European customers accounted for 10% and 17% and Asia-Pacific
    customers accounted for 42% and 37%. We distribute our systems
    through our direct field sales and support organizations located
    in North America, Europe and Asia-Pacific and through
    distributors or sales agents in several European and
    Asia-Pacific countries. Our manufacturing operations are located
    in Singapore and South San&#160;Francisco. Our facility in
    Singapore fabricates all of our IFCs for commercial sale and
    some IFCs for our own research and development purposes and
    assembles certain elements of our BioMark and Topaz
    instrumentation. Our South San&#160;Francisco facility also
    assembles certain elements of our BioMark and Topaz
    instrumentation and fabricates IFCs for our own research and
    development purposes.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Since 2002, we have received significant revenue from government
    grants. Our most significant grant relationship has been with
    the Singapore Economic Development Board, or EDB. The EDB, an
    agency of the Government of Singapore, promotes research,
    development and manufacturing activities in Singapore and
    associated employment of Singapore nationals by providing
    incentive grants to companies willing to conduct operations in
    Singapore and satisfy the requirements of EDB&#146;s government
    programs. Under our agreements with EDB, we are eligible to
    receive incentive grant payments from EDB, provided we satisfy
    agreed upon targets for increasing levels of research,
    development and manufacturing activity in Singapore, including
    the use of local service providers, the hiring of personnel in
    Singapore, local spending in Singapore, our receipt of new
    equity investment, and our achievement of agreed upon targets
    relating to new product development or completion of
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    34
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    specific manufacturing process objectives. If we satisfy the
    grant conditions, we receive incentive grant payments equal to a
    portion of the qualifying expenses we incur in Singapore,
    relating to salaries, overhead, outsourcing and subcontracting
    expenses, operating expenses and royalties paid. Expenses not
    qualifying for the incentive grant program include raw materials
    purchases. We submit requests to EDB for incentive grant
    payments on a quarterly basis, and these requests are subject to
    EDB&#146;s review and our satisfaction of the grant conditions.
    Together these agreements provide for incentive funding
    eligibility through 2011, subject to our compliance with the
    requirements of these agreements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, we have entered into collaboration and license
    agreements with other parties that generally provide us with
    up-front and periodic milestone fees or fees based on agreed
    upon rates for time incurred by our research staff.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Fiscal
    Year Presentation</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During the year ended December&#160;29, 2007, we adopted a 52 or
    53&#160;week year convention for our fiscal years and,
    therefore, our 2007 fiscal year ended on December&#160;29, 2007
    and the first six month periods of 2007 and 2008 ended on
    June&#160;30, 2007 and June&#160;28, 2008. Future fiscal years
    will end on the last Saturday in December of each year. Prior to
    the adoption of this method, we reported our fiscal years on a
    calendar basis. The fiscal years discussed in this
    management&#146;s discussion and analysis of financial condition
    and results of operations ended on December&#160;31, 2005,
    December&#160;31, 2006 and December&#160;29, 2007.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Critical
    Accounting Policies, Significant Judgments and
    Estimates</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our consolidated financial statements and the related notes
    included elsewhere in this prospectus are prepared in accordance
    with accounting principles generally accepted in the United
    States. The preparation of these consolidated financial
    statements requires us to make estimates and assumptions that
    affect the reported amounts of assets, liabilities, revenues,
    costs and expenses and related disclosures. We base our
    estimates on historical experience and on various other
    assumptions that we believe to be reasonable under the
    circumstances. Changes in the accounting estimates are
    reasonably likely to occur from period to period. Accordingly,
    actual results could differ significantly from the estimates
    made by our management. We evaluate our estimates and
    assumptions on an ongoing basis. To the extent that there are
    material differences between these estimates and actual results,
    our future financial statement presentation, financial
    condition, results of operations and cash flows will be affected.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that the following critical accounting policies
    involve a greater degree of judgment and complexity than our
    other accounting policies. Accordingly, these are the policies
    we believe are the most critical to understanding and evaluating
    our consolidated financial condition and results of operations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Revenue
    Recognition</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We generate revenue from sales of our products and services,
    collaboration agreements and government grants. Our products
    consist of single-use IFCs, various instruments and software
    related to our BioMark and Topaz systems. Our services include
    system installation, training and customer support services. We
    also have entered into a number of research and development
    contracts and have received government grants to conduct
    research and development activities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We record revenue in accordance with the guidelines established
    by the Securities and Exchange Commission, or SEC, Staff
    Accounting Bulletin&#160;No.&#160;104, <I>Revenue
    Recognition</I>, or SAB&#160;104. In addition, we have concluded
    that software included with certain of our instruments is
    essential to their functionality. In these instances, we apply
    AICPA Statement of Position
    <FONT style="white-space: nowrap">97-2,</FONT>
    <I>Software Revenue Recognition</I>, or
    <FONT style="white-space: nowrap">SOP&#160;97-2.</FONT>
    If the arrangement includes IFCs, we use the separation criteria
    in EITF Issue
    <FONT style="white-space: nowrap">No.&#160;00-21,</FONT>
    <I>Revenue Arrangements with Multiple Deliverables, </I>to
    separate revenues related to IFCs, which are non-software
    related deliverables, from software related deliverables.
    Revenue is recognized when all of the following criteria are
    met: persuasive evidence of an arrangement exists, delivery has
    occurred or services rendered, the price to the buyer is fixed
    or determinable and collectibility is reasonably assured. The
    evaluation of these revenue recognition criteria requires
    significant management judgment. For instance, we use judgment
    to assess collectibility based on factors such as the
    customer&#146;s creditworthiness and past collection history, if
    applicable. If we determine that collection of a payment is not
    reasonably assured, revenue
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    35
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    recognition is deferred until the time collection becomes
    reasonably assured, which is generally upon receipt of payment.
    We also use judgment to assess whether a price is fixed or
    determinable by reviewing contractual terms and conditions
    related to payment terms.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2007, and thereafter, no right of return existed for our
    products. In prior years, if an agreement included a right of
    return, the related revenue was deferred until the right had
    lapsed. Historically, we have not experienced any significant
    returns of our products. Also, accruals are provided for
    estimated warranty expenses at the time that the associated
    revenue is recognized. We use judgment to estimate these
    accruals and, if we were to experience an increase in warranty
    claims or if costs of servicing our products under warranty were
    greater than our estimates, our gross margins could be adversely
    affected in future periods.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Some of our sales contracts which include items such as our
    BioMark instrument systems or our Topaz readers involve the
    delivery or performance of multiple products and services within
    contractually binding arrangements. Significant contract
    interpretation is sometimes required to determine the
    appropriate accounting, including whether the deliverables
    specified in a multiple element arrangement should be treated as
    separate units of accounting for revenue recognition purposes,
    and, if so, how the price should be allocated among the
    elements, when to recognize revenue for each element, and the
    period over which revenue should be recognized. We use judgment
    to evaluate whether a delivered item has value on a stand-alone
    basis prior to delivery of the remaining items by determining
    whether we have made separate sales of such items or whether the
    undelivered items are essential to the functionality of the
    delivered items. Further, we use judgment to evaluate whether
    there is vendor-specific objective evidence, or VSOE, of fair
    value of the undelivered items, determined by reference to
    stand-alone sales of such items. We recognize revenue for
    delivered elements only when we determine that the fair values
    of undelivered elements are known. For a multiple element
    arrangement that includes both IFCs and instruments we separate
    these elements into separate units of accounting as we consider
    these elements to have standalone value to the customer. We
    recognize revenue for the IFCs under SAB&#160;104 and the
    instruments under SAB&#160;104 or
    <FONT style="white-space: nowrap">SOP&#160;97-2,</FONT>
    as applicable. If the fair value of any undelivered item related
    to instruments and software included in a multiple element
    arrangement cannot be objectively determined, revenue will be
    deferred until all items are delivered, or until fair value can
    objectively be determined for any remaining undelivered items.
    However, if the only such undelivered element is post-contract
    customer support services, such as maintenance agreements for
    which VSOE has not been established, the entire revenue is
    recognized ratably over the service period. Recognition of
    revenue from these arrangements generally begins upon
    installation of the instruments as installation is deemed
    essential to the functionality of the instruments. The
    corresponding costs of products sold related to multiple element
    arrangements are also deferred and amortized over the same
    period.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our deferred revenue balance increased by $1.6&#160;million
    during 2007 and decreased by $0.3&#160;million during the six
    months ended June&#160;28, 2008. The increase during 2007 was
    primarily due to the increase in sales of our BioMark instrument
    systems, all of which included maintenance agreements. We expect
    to establish VSOE for post-contract customer support during the
    second half of 2008 as we enter into renewal agreements for
    maintenance with our customers upon the expiration of the
    initial agreements. If we are able to establish VSOE for
    post-contract customer support, our deferred revenue balance
    will decrease in future periods.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Changes in judgments and estimates regarding application of
    these revenue recognition guidelines as well as changes in facts
    and circumstances including the establishment of VSOE of fair
    value could result in a change in the timing or amount of
    revenue recognized in future periods.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Revenue from the sales of our products that are not part of a
    multiple element arrangement is recognized when no significant
    obligations remain undelivered and collection of the receivables
    is reasonably assured, which is generally upon shipment of the
    product and transfer of title to the customer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into collaboration research and development
    arrangements that generally provide us with up-front and
    periodic milestone fees or fees based on agreed upon rates for
    time incurred by our research staff. Revenue is recognized
    either ratably over the term of the agreement or as time is
    incurred on the project. Revenue from government grants is for
    the achievement of agreed upon milestones and expenditures and
    is recognized in the period in which the related costs are
    incurred, provided that the conditions under which the
    government grants are awarded have been substantially met and
    only perfunctory obligations remain outstanding.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    36
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Stock-Based
    Compensation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to January&#160;1, 2006, we accounted for our stock
    options granted to employees using the intrinsic value method
    prescribed by Accounting Principles Board Opinion No.&#160;25,
    <I>Accounting for Stock Issued to Employees</I>, or APB 25, and
    related interpretations as permitted by Statement of Financial
    Accounting Standards, or SFAS&#160;No.&#160;123, <I>Accounting
    for Stock-Based Compensation</I>, or SFAS&#160;123, and
    SFAS&#160;No.&#160;148, <I>Accounting for Stock-Based
    Compensation&#160;&#151; Transaction and Disclosure</I>, or
    SFAS&#160;148. Accordingly, any compensation cost relating to
    stock options was recorded on the date of the grant in
    stockholders&#146; equity as deferred compensation and was
    thereafter amortized to expense over the vesting period of the
    grant, which was generally four years. We amortized deferred
    stock-based compensation using the multiple option method as
    prescribed by FASB Interpretation No.&#160;28, <I>Accounting for
    Stock Appreciation Rights and Other Variable Stock Option or
    Award Plans</I>, or FIN&#160;28, over the option vesting period
    using an accelerated amortization schedule.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Effective January&#160;1, 2006, we adopted the fair value
    recognition provisions of SFAS&#160;No.&#160;123 (revised 2004),
    <I>Share-Based Payment</I>, or SFAS&#160;123(R), which requires
    companies to measure the cost of employee services received in
    exchange for an award of equity instruments, including stock
    options, based on the grant date fair value of the award. The
    fair value is estimated using the Black-Scholes option-pricing
    model. The resulting cost is recognized over the period during
    which an employee is required to provide service in exchange for
    the award, usually the vesting period.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We adopted SFAS&#160;123(R) using the prospective-transition
    method as all prior grants were measured using the minimum value
    method for the pro forma disclosures previously required by
    SFAS&#160;123. The prospective-transition method requires us to
    continue to apply APB 25 in future periods to equity awards
    outstanding at the date of our adoption of SFAS&#160;123(R) on
    January&#160;1, 2006. Under the prospective-transition method,
    any compensation costs that will be recognized from
    January&#160;1, 2006 will include only: (a)&#160;compensation
    cost for all stock-based awards granted prior to, but not yet
    vested as of, December&#160;31, 2005, based on the intrinsic
    value method in accordance with the provisions of ABP 25; and
    (b)&#160;compensation cost for all stock-based awards granted or
    modified subsequent to December&#160;31, 2005, net of estimated
    forfeitures, based on the grant date fair value estimated in
    accordance with the provisions of SFAS&#160;123(R). We amortize
    the fair value of stock-based compensation under
    SFAS&#160;123(R) on a straight-line basis. In accordance with
    the prospective-transition method as prescribed under
    SFAS&#160;123(R), results for prior periods are not restated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We account for stock options issued to nonemployees in
    accordance with the provisions of SFAS 123(R) and EITF Issue No.
    96-18, <I>Accounting for Equity Instruments That Are Issued to
    Other Than Employees for Acquiring, or in Conjunction with
    Selling, Goods or Services,</I> or EITF
    <FONT style="white-space: nowrap">96-18.</FONT> In
    accordance with SFAS 123(R) and EITF
    <FONT style="white-space: nowrap">96-18,</FONT> stock
    options issued to nonemployees are accounted for at their
    estimated fair value determined using the Black-Scholes
    option-pricing model. The fair value of the options granted to
    nonemployees is remeasured as they vest, and the resulting
    increase in value, if any, is recognized as expense during the
    period the related services are rendered.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We use the Black-Scholes option-pricing model to calculate the
    fair value of our options on the grant date. This model requires
    inputs such as expected term, expected volatility and risk-free
    interest rate. Further, the forfeiture rate also affects the
    amount of aggregate compensation. These inputs are subjective
    and generally require significant judgment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our expected volatility is derived from the historical
    volatilities of several unrelated public companies within the
    life science industry because we have little information on the
    volatility of the price of our common stock since we have no
    trading history. When making the selections of our industry peer
    companies to be used in the volatility calculation, we also
    considered the stage of development, size and financial leverage
    of potential comparable companies. Our historical volatility is
    weighted based on certain qualitative factors and combined to
    produce a single volatility factor. The risk-free interest rate
    is based on the U.S.&#160;Treasury yield in effect at the time
    of grant for zero coupon U.S.&#160;Treasury notes with
    maturities approximately equal to each grant&#146;s expected
    life. Given our limited history to accurately estimate the
    expected lives for the various employee groups, we used the
    &#145;simplified&#146; method as provided by Staff Accounting
    Bulletin&#160;No.&#160;107, <I>Share Based Payment</I>. The
    &#145;simplified&#146; method is calculated as the average of
    the
    <FONT style="white-space: nowrap">time-to-vesting</FONT>
    and the contractual life of the options.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    37
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Beginning on January&#160;1, 2006 upon the adoption of
    SFAS&#160;123(R), the fair value of each new option awarded was
    estimated on the grant date for the periods below using the
    Black-Scholes option-pricing model with the following
    weighted-average assumptions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="61%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="8%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="8%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="15%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Six Months Ended<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;28,&#160;2008</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected volatility
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    72.8%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    63.0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    53.8%
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected life
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    6.1&#160;years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    6.0&#160;years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    6.0 years
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Risk-free interest rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4.8%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4.4%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    3.2%
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dividend yield
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If in the future we determine that another method is more
    reasonable, or if another method for calculating these input
    assumptions is prescribed by authoritative guidance, and,
    therefore, should be used to estimate expected volatility or
    expected life, the fair value calculated for our stock options
    could change significantly. Higher volatility and longer
    expected lives result in an increase to stock-based compensation
    expense determined at the date of grant. Stock-based
    compensation expense affects our cost of revenue, research and
    development expense, and selling, general and administrative
    expense.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We estimate our forfeiture rate based on an analysis of our
    actual forfeitures and will continue to evaluate the
    appropriateness of the forfeiture rate based on actual
    forfeiture experience, analysis of employee turnover behavior
    and other factors. Quarterly changes in the estimated forfeiture
    rate can have a significant effect on reported stock-based
    compensation expense, as the cumulative effect of adjusting the
    rate for all expense amortization is recognized in the period
    the forfeiture estimate is changed. If a revised forfeiture rate
    is higher than the previously estimated forfeiture rate, an
    adjustment is made that will result in a decrease to the
    stock-based compensation expense recognized in the consolidated
    financial statements. If a revised forfeiture rate is lower than
    the previously estimated forfeiture rate, an adjustment is made
    that will result in an increase to the stock-based compensation
    expense recognized in the consolidated financial statements. The
    effect of forfeiture adjustments during 2006, 2007 and the six
    months ended June&#160;28, 2008 was insignificant. We will
    continue to use judgment in evaluating the expected term,
    volatility and forfeiture rate related to our own stock-based
    compensation on a prospective basis and incorporating these
    factors into the Black-Scholes option-pricing model.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Also required for the fair value calculation of the options is
    the fair value of the underlying common stock. We have
    historically granted stock options with exercise prices no less
    than the fair market value of our common stock as determined at
    the date of grant by our Board of Directors with input from
    management. The following table summarizes, by grant date, the
    number of stock options granted since January&#160;1, 2007 and
    the associated per share exercise price, which equaled the fair
    value of our common stock for each of these grants.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="74%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>and Fair Value<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Per Share of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Grant Date</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Granted</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Common Stock</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    May&#160;8, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,613,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    September&#160;20, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    December&#160;28, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    328,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    February&#160;7, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    723,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    April&#160;24, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,913,725
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3.19
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    June&#160;26, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    85,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3.42
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Given the absence of an active market for our common stock prior
    to this offering, our Board of Directors determined the fair
    value of our common stock for our grants of stock options. Our
    Board of Directors determined the estimated fair value of our
    common stock based in part on an analysis of relevant metrics,
    including the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the prices of our convertible preferred stock sold to outside
    investors in arms-length transactions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the rights, preferences and privileges of our convertible
    preferred stock relative to those of our common stock;
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    38
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the rights of freestanding warrants and other similar
    instruments related to shares that are redeemable;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our operating and financial performance;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the hiring of key personnel;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the introduction of new products;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our stage of development;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the fact that the option grants involve illiquid securities in a
    private company;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the risks inherent in the development and expansion of our
    products and services;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the likelihood of achieving a liquidity event, such as an
    initial public offering or sale of our company given prevailing
    market conditions.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    From January&#160;2007 through June&#160;2008, our Board of
    Directors performed contemporaneous valuations of our common
    stock for each grant of stock options during this period.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The valuations were prepared using the market approach and the
    income approach to estimate our aggregate enterprise value at
    each valuation date. The market approach measures the value of a
    company through the analysis of recent sales of comparable
    companies. Consideration is given to the financial condition and
    operating performance of the company being valued relative to
    those of publicly traded companies operating in the same or
    similar lines of business. When choosing the comparable
    companies to be used for the market approach, we focused on
    companies in the life science industry. Some of the specific
    criteria used to select comparable companies within this
    industry include the business description, business size,
    projected growth, financial condition and historical earnings.
    The income approach measures the value of a company as the
    present value of its future economic benefits by applying an
    appropriate risk-adjusted discount rate to expected cash flows,
    based on forecasted revenue and costs. We prepared a financial
    forecast for each valuation report to be used in the computation
    of the enterprise value for both the market approach and the
    income approach. The financial forecasts took into account our
    past experience and future expectations. The risks associated
    with achieving these forecasts were assessed in selecting the
    appropriate discount rate. There is inherent uncertainty in
    these estimates.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In assessing the fair value of our common stock, our Board of
    Directors applied an equal weighting to the value indications
    presented by the income approach and market approach. In order
    to arrive at the estimated fair value of our common stock, the
    indicated enterprise value of our company calculated at each
    valuation date was allocated to the shares of convertible
    preferred stock and the warrants to purchase these shares, and
    shares of common stock and the options to purchase these shares
    using an option-pricing methodology. The option-pricing method
    treats common stock and preferred stock as call options on the
    total equity value of a company, with exercise prices based on
    the value thresholds at which the allocation among the various
    holders of a company&#146;s securities changes. Under this
    method, the common stock has value only if the funds available
    for distribution to stockholders exceed the value of the
    liquidation preference at the time of a liquidity event, such as
    a strategic sale, merger or initial public offering, assuming
    the enterprise has funds available to make a liquidation
    preference meaningful and collectable by the holders of
    preferred stock. The common stock is modeled as a call option on
    the underlying equity value at a predetermined exercise price.
    In the model, the exercise price is based on a comparison with
    the total equity value rather than, as in the case of a regular
    call option, a comparison with a per share stock price. Thus,
    common stock is considered to be a call option with a claim on
    the enterprise at an exercise price equal to the remaining value
    immediately after the preferred stock is liquidated. The
    option-pricing method uses the Black-Scholes option-pricing
    model to price the call options. This model defines the
    securities&#146; fair values as functions of the current fair
    value of a company and uses assumptions such as the anticipated
    timing of a potential liquidity event and the estimated
    volatility of the equity securities. The anticipated timing of a
    liquidity event utilized in these valuations was based on
    then-current plans and estimates of our Board of Directors and
    management regarding a liquidity event. Estimates of the
    volatility of our stock were based on available information on
    the volatility of capital stock of comparable publicly traded
    companies. This approach is consistent with the methods outlined
    in the AICPA Practice Guide, <I>Valuation of
    Privately-Held-Company Equity Securities Issued as
    Compensation</I>. Also, we considered the fact that our
    stockholders cannot freely trade our common stock in the public
    markets. Therefore, the estimated fair value of our common stock
    at each grant date reflected a non-marketability discount.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    39
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There is inherent uncertainty in these estimates and if we had
    made different assumptions than those described above, the
    amount of our stock-based compensation expense, net loss and net
    loss per share amounts could have been significantly different.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors performed a contemporaneous valuation in
    order to determine the fair value of our common stock for the
    grant of options on May&#160;8, 2007 which indicated a fair
    value of $1.36 per share for our common stock. Our Board of
    Directors performed a second contemporaneous valuation in order
    to update the determination of the fair value of our common
    stock for the grant of options on September&#160;20, 2007 which
    indicated a fair value of $1.38 per share for our common stock.
    The increase in the fair value between the contemporaneous
    valuation performed for the grant of options on May&#160;8, 2007
    and the date of this contemporaneous valuation was minimal,
    however, it relates mostly to a slight decrease in the
    non-marketability discount rate and the time to a liquidity
    event. Our Board of Directors performed another contemporaneous
    valuation in order to update the determination of the fair value
    of our common stock for the grant of options on
    December&#160;28, 2007 which indicated a fair value of $2.40 per
    share for our common stock. The increase in the fair value
    between the contemporaneous valuation performed for the grant of
    options on September&#160;20, 2007 and December&#160;28, 2007
    valuation relates mostly to the decrease in the
    non-marketability discount rate, the risk-adjusted discount and
    the time to a liquidity event. Our Board of Directors performed
    contemporaneous valuations in order to update the determination
    of the fair value of our common stock for the grant of options
    on April&#160;24, 2008, which indicated a fair value of $3.19
    per share for our common stock, and for the grant of options on
    June&#160;26, 2008, which indicated a fair value of $3.42 per
    share for our common stock. The increase in fair value between
    the contemporaneous valuation performed for the grant of options
    on December&#160;28, 2007 and April&#160;24, 2008 relates
    primarily to the increase in our enterprise value as we moved
    closer to achieving our projected financial goals, achieved
    significant milestones in new product developments and expanded
    into new market applications. In addition, in April&#160;2008,
    our Board of Directors approved the filing of a registration
    statement for the initial public offering of our common stock.
    The increase in fair value between the contemporaneous valuation
    performed for the grant of options on April&#160;24, 2008 and
    June&#160;26, 2008 relates to the increase in our enterprise
    value reflecting continued progression toward achieving our
    projected financial goals, significant new product launches and
    geographical expansion of our sales capabilities.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We recorded stock-based compensation of $5,000,
    $0.1&#160;million, $0.7&#160;million and $1.0&#160;million
    during 2005, 2006, 2007 and the six months ended June&#160;28,
    2008. Included in these amounts was employee stock-based
    compensation of $0, $0.1 million, $0.5&#160;million and
    $0.9&#160;million, and nonemployee stock-based compensation of
    $5,000, $59,000, $0.2&#160;million and $0.1 million during 2005,
    2006, 2007 and the six months ended June&#160;28, 2008. In
    future periods, stock-based compensation expense is expected to
    increase as a result of our existing unrecognized stock-based
    compensation and as we issue additional stock-based awards to
    continue to attract and retain employees and nonemployee
    directors. Certain of our stock options are granted to officers
    with vesting acceleration features based upon the achievement of
    certain performance milestones. The timing of the attainment of
    these milestones may affect the timing of expense recognition
    under SFAS No.&#160;123(R). Additionally, SFAS&#160;123(R)
    requires that we recognize compensation expense only for the
    portion of stock options that are expected to vest. If the
    actual rate of forfeitures differs from that estimated by
    management, we may be required to record adjustments to
    stock-based compensation expense in future periods. As of
    December&#160;29, 2007 and June&#160;28, 2008, we had
    $1.7&#160;million and $5.1&#160;million of unrecognized
    stock-based compensation costs related to stock options granted
    under our 1999 Stock Option Plan, which is expected to be
    recognized over an average period of 2.9 years for both periods.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Accounting
    for Income Taxes</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Significant management judgment is required in determining our
    provision for income taxes, our deferred tax assets and
    liabilities and any valuation allowance recorded against our net
    deferred tax assets. We have recorded a full valuation allowance
    on our net deferred tax assets as of December&#160;31, 2006,
    December&#160;29, 2007 and June&#160;28, 2008 due to
    uncertainties related to our ability to utilize our deferred tax
    assets in the foreseeable future. These deferred tax assets
    primarily consist of certain net operating loss carryforwards
    and research and development tax credits.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We adopted FASB Interpretation No.&#160;48, <I>Accounting for
    Uncertainties in Income Taxes&#160;&#151; an interpretation of
    FASB Statement No.&#160;109</I>, or FIN&#160;48, effective
    January&#160;1, 2007. FIN&#160;48 requires us to recognize the
    financial statement effects of a tax position when it is more
    likely than not, based on the technical merits, that the
    position will
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    40
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    be sustained upon examination. Upon adoption, the Company
    recorded a charge of $75,000 as a cumulative effect of a change
    in accounting principle in the accumulated deficit during 2007.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Inventory
    Valuation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We record adjustments to inventory for potentially excess,
    obsolete or impaired goods in order to state inventory at net
    realizable value. The business environment in which we operate
    is subject to rapid changes in technology and customer demand.
    We regularly review inventory for excess and obsolete products
    and components, taking into account product life cycle and
    development plans, product expiration and quality issues,
    historical experience and our current inventory levels. If
    actual market conditions are less favorable than anticipated,
    additional inventory adjustments could be required.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Warrants
    to Purchase Convertible Preferred Stock</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We account for freestanding warrants related to shares that are
    redeemable in accordance with FASB Staff Position
    <FONT style="white-space: nowrap">No.&#160;150-5,</FONT>
    <I>Issuer&#146;s Accounting Under FASB Statement No.&#160;150
    for Freestanding Warrants and Other Similar Instruments on
    Shares&#160;That Are Redeemable</I>, or
    <FONT style="white-space: nowrap">FSP&#160;150-5,</FONT>
    an interpretation of SFAS&#160;No.&#160;150, <I>Accounting for
    Certain Financial Instruments with Characteristics of Both
    Liabilities and Equity</I>. Under
    <FONT style="white-space: nowrap">FSP&#160;150-5,</FONT>
    freestanding warrants to purchase shares of our convertible
    preferred stock are classified as liabilities on the
    consolidated balance sheets at fair value because the warrants
    may conditionally obligate us to transfer assets at some point
    in the future. The warrants are subject to remeasurement at each
    balance sheet date, and any change in fair value will be
    recognized as a component of other income (expense), net in the
    consolidated statements of operations. We estimated the fair
    value of these warrants at the respective balance sheet dates
    using the Black-Scholes option-pricing model. A number of our
    assumptions used in the
    <FONT style="white-space: nowrap">Black-Scholes</FONT>
    <FONT style="white-space: nowrap">option-pricing</FONT>
    model, especially the market value and the expected volatility,
    are highly judgmental and could differ materially in the future.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We will continue to record adjustments to the fair value of the
    warrants until they are exercised, expire or, upon the closing
    of this offering, become warrants to purchase shares of our
    common stock, wherein the warrants will no longer be subject to
    <FONT style="white-space: nowrap">FSP&#160;150-5.</FONT>
    At that time, the then-current aggregate fair value of these
    warrants will be reclassified from current liabilities to
    additional paid-in capital, a component of stockholders&#146;
    equity, and we will cease to record any related periodic fair
    value adjustments. Upon the closing of this offering, the
    preferred stock warrants will be converted into common stock
    warrants with the same exercise prices and expiration dates.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Results
    of Operations</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Revenue</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table presents our revenue by source for each
    period presented (in thousands).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- TABLE 01 -->
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>Six Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Revenue:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,076
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,959
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,489
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,382
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Collaboration revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,568
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,376
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    460
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    310
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Grant revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,063
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,364
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,198
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Total revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,674
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,997
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,520
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We generate revenue from sales of our products, collaboration
    agreements and government grants. Our products consist of
    single-use IFCs, various instruments, software and service
    related to our BioMark and Topaz systems. We also have entered
    into a number of research and development contracts and have
    received government grants to conduct research and development
    activities.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    41
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Total
    Revenue</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our total revenue increased $2.5&#160;million, or 84%, for the
    six months ended June&#160;28, 2008 compared to the six months
    ended June&#160;30, 2007. Total revenue increased
    $0.9&#160;million, or 14%, for 2007 as compared to 2006, and
    decreased by $1.3&#160;million, or 17%, for 2006 as compared to
    2005. Total revenue from our five largest customers comprised
    48%, 56%, 47% and 37% of revenue in 2005, 2006, 2007 and the six
    months ended June&#160;28, 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As we expand our business through Europe and Asia, we expect our
    sales from outside of North America to increase as a percentage
    of our revenue. The following table presents our revenue by
    geography based on the billing address of our customers for each
    period presented (in thousands).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- TABLE 01 -->
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="27%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=10 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=10 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=10 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=10 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=11 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=11 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=11 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=11 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" align="center" valign="bottom">
    <B>Six Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;30, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;28, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    United States
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    72%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,807
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,492
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,231
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,530
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Singapore
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    879
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    889
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,027
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Japan
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,274
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,492
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    732
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    162
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    543
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Europe
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    545
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    189
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    735
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    631
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    953
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Other
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    298
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    344
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    84
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,674
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,997
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,520
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Product
    Revenue</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We derive product revenue from sales to biotechnology and
    pharmaceutical companies, academic institutions and life science
    laboratories worldwide. These sales are generally made through
    direct sales personnel to customers in North America, Asia
    Pacific and most of Europe and through distributors in parts of
    Europe and the Asia-Pacific region.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Product revenue increased by $2.9 million, or 194%, for the six
    months ended June&#160;28, 2008 compared to the six months ended
    June&#160;30, 2007. Revenue from our BioMark instrument systems
    and related IFCs increased by $2.3 million, and revenue from our
    Topaz instrument systems and related IFCs increased by $0.5
    million. We sold 10 BioMark instrument systems and 6 Topaz
    instrument systems in the six months ended June&#160;28, 2008
    compared to 6 BioMark instrument systems and 6 Topaz instrument
    systems in the six months ended June&#160;30, 2007. Our deferred
    revenue balance decreased from $3.4 million as of
    December&#160;29, 2007 to $3.1 million as of June&#160;28, 2008
    and increased from $1.8 million as of December 31, 2006 to $2.9
    million as of June 30, 2007. We recognized $1.8 million of the
    deferred revenue balance as of December&#160;29, 2007 during the
    six months ended June&#160;28, 2008 and $0.3 million of the
    deferred revenue balance as of December&#160;31, 2006 during the
    six months ended June&#160;30, 2007.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Product revenue for 2007 increased by $0.5&#160;million, or 12%,
    compared to 2006. Revenues from our BioMark instrument systems
    and related IFCs which were introduced in late 2006 increased by
    $1.3&#160;million, as we sold 14 BioMark instrument systems
    during 2007 compared to three BioMark instrument systems during
    2006. This increase, however, was mostly offset by a decrease of
    $1.2&#160;million related to a decrease in the sales of our
    Topaz IFCs. The unit sales of our Topaz instrument systems
    remained constant as we sold 10 Topaz instrument systems during
    both 2006 and 2007. In addition, our deferred revenue balance
    increased from $1.8&#160;million at December&#160;31, 2006 to
    $3.4&#160;million at December&#160;29, 2007 as we sold more
    BioMark instrument systems as part of multiple element
    arrangements for which we did not have VSOE on post-contract
    support. We recognized $0.4&#160;million of the deferred revenue
    balance at December&#160;31, 2006 during 2007. We expect the
    current portion of our deferred revenue balance as of
    December&#160;29, 2007 in the amount of $2.7&#160;million will
    be recognized as revenue during 2008. Product revenue for 2006
    decreased by $2.1&#160;million, or 35%, when compared to 2005.
    The decrease was primarily due to a decrease in the sales of our
    Topaz instrument systems as we sold 10 Topaz instrument systems
    during 2006 compared to 16 Topaz instrument systems during 2005;
    however, sales of our Topaz IFCs remained relatively consistent
    with 2005.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The increase in sales of our BioMark instrument systems in 2007
    and the concurrent decrease in sales of our Topaz systems
    reflect the refocusing of our product development and sales and
    marketing efforts, beginning in 2005, to focus on the larger
    markets served by our BioMark instrument systems. Since then, we
    have reduced new Topaz product introductions. We will continue
    to manufacture and sell our Topaz instrument systems and IFCs
    and
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    42
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    we expect unit sales of Topaz instrument systems and IFCs in
    2008 and future periods to be consistent with or slightly lower
    than the 2006 and 2007 levels. We expect unit sales of our
    BioMark instrument systems and IFCs to increase in 2008.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Collaboration
    Revenue</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We receive payments from third parties under research and
    development contracts. Fixed-fee research and development
    contracts generally provide us with up-front and periodic
    milestone-based fees. Variable-fee research and development
    contracts generally provide us with fees based on an
    <FONT style="white-space: nowrap">agreed-upon</FONT>
    rate for time incurred by our research staff.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Collaboration revenue decreased $0.2&#160;million, or 77%, for
    the six months ended June&#160;28, 2008 compared to the six
    months ended June&#160;30, 2007. The decrease relates to the
    completion of one of our development agreements in the first
    quarter of 2007. Collaboration revenue for 2007 decreased by
    $0.9&#160;million, or 67%, compared to 2006. This decrease was
    primarily due to the completion of one of our collaboration
    agreements during 2006 that accounted for $1.0&#160;million of
    our 2006 collaboration revenue. Collaboration revenue for 2006
    decreased by $0.2&#160;million, or 12%, compared to 2005. The
    decrease was primarily due to the termination of one of our
    collaboration agreements in December 2005. We expect
    collaboration revenue to continue to decrease due to the
    completion of our current collaboration agreements during 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Grant
    Revenue</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We receive payments in the form of grants from certain
    government entities. Government grants are agreements that
    generally provide incentive grant payments for specified
    research and development activities over a contractually defined
    period.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Grant revenue decreased $0.1&#160;million, or 11%, for the six
    months ended June&#160;28, 2008 compared to the six months ended
    June&#160;30, 2007. The decrease relates to the reduction in
    activity for the National Institutes of Health, or NIH, grant
    agreement that terminated in June&#160;2008. Grant revenue for
    2007 increased by $1.3&#160;million, or 122%, when compared to
    2006, and our grant revenue for 2006 increased by
    $1.0&#160;million when compared to 2005. These increases were
    primarily due to the addition of a grant from the NIH, which was
    entered into in June 2006, and grants from EDB, which were
    entered into in October 2005 and February 2007. We recognized
    revenue from the 2005 EDB grant in the amount of
    $0.9&#160;million during 2006,  $1.1&#160;million during 2007
    and $0.6&#160;million for the six months ended June&#160;28,
    2008. In addition, we recognized revenue in the amount of
    $0.6&#160;million during 2007 and $0.2&#160;million during the
    six months ended June&#160;28, 2008 from the 2007 EDB grant.
    Under our incentive grant agreements with EDB, eligible expenses
    incurred by us in Singapore were $4.0&#160;million in 2006,
    $4.5&#160;million in 2007 and $1.9&#160;million in the six
    months ended June&#160;28, 2008. Also, we recognized revenue
    from the NIH grant in the amount of $0.2&#160;million during
    2006 and $0.6&#160;million during 2007.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our agreements with EDB provide that grants extended to us in
    the past and future grants are subject to our operation of
    increasing levels of research, development and manufacturing in
    Singapore, including the use of local service providers, the
    hiring of personnel in Singapore, the incurrence of research and
    development expenses in Singapore, our receipt of new investment
    in our company and our achievement of certain agreed upon
    milestones relating to the development of our products.
    Development and manufacturing milestones achieved during the
    three years ended December&#160;29, 2007 included completion of
    feasibility studies and prototype development, establishment of
    manufacturing lines, implementation of quality control
    improvements, manufacturing process simplification and cost
    improvements and manufacturing yield improvements for our Topaz
    and BioMark IFCs and related systems. These agreements further
    provide EDB with the right to demand repayment of a portion of
    past grants in the event that we did not meet our obligations
    under the applicable agreements. Based on correspondence with
    EDB, we believe we have satisfied the conditions applicable to
    our EDB grant revenue through June&#160;28, 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Although the NIH grant is scheduled to terminate in
    June&#160;2008, we expect grant revenue from the EDB research
    grants to increase in 2008 and remain at such levels through
    2011. As a result, we expect our total grant revenue in 2008
    through 2011 to be consistent with 2007 levels.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    43
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Cost of
    Product Revenue and Gross Margin</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table presents our cost of revenue and gross
    margin for each period presented (in thousands).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Six Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cost of product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,764
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,773
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,514
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,490
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,988
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Gross margin
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cost of product revenue includes manufacturing costs incurred in
    the production process, including component materials, assembly
    labor and overhead, testing, installation, warranty, packaging
    and delivery costs. In addition, cost of product revenue
    includes royalty expenses for licensed technologies included in
    our products, provisions for warranties and stock-based
    compensation expense. Costs related to collaboration and
    government grant revenue are included in research and
    development expense.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cost of product revenue increased $1.5&#160;million, or 100%,
    for the six months ended June&#160;28, 2008 compared to the six
    months ended June&#160;30, 2007. The increase related to the
    increase in product revenue from both higher instrument and IFC
    sales. Cost of product revenue in the first six months of 2007
    was adversely affected by
    <FONT style="white-space: nowrap">start-up</FONT>
    costs for our new Singapore manufacturing facility and
    underutilized capacity as we transitioned manufacturing from the
    United States to Singapore. Cost of product revenue for 2007
    increased $0.7&#160;million, or 27%, compared to 2006, primarily
    driven by higher instrument sales, start-up costs for our new
    Singapore manufacturing facility and underutilized capacity as
    we transitioned manufacturing from the United States to
    Singapore. Additionally we wrote-off obsolete raw materials in
    2007 in the amount of $0.2&#160;million, which decreased our
    gross margin by 5&#160;percentage points. Cost of product
    revenue for 2006 decreased by $2.0&#160;million, or 42%, when
    compared to 2005, primarily driven by a decrease in sales of our
    Topaz instruments during 2006. We expect our unit costs to
    decline in future periods as a result of our ongoing efforts to
    automate our manufacturing processes and expected increases in
    production volumes and yields. However, improvement in unit
    costs may be offset by increasing price competition, which could
    cause our gross margins to fluctuate from
    <FONT style="white-space: nowrap">year-to-year</FONT>
    and
    <FONT style="white-space: nowrap">quarter-to-quarter.</FONT>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Operating
    Expenses</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table presents our operating expenses for each
    period presented (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="51%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Six Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Operating expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Research and development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    11,449
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    15,589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    14,389
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,053
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,151
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Selling, general and administrative
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,955
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,898
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,183
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,843
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Total operating expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    19,404
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    25,288
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    27,287
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    13,236
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    16,994
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Research
    and Development</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Research and development expense consists primarily of personnel
    costs, independent contractor costs, prototype expenses and
    other allocated facilities and information technology expenses.
    We have made substantial investments in research and development
    since our inception. Our research and development efforts have
    focused primarily on the tasks required to optimize our
    technologies and to support commercialization of the products
    and services derived from these technologies.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Research and development expense decreased $0.1&#160;million, or
    1%, for the six months ended June&#160;28, 2008 compared to the
    six months ended June&#160;30, 2007. The decrease relates to a
    decrease of $0.2&#160;million in supply costs and
    $0.3&#160;million in license costs partially offset by a
    $0.7&#160;million increase in compensation costs due to
    increased research and development headcount. Research and
    development expense decreased in 2007 by $1.2&#160;million, or
    8%, compared to 2006, primarily due to decreased contractor
    costs of $0.6&#160;million and decreased research and
    development license costs of $0.3&#160;million. Research and
    development expense for 2006 increased by $4.1&#160;million,
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    44
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     or 36%, compared to 2005, primarily due to increased
    compensation costs of $2.1&#160;million due mostly to a
    significant increase in research and development headcount and
    $0.1&#160;million related to the adoption of SFAS&#160;123(R)
    during 2006, $0.6&#160;million attributable to increased
    contractor expenses and $0.6&#160;million in increased license
    costs and royalties. We believe that our continued investment in
    research and development is essential to a long-term competitive
    position and expect these expenses, including stock-based
    compensation, to increase in future periods.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Selling,
    General and Administrative</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Selling, general and administrative expense consists primarily
    of personnel costs for our sales and marketing, business
    development, finance, legal, human resources and general
    management, as well as professional services, such as legal and
    accounting services.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Selling, general and administrative expense increased
    $3.7&#160;million, or 59%, for the six months ended
    June&#160;28, 2008 compared to the six months ended
    June&#160;30, 2007. The increase relates to a $0.6&#160;million
    increase for accounting and consulting services, a
    $1.7&#160;million increase in compensation costs due to
    increased head count, a $0.6&#160;million increase in patent
    filings, a $0.3&#160;million increase in advertising and
    promotions, and a $0.2&#160;million increase in supplies.
    Selling, general and administrative expense for 2007 increased
    by $3.2&#160;million, or 33%, compared to 2006, primarily due to
    increased compensation costs of $1.4&#160;million due mostly to
    an increase in headcount and a $0.3&#160;million increase in
    stock-based compensation over 2006, an increase of
    $1.8&#160;million in spending primarily for accounting and legal
    services, $0.3&#160;million resulting from increased advertising
    and promotions, and $0.2&#160;million attributable to increased
    supplies for customer demonstrations. However, this increase was
    partially offset by a decrease of $0.6&#160;million due to fewer
    patent filings. Selling, general administrative expense for 2006
    increased by $1.7&#160;million, or 22%, compared to 2005,
    primarily due to increased compensation costs of
    $0.7&#160;million due to an increase in headcount, an increase
    of $0.6&#160;million in spending primarily for accounting and
    legal services, and $0.4&#160;million due to the filing of
    additional patents. We expect selling, general and
    administrative expense, including stock-based compensation, to
    significantly increase in 2008 and future periods as we continue
    to grow our sales, technical support, marketing and
    administrative headcount, support increased product sales,
    broaden our customer base and incur additional costs to support
    the growth in our business.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Interest
    Income and Expense</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We receive interest income from our cash and cash equivalents
    and our
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    security balances held with certain financial institutions.
    Conversely, we incur interest expense from our long-term debt
    and convertible promissory notes and the amortization of our
    debt discounts related to these items. The following table
    presents our interest income and expense for each period
    presented (in thousands).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="53%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Six Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,140
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (898
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,261
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,790
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,790
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,100
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Interest income decreased by $8,000, or 1%, for the six months
    ended June&#160;28, 2008 compared to the six months ended
    June&#160;30, 2007. Interest income for 2007 increased by
    $0.6&#160;million compared to 2006. The increase in interest
    income was due to higher cash and available-for-sale securities
    balances during 2007 as compared to 2006. Interest income for
    2006 increased by $0.2&#160;million compared to 2005. The
    increase in interest income was also primarily due to higher
    cash and available-for-sale securities balances during 2006 as
    compared to 2005. We expect interest income to increase as we
    invest a portion of the net proceeds from this offering in
    available-for-sale securities.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Interest expense decreased $0.7&#160;million, or 39%, for the
    six months ended June&#160;28, 2008 compared to the six months
    ended June&#160;30, 2007 due to lower average debt balance due
    to conversion of the $10.0&#160;million promissory notes in
    March&#160;2007. Interest expense for 2007 increased by
    $0.5&#160;million compared to 2006. The increase was primarily
    due to higher debt balances during 2007 as compared to 2006
    primarily due to the $5.0&#160;million convertible promissory
    note issued in April 2007. Interest expense for 2006 increased
    by $1.4&#160;million compared to 2005. The increase was
    primarily due to higher debt balances from the
    $13.0&#160;million loan and security agreement that was
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    45
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     fully drawn by December 2005. In February 2008, this loan and
    security agreement was amended to provide us with an additional
    credit line in the amount of $10.0&#160;million. We borrowed the
    full $10.0&#160;million under this additional credit line in
    June 2008 and, as a result, we expect our interest expense to
    increase in future periods.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Cumulative
    Effect of Change in Accounting Principle</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon adoption of
    <FONT style="white-space: nowrap">FSP&#160;150-5</FONT>
    on July&#160;1, 2005, we reclassified the fair value of warrants
    to purchase shares of our convertible preferred stock from
    stockholders&#146; equity to liabilities and recorded a
    cumulative effect of a change in accounting principle in the
    amount of $0.6&#160;million during 2005 in the statement of
    operations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Liquidity
    and Capital Resources</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Sources
    of Liquidity</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of June&#160;28, 2008, we had $29.0&#160;million of cash and
    cash equivalents and $3.5&#160;million of available-for-sale
    securities. As of June&#160;28, 2008, our working capital was
    $28.6&#160;million, and we had an accumulated deficit of
    $149.1&#160;million. Since our inception, we have principally
    funded our operations through issuances of convertible preferred
    stock, which has provided us with aggregate net proceeds of
    $167.5&#160;million, of which $20.0&#160;million was provided by
    entities affiliated with EDB in the form of convertible
    promissory notes that converted into convertible preferred
    stock. We have also received significant funding in the form of
    loans that have provided us with aggregate net proceeds of
    $26.6&#160;million.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have received funding in the form of grants from government
    entities, the most significant of which have been associated
    with two grant agreements with EDB that have helped support the
    establishment and operation of our Singapore manufacturing,
    research and development facilities in October 2005.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The maximum amount of grant revenue available to us under our
    first grant agreement with EDB from June&#160;28, 2008 through
    July&#160;31, 2010 is SG$5.2&#160;million (approximately US$3.8
    using a June&#160;28, 2008 exchange rate), and the maximum
    amount of grant revenue available to us under our second grant
    agreement with EDB from June&#160;28, 2008 through May&#160;31,
    2011 is SG$2.5&#160;million (approximately US$1.8&#160;million).
    To maintain eligibility for incentive grant payments under these
    agreements, we are required to achieve development and
    manufacturing milestones as agreed to by the parties. In
    addition, to maintain eligibility for incentive grant payments
    under our first grant agreement, we are required to incur annual
    spending in Singapore of at least SG$6.5&#160;million
    (approximately US$4.8&#160;million) in 2008 and 2009 and at
    least SG$8.0&#160;million (approximately US$5.9&#160;million) in
    2010. To maintain eligibility for grant payments under our
    second grant agreement, we are required to incur annual spending
    in Singapore of at least SG$6.5&#160;million (approximately
    US$4.8&#160;million) for the 12&#160;months ending May&#160;31,
    2009 and 2010 and at least SG$9.0&#160;million (approximately
    US$6.6&#160;million) for the 12&#160;months ending May&#160;31,
    2011. For this purpose, spending in Singapore includes overhead,
    salaries, outsourcing and subcontracting expenses, operating
    expenses and royalties paid, with limited exceptions such as raw
    materials purchases. Expenditures that are used to satisfy the
    requirements of one grant agreement are not eligible for
    satisfaction of the other grant agreement. To qualify for
    payment under the second grant agreement, expenditures must
    relate to the development of instrumentation for our IFC systems
    and not our IFCs themselves. Our first grant agreement also
    requires that we employ at least 24 research scientists and
    engineers in Singapore by December&#160;31, 2009, and our second
    grant agreement requires that we employ at least 10 new research
    scientists and engineers in Singapore by May&#160;31, 2009, that
    we employ at least 12 new research scientists and engineers in
    Singapore by May&#160;31, 2011 and that we maintain at least 12
    research scientists and engineers in total until May&#160;31,
    2013. The requirements of the second grant agreement may only be
    satisfied by personnel employed in the research and development
    of IFC instrumentation. As of June&#160;28, 2008, we employed
    16&#160;research scientists and engineers involved in the
    research and development of our IFCs and 10&#160;research
    scientists and engineers involved in the research and
    development of related instrumentation in Singapore. We cannot
    assure you that we will take all actions required to remain
    eligible for grants under our agreements with EDB and, in the
    event that we do not comply with such requirements, whether
    intentionally or unintentionally, we may not receive further
    grants under such agreements. In the event that we do not
    receive grant funding from EDB in the future, we do not believe
    that our liquidity would be materially affected.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into multiple convertible note purchase
    agreements with Biomedical Sciences Investment Fund&#160;Pte.
    Ltd., or BMSIF, pursuant to which we issued convertible notes
    and received proceeds in the amount of
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    46
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     $20.0&#160;million through June&#160;28, 2008. BMSIF is
    wholly-owned by EDB Investments Pte. Ltd., whose parent entity
    is EDB. Ultimately, each of these entities is controlled by the
    government of Singapore. As of June&#160;28, 2008, there were no
    outstanding principal and accrued interest balances for our
    convertible note purchase agreements with BMSIF as the final
    remaining note was converted into shares of our Series&#160;E
    preferred stock in April&#160;2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In November 2002, we entered into a master security agreement
    with a lender under which we borrowed $3.6&#160;million to be
    used for purchases of capital equipment, software and tenant
    improvements. The outstanding principal and accrued interest
    balance for this loan was paid in February 2008. Upon full
    payment of the debt in February 2008, restricted cash in the
    amount of $0.5&#160;million was released by the lender.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In March 2005, we entered into a loan and security agreement
    with a lender under which we borrowed $13.0&#160;million to be
    used for general corporate purposes. We are currently making
    equal monthly payments of $0.3&#160;million towards the loan
    which is to be paid off in February 2010. The loan is subject to
    prepayment penalties if paid off prior to 2010.  In February
    2008, this loan and security agreement was amended to provide us
    with an additional credit line in the amount of
    $10.0&#160;million that we could draw upon until July&#160;1,
    2008 for general corporate purposes. In June 2008, the Company
    drew down the $10,000,000. The loan will bear interest at 11.5%
    per annum. Interest only payments will be made monthly through
    the remainder of 2008 with monthly payments of principal and
    interest in the amount of $369,000, beginning in January 2009,
    to be made through June 2011. The agreement also requires a
    final payment in the amount of $650,000 in June 2011. As of
    June&#160;28, 2008, the outstanding principal and accrued
    interest balance for this loan and security agreement was
    $16.6&#160;million, net of unamoritized debt discounts of
    $0.4&#160;million.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The loan and security agreement contains customary covenants
    that, among other things, require us to deliver both annual
    audited and periodic unaudited financial statements by specified
    dates and maintain collateral on company premises and restrict
    our ability, without the consent of the lender, to incur
    additional debt, pay dividends or make certain other
    distributions, or payments in respect of our capital stock,
    engage in transactions with affiliates or engage in the sale,
    lease or license of our assets outside of the ordinary course of
    business. As of June&#160;28, 2008, we were in compliance with
    the above covenants with the exception of the timely delivery of
    our audited financial statements for 2007. In this instance, we
    obtained a waiver from the lender and subsequently complied with
    the covenant. We are currently unaware of any circumstances that
    would prevent us from complying with these covenants in the
    future.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Net
    Cash Used in Operating Activities</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We derive cash flows from operations primarily from cash
    collected from the sale of our products and related services,
    collaboration agreements and grants from certain government
    entities. Our cash flows from operating activities are also
    significantly influenced by our use of cash for operating
    expenses to support the growth of our business. We have
    historically experienced negative cash flows from operating
    activities as we have expanded our business and built our
    infrastructure domestically and internationally and we expect
    this trend to continue for the foreseeable future as our
    business grows and we continue to expand into new markets.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash used by operating activities was $16.0&#160;million for
    the six months ended June&#160;28, 2008. Net cash used by
    operating activities primarily consisted of a net loss of
    $15.3&#160;million, changes in our operating assets and
    liabilities in the amount of $3.2&#160;million and foreign
    exchange gain in the amount of $0.1&#160;million, which were
    partially offset by non-cash expense items such as depreciation
    and amortization of our property and equipment in the amount of
    $0.8&#160;million, adjustments to the fair value of convertible
    preferred stock warrants in the amount of $0.4&#160;million,
    amortization of debt discounts and issuance cost of
    $0.4&#160;million, and stock-based compensation in the amount of
    $1.0&#160;million.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     Net cash used by operating activities was $21.8&#160;million
    during 2007. Net cash used by operating activities primarily
    consisted of a net loss of $25.5&#160;million, which was
    partially offset by non-cash expense items such as depreciation
    and amortization of our property and equipment in the amount of
    $1.6&#160;million, amortization of debt discounts in the amount
    of $0.5&#160;million, stock-based compensation in the amount of
    $0.7&#160;million, and changes in our operating assets and
    liabilities in the amount of $0.4&#160;million.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    47
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash used by operating activities was $22.3&#160;million
    during 2006. Net cash used by operating activities primarily
    consisted of a net loss of $23.6&#160;million and changes in our
    operating assets and liabilities in the amount of
    $1.2&#160;million. The cash used by operating activities for
    these items was partially offset by non-cash expense items such
    as depreciation and amortization of our property and equipment
    in the amount of $1.4&#160;million, amortization of our debt
    discounts in the amount of $0.1&#160;million, stock-based
    compensation in the amount of $0.1&#160;million, and the
    issuance of convertible preferred stock under a license
    agreement in the amount of $0.6&#160;million.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash used by operating activities was $14.3&#160;million
    during 2005. Net cash used by operating activities primarily
    consisted of a net loss of $16.4&#160;million. The cash used by
    operating activities was partially offset by non-cash expense
    items such as depreciation and amortization of our property and
    equipment in the amount of $1.3&#160;million and increases in
    our operating assets and liabilities in the amount of
    $1.4&#160;million.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Net
    Cash Used in Investing Activities</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Historically, our primary investing activities have consisted of
    capital expenditures for laboratory, manufacturing and computer
    equipment and software to support our expanding infrastructure
    and work force; restricted cash related to leased space and
    lending agreements; and purchases, sales and maturities of our
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities. We expect to continue to expand our manufacturing
    capability, primarily in Singapore, and expect to incur
    additional costs for capital expenditures related to these
    efforts in 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We generated $3.2&#160;million of cash in investing activities
    for the six months ended June&#160;28,&#160;2008 primarily from
    maturities of available-for-sale securities in the amount of
    $4.3&#160;million, sales of available-for-sale securities in the
    amount of $3.0&#160;million and a reduction of restricted cash
    of $0.6&#160;million, partially offset by purchases of
    available-for-sale securities in the amount of $4.5&#160;million
    and purchases of capital equipment of $0.2&#160;million.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We used $6.7&#160;million of cash in investing activities during
    2007, primarily for purchases of
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities in the amount of $6.3&#160;million and
    $1.0&#160;million for capital expenditures related to purchases
    of equipment, including $0.6&#160;million for our Singapore
    manufacturing facility, partially offset by maturities of
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities in the amount of $0.5&#160;million.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We used $2.9&#160;million of cash in investing activities during
    2006, primarily for capital expenditures in the amount of
    $2.9&#160;million related to purchases of equipment, including
    $1.9&#160;million for our Singapore manufacturing facility.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2005, investing activities provided cash of
    $6.8&#160;million. This cash was generated primarily from sales
    and maturities of
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities in the amount of $8.9&#160;million, partially offset
    by purchases of
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities in the amount of $0.5&#160;million and capital
    expenditures in the amount of $1.7&#160;million. Our capital
    expenditures during 2005 included $0.8&#160;million related to
    purchases of manufacturing equipment for our Singapore facility,
    which began operations during the year.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Net
    Cash Provided by Financing Activities</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Historically, we have principally funded our operations through
    issuances of convertible preferred stock.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During the six months ended June&#160;28, 2008, we generated
    $7.6&#160;million of cash from financing activities primarily
    due to proceeds from our amended loan and security agreement in
    the amount of $10.0 million, partially offset by repayment of
    long-term debt. During 2007, we generated $37.6&#160;million of
    cash from financing activities primarily due to
    $35.9&#160;million of net proceeds from sales of our
    Series&#160;E preferred stock and $5.0&#160;million of proceeds
    from the issuance of convertible promissory notes, partially
    offset by repayments of our long-term debt in the amount of
    $3.5&#160;million. During 2006, we generated approximately
    $31.1&#160;million of cash from financing activities primarily
    due to $22.0&#160;million of net proceeds from sales of our
    Series&#160;E preferred stock and $13.0&#160;million of proceeds
    from the issuance of convertible promissory notes, partially
    offset by repayments of our long-term debt in the amount of
    $4.0&#160;million. During 2005, we generated approximately
    $23.0&#160;million of cash from financing activities, primarily
    due to $10.0&#160;million of net proceeds from sales of our
    Series&#160;D preferred stock and $14.7&#160;million of net
    proceeds from the issuance of long-term debt, partially offset
    by repayments of our long-term debt in the amount of
    $1.7&#160;million.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    48
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Capital
    Resources</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe our existing cash and cash equivalents,
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities, amounts available under current credit lines and the
    net proceeds from this offering, will be sufficient to meet our
    working capital and capital expenditure needs for at least the
    next 18&#160;months. However, we may need to raise substantial
    additional capital to expand the commercialization of our
    products, fund our operations, continue our research and
    development, defend, in litigation or otherwise, any claims that
    we infringe third-party patents or violate other intellectual
    property rights, commercialize new products and acquire
    companies and in-license products or intellectual property. Our
    future funding requirements will depend on many factors,
    including market acceptance of our products, the cost of our
    research and development activities, the cost of filing and
    prosecuting patent applications, the cost of defending, in
    litigation or otherwise, any claims that we infringe third-party
    patents or violate other intellectual property rights, the cost
    and timing of regulatory clearances or approvals, if any, the
    cost and timing of establishing additional sales, marketing and
    distribution capabilities, the cost and timing of establishing
    additional technical support capabilities, the effect of
    competing technological and market developments, and the extent
    to which we acquire or invest in businesses, products and
    technologies, although we currently have no commitments or
    agreements relating to any of these types of transactions. We
    currently expect to use the proceeds from this offering to
    expand our sales force, to support the ongoing commercialization
    of our products, for research and product development
    activities, to expand our facilities and manufacturing
    operations, and for working capital and other general corporate
    purposes. As of the date of this prospectus, we cannot predict
    with certainty all of the particular uses for the proceeds from
    this offering or the amounts that we will actually spend on the
    uses set forth above.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We may require additional funds in the future and we may not be
    able to obtain such funds on acceptable terms, or at all. If we
    raise additional funds by issuing equity securities, our
    stockholders may experience dilution. Debt financing, if
    available, may involve covenants restricting our operations or
    our ability to incur additional debt. Any debt or additional
    equity financing that we raise may contain terms that are not
    favorable to us or our stockholders. If we raise additional
    funds through collaboration and licensing arrangements with
    third parties, it may be necessary to relinquish some rights to
    our technologies or our products, or grant licenses on terms
    that are not favorable to us. If we are unable to raise adequate
    funds, we may have to liquidate some or all of our assets, or
    delay, reduce the scope of or eliminate some or all of our
    development programs. If we do not have, or are not able to
    obtain, sufficient funds, we may have to delay development or
    commercialization of our products or license to third parties
    the rights to commercialize products or technologies that we
    would otherwise seek to commercialize. We also may have to
    reduce marketing, customer support or other resources devoted to
    our products or cease operations. Any of these factors could
    harm our operating results.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Off-Balance
    Sheet Arrangements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Since our inception, we have not had any off-balance sheet
    arrangements as defined in Item&#160;303(a)(4) of the Securities
    and Exchange Commission&#146;s
    <FONT style="white-space: nowrap">Regulation&#160;S-K.</FONT>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Contractual
    Obligations and Commitments</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following summarizes our contractual obligations as of
    December&#160;29, 2007 (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- TABLE 01 -->
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="47%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Payments Due by Period</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Less Than<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Total</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>1&#160;Year</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>1-3&#160;Years</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>3-5&#160;Years</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Thereafter</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Operating lease obligations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,459
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,436
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,782
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    241
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Long-term debt
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,908
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,478
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible promissory notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,278
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,278
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Purchase obligations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    435
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    580
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    21,660
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,349
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    15,070
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    241
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our operating lease obligations relate to leases for our current
    headquarters and leases for office space for our foreign
    subsidiaries. Principal and interest on our convertible
    promissory notes are convertible into shares of our
    Series&#160;E preferred stock at the lender&#146;s election, at
    any time, or upon our election upon the achievement of certain
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    49
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    milestones or automatically upon the completion of this
    offering. Purchase obligations consist of contractual and
    legally binding commitments to purchase goods. We have entered
    into several patent license agreements in which we are obligated
    to pay annual license maintenance fees, non-refundable license
    issuance fees and royalties as a percentage of sales for the
    sale or sublicense of products using the licensed technology.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into several license and patent agreements.
    Under these agreements, we pay annual license maintenance fees,
    nonrefundable license issuance fees, and royalties as a
    percentage of net sales for the sale or sublicense of products
    using the licensed technology. If we elect to maintain these
    license agreements, we will pay aggregate annual fees of
    $315,000 in 2008 and $270,000 per year until 2027. Future
    payments related to these license agreements have not been
    included in the contractual obligations table above as the
    period of time over which the future license payments will be
    required to be made, and the amount of such payments are
    indeterminable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On March&#160;7, 2003 we entered into a Master Closing Agreement
    with Oculus Pharmaceuticals, Inc. and the UAB Research
    Foundation, or UAB, related to certain intellectual property and
    technology rights licensed by us from UAB. Pursuant to the
    agreement, we are obligated to issue UAB shares of our common
    stock with a value equal to $1.5&#160;million upon the
    achievement of a certain milestone and based upon the fair
    market value of our common stock at the time the milestone is
    achieved. We currently do not anticipate achieving this
    milestone in the foreseeable future and do not anticipate
    issuing these shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our manufacturing operations in Singapore, which commenced in
    October 2005, have generated incentive grant payments from EDB
    for our research, development and manufacturing activity in
    Singapore. To remain eligible for future incentive grant
    payments, we are required to maintain a significant and
    increasing manufacturing and research and development presence
    in Singapore. Under our current grant agreements with EDB, we
    expect our spending related to these grant agreements to
    increase in order to maintain our manufacturing facility in
    Singapore. Future expenditures related to these grant agreements
    have not been included in the contractual obligations table
    above as the amounts of future expenditures, if any, and the
    timing of when they will be incurred are still indeterminable.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subsequent to our year ended December&#160;29, 2007, the
    remaining outstanding principal and accrued interest balance for
    a master security agreement in the amount of $1.1&#160;million
    was paid in February 2008. The loan was originally scheduled to
    be repaid in monthly installments though July 2009 and,
    accordingly, was reflected in the table above as such. Also, the
    convertible promissory notes noted in the table above were
    converted into shares of our Series&#160;E preferred stock
    during April 2008 in accordance with the convertible note
    purchase agreements with BMSIF. In June 2008, we drew an
    additional $10.0 million from our amended loan and security
    agreement.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Recent
    Accounting Pronouncements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In September 2006, the FASB issued SFAS&#160;No.&#160;157,
    <I>Fair Value Measurement</I>, or SFAS&#160;157, which defines
    and establishes a framework for measuring the fair value of
    assets and liabilities when required or permitted by other
    standards within generally accepted accounting principles in the
    United States but does not require any new fair value
    measurements. SFAS&#160;157 also expands disclosures about fair
    value measurements. SFAS&#160;157 is effective for all financial
    statements issued for fiscal years beginning after
    November&#160;15, 2007. However, in February 2008 the FASB
    issued FSP
    <FONT style="white-space: nowrap">No.&#160;157-2,</FONT>
    or
    <FONT style="white-space: nowrap">FSP&#160;157-2</FONT>
    which delays the effective date of SFAS&#160;157 in accordance
    with the provisions in
    <FONT style="white-space: nowrap">FSP&#160;157-2</FONT>
    as of January&#160;1, 2008. The adoption of SFAS&#160;157 did
    not have a significant impact on our consolidated financial
    statements and the resulting fair values calculated in
    accordance with SFAS&#160;157 were not significantly different
    than the fair values that would have been calculated in
    accordance with the previous guidance.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2007, the FASB issued SFAS&#160;No.&#160;159, <I>The
    Fair Value Option for Financial Assets and Financial
    Liabilities</I>, or SFAS&#160;159, including an amendment of
    SFAS&#160;No.&#160;115, <I>Accounting for Certain Investments in
    Debt and Equity Securities</I>, which allows an entity to choose
    to measure certain financial instruments and liabilities at fair
    value. Subsequent measurements for the financial instruments and
    liabilities an entity elects to measure at fair value will be
    recognized in earnings. SFAS&#160;159 also establishes
    additional disclosure requirements. SFAS&#160;159 is effective
    for fiscal years beginning after November&#160;15, 2007. The
    adoption of SFAS&#160;159 did not have a significant impact on
    our consolidated financial statements.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    50
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In December 2007, the FASB ratified EITF Issue
    <FONT style="white-space: nowrap">No.&#160;07-1,</FONT>
    <I>Accounting for Collaborative Agreements</I>, or
    <FONT style="white-space: nowrap">EITF&#160;07-1,</FONT>
    which addresses the accounting for participants in collaborative
    agreements, defined as contractual arrangements that involve a
    joint operating activity, that are conducted without the
    creation of a separate legal entity.
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    requires participants in a collaborative agreement to make
    separate disclosures for each period a statement of operations
    is presented regarding the nature and purpose of the agreement,
    the rights and obligations under the agreement, the accounting
    policy for the agreement, and the classification of and amounts
    arising from the agreement between participants. These
    arrangements involve two or more parties who are both active
    participants in the activity and that are exposed to significant
    risks and rewards dependent on the commercial success of the
    activity.
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    provides that a company should report the effects of adoption as
    a change in accounting principle through retrospective
    application to all periods and requires specific additional
    disclosures.
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    is effective for interim and annual reporting periods beginning
    after December&#160;15, 2008. We are currently assessing the
    impact the adoption of
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    will have on our consolidated financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In June 2007, the FASB ratified EITF Issue
    <FONT style="white-space: nowrap">No.&#160;07-3,</FONT>
    <I>Accounting for Nonrefundable Advance Payments for Goods or
    Services to Be Used in Future Research and Development
    Activities</I>, or
    <FONT style="white-space: nowrap">EITF&#160;07-3.</FONT>
    <FONT style="white-space: nowrap">EITF&#160;07-3</FONT>
    provides clarification surrounding the accounting for
    nonrefundable research and development advance payments, whereby
    such payments should be recorded as an asset when the advance
    payment is made and recognized as an expense when the research
    and development activities are performed.
    <FONT style="white-space: nowrap">EITF&#160;07-3</FONT>
    is effective for interim and annual reporting periods beginning
    after December&#160;15, 2007. We adopted
    <FONT style="white-space: nowrap">EITF&#160;07-3</FONT>
    as of December&#160;30, 2007. The adoption of
    <FONT style="white-space: nowrap">EITF&#160;07-3</FONT>
    did not have a significant impact on our consolidated financial
    statements.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Quantitative
    and Qualitative Disclosures about Market Risk</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Market risk represents the risk of loss that may impact our
    financial position due to adverse changes in financial market
    prices and rates. Our market risk exposure is primarily a result
    of fluctuations in foreign currency exchange rates and interest
    rates. We do not hold or issue financial instruments for trading
    purposes.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Foreign
    Currency Exchange Risk</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As we expand internationally our results of operations and cash
    flows will become increasingly subject to fluctuations due to
    changes in foreign currency exchange rates. Our revenue is
    generally denominated in the local currency of the contracting
    party. Historically, the substantial majority of our revenue has
    been denominated in U.S.&#160;dollars. Our expenses are
    generally denominated in the currencies in which our operations
    are located, which is primarily in the United States, with a
    portion of expenses incurred in Singapore where our other
    manufacturing facility is located. Our results of operations and
    cash flows are, therefore, subject to fluctuations due to
    changes in foreign currency exchange rates. Fluctuations in
    currency exchange rates could harm our business in the future.
    The effect of a 10% adverse change in exchange rates on foreign
    denominated cash, receivables and payables as of June&#160;28,
    2008 would have been approximately $0.4&#160;million foreign
    exchange loss recognized as a component of other expense within
    our consolidated statement of operations. To date, we have not
    entered into any foreign currency hedging contracts although we
    may do so in the future.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Interest
    Rate Sensitivity</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We had cash and cash equivalents of $25.0&#160;million,
    $34.1&#160;million and $29.0&#160;million and
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities of $0.5&#160;million, $6.3&#160;million and
    $3.5&#160;million as of December&#160;31, 2006,
    December&#160;29, 2007 and June&#160;28, 2008. These amounts
    were held primarily in cash on deposit with banks, money market
    funds, commercial paper, corporate notes or notes from
    government-sponsored agencies, which are short-term. Cash and
    cash equivalents and
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities are held for working capital purposes and restricted
    cash amounts are held as letters of credit for collateral for a
    security agreement with a lender and for our facility lease
    agreements. Due to the short-term nature of these investments,
    we believe that we do not have any material exposure to changes
    in the fair value of our investment portfolio as a result of
    changes in interest rates. Declines in interest rates, however,
    will reduce future investment income. If overall interest rates
    had decreased by 10% during 2007 or the six months ended
    June&#160;28, 2008, our interest income would not have been
    materially affected.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    51
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;31, 2006, December&#160;29, 2007 and
    June&#160;28, 2008, the principal amount of our long-term debt
    outstanding was $12.8&#160;million, $9.4&#160;million and
    $16.6&#160;million and the principal and accrued interest amount
    of our convertible promissory notes outstanding was
    $13.1&#160;million, $5.0&#160;million and $0. The interest rates
    on a small portion of our long-term debt and convertible
    promissory notes are fixed, however, a portion of our long-term
    debt outstanding has interest rates that are variable and adjust
    periodically until December&#160;31, 2008 based on the prime
    rate however, thereafter the interest rates are fixed. If
    overall interest rates had increased by 10% during 2007 or the
    six months ended June&#160;28, 2008, our interest expense would
    not have been materially affected.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Fair
    Value of Financial Instruments</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not have material exposure to market risk with respect to
    investments as our investments consist primarily of highly
    liquid securities that approximate their fair values due to
    their short period of time to maturity. We do not use derivative
    financial instruments for speculative or trading purposes,
    however, we may adopt specific hedging strategies in the future.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Controls
    and Procedures</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2008, in connection with the audit of our
    consolidated financial statements for 2005 and 2006, we
    determined that we had material weaknesses relating to our
    financial statement close and accrual process, revenue
    recognition, inventory costing, cost of sales, purchases cut-off
    and stock-based compensation. A material weakness is defined as
    a deficiency, or combination of deficiencies, in internal
    control over financial reporting, such that there is a
    reasonable possibility that a material misstatement of the
    company&#146;s annual or interim financial statements will not
    be prevented or detected on a timely basis by the company&#146;s
    internal controls. These material weaknesses were as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we did not have a sufficient number of personnel in the
    accounting and finance department with sufficient proficiency
    and technical accounting expertise;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we did not have effective controls in place or designed to
    evaluate the accounting implications of our business
    transactions during 2005 and 2006 and to determine if such
    matters had been properly accounted for in a timely
    manner;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we had not designed or maintained effective operating controls
    over the financial statement close and reporting process in
    order to ensure the accurate and timely preparation of our
    financial statements in accordance with generally accepted
    accounting principles.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    These material weaknesses resulted in the recording of numerous
    audit adjustments for 2005 and 2006. We have taken steps
    intended to remediate these material weaknesses through:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the hiring of additional accounting and finance personnel with
    technical accounting and financial reporting experience,
    including Vikram Jog, our new Chief Financial Officer, who
    joined us in February 2008;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the engagement of a consulting firm to provide further
    accounting expertise to complement the skills of our existing
    team;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the engagement of an accounting firm to advise us on local and
    international tax planning and compliance;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the hiring of an experienced finance manager for Fluidigm
    Singapore Pte. Ltd., who joined us in May 2008;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    increased scheduled communication and coordination among our
    finance teams in the United States and our foreign subsidiaries;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enhanced coordination among, and training of, accounting, sales,
    technical support and legal personnel on transactional issues;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enhancements to our financial statement close process and
    financial close calendar to help enable processes and procedures
    to be completed on a timely basis;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    installation of common accounting software and systems in our
    U.S. and Singapore offices.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    52
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In April and May 2008, following the audit of our consolidated
    financial statements for 2007 and the review of our financial
    statements for the three months ended March&#160;29, 2008, we
    reviewed our internal control over financial reporting and
    concluded that we had certain significant deficiencies, none of
    which were determined to be material weaknesses. A significant
    deficiency is defined as a deficiency, or combination of
    deficiencies, in internal control over financial reporting that
    is less severe than a material weakness, yet important enough to
    merit attention by those responsible for oversight of a
    company&#146;s financial reporting. These significant
    deficiencies were as follows:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we did not have sufficient controls in place to review
    consolidation and elimination entries relating to intercompany
    transfer pricing to detect and eliminate intercompany profits
    embedded in deferred costs of our Japanese subsidiary;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we did not have effective controls in place designed to apply
    SFAS&#160;123R to option grants with a variety of vesting terms
    and to validate stock compensation expenses calculated by our
    option tracking software;&#160;and
</TD>
</TR>
    <FONT style="font-size: 10pt">
    </FONT>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we did not have sufficient controls in place to review the
    valuation of our inventory.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not know the specific time frame needed to remediate the
    significant deficiencies identified. In addition, we expect to
    incur some incremental costs associated with this remediation.
    If we fail to enhance our internal control over financial
    reporting to meet the demands that will be placed upon us as a
    public company, including the requirements of the Sarbanes-Oxley
    Act, we may be unable to report our financial results
    accurately. The actions we plan to take are subject to continued
    management review supported by confirmation and testing, as well
    as audit committee oversight. While we expect to remediate these
    significant deficiencies, we cannot assure you that we will be
    able to do so in a timely manner, which could impair our ability
    to report our financial position, results of operations or cash
    flows accurately and timely.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    53
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='110'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">BUSINESS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Overview</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We develop, manufacture and market proprietary Integrated
    Fluidic Circuit systems that significantly improve productivity
    in the life science industry. Our Integrated Fluidic Circuits,
    or IFCs, integrate a diverse set of critical liquid handling
    functions on a nanoliter scale. Our IFCs can meter, combine,
    diffuse, fold, mix, separate or pump nanoliter volumes of
    fluids, with precise control and reproducibility, many thousands
    of times&#160;&#151; all in parallel on a single chip. This
    technology enables our customers to perform thousands of
    sophisticated biochemical measurements on samples smaller than
    the content of a single cell, with minute volumes of reagents,
    in half the area of a credit card. We achieved this
    &#147;integrated circuit for biology&#148; by miniaturizing and
    integrating liquid handling components on a single
    microfabricated device. Through innovations in material science
    and manufacturing, our IFC architectures are highly flexible,
    and can be designed to support a wide range of applications and
    assay types. For large-scale experimentation, our IFC systems,
    consisting of instrumentation, software and single-use IFCs,
    increase throughput, decrease costs and enhance sensitivity
    compared to conventional laboratory systems. We have sold our
    IFCs to over 100 customers, including many leading biotechnology
    and pharmaceutical companies, academic institutions and life
    science laboratories worldwide.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have commercialized IFC systems for a wide range of life
    science applications, including our BioMark system for gene
    expression analysis, genotyping and digital PCR, and our Topaz
    system for protein crystallization. Researchers and clinicians
    have successfully employed our products in achieving
    breakthroughs across diverse scientific disciplines such as
    genetic variation, cellular function and structural biology.
    These advances include using our systems to help detect
    life-threatening mutations in patients&#146; cancer cells,
    discover indicators of susceptibility to cancer, manage some of
    the world&#146;s most valuable fisheries, analyze the genetic
    composition of individual stem cells, identify fetal chromosomal
    abnormalities from maternal blood samples, analyze the
    aggressiveness of the avian flu virus and assess the quality of
    agricultural seed products. We believe that the flexible
    architecture of our IFC technology will lead to the development
    of IFC systems for a wide variety of additional markets and
    applications, including high-throughput DNA sequencing and
    molecular diagnostics.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="f39432a6f3943217.gif" alt="(IFC FIGURE)">
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Schematic of our 96.96 Dynamic Array IFC including an
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    enlarged section showing four of the IFC&#146;s 9,216 test
    chambers.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The life science industry is currently facing challenges similar
    to those faced by the information technology industry when
    computational power was constrained by the inherent limitations
    of the vacuum tube. Life science research efforts, ranging from
    large-scale initiatives, such as the Human Genome Project, to
    more traditional academic and commercial research projects, are
    continuing to reveal the complex biological and chemical
    processes that are fundamental to living organisms. Automated,
    high-precision and large-scale experimentation is increasingly
    necessary to develop and apply this knowledge. However, the most
    common forms of life science automation rely on cumbersome
    robotic systems that are slow, expensive and labor-intensive
    and, we believe,
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    54
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    fundamentally constrain the pace and productivity of life
    science research. In much the same way that integrated circuits
    overcame the limitations of early computers by placing an
    increasing number of transistors on a single silicon chip, our
    IFCs overcome many of the limitations of conventional laboratory
    systems by integrating an increasing number of fluidic
    components on a single microfabricated IFC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that much of analytical biology and chemistry can be
    performed more efficiently and more economically in nanoliter,
    or one billionth of a liter, volumes than in conventional
    microliter volume platforms. Moreover, we believe that these
    advantages can be further enhanced through high levels of
    integration. Our IFC systems overcome many of the limitations of
    conventional methods by integrating on a single device the
    ability to perform thousands of experiments at one time and in
    nanoliter volumes. Our IFCs consist of an elastomeric, or
    rubber-like, core bonded to a specialized hard plastic input
    frame. The input frame is compatible with standard laboratory
    workflow equipment and facilitates loading the IFC with samples
    and reagents. Each IFC contains an extensive network of
    microfluidic components, such as valves, channels, pumps, mixers
    and other components that deliver samples and reagents to
    thousands of nanoliter chambers across the IFC where individual
    tests can be performed. This high level of nanofluidic
    integration significantly reduces the time and complexity of
    large-scale experimentation and the volume of costly reagents
    and scarce patient samples required. In addition, our IFC
    systems enable users to address problems that would be difficult
    or impractical to solve using conventional life science tools.
    We believe that our ongoing research efforts to increase the
    density and degree of miniaturization of our IFCs will result in
    further such benefits to our customers.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    Target Markets</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Biotechnology and pharmaceutical companies, academic
    institutions and life science laboratories collectively spent
    approximately $35&#160;billion in 2007 for analytical and life
    science instruments, according to Strategic Directions
    International, or SDI. Growth in the life science equipment and
    supplies industry has been driven in part by increased demand
    for tools that allow researchers to discover how fundamental
    functional elements of biology, such as nucleic acids, proteins,
    carbohydrates and cells, interact within living organisms. This
    research often entails analyzing or identifying numerous such
    elements across large sample populations. Conducting and
    commercializing this research requires equipment that reliably
    performs experimentation with precision, on a large scale and at
    an affordable cost. The need for equipment with these
    capabilities is particularly evident in the areas of genomics,
    proteomics and molecular diagnostics, which comprise our initial
    target markets.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Genomics</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Genomics is the analysis of nucleic acids, including DNA and
    RNA, the fundamental building blocks of life. The entire DNA
    content of an organism is known as its genome. The genome is
    composed of a long series of nucleotide bases that are organized
    into functional units known as genes, as well as regulatory
    regions. Analysis of variations in genomic sequences, genes and
    gene activity in and between organisms can provide important
    insights into routine genetic functionality, as well as an
    organism&#146;s morbidity and mortality. The worldwide demand
    for genomic analysis instruments and supplies was approximately
    $4.9&#160;billion in 2005, according to SDI. Of this total, SDI
    estimated that 56%, or about $2.7&#160;billion, was spent on
    gene expression analysis, and 20%, or about $1.0&#160;billion,
    was spent on genotyping. In a 2006 report, SDI projected that
    the markets for gene expression analysis and genotyping would
    grow approximately 8% per year from 2005 to 2010. In a separate
    2006 report, Frost and Sullivan indicated that the
    high-throughput DNA sequencing market was in a very early stage,
    but estimated it would grow at an annual rate of 63.8% between
    2005 and 2012, reaching $339 million in 2012.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Gene expression and genotyping today are studied through a
    combination of various technology platforms that characterize
    gene function and genetic variation. Gene expression and
    genotyping are commonly performed using a technique known as
    polymerase chain reaction, or PCR, and often with a chemistry
    branded as TaqMan, which is proprietary to Roche Molecular
    Systems, Inc. and is widely used in the life-sciences industry.
    The PCR method is used to replicate a strand of DNA or RNA into
    millions of copies to facilitate detection in a sample.
    Real-time quantitative PCR, or real-time qPCR, is a more
    advanced form of PCR that makes it possible to identify the
    number of copies of DNA present in a sample at a certain time.
    According to Frost and Sullivan, the U.S.&#160;market for
    real-time qPCR was approximately $741&#160;million in 2007,
    growing at approximately 11% per year from 2005 to 2012. Based
    on our estimates, we believe the global market for real-time
    qPCR was approximately $1.7&#160;billion in 2007.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    55
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     Gene expression, genotyping, digital PCR and high-throughput
    DNA sequencing are four powerful forms of genomic analysis.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Gene Expression Analysis.</I>&#160;&#160;One of the ways
    genes control cellular activity is through a process known as
    gene expression, when a cell transcribes a section of a
    gene&#146;s DNA to create another nucleic acid sequence, known
    as messenger RNA. This messenger RNA may then be translated by
    the cell into a protein. Messenger RNA can be detected and
    quantified by performing real-time qPCR tests, or assays. Gene
    expression analysis typically entails determining which genes
    are active by measuring messenger RNA levels in a blood or
    tissue sample. These results can be correlated with disease
    activity and clinical outcomes. As multiple genes are involved
    in most biological processes, gene expression analysis usually
    requires assaying the expression levels of many genes
    simultaneously across many samples. We estimate that
    approximately 80% of the market for real-time qPCR involves gene
    expression analysis.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Genotyping.</I>&#160;&#160;Genotyping involves the analysis
    of variations across individual genomes. These variations often
    take the form of single nucleotide changes, known as single
    nucleotide polymorphisms, or SNPs, that can determine the
    characteristics or health of the individual. In SNP genotyping
    studies, the DNA sequences of a group of individuals are
    analyzed to determine patterns of SNPs. Statistical analysis is
    then performed to determine whether a SNP or group of SNPs can
    be associated with a particular characteristic, such as
    propensity for a disease. We estimate that approximately 20% of
    the market for real-time qPCR involves genotyping analysis. We
    believe this percentage share of the real-time qPCR market is
    growing based on technological innovations allowing increasing
    amounts of genetic content to be analyzed more quickly and cost
    effectively.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Digital PCR.</I>&#160;&#160;Digital PCR is a technique that
    allows researchers to detect nucleic acid sequences that are
    present in a patient sample in concentrations that are too low
    to be detected by conventional methods. Digital PCR typically
    relies on standard PCR techniques, but increases their
    sensitivity by dividing a sample into hundreds or thousands of
    smaller samples and performing a PCR assay on each such sample.
    The ability to actually count the presence or absence of
    amplification in this assay format provides quantitative
    measurement capabilities known as absolute quantification.
    Digital PCR has the potential to enable early detection of
    diseases and other conditions, thereby improving prospects for
    effective treatment. In addition, this technique enhances the
    precision of single molecule assays and copy number variation.
    While the digital PCR market is currently nascent, we believe it
    has the potential to grow significantly as researchers learn how
    to apply this technique to a broader range of research
    applications and associated diseases.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>High-Throughput DNA Sequencing.</I>&#160;&#160;DNA sequencing
    involves determining the sequence of nucleotide bases in a
    segment of DNA and is widely used in life science research as a
    tool to understand the genetic basis of susceptibility to
    disease, disease progression and response to drug therapy.
    Sequencing technology has rapidly advanced over the last two
    decades and current high-throughput DNA sequencing machines are
    many orders of magnitude faster and less expensive than the DNA
    sequencing technology available at the initiation of the Human
    Genome Project in 1990. However, to most effectively use these
    high-throughput DNA sequencers, researchers must carefully
    prepare the sample to be analyzed both to minimize contamination
    and to precisely quantify the amount of sequenceable template
    DNA in the sample. This process can be difficult, time-consuming
    and expensive.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 6%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Proteomics</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Proteomics is the large-scale study of the function and
    structure of proteins. Proteins are produced by all living
    organisms and directly affect cellular function, the overall
    health of an organism and, in the case of pathogens, how the
    organism interacts with its host. Developing drugs to treat a
    disease often involves identifying molecules that are able to
    interfere with the activity of a particular protein in the
    pathway for that disease. One approach to finding such molecules
    is to first determine the structure of the protein and then look
    for molecules that bind to the structure and interfere with the
    activity of the protein. A technique known as protein
    crystallization is typically used to determine protein
    structures. Crystallizing a protein can be a time-consuming and
    labor-intensive process because different proteins will
    crystallize in the presence of different reagents and under
    different conditions. As samples of particular
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    56
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    proteins are often scarce and expensive, researchers usually
    conduct only a limited number of experiments, none of which
    might provide a crystallized protein.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Molecular
    Diagnostics</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Molecular diagnostic tests are used in clinical practice to
    diagnose, classify or monitor a disease; determine a
    patient&#146;s susceptibility to a disease; or monitor a
    patient&#146;s response to therapy by detecting one or more
    biomarkers, such as nucleic acids or proteins, in a blood,
    tissue or other type of patient sample. The advancement of
    molecular diagnostics is being driven by researchers performing
    large-scale experiments analyzing the prevalence of SNPs,
    variations in gene expression levels and patterns of protein
    production. SNPs, gene expression levels and proteins often
    directly cause or control diseases. Molecular diagnostic tests
    based on measuring these biomarkers have the potential to be
    much more accurate, discriminating and robust than conventional
    diagnostics. According to Frost and Sullivan, the
    U.S.&#160;market for molecular diagnostics was estimated at
    $2.0&#160;billion in 2007, growing at a compound annual growth
    rate of 17% from 2005 to 2012.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">The
    Limitations of Existing Laboratory Systems</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Scientists increasingly seek to identify and measure a large
    number of characteristics across large populations. The most
    common existing methods of large-scale experimentation require a
    workflow that is complex, labor-intensive and expensive. In this
    workflow, biological samples and chemical compounds, usually in
    solution, are generally dispensed or pipetted into standard
    microwell plates, which usually consist of 96 or 384&#160;wells
    each in a standardized format. The plates may then be moved to
    another station where reagents can be applied to the sample or
    compound to create a single assay in each microwell. The
    microwell plates may be moved again to attain ideal reaction
    temperatures or other conditions. The plates are then generally
    moved into a reader to detect the results of the experiment in
    each well. This process of dispensing materials and conveying
    the plates may include robotically performed steps but generally
    also requires a significant manual labor component. To
    accomplish these steps on a large scale typically requires the
    use of large laboratories equipped with many types of equipment,
    robotics, conveyor systems and personnel.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Conventional microwell plate workflows have a number of
    characteristics that inherently limit their effectiveness as
    tools for large scale experimentation:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Complex Workflow.</I>&#160;&#160;Pipetting stations may have
    to perform hundreds of thousands of pipetting steps using
    hundreds of microwell plates in order to conduct a single set of
    experiments. These microwell plates must typically be moved
    among several work stations to complete and measure the results
    of each assay. Maintaining and overseeing complex workflows
    involving large numbers of microwell plates requires ongoing
    attention from trained technicians.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Limited Throughput.</I>&#160;&#160;Due to the large number of
    pipetting steps, microwell plates and process steps involved in
    a conventional microwell workflow, these systems are often
    unable to perform large-scale experiments in a timely and
    cost-effective manner.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Limited Low Volume Capabilities.</I>&#160;&#160;Conventional
    systems are typically unable to dispense samples and reagents in
    quantities small enough to conduct certain high sensitivity, low
    volume techniques, such as digital PCR.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Large Sample Requirements and Significant Running
    Costs.</I>&#160;&#160;Biological samples are often available in
    only very small quantities. As a result, the sample amount that
    needs to be placed in each well often limits the number of
    experiments that can be performed. In addition, reagents can be
    expensive to purchase or produce, and consuming them in
    microliter or larger quantities results in significant and
    sometimes prohibitive costs.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>High Capital Cost.</I>&#160;&#160;Because of the limited
    throughput of conventional systems, multiple pipetting stations,
    plate handlers and readers may be required to meet the demands
    of large-scale experimentation, resulting in high capital
    equipment costs.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Other methods of large-scale experimentation, including
    microarrays, pre-formatted arrays, bead arrays and mass
    spectrometer analysis, have been developed to address some of
    the limitations of conventional microwell plate
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    57
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     systems. However, each of these high-throughput methods has one
    or more limitations that reduce its utility for large-scale
    experimentation.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Microarrays, pre-formatted arrays and bead arrays all lack
    flexibility because researchers must specify the assays they
    wish to perform at the time the products are ordered. This in
    turn limits researchers&#146; ability to refine their assay
    panel during the course of a study. In addition, if researchers
    wish to use assay panels other than a manufacturer&#146;s
    standard panels, it may take weeks for a customized product to
    be produced, and the cost may be significant. Furthermore, it is
    often difficult or impossible to convert existing validated
    assays for use with these technologies or with mass spectrometry
    analysis.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The quality of the data produced by microarrays, pre-formatted
    arrays and mass spectrometer analysis is insufficient for
    certain research activities. For genotyping studies, data
    quality is typically measured by a call rate, which is the
    percentage of time that a method provides a reading with respect
    to a particular SNP. Both pre-formatted arrays and mass
    spectrometer analysis generally have call rates lower than
    conventional microwell plate systems. For gene expression
    studies, it is often important to measure expression levels over
    a broad dynamic range to capture all or most of the variation
    typically found among subjects. None of microarrays,
    pre-formatted arrays, bead arrays or mass spectrometer analysis
    routinely measure gene expression levels over as broad a dynamic
    range as conventional microwell plates.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The workflow for bead arrays and mass spectrometer analysis is
    complex, time consuming and expensive. For example, standard
    protocols often require multiple complex operations to be
    performed over several days by skilled technicians.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    These methods can also be very expensive for certain types of
    large-scale experimentation. For example, a single microarray or
    bead array is capable of analyzing thousands of genes from a
    single sample and these devices have been successfully used for
    surveying the genome to discover basic patterns of gene
    expression and genotyping. These surveys or &#147;association
    studies&#148; are commonly performed on tens or hundreds of
    samples and are intended to identify a subset of genes for
    further study. However, for validation studies, which typically
    require the analysis of thousands or tens of thousands of
    samples, the high per sample cost of microarrays and bead arrays
    often make them uneconomical. Similarly, the high initial setup
    costs for mass spectrometry analysis generally make it
    economical only for very large-scale studies.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A number of companies have attempted to develop more universal
    <FONT style="white-space: nowrap">&#147;lab-on-a-chip&#148;</FONT>
    solutions which could perform large numbers of complex
    biochemical operations on a single device. These chips typically
    incorporate a variety of micron-level features, such as channels
    and wells, but lack robust methods of fluid control such as
    valves. As a result, the products have been unable to support
    the complex fluidic manipulation required by large-scale
    experimentation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The limitations of existing technologies become even more acute
    when clinicians attempt to translate scientific research into
    molecular diagnostics. Given the commercial nature of their
    operations, clinical laboratories need systems that can test
    large numbers of patient samples at low cost and with minimal
    labor requirements. Moreover, many of the most promising
    research studies rely on measuring each sample across tens or
    even hundreds of SNPs, gene expression levels or protein
    concentrations to diagnose or classify a disease. We believe
    that using standard microwell plate technology to make multiple
    measurements on a large number of samples is often too complex
    and expensive for most clinical laboratories. As a result, the
    molecular diagnostic tests adopted by clinical laboratories have
    generally been relatively simple or have required specialized
    machines to perform. Diagnostic approaches that require
    measuring large numbers of SNPs, gene expression levels or
    protein concentrations are generally not available or are
    available only from a diagnostic laboratory that specializes in
    the particular test.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To achieve and exploit breakthroughs in genomics, proteomics and
    molecular diagnostics, research and clinical laboratories need
    robust systems that deliver increased throughput and simpler
    workflows with decreased costs.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">The
    Fluidigm Solution</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFC systems are designed to overcome many of the limitations
    of conventional methods by empowering researchers and clinicians
    to rapidly perform a large number of experiments at one time and
    in nanoliter volumes,
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    58
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    significantly increasing throughput, reducing costs associated
    with reagents and patient samples and reducing the time and
    number of steps involved. Our IFCs deliver these advantages
    through integration of sophisticated nanoliter fluid handling in
    an easy-to-use format. We believe the advantages of our IFC
    systems can be applied to a wide variety of applications across
    many fields using standard chemistries.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For each application, we provide a complete IFC system
    consisting of specially designed single-use IFCs,
    instrumentation, software and support services. Our IFC systems
    are designed to be easily incorporated into our customers&#146;
    laboratory environments and analysis workflow. For example, our
    IFCs are the same size and shape as standard 384 microwell
    plates, which facilitate the loading and handling of our IFCs by
    standard laboratory equipment. Each IFC includes an elastomeric,
    or rubber-like, core that contains an extensive network of
    microfluidic components, such as valves, channels, pumps, mixers
    and other components that deliver samples and reagents to
    thousands of nanoliter volume chambers where individual assays
    can be performed. In much the same way that semiconductor
    technology has enabled tremendous computational power to be
    placed onto a single silicon chip, the integration of large
    numbers of miniaturized components on our IFCs enables
    sophisticated fluid handling at high throughput and low cost.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our BioMark 48.48 Dynamic Array IFC allows users to individually
    assay 48 samples against 48 primer-probe sets, generating 2,304
    separate real-time qPCR reactions on a single device. In May
    2008, we launched our 96.96 Dynamic Array IFC, which is
    configured to run 96 samples against 96 primer-probe sets,
    generating 9,216 separate reactions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table compares the performance of one conventional
    384 microwell plate to that of one of our 48.48 Dynamic Array
    IFCs and one of our 96.96 Dynamic Array IFCs for a genotyping
    study involving 1,000 samples and 96 SNPs:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="55%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="13%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="13%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="13%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Fluidigm 48.48<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Fluidigm 96.96<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>384 Microwell<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Dynamic Array<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Dynamic Array<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Plate (5 &#181;l/well)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>IFC</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>IFC</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Runs for Study
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    250
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    42
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    11
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total reaction volume
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    480 ml
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    20 ml
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    10 ml
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pipetting Steps
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    192,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4,032
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    2,112
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The advantages of our IFC systems over existing microwell-based
    systems include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Reduced Complexity.</I>&#160;&#160;Loading our IFC requires
    orders of magnitude fewer pipetting steps than
    384&#160;microwell plates for the same experiment, which reduces
    the time, cost and potential for error.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Improved Throughput.</I>&#160;&#160;A single IFC based on our
    96.96 format can conduct 9,216 real-time qPCR or other assays,
    or 24 times more assays than a single 384 microwell plate. The
    improved throughput reduces the time and cost associated with
    complex experiments and expands the number and range of
    experiments that may be conducted.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Nanoliter Precision.</I>&#160;&#160;Our IFC systems allow
    users to dispense samples and reagents in microliter volumes
    which are automatically combined and mixed in nanoliter and
    sub-nanoliter volumes. In addition to cost and workflow
    benefits, this capability makes it practical for users to
    conduct certain high sensitivity, low volume techniques, such as
    digital PCR and single cell analysis.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Reduced Sample and Reagent
    Requirements.</I>&#160;&#160;Obtaining patient samples for
    assays can also be costly, and in many cases the amount of those
    samples is finite. Our systems typically require between 0.5%
    and 1.0% of the amount of sample and reagent per reaction as
    conventional systems, allowing scarce samples and costly
    reagents to be conserved or tested more extensively.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Decreased Capital Cost.</I>&#160;&#160;A single BioMark
    system has the same throughput as the combined throughput of
    multiple conventional systems. As a result, for high volume
    users, the cost of purchasing one BioMark system can be much
    lower than the cost of purchasing the number of competing
    systems and associated robotic equipment required to provide the
    same throughput, even though our BioMark system may cost more on
    a per unit basis.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    59
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Compatibility with Existing
    Infrastructure.</I>&#160;&#160;Our IFCs incorporate plastic
    input frames that are the same size as standard microwell plates
    and are designed to work with the most commonly used laboratory
    systems, including existing robotic pipetting systems, bar code
    readers, plate handling systems and other equipment. Our IFCs
    are also designed to work with standard real-time qPCR
    techniques and TaqMan chemistries. As a result, we believe users
    are able to quickly introduce our systems into their
    laboratories and achieve results equal to or better than they
    were obtaining with conventional systems.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFC systems also have significant advantages over other
    high-throughput approaches. For example, our BioMark system can
    detect gene expression levels over a much broader dynamic range
    than microarrays, pre-formatted arrays, bead arrays or mass
    spectrometry analysis. For genotyping, our BioMark system has a
    call rate equal to or better than conventional microwell-based
    systems. Also, our IFC systems provide researchers with needed
    flexibility in assay selection and study design. Unlike
    microarrays, bead arrays and pre-formatted arrays, our IFCs are
    not limited to detecting certain predetermined genetic markers.
    Instead, users can perform experiments with our IFCs using
    assays from their existing libraries, purchased from a wide
    variety of commercial sources or developed in their own
    laboratories. Finally, the efficient workflow of our IFC systems
    enables users to complete an IFC run in less than three hours.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Other high-throughput approaches have advantages over
    conventional microwell plate systems that are similar to the
    advantages of our IFC systems. For example, microarrays,
    pre-formatted arrays, bead arrays and mass spectrometry analysis
    all reduce complexity and increase throughput as compared to
    conventional approaches when used for large scale
    experimentation, and, in many instances, are more cost-effective
    than conventional approaches. In addition, pre-formatted arrays
    significantly reduce sample and reagent consumption as compared
    to microwell plates. Also, microarrays and bead arrays have call
    rates for genotyping that are comparable to those obtained with
    our systems or with microwell plate systems. Because these
    systems are designed to detect thousands of genetic markers,
    they are often chosen by researchers to perform very large-scale
    association or survey studies over conventional microwell plate
    systems or our systems.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFC systems address the needs of researchers and clinicians
    who perform large-scale experimentation in the areas of
    genomics, proteomics and molecular diagnostics. In particular,
    for validation studies or projects of a similar scale, our IFC
    systems substantially reduce cost, simplify workflow and
    increase throughput as compared to conventional microwell plate
    systems. Nevertheless, researchers and clinicians may be slow to
    adopt our IFC systems as they are based on technology that,
    compared to conventional technology, is new and not yet
    well-established in the industry. Moreover, many of the existing
    laboratories have already made substantial capital investments
    in their existing systems and may be hesitant to abandon that
    investment. While we believe our systems provide significant
    cost-savings, the initial price of our systems and the price of
    our IFCs is higher than conventional systems and standard
    384&#160;microwell plates. Our IFC systems are less well suited
    for smaller scale research initiatives where complexity and
    workflow issues may be less pressing and conventional systems
    may be more economical. As life science research continues to
    evolve and is commercialized, we believe that there will be
    increasing demand for life science automation solutions that
    enable experimentation on the scale supported by our IFC systems.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Applications</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFC technology has the potential to be applied to a vast
    range of research and commercial applications. We have
    commercialized IFC systems for life science research
    applications such as gene expression analysis, genotyping,
    digital PCR and protein crystallization. We believe that these
    applications are relevant to markets beyond life science
    research, such as the development of molecular diagnostics, and
    that IFC systems can be developed for numerous other life
    science applications. We and our academic and corporate
    collaborators have developed non-commercial IFCs for a wide
    variety of applications in the areas of genomics, proteomics,
    cellular biology and synthetic chemistry. As illustrated by the
    examples below, researchers have been able to utilize the
    advantages of our IFC systems in their laboratories to achieve
    significant research successes.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Current
    Commercial Applications</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Gene Expression Analysis.</I>&#160;&#160;Researchers may
    conduct gene expression studies to measure the activity of tens
    or hundreds of genes across hundreds or thousands of
    individuals. For these validation studies, it is often important
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    60
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     to know the expression level of a gene, not merely whether the
    gene is &#147;on&#148; or &#147;off,&#148; as often either high
    or low activity level is associated with a particular
    characteristic or disease state. Our IFC systems have been used
    to deliver high-throughput and precise measurements in gene
    expression analysis applications. For example, researchers at
    Myriad Genetics have identified panels of genes that could be
    used to predict cancer progression or select treatment options.
    However, the cost and complexity of high-throughput real-time
    qPCR using conventional microwell plates significantly limited
    researchers&#146; ability to perform the appropriate assays. In
    response, Myriad Genetics adopted our BioMark system which,
    together with our Dynamic Array IFCs, has allowed them to
    significantly reduce their pipetting workload, and therefore
    pursue research projects that may have been prohibitively
    cumbersome without our system.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Genotyping.</I>&#160;&#160;Researchers performing genotyping
    studies may begin by surveying the genomes of relatively few
    individuals looking for tens of thousands or even hundreds of
    thousands of SNPs. Analysis of these studies will often reveal
    that a relatively small number of SNPs appear to be correlated
    with the characteristic of interest. To validate this analysis,
    researchers may conduct additional studies involving hundreds or
    even thousands of individuals focused on tens or hundreds of
    SNPs. For example, the National Cancer Institute&#146;s Core
    Genotyping Facility, or the CGF, collaborates with researchers
    at other government research centers and academic institutions
    with the goal of developing screens to identify individuals
    susceptible to particular forms of cancer and guiding the
    development of targeted therapeutics. One of the CGF&#146;s
    primary responsibilities in these collaborations is conducting
    the large-scale experiments necessary to accurately interrogate
    hundreds of SNPs on many patient samples. In a typical
    association study, the CGF runs 30 to 300 assays on 1,000 to
    10,000&#160;patient samples. Such large-scale studies are
    difficult and expensive to perform with conventional microwell
    plate technology. Using our BioMark system, the CGF continues to
    perform the same assays previously developed in its existing
    library of over 5,000 assays.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Genotyping analysis is also used in situations where research
    has already identified particular genetic profiles of interest
    and there is a need to test a group of subjects to determine
    which profile they fit. For example, the Alaska Department of
    Fish and Game uses our BioMark system to perform genotyping
    analysis to determine the region of origin of salmon caught in
    commercial or sport fisheries. By analyzing a large number of
    salmon, the department can gain an understanding of the effects
    that fisheries have on populations of salmon and thereby manage
    the resource more effectively. The department has developed
    panels for three species which range from 40 to 60 SNPs, and its
    throughput approaches 100,000 samples per year.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Digital PCR.</I>&#160;&#160;The widespread use of genetic
    testing in high-risk pregnancies has created strong interest in
    rapid and accurate molecular diagnostics for certain common
    chromosomal abnormalities. However, conventional methods have
    limitations related to speed, precision and the risks associated
    with sampling a significant amount of material from the fetus
    during an invasive procedure, such as amniocentesis or chorionic
    villi sampling. Digital PCR has been identified as a technique
    for highly sensitive and precise nucleic acid measurement, but
    performing it with conventional laboratory equipment is so
    cumbersome that it has not been widely adopted. In an article
    published by Analytical Chemistry in August 2007, researchers at
    the laboratory of Professor Stephen Quake, our
    <FONT style="white-space: nowrap">co-founder,</FONT>
    at Stanford University demonstrated that digital PCR can be used
    for accurate measurement of trisomy&#160;21, or Down syndrome.
    Using our Digital Array IFC and DNA from human cell lines,
    Dr.&#160;Quake&#146;s laboratory was able to precisely measure
    the number of copies of a DNA sequence from this chromosome and
    at the same time measure the number of copies of a DNA sequence
    from another chromosome whose copy number does not vary. For
    trisomy 21, the ratio of these markers is significantly higher
    than normal. Similar work in pre-natal genetic testing is being
    pursued using our IFCs by other customers at leading academic
    institutions. We believe that with further clinical validation
    and development, such research could be developed into a
    diagnostic test that would require significantly less material
    from the fetus and provide results much more rapidly than
    current methods. We also believe that digital PCR will enable
    such diagnostics to ultimately be used in a non-invasive
    fashion, thus further reducing risk to the fetus.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cancer researchers have identified a particular mutation in
    chronic myeloid leukemia cells that render those cells resistant
    to the drug Gleevec. Gleevec is typically used as the initial
    treatment for this type of leukemia and is often able to put the
    disease into remission for months or years. However, a
    significant proportion of these leukemia patients eventually
    develop mutated leukemia cells that are resistant to Gleevec.
    These mutated cells are initially very scarce and undetectable
    using conventional systems, but they eventually multiply and
    cause the patient to
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    61
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    become symptomatic again. Researchers at the Fred Hutchinson
    Cancer Research Center have used our Digital Array IFC in their
    laboratory to test patient samples and have been able to detect
    these mutated cells earlier than with conventional techniques.
    With additional validation and demonstration of clinical
    relevance, we believe a test based on digital PCR could be a
    useful tool for monitoring patients who are diagnosed with
    chronic myeloid leukemia.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Protein Crystallization.</I>&#160;&#160;In order to determine
    how a particular protein interacts with other components of a
    disease pathway, researchers often attempt to determine its
    structure using protein crystallization. Because most proteins
    will crystallize only under very precise conditions that are
    specific to the particular protein, protein crystallization
    involves performing numerous assays to determine the conditions
    under which the protein crystallizes. As described in the April
    2006 issue of the journal <I>Science </I>and supporting online
    material, researchers at the Wilson lab of Scripps Research
    Institute in La Jolla, California used our Topaz system to
    understand how the H5N1 avian flu virus can infect humans.
    Researchers at the Wilson lab had prepared a small sample of the
    protein that the virus uses to attach itself to cells in the
    respiratory tract. With the Topaz system, they were able to
    quickly screen a few microliters of the sample across a wide
    variety of different conditions and determine the optimum
    conditions for protein crystallization. Using this information,
    they were able to grow larger crystals using standard
    crystallization techniques. Subsequent analysis of the structure
    of the crystallized protein revealed why the current form of the
    avian H5N1 virus has not yet acquired the ability to readily
    infect humans compared to other flu viruses.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Potential
    Future Applications</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>High-Throughput DNA Sequencing.</I>&#160;&#160;For many
    years, researchers have wanted to conduct large scale studies of
    genomic variations to better understand gene regulation and gene
    function. However, it was only with the recent introduction of
    ultra high-throughput DNA sequencers, sometimes referred as next
    generation sequencing, that conducting such studies became
    feasible. Accurately performing DNA sequencing with these
    high-throughput machines requires careful preparation of the
    sample to be analyzed, including precisely determining the
    amount of template DNA present in the sample. Quantifying or
    titrating the DNA in the sample using conventional methods is
    often a painstaking and lengthy process that can consume a large
    quantity of the sample itself. Stanford University researchers
    working in the laboratory of Dr.&#160;Stephen Quake, who is a
    co-founder of Fluidigm and chair of our Scientific Advisory
    Board, have demonstrated that our Digital Array IFC can be used
    to quantify the amount of DNA in a sample in four hours or less
    with the precision typically needed by high-throughput DNA
    sequencers. We believe that their technique provides high
    quality sequencing data and is significantly quicker and less
    expensive than conventional titration methods. In addition,
    because the technique consumes a very small amount of the
    sample, it can be used in situations where only scarce sample is
    available. Though researchers have just begun to adopt
    high-throughput DNA sequencers, we believe there are over 1,000
    genomic research sites worldwide that are potential users of the
    machines within the next few years. Two of our customers have
    begun using our Digital Array IFC to perform this technique on a
    trial basis, and we expect to make the application more widely
    available beginning in the fourth quarter of this year.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Molecular Diagnostics.</I>&#160;&#160;Life science research
    is revealing an increasing number of diseases and conditions
    that can be diagnosed, evaluated and monitored by measuring
    panels of gene expression levels, SNPs, proteins or other
    biomarkers. Validating these research findings and translating
    them into clinically available tests often requires life science
    automation systems that are able to efficiently measure multiple
    biomarkers in a large number of patient samples. Our existing
    IFC systems are able to measure certain nucleic acid biomarkers
    that are commonly used in these tests, and we expect that we
    will be able to develop IFC systems to measure other relevant
    biomarkers. As described above, researchers have used our IFC
    systems to detect clinically relevant biomarkers, such as drug
    resistant leukemia cells and fetal chromosomal abnormalities. We
    believe that the high throughput, flexibility and simplified
    workflow of our IFC systems could make them an attractive
    solution for validating and commercializing a wide range of
    molecular diagnostic tests being developed by researchers. In
    addition, we believe that our IFC systems&#146; ability to
    measure gene expression levels across a broad range and to
    detect nucleic acid sequences present in very low concentrations
    will support the development and commercialization of molecular
    diagnostic tests that would not be practical with conventional
    systems. Our IFC systems have not been cleared or approved by
    the U.S.&#160;Food and Drug Administration, or FDA, for use in
    any molecular diagnostic tests and we cannot currently
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    62
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    market them for the purpose of performing molecular diagnostic
    tests. We do not have any current plans to develop products that
    are regulated by the FDA.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Other Applications.</I>&#160;&#160;We believe that the
    inherent design flexibility of our core technology allows us to
    build IFC systems that can provide significant benefits in a
    wide range of fields and industries. For example, the
    architecture of our Dynamic Array is flexible and supports the
    development of IFCs that create matrixed combinations of a
    variable number of samples versus a variable number of reagents.
    In addition, our IFC technology utilizes a variety of
    microfluidic components, such as pumps, mixers and separation
    columns, that allow the implementation of sophisticated
    biochemical processes on our IFCs. While we have not commenced
    commercial development of IFC systems for these fields, we have
    developed IFCs for internal research purposes in such diverse
    fields as:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    immunoassays, which can measure levels of protein expression and
    other molecules in a highly-parallel, multiplexed format;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    high-throughput drug screening, including the analysis of
    molecules that inhibit protein-protein and protein-nucleic acid
    interactions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    chemical synthesis, including production of radio-labeled sugars
    which in combination with advanced medical imaging can help
    diagnose and monitor cancer;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    pharmacogenomics, an emerging field that analyzes how variations
    in human genomes affect the performance and toxicity of
    therapeutic agents;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    systems biology, an effort to understand the collective behavior
    of genes as they collaborate in networks;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    synthetic biology, an emerging field aimed at engineering
    biological systems to build novel biological functions, systems
    and perhaps organisms; and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    cellular assays, including stem cells and regenerative medicine,
    where our IFCs have been used to isolate, cultivate and analyze
    single cells.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Strategy</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to become a global leader in providing automated
    bio-analytical research and molecular diagnostic systems. Our
    business strategy consists of the following elements:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Establish our IFC Technology as the Leading Solution for a
    Broad Range of Life Science Applications.</I>&#160;&#160;Our
    initial sales and marketing efforts have been focused on
    establishing our IFC systems as leading solutions for
    high-throughput life science research applications. We intend to
    leverage the market awareness and acceptance created by our
    initial product offerings to market new products and
    applications to life science researchers and to sell new and
    existing applications to customers in other markets, such as
    molecular diagnostics and applied genomics.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Continue to Increase the Throughput and Efficiency of Our
    IFCs.</I>&#160;&#160;A primary focus of our research and
    development efforts is the development of IFCs with increased
    component density and, therefore, the ability to conduct an
    increased number of experiments on a single IFC. Increasing
    density provides value to our customers by increasing
    throughput, enhancing efficiency, reducing labor costs and
    reducing reagent and sample volumes. We expect that these
    increased capacity IFCs will allow us to deliver additional
    capabilities and cost savings, and further improve our
    competitive position.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Expand Recurring IFC Revenue Stream Through Product
    Innovation and System Sales.</I>&#160;&#160;We intend to drive
    revenue growth by increasing the number of installed IFC
    systems, improving the cost per test of our IFCs and developing
    IFCs and systems for additional applications.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Provide Superior Customer Service.</I>&#160;&#160;We have a
    global sales force and support organization that offers
    technical solutions and customer support through direct
    relationships with our current and potential customers. Through
    the direct connection with our customers, we are able to better
    understand their needs and apprise
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    63
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    them of new product offerings and technological advances in our
    current IFC systems, related instrumentation and software, while
    maintaining a consistent marketing message and high level of
    customer service.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Enhance IFC Manufacturing Efficiency.</I>&#160;&#160;We
    intend to enhance our manufacturing efficiency through
    improvements in our existing processes, development of new IFC
    designs and implementation of new manufacturing methods in order
    to improve our manufacturing yields and reduce our manufacturing
    costs. We believe that these improvements will enable us to
    deliver additional value to our customers and to maintain or
    enhance our advantages over competing systems.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Continue to Develop our Technology and Intellectual Property
    Position.</I>&#160;&#160;Our products are based on a set of
    related proprietary technologies that we have either developed
    internally or licensed from third parties. We intend to continue
    making significant investments in research and development to
    further expand and deepen our technological base. At the same
    time, we intend to maintain and strengthen our intellectual
    property position through the continued filing and prosecution
    of patents in the United States and internationally and through
    the in-licensing of third party intellectual property as
    appropriate.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Products</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We currently market two IFC systems, the BioMark system for
    real-time qPCR and the Topaz system for protein crystallization.
    Each system consists of single-use IFCs, loaders that control
    the IFCs, readers that detect reactions on the IFCs and software
    for analyzing, annotating and archiving the data produced by the
    readers.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    BioMark System for Real-Time qPCR</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The BioMark system allows users to perform gene expression
    analysis, genotyping and digital PCR using standard TaqMan
    chemistry.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">BioMark
    Dynamic Array IFCs</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our BioMark 48.48 Dynamic Array IFC is based on matrix
    architecture that allows users to individually assay 48 samples
    against 48 primer-probe sets, generating 2,304 real-time qPCR
    reactions on a single device. One version of this IFC is
    optimized to perform gene expression analysis and another is
    optimized for genotyping, each assay in volumes of
    10&#160;nanoliters or less.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We commercially introduced our Dynamic Arrays in the fourth
    quarter of 2006 and, as of June&#160;28, 2008, 16&#160;customers
    have purchased Dynamic Array IFCs for use in applications, such
    as SNP association follow-up studies and single stem-cell gene
    expression profiling. In May 2008, we launched our&#160;96.96
    Dynamic Array IFC, which is configured to run 96 samples against
    96 primer-probe sets, generating 9,216 reactions.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">BioMark
    Digital Array IFCs</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The BioMark 12.765 Digital Array IFC is based on partitioning
    architecture that allows users to divide 12&#160;separate
    samples into 765 smaller samples and perform a real-time qPCR
    assay against each sample in less than 10&#160;nanoliter
    volumes. This IFC can be used for digital PCR and to precisely
    quantify the amount of a particular nucleic acid sequence
    present in a sample. We have been selling Digital Array IFCs
    since March 2007 and, as of June&#160;28, 2008,
    16&#160;customers have purchased Digital Array IFCs for use in
    applications, such as characterizing unculturable bacteria,
    cancer detection and high-throughput DNA sequencing.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">BioMark
    Instrumentation and Software</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our NanoFlex IFC Controller for the BioMark system fully
    automates the setup of IFCs for real-time qPCR-based experiments
    and includes software for implementing and tracking experiments.
    The instrumentation for our BioMark system controls the
    real-time qPCR process and detects the fluorescent signals
    generated using a white light source, emission and excitation
    filters, precision lenses, a licensed thermal cycler and a
    digital camera. We also offer various software packages that
    provide data analysis following data collection. Our analysis
    software shows data as color-coded maps of every position on the
    IFC, as amplification curves and as numeric tabular data.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    64
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    Topaz System for Protein Crystallization</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Topaz system allows users to screen protein samples against
    a set of reagents in order to determine the optimum conditions
    for crystallizing a protein. The Topaz system includes IFCs
    similar to our Dynamic Array architecture that have been
    optimized for highly efficient protein crystallization screening.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Topaz
    Screening IFCs and Reagents</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our 1.96, 4.96 and 8.96 Screening IFCs for our Topaz system
    allow users to test 96 different reagents or reagent
    concentrations against one, four or eight different protein
    samples. We estimate that our screening IFCs require only
    1%&#160;the amount of sample used in standard microwell plate
    technologies, which is important because protein samples are
    often extremely scarce or difficult to prepare. The 4.96 and
    8.96 IFCs provide greater fluid handling efficiency by enabling
    the parallel processing of different samples containing a
    particular protein or different constructs of the same protein
    on a single IFC. This parallel processing saves pipetting steps
    and allows the user to determine the best sample or construct to
    use when scaling up production of a protein to generate
    diffraction-quality crystals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We also re-sell third party reagents that we have tested with
    our Topaz system. Though our customers may purchase or make
    their own reagents for use with our system, we recommend that
    they use reagents that we have validated.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We commercially introduced our Topaz systems in the first
    quarter of 2003 and, as of June&#160;28, 2008, 75&#160;customers
    have purchased Topaz IFCs for use in applications such as
    functional studies and structure-based drug design.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Topaz
    Instrumentation and Software</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The NanoFlex IFC controller for the Topaz system fully automates
    the setup of diffusion-based protein crystallization experiments
    and includes software for tracking experiments.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Topaz AutoInspeX II workstation automates the scanning of
    Topaz IFCs and the identification of reaction chambers where
    crystallization has occurred. The AutoInspeX II incorporates
    high-end optical performance and a full suite of software for
    analyzing and archiving crystallization results. The
    sophisticated instrumentation and software included in our Topaz
    system enables users to automatically image and accurately score
    crystals as small as 10 microns by 20 microns.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Sales and
    Marketing</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We distribute our systems through our direct field sales and
    support organizations located in North America, Europe and Asia
    and through distributors or sales agents in parts of Europe and
    Asia-Pacific. Our global sales force is able to apprise our
    current and potential customers of new product offerings and
    technological advances in our current IFC systems, related
    instrumentation and software to help drive revenue growth. As
    our primary point of contact in the marketplace, our sales force
    ensures a consistent marketing message and high level of
    customer service, while enhancing our understanding of customer
    needs. As of December&#160;29, 2007, we had 24 people employed
    in sales, sales support and marketing, including 9 sales
    representatives.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our sales and marketing efforts are targeted at laboratory
    directors and principal investigators at leading companies and
    institutions who need reliable, high-throughput life science
    automation solutions to conduct large-scale experimentation. We
    seek to increase awareness of our products among our target
    customers through participation in tradeshows and academic
    conferences including sponsoring scientific lectures by
    prominent users of our systems. Because our systems are
    relatively new and require a capital investment, the sales
    process typically involves numerous interactions and
    demonstrations with multiple people within an organization. In
    addition, potential customers will often wish to conduct
    in-depth evaluations of the system including running identical
    sets of samples and reagents on both our system and competing
    systems. As a result of these factors and the budget cycles of
    our customers, our sales cycle, the time from initial contact
    with a customer to our receipt of a purchase order, can often be
    12&#160;months or longer.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    65
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Customers</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have sold our BioMark and Topaz systems to a wide variety of
    biotechnology and pharmaceutical companies and to academic,
    governmental and clinical research institutions. As of
    June&#160;28, 2008, 79 of our Topaz systems have been installed
    at customer sites and 24 of our BioMark systems have been
    installed at customer sites. The following is a list of our
    representative customers in each of the listed markets.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="36%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="19%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="40%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Customer</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Market</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Application</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    MedImmune
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Gene Expression
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Pharmaceutical drug development&#160;&#151; real-time qPCR for
    gene expression profiling in research and clinical trials
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Myriad Genetics
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Gene Expression
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Cancer and diagnostics research&#160;&#151; real-time qPCR for
    differential gene expression in cancer studies
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Merck &#038; Co.
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Gene Expression
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Gene expression profiling for pharmaceutical drug development
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Alaska Department of Fish and Game
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Genotyping
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Government wild-life resource management&#160;&#151; SNP
    genotyping for identification of salmon species
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    National Cancer Institute
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Genotyping
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Academic basic research; clinical diagnostics
    research&#160;&#151; genotyping for cancer research
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Chinese University of Hong Kong
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Digital PCR
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Academic basic research; clinical diagnostics
    research&#160;&#151; digital PCR for early cancer detection
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Vertex Pharmaceuticals
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Protein crystallization
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Pharmaceutical drug discovery
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Revenue Concentration.</I>&#160;&#160;We receive a
    substantial portion of our revenue from a limited number of
    customers and grantors. For the year ended December&#160;29,
    2007, the Singapore Economic Development Board, or EDB,
    accounted for 24% of our total revenue. For the year ended
    December&#160;31, 2006, CTI Molecular Imaging accounted for 16%
    of our total revenue, Kikotech Co., Ltd. accounted for 14% of
    our total revenue and EDB accounted for 14% of our total
    revenue. For the year ended December&#160;31, 2005, Kikotech
    accounted for 16% of our total revenue and a collaboration
    agreement accounted for 14% of our total revenue. We anticipate
    that we will continue to be dependent on a limited number of
    customers and grantors for a significant portion of our revenue
    in the near future. The loss of any of these customers could
    have a material adverse effect on our results of operations and
    cash flows.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Competition</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We compete with both established and development stage life
    science companies that design, manufacture and market
    instruments for gene expression analysis, genotyping, other
    nucleic acid detection and additional applications using
    established laboratory techniques. For example, companies such
    as Affymetrix, Applied Biosystems, BioTrove, Illumina, Roche
    Diagnostics and Sequenom have products for gene expression
    <FONT style="white-space: nowrap">and/or</FONT>
    genotyping that compete in certain segments of the market in
    which we sell our BioMark system. In addition, a number of other
    companies and academic groups are in the process of developing
    novel technologies for genetic analysis, many of which have also
    received grants from the National Human Genome Research
    Institute, a branch of the National Institutes of Health.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The high-throughput life science platforms industry is highly
    competitive and expected to grow more competitive with the
    increasing knowledge gained from molecular biology
    experimentation. Many of our competitors are either
    publicly-traded or are divisions of publicly-traded companies
    and enjoy several competitive advantages over us, including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    significantly greater name recognition;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    greater financial and human resources;
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    66
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    broader product lines and product packages;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    larger sales forces;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    larger and more geographically dispersed customer support
    organization;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    substantial intellectual property portfolios;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    established customer bases and relationships;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    greater experience in research and development, manufacturing
    and marketing.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    We believe that the principal competitive factors in our markets
    include:
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    cost of capital equipment and supplies;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    ease of use;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    accuracy and reproducibility of results;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    compatibility with existing laboratory processes.
</TD>
</TR>

</TABLE>

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    To successfully compete with existing products and future
    technologies, we will need to demonstrate to potential customers
    that the cost savings and performance of our technologies and
    products, as well as our customer support capabilities, are
    superior to those of our competitors.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Technology</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Our products are based on a tiered set of related proprietary
    technologies that we have either developed internally or
    licensed from third parties.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><I><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Multi-Layer
    Soft Lithography</FONT><!-- /FONT#008 --></I></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Our IFCs are manufactured using a technology known as
    multi-layer soft lithography, or MSL. With MSL, we are able to
    use standard semiconductor manufacturing techniques, along with
    certain proprietary processes, to create complex integrated
    microfluidic devices.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Using MSL technology, we are able to create valves, chambers,
    channels and other fluidic components on our IFCs at high
    density. We combine these components in complex arrangements
    that allow nanoliter quantities of fluids to be precisely
    directed to specific positions within the IFC. Unlike most prior
    microfluidic technologies, our IFCs do not rely on electricity,
    magnetism or similar approaches to control fluid movement.
    Rather, our IFCs control fluid flow with valves. The most
    important components on our IFCs are our NanoFlex valves, which
    are created by the intersection of two channels. When the valve
    is open, fluid is able to flow through the lower channel. When
    the upper or &#147;control&#148; channel is pressurized, the
    material separating the two channels is deflected into the lower
    channel, closing the valve and stopping fluid flow. If pressure
    is removed from the control channel, the channels return to
    their original form, and the valve is again open. The
    elastomeric properties of IFC cores allow our NanoFlex valves to
    form a reliable seal and cycle through millions of openings and
    closings.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The elastomer we currently use for our commercial products is a
    form of silicone rubber known as polydimethylsiloxane, or PDMS,
    but we have researched other materials with different properties
    for specific purposes. PDMS is transparent, which allows fluid
    movement to be easily monitored with a variety of existing
    optical technologies, such as bright field or phase contrast
    microscopy. In addition, the gas permeability of PDMS allows the
    reliable metering of fluids with near picoliter precision by
    eliminating the bubble problems encountered by most other
    microfluidic technologies. In essence, we are able to pump
    fluids into closed reaction chambers at sufficient pressure to
    drive any air out of the chamber directly through the chamber
    walls. PDMS also supports an environment that is favorable to
    maintaining cell cultures.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    We have developed commercial manufacturing processes to
    fabricate valves, channels and chambers with dimensions in the
    10 to 100 micron range, at high density and with high
    reliability. For research purposes, we have created devices with
    both substantially smaller and larger features. Though our
    manufacturing is based on standard
</DIV><!-- /DIV#030 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    67
</DIV><!-- /DIV#051 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    semiconductor manufacturing technologies and techniques, we have
    also developed novel processes for mold fabrication that enable
    mass production of high density IFCs with nanoliter volume
    features.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Integrated
    Fluidic Circuits</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFCs incorporate several different types of technology that
    together enable us to use MSL to rapidly design and deploy new
    microfluidic applications.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Microfluidic Components.</I>&#160;&#160;The first level of
    our IFC technology is a library of components that perform basic
    microfluidic functions. We have proven designs for numerous
    elements, such as pumps, mixers, separation columns, control
    logic and reaction chambers. These are readily integrated to
    create circuits capable of performing a wide range of
    biochemical reactions. Even when it is necessary to integrate
    multiple elements to perform a particularly complex reaction,
    the area taken up on a circuit for a single reaction is small
    compared to a typical overall circuit size of three centimeters
    by three centimeters. As a result, we are routinely able to
    develop IFCs that perform thousands of reactions per square
    centimeter.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Architectures.</I>&#160;&#160;The second level of our IFC
    technology comprises the architectures we have designed to
    exploit our ability to conduct thousands of reactions on a
    single IFC. The first of these is the Dynamic Array, a matrix
    architecture that allows multiple different samples and multiple
    different reagents to be loaded onto a single IFC and then
    combined so that there is an isolated reaction between each
    sample and each reagent. The primary advantage of this
    architecture is that each sample and reagent has to be pipetted
    only once per IFC rather than once per reaction, as is the case
    with plate-based technologies. For example, a single 48.48
    Dynamic Array IFC can perform a total of 2,304 unique reactions
    between 48 samples and 48 reagents with only 96 pipetting steps.
    With conventional microwell plate-based technologies, the same
    experiment would require about 4,608 pipetting steps and at
    least six conventional microwell plates. Our Digital Array
    architecture provides similar benefits with respect to pipetting
    steps and fluid handling. The Digital Array architecture allows
    a sample to be split into hundreds or thousands of smaller
    samples. Separate reactions can then be conducted on each of the
    smaller samples.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Interface and Handling Frames.</I>&#160;&#160;The third level
    of our IFC technology involves the interaction of our IFCs with
    the actual laboratory environment. The elastomeric blocks at the
    center of our IFCs sit in specially designed frames that are
    able to deliver samples and reagents to the block. These frames
    are the same size as standard 384&#160;microwell plates and have
    sample and reagent input ports laid out in a standard
    384&#160;microwell plate format. As a result, our IFCs can be
    loaded with standard laboratory pipetting robots and can be used
    with standard plate handling equipment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Technological Advances.</I>&#160;&#160;In the second quarter
    of 2002, we sold the first prototype of our 1.48 IFC for our
    Topaz system, which featured 22 valves capable of 2.5 assays per
    square centimeter. In the second quarter of 2006, we introduced
    our 12.765&#160;Digital Array IFC, with over 1,000 valves
    capable of more than 1,000 assays per square centimeter, a
    46-fold increase in valve density and a 400-fold increase in
    assay capability. The chart below illustrates the timing of a
    number of our technological advances. We introduced our
    96.96&#160;Dynamic Array IFC in May 2008, which again increased
    the number of valves and assays per square centimeter relative
    to the 48.48&#160;Dynamic Array. In the semiconductor industry,
    Moore&#146;s Law describes the principle that the shrinking of
    features has allowed for a doubling of transistors on a chip
    approximately every 18&#160;months. Based on manufacturing
    processes borrowed from those in the semiconductor industry,
    Fluidigm has similarly achieved significant gains in the density
    and productivity of our IFCs.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    68
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    <IMG src="f39432a6f3943222.gif" alt="(BAR GRAPH)">
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><I><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Software
    and Instrumentation</FONT><!-- /FONT#008 --></I></B>
</DIV><!-- /DIV#031 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    We have developed instrumentation technology to load samples and
    reagents on to the IFC and to control and monitor reactions
    within our IFCs. Our NanoFlex controller consists of commercial
    pneumatic components and both custom and commercial electronics.
    It uses precise control of multiple pressures to independently
    move fluid through up to four IFCs simultaneously and can be
    configured for use with either our BioMark or Topaz systems. Our
    Topaz Auto-InspeX II workstation consists of a commercial
    microscope, illumination source, stage and camera system in a
    single package. Our BioMark system consists of a customized
    commercial thermal cycler packaged with a sophisticated
    fluorescence detection system. All of these instruments are
    designed to be easily introduced into standard automated lab
    environments.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    We have developed specialized software packages to manage and
    analyze the unusually large amounts of data produced by our
    systems. Our BioMark gene expression analysis software
    automatically identifies individual real-time qPCR reactions
    from fluorescent images and generates amplification threshold
    crossing values allowing researchers to readily perform complete
    normalized comparative gene expression analysis across large
    numbers of samples and assays. Similarly, the BioMark genotyping
    analysis software automatically clusters fluorescent intensities
    from individual genotype reactions and makes genotype calls
    across individual and multiple IFC runs. Our Topaz system
    software incorporates sophisticated image processing and
    analysis functionality that enables the automatic detection and
    classification of protein crystals. Most of our software
    development uses Microsoft.NET tools to facilitate interaction
    with typical laboratory information management systems.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Manufacturing</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Our manufacturing operations are located in Singapore and South
    San&#160;Francisco. Our Singapore facility fabricates all of our
    IFCs for commercial sale. IFCs for research and development
    purposes are fabricated at both locations. We manufacture
    instrument systems at both locations, with certain instruments
    assembled in Singapore and others in South San&#160;Francisco.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Our Singapore facility commenced operations in October 2005 and
    established full process capability for its first product, the
    Topaz Screening IFC, in June 2006 and for its first Dynamic
    Array, the 48.48 Dynamic Array in October 2006. Our Singapore
    facility has been producing components for our Topaz system
    since October 2006 and components for our BioMark system since
    December 2007.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    We established our manufacturing facility in Singapore to take
    advantage of the skilled workforce, supplier and partner
    network, lower operating costs and government support available
    there. Our IFC manufacturing process includes photolithography
    and fabrication technologies that are very similar to those used
    in the fabrication of semiconductor chips. As a result, we are
    able to hire from a pool of skilled manpower created by the
    existing semiconductor industry in Singapore. Similarly, the
    Singapore semiconductor industry has created a broad network
</DIV><!-- /DIV#030 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    69
</DIV><!-- /DIV#050 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    of potential suppliers and partners for our manufacturing
    operations. We are able to locally source a large proportion of
    the raw materials required in our processes and have been able
    to collaborate with local engineering companies to develop
    enabling technologies for IFC fabrication. We have made
    significant improvements in yields through process improvements
    at our Singapore facility and IFC production increased
    three-fold in 2007 compared to 2006.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Our manufacturing operations in Singapore have been supported by
    grants from the Singapore Economic Development Board, or EDB,
    which provide incentive grant payments for research, development
    and manufacturing activity in Singapore. Our arrangements with
    EDB require us to maintain a significant and increasing
    manufacturing and research and development presence in Singapore.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Our South San&#160;Francisco facility began producing Topaz
    systems in 2002. In 2005, our South San Francisco facility began
    assembling instrumentation for our BioMark system.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    We expect that our existing manufacturing capacity for
    instrumentation and IFCs is sufficient to meet our needs for at
    least the next two years. However, we are considering developing
    additional capacity to ensure that all or most of our products
    are produced by at least two different facilities. We believe
    that having dual sources for our products would help mitigate
    the potential impact of a production disruption at any one of
    our facilities and that such redundancy may be required by our
    customers in the future. We have not determined the timing or
    location of any additional manufacturing capacity.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    We rely on a limited number of suppliers for certain components
    and materials used in our systems. While we are in the process
    of qualifying additional sources of supply, we cannot predict
    how long that qualification process will last. If we were to
    lose one or more of our limited source suppliers, it would take
    significant time and effort to qualify alternative suppliers.
    Key components in our products that are supplied by sole or
    limited source suppliers include a thermal cycler customized to
    our specifications, a specialized polymer from which our IFC
    cores are fabricated, the plastic carrier that holds the IFC
    core in certain of our products and the specialized high
    resolution camera lenses used in the reader for our BioMark
    system. We are neither a major customer of our suppliers, nor do
    we have long term supply contracts with most of these suppliers.
    These suppliers may therefore give other customers&#146; needs
    higher priority than ours, and we may not be able to obtain
    adequate supply in a timely manner or on commercially reasonable
    terms.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    We have entered into a supply agreement with Eppendorf AG to
    provide to us a thermal cycler customized to our specifications.
    Pursuant to this agreement, we have agreed to purchase from
    Eppendorf at least a specified minimum number of units each year
    in exchange for volume discounts. We have also agreed, during
    the term of the agreement, not to manufacture or sell a product,
    in stand-alone form, or compete in any way directly or
    indirectly with the customized thermal cycler provided by
    Eppedorf in stand-alone form. Eppendorf has agreed to refrain
    from providing a similarly customized unit to any person or
    entity until two years after the agreement has terminated.
    Either party may terminate the agreement with good reason, which
    includes a failure to timely deliver conforming units, subject
    to a cure period. Eppendorf may terminate the agreement if we
    purchase fewer than 75% of the specified minimum units for each
    of two consecutive years. After April&#160;1, 2010, either party
    may terminate the supply agreement upon six months prior written
    notice.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Research
    and Development</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    We have assembled experienced research and development teams at
    our South San&#160;Francisco and Singapore locations with the
    scientific, engineering, software and process talent that we
    believe is required to grow our business.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><I><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->New
    Product and Application
    Development</FONT><!-- /FONT#008 --></I></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The largest component of our current research and development
    effort is in the areas of new product and new application
    development. In particular, we are focused on extending and
    supporting the BioMark and Topaz product lines by developing new
    DNA-based applications, improving the introduction of these
    products into existing workflows of our customers and increasing
    the functionality of the products. For example, the addition of
    multi-color analysis allows Digital Array users to analyze as
    many as 36,720 real-time qPCR assays in parallel on a single
    Digital Array.
</DIV><!-- /DIV#030 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    70
</DIV><!-- /DIV#050 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    We are also developing new product lines that leverage our
    investment in our Dynamic Array and Digital Array architectures.
    As an example, we have demonstrated Dynamic Array formats that
    can implement over 1,000 immunoassays in parallel. We also
    invest in extending the reach of existing chip designs through
    new chemistries. From time to time, we collaborate with other
    life science companies, universities and government labs on the
    development of prototype IFCs for particular purposes. For
    example, there have been a variety of publications by
    independent researchers demonstrating the use of MSL for
    applications such as immunoassays based on surface-plasma
    resonance, cell culturing and complementary DNA library
    synthesis from single cells.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><I><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Process
    Development</FONT><!-- /FONT#008 --></I></B>
</DIV><!-- /DIV#031 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The second component of our research and development effort is
    process development. We frequently develop new manufacturing
    processes and test methods to support new IFC designs, drive
    down manufacturing cost and increase manufacturing throughput.
    We also invest in manufacturing automation, process changes and
    design modifications to improve yield and lower costs on
    existing IFCs.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><I><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->New
    Technology Development</FONT><!-- /FONT#008 --></I></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    We have active research and development efforts to increase the
    density of components on our IFCs and to lower the materials
    cost of our current production methods. We are evaluating new
    materials that can increase the functionality of existing
    products and that would allow our IFCs to be used for a wider
    variety of biological and chemical reactions. Over the longer
    term, we are seeking ways to transfer functionality from
    instrumentation to IFCs to support development of field-based
    and point-of-care applications.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Our research and development expenses were $11.4&#160;million,
    $15.6&#160;million, $14.4&#160;million and $7.2&#160;million in
    2005, 2006, 2007 and the six months ended June&#160;28, 2008. As
    of December&#160;29, 2007, 68 of our employees were engaged in
    research and development activities.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Scientific
    Advisory Board</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    We maintain a scientific advisory board, consisting of members
    with experience and expertise in the field of microfluidic
    systems and their application, who provide us with consulting
    services. The scientific advisory board generally does not meet
    as a group but instead, at our request, the individual members
    advise us on matters related to their areas of expertise. We
    have entered into agreements with each of our advisors, other
    than Stephen Quake, that require them spend between 6 and
    12&#160;days each year advising us and provide for stock option
    grants to the advisor. Dr.&#160;Quake serves as chair of the
    Scientific Advisory Board pursuant to a broader consulting
    agreement with us. As Chairman, Dr.&#160;Quake advises us on the
    composition of the advisory board and is involved in discussions
    with us more frequently than other advisory board members. When
    the advisory board meets, Dr.&#160;Quake is responsible for
    setting the agenda for the meetings and chairing such meetings.
    Our scientific advisory board consists of the following members:
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    <I>Stephen Quake, Ph.D.</I> is a co-founder of Fluidigm and the
    chair of our scientific advisory board. He is a co-chair of the
    bioengineering department at Stanford University and an
    investigator of the Howard Hughes Medical Institute.
    Dr.&#160;Quake received a B.S. in Physics and a M.S. in
    Mathematics from Stanford University and a Ph.D. in Physics from
    Oxford University. Dr. Quake has been a member of our scientific
    advisory board since June 1999.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    <I>Frances H. Arnold, Ph.D.</I> is the Dick and Barbara
    Dickinson Professor of chemical engineering and biochemistry at
    the California Institute of Technology. She is a member of the
    National Academy of Engineering and a fellow at the American
    Institute for Medical and Biological Engineering.
    Dr.&#160;Arnold received a B.S. in Mechanical and Aerospace
    Engineering from Princeton University and a Ph.D. in Chemical
    Engineering from the University of California, Berkeley. Dr.
    Arnold has been a member of our scientific advisory board since
    August 1999.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    <I>James M. Berger, Ph.D.</I> is a Professor of Biochemistry and
    Molecular Biology at the University of California, Berkeley and
    a member of the Physical Biosciences Division, Lawrence Berkeley
    National Laboratory. Dr.&#160;Berger received a B.S. in
    Biochemistry from the University of Utah and a Ph.D. in
</DIV><!-- /DIV#030 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    71
</DIV><!-- /DIV#050 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Biochemistry from Harvard University. Dr. Berger has been a
    member of our scientific advisory board since June 2002.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    <I>Carl Hansen, Ph.D.</I> is an Assistant Professor in the
    Department of Physics and Astronomy at the University of British
    Columbia. Dr.&#160;Hansen received a Ph.D. and M.S. in Applied
    Physics from the California Institute of Technology and a B.S.
    in Engineering Physics/Electrical Engineering/Honors Math from
    the University of British Columbia. Dr.&#160;Hansen has been a
    member of our Scientific Advisory Board since May 2008.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    <I>Frank McCormick, Ph.D.</I> is the David A. Wood Distinguished
    Professor of Tumor Biology and the E. Dixon Heise Distinguished
    Professor in Oncology at the University of California,
    San&#160;Francisco, or UCSF. He is also the director of
    UCSF&#146;s Comprehensive Cancer Center. He is a member of the
    Institute of Medicine and a fellow of The Royal Society.
    Dr.&#160;McCormick received a B.Sc. in Biochemistry from the
    University of Birmingham and a Ph.D. in Biochemistry from the
    University of Cambridge. Dr. McCormick has been a member of our
    scientific advisory board since November 2006.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    <I>Howard M. Shapiro,&#160;M.D.</I> is a lecturer on Pathology
    at Harvard Medical School, a visiting scientist at the
    Rosenstiel Basic Medical Sciences Research Center at Brandeis
    University and a research associate in Medicine and Pathology at
    Beth Israel Hospital. Dr.&#160;Shapiro received a B.A. from
    Harvard College and an M.D. from New York University School of
    Medicine. Dr.&#160;Shapiro has been a member of our scientific
    advisory board since December 1999.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    <I>Richard N. Zare,&#160;Ph.D.</I> is the Marguerite Blake
    Wilbur Professor of Natural Science and chair of the chemistry
    department at Stanford University. He is a member of the
    National Academy of Sciences, the American Academy of Arts and
    Sciences and the recipient of the National Medal of Science.
    Dr.&#160;Zare received a B.S. in Chemistry and Physics and a
    Ph.D. in Chemical Physics from Harvard University. Dr.&#160;Zare
    has been a member of our scientific advisory board since
    December 2000.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Intellectual
    Property Strategy and Position</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Fluidigm&#146;s core technology originated at the California
    Institute of Technology, or Caltech, in the laboratory of
    Professor Stephen Quake, who is a co-founder of Fluidigm.
    Dr.&#160;Quake, his students and their collaborators pioneered
    the application of multilayer soft lithography in the field of
    microfluidics. In particular, Dr.&#160;Quake&#146;s laboratory
    developed technologies that enabled the production of
    specialized valves and pumps capable of controlling fluid flow
    at nanoliter volumes. In a series of transactions, we
    exclusively licensed from Caltech the relevant patent filings
    relating to these developments.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Our license agreement with Caltech provides us with an
    exclusive, worldwide license to certain patents and related
    intellectual property, as well as the right to prosecute
    licensed patent filings worldwide at our expense and to initiate
    any infringement proceedings. Caltech retains the right to use
    the licensed materials for noncommercial educational and
    research purposes, as well as any rights necessary to comply
    with the statutory rights of the U.S.&#160;government. We have
    issued shares of our common stock to Caltech and, in addition to
    an annual license fee, we agreed to pay to Caltech royalties
    based on sales revenues of licensed products on a
    <FONT style="white-space: nowrap"><!-- FONT#006 -->country-by-country</FONT><!-- /FONT#006 -->
    basis. The license agreement will terminate as to each country
    and licensed product upon expiration of the last-to-expire
    patent covering licensed products in each country. As of
    June&#160;28, 2008, we licensed 38 issued U.S. patents and 42
    pending U.S. patent applications, as well as corresponding
    international patent filings, from Caltech. The early
    termination of our license agreement with Caltech could preclude
    us from manufacturing or selling any of our IFCs and IFC
    systems, which would have a material adverse effect on our
    business.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    We also have co-exclusive licenses to patents and patent
    applications owned by Harvard University, a non-exclusive,
    field-limited license to patents and patent applications
    controlled by Gyros AB and additional patent licenses from other
    academic institutions and companies.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Our license agreements with Harvard University allow sublicenses
    (i)&#160;provided we can demonstrate that we have added
    significant value to the patent rights to be sublicensed and
    that such sublicense also contains a substantial and essentially
    simultaneous license to intellectual property owned by us, or
    (ii)&#160;when we grant a sublicense under other Harvard
    University patent rights licensed to us which are dominated by
    the patent rights to be
</DIV><!-- /DIV#030 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    72
</DIV><!-- /DIV#050 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
     sublicensed and such sublicense is necessary to practice the
    other Harvard University patent rights. We have issued shares of
    our common stock to Harvard and, in addition to an annual
    license fee, we agreed to pay to Harvard royalties based on
    sales revenues of licensed products on a
    <FONT style="white-space: nowrap"><!-- FONT#006 -->country-by-country</FONT><!-- /FONT#006 -->
    basis. Harvard is responsible for filing and maintaining all
    licensed patents, but we must reimburse Harvard for our share of
    its related patent prosecution expenses. We have the right to
    prosecute any infringement of our licensed patent rights. The
    license agreement will terminate with the last-to-expire of the
    licensed patents. As of June&#160;28, 2008, we licensed five
    issued U.S. patents and four pending U.S. patent applications,
    as well as corresponding international patent filings, from
    Harvard. The early termination of our license agreements with
    Harvard could preclude us from manufacturing or selling any of
    our IFCs and IFC systems, which would have a material adverse
    effect on our business.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Our license agreement with Gyros AB grants us a non-exclusive,
    field-limited license to specified patents and patent
    applications filings in exchange for an upfront fee plus annual
    royalty payments based on net revenues of licensed products
    above an annual license fee. Gyros has the right to terminate if
    we assign our interest to a third party competitor of Gyros or
    if we come under common control of such a third party.
    Otherwise, the license will terminate at the expiration of the
    last-to-expire of the licensed patents. As of June&#160;28,
    2008, we licensed one issued U.S. patent as well as
    corresponding international patent filings from Gyros. The early
    termination of our license agreement with Gyros AB could
    preclude us from manufacturing or selling any of our IFCs and
    IFC systems, which would have a material adverse effect on our
    business.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Our license agreement with The UAB Research Foundation grants us
    an exclusive worldwide license, including the right to
    sublicense, under certain intellectual property rights. Such
    license grant is subject to prior existing license grants, plus
    the reservation of rights to UAB for internal research, academic
    and educational purposes
    <FONT style="white-space: nowrap"><!-- FONT#006 -->and/or</FONT><!-- /FONT#006 -->
    for performance of services for other institutions and to
    fulfill obligations to the U.S.&#160;government. We prosecute
    and maintain the patent rights licensed under this agreement.
    The license agreement will terminate at the expiration of the
    last-to-expire of the licensed patents. As of June&#160;28,
    2008, we licensed four issued U.S. patents and six pending U.S.
    patent applications, as well as corresponding international
    patent filings, from UAB. The early termination of our license
    agreement with UAB could preclude us from manufacturing or
    selling any of our Topaz IFCs and Topaz IFC systems, which would
    have a material adverse effect on our business.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Our patent strategy is to seek broad patent protection on new
    developments in microfluidic technology and then later file
    patent applications covering new implementations of the
    technology and new microfluidic circuit architectures utilizing
    the technology. As these technologies are implemented and
    tested, we file new patent applications covering scientific
    methodology enabled by our technology. Additionally, where
    appropriate, we file new patent applications covering
    instrumentation and software that are used in conjunction with
    our IFCs.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    As of June&#160;28, 2008, we own or have licensed 81 issued U.S.
    patents and 62 issued international patents.  There are
    240&#160;pending patent applications, including 116 in the
    United States, 118 international applications and 6 applications
    filed under the Patent Cooperation Treaty. The U.S. issued
    patents we have licensed from Caltech expire between 2017 and
    2024, the U.S. issued patents we have licensed from UAB expire
    between 2020 and 2024, the U.S. issued patents we have licensed
    from Harvard expire between 2019 and 2023, the U.S. issued
    patent we have licensed from Gyros expires in 2012 and the U.S.
    issued patents owned by us expire between 2018 and 2025.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The patent positions of companies like ours are generally
    uncertain and involve complex legal and factual questions. Our
    patents may not enable us to obtain or keep any competitive
    advantage. Our pending U.S.&#160;and foreign patent applications
    may not issue as patents or may not issue in a form that will be
    advantageous to us. Any patents we have obtained or do obtain
    may be challenged by re-examination, opposition or other
    administrative proceeding, or may be challenged in litigation,
    and such challenges could result in a determination that the
    patent is invalid. In addition, competitors may be able to
    design alternative methods or devices that avoid infringement of
    our patents. To the extent our intellectual property protection
    offers inadequate protection, or is found to be invalid, we are
    exposed to a greater risk of direct competition. If our
    intellectual property does not provide adequate protection
    against our competitors&#146; products, our competitive position
    could be adversely affected, as could our business. Both the
    patent application process and the process of managing patent
    disputes can be time consuming and expensive. Furthermore, the
    laws of some foreign countries may not protect our intellectual
    property rights to the same extent as do the laws of the United
    States.
</DIV><!-- /DIV#030 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    73
</DIV><!-- /DIV#051 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to pursuing patents on our technology, we have taken
    steps to protect our intellectual property and proprietary
    technology by entering into confidentiality agreements and
    intellectual property assignment agreements with our employees,
    consultants, corporate partners and, when needed, our advisors.
    Such agreements may not be enforceable or may not provide
    meaningful protection for our trade secrets or other proprietary
    information in the event of unauthorized use or disclosure or
    other breaches of the agreements, and we may not be able to
    prevent such unauthorized disclosure. Monitoring unauthorized
    disclosure is difficult, and we do not know whether the steps we
    have taken to prevent such disclosure are, or will be, adequate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our commercial success may depend in part on our
    non-infringement of the patents or proprietary rights of third
    parties. Third parties have asserted and may assert in the
    future that we are employing their proprietary technology
    without authorization. Competitors may assert that our products
    infringe their intellectual property rights as part of a
    business strategy to impede our successful entry into those
    markets. In addition, our competitors and others may have
    patents or may in the future obtain patents and claim that use
    of our products infringes these patents. We could incur
    substantial costs and divert the attention of our management and
    technical personnel in defending against any of these claims.
    Parties making claims against us may be able to obtain
    injunctive or other relief, which could block our ability to
    develop, commercialize and sell products, and could result in
    the award of substantial damages against us. In the event of a
    successful claim of infringement against us, we may be required
    to pay damages and obtain one or more licenses from third
    parties, or be prohibited from selling certain products. We may
    not be able to obtain these licenses at a reasonable cost, if at
    all.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Government
    Regulation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Federal Food, Drug and Cosmetic Act, or FFDCA, defines
    medical devices to mean, among other things, &#147;an
    instrument, apparatus . . . in&#160;vitro reagent, or other
    similar or related article . . . intended for use in the
    diagnosis of disease or other conditions . . ..&#148; This broad
    definition includes in&#160;vitro diagnostic products, or IVDs.
    Our products are currently labeled and sold for research
    purposes only, and we sell them to pharmaceutical and
    biotechnology companies, academic institutions and life sciences
    laboratories. Because our products are not intended for use in
    clinical practice, they do not fit the definition of a medical
    device under the FFDCA and thus are not subject to regulation by
    the U.S.&#160;Food and Drug Administration, or FDA. However, in
    the future, certain of our products or related applications
    could be subject to the FDA&#146;s regulation, the FDA&#146;s
    regulatory jurisdiction could be expanded to include our
    products, or both. For example, if we wished to label and market
    our products for use in performing clinical diagnostics, they
    would be considered medical devices and FDA clearance or
    approval would be required.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless an exemption applies, each medical device we wish to
    commercially distribute in the United States would require
    either prior 510(k) clearance or prior pre-market approval from
    the FDA. The FDA classifies medical devices into one of three
    classes. Devices deemed to pose lower risk to the patient are
    placed in either class&#160;I or II, which, unless an exemption
    applies, requires the manufacturer to submit a pre-market
    notification requesting FDA clearance for commercial
    distribution pursuant to Section&#160;510k of the FFDCA. This
    process, known as 510(k) clearance, requires that the
    manufacturer demonstrate that the device is substantially
    equivalent to a previously cleared 510(k) device or a
    <FONT style="white-space: nowrap">&#147;pre-amendment&#148;</FONT>
    class&#160;III device for which pre-market approval
    applications, or PMAs, have not been required by the FDA. This
    process typically takes from four to twelve months, although it
    can take longer. Most class&#160;I devices are exempted from
    this requirement. Devices deemed by FDA to pose the greatest
    risk, such as life-sustaining, life-supporting or implantable
    devices, or those deemed not substantially equivalent to a
    legally marketed predicate device, are placed in class&#160;III.
    Class&#160;III devices typically require PMA approval. To obtain
    PMA approval, an applicant must demonstrate the safety and
    effectiveness of the device based, in part, on data obtained in
    clinical studies. PMA reviews generally last between one and two
    years, although they can take longer. Both the 510(k) and the
    PMA processes can be expensive and lengthy and may not result in
    clearance or approval. If we are required to submit our products
    for pre-market review by FDA, we may be required to cease
    marketing while we obtain premarket clearance or approval from
    FDA. There would be no assurance that we could ever obtain such
    clearance or approval.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Changes to a device which have received PMA approval typically
    require a new PMA or PMA supplement. Changes to a device that
    receives 510(k) clearance, that could significantly affect its
    safety or effectiveness, or that would constitute a major change
    in its intended use, require a new 510(k) clearance or possibly
    PMA approval. The
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    74
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    FDA requires each manufacturer to make this determination
    initially, but the FDA can review any of these decisions. If the
    FDA disagreed with our determination not to seek a new 510(k)
    clearance, the FDA could require us to seek a new 510(k)
    clearance or pre-market approval. The FDA also could require us
    to cease manufacturing
    <FONT style="white-space: nowrap">and/or</FONT>
    recall the modified device until 510(k) clearance or pre-market
    approval was obtained. Also, in these circumstances, we could be
    subject to warning letters, significant regulatory fines or
    penalties, seizure or injunctive action, or criminal prosecution.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, if our products become subject to regulation as a
    medical device, we would become subject to additional FDA
    requirements, and we could be subject to unannounced inspections
    by FDA and other governmental authorities, which could increase
    our costs of doing business. Specifically, manufacturers of
    medical devices must comply with various requirements of the
    FFDCA and its implementing regulations, including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the Quality System Regulations, labeling regulations,
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    medical device reporting, or MDR, regulations,
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    correction and removal regulations,&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    post-market surveillance regulations, which include restrictions
    on marketing and promotion.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We would need to continue to invest significant time and other
    resources to ensure ongoing compliance with FDA quality system
    regulations and other post-market regulatory requirements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our failure to comply with applicable FDA regulatory
    requirements, or our failure to timely and adequately respond to
    inspectional observations, could result in enforcement action by
    the FDA, which may include the following sanctions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    fines, injunctions and civil penalties;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    recall or seizure or our products;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    operating restrictions, partial suspension or total shutdown of
    production;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    delays in clearance or approval, or failure to obtain approval
    or clearance of future product candidates or product
    modifications;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    restrictions on labeling and promotion;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    warning letters, fines, or injunctions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    withdrawal of previously granted clearances or
    approvals;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    criminal prosecution.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    International sales of medical devices are subject to foreign
    government regulations, which vary substantially from country to
    country. The primary regulatory environment in Europe is that of
    the European Union (EU), which includes most of the major
    countries in Europe. Currently, 27 countries make up the EU.
    Other countries, such as Switzerland, have voluntarily adopted
    laws and regulations that mirror those of the EU with respect to
    medical devices. The EU has adopted numerous directives and
    standards regulating the design, manufacture, clinical trials,
    labeling and adverse event reporting for medical devices.
    Devices that comply with the requirements of a relevant
    directive will be entitled to bear the CE conformity marking,
    indicating that the device conforms to the essential
    requirements of the applicable directives and, accordingly, can
    be commercially distributed throughout Europe.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Outside of the EU, regulatory approval needs to be sought on a
    <FONT style="white-space: nowrap">country-by-country</FONT>
    basis in order to market medical devices. Although there is a
    trend towards harmonization of quality system standards,
    regulations in each country may vary substantially which can
    affect timelines of introduction.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    75
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Employees</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    As of December&#160;29, 2007, we had 131&#160;employees, of
    which 68 work in research and development, 18 work in general
    and administrative, 21 work in manufacturing and 24 work in
    sales and marketing. None of our employees are represented by a
    labor union or are the subject of a collective bargaining
    agreement.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Property
    and Environmental Matters</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    We lease approximately 35,000&#160;square feet of office and
    laboratory space at our headquarters in South
    San&#160;Francisco, California under leases and subleases that
    expire in March 2011, and 15,400&#160;square feet of
    manufacturing and office space at our facility in Singapore
    under a lease that expires in October 2011. In addition, we
    lease office space in Tokyo and Osaka, Japan. We are in
    negotiations to extend and expand our lease relating to our
    Singapore facility and we believe that our existing office,
    laboratory and manufacturing space, together with additional
    space and facilities available on commercially reasonable terms,
    will be sufficient to meet our needs for at least the next two
    years.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Our research and development and manufacturing processes involve
    the controlled use of hazardous materials, including flammables,
    toxics, corrosives and biologics. Our research and manufacturing
    operations produce hazardous biological and chemical waste
    products. We seek to comply with applicable laws regarding the
    handling and disposal of such materials. Given the small volume
    of such materials used or generated at our facilities, we do not
    expect our compliance efforts to have a material effect on our
    capital expenditures, earnings and competitive position.
    However, we cannot eliminate the risk of accidental
    contamination or discharge and any resultant injury from these
    materials. We do not currently maintain separate environmental
    liability coverage and any such contamination or discharge could
    result in significant cost to us in penalties, damages and
    suspension of our operations.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Legal
    Proceedings</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    On June&#160;4, 2008 we received a letter from Applied
    Biosystems, Inc., one of our competitors, asserting that our
    BioMark System for gene expression analysis infringes upon
    U.S.&#160;Patent No.&#160;6,814,934, or the &#146;934 patent,
    and its European and Canadian counterparts owned by Applied
    Biosystems&#146; parent company, Applera Corporation. In
    response to this letter, on June&#160;9, 2008, we filed suit
    against Applied Biosystems and Applera in the United States
    District Court for the Southern District of New York seeking
    declaratory judgments of non-infringement and invalidity of the
    &#146;934 patent. A response from Applied Biosystems and Applera
    is due September&#160;30, 2008. The Court has yet to set a
    schedule for this litigation. Applied Biosystems has recently
    announced that it expects to be acquired by Invitrogen
    Corporation. This may make it more difficult for us to predict
    the direction of discussions and litigation among the parties.
    The &#146;934 patent is scheduled to expire in May 2011.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Patent infringement suits can be expensive, lengthy and
    disruptive to business operations. We could incur substantial
    costs and divert the attention of our management and technical
    personnel in prosecuting our claims. There can be no assurance
    that we will prevail in our suit against Applied Biosystems and
    Applera or in our defense of any claims against us by Applied
    Biosystems or Applera. Applied Biosystems and Applera may be
    able to obtain injunctive or other relief, which could block our
    ability to develop, commercialize and sell products, and could
    result in the award of substantial damages against us, including
    treble damages and attorneys&#146; fees and costs in the event
    that we are found to be a willful infringer of the asserted
    patent or patents. In addition, we may incur significant costs
    and expenses as a result of our requirement to defend and
    indemnify some of our suppliers, distributors, customers and
    other partners as a result of such claims. In the event that
    Applied Biosystems is successful in its claim of infringement
    against us, we may be required to obtain one or more licenses to
    the asserted patent, which we may not be able to obtain at a
    reasonable cost, if at all. In addition, we could encounter
    delays in product introductions while we attempt to develop
    alternative methods or products to avoid infringing the asserted
    patent or patents. This lawsuit or the failure to obtain any
    required licenses on favorable terms could prevent us from
    commercializing our BioMark products for gene expression, and
    the risk of a prohibition on the sale of any of our products
    could adversely affect our ability to grow and gain market
    acceptance for our products.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    We are not engaged in any other material legal proceedings.
</DIV><!-- /DIV#030 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    76
</DIV><!-- /DIV#051 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='111'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">MANAGEMENT</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Executive
    Officers and Directors</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our executive officers and directors, and their ages and
    positions as of June&#160;28, 2008, are as set forth below:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="42%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="51%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Age</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Position</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Gajus V. Worthington
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    38
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    President, Chief Executive Officer and Director
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Vikram Jog
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    52
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Chief Financial Officer
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Robert C. Jones
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    53
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Executive Vice President, Research and Development
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    William M. Smith
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    57
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Vice President, Legal Affairs and General Counsel, Secretary
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mai Chan (Grace) Yow
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    49
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Vice President, Worldwide Manufacturing and Managing Director of
    Fluidigm Singapore Pte. Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Samuel
    Colella<SUP style="font-size: 85%; vertical-align: text-top">(2),(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    68
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michael W. Hunkapiller,
    Ph.D<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    59
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Elaine V. Jones,
    Ph.D.<SUP style="font-size: 85%; vertical-align: text-top">(1),(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    53
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Kenneth
    Nussbacher<SUP style="font-size: 85%; vertical-align: text-top">(1),(2)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    55
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    John A.
    Young<SUP style="font-size: 85%; vertical-align: text-top">(1),(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    76
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Member of the Audit Committee
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Member of the Compensation Committee
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Member of the Nominating and
    Governance Committee
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Executive
    Officers</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Gajus V. Worthington </I>is a Co-Founder of Fluidigm and has
    served as our President and Chief Executive Officer and a
    Director since our inception in June 1999. From May 1994 to
    April 1999, Mr.&#160;Worthington held various staff and
    management positions at Actel Corporation, a public
    semiconductor corporation. Mr.&#160;Worthington received a B.S.
    in Physics and an M.S. in Electrical Engineering from Stanford
    University.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Vikram Jog </I>has served as our Chief Financial Officer
    since February 2008. From April 2005 to February 2008,
    Mr.&#160;Jog served as Chief Financial Officer for XDx, Inc., a
    molecular diagnostics company. From March 2003 to April 2005,
    Mr.&#160;Jog was a Vice President of Applera Corporation, a life
    science company, and Vice President of Finance for its related
    businesses, Celera Genomics and Celera Diagnostics. From April
    2001 to March 2003, Mr.&#160;Jog was Vice President of Finance
    for Celera Diagnostics and Corporate Controller of Applera
    Corporation. Mr.&#160;Jog received a Bachelor of Commerce degree
    from Delhi University and an M.B.A. from Temple University.
    Mr.&#160;Jog is a member of the American Institute of Certified
    Public Accountants.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Robert C. Jones </I>has served as our Executive Vice
    President, Research and Development since August 2005. From
    August 1984 to July 2005, Mr.&#160;Jones held various managerial
    and research and development positions at Applied Biosystems, a
    laboratory equipment and supplies manufacturer that is a
    division of Applera Corporation, including: Senior Vice
    President Research and Development from April 2001 to August
    2005, Vice President and General Manager Informatics Division
    from 1998 to 2001,&#160;and Vice President PCR Business Unit
    from 1994 to 1998. Mr.&#160;Jones received a BSEE and an MSEE in
    Computer Engineering from the University of Washington.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>William M. Smith </I>has served as our Vice President, Legal
    Affairs and General Counsel as well as our Secretary since May
    2000 and served as a Director from May 2000 to April 2008.
    Mr.&#160;Smith served as a partner at the law firm of Townsend
    and Townsend and Crew, LLP from 1985 through April 2008.
    Mr.&#160;Smith received a J.D. and an M.P.A. from the University
    of Southern California and a B.A. in Biology from the University
    of California, San&#160;Diego.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Mai Chan (Grace) Yow </I>has served as our Vice President,
    Worldwide Manufacturing, and Managing Director, Fluidigm
    Singapore Pte. Ltd., our Singapore subsidiary, since March 2006.
    From June 2005 to March 2006,
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    77
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Ms.&#160;Yow served as General Manager of Fluidigm Singapore
    Pte. Ltd. From August 2004 to May 2005, Ms.&#160;Yow served as
    Vice President Engineering (Asia) for Kulicke and Soffa, a
    public semiconductor equipment manufacturer. From March 1991 to
    July 2004, Ms.&#160;Yow served as Director, Assembly Operations,
    Plant Facilities and EHS, for National Semiconductor Singapore,
    a semiconductor fabrication subsidiary of National Semiconductor
    Corporation. Ms.&#160;Yow received a BE in Electronic
    Engineering from Curtin University, a Certificate in Management
    Studies from the Singapore Institute of Management and a Diploma
    in Electrical Engineering from Singapore Polytechnic.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Board of
    Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Samuel Colella </I>has served as a member of our Board of
    Directors since July 2000. Mr.&#160;Colella is a managing
    director of Versant Ventures, a healthcare venture capital firm
    he co-founded in 1999, and has been a general partner of
    Institutional Venture Partners since 1984. Mr.&#160;Colella is a
    member of the Board of Directors of Alexza Pharmaceuticals,
    Inc., Genomic Health, Inc. and Jazz Pharmaceuticals, Inc.
    Mr.&#160;Colella received a B.S. in business and engineering
    from the University of Pittsburgh and an M.B.A. from Stanford
    University.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Michael Hunkapiller, Ph.D. </I>has served as a member of our
    Board of Directors since August 2005. He has been a Partner at
    Alloy Ventures, a venture capital firm, since February 2004.
    From July 1983 to August 2004, he served in various managerial
    and research and development positions at Applied Biosystems,
    most recently as President, from March 1997 to August 2004. He
    received a B.S. in Chemistry from Oklahoma Baptist University
    and a Ph.D. in Chemical Biology from Caltech.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Elaine V. Jones,&#160;Ph.D.</I> has been a member of our
    Board of Directors since October 2001. Since August 2003, she
    has been a general partner of EuclidSR Associates, L.P., which
    is the general partner of EuclidSR Partners, L.P., a venture
    capital fund that focuses on life sciences and information
    technology companies, and also a general partner of EuclidSR
    Biotechnology Associates, L.P., which is the general partner of
    Euclid Biotechnology Partners, L.P., a venture capital fund that
    focuses on the life sciences. Dr.&#160;Jones was an investment
    manager from June 1999 to September 2001, and was a Vice
    President from September 2001 to August 2003, for S.R. One,
    Limited, a venture capital subsidiary of SmithKline Beecham.
    Dr.&#160;Jones received a B.S. in Biology from Juniata College
    and received a Ph.D. in Microbiology from the University of
    Pittsburgh.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Kenneth J. Nussbacher </I>has been a member of our Board of
    Directors since July 2003. Since 2000, Mr. Nussbacher has served
    as an Affymetrix Fellow, a non-executive employee position, at
    Affymetrix, Inc., a biotechnology company. From 1995 to 2000,
    Mr.&#160;Nussbacher was Executive Vice President of Affymetrix,
    Inc. and from 1995 to 1997, he was also Chief Financial Officer
    of Affymetrix. Prior to joining Affymetrix, Mr.&#160;Nussbacher
    was Executive Vice President for business and legal affairs of
    Affymax Technologies N.V. He received a B.S. from Cooper Union
    and a J.D. from Duke University. Mr.&#160;Nussbacher is also a
    member of the Board of Directors of Xenoport, a
    biopharmaceutical company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Gajus V. Worthington </I>is a Co-Founder of Fluidigm
    Corporation and has served as our President and Chief Executive
    Officer and a Director since our inception in June 1999.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>John A. Young </I>has been a member of our Board of Directors
    since March 2001. Mr.&#160;Young retired as President and Chief
    Executive Officer of Hewlett-Packard Company, a diversified
    electronics manufacturer, in October 1992, where he had served
    as President and Chief Executive Officer since 1978.
    Mr.&#160;Young received a B.S. in Electrical Engineering from
    Oregon State University and an M.B.A. from Stanford University.
    Mr.&#160;Young serves as a director of Affymetrix, Inc.,
    Vermillion, Inc., a molecular diagnostics company, Perlegen
    Sciences, Inc., a drug development company, and Nanosys, Inc., a
    nanotechnology company.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Board
    Composition</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors is currently composed of six members,
    five of whom are independent within the meaning of the
    independent director guidelines of the NASDAQ Stock Market LLC.
    Immediately prior to this offering, our Board of Directors will
    be divided into three staggered classes of directors. At each
    annual meeting of stockholders, a class of directors will be
    elected for a three-year term to succeed the same class whose
    terms are then expiring. The terms of the directors will expire
    upon the election and qualification of successor directors at
    the
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    78
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Annual Meeting of Stockholders to be held during the years 2009
    for the Class&#160;I directors, 2010 for the Class&#160;II
    directors and 2011 for the Class&#160;III directors.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Our Class&#160;I directors will be Elaine Jones and Michael
    Hunkapiller.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Our Class&#160;II directors will be Samuel Colella and Kenneth
    Nussbacher.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Our Class&#160;III directors will be John Young and Gajus
    Worthington.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Our amended and restated certificate of incorporation and bylaws
    provide that the number of our directors, which is currently six
    members, shall be fixed from time to time by a resolution of the
    majority of our Board of Directors. Each officer serves at the
    discretion of the Board of Directors and holds office until his
    successor is duly elected and qualified or until his or her
    earlier resignation or removal. There are no family
    relationships among any of our directors or executive officers.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The division of our Board of Directors into three classes with
    staggered three-year terms may delay or prevent a change of our
    management or a change of control. See &#147;Description of
    Capital Stock&#160;&#151; Anti-Takeover Effects of Delaware Law
    and Our Certificate of Incorporation and Bylaws&#148; for a
    discussion of other anti-takeover provisions found in our
    certificate of incorporation.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Board
    Committees</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Our Board has an audit committee, a compensation committee and a
    nominating and governance committee, each of which has the
    composition and the responsibilities described below.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    <I>Audit Committee.</I>&#160;&#160;Our audit committee oversees
    our corporate accounting and financial reporting process and
    assists the Board in monitoring our financial systems and our
    legal and regulatory compliance. Our audit committee will also:
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    oversee the work of our independent auditors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    approve the hiring, discharging and compensation of our
    independent auditors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    approve engagements of the independent auditors to render any
    audit or permissible non-audit services;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    review the qualifications and independence of the independent
    auditors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    monitor the rotation of partners of the independent auditors on
    our engagement team as required by law;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    review our financial statements and review our critical
    accounting policies and estimates;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    review the adequacy and effectiveness of our internal
    controls;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    review and discuss with management and the independent auditors
    the results of our annual audit, our quarterly financial
    statements, and our publicly filed reports.
</TD>
</TR>

</TABLE>

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The members of our audit committee are Elaine Jones, Kenneth
    Nussbacher and John Young. Mr. Nussbacher is our acting audit
    committee chairman. Mr.&#160;Young was appointed to our audit
    committee on August&#160;21, 2008. Our Board of Directors has
    concluded that the composition of our audit committee meets the
    requirements for independence under the current requirements of
    the NASDAQ Stock Market LLC and SEC rules and regulations. We
    believe that the functioning of our audit committee complies
    with the applicable requirements of the NASDAQ Stock Market LLC
    and SEC rules and regulations.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    <I>Compensation Committee.</I>&#160;&#160;Our compensation
    committee oversees our corporate compensation programs. The
    compensation committee will also:
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    review and recommend policy relating to compensation and
    benefits of our officers and employees;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    review and approve corporate goals and objectives relevant to
    compensation of our Chief Executive Officer and other senior
    officers;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    evaluate the performance of our officers in light of established
    goals and objectives;
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    79
</DIV><!-- /DIV#051 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    recommend compensation of our officers based on its
    evaluations;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    administer the issuance of stock options and other awards under
    our stock plans.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The members of our compensation committee are Samuel Colella,
    Michael Hunkapiller and Kenneth Nussbacher. Mr.&#160;Colella is
    the chairman of our compensation committee. Our Board of
    Directors has determined that each member of our compensation
    committee is independent within the meaning of the independent
    director guidelines of the NASDAQ Stock Market LLC. We believe
    that the composition of our compensation committee meets the
    requirements for independence under, and the functioning of our
    compensation committee complies with, any applicable
    requirements of the NASDAQ Stock Market LLC and SEC rules and
    regulations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Nominating and Governance Committee.</I>&#160;&#160;Our
    nominating and governance committee oversees and assists our
    Board of Directors in reviewing and recommending nominees for
    election as directors. The nominating and governance committee
    will also:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    evaluate and make recommendations regarding the organization and
    governance of the Board and its committees;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    assess the performance of members of the Board and make
    recommendations regarding committee and chair assignments;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    recommend desired qualifications for Board membership and
    conduct searches for potential Board members;&#160;and
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    review and make recommendations with regard to our corporate
    governance guidelines.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The members of our nominating and governance committee are
    Elaine Jones, John Young and Samuel Colella. Ms.&#160;Jones is
    the chairman of our nominating and governance committee. Our
    Board of Directors has determined that each member of our
    compensation committee is independent within the meaning of the
    independent director guidelines of the NASDAQ Stock Market LLC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors may from time to time establish other
    committees.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Director
    Compensation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth information concerning
    compensation paid or accrued for services rendered to us by
    members of our Board of Directors for the fiscal year ended
    December&#160;29, 2007. The table excludes Mr.&#160;Worthington
    and Mr.&#160;Smith, who are Named Executive Officers and did not
    receive any compensation from us in their roles as directors in
    the fiscal year ended December&#160;29, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Non-Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Fees Earned<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Stock<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Incentive Plan<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>All Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>or Paid in<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Cash&#160;($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Bruce
    Burrows<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Samuel D. Colella
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Hingge
    Hsu<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michael Hunkapiller
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Elaine V. Jones
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    S. Edward
    Torres<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Kenneth J.
    Nussbacher<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    72,885
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    40,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    112,885
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    John A. Young
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Amounts represent the aggregate
    compensation expense recognized by us for financial statement
    reporting purposes in fiscal 2007 related to grants of stock
    options, calculated in accordance with Financial Accounting
    Standards Board Statement of Financial Accounting Standards
    No.&#160;123 (Revised 2004) (&#147;SFAS&#160;123(R)&#148;)
    without regard to estimated forfeitures. See Note&#160;10 of
    Notes to Consolidated Financial Statements for a discussion of
    valuation assumptions made in determining the grant date fair
    value and compensation expense of our stock options.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Mr.&#160;Nussbacher was granted an
    option to purchase 100,000 shares of common stock on
    December&#160;28, 2007 at an exercise price of $2.40, with a
    grant date fair value of $143,151, computed in accordance with
    SFAS&#160;123(R) and was paid fees of $40,000 for services
    rendered pursuant to a consulting agreement with us. This
    consulting agreement was terminated on April&#160;14, 2008.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Resigned from the Board of
    Directors on or prior to April 2008.
    </FONT></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    80
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The aggregate number of shares subject to stock options
    outstanding at December&#160;29, 2007 for each director is as
    follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="69%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="14%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="14%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Aggregate Number of Stock Options<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Outstanding as of December&#160;29, 2007&#160;</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Bruce Burrows
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Samuel D. Colella
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Hingge Hsu
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michael Hunkapiller
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Elaine V. Jones
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Kenneth J. Nussbacher
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    200,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    S. Edward Torres
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    John A. Young
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our directors do not currently receive any cash compensation for
    their services as members of our Board of Directors or any
    committee of our Board of Directors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon consummation of our initial public offering, non-employee
    directors will receive an annual retainer of $20,000. The
    chairman of the audit committee will be paid an additional
    annual retainer of $15,000. The chairman of the compensation
    committee will be paid an additional annual retainer of $10,000.
    The chairman of the nominating and governance committee will be
    paid an additional annual retainer of $5,000.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our outside director equity compensation policy was adopted by
    our Board of Directors on January&#160;29, 2008 and will become
    effective immediately upon the completion of this offering. The
    policy is intended to formalize the granting of equity
    compensation to our non-employee directors under the 2008 Equity
    Incentive Plan. Non-employee directors may receive all types of
    awards under the 2008 Equity Incentive Plan, except for
    incentive stock options, including discretionary awards not
    covered by the policy. The policy provides for automatic and
    nondiscretionary grants of nonstatutory stock options subject to
    the terms and conditions of the policy and the 2008 Equity
    Incentive Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the policy, each non-employee director, who first becomes
    a non-employee director following the effective date of the
    first registration statement filed by us and declared effective
    with respect to any class of our securities, will be
    automatically granted a stock option to purchase
    40,000&#160;shares of our common stock on the date such person
    first becomes a non-employee director. A director who is an
    employee and who ceases to be an employee, but who remains a
    director will not receive such an initial award.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, each non-employee director will be automatically
    granted an annual stock option to purchase 10,000&#160;shares of
    our common stock on the date of each annual meeting beginning on
    the date of the first annual meeting that is held at least
    six&#160;months after such non-employee director received his or
    her initial award. In connection with the closing of this
    initial public offering, each non-employee director serving on
    our Board at the time of this offering will be automatically
    granted an option to purchase 10,000&#160;shares of our common
    stock at the price per share at which such common stock is sold
    in this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The exercise price of all stock options granted pursuant to the
    policy will be equal to the fair market value of our common
    stock on the date of grant. The term of all stock options will
    be 10&#160;years. Subject to the adjustment provisions of the
    2008 Equity Incentive Plan, initial awards will vest as to 25%
    of the shares subject to such awards each anniversary of the
    date of grant, provided such non-employee director continues to
    serve as a director through each such date. Subject to the
    adjustment provisions of the 2008 Equity Incentive Plan, the
    annual awards, including such awards granted in connection with
    this offering, will vest monthly over a twelve month period
    following the date of grant, provided such non-employee director
    continues to serve as a director through such date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The administrator of the 2008 Equity Incentive Plan in its
    discretion may change or otherwise revise the terms of awards
    granted under the outside director equity compensation policy.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    81
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the event of a &#147;change in control,&#148; as defined in
    our 2008 Equity Incentive Plan, with respect to awards granted
    under the 2008 Equity Incentive Plan to non-employee directors,
    the participant non-employee director will fully vest in and
    have the right to exercise awards as to all shares underlying
    such awards and all restrictions on awards will lapse, and all
    performance goals or other vesting criteria will be deemed
    achieved at 100% of target level and all other terms and
    conditions met.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Code of
    Business Conduct and Ethics</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to the completion of this offering, we expect to adopt a
    code of business conduct and ethics that is applicable to all of
    our employees, officers and directors.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Compensation
    Committee Interlocks and Insider Participation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    None of the members of our compensation committee is an officer
    or employee of our company. None of our executive officers
    currently serves, or in the past year has served, as a member of
    the Board of Directors or compensation committee of any entity
    that has one or more executive officers serving on our Board of
    Directors or compensation committee.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Executive
    Compensation</FONT></B>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Compensation
    Discussion and Analysis</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Overview</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We seek to have a compensation program that supports a team
    ethic among our management, fairly rewards executives for
    corporate performance and provides incentives for executives to
    meet or exceed our short and long term goals. The primary
    components of our compensation program are base salary, an
    annual incentive bonus plan, option awards and change of control
    arrangements. In addition, we provide our executive officers a
    variety of benefits that are available generally to all salaried
    employees. The compensation committee of our Board of Directors
    is responsible for evaluating the compensation of our executive
    officers and making recommendations to the Board of Directors.
    The independent members of the Board of Directors have final
    approval authority with respect to executive compensation.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Objectives
    and Principles of Our Executive Compensation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The primary goal of our executive compensation program is to
    ensure that we hire and retain talented and experienced
    executives that are motivated toward achieving or exceeding our
    short-term and long-term corporate goals. As a starting point,
    we believe that it is critical that our executive officers work
    together as a team and look beyond departmental lines to achieve
    overall corporate goals rather than focusing on individual
    departmental objectives. Our compensation philosophy is team
    oriented and our success dependent on what our management team
    can accomplish together. Therefore, we seek to provide the
    executive officers listed in the Summary Compensation table
    below, or our &#147;named executive officers,&#148; with
    comparable levels of base salary, bonuses and equity awards that
    are based largely on overall company performance.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For our fiscal year 2007, our named executive officers were
    Gajus Worthington, President and Chief Executive Officer,
    Richard DeLateur, our former Chief Financial Officer, Michael
    Lucero, our former Executive Vice President, Sales and
    Marketing, William Smith, Vice President, Legal Affairs and
    General Counsel, Robert Jones, our Executive Vice President,
    Research and Development, Grace Yow, Vice President, Worldwide
    Manufacturing and Managing Director, Fluidigm Singapore.
    Mr.&#160;DeLateur resigned as our Chief Financial Officer
    effective February&#160;29, 2008 and Mr.&#160;Lucero resigned as
    our Executive Vice President, Sales and Marketing on
    March&#160;14, 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    While the compensation level of Mr.&#160;Worthington, our Chief
    Executive Officer, is marginally higher than our other executive
    officers, his compensation has historically been based on our
    team-based compensation philosophy rather than on CEO
    compensation levels reported in market surveys of other
    companies in the life science industry.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    82
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We strongly believe that executive compensation should be
    directly linked to our performance. Our compensation program is
    designed so that a significant portion of the potential
    compensation of all of our executive officers is contingent on
    the achievement of our business objectives. In rewarding
    performance, we seek to reward both short and long term
    performance. We expect our executive leadership to manage our
    company so that we achieve our annual goals while at the same
    time positioning us to achieve our longer term strategic
    objectives. Short term elements of compensation include annual
    salary reviews, stock option awards and incentive bonuses that
    are tied closely to achieving our corporate and, to a lesser
    extent, on achieving individual performance objectives. Long
    term elements have historically been limited to stock options
    with multi-year vesting designed to retain executives and align
    their long term interests with those of our stockholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that hiring and retaining well performing executives
    is important to our ongoing success. While we review generally
    available surveys on executive compensation to confirm that our
    compensation decisions do not result in compensation levels that
    are dramatically different from other companies in our industry,
    the compensation committee has not in the past attempted to
    benchmark our executive compensation against any particular
    indices or salary surveys. While occasional review of market
    surveys is considered helpful, the compensation committee has
    historically placed substantially greater weight on internal
    considerations than on position-specific pay differences found
    in the market.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Except as described below, neither the Board of Directors nor
    the compensation committee has adopted any formal or informal
    policies or guidelines for allocating compensation between cash
    and non-cash compensation, among different forms of non-cash
    compensation or with respect to long and short term performance.
    The determination of the Board of Directors or compensation
    committee as to the appropriate use and weight of each component
    of executive compensation is subjective, based on their view of
    the relative importance of each component in meeting our overall
    objectives and factors relevant to the individual executive.
    Historically, our Board of Directors has focused significantly
    on the affordability of our compensation arrangements. As a
    result, when weighting forms of compensation, the Board of
    Directors and the compensation committee have historically
    placed greater emphasis on non-cash equity incentive
    compensation together with base salary. In 2006, the Board of
    Directors determined that our business was of sufficient
    maturity to permit us to establish a cash bonus plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As a publicly held company, we expect to periodically engage the
    services of a compensation consultant to assist us in further
    aligning our compensation philosophy with our corporate
    objectives. In particular, in order to attract and retain key
    executives, we may be required to modify individual executive
    compensation levels to remain competitive in the market for such
    positions.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Compensation
    Process and Compensation Committee</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For 2007 and January 2008, the compensation committee consisted
    of Messrs.&#160;Colella and Nussbacher and Ms.&#160;Jones. Since
    January&#160;29, 2008, the compensation committee has consisted
    of Messrs.&#160;Colella, Nussbacher and Hunkapiller, each of
    whom is an independent director under the rules of the NASDAQ
    Stock Market LLC and a &#147;non-employee director&#148; for
    purposes of
    <FONT style="white-space: nowrap">Rule&#160;16b-3</FONT>
    under the Securities Exchange Act of 1934, as amended.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The compensation committee makes recommendations to the Board
    regarding compensation structure, goals and individual
    compensation levels, which recommendations are considered for
    approval by the independent members of the Board. The
    compensation committee makes its compensation recommendations
    based on input from Mr.&#160;Worthington, our Chief Executive
    Officer, the judgment of its members based on their tenure and
    experience in our industry, and, starting with compensation
    levels for 2007, the advice of Compensia, Inc., an independent
    compensation consultant hired by the compensation committee in
    April 2007. The compensation committee has the responsibility of
    formulating, evaluating and recommending to the Board of
    Directors the compensation of our executive officers.
    Historically, our annual compensation review process has been
    initiated by Mr.&#160;Worthington who performs a review of the
    performance of each executive officer in the prior year and
    formulates proposals regarding the elements of compensation,
    corporate and individual goals and compensation levels for our
    executive officers, other than himself.
    Mr.&#160;Worthington&#146;s proposals for compensation
    structure, goals and individual compensation levels are
    typically based on discussions with and directions from members
    of the compensation committee. Mr.&#160;Worthington does not
    prepare proposals or advise the compensation committee on his
    own compensation.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    83
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Compensation levels and mix for Mr.&#160;Worthington, our Chief
    Executive Officer, are recommended by the compensation committee
    based on the committee&#146;s assessment of our overall
    corporate performance and Mr.&#160;Worthington&#146;s
    contribution to that performance. Mr.&#160;Worthington does not
    participate in compensation committee or Board deliberations
    regarding his own compensation. As with other members of our
    executive team, the compensation committee determines
    Mr.&#160;Worthington&#146;s compensation based on our
    achievement of corporate objectives and compensation levels of
    other members of our executive team, rather than attempting to
    tie Mr.&#160;Worthington&#146;s compensation to a specific
    percentile of CEO compensation reported in market compensation
    surveys.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subject to any limitations or guidelines that may be adopted by
    the Board of Directors in the future, the compensation committee
    does have the authority to approve the grant of stock options or
    stock purchase rights to individuals eligible for such grants,
    including officers and directors. The compensation committee met
    three times during 2007 and we expect that it will meet at least
    quarterly during 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The compensation committee has the authority under its charter
    to engage the services of outside advisors, experts and others
    for assistance. In April 2007, the compensation committee
    engaged Compensia, Inc., an outside consulting firm, to advise
    it on developing a principles based executive compensation
    strategy to help transition us from a privately held to a
    publicly held company and on matters relating to our equity
    compensation plans as a whole. Compensia reviewed our proposed
    2007 compensation philosophy and compensation levels and
    provided advice regarding the suitability of our executive
    compensation structure for a company at our stage of development
    and the impact the structure was likely to have on executive
    performance and our ability to attract executive talent.
    Compensia did not prepare a formal report or recommend specific
    compensation levels. In 2008, we expect the compensation
    committee will engage an outside consulting firm to review more
    broadly our compensation practices and provide specific
    recommendations on executive compensation levels.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After setting compensation levels for our executive officers for
    2007, but before making its recommendations to the Board, the
    compensation committee reviewed the 2006 Radford Biotechnology
    Survey by Aon Consulting and the 2006 Executive Compensation
    Survey for pre-IPO life science companies by Top Five Data
    Services, Inc. to confirm that the proposed mix and levels of
    compensation for our executive officers was not outside of the
    ranges reported for senior executive officers in general. The
    compensation committee did not benchmark or tie compensation
    levels for our executive officers to any particular compensation
    level provided by the companies included in these surveys.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Corporate
    and Individual Performance Goals</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>2007 Corporate Goals.</I>&#160;&#160;Our corporate and
    individual performance goals for each year are formulated by the
    Board of Directors with input from the compensation committee
    and our Chief Executive Officer. For 2007, two corporate goals
    were established. The first related to our selling a certain
    number of IFC systems and reaching certain revenue targets,
    whether through system sales or collaboration agreements. The
    second goal related to our equity fund raising activity. The
    compensation committee believed attaining these goals would take
    a high level of executive performance and that such goals would
    be very challenging given the initial lack of market awareness
    of our products in 2007. The committee did not assign weights to
    these goals, except to treat them as equally important.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    84
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>2007 Individual Goals.</I>&#160;&#160;Individual goals for
    2007 were as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="48%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Named Executive Officer</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>2007 Individual Goals</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Gajus Worthington, Chief Executive Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Achieving target levels of sales of our IFC systems and
    achieving target revenues, whether through system sales or
    collaboration agreements.
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Raising target levels of equity financing.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Richard DeLateur, former Chief Financial Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Preparing our finance organization for an initial public
    offering and public company status.
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michael Lucero, former Executive Vice President,
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Launching our BioMark product and developing a
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Sales and Marketing
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    strategy for new market penetration.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    William Smith, Vice President, Legal Affairs and
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Maintaining and advancing our intellectual property
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    General Counsel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
     position with respect to existing and new products.
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Robert Jones, Executive Vice President, Research
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Deliver commercial genotyping applications, digital
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    and Development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    array applications and finish feasibility phase of additional
    products.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mai Chan (Grace) Yow, Vice President, Worldwide
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Achieving specified IFC manufacturing yields and
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Manufacturing and Managing Director of
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    output levels.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Fluidigm Singapore
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>2008 Corporate Goals.</I>&#160;&#160;For 2008, the Board,
    with the participation of the compensation committee and members
    of management, reassessed our corporate goals in light of the
    maturation of our business and commercialization of our
    products. Following this reassessment, the Board approved
    corporate goals that include achieving specified levels of
    product sales and product gross margins, completing an initial
    public offering and keeping expenses and cash outlays within the
    budget approved by the Board of Directors. The Board believes
    that the goals are attainable with a very high level of
    executive performance. The target sales level represents
    significant growth from 2007 levels and will be achieved only if
    we are able to increase market awareness of our products and
    expand our customer base. The targeted gross margin will require
    significant contributions from both our manufacturing and
    research and development groups. Given the uncertainty in global
    financial markets, our ability to complete an initial public
    offering was also uncertain at the time these corporate goals
    were established. Achieving our overall corporate goals while
    staying within our proposed budget will require strong fiscal
    discipline.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    85
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>2008 Individual Goals.</I>&#160;&#160;The goals for our
    individual executives in 2008 are as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="48%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Named Executive Officer</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008 Individual Goals</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Gajus Worthington, Chief Executive Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Achieving specified levels of product sales and product gross
    margins, completing an initial public offering and keeping
    expenses and cash outlays within the budget approved by the
    Board of Directors.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Vikram Jog, Chief Financial Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Ensuring accurate revenue recognition during each quarter,
    closing our books in an accurate and timely manner, completing
    our 2005, 2006 and 2007 audits and ensuring compliance with
    applicable financial and disclosure regulations of the
    Securities and Exchange Commission.
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    William Smith, Vice President, Legal Affairs and
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Maintaining our intellectual property position and
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    General Counsel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    supporting our initial public offering.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Robert Jones, Executive Vice President, Research
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Completing market-ready 96.96 BioMark IFC, loaders
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    and Development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    and readers for 96.96 and certain future applications.
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mai Chan (Grace) Yow, Vice President, Worldwide
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Achieving overall IFC yields sufficient to achieve our
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Manufacturing and Managing Director of
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
     gross margin goals, achieving specified yields on our
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Fluidigm Singapore
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    new 96.96 Dynamic Array IFC, maintaining or improving 2007
    quality levels for our IFC systems and ensuring on-time
    manufacture and delivery of IFCs and IFC systems.
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Elements
    of Executive Compensation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our executive compensation program consists of four main
    elements: base salary, an annual incentive bonus plan, option
    awards and change of control arrangements. The following is a
    discussion of each element.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Base Salary.</I>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to 2007, the Board and the compensation committee
    established base salaries based on a number of factors including
    the scope of responsibility of each individual and a desire to
    encourage a team ethic. In 2007, the compensation committee and
    the Board concluded that our company and its stockholders would
    be better served by placing greater emphasis on creating a team
    ethic among our executive officers and that a team ethic would
    be better supported if all executive officers received
    approximately the same salary. Therefore, in May 2007, the
    compensation committee recommended and the Board approved a
    raise in the base annual salaries of Richard DeLateur, Michael
    Lucero, William Smith and Robert Jones to $265,000 effective
    February&#160;1, 2007, which represented a 20% increase for
    Mr.&#160;DeLateur, a 2.2% increase for Mr.&#160;Lucero, a 16%
    increase for Mr.&#160;Smith and a 6% increase for
    Mr.&#160;Jones, based on their salaries for 2006. This salary
    increase was based upon the compensation committee&#146;s
    assessment of the life science industry in the
    San&#160;Francisco Bay Area gathered from the active involvement
    of committee members as investors in such industry and the
    committee&#146;s conclusion that competition for executives in
    our industry was increasing. Ms.&#160;Yow&#146;s salary was set
    at SG$307,224, or US$200,000 using the exchange rate at the time
    such salary was set, to reflect the lower cost of living in
    Singapore where she is based. At the same time, the compensation
    committee also recommended that Mr.&#160;Worthington&#146;s
    salary be increased by 5% to $283,920 based on the factors
    described above. However, Mr.&#160;Worthington requested that
    this salary increase be deferred until his performance during
    2007 could be assessed. In December 2007, the compensation
    committee reviewed Mr.&#160;Worthington&#146;s overall
    performance during the year. In particular, it noted that
    Mr.&#160;Worthington had fully met his individual goal for
    equity financing as we had raised more money than had been
    targeted and had partially met his individual goal for revenue,
    as we had strong sales performance although the target revenue
    level was not achieved. The compensation committee therefore
    recommended and the Board approved the 5% raise that had been
    originally proposed for Mr.&#160;Worthington. The raise was made
    retroactive to February&#160;15, 2007 so that it would be
    effective as of the same date as the raises for all the other
    executive officers.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    86
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2008, the compensation committee reviewed 2008 base
    salaries in light of general market conditions in the
    San&#160;Francisco Bay Area life science industry. The
    compensation committee concluded that competition for executive
    talent remained strong as a result of the solid economic
    performance of the industry and the region overall, the
    continued high level of investment by venture capital firms in
    new and existing life science companies and the specialized
    skills and experiences required to manage life science
    companies. The compensation committee&#146;s assessment of
    general market conditions in the life science industry, and the
    life science industry in the San&#160;Francisco Bay Area in
    particular, was based on the experience of the committee members
    who were and are actively involved in venture capital investing
    in such industry and area. The compensation committee did not
    rely on any formal compensation survey data in making its
    assessment. The compensation committee therefore recommended and
    the Board approved an approximate raise of 4.0% for all
    executive officers other than Messrs.&#160;DeLateur and Lucero,
    who were expected to be leaving Fluidigm in early 2008. This
    approximate 4.0% raise was applied to Ms.&#160;Yow&#146;s salary
    in Singapore dollars, resulting in an increase of SG$12,289. As
    a result, the 2008 base salary for Mr.&#160;Smith and
    Mr.&#160;Jones was increased to $275,600, the 2008 base salary
    for Ms.&#160;Yow was increased to SG$319,513, or US$232,002 on
    the date of the increase, and the 2008 salary for
    Mr.&#160;Worthington was increased to $294,840. These salary
    increases became effective on February&#160;1, 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2008, we entered into an offer letter with Vikram
    Jog, our Chief Financial Officer that provides for him to
    receive a base salary of $278,000 per year and a signing bonus
    of $20,000. The Board approved this departure from our standard
    base salary and bonus practice for executive officers based on
    several factors, including his unique qualifications, the need
    to induce him to leave his existing employment, his base salary
    at his previous employer and our need to fill the position as
    soon as possible.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Incentive Bonus Plan.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For 2007, the compensation committee and the Board established a
    bonus structure for all named executive officers that provided
    for performance bonuses of up to 35% of base salary. 80% of the
    performance bonus was payable based upon our reaching our
    corporate goals described above, with each corporate goal
    receiving equal weighting and the remaining 20% payable to each
    executive based on the executive&#146;s attainment of his or her
    individual performance goals described above. Payment of
    performance bonuses was allocated among corporate and individual
    goals in this manner in recognition of our compensation
    philosophy in which the compensation committee sought to
    incentivize executive officers to look beyond their individual
    departmental goals and work with other executive officers to
    achieve our overall corporate goals. The compensation committee
    and Board concluded that the corporate goals portion of the
    bonus would not be payable if the goals were less than 80%
    attained, based on the average percentage completion of all such
    goals, and would be paid in full if the goals were 100%
    attained. The compensation committee retained discretion to
    determine the portion of the bonus that would be paid if the
    corporate goals were achieved at a level between 80% and 100%.
    The compensation committee also retained the discretion to
    change the bonus structure and the bonus payment amounts as it
    considered appropriate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2008, the compensation committee concluded that the
    first 2007 corporate goal described above had been partially met
    and the second 2007 corporate goal had been fully met, but that
    taken together the 80% threshold had not been attained. As a
    result, no 2007 bonuses were paid to our executive officers with
    respect to achievement of corporate goals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The compensation committee also considered the achievement of
    2007 individual performance goals in January 2008 and concluded
    that Mr.&#160;Smith had achieved his goals by maintaining and
    advancing our intellectual property position with respect to
    existing and new products. The Board awarded Mr.&#160;Smith 100%
    of his individual performance bonus of $18,550. The compensation
    committee concluded that Mr.&#160;Jones achieved his 2007
    individual goals of delivering a commercial genotyping
    application and digital array applications and awarded him his
    maximum individual performance bonus of $18,550. The
    compensation committee concluded that Ms.&#160;Yow had achieved
    her 2007 individual goals by achieving specified IFC
    manufacturing yields and output levels in 2007 and the Board
    awarded Ms.&#160;Yow 100% of her individual performance bonus of
    $14,000. The compensation committee concluded that
    Mr.&#160;Worthington had partially achieved his 2007 individual
    performance goals of achieving target levels of IFC system sales
    and revenue and raising target levels of equity financing, and
    the Board awarded Mr.&#160;Worthington a partial bonus of
    $14,175. No other individual performance bonuses were awarded to
    our named executive officers for 2007.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    87
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For 2008, the compensation committee and Board have approved the
    same bonus structure and potential bonus percentages as for 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In making recommendations regarding and approving compensation
    with respect to 2007, the compensation committee and the Board
    have not exercised their discretion to either award compensation
    absent attainment of relevant performance goals or to reduce the
    size of an award or payout following the attainment of relevant
    performance goals. We intend for the bonus plan to provide a
    significant portion of an executive&#146;s potential
    compensation. It is designed to help ensure that executives are
    focused on our near-term performance and on working together to
    achieve key corporate objectives. We expect that corporate and
    individual goals will be reviewed each year and adjusted to
    reflect changes in our stage of development, competitive
    position and corporate objectives.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Option Awards.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We grant options to new executives upon the commencement of
    their employment and on an annual basis make additional grants
    to existing executives based on our overall corporate
    performance, individual performance and the executives&#146;
    existing option grants and equity holdings. We believe that
    option awards are an effective means of aligning the interests
    of executives and stockholders, rewarding executives for our
    achieving success over the long term and providing executives an
    incentive to remain with us. Most option grants to our named
    executive officers provide the holder with the right to exercise
    the option and purchase shares prior to vesting, subject to our
    right to repurchase unvested shares pursuant to the terms of our
    restricted stock purchase agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2007, the compensation committee redesigned our option
    granting policy in light of the shift in our compensation
    philosophy toward team-based compensation. The compensation
    committee concluded that the number of shares that vest each
    year for each executive should be relatively consistent and
    should be comparable to the number of shares that vest for other
    executives. The committee determined that each executive should
    vest in approximately 70,000&#160;shares per year over a four
    year period. For each executive, the exact number of shares that
    vest in any year would be subject to adjustment either upward or
    downward by up to 35,000&#160;shares based on the
    executive&#146;s performance relative to the corporate goals and
    his or her individual performance goals. The compensation
    committee&#146;s selection of 70,000&#160;shares as the target
    number of shares to vest annually for each executive officer was
    based on the committee&#146;s determination that such number of
    shares would provide meaningful compensation to our executive
    officers. The committee did not rely on compensation surveys or
    other third party sources in arriving at the 70,000 annual
    vesting target. In addition to this annual vesting target and
    the possible adjustment of actual vesting amounts by up to
    35,000, the compensation committee retained the authority to
    approve additional option grants to executive officers who
    demonstrated exceptional performance in a given year.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As a result of our adoption of this new approach to equity
    compensation, our grants in 2007 were primarily intended to
    regularize each executive&#146;s vesting schedules to
    approximately 70,000 per year. As a result, certain executives
    received option grants where shares were immediately vested
    while others received grants where the vesting occurs largely
    three or four years from the grant of the date. The number of
    shares vesting for each such officer in 2007 were
    68,332&#160;shares for Mr.&#160;Worthington, 187,499&#160;shares
    for Mr.&#160;DeLateur, 111,084&#160;shares for Mr.&#160;Lucero,
    75,001 for Mr.&#160;Smith, 100,000 for Mr.&#160;Jones and 97,500
    for Ms.&#160;Yow. Variations in the number of shares vested in
    2007 for these officers was the result of vesting under options
    granted prior to 2007 rather than intentional variation in 2007
    grants on the part of the compensation committee. In the future,
    once the vesting of existing options are normalized at
    approximately 70,000&#160;shares per year, we intend for
    executives to receive additional grants that vest only in the
    fourth year following the date of their grant. We also expect to
    reconsider the target share amount each year and may in the
    future consider granting restricted stock as a form of equity
    compensation.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For 2008, the compensation committee did not alter the target
    amount of annual vesting for any executive. To give effect to
    this target annual vesting rate, the committee recommended and
    the Board approved grants of options to purchase
    70,000&#160;shares each to Mr.&#160;Jones, Mr.&#160;Smith,
    Mr.&#160;Worthington and Ms.&#160;Yow. These options vest fully
    on December&#160;31, 2011, subject to continued service through
    the vesting date. In addition, the compensation committee
    recommended that additional discretionary option grants be made
    to Mr.&#160;Jones, Mr.&#160;Smith, Mr.&#160;Worthington and
    Ms.&#160;Yow for their exceptional performance in 2007.
    Mr.&#160;Smith and Mr.&#160;Worthington received a fully-vested
    option to purchase 70,000&#160;shares and Mr.&#160;Jones and
    Ms.&#160;Yow received a fully-vested option to purchase
    40,000&#160;shares. These grants were issued separately from the
    annual grants and were not considered an adjustment to the
    annual grants. Accordingly, the 35,000&#160;share adjustment
    limit for annual grants did not apply.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    88
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As discussed above, the compensation committee retains the
    discretion to grant additional options to executive officers as
    a reward for exceptional performance. In addition, the committee
    may decide to grant options that vest upon the achievement of
    certain performance goals. Finally, the committee is exploring
    the desirability of other forms of equity based compensation
    including restricted stock grants.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2008, the Board approved amendments to our 1999 Stock
    Option Plan to permit the use of performance based vesting in
    connection with equity grants under the plan. The amendment
    provided the Board and compensation committee with the ability
    to grant options or other equity awards under the plan that vest
    upon the achievement of specified milestones or goals. These
    amendments were made to enhance the ability of the Board and
    compensation committee to closely align equity compensation with
    the achievement of corporate or individual goals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board adopted our 2008 Equity Incentive Plan in January 2008
    and we expect our stockholders will approve it prior to the
    completion of this offering. Subject to stockholder approval,
    the 2008 Equity Incentive Plan is effective upon its adoption by
    our Board, but is not expected to be utilized until after the
    completion of this offering. Our 2008 Equity Incentive Plan
    provides for the grant of incentive stock options, within the
    meaning of Section&#160;422 of the Internal Revenue Code, to our
    employees and any parent and subsidiary corporations&#146;
    employees, and for the grant of nonstatutory stock options,
    restricted stock, restricted stock units, stock appreciation
    rights, performance units and performance shares to our
    employees, directors and consultants and our parent and
    subsidiary corporations&#146; employees and consultants. Our
    Board and compensation committee are evaluating the costs and
    benefits of the various forms of equity compensation issuable
    under the 2008 plan and may elect to use restricted stock,
    restricted stock units, stock appreciation rights, performance
    units and performance shares in the future to further align the
    interests of our management and stockholders and to manage the
    financial statement impact of such forms of equity compensation.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    89
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2008, the compensation committee participated in the
    negotiation of a compensation package for Vikram Jog, our Chief
    Financial Officer, in which the compensation committee agreed to
    grant Mr.&#160;Jog compensation that exceeded our standard
    compensation package for the named executive officers. As
    indicated above, the compensation committee approved this
    package based on Mr.&#160;Jog&#146;s unique qualifications, our
    need to fill this position and the need to induce Mr.&#160;Jog
    to leave his then current employer. In February 2008, the
    compensation committee approved the grant of the following
    options to Mr.&#160;Jog in February 2008 under our 1999 Stock
    Option Plan:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="11%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="27%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="27%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="27%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B>Accelerated Vesting if<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Shares</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Standard Vesting</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Milestones Met</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Performance Milestones</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    500,000
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    25% on first anniversary<BR>
    of the vesting commencement date, and 1/48 per month thereafter
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    n/a
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    50,000&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    100% on December&#160;31, 2011
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    100% upon achievement<BR>
    of Milestones prior to December 31, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    (1) Revenue recognition - no material changes upon quarterly
    reviews and annual audit;<BR>
    (2) Accurate and timely closing of books and reporting
    (timeliness as required by investors and SEC);<BR>
    (3) SEC and Sarbanes-Oxley compliance, as needed; and<BR>
    (4) Produce audited financial statements for 2005, 2006 and 2007
    (and the first quarter of 2008, if necessary) to enable the
    filing of a Form S-1 registration statement.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    50,000&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    25% on first anniversary<BR>
    of the vesting  commencement date and 1/48 per month thereafter
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    100% upon achievement<BR>
    of Milestones prior to December 31, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    (1) Achievement of target revenues;<BR>
    (2) Achievement of target margins for 2008;<BR>
    (3) Completion of an initial public offering in 2008; and<BR>
    (4) Compliance with 2008 budget for expenses and cash outflows.
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In light of the performance based option grants made to
    Mr.&#160;Jog and our team-based approach to executive
    compensation, the compensation committee recommended to the
    Board, and the Board approved similar grants for all other named
    executive officers other than Mr.&#160;Worthington. Thus,
    Mr.&#160;Jones, Mr.&#160;Smith and Ms.&#160;Yow each received
    two additional options to purchase 50,000&#160;shares on
    April&#160;24, 2008. The first option becomes fully vested on
    the earlier of December&#160;11, 2011 or, with respect to each
    officer, December&#160;31, 2008 if that officer meets his or her
    individual goals for 2008. The second option vest with respects
    25% of the shares subject to the option on February&#160;1, 2009
    and 1/48th&#160;of the shares each month thereafter; provided
    that the option becomes fully vested on December&#160;31, 2008
    if the corporate goals for 2008 are achieved.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Employment and Severance Agreements.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2008, we entered into Employment and Severance
    Agreements with each of our named executive officers that
    provide for specified payments and benefits if the
    officer&#146;s employment is terminated without cause, or if the
    officer&#146;s employment is terminated without cause or for
    good reason within 12&#160;months following a change of control.
    The terms of these agreements are described under
    &#147;Potential Payments Upon Termination or Change of
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    90
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Control.&#148; We adopted these arrangements because we
    recognize that we will from time to time consider the
    possibility of an acquisition by another company or other change
    of control transaction and that such consideration can be a
    distraction to our executive officers and can cause such
    officers to consider alternative employment opportunities.
    Accordingly, the Board concluded that it is in the best
    interests of our company and its stockholders to provide
    executives with certain severance benefits upon termination of
    employment without cause or for good reason following a change
    of control. Our Board determined to provide such executives with
    certain severance benefits upon their termination of employment
    without cause outside of the change of control context in order
    to provide executives with enhanced financial security and
    incentive to remain with our company. In addition, we believe
    that providing for acceleration of options if an officer is
    terminated following a change of control transaction aligns the
    executive officer&#146;s interest more closely with those of
    other stockholders when evaluating the transaction rather than
    putting the officer at risk of losing the benefits of those
    equity incentives.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In determining the amount of cash payments, benefits coverage
    and acceleration of vesting to be provided to officers upon
    termination prior to a change of control or within
    12&#160;months following a change of control, our Board
    considered the following factors:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the expected time required for an officer to find comparable
    employment following a termination event;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    feedback received from potential candidates for officer
    positions at our company as to the level of severance payments
    and benefits they would require to leave other employment and
    join our company;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    in the context of a change of control, the amount of vesting
    acceleration that would align the officer&#146;s interests more
    closely with the interests of stockholders when considering a
    potential change of control transaction;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the period of time following a change of control during which
    management positions are evaluated and subject to a heightened
    risk of elimination.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, all outstanding options granted to our employees
    will become fully vested upon a change of control if the options
    are not assumed by the acquiring company.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In connection with the resignation of Mr.&#160;Lucero, our
    former Vice President of Sales and Marketing, on March&#160;22,
    2008, we entered into a Settlement Agreement and General Release
    of Claims with Mr.&#160;Lucero that provided for mutual releases
    of us and Mr.&#160;Lucero, our continued payment of
    Mr.&#160;Lucero&#146;s salary and health insurance premiums
    through July 2008 and payment of an additional $144,000 ($90,000
    net applicable payroll withholding taxes) to Mr.&#160;Lucero.
    The amount and timing of payments to Mr.&#160;Lucero under this
    agreement were the result of negotiations between us and
    Mr.&#160;Lucero, with the involvement of the compensation
    committee. The compensation committee concluded that this
    agreement was in the best interests of our company in reaching
    an amicable separation with Mr.&#160;Lucero.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In connection with Mr.&#160;DeLateur&#146;s resignation, we
    entered into a consulting agreement dated February&#160;29,
    2008. Under the consulting agreement, we agreed to pay
    Mr.&#160;DeLateur $200 per hour for performing various
    consulting services, provided that Mr.&#160;DeLateur work no
    more than five hours per week without our written authorization.
    We entered into this arrangement to ensure that
    Mr.&#160;DeLateur would be available as needed to ensure an
    orderly transition to our new Chief Financial Officer,
    Mr.&#160;Jog.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Other Benefits.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Executive officers are eligible to participate in all of our
    employee benefit plans, such as medical, dental, vision, group
    life, disability, and accidental death and dismemberment
    insurance and our 401(k) plan, in each case on the same basis as
    other employees, subject to applicable law. We also provide
    vacation and other paid holidays to all employees, including our
    executive officers, which we believe are comparable to those
    provided at peer companies.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">CEO
    Loan and Stock Repurchase</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On January&#160;20, 2004, we entered into an Employee Loan
    Agreement, Secured Promissory Note and Stock Pledge Agreement
    with Mr.&#160;Worthington pursuant to which we loaned
    Mr.&#160;Worthington $250,000 at an interest rate
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    91
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    of 3.52% per annum. The loan was secured by the pledge of
    833,334&#160;shares of our common stock held by
    Mr.&#160;Worthington. On April&#160;10, 2008,
    Mr.&#160;Worthington repaid the loan in full in accordance with
    Section&#160;2.2(d) of the note by exchanging shares of our
    common stock held by Mr.&#160;Worthington to us at the fair
    market value of such stock, which was determined by the Board of
    Directors to be $3.19 per share. The note and
    Mr.&#160;Worthington&#146;s loan were repaid in full and
    cancelled in exchange for 90,913&#160;shares of our common stock
    which Mr.&#160;Worthington transferred to us pursuant to the
    terms of a repurchase agreement dated April&#160;10, 2008. This
    loan repayment and share cancellation transaction were approved
    by the Board based on its determination that we received full
    and fair consideration for the cancellation of the loan and that
    the cancellation of the loan was in the best interests of our
    company and its stockholders.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Accounting
    and Tax Considerations</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Section 162(m) of the Internal Revenue Code of 1986, as amended,
    or the Code, places a limit of $1,000,000 on the amount of
    compensation that we may deduct as a business expense in any
    year with respect to our Chief Executive Officer and certain of
    our highly paid executive officers. We can, however, preserve
    the deductibility of certain performance-based compensation in
    excess of $1,000,000 if the conditions of Code
    Section&#160;162(m) are met. Under applicable tax guidance for
    newly-public companies, the deduction limitation generally will
    not apply to compensation paid pursuant to any plan or agreement
    that existed before the company became publicly held. In
    addition, compensation provided by newly-public companies
    through the first stockholder meeting to elect directors after
    the close of the third calendar year following the year in which
    the initial public offering occurs, or earlier upon the
    occurrence of certain events (e.g., a material modification of
    the plan or agreement under which the compensation is granted),
    will not be included in for purposes of the Code
    Section&#160;162(m) limit provided the arrangement is adequately
    described in this prospectus. Accordingly, we believe that
    deductibility of all income recognized by executives pursuant to
    equity compensation granted by us prior to this offering, as
    well as any equity compensation granted by us under the 2008
    Equity Incentive Plan following this offering through the
    expiration of the reliance period, will not be limited by Code
    Section&#160;162(m). While the compensation committee cannot
    predict how the deductibility limit may impact our compensation
    program in future years, the compensation committee intends to
    maintain an approach to executive compensation that strongly
    links pay to performance. While the compensation committee has
    not adopted a formal policy regarding tax deductibility of
    compensation paid to our executive officers, the compensation
    committee intends to consider tax deductibility under
    Section&#160;162(m) as a factor in compensation decisions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Code Section 409A imposes additional taxes on certain
    non-qualified deferred compensation arrangements that do not
    comply with its requirements. These requirements regulate an
    individual&#146;s election to defer compensation and the
    individual&#146;s selection of the timing and form of
    distribution of the deferred compensation. Code
    Section&#160;409A generally also provides that distributions of
    deferred compensation only can be made on or following the
    occurrence of certain events (i.e., the individual&#146;s
    separation from service, a predetermined date, a change in
    control, or the individual&#146;s death or disability). For
    certain executives, Code Section&#160;409A requires that such
    individual&#146;s distribution commence no earlier than six
    (6)&#160;months after such officer&#146;s separation from
    service. We have and will continue to endeavor to structure our
    compensation arrangements to comply with Code Section&#160;409A
    so as to avoid the adverse tax consequences associated therewith.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    92
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><I><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Summary
    Compensation Table</FONT><!-- /FONT#008 --></I></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The following table presents information concerning the total
    compensation of our Chief Executive Officer, Chief Financial
    Officer and our four other most highly compensated officers
    during the last fiscal year (the &#147;Named Executive
    Officers&#148;) for services rendered to us in all capacities
    for the fiscal year ended December&#160;29, 2007:
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Summary
    Compensation Table</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="49%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Non-Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Incentive Plan<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Salary<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px"><!-- DIV#013 -->
    <B>Name and Principal Position</B>
</DIV><!-- /DIV#007 -->
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(4)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Gajus V. Worthington
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    270,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    30,672
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    14,175
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    315,247
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt"><!-- DIV#014 -->
    President and Chief<BR>
    Executive Officer
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Richard A.
    DeLateur<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    241,375
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    71,525
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    312,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt"><!-- DIV#014 -->
    Former Chief Financial Officer
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Robert C. Jones
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    247,502
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    15,577
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    18,550
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    263,079
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt"><!-- DIV#014 -->
    Executive Vice President<BR>
    Research and Development
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Michael Y.
    Lucero<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    264,517
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    14,369
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    278,886
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt"><!-- DIV#014 -->
    Former Executive Vice President,<BR>
    Sales and Marketing
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    William M. Smith
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    286,983
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    35,191
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    18,550
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    340,724
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt"><!-- DIV#014 -->
    Vice President, Legal<BR>
    Affairs and General<BR>
    Counsel
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Mai Chan (Grace) Yow
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    220,675
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    84,327
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    14,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    319,002
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt"><!-- DIV#014 -->
    Vice President, Worldwide<BR>
    Manufacturing and Managing Director of Fluidigm Singapore
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->

</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV style="font-size: 12pt; margin-left: 0%;  align: left; border-bottom: 1pt solid #000000"><!-- DIV#071 --></DIV><!-- /DIV#041 --><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(1)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->Amounts represent
    the aggregate expense recognized for financial statement
    reporting purposes for fiscal 2007 calculated in accordance with
    SFAS&#160;No.&#160;123(R) without regard for estimated
    forfeitures. See Note&#160;2 of Notes to Consolidated Financial
    Statements for a discussion of assumptions made in determining
    the grant date fair value and compensation expense of our stock
    options.</FONT><!-- /FONT#008 --></TD>
</TR>

</TABLE>

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(2)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->Mr.&#160;DeLateur
    resigned effective February&#160;29, 2008. From August&#160;16,
    2007 to December&#160;31, 2007, Mr.&#160;DeLateur worked for us
    on a
    <FONT style="white-space: nowrap"><!-- FONT#006 -->part-time</FONT><!-- /FONT#006 -->
    basis. See &#147;Employment Agreements and Offer
    Letters.&#148;</FONT><!-- /FONT#008 --></TD>
</TR>

</TABLE>

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(3)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->Mr.&#160;Lucero
    resigned effective March&#160;22, 2008. See &#147;Employment and
    Severance Agreements.&#147;</FONT><!-- /FONT#008 --></TD>
</TR>



<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(4)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->The amounts in
    this column represent total
    <FONT style="white-space: nowrap"><!-- FONT#006 -->performance-based</FONT><!-- /FONT#006 -->
    bonuses earned for service rendered during fiscal 2007 under our
    incentive bonus plan. Under our incentive bonus plan, each
    executive was eligible to receive a cash bonus of up to 35% of
    his or her base salary based on achievement of certain corporate
    goals and certain individual performance goals. Please see
    &#147;Incentive Bonus Plan&#148; under &#147;Compensation
    Discussion and Analysis&#148; above for additional information
    regarding our fiscal 2007 cash bonuses.</FONT><!-- /FONT#008 --></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    93
</DIV><!-- /DIV#050 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><I><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Grants
    of Plan-Based Awards</FONT><!-- /FONT#008 --></I></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The following table presents information concerning grants of
    plan-based awards to each of the Named Executive Officers during
    the fiscal year ended December&#160;29, 2007.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Grants
    of Plan-Based Awards</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="8%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Estimated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>All Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Payouts Under<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards:<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Non-Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Grant Date<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Incentive Plan<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise or<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Fair Value of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Base Price of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Stock and<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Target<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px"><!-- DIV#013 -->
    <B>Name</B>
</DIV><!-- /DIV#007 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Grant Date</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($/Sh)<SUP style="font-size: 85%; vertical-align: text-top">(8)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Awards<SUP style="font-size: 85%; vertical-align: text-top">(7)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Gajus V. Worthington
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5/8/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    155,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    131,533
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4/24/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    99,225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Richard DeLateur
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5/8/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    140,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    115,674
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4/24/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    92,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt; background: #CCEEFF">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Robert C. Jones
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5/8/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(6)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    69,284
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4/24/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    92,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Michael Y. Lucero
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5/8/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    21,753
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4/24/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    92,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt; background: #CCEEFF">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    William M. Smith
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5/8/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    118,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(4)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    101,119
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4/24/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    92,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Mai Chan (Grace) Yow
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5/8/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    199,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    165,255
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4/24/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    70,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->

</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV style="font-size: 12pt; margin-left: 0%;  align: left; border-bottom: 1pt solid #000000"><!-- DIV#071 --></DIV><!-- /DIV#041 --><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(1)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->10,000 of the
    shares subject to this grant were vested as of the grant date,
    10,000&#160;shares vested on February&#160;1, 2008,
    65,000&#160;shares vest on February&#160;1, 2009, and
    70,000&#160;shares vest on February&#160;1,
    2010.</FONT><!-- /FONT#008 --></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(2)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->70,000 of the
    shares subject to this grant were vested as of the grant date
    and 70,000&#160;shares vest on February&#160;1,
    2010.</FONT><!-- /FONT#008 --></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(3)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->All of the shares
    subject to this grant vest on February&#160;1,
    2010.</FONT><!-- /FONT#008 --></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(4)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->10,000 of the
    shares subject to this grant vested on February&#160;1, 2008,
    38,000&#160;shares vest on February&#160;1, 2009, and
    70,000&#160;shares vest on February&#160;1,
    2010.</FONT><!-- /FONT#008 --></TD>
</TR>



<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(5)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->50,000 of the
    shares subject to this grant were vested as of the grant date,
    50,000&#160;shares vested on February&#160;1, 2008,
    40,000&#160;shares vest on February&#160;1, 2009, and
    59,000&#160;shares vest on February&#160;1,
    2010.</FONT><!-- /FONT#008 --></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(6)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->10,000 of the
    shares subject to this grant vest on February&#160;1, 2009 and
    70,000&#160;shares vest on February&#160;1,
    2010.</FONT><!-- /FONT#008 --></TD>
</TR>



<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(7)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->Amounts represent
    the aggregate grant date fair value of stock options granted in
    fiscal 2007, calculated in accordance with
    SFAS&#160;No.&#160;123(R) without regard to estimated
    forfeitures. See Note&#160;2 of Notes to Consolidated Financial
    Statements for a discussion of assumptions made in determining
    the grant date fair value of our stock
    options.</FONT><!-- /FONT#008 --></TD>
</TR>

</TABLE>

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(8)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->Our shares of
    common stock were not publicly traded during the 2007 fiscal
    year; our Board of Directors in good faith determined the fair
    market value on the date of grant.</FONT><!-- /FONT#008 --></TD>
</TR>

</TABLE>

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    94
</DIV><!-- /DIV#051 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Outstanding
    Equity Awards at Fiscal Year-End</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table presents certain information concerning
    equity awards held by the Named Executive Officers at the end of
    the fiscal year ended December&#160;29, 2007.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Outstanding
    Equity Awards at Fiscal Year-End</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="54%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Option Awards</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unexercised<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unexercised<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options (#)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options (#)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Expiration<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Exercisable<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Unexercisable</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Price&#160;($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Date</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Gajus V. Worthington
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    200,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
     0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.56
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    01/17/2015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    155,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    05/08/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Richard DeLateur
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    95,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(4)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    235,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(6)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.56
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12/20/2015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    140,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    05/08/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Robert C. Jones
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    400,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(22)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.56
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    08/03/2015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(23)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    05/08/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michael Y. Lucero
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(7)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12/04/2011
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    180,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(8)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    04/18/2014
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(9)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    07/15/2013
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    150,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(10)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.56
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    01/17/2015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(11)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.83
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    08/14/2016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(12)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    05/08/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    William M. Smith
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(13)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12/04/2011
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    175,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(14)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    07/15/2013
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(15)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    04/18/2014
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(16)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.56
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    01/17/2015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(17)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.83
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    08/14/2016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    118,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(18)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    05/08/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mai Chan (Grace) Yow
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    150,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(19)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.56
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    08/03/2015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(20)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.83
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    09/27/2006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    199,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(21)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    05/08/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Unless otherwise noted, all option
    grants may be exercised pursuant to a restricted stock purchase
    agreement prior to vesting; any shares purchased prior to
    vesting are subject to a right of repurchase in our favor in the
    event the individual ceases to provide services for any reason
    which right lapses in accordance with the vesting schedule of
    the option.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    January&#160;18, 2005 and vest over 4&#160;years. 20% of the
    shares subject to the stock option vest one year after grant.
    1.667% of the shares vest at the end of each monthly period
    during the subsequent year and 2.5% of the shares vest at the
    end of each monthly period thereafter.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">10,000 of the shares subject to
    this grant were vested as of May&#160;8, 2007, the grant date,
    10,000&#160;shares vested on February&#160;1, 2008,
    65,000&#160;shares vest on February&#160;1, 2009, and 70,000
    vest on February&#160;1, 2010.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    December&#160;21, 2005 and vest over 4&#160;years. 25% of the
    shares vest one year after grant and 2.083% of the shares vest
    at the end of each monthly period thereafter.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(5)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">70,000 of the shares subject to
    this grant were vested as of May&#160;8, 2007, the grant date,
    and 70,000&#160;shares vest on February&#160;1, 2010.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(6)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">This option may not be exercised
    prior to vesting.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(7)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    December&#160;4, 2001 and vest over 4&#160;years. 25% of the
    shares vest one year after grant and 2.083% of the shares vest
    at the end of each monthly period thereafter.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(8)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    April&#160;19, 2004 and vest over 4&#160;years at the rate of
    2.083% of the shares per month.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(9)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    July&#160;16, 2003 and vest over 4&#160;years at the rate of
    2.083% of the shares per month.
    </FONT></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    95
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(10)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    January&#160;18, 2005 and vest over 4&#160;years. 20% of the
    shares subject to the stock option vest one year after grant.
    1.667% of the shares vest at the end of each monthly period
    during the subsequent year and 2.5% of the shares vest at the
    end of each monthly period thereafter.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(11)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    August&#160;15, 2006 vest over 4&#160;years. 1.67% of the shares
    vest each month for the first two years and 2.5% of the shares
    vest each month in the final two years.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(12)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    May&#160;8, 2007. All of the shares subject to this grant vest
    on February&#160;1, 2010.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(13)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    December&#160;4, 2001 and vest over 4&#160;years at the rate of
    2.083% of the shares per month.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(14)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    July&#160;16, 2003 and vest over 4&#160;years at the rate of
    2.083% of the shares per month.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(15)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    April&#160;19, 2004 and vest over 4&#160;years at the rate of
    2.083% of the shares per month.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(16)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    January&#160;18, 2005 and vest over 4&#160;years. 20% of the
    shares subject to the stock option vest one year after grant.
    1.667% of the shares vest at the end of each monthly period
    during the subsequent year and 2.5% of the shares vest at the
    end of each monthly period thereafter.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(17)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    August&#160;15, 2006 vest over 4&#160;years. 1.67% of the shares
    vest each month for the first two years and 2.5% of the shares
    vest each month in the final two years.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(18)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    May&#160;8, 2007. 10,000 of the shares subject to this grant
    vested on February&#160;1, 2008, 38,000&#160;shares vest on
    February&#160;1, 2009, and 70,000&#160;shares vest on
    February&#160;1, 2010.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(19)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    August&#160;3, 2005 and vest over 4&#160;years. 25% of the
    shares vest one year after grant and 2.083% of the shares vest
    at the end of each monthly period thereafter.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(20)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    September&#160;27, 2006. These stock options vest over
    4&#160;years in monthly increments. During the first two years,
    1.67% of the shares vest each month and during the final two
    years, 2.5% of the shares vest each month.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(21)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">50,000 of the shares subject to
    this grant were vested as of May&#160;8, 2007, the grant date,
    50,000&#160;shares vested on February&#160;1, 2008,
    40,000&#160;shares vest on February&#160;1, 2009, and
    59,000&#160;shares vest on February&#160;1, 2010.
    </FONT></TD>
</TR>




<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(22)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">This option was granted on
    August&#160;3, 2005 and vests over 4&#160;years. Twenty-five
    percent of the shares vest one year after grant and 2.083% of
    the shares vest each month thereafter.
    </FONT></TD>
</TR>



<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(23)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    May&#160;8, 2007. 10,000 of the shares subject to this grant
    vest on February&#160;1, 2009, and 70,000&#160;shares subject to
    this grant vest on February&#160;1, 2010.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Employment
    Agreements and Offer Letters</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Richard A DeLateur.</I>&#160;&#160;We entered into a
    consulting agreement dated February&#160;29, 2008 with Richard
    A. DeLateur, our former Chief Financial Officer. Under the
    consulting agreement, we agreed to pay Mr.&#160;DeLateur $200
    per hour for performing various consulting services, provided
    that Mr.&#160;DeLateur shall work no more than five hours per
    week without our written authorization. The consulting agreement
    terminated on May&#160;17, 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Michael Y. Lucero.</I>&#160;&#160;We entered into to a
    Settlement Agreement and General Release of Claims effective
    March&#160;30, 2008 with Michael Y. Lucero, our former Executive
    Vice President of Sales and Marketing. Under the settlement
    agreement, we agreed, in exchange for a general release of all
    claims and other customary terms and conditions, (i)&#160;to pay
    Mr.&#160;Lucero on each pay day through July&#160;15, 2008 an
    amount equal to what he would have received on that pay day
    based on an annual base salary of $265,000 and (ii)&#160;to
    reimburse Mr.&#160;Lucero for costs of coverage under the
    Consolidated Omnibus Budget Reconciliation Act of 1985, or
    COBRA, that are incurred during April, May, June and July of
    2008, in an amount no greater than the amount we contributed on
    Mr.&#160;Lucero&#146;s behalf for February 2008. We also agreed
    to make a one time payment to Mr.&#160;Lucero of $144,000
    ($90,000 net of applicable payroll withholding taxes).
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Vikram Jog.</I>&#160;&#160;We are a party to an offer letter
    dated January&#160;29, 2008, with Vikram Jog, our Chief
    Financial Officer. Under the offer letter, we employ
    Mr.&#160;Jog on an at-will basis for no specified term and
    agreed to pay Mr.&#160;Jog an annual base salary of $278,000,
    which continues to be his base salary. We also agreed to pay
    Mr.&#160;Jog a signing bonus of $20,000 pursuant to his offer
    letter. Pursuant to the offer letter, we granted Mr.&#160;Jog an
    initial options to purchase a total of 600,000&#160;shares of
    our common stock.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Potential
    Payments Upon Termination or Change of Control</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2008, we entered into employment and severance
    agreements with Gajus V. Worthington, William M. Smith, Mai Chan
    (Grace) Yow, Robert C. Jones and Vikram Jog, which require us to
    make payments if the named executive officer&#146;s employment
    with us is terminated in certain circumstances.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    96
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to our employment and severance agreements with our
    named executive officers, a &#147;change of control&#148; is
    defined as the occurrence of the following events:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any &#147;person,&#148; as such term is used in
    Sections&#160;13(d) and 14(d) of the Securities Exchange Act of
    1934, as amended, is or becomes the &#147;beneficial
    owner,&#148; as such term is defined in
    <FONT style="white-space: nowrap">Rule&#160;13d-3</FONT>
    under said Act, directly or indirectly, of our securities
    representing 50% or more of the total voting power represented
    by our then outstanding voting securities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a change in the composition of our Board occurring within a
    two-year period, as a result of which fewer than a majority of
    our directors are &#147;incumbent directors,&#148; which term is
    defined as either (i)&#160;our directors as of the execution
    date of the relevant agreement or (ii)&#160;directors who are
    elected, or nominated for election, to our Board with the
    affirmative votes of at least a majority of the incumbent
    directors at the time of such election or nomination (but will
    not include an individual whose election or nomination is in
    connection with an actual or threatened proxy contest relating
    to the election of our directors);
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the date of the consummation of our merger or consolidation with
    any other corporation that has been approved by the our
    stockholders, other than a merger or consolidation that would
    result in our voting securities outstanding immediately prior
    thereto continuing to represent (either by remaining outstanding
    or by being converted into voting securities of the surviving
    entity) more than 50% of the total voting power represented by
    our voting securities or such surviving entity outstanding
    immediately after such merger or consolidation, or our
    stockholders approve a plan of our complete liquidation;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the date of the consummation of the sale or disposition by us of
    all or substantially all of our assets.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to our employment and severance agreements with our
    named executive officers, &#147;cause&#148; is defined as:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an act of dishonesty in connection with a named executive
    officer&#146;s responsibilities as an employee;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a conviction of, or plea of <I>nolo contendere </I>to, a felony
    or any crime involving fraud, embezzlement or any other act of
    moral turpitude;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    gross misconduct;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an unauthorized use or disclosure of any of our proprietary
    information or of any other party to whom he or she owes an
    obligation of nondisclosure as a result of his or her
    relationship with us;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a willful breach of any obligations under any written agreement
    or covenant with us;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a named executive officer&#146;s continued failure to perform
    his or her employment duties after he or she has received a
    written demand of performance from us and has failed to cure
    such non-performance to our satisfaction within 10 business days
    after receiving such notice.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to our employment and severance agreements with Gajus
    V. Worthington, William M. Smith, Robert C. Jones and Vikram
    Jog, &#147;good reason&#148; means the occurrence of one or more
    of the following events effected without the named executive
    officer&#146;s prior consent, provided that he or she terminates
    his or her employment within one year thereafter:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the assignment to the named executive officer of any duties or a
    reduction of the named executive officer&#146;s duties, either
    of which significantly reduces his or her responsibilities;
    provided that the continuance of his or her responsibilities at
    the subsidiary or divisional level following a change of
    control, rather than at the parent, combined or surviving
    company level following such change of control shall not be
    deemed &#147;good reason&#148; within the meaning of this clause;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a material reduction of the named executive officer&#146;s base
    salary;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the relocation of the named executive officer to a facility or a
    location greater than 50&#160;miles from his or her present
    location;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a material breach by us of any material provision of the
    employment and severance agreement.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    97
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    However, no act or omission by us shall constitute &#147;good
    reason&#148; if we fully cure that act or omission within
    30&#160;days of receiving notice of receiving notice from the
    named executive officer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to our employment and severance agreement with Mai Chan
    (Grace) Yow, &#147;good reason&#148; means the occurrence of one
    or more of the following events effected without her consent,
    provided that she terminates her employment within one year
    thereafter:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the assignment to Ms.&#160;Yow of any duties or a reduction of
    her duties, either of which significantly reduces her
    responsibilities; provided that the continuance of her
    responsibilities at the subsidiary or divisional level following
    a change of control, rather than at the parent, combined or
    surviving company level following such change of control shall
    not be deemed &#147;good reason&#148; within the meaning of this
    clause;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a material reduction of Ms.&#160;Yow&#146;s base salary;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the relocation of Ms.&#160;Yow to a facility or a location
    outside the country of Singapore;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a material breach by us of any material provision of the
    employment and severance agreement.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    However, no act or omission by us shall constitute &#147;good
    reason&#148; if we fully cure that act or omission within
    30&#160;days of receiving notice of receiving notice from the
    named executive officer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The employment and severance agreements provide that in the
    event the named executive officer&#146;s employment is
    terminated by us or our successor without &#147;cause&#148;
    prior to a &#147;change of control&#148; or after 12&#160;months
    following a &#147;change of control&#148; and the named
    executive officer executes a standard release of claims with us,
    the named executive officer is entitled to receive, in addition
    to such officer&#146;s salary payable through the date of
    termination of employment and any other benefits earned and owed
    through the date of termination, the following cash payments:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an amount, payable in accordance with our customary payroll
    practices, equal to six&#160;months of the named executive
    officer&#146;s base salary in effect immediately prior to the
    time of termination;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reimbursement of costs and expenses incurred by the executive
    officer and his or her eligible dependents for coverage under
    group health plans, policies or arrangements sponsored by us for
    a period of up to six&#160;months, provided that such coverage
    is timely elected under COBRA or similar applicable state
    statute.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The employment and severance agreements further provide that in
    the event the named executive officer&#146;s employment is
    terminated by (i)&#160;us or our successor without
    &#147;cause&#148; and within 12&#160;months following a
    &#147;change of control&#148; or (ii)&#160;by the executive
    officer for &#147;good reason&#148; and within 12&#160;months
    following a &#147;change of control&#148;, and in each case the
    named executive officer executes a standard release of claims
    with us, the executive officer is entitled to receive, in
    addition to such officer&#146;s salary payable through the date
    of termination of employment and any other benefits earned and
    owed through the date of termination, the following cash
    payments and benefits:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an amount, payable in a lump sum, equal to the greater of
    (i)&#160;six&#160;months of the named executive officer&#146;s
    base salary in effect immediately prior to the change in control
    or (ii)&#160;six&#160;months of the named executive&#146;s
    officer&#146;s base salary in effect immediately prior to the
    time of termination;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    all outstanding unvested stock options, equity appreciation
    rights or similar equity awards then held by the named executive
    officer as of the date of termination will immediately vest and
    become exercisable as to all shares underlying such options;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any shares of restricted stock, restricted stock units and
    similar equity awards then held by the named executive officer
    will immediately vest and any of our rights of repurchase or
    reacquisition with respect to such shares will lapse as to all
    shares;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reimbursement of costs and expenses incurred by the executive
    officer and his or her eligible dependents for coverage under
    group health plans, policies or arrangements sponsored by us for
    a period of up to six months, provided that such coverage is
    timely elected under COBRA or similar applicable state statute.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table describes the payments and benefits that
    each of our named executive officers would be entitled to
    receive pursuant to the employment and severance agreements,
    assuming that each of the following
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    98
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    triggers occurred in December&#160;29, 2007: their employment
    was terminated without &#147;cause&#148; prior to or after
    12&#160;months following a &#147;change of control&#148; and
    (ii) their employment was terminated without &#147;cause&#148;
    or for &#147;good reason&#148; within 12&#160;months following a
    &#147;change of control&#148;.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Employment Terminated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>without Cause Prior<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>to or After 12 Months<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Following Change of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>Employment Terminated within 12 Months<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Control</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Following Change of
    Control<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Severance<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Health Care<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Severance<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Health Care<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Payments<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Benefits<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Acceleration<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Payments<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Benefits<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px"><!-- DIV#013 -->
    <B>Name and Principal Position</B>
</DIV><!-- /DIV#007 -->
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(4)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Gajus V. Worthington
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    135,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9,213
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    135,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9,213
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt"><!-- DIV#014 -->
    President and Chief Executive Officer
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    William M. Smith
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    132,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,056
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    132,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,056
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt"><!-- DIV#014 -->
    Vice President, Legal Affairs and General Counsel
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Mai Chan (Grace) Yow
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    106,130
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    525
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    106,130
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    525
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt"><!-- DIV#014 -->
    Vice President, Worldwide Manufacturing and Managing Director of
    Fluidigm Singapore
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Robert C. Jones
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    132,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9,213
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    132,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9,213
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt"><!-- DIV#014 -->
    Executive Vice President, Research and Development
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Vikram Jog
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    139,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10,142
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    139,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10,142
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt"><!-- DIV#014 -->
    Chief Financial Officer
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->

</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV style="font-size: 0pt; margin-left: 0%;  align: left; border-bottom: 1pt solid #000000"><!-- DIV#071 --></DIV><!-- /DIV#041 --><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(1)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->Includes
    involuntary termination other than for cause, death or
    disability, and voluntary termination for good
    reason.</FONT><!-- /FONT#008 --></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(2)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->The amounts shown
    in this column are equal to 6&#160;months of the named executive
    officer&#146;s base salary as of December&#160;29,
    2007.</FONT><!-- /FONT#008 --></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(3)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->The amounts shown
    in this column are equal to the spread value between
    (i)&#160;the unvested portion of all outstanding stock options,
    equity appreciation rights or similar equity awards held by the
    named executive officer on December&#160;29, 2007 and
    (ii)&#160;the initial public offering price of our common stock,
    which we have assumed to be the midpoint of the price range set
    forth on the cover page of this
    prospectus.</FONT><!-- /FONT#008 --></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(4)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->The amounts shown
    in this column are equal to the cost of covering the named
    executive officer and his or her eligible dependents coverage
    under our benefit plans for a period of six months, assuming
    that such coverage is timely elected under
    COBRA.</FONT><!-- /FONT#008 --></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(5)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->Amount shown has
    been converted from Singapore dollars to U.S. dollars based on
    the interbank exchange rate for December&#160;29, 2007 of
    1&#160;Singapore dollar = 0.6909 U.S.
    dollars.</FONT><!-- /FONT#008 --></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    In addition to the benefits described above, our 2008 Equity
    Incentive Plan and 1999 Stock Option Plan provide for full
    acceleration of all outstanding options in the event of a change
    of control of our company where the successor company does not
    assume our outstanding options and other awards in connection
    with such acquisition transaction. We estimate the value of this
    benefit for each named executive officer to be equal to the
    amount listed above in the column labeled &#147;Equity
    Acceleration.&#148;
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Employee
    Benefit Plans</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><I><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->2008
    Equity Incentive Plan.</FONT><!-- /FONT#008 --></I></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Our Board of Directors adopted our 2008 Equity Incentive Plan on
    January&#160;29, 2008, and we expect our stockholders will
    approve it prior to the completion of this offer. Subject to
    stockholder approval, the 2008 Equity Incentive Plan is
    effective upon its adoption by our Board of Directors, but is
    not expected to be utilized until after the completion of this
    offering. Our 2008 Equity Incentive Plan provides for the grant
    of incentive stock options, within the meaning of
    Section&#160;422 of the Internal Revenue Code, to our employees
    and any parent and subsidiary corporations&#146; employees, and
    for the grant of nonstatutory stock options, restricted stock,
    restricted stock units, stock appreciation rights, performance
    units and performance shares to our employees, directors and
    consultants and our parent and subsidiary corporations&#146;
    employees and consultants.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    A total of 7,000,000&#160;shares of our common stock are
    reserved for issuance pursuant to the 2008 Equity Incentive
    Plan, of which no options are issued and outstanding. In
    addition, the shares reserved for issuance under our 2008 Equity
    Incentive Plan will also include (a)&#160;those shares reserved
    but unissued under the 1999 Stock Option
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    99
</DIV><!-- /DIV#051 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
     Plan as of the effective date of the first registration
    statement filed by us and declared effective with respect to any
    class of our securities and (b)&#160;shares returned to the 1999
    Stock Option Plan as the result of expiration or termination of
    options (provided that the maximum number of shares that may be
    added to the 2008 Equity Incentive Plan pursuant to (a)&#160;and
    (b)&#160;is 3,000,000&#160;shares). The number of shares
    available for issuance under the 2008 Equity Incentive Plan will
    also include an annual increase on the first day of each fiscal
    year beginning in 2009, equal to the lesser of:
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    1,200,000&#160;shares;
</TD>
</TR>

</TABLE>

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    4% of the outstanding shares of common stock as of the last day
    of our immediately preceding fiscal year;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    such other amount as our Board of Directors may determine.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Our Board of Directors or a committee appointed by our Board
    administers our 2008 Equity Incentive Plan. Our compensation
    committee will administer our 2008 Equity Incentive Plan after
    the completion of the offering. In the case of options intended
    to qualify as &#147;performance-based compensation&#148; within
    the meaning of Section&#160;162(m) of the Internal Revenue Code,
    the committee will consist of two or more &#147;outside
    directors&#148; within the meaning of Section&#160;162(m).
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Subject to the provisions of our 2008 Equity Incentive Plan, the
    administrator has the power to determine the terms of the
    awards, including the exercise price, the number of shares
    subject to each such award, the exercisability of the awards and
    the form of consideration, if any, payable upon exercise. The
    administrator also has the authority to amend existing awards to
    reduce their exercise price, to allow participants the
    opportunity to transfer outstanding awards to a financial
    institution or other person or entity selected by the
    administrator and to institute an exchange program by which
    outstanding awards may be surrendered in exchange for awards
    with a higher or lower exercise price.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The exercise price of options granted under our 2008 Equity
    Incentive Plan must at least be equal to the fair market value
    of our common stock on the date of grant. The term of an
    incentive stock option may not exceed 10&#160;years, except that
    with respect to any participant who owns 10% of the voting power
    of all classes of our outstanding stock, the term must not
    exceed 5&#160;years and the exercise price must equal at least
    110% of the fair market value on the grant date. Subject to the
    provisions of our 2008 Equity Incentive Plan, the administrator
    determines the term of all other options.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    After the termination of service of an employee, director or
    consultant, he or she may exercise his or her option for the
    period of time stated in his or her option agreement. Generally,
    if termination is due to death or disability, the option will
    remain exercisable for 12&#160;months. In all other cases, the
    option will generally remain exercisable for three months
    following the termination of service. However, in no event may
    an option be exercised later than the expiration of its term.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Stock appreciation rights may be granted under our 2008 Equity
    Incentive Plan. Stock appreciation rights allow the recipient to
    receive the appreciation in the fair market value of our common
    stock between the exercise date and the date of grant. Subject
    to the provisions of our 2008 Equity Incentive Plan, the
    administrator determines the terms of stock appreciation rights,
    including when such rights become exercisable and whether to pay
    any increased appreciation in cash or with shares of our common
    stock, or a combination thereof, except that the per share
    exercise price for the shares to be issued pursuant to the
    exercise of a stock appreciation right will be no less than 100%
    of the fair market value per share on the date of grant.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Restricted stock may be granted under our 2008 Equity Incentive
    Plan. Restricted stock awards are grants of shares of our common
    stock that vest in accordance with terms and conditions
    established by the administrator. The administrator will
    determine the number of shares of restricted stock granted to
    any employee, director or consultant. The administrator may
    impose whatever conditions to vesting it determines to be
    appropriate (for example, the administrator may set restrictions
    based on the achievement of specific performance goals or
    continued service to us); provided, however, that the
    administrator, in its sole discretion, may accelerate the time
    at which any restrictions will lapse or be removed. Shares of
    restricted stock that do not vest are subject to our right of
    repurchase or forfeiture.
</DIV><!-- /DIV#030 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    100
</DIV><!-- /DIV#050 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Restricted stock units may be granted under our 2008 Equity
    Incentive Plan. Restricted stock units are bookkeeping entries
    representing an amount equal to the fair market value of one
    share of our common stock. The administrator determines the
    terms and conditions of restricted stock units including the
    vesting criteria (which may include accomplishing specified
    performance criteria or continued service to us) and the form
    and timing of payment. Notwithstanding the foregoing, the
    administrator, in its sole discretion may accelerate the time at
    which any restrictions will lapse or be removed.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Performance units and performance shares may be granted under
    our 2008 Equity Incentive Plan. Performance units and
    performance shares are awards that will result in a payment to a
    participant only if performance goals established by the
    administrator are achieved or the awards otherwise vest. The
    administrator will establish organizational or individual
    performance goals in its discretion, which, depending on the
    extent to which they are met, will determine the number
    <FONT style="white-space: nowrap"><!-- FONT#006 -->and/or</FONT><!-- /FONT#006 -->
    the value of performance units and performance shares to be paid
    out to participants. After the grant of a performance unit or
    performance share, the administrator, in its sole discretion,
    may reduce or waive any performance objectives or other vesting
    provisions for such performance units or performance shares.
    Performance units shall have an initial dollar value established
    by the administrator prior to the grant date. Performance shares
    shall have an initial value equal to the fair market value of
    our common stock on the grant date. The administrator, in its
    sole discretion, may pay earned performance units or performance
    shares in the form of cash, in shares or in some combination
    thereof.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Our 2008 Equity Incentive Plan provides that all non-employee
    directors will be eligible to receive all types of awards
    (except for incentive stock options) under the 2008 Equity
    Incentive Plan. Please see the description of our Outside
    Director Equity Compensation Policy below.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Unless the administrator provides otherwise, our 2008 Equity
    Incentive Plan generally does not allow for the transfer of
    awards and only the recipient of an award may exercise an award
    during his or her lifetime.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Our 2008 Equity Incentive Plan provides that in the event of a
    merger or &#147;change in control,&#148; as defined in the 2008
    Equity Incentive Plan, each outstanding award will be treated as
    the administrator determines, including that the successor
    corporation or its parent or subsidiary will assume or
    substitute an equivalent award for each outstanding award. The
    administrator is not required to treat all awards similarly. If
    there is no assumption or substitution of outstanding awards,
    the awards will fully vest, all restrictions will lapse, all
    performance goals or other vesting criteria will be deemed
    achieved at 100% of target levels and the awards will become
    fully exercisable. The administrator will provide notice to the
    recipient that he or she has the right to exercise the option
    and stock appreciation right as to all of the shares subject to
    the award, all restrictions on restricted stock will lapse, and
    all performance goals or other vesting requirements
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><I><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->1999
    Stock Option Plan, as amended</FONT><!-- /FONT#008 --></I></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Our 1999 Stock Option Plan was adopted by our Board of Directors
    and approved by our stockholders on May&#160;12, 1999. Our 1999
    Stock Option Plan was most recently amended on April&#160;24,
    2008. Our 1999 Stock Option Plan provides for the grant of
    incentive stock options, within the meaning of Section&#160;422
    of the Internal Revenue Code, to our employees and any parent
    and subsidiary corporations&#146; employees, and for the grant
    of nonstatutory stock options to our employees, directors and
    consultants and our parent and subsidiary corporations&#146;
    employees and consultants. Our Board of Directors has decided
    not to grant any additional options under our 1999 Stock Option
    Plan following the completion of this offering. However, our
    1999 Stock Option Plan will continue to govern the terms and
    conditions of the outstanding stock options previously granted
    thereunder.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Subject to the provisions of our 1999 Stock Option Plan, the
    maximum aggregate number of shares which may be subject to
    option and sold under our 1999 Stock Option Plan is
    14,800,000&#160;shares. As of June&#160;28, 2008, options to
    purchase 8,309,725&#160;shares of our common stock were
    outstanding and 2,105,546&#160;shares were available for future
    grant under the 1999 Stock Option Plan.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Our compensation committee appointed by our Board of Directors
    currently administers our 1999 Stock Option Plan. Under our 1999
    Stock Option Plan, the administrator has the power to determine
    the terms of the stock options, including the employees,
    directors and consultants who will receive stock options, the
    number of shares subject to each stock option, the vesting
    schedule, any vesting acceleration, and the exercisability of
    stock options.
</DIV><!-- /DIV#030 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    101
</DIV><!-- /DIV#051 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The administrator also has the authority to initiate an option
    exchange program whereby stock options are exchanged for stock
    options with a lower exercise price. The administrator may also
    reduce the exercise price of any option to the then current fair
    market value if the fair market value of our common stock has
    declined since the date the option was granted.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The exercise price of options granted under our 1999 Stock
    Option Plan must at least be equal to the fair market value of
    our common stock on the date of grant. The term of an incentive
    stock option may not exceed 10&#160;years, except that with
    respect to any optionee who owns 10% of the voting power of all
    classes of our outstanding stock as of the grant date, the term
    must not exceed 5&#160;years and the exercise price must equal
    at least 110% of the fair market value on the grant date.
    Subject to the provisions of our 1999 Stock Option Plan, the
    administrator determines the terms of all other options in its
    discretion.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After the termination of service of an employee, director or
    consultant, he or she may exercise his or her option for the
    period of time stated in his or her option agreement. Generally,
    if termination is due to death or disability, the option will
    remain exercisable for 12&#160;months. In all other cases, the
    option will generally remain exercisable for three months
    following the termination of service. In some cases, options
    issued to consultants pursuant to our 1999 Stock Option Plan
    provide that they may be exercised at anytime prior to the
    expiration of the ten year term of the option. However, in no
    event may an option be exercised later than the expiration of
    its term.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless the administrator provides otherwise, our 1999 Stock
    Option Plan generally does not allow for the transfer of awards
    and only the recipient of an award may exercise an award during
    his or her lifetime.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our 1999 Stock Option Plan provides that in the event of a
    merger of our company or a sale of substantially all of our
    assets, each outstanding stock option will be assumed or an
    equivalent option or right substituted by the successor
    corporation. If there is no assumption or substitution of
    outstanding options (or portions thereof), the options (or
    portions thereof) will fully vest and become fully exercisable.
    In such case, the administrator will provide notice to the
    optionee that he or she has the right to exercise the option as
    to all of the shares subject to the option for a period of at
    least 15&#160;days. The option will terminate upon the
    expiration of the period of time the administrator provides in
    the notice.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors has the authority to amend, suspend or
    terminate the 1999 Stock Option Plan provided such action does
    not impair the rights of any optionee without his or her written
    consent.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Retirement
    Plans</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>401(k) Plan.</I>&#160;&#160;We maintain a tax-qualified
    retirement plan that provides eligible employees with an
    opportunity to save for retirement on a tax advantaged basis.
    Eligible employees are able to participate in the 401(k) plan as
    of the first&#160;day of the month on or following the date they
    begin employment and participants are able to defer up to 60% of
    their eligible compensation subject to applicable annual
    Internal Revenue Code limits. All participants&#146; interests
    in their deferrals are 100% vested when contributed. The 401(k)
    plan permits us to make matching contributions and profit
    sharing contributions to eligible participants, although we have
    not made any such contributions to date. Pre-tax contributions
    are allocated to each participant&#146;s individual account and
    are then invested in selected investment alternatives according
    to the participants&#146; directions. The 401(k) plan is
    intended to qualify under Sections&#160;401(a) and 501(a) of the
    Internal Revenue Code. As a tax-qualified retirement plan,
    contributions to the 401(k) plan and earnings on those
    contributions are not taxable to the employees until distributed
    from the 401(k) plan and all contributions are deductible by us
    when made.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Limitation
    on Liability and Indemnification Matters</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our amended and restated certificate of incorporation and bylaws
    that will become effective upon the completion of this offering
    contain provisions that limit the personal liability of our
    directors for monetary damages to the fullest extent permitted
    by Delaware law. Consequently, our directors will not be
    personally liable to us or our stockholders for monetary damages
    for any breach of fiduciary duties as directors, except
    liability for:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any breach of the director&#146;s duty of loyalty to us or our
    stockholders;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any act or omission not in good faith or that involves
    intentional misconduct or a knowing violation of law;
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    102
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    unlawful payments of dividends or unlawful stock repurchases or
    redemptions as provided in Section&#160;174 of the Delaware
    General Corporation Law;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any transaction from which the director derived an improper
    personal benefit.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our amended and restated certificate of incorporation that will
    become effective upon the completion of this offering, provides
    that we indemnify our directors to the fullest extent permitted
    by Delaware law. In addition, our amended and restated bylaws,
    that will become effective upon the completion of this offering,
    provides that we indemnify our directors and officers to the
    fullest extent permitted by Delaware law. Our amended and
    restated bylaws, that will become effective upon the completion
    of this offering, also provide that we shall advance expenses
    incurred by a director or officer in advance of the final
    disposition of any action or proceeding, and permit us to secure
    insurance on behalf of any officer, director, employee or other
    agent for any liability arising out of his or her actions in
    that capacity, regardless of whether we would otherwise be
    permitted to indemnify him or her under the provisions of
    Delaware law. We have entered and expect to continue to enter
    into agreements to indemnify our directors, executive officers
    and other employees as determined by the Board of Directors.
    With certain exceptions, these agreements provide for
    indemnification for related expenses including, among others,
    attorneys&#146; fees, judgments, fines and settlement amounts
    incurred by any of these individuals in any action or
    proceeding. We believe that these bylaw provisions and
    indemnification agreements are necessary to attract and retain
    qualified persons as directors and officers. We also maintain
    directors&#146; and officers&#146; liability insurance.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The limitation of liability and indemnification provisions in
    our amended and restated certificate of incorporation and
    bylaws, that will become effective upon the completion of this
    offering, may discourage stockholders from bringing a lawsuit
    against our directors for breach of their fiduciary duty of
    care. They may also reduce the likelihood of derivative
    litigation against our directors and officers, even though an
    action, if successful, might benefit us and other stockholders.
    Further, a stockholder&#146;s investment may be adversely
    affected to the extent that we pay the costs of settlement and
    damage awards against directors and officers. At present, there
    is no pending litigation or proceeding involving any of our
    directors, officers or employees for which indemnification is
    sought, and we are not aware of any threatened litigation that
    may result in claims for indemnification.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    103
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='112'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CERTAIN
    RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to the director and executive compensation
    arrangements discussed above in &#147;Management,&#148; we have
    been a party to the following transactions since January&#160;1,
    2005, in which the amount involved exceeded or will exceed
    $120,000, and in which any director, executive officer or holder
    of more than 5% of any class of our voting stock, or any member
    of the immediate family of or entities affiliated with any of
    them, had or will have a material interest.
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Sales of
    Series&#160;E Preferred Stock</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The table below summarizes purchases of shares of our
    Series&#160;E preferred stock since January&#160;1, 2005, by our
    directors, executive officers, holders of more than 5% of any
    class of our voting securities, or any member of the immediate
    family of or any entities affiliated with any of the foregoing
    persons. In connection with these sales, we granted the
    purchasers certain registration rights with respect to their
    securities. See &#147;Description of Capital Stock&#160;&#151;
    Registration Rights.&#148; Each outstanding share of our
    preferred stock will be converted automatically into one share
    of our common stock upon the completion of this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="74%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Series E<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Aggregate<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Preferred<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Purchase<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Purchasers</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Stock</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Price</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Entities affiliated with Alloy
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    161,250
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    645,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Bruce
    Burrows<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    394,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,579,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Entities affiliated with EuclidSR
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    211,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    847,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Biomedical Sciences Investment Fund&#160;Pte
    Ltd<SUP style="font-size: 85%; vertical-align: text-top">(4)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,458,282
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    16,049,815
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Entities affiliated with InterWest
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    200,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Entities affiliated with Lehman Brothers Holdings,
    Inc.<SUP style="font-size: 85%; vertical-align: text-top">(6)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    159,749
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    638,996
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Lilly
    Ventures<SUP style="font-size: 85%; vertical-align: text-top">(7)</SUP>&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    89,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    359,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Entities affiliated with Versant
    Ventures<SUP style="font-size: 85%; vertical-align: text-top">(8)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    250,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,775,531
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    21,318,811
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 2,120&#160;shares
    purchased by Alloy Partners 2002, L.P., 78,505&#160;shares
    purchased by Alloy Ventures 2002, L.P. and 80,625&#160;shares
    purchased by Alloy Ventures 2005, L.P. Michael Hunkapiller, an
    affiliate of Alloy Ventures, is a member of our Board of
    Directors.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Bruce Burrows served as member of
    our Board of Directors from January&#160;3, 2000 to
    January&#160;15, 2008.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 105,875&#160;shares
    purchased EuclidSR Biotechnology Partners, L.P. and
    105,875&#160;shares purchased by EuclidSR Partners, L.P. Elaine
    Jones, an affiliate of Euclid SR Partners, is a member of our
    Board of Directors.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of shares issued to
    Biomedical Sciences Investment Fund&#160;Pte Ltd in connection
    with the conversion of convertible promissory notes.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(5)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 2,285&#160;shares
    purchased by InterWest Investors VII, L.P. and
    47,715&#160;shares purchased by InterWest Partners VII, L.P.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(6)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 39,937&#160;shares
    purchased by Lehman Brothers Healthcare Venture Capital L.P.,
    8,932&#160;shares purchased by Lehman Brothers Offshore
    Partnership Account 2000/2001, L.P., 76,440&#160;shares
    purchased by Lehman Brothers P.A., LLC, and 34,440 purchased by
    Lehman Brothers Partnership Account 2001/2001, L.P. Hingge Hsu,
    an affiliate of Lehman Brothers Holdings, Inc., served as a
    member of our Board of Directors at the time of the financing.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(7)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Ed Torres, an affiliate of Lilly
    Ventures, served as a member of our Board of Directors at the
    time of the financing.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(8)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 5,000&#160;shares
    purchased by Versant Affiliates
    <FONT style="white-space: nowrap">Fund&#160;1-A,</FONT>
    L.P., 10,500&#160;shares purchased by Versant Affiliates
    <FONT style="white-space: nowrap">Fund&#160;1-B,</FONT>
    L.P., 4,500&#160;shares purchased by Versant Side Fund&#160;I,
    L.P. and 230,000&#160;shares purchased by Versant Venture
    Capital&#160;I, L.P. Sam Colella, an affiliate of Versant
    Ventures, is a member of our Board of Directors.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Transactions
    with the Singapore Government</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Convertible
    Note Financings</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On December&#160;18, 2003, we entered into a convertible note
    purchase agreement (as amended December&#160;17, 2004)&#160;with
    Biomedical Sciences Investment Fund&#160;Pte Ltd, or BMSIF, an
    investment arm of the Singapore Economic Development Board, or
    EDB. Upon execution of the agreement, BMSIF purchased a
    convertible promissory note in the principal amount of
    $2,000,000 at an interest rate equal to 8% per annum. The
    principal and
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    104
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    interest on this note was convertible into our Series&#160;D
    preferred stock at a price of $2.80 per share, which was equal
    to the per share purchase price of our Series&#160;D preferred
    stock sold to other investors in December 2003. This note was
    converted into 832,635&#160;shares of our Series&#160;D
    preferred stock on December&#160;15, 2005. Additionally, the
    agreement provided for the issuance of up to two additional
    convertible promissory notes, each in the principal amount of
    $1,500,000, or a single additional convertible promissory note
    in the principal amount of $3,000,000, and all at an interest
    rate of 8% per annum. Pursuant to the terms of the agreement, on
    June&#160;20, 2006 we issued a single note in the principal
    amount of $3,000,000 to BMSIF. The principal and interest on
    this note was also convertible into our Series&#160;D preferred
    stock at a price of $2.80 per share. This note was converted
    into 1,157,142&#160;shares of our Series&#160;D preferred stock
    on July&#160;2, 2007.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    On August&#160;7, 2006, we entered into a second convertible
    note purchase agreement with BMSIF pursuant to which BMSIF
    purchased three convertible promissory notes each in the
    principal amount of $5&#160;million, for an aggregate principal
    amount of $15,000,000, and each at an interest rate equal to 8%
    per annum. The principal and interest on these notes was
    convertible into our Series&#160;E preferred stock at a price of
    $3.60 per share, which represented a 10% discount on the $4.00
    per share price at which our Series&#160;E preferred stock was
    sold to other investors in our Series&#160;E preferred stock
    financing which occurred between June 2006 and December 2007.
    The first note was issued on August&#160;7, 2006 and was
    converted into 1,460,730&#160;shares of our Series&#160;E
    preferred stock on March&#160;31, 2007. The second note was
    issued on November&#160;20, 2006 and was converted into
    1,493,607&#160;shares of our Series&#160;E preferred stock on
    March&#160;31, 2007. The last note was issued on April&#160;19,
    2007 and was converted into 1,503,945&#160;shares of our
    Series&#160;E preferred stock on April&#160;30, 2008. Each such
    conversion was completed following the agreement of the parties
    that the required milestones had been met to the parties
    satisfaction or waived.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <I><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Government
    Incentive Grants</FONT><!-- /FONT#008 --></I>
</DIV><!-- /DIV#031 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    In October 2005, Fluidigm Singapore entered into a letter
    agreement providing for up to SG$10&#160;million (approximately
    US$7.3&#160;million using June&#160;28, 2008 exchange rates) in
    incentive grants from the Singapore Economic Development Board,
    or EDB. The incentive grants are payable for the period
    August&#160;1, 2005 through July&#160;31, 2010 in connection
    with the establishment and operation of a research, development
    and manufacturing center for IFCs in Singapore. Incentive grant
    payments are calculated as a portion of qualifying expenses we
    incur in Singapore relating to salaries, overhead, outsourcing
    and subcontracting expenses, operating expenses and royalties
    paid. Fluidigm Singapore is required to submit requests for
    incentive grant payments on a quarterly basis along with reports
    regarding its compliance with the development, hiring,
    expenditure and other conditions through the end of the
    applicable quarter.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    On January&#160;11, 2006, Fluidigm Singapore and EDB entered
    into a supplement to the October 2005 letter agreement. This
    supplement was entered into to create a process whereby Fluidigm
    Singapore and EDB would agree on new quarterly development
    targets at the start of each year, Fluidigm Singapore would
    submit to EDB a progress report and evidence of the achievement
    of targets on a quarterly basis and the parties would resolve
    any disagreements regarding the satisfaction of targets using an
    established procedure and the parties would be entitled to
    obtain a third party audit of our incentive grant payment
    requests on a semi-annual rather than an annual basis.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Fluidigm Singapore&#146;s continued eligibility for such
    incentive grant payments is subject to its compliance with
    increasing levels of research, development and manufacturing
    activity in Singapore, including employment of specified numbers
    of research scientists and engineers, its incurrence of
    specified levels of research and development expenses in
    Singapore over the course of each calendar year, its use of
    local service providers, its manufacture in Singapore of the
    products developed in Singapore and its achievement of certain
    targets relating to new product development or completion of
    specific manufacturing process objectives. Specifically, this
    agreement requires that we must employ at least 24 research
    scientists and engineers in Singapore by December&#160;31, 2009
    to remain eligible for incentive grant payments. As of
    June&#160;28, 2008, we employed 16&#160;research scientists and
    engineers involved in the research and development of our IFCs.
    These required levels of research, development and manufacturing
    activity in Singapore and the associated increases from one year
    to the next are the result of negotiations between the parties
    and are generally consistent with our business strategy for our
    Singapore operations. All ownership rights in the intellectual
    property developed by Fluidigm Singapore remain with Fluidigm
    Singapore and no such rights are conveyed to EDB under the
    agreement.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    105
</DIV><!-- /DIV#050 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    On February&#160;12, 2007, Fluidigm Singapore entered into a
    second letter agreement with EDB which provided for up to an
    additional SG$3.7&#160;million (approximately
    US$2.7&#160;million using a June&#160;28, 2008 exchange rate) in
    incentive grant payments. The terms and conditions of this
    letter agreement are substantially the same as the October 2005
    letter agreement, with the exception of the size of the
    potential grant, the term of the agreement and the specific
    levels of research, development and manufacturing activity
    required to maintain eligibility for such grants. This letter
    agreement requires that we employ at least 10 new research
    scientists and engineers in Singapore by May&#160;31, 2009, that
    we employ at least 12 new research scientists and engineers in
    Singapore by May&#160;31, 2011 and that we maintain at least 12
    research scientists and engineers in total until May&#160;31,
    2013 to remain eligible for incentive grant payments. The
    requirements of the February 2007 agreement may only be
    satisfied by personnel employed in the research and development
    of IFC instrumentation. As of June&#160;28, 2008, we employed
    10&#160;research scientists and engineers involved in the
    research and development of our IFC instrumentation. The primary
    focus of this grant agreement was the ongoing development and
    manufacture in Singapore of instrumentation to be used with our
    IFCs. This letter agreement applies to research, development and
    manufacturing activity by Fluidigm Singapore in Singapore from
    June&#160;1, 2006 through May&#160;31, 2011.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    On March&#160;27, 2008, Fluidigm Singapore entered into amended
    and restated versions of our October 2005 and February 2007
    letter agreements with EDB. The purpose of these amendments was
    to consolidate and streamline the original agreements to
    eliminate sub-categories of eligible expenditures and rely on
    more general descriptions of the eligible expenditures that the
    parties had been applying in practice, to consolidate certain
    administrative terms and conditions of the incentive grant
    payments, and to remove various forms attached to the original
    letter agreements that had changed over time or were not part of
    the ongoing agreement between the parties. The January 2006
    supplement to the October 2005 letter agreement remains in
    effect.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Loan
    to Gajus Worthington</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    On January&#160;20, 2004, we entered into an Employee Loan
    Agreement, Secured Promissory Note and Stock Pledge Agreement
    with Mr.&#160;Worthington pursuant to which we loaned
    Mr.&#160;Worthington $250,000 at an interest rate of 3.52% per
    annum and the principal and interest were not due and payable
    until 7&#160;years after the date of the loan or upon the
    earlier occurrence of certain events. The loan was secured by
    the pledge of 833,334&#160;shares of our common stock held by
    Mr.&#160;Worthington and was otherwise non-recourse. The loan
    was extended to Mr.&#160;Worthington to assist him in purchasing
    a home for his personal residence in Northern California. On
    April&#160;10, 2008, Mr.&#160;Worthington repaid the loan in
    full in accordance with Section&#160;2.2(d) of the note by
    selling shares of our common stock held by Mr.&#160;Worthington
    to us at the fair market value of such stock on the date of such
    sale, which was determined by the Board of Directors to be $3.19
    per share. The note and Mr.&#160;Worthington&#146;s loan were
    repaid in full and cancelled in exchange for 90,913&#160;shares
    of our common stock which Mr.&#160;Worthington transferred to us
    pursuant to the terms of a repurchase agreement dated
    April&#160;10, 2008. This loan repayment and share cancellation
    transaction was approved by the Board based on its determination
    that we received full and fair consideration for the
    cancellation of the loan and that the cancellation of the loan
    was in the best interests of our company and its stockholders.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Consulting
    Agreement with Stephen Quake</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    In May 2006, we entered into an agreement with Stephen Quake
    pursuant to which we have agreed to pay Dr.&#160;Quake $8,333
    per month for providing various consulting services to us
    including serving on our Scientific Advisory Board. The
    agreement has a term of 10&#160;years and is terminable by us
    only for cause. At approximately the same time, we repurchased
    from Dr.&#160;Quake approximately 124,000&#160;shares of our
    common stock for aggregate consideration of $69,425. In 2005 and
    2006, we paid Dr. Quake $45,000 and $97,000 pursuant to a
    consulting agreement that was entered into in 2000 and
    terminated in 2006. Dr.&#160;Quake served as a director of
    Fluidigm from its inception until December 2005 and, at the time
    of these transactions, was the holder of more than 5% of our
    outstanding common stock.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Engagement
    of Townsend and Townsend and Crew
    LLP</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Since before 2005, the law firm of Townsend and Townsend and
    Crew LLP, or Townsend, has served as our primary outside patent
    counsel. William Smith, our Vice President, Legal Affairs and
    General Counsel as well as our Secretary since May 2000 and a
    director from May 2000 until April&#160;7, 2008, was a partner
    at Townsend from
</DIV><!-- /DIV#030 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    106
</DIV><!-- /DIV#051 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     1985 to April&#160;1, 2008. Amounts paid to Townsend for
    services and direct patent fees were $880,000, $960,000,
    $576,000 and $312,000 for 2005, 2006, 2007, and the six months
    ended June&#160;28,&#160;2008. Accrued amounts payable to
    Townsend were $174,000, $257,000, and $411,000 as of
    December&#160;31, 2006, December&#160;29, 2007 and June&#160;28,
    2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Registration
    Rights Agreement</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Holders of our preferred stock and our co-founders are entitled
    to certain registration rights with respect to the common stock
    issued or issuable upon conversion of the preferred stock. See
    &#147;Registration Rights&#148; under &#147;Description of
    Capital Stock&#148; below for additional information.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Stock
    Option Grants</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Certain stock option grants to our directors and executive
    officers and related option grant policies are described above
    in this prospectus under the caption &#147;Management.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Employment
    Arrangements and Indemnification Agreements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into employment arrangements with certain of our
    executive officers. See &#147;Management&#160;&#151; Employment
    Agreements and Offer Letters&#148; above.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have also entered into indemnification agreements with each
    of our directors and executive officers. The indemnification
    agreements and our certificate of incorporation and bylaws
    require us to indemnify our directors and executive officers to
    the fullest extent permitted by Delaware law. See
    &#147;Management&#160;&#151; Limitations on Liability and
    Indemnification Matters&#148; above.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Related
    Party Transaction Policy</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have adopted a formal policy that our executive officers,
    directors, holders of more than 5% of any class of our voting
    securities, and any member of the immediate family of and any
    entity affiliated with any of the foregoing persons, are not
    permitted to enter into a related party transaction with us
    without the prior consent of our audit committee, or other
    independent members of our Board in the case it is inappropriate
    for our audit committee to review such transaction due to a
    conflict of interest. Any request for us to enter into a
    transaction with an executive officer, director, principal
    stockholder, or any of their immediate family members or
    affiliates, in which the amount involved exceeds $120,000 must
    first be presented to our audit committee for review,
    consideration and approval. In approving or rejecting any such
    proposal, our audit committee is to consider the relevant facts
    and circumstances available and deemed relevant to the audit
    committee, including, but not limited to, whether the
    transaction is on terms no less favorable than terms generally
    available to an unaffiliated third party under the same or
    similar circumstances and the extent of the related party&#146;s
    interest in the transaction. All of the transactions described
    above were entered into prior to the adoption of this policy.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    107
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='113'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PRINCIPAL
    STOCKHOLDERS</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth certain information with respect
    to the beneficial ownership of our common stock at June&#160;28,
    2008, as adjusted to reflect the sale of common stock offered by
    us in this offering, for:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    each person who we know beneficially owns more than five percent
    of our common stock;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    each of our directors;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    each of our named executive officers;&#160;and
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    all of our directors and executive officers as a group.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have determined beneficial ownership in accordance with SEC
    rules. Except as indicated by the footnotes below, we believe,
    based on the information furnished to us, that the persons and
    entities named in the table below have sole voting and
    investment power with respect to all shares of common stock that
    they beneficially own, subject to applicable community property
    laws.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Applicable percentage ownership is based on
    68,217,839&#160;shares of common stock outstanding at
    June&#160;28, 2008. For purposes of the table below, we have
    assumed
    that&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock will be outstanding upon completion of this
    offering, based upon an assumed initial public offering price of
    $&#160;&#160;&#160;&#160;&#160; per share. In computing the
    number of shares of common stock beneficially owned by a person
    and the percentage ownership of that person, we deemed to be
    outstanding all shares of common stock subject to options,
    warrants or other convertible securities held by that person or
    entity that are currently exercisable or exercisable within
    60&#160;days of June&#160;28, 2008. We did not deem these shares
    outstanding, however, for the purpose of computing the
    percentage ownership of any other person. Beneficial ownership
    representing less than one percent is denoted with an
    &#147;*.&#148;
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless otherwise indicated, the address of each beneficial owner
    listed in the table below is
    <FONT style="white-space: nowrap">c/o&#160;Fluidigm</FONT>
    Corporation, 7000 Shoreline Court, Suite&#160;100, South
    San&#160;Francisco, California 94080.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="58%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Beneficial Ownership<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Beneficial Ownership<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Prior to the Offering</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>After the Offering</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name of Beneficial Owner</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Percentage</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Percentage</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>5% Stockholders:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entities affiliated with Alloy
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,732,679
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.47
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entities affiliated with EuclidSR
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,898,996
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.18
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entities affiliated with the Singapore
    government<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,008,967
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13.21
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entities affiliated with Fidelity
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(4)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,250,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.16
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entities affiliated with InterWest
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,776,885
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.54
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entities affiliated with Lehman
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(6)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,693,907
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.41
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    SMALLCAP World Fund,
    Inc.<SUP style="font-size: 85%; vertical-align: text-top">(7)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,378,695
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.42
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entities affiliated with Versant
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(8)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,879,980
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.62
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Bruce Burrows
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,647,339
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.35
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Directors and Named Executive Officers:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Gajus V.
    Worthington<SUP style="font-size: 85%; vertical-align: text-top">(9)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,836,087
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.13
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Richard
    DeLateur<SUP style="font-size: 85%; vertical-align: text-top">(10)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    140,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Robert C.
    Jones<SUP style="font-size: 85%; vertical-align: text-top">(11)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    690,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.00
</TD>
<TD nowrap align="left" valign="bottom">
    %*
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Michael Y.
    Lucero<SUP style="font-size: 85%; vertical-align: text-top">(12)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    William M.
    Smith<SUP style="font-size: 85%; vertical-align: text-top">(13)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,117,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.62
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Mai Chan (Grace)
    Yow<SUP style="font-size: 85%; vertical-align: text-top">(14)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    309,166
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Vikram
    Jog<SUP style="font-size: 85%; vertical-align: text-top">(15)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    600,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Samuel
    Colella<SUP style="font-size: 85%; vertical-align: text-top">(8)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,879,980
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.62
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Michael
    Hunkapiller<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,732,679
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.47
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Elaine V.
    Jones<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,898,996
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.18
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Kenneth
    Nussbacher<SUP style="font-size: 85%; vertical-align: text-top">(16)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    140,625
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    John
    Young<SUP style="font-size: 85%; vertical-align: text-top">(17)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    All directors and executive officers as a group (12&#160;persons)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,344,533
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28.55
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(*)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Less than one percent.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 1,866,340&#160;shares
    held of record by Alloy Ventures 2005, L.P.,
    1,817,272&#160;shares held of record by Alloy Ventures 2002,
    L.P., and 49,067&#160;shares held of record by Alloy Partners
    2002, L.P. Michael Hunkapiller, a member of our Board of
    Directors, is a Managing Member
    </FONT></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    108
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->of Alloy Ventures
    2005, LLC, the General Partner of Alloy Ventures 2005, L.P.
    Alloy Ventures 2002, LLC is the General Partner of Alloy
    Ventures 2002, L.P. and Alloy Partners 2002, L.P. The Managing
    Members of Alloy Ventures 2002, LLC are Craig C. Taylor, <BR>
    John&#160;F. Shoch, Douglas E. Kelly, Daniel I. Rubin and Tony
    Di Bona. Each of the Managing Members of Alloy Ventures 2002,
    LLC is also a Managing Member of Alloy Ventures 2005, LLC. The
    individuals listed herein may be deemed to have shared voting
    and dispositive power over the shares which are or may be deemed
    to be beneficially owned by Alloy Ventures 2005, L.P., Alloy
    Ventures 2002, L.P. and Alloy Partners 2002, L.P. Each Managing
    Member disclaims beneficial ownership of the shares except to
    extent of their pecuniary interest therein. The address of the
    entities affiliated with Alloy Ventures is 400 Hamilton Avenue,
    Fourth Floor, Palo Alto, CA 94301.</FONT><!-- /FONT#008 --></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(2)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->Consists of
    2,449,498&#160;shares held of record by EuclidSR Partners, L.P.
    and 2,449,498&#160;shares held of record by EuclidSR
    Biotechnology Partners, L.P. Elaine V. Jones, a member of our
    Board of Directors shares voting and investment power with
    Graham D.S. Anderson, Raymond J. Whitaker, Milton J. Pappas and
    Stephen K. Reidy, each of whom are General Partners of EuclidSR
    Associates, L.P., the General Partner of EuclidSR Partners and
    EuclidSR Biotechnology Associates, L.P., the General Partner of
    EuclidSR Biotechnology Partners. Each General Partner of
    EuclidSR Associates, L.P. and EuclidSR Biotechnology Associates,
    L.P. disclaims beneficial ownership of the shares except to the
    extent of their pecuniary interest therein. The address of the
    entities affiliated with EuclidSR Associates, L.P. and EuclidSR
    Biotechnology Associates, L.P. is 45 Rockefeller Plaza, Suite
    3240, New York, NY 10111.</FONT><!-- /FONT#008 --></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(3)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->Consists of
    8,233,773&#160;shares held of record by Biomedical Sciences
    Investment Fund Pte Ltd which includes 1,503,945&#160;shares
    issued upon conversion of a convertible promissory note, and
    775,194&#160;shares held of record by Singapore Bio-Innovations
    Pte Ltd, EDB Investments Pte Ltd. EDB Investments Pte Ltd, or
    EDB Investments, is the parent entity of Biomedical Sciences
    Investment Fund Pte Ltd and Singapore Bio-Innovations Pte Ltd.
    The Economic Development Board of Singapore, or EDB, is the
    parent entity of EDB Investments. EDB is a Singapore government
    entity. EDB Investments, EDB and the Singapore government may be
    deemed to have shared voting and dispositive power over the
    shares owned beneficially and of record by Biomedical Sciences
    Investment Fund&#160;Pte Ltd and Singapore Bio-Innovations Pte
    Ltd. The address associated with entities affiliated with EDB is
    20 Biopolis Way, #09-01 Centros, Singapore
    138668.</FONT><!-- /FONT#008 --></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(4)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->Consists of
    481,170&#160;shares held of record by Fidelity Contrafund:
    Fidelity Advisor New Insights Fund, 4,389,865&#160;shares held
    of record by Fidelity Contrafund: Fidelity Contrafund and
    1,378,965&#160;shares held of record by Variable Insurance
    Products Fund&#160;II: Contrafund Portfolio. Each of these
    entities is a registered investment fund (each, a
    &#147;Fund&#148;) advised by Fidelity Management&#160;&#038;
    Research Company (&#147;FMR Co.&#148;), a registered investment
    adviser under the Investment Advisers Act of 1940, as amended.
    The address of FMR Co., a wholly-owned subsidiary of FMR Corp.
    and an investment adviser registered under Section&#160;203 of
    the Investment Advisers Act of 1940 is 82&#160;Devonshire
    Street, Boston Massachusetts 02109. Edward C. Johnson 3d, FMR
    Corp., through its control of FMR Co., and each Fund has power
    to dispose of the securities owned by such Fund. Neither FMR
    Corp. nor Edward C. Johnson 3d, Chairman of FMR Corp., has sole
    power to vote or direct the voting of the shares owned directly
    by each Fund, which power resides with each Fund&#146;s Board of
    Trustees. Each Fund is an affiliate of a broker-dealer. Each
    Fund purchased the securities in the ordinary course of business
    and, at the time of the purchase of the securities, no Fund had
    any agreements or understandings, directly or indirectly, with
    any person to distribute the securities. No Fund intends to
    sell, transfer, assign, pledge or hypothecate or otherwise enter
    into any hedging, short sale, derivative, put or call
    transaction that would result in the effective economic
    disposition of the securities through an affiliated
    broker-dealer.</FONT><!-- /FONT#008 --></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(5)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->Consists of
    172,602&#160;shares held of record by InterWest Investors VII,
    L.P. and 3,604,283&#160;shares held of record by InterWest
    Partners VII, L.P. InterWest Management Partners VII, L.L.C. has
    sole voting and investment control over the shares owned by
    InterWest Partners VII, L.P. and InterWest Investors VII, L.P.
    Harvey B. Cash, Philip T. Gianos, W. Scott Hedrick, W. Stephen
    Holmes, Gilbert H. Kliman, Thomas L. Rosch and Arnold L.
    Oronsky, each Managing Directors of InterWest Management
    Partners VII, LLC, have shared voting and investment control
    over the shares owned by InterWest Partners VII, L.P. and
    InterWest Investors VII, L.P. Stephen C. Bowsher, Alan W.
    Crites, Rodney A. Ferguson and Karen A. Wilson are Members of
    InterWest Management Partners VII, L.L.C. All Managing Directors
    and Members disclaim beneficial ownership of the shares owned by
    InterWest Partners VII, LP and InterWest Investor VII, LP except
    to the extent of their pro rata partnership interests in such
    shares. The address of the entities affiliated with InterWest is
    2710 Sand Hill Road, Second Floor, Menlo Park, CA
    94025.</FONT><!-- /FONT#008 --></TD>
</TR>

</TABLE>

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 3pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(6)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->Consists of
    923,476&#160;shares held of record by Lehman Brothers Healthcare
    Venture Capital, L.P., 206,536&#160;shares held of record by
    Lehman Brothers Offshore Partnership Account 2000/2001, L.P.,
    1,767,535&#160;shares held of record by Lehman Brothers P.A.,
    LLC and 796,360&#160;shares held of record by Lehman Brothers
    Partnership Account 2000/2001, L.P. Hingge Hsu, a former member
    of our Board of Directors, was formerly employed by Lehman
    Brothers Inc., and now serves as a consultant of Lehman Brothers
    Inc. In each of the limited partnerships referenced above,
    Lehman Brothers Inc. controls the general partner of the limited
    partnership. In the limited liability company, Lehman Brothers
    Inc. controls the manager of the limited liability company. In
    all four entities listed above, Lehman Brothers Holdings Inc., a
    public reporting company under the Securities Exchange Act of
    1934, as amended, ultimately controls the manager and the
    general partners of the entities and ultimately has voting and
    investment control over the shares held by such entities. The
    address of the entities affiliated with Lehman Brothers Inc. is
    399 Park Avenue,
    11<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>
    Floor, New York, NY 10022.</FONT><!-- /FONT#008 --></TD>
</TR>

</TABLE>

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 3pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(7)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->Consists of
    4,378,695&#160;shares held of record by SMALLCAP World Fund,
    Inc, or SMALLCAP.  SMALLCAP is an investment company registered
    under the Investment Company Act of 1940. Capital Research and
    Management Company, or CRMC, an investment adviser registered
    under the Investment Advisers Act of 1940, is the investment
    adviser to SMALLCAP and has sole dispositive power over these
    shares. Gordon Crawford, J.&#160;Blair Frank, Jonathan Knowles,
    Brady&#160;L. Enright, Mark&#160;E. Denning and Claudia&#160;P.
    Huntington are the primary portfolio counselors of CRMC. In such
    capacity, CRMC Messrs. Crawford, Frank, Knowles, Enright,
    Denning and Ms.&#160;Huntington may be deemed to beneficially
    own the shares held by SMALLCAP. CRMC, however, each disclaims
    such beneficial ownership. The address of the SMALLCAP is The
    Capital Group Companies, 333, South Hope Street, Los Angeles,
    California 90071.</FONT><!-- /FONT#008 --></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    109
</DIV><!-- /DIV#051 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(8)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 5,378,019&#160;shares
    held of record by Versant Venture Capital&#160;I, L.P.,
    98,662&#160;shares held of record by Versant Affiliates
    <FONT style="white-space: nowrap">Fund&#160;I-A,</FONT>
    L.P., 291,146&#160;shares held of record by Versant Affiliates
    <FONT style="white-space: nowrap">Fund&#160;I-B,</FONT>
    L.P. and 112,153&#160;shares held of record by Versant Side
    Fund&#160;I, L.P. Voting and investment power over the shares
    directly held by Versant Venture Capital&#160;I, L.P., Versant
    Affiliates
    <FONT style="white-space: nowrap">Fund&#160;I-A,</FONT>
    L.P., Versant Affiliates
    <FONT style="white-space: nowrap">Fund&#160;I-B,</FONT>
    L.P., and Versant Side Fund&#160;I, L.P. is held by Versant
    Ventures&#160;I, LLC, their sole General Partner. Samuel D.
    Colella, a member of our Board of Directors is a Managing Member
    of Versant Ventures&#160;I, LLC but he disclaims beneficial
    ownership of these shares, except to the extent of his pecuniary
    interest in such shares. The individual Managing Members of
    Versant Ventures&#160;I, LLC are Brian G. Atwood, Samuel D.
    Colella, Ross A. Jaffe, William J. Link, Barbara N. Lubash,
    Donald B. Milder, and Rebecca B. Robertson, all of whom share
    voting and dispositive control. Each respective individual
    General Partner disclaims beneficial ownership of these shares,
    except to the extent of their pecuniary interest in such shares.
    The address of the entities affiliated with Versant Ventures is
    3000 Sand Hill Road, Building Four, Suite&#160;210, Menlo Park,
    CA 94025.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(9)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 2,341,087&#160;shares
    held of record by Gajus Worthington and Jami A. Worthington as
    TTEES of the Worthington Family Trust dtd 3-6-07 and options to
    purchase 495,000&#160;shares of Common Stock that are
    exercisable within 60&#160;days of June&#160;28, 2008, of which
    264,998&#160;shares are vested as of August&#160;27, 2008.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(10)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 140,000&#160;shares
    held of record by Richard A. DeLateur and options to purchase
    184,582&#160;shares of common stock that are vested and
    exercisable no later than August&#160;17, 2008.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(11)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of options to purchase
    690,000&#160;shares of common stock that are exercisable within
    60&#160;days of June&#160;28, 2008 of which 339,999&#160;shares
    are vested as of August&#160;27, 2008.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(12)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">No options are currently
    outstanding or exercisable.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(13)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 300,000&#160;shares
    held of record by William M. Smith and options to purchase
    817,000&#160;shares of common stock that are exercisable within
    60&#160;days of June&#160;28, 2008, of which 781,500 are vested
    as of August&#160;27, 2008.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(14)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of options to purchase
    309,166&#160;shares of common stock that are exercisable within
    60&#160;days of June&#160;28, 2008, of which 277,166 are vested
    as of August&#160;27, 2008.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(15)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of options to purchase
    600,000&#160;shares of common stock that are exercisable within
    60 days of June&#160;28, 2008, none of which are vested as of
    August&#160;27, 2008.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(16)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of options to purchase
    140,625&#160;shares of common stock that are exercisable within
    60&#160;days of June&#160;28, 2008, all of which are vested as
    of August&#160;27, 2008.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(17)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Mr.&#160;Young disclaims beneficial
    ownership of 270,000&#160;shares as all of the shares were
    subsequently transferred to his children, Diana Young, Gregory
    Young and John Peter Young. As of August&#160;27, 2008
    16,667&#160;shares of common stock are subject to a right of
    repurchase at cost. The right of repurchase lapses at a rate of
    approximately 2,083&#160;shares of common stock per month.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    110
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->
<A name='114'>
<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->DESCRIPTION
    OF CAPITAL STOCK</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->
</A>
<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->General</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The following is a summary of the rights of our common stock and
    preferred stock and of certain provisions of our restated
    certificate of incorporation and bylaws, as they will be in
    effect upon the completion of this offering. For more detailed
    information, please see our restated certificate of
    incorporation and bylaws, which are filed as exhibits to the
    registration statement of which this prospectus is part.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Immediately following the completion of this offering, our
    authorized capital stock will consist of
    320,000,000&#160;shares, all with a par value of $0.001 per
    share, of which:
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    300,000,000&#160;shares are designated as common stock;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    20,000,000&#160;shares are designated as preferred stock.
</TD>
</TR>

</TABLE>

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    As of June&#160;28, 2008, we had outstanding
    68,217,839&#160;shares of common stock held of record by
    252&#160;stockholders, assuming the automatic conversion of all
    outstanding shares of our preferred stock on a one-for-one basis
    into 58,191,261&#160;shares of common stock. In addition, as of
    June&#160;28, 2008, 8,309,725&#160;shares of our common stock
    were subject to outstanding options and 757,436&#160;shares of
    our capital stock were subject to outstanding warrants. No
    options will expire prior to the completion of this offering.
    For more information on our capitalization, see
    &#147;Capitalization&#148; above.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Common
    Stock</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The holders of our common stock are entitled to one vote per
    share on all matters to be voted on by our stockholders. Subject
    to preferences that may be applicable to any outstanding shares
    of preferred stock, holders of common stock are entitled to
    receive ratably such dividends as may be declared by our Board
    of Directors out of funds legally available for that purpose. In
    the event of our liquidation, dissolution or winding up, the
    holders of common stock are entitled to share ratably in all
    assets remaining after the payment of liabilities, subject to
    the prior distribution rights of preferred stock then
    outstanding. Holders of common stock have no preemptive,
    conversion or subscription rights. There are no redemption or
    sinking fund provisions applicable to the common stock.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Preferred
    Stock</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Immediately after the completion of this offering, no shares of
    preferred stock will be outstanding (assuming the automatic
    conversion of all outstanding shares of our preferred stock on a
    one-for-one basis into 58,191,261&#160;shares of common stock
    immediately prior to the completion of this offering). Though we
    currently have no plans to issue any shares of preferred stock,
    upon the closing of this offering and the filing of our restated
    certificate of incorporation, our Board of Directors will have
    the authority, without further action by our stockholders, to
    designate and issue up to 20,000,000&#160;shares of preferred
    stock in one or more series. Our Board of Directors may also
    designate the rights, preferences and privileges of the holders
    of each such series of preferred stock, any or all of which may
    be greater than or senior to those granted to the holders of
    common stock. Though the actual effect of any such issuance on
    the rights of the holders of common stock will not be known
    until our Board of Directors determines the specific rights of
    the holders of preferred stock, the potential effects of such an
    issuance include:
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    diluting the voting power of the holders of common stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reducing the likelihood that holders of common stock will
    receive dividend payments;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reducing the likelihood that holders of common stock will
    receive payments in the event of our liquidation, dissolution,
    or winding up;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    delaying, deterring or preventing a
    <FONT style="white-space: nowrap"><!-- FONT#006 -->change-in-control</FONT><!-- /FONT#006 -->
    or other corporate takeover.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    111
</DIV><!-- /DIV#051 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Warrants</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of June&#160;28, 2008, we had outstanding warrants to
    purchase an aggregate of 757,436&#160;shares of our preferred
    stock, all of which will be converted into warrants to purchase
    an equal number of shares of our common stock at exercise prices
    ranging from $2.58 per share to $4.00 per share. These warrants
    will expire at various times between March&#160;2012 and
    February 2015. In the event of a distribution of dividends, a
    stock split, a reorganization, a reclassification, a
    consolidation, or a similar event, each warrant provides for
    adjustment of the exercise price and the number of shares
    issuable upon exercise. In June 2008, the number of shares
    subject to a certain warrant to purchase Series&#160;E Preferred
    Stock issued to Lighthouse Capital Partners&#160;V, L.P.
    increased by 200,000&#160;shares pursuant to its terms as a
    result of our borrowing an additional $10&#160;million under our
    loan agreement with Lighthouse.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Potential
    Issuance of Common Stock</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On March&#160;7, 2003, we entered into a Master Closing
    Agreement with Oculus Pharmaceuticals, Inc. and The UAB Research
    Foundation, or UAB, related to certain intellectual property and
    technology rights licensed by us from UAB. Pursuant to the
    agreement, we are obligated to issue UAB shares of our common
    stock with a value equal to approximately $1,500,000 upon the
    achievement of a certain milestone and based upon the fair
    market value of our common stock at the time the milestone is
    achieved. We currently do not anticipate achieving this
    milestone in the foreseeable future and do not anticipate
    issuing these shares. The potential issuance discussed above is
    not reflected in the number of shares of common stock
    outstanding in this prospectus.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Registration
    Rights</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of June&#160;28, 2008, the holders of an aggregate of
    63,700,240&#160;shares of our common stock, which includes
    58,174,839&#160;shares of common stock issued on conversion of
    outstanding preferred stock and 757,436&#160;shares of common
    stock issuable upon the exercise of warrants and conversion of
    preferred stock underlying such warrants, are entitled to the
    following rights with respect to the registration of such shares
    for public resale under the Securities Act, pursuant to an
    investor rights agreement by and among us and certain of our
    stockholders. In addition, the aggregate number above includes
    an additional 4,767,965&#160;shares of common stock entitled to
    the rights described below, in the section titled
    &#147;Piggyback Registration Rights.&#148; We refer to these
    shares collectively as &#147;registrable securities.&#148;
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The registration of shares of common stock as a result of the
    following rights being exercised would enable the holders to
    trade these shares without restriction under the Securities Act
    when the applicable registration statement is declared
    effective. Ordinarily, we will be required to pay all expenses,
    other than underwriting discounts and commissions, related to
    any registration effected pursuant to the exercise of these
    registration rights.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The registration rights terminate upon the earlier of five years
    after completion of this offering, or, with respect to the
    registration rights of an individual holder, when the holder of
    one percent or less of our outstanding common stock can sell all
    of such holder&#146;s registrable securities in any three-month
    period without registration, in compliance with Rule&#160;144 of
    the Securities Act or another similar exemption.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Demand
    Registration Rights</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If at any time after this offering the holders of at least a
    majority of the registrable securities request in writing that
    we effect a registration that has a reasonably anticipated
    aggregate price to the public in excess of $20,000,000, we may
    be required to register their shares. At most, we are obligated
    to effect two registrations for the holders of registrable
    securities in response to these demand registration rights.
    Depending on certain conditions, however, we may defer such
    registration for up to 90&#160;days. If the holders requesting
    registration intend to distribute their shares by means of an
    underwriting, the managing underwriter of such offering will
    have the right to limit the number of shares to be underwritten
    for reasons related to the marketing of the shares.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    112
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Piggyback
    Registration Rights</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If at any time after this offering we propose to register any
    shares of our common stock under the Securities Act, subject to
    certain exceptions, the holders of registrable securities will
    be entitled to notice of the registration and to include their
    shares of registrable securities in the registration. If our
    proposed registration involves an underwriting, the managing
    underwriter of such offering will have the right to limit the
    number of shares to be underwritten for reasons related to the
    marketing of the shares.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times"><FONT style="white-space: nowrap">Form&#160;S-3</FONT>
    Registration Rights</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If at any time after we become entitled under the Securities Act
    to register our shares on
    <FONT style="white-space: nowrap">Form&#160;S-3</FONT>
    a holder of registrable securities requests in writing that we
    register their shares for public resale on
    <FONT style="white-space: nowrap">Form&#160;S-3</FONT>
    and the reasonably anticipated price to the public of the
    offering exceeds $2,000,000, we will be required to use our best
    efforts to effect such registration; provided, however, that if
    such registration would be seriously detrimental to us or our
    stockholders, we may defer the registration for up to
    90&#160;days.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Voting
    Rights</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the provisions of our amended and restated certificate of
    incorporation to become effective upon completion of this
    offering, holders of our common stock are entitled to one vote
    for each share of common stock held by such holder on any matter
    submitted to a vote at a meeting of stockholders. In addition,
    our amended and restated certificate of incorporation provides
    that certain corporate actions require the approval of our
    stockholders. These actions, and the vote required, are as
    follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the removal of a director requires the vote of a majority of the
    voting power of our issued and outstanding capital stock
    entitled to vote in the election of directors;&#160;and
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the amendment of provisions of our amended and restated
    certificate of incorporation relating to blank check preferred
    stock, the classification of our directors, the removal of
    directors, the filling of vacancies on our Board of Directors,
    cumulative voting, annual and special meetings of our
    stockholders and the amendment of certain provisions of our
    restated certificate of incorporation require the vote of 66
    2/3% of our then outstanding voting securities.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Anti
    Takeover Effects of Delaware Law and Our Certificate of
    Incorporation and Bylaws</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Certain provisions of Delaware law and our restated certificate
    of incorporation and bylaws that will become effective upon
    completion of this offering contain provisions that could have
    the effect of delaying, deferring or discouraging another party
    from acquiring control of us. These provisions, which are
    summarized below, are expected to discourage certain types of
    coercive takeover practices and inadequate takeover bids. These
    provisions are also designed in part to encourage anyone seeking
    to acquire control of us to first negotiate with our Board of
    Directors. We believe that the advantages gained by protecting
    our ability to negotiate with any unsolicited and potentially
    unfriendly acquirer outweigh the disadvantages of discouraging
    such proposals, including those priced above the then-current
    market value of our common stock, because, among other reasons,
    the negotiation of such proposals could improve their terms.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Certificate
    of Incorporation and Bylaws</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our amended and restated certificate of incorporation and bylaws
    to become effective upon completion of this offering include
    provisions that:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    authorize our Board of Directors to issue, without further
    action by the stockholders, up to 20,000,000&#160;shares of
    undesignated preferred stock;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    require that any action to be taken by our stockholders be
    effected at a duly called annual or special meeting and not by
    written consent;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    specify that special meetings of our stockholders can be called
    only by our Board of Directors, the Chairman of the Board, the
    Chief Executive Officer or the President;
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    113
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    establish an advance notice procedure for stockholder approvals
    to be brought before an annual meeting of our stockholders,
    including proposed nominations of persons for election to our
    Board of Directors;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    provide that directors may be removed only for cause;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    provide that vacancies on our Board of Directors may be filled
    only by a majority of directors then in office, even though less
    than a quorum;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    establish that our Board of Directors is divided into three
    classes, Class&#160;I, Class&#160;II, and Class&#160;III, with
    each class serving staggered terms;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    specify that no stockholder is permitted to cumulate votes at
    any election of the Board of Directors;&#160;and
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    require a super-majority of votes to amend certain of the
    above-mentioned provisions.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Delaware
    Anti-Takeover Statute</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are subject to the provisions of Section&#160;203 of the
    Delaware General Corporation Law regulating corporate takeovers.
    In general, Section&#160;203 prohibits a publicly-held Delaware
    corporation from engaging, under certain circumstances, in a
    business combination with an interested stockholder for a period
    of three years following the date the person became an
    interested stockholder unless:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    prior to the date of the transaction, the Board of Directors of
    the corporation approved either the business combination or the
    transaction which resulted in the stockholder becoming an
    interested stockholder;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    upon completion of the transaction that resulted in the
    stockholder becoming an interested stockholder, the interested
    stockholder owned at least 85% of the voting stock of the
    corporation outstanding at the time the transaction commenced,
    excluding for purposes of determining the voting stock
    outstanding, but not for determining the outstanding voting
    stock owned by the interested stockholder, (1)&#160;shares owned
    by persons who are directors and also officers, and
    (2)&#160;shares owned by employee stock plans in which employee
    participants do not have the right to determine confidentially
    whether shares held subject to the plan will be tendered in a
    tender or exchange offer;&#160;or
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    at or subsequent to the date of the transaction, the business
    combination is approved by the Board of Directors of the
    corporation and authorized at an annual or special meeting of
    stockholders, and not by written consent, by the affirmative
    vote of at least
    66<FONT style="vertical-align: text-top; font-size: 70%;">2</FONT>/<FONT style="font-size: 70%;">3</FONT>%
    of the outstanding voting stock which is not owned by the
    interested stockholder.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Generally, a business combination includes a merger, asset or
    stock sale, or other transaction resulting in a financial
    benefit to the interested stockholder. An interested stockholder
    is a person who, together with affiliates and associates, owns
    or, within three years prior to the determination of interested
    stockholder status, did own 15% or more of a corporation&#146;s
    outstanding voting stock. We expect the existence of this
    provision to have an anti-takeover effect with respect to
    transactions our Board of Directors does not approve in advance.
    We also anticipate that Section&#160;203&#160;may discourage
    business combinations or other attempts that might result in a
    premium over the market price for the shares of common stock
    held by our stockholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The provisions of Delaware law and our restated certificate of
    incorporation and bylaws to become effective upon completion of
    this offering could have the effect of discouraging others from
    attempting hostile takeovers and, as a consequence, they may
    also inhibit temporary fluctuations in the market price of our
    common stock that often result from actual or rumored hostile
    takeover attempts. These provisions may also have the effect of
    preventing changes in our management. It is possible that these
    provisions could make it more difficult to accomplish
    transactions that stockholders may otherwise deem to be in their
    best interests.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Transfer
    Agent and Registrar</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The transfer agent and registrar for our common stock is
    Computershare Trust Company, N.A. The transfer agent&#146;s
    address is 250&#160;Royall Street, Canton, MA 02021, and its
    telephone number is (781) 575-2900.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">NASDAQ
    Global Market Listing</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have applied to have our common stock listed on the NASDAQ
    Global Market under the symbol &#147;FLDM.&#148;
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    114
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->
<A name='115'>
<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->SHARES
    ELIGIBLE FOR FUTURE SALE</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->
</A>
<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Before this offering, there has not been a public market for
    shares of our common stock. Future sales of substantial amounts
    of shares of our common stock, including shares issued upon the
    exercise of outstanding options, in the public market after this
    offering, or the possibility of these sales occurring, could
    cause the prevailing market price for our common stock to fall
    or impair our ability to raise equity capital in the future.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Upon the completion of this offering, a total
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock will be outstanding, assuming that there are no
    exercises of options or warrants after June&#160;28, 2008. Of
    these shares,
    all&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock sold in this offering by us, plus any shares
    sold upon exercise of the underwriters&#146; over-allotment
    option, will be freely tradable in the public market without
    restriction or further registration under the Securities Act,
    unless these shares are held by &#147;affiliates,&#148; as that
    term is defined in Rule&#160;144 under the Securities Act.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The remaining 68,101,494&#160;shares of common stock will be
    &#147;restricted securities,&#148; as that term is defined in
    Rule&#160;144 under the Securities Act. These restricted
    securities are eligible for public sale only if they are
    registered under the Securities Act or if they qualify for an
    exemption from registration under Rules&#160;144 or 701 under
    the Securities Act, which are summarized below.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Subject to the lock up agreements described below and the
    provisions of Rules&#160;144 and 701 under the Securities Act,
    these restricted securities will be available for sale in the
    public market as follows:
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="88%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px"><!-- DIV#013 -->
    <B>Date</B>
</DIV><!-- /DIV#007 -->
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
     On the date of this prospectus
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Between 90 and 180&#160;days after the date of this prospectus
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    At various times beginning more than 180&#160;days after the
    date of this prospectus
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68,217,839
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->

</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    In addition, of the 8,309,725&#160;shares of our common stock
    that were subject to stock options outstanding as of
    June&#160;28, 2008, options to purchase 3,846,005&#160;shares of
    common stock were vested as of June&#160;28, 2008 and will be
    eligible for sale 180&#160;days following the effective date of
    this offering.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Rule&#160;144</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    In general, under Rule&#160;144 as currently in effect, once we
    have been subject to public company reporting requirements for
    at least 90&#160;days, a person who is not deemed to have been
    one of our affiliates for purposes of the Securities Act at any
    time during the 90&#160;days preceding a sale and who has
    beneficially owned the shares proposed to be sold for at least
    six months, including the holding period of any prior owner
    other than our affiliates, is entitled to sell those shares
    without complying with the manner of sale, volume limitation or
    notice provisions of Rule&#160;144, subject to compliance with
    the public information requirements of Rule&#160;144. If such a
    person has beneficially owned the shares proposed to be sold for
    at least one year, including the holding period of any prior
    owner other than our affiliates, then that person is entitled to
    sell those shares without complying with any of the requirements
    of Rule&#160;144.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    In general, under Rule&#160;144, as currently in effect, our
    affiliates or persons selling shares on behalf of our affiliates
    are entitled to sell upon expiration of the
    <FONT style="white-space: nowrap"><!-- FONT#006 -->lock-up</FONT><!-- /FONT#006 -->
    agreements described above, within any three-month period
    beginning 90&#160;days after the date of this prospectus, a
    number of shares that does not exceed the greater of:
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    1% of the number of shares of common stock then outstanding,
    which will equal
    approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    immediately after this offering;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the average weekly trading volume of the common stock during the
    four calendar weeks preceding the filing of a notice on
    Form&#160;144 with respect to that sale.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Sales under Rule&#160;144 by our affiliates or persons selling
    shares on behalf of our affiliates are also subject to certain
    manner of sale provisions and notice requirements and to the
    availability of current public information about us.
</DIV><!-- /DIV#030 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    115
</DIV><!-- /DIV#051 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Rule&#160;701</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, under Rule&#160;701 as currently in effect, any of
    our employees, consultants or advisors who purchase shares from
    us in connection with a compensatory stock or option plan or
    other written agreement in a transaction before the effective
    date of this offering that was completed in reliance on
    Rule&#160;701 and complied with the requirements of
    Rule&#160;701 will, subject to the lock up restrictions
    described below, be eligible to resell such shares 90&#160;days
    after the effective date of this offering in reliance on
    Rule&#160;144, but without compliance with certain restrictions,
    including the holding period, contained in Rule&#160;144.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Lock Up
    Agreements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We and all of our directors and officers, as well as the other
    holders of substantially all shares of common stock outstanding
    immediately prior to this offering, have agreed that, without
    the prior written consent of Morgan Stanley&#160;&#038; Co.
    Incorporated on behalf of the underwriters, we and they will
    not, during the period ending 180&#160;days after the date of
    this prospectus:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    offer, pledge, sell, contract to sell, sell any option or
    contract to purchase, purchase any option or contract to sell,
    grant any option, right or warrant to purchase, lend or
    otherwise transfer or dispose of, directly or indirectly, any
    shares of our common stock or any securities convertible into or
    exercisable or exchangeable for shares of our common stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enter into any swap or other arrangement that transfers to
    another, in whole or in part, any of the economic consequences
    of ownership of our common stock,
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    whether any transaction described above is to be settled by
    delivery of shares of our common stock or such other securities,
    in cash or otherwise. This agreement is subject to certain
    exceptions, and is also subject to extension for up to an
    additional days, as set forth in &#147;Underwriters.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Registration
    Rights</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon completion of this offering, the holders of
    63,700,240&#160;shares of common stock or their transferees will
    be entitled to various rights with respect to the registration
    of these shares under the Securities Act. Registration of these
    shares under the Securities Act would result in these shares
    becoming fully tradable without restriction under the Securities
    Act immediately upon the effectiveness of the registration,
    except for shares purchased by affiliates. See &#147;Description
    of Capital Stock&#160;&#151; Registration Rights&#148; for
    additional information.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Registration
    Statements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to file a registration statement on
    <FONT style="white-space: nowrap">Form&#160;S-8</FONT>
    under the Securities Act covering all of the shares of common
    stock subject to options outstanding or reserved for issuance
    under our stock plans. We expect to file this registration
    statement as soon as practicable after this offering. In
    addition, we intend to file a registration statement on
    <FONT style="white-space: nowrap">Form&#160;S-8</FONT>
    under the Securities Act for the resale of shares of common
    stock issued upon the exercise of options that were not granted
    under Rule&#160;701. We expect to file this registration
    statement as soon as practicable after this offering. However,
    none of the shares registered on
    <FONT style="white-space: nowrap">Form&#160;S-8</FONT>
    will be eligible for resale until the expiration of the lock up
    agreements to which they are subject.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    116
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='120'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">MATERIAL
    U. S. FEDERAL INCOME AND ESTATE TAX<BR>
    CONSEQUENCES TO NON-U. S. HOLDERS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following is a general discussion of certain material United
    States federal income and estate tax considerations with respect
    to the acquisition, ownership and disposition of shares of our
    common stock applicable to
    <FONT style="white-space: nowrap">non-U.S.&#160;holders.</FONT>
    In general, a
    <FONT style="white-space: nowrap">&#147;non-U.S.&#160;holder&#148;</FONT>
    is any holder other than:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an individual who is a citizen or resident of the United States
    for United States federal income tax purposes;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a corporation (or other entity treated as a corporation for
    United States federal income tax purposes) created or organized
    in or under the laws of the United States, any state thereof or
    the District of Columbia;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an estate, the income of which is includible in gross income for
    United States federal income tax purposes regardless of its
    source;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a trust if (a)&#160;a court within the United States is able to
    exercise primary supervision over the administration of the
    trust and one or more United States persons have the authority
    to control all substantial decisions of the trust or (b)&#160;it
    has a valid election in effect under applicable Treasury
    regulations to be treated as a United&#160;States person.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This discussion is based on current provisions of the Internal
    Revenue Code, final, temporary or proposed Treasury regulations
    promulgated thereunder, judicial opinions, published positions
    of the Internal Revenue Service and all other applicable
    authorities, all of which are subject to change (possibly with
    retroactive effect). We assume in this discussion that a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    holds shares of our common stock as a capital asset (generally
    property held for investment).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This discussion does not address all aspects of United States
    federal income and estate taxation that may be important to a
    particular
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    in light of that
    <FONT style="white-space: nowrap">non-U.S.&#160;holder&#146;s</FONT>
    individual circumstances, nor does it address any aspects of
    United States state or local taxes or
    <FONT style="white-space: nowrap">non-U.S.&#160;taxes.</FONT>
    This discussion also does not consider any specific facts or
    circumstances that may apply to a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    subject to special treatment under the United&#160;States
    federal income tax laws, including, without limitation:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    banks, insurance companies or other financial institutions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    partnerships or other pass-through entities or persons that hold
    shares of our common stock through such entities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    tax-exempt organizations;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    tax-qualified retirement plans;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    dealers in securities or currencies;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    traders in securities that elect to use a mark-to-market method
    of accounting for their securities holdings;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    United States expatriates;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    persons that will hold common stock as a position in a hedging
    transaction, &#147;straddle&#148; or &#147;conversion
    transaction&#148; for tax purposes.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Accordingly, we urge prospective investors to consult with their
    own tax advisors regarding the United States federal, state and
    local income and
    <FONT style="white-space: nowrap">non-U.S.&#160;income</FONT>
    and other tax considerations of acquiring, holding and disposing
    of shares of our common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If a partnership or other pass-through entity holds shares of
    our common stock, the tax treatment of a partner in such
    partnership or an owner of such other pass-through entity will
    generally depend upon the status of such partner or other owner
    and the activities of such partnership or other entity. Any
    partnership or other pass-through entity that holds shares of
    our common stock or any partner in such partnership or owner of
    such other entity should consult its own tax advisors.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    117
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Dividends</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If we make cash or other property distributions on our common
    stock, such distributions will constitute dividends for United
    States federal income tax purposes to the extent paid from our
    current or accumulated earnings and profits, as determined under
    United States federal income tax principles. To the extent those
    distributions exceed both our current and our accumulated
    earnings and profits, such excess will constitute a return of
    capital and will first reduce the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder&#146;s</FONT>
    adjusted tax basis in our common stock, but not below zero. Any
    remaining excess will be treated as gain from the sale or other
    disposition of shares of our common stock (as described under
    &#147;&#151;&#160;Gain on Sale or Other Disposition of Common
    Stock&#148; below).
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, dividends we pay, if any, to a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    will be subject to United States withholding tax at a rate of
    30% of the gross amount. The withholding tax might not apply or
    might apply at a reduced rate under the terms of an applicable
    income tax treaty between the United States and the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder&#146;s</FONT>
    country of residence. A
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    must demonstrate its entitlement to treaty benefits by
    certifying, among other things, its nonresident status. A
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    generally can meet this certification requirement by providing
    an Internal Revenue Service
    <FONT style="white-space: nowrap">Form&#160;W-8BEN</FONT>
    or appropriate substitute form to us or our paying agent. Also,
    special rules apply if the dividends are effectively connected
    with a trade or business carried on by the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    within the United States and, if a treaty applies, are
    attributable to a permanent establishment of the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    within the United States. Dividends effectively connected with
    this United States trade or business, and, if a treaty applies,
    attributable to such a permanent establishment of a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder,</FONT>
    generally will not be subject to United States withholding tax
    if the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    files certain forms, including Internal Revenue Service
    <FONT style="white-space: nowrap">Form&#160;W-8ECI</FONT>
    (or any successor form), with the payor of the dividend, and
    generally will be subject to United States federal income tax on
    a net income basis, in the same manner as if the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    were a resident of the United States. A
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    that is a corporation may be subject to an additional
    &#147;branch profits tax&#148; at a rate of 30% (or a reduced
    rate as may be specified by an applicable income tax treaty) on
    the repatriation from the United States of its &#147;effectively
    connected earnings and profits,&#148; subject to certain
    adjustments. A
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    of shares of our common stock eligible for a reduced rate of
    United States withholding tax pursuant to an income tax treaty
    may obtain a refund of any excess amounts withheld by timely
    filing an appropriate claim for refund with the Internal Revenue
    Service.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Gain on
    Sale or Other Disposition of Common Stock</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    will not be subject to United States federal income tax on any
    gain realized upon the sale or other disposition of the
    holder&#146;s shares of our common stock unless:
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the gain is effectively connected with a trade or business
    carried on by the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    within the United&#160;States and, if required by an applicable
    income tax treaty as a condition to subjecting a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    to United States income tax on a net basis, the gain is
    attributable to a permanent establishment of the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    maintained in the United States, in which case a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    will be subject to United States federal income tax on any gain
    realized upon the sale or other disposition on a net income
    basis, in the same manner as if the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    were a resident of the United States. Furthermore, the branch
    profits tax discussed above may also apply if the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    is a corporation;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    is an individual and is present in the United States for
    183&#160;days or more in the taxable year of disposition and
    certain other tests are met, in which case a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    will be subject to a flat 30% tax on any gain realized upon the
    sale or other disposition, which tax may be offset by United
    States source capital losses (even though the individual is not
    considered a resident of the United States);&#160;or
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we are or have been a United States real property holding
    corporation (a USRPHC) for United States federal income tax
    purposes at any time within the shorter of the five-year period
    preceding the disposition and the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder&#146;s</FONT>
    holding period. We do not believe that we are or have been a
    USRPHC, and we do not anticipate becoming a USRPHC. If we have
    been in the past or were to become a USRPHC at any time during
    this period, generally gains realized upon a disposition of
    shares of our common stock by a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    that did not directly or indirectly own more than 5% of our
    common stock during this period would not be subject to United
    States federal income tax, provided that our common stock is
    &#147;regularly traded on an established securities market&#148;
    (within the meaning of Section&#160;897(c)(3) of the Internal
    Revenue Code). Our common stock will be treated as regularly
    traded on an established securities market during any period in
    which it is listed on a registered national securities exchange
    or any over-the-counter market.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    118
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">United
    States Federal Estate Tax</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Shares of our common stock that are owned or treated as owned by
    an individual who is not a citizen or resident (as defined for
    United States federal estate tax purposes) of the United States
    at the time of death will be includible in the individual&#146;s
    gross estate for United States federal estate tax purposes,
    unless an applicable estate tax treaty provides otherwise, and
    therefore may be subject to United States federal estate tax.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Backup
    Withholding, Information Reporting and Other Reporting
    Requirements</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Generally, we must report annually to the Internal Revenue
    Service and to each
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    the amount of dividends paid to, and the tax withheld with
    respect to, each
    <FONT style="white-space: nowrap">non-U.S.&#160;holder.</FONT>
    These reporting requirements apply regardless of whether
    withholding was reduced or eliminated by an applicable tax
    treaty. Copies of this information also may be made available
    under the provisions of a specific treaty or agreement with the
    tax authorities in the country in which the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    resides or is established.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    United States backup withholding tax is imposed (at a current
    rate of 28%) on certain payments to persons that fail to furnish
    the information required under the United States information
    reporting requirements. A
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    of shares of our common stock will be subject to this backup
    withholding tax on dividends we pay unless the holder certifies,
    under penalties of perjury, among other things, its status as a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    (and we or our paying agent do not have actual knowledge or
    reason to know the holder is a United States person) or
    otherwise establishes an exemption.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the Treasury regulations, the payment of proceeds from the
    disposition of shares of our common stock by a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    made to or through a United States office of a broker generally
    will be subject to information reporting and backup withholding
    unless the beneficial owner certifies, under penalties of
    perjury, among other things, its status as a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    (and we or our paying agent do not have actual knowledge or
    reason to know the holder is a United States person) or
    otherwise establishes an exemption. The payment of proceeds from
    the disposition of shares of our common stock by a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    made to or through a
    <FONT style="white-space: nowrap">non-U.S.&#160;office</FONT>
    of a broker generally will not be subject to backup withholding
    and information reporting, except as noted below. In the case of
    proceeds from a disposition of shares of our common stock by a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    made to or through a
    <FONT style="white-space: nowrap">non-U.S.&#160;office</FONT>
    of a broker that is:
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a United States person;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a &#147;controlled foreign corporation&#148; for United States
    federal income tax purposes;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a foreign person 50% or more of whose gross income from certain
    periods is effectively connected with a United States trade or
    business;&#160;or
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a foreign partnership if at any time during its tax year
    (a)&#160;one or more of its partners are United States persons
    who, in the aggregate, hold more than 50% of the income or
    capital interests of the partnership or (b)&#160;the foreign
    partnership is engaged in a United States trade or business;
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    information reporting (but not backup withholding) will apply
    unless the broker has documentary evidence in its files that the
    owner is a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    and certain other conditions are satisfied, or the beneficial
    owner otherwise establishes an exemption (and the broker has no
    actual knowledge or reason to know to the contrary).
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Backup withholding is not an additional tax. Any amounts
    withheld under the backup withholding rules from a payment to a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    may generally be refunded or credited against the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder&#146;s</FONT>
    United States federal income tax liability, if any, provided
    that the required information is furnished to the Internal
    Revenue Service in a timely manner.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    EACH PROSPECTIVE HOLDER OF SHARES OF OUR COMMON STOCK SHOULD
    CONSULT HIS, HER OR ITS OWN TAX ADVISOR WITH RESPECT TO THE
    UNITED STATES FEDERAL, STATE AND LOCAL TAX CONSEQUENCES AND
    <FONT style="white-space: nowrap">NON-U.S.&#160;TAX</FONT>
    CONSEQUENCES OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF
    OUR COMMON STOCK.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    119
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->
<A name='121'>
<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->UNDERWRITERS</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->
</A>
<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Under the terms and subject to the conditions contained in an
    underwriting agreement dated the date of this prospectus, the
    underwriters named below, for whom Morgan Stanley&#160;&#038;
    Co. Incorporated is acting as the representative, have severally
    agreed to purchase, and we have agreed to sell to them,
    severally, the number of shares indicated in the table below:
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="90%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px"><!-- DIV#013 -->
    <B>Name</B>
</DIV><!-- /DIV#007 -->
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Morgan Stanley&#160;&#038; Co. Incorporated
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    UBS Securities LLC
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Leerink Swann LLC
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Pacific Growth Equities, LLC
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    Total
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->

</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The underwriters are offering the shares of common stock subject
    to their acceptance of the shares from us and subject to prior
    sale. The underwriting agreement provides that the obligations
    of the several underwriters to pay for and accept delivery of
    the shares of common stock offered by this prospectus are
    subject to the approval of certain legal matters by their
    counsel and to certain other conditions. The underwriters are
    obligated to take and pay for all of the shares of common stock
    offered by this prospectus if any such shares are taken.
    However, the underwriters are not required to take or pay for
    the shares covered by the underwriters&#146; over-allotment
    option described below.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The underwriters initially propose to offer part of the shares
    of common stock directly to the public at the offering price
    listed on the cover page of this prospectus and part to certain
    dealers at a price that represents a concession not in excess of
    $&#160;&#160;  per share under the public offering price. After
    the initial offering of the shares of common stock, the offering
    price and other selling terms may from time to time be varied by
    the representative.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    We have granted to the underwriters an option, exercisable for
    30&#160;days from the date of this prospectus, to purchase up to
    an aggregate
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;additional
    shares of common stock at the public offering price set forth on
    the cover page of this prospectus, less underwriting discounts
    and commissions. The underwriters may exercise this option
    solely for the purpose of covering over-allotments, if any, made
    in connection with the offering of the shares of common stock
    offered by this prospectus. To the extent the option is
    exercised, each underwriter will become obligated, subject to
    certain conditions, to purchase approximately the same
    percentage of the additional shares of common stock as the
    number listed next to the underwriter&#146;s name in the
    preceding table bears to the total number of shares of common
    stock listed next to the names of all underwriters in the
    preceding table.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The following table shows the per share and total public
    offering price, underwriting discounts and commissions and
    proceeds before expenses to us. These amounts are shown assuming
    both no exercise and full exercise of the underwriters&#146;
    option to purchase up to an
    additional&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="65%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Per Share</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>No exercise</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Full Exercise</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Public offering price
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Underwriting discounts and commissions
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Proceeds, before expenses, to us
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->

</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The estimated offering expenses payable by us, exclusive of the
    underwriting discounts and commissions are approximately
    $&#160;&#160;&#160;&#160;&#160; .
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The underwriters have informed us that they do not intend sales
    to discretionary accounts to exceed five percent of the total
    number of shares of common stock offered by them.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    We have applied to have the common stock listed on the NASDAQ
    Global Market under the symbol &#147;FLDM.&#148;
</DIV><!-- /DIV#030 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    120
</DIV><!-- /DIV#051 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We and all directors, officers and substantially all of our
    other security holders have agreed that, without the prior
    written consent of Morgan Stanley&#160;&#038; Co. Incorporated
    on behalf of the underwriters, we and they will not, during the
    period ending 180&#160;days after the date of this prospectus:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    offer, pledge, sell, contract to sell, sell any option or
    contract to purchase, purchase any option or contract to sell,
    grant any option, right or warrant to purchase, lend, or
    otherwise transfer or dispose of directly or indirectly, any
    shares of common stock or any securities convertible into or
    exercisable or exchangeable for common stock;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enter into any swap or other arrangement that transfers to
    another, in whole or in part, any of the economic consequences
    of ownership of the common stock; or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    in our case only, file or cause to be filed a registration
    statement, including any amendments with respect to the
    registration statement of any shares of common stock or
    securities convertible, exercisable or exchangeable into our
    common stock or any other securities of the company (other than
    any registration statement on
    <FONT style="white-space: nowrap">Form&#160;S-8),</FONT>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    whether any such transaction described above is to be settled by
    delivery of common stock or such other securities, in cash or
    otherwise. In addition, each such person agrees that, without
    the prior written consent of Morgan Stanley&#160;&#038; Co.
    Incorporated on behalf of the underwriters, they will not,
    during the period ending 180&#160;days after the date of this
    prospectus, make any demand for, or exercise any right with
    respect to, the registration of any shares of common stock or
    any security convertible into or exercisable or exchangeable for
    common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subject to certain restrictions, the restrictions described in
    the immediately preceding paragraph do not apply to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the sale of shares to the underwriters;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    transactions relating to shares of common stock or other
    securities acquired in open market transactions after the
    completion of this offering, provided that no filing under
    Section&#160;16(a) of the Securities Exchange Act of 1934, as
    amended, shall be required or shall be voluntarily made in
    connection with subsequent sales of common stock or other
    securities acquired in such open market transactions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the exercise of any options to acquire common stock or
    conversion of any convertible security into common stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    transfers of shares of common stock or any security convertible
    into common stock as a bona fide gift;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    distributions of shares of common stock or any security
    convertible into common stock to limited partners, members or
    stockholders of the transferor;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    transfers of shares of common stock or any security convertible
    into common stock by will or intestacy to the transferor&#146;s
    immediate family or to a trust, the beneficiaries of which are
    members of the transferor&#146;s immediate family;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the establishment of a trading plan pursuant to
    <FONT style="white-space: nowrap">Rule&#160;10b5-1</FONT>
    under the Exchange Act for the transfer of shares of common
    stock, provided that such plan does not provide for the transfer
    of common stock during the restricted period.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The <FONT style="white-space: nowrap">180-day</FONT>
    restricted period described in the preceding paragraph will be
    extended if:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    during the last 17&#160;days of the
    <FONT style="white-space: nowrap">180-day</FONT>
    restricted period, we issue a release regarding earnings or
    regarding material news or events relating to us;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    prior to the expiration of the
    <FONT style="white-space: nowrap">180-day</FONT>
    restricted period, we announce that we will release earnings
    results during the
    <FONT style="white-space: nowrap">16-day</FONT>
    period beginning on the last day of the
    <FONT style="white-space: nowrap">180-day</FONT>
    period,
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    in which case, the restrictions described in the preceding
    paragraph will continue to apply until the expiration of the
    <FONT style="white-space: nowrap">18-day</FONT>
    period beginning on the issuance of the earnings release or the
    occurrence of the material news or material event, unless such
    extension is waived, in writing, by Morgan Stanley&#160;&#038;
    Co. Incorporated on behalf of the underwriters.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    121
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In order to facilitate the offering of the common stock, the
    underwriters may engage in transactions that stabilize, maintain
    or otherwise affect the price of the common stock. Specifically,
    the underwriters may sell more shares than they are obligated to
    purchase under the underwriting agreement, creating a short
    position. A short sale is covered if the short position is no
    greater than the number of shares available for purchase by the
    underwriters under the over-allotment option. The underwriters
    can close out a covered short sale by exercising the
    over-allotment option or purchasing shares in the open market.
    In determining the source of shares to close out a covered short
    sale, the underwriters will consider, among other things, the
    open market price of shares compared to the price available
    under the over-allotment option. The underwriters may also sell
    shares in excess of the over-allotment option, creating a naked
    short position. The underwriters must close out any naked short
    position by purchasing shares in the open market. A naked short
    position is more likely to be created if the underwriters are
    concerned that there may be downward pressure on the price of
    the common stock in the open market after pricing that could
    adversely affect investors who purchase in the offering. As an
    additional means of facilitating the offering, the underwriters
    may bid for, and purchase, shares of common stock in the open
    market. Finally, the underwriting syndicate may reclaim selling
    concessions allowed to an underwriter or a dealer for
    distributing the common stock in the offering, if the syndicate
    repurchases previously distributed common stock to cover
    syndicate short positions or to stabilize the price of the
    common stock. These activities may raise or maintain the market
    price of the common stock above independent market levels or
    prevent or retard a decline in the market price of the common
    stock. The underwriters are not required to engage in these
    activities, and may end any of these activities at any time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We and the underwriters have agreed to indemnify each other
    against certain liabilities, including liabilities under the
    Securities Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A prospectus in electronic format may be made available on
    websites maintained by one or more underwriters participating in
    this offering. Other than the prospectus in electronic format,
    the information on the underwriters&#146; websites is not part
    of this prospectus. The underwriters may agree to allocate a
    number of shares of common stock to underwriters for sale to
    their online brokerage account holders. Internet distributions
    will be allocated by Morgan Stanley&#160;&#038; Co. Incorporated
    to underwriters that may make Internet distributions on the same
    basis as other allocations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">European
    Economic Area</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In relation to each Member State of the European Economic Area
    which has implemented the Prospectus Directive, each underwriter
    has represented and agreed that with effect from and including
    the date on which the Prospectus Directive is implemented in
    that Member State it has not made and will not make an offer of
    the common stock to the public in that Member State, except that
    it may, with effect from and including such date, make an offer
    of the common stock to the public in that Member State:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    at any time to legal entities which are authorized or regulated
    to operate in the financial markets or, if not so authorized or
    regulated, whose corporate purpose is solely to invest in
    securities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    at any time to any legal entity which has two or more of
    (1)&#160;an average of at least 250&#160;employees during the
    last financial year; (2)&#160;a total balance sheet of more than
    &#128;43,000,000 and (3)&#160;an annual net turnover of more
    than &#128;50,000,000, as shown in its last annual or
    consolidated accounts;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    at any time in any other circumstances which do not require the
    publication by us of a prospectus pursuant to Article&#160;3 of
    the Prospectus Directive.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For the purposes of the above, the expression an &#147;offer of
    the common stock to the public&#148; in relation to any shares
    of common stock in any Member State means the communication in
    any form and by any means of sufficient information on the terms
    of the offer and the common stock to be offered so as to enable
    an investor to decide to purchase or subscribe shares of common
    stock, as the same may be varied in that Member State by any
    measure implementing the Prospectus Directive in that Member
    State, and the expression Prospectus Directive means Directive
    2003/71/EC and includes any relevant implementing measure in
    that Member State.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    122
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">United
    Kingdom</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each underwriter has represented and agreed that it has only
    communicated or caused to be communicated and will only
    communicate or cause to be communicated an invitation or
    inducement to engage in investment activity (within the meaning
    of Section&#160;21 of the Financial Services and Markets Act
    2000)&#160;in connection with the issue or sale of shares of
    common stock in circumstances in which Section&#160;21(1) of
    such Act does not apply to us and it has complied and will
    comply with all applicable provisions of such Act with respect
    to anything done by it in relation to any shares of common stock
    in, from or otherwise involving the United Kingdom.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Other
    Relationships</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In October 2007, we sold shares of our Series&#160;E preferred
    stock in a private placement transaction. Leerink Swann LLC
    acted as the placement agent in the October 2007 offering and
    received a fee of $1,000,000 for services rendered. Entities
    affiliated with Leerink Swann LLC also participated in the
    October 2007 offering and purchased an aggregate of
    141,250&#160;shares of our Series&#160;E preferred stock for an
    aggregate purchase price of $565,000. One or more of the
    underwriters may in the future provide investment banking
    services to us for which they would receive customary
    compensation.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Pricing
    of the Offering</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to this offering, there has been no public market for our
    common stock. The initial public offering price will be
    determined by negotiations between us and the underwriters.
    Among the factors to be considered in determining the initial
    public offering price are:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our future prospects and those of our industry in general;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our sales, earnings and certain other financial and operating
    information in recent periods;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the price-earnings ratios, price-sales ratios and market prices
    of securities and certain financial and operating information of
    companies engaged in activities similar to ours.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    An active trading market for the shares may not develop. It is
    also possible that after the offering the shares will not trade
    in the public market at or above the initial public offering
    price.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    123
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='116'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">LEGAL
    MATTERS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The validity of the shares of common stock offered hereby will
    be passed upon for us by Wilson Sonsini Goodrich&#160;&#038;
    Rosati, Professional Corporation, Palo Alto, California.
    Latham&#160;&#038; Watkins LLP, Costa Mesa, California is acting
    as counsel to the underwriters. Members of Wilson Sonsini
    Goodrich &#038; Rosati, Professional Corporation and investment
    funds associated with that firm hold 160,956 shares of our
    common stock.
</DIV>
<A name='117'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">EXPERTS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Ernst &#038; Young LLP, independent registered public accounting
    firm, has audited our consolidated financial statements at
    December&#160;31, 2006 and December&#160;29, 2007, and for each
    of the three years in the period ended December&#160;29, 2007,
    as set forth in their report. We have included our consolidated
    financial statements in the prospectus and elsewhere in the
    registration statement in reliance on Ernst &#038; Young
    LLP&#146;s report, given on their authority as experts in
    accounting and auditing.
</DIV>
<A name='118'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">WHERE YOU
    CAN FIND ADDITIONAL INFORMATION</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have filed with the SEC a registration statement on
    <FONT style="white-space: nowrap">Form&#160;S-1</FONT>
    under the Securities Act with respect to the shares of common
    stock offered hereby. This prospectus, which constitutes a part
    of the registration statement, does not contain all of the
    information set forth in the registration statement or the
    exhibits and schedules filed therewith. For further information
    about us and the common stock offered hereby, we refer you to
    the registration statement and the exhibits and schedules filed
    thereto. Statements contained in this prospectus regarding the
    contents of any contract or any other document that is filed as
    an exhibit to the registration statement are not necessarily
    complete, and each such statement is qualified in all respects
    by reference to the full text of such contract or other document
    filed as an exhibit to the registration statement. Upon
    completion of this offering, we will be required to file
    periodic reports, proxy statements, and other information with
    the SEC pursuant to the Securities Exchange Act of 1934. You may
    read and copy this information at the Public Reference Room of
    the SEC, 100 F. Street, N.E., Room&#160;1580,
    Washington,&#160;D.C. 20549. You may obtain information on the
    operation of the public reference rooms by calling the SEC at
    <FONT style="white-space: nowrap">1-800-SEC-0330.</FONT>
    The SEC also maintains an Internet website that contains
    reports, proxy statements and other information about issuers,
    like us, that file electronically with the SEC. The address of
    that site is www.sec.gov.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to provide our stockholders with annual reports
    containing financial statements that have been audited by an
    independent registered public accounting firm, and to file with
    the SEC quarterly reports containing unaudited financial data
    for the first three quarters of each year.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    124
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='119'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">INDEX TO
    CONSOLIDATED FINANCIAL STATEMENTS</FONT></B>
</DIV>
</A>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>
<DIV align="left">
<!-- TOC -->
</DIV>

<DIV align="left">
<A name="tocpage"></A>
</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="95%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Page</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#300'>Report of Independent Registered Public
    Accounting Firm</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-2
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#301'>Consolidated Balance Sheets</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-3
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#302'>Consolidated Statements of Operations</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-4
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#303'>Consolidated Statements of Convertible Preferred
    Stock and Stockholders&#146; Equity (Deficit)</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-5
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#304'>Consolidated Statements of Cash Flows</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-7
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#305'>Notes to Consolidated Financial Statements</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-8
</TD>
<TD>&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='300'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Report of
    Independent Registered Public Accounting Firm</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Board of Directors and Stockholders<BR>
    Fluidigm Corporation
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have audited the accompanying consolidated balance sheets of
    Fluidigm Corporation as of December&#160;31, 2006 and
    December&#160;29, 2007, and the related consolidated statements
    of operations, convertible preferred stock and
    stockholders&#146; equity (deficit), and cash flows for each of
    the three fiscal years in the period ended December&#160;29,
    2007. These financial statements are the responsibility of the
    Company&#146;s management. Our responsibility is to express an
    opinion on these financial statements based on our audits.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We conducted our audits in accordance with the standards of the
    Public Company Accounting Oversight Board (United States). Those
    standards require that we plan and perform the audit to obtain
    reasonable assurance about whether the financial statements are
    free of material misstatement. We were not engaged to perform an
    audit of the Company&#146;s internal control over financial
    reporting. Our audits included consideration of internal control
    over financial reporting as a basis for designing audit
    procedures that are appropriate in the circumstances, but not
    for the purpose of expressing an opinion on the effectiveness of
    the Company&#146;s internal control over financial reporting.
    Accordingly, we express no such opinion. An audit also includes
    examining, on a test basis, evidence supporting the amounts and
    disclosures in the financial statements, assessing the
    accounting principles used and significant estimates made by
    management, and evaluating the overall financial statement
    presentation. We believe that our audits provide a reasonable
    basis for our opinion.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In our opinion, the financial statements referred to above
    present fairly, in all material respects, the consolidated
    financial position of Fluidigm Corporation at December&#160;31,
    2006 and December&#160;29, 2007, and the consolidated results of
    its operations and its cash flows for each of the three fiscal
    years in the period ended December&#160;29, 2007, in conformity
    with U.S.&#160;generally accepted accounting principles.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As discussed in Note&#160;2 to the consolidated financial
    statements, Fluidigm Corporation changed its method of
    accounting for preferred stock warrants as of July&#160;1, 2005,
    its method of accounting for stock-based compensation as of
    January&#160;1, 2006, and its method of accounting for uncertain
    tax positions as of January&#160;1, 2007.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Ernst&#160;&#038;
    Young LLP</DIV>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Palo Alto, California
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    April 12, 2008
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>
<A name='301'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Consolidated
    Balance Sheets</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(in
    thousands, except per share amounts)</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="63%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD colspan="13" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Assets</B>
</DIV>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Current assets:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Cash and cash equivalents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    25,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    34,077
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    28,966
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,286
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,503
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Accounts receivable (net of allowances of $3, $0 and $0;
    includes accounts receivable from related parties of $272, $690
    and $609, respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,495
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Inventories
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,038
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,498
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,980
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Prepaid expenses and other current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    768
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Restricted cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Total current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31,089
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,329
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,395
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Restricted cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    381
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    256
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Property and equipment, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,378
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,757
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Other assets (includes receivables from related parties of $277,
    $287 and $71, respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    436
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    688
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,270
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    36,493
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    54,776
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    49,678
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="13">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="13" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Liabilities, Convertible Preferred Stock and
    Stockholders&#146; Equity (Deficit)</B>
</DIV>
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Current liabilities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Accounts payable (includes accounts payable to related parties
    of $174, $290 and $428, respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,188
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,725
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,231
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Accrued compensation and related benefits
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    397
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    898
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,075
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Other accrued liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    856
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    998
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,591
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Deferred revenue, current portion (includes deferred revenue
    from related parties of $227, $276 and $253, respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,652
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,504
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Long-term debt, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,476
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,834
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,081
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Convertible preferred stock warrant liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    223
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    468
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,269
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Total current liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,575
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,751
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Deferred revenue, net of current portion (includes deferred
    revenue from related parties of $493, $359 and $253,
    respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    786
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    762
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    602
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Long-term debt, net of current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,362
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,528
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,477
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Convertible promissory notes from related parties
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,072
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,997
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Other liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    163
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    218
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,370
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,025
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,048
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Commitments and contingencies (Note&#160;6)&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Convertible preferred stock issuable in series, $0.001&#160;par
    value: 52,438, 61,798 and 61,798&#160;shares authorized, 43,284,
    56,671 and 58,191&#160;shares issued and outstanding as of
    December&#160;31, 2006, December&#160;29, 2007 and June&#160;28,
    2008 (unaudited), respectively; aggregate liquidation preference
    of $171,228 as of June&#160;28, 2008 (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    112,295
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    162,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    167,538
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Stockholders&#146; equity (deficit):
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Common stock, $0.001&#160;par value: 77,857, 87,386 and
    87,386&#160;shares authorized, 9,498, 9,901 and
    10,003&#160;shares issued and outstanding as of
    December&#160;31, 2006, December&#160;29, 2007 and June&#160;28,
    2008 (unaudited), respectively
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Additional paid-in capital
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,108
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,592
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,383
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Accumulated other comprehensive loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (135
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (241
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Accumulated deficit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (108,272
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (133,798
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (149,060
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total stockholders&#146; equity (deficit)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (106,172
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (130,331
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (144,908
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total liabilities, convertible preferred stock and
    stockholders&#146; equity (deficit)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    36,493
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    54,776
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    49,678
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See accompanying notes.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>
<A name='302'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Consolidated
    Statements of Operations</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(in
    thousands, except per share amounts)</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="46%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Six Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Revenue:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Product revenue (includes product revenue from related parties
    of $205, $241, $15, $0&#160;and $96, respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,076
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,959
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,489
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,382
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Collaboration revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,568
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,376
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    460
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    310
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Grant revenue (includes grant revenue from related parties of
    $0, $879, $1,758, $843 and $810, respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,063
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,364
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,198
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Total revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,674
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,997
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,520
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Costs and expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Cost of product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,764
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,773
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,514
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,490
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,988
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Research and development (includes research and development
    expenses from related parties of $84, $128, $100, $50 and $50,
    respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,449
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,389
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,053
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,151
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Selling, general and administrative (includes selling, general
    and administrative expense from related parties of $946, $809,
    $660, $288 and $616, respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,955
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,898
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,183
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,843
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Total costs and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,168
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,801
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,726
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,982
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Loss from operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,494
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,663
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,526
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11,729
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,462
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Interest expense (includes interest to related parties of $160,
    $445, $1,286, $980 and $417)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (898
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,261
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,790
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,790
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,100
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,140
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Other income (expense), net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (194
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (170
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (214
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Loss before provision for income taxes and cumulative effect of
    change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,022
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,346
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,917
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,219
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Provision for income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (105
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (52
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (43
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Loss before cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,022
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,969
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,262
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    637
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (12,969
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (15,262
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Net loss per share of common stock before cumulative effect of
    change in accounting principle, basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.89
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.53
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.35
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.54
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Cumulative effect of change in accounting principle, basic and
    diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.07
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Net loss per share of common stock, basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.82
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.53
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.35
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.54
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Shares used in computing net loss per share of common stock,
    basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,316
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,577
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,912
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See accompanying notes.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 100%; margin-left: 0%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- landscape -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <A name='303'><B>Consolidated Statements of Convertible
    Preferred Stock and Stockholders&#146; Equity (Deficit)</B>
</DIV>
</A>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(in
    thousands, except per share amounts)</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 7pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- TABLE 01 -->
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="55%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Accumulated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Convertible<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Additional<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Preferred Stock</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Common Stock</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Paid-In<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Comprehensive<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Accumulated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Stockholders&#146;<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Amount</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Amount</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Capital</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Income (Loss)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Deficit</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Equity (Deficit)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Balance as of January&#160;1, 2005
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32,845
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    76,596
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,929
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,870
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (68,334
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (65,471
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Issuance of common stock upon exercise of stock options for cash
    and for vesting of stock options that were exercised early
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    170
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Issuance of Series&#160;D convertible preferred stock for cash
    at $2.80 per share, net of issuance costs of $11
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,042
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Issuance of common stock for services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Stock-based compensation expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Issuance of convertible preferred stock warrants in connection
    with financing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Issuance of Series&#160;D convertible preferred stock upon
    conversion of promissory note at $2.80 per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    833
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,328
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Reclassification of convertible preferred stock warrants to
    liabilities upon adoption of FSP
    <FONT style="white-space: nowrap">150-5</FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,473
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,473
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Comprehensive loss:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 28pt">
    Foreign currency translation adjustment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 28pt">
    Unrealized gain on available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 28pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Total comprehensive loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,349
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Balance as of December&#160;31, 2005
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,267
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,966
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,179
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,536
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (84,719
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (83,154
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Issuance of common stock upon exercise of stock options for cash
    and for vesting of stock options that were exercised early
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    443
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    190
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    190
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Repurchase of common stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (124
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (69
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (69
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Issuance of Series&#160;D convertible preferred stock at $2.80
    per share upon exercise of warrants
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    268
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    729
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Issuance of Series&#160;E convertible preferred stock for cash
    at $4.00 per share, net of issuance costs of $133
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,535
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,003
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Issuance of Series&#160;D convertible preferred stock at $2.80
    per share under license agreement, net of issuance costs of $3
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    214
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    597
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Stock-based compensation expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Beneficial conversion feature for convertible promissory notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    306
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    306
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Comprehensive loss:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 28pt">
    Foreign currency translation adjustment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (36
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (36
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 28pt">
    Unrealized loss on available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 28pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Total comprehensive loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,590
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Balance as of December&#160;31, 2006
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,284
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    112,295
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,498
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,108
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (108,272
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (106,172
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (75
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (75
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Issuance of common stock upon exercise of stock options for cash
    and for vesting of stock options that were exercised early
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    297
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    146
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Issuance of Series&#160;E convertible preferred stock for cash
    at $4.00 per share, net of issuance costs of $1,189
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,276
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    35,911
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Issuance of common stock for services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    106
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Stock-based compensation expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    708
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    708
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Issuance of Series&#160;D convertible preferred stock upon
    conversion of promissory note at $2.80 per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,157
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,240
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Issuance of Series&#160;E convertible preferred stock upon
    conversion of promissory notes at $3.60 per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,954
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,636
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Beneficial conversion feature for convertible promissory notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    485
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    485
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Comprehensive loss:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Foreign currency translation adjustment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (107
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (107
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Unrealized loss on available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Total comprehensive loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,569
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Balance as of December&#160;29, 2007 (carried forward)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    162,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,901
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,592
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (135
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (133,798
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (130,331
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See accompanying notes.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 100%; margin-left: 0%"><!-- BEGIN PAGE WIDTH -->
<!-- landscape -->
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Consolidated Statements of Convertible Preferred Stock and
    Stockholders&#146; Equity (Deficit)&#160;&#151; (Continued)</B>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(in
    thousands, except per share amounts)</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 7pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- TABLE 01 -->
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="55%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Accumulated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Convertible<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Additional<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Preferred Stock</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Common Stock</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Paid-In<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Comprehensive<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Accumulated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Stockholders&#146;<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Amount</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Amount</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Capital</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Income (Loss)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Deficit</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Equity (Deficit)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Balance as of December&#160;29, 2007 (brought forward)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    162,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,901
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,592
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (135
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (133,798
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (130,331
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Issuance of common stock upon exercise of stock options for cash
    and for vesting of stock options that were exercised early
    (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Stock-based compensation expense (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Repurchase of common stock (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (123
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (290
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (290
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Issuance of Series&#160;E convertible preferred stock upon
    conversion of promissory notes at $3.60 per share (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,504
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,414
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Issuance of Series&#160;C convertible preferred stock at $2.18
    per share upon net-share exercise of warrants (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Comprehensive loss:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Foreign currency translation adjustment (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (116
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (116
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Unrealized gain on available-for-sale securities (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Net loss (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,262
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,262
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Total comprehensive loss (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,368
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Balance as of June&#160;28, 2008 (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58,191
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    167,538
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,003
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,383
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (241
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (149,060
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (144,908
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See accompanying notes.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>
<A name='304'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Consolidated
    Statements of Cash Flows</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(in
    thousands)</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="59%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Six Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Operating activities</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (12,969
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (15,262
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Adjustments to reconcile net loss to net cash used in operating
    activities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Depreciation and amortization
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,309
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,379
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,643
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    832
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    837
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Stock-based compensation expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    708
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    373
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Foreign exchange gain
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (141
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Adjustment to fair value of convertible preferred stock warrants
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (72
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    138
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    245
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    359
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Loss on retirement of property and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    111
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Amortization of debt discount and issuance cost
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    495
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    374
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    402
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Issuance of common stock for services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    136
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Issuance of convertible preferred stock under license agreement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    597
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (637
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Changes in assets and liabilities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Accounts receivable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (287
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (400
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (135
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (470
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (560
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Inventories
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    152
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (955
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,460
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,396
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,514
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Prepaid expenses and other assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (75
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (78
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,552
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (847
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,255
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Accounts payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    773
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (575
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,537
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    457
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    506
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Deferred revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,202
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    533
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,618
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,050
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (308
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Other liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (320
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    272
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,428
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,031
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    962
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net cash used in operating activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,292
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22,306
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,759
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11,440
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,972
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Investing activities</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Purchases of available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (500
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,990
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,286
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,511
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Maturities of available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,249
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,987
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,267
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Sales of available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,650
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,013
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Restricted cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    95
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    625
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Purchase of property and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,656
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,932
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (973
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (374
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (217
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net cash provided by (used in) investing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,838
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,943
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,740
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,177
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Financing activities</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Proceeds from long-term debt
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,651
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Repayment of long-term debt
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,745
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,000
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,503
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,868
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,442
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Proceeds from exercise of stock options
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    190
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Proceeds from issuance of convertible preferred stock, net of
    issuance costs
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,042
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,003
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    35,911
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,873
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Proceeds from issuance of convertible promissory notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Repurchase of common stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (69
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net cash provided by financing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,994
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31,124
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,555
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,034
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,638
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Effect of exchange rate changes on cash and cash equivalents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (19
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (33
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net increase (decrease) in cash and cash equivalents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,538
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,856
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,059
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,294
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,111
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cash and cash equivalents as of beginning of period
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,624
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,162
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,077
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cash and cash equivalents as of end of period
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    19,162
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    25,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    34,077
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    18,724
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    28,966
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Supplemental disclosures of cash flow information</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cash paid for interest
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,826
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,523
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    944
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    642
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Conversion of convertible promissory notes into convertible
    preferred stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,328
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    13,876
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    13,876
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,414
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cashless net exercise of convertible preferred stock warrants
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    729
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    42
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Issuance of warrants in connection with long-term debt
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    104
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    484
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Issuance of convertible preferred stock under license agreement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    597
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See accompanying notes.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->FLUIDIGM
    CORPORATION</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->
<A name='305'>
<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Notes
    to Consolidated Financial Statements</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->
</A>
<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->1.&#160;&#160;</FONT><!-- /FONT#008 --></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Description
    of Business</FONT><!-- /FONT#008 --></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Fluidigm Corporation (the Company) was incorporated in the state
    of California on May&#160;19, 1999, to commercialize
    microfluidic technology initially developed at the California
    Institute of Technology. In July 2007, the Company was
    reincorporated in Delaware. The Company&#146;s headquarters are
    located in South San&#160;Francisco, California.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The Company develops, manufactures and markets proprietary
    Integrated Fluidic Circuit systems that significantly improve
    the productivity of life science research. The Company&#146;s
    Integrated Fluidic Circuits (IFCs), enable the simultaneous
    performance of thousands of biochemical measurements in
    extremely minute volumes. The Company created this
    &#147;integrated circuit for biology&#148; by miniaturizing,
    integrating and automating sophisticated liquid handling
    processes on a single microfabricated device. The Company&#146;s
    customers include many leading biotechnology and pharmaceutical
    companies, academic institutions, and life science laboratories
    worldwide.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The Company has incurred significant net losses since inception.
    As of June&#160;28, 2008, the Company had an accumulated deficit
    of approximately $149.1&#160;million and cash, cash equivalents
    and available-for-sale securities of approximately
    $32.5&#160;million. The Company expects to incur significant
    expenses to fund operations to develop new products and to
    support existing product sales. Failure to generate sufficient
    revenues, achieve planned gross margins, control operating
    costs, or to raise sufficient additional funds may require the
    Company to modify, delay, or abandon some of its future
    expansion or expenditures, which could have a material adverse
    effect on the Company&#146;s business, operating results,
    financial condition, and ability to achieve its intended
    business objectives.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->2.&#160;&#160;</FONT><!-- /FONT#008 --></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Summary
    of Significant Accounting Policies</FONT><!-- /FONT#008 --></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Basis
    of Presentation and Consolidation</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The consolidated financial statements of the Company have been
    prepared in conformity with U.S.&#160;generally accepted
    accounting principles and include the accounts of the Company
    and its wholly owned subsidiaries. The Company has wholly owned
    subsidiaries in Singapore, the Netherlands, Japan, France and
    the United Kingdom. All subsidiaries, except for Singapore, use
    their local currency as their functional currency. The Singapore
    subsidiary uses the U.S.&#160;dollar as its functional currency.
    All intercompany transactions and balances have been eliminated
    in consolidation.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Fiscal
    Year</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    During 2007, the Company adopted a 52 or 53&#160;week year
    convention for its fiscal years and, therefore, the 2007 fiscal
    year ended on December&#160;29, 2007 and the quarterly periods
    for 2007 ended on March&#160;31, June&#160;30 and
    September&#160;29. For 2008, the quarterly periods end on
    March&#160;29, June&#160;28 and September&#160;27. Future fiscal
    years will end on the last Saturday in December of each
    respective year. Prior to 2007, the Company used a calendar
    year. The fiscal years presented in these consolidated financial
    statements ended on December&#160;31, 2005, December&#160;31,
    2006 and December&#160;29, 2007.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Unaudited
    Interim Financial Information</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The accompanying interim consolidated balance sheet as of
    June&#160;28, 2008, the interim consolidated statements of
    operations and cash flows for the six months ended June&#160;30,
    2007 and June&#160;28, 2008 and the interim consolidated
    statements of convertible preferred stock and stockholders&#146;
    equity (deficit) for the six months ended June&#160;28, 2008 are
    unaudited. The unaudited interim consolidated financial
    statements have been prepared on the same basis as the annual
    consolidated financial statements and, in the opinion of
    management, reflect all adjustments, which include only normal
    recurring adjustments, necessary to present fairly the
    Company&#146;s financial position as of June&#160;28, 2008 and
    its results of operations and its cash flows for the six months
    ended June&#160;30, 2007 and June&#160;28, 2008. The financial
    data and the other financial information disclosed in these
    notes to the consolidated financial statements
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-8
</DIV><!-- /DIV#050 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->FLUIDIGM
    CORPORATION</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Notes
    to Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->
<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#059 -->&nbsp;</DIV><!-- /DIV#026 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    related to the six month periods are unaudited. The results of
    operations for the six months ended June&#160;28, 2008 are not
    necessarily indicative of the results to be expected for 2008 or
    any other interim period or for any other future year.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Use
    of Estimates</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The preparation of consolidated financial statements requires
    management to make estimates and assumptions that affect the
    amounts reported in the consolidated financial statements and
    accompanying notes. The Company regularly assesses these
    estimates which affect the fair value of undelivered elements
    for revenue recognition purposes, the valuation of accounts
    receivable, the valuation of inventories, accrued liabilities,
    the fair value of the Company&#146;s convertible preferred stock
    and common stock, warrants, stock-based compensation, beneficial
    conversion features, and valuation allowances associated with
    deferred tax assets. The Company bases its estimates on
    historical experience and on various other assumptions believed
    to be reasonable, the results of which form the basis for making
    judgments about the carrying values of assets and liabilities.
    Actual results could differ materially from these estimates.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Foreign
    Currency</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Assets and liabilities of
    <FONT style="white-space: nowrap"><!-- FONT#006 -->non-U.S.&#160;subsidiaries</FONT><!-- /FONT#006 -->
    that use the local currency as their functional currency are
    translated into U.S.&#160;dollars at exchange rates in effect at
    the balance sheet date, with the resulting translation
    adjustments recorded to a separate component of accumulated
    other comprehensive income (loss) within stockholders&#146;
    equity. Income and expense accounts are translated at average
    exchange rates during the year. Foreign currency transaction
    gains and losses for
    <FONT style="white-space: nowrap"><!-- FONT#006 -->non-U.S.&#160;subsidiaries</FONT><!-- /FONT#006 -->
    that use the U.S.&#160;dollar as their functional currency are
    recognized in other income (expense), net. The Company had net
    foreign currency transaction losses of $27,000, $70,000 and
    $64,000 during 2005, 2006 and the six months ended June&#160;30,
    2007, respectively, and net foreign currency transaction gains
    of $72,000 and $141,000 during 2007 and the six months ended
    June&#160;28, 2008, respectively.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Cash
    and Cash Equivalents</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The Company considers all highly liquid financial instruments
    with maturities at the time of purchase of three months or less
    to be cash equivalents. Cash and cash equivalents consist of
    cash on deposit with banks, money market funds, commercial
    paper, corporate notes, and notes from government-sponsored
    agencies.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Available-for-Sale
    Securities</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Available-for-sale securities are comprised of corporate notes
    and notes from government-sponsored agencies. Investments
    classified as &#147;available-for-sale&#148; and are recorded at
    estimated fair value, as determined by quoted market rates, on
    the consolidated balance sheets with any unrealized gains and
    losses reported in stockholders&#146; equity as a component of
    accumulated other comprehensive income (loss). Realized gains
    and losses and declines in the fair value of available-for-sale
    securities below their cost that are deemed to be &#147;other
    than temporary&#148; are reflected in interest income. No
    &#147;other than temporary&#148; unrealized losses have been
    incurred to date and realized gains and losses were immaterial
    during the years presented. The cost of securities sold is based
    on the specific-identification method.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Restricted
    Cash</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The Company had restricted cash balances of $900,000, $881,000
    and $256,000 as of December&#160;31, 2006, December&#160;29,
    2007 and June&#160;28, 2008, respectively. Included in
    restricted cash is cash amounts that collateralize the
    Company&#146;s standby letters of credit issued under operating
    lease agreements for office facilities that it currently
    occupies.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-9
</DIV><!-- /DIV#050 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->FLUIDIGM
    CORPORATION</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Notes
    to Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->
<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#059 -->&nbsp;</DIV><!-- /DIV#026 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Fair
    Value of Financial Instruments</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    As of December&#160;31, 2006, December&#160;29, 2007 and
    June&#160;28, 2008, the respective carrying values of the
    Company&#146;s financial instruments, including accounts
    receivable, restricted cash, and accounts payable, approximated
    their fair values due to their short period of time to maturity
    or repayment. Based on borrowing rates currently available to
    the Company for loans with similar terms, the carrying value of
    long-term debt and convertible promissory notes approximated
    their fair values.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    SFAS&#160;No.&#160;157, <I>Fair Value Measurement</I>
    (SFAS&#160;157), clarifies that fair value is an exit price,
    representing the amount that would be received to sell an asset
    or paid to transfer a liability in an orderly transaction
    between market participants. As such, fair value is a
    market-based measurement that should be determined based on
    assumptions that market participants would use in pricing an
    asset or liability. As a basis for considering such assumptions,
    SFAS&#160;157 establishes a three-tier value hierarchy, which
    prioritizes the inputs used in measuring fair value as follows:
    (Level I) observable inputs such as quoted prices in active
    markets; (Level II) inputs other than the quoted prices in
    active markets that are observable either directly or
    indirectly; and (Level III) unobservable inputs in which there
    is little or no market data, which requires the Company to
    develop its own assumptions. This hierarchy requires the Company
    to use observable market data, when available, and to minimize
    the use of unobservable inputs when determining fair value. The
    Company&#146;s financial assets that are measured at fair value
    on a recurring basis consist of cash equivalents and
    available-for-sale securities. The Company&#146;s liabilities
    that are measured at fair value on a recurring basis consist of
    convertible preferred stock warrant liabilities.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    All of the Company&#146;s cash equivalents and
    available-for-sale securities are classified within Level I or
    Level II of the fair value hierarchy because they are valued
    using quoted market prices, market prices for similar
    securities, or alternative pricing sources with reasonable
    levels of price transparency. Instruments valued based on quoted
    market prices in active markets, i.e. level I, include the
    Company&#146;s money market funds. Instruments valued based on
    other observable inputs, i.e. level II, include notes from
    government-sponsored agencies, corporate notes and commercial
    paper. The Company&#146;s convertible preferred stock warrant
    liabilities are classified within Level III of the fair value
    hierarchy.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The changes in the value of the convertible preferred stock
    warrant liabilities were as follows (in thousands):
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="92%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    Fair value as of December&#160;29, 2007
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    468
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    Issuances or settlements
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    442
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    Change in fair value
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    359
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    Fair value as of June&#160;28, 2008
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,269
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->

</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The valuation of the convertible preferred stock warrants are
    discussed in Note 8.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Accounts
    Receivable</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Trade accounts receivable are recorded at net invoice value. The
    Company considers receivables past due based on the contractual
    payment terms. The Company reviews its exposure to accounts
    receivable and reserves specific amounts if collectibility is no
    longer reasonably assured based on historical experience and
    specific customer collection issues. The Company reevaluates
    such reserves on a regular basis and adjusts its reserves as
    needed. Write-offs of accounts receivable were insignificant
    during 2005, 2006, 2007 and the six months ended June&#160;30,
    2007 and June&#160;28, 2008.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Concentrations
    of Credit Risk</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Financial instruments that potentially subject the Company to
    credit risk consist of cash, cash equivalents,
    available-for-sale securities, and accounts receivable. The
    Company maintains cash, cash equivalents, and
</DIV><!-- /DIV#030 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-10
</DIV><!-- /DIV#051 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->FLUIDIGM
    CORPORATION</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Notes
    to Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->
<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#059 -->&nbsp;</DIV><!-- /DIV#026 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    available-for-sale securities with major financial institutions.
    The Company&#146;s cash, cash equivalents, and
    available-for-sale securities consist of deposits held with
    banks, commercial paper, money market funds, and other highly
    liquid investments that, at times, exceed federally insured
    limits. The Company performs periodic evaluations of its
    investments and the relative credit standing of these financial
    institutions and limits the amount of credit exposure with any
    one institution.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The Company does not require collateral to support credit sales.
    To reduce credit risk, the Company performs periodic credit
    evaluations of its customers. The Company has had no credit
    losses to date. Customers with revenues of 10% or greater of
    total revenues for 2005, 2006, 2007 and the six months ended
    June&#160;30, 2007 and June&#160;28, 2008 are as follows:
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="60%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="16" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Percentage of Total Revenue</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Six Months<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Six Months<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B>Customers:</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    A
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    24%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    B
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    C
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    D
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->

</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV style="font-size: 1pt; margin-left: 0%;  align: left; border-bottom: 1pt solid #000000"><!-- DIV#071 --></DIV><!-- /DIV#041 --><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    * </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents less than 10% of total revenues.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The Company&#146;s products include components that are
    currently available from a single source or a limited number of
    sources. The Company believes that other vendors would be able
    to provide similar components; however, the qualification of
    such vendors may require
    <FONT style="white-space: nowrap"><!-- FONT#006 -->start-up</FONT><!-- /FONT#006 -->
    time. In order to mitigate any adverse impacts from a disruption
    of supply, the Company attempts to maintain an adequate supply
    of critical limited-sourced components.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Inventories</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Inventories are stated at the lower of cost (which approximates
    actual cost on a
    <FONT style="white-space: nowrap"><!-- FONT#006 -->first-in,</FONT><!-- /FONT#006 -->
    first-out method) or market. Inventories include raw materials,
    <FONT style="white-space: nowrap"><!-- FONT#006 -->work-in-process,</FONT><!-- /FONT#006 -->
    and finished goods that may be used in the research and
    development process, and such items are expensed when they are
    designated for use in research and development. Provisions for
    slow moving, excess, and obsolete inventories are recorded based
    on product life cycle, development plans, product expiration,
    and quality issues.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Property
    and Equipment</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Property and equipment, including leasehold improvements, are
    stated at cost less accumulated depreciation, which is
    calculated using the straight-line method over the estimated
    useful lives of the assets, which range from three to five
    years. Leasehold improvements are amortized using the
    straight-line method over the estimated useful lives of the
    assets or the remaining term of the lease, whichever is shorter.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    In accordance with SFAS&#160;No.&#160;144, <I>Accounting for the
    Impairment or Disposal of Long-Lived Assets</I>, if indicators
    of impairment exist, the Company assesses the recoverability of
    the affected long-lived assets by determining whether the
    carrying value of such assets can be recovered through
    undiscounted future operating cash flows. If impairment is
    indicated, the Company measures the future discounted cash flows
    associated with the use of the asset and adjusts the value of
    the asset accordingly. While the Company&#146;s current and
    historical operating and cash flow losses are indicators of
    impairment, the Company believes the future cash flows to be
    received from the long-lived assets recorded as of June&#160;28,
    2008 will exceed the assets&#146; carrying value, and,
    accordingly, the Company has not recognized any impairment
    losses through June&#160;28, 2008.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-11
</DIV><!-- /DIV#050 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->FLUIDIGM
    CORPORATION</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Notes
    to Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->
<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#059 -->&nbsp;</DIV><!-- /DIV#026 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Reserve
    for Product Warranties</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The Company generally provides a one-year warranty on
    instruments. The Company reviews its exposure to estimated
    warranty expenses associated with instrument sales and
    establishes an accrual based on historical product failure rates
    and actual warranty costs incurred. This expense is recorded as
    a component of cost of product revenue in the consolidated
    statements of operations. Warranty accruals and expenses were
    immaterial for all periods presented.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Revenue
    Recognition</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The Company generates revenue from sales of its products and
    services. The Company&#146;s products consist of single-use
    IFCs, various instruments, software, and reagents. The
    Company&#146;s services include instrument installation,
    training, and customer support services. The Company has also
    entered into a number of research and development agreements and
    received government grants to conduct research and development
    activities.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The Company records revenue in accordance with the guidelines
    established by the Securities and Exchange Commission (SEC)
    Staff Accounting Bulletin&#160;No.&#160;104, <I>Revenue
    Recognition </I>(SAB&#160;104). In addition, the Company has
    concluded that pursuant to AICPA Statement of Position
    <FONT style="white-space: nowrap"><!-- FONT#006 -->97-2,</FONT><!-- /FONT#006 -->
    <I>Software Revenue Recognition
    </I><FONT style="white-space: nowrap"><!-- FONT#006 -->(SOP&#160;97-2),</FONT><!-- /FONT#006 -->
    software included with certain of its instruments is more than
    incidental to their functionality. Accordingly, the Company
    applies
    <FONT style="white-space: nowrap"><!-- FONT#006 -->SOP&#160;97-2</FONT><!-- /FONT#006 -->
    to sales of such instruments and related deliverables. Revenue
    is recognized when all of the following criteria are met:
    persuasive evidence of an arrangement exists, delivery has
    occurred or services rendered, the seller&#146;s price to the
    buyer is fixed or determinable, and collectibility is reasonably
    assured.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><I><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Product
    Revenue</FONT><!-- /FONT#008 --></I></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The Company sells instruments in arrangements that may include
    related installation and training, customer support services and
    software and may also include single-use IFCs. If the
    arrangement includes IFCs, the Company uses the separation
    criteria in EITF Issue
    <FONT style="white-space: nowrap"><!-- FONT#006 -->No.&#160;00-21,</FONT><!-- /FONT#006 -->
    <I>Revenue Arrangements with Multiple Deliverables</I>, to
    separate revenues related to IFCs, which are non-software
    related deliverables, from software related deliverables. IFC
    revenue is recognized upon delivery. Revenue from software
    related deliverables is recognized in accordance with
    <FONT style="white-space: nowrap"><!-- FONT#006 -->SOP&#160;97-2</FONT><!-- /FONT#006 -->
    and related pronouncements. Under
    <FONT style="white-space: nowrap"><!-- FONT#006 -->SOP&#160;97-2,</FONT><!-- /FONT#006 -->
    the Company recognizes revenue for delivered elements only when
    it determines that undelivered elements are not essential to the
    functionality of the delivered elements and the vendor-specific
    objective evidence (VSOE) of fair values of undelivered elements
    are known. Installation is deemed essential to the functionality
    of certain instruments; for those instruments recognition of
    revenue begins after installation has been completed. Fair value
    of undelivered elements is established by reference to VSOE
    which is based on stand-alone sales of such elements. If any
    undelivered element does not have VSOE of fair value, revenue is
    deferred until all of such elements are delivered, or until VSOE
    of fair value can objectively be determined for any remaining
    undelivered elements. However, if the only undelivered element
    is post-contract customer support services, such as those
    included in the Company&#146;s maintenance agreements, revenue
    on the software related deliverables is recognized ratably over
    the service period. When revenues are deferred, the
    corresponding costs of products sold are also deferred in other
    assets in the consolidated financial statements and recognized
    over the same period. If VSOE of fair value exists for all
    undelivered elements, but does not exist for the delivered
    elements in the arrangement, revenue is allocated to the
    undelivered elements based on their VSOE of fair values, with
    the residual amount allocated to the delivered elements and
    recognized upon their delivery.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    During 2005, 2006, 2007 and the six months ended June&#160;28,
    2008, the Company did not have VSOE of fair value for software
    support services. Therefore, revenue and the corresponding costs
    of software-related deliverables is deferred and recognized over
    the customer support period ranging from one to three years. All
    revenue from these arrangements has been classified as product
    revenue in the statements of operations, as the amount
    attributed to services was immaterial.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-12
</DIV><!-- /DIV#050 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->FLUIDIGM
    CORPORATION</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Notes
    to Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->
<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#059 -->&nbsp;</DIV><!-- /DIV#026 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    In 2007 and thereafter, no right of return has existed for the
    Company&#146;s products. In prior years, if there was a right of
    return, the entire revenue from the arrangement was deferred
    until the right had lapsed. The Company has not experienced any
    significant returns of its products. Accruals are provided for
    anticipated warranty expenses at the time the associated revenue
    is recognized. Amounts received in advance of when revenue
    recognition criteria are met are recorded as deferred revenue on
    the consolidated balance sheets.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The Company sells its products to third-party resellers located
    in certain international markets. From time to time, these
    arrangements may be subject to contingencies such as completion
    of the instrument delivery to or installation at the end
    customer. The Company recognizes revenue on sales of products to
    the resellers if all revenue recognition criteria have been met
    and any contingency provisions related to the sale have been
    satisfied.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><I><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Collaboration
    Revenue</FONT><!-- /FONT#008 --></I></B>
</DIV><!-- /DIV#031 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The Company has entered into agreements with third parties,
    including government entities, to provide research and
    development services. Fixed-fee research and development
    agreements generally provide the Company with up-front and
    periodic milestone fees. Variable-fee research and development
    agreements generally provide the Company with fees based upon
    agreed upon rates for time incurred by research staff. Under
    <FONT style="white-space: nowrap"><!-- FONT#006 -->EITF&#160;00-21,</FONT><!-- /FONT#006 -->
    the Company evaluates whether these arrangements contain
    multiple units of accounting by evaluating whether delivered
    elements have value on a stand-alone basis and whether there is
    objective and reliable evidence of fair value of the undelivered
    items. During 2005, 2006, 2007 and the six months ended
    June&#160;28, 2008, the Company concluded that these
    arrangements consisted of a single unit of accounting, namely,
    research and development services. Accordingly, the Company
    recognizes the fees under these arrangements over the period the
    Company performs these services. Costs associated with the
    research and development agreements are included in research and
    development expense.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><I><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Grant
    Revenue</FONT><!-- /FONT#008 --></I></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Government grants provide the Company with incentive payments
    for certain types of research and development activities
    performed over a contractually defined period. Revenue from
    government grants is recognized during the period during which
    the related costs are incurred, provided that the conditions
    under which the government grants were provided have been met
    and the Company has only perfunctory obligations outstanding.
    Amounts received in advance of when revenue recognition criteria
    are met are recorded as deferred revenue on the consolidated
    balance sheets. Costs associated with the grants are included in
    research and development expense.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Shipping
    and Handling Costs</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Shipping and handling costs incurred for product shipments are
    included within cost of product revenue in the consolidated
    statements of operations.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Research
    and Development</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The Company expenses research and development expenditures in
    the period incurred. Research and development expense consists
    of personnel costs, independent contractor costs, prototype
    expenses, and allocated facilities and information technology
    expenses. These costs include direct and research-related
    overhead expenses.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Advertising
    Costs</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The Company expenses advertising costs as incurred. The Company
    incurred advertising costs of $237,000, $324,000, $701,000,
    $349,000 and $629,000 during 2005, 2006, 2007 and the six months
    ended June&#160;30, 2007 and June&#160;28, 2008, respectively.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-13
</DIV><!-- /DIV#050 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->FLUIDIGM
    CORPORATION</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Notes
    to Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->
<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#059 -->&nbsp;</DIV><!-- /DIV#026 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Income
    Taxes</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The Company uses the liability method to account for income
    taxes, whereby deferred income taxes reflect the impact of
    temporary differences for items recognized for financial
    reporting purposes over different periods than for income tax
    purposes. Valuation allowances are provided when the expected
    realization of deferred tax assets does not meet a &#147;more
    likely than not&#148; criterion.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The Company adopted Financial Accounting Standards Board (FASB)
    Interpretation No.&#160;48, <I>Accounting for Uncertainties in
    Income Taxes&#160;&#151; an interpretation of FASB Statement
    No.&#160;109 </I>(FIN&#160;48), effective January&#160;1, 2007.
    FIN&#160;48 requires that the Company recognize the financial
    statement effects of a tax position when it is more likely than
    not, based on the technical merits, that the position will be
    sustained upon examination. Upon adoption, the Company recorded
    a charge of $75,000 as a cumulative effect of a change in
    accounting principle in the accumulated deficit during 2007.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Stock-Based
    Compensation</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Prior to January&#160;1, 2006, the Company accounted for its
    employee stock option plans using the intrinsic value method
    prescribed by Accounting Principles Board Opinion No.&#160;25,
    <I>Accounting for Stock Issued to Employees </I>(APB 25), which
    required the Company to recognize the difference between the
    exercise price of an employee option and the fair value of the
    underlying common stock as of the grant date. The resulting
    stock-based compensation expense, if any, was recorded on the
    date of the grant in stockholders&#146; equity as deferred
    compensation and amortized to expense over the vesting period of
    the grant, which was generally four years.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    In December 2004, the FASB issued SFAS&#160;No.&#160;123
    (revised 2004), <I>Share-Based Payment </I>(SFAS&#160;123(R)),
    that addresses the accounting for stock-based payment
    transactions in which a company receives services in exchange
    for equity instruments, including stock options. The Company
    adopted SFAS&#160;123(R) beginning January&#160;1, 2006 using
    the prospective-transition method, as options granted prior to
    January&#160;1, 2006 were measured using the minimum value
    method for the pro forma disclosures previously required by
    SFAS&#160;No.&#160;123, <I>Accounting for Stock-Based
    Compensation </I>(SFAS&#160;123). Under the
    prospective-transition method, the Company continues to apply
    APB 25 to employee equity awards outstanding at the date of the
    Company&#146;s adoption of SFAS&#160;123(R). Any compensation
    costs recognized from January&#160;1, 2006 onward consists of:
    (a)&#160;compensation cost for all stock-based awards granted
    prior to, but not vested as of, December&#160;31, 2005 based on
    the intrinsic value determined in accordance with the provisions
    of APB 25; and (b)&#160;compensation cost for all stock-based
    awards granted or modified subsequent to December&#160;31, 2005,
    net of estimated forfeitures, based on the grant date fair value
    estimated in accordance with the provisions of SFAS&#160;123(R).
    The Company recognizes stock-based compensation expense on a
    straight-line basis over the vesting period of the respective
    grants. In accordance with the prospective-transition method,
    results for prior periods have not been restated.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The Company applies SFAS&#160;123(R) and EITF Issue
    <FONT style="white-space: nowrap"><!-- FONT#006 -->No.&#160;96-18,</FONT><!-- /FONT#006 -->
    <I>Accounting for Equity Instruments That Are Issued to Other
    Than Employees for Acquiring, or in Conjunction with Selling,
    Goods or Services
    </I><FONT style="white-space: nowrap"><!-- FONT#006 -->(EITF&#160;96-18),</FONT><!-- /FONT#006 -->
    to options and other stock-based awards issued to nonemployees.
    In accordance with SFAS&#160;123(R) and
    <FONT style="white-space: nowrap"><!-- FONT#006 -->EITF&#160;96-18,</FONT><!-- /FONT#006 -->
    the Company uses the Black-Scholes option-pricing model to
    measure the fair value of the options at the measurement dates.
    The nonemployee options are subject to periodic reevaluation
    over their vesting terms.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Comprehensive
    Loss</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Comprehensive loss is comprised of net loss and other
    comprehensive income (loss). Other comprehensive income (loss)
    includes unrealized holding gains and losses on the
    Company&#146;s available-for-sale securities and foreign
    currency translation adjustments. Total comprehensive loss for
    all periods presented has been disclosed in the consolidated
    statements of convertible preferred stock and stockholders&#146;
    equity (deficit).
</DIV><!-- /DIV#030 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-14
</DIV><!-- /DIV#050 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->FLUIDIGM
    CORPORATION</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Notes
    to Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->
<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#059 -->&nbsp;</DIV><!-- /DIV#026 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Accumulated other comprehensive income (loss) consists of the
    following (in thousands):
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="47%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Unrealized gain (loss) on available-for-sale securities
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (12
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Foreign currency translation adjustment
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (123
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (239
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (17
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (135
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (241
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->

</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Convertible
    Preferred Stock Warrants</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Freestanding warrants related to shares that may be redeemable
    are accounted for in accordance with FASB Staff Position (FSP)
    <FONT style="white-space: nowrap"><!-- FONT#006 -->No.&#160;150-5,</FONT><!-- /FONT#006 -->
    <I>Issuer&#146;s Accounting Under FASB Statement No.&#160;150
    for Freestanding Warrants and Other Similar Instruments on
    Shares That Are Redeemable
    </I><FONT style="white-space: nowrap"><!-- FONT#006 -->(FSP&#160;150-5),</FONT><!-- /FONT#006 -->
    an interpretation of SFAS&#160;No.&#160;150, <I>Accounting for
    Certain Financial Instruments with Characteristics of Both
    Liabilities and Equity</I>. Under
    <FONT style="white-space: nowrap"><!-- FONT#006 -->FSP&#160;150-5,</FONT><!-- /FONT#006 -->
    freestanding warrants to purchase the Company&#146;s convertible
    preferred stock are classified as liabilities on the
    consolidated balance sheets and carried at fair value because
    the warrants may conditionally obligate the Company to transfer
    assets at some point in the future. The warrants are subject to
    remeasurement at each balance sheet date, and any change in fair
    value is recognized as a component of other income (expense),
    net in the consolidated statements of operations. The Company
    will continue to adjust the liability for changes in fair value
    until the earlier of the exercise or expiration of the warrants,
    the completion of a deemed liquidation event, conversion of
    preferred stock into common stock, or until the convertible
    preferred stockholders can no longer trigger a deemed
    liquidation event. At that time, the convertible preferred stock
    warrant liabilities will be reclassified to convertible
    preferred stock or additional paid-in capital.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    <FONT style="white-space: nowrap"><!-- FONT#006 -->FSP&#160;150-5</FONT><!-- /FONT#006 -->
    is effective for all periods beginning after June&#160;30, 2005,
    and accordingly, it was adopted by the Company on July&#160;1,
    2005. Upon adoption, the Company reclassified the fair value of
    its warrants to purchase shares of its convertible preferred
    stock as of the adoption date from additional paid-in capital to
    liabilities and recorded a gain of $637,000 as the cumulative
    effect of a change in an accounting principle in the
    consolidated statement of operations during 2005.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Net
    Loss per Share of Common Stock</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The Company&#146;s basic net loss per share of common stock is
    calculated by dividing the net loss by the weighted-average
    number of shares of common stock outstanding for the period. The
    weighted-average number of shares of common stock used to
    calculate the Company&#146;s basic net loss per share of common
    stock excludes those shares subject to repurchase related to
    stock options that were exercised prior to vesting as they are
    not deemed to be issued for accounting purposes until they vest.
    The diluted net loss per share of common stock is computed by
    dividing the net loss by the weighted-average number of common
    stock equivalents outstanding for the period determined using
    the treasury-stock method. For purposes of this calculation,
    convertible preferred stock, options to purchase common stock,
    common stock subject to repurchase, warrants to purchase
    convertible preferred stock, and shares of convertible preferred
    stock subject to conversion of the Company&#146;s convertible
    promissory notes are considered to be common stock equivalents
    but have been excluded from the calculation of diluted net loss
    per share of common stock as their effect is anti-dilutive.
</DIV><!-- /DIV#030 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-15
</DIV><!-- /DIV#050 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->FLUIDIGM
    CORPORATION</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Notes
    to Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->
<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#059 -->&nbsp;</DIV><!-- /DIV#026 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The following table sets forth the computation of net loss per
    share of common stock (in thousands, except per share amounts):
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="45%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>Six Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;30, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;28, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    <B>Historical</B>
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Numerator:
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Loss before cumulative effect of change in accounting principle
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (17,022
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (12,969
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (15,262
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Cumulative effect of change in accounting principle
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    637
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Net loss
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (12,969
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (15,262
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Denominator:
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Shares used in computing net loss per share of common stock,
    basic and diluted
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,316
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,577
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,912
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Net loss per share of common stock, basic and diluted:
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Net loss per share of common stock before cumulative effect of
    change in accounting principle, basic and diluted
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.89
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.53
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.35
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.54
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Cumulative effect of change in accounting principle, basic and
    diluted
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.07
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Net loss per share of common stock, basic and diluted
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.82
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.53
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.35
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.54
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->

</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The following outstanding shares of common stock equivalents
    were excluded from the computation of diluted net loss per share
    of common stock for the periods presented because including them
    would have been anti-dilutive.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="59%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>Six Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(Unaudited))</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Convertible preferred stock
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,267
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,284
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,876
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58,191
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Options to purchase common stock
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,050
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,985
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,434
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,353
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,309
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Common stock subject to repurchase
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    65
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Warrants to purchase convertible preferred stock
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,211
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    704
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    704
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    757
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Convertible promissory notes convertible into shares of
    convertible preferred stock
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,952
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,466
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,411
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->

</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Recent
    Accounting Pronouncements</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    In September 2006, the FASB issued SFAS&#160;157, which
    establishes a framework for measuring the fair value of assets
    and liabilities when required or permitted by other standards
    within generally accepted accounting principles in the United
    States but does not require any new fair value measurements.
    SFAS&#160;157 also expands disclosures about fair value
    measurements. SFAS&#160;157 is effective for all financial
    statements issued for fiscal years beginning
</DIV><!-- /DIV#030 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-16
</DIV><!-- /DIV#051 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    after November&#160;15, 2007. However, in February 2008 the FASB
    issued FSP
    <FONT style="white-space: nowrap">No.&#160;157-2</FONT>
    <FONT style="white-space: nowrap">(FSP&#160;157-2)</FONT>
    which allows companies to delay the effective date of
    SFAS&#160;157 for all nonfinancial assets and liabilities,
    except those that are recognized or disclosed at fair value in
    the financial statements on a recurring basis, until fiscal
    years beginning after November&#160;15, 2008. Generally, the
    provisions of this statement should be applied prospectively as
    of the beginning of the fiscal year in which this statement is
    initially applied. The Company adopted SFAS&#160;157 in
    accordance with the provisions in
    <FONT style="white-space: nowrap">FSP&#160;157-2</FONT>
    as of December&#160;30, 2007. The adoption of SFAS&#160;157 did
    not have a significant impact on the Company&#146;s consolidated
    financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2007, the FASB issued SFAS&#160;No.&#160;159, <I>The
    Fair Value Option for Financial Assets and Financial Liabilities
    </I>(SFAS&#160;159), including an amendment of
    SFAS&#160;No.&#160;115, A<I>ccounting for Certain Investments in
    Debt and Equity Securities</I>, which allows an entity to choose
    to measure certain financial instruments and liabilities at fair
    value. Subsequent measurements for the financial instruments and
    liabilities an entity elects to measure at fair value will be
    recognized in earnings. SFAS&#160;159 also establishes
    additional disclosure requirements. SFAS&#160;159 is effective
    for fiscal years beginning after November&#160;15, 2007. The
    Company adopted SFAS&#160;159 as of December&#160;30, 2007 but
    chose not to measure the financial instruments and liabilities
    permitted by the standard to be measured at fair value.
    Therefore, the adoption of SFAS&#160;159 did not have a
    significant impact on the Company&#146;s consolidated financial
    statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In December 2007, the FASB ratified EITF Issue
    <FONT style="white-space: nowrap">No.&#160;07-1,</FONT>
    <I>Accounting for Collaborative Agreements
    </I><FONT style="white-space: nowrap">(EITF&#160;07-1),</FONT>
    which addresses the accounting for participants in collaborative
    agreements, defined as contractual arrangements that involve a
    joint operating activity, that are conducted without the
    creation of a separate legal entity.
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    requires participants in a collaborative agreement to make
    separate disclosures for each period a statement of operations
    is presented regarding the nature and purpose of the agreement,
    the rights and obligations under the agreement, the accounting
    policy for the agreement, and the classification of and amounts
    arising from the agreement between participants. These
    arrangements involve two or more parties who are both active
    participants in the activity and are exposed to significant
    risks and rewards dependent on the commercial success of the
    activity.
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    provides that a company should report the effects of adoption as
    a change in accounting principle through retrospective
    application to all periods and requires specific additional
    disclosures.
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    is effective for interim and annual reporting periods beginning
    after December&#160;15, 2008. The Company is currently assessing
    the impact of the adoption of
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    on the Company&#146;s consolidated financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In June 2007, the FASB ratified EITF Issue
    <FONT style="white-space: nowrap">No.&#160;07-3,</FONT>
    <I>Accounting for Nonrefundable Advance Payments for Goods or
    Services to Be Used in Future Research and Development
    Activities
    </I><FONT style="white-space: nowrap">(EITF&#160;07-3).</FONT>
    <FONT style="white-space: nowrap">EITF&#160;07-3</FONT>
    provides clarification surrounding the accounting for
    nonrefundable research and development advance payments, whereby
    such payments should be recorded as an asset when the advance
    payment is made and recognized as an expense when the research
    and development activities are performed.
    <FONT style="white-space: nowrap">EITF&#160;07-3</FONT>
    is effective for interim and annual reporting periods beginning
    after December&#160;15, 2007. The Company adopted EITF 07-3 as
    of December&#160;30, 2007. The adoption of
    <FONT style="white-space: nowrap">EITF&#160;07-3</FONT>
    did not impact the Company&#146;s consolidated financial
    statements.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">3.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">License,
    Development, Collaboration and Grant Agreements</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">License
    Agreements</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In March 2003, the Company entered into a license agreement to
    obtain an exclusive worldwide license for certain technology
    regarding nanovolume crystallization arrays. The Company may, in
    its sole discretion, cancel the license agreement with a
    <FONT style="white-space: nowrap">30-day</FONT>
    notice; otherwise, the license terminates at the end of the life
    of the last patent to expire. Under the terms of the agreement,
    the Company is obligated to issue up to $2,100,000 of shares of
    the Company&#146;s common or convertible preferred stock if the
    Company achieves certain milestones. As a result of achieving
    one of these milestones during 2006, the Company issued
    214,285&#160;shares of Series&#160;D convertible preferred stock
    at $2.80 per share for an aggregate value of $597,000, net of
    issuance costs. During 2003, the Company also entered into a
    separate research sponsorship agreement under which the Company
    agreed to pay a total of $900,000 over 5&#160;years in 20
    quarterly installments of $45,000 to sponsor certain research.
    As of June&#160;28,
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-17
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->FLUIDIGM
    CORPORATION</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Notes
    to Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->
<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#059 -->&nbsp;</DIV><!-- /DIV#026 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    2008, the entire $900,000 had been paid. Following the final
    $45,000 payment, which was paid during the six months ended
    June&#160;28, 2008, the agreement terminated.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    In December 2003, the Company entered into a license agreement
    to obtain a nonexclusive worldwide license for certain
    technology regarding submicroliter protein crystallization. The
    Company may, in its sole discretion, cancel the agreement with a
    <FONT style="white-space: nowrap"><!-- FONT#006 -->30-day</FONT><!-- /FONT#006 -->
    notice; otherwise, the license terminates at the end of the life
    of the last licensed patent to expire. Pursuant to the
    agreement, the Company made four payments for annual
    nonrefundable license fees, each in the amount of $250,000,
    beginning in January 2004 with subsequent payments made in
    January 2005, 2006 and 2007. Also pursuant to the agreement, the
    Company began making quarterly payments in the amount of $25,000
    starting in the first quarter of 2007. These quarterly payments,
    which are scheduled to continue until the agreement is
    terminated, could increase in future periods if the Company
    meets certain sales volumes. The annual nonrefundable license
    fee payments were recorded as expense during the year in which
    they were paid.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Development
    Agreements</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    In June 2004, the Company entered into a development agreement
    to evaluate two application areas of interest. Under the
    agreement, the Company performed research and development
    services, manufactured prototypes, and licensed certain
    nonexclusive rights. In addition, the Company issued a fully
    vested warrant to purchase 507,407&#160;shares of Series&#160;D
    convertible preferred stock at $2.80 per share (see
    Note&#160;8). As consideration, the Company received payments
    totaling $1,500,000 during 2004 and 2005. The Company determined
    that the license, research and development services, and
    prototypes should be accounted for as a combined unit of
    accounting and recognized the revenues ratably over the
    <FONT style="white-space: nowrap"><!-- FONT#006 -->12-month</FONT><!-- /FONT#006 -->
    project period. The fair value of the warrant issued was
    estimated to be $750,000, as determined using the Black-Scholes
    option-pricing model, and was recognized as a reduction to the
    collaboration revenue. The Company recognized collaboration
    revenue of $366,000 and $384,000 related to this agreement
    during 2004 and 2005, respectively. The agreement terminated
    during 2005.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    In June 2005, the Company entered into another development
    agreement to develop another application area of interest. Under
    the agreement, the Company performed research and development
    services and manufactured prototype instruments. The agreement
    provided for payments to the Company in the amount of $942,000,
    to be paid in installments over the
    <FONT style="white-space: nowrap"><!-- FONT#006 -->30-month</FONT><!-- /FONT#006 -->
    life of the agreement. The Company determined that the research
    and development services and the manufacturing of prototype
    instruments should be accounted for as a combined unit of
    accounting and revenue was therefore recognized ratably over the
    estimated project period. The Company recognized revenue of
    $94,000, $377,000, $377,000, $188,000 and $89,000 related to
    this agreement during 2005, 2006, 2007 and the six months ended
    June&#160;30, 2007 and June&#160;28, 2008, respectively. The
    agreement terminated during the six months ended June&#160;28,
    2008.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Collaboration
    Agreement</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    In January 2005, the Company entered into a collaborative
    agreement to develop and commercialize radiopharmaceutical
    manufacturing products for use in the positron emission
    tomography field. As consideration, the Company received an
    up-front fee of $1,000,000, which the Company deferred and
    recognized over the obligation period of approximately two
    years, with $458,000 and $542,000 recognized as revenue during
    2005 and 2006, respectively. Also, the Company recognized
    additional revenue of $635,000 and $500,000 during 2005 and
    2006, respectively, related to payments for research and
    development activities under the agreement based on agreed upon
    rates for time incurred by the research staff. The agreement
    terminated on December&#160;31, 2006.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Grants</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->National
    Institutes of Health</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    In June 2006, the Company was awarded a government grant from
    the National Institutes of Health (NIH) in the amount of
    $1,048,000 to be earned over a two-year period. Under the grant,
    the Company performs research and
</DIV><!-- /DIV#030 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-18
</DIV><!-- /DIV#051 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    development activities to design a diffraction capable Topaz
    screening chip. The agreement provides for quarterly
    reimbursement of the eligible research and development expenses,
    including salaries, equipment, scientific consumables, and
    certain third-party costs. The grant revenue is recognized as
    the related services are performed and costs associated with
    this grant are reported as research and development expense in
    the period incurred. The Company recognized revenue of $184,000,
    $606,000, $355,000 and $258,000  during 2006 and 2007 and the
    six months ended June&#160;30, 2007 and June&#160;28, 2008,
    respectively, under this grant. This agreement terminated in
    June&#160;2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Singapore
    Economic Development Board</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In October 2005, Fluidigm Singapore, a wholly owned subsidiary
    of the Company, entered into a letter agreement providing for up
    to SG$10.0&#160;million (approximately US$7.3&#160;million using
    June&#160;28, 2008 exchange rates) in grants from the Singapore
    Economic Development Board (EDB). The grants are payable for the
    period August&#160;1, 2005 through July&#160;31, 2010 in
    connection with the establishment and operation by Fluidigm
    Singapore of a research, development and manufacturing center
    for IFCs in Singapore. Grant payments are calculated as a
    portion of qualifying expenses incurred in Singapore relating to
    salaries, overhead, outsourcing and subcontracting expenses,
    operating expenses and royalties paid. Fluidigm Singapore is
    required to submit incentive payment requests for qualifying
    expenditures on a quarterly basis along with reports regarding
    its compliance with the incentive payment conditions, as
    described below, through the end of the applicable quarter.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2006. Fluidigm Singapore and EDB entered into a
    supplement to the October&#160;2005 letter agreement. This
    supplement was entered into to create a process whereby Fluidigm
    Singapore and EDB would agree on new quarterly development
    targets at the start of each year, Fluidigm Singapore would
    submit to EDB a progress report and evidence of the achievement
    of targets on a quarterly basis and the parties would resolve
    any disagreements regarding the satisfaction of targets using an
    established procedure and the parties would be entitled to
    obtain a third party review of the incentive payment requests on
    a semi-annual rather than an annual basis. These agreements
    further provide EDB with the right to demand repayment of a
    portion of past grants in the event the Company does not meet
    its obligations under the agreements. Based on correspondance
    with EDB, the Company believes that it has fulfilled its
    obligations under the grants and it will, therefore, not have to
    repay any of the grant proceeds received through June&#160;28,
    2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Fluidigm Singapore&#146;s continued eligibility for such grants
    is subject to its compliance with the following conditions:
    increasing levels of research; its development and manufacturing
    activity in Singapore, including employment of specified numbers
    of research scientists and engineers; its incurrence of
    specified levels of research and development expenses in
    Singapore over the course of each calendar year; its use of
    local service providers; its manufacture in Singapore of the
    products developed in Singapore and its achievement of certain
    targets relating to new product development or completion of
    specific manufacturing process objectives. These required levels
    of research, development and manufacturing activity in Singapore
    and the associated increases from one year to the next are the
    result of negotiations between the parties and are generally
    consistent with Company&#146;s business strategy for its
    Singapore operations. All ownership rights in the intellectual
    property developed by Fluidigm Singapore remain with Fluidigm
    Singapore and no such rights are conveyed to EDB under the
    agreement.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2007, Fluidigm Singapore entered into a second
    letter agreement with EDB which provided for up to an additional
    SG$3.7&#160;million (approximately US$2.7&#160;million using
    June&#160;28, 2008 exchange rates) in grants. The terms and
    conditions of this letter agreement are substantially the same
    as the October&#160;2005 letter agreement, with the exception of
    the size of the potential grant, the term of the agreement and
    the specific levels of research, development and manufacturing
    activities required to maintain eligibility for such grants. The
    primary focus of this letter agreement is the ongoing
    development and manufacture in Singapore of certain
    instrumentation. This letter agreement applies to research,
    development and manufacturing activity by Fluidigm Singapore in
    Singapore from June&#160;1, 2006 through May&#160;31, 2011.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-19
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company recognized revenue of $879,000,  $1,758,000,
    $843,000 and $810,000 related to EDB grants during 2006, 2007
    and the six months ended June&#160;30, 2007 and June&#160;28,
    2008, respectively. As of December&#160;31, 2006,
    December&#160;29, 2007 and June&#160;28, 2008, the Company had
    deferred revenue of $720,000, $635,000 and $506,000,
    respectively, related to incentive payments for equipment
    expenditures, which is being recognized ratably over the
    estimated useful life of the equipment of four years. As of
    December&#160;31, 2006, December&#160;29, 2007 and June&#160;28,
    2008, the Company had accounts receivable from EDB in the
    amounts of $272,000, $679,000 and $349,000, respectively.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">4.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Balance
    Sheet Data</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Cash
    Equivalents and Available-for-Sale Securities</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following are summaries of cash equivalents and
    available-for-sale securities (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="57%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Amortized<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unrealized<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unrealized<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Estimated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Cost</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Gain</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Loss</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Fair Value</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    As of December&#160;31, 2006:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Money market funds
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    95
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    95
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Commercial paper
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,997
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,999
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Corporate notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    503
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,595
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,594
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Reported as:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Cash equivalents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,094
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,594
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    As of December&#160;29, 2007:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Money market funds
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,787
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,787
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Commercial paper
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,287
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,287
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Corporate notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,002
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,999
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Notes from government-sponsored agencies
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,207
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,198
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    36,283
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (17
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    36,271
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Reported as:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Cash equivalents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    29,985
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,286
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    36,271
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    As of June&#160;28, 2008 (unaudited):
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Money market funds
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    11,170
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    11,170
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Notes from government-sponsored agencies
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,255
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,253
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    29,425
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    29,423
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Reported as:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Cash equivalents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    25,920
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,503
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    29,423
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;31, 2006, December&#160;29, 2007 and
    June&#160;28, 2008, the contractual maturities of the
    Company&#146;s available-for-sale securities were less than one
    year.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-20
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Inventories</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Inventories consist of the following (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="61%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Raw materials
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    803
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,551
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,942
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="white-space: nowrap">Work-in-process</FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    291
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    394
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Finished goods and demonstration units
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,224
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,656
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,644
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,038
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,498
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,980
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Property
    and Equipment</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Property and equipment consists of the following (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="61%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Computer equipment and software
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,285
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,328
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,356
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Lab and manufacturing equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,707
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,207
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,403
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Leasehold improvements
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    577
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    582
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    592
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Office furniture and fixtures
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    347
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    372
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    371
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,916
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,489
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,722
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Less accumulated depreciation and amortization
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,885
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,177
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,014
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="white-space: nowrap">Construction-in-progress</FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    66
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Property and equipment, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,378
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,757
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Depreciation and amortization expense was $1,309,000,
    $1,379,000, $1,643,000, $832,000 and $837,000 for 2005, 2006,
    2007 and the six months ended June&#160;30, 2007 and
    June&#160;28, 2008, respectively. During 2005, 2006, 2007 and
    the six months ended June&#160;30, 2007 and June&#160;28, 2008,
    the Company recognized a loss on retirement of property and
    equipment of $0, $111,000, $20,000, $14,000 and $1,000,
    respectively.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">5.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Long-Term
    Debt</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In November 2002, the Company entered into a master security
    agreement with a lender. Per the terms of the agreement, the
    Company could draw up to $4,000,000 for purchases of capital
    equipment, software, and tenant improvements. A second master
    security agreement entered into in March 2004 increased the
    amount of the allowable draw for the Company to $11,000,000. The
    draw down period expired on December&#160;31, 2005, at which
    time the Company had drawn down $3,584,000 under the agreement.
    The loan, which was secured by the underlying equipment and a
    letter of credit, carried an interest rate between 8.0% and
    10.5% per annum, and each draw under the agreement was to be
    repaid in 42 varying monthly installments, which was originally
    scheduled to end on July&#160;1, 2009. In connection with the
    execution of the second agreement in 2004, the Company issued a
    warrant to purchase 37,500&#160;shares of Series&#160;D
    convertible preferred stock at $2.80 per share (see
    Note&#160;8)&#160;which was recorded on the consolidated balance
    sheet at fair value of $90,000 as a debt discount that was
    amortized to interest expense over two years. As of
    December&#160;31, 2006 and December&#160;29, 2007, the
    outstanding principal balance of this loan was $2,267,000 and
    $1,130,000, respectively. In February 2008, prior to the due
    date, the Company paid off the outstanding principal and accrued
    interest balance and paid a prepayment fee in the amount of
    $41,000 to the lender. Accordingly, the entire outstanding
    principal balance for this loan as of December&#160;29, 2007 was
    classified as a current liability on the consolidated balance
    sheet. Upon full payment of this debt, restricted cash in the
    amount of $500,000 was released by the lender and thus has been
    classified as a current asset as of December&#160;29, 2007.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-21
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->FLUIDIGM
    CORPORATION</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Notes
    to Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->
<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#059 -->&nbsp;</DIV><!-- /DIV#026 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    In March 2005, the Company entered into a loan and security
    agreement with another lender. Under this agreement the Company
    borrowed $13,000,000 during 2005 for general corporate purposes.
    This loan is secured by the Company&#146;s assets except for
    intellectual property; however, the security interest does
    include proceeds from sales of the intellectual property. The
    loan was originally scheduled to be repaid by 2009; however, the
    agreement was amended in August 2006 to extend the final
    repayment date to February&#160;1, 2010. The agreement carried a
    variable interest rate of prime plus 2.5% through March 2006.
    Thereafter, the agreement carried a fixed interest rate of 10.0%
    through July 2006 and a fixed interest rate of 9.75% following
    the amendment to the agreement in August 2006. In August 2006,
    the Company began making monthly payments in the amount of
    $310,000 for principal and interest under the agreement. The
    agreement also requires payment of fees in March 2009 in the
    amount of $1,612,500. The fees are accreted as interest expense
    over the term of the loan. The agreement restricts the
    Company&#146;s ability to pay dividends. The Company is subject
    to a prepayment fee in the amount of 1% of the outstanding
    principal amount being prepaid if paid during 2008 or 2009. In
    connection with the execution of this loan and security
    agreement, the Company issued a warrant to purchase
    185,714&#160;shares of Series&#160;D convertible preferred stock
    at $2.80 per share (see Note&#160;8)&#160;which was recorded on
    the consolidated balance sheet at fair value of $54,000 as a
    debt discount. In connection with the final draw down of this
    loan, the Company issued another warrant to purchase
    185,714&#160;shares of Series&#160;D convertible preferred stock
    at $2.80 per share (see Note&#160;8)&#160;which was recorded on
    the consolidated balance sheet at fair value of $50,000 as a
    debt discount. The debt discounts are amortized to interest
    expense over the life of the agreement.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    In February 2008, the Company amended this loan and security
    agreement to provide the Company with an additional credit line
    in the amount of $10,000,000 that the Company could draw upon
    until July&#160;1, 2008 for general corporate purposes. In
    connection with the amendment of this loan and security
    agreement, the Company issued a warrant to purchase
    100,000&#160;shares of Series E convertible preferred stock at
    $4.00&#160;per share (see Note&#160;8). The warrant was recorded
    on the consolidated balance sheet as a deferred charge at a fair
    value of $111,000 and was amortized to interest expense over the
    period of the availability of the funds. In June&#160;2008, the
    Company drew down the $10,000,000 available. The loan will bear
    interest at 11.5%&#160;per annum. Interest only payments will be
    made monthly through the remainder of 2008 with monthly payments
    of principal and interest in the amount of $369,000, beginning
    in January 2009, to be made through June 2011. The agreement
    also requires a final payment in the amount of $650,000 in June
    2011. In addition, the Company issued to the lender additional
    warrants to purchase up to 200,000&#160;shares of Series E
    convertible preferred stock at $4.00&#160;per share in
    accordance with the terms of the agreement which was recorded on
    the consolidated balance sheet at fair value of $373,000 as a
    debt discount. As of December&#160;31, 2006, December&#160;29,
    2007 and June&#160;28, 2008, the outstanding principal balance
    of these loans was $10,570,000, $8,232,000 and $16,558,000,
    respectively, net of the unamortized debt discounts of $58,000,
    $31,000 and $391,000, respectively.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The amortization of the debt discounts for the Company&#146;s
    long-term debt agreements was recorded as interest expense in
    the consolidated statements of operations in the amounts of
    $9,000, $37,000, $27,000, $14,000 and $11,000 during 2005, 2006,
    2007 and the six months ended June&#160;30, 2007 and
    June&#160;28, 2008, respectively. As of June&#160;28, 2008, the
    Company was either in compliance with all loan covenants or had
    obtained waivers from the respective lenders.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-22
</DIV><!-- /DIV#051 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table does not include principal payments for the
    master security agreement with a principal balance of $1,130,000
    as of December&#160;29, 2007 that was paid off in February 2008.
    The scheduled principal payments of the Company&#146;s other
    long-term debt as of December&#160;29, 2007 are as follows (in
    thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="92%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Years:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,724
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,929
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    610
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total principal payments due in future periods
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,263
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Less: debt discounts
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (31
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,232
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The scheduled principal payments of the Company&#146;s long-term
    debt as of June&#160;28, 2008 are as follows (in thousands):
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="91%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Years:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Remainder of 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,410
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,343
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,453
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2011
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,743
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total principal payments due in future periods
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,949
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Less: debt discounts
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (391
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    16,558
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">6.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Commitments
    and Contingencies</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Operating
    Leases</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company leases its headquarters in South San&#160;Francisco,
    California, under multiple noncancelable lease agreements that
    expire in February 2011. These agreements include renewal
    options which provide the Company with the ability to extend the
    lease terms for an additional three years. The Company also
    leases office and manufacturing space under noncancelable leases
    in Singapore that expire in October&#160;2011. The
    Company&#146;s other operating leases are for office space in
    the Netherlands, Japan, and France and are on a month-to-month
    basis. As of December&#160;29, 2007, future minimum lease
    payments under noncancelable operating leases were as follows
    (in thousands):
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="92%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Years:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,436
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,374
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,408
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2011
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    241
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total minimum payments
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,459
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Singapore office and manufacturing space leases were renewed
    in August&#160;2008 as they were originally scheduled to expire
    in September 2008. Future minimum lease payments on the new
    Singapore leases in the amount of SG$14,000 (approximately
    US$10,000 using June&#160;28, 2008 exchange rates) per month are
    not included in the
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-23
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    table above. The Company&#146;s lease payments are recognized as
    an expense on a straight-line basis over the life of the lease.
    Rental expense under operating leases for 2005, 2006, 2007 and
    the six months ended June&#160;30, 2007 and June&#160;28, 2008
    totaled $1,468,000, $1,494,000, $1,574,000, $719,000 and
    $730,000, respectively.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Commitments</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company has entered into a supply agreement with a vendor to
    provide inventory components customized to the Company&#146;s
    specifications. Pursuant to this agreement, the Company has
    agreed to purchase from the vendor a specified minimum number of
    units each year in exchange for volume discounts. After
    April&#160;1, 2010, either party may terminate the supply
    agreement upon six months prior written notice. As of
    December&#160;29, 2007, future minimum payments under the supply
    agreement were as follows (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="92%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Years:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    435
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    435
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    135
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total minimum payments
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,005
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Contingencies</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In June 2008, the Company received a letter from a competitor
    asserting that the Company had infringed upon a patent currently
    held by the competitor. In response, the Company filed a suit
    against the competitor seeking declaratory judgments of
    non-infringement and invalidity of the patent. The Company is
    party to other various claims arising in the ordinary course of
    business. These claims relate to intellectual property rights
    and employment matters. While there is no assurance that an
    adverse determination of any of such matters will not occur,
    management does not believe, based upon information known to it,
    that a potential resolution of any of these matters will have a
    material adverse effect upon the Company&#146;s financial
    position, results of operations, or cash flows.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Indemnifications</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    From time to time, the Company has entered into indemnification
    provisions under certain of its agreements with other companies
    in the ordinary course of business, typically with business
    partners, customers, and suppliers. Pursuant to these
    agreements, the Company may indemnify, hold harmless, and agree
    to reimburse the indemnified parties on a case by case basis for
    losses suffered or incurred by the indemnified parties in
    connection with any patent or other intellectual property
    infringement claim by any third-party with respect to its
    products. The term of these indemnification provisions is
    generally perpetual from the time of the execution of the
    agreement. The maximum potential amount of future payments the
    Company could be required to make under these indemnification
    provisions is typically not limited to a specific amount. In
    addition, the Company has entered into indemnification
    agreements with its officers and directors. The Company has not
    incurred material costs to defend lawsuits or settle claims
    related to these indemnification provisions. As of June&#160;28,
    2008, the Company had not accrued a liability for these
    indemnification provisions because the likelihood of incurring a
    payment obligation was remote.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">7.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Convertible
    Promissory Notes</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In December 2003, the Company entered into a convertible note
    purchase agreement with the Biomedical Sciences Investment
    Fund&#160;Pte Ltd (BMSIF). BMSIF is wholly-owned by EDB
    Investments Pte. Ltd., whose parent entity is EDB. Ultimately,
    each of these entities is controlled by the government of
    Singapore. Under this agreement BMSIF agreed to provide a
    $2,000,000 credit facility to be used for general corporate
    purposes. In December 2003, the Company issued a $2,000,000
    convertible promissory note to BMSIF. The note, which was
    unsecured, carried an interest rate of 8% per year. Per the
    agreement, principal and interest were convertible into the
    Company&#146;s Series&#160;D convertible preferred stock at
    $2.80 per share at the lender&#146;s election, at any time, or
    upon the election of
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-24
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    the Company upon the achievement of certain milestones by the
    Company. In June 2005, the agreement was amended to allow the
    Company to issue additional convertible promissory notes in the
    amount of $3,000,000 if the Company achieved certain milestones.
    In December 2005, upon the successful completion of specified
    milestones, the $2,000,000 convertible promissory note and
    interest of $331,000 converted into 832,635&#160;shares of
    Series&#160;D convertible preferred stock at $2.80 per share as
    settlement of the outstanding balance on the date of the
    conversion. In June 2006, the Company issued a $3,000,000
    convertible promissory note, which was also unsecured, that
    carried an interest rate of 8% per year. Principal and interest
    are also convertible into the Company&#146;s Series&#160;D
    convertible preferred stock at $2.80 per share at the
    lender&#146;s election, at any time, or upon the election of the
    Company upon the achievement of certain milestones by the
    Company or upon the completion of an initial public offering in
    which the convertible preferred stock has converted into common
    stock. As of December&#160;31, 2006, the outstanding principal
    and accrued interest balance for the convertible promissory note
    was $3,128,000. In June 2007, upon the successful completion of
    specified milestones, the principal balance in the amount of
    $3,000,000 for the convertible promissory note and accrued
    interest of $240,000 converted into 1,157,142&#160;shares of
    Series&#160;D convertible preferred stock at $2.80 per share.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In August 2006, the Company entered into another convertible
    note purchase agreement with BMSIF. Under this agreement, BMSIF
    agreed to provide a $15,000,000 credit facility, to be issued in
    three separate $5,000,000 tranches, and to be used for general
    corporate purposes. The Company issued two $5,000,000
    convertible promissory notes against equal amounts of borrowings
    under this facility, each unsecured and carrying an interest
    rate of 8% per year, in August and November 2006. In March 2007,
    BMSIF exercised the conversion provision of the convertible note
    purchase agreement and the Company issued 2,954,337&#160;shares
    of Series&#160;E convertible preferred stock at $3.60 per share
    as settlement of the outstanding principal and accrued interest
    balance on the date of the conversion in the amount of
    $10,636,000. Upon conversion of these convertible promissory
    notes, the Company issued the third and final $5,000,000
    convertible promissory note against an equal amount of borrowing
    under this facility with an interest rate of 8% per year in
    April 2007. BMSIF exercised the conversion provision for the
    third and final convertible promissory note in May&#160;2008,
    and the Company issued 1,503,945&#160;shares of Series E
    convertible preferred stock at $3.60 per share as settlement of
    the outstanding principal and accrued interest balance on the
    date of the conversion in the amount of $5,414,000.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For these convertible note purchase agreements in which the
    repayment was in the form of Series&#160;E convertible preferred
    stock, the conversion price of $3.60 per share was a discount to
    the estimated fair values of $3.71 and $4.00 per share for the
    Series&#160;E convertible preferred stock at the times of the
    borrowings. The intrinsic value of the embedded beneficial
    conversion option associated with each borrowing of convertible
    promissory notes under the arrangement was measured as the
    difference between the conversion price and the fair value of
    Series&#160;E convertible preferred stock on the commitment date
    and the resulting debt discount is being amortized to interest
    expense over the two year contractual term of the debt. Upon
    conversion of the notes to convertible preferred stock, any
    remaining unamortized debt discount was immediately recognized
    as interest expense.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2006 and 2007, the Company recognized debt discounts of
    $306,000 and $485,000, respectively, related to the beneficial
    conversion feature of the notes. Amortization of the debt
    discounts for the convertible note purchase agreements was
    recorded as interest expense in the consolidated statements of
    operations in the amount of $43,000, $468,000, $360,000 and
    $280,000 during 2006, 2007 and the six months ended
    June&#160;30, 2007 and June&#160;28, 2008, respectively.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;31, 2006 and December&#160;29, 2007, the
    outstanding principal and accrued interest balance for the
    convertible note purchase agreements with BMSIF was $9,944,000
    and $4,997,000 net of the unamortized debt discounts of $263,000
    and $280,000, respectively. As of June 28, 2008, there were no
    remaining amounts outstanding related to the convertible note
    purchase agreements with BMSIF.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-25
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->FLUIDIGM
    CORPORATION</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Notes
    to Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->
<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#059 -->&nbsp;</DIV><!-- /DIV#026 -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->8.&#160;&#160;</FONT><!-- /FONT#008 --></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Convertible
    Preferred Stock Warrant Liabilities</FONT><!-- /FONT#008 --></B>
</TD>
</TR>

</TABLE>

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The Company issued warrants to purchase 1,211,203&#160;shares of
    the Company&#146;s convertible preferred stock at various times
    between 2001 and 2005 and warrants to purchase
    300,000&#160;shares during the six months ended June&#160;28,
    2008. The Company did not issue any warrants to purchase
    convertible preferred stock during 2006 or 2007. The convertible
    preferred stock warrants are generally exercisable immediately
    and can only be exercised for cash or net share settled. Changes
    in the fair value of the underlying stock do not affect the
    settlement amounts of the warrants, therefore, the maximum
    amount of shares to be issued upon the settlement of these
    warrants is noted in the table below. As of December&#160;29,
    2007, the following warrants were issued and outstanding:
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="21%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="14%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="14%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="29%">&nbsp;</TD>	<!-- colindex=06 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Warrant to Purchase<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Reason for<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Convertible<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px"><!-- DIV#013 -->
    <B>Issue Date</B>
</DIV><!-- /DIV#007 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Grant</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Preferred Stock</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>per Share</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Expiration</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    May 2001
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series C
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    41,284
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.18
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) May 14, 2008
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    March 2002
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series C
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    17,500
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.58
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) March 27, 2012
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    November 2002
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series C
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    31,008
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.58
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) December 16, 2012
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    September 2003
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Collaboration agreement
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series C
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    200,000
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.58
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    December 31, 2007
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    March 2004
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series D
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    37,500
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.80
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) March 18, 2012
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    March 2005
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series D
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    185,714
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.80
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) March 29, 2012
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    December 2005
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series D
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    185,714
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.80
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) March 29, 2012
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    698,720
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->

</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    During 2007, warrants to purchase 5,076&#160;shares of
    Series&#160;C convertible preferred stock expired. Upon
    expiration, the related warrant liability was eliminated and
    reflected as other income (expense), net. During 2006, warrants,
    issued in connection with a collaboration agreement (see
    Note&#160;3), to purchase 507,407&#160;shares of the
    Series&#160;D convertible preferred stock were exercised
    utilizing a cashless exercise option that allowed the holder to
    receive 267,857&#160;shares of convertible preferred stock. The
    fair value of the warrants and the shares of convertible
    preferred stock issued upon the cashless exercise was $729,000
    on the exercise date, calculated as the fair value of the shares
    of convertible preferred stock issued.
</DIV><!-- /DIV#030 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-26
</DIV><!-- /DIV#050 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->FLUIDIGM
    CORPORATION</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Notes
    to Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->
<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#059 -->&nbsp;</DIV><!-- /DIV#026 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    As of June&#160;28, 2008, the following warrants were issued and
    outstanding (unaudited):
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="21%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="14%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="14%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="29%">&nbsp;</TD>	<!-- colindex=06 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Warrant to Purchase<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Reason for<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Convertible<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Issue Date</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Grant</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Preferred Stock</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>per Share</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Expiration</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    March 2002
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt Financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series C
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    17,500
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.58
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) March&#160;27, 2012
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    November 2002
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt Financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series C
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    31,008
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.58
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) December&#160;16, 2012
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    March 2004
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt Financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series D
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    37,500
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.80
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) March&#160;18, 2012
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    March 2005
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt Financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series D
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    185,714
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.80
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) March&#160;29, 2012
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    December 2005
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt Financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series D
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    185,714
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.80
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) March&#160;29, 2012
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    February 2008
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt Financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series E
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    100,000
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    4.00
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) February&#160;15, 2015
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    June 2008
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt Financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series E
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    200,000
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    4.00
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) February 15, 2015
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    757,436
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->

</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    During the six months ended June&#160;28, 2008, the Company
    issued warrants to purchase 300,000&#160;shares of Series&#160;E
    convertible preferred stock in connection with the amendment of
    a loan and security agreement and the subsequent draw down on
    the agreement (see Note&#160;5). Warrants to purchase
    200,000&#160;shares of the Company&#146;s Series C convertible
    preferred stock expired unexercised on December&#160;31, 2007
    and warrants to purchase 41,284&#160;shares of the
    Company&#146;s Series&#160;C convertible preferred stock were
    exercised in May&#160;2008 utilizing a cashless exercise option
    that allowed the holder to receive 16,422&#160;shares of
    convertible preferred stock.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The following is a summary of the warrants to purchase
    convertible preferred stock outstanding and their fair values as
    of December&#160;31, 2006, December&#160;29, 2007 and
    June&#160;28, 2008:
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="36%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B>Outstanding<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares as of</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Fair Value as of</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B>Warrants to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px"><!-- DIV#013 -->
    <B>Purchase</B>
</DIV><!-- /DIV#007 -->
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Series C
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    294,868
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    289,792
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48,508
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    29,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    61,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    85,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Series D
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    408,928
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    408,928
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    408,928
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    194,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    407,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    632,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Series E
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    552,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    703,796
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    698,720
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    757,436
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    223,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    468,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,269,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->

</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-27
</DIV><!-- /DIV#050 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->FLUIDIGM
    CORPORATION</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Notes
    to Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->
<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#059 -->&nbsp;</DIV><!-- /DIV#026 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The fair values of the outstanding convertible preferred stock
    warrants were measured using the Black-Scholes option-pricing
    model with the following weighted-average assumptions:
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="61%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="11%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="11%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="9%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Expected volatility
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    63.6%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    49.7%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    49.2%
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Expected life (equals the remaining contractual term)
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    3.7 years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    2.8 years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5.0 years
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Risk-free interest rate
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4.8%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    3.2%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    3.3%
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Dividend yield
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->

</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    A decrease in fair value of the convertible preferred stock
    warrant liabilities in the amount of $72,000 and $26,000 during
    2005 and the six months ended June&#160;30, 2007, and increases
    in fair value in the amounts of $138,000, $245,000 and $359,000
    during 2006, 2007 and the six months ended June&#160;28, 2008,
    respectively, were recognized as other income (expense), net in
    the consolidated statements of operations. Upon adoption of
    <FONT style="white-space: nowrap"><!-- FONT#006 -->FSP&#160;150-5</FONT><!-- /FONT#006 -->
    on July&#160;1, 2005, the Company recorded a gain of $637,000 as
    a cumulative effect of a change in accounting principle in the
    consolidated statement of operations during 2005.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->9.&#160;&#160;</FONT><!-- /FONT#008 --></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Convertible
    Preferred Stock</FONT><!-- /FONT#008 --></B>
</TD>
</TR>

</TABLE>

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    As of December&#160;31, 2006, December&#160;29, 2007, and
    June&#160;28, 2008 (unaudited) convertible preferred stock was
    comprised of the following (in thousands):
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="42%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;29, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Issued and<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Issued and<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Designated</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Outstanding</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Net Proceeds</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Designated</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Outstanding</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Net Proceeds</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt"><!-- DIV#014 -->
    Series&#160;A
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,727
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,727
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,989
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,727
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,727
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,989
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt"><!-- DIV#014 -->
    Series&#160;B
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,461
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,461
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,479
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,461
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,461
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,479
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt"><!-- DIV#014 -->
    Series&#160;C
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,365
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,030
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,365
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,030
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt"><!-- DIV#014 -->
    Series&#160;D
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,196
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33,794
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,353
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,034
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt"><!-- DIV#014 -->
    Series&#160;E
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,535
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,003
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,110
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68,550
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,438
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,284
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    112,295
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    61,798
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    162,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->

</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="62%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;28, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Aggregate<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Issued and<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Liquidation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Designated</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Outstanding</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Net Proceeds</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Value</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt"><!-- DIV#014 -->
    Series A
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,727
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,727
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,989
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt"><!-- DIV#014 -->
    Series B
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,461
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,461
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,479
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,501
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt"><!-- DIV#014 -->
    Series C
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,381
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,072
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,263
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt"><!-- DIV#014 -->
    Series D
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,353
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,034
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,388
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt"><!-- DIV#014 -->
    Series E
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,110
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,269
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73,964
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    77,076
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    61,798
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58,191
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    167,538
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    171,228
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->

</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The Company&#146;s convertible preferred stock had been
    classified as temporary equity on the consolidated balance sheet
    instead of in stockholders&#146; equity (deficit) in accordance
    with EITF Abstracts Topic
    <FONT style="white-space: nowrap"><!-- FONT#006 -->No.&#160;D-98,</FONT><!-- /FONT#006 -->
    <I>Classification and Measurement of Redeemable Securities</I>.
    Upon certain change in control events that are outside of the
    control of the Company, including liquidation, sale or transfer
    of control of the Company, holders of the convertible preferred
    stock can cause its redemption. Accordingly, these shares are
    considered contingently redeemable. The Company has not adjusted
    the carrying values of the convertible preferred stock to their
</DIV><!-- /DIV#030 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-28
</DIV><!-- /DIV#051 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    redemption values since it is uncertain whether or when a
    redemption event will occur. Subsequent adjustments to increase
    the carrying values to the redemption values would be made if it
    becomes probable that such redemption will occur. The
    significant rights, privileges, and preferences of the
    convertible preferred stock are as follows:
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Conversion</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each share of convertible preferred stock is convertible, at any
    time at the option of the holder, into common stock based upon a
    conversion rate of one share of common stock for each share of
    convertible preferred stock regardless of the series.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Conversion is automatic upon: (i)&#160;the closing of an
    underwritten initial public offering of the Company&#146;s
    common stock at an offering price of not less that $5.69 per
    share (appropriately adjusted for any stock splits, stock
    dividends, recapitalization, or similar events) and with
    aggregate gross proceeds of not less than $25,000,000,
    (ii)&#160;the closing of an underwritten initial public offering
    of the Company&#146;s common stock at an offering price of less
    than $5.69 per share (appropriately adjusted for any stock
    splits, stock dividends, recapitalization, or similar events) or
    with aggregate gross proceeds of less than $25,000,000 and
    written consent of the holders of two-thirds of all shares of
    convertible preferred stock voting together for such automatic
    conversion, or (iii)&#160;the written consent of the holders of
    two-thirds of all shares of convertible preferred stock voting
    together, except that the written consent of the holders of
    greater than two-thirds of all shares of Series&#160;E
    convertible preferred stock voting separately is required for
    Series&#160;E convertible preferred stock to convert if such
    conversion is not in connection with the closing of an
    underwritten initial public offering of the Company&#146;s
    common stock.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Dividends</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Holders of Series&#160;A, B, C, D, and E convertible preferred
    stock are entitled to noncumulative dividends of $0.11, $0.18,
    $0.26, $0.30, and $0.43 per share, respectively, if and when
    declared by the Board of Directors (adjusted for any stock
    splits, stock dividends, recapitalization, or similar events)
    and subject to the preferences described below. Holders of
    Series&#160;D and E convertible preferred stock shall be
    entitled to receive dividends, when and if declared, in
    preference and priority to any declaration or payment of
    dividends to holders of Series&#160;A, B, or C convertible
    preferred stock or common stock, other than for dividends
    payable in only common stock. Payments of any dividends to the
    holders of Series&#160;D and E convertible preferred stock shall
    be on a pro rata, pari passu basis in proportion to the entitled
    dividend rates for these respective series, as applicable.
    Holders of Series&#160;C convertible preferred stock shall be
    entitled to receive dividends, when and if declared, in
    preference and priority to any declaration or payment of
    dividends to holders of Series&#160;A and B convertible
    preferred stock or common stock, other than for dividends
    payable in only common stock. Holders of Series&#160;A and B
    convertible preferred stock shall be entitled to receive
    dividends, when and if declared, in preference and priority to
    any declaration or payment of dividends to holders of common
    stock, other than for dividends payable in only common stock.
    Payments of any dividends to the holders of Series&#160;A and B
    convertible preferred stock shall be on a pro rata, pari passu
    basis in proportion to the entitled dividend rates for these
    respective series, as applicable. No dividends have been
    declared or paid through June&#160;28, 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Liquidation
    Preferences</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the event of a liquidation, dissolution, or winding up of the
    Company, holders of Series&#160;E convertible preferred stock
    shall be entitled to receive a liquidation preference of $4.00
    per share, together with any declared but unpaid dividends,
    prior to any payment or distribution to holders of Series A, B,
    C, or D convertible preferred stock or common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After payment to the holders of Series&#160;E convertible
    preferred stock, holders of Series&#160;D convertible preferred
    stock shall be entitled to receive a liquidation preference of
    $2.80 per share, together with any declared but unpaid
    dividends, prior to any payment or distribution to holders of
    Series A, B, or C convertible preferred stock or common stock.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-29
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After payment to the holders of Series&#160;D convertible
    preferred stock, holders of Series&#160;C convertible preferred
    stock shall be entitled to receive a liquidation preference of
    $2.58 per share, together with any declared but unpaid
    dividends, prior to any payment or distribution to holders of
    Series A or B convertible preferred stock or common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After payment to the holders of Series&#160;C convertible
    preferred stock, holders of Series&#160;B convertible preferred
    stock shall be entitled to receive a liquidation preference of
    $1.78 per share, together with any declared but unpaid
    dividends, prior to any payment or distribution to holders of
    Series&#160;A convertible preferred stock or common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After payment to the holders of Series&#160;B convertible
    preferred stock, holders of Series&#160;A convertible preferred
    stock shall be entitled to receive a liquidation preference of
    $1.10 per share, together with any declared but unpaid
    dividends, prior to any payment or distribution to holders of
    common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After the payment to the holders of convertible preferred stock
    or their respective liquidation preferences, the entire
    remaining assets of the Company shall be distributed on a pro
    rata basis to the holders of common stock. A change of control
    or a sale, transfer, or lease of all or substantially all of the
    assets of the Company is considered to be a liquidation event.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Voting
    Rights</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Holders of convertible preferred stock are entitled to the
    number of votes they would have upon conversion of their
    convertible preferred stock into common stock on the applicable
    record date. So long as 2,000,000&#160;shares of Series&#160;D
    convertible preferred stock remain outstanding, the holders of
    Series&#160;D convertible preferred stock are entitled to elect
    two members to the Company&#146;s Board of Directors, and so
    long as 2,000,000&#160;shares of Series&#160;C convertible
    preferred stock remain outstanding, the holders of Series&#160;C
    convertible preferred stock are entitled to elect three members
    to the Board of Directors. The holders of Series&#160;A, B, and
    E convertible preferred stock and the holders of common stock,
    voting together as a single class, are entitled to elect any
    additional members to the Board of Directors.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">10.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Stock
    Option Activity</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">1999
    Stock Option Plan</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On May&#160;12, 1999, the Board of Directors adopted the 1999
    Stock Option Plan (the Stock Plan) under which incentive stock
    options and nonstatutory stock options may be granted to
    employees, officers, and directors of, or consultants to, the
    Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Options granted under the Stock Plan expire no later than ten
    years from the date of grant. The exercise price of each
    incentive stock option granted to an employee shall be at least
    110% of the fair market value of the underlying common stock on
    the date of grant if, on the grant date, the employee owns stock
    representing more than 10% of the voting power of all classes of
    the Company&#146;s capital stock; otherwise, the exercise price
    shall be at least 100% of the fair market value of the
    underlying common stock on the date of grant. The exercise price
    for each nonstatutory stock option granted to a service provider
    shall be at least 110% of the fair market value of the
    underlying common stock on the date of grant if, on the grant
    date, the service provider owns stock representing more than 10%
    of the voting power of all classes of the Company&#146;s capital
    stock; otherwise, the exercise price shall be at least 85% of
    the fair market value of the underlying common stock on the date
    of grant. The fair market value of the underlying common stock
    shall be determined by the Board of Directors until such time as
    the Company&#146;s common stock is listed on any established
    stock exchange or national market system. Options may be granted
    with different vesting terms from time to time, but the vesting
    terms may not exceed five years from the date of grant.
    Generally, outstanding options are immediately exercisable and
    vest at a rate of 25% on the first anniversary of the option
    grant date and
    <FONT style="vertical-align: text-top; font-size: 70%;">1</FONT>/<FONT style="font-size: 70%;">48</FONT>
    of the total grant each month thereafter.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-30
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->FLUIDIGM
    CORPORATION</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Notes
    to Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->
<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#059 -->&nbsp;</DIV><!-- /DIV#026 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    As of December&#160;29, 2007, the Stock Plan is the
    Company&#146;s only stock-based compensation plan and a total of
    12,800,000&#160;shares of common stock have been authorized for
    issuance under the Stock Plan.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Activity under the Stock Plan is as follows (in thousands,
    except per share amounts):
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="59%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Outstanding Options</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted-Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Available for<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise Price per<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Grant</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Share</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Balance as of January&#160;1, 2005
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,183
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,858
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.37
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    Additional shares authorized
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    Options granted
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,559
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,559
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.56
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    Options exercised
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (170
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.31
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    Options canceled
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    153
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (153
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.47
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Balance as of December&#160;31, 2005
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,277
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,094
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.45
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    Options granted
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,216
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,216
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.83
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    Options exercised
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (443
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.41
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    Options canceled
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    817
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (817
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.52
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Balance as of December&#160;31, 2006
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    878
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,050
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.52
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    Additional shares authorized
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    Options granted
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,042
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,042
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.53
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    Options exercised
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (264
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.49
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    Options canceled
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    361
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (361
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.66
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Balance as of December&#160;29, 2007
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,197
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.79
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    Additional shares authorized (unaudited)
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    Options granted (unaudited)
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,724
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,724
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.99
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    Options exercised (unaudited)
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (225
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.49
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    Options canceled (unaudited)
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,633
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,633
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.59
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    Balance as of June&#160;28, 2008 (unaudited)
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,106
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,333
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.56
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->

</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Options exercised during 2005, 2006, 2007 and the six months
    ended June&#160;28, 2008  exclude options that are exercised
    prior to vesting. These shares generally vest over a four-year
    period. Unvested shares, which amount to 65,000, 33,334 and
    23,750 as of December&#160;31, 2006, December&#160;29, 2007 and
    June&#160;28, 2008, respectively, are subject to a repurchase
    option held by the Company at the original exercise price and
    are not deemed to be issued for accounting purposes until those
    shares vest.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-31
</DIV><!-- /DIV#051 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Effective January&#160;1, 2006, the Company adopted the
    provisions of SFAS&#160;123(R). The fair value of each new
    option awarded was estimated on the grant date using the
    Black-Scholes option-pricing model using the following
    weighted-average assumptions.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="49%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="8%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="8%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="12%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="12%">&nbsp;</TD>	<!-- colindex=05 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Six Months<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Six Months<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Ended June&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Ended June&#160;28,<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected volatility
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    72.8%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    63.0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    63.0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    53.8%
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected life
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    6.1&#160;years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    6.0&#160;years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    6.0 years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    6.0 years
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Risk-free interest rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4.8%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4.4%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4.6%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    3.2%
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dividend yield
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Weighted-average fair value of options granted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    $0.55
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    $0.92
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    $0.84
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    $1.61
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Expected volatility is derived from historical volatilities of
    several unrelated public companies within the biomedical
    instrument and system industry. Each company&#146;s historical
    volatility is weighted based on certain qualitative factors and
    combined to produce a single volatility factor used by the
    Company. The risk-free interest rate is based on the
    U.S.&#160;Treasury yield curve in effect at the time of grant
    for zero coupon U.S.&#160;Treasury notes with maturities
    approximately equal to the option&#146;s expected life. Given
    the limited history to accurately estimate expected lives of
    options granted to the various employee groups, the Company used
    the &#147;simplified&#148; method as provided by the SEC Staff
    Accounting Bulletin&#160;No.&#160;107, <I>Share Based Payment
    </I>(SAB&#160;107). The &#147;simplified&#148; method is
    calculated as the average of the time-to-vesting and the
    contractual life of the options. The Company estimates its
    forfeiture rate based on an analysis of its actual forfeitures
    and will continue to evaluate the adequacy of the forfeiture
    rate based on actual forfeiture experience, analysis of employee
    turnover behavior, and other factors. The impact from a
    forfeiture rate adjustment will be recognized in full in the
    period of adjustment, and if the actual number of future
    forfeitures differs from that estimated by the Company, the
    Company may be required to record adjustments to stock-based
    compensation expense in future periods. Adjustments to the
    forfeiture rates have not had a significant impact on any of the
    periods presented. Each of these inputs is subjective and
    generally requires significant judgment to determine.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The absence of an active market for the Company&#146;s common
    stock required the Company&#146;s Board of Directors, with input
    from management, to estimate the fair value of the common stock
    for purposes of granting options and for determining stock-based
    compensation expense for the periods presented. In response to
    these requirements, the Company&#146;s Board of Directors
    estimated the fair value of the common stock at each meeting at
    which options were granted based on factors such as the price of
    the most recent convertible preferred stock sales to investors,
    the preferences held by the convertible preferred stock classes
    in favor of common stock, the valuations of comparable
    companies, the hiring of key personnel, the status of the
    Company&#146;s development and sales efforts, revenue growth and
    additional objective, and subjective factors relating to the
    Company&#146;s business. The Company has historically granted
    stock options at not less than the fair value of the underlying
    common stock as determined at the time of grant by the
    Company&#146;s Board of Directors.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Information regarding the Company&#146;s stock option grants
    during 2007 and the six months ended June&#160;28, 2008,
    including the grant date; the number of stock options issued
    with each grant; and the exercise price, which equals the
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-32
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    grant date fair value of the underlying common stock for each
    grant of stock options, is summarized as follows (in thousands,
    except per share amounts):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="75%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>and Fair Value<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>per Share of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Grant Date</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Granted</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Common Stock</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    May&#160;8, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,613
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    September&#160;20, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    December&#160;28, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    328
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    February&#160;7, 2008 (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    724
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    April&#160;24, 2008 (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,914
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3.19
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    June&#160;26, 2008 (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    86
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3.42
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Additional information regarding the Company&#146;s stock
    options outstanding and exercisable as of December&#160;29, 2007
    is summarized in the following table:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="61%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Options Outstanding</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Exercisable<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted-<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Remaining<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Contractual<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Subject<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Exercise Price</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>of Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Life</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>to Options</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in years)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    $0.15
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    0.30
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,719
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,651
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    0.40
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    342
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    342
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    0.56
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,296
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,057
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    0.83
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,025
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    912
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    1.36
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,587
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,240
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    1.38
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    97
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2.40
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    328
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    217
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,539
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Certain options under the Stock
    Plan may be exercised prior to vesting but are subject to
    repurchase at the original exercise price in the event the
    optionees&#146; employment is terminated.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Options exercisable as of December&#160;29, 2007 had a
    weighted-average remaining contractual life of 7.4&#160;years, a
    weighted-average exercise price per share of $0.74, and an
    aggregate intrinsic value of $3,662,000.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-33
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Additional information regarding the Company&#146;s stock
    options outstanding and exercisable as of June&#160;28, 2008 is
    summarized in the following table (unaudited):
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="61%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Options Outstanding</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Exercisable<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted-<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Remaining<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Contractual<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Subject<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Exercise Price</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>of Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Life</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>to Options</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in years)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    $0.15
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    0.30
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    811
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    811
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    0.40
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    159
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    159
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    0.56
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,894
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,891
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    0.83
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    870
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    779
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    1.36
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,432
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,194
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    1.38
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    91
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2.40
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,035
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    940
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    3.19
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,882
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,599
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    3.42
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    86
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,333
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,504
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Certain options under the Stock
    Plan may be exercised prior to vesting but are subject to
    repurchase at the original exercise price in the event the
    optionees&#146; employment is terminated.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Options exercisable as of June&#160;28, 2008 had a
    weighted-average remaining contractual life of 8.0 years, a
    weighted-average exercise price per share of $1.48, and an
    aggregate intrinsic value of $14,561,000.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Options outstanding that have vested and are expected to vest as
    of December&#160;29, 2007 are summarized as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="40%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted-Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted-Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Remaining<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Aggregate<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Contractual<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Intrinsic<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>per Share</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Life</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Value<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in years)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Vested
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,307
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.52
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,097
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected to vest
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,049
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,781
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total vested and expected to vest
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,356
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.79
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    11,878
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The aggregate intrinsic value was
    calculated as the difference between the exercise price of the
    underlying options and the fair value of the Company&#146;s
    common stock in the amount of $2.40&#160;per share as of
    December&#160;29, 2007.
    </FONT></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-34
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Options outstanding that have vested and are expected to vest as
    of June&#160;28, 2008 are summarized as follows (unaudited):
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="40%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted-Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted-Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Remaining<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Aggregate<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Contractual<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Intrinsic<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>per Share</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Life</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Value<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in years)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Vested
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,846
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.81
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10,031
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected to vest
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,137
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total vested and expected to vest
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,046
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.54
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    15,168
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The aggregate intrinsic value was
    calculated as the difference between the exercise price of the
    options and the fair value of the Company&#146;s common stock in
    the amount of $3.42&#160;per share as of June&#160;28, 2008.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The total intrinsic value of options exercised during 2006, 2007
    and the six months ended June&#160;30, 2007 and June&#160;28,
    2008 was $167,000, $259,000, $40,000 and $420,000, respectively.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There were no stock-based compensation tax benefits during 2005,
    2006, 2007 or the six months ended June&#160;28, 2008.
    Capitalized stock-based compensation costs were insignificant
    during 2005, 2006, 2007 and the six months ended June&#160;28,
    2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company recognized stock-based compensation expense of
    $5,000, $145,000, $708,000, $374,000 and $1,001,000 during 2005,
    2006, 2007 and the six months ended June&#160;30, 2007 and
    June&#160;28, 2008. Included in these amounts was employee
    stock-based compensation expense of $0, $86,000, $526,000,
    $232,000 and $936,000  and nonemployee stock-based compensation
    expense of $5,000, $59,000, $182,000, $142,000 and $65,000
    during 2005, 2006, 2007 and the six months ended June&#160;30,
    2007 and June&#160;28, 2008, respectively. As of
    December&#160;29, 2007 and June&#160;28, 2008, there was
    $1,698,000 and $5,051,000 of total unrecognized compensation
    costs related to stock-based compensation arrangements granted
    under the Stock Plan, which is expected to be recognized over an
    average period of 2.9&#160;years for both periods.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Certain of our stock options are granted to officers with
    vesting acceleration features based upon the achievement of
    certain performance milestones.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Stock
    Options Granted to Nonemployees</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company accounts for options granted to nonemployees under
    the fair value method in accordance with SFAS&#160;123(R) and
    <FONT style="white-space: nowrap">EITF&#160;96-18.</FONT>
    The fair value of these options was estimated using the
    Black-Scholes option-pricing model with the following
    assumptions for 2005, 2006 and 2007 and the six months ended
    June&#160;30, 2007 and June&#160;28, 2008: risk-free interest
    rates of 3.5% to 5.0%, dividend yield of 0%, expected volatility
    of 53.5% to 82.9%, and an expected life of the options equal to
    the remaining contractual terms of one to ten years. In
    accordance with
    <FONT style="white-space: nowrap">EITF&#160;96-18,</FONT>
    options granted to nonemployees are remeasured at each
    accounting period-end until the award is vested.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company granted options to nonemployees to purchase 17,050,
    88,250, 236,000, 78,000 and 20,000 shares of common stock during
    2005, 2006 and 2007 and the six months ended June&#160;30, 2007
    and June&#160;28, 2008. As of December&#160;29, 2007 and
    June&#160;28, 2008, there were 127,085 and 145,000&#160;shares,
    respectively, subject to unvested options held by nonemployees
    with a weighted-average exercise price of $1.63 and $2.32,
    respectively, and an average remaining vesting period of
    2.7&#160;and 3.0&#160;years, respectively.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-35
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->FLUIDIGM
    CORPORATION</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Notes
    to Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->
<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#059 -->&nbsp;</DIV><!-- /DIV#026 -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->11.&#160;&#160;</FONT><!-- /FONT#008 --></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Shares
    Reserved for Issuance</FONT><!-- /FONT#008 --></B>
</TD>
</TR>

</TABLE>

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    As of December&#160;29, 2007 and June&#160;28, 2008, the Company
    has reserved shares of common stock for future issuance as
    follows (in thousands):
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="75%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Options outstanding
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,333
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Options available for grant
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,197
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,106
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Conversion of outstanding convertible preferred stock
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58,191
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Conversion of convertible preferred stock upon exercise of
    warrants
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    757
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    66,034
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    69,387
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->

</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The above table does not include shares of common stock reserved
    for potential conversions of the convertible promissory notes
    (see Note&#160;7)&#160;into shares of convertible preferred
    stock. The only outstanding convertible promissory note as of
    December&#160;29, 2007 was converted in April&#160;2008, at
    which time the Company issued 1,503,945&#160;shares of
    Series&#160;E convertible preferred stock. There were no
    outstanding convertible promissory notes as of June&#160;28,
    2008.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->12.&#160;&#160;</FONT><!-- /FONT#008 --></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Income
    Taxes</FONT><!-- /FONT#008 --></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The Company&#146;s net loss before the provision for income
    taxes is as follows (in thousands):
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="68%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Domestic
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (15,181
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (21,816
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,372
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    International
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,204
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,737
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,079
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Net loss before provision for income taxes
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->

</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Significant components of the Company&#146;s provision for
    income taxes are as follows (in thousands):
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="74%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Current:
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    Federal
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    State
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    Foreign
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    105
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Total current provision
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    105
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Deferred:
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    Federal
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    State
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt"><!-- DIV#014 -->
    Foreign
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Total deferred provision
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Total provision for income taxes
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    105
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->

</DIV><!-- /DIV#030 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-36
</DIV><!-- /DIV#051 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Reconciliation of the benefits for income taxes at the statutory
    rate to the provision for income taxes is as follows:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="80%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Tax benefit at federal statutory rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    State income taxes (net of federal benefit)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Foreign
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Change in valuation allowance
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (34.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (34.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (31.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Effective tax rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.4
</TD>
<TD nowrap align="left" valign="bottom">
    )%
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Significant components of the Company&#146;s deferred tax assets
    and liabilities are as follows (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="73%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Reserves and accruals
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    485
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    866
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Depreciation and amortization
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,685
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    478
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Tax credit carryforwards
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,450
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,936
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Net operating loss carryforwards
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total deferred tax assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,177
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,747
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Valuation allowance
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (43,177
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (52,747
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net deferred tax assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Recognition of deferred tax assets is appropriate when
    realization of these assets is more likely than not. The Company
    has incurred losses since its inception; accordingly, the net
    deferred tax assets have been fully offset by a valuation
    allowance. The valuation allowance increased by $5,954,000,
    $8,534,000 and $9,570,000 during 2005, 2006 and 2007,
    respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;29, 2007, the Company had net operating loss
    carryforwards for federal income tax purposes of $121,531,000
    which expire in the years 2019 through 2026 and federal research
    and development tax credits of $2,749,000 which expire in the
    years 2008 through 2016. As of December&#160;29, 2007, the
    Company had net operating loss carryforwards for state income
    tax purposes of $119,340,000 which expire in the years 2012
    through 2016 and state research and development tax credits of
    $2,722,000 which do not expire. As of December&#160;29, 2007,
    the Company had foreign net operating loss carryforwards of
    $4,768,000. A significant portion of the foreign net operating
    losses relate to activity in Singapore that has an indefinite
    carryforward period.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Utilization of the net operating loss carryforwards and credits
    may be subject to a substantial annual limitation due to the
    ownership change limitations provided by the Internal Revenue
    Code of 1986, as amended, and similar state provisions. The
    annual limitation may result in the expiration of net operating
    losses and credits before utilization. If an ownership change
    has occurred at different dates or in addition to the dates
    preliminarily identified, the utilization of net operation loss
    and credit carryforwards could be significantly reduced.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company has not provided for U.S. federal and state income
    taxes on all of the non U.S. subsidiaries&#146; undistributed
    earnings as of December&#160;29, 2007, because such earnings are
    intended to be indefinitely reinvested under APB&#160;23. Upon
    distribution of those earnings in the form of dividends or
    otherwise, the Company would be subject to applicable U.S.
    federal and state income taxes.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-37
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Uncertain
    Tax Positions</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Effective January&#160;1, 2007, the Company adopted the
    provisions of FIN&#160;48. As a result, the Company recorded a
    liability for net unrecognized tax benefits of $75,000, and
    recognized a cumulative effect of a change in accounting
    principle that resulted in a charge to the accumulated deficit.
    The liability for unrecognized tax benefits is classified as
    non-current.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The aggregate changes in the balance of the Company&#146;s gross
    unrecognized tax benefits during 2007 were as follows (in
    thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="92%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    January&#160;1, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,157
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Increases in balances related to tax provisions taken during
    current periods
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    December&#160;29, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,922
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Accrued interest and penalties related to unrecognized tax
    benefits are classified as income tax expense and were
    immaterial. As of December&#160;29, 2007, unrecognized tax
    benefits of $162,000, if recognized, would affect the
    Company&#146;s effective tax rate. The remaining unrecognized
    tax benefits were netted against deferred tax assets with a full
    valuation allowance, and if recognized, would not affect the
    Company&#146;s effective tax rate. The Company does not
    anticipate that the amount of existing unrecognized tax benefits
    will significantly increase or decrease within the next
    12&#160;months. The Company files income tax returns in the
    United States, various states and certain foreign jurisdictions.
    The tax years 1999 through 2007 remain open in most
    jurisdictions.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">13.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Employee
    Benefit Plans</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company sponsors a 401(k) plan that stipulates that eligible
    employees can elect to contribute to the plan, subject to
    certain limitations, up to the lesser of 60% of eligible
    compensation or the maximum amount allowed by the IRS on a
    pretax basis annually. The Company has not made contributions to
    this plan since its inception.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">14.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Related-Party
    Transactions</FONT></B>
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As discussed further in Note&#160;7, the Company has entered
    into multiple Convertible Note Purchase Agreements with BMSIF
    pursuant to which the Company issued convertible notes and
    received proceeds in the amount of $20.0&#160;million. Principal
    and interest on the notes was convertible into shares of
    Series&#160;E convertible preferred stock at the lender&#146;s
    election, at any time, and automatically converted upon the
    achievement of certain targets or upon the completion of an
    initial public offering in which the convertible preferred stock
    was converted into common stock. Through June&#160;28, 2008, all
    $20.0&#160;million of these notes had been converted to shares
    of Series&#160;E convertible preferred stock.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    BMSIF and its related companies held 9,008,967&#160;shares of
    the Company&#146;s common stock as of June&#160;28, 2008, which
    constitutes 11.3% of the outstanding shares on a fully diluted
    basis. In addition, the Company&#146;s manufacturing operations
    in Singapore, which commenced operations in October 2005, have
    been supported by grants from EDB which provide incentive
    payments for research, development and manufacturing activity in
    Singapore by the Company. These agreements are discussed further
    in Note&#160;3.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2004, the Company loaned an officer of the Company
    $250,000 in connection with the purchase of a new home, which is
    secured by 833,334&#160;shares of the Company&#146;s common
    stock held by the officer. The loan carried an interest rate of
    3.52% per annum. The outstanding balance of this loan, including
    accrued interest, was $277,000 and $287,000 as of
    December&#160;31, 2006 and December&#160;29, 2007, respectively.
    On April&#160;10, 2008, the principal amount of this note and
    all accrued interest was settled with 90,913&#160;shares held by
    the officer at fair value of the common stock, which was
    determined by the Board of Directors to be $3.19 per share.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Dr.&#160;Stephen Quake, who is a professor of bioengineering at
    Stanford University, is one of the Company&#146;s founding
    stockholders and as such held 2,326,000&#160;shares of common
    stock as of December&#160;31, 2006, December&#160;29,
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-38
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    2007 and June&#160;28, 2008. In June 2006, the Company
    repurchased 124,000&#160;shares of the Company&#146;s common
    stock held by Dr.&#160;Quake for $0.56 per share.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Dr.&#160;Quake also serves as a consultant to the Company and is
    a member of the Company&#146;s Scientific Advisory Board. The
    Company paid consulting fees of $45,000, $97,000, $67,000,
    $50,000 and $58,000 to Dr.&#160;Quake during 2005, 2006, 2007
    and the six months ended June&#160;30, 2007 and June&#160;28,
    2008, respectively, and accrued amounts payable to
    Dr.&#160;Quake related to these payments were $0, $33,000 and
    $17,000 as of December&#160;31, 2006, December&#160;29, 2007 and
    June&#160;28, 2008, respectively. The Company recognized
    $205,000, $241,000, $15,000, $0 and $96,000 in revenue related
    to products and services sold to Stanford University during
    2005, 2006, 2007 and the six months ended June&#160;30, 2007 and
    June&#160;28, 2008, respectively, and had accounts receivable
    balances related to these sales of $0, $11,000 and $260,000 as
    of December&#160;31, 2006, December&#160;29, 2007 and
    June&#160;28, 2008, respectively.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s general counsel was  also a member of a law
    firm whose services are utilized by the Company. On
    April&#160;1, 2008, the Company&#146;s general counsel resigned
    his position from such law firm. Amounts paid to the law firm
    for services and direct patent fees were $880,000, $960,000,
    $576,000, $352,000 and $312,000 for 2005, 2006, 2007 and the six
    months ended June&#160;30, 2007 and June&#160;28, 2008,
    respectively, and accrued amounts payable to the law firm were
    $174,000, $257,000 and $411,000 as of December&#160;31, 2006,
    December&#160;29, 2007 and June&#160;28, 2008, respectively.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">15.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Information
    about Geographic Areas</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    SFAS&#160;No.&#160;131, <I>Disclosures about Segments of an
    Enterprise and Related Information</I>, establishes standards
    for reporting information about operating segments. Operating
    segments are defined as components of an enterprise about which
    separate financial information is available that is evaluated
    regularly by a company&#146;s chief operating decision maker, or
    decision making group, in deciding how to allocate resources and
    in assessing performance. The chief operating decision maker for
    the Company is the Chief Executive Officer. The Chief Executive
    Officer reviews financial information presented on a
    consolidated basis, accompanied by information about revenue by
    geographic region, for purposes of allocating resources and
    evaluating financial performance. The Company has one business
    activity and there are no segment managers who are held
    accountable for operations, operating results or plans for
    levels or components below the consolidated unit level.
    Accordingly, the Company has determined that it has a single
    reporting segment and operating unit structure which is the
    development, manufacturing and commercialization of IFCs and
    complementary laboratory instruments.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Revenue by geography is based on the billing address of the
    customer. The following tables set forth revenue and long-lived
    assets by geographic area (in thousands):
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Revenue</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Six Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    United States
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,807
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,492
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,231
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,530
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Singapore
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    879
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    889
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,027
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Japan
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,274
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,492
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    732
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    162
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    543
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Europe
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    545
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    189
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    735
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    631
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    953
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    298
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    344
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    84
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,674
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,997
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,520
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-39
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->FLUIDIGM
    CORPORATION</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Notes
    to Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->
<DIV style="margin-top: 18pt; font-size: 1pt"><!-- DIV#059 -->&nbsp;</DIV><!-- /DIV#026 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Long-lived
    Assets</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="61%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    United States
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,818
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,361
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,154
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Singapore
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,240
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,009
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,596
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Japan
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt"><!-- DIV#014 -->
    Total
</DIV><!-- /DIV#008 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,378
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,757
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->

</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-40
</DIV><!-- /DIV#051 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="f39432a6f3943219.gif" alt="(DYNAMIC ARRAY SCHEMATIC GRAPHIC)"><B>
    </B>
</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="f39432a6f3943220.gif" alt="(CIRCUITS &#38; SYSTEMS GRAPHIC)">
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="f39432a6f3943216.gif" alt="(FLUIDIGM LOGO)"><B> </B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PART&#160;II<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">INFORMATION
    NOT REQUIRED IN PROSPECTUS</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;13.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Other
    Expenses of Issuance and Distribution.</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth all expenses to be paid by the
    registrant, other than estimated underwriting discounts and
    commissions, in connection with this offering. All amounts shown
    are estimates except for the SEC registration fee, the NASD
    filing fee and the NASDAQ Global Market listing fee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="92%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    SEC registration fee
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,390
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    NASD filing fee
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,125
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    NASDAQ Global Market listing fee
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Printing and engraving
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Legal fees and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accounting fees and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Blue sky fees and expenses (including legal fees)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Transfer agent and registrar fees
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Miscellaneous
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    *&#160;</TD>
    <TD></TD>
    <TD valign="bottom">
    To be provided by amendment.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;14.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Indemnification
    of Directors and Officers.</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Section&#160;145 of the Delaware General Corporation Law
    authorizes a corporation&#146;s board of directors to grant, and
    authorizes a court to award, indemnity to officers, directors
    and other corporate agents.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As permitted by Section&#160;102(b)(7) of the Delaware General
    Corporation Law, the registrant&#146;s certificate of
    incorporation includes provisions that eliminate the personal
    liability of its directors and officers for monetary damages for
    breach of their fiduciary duty as directors and officers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, as permitted by Section&#160;145 of the Delaware
    General Corporation Law, the bylaws of the registrant provide
    that:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The registrant shall indemnify its directors and officers for
    serving the registrant in those capacities or for serving other
    business enterprises at the registrant&#146;s request, to the
    fullest extent permitted by Delaware law. Delaware law provides
    that a corporation may indemnify such person if such person
    acted in good faith and in a manner such person reasonably
    believed to be in or not opposed to the best interests of the
    registrant and, with respect to any criminal proceeding, had no
    reasonable cause to believe such person&#146;s conduct was
    unlawful.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The registrant may, in its discretion, indemnify employees and
    agents in those circumstances where indemnification is not
    required by law.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The registrant is required to advance expenses, as incurred, to
    its directors and officers in connection with defending a
    proceeding, except that such director or officer shall undertake
    to repay such advances if it is ultimately determined that such
    person is not entitled to indemnification.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The registrant will not be obligated pursuant to the bylaws to
    indemnify a person with respect to proceedings initiated by that
    person, except with respect to proceedings authorized by the
    registrant&#146;s Board of Directors or brought to enforce a
    right to indemnification.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The rights conferred in the bylaws are not exclusive, and the
    registrant is authorized to enter into indemnification
    agreements with its directors, officers, employees and agents
    and to obtain insurance to indemnify such persons.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The registrant may not retroactively amend the bylaw provisions
    to reduce its indemnification obligations to directors,
    officers, employees and agents.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The registrant&#146;s policy is to enter into separate
    indemnification agreements with each of its directors and
    officers that provide the maximum indemnity allowed to directors
    and executive officers by Section&#160;145 of the Delaware
    General Corporation Law and also provides for certain additional
    procedural protections. The registrant also maintains directors
    and officers insurance to insure such persons against certain
    liabilities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    These indemnification provisions and the indemnification
    agreements entered into between the registrant and its officers
    and directors may be sufficiently broad to permit
    indemnification of the registrant&#146;s officers and directors
    for liabilities (including reimbursement of expenses incurred)
    arising under the Securities Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The underwriting agreement filed as Exhibit&#160;1.1 to this
    registration statement provides for indemnification by the
    underwriters of the registrant and its officers and directors
    for certain liabilities arising under the Securities Act and
    otherwise.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;15.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Recent
    Sales of Unregistered Securities.</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the three years prior to the filing of this registration
    statement, the registrant has issued the following unregistered
    securities:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;From March 2005 through July&#160;17, 2007, Fluidigm
    Corporation, a California corporation, issued and sold an
    aggregate of 470,965&#160;shares of its common stock upon the
    exercise of options issued to certain employees, directors and
    consultants under the registrant&#146;s 1999 Stock Option Plan,
    as amended, at exercise prices ranging from $0.30 to $0.83, for
    aggregate consideration of $188,442. From July&#160;18, 2007
    through May&#160;22,&#160;2008, the registrant issued and sold
    an aggregate of 250,720&#160;shares of its common stock upon the
    exercise of options issued to certain employees, directors and
    consultants under the registrant&#146;s 1999 Stock Option Plan,
    as amended, at exercise prices ranging from $0.30 to $1.36 per
    share, for aggregate consideration of $123,346.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;From March 2005 through July&#160;17, 2007, Fluidigm
    Corporation, a California corporation, granted to certain of its
    employees, directors and consultants under the registrant&#146;s
    1999 Stock Option Plan, as amended, options to purchase an
    aggregate of 3,986,044&#160;shares of its common stock at
    exercise prices ranging from $0.30 to $1.36 per share. From
    July&#160;18, 2007 through May&#160;22, 2008, the registrant
    granted to certain of its employees, directors and consultants
    under the registrant&#146;s 1999 Stock Option Plan, as amended,
    options to purchase an aggregate of 452,200&#160;shares of the
    registrant&#146;s common stock at exercise prices ranging from
    $1.38 to $2.40 per share.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (c)&#160;In March 2005, Fluidigm Corporation, a California
    corporation, pursuant to a loan and security agreement, issued
    and sold a warrant to purchase 371,428&#160;shares of its
    Series&#160;D Preferred Stock to one accredited investor at an
    exercise price of $2.80 per share. In connection with the
    registrant&#146;s reincorporation into the State of Delaware on
    July&#160;18, 2007, the warrant was converted into a warrant to
    purchase an equal number of shares of the registrant&#146;s
    Series&#160;D Preferred Stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (d)&#160;In November 2005, Fluidigm Corporation, a California
    corporation, issued and sold 70,000&#160;shares of its common
    stock to one accredited investor at an issuance price of $0.56
    per share for aggregate monetary consideration of $39,200, which
    amount was deemed paid by the transfer of certain rights granted
    to registrant pursuant to the terms of a licensing agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (e)&#160;In December 2005, Fluidigm Corporation, a California
    corporation, issued 832,635&#160;shares of its Series&#160;D
    Preferred Stock to one accredited investor in connection with
    the conversion of a convertible promissory note at a conversion
    price per share of $2.80.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (f)&#160;In June 2006, Fluidigm Corporation, a California
    corporation, issued to one accredited investor a convertible
    promissory notes in an aggregate principal amount of $3,000,000
    convertible into shares of its Series&#160;D Preferred Stock. In
    July 2007, the notes were converted into 1,157,142&#160;shares
    of Series&#160;D Preferred Stock at a conversion price per share
    of $2.80.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (g)&#160;In June 2006, Fluidigm Corporation, a California
    corporation, issued 214,285&#160;shares of its Series&#160;D
    Preferred Stock to one accredited investor at an issuance price
    of $2.80 per share, for aggregate monetary consideration of
    $599,998, which amount was deemed paid by the transfer of
    certain rights granted to registrant pursuant to the terms of a
    licensing agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (h)&#160;In June 2006, Fluidigm Corporation, a California
    corporation, issued 267,858&#160;shares of its Series&#160;D
    Preferred Stock to one accredited investor in connection with
    the exercise of a warrant to purchase shares of its
    Series&#160;D Preferred Stock at an exercise price per share of
    $2.80.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (i)&#160;From August 2006 through April 2007, Fluidigm
    Corporation, a California corporation, issued three convertible
    promissory notes to one accredited investor in an aggregate
    principal amount of $15,000,000, all of which were convertible
    into shares of its Series&#160;E Preferred Stock. In March 2007,
    two of the notes were converted into an aggregate of
    2,954,337&#160;shares of the Series&#160;E Preferred Stock of
    Fluidigm Corporation, a California corporation. In connection
    with the registrant&#146;s reincorporation into the State of
    Delaware on July&#160;18, 2007, the remaining outstanding
    convertible promissory note was made convertible into shares of
    the registrant&#146;s Series&#160;E Preferred Stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (j)&#160;In March 2007, Fluidigm Corporation, a California
    corporation, issued 100,000&#160;shares of its common stock to
    one accredited investor at an issuance price of $0.83 per share,
    for aggregate monetary consideration of $83,000, which amount
    was deemed paid by the transfer of certain rights granted to
    registrant pursuant to the terms of a licensing agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (k)&#160;In May 2007, Fluidigm Corporation, a California
    corporation, granted to seven of its employees and directors
    under the registrant&#146;s 1999 Stock Option Plan, as amended,
    options to purchase an aggregate of 767,000&#160;shares of its
    common stock at an exercise price of $1.36 per share.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (l)&#160;In connection with the registrant&#146;s
    reincorporation into the State of Delaware on July&#160;18,
    2007, the registrant issued an aggregate of
    9,695,998&#160;shares of common stock to a total of 128
    stockholders in exchange for the outstanding shares of common
    stock Fluidigm Corporation, a California corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (m)&#160;In connection with the registrant&#146;s
    reincorporation into the State of Delaware on July&#160;18,
    2007, the registrant issued an aggregate of
    2,727,273&#160;shares of the registrant&#146;s Series&#160;A
    Preferred Stock to a total of 41 investors in exchange for the
    outstanding shares of Series&#160;A Preferred Stock of Fluidigm
    Corporation, a California corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (n)&#160;In connection with the registrant&#146;s
    reincorporation into the State of Delaware on July&#160;18,
    2007, the registrant issued an aggregate of
    6,460,675&#160;shares of the registrant&#146;s Series&#160;B
    Preferred Stock to a total of 35 investors in exchange for the
    outstanding shares of Series&#160;B Preferred Stock of Fluidigm
    Corporation, a California corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (o)&#160;In connection with the registrant&#146;s
    reincorporation into the State of Delaware on July&#160;18,
    2007, the registrant issued an aggregate of
    16,364,832&#160;shares of the registrant&#146;s Series&#160;C
    Preferred Stock to a total of 62 investors in exchange for the
    outstanding shares of Series&#160;C Preferred Stock of Fluidigm
    Corporation, a California corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (p)&#160;In connection with the registrant&#146;s
    reincorporation into the State of Delaware on July&#160;18,
    2007, the registrant issued an aggregate of
    12,196,191&#160;shares of the registrant&#146;s Series&#160;D
    Preferred Stock to a total of 52 investors in exchange for the
    outstanding shares of Series&#160;D Preferred Stock of Fluidigm
    Corporation, a California corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (q)&#160;In connection with the registrant&#146;s
    reincorporation into the State of Delaware on July&#160;18,
    2007, the registrant issued an aggregate of
    8,969,836&#160;shares of the registrant&#146;s Series&#160;E
    Preferred Stock to a total of 35 investors in exchange for the
    outstanding shares of Series&#160;E Preferred Stock of Fluidigm
    Corporation, a California corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (r)&#160;From October 2007 through December 2007, the registrant
    issued and sold an aggregate of 8,794,945&#160;shares of
    Series&#160;E Preferred Stock to a total of seven investors at
    $4.00 per share, for aggregate proceeds of $35,179,780.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    (s)&#160;In December 2007, the registrant issued
    6,000&#160;shares of its common stock to one accredited investor
    at an issuance price of $1.36 per share for aggregate monetary
    consideration of $8,160, which amount was deemed paid by the
    transfer of certain rights granted to registrant pursuant to the
    terms of a licensing agreement.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    (t)&#160;In December 2007, the registrant granted to one of its
    directors under the registrant&#146;s 1999 Stock Option Plan, as
    amended, options to purchase an aggregate of 100,000&#160;shares
    of the registrant&#146;s common stock at an exercise price of
    $2.40 per share.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    (u)&#160;In February and June 2008, the registrant issued a
    warrant to purchase 100,000 and 200,000&#160;shares of the
    registrant&#146;s Series&#160;E Preferred Stock to one
    accredited investor at an exercise price of $4.00 per share.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    (v)&#160;In February 2008, the registrant granted to one of its
    executive officers under the registrant&#146;s 1999 Stock Option
    Plan, as amended, options to purchase an aggregate of
    600,000&#160;shares of the registrant&#146;s common stock at an
    exercise price of $2.40 per share.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    (w)&#160;In April 2008, the registrant granted to six of its
    employees and directors under the registrant&#146;s 1999 Stock
    Option Plan, as amended, options to purchase an aggregate of
    1,090,000&#160;shares of its common stock at an exercise price
    of $3.19 per share.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    (x)&#160;On May&#160;12, 2008, the registrant issued
    16,422&#160;shares of its Series&#160;C Preferred Stock to
    Imperial Bank pursuant to Imperial Bank&#146;s net exercise of
    its warrant to purchase up to 41,284&#160;shares of
    Series&#160;C Preferred Stock. The remainder of the warrant was
    cancelled pursuant to the terms of the net exercise.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    (y)&#160;In June 2008, the registrant granted to seven of its
    employees and consultants under the registrant&#146;s 1999 Stock
    Option Plan, as amended, options to purchase an aggregate of
    85,000&#160;shares of its common stock at an exercise price of
    $3.42 per share.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    (z)&#160;In August 2008, the registrant granted to eight of its
    employees under the registrant&#146;s 1999 Stock Option Plan, as
    amended, options to purchase an aggregate of 64,500&#160;shares
    of its common stock at an exercise price of $3.63 per share.
</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    None of the foregoing transactions involved any underwriters,
    underwriting discounts or commissions, or any public offering,
    and the registrant believes that each transaction was exempt
    from the registration requirements of the Securities Act in
    reliance on the following exemptions:
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 3pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    with respect to the transactions described in paragraphs
    (a)&#160;and (b), Rule&#160;701 promulgated under the Securities
    Act as transactions pursuant to a compensatory benefit plan
    approved by the registrant&#146;s Board of Directors;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    with respect to the transactions described in paragraphs (1)
    through (q), Rule&#160;145(a)(2) promulgated under the
    Securities Act as transactions pursuant to a plan or agreement
    for statutory merger or similar plan or acquisition in which
    securities of the registrant were exchanged for the securities
    of Fluidigm Corporation, a California corporation, the sole
    purpose of which was to change the registrant&#146;s domicile
    solely within the United States, and a Permit granted pursuant
    to Section 25121 of the California Corporations Code;&#160;and
</TD>
</TR>

</TABLE>

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<DIV style="margin-top: 3pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    with respect to the transactions described in paragraphs
    (c)&#160;through (k) and paragraphs (r) through (z),
    Section&#160;4(2) of the Securities Act, or Rule&#160;506 of
    Regulation&#160;D promulgated thereunder, as transactions by an
    issuer not involving a public offering. Each recipient of the
    securities in this transaction represented his or her intention
    to acquire the securities for investment only and not with a
    view to, or for resale in connection with, any distribution
    thereof, and appropriate legends were affixed to the share
    certificates issued in each such transaction. In each case, the
    recipient received adequate information about the registrant or
    had adequate access, through his or her relationship with the
    registrant, to information about the registrant.
</TD>
</TR>

</TABLE>

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Item&#160;16.<I>&#160;&#160;</I></FONT><!-- /FONT#008 --></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Exhibits
    and Financial Statement
    Schedules.</FONT><!-- /FONT#008 --></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    (a)&#160;<I>Exhibits.</I>&#160;&#160;The following exhibits are
    included herein or incorporated herein by reference:
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=01 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=01 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=01 type=align1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="85%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px"><!-- DIV#013 -->
    <B>Exhibit Number</B>
</DIV><!-- /DIV#007 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px"><!-- DIV#013 -->
    <B>Description</B>
</DIV><!-- /DIV#007 -->
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    1
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Underwriting Agreement.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Certificate of Incorporation of the Registrant, as currently in
    effect.
</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-4
</DIV><!-- /DIV#050 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=01 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=01 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=01 type=align1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="85%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px"><!-- DIV#013 -->
    <B>Exhibit Number</B>
</DIV><!-- /DIV#007 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px"><!-- DIV#013 -->
    <B>Description</B>
</DIV><!-- /DIV#007 -->
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .2<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Restated Certificate of Incorporation of the Registrant,
    to be in effect upon the completion of this offering.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .3<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Bylaws of the Registrant.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .4<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Amended and Restated Bylaws of the Registrant, to be in
    effect upon completion of this offering.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Specimen Common Stock Certificate of the Registrant.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .2<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Series&#160;E Preferred Stock Purchase Agreement dated
    June&#160;13, 2006 through December&#160;31, 2007 between the
    Registrant and the Purchasers set forth therein, as amended.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .3<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Eighth Amended and Restated Investor Rights Agreement between
    the Registrant and certain holders of the Registrant&#146;s
    common stock named therein, including amendments No.&#160;1 and
    No.&#160;2.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .4<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Loan and Security Agreement No.&#160;4561 between the Registrant
    and Lighthouse Capital Partners&#160;V, L.P. dated
    March&#160;29, 2005, including amendments Nos. 1 through 4.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .4A<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Preferred Stock Purchase Warrant issued to Lighthouse Capital
    Partners&#160;V, L.P. effective March&#160;29, 2005.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .4B<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Negative Pledge Agreement by and between the Registrant and
    Lighthouse Capital Partners&#160;V, L.P. dated March&#160;29,
    2005.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .5<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Convertible Note Purchase Agreement by and between Biomedical
    Sciences Investment Fund&#160;Pte Ltd and the Registrant dated
    August&#160;7, 2006.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .5A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Convertible Promissory Note issued to Biomedical Sciences
    Investment Fund&#160;Pte Ltd dated April&#160;19, 2007, as
    amended.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    5
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Opinion of Wilson Sonsini Goodrich&#160;&#038; Rosati,
    Professional Corporation.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Indemnification Agreement between the Registrant and its
    directors and officers.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .2<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    1999 Stock Plan of the Registrant, as amended April&#160;24,
    2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .2A<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Forms of agreements under the 1999 Stock Plan.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .3<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    2008 Equity Incentive Plan.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .3A<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Forms of agreements under the 2008 Equity Incentive Plan.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .4<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Second Amended and Restated License Agreement by and between
    California Institute of Technology and the Registrant effective
    as of May&#160;1, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .4A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Addendum, effective as of March&#160;29, 2007, to Second
    Amended and Restated License Agreement by and between California
    Institute of Technology and the Registrant effective as of
    May&#160;1, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .5<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Co-Exclusive License Agreement between President and Fellows of
    Harvard College and the Registrant effective as of
    October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .5A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Amendment to Co-Exclusive License Agreement between
    President and Fellows of Harvard College and the Registrant
    effective as of October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .6<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Co-Exclusive License Agreement between President and Fellows of
    Harvard College and the Registrant effective as of
    October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .7<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Co-Exclusive License Agreement between President and Fellows of
    Harvard College and the Registrant effective as of
    October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .8<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Patent License Agreement by and between Gyros AB and the
    Registrant dated January&#160;9, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .8A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amendment No.&#160;1 dated January&#160;9, 2005 to Patent
    License Agreement by and between Gyros AB and the Registrant
    dated January&#160;9, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .9<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Master Closing Agreement by and between UAB Research Foundation,
    Oculus Pharmaceuticals, Inc. and the Registrant dated
    March&#160;7, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .9A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    License Agreement by and between UAB Research Foundation and the
    Registrant dated March&#160;7, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .10<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amended and Restated Letter Agreement Regarding Application for
    Incentives Under the Research Incentive Scheme for Companies
    (RISC) dated March&#160;27, 2008 (originally dated
    October&#160;7, 2005), by and between Singapore Economic
    Development Board and Fluidigm Singapore Pte. Ltd.
</TD>
</TR>
</TABLE>

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    II-5
</DIV><!-- /DIV#050 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=01 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=01 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=01 type=align1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="85%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px"><!-- DIV#013 -->
    <B>Exhibit Number</B>
</DIV><!-- /DIV#007 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px"><!-- DIV#013 -->
    <B>Description</B>
</DIV><!-- /DIV#007 -->
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .10A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Supplement Dated January&#160;11, 2006 to Letter Agreement
    Relating to Application for Incentives under the Research
    Incentive Scheme for Companies (RISC), dated October&#160;7,
    2005 between Singapore Economic Development Board and Fluidigm
    Singapore Pte. Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .11<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amended and Restated Letter Agreement Regarding Application for
    Incentives Under the Research Incentive Scheme for Companies
    (RISC) dated March&#160;27, 2008 (originally dated
    February&#160;12, 2007), by and between Singapore Economic
    Development Board and Fluidigm Singapore Pte. Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .12<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Distribution Agreement by and between Eppendorf AG and the
    Registrant effective as of April&#160;1, 2005.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .12A
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Amendment, effective as of December&#160;1, 2007, to the
    Distribution Agreement by and between Eppendorf AG and the
    Registrant effective as of April&#160;1, 2005.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .13<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Employment and Severance Agreement between the
    Registrant and each of its executive officers.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .14<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consulting Agreement by and between the Registrant and Richard
    DeLateur dated February&#160;29, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .15<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Employee Loan Agreement with Gajus Worthington dated
    January&#160;20, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .15A<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Stock Repurchase Agreement between the Registrant and Gajus V.
    Worthington dated April&#160;10, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .16<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Offer Letter to Vikram Jog dated January&#160;29, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .17<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Settlement Agreement and General Release of all Claims by and
    between Michael Ybarra Lucero and the Registrant dated
    March&#160;20, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .18<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Letter Agreement between President and Fellows of Harvard
    College and the Registrant dated December&#160;22, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    21
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    List of subsidiaries of Registrant.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    23
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Independent Registered Public Accounting Firm.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    23
</TD>
<TD nowrap align="left" valign="top">
    .2<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Wilson Sonsini Goodrich&#160;&#038; Rosati,
    Professional Corporation (included in Exhibit&#160;5.1).
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    24
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Power of Attorney.
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->

</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV style="font-size: 12pt; margin-left: 0%;  align: left; border-bottom: 1pt solid #000000"><!-- DIV#071 --></DIV><!-- /DIV#041 --><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(1)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->To be filed by
    amendment.</FONT><!-- /FONT#008 --></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(2)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->Confidential
    treatment has been requested with respect to certain portions of
    this exhibit. Omitted portions have been filed separately with
    the Securities and Exchange Commission.</FONT><!-- /FONT#008 --></TD>
</TR>



<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(3)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->Previously
    filed.</FONT><!-- /FONT#008 --></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    (b)&#160;<I>Financial Statement Schedules.</I>
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    All schedules have been omitted because the information required
    to be presented in them is not applicable or is shown in the
    consolidated financial statements or related notes.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 12pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->Item&#160;17.&#160;&#160;<I>Undertakings.</I></FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The undersigned registrant hereby undertakes to provide to the
    underwriters at the closing specified in the underwriting
    agreement certificates in such denominations and registered in
    such names as required by the underwriters to permit prompt
    delivery to each purchaser.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    Insofar as indemnification for liabilities arising under the
    Securities Act of 1933&#160;may be permitted to directors,
    officers and controlling persons of the registrant pursuant to
    the foregoing provisions, or otherwise, the registrant has been
    advised that in the opinion of the Securities and Exchange
    Commission such indemnification is against public policy as
    expressed in the Act and is, therefore, unenforceable. In the
    event that a claim for indemnification against such liabilities
    (other than the payment by the registrant of expenses incurred
    or paid by a director, officer or controlling person of the
    registrant in the successful defense of any action, suit or
    proceeding) is asserted by such director, officer or controlling
    person in connection with the securities being registered, the
    registrant will, unless in the opinion of its counsel the matter
    has been settled by controlling precedent, submit to a court of
    appropriate
</DIV><!-- /DIV#030 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    II-6
</DIV><!-- /DIV#050 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    jurisdiction the question whether such indemnification by it is
    against public policy as expressed in the Act and will be
    governed by the final adjudication of such issue.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    The undersigned registrant hereby undertakes that:
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    (1)&#160;For purposes of determining any liability under the
    Securities Act of 1933, the information omitted from the form of
    prospectus filed as part of this registration statement in
    reliance upon Rule&#160;430A and contained in a form of
    prospectus filed by the registrant pursuant to
    Rule&#160;424(b)(1) or (4)&#160;or 497(h) under the Securities
    Act shall be deemed to be part of this registration statement as
    of the time it was declared effective.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    (2)&#160;For the purpose of determining any liability under the
    Securities Act of 1933, each post effective amendment that
    contains a form of prospectus shall be deemed to be a new
    registration statement relating to the securities offered
    therein, and the offering of such securities at that time shall
    be deemed to be the initial bona fide offering thereof.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    (3)&#160;For the purpose of determining liability under the
    Securities Act of 1933 to any purchaser, if the registrant is
    subject to Rule&#160;430C, each prospectus filed pursuant to
    Rule&#160;424(b) as part of a registration statement relating to
    an offering, other than registration statements relying on
    Rule&#160;430B or other than prospectuses filed in reliance on
    Rule 430A, shall be deemed to be part of and included in the
    registration statement as of the date it is first used after
    effectiveness; provided, however, that no statement made in a
    registration statement or prospectus that is part of the
    registration statement or made in a document incorporated or
    deemed incorporated by reference into the registration statement
    or prospectus that is part of the registration statement will,
    as to a purchaser with a time of contract of sale prior to such
    first use, supersede or modify any statement that was made in
    the registration statement or prospectus that was part of the
    registration statement or made in any such document immediately
    prior to such date of first use.
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    (4)&#160;For the purpose of determining liability of the
    registrant under the Securities Act of 1933 to any purchaser to
    the initial distribution of the securities, the undersigned
    registrant undertakes that in a primary offering of securities
    of the undersigned registrant pursuant to this registration
    statement, regardless of the underwriting method used to sell
    the securities to the purchaser, if the securities are offered
    or sold to such purchaser by means of any of the following
    communications, the undersigned registrant will be a seller to
    the purchasers and will be considered to offer or sell such
    securities to such purchaser:
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    (i)&#160;Any preliminary prospectus or prospectus of the
    undersigned registrant relating to the offering required to be
    filed pursuant to Rule&#160;424;
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    (ii)&#160;Any free writing prospectus relating to the offering
    prepared by or on behalf of the undersigned registrant or used
    or referred to by the undersigned registrant;
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    (iii)&#160;The portion of any other free writing prospectus
    relating to the offering containing material information about
    the undersigned registrant or its securities provided by or on
    behalf of the undersigned registrant;&#160;and
</DIV><!-- /DIV#030 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->
    (iv)&#160;Any other communication that is an offer in the
    offering made by the undersigned registrant to the purchaser.
</DIV><!-- /DIV#030 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-7
</DIV><!-- /DIV#050 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SIGNATURES</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the requirements of the Securities Act of 1933, the
    Registrant has duly caused this Amendment No.&#160;6 to the
    registration statement to be signed on its behalf by the
    undersigned, thereunto duly authorized, in the City of South San
    Francisco, State of California, on the 27th day of August 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>FLUIDIGM CORPORATION</B>
</DIV>

<DIV style="margin-top: 36pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="center">
    <DIV style="display:inline; text-align:center; width:90%">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Gajus
    V. Worthington</FONT></DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV align="center" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Gajus V. Worthington
</DIV>

<DIV align="center" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>President and Chief Executive Officer</I>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the requirements of the Securities Act of 1933, this
    Amendment No. 6 to the registration statement has been signed by
    the following persons in the capacities indicated on the 26th
    day of August 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="6%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="38%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="35%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="14%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Signature</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Title</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Date</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 12pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:center; width:90%">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Gajus
    V. Worthington</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=198 length=0 -->Gajus
    V. Worthington
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    President, Chief Executive Officer and Director (Principal
    Executive Officer)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    August&#160;27, 2008
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:center; width:90%">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Vikram
    Jog</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=198 length=0 -->Vikram
    Jog
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    Chief Financial Officer (Principal Accounting and Financial
    Officer)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    August&#160;27, 2008
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:center; width:90%"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=198 length=0 -->Samuel
    Colella
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    August&#160;27, 2008
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:center; width:90%"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=198 length=0 -->Michael
    W. Hunkapiller
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    August&#160;27, 2008
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:center; width:90%"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=198 length=0 -->Elaine
    V. Jones
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    August&#160;27, 2008
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:center; width:90%"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=198 length=0 -->Kenneth
    Nussbacher
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    August&#160;27, 2008
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:center; width:90%"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=198 length=0 -->John
    A. Young
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    August&#160;27, 2008
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="center" valign="top">
    *By:
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <DIV style="display:inline; text-align:center; width:90%">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Gajus
    V. Worthington</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=208 iwidth=174 length=0 -->Gajus
    V. Worthington<BR>
    Attorney-in-Fact
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- DIV#053 -->

    <B><FONT style="font-family: 'Times New Roman', Times"><!-- FONT#010 -->EXHIBIT&#160;INDEX</FONT><!-- /FONT#008 --></B>
</DIV><!-- /DIV#031 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=01 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=01 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=01 type=align1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="85%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px"><!-- DIV#013 -->
    <B>Exhibit Number</B>
</DIV><!-- /DIV#007 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px"><!-- DIV#013 -->
    <B>Description</B>
</DIV><!-- /DIV#007 -->
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    1
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Underwriting Agreement.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Certificate of Incorporation of the Registrant, as currently in
    effect.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .2<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Restated Certificate of Incorporation of the Registrant,
    to be in effect upon the completion of this offering.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .3<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Bylaws of the Registrant.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .4<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Amended and Restated Bylaws of the Registrant, to be in
    effect upon completion of this offering.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Specimen Common Stock Certificate of the Registrant.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .2<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Series&#160;E Preferred Stock Purchase Agreement dated
    June&#160;13, 2006 through December&#160;31, 2007 between the
    Registrant and the Purchasers set forth therein, as amended.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .3<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Eighth Amended and Restated Investor Rights Agreement between
    the Registrant and certain holders of the Registrant&#146;s
    common stock named therein, including amendments No.&#160;1 and
    No.&#160;2.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .4<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Loan and Security Agreement No.&#160;4561 between the Registrant
    and Lighthouse Capital Partners&#160;V, L.P. dated
    March&#160;29, 2005, including amendments Nos. 1 through 4.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .4A<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Preferred Stock Purchase Warrant issued to Lighthouse Capital
    Partners&#160;V, L.P. effective March&#160;29, 2005.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .4B<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Negative Pledge Agreement by and between the Registrant and
    Lighthouse Capital Partners&#160;V, L.P. dated March&#160;29,
    2005.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .5<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Convertible Note Purchase Agreement by and between Biomedical
    Sciences Investment Fund&#160;Pte Ltd and the Registrant dated
    August&#160;7, 2006.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .5A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Convertible Promissory Note issued to Biomedical Sciences
    Investment Fund&#160;Pte Ltd dated April&#160;19, 2007, as
    amended.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    5
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Opinion of Wilson Sonsini Goodrich&#160;&#038; Rosati,
    Professional Corporation.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Indemnification Agreement between the Registrant and its
    directors and officers.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .2<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    1999 Stock Plan of the Registrant, as amended April&#160;24,
    2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .2A<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Forms of agreements under the 1999 Stock Plan.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .3<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    2008 Equity Incentive Plan.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .3A<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Forms of agreements under the 2008 Equity Incentive Plan.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .4<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Second Amended and Restated License Agreement by and between
    California Institute of Technology and the Registrant effective
    as of May&#160;1, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .4A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Addendum, effective as of March&#160;29, 2007, to Second
    Amended and Restated License Agreement by and between California
    Institute of Technology and the Registrant effective as of
    May&#160;1, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .5<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Co-Exclusive License Agreement between President and Fellows of
    Harvard College and the Registrant effective as of
    October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .5A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Amendment to Co-Exclusive License Agreement between
    President and Fellows of Harvard College and the Registrant
    effective as of October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .6<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Co-Exclusive License Agreement between President and Fellows of
    Harvard College and the Registrant effective as of
    October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .7<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Co-Exclusive License Agreement between President and Fellows of
    Harvard College and the Registrant effective as of
    October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .8<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Patent License Agreement by and between Gyros AB and the
    Registrant dated January&#160;9, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .8A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amendment No.&#160;1 dated January&#160;9, 2005 to Patent
    License Agreement by and between Gyros AB and the Registrant
    dated January&#160;9, 2003.
</TD>
</TR>
</TABLE>

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- /DIV#050 --><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- DIV#062 (OutputPage 1) --><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><!-- DIV#056 --><FONT size="1"><!-- FONT#001 -->

</FONT><!-- /FONT#001 --></DIV><!-- /DIV#016 -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=01 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=01 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=01 type=align1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="85%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px"><!-- DIV#013 -->
    <B>Exhibit Number</B>
</DIV><!-- /DIV#007 -->
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px"><!-- DIV#013 -->
    <B>Description</B>
</DIV><!-- /DIV#007 -->
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .9<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Master Closing Agreement by and between UAB Research Foundation,
    Oculus Pharmaceuticals, Inc. and the Registrant dated
    March&#160;7, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .9A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    License Agreement by and between UAB Research Foundation and the
    Registrant dated March&#160;7, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .10<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amended and Restated Letter Agreement Regarding Application for
    Incentives Under the Research Incentive Scheme for Companies
    (RISC) dated March&#160;27, 2008 (originally dated
    October&#160;7, 2005), by and between Singapore Economic
    Development Board and Fluidigm Singapore Pte. Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .10A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Supplement Dated January&#160;11, 2006 to Letter Agreement
    Relating to Application for Incentives under the Research
    Incentive Scheme for Companies (RISC), dated October&#160;7,
    2005 between Singapore Economic Development Board and Fluidigm
    Singapore Pte. Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .11<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amended and Restated Letter Agreement Regarding Application for
    Incentives Under the Research Incentive Scheme for Companies
    (RISC) dated March&#160;27, 2008 (originally dated
    February&#160;12, 2007), by and between Singapore Economic
    Development Board and Fluidigm Singapore Pte. Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .12<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Distribution Agreement by and between Eppendorf AG and the
    Registrant effective as of April&#160;1, 2005.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .12A
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Amendment, effective as of December&#160;1, 2007, to the
    Distribution Agreement by and between Eppendorf AG and the
    Registrant effective as of April&#160;1, 2005.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .13<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Employment and Severance Agreement between the
    Registrant and each of its executive officers.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .14<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consulting Agreement by and between the Registrant and Richard
    DeLateur dated February&#160;29, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .15<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Employee Loan Agreement with Gajus Worthington dated
    January&#160;20, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .15A<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Stock Repurchase Agreement between the Registrant and Gajus V.
    Worthington dated April&#160;10, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .16<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Offer Letter to Vikram Jog dated January&#160;29, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .17<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Settlement Agreement and General Release of all Claims by and
    between Michael Ybarra Lucero and the Registrant dated
    March&#160;20, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .18<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Letter Agreement between President and Fellows of Harvard
    College and the Registrant dated December&#160;22, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    21
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    List of subsidiaries of Registrant.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    23
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Independent Registered Public Accounting Firm.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    23
</TD>
<TD nowrap align="left" valign="top">
    .2<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Wilson Sonsini Goodrich&#160;&#038; Rosati,
    Professional Corporation (included in Exhibit&#160;5.1).
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    24
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Power of Attorney.
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- DIV#048 -->

</DIV><!-- /DIV#030 -->

<DIV align="left"><!-- DIV#057 --><FONT size="1"><!-- FONT#002 -->

</FONT><!-- /FONT#002 --></DIV><!-- /DIV#017 -->

<DIV style="margin-top: 6pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->

<DIV style="font-size: 12pt; margin-left: 0%;  align: left; border-bottom: 1pt solid #000000"><!-- DIV#071 --></DIV><!-- /DIV#041 --><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt"><!-- DIV#028 -->&nbsp;</DIV><!-- /DIV#022 -->



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(1)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->To be filed by
    amendment.</FONT><!-- /FONT#008 --></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(2)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->Confidential
    treatment has been requested with respect to certain portions of
    this exhibit. Omitted portions have been filed separately with
    the Securities and Exchange Commission.</FONT><!-- /FONT#008 --></TD>
</TR>



<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->(3)
    </FONT><!-- /FONT#008 --></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"><!-- FONT#010 -->Previously
    filed.</FONT><!-- /FONT#008 --></TD>
</TR>

</TABLE>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- /DIV#051 --><!-- END PAGE WIDTH -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>2
<FILENAME>f39432a6exv10w12.htm
<DESCRIPTION>EXHIBIT 10.12
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w12</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.12</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">[***]&nbsp;&nbsp;&nbsp;Indicates
text has been omitted from this Exhibit pursuant to a confidential
treatment request and has been filed separately with the Securities and Exchange Commission.</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Distribution Agreement</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Agreement, effective as of April&nbsp;1,
2005 (&#147;Effective Date&#148;), is made by and between Fluidigm
Corporation, a corporation of the State of California, having an office at 7100 Shoreline Court,
South San Francisco CA 94080, United States of America (&#147;FC&#148;), and Eppendorf AG, a German
corporation, having its headquarter at Barkhausenweg 1, D-22339 Hamburg, Germany (&#147;EAG&#148;), each
hereinafter referred to as the &#147;Party&#148; or collectively called the &#147;Parties&#148;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WHEREAS, FC is specialized in development
and manufacturing of systems with integrated fluidic
circuits for life-science research,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WHEREAS, EAG is a biotechnology company
with a broad range of applications and products, mainly in
the fields of bio tools, molecular technologies and complementary products,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WHEREAS, the Parties intend to engage in a
mutually beneficial relationship concerning new FC
applications which include the Eppendorf product Mastercycler personal for thermal control of
microfluidic components;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">NOW, THEREFORE, in consideration of the
premises and the mutual agreements and covenants contained
herein, the Parties hereto hereby agree as follows:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 1</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B> Subject Matter of the Agreement</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The object of this Agreement is the development, manufacture and delivery by EAG to FC of a
special brand version of Eppendorf Mastercycler personal for the exclusive handling of FC
microfluidic chips and licensed for PCR thermocycling practiced in fields of research and
development, quality assurance or control, environmental testing, plant diagnostics,
identity testing (other than parentage testing for humans) and forensics (&#147;PCR Field&#148;) and
hereinafter referred to as &#147;Product&#148; - in accordance with the description of Product
(Enclosure 1). EAG grants FC the right to commercially use, market, import, offer to sell,
sell and/or distribute (including through one or more tiers of sub-distributors) the
&#147;Product&#148; under the EAG label as an &#147;Authorized Thermal Cycler&#148; on a worldwide basis.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The use, marketing, distribution and/or selling of the Product (i)&nbsp;for PCR thermocycling
outside the PCR Field as defined above and/or (ii)&nbsp;for real time PCR thermocycling as
covered by United States Patent No.&nbsp;6,814,934 (the
&#147;Higuchi Patent&#148;) is not authorized
under this Agreement, whereas EAG does not restrict FC to use, market, distribute and sell
the Product in all other fields of use outside the PCR thermocycling. It is the duty of FC
to determine the freedom to operate the Product in such cases and not to infringe third
party patents. The Parties acknowledge that FC acts as a distributor of the Product
(including without limitation [***].</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#167;</b> <b>2</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><b>Up-front payment</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Up-front payment of FC for EAG R&#038;D of the Product is EURO [***] and it is due as
follows:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>EURO [***] already received ([***] USD)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>EURO [***] already received</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>EURO [***] due in July&nbsp;2005 against separate invoice.</TD>
</TR>
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->Page 1 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The up-front payment for R&#038;D further includes
manufacturing of [ *  *  * ]. One of these units will remain in its
final serial execution in EAG&#146;s engineering as a basic reference
unit. One unit will be a life unit in EAG&#146;s R&#38;D used for
measuring, testing, modification evaluation, etc. One licensed unit
will be for FC for acceptance and release of serial production. It
will also serve as a reference unit for Fluidigm.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 3</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B> Execution and Delivery</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Delivery of PRODUCT by EAG will be to a worldwide maximum of three (3)&nbsp;addresses, which
are detailed below.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>1- Fluidigm Corporation<br>
7100 Shoreline Court<br>
South San Francisco, CA 94080</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>United States of America</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>2- Fluidigm KK<br>
Attn: Takeshi Iwabuchi<br>
Ginza TK Building 5F<br>
1-1-7 Shintomi<br>
Chuo-ku, Tokyo 104-0041</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Japan</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>3- Fluidigm Europe, BV<br>
Attn: Anja Wienecke<br>
Flughafenstrasse 52a, Haus C<br>
D-22335 Hamburg</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Germany</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FC shall order the Product in a purchase order (&#147;Purchase Order&#148;) and EAG shall confirm
each order in writing, by e-mail or fax within 14 calendar days, provided that EAG must
accept all Purchase Orders that fall within FC&#146;s forecast specified in Section&nbsp;6 below.
Each order shall identify the quantity of Products being ordered and the required delivery
date and delivery address. Deliveries shall be within 6&nbsp;weeks after the effective date of
the order (or such longer period as may be specified in FC&#146;s order), unless a later date
was previously agreed by the Parties in writing.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>EAG is permitted to make partial deliveries and no penalty for minimum delivery will be
applied in this case. EAG agrees to notify FC promptly of any factor, occurrence or event
coming to its attention that may impact EAG&#146;s ability to meet any deliveries or other
requirements set forth in this Agreement, particularly that may cause a material delay in
delivery of Products, including any loss or reassignment of key employees, threat of strike
or major equipment failure.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Products manufactured and delivered by EAG will be inspected and tested, as required,
by FC within forty-five (45)&nbsp;days of receipt (the &#147;Acceptance Period&#148;). If during the
Acceptance Period any Products are found to be not new, defective in material or
workmanship and/or fail to meet the specifications set forth in Enclosure 1 below,
Reclaimed Products will be repaired or replaced, as outlined in Section&nbsp;11 hereafter.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->Page 2 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 4</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B> Minimum Quantity and Minimum Delivery Lot</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subject to the terms and conditions of this Agreement, FC shall order, and subject to
timely delivery of conforming units, will buy and take delivery of a total of [ *  *  * ]. The orders
for the following minimum number of Products per calendar year are to be purchased by FC
in good time to allow delivery before the end of the specified calendar year:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[ *  *  * ]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[ *  *  * ]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[ *  *  * ]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[ *  *  * ]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[ *  *  * ]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Minimum delivery lot per single order is [ *  *  * ]. In the event FC orders
deliveries with fewer than [ *  *  * ] per delivery lot, each such delivery lot will
be regularly invoiced plus a lump sum penalty of [ *  *  * ] per delivery lot.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>EAG&#146;s sole remedy for FC&#146;s failure to meet the minimum purchase requirements as set forth
in this Section&nbsp;4 shall be as follows: Should the ordered number of units be less than [ *  *  * ]
of the above minimum number for each of [ *  *  * ], then EAG shall have the
right to terminate this Agreement on written notice to FC within [ *  *  * ] after the
end of [ *  *  * ].</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 5</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B> Forecast</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>A revolving [ *  *  * ] forecast will be given from FC to EAG. The forecast covers [ *  *  * ] and will be given [ *  *  * ]
before the [ *  *  * ] forecast period
begins. It will be submitted on the appropriate form Enclosure 3 or a similar form.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The forecasted unit orders for the next [ *  *  * ] represent a firm order to be delivered in
that [ *  *  * ]. The corresponding written order is to be enclosed with the forecast.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The figure forecasted for [ *  *  * ], may vary by [ *  *  * ] before used in next regular
forecast as firm order.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The figure forecasted for [ *  *  * ], may vary by [ *  *  * ] before used in next regular
forecast as figure for [ *  *  * ].</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The figure forecasted for the [ *  *  * ], is considered [&nbsp;*&nbsp;*&nbsp;*&nbsp;]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The forecast is used by EAG to control the production of the Product and EAG agrees to
delivery within [ *  *  * ] weeks of receiving FC&#146;s order (or such longer period as may be
specified in FC&#146;s order).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 6</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Conditions of Prices, Packaging and Payment</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The prices are to be understood exclusive of VAT/sales tax, administrative or other fees,
deductions, customs charges, transport and insurance. The prices are including solid
cardboard packing and vary in accordance with the staggered price list (Enclosure 2).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Price conditions: net, for delivery EXW Hamburg (Incoterms 2000).</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="80%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="3" align="left" valign="top">&nbsp;Export packing:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Product in cardboard box on a pallet suitable for
airfreight, transportation by truck or by sea freight in an LCL container.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="3" align="left" valign="top">&nbsp;Payment:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">net in EUROS by check or wire transfer, within 30&nbsp;days from date of invoice.</TD>
</TR>

<TR style="margin-top: 6pt">
    <TD>&nbsp;</TD>
</TR>



<TR valign="top">
    <TD>&nbsp;</TD>
    <TD colspan="5">&nbsp;Place of Delivery: EXW EAG warehouse (Incoterms 2000).</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->Page 3 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 7</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Staggered Prices</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Product price depends on the effectively delivered quantity within a calendar year.
The valid prices are shown in the staggered price list (Enclosure 2).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The first units to be delivered in each calendar year are invoiced at a unit price as per
staggered price list for the number of units to be delivered. Each additional set of units
to be delivered later within the same calendar year will be invoiced at an actual
staggered unit price (&#147;ASUP&#148;) resulting from the staggered price list for the sum of all
units actually delivered in the respective calendar year.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>ASUP will also be applied for all units having been delivered and invoiced earlier in that
calendar year. For this purpose, each invoice for new orders within a calendar year will
be accompanied by a credit note for the difference between previously invoiced prices and
ASUP, if applicable.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 8</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B> Price Adjustment to Cost Situation</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Prices of Staggered Price List can be reviewed and adjusted once annually, beginning as of
January&nbsp;1, 2007. Thereafter, EAG is entitled to change prices if justified by a change in
costs pertaining to the manufacture of the Product. Changes in price must be announced at
least 3&nbsp;months before the price change becomes effective.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Annual changes in price may not exceed the changes contained in the index published by the
German Federal Office of Statistics (GFOS)&nbsp;as part of the specialist series 17, sub-series
II, &#147;Prices and price indices for commercial products (manufacturing prices)&#148; under no.
33205 of the GP systematic &#147;Instrument, apparatus and devices for certain chemical and
physical measuring or examinations&#148;. The index multiplier is the change of the annual mean
value, published each year by the GFOS.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 9</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B> Documentation</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FC shall be entitled to receive from EAG software files of user documentation in EAG&#146;s
standard form, to enable FC to modify such software for its applications. After return of
modified files to EAG, EAG will ensure that the modified documentation is included with the
Product.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FC shall also receive software files of technical illustrations, test instructions, parts
lists, etc., which pertain to the Product. The copyright remains with EAG, but is hereby
licensed to FC in accordance with FC&#146;s distribution and other specified rights under this
Agreement. FC shall use the documentation exclusively with respect to this Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any Product supplied will be accompanied by a certificate as shown in Enclosure 4 (which
Enclosure shall be updated from time to time to accurately reflect the then current
situation). Any related marketing material produced by FC needs to show in prominent
position the disclaimer as given in Enclosure 5 (which Enclosure shall be updated from
time to time to accurately reflect the then current situation).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 10</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Modifications</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Applications for modifications to the Product must be made in writing to FC and the
modifications must be authorized in writing by FC. Modifications carried out without prior
written confirmation from FC are not permissible. FC shall not unreasonably withhold
agreement to any reasonable proposal made by EAG for Product modifications.<BR></TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->Page 4 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Should FC make a written request for modifications to the Product, it is in EAG&#146;s
discretion to effect these modifications, provided that EAG shall not unreasonably
withhold agreement to any reasonable proposal made by FC for product modification. All
pre-approved costs related to the modifications requested by FC will be covered by FC. EAG
is not obliged to carry out modifications to Products which have already been manufactured
or delivered.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 11</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B> Warranty</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>EAG warrants to &#091;***&#093;. This includes
&#091;***&#093; under all patent or contract rights controlled by &#091;***&#093;
and/or &#091;***&#093; as defined in &#091;***&#093;. EAG is not aware of any third party patent rights that the sale or use of the Products
may be infringing in view of the licenses granted hereunder.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>EAG represents and warrants &#091;***&#093;.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>EAG shall have discretion as to &#091;***&#093;. This
warranty does not cover &#091;***&#093;.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FC will report all warranty and replaced service parts via &#091;***&#093; (as specified in Section&nbsp;15
below) reporting to EAG.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Deliveries to EAG of &#091;***&#093; shall be
made at FC expenses. Replacement deliveries &#091;***&#093; shall be made at &#091;***&#093; expense.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 12</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Liability</B></TD>
</TR>

<tr><td><DIV align="left"><FONT size="1">

</FONT></DIV></td></tr>
<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>12.1&nbsp;IN NO EVENT WILL EITHER PARTY&#146;S LIABILITY ARISING OUT OF THIS
AGREEMENT EXCEED THE GREATER OF (a)&nbsp;TWO HUNDRED FIFTY THOUSAND DOLLARS (US $250,000) OR
(b)&nbsp;THE AGGREGATE AMOUNTS PAID OR PAYABLE BY FC TO EAG UNDER THIS AGREEMENT. IN NO EVENT SHALL EITHER PARTY
BE LIABLE FOR ANY SPECIAL, CONSEQUENTIAL, INDIRECT, OR INCIDENTAL
DAMAGES, HOWEVER CAUSED, ON ANY THEORY OF LIABILITY AND WHETHER
OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES, ARISING OUT OF THIS AGREEMENT.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>12.2&nbsp;The limitations of Section&nbsp;12.1, however,
shall not apply to
(i)&nbsp;liability to Applied Biosystems for infringement of
 intellectual property rights under Section 22,
(ii)&nbsp;any other liability to Applied Biosystems under Section 22, or
(iii)&nbsp;breaches of the CDA with respect to confidential information disclosed in connection with this Agreement</TD>
</TR>
<tr><td><DIV align="left"><FONT size="1">

</FONT></DIV></td></tr>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 13</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>No Compete Clause</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FC shall refrain from manufacturing and/or selling products, in standalone form, of another
make that are identical or similar to the Product. FC shall also abstain in every other
respect from any direct or indirect competition for the Product, for sale in standalone
form, with EAG, including by means of trusts or third parties, legal and commercial
entities or private individuals; this includes any entity that is
controlled by or controls FC including those, which are acquired at a later date or granted a controlling
influence.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->Page 5 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In particular FC shall not, directly or indirectly, act as distributor, dealer, commission
merchant or commercial agent for a third party with regard to identical or similar products
for sale in standalone form. Exceptions require the prior written consent of EAG. FC at the
date hereof, is not preparing and not engaged in the production or distribution of other
similar items to the Products.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Notwithstanding the foregoing in this Section&nbsp;13, in the case of EAG&#146;s sustained inability
to supply for reasons other than Force Majeure, as specified in Section&nbsp;14, both Parties
will co-operate in good faith to resolve the difficulty to both Parties&#146; satisfaction, or
if unable to so resolve the difficulty, to use the documentation and convey rights (only to
the extent EAG is so able) necessary for production to enable FC or third party to make or
have made the Product involved. It is the duty of FC to determine the freedom to operate in
such cases and especially not to infringe ABI&#146;s IP rights.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>EAG agrees not to sell or otherwise provide the Product (or any identical or similar
product that has been specifically adapted to receive FC microfluidic chips) to any person
or entity other than FC, during and two (2)&nbsp;years after the term of this Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 14</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B> Force Majeure</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>No failure or omission by the Parties hereto in the performance of any obligation of this
Agreement shall be deemed a breach of this Agreement or create any liability if the same
shall arise from any cause or causes beyond the control of the Parties, including but not
limited to the following: act of God; acts of omissions of any government; any rules,
regulations or orders issued by any governmental authority or by any officer, department,
agency or instrumentality thereof; fire; storm; flood; earthquake; accident; war;
rebellion; insurrection; riot, strikes and lockouts; and invasion; and provided that such
failure or omission resulting from one of the above causes is cured as soon as practicable
after the occurrence of one or more of the above-mentioned causes.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This applies only if the disabled Party informs the other Party as soon as possible about
the extent and the grounds of the disabling cause or causes.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Should the disabling circumstance(s) last longer than three (3)&nbsp;months, the other Party can
terminate the Agreement without a period of notice and/or proceed in accordance with
Section&nbsp;13 Para. 3.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 15</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Service, Spare Parts</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FC is responsible for the service of the Products. FC may delegate service responsibility
to its distribution partners. EAG will support service by training of the trainers of FC as
per Section&nbsp;16 below.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FC will purchase and keep on stock a sufficient number of spare parts to fulfill service
needs. FC agrees to order minimum spare parts value of &#091;***&#093; - per spare parts
shipment.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 16</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B> Training of Service Trainers</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Not later than the date of signature of this Agreement FC shall supply EAG with the names
of up to three key service managers of FC with defined responsibilities for a training as
service trainers. They will each receive a training course by EAG of the technical service
for the Product in a way which enables them to commence service training themselves to service
engineers of FC or to service engineers of international
distribution partners of FC.</TD>
</TR>
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->Page 6 of 34<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>EAG shall provide this training course regarding the Product and regarding reporting
system via &#091;***&#093; for such key service personnel of FC in Hamburg,
Germany. EAG shall bear the cost of training, lodging and lunch within EAG&#146;s facilities.
Other expenses, traveling fees and salary shall be borne by FC. Should a trained key
service person leave FC then FC shall bear all costs for the renewed training of a
successor.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any training which may be requested by FC in addition to the aforesaid provision shall be
at the expense of FC.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 17</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B> Confidentiality - Publicity</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>17.1&nbsp;A Confidential Disclosure Agreement (&#147;CDA&#148;) has been signed by the Parties in Sept.
2004 (Enclosure 6). For purposes of this Agreement, the &#147;Purpose&#148; in the CDA shall include
the performance of obligations and the exercise of rights pursuant to this Agreement.
Additionally terms of this Agreement are confidential as set forth in Section&nbsp;17.3.
Information about this Agreement shall be released only after mutual agreement of the
Parties, except as set forth in Section&nbsp;17.3.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>17.2&nbsp;With respect to FC&#146;s distribution of any written information to third parties,
including but not limited to advertising, brochures, catalogs, promotional and sales
material, and public relations material, EAG shall only have the right to prescribe changes
regarding references to, or descriptions of: Applied Biosystems, PCR, the amplification
patent rights, the amplification system patent rights, the PCR instrument patents, PCR
licenses or authorizations, or this Agreement. FC agrees to comply provided that such
prescriptions are reasonable in nature and documented by EAG as appropriate for accuracy.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>17.3&nbsp;Except as provided in Enclosure 5 and Section17.2, each Party shall, to the extent
reasonably practicable, maintain the confidentiality of the provisions of this Agreement in
accordance with the CDA and shall refrain from disclosing the terms of this Agreement
without prior written consent of the other Party, except (i)&nbsp;to the extent either Party
concludes in good faith that such disclosure is required by any court or other governmental
body or is otherwise required under applicable law or regulation, in which case the other
Party shall be notified in advance; (ii)to legal counsel of the Parties; (iii)&nbsp;in
connection with the requirements of a public offering or securities filing; (iv)&nbsp;in
confidence, to accountants, banks, and financing sources and their advisors; (v)&nbsp;in
confidence, in connection with the enforcement of this Agreement or rights under this
Agreement; or (vi)&nbsp;in confidence, in connection with a merger or acquisition or proposed
merger or acquisition, or the like.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 18</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Compliance and Quality</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>It shall be the duty of each Party to comply fully with all applicable laws, regulations
and ordinances and to obtain and keep in effect licenses, permits and other governmental
approvals (federal, state or local) necessary or appropriate to carry on activities
hereunder.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 19</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Assignment</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Agreement shall not be assigned by either Party except in any assignment or transfer
of all or substantially all of such Party&#146;s business related to this Agreement.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->Page 7 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 20</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Duration of Agreement, Termination of Agreement with Good Reason</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>20.1&nbsp;This Agreement is valid as of Effective Date and will continue for a minimum of five
(5)&nbsp;calendar years after Effective Date provided terms and conditions are met by both
Parties. After five years from Effective Date, this Agreement may be terminated with a
period of written notice of not less than six months.</TD>
</TR>

<tr><td><DIV align="left"><FONT size="1">

</FONT></DIV></td></tr>
<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>20.2&nbsp;The duration of Agreement automatically extends for another calendar year if not
cancelled by FC at least six (6)&nbsp;months before the end of minimum duration date or at least
six (6)&nbsp;months before the end of any Agreement extension period. Provided that FC meets or
exceeds unit forecasts, EAG will give FC at least one (1)&nbsp;year notice of termination before
the end of the minimum duration date or any Agreement extension period.</TD>
</TR>
<tr><td><DIV align="left"><FONT size="1">

</FONT></DIV></tr></td>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>20.3&nbsp;Either Party can terminate the Agreement with good reason especially in the event of
the other Party not fulfilling one or more of its material contractual obligations and then
not rectifying this situation within sixty (60)&nbsp;days of receipt of a written warning to
this effect. Timely delivery of conforming Product units shall - amongst others &#150; be deemed
to be a material contractual obligation.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>20.4&nbsp;Each Party may also terminate this Agreement with immediate effect and with no
liability for compensation in the event of the other Party becoming insolvent or filing for
bankruptcy.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>20.5&nbsp;Should EAG terminate the Agreement with the reason of not having received orders for
at least the agreed minimum number minus 25% as of Section&nbsp;4, FC has the right to place,
and EAG shall accept and fulfill, one final order for delivery within the commencing period
of termination.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>20.6&nbsp;FC shall be entitled to terminate this Agreement for its convenience on at least sixty
(60)&nbsp;days prior written notice to EAG, provided that no such termination shall be effective
prior to the second anniversary of the Effective Date.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>20.7&nbsp;At the time of termination of this Agreement, FC will buy all Products still on stock,
provided the stock is resulting from FC&#146;s forecast (Enclosure 3)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>20.8&nbsp;The Parties&#146; rights and obligations pursuant to the following sections shall survive
termination or expiration of this Agreement: Sections&nbsp;1, 11, 12, 17, 18, 19, 21, 22, and
23. FC shall be entitled to distribute all Products purchased from EAG. All payment
obligations of FC under this Agreement shall survive termination or expiration.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 21</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B> Court of Jurisdiction and Applicable Law</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>21.1&nbsp;This Agreement shall be governed by and interpreted in accordance with the laws of the
State of New York, U.S.A. without reference to conflict of laws principles.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>21.2&nbsp;All disputes arising out of this Agreement shall be finally settled by final and
binding arbitration in New York, New York before, and under the then current
commercial arbitration rules of, the International Chamber of Commerce, subject to the
additional limitations set forth herein. The arbitration shall be conducted by a single
arbitrator appointed in accordance with such rules. No discovery (e.g., document
production; depositions) will be permitted. The arbitration shall be conducted in the
English language, and all documentary evidence shall be presented in English;
documentary evidence not originally in English shall be presented both in the original
language and in English translation. The Parties agree that the decision of the arbitrator
shall be final and binding. The arbitration shall take no more than one day, and each Party
shall have a total of up to four (4)&nbsp;hours to present/rebut its case on that day, with the
arbitrator announcing the decision at the end of such presentations/rebuttals. Judgment on
any decision made by the arbitrator may be entered and enforced in any court of competent
jurisdiction. All fees and charges by the International Chamber of Commerce shall be
shared equally by the Parties unless otherwise specified by the arbitrator; each Party
shall be responsible for the payment of all fees and expenses<BR></TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->Page 8 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>connected with the presentation of its respective case, provided that the arbitrator may
in his/her discretion award to the prevailing Party the costs and expenses incurred by the
prevailing Party in connection with the arbitration proceeding. The arbitration shall be
confidential.</TD>
</TR>

<tr><td><DIV align="left"><FONT size="1">

</FONT></DIV></tr></td>
<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 22</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B> Indemnification</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>22.1&nbsp;EAG holds limited license rights under U.S. Patents Nos. 5,038,852 and 5,333,675,
describing and claiming automated apparatus suitable for performing the PCR process, any
apparatus claim issuing from an application claiming priority of U.S. application Serial
No.&nbsp;833,368 or U.S. application Serial No.&nbsp;899,061 (both filed in 1986), and apparatus
claims in corresponding counterpart patents and patent applications in other
countries for PCR thermocycling practiced in fields of research and development, quality
assurance or control, environmental testing, plant diagnostics, identity testing (other
than parentage testing for humans) and forensics as defined in section 1.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>22.2&nbsp;EAG shall defend FC or assist FC at its own discretion in defending FC against any
claim or action, with the exemption of i) claims based on the &#147;Higuchi Patent&#148; ii) the flat
silver chuck and related vacuum system and iii) the functions of these two components, for:
(a)&nbsp;infringement by any Product, or the use thereof, of any third party patent, copyright,
trade secret or other intellectual property right other than those caused by product
specific modifications. (b)&nbsp;Defective Products manufactured by EAG, to the extent such
defects are caused by EAG&#146;s failure to manufacture the Products in conformance with the
specifications and with EAG&#146;s warranties as set forth in this Agreement, or by EAG&#146;s
misconduct or negligence; or (c)&nbsp;a breach by EAG of any license or other intellectual
property right of any third party licensor of the Products other than a breach by EAG of
any license or other intellectual property right of Applied Biosystems which breach was
solely caused by FC or by Product specific modifications.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>22.3&nbsp;FC shall reasonably cooperate in EAG&#146;s defense of any such claim or action, and FC
shall not engage in any actions or communications that negatively affect EAGs defense or
settlement of the claim or action. In no event shall FC defend or settle any such claim or
action without EAG&#146;s prior written approval.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>22.4&nbsp;(w)&nbsp;FC agrees to take all reasonable precautions to prevent death, personal injury,
illness and property damage from the use of Products. FC shall defend, at its expense
(including without limitation attorneys&#146; fees and court costs), EAG against any claim or
action for:(a)&nbsp;infringement by any Product, or the use thereof, of any third party patent,
copyright, trade secret or other intellectual property right solely due to the differences
between the Product and another Eppendorf Mastercycler; (b)&nbsp;the use of the Products and all
costs incurred as a result of a Product withdrawal or recall (collectively &#147;Customer
Losses&#148;) to the extent such Customer Losses are caused by FC, or by FC&#146;s misconduct or
negligence; or (c)&nbsp;a breach by FC or their partners of any license or other intellectual
property right of Applied Biosystems with respect to the Products.</TD>
</TR>
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) FC shall
pay any amounts awarded against EAG, or settlements entered into by FC on
behalf of EAG, to the extent attributable to any such claim or action under (a), (b), or (c)&nbsp;of Section&nbsp;22.2(w) above.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(y) As a
condition of FC&#146;s liability and obligations under this Section&nbsp;22.2, however,
(i)&nbsp;EAG shall notify FC in writing of such claim or action promptly (and in no event later
than twenty (20)&nbsp;calendar days) after learning of such claim or action, (ii)&nbsp;except as set
forth hereinbelow, FC shall have the exclusive right to control the defense and settlement
of any such claim or action, provided that any settlement shall be subject to the prior
written approval of EAG, which shall not be unreasonably withheld or delayed, (iii)&nbsp;EAG
shall reasonably cooperate in FC&#146;s defense of any such claim or action, and (iv)&nbsp;EAG shall
not engage in any actions or communications that negatively
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 9 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&#091;***&#093;. In
no event shall &#091;***&#093;.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">Notwithstanding
the foregoing, &#091;***&#093;.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(z) Notwithstanding
the foregoing, FC shall have no liability or obligation with
respect to any claim or action resulting from an actual or alleged breach by EAG of the
first paragraph of Section&nbsp;11.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>22.3&nbsp;EAG represents and warrants that &#091;***&#093;.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 23</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B> Final Clauses</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>23.1&nbsp;This Agreement contains the entire and only agreement between the Parties and
supersedes and cancels all prior written and/or oral agreements, undertakings and
negotiations between the Parties with respect to the subject matter hereof.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>23.2&nbsp;No amendments, changes, modifications or alterations of the terms and conditions
of this Agreement shall be binding upon either Party unless in writing and signed by both
Parties. Any waiver of this provision shall be made in each specific case in writing.
Documents transmitted by fax are considered to be in writing.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>23.3&nbsp;Each Party represents and warrants that it has full power and authority to enter into
this Agreement and to take all actions required by this Agreement and that each Party&#146;s
obligations under the Agreement do not conflict with its obligations under any other
agreement to which EAG or FC is a party.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>23.4&nbsp;The headlines are for orientation purposes only and do not form part of the Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>23.5&nbsp;Should any provision of this Agreement be invalid or unenforceable or should the
Agreement contain an omission, the remaining provisions shall be valid. In the place of an
invalid provision, a valid provision is presumed to be agreed upon by the Parties, which
comes economically closest to the one actually agreed upon; the same shall apply in the
case of an omission.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>23.6&nbsp;The Parties shall endeavor to settle amicably any disputes which result from the
execution of this Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 24</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B> Enclosures</B></TD>
</TR>


<tr><td><DIV align="left"><FONT size="1">

</FONT></DIV></td></tr>
<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The enclosures are integral part of the Agreement.<br>
Enclosure 1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Description of Product<br>
Enclosure 2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Staggered Price List<br>
Enclosure 3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Forecast Form<br>
Enclosure 4 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Authorization Notice<br>
Enclosure 5 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disclaimer<br>
Enclosure 6 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confidential Disclosure Agreement<br>
Enclosure 7 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; http Reference Agreement<br></TD>
</TR>
<tr><td><DIV align="left"><FONT size="1">

</FONT></DIV></td></tr>

</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->Page 10 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized
representatives.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="12%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="61%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">South San Francisco, the
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">17 August 2005
<DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Fluidigm Corporation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">President / CEO</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="19%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="78%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Gajus V. Worthington
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Gajus V. Worthington
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="68%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">Hamburg, the 4 Aug. 2005 <BR>
Eppendorf AG
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
<DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Heinz Gerhard Koehn, Ph. D.
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Heinz Gerhard Koehn, Ph. D.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Michael Schroeder, Ph. D.
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Michael Schroeder, Ph. D.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Board Member, Technology
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Board Member, Marketing and Sales</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->Page 11 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV  align="center" style="font-size: 10pt; margin-top: 6pt"><B>Enclosure
1 </B>Page 1</DIV>
<DIV  align="center" style="font-size: 10pt; margin-top: 6pt"><B>Description
of Product and Specifications</b></DIV>


<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>A. Description:</B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%"><B>Special brand version of Eppendorf Mastercycler personal</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">Special brand version of Eppendorf Mastercycler personal for FC, licensed for
PCR-Applications for the Fields described in section 1. [***]
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">Special
brand version of Eppendorf Mastercycler personal [***] to create the
following features on the Product:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#150;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#150;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#150;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#150;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#150;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#150;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#150;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%"><B>Remark: [***]</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">FC supplies the [***]
</DIV>
<DIV align="right">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="98%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">[***]
</DIV></TD>
    </TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">[***]
</DIV></TD>
    <TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="white-space: nowrap">[***]</FONT>
</DIV></TD>

<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 12 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV  align="center" style="font-size: 10pt; margin-top: 6pt"><B>Enclosure 1 </B>Page 2</DIV>


<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="font-size: 10pt; margin-top: 12pt"><B>B. Specifications:</B></DIV>


<DIV style="font-size: 10pt; margin-top: 6pt"><B>Performance</B></DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

</TABLE></DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap valign=middle><font face=wingdings style="font-size: 6pt">&#161;</font></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

</TABLE></DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

</TABLE></DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap valign=middle><font face=wingdings style="font-size: 6pt">&#161;</font></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap valign=middle><font face=wingdings style="font-size: 6pt">&#161;</font></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap valign=middle><font face=wingdings style="font-size: 6pt">&#161;</font></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

</TABLE></DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="14%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap valign=top><font face=wingdings style="font-size: 6pt">&#110;</font></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="14%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap valign=middle><font face=wingdings style="font-size: 6pt">&#110;</font></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="14%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap valign=middle><font face=wingdings style="font-size: 6pt">&#110;</font></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

</TABLE></DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

</TABLE></DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap valign=middle><font face=wingdings style="font-size: 6pt">&#161;</font></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap valign=middle><font face=wingdings style="font-size: 6pt">&#161;</font></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

</TABLE></DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

</TABLE></DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap valign=middle><font face=wingdings style="font-size: 6pt">&#161;</font></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap valign=middle><font face=wingdings style="font-size: 6pt">&#161;</font></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap valign=middle><font face=wingdings style="font-size: 6pt">&#161;</font></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap valign=middle><font face=wingdings style="font-size: 6pt">&#161;</font></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

</TABLE></DIV>

<DIV style="font-size: 10pt; margin-top: 12pt"><B>Mechanical features and facilities</B></DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

</TABLE></DIV>

<DIV style="font-size: 10pt; margin-top: 12pt"><B>Software</B></DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

</TABLE></DIV>

<DIV style="font-size: 10pt; margin-top: 12pt"><B>Testing</B></DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[***]</TD>
</TR>

</TABLE></DIV>


<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 13 of 34<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Enclosure 1</B> Page 3</DIV>


<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Photo
showing [***]</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->To page 13: sub-page 1 of 8<!-- /Folio --></DIV>


<DIV align="left"><FONT size="1">

</FONT></DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->





<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Enclosure 1 </B>Page 4</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt; margin-left: 8%"><B>Position of [***]</B></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">[***]<BR>
[***]</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->To page 13: sub-page 2 of 8<!-- /Folio --></DIV>


<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Enclosure 1 </B>Page 5</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->To page 13: sub-page 3 of 8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Enclosure 1 </B>Page 6</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->To page 13: sub-page 4 of 8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Enclosure 1 </B>Page 7</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->To page 13: sub-page 5 of 8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Enclosure 1 </B>Page 8</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]</DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->To page 13: sub-page 6 of 8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Enclosure 1 </B>Page 9</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->[***]<!-- /Folio -->

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->To page 13:
Sub-page 7 of 8<!-- /Folio -->

</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Enclosure 1 </B>Page 10</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->[***]<!-- /Folio -->

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->To page 13:
Sub-page 8 of 8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure
2</B>
</div>
<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><b>
Staggered price list</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>Prices per number of products to be delivered within one
Agreement Year</B>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="46%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="26%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">

<TD align="right"><DIV style="margin-left:15px; text-indent:-15px"><I>[***] and more units/a</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>price per unit</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>Euro</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>[***]</I></TD>
</TR>
<TR valign="bottom">
    <TD align="right"><DIV style="margin-left:15px; text-indent:-15px"><I>[***] and more units/a</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>price per unit</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>Euro</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>[***]</I></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD align="right"><DIV style="margin-left:15px; text-indent:-15px"><I>[***] and more units/a</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>price per unit</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>Euro</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>[***]</I></TD>
</TR>
<TR valign="bottom">
    <TD align="right"><DIV style="margin-left:15px; text-indent:-15px"><I>[***] and more units/a</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>price per unit</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>Euro</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>[***]</I></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD align="right"><DIV style="margin-left:15px; text-indent:-15px"><I>[***] and more units/a</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>price per unit</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>Euro</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>[***]</I></TD>
</TR>
<TR valign="bottom">
    <TD align="right"><DIV style="margin-left:15px; text-indent:-15px"><I>[***] and more units/a</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>price per unit</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>Euro</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>[***]</I></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD align="right"><DIV style="margin-left:15px; text-indent:-15px"><I>[***] and more units/a</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>price per unit</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>Euro</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>[***]</I></TD>
</TR>
<TR valign="bottom">
    <TD align="right"><DIV style="margin-left:15px; text-indent:-15px"><I>[***] and more units/a</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>price per unit</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>Euro</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>[***]</I></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV style="font-size: 10pt; margin-top: 12pt"><B>License condition of prices:</B>
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">Prices include the newly reduced up-front-fee-component of PCR license (fixed license portion) as
pre-announced by EAG&#146;s licensor. Possible reductions (or elimination) of this license fee by the
PCR licensor shall result in reductions.
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">The prices include PCR license, neglecting a price value for a device providing vacuum. Should PCR
license also be requested for a vacuum providing device by the licensor, the requested license has
to be borne by FC and above staggered prices will be revised correspondingly.
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">The prices include PCR license for the Product calculated on basis of Enclosure 1, (Description of
Product) with the chuck supplied and invoiced to EAG as specified. Should the licensor request
another price value for the chuck for the calculation of the PCR license, the requested license has
to be borne by FC and above staggered prices will be revised accordingly.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->Page 14 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Enclosure 3</B></DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Forecast Form</B></DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Special brand version of Eppendorf Mastercycler personal &#151; Quarterly Forecast</B></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">Forecast period (12 Months), revolving quarterly:</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="26%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7"><B>Number of units</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 0px solid #000000">Article number</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap>Period of forecast</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Estimated number of</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">5332 000.480</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">5332 000.405</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">5332 000.430</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">mon. &nbsp;&nbsp;- &nbsp;&nbsp;mon. yyyy </TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">units correspond to:</TD>
    <TD>&nbsp;</TD>

<TD nowrap align="center" style="border-bottom: 1px solid #000000">120 V&nbsp;&#150; U.S.A.</TD>
    <TD>&nbsp;</TD>

<TD nowrap align="center" style="border-bottom: 1px solid #000000">230 V &#150; int.</TD>
    <TD>&nbsp;</TD>

<TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">100&nbsp;V &#150;&nbsp;Japan</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">1.&nbsp;Quart.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">A fixed order Signature see below.</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">2.&nbsp;Quart.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Estimation with &#043;/- 25 % variability</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">3.&nbsp;Quart.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Estimation with &#043;/- 50 % variability</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.&nbsp;Quart.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Orientation figure only</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE></DIV>




<DIV style="font-size: 10pt; margin-top: 6pt">Confirmation:</DIV>
<DIV style="font-size: 10pt; margin-top: 6pt">Number of units forecasted above for delivery in 1. Quarter herewith are firmly ordered. The
definitive composition of individual delivery lots and the delivery address for each lot must be
conveyed to EAG with &#091;6&nbsp;weeks&#093; notice.</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">Place / Date: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><B>Fluidigm Corporation</B></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;<br><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
(Signature)</DIV>
<DIV style="font-size: 10pt; margin-top: 6pt">Our production planning is controlled by forecast instruments. For this purpose the above forecast
system is used. Please return the completed form before the middle of running quarter, to ensure
punctual delivery for the next quarter.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">The form contains an
overview about the coming &#091;***&#093;. The figures for the &#091;***&#093;.
The figure for the following &#091;***&#093; with the following forecast as indicated.
The figure for the &#091;***&#093;.</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">Eppendorf AG</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 15 of 34<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Enclosure 4 </B>Page 1</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><I>Authorization Notice</I></DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">[ * * * ]</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 16 of 34<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 4 </B>Page 2
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>EAG will affix permanently and prominently to each Authorized Thermal Cycler the
designation &#147;Authorized Thermal Cycler&#148;, its Serial Number and a direction to consult
the user&#146;s manual for the license information.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FC agrees to instruct the ultimate purchaser that transfer of the thermal cycler without
the Serial Number or the Notice shall automatically terminate the authorization granted
by this Agreement and the thermal cycler shall cease to be an Authorized Thermal
Cycler.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->Page 17 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Enclosure 5</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Disclaimer</B>

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B><I>Wording of the Disclaimer</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Practice of the patented polymerase chain reaction (PCR)&nbsp;process requires a license. The
Mastercycler is an Authorized Thermal Cycler and may be used with PCR licenses available from
Applied Biosystems. Its use with Authorized Reagents also provides a limited PCR license in
accordance with the label rights accompanying such reagents.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->Page 18 of 34<!-- /Folio -->
</DIV>


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 6</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><I>Confidential Disclosure Agreement</I>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Confidential Disclosure Agreement

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This
Agreement, effective as of 11 August&nbsp;2004 (&#147;Effective Date&#148;), is made by and between Fluidigm
Corporation a corporation of the State of California, having an office at 7100 Shoreline Court,
South San Francisco, CA 94080. United States of America
(&#147;FLUIDIGM&#148;), and Eppendort AG, a German
corporation, having its headquarters at Barkhausenweg 1. D-22339
Hamburg. Germany (&#147;EAG&#148;), each
hereinafter also referred to as the &#147;Party&#148; or collectively
called the &#147;Parties&#148;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WHEREAS,
FLUIDIGM is specialised in development and manufacturing of systems
with integrated fluid c
circuits for life-science research with a concentration on protein
structure determination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WHEREAS, EAG is a leading biotechnology
 company with a broad range of applications and products,
mainly in the fields of biotools, molecular technologies and
complementary products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WHEREAS,
the Parties intend to engage in discussions concerning a co-operation for a new FLUIDIGM
application which possibly may include components of the EAG product
Mastercycler ep 18.Aug.04 (&#147;Purpose&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">NOW, THEREFORE, in consideration of the premises and the mutual agreements and covenants contained
herein the Parties hereto hereby agree
 as follows.
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">Confidential information
 (&#147;Information&#147;), as used herein, shall mean any and all
information,
know-how, data and experience in whatever form, be it verbally, in writing, in drawing,
samples, displays, in software, on tapes, hard disks, diskettes or otherwise furnished by
either Party (hereinafter referred to as the &#147;Disclosing
Party&#148;) to the other Party (hereinafter
referred to as the &#147;Receiving Party&#148;) either directly or indirectly and disclosed to the
Receiving Party under this Agreement.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Receiving Party undertakes to keep confidential any and
all information, except</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">a.
Information, which the Receiving Party can establish by competent proof was at the time of
disclosure or became after disclosure, part of the public domain by publication, except by
breach of the undertakings hereunder by the Receiving Party;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">b. Information which
 the Receiving Party can establish by competent proof was in its
possession already at the time of disclosure, and which was not acquired, directly or
indirectly, from the Disclosing Party, and information which the Receiving Party can establish
by competent proof was later received from a third party, provided,
however, that such
information was not obtained by said third party directly or indirectly from the Disclosing
Party;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">c.
Information which the Receiving Party can establish by competent proof was
independently developed by the Receiving Party without use of the Confidential Informal on of
the Disclosing Party; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">d.
Information which was required to be disclosed by law or court or
governmental order;
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Receiving Party undertakes to use any and all information
only for the Purpose agreed
upon in writing with the Disclosing Party, and will not, directly or indirectly, exploit or
otherwise use information for any other purpose, unless and until the Disclosing Party from
case to case explicitly accepts in writing prior to the proposed use of information for such
other purpose.</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 19 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Receiving Party undertakes only to disclose Information
to those employees who need to
make use of Information in order to carry out agreed upon work for the Purpose, and guarantees
that every such employee is aware of and will respect the
confidentiality of Information.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Receiving Party agrees that its affiliates will treat Information as if they were
themselves a Party to this Agreement. Affiliate in this Agreement means any and all company or
individual related to the Receiving Party, whether the relationship be that of employment or
ownership or other, including any company or organization owning,
owned by or under common
control with the Receiving Party.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Within thirty (30)&nbsp;days after the Disclosing Party&#146;s request, the Receiving Party shall
return to the Disclosing Party all Information, including all copies
thereof, unless another
agreement covering the use of Information has been made between the
Parties.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Nothing herein and nothing said or written in connection with
the disclosure of Information
constitutes a promise or an undertaking to enter into further
cooperation between the Parties.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Parties further agree that the furnishing of Information
under this Agreement shall
    not constitute any grant or license of any rights now or
hereafter held by the Parties.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">9.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All obligations of the Parties with respect to the confidential information disclosed
under this Agreement shall cease five (5)&nbsp;years from the
Effective Date.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Agreement shall be construed in accordance with and
governed by substantive German law.
The place of jurisdiction is the place of business of the defendant.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">IN WITNESS
WHEREOF, the Parties have caused this Agreement to be executed by
their duly authorized
representatives.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">FLUIDIGM
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">EAG</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Gajus Worthington
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Dr. Heinz G. Kohn
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Ernst Tennstedt</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Gajus Worthington
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Dr. Heinz G. Kohn
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Ernst Tennstedt
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Chief Executive Officer
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Board Member
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Head of Legal</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Technology
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Department</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Date:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Date: 20.8.2004</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->Page 20 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 7 </B>(1 of 14)</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>http Reference Agreement</B></DIV>

<DIV style="font-size: 10pt; margin-top: 12pt">THERMAL CYCLER SUPPLIER AGREEMENT</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Agreement, effective April&nbsp;15, 2000, is made by and between PE
Biosystems, a division of PE Corporation, a corporation of the State of Delaware,
having an office at 850 Lincoln Centre Drive, Foster City, California 94404 (&#147;PE
CORP&#148;), and Cepheid, a corporation of the State of California, having an office at
1190 Borregas Avenue, Sunnyvale, California 94089 (&#147;Thermal Cycler Supplier&#148;)
hereafter collectively referred to as &#147;The Parties.&#148;</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whereas, PE CORP has the power to convey limited rights for research and in
certain other fields under U.S. Patents Nos. 4,683,195, 4,683,202 and 4,965,188,
describing and claiming gene amplification processes including, among others, a
process known as the polymerase chain reaction (&#147;PCR&#148;) process, which are owned by
Roche Molecular Systems, Inc., and amplification process claims in corresponding
counterpart patents and patent applications in other countries, owned by F.
Hoffmann-La Roche Ltd (both of which are referred to collectively herein as
&#147;Roche&#148;).</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whereas, PE CORP offers to PCR users commercial and non-commercial license
rights under these patents and patent applications for automated performance of
the PCR process for research and certain other fields that include, inter alia,
an up-front fee component based on the capacity of thermal cyclers used to
perform the process.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whereas, PE CORP offers to thermal cycler suppliers license rights under those
patents, namely, an authorization to distribute their instruments with a label
conveying to their customers rights under the up-front fee component of the PCR
licenses described above, and the right to promote their instruments as
&#147;Authorized Thermal Cyclers&#148; for PCR.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whereas, PE CORP owns US. Patents Nos. 5,038,852 and 5,333,675, describing
and claiming automated apparatus suitable for performing the PCR process, and
apparatus claims in corresponding counterpart patents and patent applications in
other countries.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whereas, PE CORP owns U.S. Patent No.&nbsp;5,475,610, describing and claiming
improvements in thermal cycling apparatus for- PCR, including a pressing heated
cover, and corresponding counterpart patents and patent applications in other
countries.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whereas, PE CORP owns U.S. Patent No.&nbsp;5,656,493, describing and claiming an
amplification system comprising PCR reagents and a thermal cycler programmed to carry
out a PCR protocol.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whereas, PE CORP owns patents and applications outside the U.S. that claim
priority of U.S. application Serial No.&nbsp;899,061 (filed in 1986) and that claim
automated performance of the PCR process using certain programmed thermal cyclers.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whereas,
PE CORP offers to PCR users license rights for research and</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->Pages 21 of 34<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 7 </B>(2 of 14)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">certain other fields under its amplification system
claims and automated method claims, and offers to thermal cycler suppliers the
right to pass such rights to their thermal cycler customers.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whereas, PE CORP has offered to Thermal Cycler Supplier the above Roche process
rights, and the PE CORP systems, apparatus, automated method and pressing heated
cover rights separately or in combinations, and Thermal Cycler Supplier has
requested rights under the above Roche PCR process patents and PE CORP systems
patent rights only, without rights under the above identified PE CORP apparatus,
automated method and pressing heated cover patents and applications.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, The Parties agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;Definitions
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the purpose of this Agreement the terms set forth
hereinafter shall be defined as fellows;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 &#147;AFFILIATE&#148; of a party to this Agreement shall mean an organization: a)
whose voting stock is controlled or owned directly or indirectly to the extent of
fifty percent (50%) or more by the party; b) which directly or indirectly owns or
controls fifty percent (50%) or more of the voting stock of the party; c) whose
majority ownership is directly or indirectly common to that of the party; or d)
defined under (a), (b), or (c)&nbsp;above except the amount of said ownership is less
than fifty percent (50%) but that amount is the maximum amount permitted by law
and Thermal Cycler Supplier has effective control.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 &#147;AMPLIFICATION PATENT RIGHTS&#148; shall mean the nucleic acid amplification
processes, including particularly the PCR process, covered by: United States
Patents Nos. 4,683,195, 4,683,202 and 4,965,188; and any corresponding
amplification process claim in patents and patent applications in other
countries claiming priority of any of them. Amplification Patent Rights include
rights only under the identified Roche patents and applications. They do not
include rights, expressly or by implication, under any other Roche or PE CORP
patent or application, or to any claim to reagents, apparatus, or a system of
reagents and apparatus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3 &#147;AMPLIFICATION SYSTEM PATENT RIGHTS&#148; shall mean U.S. Patent No.&nbsp;5,656,493,
which describes and claims an amplification system comprising PCR reagents and a
thermal cycler programmed to carry out a PCR protocol.
Amplification System Patent Rights include rights only under the identified PE
CORP patent. They do not include rights, expressly or by implication, under any
other Roche or PE CORP patent or application, or to any claim to reagents,
apparatus, or an amplification process, even if that process is a result of the
natural and intended operation of the system.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4 &#147;AUTHORIZED REAGENT&#148; shall mean a DNA polymerase whose use in performance of
the PCR process is covered by the running-royalty component of a PCR process license
under the Amplification Patent Rights for internal research and development. The
running-royalty component of that license may be obtained
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Pages 22 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 7 </B>(3 of 14)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">through the purchase of reagents bearing a
valid label conveying the
running-royalty component; alternatively, it may be purchased from PE CORP.
Other PCR process licenses in the Fields also require use of Authorized
Reagents.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.5 &#147;AUTHORIZED THERMAL CYCLER&#148; shall mean a thermal cycler or temperature
cycling instrument whose use in automated performance of the PCR process is covered
by the automated-capacity, up-front fee component of a PCR process license under
the Amplification Patent Rights for internal research and development. The up-front
fee component of that license may be obtained through the purchase of a thermal
cycler or temperature cycling instrument bearing a valid label conveying the
up-front component; alternatively, it may be purchased from PE CORP. Other PCR
process licenses in the Fields also require use of an instrument whose use is
similarly covered, i.e., an &#147;Authorized Thermal Cycler&#148;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.6 &#147;FIELDS&#148; shall mean research and development, quality assurance or
control, environmental testing, plant diagnostics, identity testing (other than
parentage testing for humans) and forensics. The Fields specifically exclude
human and veterinary diagnostics.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.7 &#147;NET SALES PRICE&#148; for thermal cyclers, temperature cycling instruments
and add-on modules distributed under this Agreement shall refer to the sales
price charged to unrelated Third-Party end users as to whom the price is not
affected by any other purchase, by any other dealing or by any special course of
dealing, and shall mean the gross invoice price to such an end user less the
following deductions where applicable: (i)&nbsp;discounts allowed and taken, in
amounts customary in the trade, and (ii)&nbsp;sales and/or use taxes and/or duties for
particular sales. No allowance or deduction shall be made for commissions or
collections, by whatever name known. Thermal cyclers, temperature cycling
instruments and add-on modules subject to this Agreement shall be separately
invoiced items.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For distributions other than sales described by the preceding
paragraph, including any sale, loan, lease, consignment, gift or other
distribution (i)&nbsp;to an end user that is Thermal Cycler,
Supplier itself, an Affiliate or a distributor, (ii)&nbsp;to an end user that enjoys a
special course of dealing with Thermal Cycler Supplier, an Affiliate or
distributor, or (iii)&nbsp;is under a reagent rental agreement or other arrangement
that is not a sale to an unrelated Third-Party end user as to whom the price is
unaffected by other purchase, dealing or special course of dealing, the Net Sales
Price shall be determined by reference to the Net Sales Price which would be
applicable in an arm&#146;s length sale to a similarly situated unrelated Third-Party
end user as to whom the price is not affected by any other purchase, by any other
dealing or by any special course of dealing.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Pages 23 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 7 </B>(4 of 14)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Net Sales Price shall be calculated on the basis
of sales or transfers to end users by Thermal Cycler Supplier, its Affiliate
or a distributor of either, as the case may be. In the event Thermal Cycler
Supplier is unable to account for end-user sales by any distributor, the Net
Sales Price shall be calculated as the price to the final distributor
multiplied by &#091;**&#093;, which factor represents a &#091;**&#093; margin on sales to end
users by the distributor.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.8 &#147;TERRITORY&#148; shall mean worldwide.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.9 &#147;THIRD PARTY&#148; shall mean a party other than The Parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.10 &#147;TEMPERATURE CYCLING INSTRUMENT&#148;, as used in this Agreement, shall mean an
instrument, whether in single or multiple modules, that includes a thermal cycler as
defined in Article&nbsp;1.11 and additional structure for performing one or more other
functions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.11 &#147;THERMAL CYCLER&#148;, as used in this Agreement, shall mean an
instrument, whether in single or multiple modules, that is capable in itself of
automatically cycling samples in the PCR process.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">2. GRANT
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 Upon the terms and subject to the exceptions and conditions of this
agreement, PE CORP grants to Thermal Cycler Supplier the following personal,
non-transferable, royalty-bearing, non-exclusive rights in the Territory
under the Amplification Patent Rights:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">(a)&nbsp;Thermal Cycler Supplier is hereby authorized to sell and
distribute to end users under Thermal Cycler Supplier&#146;s name and
trademarks the specific thermal cyclers and temperature cycling
instruments described in Exhibit&nbsp;1 (i.e. the Smart Cycler(R)
System, Smart Cycler(R) XC System and GeneXpert(TM) Prototype,
in the configurations described) and any thermal cycler or
temperature cycling instrument containing one or more I-CORE(TM)
modules (as defined in Exhibit&nbsp;1) manufactured by Thermal Cycler
Supplier, but not otherwise to sell or distribute to thermal
cycler suppliers, with a label conveying to end users (including
Thermal Cycler Supplier itself) in the Fields the up-front
rights of PCR process licenses under the Amplification Patent
Rights as specified in the label set forth in Section&nbsp;5.1 below,
that is, with an Authorized Thermal Cycler label; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">(b)&nbsp;Thermal Cycler Supplier may advertise and promote such
thermal cyclers and temperature cycling instruments as
described in Exhibit&nbsp;1 and so labeled as Authorized Thermal
Cyclers for PCR.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The grant of this Section&nbsp;2.1 conveys no right or immunity, express or
implied, under the Amplification System Patent Rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 Upon the terms and subject to the exceptions and conditions of this
Agreement, PE CORP grants to Thermal Cycler Supplier a personal,
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Pages 24 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 7 </B>(5 of 14)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">non-transferable, royalty-bearing, non-exclusive right
under the Amplification System Patent Rights to convey to end-user customers
(including Thermal Cycler Supplier itself) of Thermal Cycler Supplier&#146;s Authorized
Thermal Cyclers a non-exclusive license to use the same in the Fields in the
Territory. The grant of this Section&nbsp;2.2 includes no right or immunity, express or
implied, under the Amplification Patent Rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 No right, immunity, authorization or license is granted, expressly or by
implication, for any other purpose, or in any other field, including: to make, have
made, use or sell any polymerase (such as Taq), amplification reagent or kit; or to
perform PCR or nucleic acid amplification that is not fully licensed under the
Amplification Patent Rights. No right, immunity, authorization or license is
granted, expressly or by implication, under any patent or patent application that
is not expressly included in the Amplification Patent Rights, or the Amplification
System Patent Rights. Specifically, but without limitation, no right, immunity,
authorization or license is granted, expressly or by implication, under patents and
applications of PE CORP or Roche that cover apparatus, methods, or reagents for
real-time detection (for example, U.S. Patent No.&nbsp;5,928,907 and published European
patent applications EP 872562 and EP 512334) or for homogeneous assay (for example,
U.S. Patents Nos. 5,210,015, 5,487,972, 5,538,848, all related to the 5&#146; nuclease
assay).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4 Rights granted to Thermal Cycler Supplier by this Agreement are
personal to Thermal Cycler Supplier alone. Thermal Cycler Supplier shall have
no right to sublicense, assign or otherwise transfer or share its rights
hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5 Notwithstanding the prohibition of Section&nbsp;2.4, Thermal Cycler
Supplier&#146;s rights to sell to end users under the grants of Sections&nbsp;2.1 and 2.2
include the right to sell through Affiliates (so long as Thermal Cycler Supplier
reports and pays under this Agreement on their behalf) and through distributors
of Thermal Cycler Supplier and such Affiliates, as well as directly.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.6 Thermal Cycler Supplier agrees not to promote, directly or through
distributors, the unlicensed use of the Amplification Patent Rights by the sale
of unauthorized thermal cyclers or temperature cycling instruments, or by selling
add-on modules for thermal cyclers or temperature cycling instruments other than
as additions to Authorized Thermal Cyclers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;FEES, ROYALTIES, RECORDS AND REPORTS
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 For the licenses and rights granted under Article&nbsp;2, Thermal
Cycler Supplier shall pay to PE CORP:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>license issue fee of US$&#091;**&#093;;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>for each Smart Cycler(R) System or Smart Cycler(R) XC
System thermal cycler as described in Exhibit&nbsp;1</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Pages 25 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 7 </B>(6 of 14)
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>(including all modules and
components), or any thermal cycler or temperature cycling
instrument containing one or more I-CORE(TM) modules (as
defined in Exhibit&nbsp;1) having a maximum capacity, if fully
expanded, of more than &#091;**&#093; individual samples, delivered
or invoiced by Thermal Cycler Supplier or an Affiliate
after the effective date of this Agreement, US$&#091;**&#093; plus
&#091;**&#093; percent (&#091;**&#093;%) of the Net Sales Price, and for each
add-on module, &#091;**&#093; percent (&#091;**&#093;%) of the Net Sales Price;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>for each GeneXpert(TM) Prototype temperature cycling
instrument as described in Exhibit&nbsp;1 (including all modules
and components), or any thermal cycler or temperature cycling
instrument containing one I-CORE(TM) module (as defined in
Exhibit&nbsp;1) having a non-expandable capacity of no more than
&#091;**&#093; individual sample, delivered or invoiced by Thermal
Cycler Supplier or an Affiliate after the effective date of
this Agreement, US$&#091;**&#093; plus &#091;**&#093; percent (&#091;**&#093;%) of the Net
Sales Price; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>for each thermal cycler or temperature cycling instrument
containing one or more I-CORE(TM) modules (as defined in
Exhibit&nbsp;1) having a maximum capacity, if fully expanded, of at
least &#091;**&#093; but no more than &#091;**&#093; individual samples, delivered
or invoiced by Thermal Cycler Supplier or an Affiliate after
the effective date of this Agreement, US$&#091;**&#093; plus &#091;**&#093;
&#091;**&#093; percent (&#091;**&#093;%) of the Net Sales Price, and
for each add-on module, &#091;**&#093; percent (&#091;**&#093;%) of the
Net Sales Price.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The license issue fee shall be paid on the effective date of this Agreement.
The per-thermal cycler payments specified in this Section&nbsp;3,1 shall be paid as
specified in Sections&nbsp;3.4 and 3.5. Each thermal cycler or temperature cycling
instrument for which those payments are paid shall be an Authorized Thermal
Cycler and shall be so designated pursuant to Article&nbsp;5 hereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 All amounts payable hereunder shall be payable in United States dollars.
Sales in other countries shall be converted to U.S. dollars based on the New York
rate of exchange as quoted in the Wall Street Journal for the last business day
of the applicable quarter. If not so published, The Parties may agree on a
substitute publication. In the event there is no comparable publication, the
applicable rate for such date by the appropriate governmental agency in such
country shall apply.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3 Thermal Cycler Supplier shall keep, and shall require its pertinent
Affiliates to keep, full, true and accurate books of account containing all
particulars necessary to show the amount payable to PE CORP under this Agreement.
Such books and the supporting data shall be open at all reasonable times, for three
(3)&nbsp;years following the end of the calendar year to
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Pages 26 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 7 </B>(7 of 14)</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">which they pertain (and access shall not be denied
thereafter, if reasonably available), to the inspection of an independent
inspector retained by PE CORP. If in dispute, such records shall be kept until
the dispute is settled.
Inspection shall be at PE CORP&#146;s expense, unless the inspector concludes that the
amount payable that is stated in a report is understated by five percent (5%) or
more, in which case expenses shall be paid by Thermal Cycler Supplier.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4 Thermal Cycler Supplier shall within thirty (30)&nbsp;days after the first
of each January, April, July and October deliver to PE CORP a true and accurate
accounting report. This report shall be on a country-by-country basis and shall
give such particulars of the business conducted by Thermal Cycler Supplier in
each country during the preceding three (3)&nbsp;calendar months as are
pertinent to accounting under this Agreement and shall be in accordance with,
and include all information specified in, the royalty report form attached
hereto as Appendix&nbsp;A.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The correctness and completeness of each report shall be attested to
in writing by the responsible financial officer of Thermal Cycler
Supplier or by Thermal Cycler Supplier&#146;s external auditor.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.5 Simultaneously with the delivery of each royalty report,


Thermal Cycler Supplier shall pay to PE CORP the monies then due under this
Agreement for the period covered by the report. Each report and payment shall be
sent by the due date to the following address:</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">PE Biosystems<br>
PE Corporation<br>
850 Lincoln Centre Drive<br>
Foster City, California, 94404 U.S.A. <br>
Attention: Director of Licensing</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">or to any address that PE CORP may advise in writing.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.6 If Thermal Cycler Supplier shall fail to pay any amount owing under this
Agreement by the due date, the amount owed shall bear interest at two percent (2%)
over the Citibank NA base lending rate (&#147;prime rate&#148;) from the due date until
paid, provided, however, that if this interest rate is held to be unenforceable
for any reason, the interest rate shall be the maximum rate allowed by law at the
time the payment is due.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.7 Failure of Thermal Cycler Supplier to pay any amount specified
under this Agreement within thirty (30)&nbsp;days after the due date will give PE
CORP the right to terminate under Section&nbsp;6.7.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.8 If all patents included in the Amplification Patent Rights expire
before all patents included in the Amplification System Patent Rights, or
vice versa, the per-thermal cycler payments</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Pages 27 of 34<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 7 </B>(8 of 14)</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">specified in Section&nbsp;3.1 shall thereafter be reduced
to the amount PE CORP is then charging for the remaining claims.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;PAST SALES SALES AND ACTIVITIES</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 On the effective date of this Agreement, Thermal Cycler Supplier shall
pay to PE CORP the sum of $&#091;**&#093;. In consideration thereof all thermal cyclers and
temperature cycling instruments delivered or invoiced by Thermal Cycler Supplier
and its Affiliates (including thermal cyclers and temperature cycling instruments
delivered to themselves for use) prior to the effective date of this Agreement
shall be considered Authorized Thermal Cyclers subject to the conditions of
Section&nbsp;4.2 and 5.3; and all earlier use of such thermal cyclers or temperature
cycling instruments by customers, direct or indirect, of Thermal Cycler Supplier
shall be deemed to have been use of a thermal cycler or temperature cycling
instrument within the grant of this Agreement. This section does not apply to
thermal cyclers or temperature cycling instruments already authorized by PCR
users.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 Thermal Cycler Supplier shall send to the original end-user customers of
the thermal cyclers and temperature cycling instruments that are the subject of
Section&nbsp;4.1, Authorized Thermal Cycler notices in accord with Section&nbsp;5.1 with a
means reasonably satisfactory to PE CORP to relate each such notice to the
appropriate thermal cycler or temperature cycling instrument. Any such thermal
cycler or temperature cycling instrument not having an authorization notice within
one hundred and twenty (120)&nbsp;days after the effective date of this Agreement shall
cease to be an Authorized Thermal Cycler unless Thermal Cycler Supplier establishes
to the reasonable satisfaction of PE CORP that (a)&nbsp;the thermal cycler or
temperature cycling instrument falls within Section&nbsp;4.1 and (b)&nbsp;the Authorized
Thermal Cycler notice for the thermal cycler or temperature cycling instrument has
not been applied to another instrument.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;AUTHORIZATION NOTICE</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 Thermal Cycler Supplier agrees to include prominently in the front of
the user&#146;s manual for each Authorized Thermal Cycler, and for no other thermal
cycler or temperature cycling instrument, a Notice as specified from time to
time by PE CORP. Unless and until PE CORP reasonably instructs differently, the
Notice shall be:</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AUTHORIZED THERMAL CYCLER</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">THIS INSTRUMENT, SERIAL NO. <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, IS AN AUTHORIZED THERMAL
CYCLER. ITS PURCHASE PRICE INCLUDES THE UP-FRONT FEE COMPONENT OF A LICENSE UNDER THE
PATENTS ON THE POLYMERASE CHAIN
REACTION (PCR)&nbsp;PROCESS, WHICH ARE OWNED BY ROCHE MOLECULAR SYSTEMS INC. AND F.
HOFFMANN-LA ROCHE LTD, TO PRACTICE THE PCR PROCESS FOR INTERNAL RESEARCH AND
DEVELOPMENT USING THIS INSTRUMENT. THE RUNNING ROYALTY COMPONENT OF THAT LICENSE MAY
BE PURCHASED FROM PE BIOSYSTEMS OR OBTAINED BY PURCHASING
AUTHORIZED REAGENTS. THIS INSTRUMENT IS ALSO AN AUTHORIZED THERMAL CYCLER FOR USE
WITH APPLICATIONS LICENSES AVAILABLE FROM PE BIOSYSTEMS. ITS USE WITH AUTHORIZED
REAGENTS ALSO</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->Pages 28 of 34<!-- /Folio --></DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 7 </B>(9 of 14)</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt; margin-left: 5%">PROVIDES A LIMITED PCR LICENSE IN ACCORDANCE WITH THE LABEL RIGHTS ACCOMPANYING SUCH
REAGENTS. PURCHASE OF THIS PRODUCT DOES NOT ITSELF CONVEY TO THE PURCHASER A COMPLETE
LICENSE OR RIGHT TO PERFORM THE PCR PROCESS. FURTHER INFORMATION ON PURCHASING
LICENSES TO PRACTICE THE PCR PROCESS MAY BE OBTAINED BY CONTACTING THE DIRECTOR OF LICENSING AT PE
CORPORATION, 850 LINCOLN CENTRE DRIVE, FOSTER CITY, CALIFORNIA 94404.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt; margin-left: 5%">NO RIGHTS ARE CONVEYED EXPRESSLY, BY IMPLICATION OR ESTOPPEL TO ANY PATENTS ON
REAL-TIME METHODS, INCLUDING BUT NOT LIMITED TO 5&#146; NUCLEASE ASSAYS, OR TO ANY
PATENT CLAIMING A REAGENT OR KIT.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt; margin-left: 5%">PE BIOSYSTEMS DOES NOT GUARANTEE THE PERFORMANCE OF THIS INSTRUMENT.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2 Thermal Cycler Supplier agrees to affix permanently and prominently to
each Authorized Thermal Cycler the designation &#147;Authorized Thermal Cycler&#148;, its
Serial Number and a direction to consult the user&#146;s manual for license
information.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3 Thermal Cycler Supplier further agrees to instruct the ultimate
purchaser that transfer of the thermal cycler or temperature cycling instrument
without the Serial Number or the Notice shall automatically terminate the
authorization granted by this Agreement and the thermal cycler or temperature
cycling instrument shall cease to be an Authorized Thermal Cycler.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4 To avoid confusion among thermal cycler users, Thermal Cycler Supplier
agrees not to designate or refer to thermal cyclers or temperature cycling
instruments covered by this Agreement as &#147;licensed&#148; unless it fully and
simultaneously explains that the thermal cyclers or temperature cycling
instruments do not convey with their purchase a complete license under the
Amplification Patent Rights.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.5 No Authorization Notice shall be supplied with an add-on module
or anything else which is less than a complete thermal cycler or
temperature cycling instrument.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;TERM AND TERMINATION</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1 This Agreement, unless sooner terminated, shall continue until the
expiration of the last-to-expire of the patents under which rights are
granted in this Agreement.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 This Agreement shall terminate upon a holding of invalidity or
unenforceability of all patent claims licensed hereunder by a final court
decision from which no appeal is or can be taken.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3 Thermal Cycler Supplier may terminate this Agreement for any reason by
giving written notice to PE CORP and ceasing to advertise or promote its thermal
cyclers or temperature cycling instruments as described in Exhibit&nbsp;1 as
Authorized Thermal Cyclers. Such termination shall be effective ninety (90)
days after said notice or
cessation, whichever is later.</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> Page 29 of 34 <!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 7 </B>(10 of 14)</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4 The decision of a Court or Administrative body finding PE CORP liable
or culpable due to Thermal Cycler Supplier&#146;s manufacture of thermal cyclers or
temperature cycling instruments covered by this Agreement or due to the sale or
distribution of those thermal cyclers or temperature cycling instruments by
Thermal Cycler Supplier, an Affiliate or a distributor shall give PE CORP the
right to terminate this Agreement immediately upon notice.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5 This Agreement shall terminate upon (i)&nbsp;an adjudication of Thermal
Cycler Supplier as bankrupt or insolvent, or Thermal Cycler Supplier&#146;s
admission in writing of its inability to pay its obligations as they mature;
(ii)&nbsp;an assignment by Thermal Cycler Supplier for the benefit of creditors;
(iii)&nbsp;the appointment of, or Thermal Cycler Suppliers applying for or
consenting
to the appointment of, a receiver, trustee or similar officer for a
substantial part of its property; (iv)&nbsp;the institution of or any act of
Thermal Cycler Supplier instituting any bankruptcy, insolvency arrangement,
or similar proceeding; (v)&nbsp;the issuance or levy of any judgment, writ,
warrant of attachment or execution or similar process against a substantial
part of the property of Thermal Cycler Supplier; or (vi)&nbsp;loss of Thermal
Cycler Suppliers federal or state licenses, permits or accreditation
necessary for distribution of Authorized Thermal Cyclers.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.6 PE CORP may terminate this Agreement immediately on notice upon any
change in the ownership or control of Thermal Cycler Supplier or of its assets.
For such purposes, a &#147;change in ownership or control&#148; shall mean that 30% or more
of the voting stock of Thermal Cycler Supplier becomes subject to the ownership
or control of a person or entity, or any related group of persons or entities
acting in concert, which person(s) or entity(ies) did not own or control such
portion of voting stock on the Effective Date hereof. PE CORP shall have the same
right to terminate upon any transfer of 30% or more of the assets of Thermal
Cycler Supplier.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.7 Upon any breach of or default of a material term under this
Agreement by Thermal Cycler Supplier, PE CORP may terminate this Agreement upon thirty
(30)&nbsp;days&#146; written notice. PE CORP will withdraw such notice if, during the notice
period, Thermal Cycler Supplier fully cures such breach or default to PE CORP&#146;s
reasonable satisfaction.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.8 Upon expiration or termination of this Agreement, all rights granted
to Thermal Cycler Supplier shall revert to or be retained by PE CORP.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.9 Thermal Cycler Supplier&#146;s obligations to report and pay
royalties as to activities under this Agreement shall survive termination
or expiration.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;CONFIDENTIALITY
&#151; PUBLICITY</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> Page 30 of 34 <!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 7 </B>(11 of 14)</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1 In advertisements, catalogs, brochures, sales
literature and promotional literature for Authorized Thermal Cyclers, Thermal
Cycler Supplier, Affiliates and distributors shall state the following
prominently in type and location:</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 5%">Practice of the patented polymerase chain reaction (PCR)
process requires a license. The &#060;Supplier&#146;s Model&#062;
Thermal Cycler is an Authorized Thermal Cycler and may be used
with PCR licenses available from PE Corporation. Its use with
Authorized Reagents also provides a limited PCR license in
accordance with the label rights accompanying such reagents.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2 With respect to Thermal Cycler Supplier&#146;s distribution of any written
information to Third Parties, including but not limited to advertising, brochures,
catalogs, promotional and sales material, and public relations material, PE CORP
shall have the right to prescribe changes regarding references to, or descriptions
of: PE CORP, PCR, the patents under which rights are granted in this Agreement, PCR
licenses or authorizations, or this Agreement. Thermal Cycler Supplier agrees to
comply with PE CORP&#146;s reasonable prescriptions.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3 Except as provided in Sections&nbsp;7.1 and 7.2, Thermal Cycler Supplier
shall, to the extent reasonably practicable, maintain the confidentiality of the
provisions of this Agreement and shall refrain from disclosing the terms of this
Agreement without the prior written consent of PE CORP, except to the extent
Thermal Cycler Supplier concludes in good faith that such disclosure is required
under applicable law or regulation, in which case PE CORP shall be notified in
advance.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;COMPLIANCE AND QUALITY</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1 In the exercise of any and all rights and in performance hereunder, it
shall be the duty of Thermal Cycler Supplier, not PE CORP, to comply fully with
all applicable laws, regulations and ordinances and to obtain and keep in effect
licenses, permits and other governmental approvals (federal, state or local)
necessary or appropriate to carry on activities hereunder.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.2 PE CORP does not approve or endorse thermal cyclers or temperature
cycling instruments of Thermal Cycler Supplier in any way or for any purpose,
including PCR Quality and quality control with respect to suitability for PCR,
according to standards and requirements that may exist in the marketplace from
time to time, are the sole responsibility of Thermal Cycler Supplier.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;ASSIGNMENT</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.1 This Agreement shall not be assigned by Thermal Cycler Supplier
(including without limitation any assignment or transfer that would arise
from a sale or transfer of Thermal Cycler Supplier&#146;s business).</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.2 PE CORP may assign all or any part of its rights and obligations under
this Agreement at any time without the consent of Thermal Cycler Supplier.
Thermal Cycler Supplier agrees to execute such further acknowledgments or other
instruments as PE CORP may reasonably request in
connection with such assignment.</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> Page 31 of 34 <!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 7 </B>(12 of 14)</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;NEGATION OF WARRANTIES AND INDEMNITY</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.1 Nothing in this Agreement shall be construed as: (a)&nbsp;a warranty or
representation by PE CORP as to the validity or scope of any patent; (b)&nbsp;a
warranty or representation that the practice under the Amplification Patent
Rights or the Amplification System Patent Rights is or will be free from
infringement of patents of Third Patties; (c)&nbsp;an authority or obligation to
sublicense or to sue
Third Parties for infringement; (d)&nbsp;except as expressly set forth herein, conferring
the right to use in advertising, publicity or otherwise, in any form, the name of,
or any trademark or trade name of, PE CORP or Roche; (e)&nbsp;conferring by implication,
estoppel or otherwise any license, immunity or right under any patent owned by or
licensed to PE CORP or Roche other than those specified, regardless of whether such
patent is dominant or subordinate to the patents under which rights are granted in
this Agreement; (f)&nbsp;an obligation to furnish any know-how; or (g)&nbsp;creating any
agency, partnership, joint venture or similar relationship between PE CORP or Roche
and Thermal Cycler Supplier.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.2 PE CORP MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.3 Thermal Cycler Supplier agrees to take all reasonable precautions to
prevent death, personal injury, illness and property damage from the use of
Authorized Thermal Cyclers. Thermal Cycler Supplier shall assume full
responsibility for its operation under the patents under which rights are granted
in this Agreement, the manufacture of Authorized Thermal Cyclers and the use
thereof and shall defend, indemnify and hold PE CORP harmless from and against all
liability, demands, damages, expenses (including attorneys fees) and losses for
death, personal injury, illness, property damage or any other injury or damage,
including any damages or expenses arising in connection with state or federal
regulatory action, in view of the use by Thermal Cycler Supplier, its officers,
directors, agents and employees of the Amplification Patent Rights and the
Amplification System Patent Rights, and the manufacture and use of Authorized
Thermal Cyclers except that Thermal Cycler Supplier shall not be liable to PE CORP
for injury or damage arising solely because of PE CORP&#146;s negligence.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;MOST FAVORED LICENSEE</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.1 If after signature of this Agreement, PE CORP grants to any
unrelated third party, other than Roche, a license of substantially the
same scope as granted to Thermal Cycler Supplier
herein but under more favorable royalty rates than those given to Thermal Cycler
Supplier under this Agreement, PE CORP shall promptly notify Thermal
Cycler</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> Page 32 of 34 <!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 7 </B>(13 of 14)</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Supplier of said more favorable royalty rates, and Thermal Cycler Supplier shall
have the right and option to substitute such more favorable royalty rates for the
royalty rates contained herein. Thermal Cycler Supplier&#146;s right to elect said
more favorable royalty rates shall extend only for so long as and shall be
conditioned on Thermal Cycler Supplier&#146;s acceptance of all the same conditions,
favorable or unfavorable, under which such more favorable royalty rates shall be
available to such other third party. Upon Thermal Cycler Supplier&#146;s acceptance of
all such terms of said third-party agreement, the more favorable royalty rates
shall be effective as to Thermal Cycler Supplier on the date of execution of such
other third party license agreement. Notwithstanding the foregoing, in the event
that PE CORP and/or Roche shall receive substantial other nonmonetary
consideration, for example, such as intellectual property rights, as a part of
the consideration for its granting of such license to a third party, then this
Section&nbsp;11.1 shall not apply.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;GENERAL</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.1 This Agreement constitutes the entire agreement between The Parties as to
the subject matter hereof, and all prior negotiations, representations, agreements
and understandings are merged into, extinguished by and completely expressed by it.
This Agreement may be modified or amended only by a writing executed by authorized
officers of each of The Parties.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.2 Any notice required or permitted to be given by this Agreement
shall be given by postpaid, first class, registered or certified mail, or by
courier or facsimile, properly addressed to the other party at the
respective address as shown below:</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If to PE CORP:</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">PE Biosystems<BR>
 PE Corporation</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 0pt">850 Lincoln Centre Drive</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 0pt">Foster City, California 94404 U.S.A.<BR>
Attn.: Director of Licensing</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If to Thermal Cycler Supplier:</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">Cepheid<BR>
1190 Borregas Avenue<BR>
Sunnyvale, California 94089<BR>
Attn.: President</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Either party may change its address by providing notice to the other. A
notice shall be deemed given four (4)&nbsp;full business days after the day of
mailing, or one full day after the date of delivery to the courier, or the
date of facsimile transmission, as the case may be.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.3 Governing Law and Venue. This Agreement shall be deemed made in the
State of Delaware, and it shall be construed and enforced in accordance with the
law of the State of Delaware. The Parties agree that the exclusive jurisdiction
and venue for any dispute or controversy arising from this Agreement shall be in
the state or federal courts in Delaware.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.4
Nothing in this Agreement shall be construed to require the</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> Page 33 of 34 <!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 7 </B>(14 of 14)</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">commission of any act contrary to law, and
wherever there is any conflict between any provision of this Agreement or
concerning the legal right of The Parties to enter into this contract and any
statute, law or ordinance, the latter shall prevail, but the provision shall
be limited only to the extent necessary.</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.5 If any provision of this Agreement is held or discovered to both
parties&#146; satisfaction to be illegal, invalid or unenforceable in any
jurisdiction or to render any patent in that jurisdiction unenforceable, the
provision as it applies to that jurisdiction only shall be replaced
automatically, as part of the document, by a provision as similar in terms
as possible but not subject to such infirmity, in order to achieve the
intent of the parties to the extent possible. In any event, as to that
jurisdiction all other provisions of this Agreement shall be deemed valid
and enforceable to the full extent possible.</DIV>
<DIV style="font-size: 10pt; margin-top: 6pt">IN WITNESS WHEREOF, The Parties hereto have duly executed this Agreement on the date(s)
indicated below.</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top">PE BIOSYSTEMS</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="center">CEPHEID<BR></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="center">(THERMAL CYCLER SUPPLIER)<BR></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">/s/ &#091;Signature Illegible&#093;
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">/s/ THOMAS L. GUTSHALL</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top">Title: V. P., Intellectual
Property</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top">Title: CEO &#038; Chairman</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top">Date:&nbsp;4/13/00</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top">Date:&nbsp;4/6/00</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> Page 34 of 34 <!-- /Folio --></DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12A
<SEQUENCE>3
<FILENAME>f39432a6exv10w12a.htm
<DESCRIPTION>EXHIBIT 10.12A
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w12a</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.12A</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>1</B><SUP style="font-size: 85%; vertical-align: text-top"><B>st</B></SUP> <B>Amendment of the<BR>
Distribution Agreement, of April&nbsp;1, 2005</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">between Fluidigm Corporation, a corporation of the State of California, having an office at 7100
Shoreline Court, South San Francisco CA 94080, United States of America (&#147;FC&#148;), and Eppendorf AG,
a German corporation, having its headquarter at Barkhausenweg 1, D-22339 Hamburg, Germany (&#147;EAG&#148;),
each hereinafter referred to as the &#147;Party&#148; or collectively called the &#147;Parties&#148;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WHEREAS, FC desires to calibrate and adjust the special brand version of the EAG Mastercycler
personal distributed by FC for the exclusive handling of FC microfluidic chips.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">NOW, THEREFORE, in consideration of the premises and the mutual agreements and covenants contained
in this Amendment, the Parties hereto hereby agree to amend &#167; 11 and &#167; 18 as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">&#167; 11 will be supplemented by a new paragraph:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">The Warranty as specified above will not be affected, with the exception of subsequent
damages of the Cycler as a result of incorrect execution of the calibration and/or
adjustment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">&#167; 18 will be supplemented by the following new paragraphs:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">EAG has agreed to send the protocol for calibration / adjustment under the assumption,
that the first 2 &#151; 3 cyclers from the stock of FC will be used for testing.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">With the start of the testing, the serial numbers of the cyclers adjusted or calibrated by
FC will be documented and sent to Eppendorf for notification.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">Any additional cyclers treated in this way will also be documented by FC and FC will
inform EAG about this by sending the serial numbers for those cyclers.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All other terms and conditions of the Distribution Agreement shall remain in full force and effect
and no fee will be charged for the services described above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Amendment is effective as of December&nbsp;1, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their duly authorized
representatives.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">South San Francisco, the&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
</TR>
<TR>
    <TD colspan="3" align="left">Fluidigm Corporation<BR>
President / CEO<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top" align="left">&nbsp;</TD>
</TR><TR>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Gajus V. Worthington
&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR><TR>
    <TD colspan="3" align="left">Gajus V. Worthington&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Hamburg, the July&nbsp;10, 2008
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="13%">&nbsp;</TD>

    <TD width="37%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Eppendorf AG</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Heinz Gerhard Koehn, Ph. D.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Michael Schroeder, Ph. D.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Heinz Gerhard Koehn, Ph. D.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Michael Schroeder, Ph. D.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Board Member, Technology
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Board Member, Marketing and Sales</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>f39432a6exv23w1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv23w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;23.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Consent of Independent Registered Public Accounting Firm</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We consent to the reference to our firm under the caption &#147;Experts&#148; and to the use of our report
dated April&nbsp;12, 2008 in Amendment No.&nbsp;6 to the Registration
Statement (Form&nbsp;S-1 No.&nbsp;333-150227) and related Prospectus of Fluidigm
Corporation for the registration of shares of its common stock.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">     /s/ Ernst &#038; Young LLP
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Palo Alto, California<BR>
August&nbsp;25, 2008

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>f39432a6f3943216.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a6f3943216.gif
M1TE&.#EAG`%>`-4F`(>/ODI7GL/(W]7=[1TMA?'R]WZ8R&ESKM/6YZ6LSSM)
ME>+D[RP[C5IEII:=QDI7G<+'WJFZVGB!MK2ZU]3<['Z8Q]_F\5Y_NF)OK+_,
MXZ"OTG.0P[&[V?7W^X^CS:F[VFF'OI2JT8FAS%-VM?___PX???___P``````
M````````````````````````````````````````````````````````````
M`````````````````````````````````"'Y!`$``"8`+`````"<`5X```;_
M0)-P2"P:C\BD<LEL.I_0J'1*K5JOV*QVBQQYOV"O@4LNF\_HM'K-;J_#\-'8
M3:_;[_B\?K^,A^=\@8*#A(6&='Y@@(>,C8Z/D(.)7XN1EI>8F9I.DV*;GZ"A
MHH:=<J.GJ*FJ9*65JZ^PL;&MLK6VMZ"TN+N\O82ZOL'"PVK`Q,?(R5+&RLW.
MFP@.`-/4U=;7V-41V]S=VQK9UL_CY'H%``PEZNOL[>[O[B3R\_3R$/#MY?K[
M:PX$^``#QJM'\)Y`?@@39BEP0*!#AP0+.E1(L2*4``\S`HQ8SV!`BR!#&I&@
ML>0[CO0\`A3)$J0`DS#9H9RG$E_+FPHQQHPYT]Y$_YQ`R[W<R;-G37A!DSXC
M211F3Q)'WRF=FDQ!4Z=&?^X)-VT!L@1<O5(-=!7KS*CNR`(4@$PG/+9C^90U
M^11M/KEKV^:-NT>@`@&``PL>3+@PX`J($RM&[,'P8+7XX!)S^TXR7SP"`Y1A
MUBB@Y3P"N"9(0]G=9Q.APYV^;"7SYDZNL*3F2IN:9<^!``#4C*9TN].Z\0%@
MO<4U*]A;$C28JV[X$-Q\@L/C?<8W.^``G1/'8IP+YRD"TC%O3@3ZUMVD]Q*1
M_D[[]M8!J6_Y'B7!>';NS>MA[TY^&>OK8"?<>]S%]]HDL4%AWWWKY*?>?NCU
M]J`0_+7C'H%3=#<?<E44\/\/@^0]-R$>%;+C'QD`JB,@/!=B&(6&6M#GA`,@
M-EC>B'>4N,Z)7*18PHKMN5@%C%G(V,1R-9;@8&2Y15C=B#J&**041&)A)!,^
M_NC8EH&))81^H(F6'I-%S(;-:E,R4>455RZ1)1=@!N,CFFG":>!Q"%KQ9G$X
M]C)GG55DF:1`=6EEQ)Y:Q.G+GX!.(>B@&V5U$!*(9J&HGWTVZB:D.Q4ZZ1&5
M%D@F+`A,<(T`!1#!:!H(""!--0X(X.4="PC6H6"S/LFI62C9Q4X2H5X!IIG7
MC-;$`K090:PUQCI1@'(?PL/``0B8L.H0RU9#9Q$(2"`H`0W$NJ6VZX5UQ`02
M6.7_#K@.I+H$`@``J(`$U2K1JKL7[<HK1[ZN`^Q'?(Y*H9-+#&53$5&6P.,1
M!4@0K4,!J/N6$0FW6$0!#H@'XI(3#W&.Q@`18+$0"4@<7ZY"^$.`50?@V\2C
M^K;C*<"@TFSIA`DOK*S-`^.C\WH/SP6D.R,+,4'0#')<V1#^E*2`RR9,`+)#
M!-0[Q`$$P+5``P1`K03,,:\S\TJ4\BPLS@0K83!2"*=M!`(FCS>TA4DTQ*G2
MIIFP0-P945<`DB81X.5+".@40`$!'/`$V&&7,/;!-9.=*-H^.[&V5&U7GH0`
M2#,W-WY(V'WWC9$ET'E&HR$P=4F*"W&`X@$`4,"/$Y2P_WCC&3W.=N20WRRP
M"3E;;G;P2"R8Y.<VCA0SWNTP#H\"QA/E;NS6)BZX"258O2GN$$E:8P#@AR_^
M^.1K_R7ETPDO^1#$OWWZNN&O#F5V.PM$[1#=OD^_B-R;9"SUX&L``TPP.Y25
MK7\!T1T"KV,$,+6O8,-S&P'UIPX"T.MB"7@4\J0TA"PIP'Q"V%M`#D"86<&$
M`0X0B^EB<C_4\(UN)DB7M627O00,T`G.BYD"%ZBB!J+O'3\CPN72DKGT&0%P
M^&B`UXA`HSA5C%L!Z5H2"O!"=AB0?P\A@`,H9I*6E2D@#0BA%B4PF@.8KF@C
M(9\:!4(`-;KQC>2C@!SG2$<Y<O\`CN'#W6D<*,$C#/$NZW%;[4;8A(3]B(L#
M8F)`FH6$/[)#`DK0B!*/L`"-_`4)\MO1$$Q'0@%PL@QKLD*;L->X/?ZP/^KK
M7<^,2(1,KJ-U3$"`$_<W!"2ZXX9+J*(Z?I:1+28A(UX\("OU=H``,C)@FO,.
MAY:@1Q_^[H%JBV`RA>#(=3!@B4B892([V,<B,$5:D60C"(OPJ&,B<IAL"&45
M1MG,(O!QFM%<WRJ!6`31P<.<X?P=\&@I!!\%<9ZWS"<^GH:E*(ZSB/2D@SJI
MP,Y2.K-C[.OF%^6Y3WCJCP!1N!9`8<A-?.!2";I4F$#?$<SM2>N@"$6E0N^D
MS#P%RC/_7'*,U]Z)SLU)<YBR!`@L<3B_;;KN4D.HI$Y'FK>7\5,)T%S#0J<P
MRG]1%#[/E*@0;YI0DBTRHSUE41&B]PZ"(H&*5_UEILAYU"0D50U+7<8R'64V
MJ$)THR9*Y>XB.DU#;HMW2TLI1X4PNX`HP("(BR(SQZJJLB+AK&E(:Q2:*LRY
MBNJM%:UI(ZFJ4K@R,%_Z?&(]V7C!$`*`@B7PI5CUV5BB.0&Q:%`L%!B+5\Q-
M+JKPM"E%'VA7K&:VK!X"T3^!2E:?(E6JH&3IAEQ*A6"Y-:]TE:P?*=N\0`)D
M`K:%;&2#5+_Q>)6HO^&I;\T*7#*H]@FL/51;AW3*YC:!JT1T_^XP#8G&UF97
MKZ`[`GJ)<K@F\+:PVSUL=^VTW]6N50K&)2]LE;O53R6WJJCQ:W21>V#3(N%H
M96DOZ:1;VKW^-K95L,``-LSA#G/X`2`.L8A!C`$/F_C$*.YP>'NKRK,-&,&A
M,Y1E=TF$O@+DBD@(Z0:5I(2_$>4`.#["?3NJU4+VEPD&*,4(GA(!)3OYR0G2
M;HN/6]0&FQ<)(I3Q="LKA)"6((Q.L">#9\QC)2S`E4E,`#:Q>]F"YO<(J)5"
MDDO!Y"?;^;\+=JWO()NPCQ8!P@\Y)XR;"!!\&D',8]ZRA6N,Z`JJ$0"QHO)[
MW5QD)L0Y"G/N1)WOS&DX?$!/XZ4"3?_A@3*&E$307)Y@%+?E8X'L>&2?A8<$
MUNQB"KLWOI8^\A(R/8E-=_K7(Q@`J)\J8#X3TF.Q/C5\-;EL"WGM'*#M8;/+
M3`2XP2-KB24LD:F;:PQ3@=>)\#6P[PR"*P18U!.:;_.F@;68H/K*'D/S.@A@
M1L`XH-T9>36WWH?2U]I:O&]^=URU`&X_B'O<3\Z`N4.=H0D)M2D4%#BS)PHI
M?7M,?Q/H]V,376%<+^'24"AX'`Z.\%)L``OG;K@^<]B\0;88L>J6F\0Y2.C[
M,"!V&A]R/PT+9UTK0>1P('G)$W$!"Z"<X50:434=,IREVV[:.HOY0XJ956XK
MFD$,@&XVM;W_\X!#?0M`#X/0AQX'A1^=V.@F[3<M62^GSURD20!T%ZU5=0=;
M=5<[G3#';YV\;A-8SDH>.]F_<`%A9R'E22>M"6HN$`8PTNU?[W&C0^9+C5Z]
M[T*P99(@^="]`[S2'_=Y$L(.!L$/7@0=V`+B7Y2I!>`[S=5U[.5IS`37@Y8!
MLMMVE:WL<0I%^RH@U#G=O:Y>&%N!]%\P/<(O$`*C#\-5`&A`^*9QUSL4`%T!
M>%@;`:#Q,SS+RU?A/#(TG.(/C_C\)2Z_^LOO?$V=8NVZK<AWW>^++#<OIH)!
M1\CD+USZ.P,!G7--4A!2_"=Z_E<+``@/W7<$FC=Q"3%_!U@+"W`ZGGGG!`]'
M4@7H;1$H)_BP@!<34H96#A"X@:]P@;O7!*H#$'Z&$"-(@JJP=!]D@9/'#B$H
M@OWG@K[@="700@\V@^P`9AGX=SAH"SG%1K%3#0<`?NMP7131@D-X"BSG-+2F
M#T[XA**0@)O'$E5HA:&`A?=Q25IX@URX"PL0A<]3@V.8AHT@``VH$0S066H8
4AYFP`,HA;^S``.'B@7(H!4$``#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>f39432a6f3943218.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a6f3943218.gif
M1TE&.#EA[@*_`_<``,?&R"%">I>IR9&.CM:MGTE4;IBGN3-'>&]L;.CHW+JY
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M0]#.S.4E+#`Y4G^HNQ=$AEHY7&1JFZ>;KB$I4\:]P"E"<)9I6(JSE;;(J!V?
MVT(P+&5#.S9CG/7W^$AEACQ3>8=425U99\3.Z1P5%2(I0B-*E+:MN7IG@+A9
M3:["Y9(W3#U,976T>B$I<Q@I8];.V0@A0Y)'/C=P;LS?\][GW5=\N6=8C):,
MH^%$.J>XJ!=HLB<A(!<8'VN4I`M4HX]A;2TW>EMI7'9JFC5*E+<R.XN]T??W
MZ:S!>L[6S6J4MJ^MQD!<ID1WF];>]RE:9BE2<^?>ZA`A2CMY2!<Q2??OXI2"
MLQ@I4GM:H>?GYQ@Q8RPI63,H0!YOFQ@84#^'PA@I6B%*A"%*C!`I4B%"A#DK
M:A`A0A@Y:RE:G-[>WBE2E,DT.2$Q8RDY8BDY:STK<1`A4M;6UB$Y8Q@Q:][>
MYR$Y:R%2E"E:E.?G\._OX];6WA@A2M[>[];6YRE*@A@I2M;>YRE2G1DA6B$Q
M<1`I6M_>U._O[][6UA@A4M;>WBM"C"E*C"M"A!DA02%"C"HQ8Q@I/N?O[];>
M[Q`I2A@Y8BDQ;][6Y];>UM[6WA`I0IVQV>_GYV*$F-;6[^?OYC]!0$6`=!`Y
M:R!<E*&4PA`Y6N_W[____R'Y!```````+`````#N`K\#``C_`/\)'$BPH,&#
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MLMK=R]=/GB_WM.6-]Y]Z8@78GED")M?==.SU1QYZ6F$5WWGH3<??7`%:2-]^
M"TZX77$.GB8?AA7ZIZ%[(>K777S[S?6?AO")=R&+_7U(''L)<C>B6*_5".!>
M4C%7X&PF`I@ABM]M6"*(%OH7)'@MEA5@A-D%*563."))&7R5S29>@QB^EQIZ
MX45YWF^3>7FA@0^]6"18<#+X('56EC=;8RN>B"!<:0:67VWV:29B:(&MEV:@
M1\KX)6',22CC>;<MB.29]$D:YX9;/@FC@X[2"*6@Y!&JJ'<1\JCGE>:)IIA?
M:O79Z*ADXO\W6H]"PNHDK'*]>>JBJF+Z*:QT3LDE75AZ1NRAC\57*J_X`?@8
M@LN&&MYI@.5I;&BO^I;>ILP6B>5N]#V$8IR7RGFF9@)""":(E(X+[67#7B@M
MI_R9>*M]=LY(9G.0/BK?90"[I9N_J(6Z)*((WOHBB516.Z[!\28HI[JZHOJO
MNE+::]ZD\]KYZ(,;?PFGP7A)[&*I\`XJ,H89RYN>LPJO6K"3"U\'<)-:QCJR
MA@5#2""DY\;J5\KU_ANR542?#+3/#7\WL)3[+BQKT,I1?&3`$G+,,J4L7]7F
M@\J.+.G$8%DW;)RIFNH<CZEB=25=:OJ[Y=`GCHW9V#H>=J>Y-[[_O6?=$_LM
M+)6(S3HTR(51V/9N[=9:Y]'K5IEDEQ&[7&NY%NM';*XDWJ@=X%/F[:5Q"5L=
MVJ8>VD4@N"H>!KB6UMJL)Y`V9PXZO-)R6.FN8)>^I[N-AVH[TK;M[IG==A_.
MX-W<"ENLZ.6):SJ#M0L=<[$8*PKC:CVJ:V/UVZ?5/=J!+ECWQM?[F?;$+)^<
MHV*U[XS[][G79W&%HNT,>8$^1Q[A6Y)[7?9@1S)$L:U?26O6AO07.O^1+F?B
MRUK@)(>RV"QM?Q+4''1:Q$#$V>Y6R\)?O0Q&.8HYBVR+P9H*H2:OSP6+A"TR
M$(<XU3/U48]^(`1/9[RGN*U\+7'I<E8(_^L7N,G]27S_P]?L/K4T++$E6HK;
M&PR_I41\X2DRYIMB$?>F)PL1+W/*VASWWE4YOED)AH72FV^N^)8H98B!1422
MC4AHOAHV#RQHU-[*W`)`(Q4G2UTTX!&I."=!P4V/#GK;$(&V0=7E+UX]]*`4
M;T:O=7T)B(5D'2`CQ2\;;7)`X7LA"MFVO2Y6$"O2DQL*1=@H[=00=\EA&F>T
MQIHU18LTE>S2"/O&&6H(+6>*HR,M&;4QX5&0?:5ZF"6I-L=1,6E"+K/?B<"6
M*F9BD(2W89KWZ-<KM?1-@-D#X6"2U3$\OHZ!3O(E',>"3`02DYW#*=!MC$F\
M<9)N=A[\&'(PAO_.*1;*F^7,6#.]19S]80V@R/R+G"J#2"2&+IN.U(W7'/(D
ME.$F=12"42"'%;$#+:]JJ_N@!O/&T9)]U'`O6YZ,^#@G?=Z/8;^DD;5BQ,G]
M(`Y[$X08D5(*L3:R\:3$6NFNIF<QDX(LI.;Z7R5')S!T4;!Z+H3AJS:'2$@)
MKYTX^U7R;GJSI.:)6YE\F3E?]$6G9=)\;HR1`=/E,9D&<DQ2RF;)M/@_O+`H
MI4C](/7FI1Y>38YGWI%A5*2#**O^+8<YXJ@"E1G'6'&JL;@C7S-MB+ZPJ@9%
M]>%GLX+7+W;^KGCY3-]X(&BRDL;S8!H3EMB&Z:835C*K\H.H.1U&H=K_7A-B
M]HOD4%4S*CM2I48YQ!I#^;?)]61SM,*=7QY?AMM0*C6.-<3L9"_6NK7*M6-^
MNB35ND/`XD&36FX#J_M,AK1&]L>74YP?6*1'4M>Y!J:__2C-@./%G34'GBMR
M6!\]]D]3HHU4$T2H1'G'-U^YUY-"FNL^)<77#0+V-]'4)#W[1LU*%2V$\$2,
M1+NG+XOZR+,')A19GR@[U=&7/L<;8&9BF;LV-K9^K\1EOZI5WP7*&,;WA=9?
M%&F\5_[Q1[&$:X9V4]TT[M>4^'WQ?R;:$"0G4H^IH1E0%2I>6N(*2!D>JF'R
MV,&_LD9YV,05(/G5F+2-L[O-]1Y$;9-/^AX7_X\P:]OQ0,9E+;T9,]J\:M5>
M?-E:.CE+DHD+0HWU0.$26-!+'B@PD3A+LR(LCT`6T7TCN.8P'W>Z\Z4SF[&K
M/6S:D[31Y-Z7O8C/TKG9OLOJ,OL&2U%0C@R-\E,S'2N4%?2JB618K/3JJ%'6
MSV"9DVC)9*6O&L8O)WA*VKJNDQM-(/0FJGZU'-N5P*MI\7KV5%[AM3>GXTMD
MLE@O!N.UD%XZ:Q=O1=Q*Q:RTUXTJ=-.GVXMR',_.7692>PJT)-6V>UM<:5(G
M,2K.ON5F>G5I+PJZ+P9N,[(7`^)E?_G#M@;L<4=XR]Y%&\4S?>_#^\7KJJ#*
MS92QN+@!2MB;IK>E#O]UE]%68>M^CR69!D_H8`(.44J#^-*5[39H7LXEG$\\
MPV`)>(9#9L[/PB4N#Z<U5+3-<X0"?)_&3KID!@V;&0M/TXF4^L'YPO1Y8KO6
M4!?9FJ]--/0BW<\0NOH6K3+LH=/+GXP1^MB][O&8XW.V"JWY-.T-VU'SYNU_
M#DO+A\Y.>W[6S@</*+?5OM*9`[3MV[XV$O6=]TLFTX."IKN&VI2N&;_K222U
MU`#?2_C[A!@TY&'Z+RA/U<RA$>ZE:=3.HTX-O-5%C5OVJVSA:4B"DRJND)G/
MH+,,[$BUI=Q)WSL4K\[=O%+Y\LI:XZ$E/V`PIMV9#C=X?#/%3M7K.L#@_HW_
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M1F\?QSQ'R(`%-5R/IW5P4VO<AX:_Q5T]9P[`YH!X_W9=&K1ZH$9\?Z@]>,2(
MASB(BFAWMX&)3[12>J:!TV:(BMB!DKASDG>*?X=Y0H1U@@@MA%AX6_B(_$=J
M2-9QTW<M+>9%GDAX40B+^E-Q5YB$?K0*GLB"CR=4A"2)I:@6J80C:2=-%JA<
M8?B%.=@]N%@H%)AWB_9T1"A70JB#W<ARU6B%Q#B!#9.-?:2$E,45^I9&*^B+
MZO*.@>>+MQ1T%4B'U:AY-=1Q2KA]X8B.-I*-+O>-<S9T[PA[_M9'!<-R.M9F
MO`%-I\A;(B@;=4%YR4>,=7A\,^>"YNB-``5GZ$&0>T*!PR9;2H61R9&#&_<9
M+WA&6[A!>)20R&&`:!-)>O^G(PN#@]O'B`12A7/2=2:'A0NU?4J%B1I5@D(D
MA<LCE.51=R%6;"JUAWJ7CTY6<*E8?I)X;<$7CDU7?-Q%>BMF@[8(B%=!DC7V
M@HO'=^Q8>VFY;=4&B09WEI+D=$48;Q[)A,5HB^)8?Y_84DYY<V/A?>$U=HM'
M?MQ(9]$G<!'X>**G9URB<\I(CK\#E9>TE8#E=JJ'*WI(;#+BCSZW8X7D3UJ!
MD8&T"NRU:M?WDA\"D"%X5'O9<R#BD`"W/S<U@'#V6Z6)DG#Y(72W??@XF+,G
M7:,EDWY'>4X8/K-E3R))EW*$@4_93$4(FE/(4<5)@%^)G$1)=K\)@\*I;![X
M9*3_:8AS1(1BEV[7:8AO!XC1R9+"XX\80WZ?1D&AHIWIQR5X-U9)9Y_0J9MH
M5I_Y*&349'_?R)^AF2#%5#D.:6=VV)ZC1W^M68FR.4>Z:2'PV6CBLGNQYF^<
MI).X=7P+.95X""\-JI%N.**"6995Z8,JJ**]N7MDR(3G1Y3;&99UEXI@&(/[
MMF)+Z:)#QV!I>$ICN)V!`YEQ.8-<J7'&EX9F@8M"*"\?ET6NZ(C35*%"ZG&O
M9X[,=Z`UUX,,%I8I2GA/BGD?27[%EZ7SUWPWUXP]6*2;R)[QF(^NMX-P2F\;
MB7EJ>G`7R*$G=1L&^#?E*68#LH\WE$/S!&=+):?BF(Q^_T9M$J@J<SAJ^1&G
M1W-Y$<B24OAW>]5(`5FI5':#9_:5`NE_XAF0"N6$AG>#^VB"21AE(KB@@MF!
M6,B@GU:1#-IV^W>./_JC&T>J2'AF#&5"*[I?O"FIEAJ%"!B.3OB2E7JH:">2
MG9IWS=EHH/JJPQ>CFE>MB^IU]F2`W-IKO`=Z2;1T2AE`7LDH.$BC2?9R6Q)?
ME&A^>JIL3:>2I"J6QO<S[-ITK`,=+`2"=OA<C3B'LNAS9%JE5FA55$&0H<B*
MK:*86]F*EL>3R!=FA5.+9%F5=E>'!MNHL+B=&=FI?16I,7B7\-BO<(ES28J#
MM':FM7DJ=&:>^(>E'_N-+QI,R_^JHWV*6<_Y($+IBC]9?RM;A``+CG[J$&)J
M1J$:0<'H=#(XB]Z9='@G70VXK!O)IZBJAW.IJ!M(AEFWJ,!Z3P4W6Y@:@ND9
M7G'4I;,7B#;8I0(&M3-;IK,:+US81K4:M^DIM0S)A:/JJ:(8KEXIMH\*&+**
MCBGG<F7+MEMVM3#7J0%[6Y%!B%V+>'3[FIDG?JSILA7(MU[HMD9:>,CHK<Z*
M91PZAPJ&MCRG/Z7(?/!$<XBI=W,)ICE(D*G+L)#A+#0WA5?BCVRJ=3.+>KI9
MH9XENZ-+I_QGK7$XE\YD*3V(L1K+KO[Y1+O)B;7X@Y`FJEKJI@N)L:]9I&3J
M=X%!DQS_6JO9:Z1HAZT6.UQFJ;8,>ZAB2IE?J:^DQ[YL.Z;SQX$DBR`D.:M6
ME4Q6"H(G2;#'Y6Z(N[UQ,1A_&IZKH3Z(FJ^!EJE<*Z?P.H20!\$-Z+?-69T4
M[*^FJ*OL"KGTZ[$&Z;&Q&FR+ZIWX%;=D>XZF&W7#RKO=1ZC62H9BV\';FKFS
M:K<4C$\I;(\GR<"%H;W_"\,\O*(H3+DP#(GVF[DUG*.\Z\*KV+:O2I.0&[A*
M_)K.UI>4"HKEJ+,/*RYURV$VG(<>C!9U:ZI/ZF+DF,*Q&,+GJZC:V['66TOP
M.;>=>8$V*H&H2+D(]YTC:[S;&Y#PB:TNI[#C:Z(D",16-<=,_WR!.=I+!HFC
M!/S'-*RND3S&MZ'(<>R_6QC(2HQ+9GIY;5JRKQJ63AJMHCFFXT2=G5R0])B1
MJTRS3NR>:>S'69:0U#M/!VRJ.6IV_'J%L[C!A3R(HV6:E+S"S<'+O[S%AXS!
MPUBU0JRWOGS#<@>/TEN.K>S#:XR$4IR$<<S`76IVSBRTGFRGMBK+N/2DK`MY
MT3J"X'S$SDRCE!F%8RS#!"R/\PN#3%S/&OG+Q-S,;MR#<A>3[QN/U^S&8TJ#
M\5R&1HO'S;'"H)FVS@JI&8S%!WW0S$K$X9I-]/K&&*W'B@S!=RK,=*>PW)RC
MV$R_D[RMC`S29^?-_^N=3EK%F?K)SO_YKA+<P3JZJC-MJT_KJY%LT3O\R@/L
MTBVKPG<JJQ6]T?(\Q1IMED#<T6J,MK+,TXA[N_H,T?"\P:&,QZR1RRG]QV[<
M<?T<IXX(LS8\Q*MZUCD<RPF]UA\\;+8\3?O(RTW\U3A]U$1LS#=\=H;\S3U\
MR<C+TG?=UW\=U"&HCE(]R7J[H%6\UR[=Q*R1SFAWR9'MQ+7)UP3+M1A,V1R(
MLU>-PMZ\V6F-S8)=R;@[3\0LTS]=Q!F<UI7LUZ>ME$3-Q-1@D_4*G8W=JL.H
M,A7(NF^]R]FJVGO]<`39S@:GDK\-DJN`#?_<UI7MT5Z'#7.L%LB]UNH)<*K,
MAR)=U>[8W(C_W=CYFHW4P-S_6]U1?=E10=YMIXZ\[$N$G,:2",ZKFWG;K-V`
M;=;.K8H/"U'9J-Y(9]YY/9'+/=W\G<(/+83%_:X`OJ>PNMR=+)R#.-%..MXJ
M#.!K7=SL>YCO/<!@EQ72;9773=P2#E$?GLNSZI0^W:BW?<S,_7)F5]!A#-HL
M1]Y%O=R%K-9N_.$XO<V<;<3N2./W[;Y2W<+4#>2@B<P]SM)Q`>29R^.,3>0S
M[K$O3MU##M<M'N0PKGETO>0=6-_+6VG4P`[ZUM^O&N.DK>.47>-(3=5A_HXO
MGL]1#>8M7N/8<..YS>7`[=)T_=5M[N(0'L1A_!<4/A9UCMHW?L;#_X;FX@WG
MH5UIS+WG0B[9<GK`-#++)1W8&JRQ$1T9#VWF6D'C#^NW+*?*GMZRZ/WDEQW/
M>@R@AWG#@]G!MAPA1I[8=$GJZIK>`-KA(YW;/JS?'[WKUHW87>=]*ASHJNWF
M2OG<QIZM9.Z."'[GJ6ZAK.[J:1S7Q_[<@VWI.)VM0'[EBGW@,5[!S@WF$PWB
M1:W4R@[MGU[@69ONPRUX!5[FJR?661TA9-[1]'[G\"[M8V'B5`ZSFPO2YVS0
MTGSER+[MJ/WNO4V>:E[JR\YR[/#G1JS6CYWF%A_K%!_N22[>"-_<,7[P$U_,
MX0[R&)_P"L_9-:YS&M_Q"__G)2_<'W_D$O^_\O#\G2G?[C`?QO`)\B/_[C8?
MZ2?O\Q:OZE7N\8==<_[X\D:/].P^].$>V[T=\3VN]$;]T&,N]43_]`K=$`'K
MGRBOB_`-A9H>J?/:Z1_/X?.'X1IO\A7MXDR_]F'_WC:?ZG#O\VXOQW4_Y@\O
MY'5_&VB.N"X^['VO]ZY[]WR\]M;N<SK.\CJ_R'),]3;\Z^?(Y&8?^?'.N(*?
M]VA_W'Z-^"NLE&KO^2$.UR'?\P@_?B0-]QCNTHN?Y$.^Z(\=TY5O^?F<H2]-
M]P^4[0WMV@O/]``GYK3^S6)^^A<_])`^F%>.X\C.#B2^JOZM_(9H]>1+X8Y]
M\<Q_Y-4XWB4O\;S_AOW9G_S0#W#/3_3N..B>ONBPG\%A_O3&K^J)/^##+?[J
MZ?O$:/[&/N;^K>;C-_X0#!#45OU:M4I@08(&!Q9$R)`:MH4,)2:D]HNBQ(("
M$S;,"'$C1H(:,ZZ"R-`C0X(;2WY$.3*D0HD:-U+$)A)C0YL'#V;\F-+@PX@@
M78XL67!E0YH8=RX$&I)=2X4S_TVE6M6J1`P^6R[U23#KPH]+P:[ZJC5HRJ)1
M.;Z\R!(J3H%BQ\(<&G/@3*-T(_H46W'BVX4UA2*E6]1MT,!Q.<[%B7"I3;`Z
M_XY]C'CFKX,$V2E>G'*SP\83\9($F=!LP<\C=UI$:;$FUY9LZ][LF7?R_VFC
MD`='3'N6J5W@G0<*OAU1]V'6+06O)DPW<^6S!"%RS3SR=^W%B7?S7?CY<'1J
MJ86__#U0+MY?)3F;+C_;[UK>@]E7)C_9ZOVJM+<B)MS5^,F%,!CKM+`:.FDF
MD43B;C3C/O.(0<P>;(M!U4CCCR.9`K-,+X$$,PLS#5E+",`+=SI0.`5=DLTY
MB!ZT+C01FYJL0M).2_`NWI++[B>2_**0I)30@A$TDRC#JSKR=`PI*1E9FM`X
M)6^BID,?H:+(/Q(1XPPRV$[$[#B#+FJ1,0P9JVC%F#HDLTP1:YQ-(2K)O+'-
M\*)4BC1L/E3NKA%QU$TR%_5*<L&_*FL2)9%.-/_*3OP:_0X]_1(JRSB8_"/+
MTKN\&XJ[_2[T[2CB=G0,L+>D8ZHW'2'#S;(IF4IMU21O\BW#Y405"L0990-J
M-2=CTP^EM$*%E50P,]ML/5G=0I:^'NE:LM0+\0*5.2>Q4W$_BX":42VH'@+A
M#%K.^#;<;\6=SC"F<+4..8R.$F]84J.KU$+`P/R5J01?W2LG6Z4U$#99"]U.
MK5V;(]4M?TVBEDAKH6T4/Z78J>U1`=G3"EE+<:NNOVCOY0\Z7W.%-CB]U@P8
MWM"VO;=A@YYZT>!^B76Y9':3'?G&W0(&[#N:.Q8N7IU7M3G>G<3B.4R@B:07
M9E&Q*020#Z*6>NH/"FG_8VB5LV-)KIQ_WM"AF8WV=&2=QZZ9PJTI_:M7K[>>
M&>N=-S:[Y+&]1NSA^_CB&M.U+QU+/?B\PI)D_Q"^M5NX134\X743YT_/I8%F
MN^^&Q%,9MUZQLS?DRWVCFW#]T)66ZTB[)G`53=\B?4?(=?-YLH4K+SKFKMM8
M`>]_[MCCZIH['VUOCQ7W_#S',Q>X[*Q+E[U(T$W_>O.L+R*SOG@Q5]XXW/,#
M>]["0<M8[3HYGJLZ+TVF5&B<LDR:)\K.-TA],U/6V,#L7$?TJ56KDY%AI4TR
MZ[WPN,I3/$N1NMRDEHW8SRY"2Q"``":4%+%O7D<YG*PB>*>.?,QDTL%46UJF
M_Z4-1J4->\!=!W9WLCMY\#`-'"#)D,87BN#O@X:S&9*@`B!%26Y34L+9Z6BH
M*`#*,(!;0U\!;8)#_E`0)$,LT2JR1Y4D;DPK"1R0WQH4.\&]K'%5I*)O?M2X
M+DJO/`0$3A=_(S="<6:'E)N(#6WEQFVIRG,58LZ+7J(_QE!OA]02F\BTF++*
MB>Q(P?E?_*YS2"G5:WQ#XE#SG"4HAM@N>P7@W>.&T[@+KM!@%UR?"POID[1`
MBF2*T<I1:)C'F^C+@*_3DV1B]\@'$NIE*>+C$I$BMR=.Q4*FZAM[2N?+C,1E
MBAQ!HO%\61&0T2\D)]G8*P'IE_`=L'VB<MV<WF?)P?^0\F5]6B;;.C0?U+6G
M,7U*E]),<Q`92N0DS&2F!84WSKQ(1XXP><\";08J6\FJ-TKQ(!-I>;RBS*Z;
MN8'40?(4GWJ.L(0GK%^9@N40#WKH<^Y$I*NX21N`229MIEKFU^S8/]C(:'_`
MJ:?W/A=-!R)&AO515C_;63>0UL4CN?P'TB9ZN*=P34#F08T:"^G*?`)S7O22
M3,F8$R>>&D9-+YL.0D)IT#^Y"IHTDEMWEGK'?R7RD3/2%O5X210:03`W_1.C
M0@(*SP0J\8@4%:1Z4HH3\0C$03U+*_TV=E8,RN:.*Q&;$N&T&NIDL$`$`<'M
M\-:!`HA.G8O1GUQ(]\_P:"3_I_>;'6BJ:AV)`BXAFRF02>MH&ZQ:E4B5U5RS
M(C(S7IK*H$-MS$-P5J:,3-:.JTG-2@"GG9?1M"CIW*7YPHE*N.J0B4&IDB]?
M\K9?H>HM^T3>6H.605E93BC(S5E3,4+=&_9O,;=E7G/G&!-TV<:6_"M;`#$(
M'PQA]R;<?6X9D\;<WQ;G@\C[H%R0.QKX;E>+,U/H81E:,NO&MFR/TF*`73B9
MM-P7NG=2KX8")C&'&%B+FY6(RU9W4ITM);][6B_6]&BM@IWW9]B@:60_BT+N
M*/=CJC3MY\HJ5#::TX\J[BV!\>(RS4@6,J;4:L-RO$4XRGAD)4&M>'N%KD0M
MKRXV_RPR\+:R6@?#EJ>,#`V.$S>YVA"GF4S+64_BVL+Q?C<DZ-3O*B3IWTH^
M.58U[C(*B1H4*RNK?:7]1>J<N46MH6ZJIST8+$<,6O%:\I]3#J9)9S@W'W]9
M)4`3"$W-.JMPHF\W.WTP23DF-N.>EG@MXYF%`TK=M]7SH!FFJI3>QA<(;T^K
MTM2S/;E5WK.R),'2ZZR(]QGJ!J4M8MH--#%ANF"Q2#B&OW8.<J4;GZ,I;9_[
M7#1]Y_LY=O3W88AM`W:+PEQFQS.YW>V-&K=[-)>E12S']F"%V;K/<;N/K=K"
ML/\$[.Q/KQIQ\J91>%,9'T=;;B/DKF(XI4@P.*6OQ="J(_^((V?=4-$/K'B,
M+`^+M*+:7K.A?5'8E,D96P7)5:[7-1'_B'.N+4OXV@(%MD2Q:CG.9#M4+<KX
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M;,(&"5P_AU@J93,J\/JX^"L4H`LV#*D)(D,GDC,M\=`WHRB_*0&15FFFJ*,G
MCH`%%`0K4YNZ1S,.6/@,`20MHOHRQULY$>RUCRN,%WJ?6@D\JJ-!\J(&&/2Y
MN6N7XNNP"-/`\3,.`N0[#:,%P\(;2F)"F+"P#_2^NB,FG?@RX`O"\5,)&K2N
M$9%`Q=@M_YWPB0Y\N2V2P&"Y/02L/<LB)@U<+`[QOH#CC8830+G+JD!KO]P(
M*/5PM.@"H9O2.L;2.3YT.Y-9BG0"IEU!PE!:FMZXK4",/.A*B@7C0SPT+]9#
M+LLCD0#;E8A[.U$\N&*+B^L;0U$S$4.Q,&U!Q.XBO].C)\$(%;D++W'#M:+Y
MC%^,L#MYPE9L%@$TPC!R103TQ3$LLY]0/Z("`1+R+^ISN80+(%J<QG?K*I>C
MO_AR+4U4-;#Q/([#./$JQ5T+QXWKB+@@14]4)R0\.&1D/<>#B6Z+*W+$Q7`,
MP#MA)UC<'D7D,S<R1,XIQS^JP0&+KT84P;3KO!*DFY)PP_2C0?]2)(VC4D<]
M8SV_T\A6D["9"TECQ,-6Z\2-.3^2%*_RZ\(J1`TX"37<@SL<I)=-?#N5;#VY
MJTF1U#DRT\D?=#J8)+R(9#>W6JV&J\G%VCNC:`,JN(%"*(`"*`2JE,JJC$JL
MQ,JII$JMU,H"8`*J"<L/8(*MG,JRS,JK<<F%@ZZ]VTF3M"Q^C$5NDT,+Q*P*
MJS\B@;E1/$G&`KT.3$.U#"\UZ3@WQ,FC`SV-#+4X[,C<PSH+*D&C;+0#3"3U
M:K]>>4E>X\8-2R$&?+.N6ZK!+,GO8S>3;*JFBBPC'$J%"<;],TF5_+YS[#Y]
MC$GW`TIWVL:FPL'N>XC41+!R[#J$ZQ'_V7P3<H3'P^-&DD@P)$0J"MR[W"S.
M%I/)RC!">23-Q^.]@X"%,R@$)L`"(8@$-@A/\13/$QA/\SS/&!C/2!B#/9!*
M]WQ/J1R#]#S/\8R!0A!!X>O%LT-.$$2\_;).A@3)0&2^]2)-6%A!Q\23;GRP
M$'N-5A/0Q.3(B,''-AQ)$%Q0V)G`#`+-#K0\RRR24U2(R=(MD%!*/FM$?VLQ
MTF$[%/TM/6+*PUNPUXA(D,*&)6PURSE0>&P5`E4*&$1*O0BH`XU,[>+-"D2Y
M$$S%NTP?Z`-)5F3.BXR)&]W+SAO2Y02O*84(M]/1@M#1JBM2&W4EV;H["Q2^
M9KK1G*K+$-31_\J:#1N%B#:X`2QP@SN@*3N=BFB(A&28DA7D4X.(@6C`G3M8
M@?>@0^#POLVX+<C$TF%\$2[=%7_L+8.8TJ"4N/>Q0''#"!@$'.0TSD3ED>A\
MC!_ENYO+""^508?<C"GERURD/AHMQ#`EU9V`!47D&I&$4<*ST5Q$'-*DKPUL
MO4P%T2[,#4F\MN7`*^;AKB9E29_L'T@4-V1-"S:=R=JS.2VS-B\%&3Y]S2#,
MO0EDROB+K+LK5I.85F?5R$W</9O,UE$:4V#C0R--N(=JS7-\MI&#"!!``@;H
M@#OMUV:(@<[;%4`55$@XRK?,5.I3HVOEMEYLTT?K5-,R4Y-@.9*!Q/_94YJB
M.=;@",X%1<CDU+S@\-,`TU#$)$)+#5(1Y5$JK0\EI!(O!)L2>]!4RKK-;,,+
MF]BF2C:%M)!N0UDGS$7K^M&;%,)V=`[2HSYY+40HE-G$?(@#Y;]=[+D7F2LE
M[$]'7%(IK<>CY-*\0#D?K50'784#C54*3$9+Y<$3%$<__+RA;5FN);U=+5-Z
M5`CM9(-FX-=^O5,*B(2E5<*!Q9MO(-2J4\+36]O.6\HNK=I=K-1@HL8:)-QM
M)%>I9=J&$]HEW<#)55FK#5/E)-JLS<5B?%N(3;BS+9JYNU!X_;LG&@GI(K.H
M)<JTO=E)_4=2,XIL7,C1/=2-C4(,1-;Y:M3_%F/#1LI/Q'O'4KU4H[*<8/7<
M>Z7(=E5-$[E=76V_>,Q%A$Q#TFW%7\78D4O8=-0N(E,V$X%$WGM>S%4/$(B!
MN\U;?P58Q#6*OWV8087.Z>6_C/5/X"4JP:`NB54UX%TY_83+@*G(`2X^>D55
ME85;.9S=CNA)%V2>+V.^;Q5&QXW1`C75ZR4-111))PW(YLH^^FI89]O+PJ-,
M_-7>-`VXNC31[^O9I<K-=*1$BK/0>NW93U,C8T.JNG.]>H4.Q^3&`1U*Q7P1
M,#PK&&5A[HHK!P&JUE7B1N)(`@[B>J7=3#V6:&.":,!;]K73O9W!C(C?1@G<
MIXTZ'MX>S.79C9-B_U:U#8P,N'CKL,=X65<41"U2TZEMP=;#3*"-+NZK0F+T
M-K?K.E&DVA2V8X,HR&=;VO<UQ],<88H=8:.$Y'&$S;*U.\?"M?PRTEZK2T[6
MI\_K58!\QP-^D644X'.\6/],7`FM2W,<S7DD3>.UWD3^6:6E7M6<99L4S0#M
M8-H5S39XFBW.VW\=7I<!8_RX@X)=9;^,XZR#XG&;3KNXM8F5Y5OK"^3"4'"5
MKM8U1%K,J9HPO1F&UJ+-TCAF,+NX9K9M5&M&Y+>T2R^F*)<Y-BEID<V<W+?E
MXYW=XU#<9:;,7C]<52"4672;U5D]/1GVV58LBE6EO:621&;5958VL&63B/]'
MO=V5++3>U&>Q!4,/3M&H93>`5ENS]4-T``(M#F::D@6^35>%,.;[&%2%AN9H
M'FG1A&6E7;EUB]1=?>1C"Y5'M>&.[K6XNEWK/&*%]61@P^3"I6F&X%J+%N2\
M8.=19N-$(E\,!&6#MMKR,KWP11X0!KWKH]N3Q9/BI2>HY=D_%-:E?./?]6:R
MGNESU&GJY&41M>BWOF7U@"ING>,*CC?4G.-TE&,B-DX/],L=3-W$5=>OONN=
MY<;-*(`/0.GV]=Z(@85("%2\F=_L,S]O^^JG-F.T7JQ,)5Y1K$B(';Y=9&OJ
M').;],#E)=J:H&RX9EVM+;3D3&O&YF7,=6R@`&K_AV!G5"UK<VM95D1LG<DI
MI/5JA[#H>OYJ+;W?+LWHQ6;*590XXF;:Y]9==V9@[F[B^./H!4/3,E;K7#8(
M7HCI/9973"5BXLA2CO/:PM3?I@Y![1Y)VS8HI];>R$GNW%M0"80$69!LO5UI
MI84%E[8*F"9<7KO)A^K0^=YIQ+R[=50/+E5>[)9;HI)>Z7WGX";@\);NDO7'
M6:7PA!XX#Z]ND.[-$BZQ:Y9GUUWNUZQJ[U)&V!57?/15>_V]S8@V$.AQ$*`%
M'__Q-GC3&C;.^6K6.B:)A=Y9YQO(`E[R_#1";&B#'@?R*O=QMJ/4QTU-TRQ2
M)<_42"7@6G$Y*F'N(/V]_T8F<XA850O<<<RR\8K=Z$6V5%+$5R0X:0'/GF:(
M!--;Z`.O"F3V\).EYZ7TM,H*30C_YO*5R&LZX.GD6A:UU"A>Q^+55?(.7O>S
M<'JD5)2K;M;V<B)?=#J?K#%/9!#,1D?C&E8N6X7YU/(:N*@=8^4^7/HR4?::
MCA48`UT7@C'@]5X?`TJ:DJ)LKIE93#T+X`HE9;:]VM5<Y#XN"!`H`%Z?]EW7
M]4+(QM<XJUM-9U9,U/76UJ:NU&#39`3FW@4N,&&GRP>6R>Y2WF\64^Z3%>K[
M!2H8@R?J`'S/=WW?=W[O]W]H!A3HB+'=%0.7A7[7]\"E;W3/9EN=6X%.$]2]
MZ/_=51KE%?9PQ=AE!T*\7+^)9!%F9VDPQWA5=DT-"V!6+VY(KUB\9/%+;GB_
MCNT0QN7!-O4Z/^=>([P6[BXVP.R7QH(S,%5C+.Q-#HX;3?E];.7=YM+`@]&T
M.`,LP!LFN!I+%UMZ9'<(?QFE+]ZS/EE*7&[VZ^EDS%]+QSUT0WJ2R?I+#\"2
MN`$AP)UF4``#8(,/$,^YE_OPK/N[SWN[MWL#B`%@-TOX-,LQ8(.XIWOQ+/P"
M<-BP0?L(C7.<+]>F+M\S'EI'+>'%#L82!_I`LVI[;<>4R\923&#Y3N7/I?JT
M1V6F:G6C2'78Q%6,BZO%=B>L#CQ!CVVM+NU:;W/HI@;_`^!Y!,<"$`C%':=!
M5Z_N):[(A^K6R&?CD3OVZ*XXWZ4&IX?ZX-=0DA5-S&/)M>9&,U]>!:^MCDO4
MDJ!4$)96*5?]UK/KAM:PPEMMS13M<[?40H@$W/D`2#@#*C"&,]!__@>(,\8$
M$AQ(Y0S!@@BI,)DV+1Y$AP[C.81TX^#`C&?0$6RS:A6VCR!%A@1)K20V6")'
MEAPI\N1'=M0^MG0)<]7-ERYWFJ1)<F5(:C=AU0R);6;/GQ^1'OTI$UM)HDI;
M-OTH=14[DDAE9A6:=95*H"YEBGSJ\RS6F4=1%DVZDUI8LCR#)H7U[R[>O'I'
M4I/[L^]*EG#/PJP9^*]AG2^S_U(]&?;PSL200\+*Z9(RFVAZ\79``@(NY96%
M+1]5:50ISL=$3R+UR:YRX*9&PU8%VW(U3JU/:Q)%-V9S7B9GD!*M7+.OX]8L
M!5LEJ3HEX)]KJ:I$?O3K[9*@O985&OHO2--+M=(FZA>G4>5K?=YV+K)X].90
MU0>562@2\+P?"IQ^*73F8R95!^!X;>R1'V=[5*929:VQQLM(8>5T%6B5?97:
M<B2M1Q=/5Z74'WLGM25>52T-9M5Z8MDFFFQ]/=;8>TTY2-F)-`EEHU9+P2:@
M9:.9V)-Q[[WT7(VN@9B28"BM=)5MU""XV5)D&29E8-MA<]YURD&6H8J1O07B
M80%*%O_;BLWIN$IF^77V66ES.:9==DH!!A5*@[%35!L%&,#&"6RPL6>?;##A
MT8OHW30?F*6U5A((6"#8`1"TU&D"$'[R>6F?8Q2P5'N<GI6B4-45Y=A[3*DF
MYV/(F1432!Z=:1532,$DHD^%58GDJZ!Y"I:AVMFZ)*EFID:-"?@]^4$ALU(%
M%H7:>2@K""L\>5<!KD*5JH0[MG?4H:,!R^2+<<6:EH1MC@H=I\0M&B5(4/DD
MJFC%E872CH6:%-6&0.DJ+*XE&N4N>A&N]-2++;GZ:5H`TTI:L&"9*N2GAX(T
M;5ZBG>=I?&O)%&"46D*&G);1F=B?DH&U<4,!2`@A1"21H-#_\LLNPSQSS#*C
M($2R[AJ@&7!W8$'+A6#BQMQ\;H6G6ZT.G@&)++)0X+0J3CL]1AM^H7MO=[G1
M1%1ZKZURAJ,(,@'"T:O<%PT%3S\=C2S12+""6G&["S"*G"Y['-=J@?246K7M
M6W2MU-DZ]W4\.6PH=GJ_MQK?7/VJH=U:Q?>FW#2%=-^TR`(XTX5Y$VU632!`
M,FT'"J(XJY2L&5YB3B4%O=IIZ:58EK89=PB=XPD'5=2+(L\%NTD@U[DDG"V1
MM2@LL,T=/)@U`OXXL[+E=AV89;*&'4]68LTMEU?3BA/%>)$I&<DQ6B;=EB]5
MSY3%?:.UBC%[8!$#*0PT$PW^W^#?_S;;^_O_C3K4@;]H?.,=I@-)FH#3`2Q\
M)FMP2DY(-A:5G,CD)JI#'TY`P(0G"4%2L0F73E+$+1%2`VQ/&MO1J%$(-B`(
M`$Q`TL9*%9M9!2E==9H-O6!5DU7M:SF^P@8O5%?#(K7+.>J)#'*:11S#@*HM
M%LP2++"C'<P=JQ#LL<E1@D@O4SF(#-)Z4@=6X!%2?:AN9N14N<2$'!O"97,3
M/`[`KI:6MQ1&)1MC2FVP-JR.O64U%L)0:D8E+H[UAS6*&E97=K2U"5Z(2CBQ
M4K;P%9@:#JU7,3'DCMJ8L`_J4"3ANTN5#&>CV:V%.V*)3_I6):?Q6=`J)D`"
M*7CV28I]8_\%M#'`-]2$!3),CF_.*I&V:".QZOVK+QKD(`C8$K?<.;!;%((%
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MF)@008$`05@JLT($,2";?!.0H9+WRYB<"X0HA4X2RU@V7BVFAW/UFD-A%Q8M
M[DH^M8OBPI`DHGU1-F`=PU7`YNHP%1H+06S8%(L"!#NRB/:J3_WBH_:`UR&5
MID6[,TXDV46\A,(K2-<"+5GGZ!_0A@>EHI4*N)9%'FP]14H>6M!@&:LCN3JT
M71=-GO/*)9;@;D]Y7NUH<BM[5O>0L#[P8:F9@DK4"O)N.M%QG%"K-QGO7/)]
M6-/G!Z8ZU6\48$%HDJ5>.C-&W@B6+WE<11OH99STI(K`1SGF6@F%TCN:-25<
MX]7R5M&H)P$AF=HI``OSXT*W3-0JR$WL_Y"&E.!-BN>,JQE*6U:"4)B(YR8E
MYA%D"V<TP9HSC\`]\5]1DY(5%['%*RI6Y@H1#J`@-()Z\PN1KZKA`X%Q!9+J
M\7B:=+H6*9)WOL70;2+9E]E$QS+)DTJ6.F2J!0-6O$^5C6F40\GY)'91R&N0
MPS)<)J[%KH:W0S-(:U1@"S6LCPE.(E_*^I%#B[22*IFE*ODXJHX>IGJ^3%]:
M5/G1*L''!&.X@WZIJB#*["P_6X68B$Q3,"%M-E[:P6F[,'L&M>:'K4RTEV>O
M6B0)U76:9.-+(:Z9'R<PX2Q!W`W>)`G(:^4Y1SUA-E!P#3!Y$==$=S1,)I5[
MK05A2SH7W!IQ4O]L&U4O27T@V6=^D,58QRRHS.W9CHQIK2;9KD5,HUSLUK[2
M8!2INC6T84DE@S4ARR$71J[Y]AX]ZQ)J=QE?:B$DKA>>O#O9.RT/QYNLX$1P
MRHS,VWG<5[,(+D%S6Y1)Z+T32=1[X';VAW%:XM:%.A;S+9E3+C-?)#960(I0
MS[*6VUA*5@/\,^K@Y#5R#%@<7^X\]>$+%K-&IB"=3:[B7IBEV(CF"7\-F+V*
M&!*_0/JXR)-QYS2E.!]?Y^'(X^Q0X;"27"(B[E`CE533+42PTM=5N!*Y"M7&
M<1)"-W!.BQY"?\C'2SUP0<$HV_/FJ'??W)'7+ED=L[?&:\;C6"5Y-_C_HZNJ
M3A!ZE^NT5ENJJX=`4R?[NFQD&@N3!HF3U+'Q-&GAGEZQ3D'3I,*+R/<C.D\]
M?U3X+"&:&#)?,E^!Z2SZDLJ>-OG9U5B8QJ.FP0``3)\!U:<^]JV??>P[H;\A
MX470\W('SUS&J;H*_0@MQZJ2>39(H!'=TU01_Z?)HAEC8),]&3EX--*W5+T&
MSMA\GU#<1]/0'_U5@P*L@+Z<5/+E2&DD4N&=4_%=TCU%3%Y]2(^L2MT!!DSP
M4!0-7C6E"UFL"H1LF@="H)%UWD<`WF:H6R"!6Z(4G?K1!"W`EIH4`)L8F6!(
MT5+0TR5U1;]\V2@]D<8=R2+!"O"4"NHXB",Q_P9Z7<OW$%9.V)C>*)?`"6%.
M)4[B%)U`T0L08F#,_8K5#)59C%R%M!X5OMI%=4KP/1NGP=`2GH\CZ4L085I@
MY8TB31(LC$$NY<<W1`(0,($@,@$0<$(@!D(@<L(@+N(@4D%5A!]G8$'5)-%%
M\<VW(=H$Q@?DR8U`40,(%,(8A*(HBJ(0*(A,'%OJ691,(=J5E-[_;083`,U[
M,`0ICN(8`$&R=(=,>=M7;6(0^=9<Q8??"8G?]`Z%H4L,<@@UH.)76(UU:52B
M91KG3,].5)#'%5V#T!X7+N,JW$!II5NRN!][K9'Z9!*AL4,;V*`"'=1<[51.
M+8NF.:!%R0Y2:8USJ?](ZE3'G=@*3OW>2_$*^Y02>W'+YV%(19UBZVT9H:&9
MF;F%42W&4AQ;@\20385(H>B8=`U&FVS6@YA;EV5:?=5*&SKAK;%&JC!'N=5=
M6AP;INV&':$2DPD!@.F%*A3`1?T'KES8?^SD?S`(-91:SY#?8LE1FV@%W2B6
MHC$+&GF*2A1D4P:3<FC@<\7+%+ZB7@Q*=GU>96AEJ%1>J)3CZ^G(2X)+[L%+
MOBV@B7&4PZ@2@V`1QTA73@+74C%EJ6#;5P4A4H``"-#"&>BE7^KE&=!"`<3`
MM)#"'O"E7R*F7_;E7S:F7K8!1^PE%:R`,#1#90K#95IF,X@#)##F7])"8N+_
MU8EH48"P9''ATP\VY`=B!7$!$D^!%B;.T>_UT*[`Q4OB"BKRQIC15ER9V$HE
MB9!H8&M*UQ\U#(TUEMZ](/'H2-/]!)/DIGM\4U2P0QL&UE:4$G8]GG3M"L<<
M9_IL1QO='.T(01\"!P78).U4A=M-AFE`XETL$-G`&U*.Q(VM973D(7$637U.
ME"*MXKI-R7VJY[G$!]:)35OEE?MQUUJJ$:[4IYF,7/2X1Q[&&8[$2UEEA=L1
MFE%RH]'PU'/QAK#$D,8-#&Q`*&[`POQ<2@RL*!O$`)_0#_0]23.00I^<`(O:
MZ(VV:(NRJ([NJ(O::"1H2@'LP0H40`%`PI`:*20(_\&*LNB/^F@,])?KZ<M"
MG<YV66AM<$SDQ1UM7H=J=>1V"HOGI%US=!EL"-,,906%E<F[:(U)[.*K1"<&
MGJ;JN<GOX6>XQ!F3:*2<I=WY?%QU7M(JPIB\Q,;LL%BE16%O?LA;FHP0J`."
MU&3G<$YV#F>8_.1,XH7/-%E,X-EJ@EY=#L5]=B&XK:5S:F)1+E:)0B6^\>='
M6&5P)%,G;8<JT5C4P8J^2=*;N&:$:**+)&5Y+"6;8IB]/9.SE:BN_-Z*!,A)
MF.:>*EMV.@8@?,,=5&L'W,&U9BNV2M6T8&NU>JNV7JNU@BNYAFLS1,)3;8-M
M6E@;)%@,-$.X?FNVUA)TK/^F7-Y=1V$HWFFBJ8)%+^;*B684QX6J_JW(WT@%
M\I%;\3F/M;T@J2#?@J8867(AKA87@(`HDUQ;Q:Y(9PT:O\H1<GU$Q\*D>I4;
M47S>87%:!1HE5ERIENB=!&%DF)`G@IPGI6;'-"I?6A@`/:@)$DB*K=YGM'UE
MG4:43V*HG0R-U?A1.$5>:!6M1$UAXQ2HKUWL!3I+M`&2QLY1X<";3)D4>0D%
MA*A.8_CG(0F60+7LFU+0,N9L6TK0Y%5%D2`)</7?>`72S<Y)&TA`>?*<WX9/
M,\0`19U(<<1`INK%'4""10%A"FT,8S")WZSB3DG9F31:X53=[[CFFJY1),6M
MK-S_7KV5U=UPHZ[\XF/XA<;:5%587FZX''8E$E`$Q:D8C^R2G<6&)%:L!ISR
MQ6,PXV',TOG`1WT@(8`V'Z\H:Z_J9FHVVV30;'ZHPAYP+:TB:Z,NB7O^PU9Q
M8]DMG+6=E]&R+%^46'^8)MS>Q"\"AA;YX(*U`144PI"N`!-`0I$6`A7@%3;`
M*EZ,35AE4=-&V]60)G&<0?L:*9&N0)$60"'T)=)FE-F);+[N"F6QF834(3H*
ML/L6@@GT)6YM!15N#?O>@`D4`@;?P&SQ&URUV/#"65>61!N0`JC]+0Q/"P6@
M:]JZ%RP8;K=:U2J<K[[-Q-C2"/\Z&1QY#VG:2!T2Y(.D_Z'_(FMX!(V3L9:M
M0F3KQAT(]C`/+I@FU6IXY)U&3I>:#@:MW*F)""].:%$=ME/;XFT-@<B;]`ZZ
MH%U@S)([YNY\[*D3HI)\G08J\4T)AI,7<^@D.2]P-$-_$:Y(38C'!`8;0*H"
M2>)"N:^11K(DHT."^5D2MH$)2+(F%P`53,@9;+(D.Z*B8,].P`((G$$AK``6
M1`(;D`+V20`;!"D3</(-2!,`?L9C?"(H&VDAH(-"@A[[%L(>,,$8L#(I2``R
M`P(IL($08,$LT^]%1#,5W(`(5S,"FP"-4<$N&ZDC+I7393(A%G/+",$8,$&1
M4G)7,%86W:_[,D$@L,PXE_,*T/]O)7NG*9]!!B-4RY[NQ+:!`KQP#`?T9JA"
M#(CL5B@2#C_)'=C2$(XM$**LMI0;105)"7Z'##;+J72%7TB6V+4L3>4NK*$=
M!O84W4YCW%P@271.=P"/J-1(.A,)%SHA[;3:2G9P<M9G1&NEKCDAG)+C[WX2
MY2I*H;)(';X$#W\0$?GK8*1*([51H^YAW^I%-/!'C9WN=PWK\5WO^/T:@[#!
M0S1#/%@#1+S#-"3"V`#4I_K7#8S!5X.U6(-U7[UM#8JU-0C#.S0#6(,U`QVO
MKUK%)X\!WY(.`XS!DF:=4]W'-+R#,,3#.X1U/#0#("B@A])$&_RU!$0#MS[*
M'30#,Z__##FO3,OPPP>0@AMH@!M@@6D8`Q(TPS38M5U_M3"@4*N`@`DP`1LT
M`T#G10=\PVF3\%60)B97RC3D-F=$@P)@02'@%>PZ70$P@2(F]U#QZKBYL$!7
M=U[,,$392%8$44(CR!TP`6^M1%%G=R?Y*W/BJTG&G&I],2!U5A`6'\B667$R
M%MH%%[C`,>3&1;]ZB*O42!3O<TFIZ:M04K#JD%5W6S,B*YSDE;_1)F3,TJ&=
MKV_*;)`04JJ>-R&MZQDAU5ONX0@@2#,H"$(5V`S]<")_Q/7"9[)*`'%SQEVY
M2W;N'RR8@!`@2#0X\D1!6*UYQ$3!4+WL02SIUS=$M5Y$BK[!_P*(\54V,0AE
MA`4([,$'M+AU-X,0M-$9_`:"(`$ZFXT0),(LF;6L'N]:?T-F3TL\C,%68A<5
MQ``6%``JLP$0..)!;Q&&MH$42+EU_VW@IG6]8$-WFQHD7(D-Q5GGY%;DQ9"\
MD/BR`DBX2!*H^"1R?:E4&-WBG/?50"&:[:D?49J)=?J;(B&#&-UM(`>$W*E3
MX1!+K9Y2D@1E7<UK?"#(Y2IH&,4DLEKU?D3PF9TPU2M,[N);CEYW0%N,M%M2
M<8W)P<*CVKA-,FHB7[6E@M_A8J]G<-S>XGD'#$JK,$A"L2!>T`,6](N.`P=;
MF4]P87(,C$"95[=LLT:P89-381>2G_\`9N?Y9L2#$%B%,6!Y(Y_!U47"<.N7
M_:&#A8$BO.K7"(S!&:P&".S'"H0B`Y4S%1#C@JP3"+`XO5=WX')PDV?1]6JJ
M+7$QM_D;U3'+YG@ZWW7;AUBQAC.XFO)XMK,IP31<A&H3@D;%H7TJDG"7Y941
M6B>2A(RX?VN[>B;1Y)6J8IT9FYYA241PIGLZ=ST5LZBTI>+Z)X%%DPUL0^]K
M&.XB*H4G=3"J\HWRDO`AB.]!,DBN>.:NY$%&BF/!<)2Z/UL[$#19%&&N8W#[
M7=PXW:X".LC;9@C!&90C0A$4E*O"Q=\%"J$+UP%'7[613%T+D,M"NE^\,-P[
M2%"!O@,'$F3_\FU//L5T@`3,O0;=-IY/RS3@(#:TP7W,&B<40IL70"#8)*63
MO*FV<.D?_BS)0D&/&[_AQ)_W3*#/[9M%T*1G)_7:1L[3"5*^!J=J&8G#(70Q
M>9PM2_*LV.Q?6+]8;-O6?5(0S.`SR^0I3S/..HRWHKN4U)MUNENQ)J56"),+
M=;21^(E>;L*L7I,;G2EMF\-Y4M4#!#M8;6#!PF9P5<)5![%1PZ8P(2R'O*A!
M="@1%L15&*FQ6_CPH,&,&A6R:W,2I4$00K[]<_GR9;0"#3.RHY;QX2J/"0]V
M7"@1(B\VT6#"O(,%A$-LV-I(N%/TY1TF(!"NNGB0)ZQ"D:"^E(6E_RHU$$RZ
MOA1"=6=(;&-)M2S[%F[1J3=[%C#PU@T3CR)7M3'1-FXT!@`D,/C6(6Y984)R
M&AL#-Q*6#^H2O_WVP002"40K=^T@Y(982$!H`1G#)%(A*D"8]&2X%*/5C0J>
M=K9]^RV%2`AIP@X9@[/E%0;I\E0K$3:UJQTK_AR9/.'%A1$+OF9XE;C"ZS\=
M;J3[7*3(Y:Y'6BUHO"KR\K"1-_3=$ZC.FT`9)J38,VUU@^3A=\_Z<+Z*/%H*
M*_..NPC!_10*\*>&(L(O.O5HNBDAVVP*KZH%*>(EIX1LZDFGDF[R3SOLFA.I
MH9U(`F$%)EIT$9(6/ZBMJV_&*`#'''7<D?_'-CI,:*BR.D`JI(V<$I*),RB,
M2+J>"A'BK6BP:&.O5<X@ZRTA:$GQNS:8`(3&LM291@)2I`"D,%DZ`^(,H`HJ
MA(VW&(!D+X3.&`,Q(:,!1`C6F`!""$":R;.L;V29!E%$)<#B(5CNA(L!!L+T
M:C`&FHEKFC&FF?2?#KZ91@,&HB&T*PD*6&6LJ9#H\P-T0$""B?,FW`@AC]H@
MA5/<=.U,E1@*<A.H^8"+ZXX5?,R.N/`:I?#"G#*J3B=HY5/P688*JNA7\VJE
MAD.)ZNQP*6X[0C$D;+W-=CKQ!%J2IYMLZA9#;<>MJE%O:6TN70"[I0E8D,[S
M<+Z'!(K/.WO)E97_K_HVVNB@;[7;;A6*,'JM)MO2(Z@XB,*%1<4/8].X6Q4C
MONBYI18N4*-"OKGCCI5;9IG4KJI)!-%$:+89YYQMGL9F`*BBR+X@N[H#"1"*
MA.7(H8%("N7]J@OG!B@+G;*B@]#!LBPAE/P5I$*2+G2:#\:`),<5L#AAFL/@
MZH`TA`:RZRT`6MN/ES8*N%3(9CXHX%B"[(YDFIAA:H84(<8X?`PLACN("BQP
MZT`P-K!@`HD8\'Z+4\@9$/O/#X2!2Y45F"H`"W0"P0).*L[@)-:,OG/./!"^
MWI7VRIKQ]6!KVQCVK0Z*C8AAMTF^D#Z$L;)6NG;#&U`D7C[BF#OBF:LN_V/S
M1N2R.N=!M)96-[&#Z%GDM#W^WR)#JC99<+&KU_Q_$X861;Z85"LK@YPOCOY?
M+U2*7?5&8MXJ6"F(Q1XTD'`IY'[[P5=$V)$BB\!'([^ZBD+$0Y)5%")7M:O,
M-XR6(:%!94CHJ-I`9@>3#C"A#=Y144]2N`H32*TK4CJ?H[#6E;,8A"`):8I;
MA,2&`J"#2E8YB7+@%)RRM`U:<(I;ZW@2-;@T(Q))N1;Q0``$541I#,;(2`+%
M@HU'W488*"C$?&!!"\?AYAM"*`0M7(>.2/`0A"C$!BTD<`,@<((*+F("$PJ!
M$9Q`2RT@`(3+?,<R0\),<%`YY"(9V<A#%O(.M_\#`4I.,A""#.0$S7"D(;]!
MIP?ED#K\BA9O?I5";+7P0A0\B(^H$SY__?%7P;J6>316D!;>2X+=TY:T!@(>
M[>!P)`%K'[!RR2"!@&^5SDH6*5T72_`$<SVEG);3^N4<A1DP*[^L'JUFA0V+
MO6:4\EL00YPW3G%F93[38D]YT(,RJV!0@[NZ@]%^$K$/%N4H(-@)"3-XAZ5%
M")IMF,]6WO(56S[D:G`Y"ZJJ@PXD)#(F3#`&*Y4E$5Z`8`QJ>LM4LD.-0GS@
M+1J(%5;"40``8"X29P!1*+'A4(C^(R\K94I!'&.;-!;BDBA"A]HJ(XL3G*&2
M'+O)"D@!EZ)A@QV0$$+_DOQPM=2(Q";U"YY$0%#525;U)%AM`T'ALC>K?A6L
M7T6)5JMZ!JM>21;14*M:T\I6520IK%;-:H%F>AZ$-8=DUISJ1O)#P9P:I%F_
M=%V1&EB=AE$G*R#@9J,<U$J]6@LV62FG6+CF-G;6!T7=@TX](T(0^C6L.45R
MCKGR^I-RKO([2!U1B*:85_W02C89BF5.1#82B\VRLQ-24;($%"&Z_$AB[ED8
M&;&RDQ$I2"'PC"<:M9A-`QC1A%@@`VQA01LD;2F!4_W5DZ(TI7>AJH90$<*Q
M<&A2N$R#2"$2+86P052X3*5`L"A`G,HB-_0P`;HP$6FU&%:OK3+@+5#L5O<,
M_T*%QU1&;E0@;P`'(JG$W$$"0*#"84/"CD+$`"YM$TL!@(`%#_-1H/4<,"#K
MYQ[`7L4$7.EJ`21$H!&F$#;LV%=(<HJ.%;RT4WM(RH=8&=EP$:\Z0310\!HT
M'>FEDEL"K&Q\SC/B;"G36>(Z9BG/%QTEOW(ZYC$EAW(BW"4'4\GS`A#S@,*+
MFA1'/^7RR)*8"9)P/BBVWW&FE0%D6=>1V5]=YI95!')`D<'VMO:CH`2!9I\$
ME80[V"@G3P9VGF954)L%\F@&EVN9-D&O(/<T2NGJB;1^PG?/R0&F1U4<PS'<
M4BSA+4H4^74#3E`:BC=@IWZ8%XX+OU>QY8);?6/%D__2O-2'%'P=PZA`WQH9
M`):],<&!X?(-4JR`GMS[B03@&,,80*)-]S(/U&#8%?@>A!8WP-$>;@!*ACG$
M)[A]GJ*?QR3N=K6/`+5/@TIVHNZ<CPR02`S?[*-FS@[S5\[;BV[3.6BZNLZ:
M,V2W@9846?6*]N#>.A_*_'7OD6@O6R,LL<)KTNF1%&2%N3Q(.0T[P_C`YYFU
MC"^[U>*02RZ\05@9-H.AR?(]C\]>M;PM34J29HW`YT=R7J`?_]B=B2&09/Y1
M;J4[\PUT(*L-!JCV2X9D-&N!"4FYKG-Z"I+B[LK*2JJ&B=;,-5^X/#L<"!DP
MNITGD1?BNH!*+`L#F-"=BY[_L2PQ&&,!*721,Y1:D1\0*"]A<0-F*^8$QHK>
M8<W\@:D/+@8%4&QFVXZ-96>8%@/#1MK#\?(0W<3,>U9*Q'C.Y%=R]2U[8W-C
M$4*A9XDK6[%D45PZ8*S@+F2?1G=T97UB(`[-C_1_=!:[L<G-[.PE8-93)\.F
M!?O6IUE`<F82>!@[,LLZRT<K?;1/5H\3I#*)>/5R6H?(17K==^3@YFH(O"!D
M%0XMZ4/1<I#:>;ZNW!-GT?NTS<0)UDO[X0OE:JNT2@Q=N.-?>JY<3*`9THH!
MHR&M*,TEON$;HF$"OT$=*K`"*5`#*[`9K$X_-"TJCLJ/2HCJIJ)^*JHOWJTK
MON(X_VA![,R"*C:B#5;@<PI%2P9NM89L(0P,UW)OU[K"OH#B#/"N*R+O`*6-
M&J@`PPKE`SHH8"2B<>!"-V;"C_#*;1SO+4:`#7#J_NB%"KH-*HJFHE[/T=`)
M%D[K8ZCC1'K"Z^#"A]:+8SXF8RI**9:"%E:`]HS%X;BC@$1M0L0I//[#7>1M
MES0O#LGHER`N?)IC70B0UF;N/J9HJLBO]\0#^N)0TOP(XY;%ROH%(YI%Z`J(
MZY*'LP+D:%Y/M.@MM/Q(E3R$R6X.Z!;-0VSC0:IG*7R$61(QY[[%9#2+:U2N
M0/*#+N[$<(2@&(T1`"@-PMC@!)B1#0S@&9W1&9N1&MD@!O\4ZR98R0#H04BF
MA#N:(H,Z(!#HJ>#0A1W:,(88A9O&0J%\A"!```M>2FZ@9SY$1F%X<*.R+2+,
MCM=@JXI>2@+V(.T\I&!JP@1.JBRBP5=8208]XHO*(C4JHN``AC@^(+\B4`*H
M`BAPL"J<Z"TX01_11?KX#IHZSA59*X78P2-3KQ"VH3XHPMR:3X?B`Y0NZ@6I
M;@^>[G\02Y=ZLL_8Q5J>Z<^@Q\R"B$'H#5R.3@8[Q&'Z(N74$'IV:11%Q'U`
MJ?@*IO?*Y2GWZ6)V`I3V)RJI:WH.4%MT0K2R17IVTH^X<H$&)D*TIVDJ2&1H
ML94$S4,\JPQ'ILJ$38*"988BZ"+_9%$KN88N;H(EHH3%]L-OVF"2S,PZ`M'X
MA.(B_R&?7-'3RL*?0*#RTNP\J&$EH>(;P((ZV#%+-%(K``\JWC`EZ]'0/FX(
M<4W2"N$NRL()F(#Y8($)K@@S46!KUB,DKN2E&$`T,<0@C($(PU"+,"XL"X(B
ML+`K*(`->J,\UN4\+N\M@$`G]\H,%PUYZH0@TXF,J`$=RV)OM-/^5&DS]:,S
M9Y#V]@`O$Y'>7*D\U'-!(/-?,.X_T"<JCZO_N(DGX2PH@_*78$L4GS):IN<X
M)%&[`"HN:^E!4.X(8^F7SM,D$.WYN&8O?Z(1\_/C3%)\2,Y`PZ/W5H$6UXQZ
MU/)$J?)C__*#?LS,L$AD$2].%!>(@L:`,LJB&?8@&7;"10TH+"VH?&"!#6X4
MA+RKLTC0)4Y(BIKIKGAA/(M"2BB*&JX$,E1J(PH`I++$!,!38JS/7%[S.MG(
MT>0."$>*5@H`$"!E#-"A_0KB2A"R+$BA`)QO6?"Q+$HGOBC$,<W#.:'"I[HG
M%]/,3KN"-#XK/88-^=Q'[9@%6FX"]<AS[U[+/YFO',GG(69O;10OOLZES?@0
M4/\G0)Z%^;IT8,R%E/IM>:;)008LL-#ER5RG[9*%(N5'4><%SY(/EY(RL_C"
M17E2?Y(GN-3.`!]"8ASF5:\%0D*51TU1_A!+,`]US7KTYF"!@/^F*9=:J2?*
MZ5ONLQ#%A^C8J;`4YEV^PR-VZS`3L@!DT7_0I9Q`U*Y@P2(Q$RG`Q[J&AJ-.
M45$_$TK!@C<2*DO8B")6($W?`@O:A'[Z;(I^!4S+XEX+PM9FLROVRSEN(!XM
M@P'&H!!,4RP*`0MPY2V$84W#IS.QH::ZL3>[3((&ID^+0A9BP%IG"3[TM2B*
M!I?*TBR="5M<E%A)1M%<ZS3C8F_(,$A35D0EM,_8<VUTS!6SE60DQJ)@A\S0
MY7RBBCXE="\/4,[.3$*=XZX,"V8S)"AK@NBVU?GT4ZIHCCGEI5;ZH]&HR?M.
M[GS8:VNU<EP2]`RY`PV-EHPZ5&$B9E;_K>^T`D9B+&9:(<MO%2Y$:C'G?/$`
MX\=OW2^=YO.X;BXBA&`R_R%'DV'>[M8IBRLH&H:WME%(:-9O+],SD@3VV-8[
M5!`JHK1`_#5KJ*(C($$"X*)@T^XL$Q8YC!,V8XD?RW1<N,5N`*QWHB$2F&`/
M<@0U$D$9?4A9,.LANP()=%)/37$^5A8FHH$-^C![NL<ZRX(3-/*P>+4NUR\4
M18Y),^))H>(#"B$<1NDEBV-#Q"P'"P)3>P?:]@R0B`D3X2R4H"58P4-N2>;U
MOL5YG);PLI7(LO4/%;5T]Y:Q/N87062VA"<JKP6`$5%DY\4`YU!8B6[XY#>=
M*%@ZE2EQ9VM9_WCU*!^W-4%B1&*57ZBU,\YISCJ1T`;-:"&4<Z?O:?,39<)5
M6#=B#![/)61B.J4#9[5U21`1!%VB,BD(22D3"'H,Y*S/=5B79?FU.D@S=AEB
M!6KW+<:`"A*U]:S/;Z,7*DQPIJCA=Z%BOP8Q";&`IS#'&AA``C:%]A@`VG0"
ME-*I9#T#"(S!]5JO3FP">[WB!.83%]U'/,&P*-AD/CL4:$RB"@>NBBM"8D+-
M1[@-:!/3MZIBRKJCL/AV(>ZP/65WS<P8=FS6'',H@ZO,)T8NE*QOZP2K'),/
M0&C%1.E1EC.FY;A.6LZV3<O55=\US\K'2V.U0].-_,CKXPXV7;3VF?]B-=1.
ME'D"9$!8F(6)AY8!RK-NJ_<VLT#:[CT?MSNK$D1(3MI(#A$?%X/G4PB(%"HR
M=[>@+`UMR942XKFZ4;%*%^M.5[&Z]&2>=GUC@E&2A8MM*-=@06`AHQ!"24^U
M;2.B<*,Z""$^:HG8#(<.68.B805H(7H.-R,65GHS+WBF]>/88`3*0A;8P+)2
MR#'UU_","AV`YRQWEI7<LB"?-BYWHJ!AHGVI0<C4DRL]HE>!9Y82VC,@P:*I
M@RUMFNLB!IMR-YVH60TW]YE'PK,6(HAZ]3X5]>.D.MV`)8B:+&NOFIL79I8R
MN2BQ#.<&;=!\PJKAIXH'H@OU%ZR!QX-/:8/_@V^;Y@V!9CF51B:G;(.`P6=K
MS?*O(@B?PRFQYX<LR6/6['.($7.+X!IA4U8&_<]OFY@R23<BHOB$!N]=2WL/
MBHJEA]--;_(?4LIUL+2K]B"2!X+(:(6DH6)I,-ANLK0KZ&Z+B`L$(N%R-&@$
MW,`$8)H@$/@G!K4HAN0,7+$>8\,D./H?*,!E]<?D1N8+>V=Z8:<<8Z^&34L3
MZW(C'K4K]B:G6&MB_H6,VK9[D+9W=(P.79$@&LUFI]:92A)"6VE>A*^5VE9:
M(!0K[L.5P7N$0*Z4&G<,[U(]K+)#U7-KB>Y>E)EG=7F7]C9"D>>WP5NH]A?!
MX^4$.5<693&MZ;J7_P)M$*VXPNRCEQ0&XU[.T6+8G2L+J^5'X/9V(RRWH%@L
M*-@,01\\F#V[ZC97M#F*FM2,+8CX'Z1$0`H"=A7Z5W[:):9A#;A.T6+0.=CA
MCPD5B.JDC8O"OIR6QO*(%'`L+KYA48Z[PHC+KIB[*/`46^O;.:B[I9.!>@CL
M7V;Z(YV0KH'L)_!2F;QD#`SG<(IQT`]]<O9(T?]$T3GAT`F]T!\=<23]T0F]
M&'E;2"0OAG?6S@(F<F<)GQ7X?+;:^)#U79,,K-D5P^NGT7I#E\-SLVF57VY)
M?VJ]PY.-CWU.JE<)>NRV7DJU1\-IQ?&<;]G<LKBEEVCE/=NN,.=39!:MG?\K
M>(`ZHR[+(SR'-K'M%A9%-'`?&\BL/;-AX5R[(G1Z>)3NI6W%[#X]^XE_PF,]
M8QQ/O5E60P'DN77Y-2*HM#1[8@A?ZALB@0HZ4P8O"5#-NRCB73Q^T(WK3LU:
MG`I6(`;,O+GO@`$D!Q+*C<#L^U^VO+F1X-*\>9#;@,X3F?_B1WT/#[<_GK#R
MVVZ#E`UH9AJL(5$011@0A122!!W.P!C.0'5R?N=7@`V:`5%D7N:GH>:%7NB)
M'E&$/E%J?NFG0:-ZA]_L%V%@*0ZE>0RS6ULP1N-U-\0K*T"IHY*4NY?RRN2<
MZ2_?^\.]A>!!K[]97L*)A^"/]>K5KZ+L]F;'?H3_"2W)2AW"MQ;#%W'1M#7+
MSUZ&*X.6@SA>V&=76[XY$'A)F)TO/BY4IS5@VF#<_91OR@SV^`J@9LO"5V&?
M/:-@,=E(PK%@\]M^,X-Y`V,,F@P6\DBAV@395V`:X$("YH9;!`+&16(UP)AA
M+=H@R!0JYE'UW70/A&!2.F`:FF$!G7\:[%@!#.!X"T#!*IA?]O*VWUR+7EKU
MJ5M[06YJ(7B[]SR6"HUK6GTAFCUB;@4"_R'W2W*9"@"UF:XS.L`$PL>9T9YK
M`(+7*E[48,&BQLY@FU78L!6$A6T5K(1M#%K$9C$CQ%4##3ID5Q$6PX<&J?'"
M&!(C1(T6.4KT^'*CRH(1_WG!:A/2(TN8`Q]&M(B0Y$^).75>;,GN946&+6<>
M3%HP)4N5&SEFC!DQH<.J)V'JY"C0I56G0"7^.XLVK5IJ5DE*=+ESE4F2+6/6
M#9HQXJJD&0NZI"I29%*5((1\4YM6U0J@29G^%$G08QL03Q^N8A,-\=D[6"CK
MA:7@CN9_'2*!8+CT)JU"8T2/3AL-2TF,9YB\_A?I3.4";&Z/*&&BI-&0U,YP
M`G#['Q,0#ZF%*V3@-0`F-YD:!%F(":G#:#NHTC`&1:08,2*-P<*D@(F<*E/?
M1,@8EK$QKSM@T6U0HDIL(25^X(X8!6P(5Q)![*@4S@U"W(8$"`<NA0U!5*%V
MD/]`"0D%PG;)2<#$6WW9U$8!I"1'8HEJ=2"+9RLI)-),%,E$5U3Y,6492^X]
MU=)$),&7GT#44$7730=1:-U0$TXHETT&1981A.^]^!9@='$$9$)-YL>?CD+.
M926!<UEW$&`*L>.62E%F].!!(@7)T8]Y7?366XT)N:)(JYCXST!%YD<FDV/J
MB5&9;V*3E(\ZF90D33,&IJB=5MW4AF&O-;-"."TQV9%>3$UV!F4O<60`/:/9
M1UE@L)#BFF824$$5;4Q(@&<T8^0%@FVO"8%.&Q11`40'MT7S`0@I@3F9$,*0
M"`0ZUQE42&^C,<!$41:M(`&`:`D3R7H6A=.3D!5%A%'_J6(>!8L)]+V&A+)N
M,53J2AIJ)LL)=EG9K4$F+/A:LF\*2:9%729IU*G^;,C$0VV<%-5)!0""9\.W
M?2,!-?VAM%/`</H+$9D#A?3MILL>]2V=7:[(D%T5'>BMDA^7A-/*'O7YDEL)
MJ5@Q8"@;]5:C,N4T<DPO$KJOGBQY/!6:0CXVT9+=JM0GTT`AQ19!,4D5&)XS
MUOL41Q3UM^:+:/)8ED!J*JVQ1EK+17*+"DDZFBH%8&3F8*8&)A$(9U!Q1L@2
M838:9Z?E!\M_K]V!!!43)0A$M0W'=I.PL-!BZVA".%AJ&X6,>%L''%+A'@@F
M(,&`B4S@QU`X!43W+'5.-7N'_Z]J?5``+)Z:5-)>_%'&(V!=561216V86U^Z
M*.&N<D:"PQL#46J^U!A_A>`[6B".$ZUVQTT1Y3@@UFKF!G57E57`!PZ/CU@B
MU$W?*I:,M:S^R2\1)%`K[-OULD)B%Z445(!O2AF3NOI+#<I8J5V!X5UDR-2G
MR0"N#;I;17]`DA,P/8INC<.11I`&'_RAI%XE4\B-2!:ADU$,8QV+FU*N)J27
M/$9L5%J6]29B-81X:$7P`QN?Z%>[>CE$(#_QR9>8!#</T:6'(&&;9IJQAV0<
M18B1V<M>9-<I$&Q%('S33`?&($45"J$9MYE&#,XC!`G$8WLD8AS[:G.;R6D$
M!'L80?]ROL&`#P@!"$Q@`A9B((%II"HY0*!%@:C!&^EX+S#A4X5FA,&$7%EI
MA?UBGT=<1+N=G`$+MTE6N"ZHI(*PP8V:B<:`S+82I10B$I4TAL5LQB>8@.A@
M&=JCJ@8Y,I6$CWRT_,<W/F`,QUV$)/VR2/&*UQ3+@$277ME(D(RF$9/0:VNM
M0*:.8A*D<3'$)HB"5%Z41*@A9@28U_')7A3H3*0MR9E7H=<J-=(EO!#(8D#I
MRIJ*-Q1>]*D@?,D:N9!B$*ME+2(^Z1%;I%0\#8*I0F")D<:DU)@#B2F$1D1,
M-`I@(&3VJ4)L*8BPBD(-`V1&,W[;R$V`@)SZ1.,'B6B&Z]3_\IV0P@L+;9"?
M0:@0.<T(03?ZD8@QA"`+$GWC'0"0@`82$0U7)F<YZ82.(&/VO(TZ5`@KV$,!
MG@K5J#IU!4]U:@$*005CI`9NR\+&?.IS'Q;1J84&.1YB5&$`"&'$4&KZ'?0T
MPXDSC$R&@(F9"BU2D582C)YVD8CI,%?+AFDN6G2JB(7,Q$X$$H=><Q,KA)AW
MSS#U=38X%"M;"G3*O<CHB?FABTOY==F/3<BC$RO)R!S[(^M(*&DK0:#(*+M.
MW]6N:!=AJT>'Q+30FC9)$^310`5CF8+H<T9BVTK6_`2G(,EP:5B22"]U%)9D
MUA"OI&VH6IH1NPD"SE1.M)!8,7(9_Z6>**S5#)]0\90(%(SA!*^1%2Q6B<9;
M*7*"S>)B+3LPC6E4DA:]7$4@1Z.!#CWD5?69!BD^P`8$*SC!">;'!Q[\X!.P
M00AC``(D"D"%+)9E%50XUVBP8+@0LJ=>'Q`O;#XY-Y-0A1WW8A!S?$8_S2Y)
M*`H!@13.FQ8.M2DO3%E88!W&`!`#S9$S#**_`';D)-]D=R%AA]C&9JH(31"\
M5GKR<.`$3,[R,\O+*QY1/ENO&O'$;)C"JY78Q\*K1)*W??G7FV0K3ZRDDD\Q
M<B>3JEDG/>&YGF\*BCO-8J(+=O`J6;$.[T[+&-T62"YS;9%^&*,U.F7$NK#)
M+KB&9J:A(/^D*-C0:-\Z0R!:8$&_X[L#`\90B.>]1AVRB4E\)=<NNQ8@!B8E
M7P>$(01G14^`$@$DZC0S'<%@@Q.)^'%R9*$`+!1"@`\YR5=?`^(*L42&O&B#
M6=4BH)@\RF`'H<);$:,OWSXF9DP"$8XFH[WD=.^]S"O(2?P+6&-GKAFHWNXV
M!VW:9L?,2NHT=R0/MMLLJR0R$6H.OREV0E_:T(+R?,C-.J(VCU3;;.)LK`K)
MC5C#4N.S2!&3:AT>'YVXIRA).2W8+MX4C#WEN>]%%+Y10T"MZ98=>#IM07$F
M-;%>[-Y8PY)M>R1CA2/W)@FA-%K<-B3X#0WHA;(+<ZJ(&/LP4&3_]\+Q:^!8
M`.:8@)2C<>^2L8&.F")F<FP2B;E,;*)O*)N2KUG.=O^K&6C1C0D*D'=R[J`8
M/T(<%AUF$'XJYJ%KIR5>G-62RA5TF[BRVV;J%">BW_4:#K49XOX5G]T?AH7@
MT,7F0R_\1IC$Y_>B$^"=+5[H':TDSZ.3S/WDH=DBV=B6&%8X`ND\2!*=R<KZ
M,FWTFXN:?;9Y<E*09#;G[M@D*&?-UCY("I2AG=Y=$3Q5O-"8'*@!\0T3N>7(
MB:`DJYB\9I`QD!$M#^V)$ZFB<6,:*(/O!4&)/\T<FX!`0C`-78E4\8$5@,`S
M+>ZZ;#R%#;621NA@'3+4+R`P2N/7=1^P_QY]UW:4L1#L8#J6!VS>DQ2U0FJ7
MUS>C(Q@5005L-QKZ(CMT]2'4('AH(0LQ$%$'HSP%I&KH8DJIM!1ZHC+*0SLA
M@RH;L@(#QVBT`TCQIH%HT0P?<`.EPBZ.9C:GQR-<`F/\`D%#,E?:-W%H\WF,
MUCFV,QEGXDO3E!.U9T!ELT"`PVS\QB<VUR468AU/=#)/^$^$-E`(X2(Y=QIG
MED$+<6G7@VGSAQ"N)6RF=61F:("0\B+P0R4]81-X8F67XGSM-$YH!A8`E2CW
M%AAUE1![MV0XU`9`0`H2P(F=R(EN0`H%P"U.-A=<5GO=93)"``B>R(K1,BYM
M<`8%@`0?P`#?</]2I/$-T_`!6+`')L`<)?$YK/B)$@`(0!!!;.0$;I",3N")
M;@!JT*1T-V$,*S`&$E!KG20!3,4Y`?@JG>@&WB@!^O<QK.$$&O"-K,@&BR$<
MZ%``D4`!MQB$9R$!L6,J9Y`XPB@!W\B!WQ-C0K")S<B)@#`&5J9[5!`(^)B/
MX1AS[11)0\<2;#`-%*`*LB"1%3F1%``(RP$"Z+!_'6DW(%!($BD+T=`,%*D*
M%DF1LE"2*RD+*NF2%MD,`'`"6(!A!'050S=1-ZDTVE8QBLAZ9-9<.=*30==.
MO?<O$%=Q/\F/H!24,]:3D#$EB=AR>&AO.\$745EVJL23E'=\C:472C?_&:0'
M7,O'%WA2,AX'/](T+L\D)CYR,P$W4#QD:$:A,I83507@5%95`.C`A"4W+G`8
M)293"'=YEX;CA_W1!E2`ETP`!%AP'EC`"4RP!X7@BX;U$K1@`GA9505P84\5
M'"-C#)NIF5!U`_U1@T>!#IEI1^-A``AF`)&`'I,I+`3Q.YK9F:/).7.#@)PI
M54^%549C.4P@!`P`CQI(#T!@A(^3F9RIEYWIBW4B&,DTF)MYFU?E,RIW,IZC
MEZ*)8=+U/N2V/BQ1`"O`!.191^59GI#`F%@@!$(0"9'0GNT)GT*`!8&`GN>Y
M`NJ)GN9YGNK)G^EIGOFY`ECE.+L3<:ZW32KV_R%.*6VSMR69Y$X=1W&852?L
M%R%*$Z%A@FC:1A8303%OJ7JVPY0I9FY;`WL#H3MPN$T/)Y0086YH8HG[-*+:
M-A@T"C7H9#).LD^`0G,F<HHL82$DT62`5WN`41,]AX0?(C32TH,9$0X%00W)
MD`NPD`M+47(>,C5=J">%XG"^PSO.<1!0^CTM:A`;>0;&T"D&82D+RB)KVHA<
M`SCA,*6Y4*6PX*9D>EL0@1/&,)U1E2L[<4P&4:?0V5;;HJ9B:C94@`0`<(O1
MP`#$&)"0*JF=R`"J4)QI,0;:0B@OR@N6(BT],F,XQ&V&NB\Y`J=V:A%56J<L
M%WNLM7N@^C1>FA.6$_\)K6.K=V"K'7`'L..E-B(COM-,+-(R6=)2:K*6ID)M
M2_=ZU]233Z9]0#FFNV0C]C9#.AFMES*4_L1-]!,A'M>3O<1/<2%=0#JM2%.M
M"C>N7T.(=74I<\5->?H6!C(0>!(4)>>=9Y:$&B&O8E*O]XI#F`B5Q2<1VPH9
M3L19.>%G7!*&!1)/3^FJ'52CWK5Z]O:B(1>=0I*<"4H1Y597;;"FEB)E>&58
M%[J%8VIZ9+IW(4$+*Z`!UG('I$"3`KH'`BJS*T">=]2RKQ$)A4!H2\9+GYJ&
M0%-C0Z*OO6-!(Z,RZ60R?KA-5`%Z0J(R/!)1U*4CHY0<L`.D)]<E+2.5)C'_
MA62:25URAV/5EJ/E0LFT3)MF31''M)"Q$THRM0R!KX<VH?8&?BWZK$;80.CJ
MHG22>EMX,RTCMUUHM*:B)`[*<#PB6PLGM`2E?'RVA'PH:6VK,O)J((@H-+_%
MJA/SKX1X;P@*0-$(%`=#&)>"0S^*H^OGN18Q?ULJ-!-QMZ\[$?FS=Y2W?`TW
MM53931,7>C1J4=J69>S`9X4WL-0:&/WC3WB5ENUVFI>R%)$1$L:`!!T`CPRP
M!\+A(3/HJ9<E(J\1`_28([T4C5EQB?;C,576@NS&"S78D$LH$`>30&+9N4%Q
M,"=JMOZ$O"S8?Z_Q`86PIGS!@MO'M3V2HO(4NB<C_[66\60.@JTWF4'C&W1^
MTA'("ZL^6XF6:;XEZT\A`;<)XSX/&Q&>4D_0^!)_<QU<%A,2FW,57,)"*Y4#
MP6?/E9,$29OC-)49/$U8NKHW#)6LJZZ[];S41J^6JWJ52V02NX6YNV@9&K`9
MT;H5@RBG18@;>HK1R#$UE);2YIVR4Q0U!"7;)S5D268@L:1.!EG;=8,5TC\+
ME\*3E6*G-7NI49>)N#'1"7OU]**C5)QWH']&6[LM2@TF`()C9P)9!J'@.3<=
M07IQ+!A<YKSLAL;K:\/_(SM(K#0GK$)B\V=PG#2X\X+\6P`!_%Y3""*<"K6P
M5Y5U[*R7K!%MT#OURWE`A_^N-1BU+N4UOY7"-_ADJ&%E)^LI\D3)3U9-I_&T
MD+PBA[;&L=QR$V<JZ30R+F5NH'LC-!PF&ORBX2*QMW>[F9MF%'IN4F2$/7&&
M$W>[F)MF.6IXW;=T2#I/0V-ETC)TW5RR_TI!LBL[0"<V[D:D]]QD-`B\EVR(
M>#9M4MD70ED4$&C,XJIS7U>527/$@6HJG^H6+&(3SV-?:=$!,9";%2R6&N%C
M'W8&J!RM'5UN,B*R.2*D=>&PV^6@".N0#3TEIOJF2W8#7`?*TD*R">=!J@1X
MB.;-.BUI!,VW5LF@<5P1K2#01:LRWNJV14%D[R4MOO>I479"`^23+)&3RCJ5
M3CW_+-\*T:)7(11SN`S9?5@<K_7RTA%4L.L,&4.,*"Q4NMODSK]%-VB)HD,#
M?AJWK:)KNIQ'@PTI::7(D^+:Q:5HOP"]S77)P:VLO)R\-?>&?L\[R6!=N7Z[
MT+`'3G6\T!=46$!@?VIQ!QHIV5<BE*QQT6HA#)"@AULKRE3[JE1;L15\SR+-
MV8P-U#!\TC$ZU6`=,I+VR:/!!A`%SR2T(E:`42-SJC8")M',#L2D/F5J0(S]
MMLZ4$N^<L:YMPRLQ<OFZTV#MVB0M+?A3/->-W4YKV4']SI(]J\ED(_C:3L!4
M>Q1USI6M<^)=BA-2SCZ:N6N]WI-8UF06H\,'H])]I',-_YU#D;6$&%`WZ2'.
M2C^W9[JHRZ#5%*]2?<\CXS5K1=NO#:O@]&8G4TPK#<GAXM38/;L[80)L<%X=
ML`*YLMOAS1J?C1A86Q,6-=7I$]8B3E'0W8C:#:TB#I;.?26+I'LL8;6W`3L!
MA#,ZSLI<[*H._>,KW2T>/JT0^M7N?#LEOMFL^I2/,1F>PB(S,Z+3+8D5Q-MC
M;4Y,KJ!A2=K[(LDZGHB("Y4_"HW$9,BOBZ5M;2*"+<_4]=9H*=)?TI;V+->!
MG<5*"M]:F,3G&M1O;</%Z\2LA<6.OB2'S$+Q+6F[/6-G1K(@3EUJJ.E*?<]C
M[=U"B=`]J=<4'4#4,BICD'4<4_\QD\&.)W#::O$-^]B@-KG9/4Q`WV+(93JY
M-0,_`PRU6=O<_>U+:GUFI*XDSV'3HX&U0%K"O-VW3'GJNTY!MMPX"%&7;BOD
MS:K(XP3FS`RJE2/ES-XR3@:4'@[KTHZOM]PDTV3F3[D0:D/!Q*.OTZ[C2:)+
MU>;I43ZY\ZV@I"VJGNO/\&/.>3[3`&W@^8[IV[=&//RY(FV(#:_62SJT\[Q.
M6&,WB5S%%I[+!L\2]RYZ..$GQ''/=F(_NC[`I2)_@='M+.+E/;E_(@%.O.#R
ME=4&3*!241<)63?J91H9(,"GXG>I:/$!&]W1."%`*?_R]+/(K0VD>45Z^2OU
M%]$?NG?_N/US.YT,U@[D+YEM\[^M&:%(N@H$]4K2/T6.L>)>\GJ(W:;IP?8S
MM"=1H!?N;@@[5L#<YGE5\DLR/>]ZRH+?]FKOT/4;Z\E[,)^J0/(W>Q3\W0W-
MV)/1%<@[/:BNONI\3\_+S5$Q?RDONYP_YX+MUA+>JFMM<@\_8WQ=L%:MKUO,
M>0NGX$IM6+$-N)X./]5V-WA3@@K^Q[(<[J)WZHO/V+/Y\M$<[J5B$KT^K;+#
M]<4.=!`H+(KL]VW.Q2T-"]U;'Z9V`H%P529P`R90""N`!1^0@5>G`5*D,BX/
M[,T?$H[C9"TOT/.3\EHNLD;M977)'.[=_``!"U8;$+!X"2QX_U#@*E[A"D7Z
M%U'BQ'\?"@C$*)!@&X/80'!<-9`70XQM.%([6#"CQI6P/O(Z:!(F2(,87Z)4
MB3`CQX$#$^I4N)`73Y7L?`[DR;+DQYHF:QI$N=2@470]12;M21!65)5#M\(<
MR@L$B%78Q&)MR5,KNZ$<@XXLR9&M2XYH5VXTBQ2F0%Y1,X8,:A=62(8D;3[]
MBC&F0<(C':.D&'FB8\(9L2E>V1?N2H9^_V[.R`M;2+5N.V=&&3+S:<Z:,V-4
MW;%E;-I]75(Y8ZR-0LIP*_=D1PVV[9:S73;-N35I;)3"Q_YLN;@F4Y$LB4/U
M*1CS2YUW!1J+<4?RQ#NJIC$``$`#`/\&B9I%$S\^HBR+NX6[I%X\II7I=N72
MWNHYONR2;JCDE#)JH<'P*PZSXV)B*JF3WEK%!(CDJZB0<+IBT+N@%O3IP-<D
MU$H@X7B*;;.QW&I0IY"HDQ`[H1#BKD46Z4KKNLTV\HZO%Z52S"D0%WR1J0\Q
MT^I%M51SZ[[!(!0Q*0@3S$^C@E*,+2?#$`NJLP^7ZPFTVBIK#$.*-(MM2`6-
M2U.H-A5\\TBK7$,--(Q2D[.P'A-TT[B_GC3PC)S::`Y-W]ZZ4[H6Y4SK-;YH
M5.K/%B-UT"`#5;++21MW6@&0#LP$5;X.&!"B`!01TL[$2:VJ]$D>6WUSU2$5
M&HO2.Q=E5:#_RS*RT$R+>MPI(TTA='3-2=$*"B6",(U.TQ$G->I5NV)=]<,B
ME?J046`?7;/67$WD,[IO/Z12+3^/+59-50%CCL))@^+3,SLU"S6BQUJ]=S9&
M?VLMW.*PTE-?9XDL#C";D"U4UB=1NNRCG'HCD\[$_F5,VS`7U$HTV.[BR,AA
M"8QJVI8*6E;=E7YB2$J!J&!"@OCJK5>8#S@II(TW"S)RUP%+JHG)<WDN,;@6
M03A(LQ)7=:HH_>;$F+\N><5"@O4T<$,#J:\6HF:>B];(:<6<_2CH@0^#1>CC
M.$NK#2N4;I`GT7Q^^BZ<W=)YY)JHY-;DC8H:&]O[H#.6I1+M/)FO_Y!;&KAC
M@@ZB]F+5.#36X-#(W/A=G:GU]S.8^4VST"T3_=Q'Q#:.+>-)0_=13CQ7`U'$
MPD9"754WMTS.\T,]"\D*%MU.>-'&'Y4)%MU)?E)<V#(WBZ8'LTMTI;R:?PT;
MEB60Y5.8Y?NF&5(+>/AL`Y>3T]HC&>5N1<,MGK%!DIQ**;E8K?VY+70*8(()
M3H!@(I#Z]]^#BAN_ZANWW"(6ZJ"$-VA)3:2R=10K22I=;TI1=[XW'.,MQ%EU
M4]9/S#>Q8A'.9+HSB,-"HQ\4U4T@?*(5<G@7&%@\+W!YVYG$%-,9/N6E+C-4
M4[*\XB0$\@)FH!&?GB3WM>L,)U:L$='X^/]%NH+)<$;$4XF7HO*F&_EF2#>L
M6,02>#:K4(-H3PJ8=4ZT0.7QK&R%.^+2*F?&KH5&4V5<C`XU0H5(-,-ZUZ/(
M-S0PAD(4Q$DG.J%2B.87,%408PKY7VMR!:#=?$9"_(D6JQARI#2M`CJ-/%DK
MXK*2@;WO3R#8%>#0=A7&7&PW<B3;8FXX1&/UA3\ED1-6UN9`C5PG@B\,DT=6
MHTKL8#)O&FM*(*U21D>B9HV4.M#Z$&++2JW/:`M#FYZ\HA!CS&F+@>L+=$0$
MBQ^ND7%$HHR^4+>Z4>;D):LXHF-:@SHOX:J`X7Q=L";7F[,-TE"-*51;@F7%
MQE2'+P;J65#RDAS_MY&R>*%1%#JSQ3X$N>\M-Y+)$F/2L3T(00+?N-XW&!")
M%9C`/@XBZ$["0L@1\N2:EF+HQ3@YDN2D,)[_I$L*@WE,)$U(F8_;Y)<6Q$M$
MVM0R9VG*[N:)E9ETQ3-!1>2C7HE+97YEDLJ#Z%<`%K[N\*MH1D+*Z$P$$Z*Y
M39]0B=M/!L<J#S;5B?I,R0"GNL^J#DE>PU$B&)6"C6I6C)S`>TI2F"40F.$+
M3U*T4Y,8Y<3,"`FL^CDJ$_55.#9NC)^,W2K!NB:3QZ"I>/OIS^WV@KI(0M-P
M!X(<P.)7F=W@#56'=2-;76)9D9SHE>@PP0T*`0D@C.$$'_@`*4B!6]Q&_V(,
M3"A`(4Q@`NYD$RIJRTA"PA<GZTA,-4M%;A$-I]KS76Y.0LJ<!T/V3=%\$9DR
M$@A_V#FY(9'&CV?+G,G4%$;1#$Y(TO7@UD@+%[4U,F,^FRY9YTF-5^(WIN\#
M)$;"%4:#&!:]!1[ANYJS6IQJ))%K)%E@8/(YGPU8/[^I%9@8$IPBMDDKBEMJ
M7T<'F"F6DI5$;-:1"BJ@1P%XL(D]WVE756+-!`99[&*L9A)8M#>F.&&_PV6+
MGD=40VKU70J#(?IXDHN!4($*A2A`E*5<""J;@`I5H<8*D0QC(W^(RPW:2V:.
M-*S&]9"JA@1RNB+[0/0ILLA>;K.:80C#+W_+A?\);E&=5ZH?].D9;6-68ZM6
MQ5G$&1,SB*(I!4.48D"55'@=`Q(WZS4Z'G,W*G#95Y<]DY^Z&);$BV6T<8BE
MWQ3CF%9JP72)R583U_SFE&-]5*O!FU^M8N5`1TT5GMGH+4&OL:!M&]"!+@-(
MCH0C',.<,UZ[(V<D0[9&03:9Q224Q&9+^V`_2_2JO/ML(ZO78LD!')<'FVR]
M%CG1MTSNJGL]9R5?>Y3,[K5>$58P,VJ+<H&&7@/_K.KM@)@C:U-)-]UHZ6^2
M.'Q?!@RDEYV?2X?Z3VFTRO`&,V0*RAJ1Q+.X8JCC&HDME6F.I;&Y6>)Q2J=I
MF\FF6%X-9JZ:D!Q;C:+_<U`VOC61-ONHD&N0RZD[.A`B9D+?PM7/D7WF=>,K
MA!*LN<)^S<%EU_M;6!',S5'NE73+$\X]Z5ZSK9YOZX@<YE=7=[%2A?.\Y4<L
M1S9X89E>+6$5_,X^`2&G"R)BOHSFL&FOC,18Y$E6@:":7&NIN`7/*$R:W2_N
MZQEJB7=WF#?RQ$>)X\!W*G5$5K[I23[M@V,8&O=B1[P%QIFJ5.8AGRRPQ719
MJLSSNL`#+3"MR^-BY(/4%8ARC8%\6;R*D8/@Z1SV5;RO%-534L'FK,TD@TQN
M>G$?(\M#:3O"?_YIIUG+O.:^@E1'U5N<5+2DP="7KZE53,;G[F#6?H0X1]3K
M_Z.*UX6*DB4)JDL4DX[BM#<2^I%F/_4-)K'O`=Q;LQ0Q@IL\[CJL<2,\6J$.
M@S&\%S/`Y&(1$6FX[DD[F4(95O.GE^`=[^F)E0,>`1PBE?&JT5.JQ!"K;@NS
M7^JVIQB4T6$1V5LZ2O,>_XBU%^022:$]%=0U[NN(`M&5%*(ZG-"(ACNE=)F)
M1[FDF;+`%^2:[P.]WDNJ%G0T5BLH0J$5+V.'G+@,^(DUA#H)H*"^UUB,MT(T
M;M$@BMO"*4Q"S^`*MUBQZ2O"K\@ZO,(I'FRI#CJJQ9A#E:(^#TQ"Q/`+B3.J
M(M3!Q!LB8ED6<PI`&E/$@@,KSQ`L3<$J'$&Q*B$LU/\BHK]90<22K@)D&)8(
MQ$O[OJ4"C`@AFDI3*?M;1-1PFX9)*FU#.B+DHER1+G/JMNUSCA2$N9?0J1;Z
M&MB#M[/QKS$C*--KHX'P&IG3$4!2%(I1B;&(+\RXQ7%K$+(SGBE<QEV#PK_X
M-:%RQ=)C.\B[BUA*I?"Z%0&*#O-SP+S21L3(Q$GY(FK,H5PA,F?3*A"XM'MD
M1#VTC?KRF&\*$BLRQ>02(:V8NTE+1;SC1-L#0WV#+#*L0ZK2EJ(Z#GC<J:5)
M.^%A(*Y)L_99$0+,M(P[DE>*,^`1JW<*NHQPN5.SB3K$-X7)"8E;.UT[LJ-Y
M%<`3L\9R%(+J.0\K.G$QG=__:T6M.QESRHDO\S,R=,#^N@N11++7@Q"3TCVA
M9,B242]!$PR9FJP>C,6>+*F2A,K+P\4$@Y&C@3&.P\>P9$B.HSF#R3NY.8J`
MJQ=31$B+PT=(5)`)ZKF/S"HXH;<XJR]+A#>$A+05.LIE-+@[/!59RY+PN\7;
M\RYU4XF\7$GS\Q;!<)NC@2%O4100T+E5*Q&FI!'WRX_';#K7Z9IG>T>BJ#7\
M&QW-[#LF7,G#F$?\2`A(')0C`3=DF4PY,2?>E`H1[!!!.KGO\L+81$)>J\>J
M:Q77++>N4\Y9PL@A$9!]E+'5:DAJHY'=>24823F`PHPL2;*Z5#%:_+,1JK2S
M-$Z<_SF('SI(QB.XABNRL1H*R43`0]/$XBC),(&QWD$\CMLVQP*^G4%)\X1/
M&#I,VV,Q5NFY;WE)NUE,Y<3,W6LZ_E`)KN"U"RV6O0HF/T+`02'/EEC0(,$S
MY+0U\$L*EQ.Z!#V:UI,Q_BBW+KR4#XW%H%C0KJ@=CE1.%KV]CI&IPT.'05FJ
M%52]I]M`T,/0L,-*[X@B'&5('8VPX51!7JO1#%7.M@N1($VWL[NXL%N>+2TP
M&$T8W]0Y1CQ/LY2ASP0)$.@KNI3+A"3$DGBE!]02=8RQK7P\&0H_<I3`D]$[
MR4N1$ODBPBC%Y30E,SV<;&DXPN"1%25*F"B74[/)W$0]&?_3S(&JNF5L'TAQ
MS`S,TSQ-+E=J1KTR)\<;OB9L3>28FU7+TP8#QQEE$%Y;T;UCD(.H*ZHJD5@U
M5>ZST:[0F<=DBB/-2)2`SEF]5!RAR49E-:R"G((0R5LM'[4(1/?BD#KDD0M]
M1R+*&"\2S<<A&:)<200U0E]2S_#"E(3XB.U$&8`:-4SM#DI,U-:).\UCO`EL
MN`_I*LC9'/>L2+8<P#`52#K]DU)5O(<9/$W-E>Y1,0+<4^Y+TA,K"P0T!K$J
M4QP,IC*U42X"5F.,E%]K1H><#BRE5)WXO+/+B@Y529>`KCCEHL0"H?ILH/FT
MKW;DT%J:N00%UOHBV0@[')+!I&7_P4K.],1@Z9YV#$[H'-8(A32ID],/75&L
M&Z8L[#O<T\R,-3"%T\&_-$Z4#2%S@JZ5Y:J@9=*8DD3=<1J%B\E=I3VFY2)S
M<8VN@KI.9<-1Y1D*358Q<YO*/)\(#+TUHSDSG5<P.ZPU7<0P/4NUQ+`J0;#4
M<Q*"?;W3(T<D";T*%+6F(P[D.CU+^A"/R[3;$)3(K,A\M+6VC$1F!=1TZTCA
MP<[GV+:.U;=S_4G`L8WA25NS7=M4+4TZF4X&P=IAQ9F7Q,Z.\1KJD%MC+)E,
MC3RO\%3673:",+YO_3C:W(M:(=LFM5G8/8Q:Q9$:Y8E94M83_4.JO,)FC$S+
M[=W_7`DJ_WF.^IS>O9Q(W^62OX&%O]/4#XW7WK,)W$4'.9W(\"JW/(W07@*X
MZ5#>40V]3'VW2-Q*C'Q7=;,_,!//`93-NQP,F!E<KE',Q"/31^O=7E-(EN2U
M#H8-<)._(:U(61S2WIFI.24YKC$&*DC01N2X,9RU5>'=<T4V/]Q:X1T:`7[<
M1\L6)K7<D?'6PQ`E!$0+S;56F`._#5+>^8Q,$FT5"SV0$%TXG?P?X2`@Q$4+
M:S7;D`H9$9(GT`M29N7?U$7.V,N.]O&X]76L9=E>6TGBM36>YU#-Z,S:6NG8
M(@Y-8#%@_"`YT-2X,T;C_\-;<B1&-$:Y%Q(A5!*U']/71T.Q;O^:0(+A5QTS
M7+D1R31**J<YO#EMDW$-3DN,+JDKX7]KL<X4%Z+YC<Z]WP*4K!M4535ZXW_5
M-LX49)>4%0&Y9?Z%9!ZNY5!NMC.6$]W06JD$VE[39?=;"9*34HSP.#Q.CLXL
M8&"NXKTM#A>]/$H48H?1XWH:2C4+X%T&T>?,T5_UFDEAYEP>BP`^"$#.9BB%
M%'&^X0*C8A>A7,?U2849/H@\RXN,/<B8-'K-N$J&X:[+,$*]R\7SV"W,VE53
M2$E"0M0R93VK9PGNT-8BTX832=+%2.!<GL5YBF'E%OZ@4&ZV%)HM5N,]6*QC
ML:N"):T%U]>@6S]&X(5;.BAM1HE3B.W_C,V8OL;V=<WHU*"?:&=8UE,:&5;L
M(\\P^U^R@6;O*]:F@SJ@IL:?:-F6.SFZ55WT.U&B)E?[W4Q;GE80A4*1-D*=
MV&`Z76J*)51=%B"2[1";C&A`EK_'@U.QQ+U\OA4^E)CNZ:8+?D]#]4?H`*&6
M_4-K2B%./C61[&17M6/)F6G<Q4C)P3B<(`JFMN.!L]!9+=R$&6K[53P-O!*>
M`3<$S!T\'FG.FZXZ/&<-JB85-L96=*6N<2EB_=%EX@H-/.?#J$()<FOP?.;6
M@6LM!<<54<J<';&MG,^:0`=-$HC;/I491:[G*DXKN)80RM_5.CQ?%.ZQ5FD!
M:>WHW.<`BZ[H_Y+$^-U;$K:D-9GET+A08FX2M*91DO)N8M5E#MO?*CPJKS%O
MSLR@:5ZVF?@\;VYG%6Q;H.#/Z'7&@O*O[>#AVA1`62M&'PIH?27HC*X\8@S$
MXV!L$CZ\GFMLZ%3`@!59AIYHF]0=N!X+@RGLBPVYB935"-]?IXVQ48R]O2I5
M"N3E]!XY.*2YS([<H!W:XB2+AUDQ#A>D/<1(</-"X@[:=M5`1'Y<EC)"NL7F
MXP`3Y>72WE.X.C[G]5T,R8QFI];89?UH_M6,L9[(Y;8^DGW`*6<:2.O:T'-$
MV.@YIGQ)2&,6H`VM!";JL29=N!YDT7;.J-I;G@XMP^ZY+W+!G18*A?^VX(CS
MNPJTR1RW8]6U#P*<Y%Z6M%")\$)YX(#LYE1R1,4N<0N4WM)$O`#?-`#M:-2*
MNRP=DN'A#R_"X,T>8<)MV^;D0V?^V#HE"]1MZ$"_#RH&6MSEUIZ&9,%"\E2*
MW2H]9OD^'*;,5D<W6.0$<"3'2O!TRF(F1R@$9>@\P>1"5Z0,'!%.O(\>XA(_
M;&TR<5\.Y:+$K.`^K!1'B')O.=QV9EF"\"_$V!+$2!*6J6^:UN94MU(-7J]I
M$P(:]C]Y)7O76@S;1`>AV[;L$*RRY$)W6=4U=<K)>+J%F7`XB&3`8)%GM:@@
M^252GY"&:*?;:<OM9-J=I>->-<GYR[[&,X#_(SF23ZR$>"6_4+T\-=2FJ.'$
M('FUQ*+A._JN-,YVQMHA3:J&Z.TE1UYV3#!3/@P#6MNBW\4JO1CRR5J!_=["
M4<C%&-\C=&<F/RRQ,MIC=VBT3C<A+&=SU#D-2K0`%G;37;,MA@63)\=;?.(;
M`?,!Y6WA_FI-3:&;/NN*!+<Q/M6S/G)86/H\=YH/YG2O+XBE-SJ:8DIN16W)
M_]P))6+:[$?0UTC$H%#!'?F$1`F3=PW-%Q?8A^2B.;9'&UF=N.D7CA&!(/F4
MOFO3/WC\^#<H]$?9'2&1=T1>._IZ?5RS-D789V-!X]IY)&.>&U#?U%A'N?EO
M)WRL?/@@QD%W-N\=_[YW./=U'(3G[,=:D(*]F<Y)@3UFP8"<!46?\7UX<_P?
MA<YL9WYB@``!:R`L7@1A"1QH$):5-@<)+B28D.%$A03;6+&($);#A1T?;J1(
M,.-!C!`ODCSH<2`(D@(K+FQ(,MS!BB<=LI0(,F+#@B-Q7@0)*YE/FSYU#B3*
M$H11@[RH\0H7\6%+IB^M)HSJ%*K4@ER7_@LK=BQ9GZL4=M4ZU*?2LS&##G0+
MZVS)E#R!6A1(,J8Q$":SYE29DR14G0*=#DPYEZ'#J@.E<D6\5&_2HXDI3B3Z
M-*I.@TR1JI4[%2]2D4N%YK1)>2#0E"U+,ZS)T.[+O*4G?BXXT7/(@B9-4O\=
MB;OI1J.K>[N6_?`MR(P5C<H\'7AD[]*\<`N7B%WA\;=&@[,^S%&C\X?ED0*W
M,ARN=_/`KU._G7)O<?#B)R8_S?MH;9\N2TZGGG;Q@6?808KYA-ASEE7WUVL@
M=;48?,*U@15"G\$4860),D66AV.MY11-!8UHD68%QC:54TK%)MY*/7$6&`@L
M@H#.A1H=R"!C)UV6&4H.[=4&.L`E2`U:-^9VTGX5AK394>=A)%YO+!K9WH")
M-=809;Q%=%6..%V79$*-50>"@A=N-YR9L<FHG']H3O6<>/\EM*9@5Z;&'W;.
MG9<33U89EI%GVVTD(&BI,=7E26+FR9&*NG&49'W_B3'ZDI;\*6K%D#HIQJA(
MNU57W(/L59A?;0L6A>:398I'9IT,TB63C0;B^5]/=GZ$J)M+[15AJIVUJ=Z$
M"/&4(%K[G?:9>A8N9-")3]4$PH?3XC@48B<*QF63-(FH)$X"E<@+D9(E:6A?
MHRKZT50-25:HCJ;E>5B)#`H(&+;1#LO=KL0A%B>;0BWT7;[+;A0PF^0J.IU@
MN<UIII1#/=<&<_G>J)&EU>Z:G%.`+@C3908QZ2=KT1X<TL-ERH:L=/CU5BQL
MWV&&LDW7Y:<ML44EM%=_**(Z8<`V9=03@Q79&/#$%7>\L$7&V&;PSRWW-U5P
MCZI66TSO\6@LI,#"QQ29_VXZ%"[/5C&-IH_5&FS%M!\FZ*M%SFH=*H_/"A6=
MU*#R)FF-`A%)'7V!@?D3NWHR++C$),+]LZ$1,2>2H+[AERO*L'2E6809F>1R
MDP2R6>[A(X-GD%V,->YICZOF*#6!A5,',[*JNX:=P?\BAR-]]\G.V.*T%[PZ
M=X7/WJERFN=UV&=I0[2;<0"N;"?FC_>^>7,CS2HW@E)")Q2CR`,K]W-/Y]M=
MR3!_S%#U"XY>.>(Y7J8=H%K/I]&]V&-5)V#76E;>VAXR;BR+;]?M6#CB3+MV
MPCZJ>,IK`(P-7KCG'NA1I#%`&U?6["?`Z>SL9X!JEL(PMBZ.(&A0L&%>=,H%
MPO_E!"AGTWO-\5""&H20!$%UZ9&4GC>07)`L,,+#H:AD0YS>``=H+XF2:D(E
M.D*A2CB*$9K(*E:[T[%P@O_ACT1(TK<Z.0<O5L#A=SQU/=;()%'4P<G?<F,H
M\TQ*4G++C@X?**H:M@:!I1'>"=4#/8SDJH!H&]F@WO>N@J5%:W+""AX5HY1V
M`6=_95&+`!,WKQ=VJU\+U%W63J@@ID2'4JN1FF(B`I1V522&22J6B^`G025M
M[5^YT)E5_H8:^A`P?U$ZD`I[LY[)I(@@N5!C2)AX0NFH"B0[8Z#)5J<FU"CK
M0+^Q@@R=Z,>KG1%+/<&<,/W21Q@I$V:9Q&!"=CE*&JK_9IHO%%-NUJ5&OD6'
MC'AJ)4CP&$JD\-"6.?.C+IW(DN<1*79K6A8V?U+$O[`)*.3T"X^\>9*4`+2:
MDR$-)2V3.#0*#DV==(_J!%D4?B:J0E(RR+PJHD@0&4MJDD26QU!)D/_M"D5F
M.Z?XP&B[EN6(;[\;E0]/6DEV4HY$"-4-F<+DG*X$TBXFB9`>Z;DFKU$,F!R+
MZ:AN:<U?X@=#P=&;;F07Q&,"QCE4=6;[8'BEJE6OEZPSV8,P^4N6:)0[+K'J
M6MW7H&7AIJV`<TGLX,48$##-:>_;SADQB;78].4B]I/8.^%E5B&:;JR$NI$,
M_2B@,,V15X/QJG"V>CR6W=6M_P\;IF`"B1R&V9"#J%2+BK!SE9=0(;!'"5@\
M#?)1L9"H,B**2(FP)QFUC`A;DBRF95Y5,$!!T!A`JMM?-Y*+PRE*C&D$)4P3
MAB$]"C-4:Q(M!BN)+;S:[U4.DR,,[Q.J<TF'8..[Y:06@@[@,JRLQ</E8(!2
M(=4N2X32/:H8;\4?\%XH:&9<KU*E=RX+(JTDZ=U37HPQ)*UJISPQ&7";)`)>
M?E;LL4HU[4.,`=_T]FEE?8T>",Z07O8N*E$XO5C`P.LU!"MXPCJI4$30<6$S
M:33#2)/P,)?UK9*2:S(4_B,`=PN+7;H2%L8PP0U,0`6;MK=9KPW+;@-)MXE(
M3FN25/\?![?8W--J<)L#"6PI)VNQ'548>(U2SIH.*4^8YJXXT3Q)(+%G4U!>
M1:Y"YE&2RD:K^ESVJ>64K!-I%D2$1.EP>=XL[M;K/"\UCSQF+"*%\WREITDG
M;P:RB@@A:Q&"A6FZO#TQ.8$9'OI>NC]2/2]![-S""9^IT6*L\T%93<55ZP6O
M507UDV!-9K1NQ!@N,0;XUAG*66+N*H=#1TK*MN")V'G,]_RPF4<T*`1SZJDC
M/8BS1V@Q$Q3"!(%-[FIAL>1_0,2S%41=MX[4/Q36=HU[A4V77O.Y$69*3W!]
MR"YS^33D^FYF]_&760'YKN]5*YXCSNYDCO@U@_EQKQ_6TBW_Z5@NA<>9S_VV
M$PC3JN/FG?:K7]8;@QG[/O$"YJYJ.BV*G2E5,A\S9G#-M"8[&.N#X/>P'9\X
M4T<>S&0J,&9%Q/3-E=7Q``<,P0N).<%[[I)U65RBB8Y9RT/.62"QSL<6XC#7
MVK9;:$;/O%2PYI]!-9!O,])_1XGGOQAI]O4Y.6Y;PAFBJU@UA+16(CR\VP'?
MAW2,@8#L2B$)#W<WO&09;V[&6E`L.RWJD0.8=]C-[LX&W.D[+2NOD6K)5=WW
M861B5[,\)"?(,>M@QY]YI2WG73!U;D7$`_.*F5_*+)LW;Z[61+42?7S]0`S!
MA&-(SK6W)P*W;:&R,IZ\FY4]Q]:Z_]8-.K:W`X7J/*=NPM8)L8UO?J-.]F[M
M<'.T@%$C&<B2J1'7+CFDCRE@#`'V-K$URU=P&^%I0P[#S!7S9.[J[?LKZY?;
MP_3'E`?@=OH6SS+.V_U@3.=T"ITHS("EDY;%WGXU%"P4@_W8$)"QC[@L'A2Y
M57XYQ"KAT:$PA6HM5L<%S0:ZE&><EPK9T06V4@9ZWX]9WFJ(%]*\CS>-RN!<
MB'"51[WET%+EE_E58*$0R<0I"]0U4PWZ5I]PS&'=4QSA3&`)331AF,DXH4*\
M5^%LT_*Q$!/)2<S=D%/M5R&-$TV]$-F-!Q?1T0T94-8\2DW`4GRDX-5]VV.L
M#]V!3AQ2CO^*`-4`K06]70@7)9A-S-(P99`9EE3I:9?2--,PP<>29%*:7=Q,
MC%\='H5`R55\=14+S9?OZ)BLY1MES=H!+@6QV5W'.(9V2,Q[(%Z2")SNO)W"
M&)]1N=#)P5[[M%+"^=`H2EP5X=+#51%`"0JEC4<J=2`A5M:%_.`'SMK4V5)Y
M5(1!G156Y=TFLM`1^9:,R!HM<DKK]1<WU<_LP)V:Y="_A!)G+40JXJ(Q@@[-
M/-IJN4T/Z0@FT=-)O&&[S!:']8_9$96Q!-*TJ2+NV-<EO>`-I9A.U%M$R&!`
M;A^6#"1_X"!G'!V6A,3F+=#O]1B.)*1?(8F_8*%"R4?[,5HO5DW_?JQ,":(*
M[G"068F+/FT95C@7I6BD-HI>345:58$DTI3@[7"B<@$3%N;&?WT960U-Y+#=
M2R(<SL1)$C$C5@A/122;9)VDVZT4E#7DGDW>16F2<_#DU?0.3MH3[@2?;"C&
M4L9B])173\*'EE!,$KT&!8K5^H@?;^S.SQ#1XT@&V(44MU27CYG4N>D1W61:
MO5P4_$&.W?E&BBV8T%R3)JJAU_FEO_0-,C74Z`Q("]EACBT%I`W>Y,A(_&S9
MYTF7)9GB'"5>-=[.SK!8^_P@SGQ:5:2:QC28+')E]/AE5=W&KY@<)[*C)?45
M-\J>B26F;;#DY&"20;@89P%BJEC:F?4E_]9<3!.-B9T@V^=PV1TMSN)\X*`<
M#F_"I,@8#U^!GILU%14!VA']RE!^7Y/@%=,(H&%194KNBE+D(SNV&VB)WQL2
MA&=M6+:$R)WT2XE83D6EH-<=))(,C?1XF9JHB_ZM6:-TR3;]QX)UEP$]S2BY
M#;E$D5<5U4W>2-`E&#OZU9_<S*2\3*R=2OX!8C3I)(*)J,SX4!GNX'(2YQF]
M'K"`',$<9&P*J'+(X/MAT8>":(_VAC<IXYTA:$5@8R7Z7/PM2J24(RUIUHR=
M6G$ZG2[EWH=)2;U%3O3Q"IF(4A0^QZ4T#C@&!V3RA@S:V6XY)YW`E7IQD$AY
M552]7T90P=8M!_]=%I`6F924J>.C3)M:=%QR-58FC2,V+FB_S1L$@5!+2(87
M6HRA+!:B[(?VL=-M,8A/L83L^9B-JA&-`9]KR,0XSE^&^D?#<=P2'<<W?5:=
M+`,MT12$Z0=XUJ93JF$^N5_S\9DJ4D5?S>J&[B`8T90M5HR#JAA+AE-3N1)]
M0:#@9(5,X*I%2=RH)!2O?N-OOBI%K)DMGJ">]%&MDI@TK8>_S&9O5M#N590M
M:9950*38:1^CVA(5%-FV^40\YB?MA%#<K"E^_A%B"`MFH(N!2(9,,!1GZ2M2
M^*LL^9WC1)=`K%+[_(F8X4A52$J]'ALPU:-/8&/"TA^U0ETXVDT2LI'_ACZH
MJJ1-5C7>Z(AJ.`$FO/A=$^+<KYGH_MW3K4)KS'#;U7QG3ZI*I.I?=0"9Y]&F
M7S'<BM;4N3Z)H#E&OTG3`TGBQ5(KTQF$E::$E7:L0ZJ<Q>7-$ET1G2E1K8H$
MF!22$B:,C!Z$!JXA0O0%,V$-<_WF?VHAA!H+PU&>:V";D3T(^+T6"I'K).GC
M:$VD]L5J@GXLT$;B-FD0E!9K@B[G@MY*OL1G_J7*U%&7QQ9?)?EI]Z@7TS$:
M5>#@64'A+2*K5\;5MT+8L$[$<5TK$.4'R*EAYH[9?5+6NH&KKGCB/?6E;=;8
M<IKH;XK7[;0>R+S@:;[LS05NKV*H?*S,5-UJ_U8(KVG07.-:[1G](%W=8M,N
MK9"^$]I*5[56(#K&S73(X!%6X-SJ2+N="[[!`CH0V0K"Z]?F:WFBH4-)KOC1
MF+X4[+8&'?P=D83-GN3=;\C`I((XASG!B5A2"A/>J585;+L1Q`.BYM5MH<P,
MAYS18+W,1]0`&,11+NV"ZLD!J5)!CSM"7W88"C.^8)2&8^9>(7LA)OZ&4?)(
MX&`TW^8U:E4$R=LB1=%]7.#8Z+)E!_`YF)0.+9=Z[A82E)!-1#&,7=LIZ[>D
M[:!)ZVU^R@[#,*JRT;)U3"J>$0"[W&<)(WYZQJYA!9>-HF'F94J:*D(<V6_2
MYQ33X`N][YVPL>F@!/\8+B>3+H\E5JKW_._Q(D@.4VOF>=T=&ZU]`*RPTN@4
MUVMJU!4U3B--+4,;X%>4/)8O/O#P3H:%+>E2G"L[N:G[$-^K,NJ1LJ)?R)X$
M9V/HSN1+$-\(SQ,N76NO=F!<-54%@S(G1EZR6>OG6DBJ-C$1&H;PH3#[O;(@
M,E,GMNYK&$KI5L4H-YZI_3)L1)YID5?6G)$1UR(LYJO?1F;]F)@RGR&E.+)C
MJ`Y^9$0:JZ?='O(`HE`XSV3KA`H?][%YY-W#!;+<X2]F^)(.(Q#93%0F;B^M
MEM*)O@QJ+&AC+JNTVD39;)CJL@H;J:X'[C`\[\L4`Y=`M?#+E&&GE$TL*Y[_
M&H(FS+U<$F*I79$7C783P#Y>@`C4CJ+5JD85IY;&45ZR&K/,%*&PI!41+GYK
M\0HIRAJEG)2)`K(QF$;+,G"6\.#E&Y&-PZ;@&@FKCB(31)(S?LP=C[&QZHQK
MS5:2@+A2Z?Y(8YG5(A:L5C>':AIO"Y:Q)LUS=?DJ>D77;XZK-[*$P#463FNB
MI-B12R<&37-GXO5HIXCA2,HG%>,T[.%U7<M)>H!C^0'GY8$89@KM)R>$+=_D
M?<1/S:I'1D,E.*\B],(@7Z_U%)?&59&$+5?A!%=B.3+VSLH=1[,V626$`B_;
M$`;<!R*E,(E24&M5_>1>FP[ASM0+&"XB?;*N^;W+_^/N$;"N$=(%V2SUJPB6
MZ]"6C+(%2OZ8+#*JG<.^$B*;HKBZ*OB:U,#ZTEC]2R'C;!J%VG`]8TMGB2M6
M;GBM,I98BD9ASPF&4^P>*CKY8J/("0YALU9GW)NP4#'"TP/+L`+5KU9%+%-7
M!1$%LD,,5PZQ+L&$D5VG1ZY085?YJU)K;&`\6USW"4:E*:<JZE<=,QD5>(S:
M*E531]_=F'5?HVR[\"OOWC36&D.0G<,>(DO0Y^<2=U!S,3;P`COP`I!W7TGT
MRRJP@T\D.4>T`I@L.9-#!)"#T&B>$H,XN""]Y4H+QI6/!\@P34<,>9BGBD:!
MN8+T7<7A!#8X+K,"6H+P@O^D.CA!84.;</DO5@R9DW"2?(MZP'2EMD&25TB@
M%P20Q_G#./BWE&*Q"<2<`XKDR#<5M4$;-+F=2Z%?,+K7$&G;=9?W,L6<*^FE
MRQ0L`'KI*>-G=,2B,9XEBWK[[;!5E*9H5ZH?M0*F$ZG(W2TQXA).C+H"+7FD
MCX>DNY=V9"MIN.W!SN@=Q[K>P)5<8W=[)PDZ$#67RK;49*X=:?@K\9+V9.*Z
M573?"E-2)7"'A!^/![55XR%"M,)`-#DVK`(U5$B3I[NHQP2[S[FD,SDAT?NL
M6P49V#N[LT:D@T#<>AB_#\2<6X&^DX&EMWO:X%&Z>SJ@-02\6X6'M0(UJ'F'
M607_-CC\*JP"H^O[&4@Z-<B%+?71&<#"K)\!&<`"-K!#O;?"PLO3G\,\NOL[
M4]P`","[R9_%&1A#DW=ZO2.)%0P\SNN\1)P!D6G;&:1[DE</HU8(MMW\NJ,)
MO`=Z&YB\SRO]A7CZ80"\,11"(0@7-K3!Q7?Z*@S*S=,[4Z`\SJ^\I%M%*W@8
MSL,]1URZ"1"9,7A82L<Z+YC`"OA`'IP!-H@]WN.\UPB^V@.[AYU!X)^%7\SZ
MUYO`K/\Y-?QVX?2]#Q2`,?S"*FB4!V94D159X'NZ!!4BH`U9Z">\Q5?(&;"#
MNQ-4A_VYFJOY&4`^"*B\V*M]SG=8UJ^"VC.%TFM4S>^[_V\XA.*+^EDX!-XC
MO8<)/C9<V,L"BM-RG*K#X!19J<+]K8!(-AN',(8X!ECZ.$@40T-P&5%W\86<
M6SR+H:<)4U]\6TD/X;F%/SL8`QJTP/W?_R=\`3:D`T`4^-2BQ98;OWZ9PS/0
M![8S!"%&;(&F$(85:"027&+BURIL(/(L:9&#9(X62PIA2V=,I,1/]4Q@6\4+
MEI4V(`I!W,$1V\UZ&2-V.7/&!]`67\C\`H$QXJ<E*T!TA,6KC158L$!<_9G1
MJ;E?7SXYQ;!JU=6L(2<6ZOC+1!*")LRU6L$U:8$M$M%<PM.&##5V5N:Z/(/M
M%SM87="0C&`291ML6*V`L,H+&__:DCG0X$F*9F#$>C?(Y,R(QL?@J[#8&0.;
M8W&.3Y<.%A))L2,V$RU3G@G<M%6!ED8/8BMT:63)@C=:P:H*@CF(FR!$?O*A
M",/PC%\(7P1Z26V;5I9+HL%.MKE9YK"PL:LW\!+A52",,8^<E3GQRY>,^6UC
M[.K\JU1-Z.*3RUKXI``R?!CHDT):>>R,K>HY`P-Y=DCL,M+.N*$SH)8HP)P"
MF)(()0Q::0F-//QX#!;16A"J(W96$.FR3Y)(B1KG(CL-*_YJBN\T^;(ZS1C^
M)`.RR/ERT='''H.LJ;P?C82%Q_]T[,_(*;&"K$HJM]S2)JN:D\S*,77,L4DO
MNSQM/F/__FG3S3?A)#--+KND::K3>%F%I>)(^N0+/WX1J"0?0,#@EP1S\.&)
M,RYK%+-";,##PD;1N,%0$!(<J4#.3'+Q#`LA(FFB`A`J"Y8`PRM`D5]ZJL?1
MR^HA`\%7$P7!AJ5>=:H`=J0Z$QM7'3T)@R>^(`@-#%:ULPT0'S7TEQLN(>D@
M,N8B\)-T/IS4.*=N@(75:K<EPRL0?A(U+))*^X4:*9L4L+AS6[CD#!LX-0XI
M;`HPKCB"NKA!IE6LZW,@UWRPH9#$*D6(FN%(*L0<:ODTZ9,GF*4UAS/2J1B-
MC0=LH1`R>KIJ&3%_'>B+)VQXUCY16_#A%PP$=10E<\SY8M*P_T9:X@Q6L6H#
MO9O:R/,7,GZ2#H/'GEN2W)&2\&$#DR+\I8V;G&2.LCSL^V1C"_\\`PB2=%8W
M)]?4\J/<B9:P\+.'6G,4C15LB+E1E!("%0USTJ'&&&!S`&+G0Q/;E%/2$,(J
M2##+:\XJ*W,T,TR:0%C&O";G$_-)L_R[*A?ZP-1RSO)\3!+S\^8L7<S-:ZI2
M3+/4I*]TTXL$`<[9W^Q/]-?I+)TR=FXXV#78R,#`8#[1*.`)BT8J^(E"F"\V
M@A8*8!XT&RYR;87>I4_'!D4JWJ"0H6X`\8MYR>#ZAMX[[@+05?PZN.TOTC$4
MF_"97P+LZ`O8V0\?2*HG>N8_=KSR/?_O"[VK7KPJ,I.J7,4QP*((``MQ`QO8
MX`LF08,-#%467K`#1!&HE*$488)HY>`&3QC:#<I5/`E2S$(%")_-^G<&<V"C
M%2C\A`?S)\`5#.@30(C@#2ZR@J3TY#PXZ1AWSE>`2T3(!AF*UD1`8\)"+*9#
MO:L@9DAE#A!<@H<^.-\-?'")+QAL"1ZT%+9$N)@2#JT0Y:JB#?P0O@(48#%^
M`N`O'D22`IXA#.&KE!_2,;FLG&%`&["4"=.A&_OEX`L?FZ"@Q!-!Z0'*=R?Y
M7O@VL`1Q8>,CA2A`'@H1'YF\C&%H$!<U:!*?\]R@A>FX`4E@8P[#S*=SK2A6
M@6[`QS,4X@O_0$C'\M#PO`(D$E@^(,,3-(29%0R%##?XPOB6Q[P*+>9_TRO$
M@$@#P>GY(9BBDF&@)A6KH07N,V3HXPJ`L`)#&8X^\F'G<A97M?B(#CZ*LZ>1
M2%>>'$')G:,[DI;LU+KF)&EU9DG2/O&$.\X55$<+K$DQX%F,-`4T39'9)^TP
MBI7;S8FB5;)31\DRK,3T<((3S(.F8ABI`16LI`8+'!E**KP=8D9[$[3$!#%@
MMI&@X0PWG>#R;J"],]BO!1*<H$@B($ZRP*):&,F!O%*6D%\\X0D[&(DO;8`R
M&\PJ!RO0WDU]:H-6!+.H$TQ')>N1CHXXM('/NX1-;>!3#-SR@AF<_PHX,;-&
M#$"+-0?!(/5&$JN2YB%P*'L"M7CH57/(%&$U?589^W9,L[I0K1\QBS&Z`+9"
M:'51CL1@!4]2TE\4HG\PM4$8^E0`&YR5AUC-:APAY;M*/8$:YN!K!/PJ/$0)
M]J=430=)*!)6V9!D!5K-*FCR1L3^G"$/)O&J)1*"`0P0C36;Q:F@EH"/EI;4
M/BCA[!D.-+0"?"$):4M"(SGY,JXZC%5AN@I+%B/$5T8V(64A79+.D`3@&G>K
M)80C_W+@/4B>X0D?8DVEPDH&C)44F"1)AR6&A4'LWL"GED`9!M*A+:_NKR01
M0,IAZWBRDB:2P($TR\B8<U#2:11*JIP<0O_U&::L;"Z?\:P<Y=PY8YMLE'6*
MJXE#-V<5U.'.HZB3C,^J)&1!VH3(6P+2:3!*.X8VN:,>O=/+Z$4P!D-202>K
M%MQ:FLP6\)=Z"`.-K&0U0=])9[L_%1XWI653^P`A>+^0!V:%B3"X40<APP)"
M"SQLW.D"N("R.D-2,%@^DQAU@NO!C(1,=9I?,<8/:$8TL8PU0:GPXA>$S:L-
MO,)7$AYO>S/EK4M)8MQT[&`QXTM9I(*YA)I^2%.,%AX&$X)DY;"2N%J]]:NS
M"MJWFI6T.=B!:<D`7-76+&>,_BO*9&-&FHUVA#O+J@T2E%0_7&!8TH4C:U`2
MYD5Z[]"_Q.D,XPG_"RJXZA,2E"ZV\+@#:5TX;C=$2:5EI;TG:$I1.,WJ5&'&
ME*VU"!LS).6`_L0JGT7&,7+)V3/30H9T@$PY!07!TTR2/XGS=U'DQ'AQ5YLO
MUQ3:W&WV70YJ^NIK8M'2?C`L6;'93.(,B)'B2K9)O$<&0,9413O*BD5]["0U
M#<F>AHMG/U5YXQ1#+MTC*P;E3C/D+`4T,C1>\>IR416FZZC*:3)R/.V4BWVJ
M$@1=GTQ%Y7.[*,_N3!/57>[^LPJ$C'2,N"[`2)YIYIFRU-LK;T%-I7LHFC>E
M'L>K7J4FZ`?%JU6K)6I8.EPYDD_`3:K,&O-ZXA5XA-"L7*Y%"%'T!1$"_T^7
MK+9F5O$0\IBRPR(=P)K(UL(]UYU.<*EDD:V[J=W77X#:'-7:`$RE6[T<&'>T
ML)3@RR[B0>WE=`5]\G5T#27+\IA`4Y#"(`:\(ET3_L)5\9J@.?PPQ0"7\`Q7
M_`P&[5,//^"TS\*[?8%M"]D2(@MY`8;IRW;_B]]BQ@$XQ4`>C6,)&HG4?B%+
MLN13D@KXULH/`%`M,"AC.D9KM@9N]L]`SBW[4L9^7N/0VJBXCH8:5"8'-&F&
M?L0*",,<D,J"PB".YL@T#(<7J`$;BL4XT&`##N3Z,$SD2F)B<.H&(D97@B=E
MD(5B%FG]KN]#!B\B1.P7$&8#!J2-PJ*"/`RFGO]@(")@,2;"B[0'(:9FQ7P.
M<H(DQ^JIGNYD=8Z,.21'221CZUZ0G]H.<TIP3,2$%TZ'Q3Q'ZG"'HH`N34#@
MZ2(#2W0DZ%3GGZ!L[=ZDZZB,R.9.R["OTQ".`V90/)('IQ1!$2II^59%$7P@
M,=KF>9(@JV:*IVS@!A9I,>JA%;:J%!4CX[8P!B'D`DC1C%+&(PKN)SS,''`-
MC[Z@;2[#KS[%)"!%^]:L`+!/]=`#&Y)@,92QCE0+TR8"UU#)6PA+%J5+U$IH
MVG8+IE:E8M8O\%XI`I;`4E(F%(]I0II/!)<O]52"DU#).6#!!R.@W7(Q!M5*
M[OQ`WD*KP'J#-2YC,:#_ZJA&8@=0QBL\0JVJ(YAX"OO"K]HPR"M6(U:<A2RH
M@0RH*!C-857.8(3XD8J2XF@@PS&,822\"M>FYAV!I1#2<::6L=6V2MDT36H(
M@U4")QSYRU`<H_SB<9.0C"J4`UQ,XJVBC:?,(1HC@QU6`4$`C35:HZAVSU`R
M;`>M3W@")6)$907\(*<(X^1<SED"Y8;XD1_K8??,`6&^H/D4I!Z*#2F.RZG:
M)EXLI3!NPL8N)T?H,'&(SN+H(Q?`,!`'BG7Z0Z*LY'(^*L4$R0ZGH@_CL"Y/
MX^G@XTZ:K.J\\+*8`YXHJHC.@^J*),D,L78"JNMHPC/A[DY@\"G])!?OCI$L
M_P$`::Y@D$7N_"X=Y0Y1*L72@._P)"@C"<(480H;0(7FNLJQ;&L41LZ5-/`+
M4L\Q?L&JC$U[R.(]KJC0T`S@$+"H`B];'L6$/J+L/.)I)B)#SF?!OL*"-&TF
MO.7VG`5:U,@K$"(;00VOA@__,L;XI/+PRE$A^F0+?X$R&DK2J&_14B:0#.,J
M8G#2O&^Q_$#D0L4UY@77B".IF!,]CG&TS"QES.$V^HHZ"FP&!<O$T(,B'^4!
M8[*9OF`)K)"XDJ(L<J053("XXJ>]4"./(@`EHV^'/.AZO@BF?BL>E\TC&.AE
M'*U`G*(THLH[0*\%Q,4<#)`J5NX2G`;G8`@-6B&G`O\Q(1AP!>J!+3'C*OM,
M4%I@`]@/(0ZK`'9`1A:#-M*A#=RS11&B*_FOY1Y0SVYN_!R`-=1R6$+C"[A(
M,5[B"3R"%_;IOE;'3!BS+MVK=1!JG_YTQCP'%M(0%H(L,LD$/I).-.4$!$0G
M%](0#:6$ZQ+J,W6$QB(CH.1C2?!03.+#H@(3H:QD,]W$[:ZB&ZRL,[>D,U<!
MSDKS>+@'[R;(`7R3D<838#JF1<D"<###M/R-C.)1>>Z4-03+#\JH91Q`"L-1
M>`QE$Y\G+TATOTB0&N2A\UK4*,N/-8RGS?`H<(P*`]C!"8L5U"KN&/7+^QCL
M>#!-!'&-?8S2?1`O(6Y#C8[_QU#F(@%Q3?A0YO/JH=7N3Q%"<?U,B$MOP"MD
M0O5*<G$<PD*\RB9_!@0X"1OP<0DT;1\CX!+FB*RL4M/^3`2/3T4^`IQD$2%(
MD20(;'N^8D`$JP"G9FJ`*QC91^+LM)E\(X:DXL?:`!X+X"I-3":,0=YRP&$*
M3!YF"C9^:JJR2E/@YVCT$P220C>XZ%V,:88<9!>-E%VSA!V6X1R1PFLDAB#J
MH2$-$"O4:K6:J8T`K05VQED4C<W^,[VRJA7.J4]\0'XXR$)^B6LY:$#^T=^>
MX"F#BRG@)RWO3UXK+0PJ9@F\8EVJ1C)NQPPGLW*^1'%$1W/]B4H(,\CH2:#<
M20]C_V=(;L=T%\?B*F=2915V_M0_"-.BQ*Z=+!,R"-,QF8-5VX12:8+'$)%3
M*2J@;'6,`D]0ON"FR."*T*5>1RM8<8U79),,+&Q8FI*Z)L*TEJ>T4O%Y-FNH
M]&A>%"$=LD8"!T9NTX$=?R6P?HE]5B%<NXH*A?!EIG.ST@$$!*4T,8R=/*+[
MO#2FL,\<NF#V]`\6DB,$)P_4,L9"$&T]"REXAL73<L`K&!!1%N1XO((^HRH6
M^R:HD!1_"P%C6R%(V($,,NMC4;*]"B$/_"5%NN^MI.M`2^L):+1XEF_E>J@5
M<LT$/"G^".9X)/1YQ'<]1^+WY,<YV*$5RG2ST%4X<JBDEO^7-8Y-_R)M?D3R
MF$(F3U#H\;`/`I\J#&+J^KIKF&8()_(`8RIME_;`/F#C%_P`%O2&W;24B,`$
MP'[/$JC+)5-F;<$+)2OL-.5V^_1OI#:!]JAAEX:II6ZN!3S0C84/4'B&&O)@
M0,(QJZS7A,82BRZ@`(#@"_"!8DB"SL1+LLQJD98@(7JNGQP5%HIA<:P@="(G
M2!Y547'74LVBE37'25P9=6A,+QTU3$3G=WWN<?#D4EFLZB3S#^LIW>X$5CNJ
M=H]$/H0L46,'2*Q@<U`,[*#9"GCW'Z;"F&D"5F%UE;_94\/9,7W9+)@G<.0%
MT4[S"VZ-E5K#>#L"6$UB_>J96-__!GLBJ$4KIIQT@UEAB@R>58(L86R.XBIQ
MY24VH0!6($:(RP^X=GW[)GXXB1U`P/S^AWG.0!Z:*'!6@'DVD2`,"=><Q!@X
MJ?N2X`*N#R$@[VMPB7D^J2)TJCMW"6DU*65"PXWR1\(L1)*NU"34\H0<;4&^
M"6),8@<DR6;PX`PH-RL\(IF>*G\*`0^6`"V?A6&Z,RG.JG^V+1TPCFY6JUS\
MQ!C"IPL$<+JVHE(RQ(WBYV'@%ASSIS:NXN8H`H-BT*K1\M!"8P.$*7AZ[BI^
M$2)5I!6,`:(3Y6/,01X$Y1),*_JFRO**9Y=6X!)TA@PHZW`W@7`M)6/Y"@VV
MT+)`8(3O_PZ')J[8L`B##=`*VN@ISJS\<N:M09`W&9%5C"%!\."UBRW<U.5O
M'0P[T0.2O$B20`/#$*89-VYY#'917N)[9(65"F2,%&XRSJ-S?PXRGHZ=CLX*
M_-"78X>>S@15&><P;;ER;?ERR:[JSMDQG82>KEG&)/54@WFCQOEV+"KISL1R
MC>Z5&Z<Y3C4KA!E(NOD_?%F<BSF7Q_E5[R2='?/D+L,X;6"2&4FKTN$<$X7V
M>`6'KW)5J&$5K-5M_,H/9JI/ZN78MBIPK,\&-F"G5H!["@F,;8"E10X-`*4G
MS,%;:<LQ,II6D(+T>%%4G-:DFZ.!<.[Z.!P6!)@J+<C];F9?K/^+#/`@6#RZ
M8AHE7HQ0AJL\"''S57P@2GLB1Q`"+)1\`^9%6_0H*8J-M\B@.,@<@Z"%3]ZE
M[DZN0)P<9;B*0.J1B&XV9;"!&H1O(LX7M'FO2=XC6O)5.0I!.!OE9"RBD"3$
M6=BQ9GHU/``)(]"@'L2\!8``GWM"4(``B,M"<F[2;K*6(,CF"3@)<J1$(S=&
M4XH*@S,680K&',@#P%RC7B9/>U+$'$+"P6R`1[%AQ.<&4N"L>+:K^&JNB79P
M8T2ES15N#E,,3(0LGT:F+I,$5@OUES.S=E?W#>V0+JL&W*W.!)I$3`P\P:M[
M322U#4;&&-#!1V#5EY,D23RU<^-#E=;_V^KHPT=0E>P`?-Z?K)MYX5*%.>J:
M^5,-?IS'.2OV)"P<?B0/QD]V#]<X(X$S"&!FHQL]`F$KWN$'HI*U[PQVP#>C
MNV'AB(ODT:RR%B6<,(']C13#X@P4CY,0PT\LVD$2Q.,?'A4)6N?10*F?#QL@
M!QU&>^0O7=.B$3TR1>>=HJ2\QC<_P7MP"K&8?O>&0^<%T*B.A[&!%&=,B3K&
M448D!IK0U7"0TV#4M4^X0WM(5.<_[)K\!/A<*BS2*O&T0U3$0WL?!.J#?&AV
MJ.O#0JUH'1O6_#4@9896P@?$WH)8*F5\YCPXJ=@JM@"O7N==)FXX@XG2UTX*
MSK8<3>V;4<SQ_SZ1"P=^1R\_68>3B.9\)R\,;"8L5H`P>F:T"T!=6^/238MG
MVF"HM`9N!/<&@&!@FOUE<RHJE"CPI>LQ\`4CF)X[0(TXPHU"W3@GI(,*1UHI
M3V)H<>K+$9-0C8&@)(,_Y@,P^W!Q"!4^Z/T\&K4/Z]#`D^3[K<2ZV5^7-[4/
M`7YQ;B?]RYLY5`D@C(&`!4)@05BY8,'BE8O7PH0('1($41"$%8@082T;N'&@
M,2L$!1H$44RA%8L4%?Y;R;*E2X4(%6*$U4TFS(PU8<9$N*P-NU]^_#P9.A2#
M#1N_GI@[BD$1!@Q/TCTQJN@7ME7RTIE[8J,J.VJKM$J5&O6)GU^_FO\:39>.
MS!DR9+@R_<5V*E,,=8<J&CKWESES9,W1Q4;-#UNC>-O`PI:7J-2E3^N2Y6OC
M:56=%*F1,?RK,KM5,!FS%?KX2>?*3[*ZA2OWJ5\RDRE#W1K[+@:@I<E"?0JU
M+=S-107#.FFE#3:H0'\+/5IVJU"[:W6;!CS4W&VC25?#MO1T:E(_JZ7>-0<^
M]E1SV*[^@NW]URIJV`RW?1N7J^N)*>E^RK&D$%JK08U%%%)1B8<!-HHMM!A@
M0?U&%E-/_%9?9>MA4P`:+:!QE%4W4>0'@V2$L9T-0[&55CJAQ3<:?>)1B`T(
M;;3U'%ZP&/>+:MH=A11ZZ8E6U"_P+<8>48;_*85:B]3\ETZ1G6&WI'*ZN8?-
M1"<A1-QP`R4DT'!58IDEE@:!A&4N%EDYT$XY06110BDE1"9%'6DD4Y<3*913
M3F,B1)$Q?(XT$D@9N;D3F<541-&9-,%2*"P"G300G!5]Y.BD9^;BTJ4M/633
MIA@QY)"@-<U4)BSL6*>CCD]5UA=:1LT%VBIIJ8K!*J_&VBI3)/J%EE.HV27K
M=5PYY=14ON)ZH!_8"(88D.FA-1<UK2AFZJEW-8DJB<NZIY!$!%T%'9#<8A.K
M7-3>EI9116TH&*NWGMJNL4A9=96JU^*U+E*J<G<;@C#!"`LUBLC:&E+OHGJ:
M#7^A92JZNB*&K8X)_Z=J;67FQC>QNE->U:II4HJKJFDZ<@Q:F#:N\$D+7YSQ
M7ZKN0K;LK`2)"8MAJ+6*F*\7RVM"/2U\LH*+B%(D+G*RTKMAD`JU81W#!FN;
M&:N53:E8.@X7ZQ=8BPU=F3G4L*.0'ZF^>YVL0*XR)2S3FHON;<PUF4Z"E.Y$
M7$*.J@D"W<6(61&5"AU:)J"<WA0SWC`Y*E"A,A-4#-VC!FK2WWOVZ?='CGNJ
M$W&/8@X1YHYZR>?>%)T4)N.8EC[HI@QI&E-#@D>D**+_\B9[5:S27JME:+WZ
M$^Y>\\(+K.RF]5^0XJ8UU6Z_T.Z78%Q?E6S"M9O;AM#0`ZE0LJS^(I%QZ?^<
M:]E?@,'*VW2"L44-MS'!F-ZZJW@-DXU^8;"N9:L@V_VY%#-;O&FS5R7[?^S+
M&/"492YV9$QAQM,5>M!1.!BU(DEH.=YM_J(VM2'0/<@B3!NR)R_L0:TI/`J+
MLNR"%JW4*%GR6]IM4-0&^$$0-"!0C_>.)R_\@`1&ZZG')]"P@OLIC#>Z^D\$
ML>&^N]5H(,R3V/((R+]]M=`':/C$%](1KSIU+EE4(QC'SD47:O2+5"O;S02E
M)K3EH05:`S'.=9JT+R(2Y%])6N'[8I06`BH,,`!,!VAJY!,AXE%X[1&,%Q'E
MJ#+EXDI>>IRB]&81*]2-45]"G!%;-Y/'N8DB:A+_24IV4J<WQ21U&-FDH]"A
M2='-Q'$)D22@.'>H0E+*4*%[DZ$>!X+28<I.-A'4Z02'D[Y]:2#%JXKR/D.K
M]_0.%NUSS_ET\AEYO`=]S?(+8]""C6B=B5;_"4MZS/:9'L&B%37Z5WHRV#T8
M4J2%(##'5]RGF!ZY+VE9$V(-%P.\]R!(,;!C'99::)QE;BN<U(`/>N"3GJZ!
M@!8P(H,0/P-/YXFK*L7\#`#3DZ#ID8J@R9('LMZ'S&0UBZ*A:V!Q%@/!P62-
MH(+ID=F,<[;IQ;!XJU!,.ZFA1VI:-&G%(XRV+(J@*2%+'MJ*63L)8\X$,48P
M9KN*#?T60PP48@7U\`$9__[2HQ+VJ*=*39"7_*48V/RGI>O+*1_/\(5ZK.`&
M6SN;WTXRO6AVD#'$ZYLQAGH_]*CSB"CA)U'[%:WT:`4M\FCAXT""(#WB5:;Q
MF6;N*$J8*>WQBMX\80D+PZ'I"61S*+G;FKQTD4D-#C^9K<A%?!E2Q^5RL`L)
MZ:'X5))*(NXD^JSD<!:W51!L9%%;,BWC8BE2T1K*D:O];7!M:T0K%,J6E]JE
MZUC'W$0E"B.+PE+B%J,@G9Q-)SI!'W;1![N!>-$ATT/D5Y)V4V[!J"!:910_
M^P82T0D6N_Z"79W.Y!#P/@J[L#A#(;&KIN(<ZI^L.U-%\=DO@Y`*F9=#E&##
MI?]=?`I$(@).R4V[-+T$@>`,QO@LE<[)"Z^UX89<%7"_SM`O$U08,X54ZAM=
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M'Z$E2B;5;5A1R`\R%M.Y]<VWB1@;)27QMYO/8.YP"UA9NJ*&X107.LS1ER+W
MGDC$=RQN=^<M)8@&G!5(#N.&[PV1J,XPSCW;-W,O0ZX:O_%`U(USOEF[M81F
M+=-OV',U;>0D'X]92!]>[41O6D\@SG"&C4N1UL[$(:$"Y:8;\A'$;9A/!2@$
MPRD]\;5'770>`:XF_UMH8US=_PJ%KJ6J67+:A*3=\)]$?"ZT="9POSIPJ4-(
MJ%R-^,,S>I./)T[>-D62S@6XE6(ZI.1"7A)*C=9,A](E25#R*5\R.B22$]0E
MV_LG31D2TR'A<;Y#K_:8Z>E+NR03JIN<-\L"3B,]%V68?N^WHT/*AC$IU,#/
MO<C2@CJS0B>N38[=Y\Y;V2`&?O0RT)$X/M&^<8]2#X*86LB0GYMNYP9\I3*K
M-_`C6B`]2H?SY)HECF/)V+&&:AN!;G@7>J)S0P/(.)YG6ZC6;(ZR>6P2?YKV
M>U6B)<,G?._6)@JQ#,F7)<V62K`46C=W==AV$*\C;8I3-P%X*#?W);(G$V57
M;F+B@/_/A1`OJ&B>=&W]0@5Q9P*:YB;&A4B9!TDH@1][!UR6]B@BT2B#QQ*+
M%Q$WZ&IK9VA!>%HU,7G-U1`OJ'8O&'W%94A<*'&GQSAY$WK_QUN99A`#6#C&
M=A&891$E,7F9M3BMMWIE\G&?0ULQ41-*%X,E>$.``P+H8`)R9P)@]X2O-C=4
MXBF(1RFG=A$5P7@#078N5W8EN'J8(WV3"#KG]G&+TA'%A77T=R@#N"=@HEEV
M"(?:MUMEAW.B%1*E1TI&UH(*QSCKA4^7-HG#)EJ-QG>\Y4AMB&B71G41!C>M
MV'R7B(FK=5EX%W5LPGZM9#?*:#A;,DL_IXK"N%D/N%;2-W/_/C>`9.=N5[<Y
MHIB-S,AQILARRFB)K*ASV8AU=I=*`GB)E/B"AV=WMC5;@/.$(&`"/FB)-!B%
M]+AZGQ,FP15XN5@13;@25KB'4*AXJ0./LU4I\6AWFQ8JKZ9VW8!(;O=X@B**
M^^B`@N)NSWAI!O:$F1B2F+A<KK0Z[:=:'/A?L@<YM)@^(`&!+^:#_C@0F_=<
M#(%9E]230-@F(<B"ZVA^!'%U10B"N0@F!M&&QF9L,<D1C5*$6Q5_A=:"J5@H
M<8)L/4F-_9>'3#66G9ASDX02QD!BIWB,D&*'C5*`FW65W!9X'W=.V*>+PCB4
M@.=S>Q>,1KEQB(:3QH:4HQ8FA7*8_\+(ESR)?J)S=.C62H@9C$@I6N&5/I$C
M)L7PE'8(DL35=75W2*D($5'I;J,E>X9#$GMF>FT0A:Q9B:\F:)JVC4)8@R\X
M-\3U)ZW8@`6)#@>QD/^`B*L3AO%H<.E6D5J8.E?HD*!2D;*V6:P6A2!W?)IW
M;;PPFI1R;ZB9C#JXC3;X.!UI$J=)6JWHDZCY)B#).+SF)F=`2J&FB%$HD9V7
M*/N%A"O)@&O9$RNG)R7Q<!'7;*K5GP59;?L9A!"Q$2;0A_.I?996>F/&6R9Y
MAY-#=4<G.B)QB@VQE+"GF*L7=4HH$L5Q@*['./:6@<%U=[#72HP"CH86=<4&
MF@U(@&1F8/^9V7AQ61!5MHFDN(D/EHM\N9^((Z(-]TH2>HH&)G_M%6@96GIC
M274,6DHPNG4RMZ)NMVSUN#IWV3=0EQ)5^)'*^76O@W5=&%+R]Z/&N6F%M(03
M%RF-LH2E)'A-F$MAB)'(^7N+]WH"R9IA*'M<."J`5WC&*8R;]G''AX??MY+D
MB!*ZY(DR49+E^3B?XUF`]TAL`BACEUEF,JF:(G^1>&U8^(>_%Q.-DG6=8R6-
M@H'%89";IXB`=Z#^ADAPZ5NFN(:7QZJ6J!'SIV\4BGU8QT@Q006TJJ7HIZ+G
M9I!?""B9Z:%:BGM[<J59)V^,XR;+<*,H&G&.BGU;1701)WHW&B?_W\F+CSIJ
M((>E@-*/F@EBC'19G:F.D>I+;B(Y_]6<^B9\E8JNHV)(JQIOJU>=C=,1%U&D
M<*(X%/B$M7=(.D&M&DB).<<F4->3C2JI%2E=UR8H/SJ,<,J:V(:FC!*E5:F)
MFB1VOFF<>1H3&Z&`78JG4=BI6KAIEX40\A:/(8MD4:E+(+D3#TIV(=$1M+5;
MWSF1*TJ&SKFL($`%4*=N-KLY(6=DJ6>;^^B4UF9$%JN(!_$GQ?:'HTI]>K(E
MZJ:SD5,068J*`,>5Q$8%F/F%D(*FHKF)Q'@YW3=:B,.F?&*T7<:RN!>!7^BS
M#VH"^_AT2KB?$&%^SPA_A72@GV,WHO=B_S!VH:$F:HR"ATM(;Y;8GZ3$>7AK
M$AD&LQ:!IF*[.6.W>3M6$WO9MZ,5M3Q*.2]VD_A&K0^GL$;4M*/KN*H$>YS6
MC[1TH85B>*TH,XAH:"J:=S)!.5G[?ZEU-RYW$7D:D;?[=;GHCRAHL1\)M*A9
MD!ZZET$[2P?ZL<]9D;Q`B6M;ILP;LC?(D1'+O7*#HD/IAS5QK,LZ@X\*?"FX
MG3EGI:U(M+EZ?$SU:=G+IW9()GG2O#>:6][+L@1;#";6KX<+@Y@(FDXK2<5J
MN%3'JE`GBOOYBZN%>E=[8PS'CJ_D)2AYO)W3C'NY?+5%J8`C2:UU)7O9P+7:
MBSBZ2BQHK&'Y;O\7;*\$:29'!X*[ZB4,\7/NBEG&1JHE>'.E1R:TAVD<^&AV
MRUFH9WT6O(G8&8@HZGFY\'$U7%I^IXMJ>(FUJ[@(.Z#2YBB>NUH$BQ'P>3A]
M.BA!ZH&&5@QQ0AQ+&X5MJ)(<:`(%4``,5[)V)XK\NHQ[PZ:&,J/&X)LG"X5)
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MCK(,F.QQ?#K5,_W2IOI\LEFGRIR4C>-9Z7N8CC0];;C*\=F2%&QJ:^*'JY>`
M4LV"-A%=K^J*ABJ2;*W!8AU:`-W/!:UTW)S2_X\,P<,<GP@,D';80-0,JZCY
MU2%\A@8(K'YGV.J8J@\XKH::@OIIKDELU69:CI3\:BV'S\<H$N>LRM=JNG8H
MQX5`Q^1GG!L]@WJLQP'*HVXZ>"9;R7N#LPV9LJI\@Z!DO)"CT!79J5&MS*Q8
M;"!&7)!<$!T1QEN%D^V\R;F8UK,M-U;]SB7QG6=:>BHM*'UGW%$8DR;*G,`<
MB2XI;7M"MZP8E^$(W@4,CZ*CI"M+@Q"[6:7JJ8(&COMM!<B<6A_WC#6</O8L
M<RZ**(HZD5/*<1G1GSI\6??KRQ",EVZ8SJ.U<4@I75F,U191;T[+UZ^HWB]I
M$L!\@!^9K:S%H?Z<S/^0^G[I3+!O"Z-4LK+=7&\[385:RLT.N+37=TJN>V.<
MZR>16*6)C&T5'E)M0`4\.,?[?8/O>TE+R+%]4I5N:[TA>[Y%;)"5"X0Q[9/,
M*VO4&MSB&XQ#O;X0*I.D2M0_['CI7*LGN"<%?I6;UL=58J=GJCE?1Z&A%N;>
MAW6E*IPI?=^;7*DMR)68IV_9&M@8GCZ;I\!JG(_0"B<R(\KHO%N+M\W+6KX-
MJ\S>W8?-UZBK)3/ZYLP/G,:7^X`%+IN@"JG9*7JZN(TS"H1/Z84;:IZV_CJ8
M2,:.#J61WK*>],59,K*L"^P0_,/9V:>T'LE&2::.E&$)J.N&5EHO;<#F6J#_
M?CB4#*>W;4RYNP66JPJKP9V;B)V3!7``LGC'RFTF"-F/N#VZ!0'(PV&FC&-N
MYB9V*''@.!B19MKO=/.16C*NF$8W_G['!']V=OC`?>>LE'O`)G%O6:RU@,)D
MO.QV[CZUV-:V.]T1,TX2B.<Y"0=U7GZ0Q@TX&NZ8[+PZF`7@^FVZQ$BW_Z>^
M$CG1,4[6N?6V1%N@,?OF+?M(4WO"]=:R$GRYR'Y[+@^+6#*YP=:G4PM_M8K+
M]BTFYJ9QR8RB&]B&C`<2`,K>?O=BR0:*5K>2;C>R,ICT)7FV@F;+C#)JP>Q9
MU'>@5$?;Y&NKXLQ9@A:!0M_UMHH1UG;@#+YT$QN^_S;[.EDJ?54/"U-O]_.N
MU$9V;^XZO21\2(WX[Y0;>R:1$.A0<N;9O%@_[ZMG^+GH^`/!JI]391^K<^,;
MT@$:DE;2^EXNW:P_)[,KJ:S_^J@?G-\FR<7@8%8[W6K+YA"&J+&;OIZS9?PF
M7ZTT5UBR2R'HDC!(==.#@RTI?>G#0+J&&6EMJE_ZCCSA@NA@6>W&>J`EGK)T
MJ_R&E'[&;^:ZI'0ZR+%,G.$?.F.V9K\W:*!E1%FW8>#ZA68&$"",&8-5$,1!
M=`6M""0(Z^#!8@]!%'0X,5>NA2"*&5M&4:(56`N-3:Q84:)"$"`-@L@UD*1)
MDAL/@AQY$"8LC,8NK@2!SO_F39XK*V;\F9(BT9$H(2I]F8LB2J4X;\X4B-%F
MKF4L03I5F9,EPY$#=88UMG6F5*<A"UH5>]8I1H<$K>2Z:B5CQ*ZP(CZD"59@
MRK]B!R[\5]CP8<1<WZJE.Y)*8"HNMZJ52IGK6H6+YTK=C'-A,9P:0>8EC9EQ
MR,5/>6'C5;"-R58\#[Z&U;I-UI^PL!T<N9!BZU9MA!=L#9.DQI`V7[.K';1U
M:Z+'519?>`9$FY^:Z=IM,W(X9J?771>EB%TU+.;%86*T:E7ESX4J(WHT9MVA
M4O.S#987[]KC4^QJ>F^BB6S[SR#:8$GPK.1FHRVZ\@XL2<'?<C-N/,#*$ZD-
M;!3_3,J*^9)[JI797G+(/*@2G)!"VU[B[2&/^`HO0EZP>RE!VEJ\SL3K?$O.
M*OHF"HXV!JVHKS^%7E-QO^9R:T,E"E'RCB2[;'IH28J8\P^JE:R3#B700-2*
ML[2B<TFPC$;"ZR#V4.-,HQ<U:A.U^$*:[S.W0L(3-+;(>O%,EPY";-##+)N,
MKJP`#;1,G.!ZZ]"MNH+24<\RLJJ80T^C=--,><EC!3SP`%54//+PHXT;\@AU
M!6.P$<X840NQHL.,3"`U#U<ELA7445?(XP;B8#%F!1_P.&-%6_$H5M0\3)`'
MED^9_84:API1]EB'6C,A#Q^^^*(+'U8HQ)@VU%-I(;JX_PVU$-84,L;:6%M=
M!5H\"C!AE39,*&!59L>M#;N(.KJH2I#@7<&$#AT:3:!/OZ@'W`(*>>K=;KTM
MMA`.C5&U6%Z+Y3!?44VH2:^9"N&85%!O``&;,T@]V=Z5)P3!Y'43-*:`97LE
M%80SK.4UU`):H0:$:`^F#59Q=YQ(8SR\!1>/<1/\C%Z=.?8!UYF+M:\@6WV0
MF#F<246YD/Y$6@AHA`$C256=R=XMU'!1S@,$>4#P(6Z=CWU2K8R6L?:+';XH
MUMZ$&5;V81\B!J&53XOE&&%LC#GYYW%=53567JB].51L/>366\'S,*:554`0
MNV,\8NY.U6^_7:&`ABJU:6I.2?_&%"QC(H-(H+VF-I2NO0#KW;.U1+L43J.X
MPM,N.W$?:1E%>TN)4.H5.RJ\0,5Z;#3-,"OMJ<VL5T@AO-P[5[OKTQ^?HDL^
M:<%]^#])(ITV"ED"_A6PH::5&]SOXHQ5S.L@7T##^]"PLLA-Q`=HB-\G/H&&
M+MR`&NS`1AX*B(8SD&%OM5D!`]]GP!5@X!?U<.`#0;"*7TBN!2U@EZM@<8!Z
M%#`'.6A!#M!0CP(D;#'A$<@E5OB)+Y"!6A[R@?M:D(1"_`*%[4-#"!710?@9
M\!)>:]='K+*T)/S0!ZWHD$UX80(?+*&&,[1A/<BPBMVL((MD?-\EZ%:(`J[P
M@^\[PR__6E&`%7[A#(4+RQ?D^$'W?>&$A8AB"6^(,=;,Q`3UT"(`L<&./(Q"
MCE'\8"%N4$0'_G`)(/C%#=KW/A\($1LF*&`]SB"/UYB,@3.LX2>6D+\NBNB3
ME/SA)<AP`T:RD$-O6Z$/.(F-^QG1B"WHPLK:T!@";:$%:,##+W8#HR0(\WU)
MN$$GASG,)52S?W\$)+NPPYZ'X.%^-&SE$G+X2#"*D8T0/,,9"GA-//@!&X68
MY`];<(DDIF.6ES@#-4:Y@Q7N$1O86$8'QSA#-`CR%^X$9#>=:;=QKI"&YC3'
MO-82'[HDCS)J68I@'+,[DF6D,V9!WL(B@A<RS:0Q:II(I$YJ_Y2[,`0P'CV3
MF*A'J-/,930R`0'T7H06397F46FIW:/.8B2B/JHRX7-39M"R&AGFH)`;,(<Y
MX$C&3W#R%R:HH2D5\8O:&.,2,XQ`#@J1#C2>H0U?^,0,,^G6>IC#F05H:PL$
M2AM(CM.MK[0!!AA)QA6D`P,@^,(,;S#0-KB3E:[T(!#E21%''82>9.3G0`LB
MN;+2\`N"_84//^$#&_RB`&A8K$1MZ"QJO0BEO!AM#LJ*07/$B(1N18,'<^"'
MN;95J@QT7P[J2,C2PJ^.9%C!#/7XBP`=Q`2%)2<@5T"&3F(UDV5=0B$F6!&Z
MNC8'^%3B*@KQR8/:LQ!G6$%O(]!&,O]@X`Q+T.XG#NN'_D4@"75,!PA\2,,'
MUG:%2T#K7US3/B-F]H.7\,,9ZE'6L_K!(<P-HCG2(<;S`M*QO^`+=L[0UD^L
MP`;XRE`2HBI5,T:WK`W-YD+'^#[XH2&)"JY)2O+`2C0L(9@M\,$O%#S;W<H0
M@V=H'QL_48!T^*$0/OY@/0J!`0RH4ZI?\(,Y;M"%&9[!#Z5;P1CSVU8TW$"]
M)Y9P/H=,PQ@O(8Y?^`58+VH%GT2D=HWZ2TO.!+V1>(5VJ$&4:#@CTCB?ABIP
M/A3R,-6\GCZD+&=ZC(#*`H*;#FJH="DT2X3UO+(H=2=,#1^GM#/IBT2Z,9<I
MJF(63;RTL(/_O2W8P!/28>H@V\`&-V!O9H.XY1R8$@.KF.!H,YN#+D`WM6RU
M(1EL0(8-(/07#J9K!#Y!!G/$DAKID,>%:5B()ZC:!HP4\'!]4-8;5)7'KRU`
MM&V0CA5<X@O)?M(.6P%&[4:@B1C@$#N&I5T;AM`&8ERW#?!`VBR;>@5+*&M6
ME0B+1!D#-`6YKW9OD`X7PH+7]_1#7\/`UB>(EKTYR.83+$$&/)[A"<!UKQ_2
MD0XRI*.O&'?MJU=QAMX\V;4K"(/'PY".7X3V!M2]@:D+T6\?F,.?`BEL9C.,
M`9BS@PQ#)T,K`QMD;Q-WAJ:,-@98#6]3.KFMIK0!-HJK69';8.,;_UB".1XK
M$%B<G.C,!<(-R.#Q50<[!S?`;8&9&THDJ].,0:;[$]C=&X<H]K.A745&VA!R
M(-00#:I^@I-G6%U3>QSF3[A!"]1=``X$.>1(IC`(3``"7B@V!X&5]AF^H&$,
ME)>&EPB#JLGPA27XFO'UF.%9GU#XF^=@`]`&N1\B;HE?J'/$=31P6=.;CNSF
M8`<:O_@7+G&#7[?2]1\_M0TT[X.&:_T&GY=K:S13ELXXRGI(-5)8EH)FNZBY
M376&Z?7+0F?/-`8WO;E(H$,44X@XY?(RG?]\(I/HQ&QF(50PDF@"71-)8X]/
MTSX!3#]),Q*=ZJE&&9C*>`H'=,"W@`M>,/^'.*J'"Y`V:<,`^^FW\P*RHHLU
MZ*HH=B"A94(#8],R)4J'(J*XK"NL>RH\<\BN8QLV&PD[#""#3SA!54.R7!HC
M6R(#'S`LFW.\3R@$2\#`)_"#]%*PY%&)JW*E_8HX#@&!JQNCU+,!S]*P)[`U
M-"@]57NZS8.NUC`&D;&)_K&AB3NN1X(%TJ(X;[,$#'@"9'L"/Z*AAK,[W`LY
M&R`D8^,`&[A`#%2Z'&BPPH&%Y2JK;L-`PKL!UR(]5;.$&FJ!%5"$^IJGL8JU
MKH(N;/@%)/LV#"L`PNNK7RL`X_*UO@+#')1$D,O!#?`U$&C#YT)"D/.Z+IH(
M=ABV)"3%"`@B:7O_`AZ+LE](0B!TK5"*-G7Z@B/\PQU$N+BXCE8P030`K5]@
M#H'8(PRHP\%3-2>C+E-4Q#-PO"Q31%6;%Y%!A^[0K5!"PIC#@#8THU`$N:PS
M,"&$P2^K!R_$P+B+Q!DB,,^;(3*0PY[CKQU\O3,0K&^TH1L`1`P$`=WZ`C_L
M17,`.LB:BQT:/XM$"H'HOY`XO[W0C."A2`/,R`6<C(C(G66XHEQXJ92X(MS(
MBHUTGOX3B8'`OT(9&+_`C93`J/`!R0*\R)WHR4H3$Y`H'_0+EN9X#O0X2LBJ
M#'98A8E+J+OYO#/0.ON1JJO#IP\,L61[11L2'!H*K%G[!0*RRALPJ./3_[I?
MX,-/$"Q4`HQT4`1G<Z^^LKL->)\E&"M)+$O7.@.O6X&RLB5Q%,53@9.T@`4\
MZ*H.0LAD8QD\*"L@&+5ZP,)ETC`;:"TTZ$857#I.*IV_P`W1JP<'P#(4C!S2
MVCL;,`>[$Z$;9#V*([Q@Q`#;<[JZJ@?0^0)HPX!6\,M!1+:$`0F5HSAO`0)O
M@:Y.^DO5^S(T`$5S>(T%LJ$P:*OJ&K9-+#,_^,0=K*I?`#[CBKZT9*\,.[Q"
MP,%8.P/U<JM"Z$4,F,O0LA&0P`9:Z\OMW$&G4[M+Z((=J(<-:,-T-`=U2BC!
M^3PM4["*((A75#?02C:3P*W`LR&M$R%&7++76?^!%:@CYXM$VF0";RD$W#('
MB0`!5GLM<5L!LTO/T(I$T-(ZN4I/)//%`S.K.'2P(5.W#:B8+V`[51,C5_+.
M`KB!'?!'];K$%?"VB,/%Y#LO<;L;KQ$Y,IBX3PC1@TO/[,0.GJ3(H(S`N1"-
M8E!)G2J&CA!*FX232/G),*6S+V6(G7H>Y+`*W"B?^,`=B2`+8Z!)P\"(_1.9
M%A,X*VV4G113/M53*[522PDI3Z,(6_D40_451#54$]"2\9G`J/HC<Y(Y?NM"
M,6H!V\Q$Z<RN#0B#,%BZ&_BJ7UC!9;J?_9K*89-!7P,K&*&P5$2^81NA]RF[
M&EJ";HDR.0S"010Y/U#_E0)X'>1K`Q*Q,UXP!BA;.V"3JAJ3)_*:H5XMS?6:
M3%6SS%0%NB_+)J`3GK^HU.=B+B`;-N!JHKYR,&K@Q!\%L>L<*#]`,N!JKA6J
MAW051$*TF2\0L#^J.<-3MR_`&;P,HB=(*]8#(DOPK"]X`G_"AB8S!Z-3-1O#
M!H33Q5<;MJ?+LKIL@1T`+EMB/(2:2C^0T%X5%TXD`Y6ZCH&"5U\3H4X:JPB3
M(S+R@5/C3\=CU^240HG`#A/,L*H;"F#U@RX0O`;%V`CCK1]+KS-@HS]2PR=Y
M"/(*+U>R3<$B`[<"11'"!NPLLX5BS=NT,5)DI3]:`=Q*,E!R@!JZA!5@S88#
M_T/DHSRIE2MS.$AVM51?DP<\\C%Q,SL:U,D(-$"\70B<K!(Q18[/J)*7`LJ+
MX%/ET8@UR4F96DF]W1V[V).>4A-,@3.7D-/"N%(J$)G+XXB#.,FM&+\I[=.!
M^5,]]0P[PPN*I!2%`UI#6MW/<D_KRQ(FO<N[-#)U92_^NBHTJ$OA2Z]D\R%+
M-37!*X`R4X0%.J\P@Y^!+3,93-=IO(V#P(8SE$L',X<LE,QEND3R',9!M+TO
M8Z4NL('4"IC:*(!1(P-+\*,66`+II$+#P@<?Z"I\PX-HQ;>IK*IY<JTE(,_>
MY(V#5+$M7#J^!#XL4TXTTHVW_$6*[:N'FHB/X\-1O?\$&>-:<\"XLGJUH5&)
M?I0J&8/@U(/86R,CV=,XN4K++4!(&P`"Z)0G/WC>=,`P#7.FX'"(J].C)(1>
M]KK,&\"W#6BK5MPX_)U*MD6HPAM0F=J?&4XOJC4!E(TQ#D;'DE6G')4QV@4K
M`6D%=S+0TUP*!6D%(,"O<+U?XPTS%;.]Q@,SV17;LWN0D6@%,M@!4CTHQ",#
M;M,Z:M@?#BFS5;@!M:LY#.!077P@V:VNQ</1;@NV>YHX7_O0M8LY9U*0@6(9
MQQM5V5V!5@@M/P`"_8+C0D#0NZ"SSQU4X`FTE6P3*\@*-=T=EA@J4`-)*G6_
ME7PIL3C3S943D<J*@%$;W%G_!LK]A[`HP\T]DY'T4[P57&$.7=+],P1LE*)4
MN!)J9A2+'Y9M9+7@A5^(HPU(A\CS.+M;M4F--MTEHQWP-?JIJR`B@S;<++LK
M7C1P`#)XN#9T/8Y+50%ZWOAR+Q%*!VKP(7#5O)?5N(U=NG_L'](RMLA$+H?`
M#6:6JJ$;RQ8(P66-`&@#0X2B3`M2-R2NKZNLHQ5ND)MI1'9&SFZ3.JLLO,)I
M@U\@`[R\!-Q#KH>0VNQJ`7PX-26TO0D^8A&J"'>;U\U[.3_@@-CTX?.:KA:H
MN=!"*U[+,B#$MQ6C`K7"AE8"1?IQC8<&@CI*-A.85#*X`!R;H1Y&3N0SY]ZR
MH22D_\:V()#BVL4E;,I"2`)F/;MT>#AB+-G[`@(RB+RA@SGDPCM8N&*;99DS
MP!2ZT%F>!3HRB-'D#(,SP(>"++RAE2H'.#6Z"[+7(`JI9;RQ726N/CNW"E+]
M$0H4N@&V-JLRF^`7DSW::SF[*[QW<H`*927?6[5+[%9S:(WG-3''QN:/2\W7
M+,O\U"T0I#"#6`:>%-Q%*V7>8,#!G9KN8[\Q%<!/(PKAUE.&*,F9T@A;;I#@
MB6X$;`L3P(Y=)L/<N;R%L--(Z]P]'<!/SMM,LPBP"UWK60V#C6SFF^_<1K+B
M<(I'&K4O4$8,5(2JY*\+0&D0K@<0^+;8`V'*0D'10X.DZ__B'``"D0.NAD8R
MBW*(4<*PLTVVNLRP"^2US")/'Y8JY)M+TK)4&U"$R8Z(<YLX>,NL`I`K[3W/
M$'<M<*U,^E7@IXN`YXJX1R.02TPW,DK>="CQ2["[A&F%5OF%'J4ADGZ-S`.!
M=."XK-O!OLK-"D;B6.K'"$A$?$R'!\W?,$!9?NHK:C!GLB*C$8LKD+T.\<RP
MB&..C)AA4^W.7OLVM7,M4[($9\L!X=6Z)_BKKL.`9\*[@S@#7.7%TADE[$W&
M)[@ZZ+O1&MIO1=S*@VX#=N#*:+2!4[&PA%#RP;:Q&`5,PK,[V\8@)%Q,WAD/
M1>2`-AQSW7)7=O,(`,KC%H4VN;K_7Q#$Q\++O?<!Q6FKH<SRM=,KJVN>EBK:
M1&,`QS-02(5--F\C/!DZ/@Q0&)PH;\(=9K-(%%*VR?5COY]D"RJUTJS("IUR
MBI(<B)S@")6L=C'1"(+X28]J"42C7"I8!A-XC(W('9<076,F;FSG4P2\%"HM
MYMH@U\#$QQ-O9+B`A6IN5SA,A^E%L@]%@ZQK+<?T-6Q@S=J2,1GZK&A;0?ZR
MA"WDM\V+-C@RMH+T@^!`(/AJU1,7H>K]-M9TK1LXPO7Z2Z*V@=+<@2HGDC:X
M-^.5,;VB>!O(S=:+-C_0:76C:&BLN3NZKQE$T-B9K%&-L3;<@*F\1@S;K&1K
M&33`K=8:_T\RP(96@*-LB^?7@^R/E7.0PPX.\;RRVG&(A[D^#G5A-\$'/P-%
MB,&ZLGI2E2J(MY&#_+'0,@@2*8`KY\1.V@*+CE:2CP!W3'H:#U)5VP$L"ZUG
M$D#>..N'U8WOFD?8/.+35"<(CS@8#+*6\HUG-+:!+3"44ZM;=,'!&](OG\HO
MEJMO5+>:*SR(]X,51H>D$);DG/)IRT$SNH`5!"+H\@-8J0<3D"?0;KTFR\[8
MVX#=S\XFRT?"UW06SX%_%*TQFE"$:P,?J(=/'?QJ.GT8'WYILX0LBH`-:`41
M4BD\\5OT'ER,V(C^&US4``@0QHP)7`;"2JY<"!6"`%&,8$)8"/^M-"RV+&$N
M6+F*@3`XT`K%@0:7331FA>,RC@L1/APH\*"Q?S)GTJPI<.!`$U1,F$R(4*/"
MC$&%+M18=*A1H@ZMP#+XTZ=0A;"FRON%01&&K%JW8OCU:]54C5/9+<F1X].E
M>AO2KL!:J.R2=#9L^/G2PFR]5C;.?(J`I@"9P&0VM&AQR8\-'VARM-B@%LW=
M3V0PV"CTR>R22YHUMRKTI2QF'X5L8"#\R<=<&P661#![YLDO/X7NMEA2;\6*
MRRWJD<8&<FJ;2X4O"2;C8'&+,[_2%6A=2.X3OCG\XIE;`/FEM9#/%GIBXU=#
MIKQ`X#$+Y(;@&Y?15+=Q0_C9)/7J+8'_G.X)&1\M(GRR7>_28LI9%H%A:ZU5
M#QGFM+*"6?U=DMDE>)QQQA>MH;&$@9<\]TLA9A%GPQ.SG>4#&;_4<U<]9PBV
MFEDW+->&BI=]4@!IK;1A3`$`-GB)#^F8<T-9:)`Q%QEVM;;!D-$AA\9M*VR'
MQA-=-01"1ARU`8(/9GU1XB^PM,%B#C>8`UM^9I'XW1*195=/$I>LX`<[5V9D
M!8S(?=+F@_7@8<X*]2S&V&TEWH#9D!B8@PVBZ9BP7VW_'7A&.C>&A\VB:%SR
MA0\K?+'>"D2FV0):\]6'QH2?718!AH7XD4Z'9]F6'8\WP);F7W,]X>1T.2"V
M%Q`[S@<@&B;8_T`&;1@F<:"+9[1@Z1>X;9H#&BL\\00[L'!$Y4T=41D44$Q%
M]!-(QEATT+<M40&20U0:I1)!!F%TDK8@^=2000=QA)-+5%*$4KQ*>23NOB#4
M-#!-(1FS$Q54$/04MU!U&Q7#$4?%43%,J>0PQAE-M4I5OU3UL<<A4U/M5#_!
M@LUV9JEL&&E`^B575B[GL$."K2*8F@VXHG%#8FBTQAACGVS0*666J7QT"V1<
M=S2TJ&%PXB>;D(:!'_JU.*8YZ?BPA&Z??%+8$C3^@LV54QFS&!JHI5:D62ND
MPYQ9SSUASB]VG=6I#7GXO/*R0T?YBSD-B67")7%[9ZMPC?T"VPU^FO]5F*M1
M1O?%GX6!/:31N:Y\ACED,/CST4"4RK3*)/XR:`Y+A#'7+X1!^^9BG^!-Y!=:
M^D$-V6U$)K:7QG3!]+*3O0=MH:=?<N1DBQ=03]>0@?K%W[`LU9$5O"PXW9;+
M>5E(X6'2W7F6.9"(P1-IDIY#7EV&-Q4(>S/]"?3P:;Z!<H.B>H8-\F`35ALW
M[$?Z)PJ!J"F!`!9G,!^HO+:L%0SI.X5@7H,BLX%6G.%/1W.;.3H$.I5IJ"MI
MFA%I?D&&$YEE,C9(1^.^QIC(W$Q9FEM9=\X`'Z]];8')*QGU;N*2BCWL81#C
M5S$D0I%_Z<M>$DG7,@B2+H:,1%T,&1</-W+_,'RARR#\`E?`K*BM)!*LB^C*
MR4>\=90Q1@0I9BS*2APBD6N1<4Y0T5A8XBA'7H1E(1K#QA?4XICY.&8%E*%0
M/7ID`ZR0X8&7*,"J'KB!&\`,-F?PP:5X5@`@I,4Q?905B'Y!H0U84BWS0>$7
M.KF!+XPF9_4@)?E^H8@;=&$M"3('+%D5R@=AZ`L%4,[8*)(+7K#R4O@S!VED
MDQ9$&F^1L,P:(+_`,_>$<C[S:=8RGQ"I-D@$%NPP03-W!1M3!C(=5M'D"C:P
MA'&>LA#`))_G_C/.M!3B%\,"@J,\J9;)R.,]GMSC(1-Y(%$^!P-D8$NA]N))
M/`SFE/BS%:O40J)#_R'*F3?(2K7.D"-1?@$Q^1EEH?R9(SV186Y7N4$XQYD9
M(*S@H8>:RKT*.)5"K*6?93L#'ESI%6R`@'L:DIP/'(7/#12`;JN@B$I'F!W'
MK(F4.=M!)>?#0!&F9:'[BZ,,_Z-'3RKG4/627@%F2<MZ/(<TDCM#GT1:3FGF
MT4#S,6<Z9"A*M:P`?T_(HS)9E\%6UL,/43+416D926"FXYXZK<=#92G.!UT"
M"*J:2^`T0B^3X,LI922C1#*B1*=`\2#NRF*ZJ-`1E/"+7$&A5WA^(I"=$*1=
M4]+B4(88'H;<I(L$.XC!3%!`C+CQ6QB)[%/:F!2%+"Q<NC6C5*12S>$RQ?\H
M8I$*1;!!&9PQ=[FIZ8I5F'NXYV:-;LP%T753XQ6Z.3>[WLT*SF")#7-T-VMD
M`^9WTA$8G`%.>BI=A7.IYA6O?'=NV/"#.W$&WN]*Z2!B@45TY](5<ZPB'<[]
MVW(5$9AT6`)$T`4<9=2[*OUZ=VJD\>YTN_O<*.D7<`'.[C>I,:;EPI(:J["*
M=U*)#5Y@X\/ZC2_=`(=>$,$RNHJ09F"F"[BRA:2X[,AO"&G:!J\<;L#CC2_Y
M-/S<KTC/&%,9+\X:3.'LDN^YZ:`&'<,"Y>S&F'T@:$,K*+.<'%,7O\[U`QD8
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M.(3?\8,?8)&U#[=[W93A\+3GYN\VV^"<'KXKSJ)4XVF+MT19`;E7O>(EB7]O
M;.3^,?G<3<=5T`WEAMJX_X?)UF(9FT,>8(9YFY<K)?<J!!W^A<4J6MP5/U#S
MRR*^^2J0C8V**V*['`]A5]S+%'6CF#+GO##&KQUC=QIJMEM7^M>3K#T<%M#,
MJ9&<5^($@A9CI>%D/^;%Q;[M`QO[F]S],S96H8BIX2[PR_EWN\U1;`'/[:[+
M<3'`(T7'33?D8!XA=#&@XFKDONLF)GC(JA6B$J?DRR2D5IB\++;%6-<KB5/4
M(>BAHJV.^&2-QN")J6MB!720)!=4LB*O<:WKX6N^\^=*",&#HFM>;][5S2\^
M0R`"[1.O`KZ"KW[UYSNVL$1]NXA"%,>>6D!RIR/IX[TOO7=>8"]]^63^]KZ/
ML/^A",%[A1H1'_)\Y?YE$.!W;`0DM_8M!^X(#KQLC/>!0+J]UWQ17[8AX/3%
M'35X1?797XNE@P$5T$F8Q%3P0M2=&#N(W\FL2M*UG_N-#<2-($'P`NZ,W2I$
M'*)T3(&=WTR=S*'4WWU%X'V!@/=AW]@@"KF=F`46T-S-ES?A3M))RI.1`3;@
MCO0@70\V70%]X'A=V8DQE,"5'TTU1.`QW1*ZE^&-C7E57Q".Q!%QA/148-FX
M%P"235CP`KE]7^!%V_E%X')$7'BD5(O16XQ%VXE]1;11@S?Y(1PVX$$(#OKU
M(;VUEYRPULD$HE?<#ANZ5PBJTJ'X0?5A@Q+:H`3N3Z+_\.#;?!_-?5_9!%X?
MDLV7J6"T?84@>DE5K"`%XI<Y>`D[G!A6+*`IUIKK#<2G45JV+)\OBMX4R=;P
M[=[":-:X6($QY&*A,5%%,,5$@`#OD<M+6`1.)$4&HH0U3LE`Y%[!*%H:H9KS
MO='S_>)G>805.!;SB6,ZIJ.N;1:Z%-#^@$6UL)@<P4*6Q1')2$\;[&,<`=4^
MDJ![@8"-;"#;\2.+5<L^4E,;J"`]7DD:AD7EI9N7$5`4FMC^7`D(G(OT+`,^
MLH_"3(DU:9F7A<1#9MG^#.0^`E5H@5X</54=-40:JN3)4!/[421P;,S^V"1P
M@!E-2N).ZN.774E#G@Q"7@E!_T`D2$(D38;'_ZF43P)':3FEC?2D&D[DE"2D
M,PJ./0Z<5M(+.+X$"+BA0C81/[)?<7F)43H9<.P?4L*62EPE/SY;V9#,/P*D
M$-+D.2Y,$Z+E/@YD&68E`<'"R``E!E[+R:P<6AX$/\J=/>XD2()%7?+/^CP9
M028E-06>EY7-4K)/3Q90TE5?/L++%^'$3A2$PA!$YI%C&NFB0%3,4'0$.B"C
MMK`+:::+O?!+:FW6Q61@:2TCO%B1O#!C2E@!-\[$;+HF0J"C:JKC+SI$Q;Q$
M."ZG\JDC.VZ$8W5$/6:G''%+/UX)4*V$>[D$G0@.`8E10!Y=6VJE5:(G,N;+
M^ISCE/^<I7NYGFAN9WO>A!P5%P%J5E)J#$6P3[WX'DDPA5[:YYR4I^_YEU9:
M0;J!A&$"%42Z)]N%%GEVY?HL*(8JD7_!RV1BX)3XWD<<T42H!/O@Q/HDZ(7^
MQFH]!&Q]Z'=ZF8:*WFPZ*+;`5DAXJ(>:X1%I*(Z^YQV2BVQFI7XZY8WZ*%/Z
M7L7LRQ%=J#0N!3`:G84")X3^YXYNG846EVS&YY+ZJ+?\UU3(*&`BI>L%YDAJ
M778^&F\F#$_T9C)*)[J,BVEYEFAF9&7ARP[-'G`J'V@!*8C>:9**6K?,IKX4
MITST1(\%A7)2)_$QWV6UYCK^HINJ(W1FX'1&EJ6"BZ**Q6__+L5*F*@[)FA*
M\&D5A=:\F".X%,1JW:@N]D2I$IP8+5JZI*;FZ1!$="DNIMI(R"JJ_J944`Q"
MB`MR,J='P%;T/:.A#E$0B:;!A$NR(B,;(9]32`3`*`1\XB)LB>=F'5&];*BV
M,%%J!@QK@00R4@%O2>.XP);M&:LS*JNR\N*@B2NH4>MU.H6XIL0:J5%[!E&(
MRJ:JW2L/!>B;7FN+#H2V0FN\"%&T-J,0K:1#,(0P)I]J&8/R5:NU8&<5)6GR
M]2+!241*]);F[=8S-BIRZE`2Z8M1T"N)8NJ\I*8.81Y./*J,`F=*)-%S6E')
M7DO'X@MGO1ZQ`B-*:)ZY7&MG<>1$_YRCT:5$4!#J/TALN&C6:D;JHRZ,%#T?
MS$YGU=8:K8$HU4+MHFZ1ODA1,F8D2406O["J@XJ+N^BIN!AJ0C0125#/[JUI
ML.[>I@'M%)'A\YFH"82CC,X:JAIJ1IXFP%ACK2;1<NY+;V7D,Q[?OF1@K='>
M#EF!,%(KVB8IP(0+K=&>WV*MP<"$U#IK$D5?LSIMX_:+HK5$!C(NOUQ$!AI%
MH>W>V4)KQ8AG,<@6M3Y$[+W$$S&MDR:N2?#>P@P$<I86ZW8K2)#N6^(KL-X$
M;X[HZOTL;_6>JSZ$P;;$<TYN!B8?Q:Q1$MUKN`QL>P:O[9;KYT)?.QJJU#[$
MYPE:.U*O0_]<1*XQ$=;R!*6UBTL\*NXNA4:@IHE2HTEHD0GD(C(:S.UY%C-B
MI]HZ1)NF6FG-*MIBH$(H+<$90VQ"8^H50VQRK3@RKJUI\-6*H[5,ZT!\,,P.
MWVD5XEO*K>Q9D=E6[$C8K:-F9=A206R&L$O4JD_@+M,>*/V.L"]NUNL-(].&
M:FD]HVP%\#AF;?*QX]JBP^M:!.B9Z#7^ZMYFX.=];I8>C']1C*(E(]-.JZ=E
MKDXD8VHVA0*_KJ?!YDW4;&J*!&_I1`<+Z+U\;F\Z:V^A;Z=1&A70[)P,L$AD
M'C"N+?/*INA-[NWMD$^$[=HJW[DH$;8B[;@6XB''\6P*;V2M+6/_X:[C]BE3
M+(-.%$.G%:OP2F.N-C&S.NRUFL#G.:FS.C'?-B?2SEHQ_&PAT$NNF6C\JFWT
M*8SKI>;GQ:]JV:N>&H0)Q.8HFYY+K.E2G*;@CFRNUM[.GFV:?JUP?JVU*.U)
M[/&(LJUC>?``?Y$W6VVDMB:!BJJBGG,NLP0+T]I]]LOM>F,:S9ZN+4.NXA:I
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MMDCLO'RD5,]+3`^%12AM]+:Q<E+,!UN,R&[M.7LV.\*M+`=G.(NSPTRS0%O6
M9E'S$`&?\\+SG+#H<":R%HMG])FC3V0@/;LF`_MF;B^%2$`R\O%06&?O</;$
M915?O#BN:F:DW*[M'"L:D%JOP3PG&0,II<F6UY):Q_)0-MM+0;!6#`N$W/;T
M'-_+\"X,=:?4=/^3E@+C+JD=H^T!C!/3:U0ZX^U1`12AYDVTWF-+\N4"494<
M,MHZ,6/1,[T4[4CO]&]6-2C3+Q!O$6,1:Q+%)C4NA6P/+T^T'@6/A$L#LER3
MM$"'+7*Z7DJ,"^M.9\B>,>TV]ETOZDJ`GDK`2TIE[SRCQ"L/T0U;UCW;]#J;
M*&KV<M:JGC<J7V`##`:/:L_^)C8CZ8S.<NI1SP<?X[[P]BNC\XL[L.7.+98S
M9Y?GI4MTLZB9-&@Y'XK/+>4EZ_NNJJSRYFQ3:^7A:R[0K.5%IT'O-`([Z$7,
M.%+G]&KQFJ_V&*3:Z4<$-DE8K^^%A'Z';Q'1-<G>*>J1VHC2IP[=;A+_:1%.
MF/BX'KH6LT2^=JZX)B-PTFJAB^?-GL2RMF=LBMZP\J87`PQ]DMH3N1ZNPKDY
MSC*ASZXQ,F^BK_?K@M:ACZE44S>=.NB@N8M(3'J\^"].S*ZDB<3"2O5HC>TL
MSZB`FM8^=[,X_G.SRRA_'ZXZ.G0+@\11]PM061%N:=X7V6S+-ONF31&)_\OK
MQBRI,M&8ZKD:6SF_-#F\^+#18C?;`O.C36UTFG:65Z>S@G,ZFZ_!XV]K3A%R
M6G7#*OARQ_9JIUZ_MPN4UZ_'GBTYOXM1I^:YTB^K=;!(0"QO<2R(E^RP)RD(
M5_FO.NG$@IX""UI@6U;8VG%B8W#.LWI\I^["_U!ZIU.C,2/1;"-NIJ_TIX7O
M/Z/$`^<LNLIVQYZ$$PM:MJST<*(J%)M65N:L>O<O\]Y\O\^L1^3IZN;\6'>$
M-OOZ%OT+<N8O[39[=7.$,-Y+J'KXQ,_YHGU]IP][W+?+T4;N1A*VO'3L^\[H
M#XO$R2N[E%9G;A[WDJ=:Q82JT>:IB@^%WN]L,S?VYB<V,_MSA@]S8W,J+UO$
MS+>+TK*N1:-O,E*K@0^C.`:XH:8[C!<?\6VM)L]YUB)\PQ=\.+KC,IRFE1>U
M\<8L]1HY54_LP]_QR>]P]'W\1$1C3[QO[4+GQ/:>(E?U`">HJX6M"12"Z1'M
MY7]O]#I?2I=$I35_D/_C1`"_,49/-T&P[[3WL@!3\"$3[4<>*K,>\AH!A`EC
M((P5!%&L8+%E!1E:@;706"XK`ZU(1%C01,6)5`8N+';1F!6"&(M9$6D"A)6/
MRR3F6D;0!+J*,$$L7*8P(41C`DO"XID+H4:5RS@N@Z52(,%ERR8F;&J,8\6&
MN8R5E#AQF4"-#"$6&QF2X<Z2$TT4@Z70JA5T"U%:W#ERI4&<.RD6TRHRY$R%
M"UM.1/@Q),%B+:\>9)N2:EJ"0`<2UN@X5U_&55]*ELH2K[&U!QV:M!Q98TV%
M`AD&+<@QZ<VOI"-6]-K1K$:%FRLNQ<LQ)2R+IJW\\_T;>/!E,J^:#ASX9E7_
MR9:IR`[Y^7%%R]&74W=K5;-TZML_=^=>$T3DL"^E2P1_L^]KA"V/(GS)LB_&
MD`A3NE_OV<I"@BD?>VPNTBBB:B(N-)9NPNLOB63*+RT%32A@@4(&:@TZB:IR
MB"C/J*HJI.'\(E`LE:C@R<.I)@K/H9UXPLJK`W5;T2Z4<B**I;.4<\B$'`<R
M[2:KLJ+BJ)UPX]`@B3R,#`0=P4J.LZ.R,@FFYJI2*J_76E*QK/<$&RN7NWZL
M:4JG3&KN*BHD#)-%Q*!Z3DF"FD+OQ-"4]`N\L9H:C*BDPBS(O,JDTK'%@^:;
MZ2X5E7KMQF+(-&G-`RTT2:2Q^)0./"LXHBA."_E;_TR[P;CK3*6.*'PL.[($
MJ_"Q]!@B[<!53P,0(=*H2.E"8Y*3;#]'"262P!:#RB6X8('+[SF3LD),1-68
MJC`H*(M%%3*AH.T+04:1M4X[:#^5["5)2PJ4J?XVPZPX+=-[;U2(0"BJI8M^
MI;0@OAX3#$VJJ'AIU/MJ"E4T1H'R*KT'(2D@2^ZHO9"Q4*-*DC^_G'V*,[PR
M8DS2;H6$*3;ZQFRQ()5<NZM9A5)"QX1+1_3,S0T%W=&S8T.UJED5!S(!LSA#
M?8I+2ZGXMM@+U\UQ782;W;(AJX(V%K&_1!HQK-@Z=LDPCG(.L44+PQT1-Y1,
MJMJPD0[4Z*=?159+R(N,&O]SZY#0*6A!!3O.5&GS8*/NW85J.\@N9STE[U&W
M9F)(VU`YC*ZVTNZ*EMDUY9I05J9$/8U#QVWEM##*D`6*+8H64VI?B83]?$/T
MK/9TRLZW,];'C[9-5</5H4/+0CM!HU;;ZJZRK/-^M_[K<@#!H]8^3_O4'03#
M+A;J-0\UFF5`>8NS=?*2XAT0O];\=*^RO/B6LX!"[CT(58W(RPP\IR0Z2[3&
MFM(0)"B7LM"@*)\>2M"T";R-/WV[PJAD%&^^4$31:0BCQ@(7F)#&4PP2#6.6
M5;A)P8Y8JJ'+I(8"&">MI25@NM'7-+@1!(:&0_R!"GZ>XCY/&1`JI)&-LGAV
M.77_0<DK*K$/1J0&*=YISU;Q28B1QI*@M"V0<`#,%6#2XAXCY>]K?R&/KE"%
MD_OTA2"7TD^#5E>3A7S/8I#SR%>*LA20<(1`??)B>HI7&F/%2R%]^9RPNA5#
MUW0+CIR9#N8V%:[:N<YUPY$4?T"#+3S6;H$?Z9W(MF>1X3`Q/Y5ZC,@HH[HD
MH;%3C22AV:CXN)2(1DM;N1NDBG?(YZ0Q.C&ZU_QF1[>OE8PI=N$C\FSR+;YU
MRV&^VTBM6(4L1A:P@9@<7TT8LS"F>:1`M,E4G+SRK1C:Y4)V*0J7]E*IL>5"
M-%8<7@EG&:_"9-)71UQ)?7@)$HE<:G*06DI5]OC&E"21_S.*RHOBMH>5XMVM
MAW'<6KB@0D\I(@MZ::P?YEZR+Y7P,C]\(Z0<^Y._";:3?C)<EB*+@LG>36<H
M+%,5TT[RK&W=$HX084WR)K@C,`GD4LBS''Y6(L^EX28Z:PQ6:\!4/8-\;8Z*
M!.(=:;H=P:2-A*6\74T_A1:DX>>:2F-EO^*CNVMR!7Z40=@/$>D>`);K--KD
M4%I2641&:JZ!M[,40Q8%+2M>!&\6O:9@1"BHM`"0/O%BDJV$2C],83*&T'24
MK<9)3BT!4RKV&=U]Q@:@Y"P%3+F"TWEP2<2MQ--K![$BF(HXU7FVJ#.Z8BM=
M5T;8K1S*:D1-Y#PUB#=\Q>V?-_\)5YV*Y</R`19=AW+.37UGMY^&MD\]08O=
M+.-3%<UJ.T*-F&J>$C^8&BQ4@`6A3F)5B(FMCJT'*A]KWH.02Z4&40<]8295
M150O9BYG(%!I<(I%%#L%12%`91U:Q?I'\ZIJ++2MZ1UM.CY,?6:@T=%/N%:(
M+\DHBB=*,=*$@&JV:^%E/^?"2%X):!NJ;/(J'G$*00,V,^%]JG`9(4M>7O>2
M>[EFA"0%(%T4]APW[<PY7G1@6M8WIKJ(B4AG;6E2Y<O2J-BK2I,K+;Z2]K:^
MX)8L/+N7D=9"D>L`$"("O,E1:JA.@X:W)3+R4SUO9Z595F1$-;9)?3GEKNC\
M9R,L<2[_9I0:FSM]DBC/N1)]$>;:V-&VQ5/ZR78\$J0:WPN96:$C'M.:RN@U
MI1`%*,`!RAL?G`@%<@A$5,D:LI3,+7-'D]6J39BX)K-ET!C;!4['.L8CP(CW
M8"<<U7DY?1VI4+C3G89E8C#-RL&I:HRA64NS]@L]FJ%ZJ8+[57%&247GCA1!
M;HIQ*!T<*N@DZ5YE"9^%:BBD;<7N;0[S\S<7]VI(2<F6'2&.B-NEG-,PY9'"
MH^M3$[(HYT44?JUZ,:/X>Q7'OHQ:$VN?E:]3%AN&L'`)W-`9<0MLH>AGJ7#.
M2U.H)2^&T.K"UTF92%8=XP<KRH'-@0L($V21LFRPJ\HF8&T6_P5@.&4P1^HD
M973TZ[!8I15H,AP5=(*+3!]NM1A#6%>IZ?C>"'.D.8"E2Y0M5<VR*,4*J`1H
MY7SH%KI8+;B2_@U9Z"N@O62+<%AV$^O6:UZAXE:GH:X=.2?N.E_9L3;C:G&_
M@O(S"LH-M)-A=>$@TF^F+=6)4[H9\-9$J].)#*14M(RM&`7BO)%<4RA&UG^\
MBQ2ZQWIG=#<DAZ9)E7!ER.\)S?M3@_*?A&$N+Q?>,EY6>&H"LC5(/233#JV,
M]@F1"WO3EN/;UF:LJ("VF35+2,\^2?><Z[@D`V=1L?S2K=C]C=P\LROH)_1=
MZ,$'KT@&=`]O]++MX<0$A4COR,7%9?]'TVQ5R_PVR6/%80'F4.+M&J?LU`*1
M[ZD9(\DIR7.EE!S(-2CMH:SKHM2)$*'[)O>C&U^%,>/3IM\_G+&4.J=#YOK`
MS0:1+"L^\"4[7*+ML"Z@PNDJW@1\G*/'M`J9XD4V]L(I/H):D`*<2BV:H$_N
MMB(FZBY<>BZWQ@D]]D)IOH)8..(L4FV&%F2&'JLN($(U2N:QQ*>NED^HE(@S
MIL?**,_G5"N11&RV&J.N\@.EL&*UQ*23^.JO=$]Z[D*S<,(C("]D%*P^(*F&
MUBZB@'!ROB9R="^55D1W^$4)(2D(GVA>'&4*SZA?SN-2B*^G<BA/ZJFA".U`
ME*>)4B@JU"__F9X*0"QO>+QHLFCH4*(O(32(--R-YV+-/?9%:>2C&-[O'UR#
ML.J$6<8'+8[B_OAOP[)J_^X(=NR/<*C/(QI(H5CFWAIE*-"ED.)"5P3GMXA%
M`;>F9'*DXM"BGAB%S12G`P5IJ]AJ.U[JD&")12YJ+K9&OX#IWX"QKZ!&%2-J
MEX00760L!`7J(K)0*;R0&95%QI;/.10G/'"B<[;O9?QKC""K-L+,];"'F^S&
M5QKQZ&1)Y!R-W/`*C7PE&WWJZ`:O*!XK&I6K1VQ"D23.^UQO]5RID-1OM(1F
M*7J,8TK"M=PC#E]#("I2BM[BNAXJS3[(,@`+:F`&7RXNN(3(U;AB_[E@SG+D
MXPVUK!17Z99B0R?6I#?>[]T2(KP^A7A^:Q/G2#;2QICZ[!-[ZFO&A_\<4CO2
M!Z8,$-&(3ZCZ))_0BZU@K8>B).-$*LQ\C6[B)<-P)PSSZ?I,KS5\JABI[QBW
MYF5HT05]YD@F+`?/3752;<TPI:WHPA[M`QF)Q>=JT/!Z2.<.)"X*B&=LR-U@
MY9_.BB?6T2TA4G7NY/;0K</J$A@G`G7.*"0>8J[HR^181HEZ*#!-8FWJSQAF
MP48,DR&FS2ME".]8J\WF\3"YA!C]D%H*$:1&Y##'(^QX#20D$E=<2S2D4'6@
MZA6A`C5@0QU9A0([BDE"\N"`<"LN<ADDL?^[**.=+I"\6&X4S8L/A<K,3@?O
MKI-V6,E;L+/?K(B^KD-70,+ZW$+$K)(198S7@"E#8F7<S$TF+:HY;441>:WN
M',L\W.TU2&K):`^^OO#9#`HS:4LBGTR5T@:OB(7X&@8)'R54)F:':H_VY"5"
M.8O<((5F!.=N@,EO?LB&Q,8VLLPD!O,O`$@>FP52JG-"*^(N+.60`*V!8DUW
MT$IK+L*0=/,LY:IF+JV"QL0_CRNM(&78E,W,Y/,MC/1F@HLGE6CFSDZ#$&X?
M)XFM>`:O,BUM[A%`6:LY945P9FZRH@@UFJ(F6A-`^:L_4J@U(NW][(:M9$^K
MSC*`<LI.I44H[O3_`F6D0]=G3O_43@$53X5"=T!,3P,5J/9G`2/H#N=C@O*4
M/O"00=L3>B!E:T9I#W4"\1*,3;_&2B%Q3N\CQ7#4(O'4B)!B4!?U]TIB,&'B
M3\YIPUZ*,F+T!96P4#8OQO*I*E"I1;U21<7D`T_5(![N)FCPQXZ#^'`UE?X#
M,*"'0P;S9>C.M9#B"O_#]2S%74*B?[;"5Q,H%]6I@JQFA+*$!MTG.0)J;_:P
MAA!O2K426NWBY/#T`@T5\4!B1?+4'?U0O%JIHT9$J#)"D6Y'P7QO+4[F*ZOO
MM_()`9'OPJ2$T&@&YQ*Q.6)N30YGGBJ5/<5$$K/LSP2U+4DH5>]4O`;U_]G0
MB$@L55!3-F0'-3*Q;`%5-D^AZEW44R93$&,KYUSQ0U-%RO),3T?(!B*AQR4%
MHBM>ED&IH!\A,)7.*?`DI60NS$[E4L($U2]2B/B2@R-F(5\QHV2^!6A4U&SV
M,(":AEG7:0\[RO<^SC.4:H2`$8!H+N?TI'J(:Y[,#UW.$IEH$26@-KA(AL+@
M%(TDS"#[5$@B\\N@E6W!0I"PSV#CMBK8CZZR4(FZ:%(NY$<8)>/`EEAC%F5I
MU.$HRPZI2$3V3:M>5B+/+MAXQHDF*469E$',AX0:94D/BZX.QE9DXE#(;X90
M0XJ>HA9WC$'7`E*]\B\BD29GY3U<%[UP:F2IUO]HY]14F08WKO([5Q9Z5_;>
M7-#`E/=0[]0WK930^$7\SO/L2"Q,20RL=`78FH:3O)(^\?,ZNXYHS1>\&G7*
M%.6KH'<6R(O$H!=+#*2&1F19MW15;4(KGT='C"0J+O?USF@N5D93.35'[,S=
M.$RHB*1MQ\-320:5#/!"_+5)I=!D=;4U)$8@6`R9S,HG-8.M1NFOS"U'_#-$
M.&Q:(X?2-$/!+)6#+5?RRO5M9N/?]F<-;;9-L6]1(45X)^PS9;!A%C!G0-:)
M0^*7#`)=]>]Y0%3#L"]F.U6WR%'6#JD89B%,"6U*-"IT.81IYM?.&G2_VNHB
MH%.T?M-U5]$S7Y%S1?;_`J'7+6RQ-)+-:+NW=+MW*#2T>0'YCJWH6I726>,)
MC",*:;/46!B-/>TD+"AJ>;B"F>B0=&WH0.XI=N<IW(1W/H1ODK3QB;5*9IQ5
ME<U&?$:DEV(L9V.%:#%9K9+MXZ0':@U8\YB+KA0,L,1X=!UG#W.S194$).H*
M3,CL]`;HF-,&4%I)4W4G5F!U'052;X7Q=OGUNV`$9`RXF-^0A(>1DE?DD2&R
MQVJTG%.LU"IH)/KQ+_O74J'X*^]%!CUSG>#DG^C*3B`5`9_':BM(ER_6."U5
M2)B&`M-8K2[B:7-"K9+XBE44`Z%39')&:7V$]NY87DGV>>F-C\/,N_[8>@LY
M_V0O.(RO,Z1!>H5]SU42"!=%JT,>&:+/UU*=ROPF]%X3K"O$R60\M5R>`HL=
MQE.U,F^:=%!O-!;]^32T(D:>$,N(F2ZNUJZX`FG!@B?P"P3$>"4D+T0PQUUP
M(O!H</+"+)Z*C">`>571,Q?%FBQ<<-UJ%BO81A9W%<1D4FUUC((32)?!Y%ZF
MFE7+XB/*>BAP@WGNM6I[)"Q^[JESSE!QN9,[U$AR>K^ZPHN+6BRR`D4#NG._
M<U$EDIR6"J]ZY(Q`6[.Y-TS-B"B6:?D@4</.;A#%-"01.NT^2&=M8D'$:2<V
M=EJ/F%%"$,NXDV0Y5X]%)-A&24=BE"<%.:1%"^CB.?^D\Q3"&,U`')70<F8N
M[E69?CJX'(^`#?;6V%@*(5<^:\8YR&UP.#E<<^]GWV50+WB3GXV"/]#1HF@^
M!-@(Q^-Y(M!K_54A$*V"5:AI?O6*WH8V/]BOQ3K`93'PR$N+)A3.U/9;5<BC
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M!/B,%I\G]P[U`DT/LN-9V"8,DD'ZB&F:DL%)PD18(.O=@),Y`FDP(T[[[&QC
MKXO[W@)/O".H*J#SS,UF,/TXLSLWHS$Z/J:Z.6)X/ND\CTF;9/E7D.<<WF=:
M9AR4_U')94*]M,(/?23M*$;D>BRTMHL@=7/#R]%`;2+$6'AI^IMP*CX*`!)6
M(`\"3Y!Q%(E]IGA``!;`XRA@P1C.X))<7"?V`Q:0/C<J*EX4[EI5\5*(?D):
MJD<56^F=_IV>/C.*GFV*?C\2--E261DQLVOW^^;^NR3V%V;,Y!CP'"^4F>X,
MVCU<V"<YE(QKY5=I\,`U%?NB,LK+8I1*CA9IZ<+&HVP;")D,=19\SUC0H1W$
M9]4V%RDTKVYA-AAS.NFRNEQ-58[[BRMB5T>8`IR@QP7]^G;W[1K)6'IHR,5=
M#6EI1B*=BKIS>":%SBJ`V0K`O,L@:*--FLS7F5N).X4<!?^81UN>V]PYL%KP
M\)BT+WZT$59RO[<F4TU$#E.,.17%D@-0LKR\O7^R.DR]ZS=H9Y3N6/125V`!
M"N!Q879_#V]G-"H/5@`/>%Y"VJ!X`"+/I7IG0(`P9J68%2O+J%"Q8B(/GCRP
M8!TT@6=%H8+&3"A,B&Y9+F/%EA4S1L4@GDM?VA14>'+AR64@,MI<`0)6Q(QY
M"N`I!**-,6,^??@H8,(8B(4D%S:T,I1*4H?+K,R"6G49PI-#07Q<9L)C0I-,
M36H-VU%LPJ;&S`XU^37I6(1K3:),VO'A7(5M2U)IFW!AV(]-&;I%V_$CUEQ:
MBYVD0E8A6"J2"Q>N>SF73*V;8;K_]4RWL=.F("(7T[P0M174JDL.;:J:X>N[
MIU-O%KTZM=;7"W4/-0$9*EJMD=L2!YS[)'"I=I4G-6'7[E_@N[FVA=W[;>%_
MW+M[_VY;L_*_QH<JUAQ;M?K>"3_&3FYVF?R[*,G:9O\>?>[]N?7GUGI5257=
MMY]^Z_&'('_BR:>55("AMIM]"QWTEF(-)64?(G/-1E9>?>TWFWM7S3844]HM
M<]5">D5VG&,=*J0?6$B1=Y]FL[`V%F%)E58(&FAL@<82HW1Q0QL@%(#&)2!0
M8Y`5L*Q6FDJ7H%'/#:O`4D@7/ZY@S!G&H+/4DU[11--:.=73PA9^&)F3%0?)
MU)&//RZQ_T0K?N"QQ(]!HN$#"/*8\,4H<E)99$4&P?B:?%+A]5%)KE7%56^N
ME9CC6G^9%!:-5@D8$U3(K65>67!"YMREV2$4G'+L<<6B9W_YA=A"LS@:*G&2
M)NI4<1:^=EYVD%HWWX"5>DI85;-$2-9ZRFY8&'JS2'6IA*MQ*M=5FNV&W(V@
M7D<2?:'.=)Q]N;CFH''C`??6;M!6^!JZBEEUG;C?S>M=;+/<A9=)?Q'87V\'
M)O>A@:.U15E"@\D5GA4:+IN>O_QV5I?#UCJ,7XW]^L<?7,*]JIACURFDH6P5
M_L<<22EN&-;`\;[;XLE8_2;9?#,5HV%3G<K6&&#WKI;B2.MZ-/]Q@:L"5LR.
M(.210PY4+M%"#@6T0D8A7ZR0SB_87(173B!\\4D$GWSQRR\^H)'T"F2X9$PA
M&%IA9$=*0154/4J;\XN7",%"&@@F;/!)"RV@L8,YZ>R00PM+;'#))6:;P_4G
M2=:39R'IM*VV4CHU!5:^C1XWVE=DD6J8QZ"O2REFGH,6^HA9=925@[C-]*$5
MH,?D8LR2(7P7<2G.UQ=C]O4UT[4HR@;CRVWA.**.>-&E6F&BS2P<2LTJB*"`
MH>Y^EUYM:8N57[$#^R[L,+E-'Z3$@5L\J`WU13"Z'IF7EX.P`Y>I;<=^O!^]
M^B^DH7-H%?VHBR6L7_MYE%[X4S3(A$K_>M"Q2FYZ9I5_$5`S(2/@3$0EM%P$
M38`APY'%4',_A3R+0QG#G\)$1BGQ4.=!<,I4`%F%$`U:I2&B`6&[LN*8EPT(
M<S&<RUG&)S$504<JLN*9$?4SD_?1I!`1:$$AGG"&3^3`!WZH6P$*D`X,I,,$
M/JA'/7Q0B%9@8Q5<*]PGGD`&N26M`&18Q0V^T(4DU&,%)FB%3O#P$XS<((TY
M6((-?E&(HQBC(F\!`3;\4`_'%>`)&'A"%Y0F.3*D(QU/:$/2+G&#)SSA!D2R
M8A?JT04PMNUCX.KAHW05NUFHI6CA*IJG&M(Q!0XH9\**G0))\I"^M*@WT"D=
M9'"#%945XY>`_[DE?'B#&;JH2(2<\=V`1B(SH<TL+0V4(0@+!A6]3#-[QG!9
M@I#(.V9>YR\!XDSWW(:56:4K1?V+UV80DQC9\4X^BE'G?%X)%@_%)"^(,<MT
MT/60<II0)OJC5\CNY9$#=,M]"+F*MAZ:L(<RAB3YU(NU$IBRWR@S@OQ[((YL
MQ#,;4=!?$NT=1(HAT1M9:V(RU!`$5TH@')G35L>)(?9P<RWMN&PX&\U+YD0"
M)X*=4":]K$K('B46^21SAK4[&2R3HA`JJ/2$FJ&-6D)6P=B`0*$3,D$!FOC$
M*.8@D^DH@-+(\(0>-;%I:,!#V'S0-RG>8`5H\)O3PK:"''RB;Y`$9/]<I9@'
M/Q#.CX7HVQ?.<"6(/(0:O^`:&@IA@S\"`9*3](,YGO#53Q3"$AB(K")L<`:Y
MM2"NE_`#+_"&,%9)%4[G$XQ>*MA`X4B&B$[QB$=$*+M(,:2!VAI)-PVF3:Z.
MACBHN=0Q/B(5]XSE&%5%V&!D\LN'".\U5[D03$]Z+6T.)62-4<M0APF=!(H0
M-;!%J<%2Q!R(T,\$N<%JO[AGO)"T12Q%VQV-H-J8"_'*-C7=S&^@6C3H1(AY
MJ\&6,2#D$-)5!3J92BYQ*BH7H)EGM0`KZ+QD=<-_4D=6(!3I"7OFT&$6+0\+
MX`$-:,"#%)NX"P]8PXE?K.(8RWC&-*XQC4__G&(<VWC'/*ZQCDVLXQ>C6,9"
M)G*154R#-3S@QT*FP9*-#.,8'QG))^X"BH-<9!S_&,A9]G&3A[SC!;SO.F=`
M6N'LN@$R_-&L:$A':`V7CC3^[0PV@"N56C`E.I%M!8R,\Q/*BH:OV>`&?4/#
M%WP0AG1\X:Q]6]PO\%8:=,#"#UQ;0@$BFX[)GGFT5%LT&NBL10Q@`)!->R(4
M;V".JX&`B,580).E'&4@PSK',*XRK&,]Y2W+&L@/X#*3<7WD6'.9UT,&MK%[
MG>,'X.'65$;RK76]XE?;&,LF7K*060QM'K_XR6M@]J[S<`#V[B93PJH9KB::
MJ`W#TYP./1&'2^61_^,L1RY]00N&AO(L#!VP?Y"Q\'>TY2UJ!H=["W,@2#4H
M0X.%8-D+"/<!'OYP$H,[#^!N.,5-$&Z,AR7C'->XP\.B\8V#O.,1@?@!P!WR
MC(<\Y2-ON<H[_G&3E_SA;PAWS4\.<8^?'-PQCWC.#U!SBD^<YSBG>,XQ'O$W
M\'SC/D>Y"6YN\:6;?.<.ST/(;RYTG[L\Z#M?.LO#;76R`,<@A;BD#[Y0UWI(
MLNQH2.L2/N&#R!;`<9!%^Q)6L`&_?0'M3M/D&0I0CPW4]1-=&'2@J?:$7SQA
MT2W80`XPR<A?E,@@QL"&8R\]:L9O8.\KR*2G04V-*OI5:?7X`ALQX`>O&/^L
M'6_`^LEU3G2,HQSG$2>ZT:<N^XD[O.E(?[CL(6[TW_M\]SRWNNMG_WJ3*WWV
MM\?YTWE/?)DSG^8<=[[6F^[[WTN\]Q_W./>U+W2CB[_[,6]Y[K-^]:+7?@$,
MOQ#]C#I#=V[HP9,YRZ5H=L((C7<NS#D?M,+R8-F3+^,F/T9T'/[F'1AV;^NU
M403W0`\H0V#!?@L`;F_0#K+1<D-Q#""7%+,P"^V@$"!H!2)(@E9Q@1^(4A=8
M#"<X/"(H'\>P.MWT@0FA@BQX%228@C2X$.TP*RQH@O-G!<?P2SO($/>#*R/H
M&L<P%#PX@IGS%DB8.2#'('BQ@>3$@LN#(BAH#!O_B&\NR(&\U0[8@B$-<8),
M>!;VMH(Y.((=H4KH8@PXB(0^Q1!_07:%@T5D8%:?<`/IP'9N]PDK$%D]\@F7
MM@*?8&DW8(<.0#:+U`H^0"=[5U=`,&B*%%F)1SAXIC0W\$=7HQ3R<09MT`64
MF'E*PT9A($F8I5=/%#8N$6<%,"5[=7=/H&H^](%GT1$P&(:O`8/WPX7S@2[V
M%X/&<HN9<H&S<0P@:&"\<QT;R%Y&6(L:"("^N(7+D(LFH(3S(837$8VL,BM:
MH808DHMN4Q7.L(5/.(-:V!9A.(38F"[M\A?'&"%(.(+S&"$(E2GAIF$;=BQ$
MB(+GZ'X`>(,IZ#JW>'(+_\!^&:=`XO0AZL0A?($8T"(LUJ-4DH(MY_,;Y<([
MB^)@VK@H#;4I\8*`W0$:[;)?&M)!)\,]*5DT>$`#"Q`?RD-N40A50@-1(,0O
MK/%2O<$@=<%.[&%P[`%?J@%?J;%!](0S*`E"K80:CZ(4$^.-YH$:U%0>YL,K
M)U,,2FA2/G09@G&1^T$<5,$0*`52"5$N:C&6)W$5;B@LVA*`Z4)V3;1(?`A6
M?*@TFY1W7Z!)A8@&FDA72_!$+$$&-["(-E`(3/,%Z7`#;R>)A(8&E]9G:#*(
M=>4#9/`+;0`+NX$.5A!:CK,"?O`$C*,T=)9X?W0#34,D9-`*&'$&@5D(*P`$
M9/^S!.E@#D:R0X5QE?01,R-3'9RR#%@9+&/Q.Q=I+.'B0W-Q+^PR/*_3(!AR
M%;XI0J;"&8_B&B)4.EP!@+E9*['C0=TS42BB0=S2CI#2E,2#'RER07/X'`^Y
M//!5006TG-:XE4PY@!AW8N&V,A4I4(FR.@ZQ/";SD2/C4,CB*?\UD+TI</34
M$!II'M6E'580DMQ15,=B;\=51`[E0!8*4Q*Z``_@DD$U(@Y1.2C1D1]AH44T
MEC)T%2[5&QCZ0*)Q+P."E!/#HASUDPZ5<!=ZG`QJ+$/E0*RU/2M*G.9Y*<IT
M$I637ACV&SV*,Z7C%++T4&69(@$"&3/Y6T:T%@Q6I5'_*B!!J&\8"D`SA#`'
M478Y4`\%L`)+$)II59?I8&<W4`B7@&=/8`.%N`2:J$F&UW>%^36855=?`%J!
MAGGI@$A]-*><645/LB\UP32?4`^2TUB9R%F_8`YTLZB*LP+U\%AOM(=A`*>E
M]0OL<!#FI82[8XV8XJ-56AFD*E`!\J/YUDT#!SL#,CXP&EZ"P4P6%6"O9!6]
MU!0AUJN[,5P+`8-?H5"ZI8PEJJ11*AOE5$M;2!T#QY/=PU$H.7#\)(5;>*1(
M:423DBBOTFYVT8'L$Q8T@`<'\!0^I3/<:BO#I(W6.)T#:DX:I*X*V)'FL3X-
MQE[<\AS1)3)/,0L/^@\0@3GK_U)$!J>L06.>QI`'/.`#*%%=\.F!;G,`4E$(
M!U`(OV6A*%JP):JL8XF2Y"E/-GJA%=I1&SNR/<JQRSJ'PS.R+#I@(TN<#M0@
MC7$OE`%RY-2CW85;_;I:YAFA94%-.WN&QP`1+#HBU,%;2CI,\$)$0"-$%(5O
M"_$D9I4T5;N7-J"F;6<#9'`)5?MXFEBH=8JUD268?4<&BY8T@=8"?LJ8EV8U
M?.1'EM"U?OEHR'$&7ELX?S99>YEXOP`"E,FU35.U=5H(@ILT?OE'%7%!QQE5
M#01`.KJ0)5)=%D54U+D5`&@PLCIF#@6M3IL0.;JKMV,":4EA]V:YYJ4[@9&Z
M1/-<8/\Q2[.!H>1%LD\!*@[T?TZ;L+\%&0?;H\&Q6PYRG=0QHQCJ;L?)+J\:
M;[G$@7G0DIB2%E&KKL@A8.-6&/#YA$6D'3L;8/1S/UJA4.DUNL];")/2AM>1
M(@`;OKR!K!][LA[H0")68D2K495Q.VF#CQ3&NRF;<!JKK",+O=Z5L;Q[LLF*
MLB3K&O$'HP5\LA%"M%&*GSK).@[2G)7#&19*0ZVJ/@$EL^314"_J-F+AL].A
MP3`[I?JXK;]E'$KD4!-;/Q,#"]AP`ZM)!C,<63:@130<6;\0-1M!28T$-:?(
M6+_@!V=P!NF`M7X0-44\P^E@"5`4!JTP:M2`#42L9C:`Q*C_Z;=G0!-D1\6K
M:<-D0,1A<S5G@`YM$#:LN1%RJL-G4`B%D&B,Y`=@4A4_FCFN03\'%*N[T6[`
M<3]RL;CB:)T=^)$R`\()9!;/!;T2_%\Z\TKY6J47`J[=],?4`5[0DKM*2*+M
M^T"NY($`,FZ82[)OP5XGJ[$_&F"WZXP*S)`-@9(IW('ZAHV9`APF=@#JM2B5
MH8'_.RD`\A;VF"WJLY5B^*J*\AS<4KZ#`8/V!\I6`;#:`8,MJ\H%'*#7@6+"
MN"^[2A*P@A8"G++YJ\D8"B#12L`I2K(K^LT#S"DX`\WK?(.)@EM&6,$?*84,
M\8VEFJ7TC$P,:D+5=8UT(:[F2%13_^J?ROK)C-QNE9&Y42O+5>HDL,`.@J-X
MH\9(BC!J82-JHO8+DW19DQHV@F,.&(`-;=`&V#!)D2<XE*1)C*1%?B";YL`.
ML,`+AW19LMG1:^);04'2B?=GHB:H660.JZ84(.`'HW;2DBJGC31)BB?$L-`&
M]/2BL#);*V1>QUF`3UW'+V@860%5OAPJ(K.!J/O/F-*-O\6%N^J&4TV2XF3'
MW60<+XJ>6BW5[88K`=+-P5H2"QBAROJN1EM$KI&6ZC(8]S*JT\HL4]U"!].M
M[E<R/%"N#&B@Y5@AW5N1J(N5;H-;UB&#/%-3`;@H6!@5#<:."^V^Q0"PZT-=
MTLS.%5I3Y/]J+*S2KW/<D>>,VGRMR7Z=U=#\L=U,VWR=SJG+HBH*S:S"LF/=
MUK*2.>3QS`$&H'-QC19ZFWUAGD^)(A6LEA9*/K'EI23Q?G01H-,]//J)3Q@K
MM;"P"I+Z"XTDQ.8@#V'#WNV-`>:0>F3PPMAP2"'=)2],#4&<:I-J#M1PTOV=
M#O2=$_.])GX@>JG7!MDT2(>T"D0MJ-APTFQ22!!^WD]@X'Z`#1U--ZC7)))K
M8-H!GO9QADF%7QOY6Q59'FVAA(,MH=N,+0B5S<TXH-S2EJW:$>%V&+#"UL4!
MV33NSO'WB\<YW"W[(1X"/P!MP9K<L@%X+)M-OCTZKR=;A;\1+)/_D2EO46)Y
MH*!GZ&X#ULLZ"7+E.#Q1[H'`PL]I`9'R!MH+Y=CF4]IA@96S?<XZVIO+@&*V
MV4JZ\^/>S-?#*\T[N;BX/<XD2]M+?N*[*^BI_8'N[,")PJK`6RT&DR_._=C#
MH\_0[5\@+A]P#M!%,U^].K+L=96,,K(/L:6S4-D,TE0]6A'T3=\.;1`5$=,O
M71'L0`V3`P(%81"[?A"]'A0541$N,=(A30N&%-*\WM"Y;A!&PB;8$NL0O@JJ
M%NR]/C`YX>JT4!`B+=]^T`K,/M?1LV!;'835D9:<SB'Q\N7C@8$-G,N_M;WG
M#N_OB[EU/!;DJ#-HWJT@_N5<NCT%^-PB_TX^E>Z^T%Q3VVP\)L'-@@ZYE]VO
M?K&CQFO05J$Z&@6U:`Y5;>%J5D<=5IX4UPC,D;W!<(XSP&+I*$061ZN1#[9>
M`_C9/A6`Z'NS?:[H...Z5I!B@@POT,&J&&O;=:WP/S^-\%+R?B[S/P_.)X[!
M=>WG2\JR6BD@^1KF%MQ/REJ.(#Q#MP3.0P105,B&F_*>XLVJ1TLP#]^,X2S8
M3[4Z/:H9P+[K3\(9P.XD<;_K_[44>L,6)M`F<Q_KJQ8F;J(4E$%YO3X4"8Y.
MGMXF?E\0?I\22-H5O$XA@Y1-2U'XZM3<EOV?.:.O.I\6DOXKMG@LS&&YK!,A
M):Q.YMKB9:XHI/]B7?X5@/E4UG5\+UPU*ZIT?VX38KSJOKNQ@?,4S<HQ7P/G
MP5$K\S-JD>]\^=-)W#^JY,<BO]KXO+S,DO:I0/96JIF++)DLS&6>+[^,+0WL
M0!:?2[NA4!M/&<][`).BW`#;D</?LA9,*O5C8@8?L:-+SS@OH;O=Y\-_D:HT
M]`!A999`@K,&'CQ84&%"AL:,#5QVS)B5A109+F2XS*'#C!M-4!%HS,3'9282
M%CM@8J/"951*+DM8TEA)A<5&FEAFQ>:L8BU+%H-HS*9*$PN7+>MI[!C.F0>%
M6M&84*3-0L=TFA0XD"!%*RXIMA282ZL5A\4H4AFY4:1&AT71JH2*5JC_0ZXV
MK:3]FE:H"8DSIQI#"Y*L2K,X"7HT8;8K41`;0:KTFW:61I6S`!N$JE3FP*$.
M-:(MYGC639@M<89^*/#GR)P\JWJ&_)GIS8%RD29VZA#TP)M[`<\DVK8RY:*G
M+:H$&_0V<I%9G4\^]C:I58'.A+ZL>#$C89P70U,).O.83ZW:8X(7.?*`R.MH
M%]!(F3C]2.FCCZHUFUOI1"HS%TML336'),I((M9V2L^8`]B"B;Z1;.KIHYO^
MH;!""R\\H(#4,.,PNX):0@TFI6C`(R>-@`K)MLQ0Y*DIBYXK2+OG!I+(+.P0
M@M&\['#LL,6'+!MOQAR%U$ZC\38,::G*RJ(L_S28*!I*(JL0\HDC@KYKJ;S.
ME"QH*L-VLLDE\!0J:C+=(DK-R9X"G,R$`A;`*3F,"'*),ZR<(FFP_M:ZRK!E
M"OFH/Y[PZBJUJPXH9$R5]BPS/8%N8LVRD:!T45*\VA(3*;(*`:HD^L8+K3))
M$1(I#RJ`8J^O)Q^TK"K)ALK/RD$1/0:H10<T:ZG4;J+"JZ5`XNU)R^)[2*F/
M^!PM,:A,2`FM-BLCZ\>0:!,H5)V:LDG8D&;RU*RD,(M()Y?R&[)'U1*K<R&E
MIL5)61G--=)!E[(<"0\:\HB0U[1@9<NZA@"$:2"1]EQ/JOV0[,FEF8H1U$'Y
M@'OKV-N$&^E"BRWDB__<'AGB\43V.#/F`1Z`&JW2_0Y"[B"-`N8X1QZ[1`HZ
M:5_FD&::YURSTZ9NKGG.CC>*&:*1#/1O4%7!)0U)F3E2&;`3S0R5OHSV1$HH
M23=B2-FH@/[QJ:BN/&:%`@XX]:B><503JEH-FHJRICQC^[>6`&Q'J7DY6AFH
M8@"%K$ZVO`7L2%491BXBG2>:)6+V3$QW;K_Z0\I(OUK[J4^F"`Q1((GF/:9&
MV9(*>&&="B%[<3,UE9RM>=V^SR`G!:("T+86)L],IVV+L#\G#7HZ,Z98?'+E
M:X5=V2?A+4LM(A-E/5G'@VS"VJC(W$2\91Y1AO2^H^CC@8?2]>U;+P!)U@G_
MS4HM92Y@\P.N=F47H8_X;@/?FMS3P):Y.'^EK7?9_:-U(I&(-H*B$"&O1IPY
MBL:<Y[*DV*A2+O-9N:[7/M2)SGK.XY_K-).FOJ2G5EEIB6?R8RD1/B]U5.(:
MMGK#OA9)Z2@BZL_XG**S%L*M3G;AT#(0E9831?!T`N/6XG8#E1,9[V/Y\11/
M5N:C>$GH3FNRS`O7PJ)]10LB[M.7U9#W0]/9Z%6BVV"")$/$R)E$<I-AEX!R
MXJ0FW@2)35G=4GIB)^.LRTS6F8]<<G.Z"%G04\N#R;>JM9%C%*DI>7.?B\K2
MHI@]+6?N$Y;S]C,>'H4*+6\JA#,R>)&(T,<S`Z*/_[V(`BF2*"DP%BS?@+1U
M%/K9CBVR2J5F2,4KA1'GE)^$U'[R=['6;#)&:E0*Z%#4/9S4ZH7!`]#JS)9*
M%D*09L++F\U^*4US]8A;DTG7V::YP!XEDBW0X2&'!@0W=HFP2YMC$YJ&ELH]
M/1!-`#))3P#DQX<DT$RJ6ECB+J*XDFBS0]$4"27Y4C0$`J=3T/)1/GVBMI&@
M;UQJ/"!Y!`0@MC7R0/,QF?D>]10E[J<T.QO:<@ZD1@@!25.V&]?I&#J77#9-
M)N7#C6J.5@P"/0LI_#Q(!UM#&)!!SH%K]..1@@:SPR&'0"`T&T`;>2;M3?!?
MY,1,.]YR@!5``D[DHZ;JC/\ZD\",9`$\,)7#-D?*E(%0+1Q"#=$ZA9;.Q<RL
M?7%.U'BHU:&)!S!.9,LN+38S9SZ'0=VYUI1X0(,QAF9*;"O8M<84MQ%.TV7(
M6R,E?>A+:F;E6]C4U@5]1EG)-=1,>PH29CIW,H)XBJ(F-!"+EK6O):XEFRT:
MY4^9(BU0?2U45<K)^:J5E@?U58,B:NAM.>8DR`TJD$IA9/GN5IFAX"2;54H-
MW"I'42MXCB0DI*X!782Y?%JI=>DQ2X)Z]\H*?O1'7\J2IQXR%)<`-F%+;"!D
MHXBBTR1Q,)"1;,DHFBU4%?(HA<S,JMB7K:,B)&U+6<]KMZ6<D,1,0?7+YC:G
M]1/_U%YR`9!8`4*=:5C-&&X^BWI/'D@)&H>I*&Y2*LATWC8>^UDM*X2<681*
M,J]3Z<NPQ*%//_&G5PLQC;*JF9=DGF45&BS@;]CDBU1P8QH7MZFQE9WOHUCX
MXXTYMD/RM)%7SH;!R1KE)E9!I`L_A!8*<R8E?9G:2S`3I6X][W(QFDHA2F,5
MAFT/=FN\DZ28W"*-T>D`T'ORD#HC8W=I9SR0VZA$P):\?1$%S]!;\VSC]A'@
M&492XQIH3G3ZXO$HJX]-[N=*);44G<`SJAW46[M8:`)G[#8Q=5N+I+(5:30)
M*&.Y:8U<BF$3BAY,6'U#D:[*!%,!(2Z?&Q5)AQH\5CEG_R?4M4:>TSSY$$MO
M<C6A,U!T"E&`V%1992H!U;GR:()VO"<^;UD&.O+@0=;`;9Q3WJ"P;KF@*[V3
M3;`&D0B=F)C$>"J7?BD&CRV$O$![>W8BTE5_:<"#=@`I98M,4LJ6J$8J'["D
M78:R4]LW)<V4BT@2IN:SVI)?M;0:7%,)[:!(LEB(9&I0\J36M[%F0KXP1V>=
MGN]H&M*N,IGD>MTJF&8-,NH6X6NS74'3JL"#PD".,254_"9$).*,,ADI1J%6
M$HT^XA0I;2C9@$TVF?06T%GE)U0[&:1UCK+1AJCP2V1#8KND%<*(T"C";=(Z
M5G3%]9E7%^?7BJGK8JH\&DF+IO_M>EE((S7!DAJ6-\C)'NPVE,&7Q!#Q,#V<
MS28Y^;MDKR7V6H!XNYH]%LLENYD9S]I*VYM9RSCEJ+_,N>*WL$5!"AV='(C`
M*\3(2&XRH(-$J`E(1#+V9*6L5T-9-J^[91/^:.+^O&`&9^2ZIY602-?C&<=P
M1'=3LM`Z:%:97(IVWR.Q*$)2\DHGNXW`T<;8W_^=:/&JQC(@Z[%."&DY1H?N
M,\^@WVG[[Q%8HR@T.3DP@QRBH:Z(`+][6B0"5"Z8`!APFSD@@2J?2*DRHZF)
M2+JNFXKVJ:5!.AH"Y!U*^@EC`1JS"XXW.C3>H0L6!(IYZKJ:F@47^A$]NZ%^
MRHT/Z:[_#_HL"GLQ$^";_YHR'0R=&4.WB(D3ILD*FFDNOCB5YNN4KZD9MJB1
M@C"0E;,)&KB7NB*K'$.3M\@O!FPRF1F)5LO`@\$J\^&H4H.4U,.Q4EHO@=`]
M"E$.K%K")0P/9%JQ!\`#DS,2A).E%@+$0_(HI^JHCPH:0QPZ[,.^.U2BI*(D
M0[R^1ES$.\Q`V$*.$5(QEL&FJ3LN#G0&K**8CMH\%@&2J=-$!0$WG[N6_?`;
MCF)!)?&+ZUD3#SHI_`,\X!H.W;JR[R/$Z^BPI<!$5XK%1=K$GY*G8B&,H8@<
M*SE&4J0D-MJBSZBGBY(L#ML9*B1$!XL<9TF<AHHFLNBZ0$H=_YT1(.`JH_IZ
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MMM88QVW1"*@<QQD+F)29!:GJI$-"M?_3P9N#"RA$)!DI.9"E(4?Q:$:`F:(?
M`LS)7$RE."VAZB6NQ!8_RK3_XJJ^,$>C9*9D(:6QFB)HV\?G0<*98<&E8A\%
MQ$F9X4Q/L9<\L$R'R;2QDI"=2:N=22769!#]>RNF7,Z`TLR"Q$@YG,,XK!OZ
M6TF@5$*-*)C!VCK.V+L663JV$97;JIWIDR_4V,=)]$FV'+JD@$J)VC+W+,I*
M9$&?6Z(36C-UHK_`20^LU(RZY"W`PJ;]`$L9NS^A48G$XIWVZHX\B[2:ZXY]
M!!/>,L5#;`>B`)VX&<+]NT>^P+-Z"I?.:!/SRL@&9:Z78)I8(X\$R3G[<(J(
M"1U5XHE>,P;_J`S0:.*IN."5H&#-3K2=J:POK3DV)4D)<G2NT.D.PI-.&8T0
ML_.W"I7`IMN9GP,IM\H6\5,S]H2.WHM/CR$E8M$A;MF>#]4@"HVU*50H$@R.
M`8N7'TD8M!@L$;.?H6$.?H.4&:2=_RE&'H3-NV*9/PS#I#2I#VNOR1@A@S!)
MS[I1+<*_@6P'&42-8B"F\&2H@\H8$'S0,S5$SY"R1;5/1H1/*EFZEZK/^_S)
MGCD\#U69>ES"A-D/KH24-,2O4*7(CA115E2B8JJ>0*U0<7,6@:15G%B/1;63
MO)LUT2H:.3(^]<&-@72=P+0L&42HUB,,S>$4/N4="<1*RI'!FEK6_UDHA.L0
ME;8J-"!!25:$MK;2NFKTR^J<M5#MULR[T6T]3U\5IYV!*K644:@X@%J9U=$P
MD%ZZ3[:X,VAUHV#ETZ;33BHQB;NZB920MKJ2T9]Q-"])Q(E*DL`1481`O\/J
M$RH8K)18-^IDL7WK)P_JN(S<CS(9.HR:M3],5P5$+G9I0^!8Q(-HU./+KDAU
MQ):=0>'C`81CG^AX.)+3E>TQQ1E1BH93LU*5VMJ$3ZLSJ96\OJF55J2)KC!4
MFP&90BD!L!$$-X-UG$B)FNBHP5ST.9GK'+[KC?T[O`?QVFXEBD**U*UIBY?(
M#V;94P!4RU!K3V8=R1,5/.<#CQ":RB.)E/](^5JJ`\Q8@9;N"+ND"RG[TK,F
MM:-1^:&:6@O3ZHE,`D&XF5<U,Q,]`TSU:Y#!`ZV-LLA8FS6FR19_>Y8T+3.5
MO$,%%!C)`D.CJ\0!?$(AB5)_<Y5=/2CYRB'V:-N7,$L\R3M1X;3"!9<K#$Z*
M88T@0XMFZ3<*W53,V#P0G1O'#92V,#"9B,0'S:56G3Z3A$#DO":5K$UN$9"%
MVZGSW;M'J5""!8ZAVL<&)%:L'=Q55<G[>$&IE,0`+E4!I<>'%<-(^MZF.1KV
MHPUY<AM%<]E:6L22&*W<-`81DT&;6KSG@)ZX74ERH^"R1966PC\U,2[\Q+^7
M%<K%+%C1Y)::"JG_)M2BI#RM=SNTTEBRD90K?ZV2(!TUOP"8OP0O]6LKF3J8
M"O7/@Y&9&R6)YCH@!HP.LTD*HWH)I"0SN;+@V_)7GR1`T/D^/,4JAEQ0(E$>
MT_@R5CGB*3,2.?K6SLE0`Z+(17TWX-F\KSHS2%&8*UPAYU)A>AQ0U-H@2DJ/
M-]`B(%,>4[2;@*7+*>/9.>S6^]-@!H[4.U(?^BUBFD3D3*-`$=Q9ZLM1>!SE
MVI16]<3#BS1:YCME%\[DG06A[NA0HU0Q2)4GZ=4@3XQ/EAU`8W@#*J#4=[K2
M7.:(!CI...4MO)W"8K)8_/MA"G2[Z#BLY#6;0-S.>_+;!SV&NF$-OC62_V2I
MDT^Y69FAV%[]KP=IK6[VH&?ICPK-XL4KG&]^6_F[J+JR1V,AF\^,FJ-X@\@A
MD!O^,MG%,25-9R-&.&\>CH'6I,\JW&L99=,\KE+JC2MER3#<,M!)C[>H$X=P
M!L(SS:7%18DYY29<O.DXH(D:4#X>,>6AR(]PH?AQ5Y2N%-4DP4DBC3#U*#VV
MS'?&3?QC7R0[I'W)YE'6'H$@IL_51YE,RC-ZY0X5P57.9/A]Y5>^)KZMZE66
M:JU^9;J\)ZG.8!?J)0$T4-_,1B51DD$537]M$XPT3W>-"M/*WU%;O)U=&8X$
MR^KRX<\DD`CL:J;I3:,>B76[CXSYH\114F$>)__!Z<PV`12^C).E,*::&JUZ
M#**")9F6FDQFW)[\[)P8U*]L5(_KV+M?824E38MZ-*P--D^*3>?E,*8;,L$K
M9@X7BL4#V6)4G@6UVYXJY8N?Y1VC!%K+%>1ZJJUH)5O6WED@SF1_X\L7^NQ$
M).:`R0/XR%EURB5?=!@&L=E$M.,-<>[+-.N=I6&$.U^I-DFN^J].,Y:J/F41
M!,\D`Z>,/(:@ZZ3MJ<%(I>!'=>_^]N^=O3'#_>\!=V_*8,&&[N\'=AVJ6],1
M%&L"T3^7=;0,5NRUH3Y50RYQGHH4;9<%C4\SXJV/7!@MTHQB:KJJ;N2K[>KX
MV=61E$ZHA(Z".>RXZ%+_TY)L8\!']H;G#6W2)`7,7];>M;AQTXC$N252_:QP
M385IR!M)R6;FDE@0FS+/SA2)]:BKNQ*/PNT4']>A)3-?EAF:@A64JJ9AM!8\
M#<YK_)0@S^C*KE$AM1ZH_,Y@L%S$/J(-(%%LE;#(%IJZH?LJ$?-"GG,C`*EO
MJC0),,3F9/Q@]8L3RK7,.G\)&?3N4S;)-X!G9E%-`C>(29V)[E%`3;7PL_M2
MTWWETV)K34=U>GQ0.4]U`L<]%?_O[\/!F"6:#"YQ6L[Q11_)N;[DMNU5$VS?
M70\8"/G;G<4-)1G7&6S&F.6WDSG?4P[<N:;O;NZ/<RZ&=9.G0F!)Y@4.Z+VV
M_Y^84B)=KZJ83YD044$=NE7L-,-B%DT5=[ZN$3=R\,JS*Q_O8!_&#?%P-%E,
MT4@'E;^-E`?3F3=-#Y91\(&J%4'FQ.5F#;.4B<T`X/)8"*_4,3K?KR85MH7_
M;PW^B.\[<OG>],^VZ.J.CS^<TO;"L?A(V9>&=&]U68EXNC;1E0\F-(WO;Y,L
M&1]VZE27"!)9W(_%9ELLLU>6.&EO]0$/9]0]>E378$%D>K'E1-%<]/DHHR+V
M=3O_R%TG[]\&Q\@P76[!TU%NTIIK'AG=T`S&"4R*D/Z.=CJ7>=>)CYJ+DDZ;
M6"_"#>38+?6JC0+%<60/9O58.E7D;\!4C]U:D+K"1_\%G-AJI%PG7HL\0`?>
MH=BL$V;(4P_*C7E@7M<N;[HE+R9DI]"4./(6_G%QE6Q5>W7R[AQF`0$5O\1D
M>YFMD'C`,ZA5#D0'V7!47VOGD\X['T&WMHPZ+=@9(Z6$>6G(,^E!C?2L-Q"3
MZHFPRF_*`)%4QWD^U15L3O6(6+B&.SPYK>MV._7EMIH47WK_GM2>&,M"+G^D
M?\M)W_AQ'+JZ<?+XQ$=CL?!.L@Z+_^WHGWF`6#9KX*QE)HZ9,#'PF+-E"(\=
M,S;01#%C"0T*)+C,6#&'&P]&'&A,8C&%!&>AR[,"THH#LTQD/'G28[&",`F6
MA"C1Q$B=`BW>3)C08C&$/*W_S!JYS(J5D@<2)HT(<6-!HS834N'I\&)5B0.I
M'"AT<&-$F,<$&H39SFC"B&F-H;U9D$J>BQN-25WV\V))H5E?#EW(4618K0[Q
MGB79-JF)IQ>!4NQ*$&C(@GA_PNTH5_!6F,7:79Y5S!G<I*5G(4W-=#7KFF1#
M(QW8\>PLHPAKRIS5#G?NVG@/\DXKM#+9J;Q'+N!Q`"U$H6V741'>N.=9YS!O
MOCX;7.>QFJ"/9<VZV6'$Z+W/G_RG?CW[]@/?.CL;$SW]931X9"2_UVW4D6_F
MRT066L8XPQM]!]8G%7_&_&<@@@^>AY%H'D&8VVQYX42>9UVQ=8Q&Y.'5CD:4
M>36A_TZG6684%=^)]M!(+^GV$'@Q%;7,;.1%)-$R#54T7S$'K,#$`H64Y&!N
M&^D555PP_::C3E5!I&!F!L%U5U,C%6,%9,90H=UA(N*(&$^,C8779X==Y=A8
M2MHH9I1>)M00@35Q&5<>70[5SF',1?F;?`^]UM5NQH1U0%;R[1F53EA5^5Q(
M'>'UGHPVOB<I2:%9%I];VGTWH(>F+84:4YHM4(`)3.726D\HOG>8<Y\&B*E,
M;L:D%UB&P50<J^3AH1Q2G;65HT'B@:2A<U3`I>!4,TF%HG`N@HD8;16FUYZU
MZ\5U5F74YF;%?=,6E^ME,,57HH5(2L8MMT5=-R:5ZN+T'/^"Y+FV+;Q0\C?0
M=PCI%9%F\LIFT%0T/K3A>P>]@2)H0N'E53LFO#'5318I&---)55UT$VT;<2;
M%>X44.H!EP%X9$0B-OQ;0\"UFIA\?$W&4Y;0;3D29`EE656_+X\G[Z,@L@6P
MOQBM==!N!V-7Y4LZ$<N5S@*^)=I$!\#IJ45-FW3C2XWV["Y_:*9XF8,4KE6E
MRU[15+9K+UJV#`@V&K3`"B@(L8(Q5J2:*E.'Y7N2=09KU-QF!P.:(4^+_<O3
MM)::L``>+K7X:KC.O6;=6?_99F]QBR=.T6$5)6POM]>27EVRL-Y+$`\\C.G:
M8AGK->9Y6I=4<NH1L@7BX-3&'N3_`KO':M)=MT_6YTF:V:8;B2;%W#"SA\\G
M\+*R.7.`8].R2S%'KE*<$9SO681199&=9)%CLJ*')KL*]76,B($S2%OMJ&E6
M3'3%@&!"`4PPL4)"(&@)*W+1C/.4)!L_9<1=:;'1,=1DL:T(I"C@6I2E)@*5
M65C/!%W*#V)*`YV8A&],"P-3G&8!%L?4ZCH1_*"D`+8A"4$)?0>+H&U@*))I
MY<HF6:J(!GE2"!\(80-.^,`."G`W6.1M5*N*7@/Y,KBB).N"$](8YS3DLMT,
MAT9A2LX;3"04*))&38<#3$+.]Q&VE`A2)HB/%J,TLB4ISESJ(MVU&M,0B!`/
M)ZLC3^`B_R.P=Z%G>H#+XWF&<Y$WR$Y=)5D`$+"`@@WXSW89NZ$DX>60A#%/
M)(UQET+T,SB*X1$G"`G?3`YBD9D4XBFI9!X$+P*:E?T&?`+!WFV&(A#@]25J
M"'I8[+B22&9U3S2<W.%(3/"%$_P@&D[`0B'N!@*;E22-BC-)P];R*4!.Q2A[
MF6:))":0A=D$;=B!2%],@,5#G5)247+=,JSI'=F)3RAD4B%NJ)0P2FYE(;+3
MBC`S4K0GR61^"*D+\,`F,]10Q`KY2T@!@$`"%*!`"B?8@`\*`,!<P`)O>VL8
M*Q$BG@@:3"L7X9=-"E>\A[10<)G$T5GRH)S:1.D_9OG;RX)FEO_J.+"/-@PG
M0I;6KSR0]'9TM!9/"DA(*_``#S697FV*M=/<\/.IA(1J8\)2$F0Y(Y,5,@80
MQU"``JS@JS?0*N%$\I^I]E%6RQ`C*\-GGIB-$2<4.\CS#/(9HIA/@S.Q2/5T
MU$D*^L8FY0,)7=D6H,;\R'T06LP"Z7,X'&IP-<\LQ`J`@`(/,$`"0O"!!HT!
MP/Q59#`Q%%Y;WF<3&Q6MD_*$:93T112Y-'8RYC'(R)HZSNO4LV(6?*LPJ?D4
M!EX0(W0]6"S)A#H8+@LCN`&E''M;E@(8J8):Z@Y2(%.`':"`!$%D@@2P`(0=
M`"$/L,AH1E?#0X/,16,23&"RC/&PLK#_JV"+6]KK-/D4CWX*,0D3T0(6,+)C
M(#(CO]FD+2E"X+%,TSE9Y5,Z`P:2;C+L3J:]UU#;HZU*PJL8JQ-1IY#V$4KU
M1FTZBRY:<V("L=B4?!!:1AY4$B0@?+4`>2C$#<ZJ$7Z*#:V!RPL6/[):!Z,/
M:+Q)+3EU6KBL#F6E:#0(F$9I%J]LYI]0H5!N;D;6WJ2E.PLD\0WKU!29::D0
M8&7"!H00`PE(00A`H+%G,QI:+*F3A0(K)7.@4L[E&F^&&PKJ#*^2F,9P4(7@
MBQC'^$F0GI+1O=HD7+YT-Y"L'E=VWZD7I?8ENI?<5V.25%_'K*`_'V!7"$+8
M`:F_H($-`.$+_SYH"0C&B\14T2DZALQ/H=>8Y>I(ISLGJ=AVA,+@/@G$"LD!
M:M_:02RJ+2-TUHFGY>"BN"A%CYYPU>`?A5IA;.50QTG-;6DLTL%SZ85"1M7Q
M\_R"D)P^J"-OR,-7F3"&,0@!"3(N0"'J_081$5!2&.8R@BXDI:O4=S=OJI7T
M4!3?1%Z(L<V1T?$Z1+ZM#/PE!C*6AX!7TN'0IR-8E193L9RRI51$S.T&@@^0
ML`$V:.`#J*:W"4``@E0]TV8[#I'64K0S#1$HE#O3CB:79<T5PNETBZ*U*6F-
M&.9PD#9C67C#!!RLENED-U0FRTP<(G7BA,FTOT$Q%$OV*[@T92/[(_]!#"`:
M1%*3W`!86/6J5U`(II17;SS,XH=<5IT'DT8HOQU1<Y($/L%U.R$10U%RJ#8X
MZ/CEIC0UUO5P1'>H:RYH4,+P@:Z]GDOG4<,\,"U+<81ED'",(93/HW0TMLI!
MHJ<=;SA`BX,444"<(`8593>-"_$?/O:KN>F&D)Y4"B7"^AU?5828?/HXRE(Z
MBGT%3^%P=/W[P!2_CQ?)]O%F6G3<*22U[91AK+@$%V/\$`D^``+Y@[2!&'P@
M!N#]:C-=GM&[N`4MA/:@?-@(\:OX%6WQ&QA,UZ0?LOQ+.RW:FDP$M`T(H2%=
MOX2;7<B3?BS$I$Q1E$A=KG3<Y*7+1D1,#FG_R%-(1-D`2&H@B4$P@9E]@`$(
M`0F@'7CY``FP'=OY3ZN-UVK,DQ3%#'<$BQM1CFM!H#H-S%0@&0$6Q+#QG#KY
MFE18CD?0E+:4D=.8"+01Q,(`&+4IRNB=A^6I!^K@1![1`!X$B(L8S9&,3&E%
MTX21FT80"T04QG#U1G`D6XN!U1<(P0=(@`0`@@$`05BU6+V)A9U161G.2A89
MA\`<'H"=$FY`H1IF3%#]"UM\B*8AGU%PGL9,V7P!7+$<"8^TA<5UQAV]3@6B
MAJB$UHG]T`:<0/D%R1<``1)L5T71VPUXED8]TUNXSM%%Q9I$B4BMR?RD",9M
M35`%2^^5199!&;A(_R)%]%XP"2+<7,?=C9-7'-P7"I?3;5`AH18,A4ON"0R#
MT-"TI(:H6,3^R*$!/-(.K-T7H.(:@-H*^``3D)PZ^H\5()%&S=V/R<9[#5@V
M;M+U_-7"12)$W%/&',1]O8]#X`$-4`WGO4EUE!.!*>$2QLDMHINB-%@B^@M)
M28B#\-M`6.$_0$A&]L8>=>%T?-[2&1@53A6AK-&)+9ILI)XSM-B,K8`CB9H!
M?(`<"L$7L-^,U1OD<)\?^ME*7IRY?-C@R(CS)>(PI<53\(9F9)5HV1:A1-NY
MU00NV5%@](;G`-H@S=F/#)<(D9),J(:G,0&I"8$4V&&,@94Z]D]:BIPK7O_4
MEVF,.!47R2P+DCU@7#A,T'B%-TF*,'D%5*:+TR3E;0A?`BV$>7!E7-399*C)
M-2WC0@3?5>J:<L6())[%<O09.'7C:I@`$'R`!Z"`#V#!#HSE#GS!6*K:F*VC
M#[#F^/F/JS&%MV$%>OD-0UQ$5DA'XV4.(@)&W\P"(CV6[$!$X3%+WR'-@7F2
M`RT8@16"`QH$H;%DT=B0%*[5O@641EIAOUWG\7#G0&SA&H)8N1E%?!2",UA(
M%G8G2_;A=;;%*0D%<#)#1NY('N!!(:C$%Y29J)49^F77#O@`'N0!*NAD>4X/
M1JXA>LBGK2VA@<C7\W0<9632,V*'KVT&\D`$O@'_RW#52QGIXF%)HM3(Q,3$
MB1JF!6XDTGNY3DVHAJB8`!#M0&4AP1B<`"L6P#J&%5JBI?^<@?M=598@&C[N
M6).QCSZ5544\14'45M$LF'=8H\&0AXB0%%=*!"E=$J;D!+[Q1TTTI06:SU22
M5G-H)TS%A7F*1EXA5FR<UL&H1D5@@0200MVLP!@\$A:@(!9L`!/@P5?E*1Z$
MU0KXZ?AQUGC%')>HD8081($`'ULXT&TT9C\^J%$<`)T@4I04Y`'$!L0I%D$X
MQ\@LF*)20:?JG:;-58X@I*"!*$`!(81L9'09:(74Q(89B>V442K%%)]Q"Q;Q
M2W015E!$9(0X0RKDH3IB_X&H"0'=%"L*G(`0+`$*KIJ,S=@-U$5XLB1Z@NBT
M(NAAP5''":)1Q@Y`*<\H+4YJ'>D?(<2"[5HF'IK&W!?R!4O)%`-PUI??V$A6
M-661<:6O'8VE*&98F@"9J9F?(H$J&@`D?=6-]BG[U1N]K<`9>-8SQ2)0T%K?
M"8@%202DQ4Z=+5Q$4$U-(,\::49&(-EG\`N]2"?E-,8U[9^BT09H4,U5S`*D
M"1^_K*3C;>>1A`8?_6:H8J1G6,2HF$"</A([#NL)?`#=D,`&J-J?IF4!Y"G3
MJN4=-BPT;11,W,K=102]SNI_Z81C*&7Q'$KPO8DEHB2`.4ZDXHLYQ430R&RH
M%O\+V][4N0',44IKC,#)G]2L3&SDNMRM3-P'M1KHIDHBGM#(W>)&/>TJ@#Q+
MN8+K/YZGGKQ!*LR;:.Y`?HH:1"&K%&17=F$!@,H8*N@A,%"KM;HJEN'>+?J$
M1L2'!F4JOA`(3D!:@=+6<-"?$[I&ZI[,QQX#BL%*[#2FZ`J'0!X/:2C@F[@7
M8#P%9F8A39A&EFB)2I`?_R!!#)2``<2``9Q`6(G<O!7L#20L6!D1P]Z-CW$)
MY%DB2Q&O?OP+)_I:[1(6'O4>Z!F@Z-7&;TE'ZZ;(PED-=[A%N?@9[Y96073>
M[*AG5@&P_A*8N:P-EGA:C9(C.^Z`$%BO`8CC!JC@GZ[_VI[B(5BQ)BKZCV>]
M8FI41.[<8%D06%9H2D*<'M!9XDEIQ<_!K3%P$90D#,&I%&G@26.&[1)FT[+M
M&%--W),,V,D@2-X*\+6FI]2`I.@RZ+(=6($<R%+J%!6ED/7<%Y(U1$&D7K(=
MP+Q55GYN0)G1S0E`E`%(0'8MP1)0\`HT;1YPKSFU:K6F3ND6FA-"72Y:!@(:
M#AW_X";5BFZ]!Z39&DTTGEP9GA092$KZVGSPTG>`!J%Y2-#,;=O023%15O^L
M``)L@`%H``.D'-'>:(Q],KW16,&ZW0U0@<L]4V?YBVYLA4"R2R]IRQN(;$/2
MLG'0+1^7E%[0;T^1!D[96M42_V!GM.R.(-A%+!@Q6ZTN9^(U)=M#[,9:A*>!
M6!-`JM3($L37X05E?1<3C-_YO8`'&,`+Q,`54'`+^JF?YJD:]^GXF6/_\$2K
ML89-Z&ZP($8&C2BD;I+$2G'=0<055V*<E.USRHJ_:8MMAJH-'MBS'>$!MA8<
MZ]2MV;%#SP(1O_$;P[&!?.<3OP0B74_O[BUX\HLM3N@6FPI)#BYZ[LBZL=L*
M?,'0&NT8/!0)%"T*Q(`8QS0)D$`7K$`>,`*[<>^]@2B)L:H``Z/`84\`I]0:
M%>=7%L3K-DHO[=V-&:=L%$Q#.(1M1:F?[9V!U`YM9?5$F"=Z\0T%_@D9HH:5
M;(28N?\=6%F6!$N`!H`S"AC`P;J8TR+LTOI`(5`!^'I6CSCI%H\%DG5&07]3
M%DGQP"50'M!O(CO*I_S@0G9KE`[4;XVG<%RL:"#9+>),P8!8[#8D@!2N3V55
M&-Z11]G(FAK$"IQ@.V+!![R``*B`"D@`:)Y@&K==J>PIG_(I.[;F=YD*>6E4
M;YEL<QQO)L8N0P[8"A<P(3)?L#2.<C!(:+@&><QP9391$1*W[,H4U_Z?B[@/
MOVV%I@@'F=8L$0>UW^XM5\\"2(:VM2[D&MDGXIRGOIRW!=%61HP&U:82"F7E
M=X>NZKFA2IR?.,8A1.$T";2V.$(4*<3`T28!1/VGC/6T?4+_3GM+M$1#L6S0
M%3%'T(UE((A*V:=L*$+D:U-%X<7D,^!D6=;H!B!7ATT\A;D^FG7@VZYU!TI>
MY$14K/"$-,[N#@B/1+WYJ0,4`A!4KPG*M`<4;=TH+([&6--Z;\%:U!E0@609
MF)-DXI':1CEU>!/-TI$6($C`N"3VRV]E=N%NDC"UK)^9TU,:-DF:[8QCYKGI
M2[GF$%.FN2)>97L"E7<4S-UX8QY8E@1,E"-IP"!LP2,4`0^<``-\@'9E5X2#
M%6ZOLSFKFF\OPWCIS:@`Q@()Q>E=!R*!>GBG,(@"<FG@ADK1"0_00%WD*D&\
MKAL?3'%S^";117BC9(H#"\RB=X@B_]MTK*L23W1V^E.&;^?[>(?HWH>Q(WN,
M9%H><"7JU%/HZ@;AK'C:*O861VICE#IZ=@3KT1M8[8`8GT#L3=1#?4#*C7NQ
M5L`.6*\99Q<)``&`TJ?GIA(9U@JUUCB6\=(D=2?$#9!M79"0RKB6+F$N6\2D
MYBO$(2]F[VKD0*52"Q.DQCF:.P.1?>%L-$2#L')**O9.>(RH6,%:/6]8,8$!
M2)39"4&Y(X%J;X`>%JQ*Z*F?.ODY&\..`M"7(=Z&.T=^0PRFY4H1IJ1)^>/Z
M-M$;&04S"(?Q4BTDMU"60;6"(IN7>_;-9$4]+<<7(GRF!7R^VD88@M#W><YU
M?7&CP_4'5/\`#L!`$=#`&M!`$;B`!DA`T7[Q&N`A.JNC;M.\!9/:"F0Z/*;*
M)_+02V1%!G$@HQXO@?IR6*".Z9:JC&2?$+8Y58->N1E*^/Q@IA&S0RHHW%9H
MZ.;'3)W%D#@&B/,&$?N(:7G'ZM<C'.-;.]P'F.A+;BEAZ>70T>1KB>][20'*
MS_66C%&1"1!4L5=[5A5`W3BOF;$!]98[LIX`V6E`YA:K"1YK!2@K"2S!J.4I
M?=+>`>Q^[ALBB,^^;KA.6/N<U+P^IK:3OKAXX?[3MAB$J\<)Q@[7U6F:(2KJ
MQ>]P0Y,+0)@H=,S$LEFS#,XJ6,R9"8+'(!YL%W%9P8.SC)DX`&G_19YEQY85
MLS)KI)5EQ@HP0?'A@X$8!EYLV'!"@A0@$B08$!(#!9,"A0H5*(!GJ-`5*_"L
M^!E4J%`KQD`4@V6E&!43&@TV/.#PZK&&#C]>U0BR8AYGRSX>*];NI-4\%C,>
M^.KPJU>Q&JD@W.ILXD*$!`L=.#9KXE:Q(,6&O;K5H,:":0VBY6JB7;%9<RN"
M;#AXEF7"$`D>,/9W]$@J(8\5`K(#"!,L*!AH<&$`QX,B/+H@0<+CP0D/'D[L
M0+&AB](\*WPD]Y$43]+CR;\``;("A!4K4ZV/1%C0\8$#:9T9V^I]LF/S"]L9
M@_@&Y,&U#[VR?8B'QH(#GM\39%_Y8%B"_P[M6BPQB`0TK*&*#!-L+<OX:T<B
MSPZ:Z[#`N.+//0?_R5###3E$Z"(+UWK0/<(N"M'#SB:B@8:$.GNPO,;,4VM$
M"UE,B,%B,OMO,(:N<J:8T/`:[RW./F0H#Y44&`,((81`X00#3N`)A94D0"&&
M%V+XH((-A#AA@RV=G)($%+;8`(CF\F!DJ3<2LO#$-]V\\:_!('/33;1`:\^R
M9>8ZIL&T0'-0K/%,<.8BQ2!*",^N#(U,0CZ-.>LJ]HR9"*3_3&"S1(C8*E1'
M/W\$U002.S,A)286*,B894HJQIB@5E!)`@T\D,(`6W?20`(L--``5R`V\`FH
M`HY*"JEBA1I6J?\5S@#!V>J>NBLM]>CJ--,?)[7*&8*LBHS3[<C+,Z-$+]L*
ML;L([,H@@I:I;)D#W@+P&/4@.DNAJ]`B3ZP^YTP(T_;P;+10/LGJ+U%,]S2F
MM(Q,6&$U)GQ@@@0#&(C-`Q5@*.4!&M;HHI12&A!`@@^8%,),HGSX`F+DDEH.
M*1]VV*$+(-;(HSI8<LFN188/*.0P3`WCJN<\@LZSHC=,6+4_/KE""\6K>*!A
M2$>;;C,ML`C&]#!/![V*BG3OLHC4%AWL[R*@A3Z,,`8[X]#M#25J<6P60_2L
MQA+[>H"'QT04;S)+N;*71#G7OK#%L!#%\R%#!PTLC\#R:G"M-PY800C_"1CX
M($N7K#S!R1,NSRD&SQF(@80FA8A)3!26F!*'#;Y`DZA"\@!5Q,(''[QLPM+J
MUS,'?[<[,[`^!&W@P]D#"SY3S35H3TP%QS'=&O\3K/=[>ZQ(4L'`8C`\21=E
MU]+&0CK[.(Y&/8VJ96Y@BE@49M6`%`-F?4G7&#1H28J>3$9@V..&4BQD_818
M36D6")81E5>9P"KXZA2=")0N3F%*(5Z1S*5,$"]U6>HLPS,>FRJ"%7K!Z"P$
MT:!#^H41I(%-+0@JR&;D4[!,J<ML^6F7>O@B/0*M:E[N6E5%"K`:$BCG-1ZH
MV`\8X($7/.(!3?Q8$4J!`P&\0"=<(L$7D(,<_Y<Q)SDK^`(6=K"&Z'RA$,:P
M3BYR9AU7!8TKU3O/50H1@J`8!FP`<MJ<Z&*BK]"`!]Q3G!T5I9^(_&4Q05/,
M>2)XGLR4#T5D"]YG-$*AZK$+;[-XVR7AA)_=V6AL)EK0@51TK<,Y(VB;02%;
M\!,WNQWJ(MOASF-TA)8#*28/!>B*B=CBC#>DX@8%&(,$`("3D<6@`E.B7Y4^
M@`(#0`E^*!C3E*0@!!)LX)D5:%TQES,45/PD%7R1V^XRB3<<.22&!@&>*F^W
M&7)1[2%EDX]#O!.9#!Y&4?XI5"-S9)$]:<4A&>D/@"ASS[K@RV!^2I0]SQ(>
MA?CHG,:HY5N,<1I7]?_R)PXH``)0H`$D.N$#&LC<!R1@1`GLA`$&0`&3S-1+
M`2*%6,QIRE&"4D9G*4QA@SI-9[1'$$,=8RMQ0Q"=B#<\>#I&3V!IB+5VA!#*
M661;2D,7H>ZIP\R`RS)K0="J^A*2;>GI(84R47^09AG0&.,-D1*;0D8SSD(P
MH4D;V,$7=D!-W_3*&MFHF`H:8)LB0!&*,#B!%(+3I"OZX%A<A(X8F0"$+RQV
M!TRP&7;26!$J2)([XRD:>;QS@`)0`1@`"A?U`/2&P2DF:@>8Q7]6V!X4P:=2
M#`(2HPIEGD)LE:R6;6-[=O?5-ZVE@4,2T(YR>\FWH3.<C5REV1!R(&/H;3/_
M_BI`+0U3#.LYDE2$8]':VM$CK$A$/`GY2DB01H54^4EN9TF%"6Z`WA6@(!&D
M2`0`DMFE)DFA2D(P@$<_,+$F.1,+!B!!,4G@.13@``5H0,$.FI/@7LHE=[AS
M<(WNR;1V?5-N=',06;G2RKX\A&P(\MFBF%$`P1`$0B?AGJ'6M@RDB6=LQ[`E
MTL06PO_XJ"&;">M!3FF1L!R(('^Y;C&JPL"K&*-]2X'5!EY0,27\0`).H%5-
MA$`K)_U`5Q^020R44D#F'(ME1#%*(590B&99I3H9*<0B_TD@G'KU,DG;#&$(
MRM-1?<26`"I;5W1,D#LGC9(JWM%8,`*O##OH:E[9_XXWO_+F?'EK5)"LL:(,
M9H+W.*8BSBL)%59EJ@T8H`+2E`D6-J!,#\R*`3_X@34T<(6\ZM4V/(!!275B
MI2L4]F5:5`YTOB!&Q3XVLI@6\KDB26G'$$T@A')A8"*#8T'2R"%OH`(>>)`'
MRQ!U5&7S#WM,I&(&U@YIX4E0TZKG,WP=:),S*O&%>`HD$T[8<,)U6W%9!*)S
MOBDL"CE`%WBPKH+PM`":P/-W3DE=W578;`!MFGO8M:W`G9:.$M$ETFZ0WAND
M`@]`4(!'-6#2$PACF2<X`4A7$NLI>=R9(Q_.!K`PIF(N80FP:PXC\!"4/#3H
M1'8JL?:D1QD(V=QLP&N'PO\IN=K)H-L[J.V,='W68_[84[1VZVJRR[68T1CL
M.WO1GHP/4)EM-<90[Q$-C$OEO(.4)".O2E8A'``K)(C,`[<Z(N:H3+]>Y6\#
M#!@I%NR[E`!N&0^$)6R6PZR4&X#@#%"):#&XHUH94T:%B.GZHT\+SXRP*;:I
M]9!.!_9S21,46SX:'HP;\C7,=]W/8*D,0(%[E8.,BY#>%<VURF;5'@/F+9XI
MR5/`W-_9N,0`^45I:X1@Q"5;@P\:$``,FMA$ON+`!3DA`19>@`*E,`<(7?C"
MK96SV.NWQF;7`8&O1W.2@F!6-.&.I+][9AYS1=C9?5X]>]@E`AJL7R/W6?K3
M!Q?_^J=7KY1SL2R!Q&ZWYLW"<(J-U*+\,L4]W(U#W.E&&M#G/,1"""U3CL8$
M^(AWZB^#Y`(PR*/K",VG#`>7I`LT0"A0",GT0`-/5J@=8.P&,N(&4"$/8(9+
M0`JPG(0!0,=)9@5*/*XEGBG43@=*A,":IF3`EJ`"*J`>EB/!@,(CZ`V=/K#&
M8LA0'$0"3\2<&@DAM*U>K$U"((EG!&-M2&G]L@W&5*\RV&*%(@Q<%N,*M088
MR"I\'N,C%FK"#ND[)F+J2((D<._L'*!]P`Q8A`!8YDH#E""DFDP*\F=6HLD:
M[,ZD-@#+",BPL&]9:HDISN`I%$:-^`PD9._@$,1>'.1`_]K,(R1#,-PE<-C)
MJSY",*A0J0SM7<#";_AB"PL%#6?(T+[B#?3H##GL(]C$7;C'$WVN%;G"9_9P
M?4P%"%9BU#[@!3Q`5TX`"Z1#.K"`)D[-&J;!&@:!'Y!/^8K`-G``)PQ@">QK
M`UQ&U\0(.FYM-19+L0K!"D"`IHQ!)!#";])O4&Q+'S,07Y9'I]I$X9#&(!:@
MC]ZHVH#N>-;"E#3E&)#F#7R&CF*K.ZCE#&NN;CZP<"0''QT"1^B/,!80;MK$
MN!Z0)#W$ST;(&53$7B*)V.`I7G`+GU0)`A?2X$0K\N[IG4`ET1;D(=&+R$P@
M!ONN"W8`U"YG?B)A)?X*2J3@`_\$C"8$[*0@<4J6P$N$P!R/<.7>ZN5F)Q4<
M$+DR,E#J1$[04$1H+D3"!V"2BRO:#T_2[UOZPES4$E$43^$R9>I"2$#,)H2:
M1])^#GIZ;.M01-O$PE6<9B1P9+(J"NV8XBB88&688`,ZR@FH;.X\BGZ2Z`,8
M@+XD(`:`0"?"3"BP;SF48W:2A5@4A@K.@%5,(H((#>A`"(90Y-'FPBX;S1EL
M3&F8IMM(*`*Q!L:\(C0JA1G\8UX(8ZNJY2L6Y"]YL1V885S^,E(@*5-4B]!<
MK"L2121.(B64B11P8M3B1P+<ZC$3:P?&@&*63`FF@0%<H`*82&/>\P%4P!E'
M+EA\H/K_KN_6B)(U8@:Q5*:,:*HZ2"(L\A%(>D8B,2M&TH8"S8DAX&/""C)>
M#N`T`!+_7K.-DHW_L-/_?N8-&L4L3;)-R#)/$F4RD,:20C)#9C(+RQ(CW7`]
M.K(=HN:>%L.6Q&,KI@:Y1M)&(##1#J.$5LA'+J->PH(]:O$-WB"]T"L5:*<Y
M9@:NZF%B`,$E/.>8PN1)3"J9G*283(H$GLD`K*A)#&P+G*D>8J<YPBP/FA,L
MKW"KYD1():<!-5(F,7!Q2(1I%B.AJ"!HV.1Y8H1%;%,4MP,^',0A?\MY!"5<
M(LR#*.D6#Z5ZT$)IHB6F"B#MC.(H,/52F7%6G"PV2(T4>F56_ZHD&DG&2I`@
MR[I(.6R-L)K"*`I@\.91))YB7H+*@V3I>)KK*YCA1V.TT.S%5TLH/B*/8%YH
M:XZG`F,1&'7*4@"&7-"PG;:*"H^A@6QGG.JO'D_B)'+/`$9-`YP@/.<G!JA1
M.A)K-81`,ZWAU!B`#US@"IBH"-X57BM@U%3'2ZXO/[,/KMPJ9A9+UWS`9YPE
M.USEMQH'JA;#9RB$+N["7#ZP2#V1,`HR!'ZT+R;E6SZ12/_I/!3N1O>%`B]R
MX-#2+-G&JMX)_N9),%(T0VCN"E>T;GBGQE"K752$,9RA@226=D3LIEBVYG;6
M1]G$+DO0(DH6E@H%(I54YA*,-+N@"_^H:25:@@V<A"6J]`-(04NDTJ2ZY$N*
M4"?(M)J.T,!V8#G.U`$\`ABRS:>VZITF3'+8U$5W%D;UI#)"0S04[D?4D`H9
M@D\;5"#7L,UF3*D$Y'BT3F.]:X9Z9*%6B4`+`M.T]2@J%58<4SJRC%@P%0CP
MYP5"5>X\*J22:"7F+@::9`<P=55)<[%\0"B,A5AD:AZM8SL6*2O:J%`/1K1"
M**&\HU*N#A8!J8)T2JFH0%+X(C0DXW`IT#+4"5<?M,TD!21HCFD\CY(V[!;Q
MI"+S`O%,124ZJE><;'-UPAJID0E4QAKAQQK251O9$_GV:J]LXQ$JX%NE<AJQ
M2#FZP`?V$]3_6"/7[K<URN@ZJ**FJ,`JG.U`$Q:>;$LN8\NR$%4@F7=M(A3S
MVD-?;.?G5B@8^Z,AD.;U0,.V+/1C:3(CV;9'Z;;^A.(`4O8?2`720!8"*X/%
MZ&)X\.V[=.DJ1,PP=+1M(="50I'J4$P6[X_!?NX`F%0@P,RMSC0/G)0HZP$%
MN+0FHI)^[,ND1FY^3F`)3`I*GH]U3F":1@X-3@`)E\#Z\&"Q8LXL;KAP_63'
M-#)D4[B&(S#TD*8*3TN#&&,Z&P(MBX'8@N[G]E0\!@,-_0_'!D4_V.:G]N(D
M9V@K+,5-$((*"H!AKL)A5B#M+`HY0"U8,O52$PL+-#-^=,6(?L`#_V)@&@R`
M#9:IHS[`!\[Q!J;OUKP(U/Z.6%CU=$$`%A1&5BLB+IBJV?R2@MYEA[A'H`)N
MA@(#5%;L.Z;-.R9-@AYRVAQU%T6L7;1M(-O,%;]R+<2#+[Y"Z-B%71`O4A5F
M6SDU?DIMI*0#":AQ7"/&>X6``1R1`9:L/1_A$<*Q"%A@?5\`B:#8O_R.!K0O
MKL:$!!0+KL((KLB(?R.J[$JE@&.K=BADF/&E.PP)<)<518PA:MXBTKH&"P>J
M0:.W:6!,7[@&A<^R@]FX>=EEQ*XB!`J@A%=6I$URTJYJS_3&(*Q.SE*%"ICA
M;'>6)H]&1W(R\B0E<)XU4Y"F$-*K$'R`2_^$(!+"MCE,X0M,86D;X)D^SBGS
M.>.*Z>,TH"I-3IE8IP(\SJ268)JHN`+0P*Q/P$Q]X*E_0DT'KERR0L]ZCBS9
M9J?I>D@/KMM"XRV8P4.T(B,^M!@HRPU?CQ?%\"$,A"!$+,/,B:<&`A4KN"ON
M(RW`:<TR(B648I*/@AFQ@`E&MRG`+%8@A@E"Z@,\P-1.P*-BP^Z02',<L3.M
M!`A@I>_N=37<ZI)#,\QF66$$5+H8B*?D"9ZTT%!(*21^N+6ZK<V:+KN*;KH<
MLKLBHS$T118;I<=VK"9=T:NRRR$Y!4?@V&VAE:#@>BLRC21<)2@VK59>0`J<
MH&+L;A"!8%RKD37_6B.3BW(#-"`;?H`/IH'*2`$&TC?`'Z`"0LID?"-L<8T&
MA,-SPG8U^%4Z6",/-)&F1H)AWJ)GJ(!RH$J#''(?)S*\@LX@D*8@OT,,WZCI
M!JHLB_243.G"`0IOK0U$752G1?0XO8-V>N2Y2OB$;5@FL\M##3>'.HN/).0L
M]G288WRG&XG01LPA@Y6A"),L0.,X3>"\Q`(Y$FL,8H`GL,`4\,`4Z+<+ZF$'
MDCBK04I+PT3CI"#ZL)2*GBE,-JT(O=3CSMH`T(`$K"]VOB!9&"JRH;EW&S2-
M>9R#R5(+U;`K&.XN[O2G(NPY%57%S="P":VHK8>4TN5$@WL\U*)LOH(Q_R("
M0JP#!(9%*!S`8>A;)E;F[QSWI49[!?HK?OA`"GX#[C(J)U!`$7T%!?K+)V#Y
M"VC@/E&*51UW<@NA.F(5]QZ#H&*8((!A+9U&T8BSV]ZI,KSC-);!+-;R(2:L
M>_HBAYY\QTSL.VKW!+N;I-&2PW85A`)-6IY"LY@12V^EO3L7"^B]&KVWWL,7
M")"@*-<9B0"`#S[Y"@`\?>,97D>M[3PG..27*$\'?J8Q9F)F9F:&"?"@\#9Q
M5MU(+'`<JF+X*ER<0/BI=ZTS:4J+TP,9-Q764#&RJVQ'V[8BZ6"L+#GXI9.\
MQJU-/)ZK4":4A%.VI7M\+7;5:'3I=X\SE'AQ6__*"ABZZD-W=B1K\M+I&*P2
M$"<?SF>*3+3C^R62B03>ZJFC6LRGFBJ=UG/V"^$[SJJU-*LYK2J1T+^:%@V6
MR8NQ0,_Q0$W(.+D2!>FQ,`+ONN9%-HTMF#PT;U)HZ#+R\EL4ERX>!,9.]/)`
MFCT6I=FRXBLD*0H1R4$0<V"9PJ+V(-2F9#Q'-U./HI8H%V*26A%)35<D8,DT
M\\ERPNZ&@R>6!3D8RZN%(&RS:')_HA40J*:FE6>B6Y#"@YRH?@NOVS8!:HZ+
MU$@=,B24OD<VXRP@__G+0\Y$BSD!!+MH'EO.^&M"(B^O`@2N-]3"FA0\H+WK
M2[ZM,;[/F1H;JUSO&W[_UK74L'K@X56>BP`&YK/M7@,@4-3[XN-+EQT;EJ`P
M@(+$AAT0#0(YN*.`"1!6K!0S9L($E8XFCAT8:>)`H0,=CX7LB!*EB3?'1)9$
MZ6Q6NV++G+TTL8#'@5G+EKT!V='9,IDOCRV["53ET&,WV\W267*GLY@UI1:3
M"G26S6(V9VT5JY7K,J]GOX:=)3+/@3PK_\F=2[?NVK1IRY)MNC*DU*$FG&WE
M0>.E396!I5X-W+5QWKU'#U`-:13P,:--+PNM"MA$H0(%@(C>$,G`!PD&A.SH
MPKIUEWHD%)(@L?##"12X49\P4.&#AQ.[%_)>B+L"BN!+8N]&4\&`@26L\7S!
M_X.GP`%@1V&V.ZH9K5JFX+TW!@^6?-AC)Y-VG'K,,M[)C&U2(4F9Z>*49X\2
M19D7<<BE.NGD$E1D^=?165:T`X()-WSF0"%[K`"$`5)\@`(6/JR@X88<@E9`
M'AIFZ`,30D@A@1,__""!!QJTJ*($/VB`0HL?,"3$!DR$^,476*!@FP8Q()'A
MAI^!9@P(('!DS"P<#7@63CNE)%5[._EW65'.&#.243-A*55?1;&W$V!#!053
M3E5E.1)*EVVEWU"831757C:UHQ)4^BE)%(@["''<":>U*,$'0F`!!!*B)0K$
M#DA@X:BCHGTA&A8;G+`!"A(PH`$#FKY0P2-%A"KJ`_\PO""%`214<()J7?C0
MQ0:4'G>I$$GL4,]$J^V`Q0YY&&-%DL90$2R8+M'WQF1KIA333.G5!!15,2V`
MQT^+M:<43%E6%=A8V:7$#%?P'7"G47J-5]Y>8XWEF%?A=;7,?!^R6=>\=+6+
M%[M[+7;?&\LP`Q*_L]!`PU#%W,=84!V9)=YC!?OGS'V:P6G3?0<`=D.#A:SP
MA818^`G<:0H8\)!KK^V0A$+)X2:%%,#M!AQ#4KQ@`!J[22$`;B@LP=L2NS57
MP1)"T(R&`+PET<6.IJR0,;__V9G8PM^5=^ZZ44>=DTLSN>O4?^>I5]-9SI@T
MU!O<.O/4`<;H*R!-73U<)9K_;KMTEE;+'/!11U8L8TR#!13B0`$2;O!!C:L.
MR>'A@.<!FH8Y2HCIIC\X(84'I*1HJJ8?<"HH$+<!(:(//=88C10;`,'$D'T7
M>88Q9P@+94<<*=4.,\MT%,(!RQ3\$IIH`Z/2646]@5+:VH8$U;<LY:'49F^P
M15/MQP!CS)E57<E9?`;7]#"!Z9;U.Y/X>98Q$[3AYMP/UJAX@J&*)OKHHTA`
MQ/ZB8_AXX^,M:FH`#`^(^LC_15"!S$YU'!1`9`<DH)00#+"#AI"@'JQ9PXX@
M4KI>&>."&#R+EEC2$N,%AB0F@595TE.4-[5G&3TY0#M2$I)G[0<E85D,3$S0
ME8:%_^0I*W'6O;Y#IQWF16IA45=46&*18]#KB'<13[DBL\++Z,0I;C/!,GC`
M`YV,+8K.HHH.E=@5J=1.,EXL"6:H$A6AY"$5A6!01R3$!"!@X0047.`))*"!
M#R209*^!C:IF8P!25,@YQS%1;XX#2`D`1P7.J5'.C(,JA_",:#.K@-%VU`4\
MW&!:4/%=?.YE'GLI$8CDD8J6(I.>(&JR(\V+BDK$M<EBN&4GZG+&?)#R-?K\
M)"R1&5=@OKB2W&D%=@?BF]]N4``D".<$+T!!XP[7H1549P6+"]&(=A"#R*%O
M&@SP0#.LD3\/<,HT&I`"I5*S(1\LD(X,``X*-K`QT'RF$/\^L`A&+FB")=7N
MB;GSG74.Y)(W:$E<5/**@*0X4.!5"2S%.(!U)..?NN'G`-^:2DFNY!+=U5.%
M6QFH\9Z'+JG<I&YZ(THA%L"C#9#@90R8!OHD((3V`8$3HHE?HQBE*T;M"@OE
M4PVL+L4I)W!*`BA@`:A"-=0'X*"/'MB`$"IP(X1`!`6DV$%R-M"`>@RD"Q-Y
M%0F`@`=A95`C(4G/21##2_H$IBIFM>(-U]..%-X))NH22<5`HA2VL-"C4X%3
M"YWVM4\&46%4ZR2=YE0,8,RG)4>DER?'(Y;%?-$8'BV)+Q-J@@?@H28I^<I(
M@F*3W0&685P)DU?*1!4XM<-L[RS_A&HW,"(W"H$-3(CM"K#`!`,`@E"W6<UK
M#M*`DSG'`PSI(^$`Y8'FF,8#$FC.0HA&`E15@&8G^`W-&"(`-*#!`$2#("6_
M0$S<#65V/ZR:8`,+RO*()"@#54E6#A.E(`I(O>`RR4J`H363H&0[_TD)[AJ#
M&+TR@RJXBX\5A-61(A7B!@YHT`HN%1QF`@YQ&GIPA%<@A!_0U@=`B($&6)2^
M$[1H4PSX`#9-HRD&2`$%0A!"`3`L'`-X(,5-;56$%U>`,_RJ$%18AA7$TA>C
ML/(EO7(:[E8(0]JM#;)I8N_89L%"]$C&;,J[6B$$4Q.D^&XD!-+7?BT*F*N(
MRQGE\@KX_Z1HC,^8KHV5,H`&4F0-"90NMJ:+L_O<2&>;Z@H%F//3`9_*`'3J
MKP']\U\1_H?<$RC$.:4;T@XP;*MZV*H!!\$I!;EJ@M45(V]2O!O6!CJ2-$H&
M)/*EB7KMZQ>P]`0NIOT*8DQ".\1L#2KE$2&89Q%1K@A67>&]]1+Q5;:9)'9>
M2337++"C5R@6MA@OB>(!:%#%O$K17R`1S']+J$1FQ!(HV-I*,3HCF#=X&R2?
M60'H6KHHI:(`"2F.'XP#^0&C03"/)DWQ<'HC@5,9X#8N/H$`"$<S4_'FWJ9!
M0W,+J!SL&ER21S-%/?#@3+B`N;S?BN@.]9(N^G82VE"!%@X%H_\8*K'5A:BL
M:S'DFD-VU:U8B<G)UIQUVOX>2#]WJN<LP*K:U"4XW'VZD>F:.6%H]MR9&JK4
MN<NY`V]R*D8:R)0U3*R$&@W.`/6F5`Q0`(0-6'T#&DXQCKX`01\\D\8W.-(%
M=0P4#^).DR[1J)6&,CRV>Z1,W_)XQ51.DAD>2%OI-1M1=NEL^`X[Y&WG&EC$
MXI6/%`)$I],00A:"3@G$``M(B&T;VX@H.K/O\@B)A#<'MR(A^(#1BX*Z!IR@
M`25(`0<P8(%0*2'4(ACU!1Y@V1)LLV@?Z"JKJZE'5>N1!"&08,^4QLB[C'$,
MXD=[3YSY'0B5]Q29D&36;>5!"(HR)X__[X3NK%1*1/5N6MH!A1GB+49$O_\=
MB7L%&.6)J/?_ZIAW'>#7=;G)^.<F%OH^L3W\NLIE)M;?H#R`!["V+Y5Q&8KQ
M$DOB4>(G%>C'%<1&@!+U$J=E,7OS&5]`36RP4R3@)QW34I3B$(!2(P^T`[LW
M&QFH$#]S'!_P`H33'*CA'+^U&_\6@XQT7<^A$-=%--<E<%=52=`4`N01<6H1
M7O9G$]8F%1%56,.6?B5D16!66@YX$YWQ!M['.\;C12J!:HD!;1R$/9LA)6"Q
M+\KC-/KA5;7S3@_R((#31CM@.H;#3(?#<!SB`^:&`C$`!$JS8B2"3AJ`31P6
M(].`7!N&9XY'_TA",`9RIDPZLEN?`TV@<0._<D&7AA,B81U+L4ICLBQ?AE8T
M$39?EAT9M4H641G%<RS"0QG,`D,SH13J!3:6F&5.87Q9HA)<,7-04@!KH"MC
M,$V7XF(>8"&%(AIM-"F61V?$N"A"<!J#0PJ]:$"?]WE?P`0;`'4K,@UU=`);
MP`(J,&C^LP7*B"HH\&([4(&.-HZZ9U5)0((/L6=XL`S`$E+$1WPS!$+*PG;V
M]1%R1T+',&PH1`,.=Q9&-B9&82WTZ(`Y,38'PVNSXT5$6$.S0WX*N17K%Q7G
MPA3TA7Y?,3LO`7]T\2U(J!7`(''6DA);@1B"T7=2(3"2,3%/\1?4A_]MV]*0
MX4$[(/DT9N-MWA9V-^`9>>`J0$`""A`#&>@G=0@IE&)2/E(A))`$5I64*:80
M)W`))_`S/.-'A.-B+LB+SK$;,K,047EOQJ4J-FAP1%,!E\`:`Z$A>?`&\E<6
MY\*11(A78X$=>P$>U@8GHMA7:G4LP]84E@%F<?<O!&(G]!$3ZA4VS;)>I>47
M_$<4"`,4'V$2-5<`9Q@BB9(C$B9A;BANI_-Y0"`$,3!UN)$AB\-B=+1FV4`*
M'Y8B'[!FCL=-]98:J;%,$U80>70T7\!:/E<`&`$LE_9%<+$LRP(GO*,47;)6
MJ&043_0M8;-/,]0>5)!M:=**>T<9F_$PIX7_=\\2$\@#9K5#!4P!/K:WBS&`
M$$*@E:D!*7)V*.TS><_(!,\8.O56,Q\`E*+1C!GR!21P&J6Y82J``RP``[@0
M*KCP`(]0`1[P&RZS!%B`5;7R&E6EE$D0H;.Q`8X6$7!A#'J303P&&'#!)F>3
M'JP$&!UD%6:#!S00`OD(##>A5FWR@"Q1"-K7<BD1)VM9:^<W'N!W+V,!DV@!
M?D-(7VZID,ZV#!HY%W1)?^!U7F02D*BT%,[V,"@I12II`O_E,"ZDEPD9<0A(
M7RK'&'J'1CF9DZ@@'5CU>:@1"7[2$'"V*#B5@15`1RB0!!MPCGZR!*I2`<UE
M',:!7"HX'`877<X!_TD>\`);\%S.@08\<P)HD$S*(0".6EUQ"D%G>7C.H**T
MUB]9V@X)2800R:4W6I$Q%#8Y49T+J4E.\22S\VJHZG)^*9C*DR;7N6DUD5%1
MLE[Z,5'$IV-EM@*R=8:@X1"&8ID;@ID^%X<CTEH]XGA^PA!,P'`/AF$>%B/<
MY`3(E3ZGT6<?\`.`:`!`,)^&4P#N61#B.(YT5JR%L)MCAVPG,1\=@1WW5)!]
M,4/+``PS03R!`0Q/Y&5PP1EEEW_0@TK&$S>!83;[1VV)"7U=$1-!@6RYPR09
M,P8X%0/+B((G9H<C,GG`*'DCPDQXT$:8,B@+00H60AO)$8[BEB'DHV;4FO]T
MSX$#`@!```0#*L`B$M!<#.%H#LI[$:JSO.<05.5HBW*AO+EC0+$F;,)"+;%I
M2=M!UD=%&)6J8_.$:P.PFN$4,8&`'.E1UD9?$/E]>)460PA>;[FC68M+YZ<?
M-5&D<I&$%A=QVE.K:C6PNT,[]/H275!%';%]1(%%M$85F"J341&D$N5/;Y$*
M83>!U'$T7H<'72`%I)`:L+(#LS4&DHL0LP%5#(`J2B4$=GH;2Y`<UW4;C'1<
M'\""+;@;P!5="X$&Q_$;,X.Z`A<;:.`!1..H9"FI7Y`Q>5"I4Y&$"8F$81M1
M7.J6<\,,T@-&5#&\OYN8"NEEJ`2\,B&<WX(.;I'_'K23B=D'JM"R7QZU06A3
M.\N0!TP`$24PF_5P(XT#..I;K,1:3K%%3=ZZ$#%P(XD&384@*3MP`IKS`]3H
M`=:0/IKB`3$"=2:&8E+04O&$88NR6Q":!)?0DT*R.#>`$5;`$?5D>"C!+\K9
M8X)I`NT`I/RJ1;%J/&Z1P42H7TTH1G*R-BE,0W7+<2*$J?@B>/5D#'PR(EAG
M*;XA!15`6S4G>6=V.K$E(D`7(D+`*5.7*5*`0(MT8JHQ'4/R!4(@`<*@9@$\
M#]@(H*(R:!4@!1K`1R=0*P8!&TFYLQ$:H3C@$*^Q*]/A51DQ<TSF&9MVBFD"
M:AUZ5B%!$DZ;D`?;+_VR_VJXPPR6D;V]V[:96EB_*W'"Z[5:&J1:RK9[:7\2
MTPYJ^P]9Z@P1Y\?HQR;V)T8W`0PTT9`E\7]7,["T-E&GQ0P.ISV;-:OVE\G>
M-SN*HUHXF0?4L2/4P;BL\0$BNTZZLKE`4`!,S)6IX1"TX;D92#XHT!PTLQ`L
M8F\N"(,':C._!5PHPQO/E5PXN%Q#0[N2)*E=`$^I<#SRAWX_BH0U8<Y[B<D?
MB<G5B2:!L;6]F\[;FQ6M1A1#^%ZFC'X%L``[T3OS*A("C:G8H5\-"Q;+D$8<
M40AM]$:;8BF;BR-WZ"$4#1J*XR',U*V.US$V8F[`Q4X,ES&@$P-*P"D!?*TJ
MDO^M'H`"4J!2FU(IXYDA56=5)J.4CJ:4"($CJK4"$_PK!\(D(_$1>@FO(C$5
M5($\NT09LR`\_4(25`@2,GE>XA+0@4R2(F$,Q,88PA,]#RBJ9#%X'!$4QK!B
M&9(Q*'`%#6`$Y)`':YAX*W#1DR=YFUE.(>)A#(`;3F!(R\IX@I(S&/)Y#`<Z
MR`6(#/`"&Z!Z+!`JJO<_,RL!NF$I1F,REU#&.GO&EV)`6+4H>.`K&:$1*G$W
M>%P2%N&A']1I:!,\+5$`/#`MK6:0ZNQEKG8`A96*67@6K[W.N)W.QY;/X`6X
MC:P]D&S.%B63SE#)P*T]L'R=6<B$DW$LA:43S*9W1;'_P<<BW7)[G!_YMWZL
MG&]PT>YT>'@`V.$=WF9)`O7&!B<PO\9LS.4Y=3?B>\6Q!%>P`8QX`_5`2--%
M(?66N@;P`AJ`3"XH`/DI,\YAH*E+-#*3'$O@J`;P"42S!4JY6P6`![O;+[?]
MVK"LW=_2R;O$A+A=D<>F=^J%SJL$=Z>5F-%#6290PI*1R62BP8IAD$XJ%@N=
M,>)VC"W2BZLBN:ES>!9=T1]2K)J98<I*'%:W$"MSH"(CFBN&;A^@!"#V4^C3
M9PQ`"G0T*$EWY'6H(17(&A0*:1!:H4A@OP5PN,#"$3G68X<Q-L<"K\GV,`$2
MD`/2&53R%/,:%-G'I,?IDMJ7_VS5J3TXU+!>H1$6/*RSM0/_5PI&D`*=P`.B
MH;X8/<1"W#A#8DZ.;0`QX,7S61O(14<`T-<.T8PA@@69,GKZ4P&M5P2X,%2/
ML`4M\AS'`1'C>,:TG@2C$!N^=Q"20A`@D`N$'CM!H7PD\:J82&IBU!G[RFS7
ML37Q#%Y#H241LQ+V5:GH'-S`6\C8_I%\;.W"?>'53J^7T<F5/#OIS+;53B7N
M+$,#JU[HYPP/4!C7_3!B@B6`.=6^7>YF\Q:@@05C@,`$L;C480I=(/`F\X&#
MLRJ76SZXX1`IIJ?K-"1(@`0WL`([8%SWIF]6WHN!VH(&YP$Z$Z@W<ZB'"EP5
M8*C8Y?^HM+L$-GV6T]*JOMW;O;W=VSW;V,*$B"R3?PM>>>F7`?TO_6+4UX,M
MPK-/!&AD=)Z07?K3E^89'K('&U`":[8IJ>$Y]AN9&+V^T%3IG5DC,9#>N"&4
M'V`B*Q(S2^YSE+>:FZ($T_`"F5)BF:,B!J`I?T2'SK@HYFA5E5VA=JA:!V9C
M"^(1.V9\$H.O</M>/^]E=XYE7B8NV/%JV=U?_`(,I7C<TTVP<IX3?%$F7K$1
M"F7C"\"K:]``-%`*I)\"I:`-(D`#EGG1BJ.9FBGJ3/!&%5(CI@&#HJ<Y'_;I
M/&QU_Q[8,[(B+>($A#I4HC*@CR``&O`"+=,0.%O99WP)MW[_"29E*^$XOGG`
MCAF*H6XB$R?13X"<?!Q4=Z?6W$:AG%NCEIU<+/=EO.@,\R]_[_-,:[/SHQ]>
MR-7NX8*!$I6LX>X/$,N8M3OVQH3`9<Y,'#CFK)U!$P[;T:!QX$TQ8!"=`4NX
M\""S-P=,%(SH;!8PC"F!.7M3*$^A`E@^2%%P`DL7'WAT=NGRA2?/#2@,?"`E
MX0,*I$ACH""Q80.)"BBBDMBQ8@63#3$^,"FT8D,%`08,H#EAP(,$#P;"BEUK
M5L58LR_0&"@;MD):-`).+,DK`(T'#VB6)*G7I9Z/%7D.J#S)V.3CQL`B+S/H
MK.,;9Q@%MF.VN?/`@21-O#G&.:%H_\P#@1TST7JAY6,'#A0PB%G@+):C1RZ;
M-:O=LI%4#BX[`[/`GA5`##CY88V!A@\;F*PHX++0]0(%K&K7;M4J$R!"M'Y8
M:B!I#"D2)&B0(,6#^P\&=N"AKIV)$`D,]$][G__'CP_T\R#`_!B00HBC@/CB
MBQVZ2.+!PNK9`4(@=D"BNNMN``$$8TR@@K=VC&%MM,T4,J@A9U@[AJ.!*E/(
M-9(LXBA%W1I:2;?1BGGQF(&<,7&S8PIRJ#4?9P&.-6.6668V)ICP83KP&FB@
M%"JK+"4%;198P8<"\LCNR^^V=)*)'5`@2@(#V!CJ!*'68^`__0#00`,Y-9#B
M!"&P6-`'Q/]V."$]]J:1X`08'BD"ER**>,10'`0`S(,*#*B`A,(<?#")49*X
M!-,'FR)L!P:[R,,$8THUQHK>0I3M@$(8PI%5V6I<M=76WL"#AP5TPPPWW&H;
M+;,>%Q*)M-TD,\G8R'B%#"5F3^K1L60A.Q:C7M\H,383_M%V6VZ[999::4_B
ME37,,'IQH]9$<H89&G@0J9W<U.TLMY54=.:`9>`5]]B$#GC)OA@D`,"H&(#P
MX2=3OC#E)P=)0.%/]NB*@<U)G7*83::`R&X,]#Z(;X]"?"!!+;%.0".]]^QR
MM()(ZU(K+0%>>%D`H>:2BX0E/O#`40'\&JP>H.G#XPW.EDT6V6__F8WMF(0J
M,PVT<)<EETBHL27QLY!6;7JD6*_.]\7*>"O&2.%:N\&X/;#Z0#T-?N"#C00Q
MA,DE+[VS6\SPU#-`B*'V'L"`]=BSLSTII!#@@Q.^0$P[()B(08/G?GC.`PV:
MJ2:_P1E8FP$/D-(`B2Y`K>?2!R=,8@/"L&)"[ANHV+##L6=1T6L3B7RHI&58
M\Y'(>X==TIAU*1N-M&4XJG4DCIPV<5F%&IJ%2-Z`$[$U)G`68@,L?!"B@0>H
M+(+*%*XL11MM2GFRRR_SL.K)J\);6X.RVCMA8LI_F.;^'\IX;LXYY92B@H+A
MY`LKV,$&EL,``TS#0`;`P0,2A8M%*0H&_P*8D\D01X(D?&%T25C"$G"`J4UE
MJBD[:,`.3+B#/)C*"J@J!G`\XIK>K0I&'BE`K`Z@$![08`&CBLAGA%>;8I@F
M-QYQR(F.Q2ND@6M?T4*B$ILU+:3A1G<.21&^LM4M+&YKB<M2B6J6%RR-O`@8
M[:I=25I3/-P<KXH(^0QGX/6&EW3E/F+Y@`+DAX*?^(1A/*D'"4@@!!0494#F
M$4(A4;`$J2`%"RLH!!.&(@6/E8`\U?F"4,)2E@K,1&9S,8OAPG(6F7T@+W`9
M2\\<Y8&]5&`NGQ``*U\@@)\1ADMXV`@3C04:SP`)7S>*2&14XD35F&MX)F@C
MC6HS+1.$H!#&D/_-BG14P]J@48JN,D8[>F.%97P))@[PBA0TD!8#5&X:*-@`
M&X0@M[EEQVY0>A(6I#"-^<W$/&8*'/_44SA(%JYSBK-*XY#PN,@U`RW6:(9^
MG%`Y:]1/@72)3H-\0#J(^K$>JLM.AD"P0F-\J#=+.I>/3%296=0F-KMK)C-,
MT"K++&E%`H%(99BA$(;<$".5V0V_@F4"SIQQH\+IRL/B<X*R7*%[#BS%]ZH4
M/O(M8)'HJ\_ZP/.!:0!@?NN9)^`8<+]IV$]R<>H?Y"HX@!VLP2<F'-D/7J`?
M/GP3!HEBJZ(>,,%!;4$L!L"@@[:PA5$L082CX&L2<."4'=0#"!(JP$7_485-
M#Z4K(B(YZ:A$0I+8A."D-R32`F@PJCQDAD6^(F:).&L0EHXFB:-E3-*6^,2C
MX0:7G0$M:%X#KRS&UK105.)CJ":0A3@3&*-Z``\Z<L.BR4:SQ5"7[=KXTGO%
ML0#A04$,Q'.",WU`"%39XQ[[Z$<#`(@I6-C!$LK"%!3LX#J.DT()AC()2'Z@
M!"C8PPVP(-=-1FH]@Q1`I-1R`L"\[`7N6<M=8&F6)>QL"5O`[RE]1AC"=*$`
MM$1MU'`#KH4DY%XF``9JF]5@)(*MAPB!2&M>^JI17<18L^&:D7R3NY&,Q`K%
M,,$.]N8#(.QA`Q^(V%7;4SDI8&$`*,!"EZSC_^,P;<D'8P@0GMJS-WKR3TX#
MLV/A/&8XP*#`8'C0C@_^R0#G9(,!:('<-`JG0`2E1PD:<+%T?7"82VUP4YM*
M`DZD`Q-&FL"P'1);.T3BKUWN"%_,8,TN1],0QD(@-@EQ8?!TXZ^(/.0`S&Q(
M,6*SJ]4*Y$>R(Y613$#`/P+N/QI`P16X5XKN>>^H6-)&)Y9:M[K)A`)2!9P$
M8D#'_&15UO;3SW.>(R<&`$!R&C#/!AH4NAV0X`3L\>8/)(""0CWP$2Q8%`S"
M:=:28;"/'<14IJH]"JC0-;`*PH,)5HA-*HQ(1Y59U6Q,U&?9%$`3$0X)#;JP
M`,:NU%<K>HR&?<1G?/\9L[;*.IH3H75$VB8-./*"Z4><$=LL(BO@_&96;H+G
M\!>98`T\6->Y(XZ9<_V*WY9Y0RJPPP0L_+&Y#YL8(`9U/2Q4:H\-FA#J^(:4
MZ387DXML9%;Z9EZ/32*2&VCO$B+U2KB\0&<O`"?ES"(6P.3%DV%AN@%>*>!+
M+$$`\_#`)^8AERT09G1?P$,>WG!A?RO<1<W;R+^;*)D&YP:DQ\(68S%^#&B.
M1%^1U4W9C32B#A4""$D1#PJD<%`T714Z'Z"`H)82@PU@R$M,W=(*9"*%PY.G
MN08`%/_L23AYXO,]2]B!#[X`!-#/N-9P\H#E=NTFH>L'D`9`O`8-`R&M/VC_
M4Y_?`!*\4YU362&C^7)TJ_I\&E]MQ$=+BDA'BK\,9OJ()`B)%;E\Q,S:S(B-
MN0P6TT+4F@+X(.0*PD(X&>"$HS3@$:`NJE'#5Z6D5H6ICA/84-B#N!@(8#W_
MP:I6M[ID.D%./_\QR@`V,%8&^8IF<`']TX`78#:V>H0'6,`&H*#_B93P0K!K
MXZM+R*LMZ"`42`(38H)1R0580+X..88@DB+,8BS*NC/':HVVHPC%*`A?,2)F
MP`B2J`QC$9Z-(`DN0KM?&JTM\B4='*T9C`@5I"F$PZ*B83BS0PF6P`S."$(?
MZ:W2\)%YNS@<+!YP>8.6\!+MFZX-B(2E2`HS\8"E_R@DZJHNH$F"IE@"0T(*
MEB&GU7&\OY$D`Y"D)W,R\DB\`A@9IR,9LT`+3P(,1WF9M-B94YJ+OO`+7IL+
MDS$+1Z$ZP8B]G,BLI`D[C%#!W;&-XZ*^HO&A-IH17?&1HHD1AC`FMUL18'`-
M-3(QY,,^QPND]"H+_3.*:=``4O"F-S&`,2BGQ+B.Q5.G\#B\^4$!\1`+!>@J
M_).`)DNOF=`9P/@`SE.0Q@&",<@N!N"#^ZD?_>"U:;`&2!(0-*$+7S.A,V2S
M#2J=';@>NY$S*^"08T@2(CJ&/*`W>^N5DH`XEK#'A0`)CSA%AGBC3YP,3N2-
MNRL5$]`.!MF!QM$^%*`<C_\!*D\COU`[JBM)@6&@@>G0#@0A!8_12(^)CQ>`
M'/NY'W&POZVB$UL;O:U"D^O1(U#9`">HIQ_@-`54-D-Y!!AX`;2(CTDA`3;C
M*[[2*PO$-N^2-CPX@`\TE20QL2I*P0Z;%5<QB%7Q`1H0@>,I18>8E^-9J<ZX
M$=MPOI?BC`OKMTE4.%O:P=PH"'5)'I$HPFY)0K=T.*S\E8FHB(=;B#>@QZ<<
MOAYA"8_3#BS8`$`J)$!2"F&$+B'`&"%(L,!BF`9XBC]R&!0@"V$$@A5`#B08
MBO@PKTF80\S\`)V#/"2X`1]8`J1;B[-`BY3YI$_:&9C)+].$)2?("P%;`JJK
M.@__F`>\0K##*,I:@J+5XD>/<A%?<K`<W+C:P<3?"K%HPI83.:;989I90"PX
MH[UP8H^'D0+[<;4WV;(/>`$O<R[$HPZ7R`[U`8*@6,-",J#*L[S\(S8[I#Q]
MTALAZ#S$&+(-T+_F8(]:TYPW.0L[L9^]&8H3,AW2V:`E`#V'`3TG*0!CN*A5
M1$7%HB*U&Z:-$)Z(@(B&X)V"0\58J3C7((VKG+[C^@W6R`,R04C04QSSQ*\U
MH0ON(:JBLI+Q&1\1H(%V2@_X0Y.R`)20_`%QJ+^MJK7\V[\WD9R8A+SY_#6?
M6$CV<(&%JH!D*X('B*`'P`'*X34V'(P'L<"[PJM1N*N'_V&*4?@".>.04A&;
MNTN78>&:5KFSJH25',HL-94L:ZFW87*F'IF%#\.,C!@)+&0:'BQ.*-HX'VRB
M)62F>B02MN26"NLB-CK"1F46>"$18."SL*&!!^"=#RL)',RWDY#"OERN,1BY
M2!#&P0PD8303H7"N0B*KQ0PL/Q+&BZ&+ZUF=Y4*/H:##^/`8SE3&^-`"O?LY
M/I0_P)`9I^,<<`I$`8`R0DRZUD0#G`&,3W@4O[@$H!F%GLB#L7P:@1BIWT*C
MQX`:9Q$(L*M4</V,J4F-IC%!@NLS87&>2]P-8SB;]4&,%1`"RC$*,]&`[_0/
M#7`N73.0[AN#Q*B.?AH#(0`]I/^HO3!;CSJYM3FY)SNL0V^BG+38`)RXBMH#
MJ.:8AC%C@&:81;:IH+9!L@,1Q]%A,]V4LA5`@I>3CL)*$MU;"&,P*41+R\MX
MUTFMC6$Y)A>!QY*`([>3M$,C)N'3+!-KAV(8&^`@H(2%,1-:'RP0"BF@"Z:8
MDJ&*4?&Y$FU(`<MRIV/3BOGAF[\KTI`4R:P*TOV!G(#=*C@Q$,0KC`9A$!2`
M''^5`!58JT2AT@?8`A=P`@,@3?.XE$O8`C3HT@M4)14@S24@`1^0LU(!@65`
ME33M,&(1B1"0H=I!M!!@0=*`%9=8$=R8T*_#",[82AVY&F%Y#8QXJ9<ZN]:5
M-"1$&M?_S25>.C<:7-1MD31FN*5-)-?6A9?7/9?B,9$#:!<(@)Z5P,):&2GA
M]9$\^)=[)3DV>353_:.CR#0I(`6E,(\N:(H&,`P_BKF'81/.*X`S`(*.42]>
MG01),B_XG0E(TCD#J`X@D$VUL!D[V9F9J4V+!<2D&XN_8$V8,:5'F=;#S91Z
M&`Q:6I=;XMTU(BF!V,K/J+B-"\C/8):M9,Z/.)&%4`P*(]<258SB@1>":(V\
MZX[M("`4P,EP>C4-L(8?:`88_E?1^P$%V(!IU!@O"8\-H,S[``($"(K"*<9Z
MJI,ZD=B.?#+_M%@!`!4^,9CN\RH&H`#`P++V")""`I0WT0!\_TU,"2E'-N/)
M>E`<$D"@\,H#6."092@;(4R7+VH'""B$$*BA=2&B8H`WY3N`#XLINXRXX^G=
M"3.!S)K4&^I=(QF(C3(!']B`$S`8!<F^IL+75\,3H5I`4;,2I,J2-6"/8P,]
M(<#)MOF/LQU)_-FT.,DU_=N_1'A;.R$G">D)'W`Q>Y(<#\`!0]E;FY32NP`G
MND*=3+FK!-Z"L+@K1_&UQWT=P_*-$?D5L$&TEUB^<HO'!>`!R2HWQJHXGN61
M'JE@J'&10SN`E7B:2MV(WLW@UBUGT/#==3G"X-E4F)(I8-!=;:G4HC%7<Q7D
MD]!@<I5"=>7'WNJ7'K*,QZH,<X&C?_^YCU>+A+Y+3S`\3^L=BC\JBQ-`'8O^
M(T1*)$32F!M@@HZ\N3G<5;'0S$>R0\BKCAVX"Z`;BXC-+T$4Q*K[@%-Z)4=I
M`;#PBZI;@DLP@$'P@$%P`E@JW%'HF2[X.M4Z%MO*MPFCHG)VEDVLN-[%B$JM
M,-6HW=XUOJPIB=U2K*\D*1519$=K#;UKJJOX`K\4BU'5BOQ0`NF*`0J0'/&`
M'"1[VD*B#AC+#B0PD\)1#X?MG_U!1GSB58H-',#0`#1H$`5I9"*;X2HV-C>A
M`'MZ',"9D^LYD,&R%`G9`6L=A7KXRQE#DQZ#A75L#1!X'G7)#%>)"(Z8#3=E
MWF9R#4]5B%'_\9$.S8@U#9Z0>*'%6H8@BL%K,H8"F+'$(6LP*8"R**2E(`%,
M#C7SXUHL,0(F^+Z$9;\B;66L^M&T#5*3+$"S55O]0-+`*N-9KH"V(84?&#-4
M@@$'DE(88`$IM=(?<`+OJNAZV`(2^%)B_@3#5<2+28+'-88V^+;G.1Y\]@A_
M$8X39!4>.@`\T*&%:--"&*+@2XC8'=Z5Z)779JQX?*E\GKY(%5Z$R.=PE=U(
M!2,<7`EZ_@=S499N9A87;]UVAF=!-H$NH+@(W1$:/(EC2(5_F=KY^:Y@9)-@
M;`JEP!C$09RDP"#LP8*,/B0>RPZ%ED/WC8_-5"\#V$R<PSGY3:\!_P`9$I!-
MFGX4:J4@)Q!S0&2Z:249,?\F-%`EJFN!M*B`)=B`%VB!)SYDI"Z:L?L51'9Q
MV1U4!]:1;M:7=ZXP4401/T5%1);"&AE!(SD;\*".JV`D^T`"1PX*<A(":XB!
M5Y."JR*G#V@&.4GKK*#,RK2*K-AR#S#BKK(\PO%5^>7KENX<"5$0)`@/;U*"
M(MVR:0A9_;RJPID3UFLN(7BH+W"*E#T=4#'/LYA,$&@#*C`5%E,7(YDP<DNQ
M#VZ(EA#GV)`1DGJ-8VA3>"F&%_10BSBTI0&1L;&"2^,;(:".?WF)7KQ7JST!
M$GA1K971318!_(@.*ZO;(ITU(&4`_<G&.O_!SQ]H9<D1A?W[IAB@"@E9$#_Y
MV/US`A6H22E=[RI=CQ.(B@P$(?S."_.]WB6H!SP0[5S`J&,0#MU:C0_V"*B$
ME57!(1TJ`&'YW&X_=P>^:IZW9T$>J4.S>1F!<4'.YY6@X'9^YQ&/Z@MW8-S%
MEP-(\0K;Y]YUYZO&YZW$#27\4R6D"'5!#6P!Q8V8UQLH@+2>F`\H5:1@$^F"
M.2'P^%1]&-8[3$#`$S]ZBD-J"DG/:SJL\ESE3/B].<^$3WRJV@LI`*%XE)>9
M$P`6\YX1\VD]<P.@.K^(39H>"[DX"P.X!,JO@*)F$;0#&]HN/A8)]`HKGJ)?
M"6.QY^"9ZJUD$<K_0+1/K"(B,M?C/(;?+@"L*/;ZP`YU8@*DR,5"VC*".8%L
MB`\V\/0?N)X!P)-WGX[D(%M\DO6'I1/U4(#WB`\ZBG4N.XO\XKPN4-"@"!`%
M6H?XEH""NJ?S[L[U6(\O_&%?&YU,,:'/<]E7ZS6;;]`'G9ZR`PAG)@Z8R&/"
MF;,W!PR::$C0Q)N&$`<23'C@P)MC#8$!<Z8QXAMGRQ(.;!CQ6,9CLZP<RU.`
MB9`30@H4JIFG9J$"+@L`B8E"R$\8#QZ4(EJD5*D42+6ET*9M@1`#*+#X0!)#
MPX\?TZ9I[?J#`5@&`#20U0``[->L7\.F92`EQI(=#>KMV+'!0%D&UGZ\_\`A
MM,BC(H(?-+CB08('`TM(;-A2`<T6`XE/&#!0`87E+:/PP+)B!<0R*AI'M@,V
M"R5%@B`+7GP(D0>-!1<E1J1H\`VP9<R6`6/FK)UOX,YV"X1(\&*>$*J9`2L&
M#+AI9[UU0W>N^WGO=L-+[Y[.G#I)E`3_D2]O_KSSYKF#^^[>7;WOY\P11I3>
M[@$-@AT50JS/>_X9-Q2P0B0&G!!##">@L."",1@`E((;"`'43U(=N.`)'R@H
MQ!(H++$%"22L<8,#44UBP`<?H/C!B248X**+'[AX8HHI2G&C%)-(80`2-S"Q
MA``>"!FD$QH@YD&004H0I)`>.&'`"T)^DI@`G_\($"0:4AH@`!KS:#!(8DT*
ML`0-TCDGW4#'(-30<+UU])Q]OLWBS"SJS9G==MD1QXQP'964&I_[E132F\4U
M9,Q*)JP`5`Q?T(033@6\M`&E&Z!P@A0,?"#$!M.0]0$*'DQ3`H.8`0$$$TP@
ML4$,'T@AP:L*E&76K+!*46,)-MYXF!P2^"J%!U*<0$(]7>S@@X0H2&`-`]-8
M8^0/&C!@I+0W(B;!-`\N:-<&=B51#Q!?^``$%DLH:"`*/A1B#`@@'+K,,AJU
M&=$!LM%7TD4A*8211@O-YE$A&'E4D:"J#5?<&QD=9$Q&QAPSX`HK`('"!H_6
M)"E--.4A,8647='`4$C_E7*4R*5HDU0G/)`0@Q!?,+$!&UAQ-;-::TE+E@1D
MH9566SM'^]8&]0AM%PX>3"NS!B^H\-<#13Q@;`,52/"DN15L:4!D'KSPP@=<
MH\CE%GG`TAD(QIAPC#&_G<F?1!.UEL=#SA"$1VRS@=32`0$?<`QSO?W&7D>E
M%3S;0`50=$Q'<DKGGID<?3<=Y.JM-WFA)XUW'N;E<90>>[\M_A]OGL<'G4"$
MTI#?021E=`!"D$?$Q!@[H,"&@3%<ZB#+"3(X8;FW;UJJ@IAY>`+QBWUQPPHH
MY,KBBS*^6!F,!M!8XR0VNGJCJS$`<<,.%3`9I=:'B>F!!D,&.8AD3+KPB61-
M_V:)9)9H?.E!"QX,,H@&+7!)*)T*(200Z];#&^?(R3L<:=-V/C><T.&)."<Y
MQD4*D3H'.B0D=1J)1D:SC$(`@0TJ6D$A;@"IB]6$"5@0PAB$,#%834@!8-E4
M#'Z@!`:48`,?L!VJ4+6!`1C@5;XBRUC*`@!?*2!8*:H,BH#U*B,=1HD",!!=
M=O"%";%*6DK(RK,T8(UF,.`%.I.`BK)UJ1-0BC%UV0$0JD*I2V'F!'$Q@3'B
M&$<3P,LCJ9.;3FAS#`BF+E[_\I=&)L(?Q,E-37ZRF^<RDAO_F&UC`QJ0$)B@
MDYSD9`4ZN<E.IG@@4)$`9$4Y"F$>(3*G:&,8-+#4!O]<9D,&:(5F:Q'+K()8
MAIJQLI:LS`I7-/"6)/`R"23HD!/`H@1G,<`%%7C$4(K0@%71H`$"V!&F?@@J
M-L0@"UQ@0P\(``@V<',`A:!%N^1HC&7,XDXF29B?Z&60VT`$@C3HP@(*P4=Z
M(<<A(F&<<.JD.``6Q""M^9=IWG2G[MS).LQ)SW5`M[F.U&E.VJF/"3(GT8).
M[C]T8JATYL2GW<0G=!$!!@UX4+K^0%`[?&I3'I!E`):M-'@K-1`)4'##!0'%
M4C^)BDV#=RDP7L9`"B)!%\@`!`?52'K/BUZ,JL<B%4G!13AZZ@<<4(AZ,&E*
M3&)`DYHT#RF13TPM6)(!T%#_)0^(=0E+$.N5I@0FK"A!`O.81QZ<X1R%C`2`
MDT/@2?<4N.[H9H&0:X])2T,2D<AM-@?0S@$A6)N_M6,9$3&;HH00+`,P(80X
M,<$(.4BI"0E!`FK!`EY`U2I6?F!5;^$4$I@`!$NY*F<Y`V*ML*>B&.'(5^2S
M[8UZ"$6Z?`$(2-A!#&S9#`D8@)5@_("T&"`!%$1K6@]:[8)0R2A8W06,'#*!
MN[!KA66<[:$'*4@(\H"WD&AG;Q;Q(T&*(1T`L@Z`OU%LZ&AC@MQ$9S=[@Y<Q
M<F("B/D`8RZY24XFJ9,!`<%`E3G!QXA"E`8,@A\X$%E3M!$"'EB**D`8@V==
M&98@_^9L+&-A92*R8LNUT%(#!AC`MW@Y/`_,$"O92!H.D.FTNO#@`2IX`;`\
ML!<)8-,+.A`#D($L""$+@A!J.`,5YEC.66AG("#9J-S\*=XT400V(A@(/PMP
MG+T)S&^!;=-UM(/'$.@D(UI.TWH':E*&)FX]H@.=XNJ[N(X4QQD2S5Q&%W=/
M^L:YH.N%<G<:\@"1.L,@J&G=2)AS##Q`-P8D8)0!)""$!-EN0QMX]&4FA*$V
MHB`&E^ZT2RE3@<7XX`P(>-X1CVK4V5JO1MBS%E1SLH/VB2EG3A#2/()4OJ[.
MHWY;$M(@F.2!+>QP$EF8!+(G(0<%2*$%?-#`)]`@`4(I1/]-<CN(27FCF]"Y
M9R3Z/)A\I--7DRYP.!#Y'[^<?!"^\E%@P"G&,LRV`E4)X0,2B,&C,(L3$4HP
M)TP@08$K\P%6C@$+$LC&5[`@A6C-%"BH52,*EDBK(`X15K!2$?1L=)B</15'
ME7EB$J0(!.!&I5D,J$:TOJ(!"BA7`T^Z(5ZD$/%H58/E8)3`M`0P<)G0!0MM
M.(,QSF""<G+W&+PIR$&.40C9$&Q-7,;@1MZ[K_E:A)`580Y_(A*?Z'#W#<4P
MQJ/FW5]+1@Q2`!ZPI!A-1ID:X`HA*\H#8,`/&"`E!1'N!%0HIEHD>%8M8`DB
MK0@@!AT0@"U^'W&(0ZR!#Z1P`[[_K(`41BWMO?"A&<QRP0M"YK2H&8TL]!"\
M&,P@^M&3OO2B]X21SU",=JC7)&>C,S/4^1!ZL88&:X@KOO+P!N7TZP#D%%UN
M_.J;OLXI-1>!H$'R_+C.0>Y,^83<WSP7[FP#XW)W-L^9.J=1^M(IS_+A-F_H
M_(8NB)1-!-N^8TV`AS6,?`><>G0,2!$B`SE<IS?]](*D<BET5<!!!D8#\51`
M/5A2@3&/\ZC()'#!B2A5C2R5]<":K0R`I"2!L+V`E725^0R"!(")D-P:DGC`
ME.2('$P!"3;!%#0!"IZ@"9K@%(3")*3+(1U#>1%*=X!;`N55XH3.FBF4>H3?
M,E0$0K27_]/5!YC1G@GP"='MU[PA@1!H`!98#`GU6Z0PP50("V;\0*N@R%<,
ME19-"Q+0#L7X%KFPBA0`WJPP46XY3Q(%"ZP8B:TPE6Y]P!*$W!FM2J21&+6@
MG+V5!7$!"[+%02@8@B`:0@8,8B$.8BK=`+N`P&>8`.NE7V'M#010Q$1X#C\%
M$&K$WKF5#D)`$+K-UTC07DBPQRQP%T30Q'Y]P0Y8TB2-D,:DG:2LP`8H2`R\
M@!`(Q=NIP#PTP%(D15.(0/*@@,B-`5J`!<Z\E@:(@20,7BW5C#(4XRTM7@SP
M$`K\4@5\P+!]B`!H$5<,$Q^XP!7`0`/`0`6X`%DD`@'\F"1(@O_H28(G"$(5
M5$$F9((7S&,\"L(BL*/H$0/JJ0$5\$=[J4=M',Y#^$LAG`[OU5,>_..Y,9#B
M!(I?7=1P!-(!G%D%)81(^$U"Z=7D.-\"+=^XW>!#7=]YL%E?'9!&_<9?@5L-
M<E0[',/I$,2AK9=Z"$0AX($/Y"2W/)I,C1'+<,CN4(BFW<Z"7(:CQ42D4894
M`&!<#`@2+(]1N4@HD&`6I(A25<^MY,CUO`I7P@H2%,`>B)68Z!H39964;",'
M2L$(DN`)MB4)3B5;EB`+3L$$:,%M!&'J"`=!-4[T"9!W=!_SM8>@_`]$\(:8
MG1/B]%5M$`0YE:*^20P2H``36%)-Z%O_9N7-"KB?I1@`*7@*`ZR4!#1##[G*
M-#``%K#*5.P`%IR*A,0`,I:%',2!;-X*$B41L,@*Q]G*K:3($XU)T-1%MVQ`
M)""7I^R8!PR7K_B*6\AF'`PB(68`=$:G=$HG(Z#"#7B&%9C-ZO7+1)3$'JG;
M>EUB)PY*(B4,?9B77?E&PCB92NY&*382",W;!DA2*V)2(>P$?NJ$#_A$&WE2
MTUS!TO!B4I"2-AC!OPD!%O26:QHCSL#6CXD!`90!`;A!XKU26.@2@MB.AR`1
M&HS:AUB-!F3#7HB8"V">`+@`*Z6C,IJ!.RZ"%WB!%@3!'NQ!$*S``#"!C&K!
M'M3!BPJ")Q"#_QGPHY%)$$(@UD?(I.LIQT*8``_P@.Y%D&&91)I)'WQP&V(Y
M1WD=A^ZAQNRQF5P=4'>H5T@TCIOE4^/L27B2I'F`J4IV'_?M"6)I6]]DWW/@
M!T;4!W"$WV^\@03A@9_Z0#TTP&:Q$8+0E%!6(QO1U(%<QKF,08>@B($`X*6,
M6A>`Y5TH%8J\0%O*@0,^H*[4UJ_P"$V0P)5DU8E^"6)DR?EDE1S(P%K.Y13(
M013,:@],@AN40`]$00_(0%PV@0[4I>&PR<$@5GRDQ[`BD.2<B9O=B276!S"L
M9YO1V>PE$$DTA-&U`PA$"KFD"F56YF6YXJ*LBKT9#1;6&Q<Q`((TB_^&_@0)
M(,%J0I>]>9C+R<$@[F:,])"U;-RO[&:-H(&')$'0Q)2$`,4'_(`3_,"S.<$T
M>,!7W$AL&B)T.J<@!J)S%F)TYD-UI@+K89LQ_,N^4-N?6.)QC"E_M(YOG%N3
MW5%%A*(@=5\IS@)DL>)J'0O&C-!.H!W&],1/R%0%@(R"X8`*7($H09A3B(#L
M"`$:684$C`4ROA8!/*T;R`"$SA(#S)+-2$`)K*ME1(EEC!H.?,@6B!4?6,->
M7)%>2$LB2.B*MF@=!,&J[`&)%((#[('V%(`#V.T-H$`DQ.@B+`*0$@,A&%GK
MX"415M]`W"=%X`$/A`!K^$MM*!(!M8E'UJ3_WR3.2QY'.P'0OA!2G8#9?%0K
M7DE'1QCK`;7)EZEI>="DERG?FS1'Z!;*`>E&3&(938);2]@$3AJ++_&DA,34
M@3@<394*IUC-H@H/&V4(NJ"!@9!:(=`MKIS(6BI`"1R;CK!(Q\&:+NW(5P[(
M!E1)D'S56'75EDS)KHF@"I*@JP)"B4K%I6$*Q6P`$AA`%BC`JYJ@!>Q!`8AN
M7ZJN\W$#]W4NL>JO0-T+81)*\+W)1PBKWZS&,<";OO&$$$B,Q>B;9;HBLIR0
M5.#<2KD*`R@!@A@-5PC!`("*:B+!J0"%Q.7,)#2G(9Q('&0<L/Q0KP1+L-"F
M5"P!I=1#B$1<B%#*_P"0S[34$K;\P,-*YR`R)PI,`@CN"'-6;'2R`BI$Q$A(
M!$8XQ$'0F7'PS[6QR;.>6_!M8D?(9!#R#[V8)Y/-PM?IVP*LP+CLP&2RXLWN
MQ`K\UX!E)A5)!0YXDC(!J%`LQ<DX!1Z<$`F@$:O("JVX%A"!A1M`J`PD@AM$
M*%C`BNWP4`PH+UF\0(=NP1:`K29O`<->D0R!!1^4@1OH`#M*`C'H01#8[0H@
M`1*LP-R"I8T"08WB;XD(P2;,J!94@2#\+2$@0]H$DK.NUS\5``3!!MQ<A.%4
M!/]PA$/JV0%%L[@=C'F:1!4#$DTRT'FRIY>V;GR\QTD.!^J21YO]6>O6;O\T
M%\I\M"Y(E9_^KG-'_&`JW&<!^$`7!$WONA^%4`R[MA%0]-^F,8COTI34F!BC
M6@VQX<$9Q"\#E@".Z(@)8F567J^MQ,`>Y`00A*V0E$6P&8!::4!OLBH*FF`H
MM,H'/--AH`MF>,"",(9DI`ABR.446,`5B]LYW_2:T61\J&[M#C-&J#/LEC'5
M*>9$L$M^Y<1^2M)%6Q:DM.)]TC.E8`';D:L$\)V)S8X!?`4*,*$4=`L6F'!/
MQ(#$E8\<(-L'-.<+V^:UN)9N5@:G;,!IU@-F7(;0G(K[W8P&*(&1B`*]&O%L
MTB;&U69EO,"ER.9S7FPJ<!=&7*[`*#`$\=$T&Y;_H."&W!CP>M&N8JW7X\[7
M=IH-%6`,`=(L&Q?"'/M7?@Z8#T@UI\2$"OAL*30`"_!#T"Y%A)'#*?W$%ZQ*
MQ%%+@WY8&20"<(-#&0!9X1$7"O#0J&UCM/CK8SR&8W0R9$@`'ZP%'XB%X+6C
M'N@H_+XR`C#!)ES8!@`!`B`!`LCB`&S`>(MW3XP!$@1"%>BC)ZA!!07D(?G+
M0!@#;,A&,F=QZP#UX$KS.:_SX!;6ZBQ``2Q`7'VSGE&$PE!=.=,9[`IP1XSS
M/Z"S3E_X3=>N@(>4A4?X,JQ3Q@2J#H<(9?PS?P:/$,34I4P("5#&N93X!E@-
MQJ%`9!A(0I_!!N1*5KK:_P?(018X[!34L,7]"@JLP!D4P`Z<%9,@;+"=)5ER
MH`:,8`J&0@FP@5)6!@W79F`+]HW,PP=,90KN@2-6;N7N]-;Q=(97[B86$NRV
M^1`&I',$4D-D)TW((BOFFROF>0%@`1IA1@PHK`<@P0DXRP](P`8`0%O!7"20
M$5PCRZ1)@1LB!O8P9XK$@1*_EFT5T8XP!J4D>0P$"PH`K"^MD83<3%;T=<0:
M@FRB00Q<!@I<1@4HB*RS$8<HY20(HG3F`RJP"26B20"-,45<]G%(1^\9$C1;
MQ"=>]N.F'[R80#%\MH$7`-*.W=A-TDV@W<;@03V#%F-<"@X015'(W3RX75*8
M3/]3#,.BD%$7^-9N&PG3)E=6E($R_("$$H`"&,"+ZH`!7`)>>(H*+$$%/,8)
M`&"'HD'!/P;YS)!8F++H+4(@I-8FC`'\^E9XK\H`F+`0F/``>-H><(IO#4#&
MC[<%P,$^$H($_;J@4"(?Y3?2B8?OL2E'!'CB0/-.W[1)//9"'+AX1?C*$@0$
M^(\T]PV&*SB%R[R&I[,Y9WC?<+B$(^LBY4$>X$$>W``>[,"HISBY#&7P"H^"
M7,8:G0N&5,;^'9&Y*.\)@$A-V)"K6._:_[@49,$(,IO%W4B1WZT/)('57(D7
M<6"5@+0';)6T_/TD$$$*$D!5HLB5#W9EV`Z4"#82/9'_BIQ`#X#Y3!="A$.X
MTI<S/!>*P`0A(07]@Z,&$7Z'0"09=F$6Q%P,%.*$?=*S2T@,%C"!4FKPO>&<
M%"`!N;J%$.P(Q?S6JD0%I./6CKA(9=RZI2<G'TH%IW#+2M\P"5S"\W,Z&GWZ
MM.#Z(::U@3F^]EL(BB0&&ACVQ48QOT!KZ2!.&/\380X[,'R$`/>T$&+9?A3D
M'FEG(Y+V@*#1V&D[ML,BV0$$GA4^A'P@@2)&A2L/'I1ZT$"%BD>E2FDKE4*;
M-B-XA*#8L`,($A02)&@P:9)!RA\_&+!T4R*&`2]BO!AP\4/#BPI;EFQ!HP+-
MB9]H*@Q%<W1>RD0Z))DAI@<?_Y(-"`KL<5!@TQ@46K!6W50"B=<"#F+$0%!H
M3X%""(2,V5.'F%-":IP!J^OLS0$3!XX=R^OL``T:"Q;X-?'FF#-GS(#9M<MX
ML>.ZDB5#9E:7\9N]>?+H-6$"TH$#;R8[^SSYF.C#!RXWOOO8,>6Z_VC7MGT;
M\VM@K5_GIMR:MUT:/$H'[^VL4!X\>%(5^K(CR082'P^B0'$"14<A)T[$L'[]
M>X43!H14,(`]^W@/'DX4'8]FR0ZT&R9)L?_AOGTI"N3(4,!?!CG`*J"`%8`@
MP0`!UEMP/30$4-`%#UI8CP\-Y)"CB29"Z2$**0RP3@@#I!#```,^^!"+#43\
M4`@5/?\H\<0/6MQ@@"RF:&**"?9H9[?)>MPM-MWN\NVRPQ33[(T@99-MK\/>
M:(>9998QC0ICK#2AD$(*S))`+;/\,@\NDRL@CP)\``((+%#X0`.5A(C!)`,D
MD),!"80HZ(09T^Q(1`GT^^!$`THP8)(X)BEIDDGD\-.Z#>I)<3L3*T!A"1R6
M((&$2S*=KJ,8"C4D@PP,,622$DT]%=54K3/@A1>O0R...$`-E9$\$@/&,+LT
M4PR8`_(X;*]C@'DCKV#M>JVU(/]23+1E=-VKD,^.6<:*:D$P@<`"F`#)AQ56
M()/`,@O`(]QOR<7CB^Z$(&$\&!IZX)$75."GH10JRDB;!7C_R&X#-)&(P0,)
M`#!IX#)6:DD#"6(TH(<>V-!@*1TB6:(G\=`PP"B@B@)*!0$T`(`I,P2!Z@PD
M!F#B*@<<6&&,`;Y-:X\5/MA@CTW2(BL&)K"R"H@!-M#"@4P$D8N*NS3;BS1=
M11-L@29'D\Q'7GO[T3'C&CL6+]$6*(187SDSTC32[O*,V-,>\ZVXWFY;VS;=
ME*RZLJEYC6TXRF"+;+(W.%M.RR_J22(Z3._\SCOKT!-B">ZR6Q6[QLDK\04/
MN0O*@`J66*&0%=:4`C_\]+-/`2DDX"]'G?=@8@.@UCO)@P<_>=#!"5O_1`,9
M9,`QQPT`-F"''38X8;T37Q3"AR\,_QB^>/Q>^,`#YC_:00@IY-`!QPD*X!4R
MUX;,WC<F#SAR5]<84W*QT@#[3.Q99I&2"A.,N3;+&[[5,ELRD\LRS/SI-[-?
M%$S\("4=D4!*&%"0-GV@+"5"`1:P`(0-O$E.4O"`?01E*L]Y0`Z3,(2'4'")
M#:1H`_XKD>5X0BF>D"`)FKH$"@:PA%&)RA!Q6()T'B@=/J5*52)4H`@U.*L,
M,&)8B$&2,_Q"+,V(!B]Y2!*S]L(7N=T-&,O0"VFD:`+%I$8THCF&^JIEA6L1
M:`7;`L*WO@6N,JU@`2L0R`+&52`LL&A-5VA`0QX1$17@H"$620%&M"&"':!@
M.CN02I]00O_`E&B`<P:(":N<P``-D((FB!/"`#`&%*%P["@^<9`+%!"RD2&`
M9U,I``*8L`($($$("#`E$IB`@!A,)22JC,$`@'#*6DIE#*5$@A>&1@Q"4,$P
M4Y3:,4)0"*8=T8I"&A_WLG<W'UE-,5ABHVH.4(`#A,"*X8OF]\I6K+GU9GQW
M:0W;R-D8RR#+?+$QIX_B-ASLI3-(IMD;'@J!!R#4PX:!7-=UX/@=\)Q@.HG[
MT'E*-!Y3D0)CXQG/%DB@%@2(Z'.?\Q-)I-`#"VQ"?APZGH)*XD@/O$X`1W&0
MZP3P"2G<"$=(.-/N@,`$(`!,"LMKW@9\P(3C&6`#83P>\YKG@7[_'<@^`PC%
MC;Q0"!Y]LYGB_$UI]J*8L,EM,L&A3&J:I)AVK&\957+?&;)T%;442"U@TE*9
MZ">N%6"A12`:X.9(,8T"&J!-*2%!#*1P@@U\T'?6D2`%`U4"S@6L)+%"@Z/N
MBD\4+*\"FMH""G9B.8I=(@DDH-@&0A6J&&Z@E-[2[+9BP)W.=L>S"OW.>$;+
M'0/(JK*H4`U>P-;$HXGF5U+3BUZBBAF[;=.IHV&M:`IQ`&,L8Q;5RH473>`#
M,P%A!]UJ([G,5:`5Y,%;XU)CB`")'1+,\2$PN((*6$`1C/!1&WE`ZPQ#0DF2
M#,R0?EI8!3R`L!<LP0N1(,$DQ5"4GVSL_R@A[=@\--#)IDA"#ZA#@H$04$L6
M;@`)4DEP61`LA`63!PEC0+#N7IE@"P]`"+PT@QG4\!G/F&\S@ND,7I2Y),B4
MYEA7TPUPQE8`PA0@+ZFQYE^.I3=A9<V*NH7:DF)#3K:Y#6]0+)]L6'PU=U;&
M-<?BC3-2H1P\A`D/]4#ANGK7$7]*AY^E797_K&,>\*!``%+00.6$4J(M)*$`
M-]A`1.U#43])80`%X.H74-"$#`I`>'Q@P"`\\(+7.4BD(\5@A@A0`I```04>
MB`$0OH#H"98(>3Y@%4Z]M5,3A?EY&V@>$"PP@0Q9P`3BNZV*KR8;&@-&;$HR
MSF6"W(YB[25*ZO]KAS&V6J5"R*]+8!6KN,P(KA6<`*W^\T`SIO&#F3FR+(!*
MR5UC\`(42(6!(8R!YTXT*!/I1P/-6P(2=F#9[4@`D)I:0@6*XIX3`BX)+JRL
M(9:`!<Q]Z4L$XM0,U[6N^=80R_RZJR0W<`D?HL*;0]3;]R"`+5O1UBY51.*0
MS)<LTWP/5ZIY@S$Z(RTN5@L6(("NF;@%1C,)I(W+E>Z9N-P1A32`(@ZY`C]@
MD')M?/</"U!3?`0Y@`^4!`"']%`,0E<B#5#`&AX@H:7FZP5)),2^0-'O44Q"
MBDB(P0R2T((I';R'"+<4PPFFT8('D.`2(#@&)1#")LJRX!@D>))H0L'_&!"0
MB:80H\-Z@1J23,`#'G0FU6_C'I*!]*-TRLT$;%R`$K&(Q&.Y=INC.<9G[L9,
MW_AX;4EV.)%C(]7;VEU(MB5U8U+C9%04P@=_DS+BK#-?PWVY121`0^$V8!X+
M%E2!)B)*B4**@GH4@`QTU8^;Y:#H0I"A$`?:0H(\9(!0-$$4/U#"#SR@@9"*
MU'4.PI"=92"%U-\433N0TWI$YP&/;(!Y,AJ(!!D$[L&M!R1(\'03+%`([9F8
M2+DY#;.2]C84W[]J#\\+<($["UI;Z0:PY`9T36>XA*S`)5S(Y+D0[8-.0`I0
M@"5DQ`,H8!KXX`-0H$VD@`T4Z3SNZB-NR$-B_\1S1`>GLD_*EN"F#.$2Q&WX
M@H(HT("A("LZ9B6&8DH(WLU+PJH`U@10>HK:FF<\>.H#S"/\]DJ#*BL5#`^+
M@&6V2&.VDHE9?.5[`(.V(L-[DD0*F^HSMO#BK"`78&'C5H`$QDBZ#(1`SJ5`
M\.!,OJ#1H(<\N`R[*.(!6(!>*L)>7DX;AD'FK*,>T$[,'(ESZ.H#AD\#FB$:
MA*XG*(8$1J%BA`(->H`F0DH2F^\%3@`2-VP"`L$!;F`32V;15*805L;F4&8L
M1DD"7"9E;L!/@$!E./&E7`8?;@`?UJ('FL(3]N!6&J-KFFH!'F`!#L!9)$]N
MQF?'W`8V\D_)3",$*O_N"8=DX9IH"O6BX"!NQ4IM,B`/-ZQ&R)(,68(D6=Q)
M,<()G23#U>8I.4(OLI9@75`'R]##<`9*<5KO/-JC/4S%M"2H<DP%!G=`+6)@
MHDB"45;@#&[`!S9@"4:**/PG"V1`%)1`%(A`%%IGZ:!O$C)D"K*@>;Y/3@P@
M^V"J528(!7HG_'+*!UHEIF+*^_9M@M)/J'`$`4+M&+GQ_L9&;):%?,()2*S0
MMH8$?:RH'8#+"JRD?>!M2PJAE,(D!S>N3):R0$*H1<B#%!+FYN"$`6(`"P`H
M)<BCKEH$A&X(4$SDVGPJ^WQ'110H"3)@!2D&!2[&!7>"8I*@'FC0$&)@]7+_
M*DL,A`RUY"#0X#JX@SLF!3NLK*#\"3L^1`50*P/R`15D:^&R*+=FRVB<9HH0
MKK;NHHD\S%:>Y6B`LHLTSENVY0N^!;JZA;G&A0E\`#7/!#7_B#RPXPIP8"(:
MPB&*X`JNH.7L4!LZ@0?4A`3P"97\)($^0"@D0`FR@0$JAR<LA1$9,>DLT0MT
MX"=ZP*\JT0/<@"F(81'83BVLX@;^)2RF;@\0``5*``AB1I6`X!1;B94<8#\&
M#`E4Z5\6[714*1!ZP`LV[)>N9O$@TQGT!>*P1IV.(R:/@YFX,<GV,P^:1K?J
M`HN6B*IXI4&;BM6D1B>!`1MM8TF&3*G@J1NUY\B<_VK(N-'A]$8Y.*,`ZD'*
M,(4$U"0\`(FQW)&Q/N152&N$U!$%U^,%CB)!SF,)NN`,F("N$$D.#$!G!O`+
M5.]!,$:$PDP&<HX(IH`(I.#/`DT`)N%&ID`!EJ<$=X"E7`I@EB=0B`<(1$0`
M<LJF8NH#7L!$^L5W).C0-D`!;D0'-F%J@(/4>.,P$F.(GBA#^[3&/DQ]BL$*
M/N,&C"'>NB2ZP(HI>4T@U`AU6N1-VHN`UJQ.\(,J<<I_/NBN(,5_3B0$/^2G
MD.L@:A2%5O`2*,80+D9C'"M3+L&R#,$>[5)+HHM+4-"@<$A&3V55<'56\B$5
MSL=ID,E!BV4*AZ5)+E,:4?],,GP%&H'Q64Q@\99!4+O(&,`*)#)+C;HEC=*H
M>-#D.;Z`";[@C=SQ-1NB"!@"!N2%Y?(H(T2`(P#)`P<@)KS#YZR!`5K'+15Q
M"1C1)U0@0="`#0)6!3Z`)C8P8'0`ZJ2.E3;!EC9AZWIFP@;@V41B`'R&#9ZM
M+'RF+-K".S`,P\;`9!PLPI!@:#Q!#1*#JI"F,?QSJ81$&+%'?%Q6F5YC/ZMJ
M;#[L?)(&6(VH6*DFQ9SA0FM#R0Q40XG6F=2I;IY(:9VA'9IL.<(D]%341N_$
MREHT3_@)CA1(*+K,?TS2`/QU1^%C!;I31&9F#^ZR'H:/1$;H>%XD!CA*%*9`
M!B+_)X.`0D?EX$:R(%!"4NW4%"3^*%#4U*Z*QP')XPLD+5!,I8&@)W(0S'<^
M(`IN9`(*06E3#&N6I>#JCT]Y8\FVD8DTXQBN:AF,@0JHX`RP)12+$JS*B-<0
M4+,,I(9.H`=3`@GHQ)$V("H50)&\8T8^XH$Z58$0S*4<*$04Z%(\")].5582
M*I..U]\L*PY.A7AT4`=78)%P=3!%R'%.)5"DX(5^2#2P*6M&PXANC*H6;K=F
MBWR-Q-2@$5H7E+66H2]^RPNK!5O"B%N\!375R%O4T(%(H%O_5D5&Z[ID\P'X
M81XB@N5PLX]\H/3B]55>`&$0D6)X8CDK1ND04@"6YSG9_X`4.DD,)($8X*``
MWG,%_B65%"P^!V`,QN"5;`Z!QL``*G8JY766;*X$6.C`**G"6A@.XN*7PH9\
M)X-E^Y1/IV;'5LUH=TMJFFH7_],TL@E)JC!JN#%H::-RR2=#H>I#C3A#YPD5
M"J`+I&,)&$M3Y\O+#`<[Q&.@#')KWU%P(4T"/.!B2$0`$BM+1`();JT`@&#<
M#&`>/*0HCL<%I*",(:WY[E4"IF!(CZ("K%1#(N$\K*-W?L=#\*IJ9=1W@><"
M!:DZ_`<[/'!-/&!&H&<#CF].C<&+I699SH="C;AR!31EWT!*W&=TMS`',:=^
M$%`YTM"Y]#>$'@BGX,0)HN?F;O_WF%-B!Q!H13?U@81@]82@'M`$34((/PQ`
MLC(%<%@PT&#E5)=@FZ%W;0LJI[XJ6U:@++&7G'=`3?H'<BX-+`W`AYI#BP`C
MMAXN,IF5,84HFW0L,HD%[YC(,J=E?J<U%ZZ%7-AYC`8"-9E@.0;B2%$@37R'
M!'8@7289FPL87>V(!5#NNS(B!/[H4NKA4@Z2%%9"Z'A"I1.Q@C7)CAUD'M;#
M`-C@`YS`#0@`ZD0F"`I@#,8(`1",IY]M!7PFP5`@"A(LZY!``9[M37[&/AJ,
MEESX[`3LE&:X`!;!*>(.:5[#/P549E<9EGD,G\<F#W@E+XHUB2#@2*:(?<'I
M+J[X'[[_&JK`>C+`D:XIXPU283F>;`5V0%.L(SYF[FK7Y8\_1#Q(I"_+F`1<
M#Z!"I/G&S$$2Y([KX08&D@QNX$CKN([;-ML$P#I,H@*D@,]>I';D0*1:<@H0
MX`L\T`,/8GD\HEL&@H;N:CH2[0(_0G\/I+5'-26!H*9.^$9"(=1BV2Z:BOZ(
M&[E_5C)25B^FQ0J6P01N`'[2;'X*A-?.*+8+I*6Z!74X\CK8A`)8PCL2IB".
MQY&0``N\PW?7.U2SKR#6@Z%*>E-.=0L&>3S\C=VF(Q\J*WIQR"[9L$`01)U/
M16?0F4#2&49,Q0,0,Q]H.8OX8D&-&U>4"'Y9>0J'J+C)=S2,_]N;F(5IH=L8
MNLB+H,M`L"`T5^!P?QNB670:`.JN?$#[9)2Q%D(VM6LA+L(B\%`;0B"$`"F%
M3H`X-0"@$G&E>V(4MJ"^-?M!FL\)2L0)$D8""&##/*$.8O'LTFP3\6$#2F`,
MQL(!UH*N6+$4D4`48F`%6M$!/B8L.+$[$0@!9)$3:W<`;J`./,$,/&$TG$@R
MC(`'#J`8PSJYE_9/G5$TQ$;"J3#""[W#,Q2N!3W0R:>+'[TN?&6OY6<'LIFQ
MON,@7&]-L*.,UQ)Q[HI57N1X!'G29+J.Z1@-Y.,,O@`'-/L$6F6.%<0#^$P#
MG(#4D]0#5B)A4&`%UB]'JMDC/GE%*/_9MU=[1@13<K(C-6>[4Q+-V0!IC'P`
M"WI@"J8`#HYJB7L%"I5(:E99TK6GB2BW&&BMW`'02ZI;9Y;RN4H<"`K$=[@2
M_'PG)E#`K;Q#`IHA)<KB@&1<"%)$@)$+N4)(81RK4HXWA2QED#&&)\#9HBLK
M5.+`GZX,<Y0+G1=G<;1#XUNDC-Z]C[4#L+^CC'T(#)8A+\KZN,]'K9F(,H<$
M<W6+?%LY+Y;(\$"W'4S#&,[=BS0+N4JII@[W"Y:CIG[G![X/"VC@.3I].PJX
M%(H@Y5(.O/!P`4)D4MJKR8F<8E@ZZY%<@Q][/4HBD:<!$)I"#X(@%.7S=#:A
M$.1U`S8AP4[_B:Z0``A:)L&JTF1B8`Q60`$D`&2](\*BX.Q"=L%R:@#$@!C@
M+C-[@V4=_:[G&JJJT"X:LXD8D^6CL6RH438:O?$;'_,V_S6DR,G"9`5.L/0:
MR"`G!;!=CZ"N`U-B[SP4I*[,`[#4U(XKQT:'8J/0X+%#:M8O1DTOIOF40/BE
M(*?R80*N=`)^-QZK2TU#*-ZQEE+6!7CR1)2_NT3FJXP!Q0.USW]*X$IO16D7
M]-0\W_,'[FB<.RBOY*O*R$RRY8SZNE_>J-[5SB.T8X``Y0%Q(CLD50,``L48
M`R@V&-RP(V&]#2AB&*B`8LN2)1*7D!A%XM*2"F@,H$%306)!'P4R_Y@T%,>`
MRI4KA9`$`F3%"B$L:]H$4F#%DIP;#'SPZ?.#@`]$T1@RR>B`B3<F#CAS]D8I
M,&=-GSY5>L"ILZG`IE9U=NQ`G@-,M4ZEJA7M4Z9O9BTS`=>8,2O&\*SP`82)
MC[L^?'SA"V2'D!="A)!(Z'?#"0,D"%[!`:-4J2*2)6LKE:*4MA3:.O$0XD&"
MAQ-+,)*PN`1':8I;)&Y!(P"V`!<:--#6(,$)`P8:2.DP(PD.$B";D`Q'$D,(
MD@T#Q@R,$:,A]!A2I'R(40*Z%`E2H&>/H4!*">DH4)0P,(#Y&.1>))DA9)7K
M4R,\G,J_OS6_?/W\\?O/3]93P$05(%19"?\8%EE3$6A5@F]$U=]6_TQ(8846
M1OC?61D*F!\-/'"XX7]/Y9$''GB@4@@>22P1$0I+*(;""2>4)\1B!*%`0@4&
MG(`&"@(8\*,!'GCP4'DOA.;!CTG&YI$`.@(I@)*#:$!DE#TN\1!L'O"A!`,&
M;`#$%U],,$43/:"PXP<>_+2!8=09@,5A#JGD@10$D=#3!RXB%,-/0M:)(XLO
M?'"0$'9^((4<919R#(;.D-4H6R`Z&B*E^3$%5U9*%3.+%<6`8(P)A110R`H%
MD"K3J7;EL0(33``AP330H0`3$(6UB8(4N^$FA`0:_'0=;R@@0=,.;2*T0STD
ME%?!1*ZE9M$E%Y'_L`5')U00TA)"[,#$"AL<98@ADPPUZ*!KZLE$(6#>U2>1
M+TA1[@>#ROL33BN@P),4=0XYI+Y#&G")21F@\L9::4D%U5(+-O65A@D7+%8!
M(2S%GX$%E[7P,6_!%1<(I?:%!1!]^=77%VN$N<,)&V"Q`Q!=^+7#LM&5AP(.
M#TR&<V:<<:9-SPO00-,6ER1!0A*C0#L1:ZR]%N61M3GQM`:\.>$"(&*8(4@F
M(>^Q`1(K##0``D*DAT0)UPV`W=C<L3&`!"48"D`)8R@@`0H#*'"=>>B-D=T8
M0L0P`!,#3""(&<0TBM\"]57*N*7X/6H"AYI&#GG!5V%U##!*%3Q55DV5_S4I
M,!:.7F'CINOGH>..OY&*B206\L5IY5W+XNPZQ@B1`4)TM&-Y`DCQHU!^=L3O
MDD,R^6/RL0GP"=1.+$_:)01IJ8$3`!M+0CT3-#%%#T+^N2:+2YSPPI<X&@#O
M!Z)],&.,=I;7V+S]MH^"O$*@<#^1Z+M1I@4F.'R6KT2%<ZH[G7^.\:`W'",/
MA5#*,CIEA66`R@2D.M4*1I4J5IE*)DSX03/0)`21^8`A0MA`#"H0`PDP0`(;
M\$!M>K.!VNB)9B4\"`GN=YK34,1%$\%(TCC"D8\4)"]`0,(2P!4'?OD+7D-"
MP1<*T+*[H.!=:RK>OO;U`7OA:R9'LJ(28U`/@?\1+(!:&2!4V+(PK,1G*PC$
MB@D6D`<"[N=S!J(<ICC&L648@U5X"=E=](*7OJP`"%)`2)B^4#(@-,9V)&C`
M`RA3&<M@9C,^H\$&DH#))`PM(ZH9A6L\V9HH#<D)4'OAU(;T@AZX1P]["$(!
M'#"L%6P""`@HQ`#0LP+C(``)!E#`&(IHG#'\H`3!),YN!@#,30S`.EY#`!,V
M,8;NY&0/>B"&&=20.?[0QSX%[.:&#&251SFE+%4Y2U80&)5R/J4J;#$C?T@'
MSVYZ<RNI,V"$WE`B$Y5J11S9D6!.8R,6/:D"BYE1!4BP&/T9H(L[6BB_A!0E
MAR8)-AV)4FWXH($?]<C_1VAX#9#0,)$5D:9,4?">G?0%+X(XY'TS6BB=ZJ22
MA.XH.M\3DKYB^KT9R<A/+\B"'+@7.8>!\V%KM.?IR/(&8"2(8\Z`X*?.,"H,
M6C!5IV)5`0BI`1H)\@OWN]4.#`"`NN%-A5+HE0H9(`4LY(T$;"T()MDZD9!(
M)",7H0@0(7("$A#Q?DLX24K\!)25H"!=4?1!_7PR**`(Q2=!TB)/Z#6O>+T@
M!D!@A4GRD0JNN/-1EH/05@:H%`Y]5BQD\5Q^*K:YSEWLC50X!AY-``(*[F5E
MB"09(DT%!`V$#`@T0.07>KL#-,4(1S:[&21U1LF=:4,$:ZA')HMVM.BZIC5;
M_Q"`"VOC`E]53VHN2)(!QI`)PZD!'V?`QPUB@(0].*`0#KC!``BUAU<6H&P`
M2.\F5L`U87P``2O00GS+\(,QX#>^T21F`=2;2RF@P`$.*$`UKTF%BBGN`$:=
MYWX@9,X\6(5!5A&+@#B\%@V/MK1!S0\\25=AQJ7.PA5S1CY-5(`O\%,E%6#(
M2I:U@1RI!`4Z^A>0?MSC'[%(`+Z20&R*MSR*+J\%M?F!!@;Q4HTNX1);.-HE
M4,"=)C0A%"M9S._>53Z5`*LF\DJIF.E4DZ&L:26(RFF8?<(%+1=@4E_A;%%9
MW+C0#N@`KE4*7-I1#"L(^BVCLF`A2K4JF<B$J[K#PO\7`(F7OV'!`#%X`0.F
M\0,&]$0"A%()65=VHP\<QKG.=5;2+K(BUH`$I"5<07`+@H)0@`L-.I61K4\0
M@PWXH!!AXHE.A_N0&,BH(3,BB;=.A848H$'8MB8(09;`!$9<-A4`LMR"`@2!
MAH7%G6=Y0P'@R&<Z_N=`%F-8`X]!!5*)"@3>W@O+]K*"VFXP!K454V_%U(57
MET?8*C!N)"5)R9Z%8`>97)'15B/=CT#-`[=Q@@=X8V0!.$$(*Z!"'0P7!%FN
M(`BY7H'8TFL>(2``;<LI@0328[;F#',#)C<``C0`@+'1;0#O?=LR2["!,20'
M`09@`^'>0P7\;!//+%;+5++_/1;+-8PJ25^G6=!2H*9L+BOR.?'HB%XI'GPH
MQ:/%IXE@W(5E$;1W+D+3CX4$$1;!INPGL&)B*V!=ZQK/`Q_YB`H^LKS9:*`1
M/U#"#S#J@D\@A%HOTM&/B,"]$BR&?5TNB&+*MQ@T^<E&*##6"7XR(YK8I(1Q
M(A+\ZH=Y`Y2@3`@H,6<A,"+$8;V;!8H*XLH2EF58`8(>.U5.*B@3/!3`!]UR
MM0>P`&^^^*4QO"3(!ZS!@(9((!N\H8G4*$VS["6A'L[%Y!9XB&H=MH;6M.H6
M=.ZGKZ-DP!!CM@E!T@43*0+E4#\I7_M58B\2\`2Q0K&.D(A"JP+D`RD0L_9I
M0ULY_^;$89JS%`>P`(RR9R6V'Q9S%222%6-A`J%2".A@`F=@#'OQ!2VS%WY1
M6X:U`8CT,F)B;_E&,Q#12#>#,Y@Q2<K%&7E`<$9C<-$U"IZ$!B[D<$^C+U3R
M`M9E`'E@#&>@!H2`-;N4<S!A'-@!'0,P-BDD!7CC'1(```P``-5A-@P@#```
M`$1A<E+X*TBH/@J0'0-@-Q]0`I%0!6;@"6J0.(NS>HTC3N%$;J7U='$H=9*C
M%5AQAW7(%59G(5P7(O5$=`/D=7CP!::0!U"T!"#A$8:!)P5U+3X"/'3R$RB@
M)4\B490X)**Q)$[246AP=W7G`9^P)7WW=QY`*T-S"1M0&O]:,@FAT`03L!SW
MYWY?`A.Y8@`M$UP^%CY,\`5M]P$NX0,+91WEXP';`@0;H"]@<HS_(B^`X(H3
M,&>J93"ATX88XDZ?(Q^P9P*R%V@15&B%P`2D4BJ*9GM`$`.*)A,CDX$J(UP;
M(`$_`!0QT'PHX`'34!M_0Q#45W!T51I%@TE'4RU#!`1QTB8[%@<"@R5G-F:3
M^!+P)GE#`9'O-XOVLA/>\CV(\F7"0RN,L'\9D`]-=T]1L0P0@$9@X3ED\3E-
MT4:6$R#WT6TBEB!Q5`!^YF<1"!=]$1C=XA=K4%L[L`9=8#)?T`7`U05%B5#.
M)@05@`,-D(*5D1F7$7`\L`-#8S3_,PB06S!*#%<]N8$;R7,"0%`(9P`";5`+
M0LA*"$!+>X!>181+0O`VO#0>`V!R8W@VT_`![Z4`Z*4,/P`XHJ=SW#$`R!&8
M0I"7WH($@:`'XB5'SK!-?MA-33<5(`EB+J8@!L)-XM19Y&:9:\2'%5*-__$`
M'U)`_E$6`U0B/M`%NH<']<!C-%8>#>41K_D"!K48.WAFR?,OK^D!#D=W5O(1
M0<0143(/'C`(/\!\!O`BF'1)SO(1UU<F$X``7U5%:D*+0$"/!H`$7V".=6(N
M915O,4`D&]`J/N$![Z(FRMA":043R.A^[Y(%3:`##J!:%U,@CMD5E))`!N-_
M9&0"QV`,_[07*KAG>U1502BP0;HW,GZ!!8:Q;[&"&WKB*Y3V$\V'*]6724/C
M0P4G+:>!!,:"$$@P7($B,!OP$_I3/N7S(RBP:^EW+RX59C2#:XAE`/%W*GFR
M)D,A/)Z'$YMP601#C6FD5`.41IJ23@63;0]21XYB1DPQDP=0`&-!!:(2I<8`
M`GF`DSN0CH>4;SL@@J@IE$6Y`R1(/SP&`_ZF@E#),SW#7$8S-*5!@_SB!+YR
M70[W(S6V`A$(`B``"VK@"690!S?`7H"*<YNP!_'E`-0Q`/V%7T@@!3&W"4R`
M`&(C"PI`2S&Q!\T@#"@0J;(T`%,H8%K@<4*@`25P8.H5!&9P3?\A($<3]IF6
MXD:H=Y)703&=HT:8V6$,`ZNS6CGOU)D3@B&,XY+]`8A<0:Q;L2$DF1664R)"
MN0)XX`,D0&LK`1$\9B.&MR/7\CT048,F"E$OQ2]1$ANO\1IU!QNB^*`%<0G.
M)2V)2%!+0'W]XP.\-)V#HHS762OTN"94)`3:28^_>!?DJ2;O(@0LLP%'LEO(
MF*^($@7<LP</4D84\ZNMNF>9N9C=QC'^"4'>:$&G\C&F8GL[D!.YEZ!]T2;W
MTU!20RBZ(@$20!#O.$/E<4D%AQ%427T)H9U%A`4'04(EM`,"DP\]<69LMF,-
M*1.2%UAF)R-G9B]"D!,T,2CD$A1#D7__'8E9EL*`#Z(PE@F!E1FD#S*QCD)'
MV7:`(3"3KS47QY`3VOD7=_&3@1$F]U:4+E.41:F*,[(L*``#3`E)3LD9F,$9
MS[`&U%*5%`$^F<B5HO$C>E4(5)JGL(`-:F!-#,9>ZR4W,L%?ARH%@8.6N_0!
M`#`&NV0<`]`,4H`$8Q"8"/`#RC`LI0L$RW273&`<@I,=>U!$K>0>:@`7!#1T
M]NFJ9:$I"?.['39.4G>934&2Z906X(0?O3HAP6I`&3*L^F$Z49$'V10`5MH%
MII`37;`1TLJ:R_)C,?(]%?40I-&M2H*X0%(;H0@ES;EJ2F8`UW=J4\D1U3)E
MJ<D$I.=JZ/.T_S\QL%]E)]QBG76B9@JV`Y,&+^(9C/IBGJ:()Z!12.LY)&I2
M)U*@90VK(`.$>O?)P902(B("@-S6'P."1[(G:""P#(5F*N.8*NFX%R:R@0GZ
M!?A3(R&D*WI""E(@0_4S#;SQBZ)6<)I4</7P,NB88RMS/PF1%RN`"@+3&.;7
M$N&8?CZ@>4,14]5!))=7/EAJ6#)!HBYE?K1R%^*'"I7"@,C:86.1!Q-3,5]1
MG_T!`>?D#'&\Q@U4`/W9,59@`LZ*%Z9"B"W36T#I%ULZMV":!&C2$VS52$WY
ME&DJ&0T0(Y?@27!W/*$A&G):I_)7@>@@EK`@:&J`JH4*N\0Q+$64'?\(8!X"
M(06`X!W=$0,PIR=9&`,`(`X:T#8``!T_4`;7088-408G]S>!*1Y"$`BWZ[`7
M,V%^Z(9()1:-LID`(F)[EKSX]&&:.50NR;S_X!_%ZKS&.L+&&IK<W,T9DB#Y
M$0"$F)IVD035`B1VBR9#H4/DBR7^HB1@MJU$,CY30B76-0^=:'?D6@\ZT2R7
M(%<=40&2W`4B``$.,`53$!.3UB_]XGCWUS+;>46CD;,VY1),4+BA@3\,,22&
MU$(3W"]E@@3V84;/^\T=S-)V!A71O"'IY%K=*&C>9FBCTA<6%"8)>F]]`90W
M9!"Z8P!24QN$Y`2YYA,16D)?8J&CD$GU\$3_%<0$8"(8C/&!,3$7EI4!-A93
MP_9K2R`RA@0$XV-V*]$O.V+%)31<-H9YMS9LE?<%8>21J+#2]^%.!X*'8_%T
MP(!ZH)54W?R&8#&3:\PPQJ!'C'L`PJ=H&2B"(EC(^=8%1*PL-S([_289>ZN"
M*9`9.'`D>@(;\@(DQ5,;#[$C0/"#IZVG5@`+>]JGD:H>RU&Z;S(KV!%6```(
MB"(%;L``R@``=!,>/R`,*Q16=",*4KC*XJ'#;H.$AG*7/Z<&^ID'-$`#UR"]
MCL/-$=O!!!*V#8-TV,;=)M!TV686X@TB5<>\WCS.Z*W>UPT,@+C>V[S>F+D@
M>%"4)K("!!VMTNIE_W;B4#&2B'6:B$)")4C6T>3JSQU%D6TZ)$L@`!,Q-$G7
M#@6@OP!\D8Q1B^63G4S0KXGUB_Q:/@K<)S(J:BU#HB^P6UC0GBM1)EI@%=7[
MH^)<UROMS:W'9QER'WT6*B8L:(66$X5P`^GHPC)<6X5,0CVQ&*30PPZA`?8H
M`33!'86Q!"'C7$X]"D1\08?F:CO@`PY10UAJ#&W@R4V,$F8'HPVU&,(&H\/U
MQ%?L8T3Q)"AE(SNR!'-B?C$0+AG`")IP*0(2K.FT%:3U(%NK(,7J>NE];1"#
MA^?6#F]!I<MP`#@);PJZI310R&$*IOE&?9^'(XZTMT\I&3BPF[OB!,V0)?\D
M73TO$*U?4(%4:@Q4():"1A>0:P;QA9:F4@+(!*(#H):XC`1HPQP*("O(`3A"
M<`>>FX1`(`OJ$`.FJQRS;,M,L!X@R@`?0+L(4*A7LP<FT-?5JW4A$-\<#-\P
M_DU5H==S>(?!2ZN70V[I7MU[>-[L/9K?[B'LK2$?#""5^>A%^05Y\`7C4U%H
M<!!8(@`&)5%T`GERAP;`8[@UJ,_/XXGN&]`^0&KX'24540\+\`;(>@`,[="Y
MU'9G%P/<,L,_P:4#S!(JXQ>@1W%,4`$*I1+H^2XB_68[,@"NB`#7_.TR'N[W
MY-TM">_9K9+;".L@D`H<NP*`RA?-VA=\[#(E\Z7_,0,G!,$04B,$P+)"A?&.
M*ZLR,,&F1>SC@)'(*],RAZ:GL-`/EF4(X[-C9F<=:T8D]((^+Q_G;0=3U[G?
M:Y*TO2.)Y9E2^G*0^8`'S)RL\!['3D%:R;I4![#!IU7>?.[-:.%.3)$PQS`+
MH<*X)M`77)J."?'8EA[9F-X%#3#9.%(0)]B4I?``.$!*"H4;-5$]67R+A9"G
MIRV6H!)HK2[K!4!>YN4`F;L"#'8#AXK+IE*H2*``JKL'LB0X_E!?D(I?LO`-
M,<!?UC[+,;<'TS\`#$"JA5H`07"[)QD6E+X`&VQ4`-3N=NUZR9H?D+E`YIY4
M8#$6DL,Y\)W-$LL?H;EZ_XQ/1]?[I0#Q!<^&+09.&!"`HD*%@R\,5$"!QH.'
M$Q70(/3P0H"`B1XX#II8P8`'"1KX"$"3<LN6>O5VM*RWI*`'-!'KT<!SP-G.
M-P=63&FR`<@&$BB$Q#B!`H50+"@<"A&Z08@0%$F7"-V!(B.*'3LV?*6J=(-7
M(2.7[AB*I:A1$D"U]'RS$YBSN77ETL5K5R_=O7;?O#$!P=F!`W'GYD5<M^XQ
M$XV-+;,2V5BA`I4+468"9,4*/#Y6^/#1Q<>7T%U,=R$;UH"&9B4-Q/"@X:B!
M#Q.1QB"QH4(])BLJ?V8B56G7+P4*43EC#`2L=J@R&(J#PH`!I09>3*S=4;M#
M%/]`NF)!XG7,!BS>D0`I*\7#!S0QIE?WH%Y];?4>XAC*P(CP?L*&$SL#C#`3
M0LA#)V!Z.L"$PN[J"R_$$(1K)PF=8>R898RA0KEE\A@-""8\^P*U+K[8X;27
M2JRG"YB22(H$%TFXHH$'2BFEB`8J4.$$]6*HSHD/JGM!`H\>(F$%$T!`,CD3
MT+$"!&.>-,&8.H@Q(XA"]EAACP)BV`"!X,;8(P8I8D!B`!3&$*($#6(8HX08
M8AC@!RF.RH+-,GZ`\X,2CI)"`10&>&T`(3Z(`8$_D4!`$C/4V`]!&AY88,'_
M&IRT4L2<@4#`!`7;+[#!%IRKT[CZDS#!N"H%YA]55V7_M=5+&X0551IX0-7!
M6.N"(,"XWL!#Q2[P^&(#-"S2R(":1)IN.HD,FHXD8ZWSP`GMAIQH$`T\$J""
M2^K!8HDD6DIB"Y2,)>'7`B4E;(\IIAA@+"#"*VJ)W')#X8,?L?)N`Z.(^JK>
M#T[X*K.AEA`B-Z*DHT@(M(#PX:O<=@`*`4GMJK76P_H*D"=0+=X+L,:H@"PR
M$_(P;H7+"O!AA\U``VU$&D@+,6:OC*HWMFD8^/<#!D9Z,[:1)"!4@PT\6YDL
M%$C8X0N333@#!*:5LX*5YY8XB#KI[.U("BE>F"\^ZC8#.^RP"]A@I/6JMIJV
M:>N3(HX,\LF)OP0E3>R8`\Y5_]`$PQ!4\`#!;*VX/P7?Z#C*92Y4SIC/NNIM
MA1!+-`UR%1MHB7+*22"87B%P:$#&!E3(:+H*A%@"8>H.VGHZ$H`HP!A>VG`R
M]L>L**8Q!0FA<H]-RD2"B7;+E**$#6)P<P`)`%#@`RXD*.&#'Z9)'H#@?XA&
M%#4!^$"*:<11(`9`@B_A!P!X=',#!:2(Q`)%U>@[;QX:6*'`OV^U^-7_G!F\
M;YT0),S!_GOJVUT((YA8.:-5!V15_>C7H%E!8($*Q%3_G"&"7J4H-"38PD6X
M$R^.>,``2[C.D#B2+(F`Q&S6DL`G.L('%2XA:3+90!(N,8J"H($$2>A"'B!4
M&`05`/\H4-D!:(92,.&0X`0?2`C2&#:4HQ511PDARA>`,,2EA*5F*+B*=ZB8
MFXCIY'X%I%]BX/*&7&T,@L!83&/>`++(+*,0)//-95;`,):%:$1?P&-H2!,Y
M`TC%/0;XP0^`)H62>,`]$F#`>KCF@69L@`D?\@%ZFDB:`E`!%B!`1QLPA!QC
M.`<ZTDG;=;;&MOA,Y"E@*X#84+F"'9A-"FA+RDCJ,RW[X`<5FNK/&"D&H`3E
M08=V\R(O_V*J!QX&0B$XP#'TL@S&+*,8B#-!(2))G,^0Z#0I0DT]DO"2RFDS
M"6(Y`>9PM!#:6,U%U9E.0QXB+R,MITF)`X$5GO28:"9(#9[_,$,F$.`5)"#A
M3U@8`*$&$`-"Q>!\4OB``C0`B`^X07J`$%]#&:```]R)H6Z0P/<PZJ;SO6E,
M2`B4!:C$J`0A\P`\Z`(/(K6Q8I[15F.\VS$T%LS!Y$%";T#F77K"H$HAT*<M
M!>H#:.72,/XO#S30YH@VL`2+",!86,2(`<1I-@$LP0,NN%8')R*`#ZAPJQ-A
M`$BJN@42C&()9D7#%BYQB2ZL5(<:TZ$)U,6N)?1.BB2@2FZ2<D0#4&5A2%A+
MP93B%.K@E0E8($I%CC98`\P)*D/15T1B((2($=5^13W5&VQJ6;UXC#&1L8(;
M4[D9.3*LFG8\S6GP^(5Z[*LJ'W#"_P\TX*,-2$`*1HG/"_I5DJ5\@0FM7$H7
M>E.(IEWR#$VZP9,.(#5#4.T]5WM!;;AVG1=05PK4F2(6T()8J)1GBCXH2RG1
MALZ)R*>44L!//E!1T[@H:"?]\PL/D1D7"+AW+CO]E`,=5#\`PA<O[0"0"0YG
MC(\YSBL?^@QJ2H0B%=7#<N!*0A*82I72G8`D!V&+ONBEE!,D!8L5P$(AE@,+
M*S3-&$T#+8%-0(4#%.(`]ZR2`_:`@!4XX+9>&@,2MC0^!&P@QP.0@C#()(0!
M`/0.`!C/`,:``%FHHP1(&$..8U"&\3&AGTB(P0\4,&,$%$`/9EA43T0PLJ/2
M`!(Z+!!/@?_JTAV>2H*A(M6G_!=,^OD4@9RMWZSP3"DX`R@/7?@6:.J109$X
MQ*G2X4AT$STL`ZC0J3.Q5D<N$ALE@"21EY#P)="`$AG68P$!H`NI!+.``/VD
M">W2UP<:.Y$^]LN#0\F*0[)#'5=S2;OU4MM$EJ(OZXSE*Z2`EM8,T(0F[&'-
MELV4%R-TL3/:I1V,,4$SVTBRT58FDGA(L&H?9\<4[8!@5#&`!*9A#4%F3PE.
M4,\+IH@""3A!`HZ,[%@\<R1X@F`9\:2"[1CQ'$.XYT=525;`!6Z0(E7&X`<W
M>"%`.LID_<NY`T\6?C*0"F8G^[U>!$8N0W`,`%Z<<(/QU-U*E>;_^IVK,(>A
M"S.@;;L5//*N1)-B-UU".9A0+L(1+LJ\9'DTKWP%"]HD@4@*5CH2%``61R>Q
MB6<7F5D0V,4FP-\>"&&&1>#C!F$X@XT'4&,'%,(!,:BR[O:`!`DH`P6;6(&7
M!M`!`%RY-_?X!IF`@``$3%D#6Z>[[^0TVB!\V1-4D"EA%K"`-=!`!&]80`#Q
M3-2,Z5""%[_XX^4,.%C9^8#,YC-1&WBIRT+0X[Q**FF,F!(!.*0>F(OJI$F2
MD8ZPIR/&$L(+-'`M#_"!`7R@R24RN`5OU0,/\[TI#PM#F``X0`=-Z,%7+"S+
M]2CEX?K:P!.SHVH.4_\J1^1J*16BD`^\_X!T5%F/*TO0A"D86\V66C."/(YY
MRGM>01@*V3)&2]H"`($TCKOCXT:D(FY&MEYET0`&6!/9DX"^`J\*F"6I>!BE
M(:[E``&E<Q)Y<KI]RX`E"#B#^8H,1"S$(H\,+`H/`Z6TP:*#Z`A0XHX,1,$,
MO(0,>!M4Z!ATT0G!.3E>THGZ@L&=&!`(V2GZ`2:10R,'R1L3*(#&&0VO@+EL
MHKG*B3`'^Y:;<Q&'J0"AX98=X,`D*(H/PAP28((C03HGF:=X*H99F`7&Z"7Z
M4H.I$P0M>!<@V`,4Z*<-<!,@`!0ETQHW*8'N,0`````W88`Q`0!E<(,8T`#L
M*0$`Z,,2^!XWT?\`"7@30"`30"B!`1`$,_B[4BF$!:`!PRN0`O$/,#J_S$N,
M7(&+_C@,3IR+8R"Y/FLIRW,5BMF+^CD_H>J\5_3$PTBVGD`J'!H-F9B.C5`(
MA!B)A\`(FB#!J_*(3WB(27,!#[`6/IB]04C&)5B"FQ`!4#,5O."/P7&&0IB`
M)@@%=#JBW#J=9&&L9"FE=`JX$_BC9E$/@?L`D8B!"E`U=LR")M`!!P"#/:N8
MOX"ZC&.IB@'%PVB,8WB2)GDC5"J$.;J_T&@9;#(-FML!O!JL&$"D1"K`?=$P
M</N`AV&8`F@,=X*%"TD.`BN&=LBW-Z!`0P`E#YN*EA2L@OD^+%I)$A3_$NIX
MC<'",,;B$:.@BI;$*[QB0?5ZQ4QQLSQ(/%*4$(O+%+VA04PQ@4C1&PBA'QO4
MQKH(D$)8L0*`!./XL_)H'!*AG"ZPN16YN;(LF-Q8@HWL0)Q#2VG40N-H@Z-K
M$B^<G5FP@C&T';UA2A/X,F+(A`WXG=\QJ`\8J-<`.PU('D+B`D#8'@WX@#)(
M'F6(AA_@`D-,*'$0AH7J$WM1ACTDGLDZ'QV81$*@@@FYFT=9@6S4+WW,O,["
MI<@+.9IZ//:C359DE=;\1(O9/)3[(LN"D`4`M'H0B"Y@JI3`EF?AB(T8"2=`
MB`X"B:I!HH[X!)/0`&O1``%8B119@%1PD`CY_Y3A,XQ"L`!O+(&#^!>$Z+[7
M,,]D01OK2$^;=`B(FX[X!*5Y3,?I`(10:(()*(#]*B#&ZY\R(J-9)%#%V"_;
M>8QEB*;-Z(V2`8UJNB81>4@4Z9?HDP(-^(%$4@J8%`KTF`YYBZ,SH`*0E$`5
M*TD"6P8*K,"J0(H..P@TZ#"#^*.#6,>&6SW[+$>KB5'Y3!:W>1N*^X\Q&IF5
M^KCXHJ^>`+6^Z0F3`\\BE9`7;)3["L(5BR;;P8.7T(QJ<C!M8L(F+,N;(PH2
MN(2UF)>E>A$749E*@II+>I(,<::[9";;>0.9`J!R4`,PTZ?ST`(#&(!^XA(L
MZY[A>1.#*H/74)X88/^#9AB?[-D391`&0M$3X@$`1ARHR:+($O`=(?""]:$"
MNZBO1UDI)=TI_0(&4G6&&L@+`LK-77I%&?P?_C#-&NR\_[#-5<E-6(0565PS
M6CP_".F50/.!02,]*4@(IC(;CY`(6DH)D0")>9C.ZH16#Y@'--@6P_LXO+C%
M-KNI32`_+O"W@3N:^7P/ZPBX?RF8<C*(URK7$X"*>GD!$'Q/`R@!H+"`&T#5
M7:T8HMR5?_0\^GFVCW&,D4DE'S".@06-$$D1E_"5!@,"U(@^()`.<4LD#$,:
MTD"/<%(:C\20!X0:*X"%8H`2K&P'O5F&-V#!"N11^52U>5S9\UH/KF*6^4#_
MEF21-:ZR%WLQ`!]E!3"`%?[0K`+`N/TB2@`9U;[)`S)#IL`(4&8#G&3+I011
MHV::I\E(F1T@0FX:RR1H@"\M2Z^P0@W+0J,84Z%8@.1*$B2!DB<I!CC%G[PY
M%6`8D#R`,3T(@@)P@`*8$QJC,0=0DT+I)P08`P5H!K_MI[4#@`V`,B18`7JX
M`S*!LKIC``!``00XC[H3!2G`$BWX,C,`/%3%BS?@`1HPRL)P6E*A36QU+_1[
MT@99RG*XFX]3/_UZ,P)%C%I5E3!B/]4%A@9RQ?-CD-7<)<^U2L(X*BX%EDM8
M"(DH5A3HH)J8-+&Z"(3Q@$\0@$4$B>F="#3PEB3(_X,`0"-5%4@"F9NWW8E"
M(+\>,*+P2Q8AL#\4N*ZOR(K404\A((V:85\@",?HH@VN");X4!CO\!K:D`)B
M6X%.7-53!4AL]!3-FI_>+%64LPOAK925,X'(H(R6(UAK(XW2>(FP+)&&Q::8
MR`KWS88,O4@DB"3(2AJ368XV,%LJH`+0"BT",P:;XK@WZ(>3[;>4Y5'[Y%$.
M(\<03-G[8$%&Z$UG$%^<RBGP-288Y)25.H`0*`!2@[R*06+]V0]EBE/(0!S@
M!-$BY-(F!#JNM5A^D9?!\I;<\($;8)K8`8%\HV%C*,E96(:V)0QE*I4#&#R_
MJP,'\&/"S)(]V(-"`+L8>/\D'),"98B!=^FG2/"'MHLR1*&`;WBR\<`R*AL`
M*_/3/DR[3)A$3\"4Q`C=H_2;`=$;3OP/S_T4'5+5]BLJ\'ROS:IBW&1:V_T'
M!+Y7_;I77)Z+7:8+!P+F4J4+6<P+7#'0&OC!![85!P(&X=7E3UF`+UC"T%B"
M99T6JQ(2UKN688G"0=B(V&#&Z=T(:IU&/``UIE7FTM4)5+W7-P"*";``"\N(
MVO@`^O4!]^VC1W+?]:@/(8@DK?B`#?@,V%BDZ^@.[U"/#MV`Z<H>.2"_&]B)
M7>YE!!;FWJ48=J8+]?L4F4KGB?YE6YEH9?[>25'0%E.QR<B#ECNXT1@-0&LP
M%'G_B9=NBG`=-R60`*[H.1`M@!MP)WER$A.X@1B^2SH&IJ,%#&=(R7):V>YC
MZNARZJUAZ%*:KHQ@N&:Q+9HU+_-:)`.0.%30!US^:']<@!58``J!+V;FBS(R
M$.+=Q#RP&Z,L`$[L'U7^05-UADU<*;DX'/PQ!MIYDA5P6((MPK+TIB\5#1))
M@JF0BL*RPM4YCB/A:2^D`JR,DEEH!SKVF-GU1\(H@#LU`R\0`L4M,B00`HK"
MLC<Q'NDAGNX),F%@'MOB@A^X!V5(*.R1`&$0!@#X'H1*9`9P$]26`!U8'SSV
MZ`7@@1#`E'/YBP48W4[TZ+O1B1"`NEQ69@E&56`^593K_Q]8_64)PNB0_N6+
MP6A;!N_#^&Y,P>CL!EX&D45@OFYC)J!@7F;SSFYL/0S"^%4<,HUJWC0!F-:E
MVC1)F[1K\2KK'!+JQ:(D^#WO1>#P!AQMC&@$-H'Q#`4S\>&^8IC8ZR/0<(KX
MC"Y_AEC:$.A[QMGIN*WMZC4/V8':F`XN>.?`>&#L]EQ?KFC!$(SO=J#8[0^)
MQHL9[W&*7N^*!AR>R$O',(942"4&3*6&%30'PR,5P2'A%#30*!M$NFFP.($5
M]L@S*(;B0ENGB1(!L^Q9P!^/W`]]<([GB`.G5J2F9NHV7X_<BO,X[YJJR>:J
M2;>M,:7SDCA&X$Z,SF5-`3XYB__Q7480P?"E/"`0\5404DLS!D9@".#Q"(IK
MHUQ=9_C7OO[I*^46WPB-'?!2PQ8T!9.*,'V1'3`.&$X.+SR#(E\&.F:&O)G-
M[QR<$*`209B`,9##''/?2/Q,%'`#Q+07H($HURZ!,D`H!E"',O@``-"`$I`"
M<9@&[/D>-G">\4$!-T&"'A`#2E2#7][E&C#N:_`X4QYKYB:C]^:481J^=>8+
MN8AO'H]Q8>X/49L\9^[H9V[P5+%=L)[W\'[F&L!NCQ;XN="S"([PB49K82[X
MB4;F@8_P3"G>)62ME=@T8I6.ZQ"K9EE&CA"2ZZ7>89%&&E@`<H_H9YYW&]^)
M8(8S!%C_%QV(`ZJ>+JX``MC(YR_89_KP`*[0%_40@H$6):H&&+7P>?O#@MSZ
M`(<NMCI&>$"/<.K^<>'USCAS>K#&\>H>>(C_W`6QF^.8IY0F&LJ(I-4B$3R*
MZ0TF#6S+BNGX%YX$4:Q,DB>))R>Y$(!=AG9@AO<R*1T"@Y.-@ZVQ%XV@9P&X
M+E5SZNX;I46:OO(RB-JXZF8II=S2FNHBXOR@./E&U7HW%=(%IM_]Y8R)XK:&
M8CW.I0CQ<5WN&RDV7;JH8V;JZPM)::]0FL7AV@A;K1')#*(H&"N\A!W`@RU'
M#B\$\RH=R&6`6_V1J>YNE&/(%=R1!$'0$CYE@AY37(HDD_$8_P,@*P,R^1,B
MHP``$!0X08)I$(82R/XS`3M&+),?>_85J`))(`9".(:"QY0'-F[D_DZ3,\I(
M(5^`<';@@#,(;P8>)`@!V$((SH`YJ_'0H42)$!\ZRSAPHT:"$0LRO/@18LB/
M-1;^2ZER)4N'(1=.+#EQ9,:7(R'4H,$C0$.&-TM6C!FS)\:>,`_FZ7(I29(N
M2BN@02/`@X!!&CQ(D#!UGH=/'CQ8_?I)P(NH).K12/7&),:@)#%"A!D7Z9X)
M3:9P\2#%PP>])S;L,,!W`Q`F*/:^V.LAQHX-)UYX$++B2P7%4B#'(+%A@UXA
M0(#LV"L%T)32)M@&3?VSIE&&!]^L1?^(DZU/U25)RJ4IU-G!T\Y,``=NS-B;
M`BM\K"A0:/(7'\YW?'':Q?EQ/,D+;$!AX`2*[DNP?$E>Z`P(6"!`H!MNS(J)
M8LM,'`"^MN:Q/'DVZF.4(8,A`P*D"/"!%`:\8$!F&V`!&((;+/&!8'TE%N$'
M+SAX`H$>;&=AA!%Z0"$*)!ABR'ZI'+#6137`5B)"KI78T1NS^<3B&_`=D$<(
M>12PP'TF++"1BK"Y))=!/OHX'TG+'&/">L/EX4,]6"!WW`Y)++%%!4O4L\-T
M70#QQ0Z-"7')!B0DX8-RQMQ`Q1G#@3"<"84$1\6,)O06GXD=#60"3!`4X(D9
MG@3AP`<#K+#_AQ8K.!`#`#$@@``0FXRAP`^,(E&I$-\P4.D82*P0S3<&5(H$
M`HH"0*BH0`S`@!1:$/.G&C#5\%8-"_!P34=YZ!A?"`5`<M^+!0V4$6\(<20K
M;1G9YI!#>19)$5RHT>26,RQ1NQ(PM]$$D42P'JOM2`_P\*RW%B%[++G&GAO3
M&R'@P502]73QQ1)13>6!!AI8-8B]5'UEK[Z?^(<&"DTM\.*XT)XT+K?#VIB'
M!:7)`0AD$QJ`P@Y`'&8`83Z@H)=@!GR``F@H?/#!!L>17'*!(5^\06*$?8$%
MQ5F49D$["./,;;K`O/;BNGJ.&]+!JFU[(K37#ND1G<?\9HR2R^!X_]QU*W3I
MPQ=7:QD>=<HMMX-V%0BQA!`[(`?GFN59T::;[RTSBS'QP7?:13X6\$8J^?!G
MB(,&\-WW#M<5$+AQ3%C8M^$@\\U=X15KU_?>?0.1#]X9L`(&0A$QA-!K'PT[
M7Q[SD7N4BC76N.N-(9AP'T?!`C7L1BF:$$*)1A;33I++I&U"`5V0`$24/FP@
MF`<G0.?4%Z`E.&829ZU0"!4FG$$%%>>I%UP>=&)/Y)T"O1ZD0(000\PB0<2P
M`0),B+I"#`K$`,0&FP[P`0,Q(#&`$`,,(`L`]\<P`!+""*,$_-L`J>AG/R2L
MKP2+"!\AJ$"1ES#$"#Q0"%)XM9$%Z,A7W/\KB#,"P*P9!2MA;&G-1W+#L]%Y
M!&D0#-(*A>:0:L$P9Q`\VFQL`RX.!@5G1"NA6QK20V`<XP!38DH]G+0%>GE@
M'@:XU[T$((!/2.!?3A2``9:PA"3@(14NT>%-A&*1(=W'/H70P5VR8+B_.$<(
M!=J`<TA6H+Z=S`="`)ED,/8!*L*Q,(&)S&=VX*`23.$N!>#B#EO8$.XYY`V?
M^V()AX:SD!0RD<$:UC&`T0ZG*>D,4#L.$)0CI2Y]86,^Z,(*\E"(P"T'8P:H
M`,R2D\GI60$65D@;%=QD@F,@Z9:C$U9\#G"C`]QM/QD0F.)BT!TS%2*9RCPE
M"5!@H6="<SO=T8[_@[H3@V=N1YHH6,'D,I"*`'2N(/"!31Z<M:V$0$`VV)(1
M?`IP@!X5HD>74V0Z6^2MA,BF(-=[74V<<4D3X,YI3AK;"J0D`0HTPP/P8H*7
MOJ29>FP@"3LH@#'49(SQJ`T$P2E$+V$#GUU=;FX^P@BP#K`'0IB!&)G8%!*$
M((42(`$%,3"F&P`PH!)(@0U2^($R)!`#";ST![+X`2`4H(`/2$H9;BC9!W#*
M``W,M`>1:)4G7N6M9]$J!!,Y"`9_"1_5;62+-2I(0C;7PK:8RR0)R0-(3(C6
MM\!U(1"!8;6((BUTI54U.@F`T6JP0]60\*YI%:*[BGB)(SJQ!5_1%QKT_R4!
M?$TQ*E6BP1O`Z44N>FN&&[%/?1YVEPHD#@6$4:4!A(`%TC9.M%_2C@<LM@,A
M3%.:@&F,`:0@6BQX#06A*`T"EG'6'1+%6"?4DT`^AZW0.3*2CCRA1P;"-&<P
M8QF_`2AP`N>#3B[GNKY#PI=VP`14)K.@0JB`:)U#T5B>P00@6-,L9UD,I[VM
M$$R33R\)@J(\04*1C)A<'$33KQCX(+P%+>@I2::7`ROF*P/BVUX>)X4'7^9Q
MW<P'B=82@,]I3JN-Q`A2[#F4D:#SG>^470%"$)O1O0&"^$QA1NH94G]&-TE*
MHD(A:)"E+DUI"PSX@0&8TMTQU2,)."#!"J"G)O_@I-<8R\`D1P\`)X%\]3X+
M(&Y$B*0N'Q'"3Y+8%*H&A,#^#4`!&I#"3-D7`YY^0%%I!H#^8B`%G\9`&3]@
M7PG2'(,RE$H(/1"$&<R@!A/IK"!XX$$(2I+.!3!A!?(\AHYDQQK[$"1S]W'&
MY_J)F];]E:P@88TA,=U("-"56I=N30T)29L;9CK3</V)#VF3R!`$F2E.68(`
MI-(O?'U%`EZ92JVOU(4\@--9R<5L6[A:(A'@R"Y-F(`0QK29S5#38KZ3DA`T
M\^P&50PP*V!H8ZR]F3EZ@)6?\8%G)U"(50^;7%]\"3JY]ZODIAM:KLY<L.II
MZ5DL8QG/8Y)QOI#H5`K_00(,`(`!R%;0::_@M1MH3G*,T0;JJ:VB[L4W?.IS
MFH.XCIZ(?,.4@[F?.!Q.,N%M3'A.&;S#(<YPVOE/Q0J'1Y4+D\+N=@:C4?Q#
M90E$6<>=24)J#I\>E;3=7USQIA<2Q!61U+?O$8[3NM#=+M2#!/:J0#V`X/3&
M3*D>I;S!<&Y@Y.G-F*.ZNV7%3U<`#!]@6?P4W48"8`(UM$H,$R@4`A"%`O;Y
MX'P(0`(@`(""O5<J?Q((%:>FX0CZ?08!*'"#!`A5]Q5,0`Q];N"F#7VMK`HE
MB"%8@#M_-NF%E)58*!Y(JU,M[T!?6ESSQDBH69(MU9M^AWL=8:=-O3,2NF8!
M_UU(PB6"[)^/+9:)5*FU9+N`AQ"`,_7`Y:)!7D2DAC'!+E,8@+<_Y$84+`$)
MSF$"$*S=3-C>\03-=LYUFPWM[A"H.X1!0"!UL`D3=)K49R7):]1N,$+:E?DS
M3$A)A24L8+3->[A)U`!!<E#-F8U`,TB`R!A@07G)9XC'V9P'"%B!>CB-%;1#
M[4Q7C>B)1Q!=O=E(C0B3(8"<@[P`"GP!UUS'*:T`-5'("T887_0-8O0-A5`,
MXHC(?C!"/X!!Z)%.B00:N53>4&06]Q!)G@S)6BC2KTB$]J!5$]+)(<%%<``'
M"$"-#R1!1#$%&IS`%4'4EP09'L")FDA/FM12]<!'(?]<SSA%68F)7K-L59$4
MA!J@E"1401`8QQXD"OML@MXAP4ZA@!94"A",@3H`@*8`@18(0S303Z4H'@`T
MW@J("@((@B28`2%$868)":T<0.L45PC\DG/%A:^`$9"L6*39GKQYVKIQD4FT
MGK7(7ZG%'EN``0_0`!&J7KPIU[.DQAO@01>,0A*,@@&,1;_DVB"X0%<8`!I0
M'0V(@)'D7P^Y6[(8(4+$CCO=1R%L0B"%0A1T1S,M0>$(P=@TQF9P1]B$#<ED
M6^]\FS-]2#-IAQ2(S69('P(4`B^^'KJ]51*>V'SHWQ,2&VZTFVQ(Q+.T0[XI
MR47AB`\D&A,$QC10P`\L8`'_LF#57$="1H\Q4.`LP=<M!2`0?15'2!*1.(3J
M7(-^?-PD=,B`G`S7H%(!^,"%^!>"?47%P)9-QB-?Z$5BQ$$.,D(JU$2'K<ND
M'<Q+%"0KCAJ]P0Y"2`3_U=-:),V*'-)+)%\_9<2<!,=Z+`,>3`D)D$"5;`&9
M2%26&%\F44^:).32O8GJ9,\!N-,OK1A875GWN`8=FH$D+`(";$H+E@`*M-0`
M;$#\L(\0S-0`Q``#*(!,94$,C($&`$!?E@`;S-2#H<``L,$`5`%5J0$5]-5;
M8=[!($4HSD:'C:1#\(;LT$C:I6(A/1(-U<9'O*)*P(5;S:+L[<1LKN)J1HO\
M`0L/_US"*%2)5'R"$]2+6%!1!2P%'C!AMO#F0-C(6JB&<]8(;!R$"'"@VR'`
M780"%Y2/]3G(9KQ6##!8@8A6,_&-^9V<\(1,M2T!@6S&`"B;!3@`,%2$7056
M1`1:/272Y_"F:NAF?;((0:1(BI7+_T67VRC)FUB'OX52QP!5Q4P4"QK<&))'
M>JD)[EA![73DG4B:7)+5$59C*J!DB#Q88A!/\Q14X'S!8238@1GC9;`1$_3.
M"@A!7R@8A?3D?N0#*N@#?0*+[,"A;5S6#+V%NZT+D)0+1QAILP@7:^A&G1R#
MDJG7>S@)E6S!%ES1EQC/`FBD1K;)\R3DC#F96W:4<YK.Z_^43@ANF@?1Y8?N
M0:L0@Q?H``J,`?[<SX/960G$0`DP@"B0V4LIBC!H0)UQ@0'P*6+JZ4S%@!N(
M@22$CQIH0L($H:`1FK?TQ%IY1,:)GFFRZ6N(9&[6)FI$(SY*1&RFA+2$JG+=
M4'#])Q'B'CYFS@Z,`AI<Z1%Y`!IX!54LXQ9<`@UTHCGA8EP12X^`4U#XTG-:
M&1!>I1<T01.$P@>(C7D:`!98#`J\T5>L9S-]0!<VF[4RV%=,4SPV6Q2T7R$L
M9Y-^$:K.Q.<HX3,*&T"FZM&X3I6UB)!F!#.TPR7!5]1X"1*,R1+(%*,8H'6<
M"7G$TKX-1S',$KX%41#Y(\V%H'W_6%943IJGY@$8C&`<E,Q_M$\A6$U!!<^$
MB.P+1,AE-!@6&$=+!@]?_(<`3$(.9@`J@(&S^$C!N!NP,@1RF9!1H(@BK1V[
M?=X/(MT*W55#>*K<O)?U0-WR+(%F0-T.X(&2K-=Z#<>:6""-J*$U#H3I>-7U
MW(@IV2Q$K!@TTD@(P-U=BL$`(``!;0`"Z>G]L$%@2L"B#(`;&,`82$$92`'>
M)F:8*4!I1:803(`.6*(G$$(E69K\\<`$L6J`EM!8@9%'+`M;)<T2PFNK(J6K
M&I*I_H-)3&JJP@2X\)7F!F$L%B7IJM@U+$$%$-]4?`(:?`6M;@$-E%-N:HM1
MN-M8J=.A_RE:CA27:FY8(2C;%'!'XS`.-7TK>2+O-"U.8F#(=HCG"\1`*#3K
M%-Q`.UP+@)JNJ,K(Y-[)]FIO_`%%0XCD[L;%18A$.S"#>U2AF?B`UX`,"HSC
MPA44'B@']"B)>;!)1P;@S011W`1)C>0!H]T?;ZC.`E29SUQL-QG"-`G!%WAL
M`2:<.S)O=Q1O\18@=B0'QCB3,<6!,,6L/H"!;SVESP*AY0)HL/+F[5:C?<'%
MNA"$+\D3#A5;BAT2N?B(W"Q#.\S"FP#'"KP+$4'=%ZB7_D:<DF3HTI'I1M0'
M4MC(E*%3!H%B$T<E$/J$]JB!G]RE`PP`(`C!)A2`'B*``>Q/&/_O@20J8-WM
M00$XP`\(`Z&L,1=+@0),@!9750!(*G[J8U;A%9MRT(7=!_FJ)C``,O"2#@3P
M)\+<9VK@7B.O6JF:JNE*,M&RA2U.Q.W]UI#R[.>R10#@`:U1Q:X1'QK40Q[8
MRIZ([R$AQ(UP4%B]0:_DRA+NKKH4P`0$TA24P.%(;]^<0(#T10WR387H\N%P
M02`MVSV"05N="[?4'G/97ZL1Z2*K<%*&%?=8UOFR!5SLL'O`EW4`SQ*-6?E0
M1R$LPWIEDGJDS=(EB3]Q6'TIB^8UC$($Z%B9&%FE`BHPL$IJ3"&X3T%UC&)(
M0*[M14!CA0><S`HL07)LP$![0(@(D\S_>HOH]:-#U+.0M$YNK-ML?`21U&=3
M_B"N0*51;FTG<IJ+3=)%4*&2+$"0-0!:K(!&RI(LK4E"%L,L\/!:DBEP'`"C
MV<C9A9Z4N=,;MEU,D&0-!``=PJD81,$7HP_ZE$#CZ:6F"(,4U(__,`$`_(!?
M'I`0Z`#A3IX:'$/^$>U"+&[:K1`B180/4IIJWM?H(+);D][\H>[.WH:09+2D
M<B[FNF9#B&Y;X,2HAJ\>LRHC&Q*P=($`X-JMHH$*D("O)I\NOC"QD&('22<&
MU6P(WI]JU/(M1T$N]XWQ+H[\9L=G<P?*B=\&"`'-W,4$[`$T^O7X@BK_W2SZ
M8G3I_A:L$`5'_W2J8#O2_^';0=:2&EH-"50`=RR<F9A`VK3)3)O`#2AL$E,A
M@>()Z[@8CCC:.=6(/)4(1`P$/N]'B$Q"'&P`/\<H"F3%>9^W$Z!W5ART9!2`
M$&#%R\(L(XAP6DNT0^PV.AW7)/MU1+!I6-F$``.I%6_T9J6=I%J9_V$/<-22
M(EU-*25W+*6-FPQ'`,Y"D@@M"N$*D.(3KOC2\V%VDOJ(::*(&NB!EHE!%5A`
M81*F`*$`3AE33I&,!*09C,=`4_5`%31J2A'"GYFF^'X$'W?R)!D$*9)F1ES8
M"9..STPGZ7$O)TNJPMQN4@H%YZ;RE9-:.SP`#93>7"^SNETRSV(6!/\L``D,
M@CCPP2`(0`48GSS_-98_I40WY:Y@$%AQ7JZXZK8X0R'``?5.02ADP0<TF]=0
MB,I=S!RQC-?<8/PBP03TP"W/'51F]/S%8ED]98M%^9MKKFOB8M*`TT`4ZURO
M6@92G#'DP7%\P;L87!YPW02"0#&DEW#8M`;J-)V(!-$!@R\%4:Z8M3B%HK)Z
MT#TSL"%L0`&X#W)T3$$7=$`3-$$?-`J8R09,@APX=`;DPT\F7YS;$^A=3I[P
MU5^#>;*<!"N.+4D=Q->BF-$:^"2YCI.#7F\\3?6(T?3(DG(GJ)+Q<#',R9C6
MUSO9AWW@T^E`&D(TS"_-1@"L6+:?^P)D<:O_2((@Z$`/](#]],_=^=0`Z&F8
MZ:U,#4H,=/6.7R(F0H`T3WI9EUI"X#%E?Q[*V[>O\(SL$.@I'L"W8SF04W*Z
M3@3G0KENXL;L93+1:'JFZR*I900-+!&/50#M$L5E_55<ODBG#LD"*%K-SC"P
M!@4$8&=IE-$`%.!A%(C)/K`<U=;)&$9MP6`4#,!NW84]2M>UZ/&\`?:P<#A_
MPH0.3?+V)DW&13.V<,Y#'.A!.LVIX\&#FU*7GLV$FT`M/8WZ:@2-0&<'$5W]
M@=6O9HX\!;+8#H3'Q5PH;=M"NVB_S.1E8`'(%E0]Y*@P_23,=ZIL"`E:7PYN
MV[S\C2U/=#CJ/+/3_[<=T9%4?542-PO'OFWD$2M934M7:IJ`)JC(+[FAC]C'
M\ON(Z:A.BZV8]VP$?-"A)SB\&'A!)CCZ&"#``/@E$OA42_4/`D0!%WB!%^PX
M,1CNGTTZ;^>?D)^$'R.Y1+.[#_+?_`NU"]\<0`"#()"@LQK."`Y46/!@C84&
M!_Z3.)%B180+,2;4"*&A,XP'@3W@X;'C1H$&48+DF/*B284=5:)\0^/$BP9Y
MWIQ,J+)C1@@'#KPYL.``!&?.#N0I*C3$@15`%RS(`^F`1XT!'@)#Z,#+E"9-
M0DU`@.*#%`$?7GQ`P03(!@,OA*SP(>3M![M9O'Z=LL*$U8P!>FI5*;`GT/^?
M>?)`,$K8)V&6,%EJO"BTZL^@D%=>//CP:#MG[8JU,T8EZ8H"!0HM@P6"BK$;
M5*Q8,3;;F`EC59TMTTH9J%5G;][@!`J\:E*@>0)8%4H4\9N.2<'DRS"=>KT5
M*]P:T*[]@W8!V[7ON+XAGW3J&1BE$AH<Z/`0SC6CM&STP'N2D1L/1*DU8?OA
M_HFKK+WWF`J.-P"?:^\-S]H1S81";*,MMMJHL&V96=I99AD`/1)**:E"4,K`
M$`IH:H$`#RB1Q*!P0@I`Q_PK"H(WU""$&#-PE$0,,3()PH$?$2B#BSU\K".(
M'27!$4="U#`AN97X\VV_CWC@H:B#*#.J!@\[/&[_I0"2ZC*/$#PZ*LP9AVOQ
MHY80.FHG-A5J$[*2(*C(3HJ,6DP_H^33:L^6]A0H`(%$&C0E/?U,J$\MRW3H
MHD=U8C1.16?TRQDP/,+T4C<9W4RK__)`2JFD+'OCL*$@00R2)X%)3E"M#!UT
MH`#>V&2"KYJ8(A0N2M`N+11VV("N#TB0BRXIN`@EKR9TV&268W":M4RMCDJN
M(2WUA,A`^EK<%$Z='@U,TI,.@LC%HEQD-4Y,X^R(38268::=69:IS80\C`$!
M%BM@,::0V2*\<)EC#CBFD#?:_*V]4.5[0P3*WB#3P_>ZG7',^A*#B%:E\##O
MO`R6F,2#D4DN>60)I-C@_PN/ST,%#'W`,%`J%H_RU*KD7,QI6W(9[1,E68&&
M5=3C%#2*/?H6,"'B42'`*829BR)WU*#<9.88VPHY(-]Z[:W0!`:9.?<`$_@\
MC*BDVSL&1*F@+6>YH0HHQ[`\1/!/H9QB+#MB2/3PY$8E<?3$$T%V),9OP`,G
MQ%3%?).U76PA=:9*,EOMS:@`$$,73*HA`%.I)Y72#_/0/<J\Z7*.TB]2@2#`
MM*!`LW54=G.-NM/V5D_"2BLPC-)4TUA_%EJ@941RYLF#=/=-4^21AW525Q=S
M%6=V6^W]YOV\];UFXYDWWJ,T#W@RJ8PM*\JX!5)%N-4V#=VS7)QK**0`+2Q8
M=O^*^^7((HH-!HA!BBQB8($)*&M931#+P;J$&X1@Y5+ZP92L-@7!+"'E/8IQ
M'C!,Y2W`,.IXQH-5]W27G/8,Y'.-.HJFJI<[D[0)-*"I5X1`$!O6V,L$)KA0
MA@;F'T[Q!CDK01-00O0]($;L#>PZ3HA"A3.+T0T5+)N.(0P1!RE.P@!4M*(4
M#?$QZK@,9JE[PP*0&+[->&IZ0D18TX!S$G8USWNB@Q6U]F0"J<PL3ZR;6E!"
M%)0T?2A4?-K<</CTFQH.TC:S*`:$:G@,T`!C&0=2WT`6=J*FO`UJ>L18B>XX
M%*)49H$#0IA5_`-&-=3(;W]#G)(,QR0U:"*#C4N4!V'_&:L/+H`'(M@2(#$X
MR?]$S2@BZDT(G%2M76X.8DIQ7@-31ZTR_:Q<'_3@8N[S3-O=*7K4,E3VMM>X
MBP`O)#R0GC;7=T+?N-%[LK/6-\.)PC(NT"#PVU[K7.E!B#7%<LZ@I_$N5IP\
M1"5\TW)5+-^X0-ZL0`L(F,#]<I6K^RV4H7J9@@XFH(4\9"UJM#(,"OFD*?:]
MTJ+H$I$XW9C.:H'+6AYI'T?/]<.,FM1/ZDQ85MSD#`S1ZX6TJ=<R0%`;1"[#
M,[O18;D<^<Q0FFJ7[=$*3B)6`,-LZC!*R0,C&.'$#$"1JE6%HA;SP0@PO&Q]
ME1L?VSH74'-="F)H>@/.V$G._Y+&TUKCN]CU,#@F$QA'0?49BE(FB4$`0?,-
M<YVKAJXVR*S9L$T'(AM*_$-/RB`Q<_Y!3(CH>1S$C"F#'06D!V,TU[&IH0![
MJ-%GF:3*439):4_B9E@!FEI#3<Y`\,%<4-!$NN2(*+:PQ2>Z/`3;W-;Q*`L4
M5#N%]CY'^0FDLG33-.WD+5AZJYF70QXY$?4`&B@WG1F%IG&CQ\ZNCA,E[.S3
M-Q_%.V\)KTREBM$G#P2@W$9KN]R<GM$<^X9"[,&@/?!"*'2@*_WN=P(3L``"
M$+"",QK'B[T1*?=@.9`,KH>HL$5A@K,I.FFI$)Q/HHP(^_D[:KGT@M`K2)OD
M9<AEV/]FD,:PPH@)J;ZC$,QNK'-D(!UK413!]@!N2PH]X;<TC*4"%8Q@A52U
MB%5&H**([<`95H!B@CP")3GMTV"Y2G6N03%0>-D"3"P%"L3&_K-\=HT1B<)8
M5P65E#<F.(:\1ISD)+NIKPIJF'H7-J82M4?)8ZHD$,$\JD$%U<)[!4HY(*`)
M!0UR;":@@JD"<`P?DA>[KPR4529G',7L]C>35'`>C997;NG6<KFT;0K=N\`X
MA5J#SF0J<BN2)]>A%IZMUG`YGXDSD:C:+QMVD[JPVTYS=?6;\-2UKX?+J@#H
M!J2_O>7"3.4AW5$F6@6:45G9:;-L&>3+R4Y1`3:Q"2UH&P[_"-!"0;V]AX,!
MIX>Y/:OQUG/.=QJW!GHMRL;.G2E7=D[7W0U:;]D%O([^\)/9;!^'O?=A:E&K
MA;.@H87,;`RAU!`X;>IRL@7RX@>V)VEOD!M]%,3@H2C9MH<Q41%AUN.H8G4Z
M^?CQD*$1G!-U]=DQTB%(??O,"Y?O>J+3-85%=Z#(GMNR23G08S?I6,5"SY'*
M?-!$":TPN[7SQ966<S[MBAA,6O*N3],LU9>*;@#A;#@-7ER>\F1"7_^6HZ\*
M*VH-900>-%:/>9";)?WH\UWF"6+_(5.3EUJ#?[J3N^O;S,]NSJ?-0!`,J*;(
MIMYH/6QREXT>+M[RD$D]5B7XN2F,_]Z$&>C2\4HONVKDH*C_0Q0+BS[B/A>(
M'"NC&)]C!832`IIP]/B>KMNG0[`_:XLB+AP"A>]RP7F2N4[:1LP!QV*_A[QQ
M?6>]2)7:(W=3BIE@>Q#Q7GGS/QLU9**4H7D]B)!]\8Q?>P,2'N:$[J.JF(LJ
MF<`PO6=C4T,FQH9R5C#40!\!2,4U4I&*K>I?'_K@?\R:0_38J>NBI3[8`X):
MQ6:NK%0L)MXJ3W<N)U&PXH>ZCJZ6`JDHZV$&!(Q&Q4#VB6G*)*C:1+.:0Y!<
M[E$6J^.6QLYL#"I"X&GPB"D0HY*"XX[\HNDLJ#W,*$[*RU$P:N]`**!BY>]X
M@`9$`/:.\/\H=(R!/,<HY`8QJN4P)BV/SBAGF,KR6H_E$`QZY`.9KDE3#&\B
M\J2DKFEV6@UH@H?>:J!08*Z<A"W6R"7@3.LD)HS6.,(.>>UZRH5Z\@14S"LQ
M<`E,9`\0J<:,8`UX'$6$B"*#A@*V+`9=?F(1,^W=?D,2'S$$ZT;7!B\.P>2L
M#F-QR$5=Q&XSM$?OS"7?8&6$&/"92JUWM(0,NZM=8DHKK(;04F06V2/\^A`G
MZD8A*%`$?NV+;JR?;ND]CG`I1`!:O.12DFRR*@-T]DGV<@(,@`%3'&(8$8-Q
M_+#\C@:"SLZ-+*/)HN7LMJ>DR!$8SJL/*4[`(D:QG$8J\B!N+HS_.8CB%9F-
M:LHELZCFBRXF@S"N:#;EB$(%J?)H!::F:4*D`)@C]JJNLI0.D!S"[R:(`,].
MW5I'3\@P#F41'&DI!"`@Z&1D@I8(M^I#,48R3T)'4/).\?SNWM1M$]50W=:G
MU2XE#"5B4[KG(IGJU2`0`N^C>!:P@>AP)A506D9M*%FO3"3/>F;%*"V/J9AG
MGLA'TKXG6JIR*H'"B(#"["S%'$?H((RJ:20-+`WCM2RG?`3"_2"@*9YO$V.-
M,G:0C.HH\UR1N2[G*.OH'PU"1!1%O.[P"F%Q\"J/4:A%*([BZ-;#X:Z.3)AJ
M0*I"5L:O>I!BDY2"=RB0LH2BHX(#X\`D_^AN,/Z:@\H8*&*2`A[%TD,>!CYF
M1`-M:PBW<`=]CYG4T*2L+T9(0AWWR>(R!V)F)C=#[ZY&"!WM)D[\HR^Z##A/
MJ'Q(AR/2R^YF\`6I#HP@BS1+LQ'/J`9BA/!N4S-_XAB#HM<X42$@*`@[IRD]
M:')*QS^(Z=(L:7.JQ9[:$R+A,O-NQCSC9".=3#+7Z#Z8TB;_P0Z]Y0QIYWW\
M1%;8A0W/T2)GDGK<$"+,CO,6M.;,T2FMA2G=;6F`">]Z`W/HR2&8XC'SJ?1T
M$0T3T4,GJ.<L;D,?,BC@<DL<Z4.'TQL%)4M.<PY?47E`BEWXD!7AR11'B$9=
MK;C4B"1Z\BBWI_]<%.883%#-SD@@LO-F\J;Y/K2"3"J?&,91%L9\6-3+B,-4
MV.[LB(8H1$U;=,^I\(BR8`LRU7-1'.>W1(1`'")HRE,PVFJOW+`TS;2N3`3J
M,.:Q,@F("I$"LVXR\Y01[31FU&NQXA',YHHMB6+.0FD&VR,YFDX[[V:7="R#
MXE37CDR%>O)5VN@D[(`'0H!2(XNV6H6VS(V!1,2B2$?OD.I&6RT4Y:TB]\1Q
M:$=':]4@_).ID,G7],,'71%4-64@@%(N9U(_R]$702T*68<H;VU<F)!Q0N@*
M!35&1-3ER*\YAZ/TV`]Y[N/*'&>$OB=$M-&85,]<.X?`.F=I)M`XRJK_PQ+H
MK"[+AZ"21[MK#X=5^1A(!XD)F_`2,&TN=\BH"]=#KX"CZ`R"W,8,OG2(78H.
M`J"E`/9)])"'V4(G,5#4,.#/<FZ)*#!M3#MQ.3[0Y3A'B/PU)]G(KC:3/XDK
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M"`>/,W7T#ME\ESK9KSZ0=@6:@GN,`FE99,%J%EV6K)YRL3D8QU$B)A+/1D0<
M!F(JU#$/UT9/,V*$[[?(4>]@U!.MM?0RZ;'F#)@P9HY<+BI:=5:R])..;4R0
MRD.FYJRR%9B6UT]U"2H`6&GGR'YQ=CA,ZQ1K#NJ0%G5#D0XAR$8U&-\DAU2A
M1UOI*D#B#D#J*0"4K%',\_><;%T6",IZ5Q2%]83\,YQ\]7?`53[^CBX]Z%CK
MDVW;R;F8R8?%*Q'/U_\Q[E)@P[4N(?`WQ4<`?^A)4&^#G&UH)K!M&<AW.R>'
M8Y,^9(]%K;(!#=!`+$SW9BZ)[:CADD(4V>5>7?.]?/6(U11=1K<I]?-P#U'"
M>G<+?\B,H(R'O)`]HK?/V))U+]/G(.!>3N1SZ`ZR*,LA'A%>RX=BSFI+-!`>
MQ?4.A4,A)54Q3(`U$496P`>"<+),6+8W7(<)"6("@VK1CGC28`]IERQBZ@QI
M#R1I^"GLHI1=,NEA.K,?&>=XQ16(E&I\QT<A=RZ/0.2.GH:R[B-J?Y5F@4(A
M]7=:*6P+_RX!$XQZJN0`P!6,JS8QCI:9D:S<\H@)??:2V38GZW)'.4)<I>W_
MN6K8(_#VAW_-7(AX)U&B6`DE<&D2=^AM5H`71[V0$\UNC6D-I#HO5K:W[@`1
M)T!Y81A0]82#$!'-"GNT5KT1D!31$0UYHQ?'D#LDZ,@G6=O5H3^16LMKC64T
M+U=J5HV2*FG+%,'U))A*5BPO,.UX4#IZJ<*.<A\&(DZE/M[,[9YOD9-BNC33
M[71184Y$$IMO5.J1`!U&1KR8+1'7GB)FC@88.T6DAT+0::+O%5-95,3V,A#E
MGX73:!LT(AT'C3YPGZZ.'\',0,16*:!WA#R'*A7CM>B)B_$J*C3UCYKBETF3
MGIH"6I#V41T3'LT5JHGB*5":)H4M51'XBY0J1%33_QO]4BF;SX1^SR'PP(/%
MTVMYXW*&PT--)SW'D*=9RM[2\'=HTQ3%\T'EK27IL%<MU0O-<_KR>2Z-`BB)
MRR>EK[RT]O?LV#[3"IO;YY))&G(CL8+RFH'ZNBK[Z:2KLH+*9S/8%52O#V5)
M>:D66+LMQTP=XHZHU8)&TW)*-R^5*RBGCXX[2(^==*DT[7?1^^^ZV7MH\TMX
M%BPK:#[OPS*%XF'8K_R.8X-:A>.,J5_WR3@&^Y'O[AKI!O68BCH70(@VYD=+
MM33%6"'4[$0X[DR&J$4LTRQY+YU]>-(`]9-OF'>R<UC%=2;;Z(M,Y#TBZVR"
M;F*B(GOI*GISD&C.2&+?6O]!CJTI#@LPTO%#D]G&C^-L[/<]X'&?3G.X`=HH
MQ20$H/>O\8J`>QB;Q6OZ!`5Q.0(]23H7YT9&C">!-Z?)G.'Y0FB,V#;,]=N'
MJ+QYKMKRV)M=YEFR(Y='$T*%IP4"`/=)^%!.<1+7-'$,-;%"!7<FV\?F9!NV
M,1>^[&-T#&-=0X=#@2).)<W$U[5#*Y30;\9]-WU=X4QSSNM]+XM`(:DL4?6<
M0G&T6_J;9-LM_\C4KW96&F*#S\[O6$U=(/8:.*WCUC@$L756<HL25:_%,+0Z
MQQ!&C1HXL<5#%O'2SPN<AY%J)BY%P\>QEAV/()%T??9P';U2^V--`P[L&L6X
M\=3_`I'HSN[W9JONLL"@?QD(.RMXQL:,(!S3'U7NKJ[NKN`:5#3),;DY;P&/
M.8<"RRESDQS2NG[+WLB.T3^REFP;DDZU-5O5W"YG;#&ZM3VLRKVQG*SG6K+K
M#'.G5]=8I3'"^ECQRG@'=Z0+P7S7GZU9#Y627XF;":WO[[(X5!4/`M'D/3ST
M:2N#6RT'Z1.K,O*P+DV[-\JUAZ([ZK'"<[H88?+MN2Z,@CZ9CIL2GMTVK224
M9R]LZYL2QMDD@P$/N/*9[`UCYG!'B$WJ?4W+R\2H2]BRV\>F/J`F=UZ<-Z!F
M^I*J;L9=:8D*K^KU[?L(4&FL9MGV.`.`\%KYO%+9,A2+_[U#R.N]JCIU%B3C
MW?,3FW/2NCY4>&&@<^BGYGC2D6T5.&RU#$1BA`/OK'*_L(?S+3B>!O8;?`&E
MSX_4?:5WVQGL@`:N@3_?[\]"YY84F31=RV<1+WKL7+=C"8B5>%,E4Y:P>,]U
M%23F$`*W7[]EI5#,CJ#G\N7USID=PJ`E3P__;;\-FN3)MQ@=VD,61P;/2ME,
M.S0];NEP%2!J!`#FS-E`"!`"'#CP)H#!A6\@O#F0)T3$`&_>Y(DXT2+$`!"<
M"706LL;$`R`I-BP9$HQ!8"$/`G-8$B3-F2)KDG1Y,B%$"#5*O@Q9$R;1@P8A
MP`P0U!D8HC,5+I3XDV1.F"Z).O_3N-"B4H04%S*$X%+J`1$J,>99<"#$6)(0
MQ&Y,J/%-B#QH#QB5N*!BQ8@SQ=X]$)>AVX^%MX9`>#*L0Y5BG<%T)O>`P<N3
M9\(4C#)F8X8N1R8DZ%`@Z8=B4[==6^!P5XI][YJ0V[=`GLY4*;I-FK&B6!,;
M[:Z=2A)C6[%?S0Y.G8=U"!.'\>9IW74BX-(@BY.<S)+KVMO'.5XL&!KSP?-6
M:UR&@(?'XJPN"08-JSI/.8@+LRO,0S3KP-)6W>143G`1Y)]5!)XGWU?%35;#
M/Q!&*.&$+PWX$DB:)853A3;!!)-Z#_#@T%,XE07494\Y%9-Z,>&DU(@#EH73
M?R^*5*'_BL!$%..%0-G5F7%>*=372G%91-(!;*TTD0AO'+G1<0:QJ&)2_V58
MY$K.E/.D176)I)!'!YB@)4@MV?A4`&X]QN1V(ZZ(8E(7#C4@4`YA2)./1XX5
M4YQVJO>?>C+6Z*>?,X6$G#-N-5DEC.31*1%X>0RDHY9B94=512N@Y"-7%`60
MHEJ4&L2?<)VZ^`9;@[G8UJG!306>137DIU%I<=EW&TA:GG1-4H51"N"?ZU4&
MTDF)MN3FKPT6%IY$%L6VUF=L%<#661WUM8!K$?E%G%+'_261EGGU56=N8@%*
MF6H+:5E1;`N<=-NURRTP&D)S:E;CHB0)MRYAKT:ZHYV%&M20_V1,#54##SR@
M9&9"*CYZD@AYY'M7I$M1=!F&4YY9(IQEQ:C5H'7Z2?"`,'H(TH0H2TC6>AV/
M%%J=W`U$\HPTB'CQ4E[*Z=+.#=+TWTX%(3722*=I#)*,/Z\\VGJW`5;81/Q!
M-.!"UT`V5F#1[1>1R!V[-*>"5UZ&I)YOH$74V%!#Y:BD<VF-$';DO6G:S`S#
M]Z;`L1+7](OV`C@2C*/!S?//+Z<%P6T(B2Q:UVPN65<-.-%G66AV07(-6H@K
MMM`"<:L5GE?#U55C7YN7J35;&(7PT$:1%F8<PVIM2AE:HN.D4;N!:Q=461K=
MQYG"4/TL4."D5;;GJ;!9]&1S!T""[?]W"[16@._,']9BMWK"]!VV)KV&I5EM
MY1N6LZI/NP!;TXX=H(N,HR>:01-71%+U<UWV/ED:(8Y=B0OP($*A,"):``+0
MKJXPK")'R0^=2$,HA^!D<<ER")_8%\&<07!$*<M@BV1&(Y(%;48&.I920I2=
MCLVH@03;TZ<"9J+V>:Q@'"0-`^-$,G-!(%$TT4V='`.6YB"D5H1QDD>\4J)C
MN0B$V3E.H:`4@-O<YBG@4:!FZB2953G$6Q[C4<:B%*>-<9$I&H%8?A"EL+)P
MC60O:N"]_/2B>U'&*R>9(,R^^#6H67$II&K=?E8S)#)1Q%;?\Y%*HK::7.40
M-LVA(K-(IY'_F%`D5U-IXAL^I0E(.<17&SF/1"0($G-Y+2M<Z0MX]#,3-N*D
ME$D1S,">(AS2=:4Y(3C?8*@GR[^`YWQ[4]%"?&,G=_7E(:Y1H"Z/8YD<#N=:
MLU&>*!<`'88TI$TT3%''/`A*361$-V*Y5B;/R,HHHB1@!4.8"`B&PA1))"\0
M25-2,@?#(JH(FC_[V12--4'SW&M#*<I@RE8&-PX.R#3]'-FB2$@W1BEH@&<9
M(,D.4#6%SB@`:%$H_D*0BFO4;2M5N\;`A`>S>1EG(0(QRZ,.,Y.R+4`$:K%>
M$P5SJWF]`83$0T]4D!.8U+R!>@RI2LL>$\E5Y6Z*7MH8/Y?R0,`-_T0W)J#=
MX0CS!D+ECF%_ZUM1+13/P,SE)/JQX$&_-IF.T-0G]#E)0[9'&+5\9U4J(M9J
M(O*[LA*+D7_3C5\B0A6W#"8D:YK1+MLBD4WM1I'Q%`WA'F6MMW2,GQX<#6=T
M]%%L(FDMN$S?+L]'`QKT[P!:6@`-NM"NICYF+0C+R#4^ZAJ+T``/U_K)Y<1X
M&!V!H2/#84XLM453"^TT3E%5FHGX(A81+(`)0WJJYQ*ESGFV)P0NLY\$01G%
MO0U0?ST#6D'G%!_!"92"'LV9?_"I3Y2Q4$-M<IGI`$7/%)%P@YVKD4&NP0,:
MA(A)`VQOB$+0,8C*-V&O%8%\.3>C$#S@O_\\6,"N.ABHH31&?*])#4E$8%EB
MHDLW[F52H5!I(G`NXTQ^JM21[H(1(%:-H5,"UH<;DI8)CVN>7BRP&5%4I+.@
MJR$`#3%00RSC$CICM=>8B6\1]F&&7.@`1D#IC?6+!Y3"#*)&6$"273G@/+D%
M8@TAU6`:,ULKAL`]J<'=JC:'!R,TR2W0\<TDQ4>ZB):4I?RZ"'>PEY+#&*E*
M7%RAG3:\O3$7;,5R;C%$2JE6EIYO!:[L[5IHT(`&/,#0OL7#&AYP*XQH*98!
M#@`/BGR<1%%$!#"P;!^!L0``5XHIC5U.MZQEUS$>V71MK.',."FPVT1G`9`8
MTIND`K[\*$Z<J3[_4\;`<IB(;B4_<X2FC.ZVL\#=BYY5!>\]WP2![DXH=S'^
MFW:!QC=&@:%F51UJX$S"`Q@\X@$PX(%&,?UM'N1A=S?F`0L>\(@&B.@:CX#!
M?_&@L6LL@`6&?L0C:!"`AB)4HQF%KY!..EJ3%MDMYQLM@]T3&]_ZYCA&8`$+
MQ/V0BJ(DHPQ5B`A"H%&%C%;C;>M-E+?,$%+ZK"=:,WG.:');NW%T3L"!I5R8
MM*>5Q6EE4;U)L`VR@$=T83'Z;?>^:6>G`_"@W0+I]+<?(>2R'/K;#[#L78)D
M',CFP9J#$2->TH2DOJ`EEDR'6@CPD%--A8`&WD9I?L;6-(6:]"[MTH]O_Q#X
MDS:9I>U64UAR#Q*H.ITD-G6G[E`ZQBG0A$20F;P=:\XG6>@UP-N$9@%G.TV#
M$$!,!$9`+6AY\(9X6Q:T)W6+N@/<]@`\8!3>[HKEKP'W\W&>\9]G/")7<L&5
MX^Q`VSW/<4B'<$#3W"%I6YWORLAS_YVRH[^""5?$VI;E1DGG0TG:-%V.%6:[
MC^715]I`G"TA$U-PSM+DTQJ=<=XL!LI/UP`WD](.;Q@07*$@$<'C3_5MWTY<
MP*N4B+I1VG,8!/D!3"("`&@$[G5H(G(J#Y`$CR!@5V9H[M9>X58V"(,D/-`%
M`/89X#8*3/<448<P218B_N-?7?`([I%^G'=E"?^S$4\!`>5@$8DR)O229RU%
M$;##-6629REF+#`T4@L`:*MB2$`%0S363C12*&5A!%W``C"`4MWV`'CP`"P0
M=Y,A:?$V"G'A>?>6,)W4>9GVA/>'2Q['4+^%,-H42XPW=ALG`AO7'K@42Z-U
M%IK66H@"A:/P`!IG>:CE6ZA2`[$4>Y:'$@0$+YED))\2$EKB*WPA5@DQ*!>C
M1H*4&CC$8B]Q'976&<618+QV3-+R+(C$%N#V>C#``I4U?T<'`Z:XA$\(@!(G
M;PO@;::8,/=&`Z_B#`)HBBP0*9UF:"'R>%T``Q``;DH(`WE@@`>`=BC50#($
M,`[4)B?T3OD"6>>S.8#_)B[=PQ\"H2^-\2>XUHQVQT:@LA"^!D,H)(1Y1DT;
MA&Q(-%YW0R/<%R'&=G-])WA,<5&C05"'%8],<0"?2&YX$`*KJ(1X@&XB\`@L
M(`)VP(JFH(029X<,HPOWYF4!@`>9AFDT8`3J9G201Y`A@&3]9P3#.'&A*&^A
MV#^&9GKRUEX08Q%H(F^?:!"A^&WMH80/L`"IX#_@1@/70`,L8'3[]B6*0AE#
M0H-`TT%<X1.95!/:5U3?%Q2@9EL7LB[7TBZNM!B"ESL[`FTO=PVZN(08R9*/
M@!),R6G_%6\#!&XD&(54%`#Z9F0LL(#=9F[>AC`2)W$-T"ZNJ(3`%9)T&8J,
M_P:%&P>%IEB7AA$`1G"*.'`;.AF*[A62,``&X!:2BB9O91.%T.,,]D$\"3%<
M_'%.NS0>\>@?5,96KM9V0PD4+B$7&5$FK@922^4;SN,6T%-8G99I=]$`++`&
M/&";"_!X#8`'C\=>WQ8`#3!T%:%?WH9:Z[:1)T$#[:9N"T"%=7@^\18B$.!;
M:">*N[EOO]DAF$DXT[8R!W)0![`"D+`14HE+AO$CFR))R#$0"*,Z38E8N640
M!*0;.C(\?7=[T050-2*?1T9MTA=]7-6.$#)^P@9>6R03T$1"`.-:X&42`^EM
M^.:1Z\9>WJ8?!!1O#5"'`EB0M<@Y=;)_\15NI@=UC_\``4>'D_O'D[888&39
MA%<6A>!FAZ9(`WFQ$>FV;M,Y6FD'`>E7D`T1H7P)41,WG./48J+R&F]3*"8Q
M0'8Q,-[21MP(3@G*B$=3'+?S1Q:Q`D_&$.Y$8`U#(W]#)P+S"*8PF^96BZ'8
M`*,5$P,Y:5#8$*4H<4;P)YW7`$9@$(^79/K6BI:5A"*`!^WF=3SPF`NP!NO6
M7@5I!,VY?[GY`%5C;A/S!NPFEWTQHSOF;0N`!TUD!,!H6<-9J#"@44B2DE=C
M4)6T2Y=4$9)D<C5RFMY#%(A71J9#1L<!:B8!FR6W5"$`F_$"=V=%J3`P>5!H
MDZ,*>=TVJKOY``=@BFQ!;F;_>3[8J2EYP)CK]@:"V@`5(9&0VF]F&8J^9983
M=QU?LVL7)2DJ]*IP81>PM@8/5XR;HA2L0E>/1E/OB31J]$ZB491%V$DP,F=$
M2%0V!K`VJ$6?V3/-1J#T:$+(YY0'150$)5XP%3+7D`<$.'$;EWI']PBTB`<`
MAWF>QUXL\'_^AQ/VQ@+]V'\BP!Z/@'H+``:YR0,UN:B'-I"C$&"/1X6R.'J$
M]@!<F#"6]TS^)7EFB0<0(&_*J9,HX5]+>),8<8H^RTJP95.Y\UJT!1)M!SM3
M];`+&WWLLR1CTQ:,E[4CX4'#XWS+R%4#=`W!&))&9VB%"J3]%I&G*'$5^5_2
M:J.!_Y-V&-&6>?"CO3B3.GD^C^>B41=OQBFX'GJ3.EFHWR8J%1%+(7"*?.E?
M22`B>?"HZ/-?D8=:(UBX3AH"!8!-V<5*5=,<*R$6/L)/ZNI@,`9J851R*%0#
MKZ(GFI.UCH4?FHA+FN`6X.9N.CF37I@'C_<`O3BJN?F5\>8>>""*W=:;68A.
MR?I?IAAT#2"VWQ81K6B!NID':!>*8`DXMT4CNM4W:MMJ?>$\NW17(?5PS_4Y
M*-$>1VHW+C<RP[,2V.>=K#NQ7IN_:T2/`8H>VT6@_P!^.FB@PR->DLB@KZJ.
M97%EF_4($-F$S9FA(E"QAPN`9>.57;`K9Z)N8\F@0\NFSO]P=.*F;K'TB>`F
MG8VY`$D`@(/[J/HH;Y4E+R9A!,/Y@208`/(V3NPU"LAE=!,WHR`!A4F0I_,H
M%>BT$C.21X#H4P-;8ZCF3A@FB68U&-#H%04+IN6(9_F",.RV;B;)65!H!$#F
M'OHEJB.;G5VV;N=V&8_PP@08;BAQ;_AF65#8%XVZ;NRFK%VHDVC1;NZ%LFB'
MIVKH+&@'=:8XC/MF%]WV<T@"`_D6A9IEFRRPD6"!*LU189VT80K39JUU:F"U
M+"="$]="5^0K%8=A)\HQ<LM1+&)K=:65R`TP@M:RPD_W>)=<@<QZ:`_`IQE\
M4NZW.=Z[;T76;?WS7PPA@#A)?UO_J4U0V``#U,!91(0):J!&@1$0PWNW*C!<
MARVJ40[WBFIH5$0'T13]VD;DN"(#N\7?!;#O[,XGH[!"=;!5^T441$+ZJ6T_
M(X#_)7#I9[SB5IT:+(!#9Q.%V@45:1,&X<\*;<9!D7[RIF.1)H"I<&6<"X#7
M\(02F#"Y>18(TQS,.71,R6!Y"@8+9WH>RW.0FA#^7*A&5I@/L)%#&18J*;#Y
MDQ?1@25F!%7]*J#])+`"<T[F4Q&CB\I)F;]!I=1G&Z8\N1&.:[PS;70`*!)\
M>'3I!G5';%'_X<LCR*Q/@6FB*-+NEY/"BP.'V\$#:5G=MG$1)I')3,/F-BV/
M)V`86<DX_TG5//!H/F>\2PAV2OC)3>1$N+-3*X,E(_%(R`$?&5%JJ_1\EKFD
M/LT5Q7)F=N7*M4L8]&$MM>N][J70$*,EA.;9AZ:I[9$P^E615]8%".,>;^`_
M^Z%9_G,<-=->9*<02=85[<4#%FE7GWA&$J&4XLMLXQN6A[?-O'<1['J)")02
M4822UP7`WP=4.;=R8;E5N654WW>^_,24`TJ@!DQ-LS8H=6,ZP,#`5*QL`X01
M5RJK5.0?3AI^F4D386H08.`S-S:"1H"?9!(X#0&:5E2--H$D>X2K=+2()''=
M>[+>]&D0W<:I\6F4387@:H$^K^:90VD:N3-8SQ0G]<40/0:LO?^Z4463%%V3
M$.C5E#)C(K#Q=6?1/^(V0&YH$YWZ$&E,<R*39$EF9/"#N&:(DQ!UP=>`F^WA
M9?:FAZAU%FB1D]I4,_"R2Y.FDD>N645V*N:6$)O7/Z>KD[(X,(LT6TPL;(GC
M,YX3&;P3JTW1W1L^4[I*(VB2&D;9%I0293>:!Y"08+$9M*_4%YL5QIHV+4JC
M$9<=%#[1J\]2=<'$,'75*1S#R%P=54\QIOAI1"%S:B8R+,`:,8SQ6",7,:QT
M:7916:E0WG?&(^EL=^_$0C&U:W:RX5M\1@=*L`9!P.P,V28R/-U]-.<Z$P2U
MB/]YME/HW:"FZ[E5)F3AZV_#."NH(B[_H5^XXYTA4]XJ\A=^Y!%;0B25#FI&
M^*]I9"GH43.C]4)),3P`]!UW/DMZ9(11@N)BVB$8T4>+B.("T1QB!!*`!Z),
MR;HNQ)_QJ6L:TRD@D2;QOC[:MZ2=A.SQ22;OE`>B.'"&DR\;]Q%!P:Y%.3SH
M^9RY$0`T<!P(41;/0CKW>Z/R4L)U#5%E=3BW$TM4DMZX"A8Z31C`4(GX^S?7
MS2=R40XQ01:04@[S4VIM5Q>]^H?VL>>BQ!#MXG#GLV,VN@+;O)D@<='AT2&O
MT>:LLLI`X:/=XNX(L5H1848,W=X!S,_.&"@YCW)8#I^NMAATT7QU@9(JKNY(
M8VSCNQ3WQ-!>_U_.E>[KD`UJ'8^P+63BM/[W;@Y`YIR.37E>[5/=]TWS*+XQ
M5^HI?<_M2$3S.[C>K$O>QJWB+;9$?Y$F,/(4)W[JI53I&W/?9+*"_GI[=-$<
MM?18@S'-H=\P_BXP3#(8G'P[]^$62W6K!J_N?^+K![5`J.Z3'_6ON/KX)S0B
MK8Y&^"H<&SD8T-\D9[(:-'B_L:0;O'%6F42#2`*;[\2NW7]RN]<0EJ<\JR$J
MQK$`N6(TQL;W(_%H9?.(X5OZ[7^VG$&?N6J?">&KMPH0`0Z(")#G@,$#`=X@
M7+`@SX(#!T(<>-/PX8*%$Q^&:'@P(;"($4.\">`,#(2)$RE"*!>"(?_$`,`"
M0!!Y$`($F1!BS@P0H$;)DT!-FM29<V=1H#I]EMQ)=.?/-Q-G0JB84.<!B"2=
M!7`XM=P"&@]@.C4*X611G4.7XERZU>A/MT)];G5*%&E<"'7!T#V[5RA2"/\$
M#R9<6"?<M4>;-O5KU/$#'DQ_`EXL<ZO`:]=V)FT;U');LUM_*KSV1C/3NTSC
MSO2[MS'KRR%+YIDH@H?6UWKY*C5]+?7DGE)+(LWYTVC4!2(>1G3H,D1:O\`M
M@[F6Q_?,-R$E;@\M\")"EPD5:I7.&"E<SSR/OCY(,GL(GI0_Y_1+%G9NOU0G
M:O9(<B#WG20R"+ZMJ,J#-IMD>D.$CD3(+@__G0[4J*0::&K.(-@$Y"B[`WS;
M3B*4*,)JP`,*S*^^_'Z**(^*$*1HJOP4FHZLE#`L*JK^>CI()8/\2^F_%R&H
M;@&.()JHG(.^"\FYA@I0Z<D<=>)0I3>"P@JB`4FBZ4.MVE(MM;?D0FQ,GCX#
M#KVT"K)*(1$\FJG'H$CLR2`>'E!NS1F!8LHQN4)[K3C6H!.M3$('E:]0\_H$
MHS!&"5.+S]]@2XQ/9R#K"4W.S-)))]L>"&L!S>:3%-(`HBO)MK`\[4DMHEP3
MU$O[NGOO0Q'P>""^H-`\\;(%>*AS@9X.*^F:7A_PU(@JZ5*LNQT=$I`&&GA@
M,=%'3^7!"*(^[)!#_ZNNM(C'`S8U:T^>JH7N5=UX"@DE7_$`M2=1A54+O;BV
M(M:(!8P8R2^5G"G'1H6<"W(F`2.Z-.`[1^)!!)>(I$VJJ$A<LZ)H:8")MXBB
M]?7=FBB"+^*42,K3P6!CW,ZB#AM23+:3ZA/H0]6N$6DDA33<3L<E$4R6)A$*
M<`@A`1UJ;KN&'Y+X9XE(JF$KHBF:[,&'RN%PUJ1O2N\GXPB]R]16!ZW7RSQC
M$\^9C+@U6$K:N)WH#1YH:--@$_&2B=Y)46L9J<4F"XI5%,^5RZGN$(.T4<(#
M]9+,2+M3RRQ+Z?M:U#P>@,'8+A;6*0014KE.\VLF\DMF$4)E;8%18'BDB_];
M,R,I,](D*DU'U7NZILV>V`SA]8<6YJA.]ZK33*=K-+]=,H$DE_R1`[(V:P'C
M'W@$#\U,HUW'5$)0B<&&L*>A@4=`E;GVA&3NG*``1'@`#X$X$D$Y!\<G\J"&
M%BC`9@>[4_Q$O_D.G%S9K@FK`6,!2R:U&U?M5A44`FYF`8\PEEA.XZ;JT(PG
M$6N/`27B'"W5`'XN,1^1%G(AB`S$>G(*P#4>P+T&N.T`G\$*``'8A06HB#8&
M:=.#WB8<IOC/"`HY(/@N8J2PG.8-"[F3`76DDA>-1B33>H_$?+2B*`6L2#4I
MVM!6]!TD&N1;6L)9>$BB+B:9(&`NHEEW'->9N$G_2F]Q62-G](*4!]TD8`N(
MC4/DF)T%;.H@(KA)G?!0$S')96ZC0A1>&,,70Y+I<3P1'/'LAR+"-6I>G,&:
MHEZE*:&H*E&8=$H`>,""!Y`$<Z4Q0IUX`*P05,Q2`0B!K<ZG&;\887*A@X^O
M&.:K-Q@A6L9"EFTV-KM4M8]YQH*/"``H%@:ES@@-S`,KVV;*Z\@D!(]X!`^H
M"9]R7>,1,(A,5$+'%6,M;$&0"<MMP'+"1ZPA<C"87"EY,!+S'<!7T>K"#FV3
M1U.$!772"D&=C-4`H4$"1_%+VMZ"@DE%MFQ0><(D@&@`RFOQKH28$T]V(G@:
M5BI'=#KY9#47!CHC-:QS_YC3$?8TBCGX8`5[XB'6`O#`$3R0[QIKH$'N'D(#
M=RGG7Q01`41GV<Q-F1"4T%*5-]^9/>LMS$C)^2970!FZ#M6L-"UU%PV!E;Y3
M,FA`#!OA?Q*SG3R40T<T%(E[$-*FZ55(33MBT<F$=M:*6`0C'X*(14K%-)@Q
MBV@5\4]'1@(!3$UG4P;UV]8VI1A%=D9*!WG:B-QC$Y_@D8GMT8FMDL,MPV&*
M,F>ZSZLXFRY,AI:P7L)DF`P524:I45*:RI4CS>,72PWV:](Q'PQ"ER^&78,%
M-%BF;64YN4>PH$W.RQ<+;J.4GK*`G8]PQ@(!*-P`'.^3OF6!<NU0IT?D89NE
M-/]=KQBTS;;EZP$L\.3DK`F#:QBA`9.#`0N`A4`>C$*Y(N#M-8@B@B38*03X
MNBT+C(`'!C*(!=M4;D/8><+=TH"=2N5F;:-K.@6S0)X,#``[8=``4!Y`NL&E
M`20<XJ"'K,`E,YFD8!.S/]'*RSM?S,.`"7*9\AW/O?)4;G4?T"$>F&YR>8`O
M*!=@!\R--P22@^%XJSNY!Q\X!!:F<(Z5:]L<6Y@&2WX`YMBI7+>MH;K5;4!X
M4K)-[L$0*V_@%`L:\-*-0,`.ZPUNK3#<7N."Y<WN7>:1G?>(\G&SSG"&S'J)
M%=PC$\G(U>W"?S*H)I7LQ3D&Z9%`4#E#JZ"-@^'B*_;_EK,=MH7`9QB9JU8A
M@:#GO$PE4[E*P6ZBH8MPL;2$]-IZ#)6>PN)/4@7!IH$^AJ501RC4`\+F3]KF
MH+E.)$W">F3<8.TJU1+[H"A"I!L#U3?$E@FUA:FDBA&SN-$J+R:KI,]A.3MD
M&"1GF]V;KH479ES;^'>!I6LO#:X12_,:@2!@B/*M`D"#:CX87TB^MW()_./V
M,A!SP6UGY,C+/8A\\KMX_B2P1+/`R8%RMP?PBP@"+(+VGF^\C\!P]^RP6UN%
M&P]F=JF/&7B:R3GO`96JYC44S@,`YH&=T>+>&SC.@U0\U-*:<)>'K:)9Q>XD
M3&DR$QC-VE,[_=;=#\CO`DR7_VYW=Q?I,,^W2=CVY`8L#,`99YCD\F`$CJ?"
M>+;I`D37.TTSGY)YH)1W'A[JJ?&Z_,*]8@$>>HN1-K42T&&9W$(2TE-?K1<&
M47]$M"YLS&HN8+<\,(7(NVL$XW9(P>;KGH99\&>`;O,`ZK4MACW%3K?O.%R`
M#=B.R`R!-H&:9@/Q>WCD2!6&I8TW<L7(DX3V/G@:S6$A`36&M@*&!R4M6`7I
M2);TYUJ$)AO:H&4V=J0"%0]>!2:1O9BC$P)]3]V:1WXZ5/Y:6Z!,<29>B?GL
M4DSL?;]-FS#E6@L"@7._8:\VMJIM8PW8-DOGXNNI1I"W+-\)>7'+.A&0-_50
M//W")O_)&3`R8[K(V"ZG6[GR>@!YXX'.P8/S2HYBF9RU"X";<SGA`K!0RC$[
M@(T<DT`:D"\[T!(PT+!9>J@4&B^EDC?%LQC)&<`=^R3>.AT$W";;`H,3HL#Q
ML@T&.H#NHKH#6"^Q&"\TBQ\/"RNE6#5KNP]C&ZPT$3XDZ1`S,X(\^"0[,1Y3
ML@UNXL!Z4KS*"2#U*,%44(ZDJBZ,,"'TJBUP,X+.&2]].BJ.XSBPN,,&V#=/
M":X\,"88Z`(M<QL%VR'FP$%JFKD?F;JU`RC3@0S(@+C;@"C)(1*$`[R>>,!1
M<+<A8P'3N+EMZA7N,3A?Z2X%N[%`P9%&\XX?6;U%C`BE847_X9N)&OA#GPD/
M`>F9W?,(K>H(HOD9J3B,]U@;$DL?H_$1%301V=(:5RN7T0(<63,+'%$/2'N3
M%]D*1DL('.$BV@@+^,C&F^D^KLDV\:L;8E,,4GD_9GM&@U*_P<@4EQF@Q7%&
M/UFH54*<1`F`WC*6I\.X?9(6_VLEX1HR!OH5T9&E_`H+3^J":@K#'&O(*@/!
MO5BFPJN3]3$6\.J4!]A$72(O`*LF[B$6Y_$D]T(-L$LYKF,*KN`X!",GB,*I
MCL0IR7&7E*M![2H\$7`&]5)`EBN\_.JG!NB")7N$[X*!5+K#]G*8!5@!B^@2
M$X-&%8O*H`N)%83%!X,,+@0WK'PG_SL(PTL<,%^Y%J?@PE[Y,.Z9')D9+U%\
M!#<$EJMK('=C/,G9Q%1AI^28'!HH.U_9IK"(,\DQ@JLP.-1I+VXB&NTRK[*S
MK0,+2^W*NA8SP=URNNY!.H*H+?<*GB"D.I@3N5#,L;T,1,][`[B0F0MZ+"]K
MM)JH1DU9HFF1HPO:"+IZ*[K:-(F!'V<A()G)DN&3F1&BG??@HKE)%O/3FN_;
M&WK4$WGQBVG<BM]<$1R:QB69F!ZQ+*E8(I(8K6X[',[HC.-\(\7PSNXP'/3C
M#'<4#/4HNO10+'(\#$LQ$4*)CYT8IP?8IX2P`[CL.B,8"#LIGU3I`H)`+HQ$
M'9>[EB&+#/_)`2X'Z:"9$$EF,I]]FAU_LI/O*J$Z09U>\I48(Y^?$,E]\A2"
MF(QKL)4[!*)C.I\U&+QS:H@(I8&>\*<=FB9N8IP#$PN.@(P\R#J)J),_Q+<D
M:"^-:*6L6*W7N)_+T#;$$);TT4;A0#V&Y$<*'*:PY(A'P!9C"1UCT1A@D1)K
M`J#G$<)A`I7QPLC(L";RL3A/"0OZ\I5P.E/G"1T`LL!C2J&&B#-\>S%GNC!T
M*KSJ$)`M12>AQ+>M])_GH;*OHYS!6Q\`HD`/1"]6>COGD9919)X&V,*L8YX+
MR[@)`JLOTA`O\HZ(B#T\036Q4@I.]8@D^98G*9)=U(C;6PG@:YK_-`F^D!"!
M<M`/BCBH@SFL<3&LH*L+1,&DB)D@CN`)YTB+8-41.T*;JWJF%W$TDC$4XKD,
MP(&5EHE67`6_[D0@91&D@_'.K2C/?T`/^$1.!%**5N,)V(H,<RT5G6B-(N4)
MUI$2X/DB'N(-WL`H>#$B]5!),,"WV[A.I9`,TZ#7$OH=V3'8!#*-X5N5!%+)
M$B(S`[(2Y_BCVG$.CF#*X@,6A'@=]6"Q`#L)?WW8MV&8Z?$.!JF3"TLIH1D;
M9N15U'C/<3$*V=A&]=@='K"#A``#5/DH!H&/?/$-MOFEX>LG3U$J#"66KEL\
MC"B?ZMM"8XFI7K&E`R`JMPD`78@?WMH!_\B`#_^!6AI8$YIP):6JLJC0"(TD
M$B+!@W*"IU/JVF)B3)?0I7?*)>.2'1ALVWY"6UQJ%Q5M`"04#P0)J['"19I9
MD(*9GLN8(6$K$(](&X7@-+FBFI]QB*]X$-DD1B^S"C`H/>O9U&GQ#J9PC4+:
MC/!L5VP=BLV]C%VMF<M2B%2K&0D2"`9Y+`CI"3QR$&<H!9P:EV"EC*#0ULW%
MFW=-$[T)I,58"O4H,4;J5O=3R9\`5];0D\]02=05389-WF!9)>J]7FG-5VP=
M#=6MUD'!5>%]6?/="EW:(71U3R0%O^[=UFV5E<-2R0&:7^-DSK49FK2H(AJ@
MB1]R7,30UF5"'_^3L$!LX2ON,-R@VLP`@PC]V"GD=<\!`E\$D@F_4(V[6K'2
M*YDJ>4*&+:`TZ=:#J1VKL[\1HXD3[HD5E!R$'1>],9`$_2(I23T"*8@V(1(1
M*Y=OP0BH>%S'`BK91>!PX8H!J5V":8B*"+6*#:MFF@GS@2[4&R\?2ID5D1KE
M6``,JZ[NR4:7J%5CK(T7P0I:<Q/>4%P59,4:&KZ7ND4$-AI($!BN:)BZ6J(?
M&>*2,$P9YADE'9C0;5<_5LGP-(D36]Y&PK20<ET!85=:(PE>&S[:>%R7J[)-
M.1#V6XP+EE;@:U[DY-[@+1G3'2U`SN#T7-?H+1#HW5YS3=W475BEL&#_3-8D
M\,W7Z/V)<I5E00YAU>7>#(XL;2WEH/@B079/^%4/4E[7=0W?W^O>[<7@7SZK
MA/`(*7&I)F21(@&86';8<1TK5J+D,:(X@E$.+5$.(U[.4M;E5';>T*VC/?:V
M2E;F9%[E7'Y/J!@Q3TV3V""?9<YE"@K&P4V:&OJ7*0.8#](B,K,2HV&8BCJ(
M?QDU1IL0@AF)E=62JT"K(<HHE1R(JU`)7#/<'^(!J)T(A_FKB$&0Z;$)+&F3
MPUH0#-K5A\&0I<@(E($G2^,(Y_R.M-%HAP%F5@(K<0&C(1:^ZW1G7/&:NW$C
M\OVJSNT*9(6/:,8FZYL@I5Y!L+`<KHBTHP:__]&PX'6]9%N^WND5ZLT0:DS6
M$V76"7#=ZLN01UWFZF6.%NS-9UTFZQY:#:%VUQ$.9E1.7G@>OO>-Z[XV3O;C
MZDON9/S-Q2\*C\>-'Y!>2@\BYAX*X?I-TI00MH))"*:ISH=9$Y%X:['V:KX>
MJ]=D6;:.Y^Z]X.YHC1!VB2=:6&R%Z_B4$HH*QHRFC2`]5>>8H)4R"&99CC_D
MHO]0PRT!X\(]&00A80HJ6;4&;8DP$M9[J[IB5:.1&EHCZ3"N$>M9DR_^7&P4
M&"X"F4MC5:&I8[FJ8Y<P&I9U3CZ^:)?0CQD"XNP$O]!B/W:&UL&2;`PQ7&Y$
M[/(I(UH3#CJI6I>.O_]7^[W#4I8"OUY23FO.EN5K1N:YCFOH!>NRWF4)CRX6
M)5V_WEQY7&7Z7?#M->T,]_#3Q0Y<[6-SWFL,ENM\ON",L)DO?F;=BQ\D3G"&
M57#UKHDFJLZS>7$.`6+9F/!Q)6T.OIF5#G'5[>#K#>`)_\T`@&`:7_$.%U87
M\>V+N)WM:(D_A"S7;8XE9:7DV)!,!>EFPI$EJBAJ3@Z`@=WMR.5)OAYPY`@E
M^=$?:I/<;$51`BO]OF,-X2)/+=G@;A,DN>X8UX[R;@B!"9J(WMR"X>\WR,X+
MDL7J"^6\?N]L3B#P^Q#KZ5S;M1[)%@\I$C6IL"7'/:RC/G!V]A/XC#]C]NO_
MN$[N5F9E!(?>^?5@$6?MZVU/AAWM!Z=>#E>+97[R"G=M;!VD%`?R^`UE8T=P
M*3)5L'IFJ2AT'X@?&<[U6XYK0F]B5B16@S!H;$*.B1$.O-[>TE;F!";&\X1U
M7I=T4[_>F^'-MR[FKOYUD.F0T5B0"PG&!:$-VHGF7=2C`\$*_C9&F("8'RD-
M\ED.<)\3TWMK7E.]@0CO*OZ.$.*@0X?QF0$89XB@X@:C\/!B]G8]5HP?,EIN
M\_[%*E=HT]BKZ(WLV."UH'F1UDJ^09YU$E;V8"$1;AZCP^[M35]:1VOB\"(9
M^<[5EUUW=#WU$G_GL1Z78%?FY.[>LV;8KV9U>QZ^_[18I:9?WL3`7EKWX#3Z
M=5M/YP_.UU47=L=F^0\&<>SES20&G^@+8I#QL&=E];PF<P[R;9*1"'#FB7_Q
M#P&AUP71Z;Q>\(S>8Q+NY%E[^DJVOV5[V3$SQG:V^0F?W\N@(!8)S!'IBLJG
M:8"!`$/O;=C6/?%8K#^LO8K"D@/XEYH)W-&?DY`!Y"3.<B`Q]#?6F=N;XX/>
M$=NU#E[$[HQP/=<T8T<6F,,">-ATD"K2=^:XDAD*=$C[JY<UE7$9$>:XX5IS
M[(:-YX"%L8"M^2.2F:N*F/"GYSD2^H.8"OM$'W3'5J9/H,U%7N)=?ZO7^A"F
M]08/^_`UZ_(L^K$'"&<!`O]`(&BP(,(`P`8B?,!C($$P`00FK''0(,6!`@U:
MG"A1X,:-!2=&%`@FY$$P!2T6S$B2I,N1"Q.BS-B28X".-W<&>),GQ)L%>42\
M,1@BSX&>0_.4>Q-B`=0#(Q-"4*D1(\2@3D,D+8<4X0$1/Z6^$9&T8%FS(0(<
M6'"VIUFL)&_.O7@`*1BG20G2?)GPI3.K(S=:!&F0[8*"U^Y"^.O2<,RZ?@<Z
M9;J@\L`#-$(</>C3K=NK"U9P76#0:SFAH0\_C7I@;P"U2-<>*!T@=,*C;:\2
M#,K5;-D\4(4BK=T6JO#7PXD#11R`\]$0"<M&WUOP;O2B$`3^''LS.&FN!X**
M&/[_]'7T%6)#NQ7NMCG$P_$[WGW.-0\-X7GB0RC*.[Y)&\DGX$CQ98;4;6&M
M%51M:T$T5%'O.=@3#P^LA19_!@KX$D,0C:13`"<Q)-%A4W68D6%4\99B71G]
M\R*,,<IX$8HT`H;58"0YA.-%*5%DE8B%\5C57T(2>9%CO/VUDU4VVI13AT>6
MB.1%,PU40UBOQ64<0D>)L"57;&$G54LB\D156,_EL5]C8KT5UGX#Z7;:FET*
M-9)/4N%THXG7$<56F)/UA1*4?2'T8:&8L84@3U>IR%-'-8Y43EL'X`$4!%[=
M91:;E#TU)U_(M?4&!+6]$51WA[TQJE!D*E5:G*:V=Q9:_\;E4523/@'%*7)N
MP=G640O<MYQ^F1%U7Z#7(25"<S44]%-TJD87YDC8A5`>>IP1]U-9M4%5'E=A
M]FJ:AU,6"%>PH+G7688=&O@NO/%"!!VJ$`$;WP)_(A;G0'D\L!E$)&K8[G\"
MBF1@DU5%M'!@!3HLT4T;6?DH5C):'".5%<TE6,94F4+#B":R:"B2'+,X<:$#
M6?GC2EB-/*2@=:D8F$!6KNR1BMT&VU@`8QET%[]#[;5JF"#._'-QT"5EK9Z`
M+CW;FV$R;=`UR69<%]%%+3:>DQ<9Z6.(2UY465%W68<CQ4=3G)%30G%V5]G1
ML3G2FLRR6=G;"-;6L[#U\8SJ4_\B\-63;J'MW>!1?TV=D7''Z9?EM:KY6MH*
MYDEH*U?:`5I=A[5!JUU_G'GWL^CC40HK<F_#.1QVBPV%'+-OD'BNB91]Z=YQ
MJO$K,+R\R_NN[W>5`UV_\/7,K(,_X1L"#S0(_COT!I[KKL-*4@]EP`F1"'&4
M9LH<P,7A\Q092Q[AR'%##WG?<*$B/LD^70A9=3#)&O<)\>P\0AD9_#CU;ZY\
M>*(7N2VM.FAY6Z8XEQFND*Q\I#O*J3P7@J88AW0^J^!UHG,-HN4!+(&23,M(
M5\"SJ>UJ)5P(V[A2CLV1ZGN#*DF/;C:5@GA%*&*)RP+'`KKA=0<HF5N,TKP2
M`*]`ZRW_SU$7;#;7-R$ZS6IJ>IM=KN4>:,D-.6,)%PTJEZ^V0.UMLE-66/[$
M,^QP*RNB:PY%)`@?S^F'60?P2K#T\S9MZ>XNU^`91#8DG]J4!RI>$M9EHB=(
MA,FK06K,"K,`!2V(7$-Y/.#!\P;BNT$.<D/G.IB'>%<[`X%H0`8)W\4`F+*C
MN>Q$`=C1E:AT$:N`2"`="5)*S%<5D<#2,0D;7/GD)[:6E8DN)6N4*V.YE<;-
M\0!`A$V6D$(T9(9@@YVDV+T.M$9&+6J:;X*0G%:SJ+,TB7Y.(QS7!D>2CL`P
M1__SY6$J6,$H@7`^AV&)R:;4$^/TD2GI/*/F@O.4,A*N._4Y_^)KROBL];BE
M,6A94]^F":J1(.LMH=/=?6JH&M6E:P&02`Y$$<27K?CL@<HT8Q'CH\_7,*1M
MJ@FHMZ:HFSBZS2S:E`],[>4>'WA).)&D9(AP^JZ5EH>13_'/M2)9M><]4@23
MG*1.?T>[=U4O>R&39.TV61!06HR=/9+).V'J0&#\:W"(BDB?NB?/JUK5@;7K
M)/NL&M5;!A"J(Y)GDPR2*P@*BS+`*LJJ]+6JNA).7VS1UY$4%IAT^C4L<?N2
M?_YZV%M!!#6`:M6K+A/5>R9%+^6*:RJSJC"-X,]$SLI,(#W'SLEZU5V8)"?;
M]K97MXC16-B1EE!XD$1=M29N68K+L_]X*)3$]BMUR.34V736VNA`0FFH8IVO
MNK,<MVQ&CDGL&>>JU<-R$5"D/?1/042WQ;=)KCM52U=YS/+:I+:F-2DE9.^2
MZCN!S3$/U^CM`MX+W<1B$PQ%36IZ\2M(L<5KLS&=*E4Q=C^R@G6T[$1EB"*S
MIQ#&A'L,R^PNN2<B>3(XP1;&7D$6(M>"<`Q[M"P16[>"*L;V2U\V+`=#-;H4
M%"]0<Y.94I;LQ3E-V0MYE<5A?Y:RM"]QYC;8#1N0X8:N3$ZEPY--TH)!F\-R
M43BS@G$P:0U21NJ8+4X(H4YG"I0'2"3(0+J1[7/&T\@&#80H98EO(`_C-N&D
MTS2XE;)MG.;_SRP-)SG6DIQR5G"</AZ*.AWU4[0Z!"V--J:1].I<=,HS0/U$
MQ<?UA`00)X3?3=5909;-KR3UN],>"VLH`V&MI!$+$3LX;WN9UC2J=<I?Z`48
M8V3M"*S=%>L%HW(D^,/96XL,X5W?$D1H[=`M=4W:)3E8P5\-:XG&'&,H&LM-
MVV0(9[[TM*9A\-:(DBZUQ6*4@AXH:-SN"5\K$U#M0'F>S^,262<+)&$#N7:*
M6B?/V(I)_LZ:PWA*9`"N$<BV9:E`</2;O5CKJGF"9H-ATE3B3'67!=!X7FXC
M%Y[>TRDYW8HX,?YWI_LVEEXA*S62`Y6"!)K=I4C:ST63)@[G9<A^_WEKH@T*
MBN2.ISQ4&]JF<+'A[N35K53G^R?Z%BI?/\VO@=R7YZ=.-5*3.KV!M!I&(/9F
MDT&<DEH3&,FDG??U%B8_K5_/R+EVL%F_'B#J?81[F]49F_MYELJ0*RW7)-<3
M12A/7R^0F=*YHMTWM[<%TF:.$\I17JIV1^-HCF.&QSJ&92T?=L$[ISG*JER#
M26&S]XQKIHK/M(RH1MYN:N8R=8V#?K6?,!TEI+TI#T(Y/\?!.:6/?6-((S\N
M/$:?U'.N7Y-Q1">6%1KE)\`IZ;3DFT/.<-Z?-79/I\-%T*&$Z[GZO0;R.B.L
MR`T=7OH.-*KGB.^@7_]=13<Z^-&+WJ3+J__I+W*46$V4L'(/IJL*LW?Z@;SN
MK\LRLT:SWF$&6R;(`Y[>:LUUUQW,6-C8$P7*,BF2`:J3`=6=0F3=N:P3`AH3
M!`:4U'P0&36?V$C$`:X3]PP62("=RG0=_,F5KCQ-<SS>^Y'=BQV;NVP%`QI(
M#VG>M+00X4B1$3G%1=V.C$%+7/@&U*18L)S@\$W<7F6'!]59\XV+6G@.$G(7
MR;E8YSE(!@F-YA61\&U.C]78MUQ1NMA4I5QAJ@'%-53-=D$%#QB/@4`?%4G:
M\PT:\OA4,[T+J=U4^/'<>E&2[R26^?V#4X75A*D;+14$@CU>*YF6XC496UT;
MA!4;DVG88.3/GIS_%B(B'EH(''H8$O'-2Q&AA_"M5#/9$>F\UPBF8+58H/*$
MCD8A!GR`"MY`X-9E5YA<6H_`U+`QXE@=Q0J162:)()!)70H^6#^]X*&@RT+U
MW,N!%/8)'7*PV.:LB8.8QAGM!3WYT8\U"#45C[/U$[8DH4I)7#T5T4^81Q(I
M2.8@(X[UG.@PXQ/Q4PVF3K@@W^T\!1B"'QE6C7#0@`_DRSS:H_8Y'WE!1T_I
M0KX=Q3P&0/,,0QTFI$+N(55TEO6("%LY4`VXG_P5&?PUR3,!&PIJY(89XL(D
M'N3E7R*VVZY-"48:1-NLXFJTGG^D9(VUY*<`%8F1S56,Y($D%BC:GO`U_])[
MP8D(]"3QG6/MO,9><$M#:M8BYI\#-LD_>8XN<>0*EB3BU:`P_D4_L0O21`N>
M7`NH@-84$=9Q),5^X`U10`!7;%#R0:%[X09$R,9[#1KDA".>50KM29!F?*5,
M)2-T)6/(L>&@E9SHA"/>]`JSP)%"@I:VT!$-7,H5#I6<(,]/\EP1Q5>9P9WW
M0=)AHAKOF!H>!DQ\[*%4.AE_.>*!/80#HM\*?D1)@L@?EI7]\:(H>59)$ILL
ME=L>V9.RW!&JI)S9]!9O(LB9!8H-P4;_703T,=,BQ1A!^.1:>(4;,0C9;40%
M[1R3?56!F>19[=IN*)+TS)U'9B?VD&89]69;W?\;4IA&@1@:5H)6I4`$(%D4
M#Y@(@PA%F:E=?+F@<(B.NXP*CCV+ML#E7Z64'[5.KS"%>(U+1_7ECXD%7S)H
M'&JB7D;CI[4<\Z!']25D(XE`/N8+9ZS!MS`2ON6;V^A;0<J+0`[$B3X'LUQ?
MOI@HJ1E!9MIA?I'?[S#D(8I2)YDD05"D2+[58<P?U[U8N0'):7;D6(V@UTU)
MO;D+2<P?4S*0G'A)4F1B#0K--SWF!065,;$EAS$991T?W;!E:G20VNF;BUFE
M8:$C.XVDKND?5,KGWHU7D>"?M;TID^8%OJ5)UL'4>;Q9-0$<8HZ%WD1%FAG+
MA\+=J"2-4DS?A=;9;7+_D?$LG!=N'/)=2T`1BU"4@UDPJ.<5SR+E)?%IF8/&
M1U]>X;C`21;&Z/5YZ'_2P(="7PB<**QR9?<)I*T&P*W>*HI"Q(G2JC[B*K#J
MZO>E:(SB%XWJ%&@J94DFGH-UTT`,HFTJHK)V9+#U8H&,G9UB3T>0IERL7Y""
M9U-AW02FW?'`AA0]"&^*6KDJYR_F"(CHXN9@X80HH.?PWH]Z2JQ\4%.Q)G^-
M(E1FHE8N)=>I']:Q%7`V7M1=);5(!#]>2.\%(<55U^=UA[U"AY<4A1OY7O'I
M)^:YE/%$3KY,3D5EZK(0B^CL)I7"Q0V-H]T`)E=*6L-ND"9NH<7R5F;J&P_@
M_P%4Z-MRP*I_7-\UZ`*)<F52I:A`0I^PE"BP5HC@G&BN!BO4%FMGYA0E,61<
M[:N7=NF'*02/.IE)V%*!A%U(;AWV!%"TMA7#U*F'G>8MV6:.7JE]%!"S;47?
M==0&`J2D"9O`/*`%5L>JI"+3,!NR*2!\;.1UJE_MZ)^#51Y0&I&1CE4BEAWD
MN6#<MLM4JLF?#=%UL89Y#),]NE&!1$Y,,M0?B>4[ABJ$9IFG:!!!_$9^WAD2
M4JIYJ$5K^%%\\&/*J0GR7*'<&(]Z?I!]?,G.NE>^Q:BNML9BZF,?K6B^(>T8
MBBADKL733B_4YBIGO)?31JTN%)6N1@_U/JW4JA?3F?^?V2YK*C45DR$89GDI
ML^I:DT4*DRYI^0Y;D7Z5_%;/K0%@E,)DZ1SC58X%!&;>IOQ89LUB7$V@NIZ'
MPWG.V7SD,`UD.$&$3K"?M18PD[[&5@!E]>'OD<UFUKV;OF:M5?$CH1ECRCI.
MOA`ON"E0-BV<$4%+B[[&&)Z1*/)=[D(7@UZ@V03F1/U&[29'%:4.KFR%M-TN
M@&HB\B16I*7J0/:0MBBM3GWO3BT`#U!QM'THK@[5B@;5RS*+%'^Q]NYJ?`@D
MTXYQ]4;M((%O^`I2LO[B+I:MXU&MJ4%`5^GH974G4Y'(K(D?'G\K_?DK'*\O
M\`#RGIJ1I$73\<B72^;%M0C_W^M>"R<1C'_M460>R'L9&I@8$_`.92S.G.^0
MUMEZ)N;9U)^,%QY?*R3JZ+F0DWU($U-%#Z#]E!$?FCXQU]"TQI<`5E@&G7V^
M5RRR5O71V7,AW_0U!QP1LUWF!W(TDD2ESLS=4*>6JAG%HY?Y7A)EZ/6B(Q2G
M,?0\;>V&%R1G\9?@:BZ+@"[H@J]B[QG;*CL':ZZV\SGCZHG:P0.8LQAG+["N
M\QG#"[&:\1I#1+(R*2Q'#X+U\5'%!R0NG5.)\JE!XO:@[[WR<;Q@5@A%=+PH
MIYJ\%WE\$*C4C=9<D95-]$<6$N!.RU]]#F5&\@O>L!R'K54!6^]`P%"XU)1Z
MGD(G__0=`P^\C&?*;9(@\9ME:JZ7=%E9T$![2M_#^53N/%?M4B[?M"BIFD:G
M[E,(X`$[\FQXY1YRY(>TG9D5)52B,;$TS\NHQ@>S,.^\0(<*%VT^H_&NJK'U
MYHOS?(FM\NSS_ARP\FPSQ5<\]S4\P[,\NW-@.^WV\@",QK,^)S8^P_4^YW,_
M'V9`(_31R<O>\D[S7`-2'>MF,C1GZS3T*+0<>S8AD>U"2_;X>5G?=G4`CRIS
M=M]IXW'2&::QQ`F6I:F\=`88F'(?3S1H:]+M:)L-L2%.+2Z\^-?,;:=I*Q63
M`O4X<N4*R%?A0"RX$6H+&1;L>!EIN`TBI8J!M$?RG.Y+$?]4#H]LTLJE.#(?
M$G8L\_&6@\)LM*VU[HXS3N&S/^_S8K]SOC%+79TSK)*H?_,WCZVH%__U8.,W
M@;.SK3*M@0\V@V>O@SLVA/.S&7<O^$7V[W`FU::7$=``C`[2L8HVB">W1&>V
MT9&X2+^@[D+HS+:EH/ICJL$K\50'$QN(HA`/'PL,AJ-7@3!RI;J47V%:AK]V
MD!>/L=AL&%(1J;J'"/#0"G5A?*R+\C22FG2:2.W3%OF4QI(J\D`+=(?C@KQW
MJ_R&R?K<J6XYGHTRK8XRCRFQE^1NM&D;-XLQKT:X/A^X//^WT";M&"Z`$333
MT0H+?W,H7?OU.2-XH1MZH<OSH>O_@@@\P`,8>H,;N%_7>1B#+X53>EL/$FB2
MWX</N9Q4R'L=](5+M&DGW1T.^8>?^AH_<`W6-+/91]_Y,)"'MOCQ#GK8E8P#
M[Z8MS>7-^JC?MG!`PII%FW"#>(XKU7>]P3%U=J>_BZ8:7S9EW(.:5*I*JA?]
M">HQ\4:3*P(^Z`+U$6RTGMN<D<6.;!<C'SC6+H>F-8/R;BZ[=YJ3=;P;K6+/
M>?<BN&`?>%WWMS@#^I['JM!"7Y\'?+Z\^Z$K^J0?/*'_=8480:(_/,0G?(%/
M?%_G>V-?NH'0.\8;B(5/]G`;2*/S@,QZ>HC[>HPV.ZE[/'YE<Y3FNKE2D6BE
MO,D;R#HU_^S>Q8MX#"0:DGSV#86KVE0*ZWKXD0@(%SO/I<4;#M-ZD%C/,0>^
MV%#TZ:Z"X,OKO)1]L"/?Y&=W0U0Y1H?)VAXD]!&QUZ[.ZL88SO0'#17SW2X7
M3\@,MWOQRGG&W_-;HZBNZCO%"^V@ZWTY0Y\Y`_B[E_-/YO+"+WK$+WI@CV$I
M/(`=C"&^5SSD*WS>3[ZE-WABR_U`]();CV_3B3CXA;RW_[/HCWXP>DK0$>2#
M](U\%VN,-<B8Q4M1H#YTA6]Y^=$4\;)"0H!C5FYF/GM;&!KA;$:(#B0@)1'L
MG">@8(OG:5<57Z$/2IIYG7Y^EA>I5K$?Z5M8?`L/.&-I+`>X</^EL(@%[Y(<
M(\6&%,'LNY<H]59OPC_^T1HZ]A[Z&(YSP-/U-1B!\`:\WP>M"`"$$1$BKET;
M&$+$@FNZ%C+4Y1!B0XD/%Q8\(L)(`SLB'G9LV!$DR`"Z1HI\6!(EPY0D3[8<
M^?(ERY@P99(,<!.GS9O_>/;T^1-G4*%#B>($0_0:CT</%H@H^A1JU)O7I%:U
M>A6K4*I;#P:@*B)/B((+FH8(@%#$@:8'MGK-.G5H6ZHAFH*]MD!LT+D+>-`U
M>S>OW+=1K^49N.8`71XT:.!M6Y2JU<AZ#1\XB]<MSLF#'Y_-@W>-V&M^#2<,
M&B)/7\=>[S:FJW!T6+Q-M\Y>0?;O5+S_";^&I:M6+-V"AD/@:?O:!UF\K_DJ
M%^%W`1ZR>$+0-<R#['/6`1)V+_A]8-GOH[O#'G\>?7KUZ]F#ITWN2`CL!`TN
M,`+>"`_Z"1<<*2B"!_T`O(:<]MK#Z(%''B'(HY`<I.C!DEHRB:4*5TI)PIEL
MJDG##F'Z"42?!AOL#1'LH.&!%%5<D<4677P1QAAEG)'&&FU4L0$6'VD@QQ0;
MV/&!'WN\D<@6@1R2Q09@R+&!+GPL$DH<F=R11R2CI''(1YR\DLA'8`A22"F#
M;#&)()=:4<D'OGPR02;95'-,'9G\$4TSK<P1R#'Q[''')<,$<DD_GZ02R#/A
MW-'0)^DT=,]$_VTT%%(5(TUQJ4HIO?3,'Q5,$%$%.^W"TT)#K=133CL=%=54
M2^5!H(D:A/!!!S^*-<*.+G0)5PPWO&E7#DD*$=@11RPHN.I&*_;8ZI`U5MEF
MF57VV&@12M8@L9Z;%B%GFR6H6&6YO=;8YPPBK[IOR1OM6'"E#2X\<<,SHMSL
M`!3M66JU;3;99[.5-MWLNB4(.^>:>X[;X-9=UEQL"T;WH(0";HXO:/6MMUQR
M%9:87?W0H@YA=+O]^%Y\BTTE.N5XH"[=[OIB%F+'JN.+ACP:ZPZA[)JJ"T`\
M^,/VN@5HN)8@AZ4K>"#]E!N8/Q%HD"[`XFYN+$#[;@XP:OORJ,\Y@_\&2L@(
M>;4^6J"MQ1Z;[++-/IOLL#'*3VPC\`@[/P'#9G7M`+<V(K^Z\L.[:[3]%F$8
M_V"%:'!879T5),1CE7!"77&UT%=>:1H)V!"%O1SSS#47]JC-;T)ML@/2\@HU
M9=_P_*HW1B,*+.?*S0/SPLQZJO3G$DO(L#PL0YVHL`)XH[K=>2=*8K)\UZPZ
MW2<KD3C8I_K,>&6G0FVY$`X`?B#?@E(+KZN#4JZZH(`WS-_(L,[.M]:5\^WE
MH]DO]Z#)R!LH,I*T%G=7#<&H:?^4TFCI?[02($6TUI!V+:0[1WC(`77A'8O8
MAT$8&=NK%.<J`DZD(H23R*PJ6#C#?7"`(6'_7(8:QZ')50Y$PU/A"EG80N)9
M#R>E\XUA3N="K#"'+&HY`'&$!;QLU5`HJ`F/9:CG%Q?&YG,PM&$`$F.6$BV@
M-+.[B>A^J!FP#$1X3YQ9'IR'/2B6SC/*.IYGNB<6"(0Q+&.\R7/()[S"',UZ
M;#19%*'G'#:V2UQ6/(@4_Q,_F72H0K4*).1D%1(.:HTB`Q&(VNY3$'*L;6O#
MN(\N+B+!M*VM(@JLR#7\4Y%=9+`@#+G&)QE"2E!"R((1,60A$Q="QMG*)#&!
MG(<"@$*@+!&7N=2E5'P8&>#A171.V654U"*SZ.$F?".2H4*T\IK$O`\APEOA
M-1(S136Z\#FGDUTT_Q<@E!V"\280*$="A(.3-RP@.?S9WFXP$X`%4!%T/C3+
M#*GI/2I>4XZ3L0X/B&,]Y0QM.<]QGUAF$SWY$4P[]KL?020WRUC61(2K5&4K
M&Z1(45ZDD1*<9`,Q4A"^;10C_;D&WC"BP)`VDI0*%)Q**<)2_RB0DA/YY$PQ
M>$J;4I"BK\KI0V'IH)50Z"&V%-$PB5K47()NC6(QC%&+\AKK5,<'U'/>8&P7
M3>W$4#DT\*(T77B\:.;RG;JYR?C*:<7DB>\W:EP?#8;R3K*<KIN>*<<7A;<<
MLNBEF^V,85KB6CMDR@:.OW$:.:N5E*/EI%I=80E:I@510LK2IZQ4G$X=LO\0
M<O`EE)<5"$..8)^&'"$_H>QL(SD)0<YZ]H'W.<)+2TD@SEJD(N1@B&P+Q%E*
M1@2FG+PM2V5KV<J>LG`<].!.@?I8B+Y$J#UAZG*9RSLAI@4PS=T>6`Y`@_8U
M1J]O"0L2O7(\F:V@,>ZLIQ1;>,[9J267A8D,:H+(5VD&DRY"^0PX?^>S=_+@
MO5?L9C*90]X`U+&M0FSO7<JBG=+)QSG`(7!S]F6\^>1QH519K-@@2\@0@E"B
M%@PE)SVJ2`];$F\+N8C>/&P12!IA&!)\J8HY?`3X<-(_+W;Q$7:Q6MWZI\:<
M+%"+=5$@!?KXIKG=+8<_"4H,9IBRJ1P@2CZ27)[_2!?*47X+0M+H7^DZM8XY
M')88FX*\TFQ1??&U85C/PM`E2N\L>0DB^[97.Z'0;*K\L2]YL78U[[V1ASC!
M'5+W>E8OOV:,-8->_(YV,V4UY6$*`=K6"O*2L7U$EJ]\)4Z1C,K6WM@AE3RI
M".`#28N00R#^X1NG_3,,_?@GI"FF)*@!U^(6^QC(G7QIK%\]:U?'.*8OY7"N
M*[N+3&.ZMD8FW+`[.%$!(M?)4E;VLI]"S:Y$>;WS75]VL1*;;09:.9!82PBP
M>\WA52N)7&7A-V\2%G%_#BS)3&+IEO>9:WT.>FO0'DZXAQ:V!#/=LSNP;S8#
M/V'VF38Q3`WX#EWH`QN<_WXWH]]"2+<UL?3JPI,U]F]?JTE=F#*FG!Q(BD\]
M4L^NMF@BL/&I08ZW%&/4"*M%N<AG#!^7JUSE+W_Y:F<>XY?.6,<VEKFN8WQK
M`NGVE"HE\B8K2U'$"7>`3OX'LYG>='0#\<SGCJ'UFK6^J[XE-E3<B[[)LK3=
M&'.I+:1F"$Y'7Q>B^:N02=[5F5@N-7OEBMHACWVI>QHHT@R&8H06W+,ES=KY
M-^ZSFSMNKF6RNL3K:(67<T)9X_#)3EJB$]]@:S\I.-NRUN;72+%&/;QB29Y8
MY(]<&TE3G'(7+Y+F,%=]S5??\I;#I^6O]GFM9>S:G^,8TQ;W;28]&=PD$S<D
M2O]W^O")?_:U-+4NON->]H2U72-V%S/%)'QCM&UEWG$7S4N\:EF?<CL^/\_L
MHMO-]:ISSIA-*R@).8!TCA<;9VHF+'GL\W;33V6JU`6*W0N/='`#F$)KK3H>
MAD%&`BWHQ\(>)(,&YY!^S?(^2[=V[)-H3?,TBJ14#I)`BV\LL`(_BN4N,.8N
M8L98+O5"#P133_5F[`-1<.=2S]5D[.4XK$!VS*5$[.)H4-A2">F*+OB2K?AZ
MT`<S!W0^8S,^YZWB)XVH#2NJZIT,S*W,0H?(`A*6QKIL""S03>I4B,SH`NJ:
MK72823.68ZJ@+UO8*P#P`!($:IV@,*ZPBBR&4/_Z32'_L@L`<8.'``/!D,DQ
M$@TP"`Q`<(8`Q4;B6JG8BLXB8BK3<@T&<VWG8.^E2"H#-:\"48[F)(D'`F?E
M2B[E+%'D+-$25RMP1%#E`@?V2)`$35`%39`<%A'F:L_%;@W(8M`0-:GRADQP
M..PC<O"#A.\'=Y$7K0*+LH7MLNJ=J&<(!P.8JI")YLN:A&EJWFK,],U[EN@N
M(N,SJNTWLLO[UC``RF']P,<RY$PM)J/0_NTR%`*?7L8-T2*(XK`LOA".Q,7P
MXB<\_J]L!NCH%+#BAF[((C#G:HWG7`X^AD'C2*H21T\@)"G4CL#4%@EP-H(3
M'=(388X3%5+U`N<3(](B*3(C_R>2(EWL(D\0]E+1]4#RYF`/!F4-!GU+MG[L
M(6JQ%G.JR7BP%V>2)O7,6^!M=LAB!;#CP-@.ZVRG.ZS(>>K#*<1O`2"A&*]O
M^\S,AKZ*/*Z0=JJ,,MBH%Y#G[C"C?<;/*[Z(\$@G#\KA[_2B=OHMW<AQ-&;C
M[1S&T&JF912-+2/&X>2%058)Z3"(YVK0UU;RYUSP'UTO)&$.QE9KD2CQY#[*
M$]=&(4=M&`*';TYN(S=Q$T%P,2.3(RLS(CL2Y#"S(TDQ!5UL!3_P+V^N'W6-
MR&)J%O52E&!2%VN2-7<QW\(NC,"BVP"-#`>C',QMAOB(6=*GS)21A9C'*ZU/
MA<`)_?^PK@#)R_NBD8EPYZYNLW5RYV6XY>[X+8G>[<_>KC>-Y30<CB30PE\(
M9AP/(AX1BBSF`Q?Q,1\?`C5YK@5M+/5F+C!'$",%TR`MDE4LDA)1+,7L`,42
MD_06<S$5<B/Q$T`%M$`#%'`$]"+P,T$!9R(#%#,?U`(]\2]7\,54$?9ZC#1C
M#4*$[B5C,KE:4T2+[RS7;G2(,+#J:""V#'ZV3H]&QXC"13@S1VO6#9?0#(N$
M97[8SB"(XZ`,+<V(,GJ\Q]UPHX92AL[NR(V.<S(:B,H(*BZ],_$$BC_ZI@#[
M$()ND=(JJQ9]K0%[+N=F#B!1L")#LA//U#\_*@,!1TU1S.3_%K,Q-=)`#10_
M-7(CZ51`*?,C(30CYY,C,[,3&=$43W`D=RY,7ZNWA*ZU#!%"5G-$'W79!"M\
MBO,:HK#;6N/N6#0QR*P^V&**VNF-I(C<KD\9S4[LO(K,A"4Y-^.>WNZ-Z#`G
MCV:<B`B.^DTVTI%^MG-?ZN\U_,C_WO$@6$4Y`"-I'FPN/4C$@&X?:RTP79%,
M/W`81C%"(Y(R3>ZC`I1OH$&2^%,_,=`.`+1`-W%`Y[1.`[1<R15<%=1<S_5!
M^_1.+;+30O!969%`W!/&9(P?9S#C!,=1(=5?FRN^GL^=,`,P;B,`C[++1H1]
MEM`LKE%4F1`XS`IUR.7N9G1XVDG,_VBT"S=CKHQ'+Y3&7W+2-=JQO]3(VKP0
M)P)*?J81,V0B6`VCT;PB8+!C&N7,6#VN:Q!-D4))@U9JE%ZKR%82Y_SR%%>Q
M3R]33LN50:&!;_A30.V`![1U,?E36[45;Z263L%5:[>6:[LV3]55:1TT3P\T
M:2]30COR(LD!33M33&^NDV`1QW*M7_^5;HFJG]BH89/G+YYF`<"K+X0%F,+N
MC82I1J<(=V[".9&''#$'8U'6A<*1")-RRV0#.<73FZPK*,NM#;^H.\P+(=8Q
MNN!/H'"5*<]R&BND/`WM:P3P+O:/;4*@;^@R43.IQW+N/4FR,X]67/UT0956
M(]O4"+B5/_^'@6KAM'B'`1JJ5GF1=WF3EWF?UWFCMWF1EWJ[=FN3-ET==%T5
MM&S_-%`MT4*)%C!]K+7FMF[/=XFJQWN*Z!KDJ<RZ3LLX`VCTBLJ>)V'A+J[X
MD-[434?E#C7*X4:ORBZN+UM,MF'DQWCN:GIP(WJ<(C9,`Z^RY6/CKTG'L'2A
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MR26;/M<S(#@K#N(`\&N!]0D/A(<W-(,&A$<^W,AQ)8,,3;6%0!4)><<HM7$;
M=T.*LB=@(J,7R@&[D`FKJ.AC1S>"5U0FA`,V>L%^\*\I0(+;'(;3%$UJY@-N
M@*W'.*M"4YAH-1%M/7E[KW==/[F6>;AJ_X,W&.Q`HU%Y&#*:HU?9E7<XED7:
ME2T:I&&YI$E:EG?XAR4:3].5EQ]:0D7Q%&6NF(\9IP=#.-ZM.+/3"6&C@`'8
M&H,#5#_#4R\C+VYS-9AH-;C8?*`K*PHW^XXHC[AOFIA#FF2'_OZ+.:":J0-K
MO0@&.[/%<0$#9C>$K!^N)#087B1L-&@@A+NC#_,F;"YBE%SK+NLU-`6U$Z=5
M,XOX$SF10"NZI6DYAHF7/^U@E37:"%Y9>IDV>5'LI"?;>1L;I1];I%F9I:>W
ML&VYI8TXI@.[>S43,QEQYFXZIU.[*GA#8'%#S_0J?LOLB]^,ZLK(=%$VNC#X
M"QNV">G-)PG#F?_%>9KPHNS0F85*M*QW0YC<Q;JPLIL(C'O62<"L<AH/BM%B
M@F7SPGZ"]1;5LF\\KCG8IJ-DK.+@<V@[<[0G^EVSUK,)^[$=>Y5'V0Y*(1A*
M&96M]I4;.[-+6K+AVZ3?^[U+.L!OV;T].VO1-:*=>(65V+2/`+55&\)9)RW0
MPOGB3XKVQ2^N3H(E(SOL5YB"R;>AR'#_K3Z&<D5'G,/U38[%CIE,5Y?TN7+1
MT%AV"'.A:+W:<`IW&Y^Q*G2G0CQK@E@Y@B7JH[KO)SM&JFBZ1C\N2S]$J?+T
MNFAG#$T1%'L1'(:#&,L!?+^=M[Z#H12@8:-'N;Y/6K]5V;(E^\Q=&<W_I3?-
MF5:4(_O-W=RQ4]J_81F4#1MZ75C/4RRB*;*)%?+E'CS"!]V=O,6/'6/L!.]E
MUG>,IYHP8%.-ZX./!+?#GX=P*UW2I:*-_S>`_R+MTNNYZ&PL6>:P%AAZDO1E
M]()87?6`L;O`&$Z49F-L1*\_(+DO%NGVA':AQ]3/99J(V;MZ\9RR9SF_(]O,
M&?N4C:"^UYS-39K.'=NR,]NB^3O.]=NR\5N([7RS*[J68;J3ZW0^'5PF"9W<
M@Z(7^@E4Z4*8:N;"3YR+T1B<G3G-@H,W26=:%GDJSJ4TZ.?0)'=Z\J*GSRZ9
M!GB8R"//O$)TTF=OP>??U-U?`)F0=>(X96*A_T*@):XT<=BZ*00GI/BB:P2B
M*6#-YE1QO>U43O6TO7_XSI\]>L\<SB%[ECOZE$OAAJ%=>=L<Y[$]VHT=LB6)
MYYF]OZ<=YIFWS>?\LH\^SW&X>MG;3A,T%`6]W(_98JZHT<@%2;6X6)[M/V8;
MWM$-9F7;?'*G??TBK',TU'-5[1B=ZS5'>LC%J.;'@,/#>\`P?LJ,.^09X`(C
MJ9YM)"+L&JI2%[SSX1)I'H6\QP!$R14I(5O,]0*SKR52(9%8O:M6(5=>R^,[
MSK<<YET>&H+AE&\>VT<:LX?]>7=>]$__Y5T^I(>^V7V>]8V>P(,=0+$V\N<4
M;3<1ZG-:)W+Z+!.>6/^NYL8KH\QB5HBN!GO,!W3\O;TN_)VXHOE'8IH#@^R)
M,##(Z>#C(KA_>[@!_IN'*1LWXU?-`KHR/&_'8C<DC#74^:!NE>)Q!M8#/SP&
MGY(FJ(^49C`'0N0+]3)W=Y<!8MB180()#AP&#2'!A`P1,GP(#:)#AQ$I&DEX
M$5K&B14K!C,2+")$AA>'93R)L"1*C1$WMFR9\J7&F#-%<JSIDB5+BAPSCNPH
M\B%'A0D)&CR*M."1?TR;.GT:(&I475*K6KV*]2K5K%R[>K6Z]2M8KF$#E!7[
M]2Q6M6BKLHUZ+<2"N`M"2%T@PFY4N2+NSI4J5V^`!74!B[B65>VUN8@#++;_
M*W=QXP#E_@8N#+<NW0`B1!P8"S<OXA!YI;YMZU7RWK]K37L][9ILW+RL0Y->
M$"!$B&MT'^?.PWE!'KE6'^?IN[4W8[.]'HM8H(NJ+MYS\4:/?DV$D>='LFO7
MCE<$#UU'RA\A=]X\^H'E!;8_R-ZH_(5$@=H,"BT8S9/YC="D*%1_,OGDD'\?
M892?1"$!R)-(^G5TT8,2`;4@4/Q5>%].!2)X'TL?W33234,U)-]!(L2WU%,J
M-A5;;-*9!6-5O<#X(HUN385C65O5J&,`,Y[5XXTVQJ@6CSD>*>2+81E)U8Q#
MQ@CECDCV:"2.4HF0QVR=[198:7N)%L)P7N8&9EUC_X89@I1:296=8-GA%5I?
MF<'I&)V./=>79E:&]=AHM25Y8Y6!%J=:;V,M.6B+4B):U6Y6PA598<D]1]A@
M>EVV&VYO5C=9G9W]115UCRF)5V374=?98==@]]T"V[UZS3`\;-==>NNE)]")
M[I58T'SUB1@43R'YE^"#QC*HD7XG#>M10@N&E*Q-T!ITW8ZG7M,>?0^!%)&$
M.BV[4X(U!1BA3OJ%!"U("$W+K8'-MMO2@SZ%V-%021FU8KY1QNCDFC6NV:*0
M/NXI5;__'KDHDE`:3'#!8M78;\"/!LPHOQ,S#/"^N85WP&QZZJ:7Q[O%I1ND
MSV696\E?"F:C6KK)2>9A=?_2R5MGB+TIYS7'D>;H6FTZ1MID2A)\%L-`QLCS
MG2A/S/2A70'IG0CE8$57TG`=L``/E`HFUW%XC49;TJ'*Q0-AC4W7Y6ZZS.A=
M9*M&1TYXT)WZG*RNGHAMK+;:JM2)V2KEJU$-_21LL<V&ZZ!#'Z*[;GZ*#P-M
M@AM2&Y8SEA>#>>;<9#Y$YIE;;CD$$`0`QE38F;>0X^\^Q.RYJK].(8.10RYM
M[!7>3CN]@Q-EU$'YKIC8H&\-W=J_IQT/I<`9/ZU\RT\FSR3TR0=/I/).$A]\
M7,=!6BF9F'G\)6;>AU97J,_95>20!^2U%<AMDP:8;B23=AC/6/*&L&/#C:8R
M:@?_1WPP,ME%9S*K'EL$Y1KBU6A^HE$8:7;6J#S4!0\]B]ES^*>E_E&*,`4T
M"_W89Y::I>IMT4F5S4[7&2/<+6^U0@^VV..WO\&P=]KZ%5`4IQ.AS*Y8N5/=
MM,2%P\,9)3I2$1WHF%&,(>1B"-M@XA"4Z,1M2'&*V\B%%'.Q1"QV[G/<")TS
M1`>6Z_Q-=]!RW;`:YSK'E3%W&?&6Y,3%$,9%+EB[*\HP?J<BYS4O?^G#7O$F
MYL<$.NUH0SL8HF`S/40^KY#/`\V0^MC(V82,9Y+TDB1)MB63\>9E8**4('U6
MCOTYAH`HHZ1CUG>_JN7%:M.;#=#ZQ\A`3DEZNJ#D)<G2_[2$*1)M)2,9_HI#
M/TD!C0=RP0Q5^&(V^7&&?I!9)6&TMJH?F3!-THD:^UB50A&0(V_D2"&MT`/.
M]!S!;X#[V[WJ^),(/0Y=0#P0AKJ%0]H]2T`&Z<YTHE(#T!5C%EF$8A:G2(LF
M"G0;`:6B00^*4"PJ=`A6*`8SEF&Y&H`Q1],A#^I25Y,?)FZC\/3AZW"G49C<
M<'<(21$>6>0OI^$2-HQLS1\)^<>'K52/BW1>^M)"4^8-#TJS^>4#2Q.TQG0-
MJ,LA$P3#M"7B4.E)->L8T/3T)KWHX@#$;,SYCM,IU_14@*C)'_,RXZC("+)*
MLA2>C3#(IJ`1;'VZ*2K6ZF(VN/]L+`04)%F=;B-6ZBR`!C(SWZ=X@QU=A$=5
MU\'3=GA3*Q7.ZD3A?(]29@@X;0V.7FF$G0X[*L>-8D@A[#E"Y9@QBV+D(HE6
MS&(_ERC%@A)4BD-0+4*G&(YMQ/:UM*5B:16*B'TN`Q@0<$94P"!&\QR$=\G*
M71J-1:$XUBZSE1UI44[JE)PV,I9F#>!8JYM2LV)7339]S?)>RL?II;2EUW6D
M6J."ISDUABXP(PS7[.3>,`D-+6)=S2;ARC6B#J8TB!F:=T8SG/!2=Y!/HDIA
M#-55['X%39W:C)K0!M>I38<VA,%-6BNLFSR8#R\T$-IBRG:8']624_V=3GB,
ML*H4DX/_!XO!&SE6O!WM"+<\,>S5O>A#7/S($S\28B<[NP7D8$6NC`FQ9P`@
ML`S,F7;)6*PB:[?1AB:V(1>N32U":7&+-MP"RUJ6XBUN(=LPUW;,"(5%%14Z
MVF(`PQDU``-P+7H$^W@+N89KG+/@^)..=D@AT$6I2C_Y59V*=]")`G2A7>K=
ME@:2O&T9<*+'>Q6K7=)^DRP3*RD9&;4NE;P_FU/..F.82GV-*[[9:H(-W9J\
M$@=0U+6NBVAJL^35-]+5"=EA./BG:ZR!4B)(SEY--:?PK,HL(VXQ"7$&G6-K
M;3OH8;$1:'6-6_5JG+D:KD(D"ZPY&@[(`')0D'UL$\]&I;>8_VNH$IE\;M0.
MM(IMB.*ZGQQ%+`<4S-N@]Y;%7._4SG;+MPA';/\=YMF2><QF1O,L9K%;8)`N
M.NWQ-NL<#F1P_WC;]^DS4Z0;P%8+6+P9[^ZA,9Y3C7?5U1MG-*0736B>@LQD
M'[/D;1C3:8\=1C3S1:23M`27_]Z)9EN*=?[Z9&I==K?C0^-+8.Y[MNHU>KK9
M.V]:'7662CIJ+L5T.GO="[1/)4U+)ASV=%I\0E;A!<7=V45V8JS"8:10VB+8
M57QL7!3[4`3<%`^RX29.9&I)Q7+N\-P2TPUX+$Z9B5.&LA3][6\H,S&@C!<H
M$ZEH[UM@P!RW,`<&*D_YS%?^%M2@QO^7/4^-</"[WZ)'/.(#?GA\D_FV"L7<
M+)P!#.!Z>\BSQX_M\<S#B%C\'S%%]:E137+@#YKDP;^NR(W_>Y,'#Z;&,\PD
MNX=7ED=E?=\['VF<"EY!T0]2\ENES;Q?0+6P%:U[Q"E;4,5!'V&U:24?/BV3
M%W3N2S5&["W-7_!T0D\31A>KY#IM-MEUTL%_`3@=W11CJN)9SV$$B^4?Y"1<
M@2,?Z#1WMJ=M>'=[-B$0UQ$57W0YGN-/6B1XY[8-9B9;G;<*U+`*M[`*EO<+
M&!!Z5O1X\-9$M+!X4Z1EYO`$.&@..\B#/>B#/;AY.QB$7Z9YFE=YDX>$EF<.
MH3=PMI4+5@#_!CUD=W,D<10W<:JS>R#'?$/'A1_G:`KC5>6U7<F7<AJG?.WW
M<4)R<Y*&::E2:5SBAMJ38367<H[4)D+5&7E0#B*4%Q`T**XT/X[Q?F:8*!,V
M6%F22718?-KE>WSB<VG503C"=9@V6!6$:UK30-Z!86-#@'=B0M?R*=MA=NCQ
M;`M@$IWQ'BA2;?,Q60!">S]VA7!4(0;Q-GOG#`[E@:2E15.6"VU@9K`0#M0`
M"R:X"K_0@BV(`1APC#U(#>T614SD"^[@#D]$C:W%1%1P`VIP`S=`!?AP`V>@
M!F<@CF=`"V=0"[1PCNE8"[7@!^MH#K7PCO'X@^9@"1A@`_>(C_AX_WD`)W`(
M)7"YX`QQ9H6U=X$0%W$LD879Y7N_QW2(1'2])X;9QX5;J$B"5I$/B4!@LUY\
M051[^%29Q)%YH2KNUX5R%52KD28[QS."\2_E$&NL)#'^<R.D04QF0BE999'2
M!88*$Q:BL4!!<S!18R8=,QPVB8?/L0(TX"@W4V%S040FQA<DU$V?LDW800YH
MAQ[\]VS?X1[C]';P(3C7-E*TQV-E.4>]0T1'!CJ;XSF9TXN"EPNP()<F>`O(
MF(S)B(S&:`Z_D`X[F`[IX`=^0`8@``+H@`[N<)B^@`Z^8`(A4`!U40`A8`*:
M8`)48`),L`9`P`E(P`E,T)E`P`2AR00K`/\)*[`">U``J%D`JUD(K>D`)J"-
MWSB.8>`+YHB.3X`!]:B;-F`)O'EY!'5O_"AF`#=:NE"!!GEWR5EW"9*%*$>1
M$ZF%!/:0#N-'Q*>32V>=A"A+QZ<P$:-TFG0EXA-7>T%,?O$RC7$]B21H*,DF
MA4$<#01(WI%U++-IT+D5/T(^-,!!NE&>23=@WDE@C(B?[5E!G)@558-U06.4
M62<"NU8^,"(><"6`=Q5V$X9BQ%11TX%VYX%V9.=88!F!-E0[4[AM=-<?1A`=
M8,"!W+`Y;.EW<=EYG7>7^6@#]FB/2LB#?QF8@DD&;4`&XF@,-V`"K2E!"P`)
M-,`)6,`)I7D%I.#_!(!`"OQP`E<@!#AP!5<0"51*`EM*`EBPI5@`IETJIF+J
MI5@P!F"*I@V`IFN*!%@`!`7`CO-8CS;0;V36C]M0#&!PD+`XD+='9-N6D%&1
MGDUB:!'CG4YBJ("&GX2:J$,RJ(Y4GX0Z,,AW?(_Z(C/2+X@J(X(Z,$.3J9SZ
MJ!A#4S_I<I9V)IHA%ZCT2^^WJ'H4=9T1*INR7TFG51]3&VJBJ9RJJ[GZ+W*A
MG_KY<F_`8@ZSJYQZ2(XJ2+EJ,3#B)/EW85Y'?X'!5W72"ZBT:EO#5YW1'#W'
M*0((=LDF=BUF3]NTE5FC';3B=B!:0ZU(HB:*>W87`KT%`<?01>[`#7UG_Z^;
MTP;VV`<T2J-X:0Z`B0U^``*#>09!.J2%D`>/Z0,TL`9=L`8-(+$22P);H`("
MX`(:(`%C4``HX`0:X`2D(``G4`%76@$G<`(H4`$GN[(MN[(D"[,P>[(H>P(J
M4+,TR[(DBP)7NK-5.@9=BJ:<L`:=R020X`.08*0+\)B160`'8`)/2P512P7H
M<`P!<!'<\J<6F)Q9*XO-63V8BB.:>JP%-DMBRZR36K:=:C'-UZJ:BC&7"JJ3
MFJM@RRB\VC"/]"A@B[>N0;=G*ZD#"D!L>).2%$(O=X?&>B3I.3!Z.Z`O@DEQ
M8DKW27^:$7]D]2CDI2/%A)25@6M2LR_1<[:+B_^VDFNI2(*?LW$`C4L:4Q.Z
M5W=K-W,^U<$8'!2[O(&@@!5"J3(WK'*`W8$>*<0#:K<=79DK2#%<`4*0[EJB
MR;D=!S"O+`H!]EH,TMMWN<"O^-B;3X";`8L-!CND![":"Y"4#;L&Y?L`#1"Q
M$SNQ,-``.."^5Z`"+Y"Q3L"Q%2`!("NR)'L%+]NR*LNS^TNR+1O`+CO`+)NS
M`MRR^[NS)7NE0G`%*.#`5'H%)$"E#BP$)/`*79K!98H%:MK!)-``(*R^#=`%
M#U#"#[`&#T`#/,#"+&P'/&`'=E`*=F`$,?QL!V('(;%[?=NX:DNH/QRW$+.V
M%J.X?HNXZHFX`ZHQ86O_Q!ISK)*K=`]FQ(#[N0V3GCVLMM_I583[5!86?=YC
M2\C**-@CQ`-*/^_30;$*,ORE::)K)?@)QVBKQ"^"%Q5&*64S:FH+0),*Q%+<
MJG$;NDK,-FT\R"&&),54*B.C)?LY&$W)8OTUB:?R08=!-Z]R&(EU8FHW0^8D
M..Q*9%7(IU78'R)P#*)#K^[@#-QPRL7`#>BP#?2HO1Q@L);9F@60!RNP`'C0
ML`X+L>@[PA++OL#<`.P+PDD``SA0`?'K`DX@`9&P`A4POZ1@`/H+P"K;OR5;
M`=9\LMJLLRZ;S=Z\LMJLL@7,O]S,OP.LS0F\LE?ZOU=@I5R*`URZI4D0P@U`
M_\\CO`,IW`40:\(TH,+^3`,)63%28K=-S*@&G<5&<L7+:B-M2S!4#,5,#,1-
M;#1Z_,:O]JA@**F>.DMX^\=NS,63%H?,E"6(8;;(>KFBRUW'Y(9MW"0X8S.!
M2#19S,2N&KK[1;M[Q4$F+=%5',A\V],$C;=EH7/]XDN3\2-O`F(%M!AVW&MM
ME36:44W35"W!1%@3]AUD%P+/=HIN9V/'*Z+BPJ?+&\IBG1=O,*]IK0EOH`GE
M<`!O[;0F(*2%\)BF20,.VP#G^\M[O;Y];<_U/,PD@`,6*[\@&PE[X+$@^P(O
MH+_I;,W[^\V1O<T(W,TO.\[C?+)7,,`R:\TR:\`(W/^_^_O`_[NS.RO![$S!
M\8P#55JE)'#!7%JF73JQ';P#M;T&^;Q[8TS3!L3'#5,6<PQ(%LU3G]*4Q<W(
MG*I7QEW</LE]_46L0AW<#OTO/-S;B-*WTZ/$>5O=5C(;Y3`VX<$E=7R>2Z72
M9/O;O(V2K#0I<@.'\Q?$/ORU20S?O%9A^IG&RQK'TO,\6-S;"]VJA^NX;=PH
M.ETVPQ87V5HIFX)?7O>M)%1+1A`WVC0=W1%CIIC5W_&`ZDI<-U'6H$S6PV`'
M(%XJ!Q`").XUSW37Y9N^?,WBPGS/]SS"QMS7)'#,R2R_3N`&SNRQ3A"R-LO`
MWFS-V@S9!.RRZ5S`1\Z_WHS_SI_]V.2\P*(]VNPLP:EMP:LMV!<<S_)<ST"K
MIEU^VPVP`UF8WV/[MD`]TVEKW2DM`EB@`J3@`A[@`6_NYF[N`:10`31P5C1`
MYW$^YV]>YQY0`6L@57NU!GC>PV,.WU2\,$H7JL(-Q!_-T0FCMST9?N=CGK,F
MQ$)-W9"NJ^VC->C#K,@6-JPQT1%]T%J\(\TQ,^&Q!BWV&7!;T1#=Z?`-WX:4
MN&ZA)T;]'/.]08(^2G#U',.ZGRQ6/M54*DY94==`3(<%-V<G*\LF8^VA*V^W
MKLM%UF*MG,4"$C',`RF>PBT.[BT.X[\<S,$LS,3<OH.MS(:-V//[`B.+S=\L
MY"6[_\#^2^0"C.3]&\";;<#[KMGG_-GJ#.78'.57NMI4&L\3',^M+<]D"L(=
M3-NT?=MA;G&2N]'E7>H^O>G:S;80N@8CT!0=(/(BKR).T`!0$@)KP!0C[Q0=
M\`\NSQ0F[QAK,,$[8.A&'!9Q7,1P:_')FM"*LJG^/<37/=&7AJIS$6NG+L2,
M3L0]O=O$2C_Z&1X!4)Z9_M#5$Y5XB\CE0S8!,*T3W=`7W<=9W.AV"]Q#HG,V
M$AE@:S/KPU?'3CX1"DU359.]5BT7Q&+5TF*N0@YP,TY9<Y7,EHHV%I;(NZ=;
MFQ\?$<-%P`.,_P"/K[[L:^[A3OGB[M<2>\^2/['TS+[NF__,&*NQ.NX!3N`"
MI.#C5XJRZKS`DIWDX.S923ZE,CO`_][OL"_`M$_OHFW:IMW`5TK!!G_![LS:
M5LZE:@K"L@WQ.X"^%-]G/K)40C_%9\OI82_4DNI!:V`-'>`"0J#BW>_]^JFV
MV:'B^>S]*EX!#!`-3M#J:["EG,`#HQ07\<\E\D__MNO<_9U`>QP;<9PP`!%`
ME\!>`00:'#@0X<*%O:Y="P$QA`@1(01"7)#Q&L6'!@L>5%A08<*'$2->.P@R
M@,B5(U6.W+B`1T:*"RHNL+@R9<J/+@=.K.E19X`0&2<N>"@B(TZ4/1GJ3#AT
MH%.G*H5:/?A1)56#$$5<*_C1:T?_BN6\TM1X,"8-FQ4%%J7X]6+,HB%T7;M+
M3H01I=>.^`W!8]A>$<..&#YRV/#BP]"&.8;F.!BTR96A&;&3.3./(@\\/^C2
MX$$#TJ4;)"&-VO1JUJQ5GR[].G9KVJE)PRA-`@8)'%M4O'"A04*D/14\.)'P
MPL")"A6N-*_`'`5TZM6C7S_!G#EV[=VC:\?^/?QU[%>8/W>>_LIS]E>$K$>Q
MWKU['$+JXR`AA#<)_OVQD,"B@0`#W(&3!G;X)T$%%V30H*U2FNK!K*P*":H)
M6<(00H0*HN&%#@Q8PZ801B21Q(HB6F@@KTID\2@LG(B&E&MH,'`-$0(0@83L
M=N11!1ZS_^-GQROP6X,&N4*J<*J1>O%IIP@K="I"EI(<*@`:S/,QNP9PZDHI
MH/!*4:<,=2DHA"MWY*<"$L84RJ6P+'2()DC:0BNBJ"Y,*,,5E:((PL"6`HJC
M`U"<\,E"GSHTPRF'6K0E"P]5D2.7-JJ((Z(JBHDFD(H*T4M=[JJ)HD\_I32N
M48^(:R]R4#6"K\)$2.PP5!<;IM9:(3,B&,WL*(*S!WCX[#/1&@BMMMIPDXVV
M9&M;UMC2<)O--!A@P*&"WUQ`+I(54,#6!5)\K"`^\J`35USJP,NNN>[29=<[
M=,5S]]WMJKM"7/;*E6\^'-8C84C[WKN"A%?Z`Y"$!@P&4$#2=O]H@$&'%R1(
MS#"U,I2KGA9],RHV(U;HF@:$J<9(&M;888T&2$:Y9)778+EEDQDNV6268]XR
M1VNB66HFE!8@I0.??^[@CJ"%)MKG.[X9(9IF&'#"@"NPH`%%)35DTL&JWTQ4
M0RDEU!BD%^\`NX-H)+@BZE(GRBE#"E>Z9H$&#(BFZ!@KEO`EJ)1:JJ:9TFI3
MJBH12BI0M,'"B*V91C3*;C:Y,M1O2"5VTV^Z&PJ`4I0BC,FMP3.-JZNB>,![
M`;7B8FK44D7-BS!7^6+]B%5EK54QQ2)[S`Y@@_5L6&=-4ZWW9VV+UMEF6<.M
M^-N`W[UXU'#H[5KAB#OAN.0,4"&]<*W_LPX\>,-;%]YV=^0N?![A1:\Y]LQW
MKE[UXYO/OH#?SP\__@;F[[\!%<:"X8?WUQIR1Q??BD+\MS5#5>PG5_B&!MIF
M``8T\`<-;*`2(,@`/CSP@0QX8#,TJ$$-7-"!#&A`"-;@@0ZL(2<ZX8$+&&0T
MH+6P`P\3VPM"=#D'<6Q#3;I3E/QWJ`M=J`$,8-`=FG$"MN"D*#1LD@[;1@(&
MO'!!(W""U7JH)*RQI&U*X<%19)*6JMW)BTRJ&E#@HB*FM"U$;.%3720&0+H9
M\']3I-J#=-@2M95N=!II&XKJPB>DG`UT1F$2J&Q2NKM<PU4+((?I"#,3UL%J
M58B!Y.QN]9C1_Q@/-I>T#;)6,[S=M8:3T-K=\'RG2>(QSUK`T8`;M%4!"3C!
M6^"RWO6:,YUS00=\W1M?=K)T@EV":Y??^1&ZM#<OZ*#G.?:*#_O6`[#W+7,_
M!$.8_?"'H/TYS"H8FUC6,!05`FHS40NH0#0$$(`%O&`:#YQ&!W\`@&9HX)P8
M3.<T&BC/HWWC#M'0@##4B<$?<$($/#A!![`@@BZ24P(+ZL`WHK%0642CH0^E
MP#>^X;.'C>`$//`(F=R$DHRNT5&&`@N9D/BX`F(!B`[K@!,&>D0X8O,:/"#%
M-RH:13(]CF)RQ!M<EH*4K#6%;36\U%<T59`K*H4M0%D`#?+(S6S2S?^GD^M:
MUZX&1SPY"*1ET4FJC'*7HJCHB#1!$5H6D)!/!6:IIFL+#_!RC5U<@QR,)(SK
M$`,K6]7U5HXQP@-@@!I2!F\UH)36[S0)+5`"MI.8;``HD\5)UQP/8<U#I1,B
MH87H(4<Y\TH7]L[%KN]4KT>\U&5H1?M9T8+K1]N+CGG*%Z[SM4>9_I)/O_JE
M'_R\XF#_.1C^2%--AQ70?QF+HQ<IISB[Y?`@"[A"-`Q0#IA2H!G"B(8P-"B.
M:(BC&120+@6F@5UA4$`<"3+:-*)[W>[*H@$B@$1`29"VRBU`A0J:QAH>,E_Z
MSO<H#7A!,U;H@37L)%,TJ5IQH;(1&O5+/4+_.!E.I*JX'U;3HDIEJG"GLI$K
MW*&:WW`"E0K8"[S-9"8W:AM-1!`U+KYEIR=&L4QNDI0;_80&+Z:!AV5F(QJ*
M!+@8"EW>Z*NBJ4:5AU%ME$8/93E=<*07!]`91FB(D:2*("$XR<A,1B40YO()
M+Y]"%5)X0(ZVN@YTK8)58AX).]@]QLR1T>NT`MO83?I56;_CW9H/&^<VA_*O
MU7+><+;5K6]M!SW$S![WL),E0@<3M*#U42]'>^A<CDM[Y#*F>E#`S'TQ,[;0
M+-AM!80%WC;(QY^&"C9]&V'BDKK(X1PG)`0@#'%L]P?"F(:K63T-Z_Z@&;&^
M]=".9NL?B`/6S1!'_P/R`-`.A+"F`X'I@I307P&KJ"0+6,,+9*J@:+S`(AH5
MP16F80TE:.`*'#UV5I9X`B<DPAK9J$8U%AH-552C&=:P!@->0(*H!5<@)ET0
MV!84HP:,U-0B](`J]NV$)TK@HSH!BDA"@`4^6"/6\5:!46*2Q;1$983P5L*V
ME8!QCO_`&HE@@`:<\+2]#6201Q6"$S0XC1>(CJD"#@$)2,'M;;M@!S(1`G)?
MC(51-WM1.+RIGO@D`K.@+50C;=L?[8*CB,CDB*/2!5PD54C"V"3+A''DF!D3
MNTE"AC(/P,'QY+PLQO)5>,8J^YS5GEC=0#8XDEU!9:=7O=5J5M#:V26B=_^D
M@D3S_;-9LA:C$[WW7+Y+7<6DCOK2QSYFSK8^[MD/;C.=L$XOR-3-[M_E-8_Y
MJ""7'N/DP0=N/8UF]/J<LFA&--2QT&_(8@0-58<LA&9/(=Y!%A3(QJNM,5`:
MJ.`.ZUU(VPBNH!^L8?,LP=$($<H`XSMH`2>@]@E(#9$KO8`!U;"P@G3M1/".
M(!&DJ("-2-V+!BM(`R]P`O>C,?(C"9@'5X"1@K[A@O4\,<,O"=2->A'M%29B
M2TG1,8W1A37X@<I#J`X8@6K0`%+@!Q(0'2T"G1/0KP1Q@K'B/*+@`15@@!%(
MD&]X@2TIBBM`K@!I@`M\.3?ZHLO['+O8G#$""2;_2Y6H.Q$1NQQ!<A6\:"N]
MH`@C6``PXPO728PP([.Z\KK'R"LU,Y["^JO6,*PX`RS9>,*U.ZS7X*37X(U3
M<H)!4*4]<R52$`#,`K3#$Y^\TSM=(D-$&[R^"ZU"\[OON3OLH27T4;QDRI?8
MJBV"N2W*,\!_,,'B^KD^W+P($X%PXH<`"#U@D[5L$"]_8*%_L#"*(AJAZ0!_
M<$1UN#4-.J\%X(=_P().4(ED4Q!KZ*_Q"R`<:8#L2Y!F6!."6``5H#85\#=R
MPJ]I<*)H8)K+XI$7(`4-L(9I^X=H<`$2@`12*[\$^<`=>(%H4!`ANH(LBK!>
M$*$3H,505($068."P[]*_Q&1$+@":W"8:DN5$?F*D0J`-5`":F,:)U!'=10Y
M)VB@9A@![J.`D4,*I**!$Z@&!:E`SC,C`YBH?_B&'ZC&:Q,!+`B!!M`/^?I#
MS5M(D+@IIH+!P;F(B0"+B<245/D*3`F,N+`+4N&CK\`R<N`+'O#!PO"+6!E"
MNX*,QPB&8`"[Q(*-X6E"F!0[.:-)3Y)"M,O)9^$-WX@L;4&!=50.6,*>$S"/
M[>F1P#LTOEL.OG-*O4O#,C2TO!,?\B`FHT0\Q8,/^7B/?X$\^?&/:-K#?PA$
M`0/$LR0U<!*GMLFO6],N1!2:?S`:1Y1+"Y/$N'S$;P`V#>*]$_B]I2.C]TJ0
M9?\KRZBXAC501@5IABOH/.A+D&B0OI=`KD2H1080@"OHE!,1QY&Y`E)0`E^L
MAA-`"F[J!7Q3D`]0JG*R!E2\@Q.@,7$3@370`%^\`SX0`K42`6I*$"CBICP2
MHZ02S&KX1R':FYP`$VX:P`),$`;`3)=A&`/IERNPOG^4RV\008Q0BA?(1PIT
MLF8K"B9Z(;&AQX40H<!8`T[`*+0,$U([.(U9$4.TB>.L'$LI!XI8NE)!BC(2
M,9`<%3[ABROSBXQHI+]8%7(@!\:0'5LIPLC(*]VPI&BAPILD'N31R;5C+#K+
M26HYI;?K@15@I2ZDGEHR2C#D#JA<2A/E)>JA'J@</%[_ZKNG=%&J%*8WM([U
M.2;UB:V`L8_YZ8\Q.)BQ5,\\"=(@12[EZH70>R=QV*>C`1N)2JB$FKTF;5*`
ME`5Y^H$?."\>X(<.`+ZHX(&#@J]1!,0CG<!4O`*0:,571+H32$Q'-(`LZ@I3
MBSK91,4..($62XEB_(<7H('*X<8F6A`&(`&"NH@%$(+M3)`[$,6<B$UL)`FF
MB$^BD$#P(K?$Y%(1^93U%(@U\,8$<0$QE4&AL@D,3,8GVI+V$H%)I4"7*Z[#
M]`!?C`854*I6[:*&-+4@LQL!LT^!4+%R4(GZ'*O.(0DOH8F'R,^:N#)0H3@1
M2"2W(LD0^,'7&;,R4XPSDPS*_W#)L`NLF:RS3*I)-]O)<%6[).A)YX$[%#@.
M)_#"S)*7=NDLO%M#IZ0>%9A7ZOE"'Q&`J.R[>45#P3LT[FG7<9%#YWBM^8"?
M^NB/@ZF?L2S,7&W8A[4;M10`MJ0`YXHN"D`][H-2=:@G?_!%N>38;U`'YY(%
M\QHVOS2VK'`O96N^ACW,CRV^QHP^C<F1!;$&$HC%$WP+595+$02)<M!3/DT)
M@/I8##.^F-,`!K&&"@!,#KM&!>'-M\"4Q-&%!5!.L3&9X>N`9OBPCF*J8G0"
M,?U-["0J)EH0":"QMCF!3OV'"H1(AQ"!%^!`\)*`>C-+">O#&AN_Z9.4MMD9
MGC+,/_\IAP@[H@^S'#I)UH?XLJ]XJ[@P`K=RG0)-C*U3T#-[#,HXPFE1,TQ2
MPF^]4,/B5G$5W=;`,U3:P@K`%B=X@1<@RG7I#K]+0WU-47P]@2_,U]I5@7O-
M5Q7-7=#275V:5]AMT5LB7LX*0T@KV'^1'_N0/"`5LF/[PXI\7ANSH7`CS>IM
MMD&,!GY@2V6X4F'@)P9@4B%ZM7RZTG.R)WM2!P8`WQ^0IUC;DN?CTFL[B"]=
MD/BZ0"22WV5T@A8KB#1]3%@4B<-DVZ6]-NK=O.=KT_B23],TQCY5D7)PFZ2%
M6FN03FN86T=\@1UH/Z)XVMTTN%#U38Y@T\?T@!<K8;D4S8?_$-)P6X-$4)!/
M'0C[M++V$IV-X(<VK8;X=0AMTT=6S9."U(!XE,MIN`*W:.&?L[%;=<@@'>"R
M6!&4B`DDFF(D"B2,*(JQ\ENZ>%Q%2JNV:!6_((>3E*LR4TF6I`QL?4G@@1;5
MZ%QCZ:O1)9;5*)8YMF,YYHTK$(#(8H,5B('475W32C1UT5<U=-%Z[=W<Y;M\
MY0?JX0?=;62G3+3;S5U^2.0U+"VE;`[/"CQ@.CRL5`^"Q5'Z0%C^P(__<%Z$
MF)KG=5@3O!H>6Q(!)(A,+=(7,$31BS4*L#5Q4(:@>:'J*KW1R[6?^08&T.5L
M@#7IXCU^^,L\:1O!_(=E*Z@)F^6J_YF1;EP0#<#9+@+@7U0!M0`G)^H`/K7F
MK&!E`1Q`#UA&T9RPH*4!LIK/:&O3#NA%[K-@(ZGF(OO@?^!-HU,PC."!U93+
MF[4)+*#@?V"`'6@*'!K`<TP0M)5!+2*H(EN*RFF`@[Z#9AQ5;%[5J3$3?N"#
M[&L&&1K-6>:)<^X*,-*H5Q8WE59IDV8JAZ#(B*Y!)6,2)3O.:::48NTCO6B+
MCM0%O>#!4MA!9OV+6'D=6C'C!<56.T@S)&26";7)T'668@F-.K[JTJACTP@-
MANGJ.<[JK&88UG`[/G""#JT`)Q"Y0(Y13);D0UYD>HUKVWWDNJ[=?!6`?'T!
MW*5KO+;DO?].Y$6.4>%%4=#29/`16#FDP^AT'TQC6)&X7M*T7I%ZZ95V99A^
MB5Y02P,XTOQB->T2AFP0!U^^`W7H+ENC->TB[8"LTNG"Q'\*J$Y4B048O@2)
MKT]Q"#"Z'/L:L08X`1A.5&];@"5^ONC#"R99@Y/ZAVJX@@/VPY4.MVSSQ;"-
M"G<.-16Y1_%UF`1RP)!2B4:%6@E`FZ.PD\`0@EHD!31:`]_K0!',$\LFDQW@
M@Q@VH4JAX4IINHCHD`413:#PX031@+$"HP4@@?SJ0&^+FA;FF"5I8I<`"05W
M\&<,M_<<G-[D"$IIV@?7;2P:I&8EA[9@UBO[<-#9BP48!C&.W,G_57&[NEPT
MKHQ@2"Q+>E`HE.JH-A:KOF/2&(VM-HT='Y9B&8TYX_$DV!<5F`<)$+E(8`+C
M$#D7>(%\?5%)EFM[Q=T59=T7X(>]?O(GS^N\?F0!>&0#>.1*SFL#`',!,/-%
M'G,QAW(79=&V]BQ#WHXY+Y_I:`^N#!B!B3P28-C,IJ)SGN:&0&<Z$K(`4Y'V
M/*[DFM@%^(!S(CU;R[6)NB=7TR[KF@:P:=(?D(4?4$33Z\OY[:)GMED'-)RD
MVB+#81D2,`"!1L!F<((M8:INCM6#B+D,UH`=D.PNBO!9/DR'7FXA..YK<.!_
M0$W<AF?-)H'X`Z]J<(%^4YR-V&<H,B(O_YG!-:AM;8XR0YUO"I0OO!W`:5`0
M"3BOFW`R8RV=EPH,QTR0%6Z;"NC4#F"`&U:*;@Q/8#RORRDHA_B?3`VDCX+G
M8XNP8X=N<UZ1NV"*]BRJBJ!F4PNQ`-2%(Q@D_L2Z'J0(R945K:.5KKM<RW!)
M!ST>-Y8ST-U)'"^-1R"6($=YL)[C(`=RE0_KE;_CK$ZL?=ECM3YK+G3RUK6E
MSHIR,F?*+A]S+!?Z+0=S+C?Z+-]CI,=R`[CRWCUS>V7*%W5S-83=1GLTUF*?
M?0D8_-A1/M]#S-;99Q2(3&5BAD9.L-=>[N6!_&JUB)I+2=<WF0H;1AR:A')$
MI9F&T,[$+;UW-/^M;;E4&FMXM\$7?,&/!NH$KWD<*!8.-UF'13+9WP?&U??&
M7EV@`5)81A4X8.OV"6N.MD<<(L"%\(-<D`02JN[L,"QPHCN(.)MXL350=XNR
M"\BN9G/4Q\5WNMU6L/;B@7M<D`H834TL4PTP$C.I[:TU`*+SMWXG>Y_C&-J'
M[^?//(&PST_9_>97DJT:^WRN565]J7\V^!)WUAW<LKA"\0--R:Z+C!=OR6R=
M2<!J8SA;.Y+7'=!X@!U`^:OV\='P<8#H\J!!%X(-!@X\J!`AP8$"%1K$L47%
M"Q=.G$1:0:*"B@I7<#0(*3(DB08X2."XHE*EQPHG.)Y0H2*F`!4U!>#_%,#O
M!<47`E[LW/GS!=&?0GF^.($T)[^:36W:/"%`JDR9,:]>=:GUI<LK)ZY4\(AB
MI1"R)T_^2ZMV+5M=`=SJZ@57[ENWU][*I:L+;@"Y?/6^K=LW[ES"@0OW6E"!
MGH!K"TA1:-9,UIT._^Y<_M=AL^;+EC%WJ)RYPS<*XB@(:["`AHH[)$+@O<O#
M!=O:MMG>X7."!(T0UWH%]KO@A-IH)^S2>+'VQ(*]>MWZ#6XWKR['Q-6^:![@
M6@,&:U_0*,QW;P`1:YJ]6'/-.5SHY$/L6#O"B>,%(@:'6-#`B5H&#:XY%@(-
MJS6CE@98N'=8``%TIY83:X3`PS4AB"`"7(Z)_Q#AA%AHH%8'S&EXA34.+K#&
M"]\4!]Y=[B4XGF#14?=BBW\91EY[>.UU385W.0;@7NY%-QYT*RK8RXHZ+K#`
M-318^",Y]D7(`X5&B$`.#\.(8(01Y!QQ!)==#G/$,&&..0PT9IH9##1J!C.,
M'0_``(-(<LK90!(-U#G2G2+M.9*??Q:D4$$#K:'0&@\,VD"ABR):Z`..*DJH
MI`(=2@,-/&#*0Y(9'G#-&P&4L]TP/,!)P@Y,^*#HI2&4HPD$W,#JSC'<E#,.
M#S2LD2NNNEZZ`*:76AHLL)FN]NNMF0J+J[*Y,LML`YR(A$4#)&!!`DHIK<32
M5E9AY=)+)WP;5EA7C/\U5EDD?"2$M;?9%I>"+A(&G%N"Q7O8<SCB%9B"=0$V
M[P)71"-`.3Q\,,T/##2C3F@H?G/''=_X0]K"I#G<<`?W_/.-+`9/,TT#(@S7
MP6OC+2`!NR?C]DTUUFB@PAKW\;6`"L6IL.(:M*EUA79SO7N8NX?]NY8'-.2%
MA7?8T9!OS]5%J"21[MKX5@AKR.?$`B%0:.%V_Z*H6060A*!+?O;1<(5:([P0
M=GORZK)&(@YB(:74(%^8I&\A5%"-6M:H9E\`5TS3WPL,C&#9/TZH%K:\2_/+
M,[QLT[LX7_0ZEZ]=.TZ8X7H+0LTY=85%3ICH]27)@PCKK4>.")I.6>4U5%+_
MF:679!XA@IAEHGGFFKNS&<P#.,09DIQWYFDGGB,5[^<C?QJ$4*$%=?'\HP=1
M*A"BUQ_Z*`T/'*OI`D9<?;IO=WWZ*03'0.",.^X,T7XQW$`0P"Y&\-#`#I`4
ML(:T:RPPCB;<N.-][X,?!,:QFC4$RU=)6B`#&^C`!G:"@1&<X`(FV(G\=&*"
M6-M@""X8@G%XD%4<W&"%DF22F7@+7.#22E=:0JYL78$$KT`+RM0"NAI%YRTK
MLA&\I/,N(3UG/$:JBV*B80#'O*`9PI@&!1KVL-%([!NDB9@4-[,9*7Y#'<V8
MAF1VL)H3N"8$U'$,SM)B'&NA,8UI!(M2&!`-#S7#_PD5"(]P9F;&$VQN#?S)
MV0)\-A@@Q66'@@F:6D@1GNTT"&D\C%?4?.0BP,C%/&OYAA/"ECF8Z;$_+[./
MV+!6HC=JQAIKZ&';E.`@U30I/Q62"X"@U``-8$8S)Y`2R/XVHK180PF@O,PL
MB60D%OE0D#>BT6#ZLKEADJ=??-'1Z<2FN?8(25\]5.8?K_$DD&TJ1Z^S3^R.
M<`UOPBY+MOL2F<J9.]VM*1A&"(8ZX92$."5/>,B;YT@>L:=X"JHAV8O>]81U
M+`4NL$(9&A^`KE&.3P7@#:XZ'P08R@WT%8,9[9OH$-[7EV$<<`6%6`,)$-@)
M_\&*&\6HZ$,A<(U.7,I[#O^DX$HKZ%(-AC"$Y<#:3&?*JG+@-*<X[84F`J")
M5D%`$ZX2:E"+*M2CSI0&#9@)4[^E0G&]!"POO,*Y<*"N&JJ%<4)TW-("Z;-^
MY<5>"OH-O40`L!?T@@:D$$?'4!.9`E7F81386#2:,==FA":NTY"%,)3(17%\
M;`'\$!EL^,(#D^VM`2-<K$!]5:@K)'$MS3"`TP(@,YK9;(]IT5GEHF87SNDP
M,+]9``G6\J"Z)#(MX`'MO(1(UND<YC?NFE`#)JD!2XZ-0A4H4%HJ8!^0^68O
M^8&E&3V@N!7E90=\@!N%LI:A'6U'!#0@@1.Z]@\&0`A`%1*16GYP`B>`\@ZD
M4,W_,6.#([;193U>]6QHMVJY]MH+0,UU9G`M5[G7S@6Y._1+=%"W@-KY:D>Z
MJ%#L7.<E7=0.=EJR73EO-R9TLBF=Z803G>0Y/'H>;T[,\U,_AY52394"#YL2
MJ&_*8=!>A"H`#5TQ^M#GT/^MN*'N>-6K8#52BI(4`KV(X*T6D#]%5;!5L'*?
M2.$W4PB^E()*SF`'L1;"Q=8TRCK5Z4^K[%,H+'2A137JEK4,@7*0=B9706&X
MN.)"&,;0;%C]!PZG\UF[$'.8YWU:D-[ERP3)I8@O>`,/#&"P'XB#`3\8],,<
MU@Q`,\!@#`ATQ1ZF@6P(^F`=P\(7[_"QX)!Q+3]0#^JJ_^-I`&V'2!/B006B
M83C-7,%"CK'C/XS#RAV4\1\ZVXYH@9E,0.I(S6D9FEU2^P_P.$>0PL37>G+8
M'DFJY0Y6NV1^,FG&EX&L1RL*P17TIIEO2&@P=WG+&@*7%L0E"5?V"7>XUW`"
M4VOF#C_0&>JLP]M_:$"II+#V/Q*A,[4];3LWDJTT]>*7PN1[F6"]4'.W5M_^
M<L[-,FK1'^N2(R4]:=RJ`U\(J,2E:^SBF^0@QX)A1SO<G3--:UHG.WV'I^#!
MX)X:9MZ>EN<GZST@I=_[[?C*`1P5XSS&75[Q0EV\8@(R5,;_F]7YN.$,D;9O
M&Q2%7P#^X"L:%*`03%!5)USE#O^DDW3&$(A@DKA.00PN,(+Y62S6QO'!F]XT
MRFFG,I5Y6HZ@0B&H1,VRW+E,U&N06LQ8>2H+OU*!L5`US:5=<ZWQ5:/XWE!R
MM';15Q>?EZ>M2`2EYH<N>$`*R4R&BTH\=6FB(8RZ4J"NDYQ&-)BH1`I0X&,T
M.`%A+V19S?Y#E*0T_.(,>J*U1(,&H1H.9KFM'+7X=FW#9%N^[T)(U2;-+;Y>
M;7YIWSGR%!XN(AA\6N8S-NV(X`7T'AHG`S#V'XF`N+)L)HY*N;<7:"M;!GB!
M$ZP1R[1\PS^^\HT.3W#+Z[Z,!R<807$,N9T8!5S"U=F;_9^](`9^I1=>5(@E
M78WKB0?_[2T>YR#7C_S2IVD.-JV.Z53<Z7A3QGE3EZA.*1R!EAB!@SF8F>A.
M[[#3A*'<RAV/RM5)#-93S&W)YMQ<_.2<BGG94''9SC54ELW*0FG=C/D<_&A=
MD4T4+1"9CHV#")0").3!1@%9U4%``!'9^WS9]7'=V%V0W8A=!379DW&03=54
MVJ$=3OT44.T4W?'@SO'@C-'=3)%`4^V=M[#0F9G%FK%9,4V3Z/@0,DE'C+"'
M=$S.OZ77OT3#"R#1GPG##W3,#SQ,:!R:,&A`H"%:HZD#`PA#HG',-&"!=('1
M:^A%IG77*%''&'756RS`_:4%"33'9=T17="``2Q'TD#2C?B;_Q#IGX<8@`BP
MTO+1T:WY$;RT"%V`3&V=C02(30/J`@W<WQTP"3/6QWW\!@DL%_S1P%TDH*_I
MX3_,ARM*"89L#G=]VX@U`%ZIQ3<H5C114VO96I%$4^$%(C/YEWKA(N.Y%P\-
M!G_9XUY`'/C,GT#I`CD@&,9QR9=X"0\H&)C@CNX,0X2Q"<E1V/'DR87)TX;E
MR0,LP,TM2/S$6-S]8$AZF0_2'?J,I-:Y"OP8817*F$K>V!`H7?L0$#ET@J84
M0/[DRM5`P=5AW2%@X=:YE$MUT-5<T!>*X0;AE-F9W1GB%%.RW4]A&4]A6=S1
MG4@&%3>T(0\&@/[MG=[9X4N@@%A,E?]*Z"'4T-F^$&,N&AYKB14Q2E-=2%[`
M!(!:"0-;A=X=^`.*Q%5>WD$T/$S#*$Q>?<,/')HX+)$2J=Y@C4R^'-9:R!YH
MO0MZ\<PUB%]O*0DLMEK-O(59G=J#R)D^`A%<J-797$%A,<C1(!];LA=B4$Y@
ME!`R5I\3S,WID((ZQ*9!94V`9(TJOD`L?8B2\,P:L.*:C0!O!)1<C,U>``Z)
M($F)O,`N58,!Z)Y@'%-8@:8!*I-:7F=U8,[W"9/B_<A[=18T!=N/J-<"D,.$
M4,GW5$@'(AA!?N!!CB`):@G(H1,TI%/)E1PT4%B%O>!%6AB`BH22J!@4J)A'
M(NC;\=R"9F7_2&Y90Q4AA,(/T5E=2[Z*,[P/CN58`?%8U.E*_VC"U=W82,'*
MEX$9&%[-!GTA!CE9DW504]+4!TG9E-$H&KJ=)O1"0UV9W5DE#_KH&Y`#3,0$
M4WFEF4F51TQ560;BK=VC(/*A6ZXFDSYI,?T+8R"19(A#-*!(:'C&9F#&EF*&
MPX0&:3"1YHF#9%":_H71*"Y`K&U:?[%C-`UD9?Z#;UD6JQD'880`">R2-9"`
M>NTCPSEI=33`_25"`_Q(.0!C/K9C,?G;`I+6)#D!7#0;NF6,$ZS1N9!`64P+
M=5D7WYBF\J'F-*!?!:#+IH+%;AG.':B`DHR-U&R*+1G(N&7(:EQ!_X>D136,
ME];<"YXA1EK.WJVQ4G<^$Z8]3I,"XN=4X(]<#9*H3H7`)\9]D\;%9Y=T7'V6
MB4/N3G[J9W]6F']29)_T29Y(2:C$3T\UE((JJ%:ZH0^R6(,>@Y:I9-$YU*S,
M"M;%I$PVE"YPW0(4@K+T3XWYI/N\SS'4RDL-I=@Y68JF*-G-E-G-:(VVRL2F
MX9=!`4_!'8_V8!M:Y37@`+@TE9A9Q5:(BU0!GAXZG#3):6NI)G8FW@\-HWWI
MV5Q^P!8Q417Y0\;DU9=>1F5(D9C*`F$Z(ELU`V"!C&*&#6.2@F..DN$1!J"Z
ME@@PP*G)VBOBJ696A[-E3*N*I_"]I5O\R__["4#2K`@)H.:O)=_S-=[SW4AS
M@0SU>6,E^==UI,4=5`,#X"T?)((UY"T#Z"W>5L/[_6:Q[87;G)("-=:M5,`T
MQ-(TN&)ZA@^DFM7]:0#-V8=CD(`+=,T(:`"[!2N]M.77ALY[,5/8--<QL:UU
MQJP!.EQYYHAP58E`'4$(="#&%>0N5.M!8HD=D&"VYHX*ZN>:]"=%8IB`_LD"
MV-R7-52.'NB!(NB6^92#MJO.>1F%3B@!76^-%<-+3A06!L`X/`D/1)VR=(*0
M6:%,_B2%,"P'%>7"MN@&C</#L@K$/JS$TBB.XN^.9BR6]>CT+E0`X("WA&RW
M:(57_)U4D>6:H2[_H%:@OL&9IP6)>HF:C4R@,MG@Y@"J8JB"`&SE"[`585H,
MPPAF%&&1P^!E,R",(W),:JQ&:[R&;%7'`L#>IGF:#OE;L4FP#IW'6EC:?6!F
M-*C`TRK&J6G`?SB<L,76Z&AM-)"`+U;':7X''>T0`\.9#I$'#NO";QVC;3E-
M.=``:HYI7.55&(]I&??'?US(&IC2MW%:LU8'F*V>-1@.'[AB*UUN*]F?@4!;
M+3'-&G@`NG5`-8"(IQ%R#H_'D5!P>\`P?'&GY@2((RTK!AOK`TOP`RMK/_IC
M[%I(Q@TD@@UD[FY<EX@)?6K)F?PN?NIGMYY<AJ5<G1"/"R:/"."4BKU=__3:
MLJN\754^J"YO6;S*6(Q-*(V]"OK,ZXQA'4Q.%`'M@A/ZV+^N`20@;X@BW8T!
MD(Z5`TR%88HJK$QY4*V<G3<GY=I)+!24`SE;;#FW2HYJF8_V;\^YRD:`K%6(
M[`J%B[B(I9(^\=,JLC['EA7[C'H!1S\N2"4S$@S/5A$U!B0DD61H:<6L10?X
M0R1&=*'U)>J1GNG953.H'NM](@5;'M..CKR4E^OJ2'5)%@\<0!;3+1!/\0[#
MGPLTQYL%TH\H\M;<'O(-T5Y@P34BWP[EU^L^[7/D]-A42'R<C1,`%VD9#FE8
M0U,W0U-#M61`M34\=3/L4@<(@':LAW"JA0NHQ_\RJLTR\@#`[$UIME*3X-T)
MT!L#_%9,/VWV[=(_N$!O'"LKO6[D$&X^/[!Y#EB&Q'!8,_+GU/!=WY#H4"`F
M9W(,[T(G2^OM>@D(BDED#P/]3'8IHR#P[B<[#6]%"BAG^PD-C`,M+Z^.>:3S
M.F]5-FA1N5C/_2"%TAA6$O,O$W.&)MT2?B^/^2LDK`$/E.__%,,A=*](!543
M'F6+$B7[EEW]YI2,1FRM2"S^8BS^3B6/LC,[KQ@\,Y4!R',=?H7?10*2ZF$_
MVF!U/-Z0Y(C#52#A.O";C;>^N?<3+VN5"D#E&<"@)9H&V'>A^0,*3X,&3`/>
M'HQ]#YH&4**`_\`GKE[_!RC6D6REFXZ2-A*R%0_VA&AMW39Q#./I<<!9",#F
M951N.=#T!-;%#O&`$_!?6DR#A``T=YPML.6S/?:S74_X7@@4LL$??6A*:OG'
MPW&2</4XZ:S!^_&!$%QQ:GFF#D%7#.O'B?]#=(X/I%X#.1Z.IF@-!@?2*YU:
M-7!6(;O9&-TU*VE;RLI6GC63M!&V(?]?4(\.)?\J4-/TCF`4079R07ZR?'))
MF-R.F/``-!@![YZ)G_-.*OL./'UK2,`@G]!3;X"*\M9RW-WR#YHV&TKO@X8D
MT*&/U@GSC!GSO7(OP>XKUT4='GA4JUQ=11$9TQD0&+*H!XE=^S[94L*OC,8O
M__WF5/S2*(KQ5"]<;$\9J":0\W2O<SOW5`,(\)@9^U-U=\E60%DRTF"?]^O^
MFR7/5G@:M#WZ]!73M!47$3_@W>45;>GUE3AP!FD(`P64:;DSD3#TU19M3+A+
MAFKP@&(V22`U9F(YUW.16`FM!K$[03,P>:N]@"S[X]7:HY'@S2[=`0-<@934
M-`2/FA#P0=?<@37T!N&N!S`:"7_-M+,_#03KD/IV^'Q<C9JFQ8<P28`(Y'KD
M9N0F1[)9S8\8;EIXM0338W4X1J%(D6940]I,B-U$N;==U\F'.,&MGK4%<GH0
MKEVW%WYQO!]"+3WVO"417[-/N)@;=IK3M.MF/3-=4_\G$V2TYNYCCXF#\6Z?
M][D=H+V@Y^=$%KH,'GJ&A00/V!RZ'FB.UG)I,^B"ZKV6F21+%I4Q%Y5*:D*+
M8:](=?J&@N\"_>N`A(!0V5AP$U`3MFA,=1T7JNCE*^79)?>L*W>-DO/<2V4Y
M*Z_R#A7_IK:K,$@\&\!3;'>1VK-'Z&$#0SA\$S*8S[1H'7&TC[E/\QM`2[N>
M(1%;<1&@&8P)]R47:>*@->(6`=HF%F;'G"F"&X"E69(.M:FD$D7V:W_VDX('
M7`3"_'L')$(%\$`^\YX9!;'MX]T5,$`LW4$BN,!N-("E*!`/K,$.?*P+R+$9
MC1=`A-`U,$`O70<:,/BW\-__"QJZ`NBZ!G$B1(L5!THT>-'@-1$+2##\]TU#
M"(1.&#)8(^*C"(DA6`Z\=FW!`A$S0RP0TH&A-1(=URAAZ&3-P(XP;P[,J;,9
MSP[1*BRX!G-!@"O6&&J0JLM@UXD;/U[1P#":$Q(A9D+L-3'BM8@R"\K,&.#:
M1JX2/29EB?9B7(IM_;YUF_'OW+IW.Q(F3([E3"/7=E4\<HW<+G)'CER^/.P(
MYV&?AQFQ([J4$=)V@J6&EIKU`QBO&\"(W6"V;-NT<<N>W8!'N7*]()2#T$M3
M``@0C&LZKEPY\N7'GT-HSOSXL>7<HC?';AT[=G<0NA<;,IX\-^S#A]4L4&C!
MF@4A_X2[XR9^O#MFWP.,"]$I1/_W_/?[;[_^!AQ0O_[XT^_`<@X<QS<&'_0-
MBEXB'$>37J`(#HH+-=DP0^JDR^ZX<AJHX`053A!``'Y4,.!$%5`TT<039*S`
M1I%PS-$HB3(Z+*->Z'I+,8QV;`M(MBR2*"*[N!KL*XI$N"(:#6@ZP04)/'""
ME"M)T4`#!C1PXDH/L)1`2R<\N-(%4B38LDP75EK#A3O6X,LH'B3(\8X]^>SS
MC@YXRO&?$1AX@80%RL%H`17(4H%(BT!ZX8<[%GHJ$2U7-("?%TAQPIIHR-+@
MA)6$Q"@AD1RJJ*V+9`+2J+I6O:LNFAH0B:2/5`!UH2ND^O](H*EJ2@K8I'*B
M@0]*1](@J36P6H@HN)1J#*\%>%#!FD";X74FEBIH]A^M*AI,,%D7:,")$1:Z
M(Q$<WI/+78HVHHLK>0F"*R^!D`J7,'KKU5?(M0@;K%["$AN2)7)T66"RR!B6
M"#-R(.9,A,XH!DVTB^TH@H<B1F/-8]=>NTTWW7*CC63<&D`T@.*<,\XYY(QS
M.43J0&P.NN>XF>X8[R#86;KS>'9GYV*X(6^\8HA&KA=R:EJ`/1H6Z$0Y^<@3
M[SQ-].-/ZP#YBSKJG+8&,.L0#B2;['+.=E#M!QV4T&WBX.8P0^$ZG/DYF@-H
MX(03-6UQ10%0#'SO&FVLX`I!$8?_-M[#``XX7H/HBE>C'XFTBW'%-@JW@6JB
M@7H-+$AH@`020&\`A]))3UUTT5-'??301Z^)A&:BV<K)!5Q`7/=_`.W@FVBB
M:8:/0DG@P<Z-%CB!(55.V)')$'BXP@4EFAD!6<0[N".::A@P(&4>=YSUU$H%
M>"@QN[JB/,D=9=5%A%H9&L&)<C4(M)J57I**JIS2`C:O]TX0#:?<@09HV0$?
M&`*G]LGD/1/9UAI.,(U`6>,*/)A)\IK5@?D-#'Q,DL@:/%`-2CVE`@5DBU>8
MM!'TW04OVQ(!6FB"EO1YI4A/6M+DU'*Y5Q$,?(H92&..L`!R4$871]#%93+S
ML"16[#.=__E,*49C!SN4X@$/*$(*C!",U;0&-K"IC<EV<[+;\,8WP!$.W(X3
M@`P1!SDV@X[-X&BWFVGB/"'ZCG*XPQT(?"<\]!G/(9(6@',P;0'K60`D$*6<
M^0R!/O/Y3B_*AB`"<2TG`2I0?\:V-?TPR&R;]&2$'@2%,G:(..68D-R6DZ&[
MA0@Z)#`1C%2$(@&<B)8JF-'>:$2C"NP.1^Q[TOIF^*,>!8R%C4N?O"R'&!ZE
M[QHT((4&C3?$1)5#FI0A!WQVL8MQ-&DMU"3'.(9XC0>)<RKF^H83*F*7!9`"
M>.UTYSO?V0QK:(`4*A!"RF8U3*XDKYW6:%[CE(F3-52`%)_R4_^?HE$H7AV/
MA3XR5SN_<0(:``Q]E?,A"REBD1"L(1KJ`%XS7B""%UCC=]$HGT"40JT%I!2E
MNL@)#T3`-!IHP)TJ6.D::`J\%Q3E20"CB0@`]M(KT,ZC#+@"6A9P!0:TTP4K
M;94R$>/`17VJI#MU%T;2UR19"09Z.7FA1-K50QYVT(<%(T@ZA7G1(1V1);NP
MR1$BX[#*)'$S3'3B,*`A1=*(AF,/X$$*/!8,.X"LB[5)PA='AC+<J*P<`8A9
M&B'[LE5.YXW0L4[/[!B=Y_#Q.-OQ+`2(9K2C06<7G:A)'@H!MG+043[%.`0C
MYS,BM(T-;+4U;2=,.Z"H;<U`F!Q'@SK_"2%0FO(WFG`;UJ"P,@Q!P$/,\1`K
M0]2+$O%-!?Q0D74%%S@9Z?(*N^0E0U18S+3V\"W!S*HQU>J\'J90(C28QC^B
MX8$37(&^ANLN?>E[J(!=(WKT10%^ZUM?!GQ#@T[=H0-GDN#^);B%:$VG`Y7)
M)`8_V(,>O"`/:$"#-:P!:D+4UV&P:A@%,SAS*ZPH#<7;(X_8),$M27!-6IHO
ML-J$@2^,R8C3TF"TJN^G'?DI](:5$\:P.,%9)>N.>33BR04SK>'-2$WXVRZ:
MA)C)4%W+>3'*OA1KN8>0^<@NCM#6(E[#B$B$V!(]`YK/F(:*/("B:!Z0,2D&
M0QM2C$W([OQ%_]P<EF1CA('*E'NAX3A'.-))3F196;/H6$>1UZ$C=+EQ#$7F
MT3Q($VT@R6':!1R@$`?PS<^()AZK<>,[P2D;@'AKR=L.*&R2!-!^&O1;6?]6
MN!22$(4PA"%3QDTZ4-B0W7[=:Q+L#7`&^)L*9@FX[.8RE][][C^X[&1N8A2@
MCY*V>;-LY*Q.A08NB,8((`J\WXV[+&OHZ4:C45)PDQMX(_B&/VF0EA6FE]X\
M#*\'H9IO]3JO(HGJ#TZ&J-Y[CU>86.9REL<K[9?$)'\WL0E+7+)P$93C/1#_
MJ<4O:N2R^@@O'^D1C"?"-..Y6*U,UGB3$5YP]E%TQ1^Y>%A3KN5?RO^%O?.F
M]EK=)8+'_#0R1L0,72OF1"9^1HJ#+8)H,A;G.4LQ!82%#9_!.,;=*+8W`?C-
M8PL-',FNDNN)UJP<CU/JG'46.MT!CQ^K=IZE70,"M+@!.I#FG4J_-M3+45"!
M>+MJO>/=0)R4M=D2M+:U,4B4OR$N<46Y(0P]MVYUFUF&\D;+OQD`V=9ET8MP
MV6P3/7LA*K]Y605N98*#7L(55@H-&G`%6F8>17OC1_$4`SW69S[S.$A92W^)
M;=U'>*RA'RM:33]ZL1(3X0/'M\U17&4G;QLI,EG*3?(2\:F0_",/EU:$+5IE
MJ"(%8"Q9:<N]VE-]']SD]M:WPLLA`AXTS?O_+#:_ML6+Y>!O.<M$HDQ;C7"3
MN%Z&S)G13-#5#!K6;+`V!HJDJ!0X)AB@*!@("[%$)NH0BS80Y=,*PCG8R&6$
M8V5NQNLX,(XN:X]`$`3UJ&<>#3R<H=)$*[;"+A>HP1S\P!RH81MRH1C``P6'
MP#P>26T(Y-6TQFMNZVLT29(*Y.Y^*VV$JVT&;]<L!&YV3=`ZI&Y^C8VDHQ=<
M"=E2!'!>`+M.9):TB]EHA/.@+=NT3/GH[=IXK^8\CX668OW84*7:4(9DY2/:
M$&K:</T0!?B$K]XR+OY(+PWW+:IZ[PSY\.!X[_/R<-[8:_KXHN52BL8D@N2>
M[_J.+^;^\..$)?H@_^[Z2D[T\&T0A\3@.D+]%@!J6J+Z*I&L`C':#+$3UPHR
M/,((W$<$AH',P.S_Z@HS0..N\`JOC("*-*;HY&S.&#!D8`#J:`/J$FOJ<*,W
M&JL@BB.Y+#`X-E#1[(:RH(L:W:C1,&OL%DFT;A`"G&$(J`$#,,`&GL`<R/$6
MMB'4_"AII`.<6$T(<<L'@5`>`6\_9JN3R$9!9DVXV*;P)D24QF%N3JD@G4N-
M%`\"8*`"6L3R7J!%7B!%`F?9F@T,!\X0QVKW,)*83B[X+`?'%&SX5*S(<*P,
M0V_WL(W@M*_X6-+\Q@]S8+(0>\_$5`X1*S$OTH(Q;*P4%S&&O$_&:A(FM?\O
MF"YH$2/1$34R%<LO*-FKH421!M;/^[PO^_)-_CQQ#`E1GW1A%[;2Y<@A_Q"&
MS)#H&H;A_SA#Z$!#`+7("#1&8U*@Z!(P-4`FSQ0K"1Y0-I"1-JKNC%H&\B)+
M`].(LJQ1LVSF`RFKU'X&/*QC9^8#[8YF/LC1!FP``Y[`#\@1`]31/!:):$@-
M.="&[_*.DK1F:S+MFCKA[A*$;$[3;"!$UGYC\`KOUBPD((4C"I7CUP2-"D_`
MNJY0!1[R(4_@(2EO]5IO\SA/%6\._M++#%/R#Y43)06Q.:'3X/30)"_2)<?O
M.962_I3S_;`R%;\3#=T'YJIO*WPE(\I3)_%0*)?_DQ)_BD>,)_PHT?=.;N4H
MT>"X[:7>@UJJ3P2XLC[)#_32T.9\"",F(C*^<C)T;B*`SLR&[JX$,$+S*F,X
MAF.FB#4&BQBG[A'T[`&GCAF=$3BTKM!(=(XJZT2ID0,ORV<TX0/!XT7G;CS:
MH#R*81LD\S*?X`QNX3)OX09=RT?KZ+>N:1SX0P2TQDCI<1[%AN^RQN]6LPC[
ML36/4$(2;]?@)B&AD#ET32$9TMA6Y"&/K;JXL/5B9&_`T/-L+L2B\SLW<?[L
MLSKA=#[W<$VG,Q!7,D[Q-$_AE"9]+\4Z,A9=PB!:HDFBLB-@RJM4\4^'DO?N
M[X5ZQ1%/,N5,CSH%$>5<_XX4GS)8Q)`H.?$J-U(K]:6(=/((\F\R@"Z)/,.N
MTA*O@F$8!`N*XBPN@X$M34=#N^@N4:88=Z/J!&UEU,@X@,-7(>O0JI$P4?18
MR4[2(JTY^,@Q82L7+O,RJ>$&MN$6K%4=0VO4&&UI0)-KE#1LC#0>M29K4+.3
M9LTU!<_P$*\7V#7QV/4)H^LVWV!"2$"6K.L%!`!?CXWR8`3S:,G9O@LY:9)`
M!71@SR\Y44[W+@<Z(S4E61%/'U9/)79B*;83;3(-IT]8J,(G&\/Z(NXZ_9`]
MT^NEI/(4V?/>'L53T50F1+%I,`S&L#,FA4\\,=+^>H0K(>,K=7)B;'&)AFY5
M)?]TBP0K8[(H-8JN`45&9`XKSY*1C(#D5Z%Q.%C&.2A+9N+(6$4D:S<PTN2.
M&<AC&XZF1GG46MN@$&BA6JUU&]P!:0#)/(X#DH:TU;HF2?=C-"4IDQ@$2L]5
M;UN3UL9!UW*M2G7-UU+I-GOM-ZI015[@`S;E7E.$-_NUELR4\RZ28.W38?,P
M9#V28C<Q3HV/3CDW=$5W=.MM^3;U$1GN&C0-^OH3XQ*5)5>R.:G")LKA9%]R
M4KE3)K.,D&S"#M>/H9AR9:UR)M7*9K?R>/DKIG1.5)?H%IM(S791+;?("-X2
M-01+`5'#Z334+L/(&)-Q+P<-6`<-.9(+&JW61"<+6:'_B]'&CK,PZP3I@Q;(
M`Y"V(1W3M@T*8`C.=ANJ%07GPVWSXYI,,UR5M&[C,02^:4"HJ1_59F\;&`DA
M24IO34.("Y+DIO%Z;0JA8-AF*0OS-5\?5]G&E#B5YSC%$&$M-R.#EV:U,U%N
MHG:C2LE8*%$:2OP2)21E`B3#)<>&9"H0.&4+E(@*-.`RXH:#&&%\R(@)0XGQ
M`HES^(4>A885XS-Y&,L2#(8P2IPDCIRH+U@>#H?7@L&$*<%@6!=N^$EP>"#\
MC>3X38P)!B<8RB#.6%84;.*H\EX@KFF:)@2X4F4#5&:KDN",=RO#Q:V&0><4
MIF>1Z$'3,FB-5HJTX9&+0"Z)_Y%[\4SJ,'D9BRM8H5'K@(-EIA9]P6XPK=$Z
M$',:05`^NG$\P)9HT#9MAP!_W6$(^+=:W8%J--/N$/A(<<M(<0O5J&D?TW7P
M',36U`:2;,WPV/4U?Z-=3>D)S0A#+L37IN-#F$N->@$'&/(W\]4WO7F6(+=?
MM>M,^>U3^7`IY?1/`[$F,BS#8$X7VCG#C">'UP"F*D)392*>H7(BTJ^=.2S#
MA&44?8A:,HS#DH+>1`"@AV2CYEDBHO*J1I$&8#A<^%-?1M&I/`)J*N(CVAE2
M^:LW,D*F_CGBU"JBY?DF.F(472*C:6"E]^(G-:P!-LR@0Y&FBTG]W$.J.`PC
M1,"@9?]%PS9,IM>/2!(::IB))H!:IK=")GA@PV"**S",P[S8)B2L/&-"_8P`
MGU52)JT29,WY77B$*R>C$]8OJWE`B1PT5=,L`",T-9".-9#N:&VUL"*P`2QY
M5QM+1%E&KP<M6-OHKT]TE#O0Z_"(6<,.',V#E<O#'7+A6F6P&&BA`';F;&GY
M&&;Y?YU!.2!)/[[I2"^I;?P1USA$C79-0S2$0D2)N:ZT0YJ0.$Y)ZS+$0W)-
MT%0ICAH+!T(X"_'5@\.47_VUA)]-8(,R*U&N8;$3_M[G!5Q@MRLH?9R`GEX@
M"Y."XD:`%.+-C$G`(;HB!+R$%/#U"FXBH:/;4S0`7^O$?1K_P!H,5`1P8$U^
M\[QQ3B+,Q04:0%_(@0>^P2%J]QJN0`4F"B-"@`2L@0$.FD=4;PWBZH->H`*&
MB!P:@!3JVXQI0`6<P#>OX"$F0J1.@*2CQPFP\+K5B@1<P`6"DR@BKARNP`/,
M32+R5:)_J&F81@"JH:2B@0^V(@1HX`XTH"B$B08,8`1PP"5$@`3D9Z76`K^M
M8<7=1P.LYZ.<H((89PU&Z@H(`WH$(!':B0)4("G6(H1&0+NOP5J^@0]6@G5X
M_"A@JOHNJ#__$V'G=&:/6Y")CY#9RH(R(ZL5>9&?-\TBE%5?U7J'%K`$JPCN
M[))CXZ[K.K&8443'E]&)`P,1+1NO_W$#`SM$+@N/,(L[6LL;OV,(TE9^BP$$
M"J`<W`%LSY:.7(LS1P2<,FV7^ZZQ.(2-!A.5LY8Z/L0X?BVV,]@:F\N:KW8*
M<5MQ\W6W!4!3BEU,,2]R+7+?+-='-++$K#,F=VP</H`HX/!1C,K(`V8!$DH%
MBJ(<LAO#W8</P%LB:E>%=@$+5.`G"`,DF@&&W>H$G(`&B!C"Q&HB0L`)/B"Z
MB7@\"46BCLA$'J)':.`*GKL!"OP:&)+'-WH-JJ&`(.@$D#BIG.`2638BA>4*
M=LK>T^O`)2(X!]ZEZJFEF<4]I.]0;2*`G``'VAFE$OH?R'R'>H$&7N`.P+L7
M0.(?-LBE:/_@'ZJAOM="!/C@&P2`6G#`&N[`NC-"3JJA`NZBIP7H!1J@H.-M
M(\AAP#K`J!)&";[A#I3`/5+O"G@<K&!J)32-!\*2XU]WV[KZ%%,8K"7C(V;Q
M*Q/Y5,E!K74Q>O$*&M[:K2WTD1_!5A'++G%UZB2:0J3V5\<7TDV46..(9L`.
MTMRH[+9QE<>#U(K!L1D)'0I`$V:9EK>A9_ZW,YF+L\OA2!U$.B1-$PJ;!!E-
M/F[YEG>&CAA-CD"D&F\?NBA]`T_Y.!0>173[7C=%7[\YV6F)G)O2Q#B.%7-O
MA6G.S=OK?@YZ875!`TK(XE(Z&AK@(>,MW+M"!++]BQ5C^QN@C&G_I1HJ`MU,
M2"3?I1SDI`&PX%EDXKY'8/M5P((J@!_$72+Z&R`:7'&R0)>N:P8K\%NS"Z'!
M:T9(.%FCHL("<@A%D&!PY:+!APM>G.CDL`$I`30<?ESY\8H*$@MH..GX\1H-
M`2?6:%@C(H0($>5X^/QY344T)R1XT%C@,`2-?PS6K.REB\:+#E=$Z%I`H@-!
M@^2>5EOC4`2#._Q$7!,AA$^S"E1UK7'QMA="&J0Z"%@@8H%?I@;M5JOV@X\+
M$5>:3;/6C(0('IQ(-+AF-R:--7Y_/E9)M3/EP+KB/OPH&C1+T9]%VS7M4*7#
M7;K(B3`BX@BY!4;(';'-6[?N84>`#Q,^_WP8-./!C-A)$:RYG>7/E1<Q\@"&
M]>L-8&3?WB![DNW:PW?G4:Y7N0!0`D#HI:D7!/3P(4`H)_\]!$WU-:G'7_^^
M?/['_!<@-YH<PPT$!D+@#@0',L@@-\4,(>&$[C@SQ"VW;+/-$,704H`F$6I(
M"S<D%D,B@NV5,TXGXX3022<AC%/.C"V&8&.-G903XXXU]JBBCC*V"&2+1,[(
M8XP_SJAD>4S."(5Y4,@'!7WED:."`2\(\$*66VJI@@#\X*3"F`:,J<())ZCP
MSYILMNDF::$=I!I+",7569QWQFD:2P_E"2><:ZT1#0\8:43"%>2!I<%,.%RQ
M1@@(W?;-&@WPH_\"5R_0\)%9,Y&`PZ,KD</)"R2LE`97U3C$U0AJK=3:0;`>
M1,X+5UPV9JPA\#!I`R=4($(%*F@**P]GQK0.3[HTI$N:9"F;;`@+N.!"!6N0
M\]!M#0#KJ%8&A70"M]<L()!"#;2JTDI7D')"HPPT4-!'G6#AI5KD0,N79AB=
M$$TT##A!2E94B?`4'U+%29E5=V2U%0G_:%#0-3;]T\QDH2W`P`@5A)#L&DY$
M(X!#<ZER16`-,-"!8^*2XL(+/"`$<335O.!$5$YH(',U5Y3STU^RQ<0#;GWQ
M==%G?.H)VIUSVHGGT;$:79JK!CD+$5\8&4%;;+WM1@YQP17G-7+*V>'_7#"E
MV&%$,'84\5PPU5UW71+8B2<>=]HU0,.,\*5G7WWJS9>??_\%_K?@@P?>(.#X
MN8,?-P9".*&$W+A3#(;A;-CAA^X,L>$V[I1(8H-3CM,B.2WFJ&,G"[R8^NJH
MOPCCBRZ^[J*+I<?(8HRBBWYD[KR+_B,4,D[Y9'O$W\=>+\.,"::66W(9Y@LJ
MO!#FF6.FB::;V+>YIYY).]WT::PAO32<W8<FPAHCI*2+"`U(U(#&!VE`BF2<
MT#`,2.FG?`4)F78F`A\O:``6&M`REC0@@.<25ZHRTH!O>*1IKOG(;:QQ@O:]
M@`$/S-4W?L:_1IT@);#9!19<4,$&6*,"!;S&_RXJ4,&/.(L<5YB&8V#CD-NL
M@01GJM9!C`"]5AU$8+QZ`4]@\SU=7.$%%>!$`\XDK(\L0`51J4E?IFBM:^BK
M&:0X4[D0XA2H%`PT-\&*6A:``Z^\*RS_J,8.RL*';YS`6KHH635.$)>YO.4S
M:S!95E)VASM4"V(AZ(`UKG"":JC@&RH82#.RHL)KW&8!2EG*SG[F%X@QS4]/
MFPKX:F*T\1&MDRY[2`BG:)O90.P(NLB:;FPCG.!T;3C0B&78@C$,L:6M.6A3
MFS;8YK:ZR4UNW8'!=WQIMQ#T`CUO>(_>_&:?_?3'/_CA#W\(%\V_1?.:"#H<
M@AX4H<=Q"`(7RI#E0/^`N5QHCG,D&@*)`K0>%9&.12((TF.42,\&U).>6+AG
M=Y1HSWXJD5+Z!*@_N^//-4"B$YH8QY3*,25-0`$*#I42!*9$CA.`B4O0DYZ6
MEE>FY:6)>FK*7O:4IC36U(2DH4E-G?[$IY4^+2XK/0@/[`$3B(UC`8EX7V#X
M0).FW29]X9((/S)5%HZ(P"[G.L@!2^5"KC0#([L(P1JL42Z,C`:"W6H`'TYP
M!9=056..U!4/QL&#@4"OB9T@A4BZ*C.R6&L7S&IDJ'32`#B"Q9&.;,!,5)5%
M;LG*D1:SR+E40L@&[*(<):/80Q#C!*W$I6<^K&@T7%`NOI3#(`+[!U5Y!K'_
M!9R@`Z3@P?D^*P"M0.PI$Z/,6BYV*;\(H!E.:,!#0C:R@]SD#A/Q2P.B<0<:
M:$PV4&E?,ZKQ#0&ZH!H6$4$5!1;)>]&`!C]K528=`E.D?3)/XDLI:O3TR2)*
M<(J.-*5NL.8;K7'M:\<91G*>H][U/L=L[\5EV]P&GOJ&!YAU>P!0VB.?OM%'
M/NYA3P`"<)YRO&%&!U[2`<IQ@!`TN,$VLM$"H$7AOUAX`9I8T($.U+AN3BAR
M0PB'.#GDH3>X8T.TV$;D(/0YX^EN'-=8D8K(>@47D,)?TI*`"YS@`AWSV`E`
M[K'*_"6!(`/YR$A.LI*1[((K0(*A4%91+YX4I6KJ_^<(5V)>])K'I8M>R4QF
MNIY(L0<:Z@;&S)@LVI]4DYKQ,>W-5+$B4N[%@W;!3Q<:0)1F+!DNH(9+`-9P
M01-#P--[^?`C#?B`8A&BP-8\,2I"\4D(B#A8'M`JGG]^P0)H*%;`OL`:F3K(
M+FC`AW)UBR-&<`BPRO43J!YD#01K34.FR+Y_T9"'WUHN7Z"5YTU?]2$N>1];
M8GLNQ#BLI42TB[Z$R*<N1H-672T@^Z(Q@OVIH!DCX(1CG=*!9I`%LV>A+`E(
M$8U%%H0J=JS`9\[7#-R>X%#?2!]8%^!%CG4@*@UP@2K>R)?."FPIY!!M3/@"
MFY)F%Z9\0GBL.#.5Z[+TJO^1RI5O^F*;5%Y#E;MQ9==>"<M9JO>]S$F;+ITS
M7V&Z#6[9$>9VAAG,EH>@//<)P#3926#SV`C"]K+P<R^SAIX+4(`D$,(5A(XF
M-`G@`UM2F02<O*`%.<AQWC11.+=!BUR@@YP9IOJ&.E>,0YBH/N;)W>W,,PR]
M\J$P?)@&`_BP]K:SG0%P;SO<WQ[WM]/][G'/.]PUP`?Y84&A$$WH0]GCGRA-
MM!S),\!&N:RE,(5I>=2SWIG&3&:6*BVI!EM:G#.924YF?GM7)<<:!#"SFKG@
MVW9Q02+BK@$:5'$!UFC9847@A%!C=F9LUP`&+TLR?L@V5N)B@%4;0@X2N&#O
ML87_5`@=THFI>B2J-+"&ZW6!NMA?7#8,^"!LR,%"]>V"^]1*UC4&D@B^M^M=
M1^`80U28+*[T?5$D2#5LGNBK2$FD[QPAE"5IV$B)]*OV-.!7!]$)QB>`#'<0
M5Y`(*-%=3C$8P]4,WG94@<(`T?`-U4!L,,4#U1!K`=,QWV"!,^%;HK$&%U1;
M8/%$&E`-^P)J!=2`F4(#5Y!G/$""V6<$F0%8??$S/,<7W/-K#^<9I8%=GL1Y
M<M)2XB=^CX$1Y&"#%6<MJ)0UMO$;KO0UPV`$/&`V'U<V8H,V:X-+I?`(](5?
M]@4><U,N2_(>`N8@`:`1'\`\'D`*'N`"'O!C/N9C1L9D_S^V8SPFAS_VAE>0
M8?W181+2!I`3(1BB(216`,>0.9O3.5[78BFB.S,F(V6G`7QGB9CX?HOB8X.`
MB9YHB=)2,YNX8YXHBAK0B4!VBC439*_`4.,`.+!((/Y1#E@6/5O&>%WR>)`7
M9B%%>6RR/6:V)W'&79JD4M5U9D,HC']R#3YQ859U$']A@T,3*4,#$N8"C1=V
M/ZVQ9Z+V0[X&*[NP,Z7@%Y-V5<HR&\](#K<Q#"XS#!<!1[>A7"[3%^2P?>M#
M<,G2%^.8&4>P?4OH5RIT!/KH%R0A053S$*CS%P4I:H,5-+A1C:Y"C[^V&G$R
M17<&4[=!23?X$/9"2?#C,H\D`O^4YA<:*8^DT8R.!9)!0TDF"5@Z=Q%]L0:B
M%5X%\4@Q@1D'62><$8QX@GG#6(0^6(1V87!%Y#(VJ(2B!4='<''7!X4;1X7#
M,1WOI1QADP)I8P3,P85V4'*]E')D"$SU]7+G$1_H`0'%L!XWL24>X`$O,`]L
MN99K^0)P.9=QZ99R>9=LJ99ZZ0$"(`2:X`P*$IA0]SA2)V*("`+D5`XG=DY<
M]XA@]V(P(B/E0`YZ)8I\<)ELUW>THBW`$HH"\"4R4T$5("T!M`4OL#(RXP*?
M.29.(`#2X@$J$(>UUXI0)E'/U!^3>272PV6,%SW+(R;\4"9IXHO:PY,*=U5!
MJ(P1I&;_!]@GSHE5CO2,9?9]T3E8+?4JWZ>.W^<JQ!<UX"A7KZ*.CH1*KW&$
M#<%^1+24$$-#J"0KL>%JVOD:CD2=#:&>OO&,]AD;R<*0XQDUK3%\U]*$['>$
M#*F.PX<0SD*@/H@:ZHB,HP$QU6E7^ZF$L3*,5O49Q(=7=.*?500U&6I5&&EH
M^N>2&+$6E20;-D@#M`%'2954Q[D:/YDGUQ5*WD61+%%%-D@O5+.4];D+4'B?
M4T@<QE&%9J,<9>,<6C@V1\J57]D`<&,=W@&E90@43J(>[J$>9VD3`C`/6C(/
M78(#,(`#./`E`E"FGRFF7W(%V;*:`E`!.+`%9O*9P%*F))!A_XS#((+X.)(S
M==M@3B6VF"G6.=PP!()Z'\!#))U`.I28;T`V"/TB,T[0=XGD)8T"9JN92)Y2
M`17053B@)5>``RNCJ1612%\"+'&H5B00/.-@'L?C4-$$4>\A`LK#F[FX)8\W
M/9<ZG,2Y)K#RDVI6-*7Q*B_JH'1RG)[7>1#WJ\M9-`E:$\H20;(F2F#!D.Y)
M1-)*0]>Z"R$D?@U!0]T**XW4K>'*K8UD+>;:C=S)K?KIG]OJ,L\J-2XD5]A*
M1,IBK9['29@'*+_JG*]RKT;X:]:YH?]JH8:VD3BHCGVQHCNS%);4JSVHDU##
M20H74X.5H#X)K:1T&[EQ<>+WA$X8A?\9-X4<-QQ4^1RE``WK-7)<6`3-P976
M@7)2FG)U0S?9H5]C::7Y<2!50:99LE'=(1EOZJ9BB@,-\`!B:C<X4`$-L`5N
M"@.>T@!)ZRG54Z<-LF'I-"&$*'6W4#E45PQ8QXA;!R&."6`J$B/U(IGLLV,N
M8(G00XI.P`]C>B:-`BPXM"7K\@J;VE4NX1*)A`,O8`#`@D3[<P6:*@`JPY:<
M@%"K"F4/11^&EQ_)PSS,PYL;Q5$J$)QAMJN\^CTT>J_]6I2<^Z_?\Y.8][D\
M&;`V&K!&B*WFBJ`2-!H=NJ[[.:'J^JW;RJ((RGY+B4KEQ;&\$2G]V)Z\87'U
M&1O?>JY0-:#_L@N.^VF/L0*OX!H;H42CN3N[+9JL^=JY/OBYT0N4V;M=&YJZ
M-6&B^!*/512/NQ8N:H$Z5*2ZUWM2$;MPQ:JL0;E]]%@O-A@I'/M]NUM>OM%*
M4#D<ZU65\94<5AE?;0.F<6-R7CE,84A05'H>>M,W\K&S9*H\*K`&C5*T73"S
M#;`##]``74`#4$L"#_"TA_(`)(P##U`!9:("6/"7"\(?$.)A$M(Y?.JG'U(,
M5*<Y):).D3-1[?%BOH-X#2";BP(]-2.IA_*I>JNTIXFJ756F%2`2.)`FA#LF
M4]Q5W>$2TB(M_)"JPJ,D$`6KT/0>D3NYM"H]NODE%@52O4B<6"6P_T$9NNCJ
M7<OZH)[7N<O:KZJ+592&K4<XO=3*?I'RND3T5ONI$MW92(VTNTW)E#SJA)&B
MK?+:GH^<NY1<GQSKNX\L?BQJC\X[H-]JR-XJN^%JRO%*QWB\QY2&O?L*L'L<
MOWG,N;)!*`0I*T)10S]3CO%80_T&NK0<OW-LQ_DZRVM!*+)!<?9(R:JT-5KS
ME!QW'-`0-D:J-K@$<KGDLG&3<D^J<F)H3.=Q3.L1<VC(`W-*N%Y"`S@@&0VP
M!C0`IR1``P_@*`1EPNW3'5<\PO0,+&9"M=G4.(-I.8-*#2.&F!\RJ!J"3H/Z
M=2[6.TB2MCRV*'QIB7S@!"HPIM!#M(1[0/]Q*`#C\@(JXP+\T%7``K=<!;5+
M)1"Q*8<K\PH*I0F,.R6W*1^(IWAKO"6^F5&7>ZEBHKG_,,STZUVL+,MZ[*'O
M:]3^>LRN>\?/>H1OI<I)9:_VZKI6A;S!JT+;68\3"AM/J+L'\83$>W$^6H\^
MFDK<VH_ZV8]O-<F23%ZBY*[^.;OU>LC4*JX,V:P*"KK'3,S#O)RU[+E!":VQ
M44D/V2I_85J%K1;ADJ/`?(UVO+U'7<QY[,<W2H^`903.`LG\VY2](85".J2P
M-!QV4`I:Z1Q%@,U<R)7?W)5B.#=`06#O@1]]LR!5,:?940&?&4D/T`4J[!(L
MK,':TC[L3%`J7+3_--`%.%`F91+#)R(?!F+#-VR(&5)U0^`AFJ`YUZUB.-QB
M$]4+O2.992>;D;IVF*D!)2W2+O`*6!!L`K"68:S.:IO24,O1A.M[M#(F8QJ'
M'A#&,C)E#N6XTA0X`9`\SY/3.@T]97HF8C)YFAO9EOVOW"N_DNW7R5KA&%[,
MG"NN[WKAJES7I]RZNUN\2ZF?[(G6NSO6VLJC9-V_P<O)7\T;/OK))*Z[S1S6
M38F\Z#FMM"NM<E7(I3P:@ES'%*Z]W%NZ13W9`9O'\1@"M,&,05,;/?-=0,.,
M^0L6$JGA[BNP6U['T&J#(;"4N+&>TOM]9:U*PP#-0CJRZ86RR:$VI9U+_Z>M
M-B'LVKUD<MT<L^]#&>>Q'NJA'@?2"^C\):!Y5DEK-RI,MP^P!G":2-U1"O!,
MPN],M%#;PO^L"0VB80SB31PRJ!F2(4,``FWP(1*RT(UI(H`Y'^#=.S,BT6N[
M*.6]*!DM$&+*MR6MMP+@$J?98XGD$BK#MRJ01:1Z$D=D8Z0R#JY:M0H2Q$XW
M'\F#X%["TQHU)M-S`D`MV$-=RQ/^QQ7>UY$-X1$[K]'+?AT*XE8]U_1Z2F1=
MCV0=KC%^O%D=O+J1XRX^GO3>XI+<NV(]7E4DUOVHU2Z3XBR>[@3?C=%JR`=!
MRMR^[:*[U!D^X=^^O1`Q27AURTH8-&#A$\I\C_\/$QM]<>3$W.5T#-CWN@OW
MHH[]]JU8D\G^&\VM-+*P1,T?%S9PCMK/H0T)?.<HU]I.FN?=83H!IDQ8NAX\
M`*=F*BW!0E#T3%`B#+7`HK240NE0JZ;M4P$D@$-G0K4#(A\U/"$$S:?;<#G'
M4.HIMF)`?"#ML>J\,R/CS6.#X`1O;XEO/^V%WB5E*M)JJ6.HN26DF71[?YIJ
M"<8P+2-";,8U38N@J<9KC*MO_,)Q[(O@3N$A+]08'MBF._D.+^2:G]?]6N[1
M"D<J[^XJU._F&KQYW:/O[N+SGC7TCA$>J_HCCG'LWH\<[KN^L=7CNJZGO'"G
M+&OC6IY_7-G=[J\//\O_&0Z[!9N3YFNB3VX0T$(O":M<LM)J#B_\V"[RVSL;
M\H@;KK_(/,K6:+Y*`!S:;1X,;OY>5YFR6UCG;_.R#QPW+%<WD&(>\.$>7$_T
M<_HE7*H"3`\0)!I<@4$"!@X<5U2HJ(`#1@6&.$A`E*BPX4(5)#1Q@]#Q&#>0
M0T2.',)MR*UPMVAM*T:K@":1VV2ZXU;LD#MFQSKV*C>NU[AQY'R6$]'`A007
M3IPD3:K4A8>G+D@Y@2J!E%076;5.A7H5*RFO+SR0>B&V[-,7),9I@@*E7"\H
M$#1ID@L!"ET(`<BI$%#6[U\5+P(+$,!/`,:%)U3\8]S8\6-=D:]%IBRYLJ[)
M_Y@K9[;<V;-FSYQ!BP;]6?1IRIEW@=Z5^5IKS+!A3Y9-.[)L7>1RYSZBF]R1
M:T=VZ3X2._COW[MZ%T<.?/GO:\VE/Z<^_;ASZ,ZOZUK.G+OK[\J#OZ:M^K6N
MU;IWP]YMW#UZ]*A-I]Y\F3-X^OD_SZ^/F9R(!0`4@1QR`M0MN@!%,"*$`@>,
MK$$1(FSPP`G[TZ\T#$G+$+[2,OMO@1".",&(!71CS[?>>(NNN]^&:?&(86`<
M9D9H9ARF1FB"&2:88.Q(P0X@?RS"#AZ#>>`@&)*$H8$EE702AB249++)!AH0
MX:VW`H!"RP`Z@N`:'B!";*$M$*K@S!/.A`@BQ50XH?]-Q.!L4[$3-.+('2]!
M*H:D(=S9\Q9`96JI@&.&V(860_4\I!B:Y(+BIY]Z&FH8HY:*"BI,I1K+4K)<
M$$M34L;R`*JS//BKKQ<,>Z&OP_IR@1\LQKG++5KC\K(CNO0Z["]>_2J,L%]5
M,`"CQXIU;,/0;NO0PF4OO._"SIYUED/45K--,_7(>S"VW6Q++SYKM2N./._&
M:TTX=,6K;MWIVF7W77>1&X\ZY<A1M[5S33R.N_:VC38^R6`[<+72V.,OV?RL
MO<Q@#`/^]V#_1."AP`4G"X$'!W/C(<`',?9P8Q&L]?C!`%TCF#.&Y5,8V<Y6
MON9BZ!988-SUNL6NNAA;C-'_1IYOK#&8'*$Q(A@C["@BF"&'+-*.(Y]TL@$<
MHH2RR2B9K!J&!Z[D*2^NN^Q2ES#79&@A,<D>VTVSQ59S[3.W:$A,.W6JJQB3
M^*3[))FV$0F$E_;,V\]#^N1H)RC&Z>DGP\LAIP&H/"T+6%0?'VO5P`)[O%>^
M'A\3HS0A:B`P3U]9BR?#9ZWK](Z&R;Q7P%85C*\3#$/;6-H3EA;A@^7#73Z4
MD5VY998UFZTVX2<K[]O5=CEWN-SR%6Y>Y>J]^;IXUSV"Q>NO_ZV[[+G/OOKF
M5-0N^N?.73&WX+:U-GE]'3;9>&HO2[C9WYO5';_/ZD?M")FO(7$!(Z!'9OV;
M3($6_S"9`8H`6P!$D,Q$4!X2W2YXNIN6LTBDFQ$M@#W(VQ=QFK.<G%W/1C+B
MV<]^5J0>'6U(1.)1*1[A-*=-:4I-HM*2K/06")3#2WC929A44"8@(F0+5ZA`
MF1""`R-NP6T52`(.,G(0'#0@"4RJ4A)XX,0Z;00"'-&)GNQFDD!M(Q>#@HFA
M5J(HNN&)+9`"RN'*<0VC2,!4KOL+6EY@QU[-T2]S[(H>65<63/&C`>6X2U[P
MPD-NR`T"QSB""E3UQ[+(+E6M0@SMC,6R\V3H9,I23;,L<S)0[H=;MJD6?Q06
MRH$9#U_=2D_R5FF^WLS+7*]9CKK`1YWNY;(WV^.E]EA$(/\":0^8V]/E+:U3
M'.R$ZS?H*\XKCS?*]9&'/9D\#\JLR:S3$`QX&NHD_EA3F@*!C$`)_,\%(^;`
MWLC,6A\"X#@U6$``J4=_!-L@LJZ5R0T%*$3DP%C[5@D<YJ&K73N;$8Q(:"-H
MF!!H*.R1'8PPI!\!J6E*,@@,E22U&E)1!$,)P-9ZT26=]")L1Q3BV\XD1"*R
MK8@0&6)"6GK2BZ0)"S11)$WV],5<A!%1("A$&?\&$IJ`9">2.ESB>D$#`3PE
M5%_1"E:8>JFC9.4JC?.*5*,B%E,Y3H]7H`%;<!476W7D3H-3'1U[59A5$88O
MCA0`G"Q9+/@\:V6GG"!]-KG)EO'_SC[8A$\]NQE7]Q30,L]\)7&&,QSAV$NQ
MTI.>,8LYS&"2PT6]<9%D@?F<%\$HF#'2[#"]USW'*N<[B66F^9"7O/($##S:
MPLT]^6I7AP',=KF+'UXM$P*)D>,:T<GM9"16HMS\9V*\C6!KA*O;70#("/#L
MGR:G=5=.Q@^PK2'1`RM$6/&-YX.3[0Y!2T@CA3(T&*7P$9"&I(V)6C2&5'O:
M#0-0C@!P:4L0*$9>>+!$E:J)(6LZTW[-EC8`HTT%7*6;6,5:$SXA&%"W$.,0
M7%(H,V[#BWCBR!J+&JEQ0$`$:^`<VM+4N2N@X`HCQH$0KH`0$I``!U@0B$"P
M4*4&<*(!_VN8,8W7<&,<KX$&.J;!`CK1"Z_BR<#N"*K<`B""U;U@'F<53*H$
M8X##"/BMD+EG*)W+K=ABN91:ABY@N>SE;48W-<-KSS/MU4IPH2\\U'-.8^'U
M2\]F+V>3_2`Q+6M0[0TC.'3N[B^%&<PWZ[9\!.*.O'HCVF\U#YK&&5XW;2N\
M3T;:=U=>WYC!#&DM=\)`_C$0.QWT,@-=`T";1I!U1ST@40,0N/.Q,J;Q5\I4
M=T(7PV#@;B--G-<HMCHM0@Y!#TJC&RTT1^(%$GF/9J09.JFBZJ5BE6RX42Q!
MH!=<VV)>BD)2%:/8(2DN"-1:+!`8A[M*.X`QN<FMXP,,02XZ^?\(@K]X$@8?
M*A=\<T=,9A(2D`P.+C[A"8;+48X\T&#'`B<XP1?0XQXO8&,;DUDI&CY`3?M8
M!)KNQ,0GW@F,DZ,3!)(44$Q7%V[P,$^I&PPD7<>772VD,`N9\K'F2LJ^RE72
M,+^-RLPC9M%4>N;2-4TTIRG;U'(0H`!%#KYHZ=A<$I.S?%8Z"+?'73_G,H23
MS1FOB;E+T+Z+EMPQ^O.`DS[DH6>5J=V-;S;4:M=:&3=GW_FC79N?4I.G00!D
MT*:'$Z`$D<,(#S0NWB?.OU$':+EKKW(%8TXM;7[H@1$Z8'OTE3S>)`>7O=S9
MKV\$WAT-F]@1#=*1'/(DC$H-HTF:H4;_L?311TF;OAW1A0@*3@,>Q%[V#E_X
M`/^7P`#E(4(1"D$(7K;;<KR!R"/?HKM'4HP_Q3L7(B%43,Y8$S\-;HT^H3[B
MVJB)?_\;^W.92SFPG_V>='P<G0!*^<=_?O.;7RC4Y[=/V@+D1]$*+K/BOB;>
MH+K(L8X?399=8!0SK,5H.<9P-3#[JYVSM&\J/"WCD$K+)MAR-<A;+6Y1#PH4
M.[$[CV0:NEP3J#<#+<BZLSHS*!#$,\G*LUXS01>9.E_J)<HZP<O"GG@IM$.;
MP>C@ET0CGC+3#&J*P,W@0;>+KE#2G]IR&+KB%H41$'W9F!!IO9$)#I!9C8MY
MH([AF.@`&8G9_RV\$L*XHB?\^!TLS*V[,P)"TQ9%RY?=>#/OLCR?6:AA&!KQ
MXA&C01H[>"'U<AJ!F!H9>C:?B*\MT80N\1(NF;:.ZH@_!$1J\QI"3,0=NI5#
MNI73H0N<((DV&(*[T:EY*X!Z.Y1[.X1\$S(VZC?KTSB-&S^,VZCU`XKU(S_R
M"XJ,RSA29,553,7T*[_"@0M"(B3XHS^[V,6XZ(4_2+*R6#)?Z0N4Z[]*$L!_
M\+(-,D"_`L($%+-EK+E(<T"`<3MMNI;'(SLSN\"N6Q'$0KH_H[IB$L$0HKP3
M)"%T+"C.$J'GF#I>^YZDPYXW8ZRBRX[S<":@6Z4#H:;Z^$'4$K,#E/^MN2+`
M!^PD7>@$$ED@O@N0C1&86ON?Y2*9P7.@XGK&?YRNO.*YY'J@"]*M"'(/?027
M](DL$.*>RNN9RZN1S'M#AC*:'YFHSTL2@QB]IR$]F[PAC\J++9DO+=D)1:0V
M1ZP+D5M$N2G*15HDNN`A=O,BDE"PE&BP!S,40Y$P1JD)Z2N<1Y$57/P)C9.9
MVG.X!0!+L(PX'_.Q4L0XA*0XAT/(LF3+M,2X\AO%59Q%K7P4NI@577"B_&.=
MRA&,73F!M@I``21(2%/`M(NMP_PR3(/`^5%``F2M:GR-L#.1ZJ@7Z9F7Z?BS
M$NPERTK!=C0HG@%-=51'T11-&Y&L$:H\$J3_.F"JNLKRGA@DND/3M:TSD;%3
M&%4JPGMDS#!#.^G2S7[,LK=+M<'C+0<B!]P"+N/LM'AZ$.4JD8X$R()1&8MT
M3J\L$>*,CMI`K=48M)O!NCE#280"MH5BR9:4*"1YDAE:-HMJ-G*`+QWR0UQ!
MG4)<Q$><3T9T1$7RB,&Y$R]1)(XP/I)(/IG8J9ZRMVT(JI+@!D]\%%R,/TW@
MB8Y;1:)J([JDRU0<!K3<4+3\@[D$BG-`Q7'X@_(+T7.`@A,UG4+JA5[`@;UD
MLLKY%3@1S)93QIN;+64L3&AD#6]Y.^"\-!\M'H$!R?/0%V32%MJ4'AED06$"
MS3Z[.G8\2=*<4BD-_TTK=5+O.LV"TJQX[!XZ`[3,E+R1!*C@,#I\"<EL[!=\
MHD;"ZT%I[#(V54#"HR?N"`$&"J[<RHW?,I$(&2YV8BZ\`Y'[X$*-3,S3.`(`
M*07E$@%:X[OC*5+ED::BPQYQQ%+Q3*B5=$,48B$B$1+/HZ@ZG)J+<A(:"`&>
M&,1`U,DN`3)#^L/Z_$G4B57[#$JE/$JF'())5+!`&:.HC+`THANABM!:E#^X
M\$,'C<\<JHN>Q$6?"%&A,%'S\U"@V#B@(%$23;_XVS=H/8<0A0M;;(O[;%%@
MY)7]FR3_:Y4V0<9D-$R,7$!K;+MI=$:VXTT"_!:S<[PTRT8WTS7)"],71/_#
MS@Q/*BW--%PZ&8G2GCE8+,6S79H1JZ.S=>3,RN37>L&,9K(71<N6VR0[(YPT
MQ_PK.+U&Z33`:$FN`/FZ1B60YS0>31N0<F+.O:.[1/,,OR+4'"U2Y<*8YQ1#
M@,)7]:C,%938T>P9'+D\86O)-T3/4+6HJYDB&*`!<NBWMW"+5=5)KIDVU=.A
M9-U:^93/6$W*_`3;H[R5L>(3D2!0O1D">HNP!#6)?/.21_%66O&J0AK*13RD
M]\-*%OV)$*U6$34_$V51NYR5^).5^6L+0O(JD:,+<?T+83R5DVL5P^`'ED-&
M&Y7&R[U9S<U<5A/(ZJQ.?Y*F"40/LZ-!?$$1>WG_%^ZY,Q%LW77TM:6#W=2<
MW82M7815PRN%QZSC4JR;QWI,K&JJ-+-CGL=+L]AJ4P1$WIDC5-M2WK4CF`89
ME[F3D$W+#;\;D$"-D+U3CTA+F4(]O/CXD(535`#QT_;83DE%K,CS)7BD76`S
M6LTSSQXIDA3XU)B$(=&3$OV%VK>(T%6-T&25+ZN=-KS06EAU1*_]0[O53[)%
M/I&81$I$V^5S"71`T#2BQ&#]5@UV%!ZB"^GC1<+=M[A%41/MVVWE5EG!2KIE
MBZ3,6R!CU;9`I%L)`!=]T5ZA7'-ME6%15]Z$.2LS5#@=PH^5URVCQH%9#]8J
M4IMQEWW%+,KRP))$32O-_])TK%+QO.(K/EB#-<V$[<PG[EW8K"5Z`0[B4+04
MV<%%H\;/75,BYL'&_$V"=)G(0,(IU+/DXH&(K,(`:8UA`)D+&M3-)<+SK4'?
M>`V)B;TUP#LCZ`2,Z5E(/;HQOCKI.$G<Q=2C71I,%J_T6EH8DJ$',-6WX(DM
M85'5$T15+65JTZ$`N,M&S$_4`=L%#KGBXY,$909X*U!<Q<2IO+<%'1R[$-P'
M]:J.**3Y9.5"0MR[,%S$A=9Q0.$0C;]LU46[6*.Y/=Q8':N=<"*3(T;*H:1C
M',R7P]R,U-R!9$:0#3/8:L9V/>(C5IXS1.+$.JSE6-+/8M\[8TTM)E@KQN+:
MY?]G?\YB2AXA>[8S7F)BS+K,LN,Z)(Y4,S5>Y<6RAV;C-^W<><TYVJ"U!5B@
MB+Q.N?M(F:FXB:E&4ZJ9>ZU!XDDNVJ.!YXP]`PG),TW?=LG,H1W/E%Q)^=U4
M'OE43@8]_5V#]V11^"+E:2,D`>:2CM!:5;:5^BS$5I95_`1;G:";FTI;2KSE
M!FL#75Z)E9#JH!(RMIA:7&1A8CZ=N/`J^&-A8"X<0BH<%&X+67GF6ZP56VEE
M:D[<L:XV7Z9ARQ'&Q[T<M.*+_0/,RAU,=JTTG7L[Q!Q"'2U(Q'OCD!W=A7X\
M#_I&="E3U;6S=3R"/S!-+9[I?_YLT`[MT3PHA?7,$M3_W>E`K,-*7;`3W7^T
MUP5L5XG6S6MT8]J6;1\\WLFHN)GA-``:$,8K#NLED07Y8\JH6?BXUU1::,D<
MCO+=F%+`&-A#)]\X%S-N#LN>#G$L02S&D1RQ:9R&0TWFY&5S6AHB/1KX,5$6
MZE&^6M4[Y:U593^DZUGMX*]U1`6U&[3=*5W6FVVX!7=8%*O$%;F=6KN$6_M6
MW+D6X6\UW&9NYJSTN&^=6[AUE%^&O[H(JT9I%([0:TA"E<$(EBA3#!Y^N=>.
M5W)^1LY59^"\R-Y$XC?%0%JJEV4B$-6V'M1F3:J;XLX6;1__<?&L8H+-+(EE
M7^J@9\7BC>@AWL-;I9JA-,2&_V@V?M>><Q:1I0P%R6CCDI@0T%.'0ZY%E1GD
MJO)$$ZPDAKQ(M5@1H#V,.3CH'I!OB6<R76T<;]\J)EKXY9'XO6DC29+[94]0
M72\FX5\6[2@@ZR@`GC9%?^]#5\2>?%7\C-577=P\<>`''H)%@3<&RX5<P.I"
M*=!M6)2@8E"X?="PKML8MG`=*FNP0F81=O#X>^84_E96QD]4-QT9)G5?;MS\
MZ^O'V3^U$NS#X.$>Q='8DB?&Q(U7@C1D+W;&EFUEJ4`SE4Q=&XZC:V)WD<?K
MV6P1,MC1!G)P#_<@Y_$YX]T5?)>*#9_%VLV0?')'2]YW%\X=75.;'4CN[=@B
MS2`R%O\0$5E9Q?MMZ%KV3%)ND>0@AN8GA@M+V2N1H3NLXW`S\BGHA@6A+,7S
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M*0BNZC!:/JRN8#.ZA:IDT)N//U.'T`-GX6$&8&EC"V26%?#76Q0%_Q0F)%D1
M5K$52ET4.9JJ-KP0U[[P==<IU_U;*[7:8<MM=NA-[L$'"%VZR.G:5?!:P8,&
M=UU;.#`APX4-$Q(4R##A0XH6,QJLV/$AP88B=QTA1Y+<D5TF2[)LB?+E$9?D
M_@R+.:PFSILY=?+LZ?,GM&'0@@X52O2HT:1(?S)M>O/(SII'_L3\0PXE2ZPP
M&68]<LTD6)6[Q#:\2+#B08@()0H4_SCQHT6$;2>F-:CK+<>'=O%ZS"C0HTH>
M(LZ2X[%`A$$1AD4H#GEDKL.1UR2K/,+XJD*0(HP8$7%XLV$>@K&*3=FP)%>4
MNF*>C*FU9$UR.J$R+1H,VNU@NG7;V>W[]X-',&#@&&Z<^'$8)(PW8#Y\#;ER
MO:9/#]`K`)1R$"#TXNZ].P3LX34%V`Y!TW;TY\V7-[_>O?KUW-QS*S;D/OXA
M]F_=VK9M2!MM%.#.$/[YYTY]W"AH7B_90=&@)@V6`P44FE18X7D88F@A!`XV
M.`X4XYP38HCGC".BB"%J`J*%$*9G'A0=;G?A=O/9",%\[O6"@P`O^/@CD#T*
MH,(+`O#S@O\*1JJPY#]-.ODDE'%)M)==%V665D)KY47771IE:=>65=(5D91_
MI7760!V-M9))*KUT&DJM8>5:3"SA)!MM3T7E5&U*$75344@%^B>A@`K*)Z)0
MY7D32K&UU!5I*:'&TFDGJ5F62%NJM1%!;+755Z=F?CGJE60:-":J=E744`A&
M+"`7.0L8T=!AG;A*3JH498JI2@_)NL`"7HTUDF*N"@;5`CR4<EB<*[F9$DS1
MNE0G2E0INB=/A`8SS&_=>JM;$<B)6]QPRQV'0W/)-?=`"--)U\N$V)77G;Q0
MB'=OC.!IMUU[[KT7GWGQ`:R>.SC:EY]^0_!W2SA#Y#)$`>@,08O_@?H=4@R"
M`3<HH8<1"BPCC11",*&%#Y8((HI0F'C.RB!N'+*_Z,D<H\SFY>@O=S@D">2/
M/19Y9))#(BG`"4-">?23FIIY:F2J<HH177A)'1=&:)$I*M.C9OW02'I=(RF;
MT+8FIVMS7E4353C1=BVB/@TJ%-Q(Y<8M;G1O.S?>1Q6Z5-M,7?LW3'72^=)J
M69465D8A111U9&J)Z7B9I6IY5]-:=^FTY6,.%*L1A'GFZC"RJG8UKI13-I%(
MH"?;N;/DB%"*89SQT(GHC%%U%6K-;F7:X-2^Q.BBBP(*=V[%[];;M[X]D&YR
MXBK7?/,-L`OO=!$&H%V#\H;787GV;M^>_[[IE0<P?"^:_YYYQ]1W<!OW%;-?
M?]NT#\*`!5+\'X(*WKQQA!3V'^-Z:(:A7EC(0MIYT(=0=K*6I0A$%+H0R3"4
MGAA1L$/DLQGZ>K$%G_&L9T5"TM#XD:0EG0!I)J3:E;1DJEQEYB*>^@A<KA0F
MJKWP<G6A#$A*(Y;=Q6E:=+(6GG(BO+XMY6UYNUO=CFBW)>)MB8'R4]^:DC9%
M28M.+%E-M$@RMHET*E.ATHM;'D>ER%W-A4L+(PW1&$,S4HZ&7XO5`O[BJLY\
M1G%EPE5$VF22@91D,Y_;3+!>8@0:$'(QQ;H*(BWUIM9@L7==H9-49N.4/QDO
M>=\J@G#(E1Q-0O_/.3!80[O>E;T'66=>WKD7]_*UG7WU*V`ONN#'W%,P'-4'
M81=36/QRD0L!2:Q`_M&/.RYV,PIQK$$.JAF')C@RFA&00@X$D8E4AB(3H:@7
MXS"@_P"H"?0($#WE2":.PAFSG!&)@QX$VL^&)(`AC="$2`,CZ;QTJD]M1&IL
MF1(*V6BUR8&JG@ZI2$@ZA28MBJTK8\N*5GX7Q#RMC8AQ,Q04[\:MB2*QHKJQ
M6Q(S*M&W_6EX0>'3WX3H*+.]AH>5:8A`88C#-LHP5%?S"TS[PB6^^)-4;*1I
MU:X1NEDQAHZ=J=*90)*9M:#4C[(:S#`V<Q7%T(`'-%@69V05`FI-"BS_+#EH
M%<LF%9KH"2AQDZ@EP[J\3IZK>>9*PG"D%QWJ4.\Z]GJK]KSGO>V-C%_J(0][
MQCDP5[XG?_CY3_O@%XY?TH]`_J'%+1"DGP6MTF00.J8V7WDAF4'(922"YLEV
M<:*5$1."%4KFABC((8#EZ&8=VA$'Y]%!GY632/P@&CO=>31ZIO!QDJOGIN9Y
MS[J(RB]=E"<8_=(1'(:%33N\ZB,?-:>0=K5M>Z.D1G&#F]PDT3?2_4UU+TK=
M)M[F4%'D24A?TSNLP"EWR.UBKQ;WSYJ*"J!/Z]H9P;@JC8R1M_"42POO$BM`
M]G2/ZI7,2"+2JSX>E0:=\TKH0$-(5X'&5:5`_TPBFW5>L"7W4;!AVYX^"MU*
M\B:LX'H$)\M*UG2EBUW2$25VW*J]N):G7G0%CW?&8[Z]QM(]QZ#EP?(#O_X\
MC)<3JUC^\G>>"173030S'P`#>!YCDFA$*)OF9E$TH<[2"#ZBM:"_3)LC].RH
MG#]2+9#*^=H1LI-)LDW:JN`2*IJJE[<NY6*7TMQ2VHJ*<6A<VDC06QDMAFW"
MN%MN$(,H22)JBZ(:U:YNIHM=#E]W-XU&=$4-_=".@E0G>+*)X`2W.PI;52QN
MNA294$6JO'!M(XF+'%K6#!GZPIEK:L;S,&+WNLD\QHNN5F^O-K>9SLQ.="QQ
MJFAHL)E2$+*I(ACI(_][*"VSN608@E9;GX;"80]W:WDL<!XG0XS6Z+%K'&S-
MGKSHY3UZ<8]?'=K7OM#3GG[=%7WN-A\WG)'C]KD/EX?=9?T,A+\AZ`]&'(-L
M`5^I9/50D,@.@J:(5M:R!Z[H@2139L@N*,XM;T>#1.K@!WOT6A"..4DB//.3
M7/@6HDJ)Y%X;JLCOFQF/V!J^Z%UY;WN%F=*@%%)^MF))_HQA;-6&4$'9+K>T
MVVA%4]O#UWTTT.?VQ(\Z9>>-"IS.E]V51H[%:^E=8]<41_)7WQ!S&6&SR>/9
M:K/`.EFO@CF:BKLFA>SBJ$;@0:-\'0)B+U@PR3+V,"IE<[(%SL**8ML0>T+_
MR:`3/1C(HS8F0TS6Q4NO$^YB:SFL\YW)BYL[>`T`7NDJXW_A+);D4U"._Y,P
M_@P6L!&[S_T6B[&;&;R9_)NQE;-I<`5"F9K1C.:$<B^RB&]H1IP7I_EZ40$O
M8]Q'/2+2")%D`#.#_!]P7J%*LR9GU)'IMR)_=:M=W4:Y?.7.9L)CF[ZB0YM+
MG:H+!2^A#15IXR&]Z.X/ZZ.96+>])4I/55%N[T[R1F@)2_R>%@E::)\=P9ED
MG%JFF,[7?01=O-QON9=[V9KIN$Z<P!FN,.":7*#K=`;L+(`@&09*&`:Q/5BQ
MT8"SF=_-09T5/1US-5>V;%CA=4MOI(#AR>!OA,MP_RB><>`@#*!5B87`-8A2
M]E`'Y:72>'3'6WT'-[U!DNE5^9P/>B!(CNF8O<D/OAD6D/$;8[6(A["(_[C2
M9&&9R4R(9340`YW(B5"([CU6N^V>P(T3^CP(C_A,:AD?""$?DHP0\X&<E9#<
M?%7?J?GA;YV<'PH@`OKA(#:@XYA$680-WTU8<DD%<P6>3G24M&$4HKT@M1W>
M;AA!AP4#)[Y?HBV:_#V4WW055,C&,%A%IE61U&D1KX#%R<%<J$5?(1(7GET?
MK+B%4"$@(9K18Q#.L!17FGR:7@A29\R1JQR!VW$@(`W24S75@?50(_8=;+Q&
M"4+;H`G>)`K%W4Q;AZ7`X?_9`0W*H!TDWN+E(.,]0"><&`&Q%7<\R.29TA$2
M$%VUDHRUFQN^&P3<&.CA![WMV#8\3"Z<WC;<3S$(DY!YEL&=0XL,C`1-D!8J
M$,N@C.U!F9&)X91UR&0=607A(\Z0TP?Y")C1H9$(C<?A8?,UR>G,XO/E8BS:
M4>D,%/=)WRUV34O&5P[IT7$1!/GUY(6A8D](XJ3)GT6!XK=HHE$FS]#E#=UX
M5"G.QM_T9"OFS@Z1A2%:W?9E#?6U)%Q0G]6UFO5E'1J%Q*9`AO^A%`96Y4ED
MX.MT1@;R0&?<!.B`Q@(\@&ATCE1(W7+YD*)8RU2@'Z+8QM'!H&[08#`89F'N
M1A'_-,"U:1*YZ.!Q,,\:=,(U?%L0JM@0DINXS8MZ[,OV+"$R.2'Z<(/Z_!5^
MP,^]"8AA^=(0$$B_5=R_M=YHT<AHR8BW><AE+=`TD<C!F8P`B8<`2=;YA!/!
M6=R7!<D+',DZW>%KE9D*I.0_*,16?@1Z9<I%$&!7DIU86HD#8F6:=9]W>EKX
M8=7-Y9QL8,538!K/;6/<_!Q%)>4G(H]\_L9\&EXG(L\GNI^B952AU)_:7)@)
M2AT?68IX(@Y'<%]UJM0-W:)0+<Y7_B$%2B<N/LU8K)TB6J7,I=T<B8"!:05<
MBL`1V`I<)E4I.",'CI=4XIQ6,(K].==#=:.'@:-OT&!O_Y0CB"V>8W;2NC@>
M$`HA]K1C/,[C*E6<>V`>[.6CQ.'8Q!1(O?&'?_38Z=V/Z"4(-Q0,-J$A,?4/
M.('3DI7,AY@,-$4313Y9;NJ>C$10<#*<C&B":3&(SNP,Q@F)"!6)QY49=(JE
M>UVG(48H6*(<%R%$(,J9>[51=?[%XB12S9'$_NDEIKG&%*VG-E;B=@UFT2'E
M82;F#&(J.8ZCAUEJMTP740ZE3P0/\.!)2?6D(JW)6>R07/P7=:8%#K5:RW&G
MA+H:0J`.`C(@1.3%J@:83GX:2_C1V]%.-';"B"K&ZQR;8MQE"695IE&55:#-
MI0W1SC'%I%92?LIH8HIC8LK@8O]"9HZ.V`.(@&4&H;UTAXK!%9%FA[EQWERU
M4LV(9E_54G[0PNC%3T"JIB\AECL<I)#-B":,",DPV6Q:".9UI#$9G!B*:>TU
M4&XZD,<\5H9,+#?!DIN:TTC*J9`LR1V2T'.FI$SR8J]>#DH)XDS>JJNV*J!*
MZ*Z0W7>:V@6B5%AX18J>JK6T**1"UWLFY8S&(/*0XZ5R:]".8XUN:@S:YV]\
M8GXJY;;\'*7]!*GZI7@I&Z6<%R+Q3IJ@A4T*5:&"W_=!3@&^:M<&52P2U?4-
MRZ>Y27']8DEP!F/`';(<&+(H"XCN%&P,`V=08T(]TNVX1G.M8,\I15$2YF$6
M;8?]+`__/,*UW2`Z0H\.JN,/6B8IP=6X;8\1@@^1MNOOD4^-W9AZ].-]B-Y]
M+(S\.,SI^=*48@QQ%MDU&=ELHD_%JH@S79;"T1YO]D(T%=F%-!/,+"'PZ<@6
M<*PY>5#R+0D>YN&9[:E5HJQ86F?:8>4L#H2LYA'+,LU64L9*+"*JVER=T,3Y
M!2:@;(LEMA_A\@9B<BJF#FVF%NZE:FJF"BVU-1I&B6K]F0VR3>555%W^HDGW
M)6A6YE`!/J"#MEG81BC_ZNE!O%F%IH9."A3-M@:#O5TIX,[;+<#-OET'EH*=
M+(`&FZ=X404(WVTV"J7;?)4E)NV,[H8,<NH*]\9B,J[CGJ-Q_TRF+I3K=)RK
MO6C/*'D'N[Z'9VI>/@ZGOZ@/O8HN:OZ2OA;D+Q5#E3*6!8U(_TC(78E69%5(
M-(7APMG>PMFN91W3B%2($=+F0YH6-^F"SL2IC]BA"HR9<Y902MKJL&3E\K:0
MV=I:],TJKP"@FLBD@.U1<1D7U3;BM,P)"TJBAAD%C(*BC`*MC!X>C6XJIOZL
M?=+H^QIF(Q]/\GQB=,%-T]T);?2M0=T<G\'$@)(=]5YH@Z(EUZ8)9;AJFQ4J
M`%/G*RNJVK[12WQ:M/C1LKSM3G$&ZUC&V^&MV_+`-8*.>LY$-0(/M*DG8'H5
M*>*-)Y:OMM8HTOYL<(28XCTF6:EC6_]]FW5,;KV8$BIY#[L=V>_QU3G;#+U*
M(>FV`;X90^C^$I5N&98R9,AHR.92D.O.+F?=GNWF+HE,F3U/685@1\E\I+_`
MX9(("7**V3J)4)*<@/%"9TJM*BQJG?ZRLH6B[2J'11ZK%RH?<)X!U2U_C:5P
M6HKF7-K$1C9&*C<^&OGJ1GP6IN$>[=&V<"4?[@I/LGUR*Z>*XTV7+],.Y=,&
M97KFW"!+96I\!4^N!4B#!"KGF>GX8<G*W`5"'_9:KP(NQ#^9ETGGG$KHW4N0
M`^@8AD[,D;,!4C%SL+*Z[3-`A=O>["D*$0E#ZO"\Z'4%7?)8<J;NM-"68W,4
M1[:1E>(U0`/_=$(-ERLIH6MFAH>]1(@/M^NZ-:$0FT_!S-MI3J'I62'%+-9K
MGIO_,%D$!1"7>I:'+.P"B6F)Y&9O3EDSE0QMPAXWS(QUQ.%JI?'0J!,>$LW'
M-I^#%N!(#U0.3755,^]3YY&``2H@8B!Q'P2T@`6CAHTUM@0+EO"+GC"U\;5-
M!RW2MN\CMR]/!S4U"^TE<RM2+BUN<&)>WP8I0FU731&*XF]E2!@%IJS,:?3S
MJDDJ<R>NE:QPA[1\%017R*QT-TLC)=4PN^55?*BSO5U<RL:(PO6(EF")/L6S
M,10V1A'3%8HW8C)-JW`U6[(18-+B-BYR0.9Q/``Y>%NYEA(\,C9C_^NPYC:A
M1PYGDH(N.SNI._L8ZO(;$__KE9Z6P48<P.+S[I;,F$J3/S<9%SO(E(D'A_CN
M>L1KAYBQ'3(T;JNQ\6YY;X,<%Z476D9URF:MJPJC2%LU6F**2$_U__%?(U$M
M"L9Y2UOW1VU7**)P-:\O>8>W=\OG(O_&GYNW^5XJ)'NWGA>==''R70-F0VE:
M?!O45L!B20C5(JZR?=MBF7^Y?Q%7@*WD8YA7M/"DU.V:8ABK$432L<*EKT'%
MB`9SB=9MK)VZ4>.L))$P)8:OW=BYMP1ZH7]W"GSKN#!NN,)P9(8`.=BPR6`'
M]@2I*4$V7F7>.(T/9;O2$Z[/?=#;Z(5#_/\`2+ZEWNIEH48.;)379L`!T$;F
M2V<AW))SL9,Y&99JQT$'')5;66W#*<^H<<=R.?+*UH6N;+_G9(5>*!XI=\#G
M:DX^;X*Z*IGS2F5L3N[`.?=.=W6S)X?']*ZS+]%NZ]#Z^;8:K?KN>8CK]-&"
MN*<ZVK6V=U.<8@A'-TKKW)[U+R[*<E9?-)X68U!5I<!;]0)/H%7M[WSS7[2X
M+0;'K;/)1K(0,ZN?.DJ\SEW*!F>DYX0#WJBZZ"&[8&XL;7Y*LOKF>2.;H_-L
MDHFKBXJSN`V'6V.'LV.G_93KH[R2#S^:9I/B*[[U4L4P,1-7*8,TI$96+)85
MN6P^")+/;L*=X43_JLS#GDP8Y@LW?622=AGQA230E.0(2?260R>9HPE$''"7
ME*ST]HI(8*]T$K?8KNH.:9^`<<6>\=#>#3)=\\E17"N>JS!2>GPC,_*']W0T
M^[(OIS!0MZ]Y[W3'\WXG?JK2L>=3`BBSL7P/\5&E]VKII]WSB_[RFHI"_)87
M*7Q$F$:<4%WA*"I*+"I9+T#H*,M+B(;XPP;L9'!)T`0&WP2SGK6L3_W$.[-'
M:91>6Q+0]CXD@Z/M`T21!BQ@X(!QL.!!@P81-G38H%,OB1,I0I$8`$J`7A`V
M=N0(`4(`"%!`0M`44I-(D`%.FA39LF1,D#"Y%2LV!&?.F[=NA=M&*U>;_P+N
MAFPSNFT(MT/NN'&#X%0322A138XT2?(D5JN:>D6%`J7<U%Y@H8R#<L[LN'-H
MR[:U^%9M6[-AI[Z]6E5FWG,X5+P0\,(O8+\"!/1545A%8L4G5/QS_!AR9'*Z
MKNVZIFMRYLJ8,5LFM^MS9=&@.U?.#-IRZL^K48]V;9GR+LZM5^LZ0N[S$<Q'
M0-_V3>ZW[]O#A!\9=MSX<>7#H#$_WKQY,&C!J%</9J2ZG6`IM*<(9H<[=>_5
MH4$_(N*\B%0'KJU/]>:&L1LWSM2O3\:^L?KZ^><_HW\_^N3[[P83"C0!P3<0
M-.$`(["SCKQ@AI'.N>:6(VXYXX[0$+C@@`-N%_\//[RM-]0RZRRVURX[,;36
M8#.1,W),8S$UT3IS\</*>/MP1-Q`!#$X$7@P8@$'BQS&00=Y&`:X881$T@@1
MC%@RN2FA3%(Y+)&[D$LNH7NNP@F9DU`Z"*M[4+OOQ%L3/#6IZ^[-(AYAR"$Z
M%7((SP=PHXA/C3B2Z".,!/TH(PC*60DDDE@J"::86GI4IF.>RFF(-G#:B2>C
M@BH`G:)H,6H(FVKBQIV2IIKIU*@@3?2JK[[JZJMQO!K+++1LK34MLG+-=:RP
MNKJ+U;QDZH6OO_H"["]^7C#L,'X06ZRQR*1];+(C3.M,LQI),\W$&JW5=D48
M;3RM1=9@S/8S;$G[K;?_'CTLCAP,M^Q2.0O)G*Y,,Z4S@CGTU%/O@(`71%"^
M@NT[`S^$R5B8C'0X<-AA#I[@@&*'&>9@X3#(T'AAC#7F>&.&0P[#XXWKNR$/
M?*F;#M\)OW2.7GGC_:U#=]T-L=J<=0%7-759>^TT<6MD,4:?43N:MQUWQ!FX
M:ZRU.6D>IRPRWBFC-([(X\A1TL'CM'2PE*[!%@'#4I:,F5X+81:SS#%55EG?
M-=5LL\WMOAM/._!XF!,&@A9"R,Z$\#RH`7(D*H?/Q#_R2*2-&L?K4)<258FD
MJDX-*:]&:Z)4IR$R_6E3HHY"RIU#BF'*J:M4994JO$[*RM"OZ")+U[+.L=WV
M_[C&X56NV\VB_:N8*A<V)F(/$^ROP!!S]C#%G(]V6FG5=>VS$LNM,4;>N/U9
M-W)GH_%GV8AN<;1O<:/Y77>'V]`W>;M4^TN6R1,A!/=,4!#!^.S#+^..R<"8
M`R3;V,,D1K&)%?`)E2C@`BE&,9)Q`!\1#`,^)DC!,%P0@QG,X/\RB`\'%$($
MUS'3=-@&OWFY3VO$X5!P<)8^WZ"F>SMC40Q',QD<I<9HVRL:T5R#(M8LK7OH
M`Y'3@-2C8="`7Q\:$I.0A,04#HEL2%IB<H;$+RE:\8I8C%G\UL;%\MPK7W%+
MT]WL5K>\X<UNW)&3W_#$D,`-#@8/"$'B$J>1B2PN4/^%\HA57O*2F0AK58T"
M25-N@A-+A<ISM]B&(C?5J9^`RB:':$JI$B65UZ'JDENI"ZQD]2JWJ&5WMK/5
MK>1REEV1I2LLN9Q58N*4U('$>,L2C&#ZXJS"W%(%C$D,8Z(W+1EUKS>5L<RW
MN.4T(I*&7)[1UOAP9)L3Z4A&(3*FTGZT"VO^QIDL?-=M_K`A)F;H?6-RF;Y$
M<(-6_,]A$SM@``.(P0B^TP$>=,`\Z8D/``*09/G,9SLU>$%Y>A"@[Q3H!"M8
M4`I&,)X.T((#0@"A!Y6)BV#BDC>)PZ,C=-.%/7+F-8!3&NW=IF@@!2ENL.5,
M<)'H1"--FC5+A+06RH9F+2S_H@M#M"'<#&EFY"B2E(8TQ>,LT6IA6TX5@YJD
ML"T1;?52*@G;%L8SZ>M!WC&CW-HD531N1R""^YL;[]20P!6.CHG+B$?(^I&/
M<$5RA0J)HOZX2D"6Q!V%K!2E<L$3G_Q$**([RA"(P@UT%(,;DM+$ZR15E=;!
M!"9CX8I<>A6KVXDR=VKQ'5QZ)[NZ#(]XQ#->\OKR%V,1AGG/<UXOI:4TIV$+
MI<%,;8^&N9O=M`NEU@KB::89&NVQAD:B66U&M[D^%'IIJ=&!&S3R<,$;(!2>
M>PC"'C:AW"`$H0#/C>YS'1"$>5K7NM>MKG;IV5WO=A>Y`[5@.]FI3W]6T(,(
M0!EX_QYJG0FM3$)JHU=RAM%-)MF4MS)56HBZ=5H@Z<BUF2$1$66;FI7F1C6M
M3?!(K<DCV'84:A%N'TZKQ(,E5>UL?Q"!V<X&I>683:C#L`,/PF8$.VC1BUTD
M4YC>YE3KI&D\=E-3>*KZIJN&YP&/Z%M7>0Q'ASR@$X8+*T4$E1$C#VHC>12)
M2I*\J.&I))"1@H!<BT(IGC"RD9Z"9*7:X`=S^`',8?YR&T!0C$M6#E)9D0JL
M8D597*V%+6RAE2G;@I:H*'9X:&[E4XI7K&,ASR_\.(P`0@LMZ)'6,;^\EFQU
M^Z'^$G.8N2$IH[U5FV_)%K>QC;1(G=92WD+M#_&:V3<U!/_<Z)00OM3)PW&E
M:]WI0C>[V?WN=V_@@%KCH]:YGD\A;%V(&_C:U[\NQ+`+<8!"Y.$`>5!V"/(@
M`F<O0`1%,JH12F&'4CR@`8\@022\4(<].*``[1UA?&'VLOD:ITF?INEJ5GJ;
M:G%4FDW#F6V@V>`2E<_`_-VO;D@4-7>K^V89E>)%G41MY5A8BU;Z*8FSI'`1
ME_C$8++0Q"NTXO*\-T)QHTY[SWA&,DJ5C!^'L4`"9Z>2P[%PAAM'6,=Z9,PY
M#H\B*118,(?6FO\QLR8I[.9P@I2<U%61H,MK&Q9ICDH\P1*6Z,/2F;[T"_3A
MZ7VPA`+]@(["FFHD7-%Z7<;AJ[G_]&XMH/3=V'''.]B]=<\EV:SR9-E9Q#SK
M>2=`-&2HN=L9UA:VP7RWB=AES';Q'<+$'+#YK(=2":OOONC^[7+DRYSHZ(NX
M\_EV`2A?B`)8GO*4S\,*"J#LSBL;]`O(PP*@37HBG9X'IA]2D:1M-;"-&,0D
M-ML#:/``V]^^`0V`@>YU#X,M)(8?;.B!=?=0@`6`?./Y:AF%&G\A^B8'.-T\
MO(BB)L-UF2:(K_6[;UX+1/XB.-/=^I&/_#W]@$.MX*5HDI2BE"2'*^E*!O<:
MM:%A8K`9@>)=9%O%QSE.Y;]87[QC/*PJ.Z@JQK8C;];HY`!'<'RL<'9AR"3"
M(ORDK!@G_U`PA\E6HG5@">=6!:ZF+">0XI`2:9%R(2ANP`^03NFB#NJ@[@)>
M\`5=,`:GC@-JH19H(2M>QR)&PE7&@G9.:>SB[)1XQP<Q0BMR+G5>R7@,XP64
M!5D$C=!P*>X.#=%^*:4<K6D(S[:(QC>P[Y@:+9BN#](N;0M5"X9*A*:V*5[N
M*ZGB9\4@ZJGR((*L:P=\P`=HP`=X(`]I@`?XD`\M#!!O3Q!S+-MX;_<`9R%P
M0!$KX`H8L0(>L0)$BS`\:Y8\P!(E@!0D0!.=P`D8```T``"X``$<H/CR``"M
M@V4<C_'69J)&C7W,ST-@"$A@"/NVD#=PIL&6IIK`3]^^K_QF"O\6@Y%]_J#@
M'*1*2@Q*2J'AJLAK(HXYJBULK`V+*(ZI5%%E,`YNS$3<9NQ-[@9.P*,[/,X;
MV22K=NR-W@B.'D`$5BX");#(D`R//$*M#D6/4,(>!8E16DFND,+G@,XHJ"$%
M:V$%87#IIJX%GPXA89`%*T&!:I`*O$)5Q&+KYLPL*!+.Q*[LSL)5PL)76"FS
M7HG/^"P`_`Q9`LVSFD>T%F/N'B.V2F.8MH??OG"V5(/P"(S=O!#P9O*8(.P,
MQ^]=]&M$*BHYZ&OQRNWQXF;5;@"Z*@`'&!$'KD`1HY(OH/(*6*`1(S$2G8<P
M9@DP/$`3-5$#)$`#&(`L$^$'E`$ME4'_&+S!&Q+`+1-@!M[2+:4A`>CR+>U2
M+M\2`"8`'[2@\^K&.K913,PM9H:#24(-X+2)-/@.)X_I[UZHT[P/B'`+%U=#
M&"]SFY@(J7ZJ:[+H.(*!!R*.:RS$]4[,W.`'.NZE__XO&S6N&V6,`!'0`,6#
MO=2(;Q""(+2*`1VP$W:!'>EH`L<J);JB`E]NK<PJ<E2B)*"L`_](4G@.*6C!
MRGC"')".(*/NZ1BRZ1#R(!6R#QB2(6O0ZDY%43;25=YB+"CR+(2P+=*S++R"
M'O'Q.?G,E9S!E?AL"9<E>3RK,/03)0UM)1.-WM8%"S$--!;-T@C,"P>,0*5)
MM;RG[\R'WOH-_PV#4?J48RC#"4S`"&X>)`_.`!^^+0:D0`(40`&400'*``#<
M(`O<P!MD@`C:$B_ITBY=82[S4B[Q$D=WE$=[E$==@0AZ`!]&L1"N2MQ(Z.),
MR/DPQ!5K1ILBC.]ZD1<G\Q9)Q'JN=$IE"C,E#"C?Q;[:9QB0*EZ$RFHVD]JF
M[<1,+!I/3$*>@ZFJ$8Q<#*I>,TW,".3`L8P&4!P!4P`%@HT6$!T?8AC:D2+^
MI"/>L1YA3N8B)\FRCG)B0CECXAAXKLKZD2>>0`9;L.F6KA*8[CH3,@8Y%3PK
MH1;.`#ZSS@>GXNMJ1^S28K*^(BKH`B]*8E*;PE:?PCYQU58!RRD"(/\2^U.6
MVFY9G$?0G(>7`A2UX$VWDO6ELK"8PC#PALA\M%"V7'(GS0?\=D08\:NBP.E"
M7N;B4LU,5BU$@X`+B"!&VY(M$X`MV]5'?=1&Z_(MXS5'[W)>[S4OVU5?O2%&
MT;5=9:`$0A3<3.P`,PY.PP1#EW34I"\Q1Z29=L0V9#$7)6W?SM#=>,1A&S8-
MI^^BA@,W4F@80NP(J,W"#DX9O:84B@"HK.W$I/$Y5#-^Y,?_X*LU-0YO"'``
MR0A/98QN:.P[Y,0@<K,AV,C'&@(B5NXWA\S(BO-Q',?(,`=J(V<YHPSGGL(F
M0M#*9)`%.753-94[#S)31Q4\R2`'1X(C5Y7_([]BLDBI(B$R+]S!/KF!&::L
M*>S3&9SA*49%;VU5%Q0C6+>R>?QS"A,C0/_!0('Q)<.0HTPJ"^7-<0?4T6++
M[VS+)AFWP+*U2Z&&OM:0*#7T31W*.LI)*0L@"B9!1=V`"&"4"+(@"F2@+=^5
M7=EU7V>7=FO7=M?U1Q.`7MU2!N:I^#@N,%%1%5<Q896C21+O)S.*W:3T^YKW
MA7#1>B3-1V8J<S46&%VHFXC1%3'$.'AJ.::D36%O&<,W&H7*XMS&-5WSH<8H
MY&:SX_*4-D.N;@30"/RT3@:'JP9''<GA'"+0(GI!4`"E."WP.%FB45M":M$.
M`FK5D*H,)_S`$F(P_SO!T^FZ5H)=L(*_E@/`<X-M4"Q0"946:[%\I92"1U)=
MJ29$I1B8P28`JQCBUE:Y(5=3Y^IVX5<[2UF8\'F>19=.H`(*]R8/M#5B:WDE
M%T?JCMUV0\!@LM,RS;;49;^X5`U+S5N5BL5<DSM283Z"8!,&(`O*0`9<5W53
M-UUI5W9C%W;36%W5U2U?-XW=<G>)()Z@*P_"XZIH]@T)<TF9"-TP:DM!XX=R
M@UN^Y3%_!'WT;4OS:YL0LS@4#_I`=OY.-AE#-DGL@#2M[3OLCTW'Z1KAL&8A
MA'VKPXZS@\:0+V?G%\9L+'[;1`$;\&\:L&B/]AKZMQV#\XZ8%H^.TU`N4/\F
M/'"!0<(9]M&0JI,@O[-K1;53P18[N9,[1W6#&1(==)!VZ.+.JODM[`(D2H60
M6+B%N=F;]Q8D>WDY=T$Q^G,_A34E1RM`N_"EV&7P++,R@P,,Y_EPV<46/\1R
MJZG?A#'4C#>I-G0UG\I-C."XHFL"PE@&P)A?T36,4Q=&Q9B-T?B-)QI'%QJ,
MQSB,P=A$4[<,.CI&@R!$5\`492QX(61X"9,H5TB%\"L8,U9BHT:F*C.18;%Z
M-9>;%.]XTZU+W"]+0I-?U/2+U+1EPP:,`CI]!1J48^QF15F5W]>JPE%^1_EG
M;W-H=[-H"8=):-E_`3@XX]&K/2(EU"K)-@(?A87_*?;Q4XAY(;6SZ2J!#BA8
M@I=Y.S55;!FR%L:S%^@B+$8"SW@05FBU*5@8D6X"$6Z"A4?E*>93G`=K5D&"
M''Y564ZR[?YSEW;I$8&X72C3<5N2B(^8W0HT_)*XFFJQ7099>A/3FW2Z<XG7
M.>343(Z@$#QH#Y!`HQO:H64@"W`[C+/@1=V8HB=Z=^&8",H@+-D`$$H`$)*;
M#13@`]A@N14`$+)``5Q4"_!AN8HT;TAZW%R&M;ED#5/(2:\W8W&C6_99%I=W
MIJWWA7CKHCK$D?D8DKUU2.S%IX]CQ!RD.5C6_IHJXS3N0;0AE%^3J;D13^E&
M;F(S/'@V9]VD%/A&:*T:_Y8'YVAU0:LC<'&<%E&+#`,SXB3&F@/)NCE_&230
MVAP&<H+9^COIX*V3&51#59G;6H'$MA:HH"Y\I6SY2'-6^"9N(A>&H+!9F!ED
M&"2EPK"$9[$#@)P38RN-I>VB,)TCL7`-%)N,V'$E[<$Z^[,?[$&9)A8U;3*A
MIIVCC^`4#VTFKJCU)1R-P-<<8!.T8+>S(`O0];;).'5]^[?3F%[CU49=P1M$
M@0$D`!#8(!)BX`,`00B2&Q!,U`U,5`$`(`$L($0O+Y4'&A571N*Z)*6[5848
M=KRIC[4B%]3_[7S2^_S6^_#\.+6W9-384%XZ%QK"AC2K[?6(^DQ9MCHX^:A=
M<__2$SR-X$3!YV:443FJ/<X.Y,2KNBI0)3RK"74BQNI/#&7)+O!QZG')PEHF
M(C52Y+:!PR&"79R"&5+%W]I3,7AKMW93PS/&P9,6C@%64]54<IS'A\`$>]PF
MF($IC%P"T],C5T>S'CMPF;`_*=MYL)(*24NT_PZT*Q3A`6_3!*PV=O&CQ.]I
M@(F\*13,WZ5;T6VUB3=)(P3`1XC72#$('AI&99<MB4`N]1R.5Y[E=7?E59[E
M@WM'Z5(9RD`9AEM%`:`,P&&XA]L-`&!%IUL4!L"#@J`0"EQN1"A"D!1ANX1S
MFR2\3?U)0UL7#4_J,3/,G]1+-P2C.I;,#?.]_QE)JBW_UGF@"/CE.\SF.]@T
MUP6:?2<=-NO49Y]:9P]<9Q-\J=G$.QJ<:'?SE9.]`43@'&:Y%RI<K+AZ(C+\
MR$C":0D%(^QQEUVG:JV64B(8@YGNK<.]#L0]@YEYKH^Y#S;XF;]3@6AA=G0P
MQWMNWG.AWHO!5-+BZWCEL#`+'U/B#[(26'48[IZG`ACCA]<YU.LMX>&-B-D9
M"Q'>GMUYU)4_S+D<%K67>R?JTN'TD\UHS;_-#61``;A@`!0@"K@`SL,X=WLT
MN/5\=_65"$1!%%14`Q2@1"U1``S`]RM@"Z!2$1$BV^:$!5A`!0""C1<'^!P4
M,!(L6`J%"1LZ;#@,&K1@PR)6_[PX[,A%C4?(53QRY$_'D;M&DC.)\J3*DN14
M=G0),Z5,ER59'K%Y$B=*D2)!@OQ3T>/)C!XU>L2(5"/2BM!*\;`8S`X/BE%+
MV;%3"F'"80\=:M7ZT$["A6/%VB&;0NS8A&+1LEUH-BW#LV6CDCVK%FZ1!SA@
M^/7+XB^,P'[[%A;LMT&G7>?.]7H,.7)D*`$H6P[0"T+F`)HA0"D'H3+GT%!"
M0SA=^;3JU:J/0>!6;,B0;>8N]+E@NT^?2G3HU*FS:%$=.I5TV\Y]7/?NY<J5
M5WI.G,/SW95JH8.@J73VT]Q@#\FU+9?X(<6*=5?="\JX<^O50X&B*7WZ[:SI
MU]>\J_^""@$J7@CP_T)_*@Q((($GJ*"??O\LR&"##I*S2T[DZ+)2A4=<$^%-
M'64(88<9<G@$A;M<LR&$)(HHX4T=4OC231BV5%.*-&EX4D@C#7/44$A!<Q&/
M3$7T$%@-J96'`S=L$D06,I11A@S>R$!$E$24(0H1HE`)```*2+"E%%)X\$&8
M!AAP0ID5G(G#%CB00$(2)#20!`P-/-+`G',^<.<C#^S)9Y]][O7`7G_A(!`^
M!>VQ@%QQ1960D,%,5-&C/RZ55(XVSJ@33!&J)&%.,WWJ:4THV93I2#;^42-(
M.`J54:M%X=@JI4KM:-$P1EQ%U:U37865'8X^I(U:73'JEEW_>1G;D*)S*0K7
M6LO6Q9!==:E5RB,L]$488MINFU@G$/;BF&.2C:M99KU49FYGFW7&66KMQJ=:
M`-F]H9HFI[D&P3'>M='&;?[JUAMPB^BAAW#$-6=<;KI-]UQQ"U,G7<0.5\)!
M+=J5!H$[L7TG7B[DP;9:>NZ-\YY\FE3V7CGOL>89=BS'F]^``<XL8(#\%5C@
M@14XR'.#)N'$$H<?PFBAIA4"_;.F'9&H-(0D;=AB3#%U%"O5E$X*)%>0=M76
M7'G<@,\F!0PPYLT&W(S@@!48IJV=C[S]@)Y^SCWWVW;*>1@.+%RQ-]]GZD<@
M?R^\X((+I+A!@`-A.+!"'LX6^]#6_S[ZF-1&.F8$4DRE2@TUYY[+5*JHG_/D
MDZI"J1KK449]M-2L5ULTT:V^-FI'$5E=]6LP7SG4=;3%DJ70L<$3RY;O;S&*
MU[)M+2HM0VGMQ7;>,/05/;=R#L/8N-I#\1CWF)F;;OCJLNL99Y1U]C)KW<76
M1FW^\B8P''!XX445<`SGL+\**R?=;M(U#$`.2(<X`*P.%52C,8YYK#SF40WW
MVE..])",>_!YCW9Z89_7I(\;&D0-.?0CN/T(@!_\01O.3I`@!?6L9QT*40M?
M.#2@'>U%*KJ0BH36PA$-[88F6AH/G08BS='(1IESE>N6,CFM#2LL"LE#(?"Q
M!P=\03!QF_\3G1[A%SUI$4]7Q%L#\)8W'.A-;Q5@`>`&5,+!#8X4+I"`!)S@
M!`!H```,8$`B$C&-/`ICCS-(@!__*(T$>",(B]/"`>)B%J\D9"*+Y(HC8?<Z
MHJSN4D_;7$I:`JI,>BI4FD0)U4[G$QQ-DBBM.F(D(4FYBAC!*@@)5A%N994E
MRO)Q:TE>\I@EK+LH3UK"@PM:A$<76R:D"-;25K8(P[;J)09[NP"7,[47&<QP
M[S&80=?X-G.^U&0&"F\HS6@@`)K5V"M?KXF-'VYC&]\L8G[T:Z<7](`_A,FS
M@!1CV',$&)UZ6N*>9,@8,V0SGO(P@X.>80][H'#0<8@,@]QS8&G_X),^[KR&
M@P0]3<S0.,+_"&@_..OHSE;(,Y(T#8<NBE#0I(9#G.@B:2+MW,]<RA(9C<HD
M(GG5ZE['(QX]:J=<462Q[""")SK``4S809KZ<@4<7.$*%6!J@OJCQL&U$8YT
MM*,RKKI'8?S1C]((I%<3$$BN@G6K@"3K5L-J5C]JP5!:*,1"W/+6)6H-DK5J
MW5$DZ9,9?4Z(>YVIZ(;H$IF0CB>8"Z6E6'=74YZR5I/;:>QBV:M>=44KPJ)E
M\6[IK.$!3UG!-!XOB_>LX=&E>6^M'5\&9;W4+G,<S7PF-+L'&<ZD1YJRO29I
M;FL^TWCS-..\EVK,T[[WU6%^.BBN<750_S_\Y2]_"ZMGP^CPOWMR`+H2(R#%
M:D&>CI''/`3MQ3C:0[)SE"QE\,E,R[3SLO-0=*+L54W,,NJ?$I*PHRI`(8)0
M^%&0-BB'-,PA28MFTAS2!(8"%MI+`ES#`)LTDS91U8ULNI%)48XJC!S671;B
M1+"%00M1`(`REK2D,A#!#0IH4AG`D5:TIG7%8S6K*\P:UAB+=:PO7K$WO&$!
M0^VA$(ADE"(7V9"MU?5J'%$=CFHZT[XJ^6E\S9RI4D6ZTBGEDZ*L\B@O5[FK
M4<Y'%''D3F'YRMKESB&_,U9<G[6\:&&VM)I=U/+BVC6YJ!EXR0L&,:\%F.GI
M&;6J;8`(&*.+<_\$^K71G.:YO#=-VZ8+MZA!GVEZ>R]FN(,:Z*S$<(^+:2_<
MKS<%=`[%IMLP?-Z3-],%=3X!R*^/-?`T#'T/R40&&@JJK&4154UW*,H-=^!Z
MH@1];\T$E%'ZJBU!^G702V6$PY5ZJ$0HZ6^$E'TA&1X[4S%E\@N3G#E450U6
M.(W41+;6$+#`57="Y0`"LN`-82@C`42XL3>(X*0;EY6L7VWQ5P-98S]Z0Y""
MO'&4W/UN@/M;X%(2N+SWG8`!X&-Q>TC!F<_\8\GU:,BQPDB1,=>33BY9KYX,
M;(W(,=C2P8I55"LYK&;%D<5J^4<4=NQ.=5<[,8<;M-%2WIF#26=?FKG_+G)Q
M"UWB*N?1I@7..O_Y6J"7VN@E$S$-T,:WQ$5H^5"3,H\AG_BPV1G*P$N<WVS-
M1-OP!'_1`0Z8+CL\K<L;>G(ZU*".V'2I^VGG7K<8DG9&O3`FLHN58SL9E*C?
M-7CK7`=^\*NY*$=MAD;ZXA=!9RKV?CE$X!K*E,`(!A&"/22A#%TC\P+^H24]
M7CJ1G+SBE$KBRYG8YF"((!5#Y4`0HG`E!<P`2E'*0A;^;?!]YW[W[N9W[UF<
M5H0#/ZU14)P#]G"5H>-<(6-6(L4K-TG1?[QT?]TXDTU5$E/YI"<9'_GH;<3M
ME$^9=:U3>5USZF5P)^M6KY3E9HGGO#@K'^C._RL+_9G5K#7O/'CW1Y9<[GP8
M@Y%G`YA:?L88S10NKJ4]Y0);\F%;HG$^YV->6,<9D(8O$%`,;6`)N-$'04`_
M97=<>M`;(\@;UB5`I59/`A0&GP9=8?!V<0=W`H0.YN$.JP%1GF$OZ%4?]H)K
MNA9X[@"$N>8.0^`.A^"#@W<>$.!K-L,/&V4@:I,V*>1X#')LT`9#&%(B)Y42
M*75L*C)26WA]GR,J161D1W1$6]9R/=45/<<0T%`DQM<#,B`*3O)O41)OPB=O
MOM=O^G9P?)B'PP=\!0=P@F2'[28E[98%A`1%"%%FLO1M799$J41ZH\013M9D
M??57>>5D-#44II,1(?_';1]Q5^1'>N:'$8V5?E0!$4$B+$8`.7A!=+>D++]4
M=$.W2[8X;J5%?]*BB\=#?\1D&-FR9\-8@$9P#N20@%$G&52'&:0!@:*A:.4C
MC;3&6[;F#-P0=K91"<0%@L7U3OA#'-`ECJ0&=RD8'>(8!G3@@J)V@J1&"^BP
M:Q)%4.IU:T?8'4!HCYH@>/?(#49X"+EFA(37:V<40B9$7T_5>%/X#YV'>9+G
MD)3'D#S$;)PW*D#44IN429MH%)18>G75<JA7?V=A!*SG`!S@``-@A[37;D]R
MB'<H?(`(DS&9`$P"`#*@``K@!C)@DS?)!FY0!C=)8DVBB'O``[>T?,SW$#W_
M]6U8(RM6-@P]L2JE@Y&8V'%/IHE0J1*?B#H65TIE6$J3:'[H!TE4X7RGMT2Z
M9%EL2'3U)V?]IW_&TW.PV&:Z&&=Q)EII44S*1(QZ^1=^AHR`EHS;(QGH`HWK
M4EM81X&-%AKCA"_XX@XV('86T(TAR&GG2%WX!&HI>(*8F8[I>)D#=(+6L8]!
M6(_[R(\_")"GB82#IVOVJ%X6=48!PE%.."`Z$X5_HY#_\%)8"&"8M&S75C1#
MM&!3J2%!DS2DTDF6"!3@MVW=)CFJJ#L^QX9VX$2*@P\#H)-1$`4Z27M18'NV
MQP7<^9)DE6_Y!I/FF0#FZ0K>H`$,(`$E$`.1$`-L__`!D<`&"C`&;N`&)?`!
M;A`#(H8`88`/0;``T)`"KAA:E>400L98KX-R0U$CRRE$EH2<&OE@('=R(?&)
M%U$4G<AMKQ)AIMB1C$66+C=+".ICO\1+;Q67\:=SOK1\](=SMN1PSB(\--<L
M<Y$L#8%TJ@5&7P2D<E(G?C8.Y7`-O1!!RB@?Z')HSTA!3NJ,WE0:VP1IOE5.
M3\"!^.`%W4@`Q@6.H.F"GPE=HU9JTQ4&G9F.9;J9O%$+;4"$IMF:^J@)<WH(
MV6&G<\H-4,`-<KJG?:J//FB/_HB$&J0+9R0SARIL")F04\B0E3=@I,))%JE7
M,5))24:IU?<I#=:)'@JB*_^G4UXV2VMAB]6)#S=@`3K9)(=HB(<XGNGI1^I)
MGJ\JJ[.Z5366;X%4!@Q`!(D``(```&XP)5E2!LI0!ED"`&7@!CBV<'M0`&V!
MBX_S*Q(GB2%*BD^YD:FBB9ST5]D76*:"*J%T<56#9217<2DGHDB$-9_J<DH4
MJIGU<T"7%T8G="_*?PG:+/WG8PMJED#V;1(1$1(A$48@L$;``S3@`P9+`RM@
ML`>[`C[0L`^+!PZ+!ROPL`NP`H5@`AB;L0=P`(\!=>/R/8<VF*91F+K5+HUV
MLM5H:\?@#(>0C97@@3V`:5VJ`S0['/F$F;UQ@F,J79O9F>IXIIL)7;5P3[2@
MCX/_IPG_F+3=L;1+NZ=*"[50R[3^V)K_"*@"J82QB:@FI#.V^3?YY7C3QE+;
MFF#8AJDI@IR8JK:9JGTF\97BAZZ1`B2/&"07YCM`50@$@0](D`5,H@`R8'O<
M>7LO::M_5)ZUBK@K5KBQ"E93\F[%RB12H@RKBGL),`'&MP*8A2Q+Q$B/!(F1
M-&4VE7)3`UB>9*$?ASDG)WJI:V0>6JZE>*X_PF59TW+J-RPH6G.XDP<'D`>]
MV[N\Z[O`N[N%<`"%X$3&:P).I+S&R[R%X+S/"[T%4`C26P#56[W0F[?8Z[P.
M,+W3:Q#6NP<4&[[ANP+CNP?F6[[GNP),L`?LRP3KJP7O_XL`3,`$\SN_3!`(
M]8N_3%``2:JD4]>,5:<RM749FE'`GU%KY60.MU$)6K"E.B"S!-"E$ERS.@".
M]X2.H,D!*]BS$=."9XH/8[J9HB::NJ:/==J/]XC"14BG2>O"*.S"3ZO"14C#
M`1EX[=4+ACJ;!@F%9\)X396;,%2I.A$ZPNE71IRV&@<Z5>FA1-24M`(52GF6
M+AH5T)"W8(,`44`$"E`""J`D\/9O+I96Z&FX,@E\@81P,Z![_`9\Q;<X3%"7
M:CD6CO*(GSJMY#=^TC<2&5>54M:MW%<41B%]'[&1S4F*BG6N8AF)J:B&[0I:
M*<`##P`#6%``-V#)EXS)F6S)A?]PR9R<O=S[R7E+O09A$,QJRN<[O@6`RJN,
MRN6K!7N@!>7KRNN+``@`!$@0"$B`RT!@O[P,!('PR[HLS,-,S,2,!<,\!LF,
M!&/`OV_PL?\[38F&0>)#/J-AS>/$F!F3,=1@";NA!5I`,-Q(LS2["&A':FVW
ML_3DL^JHCNT('1)3"[0PFDQKPG5JS_H(!8>@IWSZPOTLM4FK:S8\J+VP!3A3
M0B=4FP220F!;;-=7Q$E,Q,6IQ-:'G!.Z?7L\*Q`VHL]988U2BUTCDGFK.!P&
M;TL2)7_4JF:LTBN-TB*6T@G`!8J(`,DG?R`M2UYVBJ?$D4;1H40T?2H!R"TA
M2B$!897_^+K;ALBQ"\4E6L<?>;LY^DL-0`(Q(`0%(*!@@]6E"C9&0A!</51>
MS;U?/50%<'Q#%46LO`*QC``KL-8($+^;P`3Q:\O&?,M,H,MSK<O)G,P;,`;+
M3,Q]#=AZ#=C%3-BX_-=C@``%H`G/3&BB<2Z/'8V7,:7H8UX;%!MA![._H0?L
M5+,4W*4W&T#BF+,"5$!NYX(AC()D&FJT$)`^^(^"NL)ZZ@Y04(1Z>L_WW*>I
M682"YYI'"`&Z<`7UA4;S=9`__,-7$,0?<L2<(RIK:WW/7:E34R.DE+KCUVUR
MZ\BB.EIN>`.$%`0]($B+R]);]8<QR9(OO6(EG=+2H`!:(*`(_S`5=*E9<QPY
M/$41=TRMI:3'U?T3%LK'G;C36OFAUFVN2DTKZ+=E46S?LC1FHK4$)V```U``
M"W<&!9'5I6HH60TV9V`D6CU4-^#5("[6I*S*K&SB)AZ_\0O+::V^KZP%]EO+
MM5R_\YOB,V[CM1P(]AO7.]Z^/<Z^Y<OC6L#,A?`&RFAH(BMUEK%-T)A-DWT^
M*MM;KA$;YF`#F5T'FST!,UM<Y6Q/I2;"F%G:.[O!85`+I%T)3S!J#5,+-4S#
M3UO/_@C0\(';37O;+PR$K^V:MZ896Z##!XTS@+/0BQJVSCW$1DS1V,9Q9"N&
M_2U*@1R*B(R&95FW]F>4*>"&#K`)B_\S`,#WA^CIZ808QFQ,WOK6;S*PG40@
MZN2-<`:7ZG\D`Q9PIO`MEPK!AC4W+(Z41*#+H>(GR(%,1%&FNB7'$<L9X'AL
MX*>$BFGX<E+<KKU36E-M`"@0!&<@H!5^IM=^IM2.[0)Z[=:N[=1>X6<@[C=P
M!EAM[IJ,[IE<[IFL!I;<[C>@!L[;[D;2[O4.[R`>[P81[X40[_NNO=%+O?&.
M!`B`L0K%V(U-&=44']#X@./C,JN!+]S@#+&1"^;P!&H`3\/UP!+,\1;,:1#3
MSJK-`;O1S9JI@BC(`?L$0-2!750KJ/U(PR],VW!>YRAL\[M=A`)=#,=@'MRE
M&3Z<>".$T/?_%>C(K9`6W=RE"]V+?HF=E'V_[F"B9]V19'J-S#4[6J]1D0HW
MX-X.,`$L!KAR(`/!QV+>(/:NBI[O-O:L2KFT.@-L0``YF07>R9TRP`6H?E9$
M,`%GJ@4T4`1L]G.CI:!!9M^Y3F1(;41/*10GH6U",<APRY'E=^R>JN#>5J*$
M[WZ454MM-M4Q@`)[<`/77@OIP`%^4/JF3P:UD/JI?P9D(.ZO7^Y4@,D9F['.
MJ[P%L`"XOP(+8+$+@`>0P`-X0`/#3P-K8/P/L`;(7_P/0`-TX_Q[`?U%(/W3
M3_W37PJV4PK9?_W:_S8P\`J1X`5K,`:!4``FX+%**DV/;2[H<C*2_^VD[E(O
M$#]1L;$-?N``<$`P&A\%Q46S`*%C$1TZE?KTJ<2!`QT.E1PV;.BPDB6)"A7B
ML]@0H42#$SG0.N0NY$B1)0]I.G3R$!1W4%"^5.F.&\J9(6NZDWF(F[,W)L[D
M&C*D&(1>6U0<12I`A5*D1RNH>%I!ZM1_5:U>Q7IDEU:NY+H>\1H6[%BQ9<F>
M-9L6[5JU1]S^>7MD&+EA<H?5I6O7[EV^PZ#Q#38L&+3!P0P?1IPB6`H[C!4'
M:QQ,Q(U-8?`A\98@<P+.G;UM)M)9M`P";KQ%D2-#M6HY661T=L79&P$V,U03
M6?WY<VS8FF<D()*EA_`HHCGSCCT`7Y@@:__L0%8<_?GCQXBM!PY\]V]?[G?U
MYH4+USOXN^3E'A&/_GS=NW_XKM_;7?Y\^=L)"\:/77#A^]>M&S&,N@`7(Y"Q
M)%`P`(4]'`@CC!L*,:4("2>DL$(+)2S%P@PS+(+##3'$L!01.YSP0Q(WY/!"
M%5=D<<(''H$!1BQ>\6*-`1`HP(1Q>N&Q1Q]_Y#&`7J`(@,@AA20JR0"4)!*"
M)"&`PDDIISR&F:#:H&4/+^#0`PXOO=!!!P+$U*$.@AQ":*$P(H(H(80L2=,B
MAN:,B"**T-P()&Y,HLDDD6!"Z4]N3AHT4)50TDFE/;EY`XE0+*C%F&.X(4JJ
MI/AA"JD3H.)T*JG_KJ@`*U&OXFHK4]E"52U54V6U+;>\@DN]N>3*:SWOYMON
M+OVP^\^PYPZCKK''C"ADCQOPL:`,>KP@`C<9N)#!-1F(2*TWSL!QHXP$LN`B
M"VF](>(SXWP++;AO-QM7MF9Q4T`&!0`0)5XWW!`%'D>\<22!'AAT8`<>I&.L
MP%^K`_`PP0C#SC[Z;KU5+_9DA9@]\=@;1CRZ^HIO88V[^ZOC_#[FU6#_1K:N
M.ND6:\R(`V-`804&+2N@GGH>:."1!V[&^<6<;VZQYQ5YQMGF1X8F>N@884`:
M:19@8*%IIYM6@86HFU)*J7D$F"=KK;<>I&LGG"`%BS&0V*,0(,_^$0H?_XE"
MDD=-BNP%@B*+?#)NN2'0A$H(N"FFF*!\04('/>JH0P\OO)@@3,4'XN@AACB"
MZ,X[,U)H3870O-.@@YZH122=1-ISI)?^%%U11`'5B9N99%)=)&>6*6`3!T"0
M:5)=<&AJ*=USCPHJ3T$=-?A6AU^U+:_<0CYYY9=7/CSUT#./O;PH7MCCA`W;
M#]@!&^/^,>ZA*20(?/!!0(89``''FVA=BT(&<-U/UYL9?HOVMM`T`U>TS(@H
M`X#6%%"`!N`EBC(H`!!E<(2]A)$``'C``Q^8A!0<.`@-#$(")XB!!Y20C6Q0
MP!%1"`(''``$&C@F0`$3EJ]&UA_\^&5C#*O5P__>8YZ+>46&\*'>"W6H'>WL
M"F2$Z0_)KF,$[Q&(0)%1#!(;@"`4:(%!9WA0/9(`@YH=+6E7A`$.D`8C&%UQ
M:5]\6ABG)C6I(:6,N[.:"JZV-39J;1#S<,$@XM@U.M(Q`EWC0P3XP(=!Z'&/
MC>!#(P`YR$`V8A`D&-L>#E".7IP#;6B;6X^B5`XC)2EN2R)2E.QF-RGE34I^
M&P(Z]M`#'7C!3(4[G.+&-)""=(1.%7F(0RQ!$3DIA`Z6DT@?,G<0A-3B<R1)
M":)*$BA#%3-TA-H338#ICF(PZ@W&8`;KN-$+2QTE4YIRBN\^-94K!&]4IRH>
M\<0ISG`V[SQ_B&%Z=NC_0ET=##$%^U6!!&9$8A7``?C80Q82D#[U2<LUNBE#
MN-"E&?ZI)@L!U``#1,$``!A0%.(0Q[W@(0H!G&`2)3#`)^8Q00\(`0L&X$,V
M&B&.!$@`#4O8P`:6@`8!?,(#@_#`!G9P`@TH8:2RR((6.(`/(#P`8-,1F,D*
M9IV/\?"%#IM+>]Q2%X<ME5:TFL]YGK'.^K@P5R`#V6$`E+V1I6"H\4Q,4%$6
MC!V@@&5,>!D^"C!%%N``!RS8PEOA^E:GE-$H6&MCUMXXQSKV=1!\Q&,?!2O8
M.](1L';,XU_WN%C&^C$"@`SD8A\;627HL;*"C*P@E7#(,8RA;`%PY",AR2.V
M_ZE-;J:-6VJ=1+=-3DE*QX"`W]Q1@#$0@`!>6`3AZ@"'5"ZN(*UT7$0:)Q%:
MUI(#87C<1-Z$)UU68@B>\Y-.8#*2TAGJ3SDQ5.ARHKIB+,,9?0,O44"UJ=SQ
MSG<JN`)40`4\;V:%G.]E'O)@%1?GU5<]]G7>7-Q##O?4Q3VRDJ'&<E48(0XH
MB0'[*33RX(![[B$*TF`H`&10!@EH(*$79@,@-`!1B#I"%![8PA:BL%(!M/2E
M!A#"!EY@4P["0P-;&$5*EU#B>;1@$`+8@0^$H,%&_,`1&A#`)9B`@`U@S0,N
M:($'@!`((3B!#TI0@B/<8('C(H`'T)EG9(P(5L1@]?^J4;WAP^PR/:>&V589
MHRJNC.K#70'Q>@4.1L&J8\0#8QG+*4A!%Y;`,B0XX`8-*@!47%`U%RQET$>9
MQQNQ-@@5\-6OCW[T8>L(V,0&5H]]S",?*=VUPO95TY&&=*B[UH`!($$+!=#$
M+D0+)*(<B4=-(FTY+#EK(N6-DYZ$[=[Z5H!`V'9,>@#VE\(4A5^?J1*M9(A&
M&M>0R2U$3KBDR$9DR<M*@,0F-B%=2-R!.N@>*I@D$>:@1%(,9QRC$"8(2C.G
M6<WRJF!348$W-RO0S?9>)9SW'HORQ')??C_/G/%]GGVE]QTT;TQA;+8.6('J
M&"TS)A5!*``^'-"#!*!A"RC_B(,!6*K1%KC``R38`$U9+(P/;^$+FV`""33Z
MTD.N8`4[@'(CLB$.4:"A'DA`P@;FX5()4-`#D/!`0G^@!)(+``UQ"$5&:^P"
M?GS@%4]G`S\DP`=AE$$Y8=`"#Z;S'"2.5<L%+BH[Y5/PB\7*OW:QF/3&GN:J
M'ARK;X9SPJ\#U"/B.:@,S[,0,(B%>P):`%#^`0/XV`@YB,*F@D2\9I\L:5&'
MFH]W+*RD]_A72"<ZKR6N&AG'^#0L'HUH."O"`XKP"!SP8&R0*,`;5HVV5JM-
M2)F$VZSC)NLGW6U)3LJU.ZA06P*484Q<\I+BR$0`0?SVV`592"NEG1"#%+=R
M#$&N_[(GDLN#.(0:T37)ZE(2$V];5]S4Q<FBW"&4-R`@%%H(`SID`H';58"\
M[>Z4-M<[[U#5VRJO>N^^Y8M?]9#C>/FE"_Z*&/X*P+2KH0"4(1LJC_?0H>T@
ML`?TC^A`H6!Y#&AP@$V0N`&0!HOS@14`@DO(FB.#*298`2&0@$:P*6&`!P^P
MN"B(@Q+S@"1SH!/@!#:0``E@`"40!R*PN$D(A4D0@)>JJ*>+A:=[!7[0P1]@
M00.8@@AZJ1<0@EB0PBFD*9J+@N78`SSHGI^*#B."C.M@(?U0&#!K*HRY&(JQ
M%31D.X[QB^P(0W<*&>PI#*Z",R+Z0N\QH3K#0P)Y`!*(@?\8V("T<@`<@*D(
M0@,T<`$T^(26:B.LP3PT8",!@*M)#".F21JC^3R;T1G18Y$4T!`5$;V<L9F:
M>80&\"*W>JLK.*.E$``<P#D<T835>Z32ZH6V.:VYR:0D@0)9XR2\>:UCX#UP
ML"T=J((JZ"U?LRTXJ(-C8\;?X@!>JC[FFYSH2[9DF[[,8:Y*\*64P#YAZA-"
MH2[M$AUQ&Q1LXX8A6(850(`@H!W8X@9=8+=VLY2I0*]MN@)ZL[]_P#?].R?P
M8!ZS$P]T2BI904!T4B>H.H^(B9A9";""XPX'S"J2.1F[0[#G@`;P00`&0P)I
M,+HE&(`H4`&72K(7(`4AX(17^`#_4G`"'10&D]J"4`@%*7"I03/"6#C)5UBQ
M:8`'HXN"4)"#E9."5X"$*93",>"#'UC!0^R!4&!!`8!"3H#*J#P!)_@!92@!
M?EF!(@@6`]NZ.0/#.13#-4S#O3C#AEE#OO"8`?LA7D$8.!0BKY([D]$>`?FI
M>:(!$D"#&(@$/VN00F@`M\HBSR-%H=F9PC2:I<$BFGD14JPB+-(B,&(!59R:
M\JH:&FLC.<+,QM/,.BJT0$`"'#$!6:S%T23-(!F2'BFM)5&M)FF2NW$M30@$
M,4'&,#E&V;0M03"3XVNEA8#&YJJ38\N(,*B$Z),^CJ"V/L`);@0F;?LV/M&V
MF[")[\N^__'C!G0PAD*@@B'8DZ'H!1QPO_)ZM_@#E=^9MWRL"OQ3BUCA-_7$
M/X-$0`0\C^GAK[-30_,(#^JQH8LY)[:SGNQ!F+D+D(7C.H!A#`L$`ME!@@1@
M032`R4F`HT$3@E?@A"(\223T,0U@*9B4@A#T`$X8RJ&,!4C@!PWX`6\P.@/H
M20\X`0/P`!3@A#&`RC%XA1,8!`9P!`DPN@'`J$@0@C^,`3:X`KT#!"FH47C(
M@GMR@!4HA0%%F3S4LE^Q0_\(NS2+CRIEP+/DH?MXN_P0F?\LL*&2NY+AR@/K
MGC&=#E/8@!@X`13HNS!P@+]L*[=:&BVB4\!$&BU*KU6TIJ6X1_]YLY02XQ3T
M"M0'Y:LY2K2N<;0X4M1!<`*O\:M&;=0*BM2NJ2!&I50*JB,-*#0FP`(F*``J
M$$T@,1*U&4U+@C5=Q*14]44GT80W@`3;]#7:5"5DO*TZV`AC.S8X@4:.*"XZ
M<3;@LI,TT1R$&()E,E9B4HED_9QCPCZ2&`)?0`8U0`9D8";5H::G<#=YU"9Y
MN\=[-$]]1!6PX,=7.;N#S*_\D@N!S$^*(3.&5+NERJ&)P:$7NJI=(9F!:=+%
MP+.M6PR,/%`$(`(@BX&>G`0/@*,3P`*BM,E7.$IA`#(#&(`?-(`8,``I@-&H
M["P#<`(;]0`!,*L8^(`-&`,V^`"018'_*SB!H+,P%RLQ$L`!`^@L!$DH%<"!
M%V"`"F*`'Y`!]`N#%="ZB6S2A1L0*05+JQ)+AKE2I*4JCV&GZ^%2+C4,+WU+
M>`)0.C.PL<([?F4,.R`!!(D!OG20-7@!%W@!`7`!-A``4B!)4E!))[A!4KA!
M/JB&N3V%:!B!=;"P1%,!?C@!IWP!!W*!K_&X%_A;`W@!PYV@R?NT"JI4.4I4
M.GJI.'JIR86IRHVCGHNC1K4@1[U<"FI4%S``)OC,/0C-4.T1(3%-N$%-U5*M
MNEFM*=&$`K``6A4^58)5`A`#0BB(/L#59SR("VBN2GB"YDNV-:G&RT&(X&6N
M/J"%Z+*NY2P)_^P"/Y(0QY)X5F2`A$S(!&D-OVOPSG8CK]XA3U#!`7RTO[@0
M0/KB-_U:3X:$*KQ`R/]BF/603[-L5[!@JAQ:6AXB,#J,L^O`.^A`(F%YCD+X
M3"TH'P8X1*0K`1`S`)CE!"R(T3%``0W@@XF:!S3HT0\X@<Z2@@^XP1>H`,%C
M7'B0@$]``Q+PP[$1@HK]`15H``%@``:0(Q=CP08H!15`@24X`1>H,!QH@"O0
M``D(.IU%`$`KH3LK4Q-2(<C0!NMHR[`4NX5Q2/W%THMDLS>40P*3VB\=VK#J
MPL@08R>EP'RU@Y";V(@+@S/@*5F0A9M-!`D`@#F>8P5@@!D0ACR>`?]9Z`!1
MB89U<`*6.H%(0)`2*]N.%0##_5L'(N(;M+`A]@`)4(`;!(`*`X#`>V0^L.`?
M.,JCA+)/!F507CS&8BP+QM1+A2D!6`$D"(0<8233E:37"Q+4DCU4C1*Y\20G
M"8'8C-7:%;XQZ>5E1`C@8KX^`%YCGC[-L27HLZ7+D:6.B(B-J(7G@EY@*J;2
M(9WH4L[D%`DU\((Q(00U4`-*Z87TRE9L<@I/&5]O-<^PF`L")-?C01X`Q(N*
M><\`RPL%G!ZS1"KN.(*IPIBD;4#^C4C_B"<*K$BL#08#1@)US((?4(H3J``I
M*(%`&(,8*(&<#4*JI&$2_3`!(($&`#D@6`'_`_@`#7@!'"@%%[C9H'.Q>:@`
M&BB%$FMA#Y`"/GB!-5"!F]4`#X`'&JZH"IB@K@'9B?51!V*`,I@`0--"/$.P
M)@U@KP13ITT8++7JO@B,OV`S_XW:N"N8KZI:ND.PK'7JBAQK`C80LS(`L+V!
M%;B#?^@`"E`"/C"@#P`$4L@P/JZWN]4`*7@!*5``*2!2)4BHFY6"BJ6@ABH@
M8;B*=;A9-U"`$B@!NWX7"3``%=`XS$:#%46#!_;LSW[@#ZA8"2)MP39M*:!D
M298!AHJ7'P``2&#ELADMU*7MTTU=4JU%6F9=)G%-"#@&2.@!6L5=7[9=WSH(
M8TM>8P9>X`U62RC>_^3C@%IX',F1-FJS!%_`9F-MUI)H'>T>B3T9`F30DBG0
M@7"F5O;SSJ=X/Z3HG?2BO_F[`ASX5K#X+_00,^@Q0/_"YX">U_[NCKWP[S0\
M2RUVLR$RF3&&#L=0\.=(!2#X3`2(`4?(X-)K``]@@@VH6`MK`!JX`CZ@80\0
M!V70@$\@@5*X@K\5@$%`;90F@9LEXD%8J(YUMQAL5"DP*Q3`<1S/J(4",@UF
M40K2@`\P[0JS,`:`!R+H@>5P`#R8P`#NNBT#._V8XJM.,RUVR_P((B&::J_\
MPJO50Z\+XP67P.DP(3M8H@=>D`:Y@3T8@7^0!4[V`"U*&N^,!OOC:R:*@?\>
MH%C/_H`^_P";1NU)!B!)%G0)<`,Y!@`WB($!&%@ND&PNB`(VB'0][X$2N`-_
MN(-,O_0[^`9_^`9UB`8/RF-A4(92+X/^D3#(S@+<S0)PB`99*(-5!H*R>658
M)E7<;AO6A;TFF9O77(%O%FXQ(&Y?SBV#H(.-2-X+6.YC'E9;$LY;2K[ABD;-
M,0AKZ[9L/M:0>-YFW;[Q"V\U@`1"F%9-4)WVPU9LFD=U7J][+-]OE>=9B>=W
M/<BR(\L`"^A[3]HJ7KLUU&JHC;NZ$W.S7HP\0(`#'H![Z-@*".*.'=L'T@"H
M,``)D"`/8``1GP<4T+L4/S&CUCN*1>H/\X`'5EG_"ZNP=Z%CA8*'B4KT$I`"
M;Y$"&1`%98`';TAYFL<7;\@")5\`,A=0IU[B*-]2*M^ACLF.K;Z>+O[W7XDG
ML-I*?>U*M$XALQ[@H"TKBEV0Y0B#`J"`#N!T=1"'%Y``4DA))]``65"&1'<#
M92B#;\"*.\#;$L@&+@"`4:>`9FB&F<L&81"':1"&:2CU'^B?")OC>8%L!8B"
M'HCTPQ]8-JCT*"@!QX\"*0`$;\F"R6_Y+)"";K'\;L%\`/+\SW>#T@"`4W]M
MG"L;U?,1(5%]TJSMTS422<KM2SK52X*2VW.2/("$8QR35`*38=<!0?`$7B*(
MWE1V9>_-/I"3.1G.Y"*N_^I.7EH8`ICH-FNFKM,QUNGU'&J>5FJ5"7<@BO16
M[W..-VZ=MVZ=[_183ZB:SP4<2#6TTK$4>BM>)P*/PW=*(GD2\P0?8Q%P<(``
M@@")-`_ST)!`X6+0H!8>8GPP<,*``2D>!HF"]\.#!RE2)&@(J4&!%`4F%6@`
MD-&;*`F3I,A`*4-E1G@VX7F#ER`!$1D&8D2*)&1,I`]L(K&10*0,$2+>$LC`
MA\]!`3LIK`:SBE5KBF!=O0;+&G8LV;'#@IT=!FT8V[9NW\*-*]<MVKII@T&K
M6W9O62-CC72U$U;PWJZ&LQZ^&E@Q6*LI'G-EO!@RY"XH3IQ8X>!,F#.%FG7X
MU__ASC>5`-RX`:!,6)F39<I\^R=;]AT*&F*4*:$``._>I]TH`"X\./&3QH%S
M*2$E.1<N6:1D,0DHRW3JSZ-;;\YE>18N@$H&!WX<@((K@%0K`\`$"9(]!325
MZR5_/OWZ]N=#"=!+/X1>^?/W%V`O$`1`(`0''JB)"7MDHD<F7N@@1A40BA&A
M#A=B6&$5==#11R4=]A%B'Q>0.**(?5C2!P<<T!$&BRNVR$$EE7@X8X@STNAA
M+;0<<H@[/AZB"9`__C@DD442.62/2`(YA)+N<,.-,[W@4$$%*IR@@I96JF"E
MEU=4`.855^`P)@ZSH9GF;.0<P>8P;)+SYC!_Q!GG,&W_MG4$6W:^I:>>=P(Z
MEUM_LN6GH(<>NA9;=C'*5UF&"7:55XY%ZAA>`R&!``*@:.""%#&4P)$$HWKD
MD0(2H,0`3O`P`,!(4O`VDRBB,%"&(][<ZLA.WG`120PQ"#&`$$B1@I0;336U
MJP*<8,$L)\^^0@*S@+S&U%/>.!`&/E5!ZI6DCTTZJ:1AI>!766?E=1>ZB+*;
MJ%J+HJM76/$Z6J^]B)%+[F*4/D89OUA!)JYCWSK6Q1(GQ,"$`_B$$48A/]PA
MVC]WR/!#&:B5L=IIY+T6&YH=V-8#`%%(,1QP4I20LLHE9/'<=-!-=])IJ)[D
MA@2I\98:<#>'A_/,Y`EW,VH^_P\='`"MF0>`,,(`P`D2@3!1P!O[45UUU?I9
M#85\_06@]8!;?RV@V`:6@Z`FFE"AAAYP3.C%A#I`B*'<<"]"R(TY7F`BB26>
MN.*+?]-!AXTUWIUC)9;0(J0[12[9H^)/.AZDDI#[.(0[0UC.33&'%!.E+E5R
MB>665U[1I95BADGFF&JR+ML1?[S.)NR`&BHG[87>7GN[>>[>>Z*,IGNO6&`A
MIICQ_(H%S0KL(;")-/"(8AITW2E`A#)-/;63]CQQ$4,/W@/%Q@=&L2%*4^9+
MDX`WD:P!B?L++`#)&IR$``D;`,Q4AK+/<C(&%F-<P2A%`8`WLJ>]A>&C$#PP
M'@,C\_^ML1"&+WF9%Z/>Y;O=`:^"C;J7N?X2F,&`,#&(P4IC#L.5$D+J>"9,
M858>((08G``!#KB!MFZ@@8C=832S*@-O,J8,'O80`#-(4P>BH8$2W&$W2UNB
M,-+#!>*@IC>HJ9G/@`;%W>2,/"8!#@`D,).<%<=F1MO-3(HC,V5D@8N]&0,2
M!%(`*L1'/W*\VGRP)A\[UE%K7=MCV,(6(`0!$@+N0,<>V`:AMEVH0G*KD-L6
MT0?!X6U$)<J;WCSTMP^Q*`R0])`E#E<CPU6"1T":').2E"12-DY)F!N"YJ($
M)<^5Z4JR-)WI3F=+,YFI=:SSDYOT5"=`\8E0NKL@,8L9E[7_K$6#\B)+!P=C
M&!423%Q741X2-L"$321`&JT!1`G8`"Q?&2`28XB!`F10!G->"P!GT\3BA+2`
M]L$O5DS9U0<`B!0VX/,#;D@C$=*7ONWM)'W>D($,LA`%+LC@6@74GA:DHL!^
M`2Q2X7K@5_ZRE[MH4%'&?$LRU;7!L$Q0>&0A3$7'(L*)IO!?X%+,O\!"L`92
M)@5=2$@,@%``AH7A!BX8`6WNL$,@*@,</PRB+$(SFPZ,X#8=4"(3EP:`$@S'
M-V'$8LY0)9XJ[H8X0).J%L5C'.B4I`3;24X6=*,,!81"#J*0A3JF(81,,6$/
M)H@/??I#-3[.QZ[^N:,>O;:?_X`M_T![--"!C@$!9[AC#W+S@AB\X-A$S@UN
M@NC0AT*TM\M2<D0VJ,2+9D2'%T$2E(7C9"V&\#@F0<Z40'K<*$]YN<MUCANL
MC"V5N'2E+M4R3%]*'2[/I,LTX>EUN!LN[P(UJ+@0:J/*E4M&*;B79N9KA(LI
M'O(<4P`D#*!YRDB`$!:`C'76#Q+26L,K2,&49.T*$*=R0R*4X8;F`,(-,DB`
M*[9GP.VU1K[E=`JRM%>&,7"""[TIZ`"BT#.,[<0"#',`'B0SL,@@3Z1XJ4OP
MX*718E;XHQJV%V"&5QB7"N:$_HKIP%BZTA)#>(7B:N$&)H*$&3;L!B^(S6CN
M\,-:G;.)/_]$S0]EH28C(I&I31W9<?:I@.LHQR31X<(DDL,RE75'K"N;LI2I
M'(4J1WFL6G:#,DHB!YZY`06!<*,)`E".`*"9:ERCXWV\AK4"^8>/_0'0@`RD
MB4`6PQT(B-N%JC"AQF9H;AORD(CRMC<359*S*YJ1)C-IHTX.CM`BJL4V>I3:
MUF+:M:/$]"%6J3EW;"Y*W`@`Z&R;V]V*J4RJ\^UO9Q.H.OTI3H:J77*7:VMW
ML:6C&PRIHPA#TA1"LU(!*\`&!@"$/<RW#*0`1'RY^2LV`"(&62`"0+4'#J8H
MPQL]`0Y!SXNL[`'B6>?!GT$'P`7YXN^<"RT#"CA1SFKM4[[=*:#_`0>0K1LT
M>,44I=1$?1T6Z%Y4@VFQ(*[QXM$,\UK"?*'H"%V:4F`+.U+^$M@S(P[1%?.`
MIAO8`T[#<()HR&8T\#C::12@C*%NK`Q%3=,(^!"#;Z2FJ4LK`ZA4MIV4.5FL
MUED.(+3<LI<]QSG<F4YUEL,=YSS1.$I^F7-(PN4CJ]<DPF`#$)@0"+G2AS]5
MTVN;^2H?KW%-:V(;4($("TAGH`,2<%N[V]K&9T$O(G!X,S1F+7L!1=,(DS#"
M48@Z*:)([XC3J&7<ID^;2M=BKM/<\%'GBM&?6)I:EKI%W9A63:96HTFX>T+N
MK3M_060V%Z-\`7ACI,FO8#\F#]A%PB:X_^"-&?`P$07L2<NB(P-D+<6``(Z!
M&UZSS^0HH%K5REX6A(`%+\I@GU'H00EB4DYZ[\H-@/@A08E03G,25%?;BT*V
M'+`"?,%T*S&5,,(K"'J"$_S\:,GPP17>X0B"WUO2]197+#5=%=*?@9*1[OX?
M#!D>)`$*&,`8[`%G-$P%5$-/"8,&E%'PH=P7"4/$H,D(,,`'.`)OK$93E4$/
M=,=V*`#2&=T330_3M8P4J-=SB%5SK$S.41D;=%.549G*L`')G%7,F$09``(3
M,`$"K,`-E,.9\9'6O=E]X!%>Q=E_".$?08'900`W'$,0/!:$.!;;1-9BP4'@
M2-IE(9K>X%V(^/_-9\D(C:1(I)U()=R"+VS:X#4.:HW2*F$.+6S#-L!A'%H.
M*UV.J'%#;7E);H')Y/&6Y;$:YAD7YPVBYQGBA;V+HAB<,BT37_A;_D73\?1;
M"JC>`&#!)O2`-Y0!/XS34OA>"41![V'?:U#;3F#!&D3"]7U@%$1!RU2?4V2/
M>W&9MA%4.4U;]='7]OP3+0X4]BQ4+NZ$#-Q;`4`4"Y%8_A%/N?R;!(T%^RUB
M(D)C^K7?62A<O4305V!C1#&<B06,"DD42U'<Q9G8)*8`#]0#"L0`"NP!#34,
M"30#;71``FC`:]Q@$UV,SBB#Q\Q&RTE!>AR-S(E"#WS`=K0,#";'=&C_1PRR
MH,K$0!0TY`P^Y/*!S_<X)$6"3T5.9!9<3!0,`%0=C0+HX-7=P!S)T1RMV7V@
MY-?T41\)%H*471,>@]H84MNX715*5MP)CMT=FJ%)$F?EB(K("(M\UN#\Y(F@
M2"U8&J8YB9/0@AO"X1#`(1RV01QN0QN$PRV$0U92`S7<`N84P^;D&>=$R37@
M0*E)WBVE3IBH6IF4)>:MR7`=P:P9XEP>4ZZIA<!1V(11HZ-TF$N!W^F)'_Z)
M`!`,P`8@P``0`0",`21@`0_-A`QP010D7^_!HGV5`3@L!1%T($%)IAO<E_;X
MD[;Y8K61IO;45VEJ#Q$$@514!;YH(V!B(P@1_X^C3"->>E2\W*993)A(/6)L
MJMB^](N)`4SQ,`:*28;QA"/`P%16%,$."*`ZXM098,$TP*,T*(`HW&,&ED'+
MI$8^LEPVC`00R5P9..25L4$/S*`W4:1%1H%Z-N1[LB)$?D\/S*?W6.1$-F1%
MQN=^-B0H*L=I#(`6B(PPR((;Z&![%((FE&1^[(><I>1=V0<>"4B!O.1+'LA7
M^H(:U($>5`$<>"@<O-V%$`"&.)8>!`Z(:"'?(%H8W@W@V`@9EB&EN2%4#H$<
MVN@V7.56W@)78L`M8$"/8H`YW(*0;F4X4&4;6(Y8SA;GN,/G]"&JW9*8F`E;
MX@`)N*5L'%<ATB6N0?\C-"`3,JD%F'HIO*!%;@8/!^W%<+X4ZDGB$3!!80Y$
M*6I/064!9T9FG7XF:);F/^W$::+FG@+4:?)I0/4IH>X$QVW+Z>U;-]8?N,@F
MZ9V+;N;FI.(EFGJ824E4N*A4,7YC.%+7B.5?2W7+.+Y45C3`9<3`.C9,&##!
M#X3</TB#!LP*</B0%96!*DC@;-Q!-O`!%_CC>.JG1=+G1<Y@"?2G]\3@E?EG
M#$Y9E!U9%@PD"K:,`NC&D6&1S;A*#QVH%A2"F9%D2;+9@Y(DV*GDV+DD@F@.
M.M0!'"Q"N[8KB*Z=37K!(G!(3F(63UH6X13.9PVEX1AE&9H#D/YHD/;H5F[_
M956V02ZL4C$,`3HT[!`P[(S.*,,JGN70EJIYB2Q17F]9WN5=:>YLZ3%]:9AV
M:33J6EHX(Z6&E.@)S\-1AFN^;&`JSQAD%P*(@C]ETY]^FU/\::"6IJ`6:LX"
MHY\::BZFCRL<K33XJ0R%@0,LD**>$/),UZ7>"S52JIG*RUYRF$F1Q5>HJ0.M
M6&2$:O^!R^F%XV2,&-F2F!U8QD3LP<(TS`HP@&A$S#?(@"BDAPR<',KUWFJD
MR1U4`Q^4@#"@QGCB7,I<F10H:UD]F9-A1W1\H'>0!%1%D9&9C,[T1G!8E555
MD<[LQH@2@-3]`!`$`A)HAH+R!TE^#1X]*'TPZ)QI_UU+,N%A%0,ZJ($A.5;N
MQDT/S$WNLFN]ZLU.&F6D>990L@B,;J&'-*4[',/B_$@=0J_$2N_TUJ%LP1;G
M'`(W-"GD]2'E_2$@EJ65?JR6=I[!C2R8VF;Z7JTR:6W"C9YL7F/#!9OI010U
MU=0FZ$_/YN+M$=3M;8^?^BF?_I,K9,^@#K`NGF8!`?#_]D1!R8`<9($<]-,$
M+,P-\("^*2=LJNEL*F,P0"I(1:I>G*ENAI3[]AJY=.K])6>_"(Q?<J,D@J/+
MBMA+/5B_6<:O]*`!%@`#1$QH^(-*N-?1U&H/E8$P_"T%]"K3N(',*8-N`$?4
M49%7U<S,2'%X2$#F:JY72?^1#("9<-@,SJ0&%V,,LIR<,*@"%EB=%KP'FI7D
M'IFDN%J-';UNN=99G;UDNJI-[EY(%,H-[TJA%_QNW%7"O6;6W]%(WOCDWFV2
MI)U(WE@"4B8IYEP.]4KO)+NA)7L:YBP>P[82J4$>Z?AAY94E('JL6^).K2G7
MF-IERJIO*]<F!>6%"3-3UW(ML$$B;.)?,"Q/#+3'?`7M`6_/[?4$S_JL:58;
M]/TO0`U4_]:I,*O/,C]%`O?O-%/;`*SF#?A`<<KP_8D8U=K+!.'F;FHMRSK7
M<_U;2?FF_,X?"\VP</ZFHI)J_*58"9D>VZ*``&H&3A7"#4W,Q)0!=A[-#YU<
MRBG_@X]]3#0(KB,`!Q-G0<E!D<_4C.9*T>62!Q9SF]#$BA?QC!9Q]$R(T9%!
MQQ(G0B+\``-,PS=@P9@AP!NQ,9H1")K-L=5D79N]\6"1W8%8:!,RK.UJ04WJ
M<=S\\13J@1[4`8=(TB2)2(KHZXWP*[_RW;^>B#G,J&Q1<E5/+UAB[^;,%C>0
M995T;RB+<F]5:95>Z3]TGIC:I?F2Z?JR=?H&SP@K7&_F"S<*&PQ'5#"H'B]O
M@@)XPS_Y]3'C'C$'+3`^,^X)LT(E%$`U<$$Y1_4MLRO26V#3FR9*0Q3L@;9D
M<P.!F#1YXUR3U`>3!;V`<%Z.L-8Z2DG)-0V?V)H*C%8T_ZK_>6/%Q;8X.A#R
M&,$:'$P,:,:J%H($T-@_^,,_7PQZ\*UJ&/11(70)%.@2-]59>94:9>Y5E=/&
M*!UX6&N3Q>`DK$QYYN>O]$!%?O<`](!XDPPX]!X#,$`SW($0(``3:(%<M;00
MPAGKMJ[7\94<(>$?W3'#M@$5U('NPHWN>H$?!_B'Z@&]UD'P2I*^/G6-@-:'
M%&6AE>%23C+G+*7$8O(E2_*&7[AL63A8:J\GHPY:XA*9L.6J!6*KD2^&W66+
MM[7*YF4X\\4X2YBY].5<4YS\5==D!"8E`D$/;%P)Y"EA1S;MW=YD:]M]+;,#
M.S`L$A1"\>SL\:]H^F(K=D?_-O^P*\*B-S!``B@``N###:P`--$U-Z_4;%;C
MC).%^YKV+"^C6&"C,=:?'=A!$=1Y$>!YGA>!*13!`_CYGS_"G^NYG=NYU/*?
M-*TP/1=G'GR!$`@@T\88*<0&#LW*;[S&CE5T$1-1R\6`+)#'WN[MQ;`,6#T'
M202=%&CW=P#"!ZS,K[CZKPQ`)`S`K-,Z=DW``"#!!$P`>R"!!2"`!5A`IL"!
MKVO!L*]`)L#!K7N`,A``.`C5'=S!"4#-2E/!U,3W?-\1'&.-7W5-MH<=G!U(
MG1V(,T0L+00!(DDAVP7X%!HX'!RX3F86I'V2(3?UHD5X9N7-$VRXA5.XAL_H
M)$<LP*__TO5"+/86_/;&DO=6'L>&[Q60`%F/[T9U5$>]>(R'<*26MEZN>8US
M[4@EXVN26,C#5!Z\Z0!@(A'4UVD2+4\05#,[=NVQHAS\(I5+-E34:013LQPT
M=O:(P@]HV[2QXI5/,YZ>IA(D0!F`.3Y\GX/)MF:[\V8/#VBK>9H_2G1EH\#H
M^9\_``QP/0YL@9:HP`NXP-@/0DCPP0]DPS3P04BX@)9L`0PTP`/@>:-R:@N/
M:FW37QX4@`]LP&4``8SEU`=00$_1RCT&=+6HAM*HR0@H0:<;&4BK8!1LP`2,
MP:Y3?JZSAT#`U0HPP0I`P@J`_N=[_@*L0/SX`!#40]5E0`8`_P$2K/YZ9,"N
M6\`$9`*P(T$FR/[L`T'M[_H&6`P1S(`L%-4=?$#5(<`>4,&U4RC7<%U]X_==
M,2C9`4C9[?<0M($O[-D?LYV`L_N'>J@CY2M/^B2.'+(7P@@D+7*AQ3LM=$[U
M1N_[8_+E=)H;\GN'.TG$BF4O//R8I"5`7+E2X0J.@@=Q&$Q((N$_AP\A1APV
MD6)%BQ:##<N8$9I&CQL_:H06C"1)C25-!AN94B3*DB==QI19T@A*(RE(IK`3
M#*=.G\'LI.CIDVC0HD)W"C7"9,"`%0-D9(D2I8<,(D2\9;UJ]6K7K#+`9LDB
M(PI8L%S&$DFP5M0/(E&YE`TKPYL,-_]BUR;PEDV8-R)3XV9Y:Q;L5AE2I&K!
M=\.!4:`]@QH-^ABI4)Z1>>:467-F9\\D.>\$6G*R3LHIBN!XH8'/CQ_3K&6S
M)F[VM&RVQ67++4Y<LVR^A?WNG8VO[MBRIS$8Y$2`B@HX8#PHPI-H9<D]3T?.
M4V#%!A0&D!3`%R;,F1C5'':X(TP4```*`)01INQ]%@5NE'6(.()/#%ENI%`@
MBQ)*Z*$$`-RP(!\@F``B`TB80&(#!BV8X(M`,LG0@@TS06(".`2IL(HJ)O#"
M"T&J$$3%%%$<<40OX/!B@@F0@",#))"H\$8/,QA`"0!T(,`N>CJ0`(D]`EGA
MAC<":#(`")K_A#*`7GJ9DLHKL<RR%RBHM/)*"'H!$TH(H'@2@C,A<&:(-=&Q
M0`<OWHS3Q#EAA,-..TV\LXX^+N"SCS__K$10#@0%M(]*Z$@T#`[H0-301_OL
M@Q8(N'&'&VZ*.213=X;@M-,UU_045%!%)76(3$\]9,UB.@T@H8%@%>@Y@10J
MR""&%B(AHETANLA7C"CJJ".0-DHIIH]>4NDSEU9:UC/.4,))-,U*,\HGR2Y#
MZK)M3;,#&A_&0`$!)*P:*PHNY``K7;.R\"8O941Q):JYT+)*!CG$4FNM9G[P
MZ]X>Q`J8,':SB"&&`2;8$`$M&`["88<="")B!RBF&!]\&JO.L:,J_[O6,LBD
MW=;9D6V:"3MIA:JL`A<8>&V::7CCJQEAFIFY9IIMKEGGG2EHAH*?@98%Z)JS
M44*)'_C0P(4'KBOM*&NKS2./[E`XX<@;R,-'"&L<NN,.>$0I0Q0W`%!&&&'*
MN"\^8?2#Z`XE2A#F/0$!*2&*`^7P$(A`JLB`!C@J1"(0.&C,I`HO,MEP1B!D
MM"#&A!U7?()`9IR\<LEYM#R#A"?87$=#&`!@!E?HD<6?;P#`@@DFM%C2R2F;
MK#*`,KO4\DHO;9\2S#!Y']-W2EEMPY<@X"S^S3GOA$./.V%$?A$Z'@6T$D(%
MK;YZ#K!/5-!&HX_T3W,T(?/,\"^UM!AN-/_EYE-6-=5TU/?75)754T$]W]6#
M!(H5(5MMO14'AG@5P%]=1%@3&4E(B(6LC32+9`UL8$UNXA*<:"8S/W&,TSAV
M'8ZI9`5(B,&X!#,6L9CE+F')@ASRX@TE)(`(4D%+P,82E;N<4"PE,!C")H``
M'6IA80MCV`^U$(0]0$QB#KC8$<<3AB2.!XF+<4`1)G/!#((,9)&9X`0S$T'1
MU,0.VGC@:$HRP<EDYC&9F4P1/-`RU_Q`&2\3!\QVTXSAS`QH/Q.:+/"81SQ&
M0Q9\5(<L_JB.>T1CD+(89#-44`2B9"N*'ZN63O)0B!5@X3L;V$,2PT""::3G
M#K(H0]G<4`:S*:/_#&X@FS)4L:NWQ4`<:;,/@=A0`K(A`0@6&!$0#`>X0'BA
M"CFJ`N$LD`DO5&AP'TH<C#(4B$`8HD:=RY$S`V&!#`"!<)[K7(6<.:,,C$$#
M&J`'*+RFGD1@00M,0(`)F.0D*4D)=K9S9^VJQ"4JT4Y,8GH2%,[DC/G1X@8Q
MHE.=E*<'+>AA>7BBDYVX)[U`3<]Z#6T4]1H%O>Y)+WQD"E]%N4&IC%;J4NK#
M5/M0-;]2P8]^0^#&-1@B*QP0)'^U4@@)"I)2``9P5P/L"+!4,A%B';!8/77@
M3T<&+=)$2S1),6K*H#9%I6*F@U$``@)"2$,W$&R&91&+%$H0%\AQKG(S_ZK0
MABR@PX5M0HA%-*(1FYA6)&:-/.3!WEL7E;6+W8`'=D@J4K75,2M2IX(Y$0T6
M@>J9::&,6U;4R0,\H`$&++9E:G29&V$FC-[T<9#?4(=EU:&.:`A2L_?@["`%
MN=G.=I8"?&":QZC3-+QF)I(KV`$*8B"$/6"-/%A@0-<Z<(_XT$>4RJ`/@M9V
MAXC<81T?*(,K%6"W&$1!`0JPP"ZKD"$3!3-&&H+1AX)I`1C5:)@;&J;@`K$!
M&B2.0>15I@60P`0=Y2@#&_`0C6HY`2!@00(:^$8XA=N,,:Q@;ZY[G93*-#O<
MO3-+5IH2/:E4SS"9"7AKVL;PM(`G.^DA"!2N0_\=*FQ0.OWR>=*KQ*$.U=#J
M'8I0C;K>AR'E)TMP`Z.4@H`FH`#CBKJXHQRU5/E,^BGW#4%5[RN&.UR5$(/D
MCR`N%?+_KL`0)=.TI@,<QK`\\F0$H@0F,`GLE9T5092,$3N-I,QILG44RFA0
M)PM``'@0P-PH#(`J@*%*4YH"N1UJ80\3.^MB%G.#N59L#WW>PR;J;-:*#9K0
M%<,']LB0:`Z0X0F-ML03+!%IN8Z'!WBUCEXM?>F]8L<E6P1L,"`(1IJ$C(R$
M19EED@J#^@*@FZP&P&(!\(/&KO%EPB!D-+XQR'M8-M??P/6N-_OKT0)RM'R$
M@2)3YK'J:$PGJ9`D$*K_)H36M14(&L"M-#[9GMZ2$KAEDT5$.K`.";C'#25(
M;H&B\($$D>BY@DC8X&3$!$$,$T/=#2:-HDDC',WH"S1@@@_\O08FK($&`J<!
M)&A``R1,,T(X`L(7ZH&$+WP!"$#8@0(DH(X.J$<]WQB#.1%P`Q.\CN0";B>!
M;Z<E+XEIP6=BL)J&D(MM/%@-#K/PA>EPX0L+U)_%FY,>3&P]$(LXZ(.J'AT(
M-5%`N8-2%V7QI31QJ1=#@>I4%]^+-=I1\]W8'>?K5*8RQ0U7P516M'+I07"U
MD/_IBLF]^M5-"XC`DRAP)E[$,DFV6!)M[$2H>.=):#1SQ;XZC<Q)U>#A._:3
M_P6L(`H;T"$2=O@P0Z/UK(266!`*@'F'9=YA0QPB$FS(!BE\8``(R/S$ZEQH
M0H^'4$_@0*,A_>BW8D^)>#Y#'D93F=0F7K7)=J1?1=;7OYNL[V+$HN"571T<
MC%L#KFYU\YL?.L:V;!J`]/7U97%]8%MVUY[=[*XS"TC0XE$%#TC^TZB(D]9"
M.P;BHFT8F""!:S=?&:'<-KGE\PUPK^,'4D"0N0DD"MC`/B8@10P01<3@`%LD
MNH!@`MPK$-H+O7"D1AX."!`.$M8@`Y%`=0XNX3#PX%;G"U:'09@@$-(KF@9`
M"C(.O]3CXQ"`"1Q@Y)H$#-1)=G@'Y=X)=W2G=\S$3/\P!53:8.9H80AI@1IN
MP0^>X%#PX<(TS.=@Y'D:*L2D<'NX1\1&S$_^I$^TL`V8[DRH#L:@[NG",.JP
M+GRX!)_P"<:F+J/(YQBT+@#2KB`(HL@0XE74[G_^I^W<SB(**(%\RLKN[C.T
MS"8^#=0^S3+(*/?P3O`:*=.L1?<0CV-T0@16H`<&`.0V@<Z&B&($S6(P)F(\
MK\_*R@$V<0].+_,L@`'(YCU&;Q-4;]":2,_(@PP6Y?4JX0FF9_9@K]$6#1H<
M4:F6S8H,JS2$+UI*;:CX*A&OJ)$*#Z\JH+ZBKYN>#_J:[]5"YP>$0;-Z+;.^
M`9`(Z8]\[;)^;;/H(9"^$9#_-*`!DNTQR(S9[.``N.,+4.`[5L`!VFH%2"$]
M_N$;1$$&1`$^?.N3X$.4A($>P*VTLN"39(E`[$:6!D"9.&%U!HX)(&0-(,3?
M."&9?(!O(,$',D&95B<3!`[BF&`#;@0(3'("?"`E\6":A`G?ODN[<(1P-B`*
M-&`:SF8^S$8(2A`!"D$&9Y"=VFG`<+!*4FYWD+*>T$2?8F[FAL`IM^$6I/(6
MS.$"K+(2\*&@3.1X?JX.BBYZ`@7I$JI00BRALA!0^L0<T.$0I.X8R&1+JB[&
MHB[J:JPN-TKJ,@KKT!!-(.`:&N`@MJ"E:(5_\/"E_J<!]/`A"$BG#&C*6@*H
M^B[W_T(#L)8Q)P2OKRZ3C)*"6PH+_7AOJ3!-]XR@``;`_1R@'C%I]EKO%ET/
M'S;O\B(F\V03-H5H$W1H!;0`T.KL_8ZHK18->_S@K7#1]5BS.'>1`\*@$`JA
M``HA#PPK&#_S_)+-\#@SBBCH&('/-`;OTJ+3#E3`"5BMU<8-&L/3^5B-`:;A
MLD!+V+3/LK(/V,!OL][3UP8I&W``BJ`S^1XQ%;C#!V#K!$*NK0K@`X1+N/RA
M/8C@/H[+MTQIM_0/(CH@&OA`"MJ#N0(PEA1@`&AI!)%@))$@X3;4WP)!X"AR
M=91)F?:F0RHD$_Q)PESD164D1PA'</JFEBID`V)`L4II%?]_(!*>"@9-0$IH
M$';`Y.2*4N6PA)YT9TQ\D%5HX2FW@1:VX2FGDBJMLD^P<A-ZCBMA1`^\DBRQ
MT%"R!\6BQ\12C$^>X.LZ2J.P3GSB,L;BTJ+2\,78D"\KJJ+\LE8&<W^.;.WP
MD`38+C&#1<HRXLG\D(&^:%H,D8(X+1'!B#*-:JA,8U*3$638<3HQ]=0L+1(+
M#QI(4UPR;P_"@`R0LU3C"CGC2HE>T1.-2!:7Z`S*@SQ@-=$2[0QL]59O0.1R
MU00*X0;.@%1G+U7;BCQRU5?/X`:8H`NDP_!"$SJ%L6,P4QG]3CL)*_`(ZY&B
MTR<$0!K#L[Y6#?K,4P/*X`<(B=?_MF\^QU'7.BO7RO76!JG\,+4=#4\$"J``
M_#,&3@`([)$6"\``A$L_[J`]QH9L"+*Y!E(8P(T_N(`!RF`AN:`A,Y3A*&<#
M2E":("$3'#!%-228$H=#*@0.$N=#9`2[9(1PNLNKUHMR;D2:<D2:)B`.NHF4
MW$`!SB8&&`0!]@"=2BYVAO)(<Z=VD/))&.Q,6"47GE)*H70JPZ$JK_10ZB#"
M_BE/*,Q,T3),$>4*'T7HPA1+:2%]MN[&((#I\K)-T>2BT&2CV!1MI8[I`J`!
M[+`.^R>FDNQ/W390]7!0*2*GB"59$!6H*%."(K51J36,&)5P)W48XY4[W3$T
M(Y$HC"`/_SP("``M"(9U6)E(B3`7S_0L5X\U##CW5D$W=(VU6&]`.95S.U!W
M!1:`.[:#-]WJ=2MW41K-#PH`"S:@`1[`%/"S67O/]Q;WJ,SH.BE59)"O&;MS
M6[N)`32`^9R/&LM3`WX@^\11/4,KD*27UZI7&\$1D&3!!6#@.3USV41`.5=@
M'@T`!MNJ$&)`_PI4%-QW%7U+&&;V8'>%/TJ`/A:2(64I!O`-<&@4#F@4K%*D
M>4H$<`I8NR:`10UXJVX$8S,@F#8'1UP6`3J'<QY81P:`#\KF!V96&'Z`'\C)
M]&Z`G894:(W49XW22P1LP<*D3'Z'5:(4*J6T2LV!3YJ6`^K`9/]+9$Z>J\[(
M4@O])%*P-GJ&.%(NP!*>E"U-JL;.Y\?*YXDYZBYM#(KM$E/$K@%22D^-+*82
MHFYQ`(L3TR$:TU#SMLJ4):C`2(LN4SN]##O+J%++R,N\["?"-_&8+5,YE?>"
M003&Q14+P0%H<5A+536Q)QUH572-0>1,P`2<+16D1FKP(`\B>04*``]6X)(Q
M>1-P<P^T8`7,"I-.U?5P\=$@#=(X(!UV$1\Z2`B$@`0:H`B@J'$?\5G)[%(Y
MT]2H92@N]:[NBME6@QJ?+US-DV&S<1MY[=>N3QW*L1RO5_P(R9`(B0&VP#-G
M&:_L0`1X=066`%_U]09J(0P<``6^8>/__N%KVL(][N^44$F5^.`#2&DAZ^9N
M%(`+:DF8`!@.H@L)1H1C>2F'7A()A&E#^"9ADFE&6M9""&=O$EIQ-L<+-J=$
M'EJ;QB!I7$T"QNT#L&`/F&`/SB"=9I!GC1*%?Q;!6NYWF/(IH51*HU(JMZ&&
MK]0J^X`#@D##$J9#2R$$:H%,;1B(`Z6GB7B(#:4-ODY3NNX0NHZCS@=3S*>C
MDKJ)K=CKG+H8G/J*XY!/[5#M`'7M[+;M;DK*Y.Z,T=@8-=/OHO5D`C=;LA,S
M@S',VE'9GI-90?..@^$(^@$$:#4=+(&051-8\:$0\``/%@`/*ID[ZI4Y'4#/
M\`%6]RQB@@`W_SNY87IS5+$G]B#-!OH@TBS!LC%[LS=[=I$35L_``9A`"-J/
M!!YA=WEYV?!8M8]J,W&YRW:/=W]1)WY9>9OWML$U>7\@F2VK'-N3V#)+LP))
MUVZM&]5!%01`D:I9/Y/-"!9Y!83@.Y#`'HDU$M"C0-GCD]"90;<;88<+;D1!
M&0XDJVR(N;(@$!!`1C*$H&.TF"A613XR1>)[1)A@GZ/)`NJA!)%@!R`A$(!`
MX`#\"SIG`R`A`S*`X@P<P2<$")1``GPK/@!`&$@AHW'V!H[AHTLNA44:GC0<
M=KC$Y<X$4XPVAE%ZI6_!""WAI6W@T5S33BH$"Q[AM!7)!&JA:K,0IO^S5J<7
MBDR-N`_\H&L_Q:/"+L?<`:32YWR.7%74!Z2>NLG;-HN-S'\*4\G<%HS#V(#\
M<&\!<3,(%SM/AM-09B=2VXR&8J\(+Z[!-S]9FW%EVPZ,@)+K]0:>H/8NYLXF
M#V/P[!,M#V)6[V+<"E@?+=`C[;(Y&[./>-`U.\4YV_5^DQ89XX]]M1`0(+IC
M8`M>N7$]!G&M&5HOC9$R71*-E]D2ZWE#AUNC<9A%X9A[S5U%BWN[\1X,*8_.
MAI24X8Z2N_>6^UJ,(!5N@&K`0SP<?0R4H&O6PWV/:]L^:17+H&T>H@/XH`08
M-@L`X)4$<&;MA*`/QY8.AY=<1!"88,!IR<#_*\[`(6$#'#"]`!Q"_GLB#8X)
M_,T'?`!"_@T2,'`BF<"V)*`]N,`-N$`9-&"_-MJ_2&YWB'+#5RZ>!.QW(&!^
M9H[$3;RE+0%-8:$=VL$*6L$!M&`#8_RT<0&6GX'&>1R(<=S#?AI,(^4)GC2D
M>HQ3P,[(445]6A[LZ$?F5?Y\(`"+A0QNCTS)LKIN73F,_Z&K&=-8LDRLV=A2
MP_Q:PJPZ=H^6-_6.,=VM[UCJXWI24\`(!+L0S@"5+6%Z_'Q1CLA4@?4W=5$U
M&=T6B7,X.2#28J_0"YW05]S0V7[119GV&*-8^[I>5X`)2``%MB`)7KF.5WNY
MG[6*TF^V>YF7$RNW_\%5>4O=\1W_U2C+L_!HU@5R0-YL#-#+A_@\"!!`&!Q!
M&`3`_`B?V:C#"-[`!*CF!#(:'[XY#+"`#W"+/>+#E'J+W-:&V1]""3X@"QY6
M`@;$;IA+`V#D<`P'<33D(Y,)0V@)`8*IO#)AX.!@7(#`!P:NXD30O2H."'#$
M!VAI<#X48[\?#C9`F6QD>1D6`$2!`>A#MBH<*%^G2HJTX#<\GHS2=Q@,AI]T
M2AL>(&X)#'?K29\+K<`H!-8N#XU'#W`5P?5H8A$[/)@$H=.GX\&/%SYZK%3)
M8T>2'$V&K-1FR*%B+X?`+.9RYLN;,X=PHYES9\R<-'=R"]"`!(DK.)`JQ?^1
ME"D.$DR-XBA:])_5JUBS#@NV%1K78%Z#B1U+=JP1LBG$V@F6EJW;MG92Q$T;
M=Z[<%'?OUL7+-R]>NW:#`?Y+6&]?OW[M%I[+>#'?N@4*.;@1AHRE)Y4X:*[T
M1#,'S)<M<19MZ7*ETJA3E^Z3^LF3T*5/6V(]^X(-VC9LUSZHNK7KSAS(D`GC
M8$^!/2L*,%G!!`@6%`8,G-A"(LF#BWWW[D6\?;#AM'D%?_?N/7$*#QK2`]"P
M'@`#]1K>NU]?)CX#8;+R"W.#!(%_+4$$X<"`#N!C(#YTA.&99F$$D8TPS;SP
MP&-Y*3:8'7:D<D,>&Z`0PP8K5!9&&$AH8%4'=\C_(@H``+CA1AG**%.&&P"4
M488P=V3UCQ(?1,%&"0HHP$4);,2@```6!*)D)DHVB8222`#!!"1,,K&&DFM`
MHB0-3&#9'!),(#'!DQ.,:8$%968R`1QJ(F$!'!.<":>;7DP`A`0:*!.-+'M&
M(PP*>S"QQPTF!&#HH8;VTDL`BC::1J.01@HIHXM6NB@4`4`!00`0=`J!,S3E
M,L0VI-(RJD"W;$.-.0<9HTL:1T!CQP./U%K$1+56A,L5'T2221UTE&121R$-
M6Y*P?9!T[+"FPB33(4/H].RT-E7[TT_1TD2M3D1!U=2W34$E+E5&D5"5CNC^
M,\PPT*S[U5=;E25O7&>-_T576W*QQ9B^AS56(87=F??=OP0#3%AY`1/L;WAV
MY#%@`9,I^-IL%,.VVFRW58S:!:EUI!IKLM%F"<<<HR;RQ:A-G+)KEW5623H<
MC'A#`<XA@<4&`P@A!`K0O>"S="=4]\!UBF5WL-&.&5P8T@4C_!=Z[;$G=7Q2
MOV=U?.Z)(PP%S8@2!3X*;J8L:,)2[)$E'#BPM3`"3&CAT4OCE4HA!>S`LQ!:
MX$-&+6$`X<2)*8JB01D*T!ACBS7>^(V.U4@10P]`"EE"%#T<.0827T!"`Q)K
M-`<$YV$"<663@0#!)!"!G+ZDF!.H&2><7KPY0>QP>!%[!O6TZ:8%&2"1">]`
M*/\@03-W=&!\!]&PL0(2@Q:*:`!@'&JIHY)6;SVCF_8"@?:;=KI3M*62>NI`
MM[#:QS*Z8+(/K;D^@@LENKJO@@:)`%#"&'4`2\?^RI)DK/_'`J!'0N*'FM0$
M6M**%DZN!11LQ<2`02D&-R!0%&\M!2E.$==3-DBN=*%K*R`42[SD199ZV>M>
M8@%/7/C%+[R(ASQ)ZQ?3WI:TQA2-AHA1F&,PQ,.+&,%ADB'0#313FMQH;&,?
M,2)M:..:D_4&9;_!C&LX`QS/N.8S5!P-:+9X13+@PP%8V)F'8G`"#T'G`QYX
MP0>`AH(RDJ`+#^#AP-ZV,!O.<#P4$IAYT",%*4@M:NO_D0_6K,8`!BC#$100
MAB@BP8&R]>$V(2'9R`X2R=*DS1'"$(8')@0W'.YE`87(`Q#:*(054"9F3""%
M58HGC141[DC*$$:+"@<`92PN*^H``.5*4`(W\))(1QI`!J04B&%V:0(;8(*:
M-H"`3-3.=56HPNR\`#MJUBF:7JA"[:AI@3JQJ4QGFD#OD)"!<983">3,`""&
MAZ+BW>$.RD/`'AQ@@C<\3WJ4LIX^J[<]167JG]WS%$W"-ZKQI2H<K+(!"(ZP
MCQ2X[Z$2L4BM6'"*:G`M$6X80"``5`<UU`$?^MM?L`#8OV4ERR.U:$FV$"B3
M;'&CI=5Z5@-A2M.6#J4H,!`"_[@VN$&HD*N"Y_(@5M@5PA&2L"QK:8M;EGJ7
M%MH1:?ZZT+]@",."=5*/"8OJ7S!4!!Z8@@8TP(-D;G"#R90U8BHK&6IL,+))
M/K*MEE10;$RSH`6%P4`$&M`7\[K7S;R&-2&9)%Q+\X3A%&<#8N298A4;@\4N
M5@@D&,,.,"3#@0F,CGF\(U;S:`?TQ"`&@/@C>^1#6JHQ(&O-P*0H>A"&25[@
MM9'D#<E.UAD'I#9"C^`.W!`3#!$4HA"CY!D3]#:B/1A@E1WXQ@_D(`Q:'BY(
MA;.ECCH@C"S\J)>\C$$4LI!19$)"$+T+!)PV$`AI)JD*L3M3G9@`)PL@H79V
MRD05(/]Q3@1L8)SB]%WOT"3.;HIS`M+,@.W$.0D)X,B=QE,>\^AI3T2!H5+Y
MA-2C]MDH1N7SG]KC'J<\%2U:;&-4V_#P-E"5*FITY`Q'*`(E<!$1]DGDQ2Q0
MP@BB0>-FQ,.7;"C2`"(Q@#'X>`!NT@.P^C?29`E+6$^@!4UB\L`$OO2E+<5)
M2VG:Y&SII!@4E`I3EI(4#6JP`4^ABE"U`J^CEJ5>2EUA4_<BGGOIMJH+8YH>
M+[O#RB[MAC5,@1&2LX(5(*`YR^GS#?P0,[#=`!]G=0`9)J96T7RFD9CA3!9#
M(QO12)&*E_&,I*4XQ2O6U8HLLP1;4Z89O"YO#!NX'!:`\&?_!*S`.`Z`&*)'
M1`;-+)H#9\@#'I5&U3LFK&E;W0<TH)&'/.P!`1,H@2SA$[736LT]]OG!VLH0
M@T:FIM+7ADT5'8#)9FS2,'&6JA$*80(?*!8!IPQ#`4[0@7^T4QD`D.6+8@D.
M``3)#<*X)592)(4>:%<!DXM"%$H`@`&@3@R"2%TTX;"':#+)=MVT0"8R04UG
MPJ$*3(*#(#+QW=Y1?$SBM9-X-P`$-.TWOT`H9YA4'@D/6,,?QG,G*9C@:GI2
M`5&+LG#.*<SS2F&J4IW:<*=`!>(0?YA4J")5&V9CCE2HN%8L9K%%BL""0=!X
M!.KX1C2:D8AI3.,'B6``1@$A!0DP_\#KUF"``C(ATDJ,%%DG[4,MJBS3E?+D
MI<5PEK.F9>4IP_2FYL+@4:+R97,9O@$='/-50OB5L,PKA9!G:@OS;%D=FB=@
MO:8\GI]Z><H'`Y0#VL,>-N%G)IC>E+<>41@.358#5>8U@7VBR5C3D8PYL6.$
MS<RGZUKKX/A^0:?YC6>&HWK7B^CW"^H,<*H8LS"<H1!LJ7-FPSWG.UN?+T5P
M(;%3\?P])!N0I@U_(9T]#6&HEK6=WO2E37-I!JFM&9ILP&&FFMFTC/L&YBXC
M$"C#MP)$(D<`N"*R5",R`F\N4DO*H"-W0`\*,`#^YDN\%`4Q4'#4-`&I4R=)
M`EZITUX3%_\[[U4FNX-,R(9,@6`EIB<EG<,$-)""7Q(E0/""Q`0$/@!H-!`#
M$C`-WX!@=R`!4J(%!7`##>9@T]-S^G1AC9(]0><]`U50X4-BVQ`.&6,,*7`K
MN3)UN,`"\[`.(["%,T9CJM`,8`B&:3=^:&<--N8&D1!2;S<L?<`!T>)D;S@3
M0`%!?<<3=?B&,C%!1;%!@I=!/?444H$%YM(`BG<5C6=FP6!"**1F*_146J4T
MEE<T<5,>=$9_<D:)D9@"#I-HQX$<I#<HFG%%8<`W=]5Z"K)H!C%;JC@RN0$2
M;75[O,%$6?1HP+<9NV<9P8<9O+=[OJ=ZQ3<B!Q*,L?9"DPALEB7_575D?=TQ
M;'ZV"4@0`W]$6N[A;`Q0!M-H2&LC"C$0!IFA>Y?&:<$G:>YG?M[V",1(?4>#
M!QJR`DO`,TA`&3(C!/[@;B@"#P``#X93@-;((K&D@/Z@`/[6`Q(P))/#!FX0
M`]D4.]AT<8*03=CD!4R")D_B7KN#3IF`!/F`!#ZP!IW3D9P#"1MI)3[P@NA$
M3%'B`Q=)3!8P`!KP`[*`(C`I`5AP;#_H/(<2/=`SA+TP841XA(JR/9RB89X"
M`0-E=$<W8@.A*JE(!B*@8A3Q8K@B`'RPA>JPA5H7#5VX=13@==-@ALU0#5\9
MA@#`!A804OUC$I5@*C"%0-HB+=:B=W>(_X=6)D'%0!05Y!1]6'A4016"6(A6
M\2Z(R!9HAA9)A8Y:A6>6!VZ[Q7F/N'F+R6LU-%9F12"=>$I/D#&<P2"E>&CX
M$(H3PU8AD3$<\TBD*9H=,VJV%QJOH3*$U7Q@$XQ?U)EU=8J^Z(NP&9MZQ5<%
M$ILSDWG7AUEQ\YN/$7W?(1@[`P2;(`0L4DCV,8W..7[N47Z.T#6L55>921*1
M)D6SJ380\@+R5UG;D4,_9`PKP#,Q@`4.H"!A4`ACL#@`"`\:@(_SE@@R@CC*
MH`H*V`$*((%1X$M#(H$R@)!PP"835Z`85Z"_,W%(4`^^@TY/$@A?\`5,L@8C
MV1P[\()?`&0C^?\Y)*DD[A4(9_(D'NA?&]"2LH!@'0``0K`'6M`\]_1@E!)A
M/5EAD_)SW2-TWW.4'F90MT`+!=$1?N!T15`1[G,K5\@'%&"5W\"%T7"56U<-
M71F&%@668`F&TP`(^--V1>81'*"6!D2'#62'#V2'?A>'.O$&B"<N5^`M'#05
M/0544T&(?EE41S68^*)F.M281G,A=1$7%_&GMV('@7HKA%JHAGH1>HJ8U\=9
MCI$'9#49B#89!!(&Z<!HKV5IGT$<D%H95L0;@[4:MT%[LM<:IB%I)%%7Q:$%
M6N`?K(H`+;I7>957`L)7L*E7L7D@M7E7NC9GO\9YG9>,%7*HMW(=*"#_!<DQ
M!F502,E:C87TG-2(C8FD#-L8-G7%?+-Y5_@0!.(PG1Z06]I1C$?3,!LB1NAY
M`WQS`UA``>[V#W<@##*@#(7S(C8R(S1R(PIX!P?I(PH@!1%H)%D`)IS`!)R`
M@I"P!BMH@C1`)26H3"6(.@O;)$`P)JPS`4S07_QU)G)B)A+9)A@[`?5@=L(0
M<RB2""OZ:N2&<S<YH]8#!?[T<X:R/4DH4""VHT;GA`AU$!QP`$YI*Q)1=:=@
ME2-P!R.PI%M88V+XE100#11``=70M&'8#-,``#V@!6VG+"-1"S7%$PQ44U/6
MEG(YESJ191K495X69H<GB`V`!7):B(P7F&.1_U0I5)C@>I@R)*B%.C1X2RN(
MAW@PX!1.L045$+@J4`$G,+@P4!&/")E.HZ=RX5MFA6B0*ZER!4FP!3*E"+FT
M%C,H8S:AFC(M8ZVNB:UX12`"$B!!H*HLN@FJVJ*;,*NQ&JNW>5>R&XRR.R*:
MIADW(`*^68F/:6=U-*0P0`(P`+@J4+P"(`4`@``%@`0,(`J%Y+S-&[W..[W,
M.@V81`&B4`*J%S/(IYFC&P2CAP!(,`"WY0$P,'^,V1>)F`=T0P(H4`%(4`#$
MU3?-P*[L*@ZB\`/WAH`S4C@P@BX=X`8],`#]F05<P`5L$`5!8B=2P@0D5[`9
M<((,NH*08'J=`R6ID_\)&S!QX11-T20((!S"'KR0PZ0FO8-LXY1.\8$C,-D!
MTW`"+.JBSP.C.JFREF)A+,LI&[9AWT.S1XD!2?>C??`$)J!B0QIUN#`(U1`-
M5<F%0+MU3VM1-*:T3,LU3@N6UH!1;!<L:^@1+9$38_H3/D&F9/JU<?@26$8N
M?\@4>PAFXS(5A^>7_Q"8@_D6_&)#?EH$>0L1?)L$P8L#6X`#@4NXA'L"T:$"
MT6$`B*S(B2P`!N#(C_S('^#(+V``E2P`D+Q&+Z`"4Q%'D`BN.:2GP<"^7\1Z
MAF8@K?<9(P-;K\4:1%3*>L,!MRFK#F"Z`=*ZX'O+ICL@I6O+KXN;I+L'`A+_
MC'0`-L5,NV&0(-PK-B0Q&V>3:7?E`"NP`,!Z5=*GC,;HIT[P`U_'S3^@!#_P
M`PP@`3$0)<]8`A*0K*)`O=0KSM`;2Q2`26YPRZLJ)@0\"0HP./DK#MOJ"(@4
MSP`M"TX``^<(RMKQ0QS",QL@OWQS!DPP#>L:.*+@!D%"@+/T(@#0;EF!KS$P
M`.A\P+Q4.1F5D>(U3"&'.G62`=\%PG62D-T$D;.S)F\B)KV3<KUS7QZ;<F-B
MTX'P7R97)EZ0`1.0S^(@LG?0#!^@'/-43S<)/3*J*!-V#C;LLIR"*0'5*4L8
M/DB7E*M2+&1@!"E`$0_E`EAIE4)+M-%0I51:Q5,\_Z7-P+1/*X:)P`9ZT,4C
MT2Q=:W=AO)9?Z[5VJ(=W6;8D\`ING+9[:=AKJWA=X;9RP0-YVP4-\,<DL`57
M0-GOBP);<-F#?`*$?`*>70&,G,B(;,B+',FAG<B2W,B3+,D?\`("X-J3+`"#
M6P$X`!'8@4>+JWGK6PAD=0;XX-NKA\JSILJYP<I#C+N[20:U7``!4LO.'2#,
M#;[._;K4#;NTNU>NZWK6V4B-I"P5HQ*4Q,JMW)JKAQQ,X`,\($?'R*B0*(E5
ME0(-X`'C%\Y?U\WB+`%!4A]2\`$EP-\?\`'(6XT_H`SA7`:B4'ZRL#:%(P$L
M`@#Y&\["H#5<@TC3B4F9=/_APL``+J`"'C`/\R``6Y!]<T2<>F8$!<`A.X,%
M*S"_*\``R*4B-L(B-S(#]D9+99`N$-A+6="O^1PGOE,%YP7DY85QY24(<?([
M=2)>:.),L3-Q(=<?=0($<""1"%`G]5#EXG0[<>+3XO0%?C0-*"H+@%``\D1/
M#L8H.%G#/-ES.,PH5KW#2C@J(B;G2"D0(V8^0TP&ST`)0XJ%6NC$3/JD7SFE
M3(N52MNT<-VT6-P,UF`-45L"O^)V_G/72U;I=9<3>:TM7IOIW'`,B/>'7Q:\
MYL(4:GNVB3UFB'@6=)&(>.`#@B@$2($"0E`!;63(MN[9GBT=NF[KNK[KBLSK
MBSS_VHV,R(X,R:\=R95\R9:\[,G^VL5+VX=+-`8-GC5$;*1\:&=P5]DNW*<D
M&ZR,J;\--M4][K9ZFP>RF]H-?+JGS&)C-N`MWO!NW*,YFJ/6&<.!#X40*.>-
MWAC29KVZ6[\JG#"`'NF1'O,=S@3.S\+P`];X1_@M`7T$"/\-",(C"ELC"XX@
M"_%,X4N+'XE$X1J?\6\=SV\-(1$^#4K@Z%TYT(JJ';Z5!_6P,QLP*+4P''OP
M-^YV!_<`;]8H`S<B#*_D(LJ@T?MF;P"0!?9&D)73@`C031P,D8%0)P7:.A7W
M.P/*Y'``HO`E<227.O7@L%&B3%)"TR6'3.@T)E\0L5+R_P$W")/%\PT24``M
M^H-!Z-0Z]]0V[$\9!K-#B=5#("I&!V*H$@ZJ<@LFX0=-*3]\4-9<>)5PO;2$
MGK1=Z-9N#8;9P.B-_NAE>98G40MXO99::X>8[M=WR!-V*16%9[9[.8AJBWAR
M#)A'11<B4`#*X1PZXUAMU$9`<^M`X^NYSNN^WNNAK0(?<`*97.S+3LF3K$8"
MT-IJQ/RM_=JR70$PT``0@;>$*JB*F8GY8@2^U7J4$>Z^C<JV^QJ4BQJ:*;K&
M9^ZXFLP*PNZ?YMVT1RP@04GA'>^MG/^R]5:]`1!/+%EZ\H3#DW0<_)`)X\!!
M@8>%)!X082?%Q106+VK4N#$CQO^.($5^S(C#@P0-*%%J8`E``X,?PL0U$T:3
MICB9HC0HD-+3IP(&PAQ1D$64PE!90X\V<T23@C`*S8@Z*CI4*86G6+%:<U'D
M8\>0*8*)2%4`"`D4&YC@"\.!S!X/__YUN/--I[(R`,HH`Y<(@`(W`)1]DUM8
M+@#!"A0#*A$E!N`!%N!,R)3)RP0+F29;J%)E0B#-7BP@L8P$"1PO2"RLMK`A
M$!`F:YC,YL2$AFT:-"`!R8>$23TD0(!\"2X<P1<@!B1,H]O\CIL"3/8X,/$F
MP'4P`;)G[]7=>QKOX<6+#]`]`)3R$'I!"`"!O7MWS(;0VC9D6_W[M_3K#_?D
M0I\^+`G_8X<B'F%AD%-&&.$;!4>()IJHJJ%`0@HA?!#"""=LIIIFUFFF&6M`
M!#&11"3P@HY**@%PQ3[\&**8%X>(,488BSD$1AIEU'%&'&4LAIMC&FB`A`9P
M(`&'(8T4DD@2L!!RC1W66.,V&@RS\LI@LM0R2R.RM"C+%$0HY(8;'F("B#&$
M0&'--4]`X00X#8AS3CE/D/-.._,TP``5]C1`@#T!_=.`%_X4X(-"$R7T!$#Y
M$<!.%4Z(E$])X92T3Q5P@$'(!Q[@X=-2C(!&2X](XJC48.R`)H\QR0R#K3/P
MN>'5&_!AZR!+^KA@U_\LJ80#8(']-<5@@TVQDEP#7/$_9GEU__99:)W5E5E=
M![+V6H(*TK:@@Q(BX]MOSR#C#'+!)<.M8`TBXX91+3JU5'<Q(NDK4T>R2`4/
M4I)@7WTU<((EF*816)R99I**)IF$F4884?XJHZ:G;'*JJJ*R@DHHICYLJB9A
M.O:XXZB:><"KD>BUPXA"\C@+!2$0F#6,,`H00"ZZOH%'!F40>UB8G`&003!9
M.K#RCISSRD*!+$HHH8<L)!C`"\\RJ4(T.#KSHNK.JL@$B0TR0"*0KK^>8`+3
M1JMGMBEGPT(X(&1CP@?9`CD3"+F9^/K,S-:P(`HI?KC#N3L86&$/PF^P[KKK
M>@'#O%[*"P^\\2+W[KS&T7L/"O<RA_\QE_OPH^\6#&ZY+YQ;5JS$@0]@8,$%
M)1I<T,$(-_P0JPL?U)!"#B?,AL,0K?'=]VD8D"`3.E@TO18?;TS^Q4-XW%''
M'G&,/H`E26!22$X:R)X3*:>$Q(<%5E@@CSP.N/)\N;94?TNQ@F&57'+++&`%
M+(2H(`8WV7P33_[UU+-//NV)47("%*,^<*A#\>.`+T`4HAQEJ0I<X0I"N(+U
MG+2#!G0O-PO@X`)$$`(0'J`<Y=#$&S0!`4V4PP[O8F')4@`-,9&)7###1ZQ@
M%JM;"<02T-(5@*+U0R`&45K4PM9`!+(M@Q@$6.<"5QC@=P,31#$5!TA%*D0@
M@E%!8U2I`$'_.FQ@"1O8H`]?_&(Z\A",DKW+(V"15ZGJ=1$![$N._)KC2Q@`
MDQ_D,8\$DXG`_-B,HA2E&02;Q@\8\))I,"4J%HM*4S;V,66(XP?*^($H*OD#
MG&!%!46(EQLO$@PCD.\+&T`!"8"`#S+4HB$GD,O?OB$.!2@C,'LI0R+R$AAE
MW.%\P@"`&QC`!04PQC%'ZP'6.H.:RH`F$,L,!">2.1M!!`(2@>A,)@(!ATS,
MI@O%X9IID)"!#4`B`QF@6Q7`-@$XC&8"55`-99`P@1X`PF_-H0L#F*"%Z13B
M&(C#CG8:]T_Q0$YRX7'</QWWGO:XAQL]V@9][+.-_8@N'+GZ3QA6_T`*`3B!
M#]F(Q@CJ\J`/58-WTU!",VH'H0U-2*4<XETSLN%2$`'/+X#00_&,%R!J2,]Y
M,%*>3I_G4Q\!:4A#)4'WP+>`0AP@BL9@JC&H0(4H%B`/Z#O?^D")1C#9(4MY
M(),,GUBF%3"!E)9B4P4LU3\_^0E.$90@"830I`8X"0O=FQ(/.KB`$(9`A`<H
MH2;\>@P4^E43Q^@K834A0A.4XP!Z+4<(&@M"QY:#'/"B[+SB99%0UJI69X!9
M9V]HJ[8(9%I").VN>LBL9"GK6CI\0B64Z)9PC0N*4#1!%45PA",,0XNCPJJ\
M4N7&WWXE&$=81CK`*,8O/L$$T.@D&^F5QO_G.G>%\Z"C$^1H795HH`P,R`L#
M1'%'9<#DD`#3P#2(`I4?>.`%+S@)2A8F$V7$5QFB*(,,D#:)*/1@`&/#C!P0
M\U_$Q&0ICW"NR4)9"!^04@A(N($JPU`((0B-+G<0AA1DZ8:]Q+>7O50&/:Y$
M`>&Y01Q1<$/2N!"%#[BA!UC036P@P8EEKB&9D-!,UJI``T$(PIK'!$UG:)`!
MLG$-,T*&`Q,RH+78U.-J@7AG%;XP-CB\TPL]F,0/OO&W._QM&IP@W!X*80Q^
M9H>?!1THX\:#GO94+J$)S1P$-G<?^SPTHMN@ACG^TP<Z[$$"#+#&-#1`"HY&
MXT.R^P$?&*"$$)W_-*44B`:%I,+2E_8.>(9D@!/8$`2;WM0</%(>\WKT/.CY
M2-0U@H"0L(`D2.1A?!PLP`+P``D:^"`W4^K>`]9`52Q9%4R[=E]7?7V#K\Z/
M"?5[TUI1L(,5)%O9A)O?'@K0:E47(`1Y@"Q>(7OM5H?@KMOF`206\*D%T"#<
MX]YVN<NM;;R60P0-&%D++=O&C(#R"%P%=@T]>^\PG$NT.^35:7OX[UP-)$!%
M-&(1D27P9`V$`U:\(@RA(:K==DE47=*JR:*[1D]F"1I'2`49Y`'&)Y#A`-"`
M[KR>:W(WOJL([<6N!+#;+SO>\8X`\*YW->`2EFC@!X!DBC!^X))#ZL4E_U'@
M+V98LYI-6(`52E?Z)@:@@/_>'`"B6)A45/"`=_LVE'E(,%H8W)8PW&`,NL1R
M,^0`#S<`1B]E2+MB@J*.;\3]0<&3@`)D\9@2L,$Q49!`%+``B<XL4VHWAIHU
M+:.U94ZS;M-DPHNEZ8.Q60`(%L`,WB:P&[)-?@*7`3+GO>"%SF=@`'T+VM_H
M(@P2=!F*8=9.>5P/4(&6V:!0Z(YZKF.Y]R@41_3I''U"IQ^(/@%`E;"H!IKA
M9U*00N<AXE`S?C`-/DS#&KM[$.PV!"$*:<A#'^I=3*TA<P8`(!-U8!&U6N3I
MY.GTTS\5-?2*$8`U-``&3LH@7;O7!2C%54@8;/\`!G%MI?7IDO;Y$JW*@S,`
M-AE*P`.,GT(0-F*+@0H0`F0K!"J`'PND!2J`-5B3#4B0C37H0`]<`^Z1$N[A
MA"@Q012T/Q6D@2G)C=R`A&X+-V\3-W'K(,C"@DUIM\IBHT[*"!AZ'WP+0GTC
M.&MAK2*\EH%+0HJB*'][%@!)AR[1$@+<P8O@I"*X0BR\0CO@)),[E<L:KE1X
M@V5X@U08AAZ4KBX4B>:RER)P.3K2@'R1HY1X"9JC.9DK`^T:KY70N6@0I$K*
MB[Q`#`7H@4W(@$U@A4-D!41<.E:``T:T@`RP@$D`,)HK@Q_("@:``36ZK%7)
M@Q78`#79@%E1I1O``D;_DX4/$9X_(P7U*I1(J0"SJ@`54($(8H$KP`&S4H!O
MZ`$%X`*EB0$2*P$LH":MJ8S.@`2H,:?/,Z?7N`WA\$#8N(VS`8(ATSRZH3PF
M"(35T$;0RX#/&R?/Z#S^D@,E$`;GZ(!FB`35JP[MV`[L:!PR^P[9FQR#4@^$
M:C-GD!'.L0]:D+/]H#/_X`!\V`,AF(9J$!X7$"_9`1$^2(3IRYW:R;[F&[1(
M>ZE(`QYKH+1$8``V()Z;TI4G:(-1&TE0DQ$0V!'U>Y%2&Q(B61*B>DFYTK\+
M^C_#T#5>^R2N6D`$/,"=_"HS`8+ZH2`L\($"&!,0``$_\(-T\(,V$`(LL!ZW
M_YH@J10""J+*J70KJ'Q*F<0>#%+!%H0U'J`!NQ*W&*Q!&P2A,1```5"!!GBC
M`I.7D("A5``VA@C">Q,69,E+7[$6);RI9BDM:.$`,\R(%;+"+!P94^@4Q6R`
M+A"2)!"2QGP`=E/,3M%"KP@+L7BA44G#RL(X3TJY-2J".9RC.EJ)\#ND[:*Y
M[]+#.=2YHKB8GP,P/`R%37!$I4LG.,B`W"S$0F2Z39A$2PK.YVN*J+BZM[P(
M&"J$3T2+,7B96K@!)GB!>9A%6KQ%'+A.3;E.&-`4&.A.[^Q.7#R!+/"'Q_!%
M+M`[!2B!,;",POL\';.`PJ,\K7FG;!RR=OJ:R0""3/_81FX$#=0`#='8S\E`
M)]"[FLA;C;'A@DDZQVHX@2YS@!M@/3%[O7@D#X`R*.^P/<M9L\Q9*!GI'#B#
MJ/T@'8%P``1``0FH!F&P+CYS*9$"'D1;APG)/JQHOC[#R-_)AAS]'>D3+P9(
M!#<8@SK(M'_K@Y",$>7IM!DI2:!ZD6*```PB$B>Y'J@D*BDU-2%I`)HLC``4
M"ZWZ+:T*`07<203L*@LDDT+8`_H!1:H<R@(@%Q`@`UB@A4BH@$BX@CM%`0FB
MH#V=H*JD(!(8@R9IDJ>,20SBGOIC01=TP1F\JQA<`&_C(!!Z!08PM"T@&7>S
M.,^T@U0P`<[RK+H,0EP1N&G_&2W`/-5=L81T6(`MY($B4,S&;,PL=9(-J%42
MV`#KP=6WHJ`U00NH?,P&>(3*M,S+>K=-]$S07,-2>54WE(!!X)<XE$,[LD-J
M#;KLNCEQ@!!'\+F&Z5;$T(`)8(5P#=<,:$1%=$1TU4W1DP&<T)A!RPHG@(%D
MS8AA2`7RP=6T<(`PJ`4RP(<%Z$[*?(!'"%;YP\XK@,597*_DVQ<G8(!@NH/R
M5!K'0!ITVKS.&!M!\`S.2"?.J((!A0/4L%C/\(*,W3QDJ@POL*;5P*:5S:8,
MT`,M0``+@-FDH]G:C`*8.$=9^(`"(!P*[*<)79S$":B!BD<-O0[W6`\V@P!G
MV!R'_\(/B/H].B,(+/@`!DC%ANT="0&10ON!=9#(0?N0X`$_/IL^C)2^/I.^
MYZO4L>T!C_Q(&[B%''&>]@NU]JN1(>"&E:0_J+0>HBI4_0O<'=B!+4T?7<O,
MS.PU,M5)"^1)8..L^+D!Y7S*-:F@+N`J$*#3$Z@`/;73RI5*T*U*J'P%)WD%
MN)*K_*,K177!3P&W<C-+20T!3E""2MVD3,7,CT`CDM"%3OV6?(,9M\`W#C!5
M5"W>9[&!)P@#']B!0MT`+,#5Y\6"P1V.MWF;%?"!ZA6.P65>7`5%ZZ%*M$`!
M6"0!&!!6+@P)]+47N,RZ]?4D.WB`EHM6T@28.K0C#=`)//_,N=;\`5FHF&D0
MA>^ZI/F*`G4-U]R$Q`..1`6>@#@``'?]D(21BFP0`))!.3NHUV?;`;38@`(`
MNS/8`XQ2`?9B@/CRAAF8@01(815>X15VA10N`P6X@RC@"2[X@/Q2C$@(*VH*
M!!X(!$'HP,K(A#6@IHR=#*V1C"H0A!5(8CBXIDR@1G3"`W32`BK6@B"X8H>P
M%=#28BYV`'QP`!2`"2RK&5(8G.F(T-9SQS1SO0HU,\>A',>A/7M46O=@,P^%
MVB$02=*)*&IX@ALX@9WCD/+Z'9,"D3O2`&M@-'4`*1$)GI9CB1\($>^3/K5]
M/CY8V^!)!`404A7QH1XBB/K`VR7_73\=R06[]9'WB[_`91(<T,KKH3]8%I+"
M_0?U$4`OR<P"7-R>W&7&/5/)W0,L*#8^28(#0()7T-,[/5@_I:!D%MVW.EV9
M'-PUZ`)J[H+![0*Q;%T[X('&=-7$5$S8E51(O2,E$`"L<TLU--9/T@6.(P."
MX(!][2R&8"+B-5[C%2.">#!E4S8?Z.=^3K9G8Q6)D(AG*^@5F)^PFAN@=%Z&
M_MXE$%]8Q`'SK9=C/3EU/M85@M^4>%8Z>E:8P\.9.TV:8PE^(>F@B(:F$"3B
MO!A1&``@FX!0"(4H"`4YD`$9((*;)@)14`:?4P:!T:-"8@#S@@H-T$2*1DXC
MD"H@(*4-_]@#F&&(`L"+,B@#(B""^K)I-[CI!'#AK>YJ%DYA&<B"#ICA+.`"
M7^1%-Q@`&@N\3,@Q)I":E&4")M8#2-`#/<#B.O!B+M9BF*&#+@X"!PB"31CL
M/:!KR8`#!##9=JH"R)L$[>H`Y_B&'^A9+[N!?6H]S&X<]IC'-W;C\TBS.FXS
M]\C'(>"<AH+:.>OC#3`^'8UD$#'(1K,&)YAM:^@H!6D&LM67/6M1D0J9/E."
ML8VY1#`T/@N_$LB$2D"1F[H%D;21)2U)?612&ME;4U,2)M%*5Z8_#!K<699"
M]4G<>!,!,]7E,XV?7C[30``$XF8``\`#)H@$/;T"9);O"GI>JO^\;_UAWA/X
M@`]PN9B[(SX(\$VRA4?8`A)X`$IX!#08A>YD`1:0S#7H-M@-@0*H5`:8AP:X
M77@SN6"`!C`X@F!(A5;H%4L`%K`#.PZP9Q5_%H)8%P=HP*(L:!F7"`7T930E
M:(0.*^0``N;=@88F@2M8@@BJ@"V0Z)$IN?0]3O9-@2(PA?EMKSIJB:`[Y$,*
MO]'<PQ_HPZ/`BD'R.980AJH&8/D2!G@H<T>@)$M:F$)Z/D-:<YC()&OP`$QM
M(U5):I5AZCWXU)CQF:,IL;+F@BP(]"PHL1+3:J[VZ@0H@RSXAA*@88E5`*>Y
MXB#(ZR^N@R_V8KVN=(>XXKL.`KL.@DS_T`,XB%D$R(#C*'4F*/71(([*VQK[
M="?*@P-Q\H(H$(PQ[H!O4`7*AE`($#,U9@_$N=`+[6S*Z04Y_NS0SCW=^]"'
MXKW?NX5PH`8R\`"A]AVN93X*^+Z72.0'486Q#9%I`(!_X6T)P3[N&]M_:5@+
M#YY()A%`&``44>Y_<Y&Y!2J1?!Y3+FV4?%+^<TGK:64DT<K`C4E9+MQ:]M(!
MW(BY7-PGZN7'??C')1<'2._?40(7T`WZOM,ZQ=,3(`5)62\"(A12>`$2V`)$
M-JEH8)`1\(<&48=&$`!*P`48J`")?@08F`<'SWF9%TMQBU2\0@8`B#X7P`$J
MQ+@58O(K-(4B_\`#(^`!.\@#$`"C"S"B2N!78!&(%5]QY'H"/W!<!!SH5HEX
M,F@%<XFMKY)<&$]H[1W<Z+6>SH7%(L_!.:>L]#5ZT,P(^+4NCE8).42)*J=6
M[1IIDKY6!JB8CI&`"IK%(7&"F7`$J\@*JI")/!+JYRLD@<&C-D^DJ"CJH\Z(
MK1LEMUH!?'`P!Y``;PCK0(^"$S-KLQ9T05]A:5AA(L@"63B:8"H!7Y2"M"8<
M/:B#/?!T/?A]N]:#`AA^/<@$+0B$X]<"&LLFP9,;;[2`+_!&)GLGR8L\N]D\
MS-#^L;D,[8\"&3!'P)$%,W[QRU;C&E`S8:?'?[*]>ER/RTEVS7':$/_-CQ&E
MA16(/D1[J4(""&O5*%1K9DW@P&;-IC%@8$TAPX,#HU&L6-`@0PD:`6AHZ-':
MM!\,``!20Z=2I3XJ^URHU&9(L2$R8\*4:?.FS5PW8Q8[=&Q-@P98@I(@T<`H
M4J%&AP;=T6#'CG]2IU*M&NRJG:LI@FU-8<?K5A$W;IPA2[;L&;1ISZ95:W9L
M@4!LLAV<YJ1!@4@HKD2ZPO<*BA,,G+C0H,'%"P$OG/#1(&!0M`Y5_W7H<&?$
MB%.#'L&8)T"%"C2/6>!B\>@TCC4\(/$H!6E!B`6:2#'X,:C"5[`I4A0I\N#W
M[].G83QJ`"/)TP9=:.0A8Z./C0O2+:%\8LG_DO3LVK=S[^[]^P4;EOR0(9/6
M/!FV:4&0:=4*6ZMTV-*E(R._//ZR-PKQ+[!BA0],K`$$5$YA410)2UQ1`8,J
M5(`##`_TIEMNNWU5886[Z48A;P\XH9%&@X0H@08?DC@2`QIPA&**'&E`(HR&
M"4.!+!3810,-1]'`PPG3-$,!!<TX0L&,/Q*I`2DO&"#`#R$U*=*3/_P@S(S6
MS'.AAF`%8T0>>?B`!0H;,($/&;60X<`'KA"1119NL"E#%G"Z(0.=<\J00`+2
MX.D*G@F4H4`S"BC@A@(E&)J%`I$@L`<<56022!6.0AHI#6)$FLFC@03R*!.:
M,M$I$T`,.($%/B#A_P420"!A@05?($`J$Q9XD<$$M4Y`:ZVT>C%!'#((<X=E
MP7ZS`A-[.'"#,0$H&P`88"RK;"\!1-O+M-)2VPL$U&:+;;10!.`M%!`$``&Y
MXY(+`3?%Z+3--K2P.\0M&-PR;QLFG$#7-$I,8\T/#R4T4$(8,;2O0@=5=#!%
M0!:4$2D2.&&881XQP(<U#;F1"1TGJ72!2I8\81---`T!`DY#Z*133C/!!`$-
M:SA%U%$'QFR44$(-Y913D^DLU54]8]55EG:(A19;9QG=EGIFK;4'$I$89(T2
M&I"01R05^,57!57S`P`?2O`Q"&,ON,#'.NN0'<T=:5]V&68CJ$.!.GS,,__/
M#X8-HL'7:+"@PA8"?`;#CC2\M@!LY;#A1")\"&`A;[YQAL,6?(.F@@`&J&`Y
M@U?@0,(./N31RA/11<<2>*6;?GITEHCG<7WXD8?>&>VY1Q]]\J0CSWSSO==*
M&VVEQ5\A!2P`(!`$0H6%4PA>H2"#%8!6082]8;CAAECF-KU7#[QH(H@>@/@B
MQ"RN"$"*+\8(XP^RU+@0#`W@H'D#KTQ#P9".-".,.,((&:0+5S2PQAI<P("0
M.,E)M?%1D'[P``UAR2O!P(.7ZB&$#0`!'V$@0Q@<8(`$>(-.1)`!$8C@#6_T
M*0%\XE,)72$-%!)!`>`@%*$,U8,2*"`&2.!$%03_\:@J>`%37H@4)"X5""`P
M07#%HP$3D)"J)$[@4Q-`@A.A&`@+-'&*%N"$K6HUJPG`X58_S$`&HN`&;P0+
M6,!B@A:,58AD,<M98!#7N,8UK6M12UIVK%:VOA5'<9$K7.<ZES-DDHMM#(%=
M[MK&O.9%!28H82%0ZI>_?A2-BX"D(7S8U[[Z%0VW(8P"DRS8-)#T`0D`@",N
M"I_$>G"2E+"DE9:@1DUB*3*9O`0G*-M),8IA@@5TX2D'(@$6<!"SH#"%*0W@
MQ%/6L#.=7<4(P?B*5K*"I6"(16EN40LVL7FTN(SA('310`7R\)>^[(4O)R`%
M9?X1#26L(VJ#:,S=&*,$_VLTIIX:>.<@\OG.>^)-"4JPQRE&D#;)1*,":\`1
M#VA`N`648PQ.^`$?7E"$W3P`!I%+S&<^8[D3-*]YFC-*%_"0"M"ICG31.1U*
M4ZJ=T=G`!D^@CQ]H5YY6R(X,V+@I3K'!#OC<E*8@:,5/EW$&8YB@J'DH@']\
MX`.7"24)OU0>#CKJO.<]8J(9:B#U&*?5K_A&1!HQ'XQ:\+TRJ"A\Y.L(1V`4
M(\/\2!8_*I%#%/*C(0%)''5C@/YDX8C^->`!-*B`$PCXR"@)8TC5J$`1,F2A
M+7EI!R00`A;"$`8.U.(&*#`A9D]8PCY)`Q2@D`8)\_19/'6PE()2`""B$`-$
MQ?_``H'X816Z^$/9"D(0&>BA!8`P`21:(%53))4%X."%#0@Q4G#8E""J$,38
M0@I7<+!`!JKPJ@DH][9>R,*OS&B9?W!B!<9R`!O;R*QG0>N.T,JCM_0XK6RQ
MEX][_&.Z9&)(0B(RD=LH@`>:40V)Z2L;``/2TQ@BL8]L\ALC0-@D@V201$C@
M`Q]X6$<TX`80.:PC(W&"'E;9RI580F4XB<DM!7D3E-VR&!@X0\M@AA0LP&`,
M1ZF94)S"U&5.QF<]`QK0A#86HJVEQ[Y+&M+*4H`DQL,:=%%<'L903B'P92\G
M8$,]&X,W/O!A8DJHAL&^<0=AJ()*758``!3`)C=\@\;_4NF`"@XJN`4H%#:Q
MD``#E.`"&,"@`GZCW$8WFKDE;*[/14G"#KJP@$*T0QZ*:&EX5*KHT25:=>$1
M#Z15YU)%/,%V/75/&\CPTTT#%:A66`8(EB%J8QCC#44M:B$.T*4N+0`/"6W9
MRXJ"@_=MP2]2[>CD5("#!V!5JV!I(/:*\`B-<,^K:B61A350AI&@M7SF`Q^R
ME4$C(-6(?M.FZY"$(6!Q`,D1PB#%YBKP`@;8M4G3$"P!VZH$7O^:0M#P@6,G
M>`;)D@$?0MCL9E&(0GQOUAM_4@:B%,`%+L2`"X6:@&TC9<4J:,H"#&=")B*5
MW.@*8E>SG<`/,^$%!%#QN$C`_W@F@&`(00R1BWM`@!;T$(1-!*$.#L`'S&%.
M!RU$@1ZR**-EA/!=!U`!`LT2KWOA.$?S+BN/><26N<SUQS\6@QF%=%<AV85(
M>17@!`)9B,2J,1!/$J1@4#MWE;W6C$VV[6`*`R4#/F``4JAH,"`BA12^ZA$-
M1,(D=-@8QRY@B5OH)&0E,YDM4Z8R&QC#!T&9&3!A(+.A,.5E.#,S56SLP'9#
MLYI*.YKO,A]DM3B@4]/`EYP7P`DA[`4%?<D:"MBP-H$*5&T#%3@-`>`&V;N!
M2F4H0R*4H0P`W`'R__#`_Q`*"86&`!(N2)QCG'<"%2S_!!SE*(-0,&L$%:4!
MR%$.#__R8()EI(/2V,'.25'*:-$]6M*2;NGY(>U2##SA%[^0A^U@T6D0T'\9
MI":U"4IM`E.?V@0'2/6JY8$(Y,%"X4&K\0`>X`@-=$$O'04);$ZM7<$6W-JM
M/<^#5%6[^1H#;>"O/<*'0-N(?`_$N,A9D559J16T=80PU,B,Z%6W75N0Z(\X
MB,/]B,/G"9B^-(,-GMN3')"43(/]4,`6+%"64(@=[,`&3)`%A4$MG`$6\!L4
M1F$)E4$6R`(-%4H)1`$-E<`80,(:2,JF,!RF5`$G1%RD5`$3B($.94*C/`H;
MZL$>J%P0S*$#!($#N%S,X8,#[&$=SJ$?;H(>:,$F(``<:('_;F7!-R@#SMW!
M%>R!L9!%#3!+#;A1'.V1>46+M+#7>76+'IV+TBT=-\A7U+D++202.F"!!OQ(
M)DV,?W%=-'3=0SS$TQS$V!V8@2',ORR8!K"!`<2=$P"`1D@!*<"=$PQ8F(U!
M$)A$2G`,=,"2A\U2B$7CB,'$B=&`@;S8BQ43,37%_^R`,OG>/VR)5D03CGG%
M$>R8-6&>YFG36A3"'@1"(GA3U.`!$PA!7_B%Z57`"?!#F2V39?P`,)(2E:S@
M-Q2D07Z#+*0-9KSB*?@3E>63"ZA``^`(:[39`E`!;2@!`[P`\U%@\RC(YE0?
M<B!'H*D&'HC``2Q#*QA:Z(Q?HHF.__FA7TO)I.K4I$NYU!,\`:4IPB_<3DZY
M1RM8`5#97_\5@O\50BJLFJJMV@+D`1X8@0&V&N&X&E7R0$*]6LL\0"\UX`/.
MF@1:C4=*U?-L`0Y4U?5L(+!Q8!$T0(AXC[&!R`>N2-O-I0E^U?<@V_S(PHQ0
M&PS>3]T@T(Q,`YS1X/WHCS!D`P\:4"@58ULYP2-8#UHZUA((P0V421C@`Q,D
M0`B)0AE\4!F$EA1RT&81`1>H0PD@2@EP@:$(W!C00,1E"AS`P3OJ`1P&0<K5
M@1W6`6[.(6[6X6X&P1YLPB:DD7!N0G`:YR`.8A!DPB!:@!X`07!Q'!>MR@1D
M@30HHG;=P?\):$$![.$9,(O/@:>RE`L<'9VRI)?1<4M[)=W2`5*Z#-*[2%U]
M,<$+6,,Z+,1!](N1$$37%41!4,!]^N<F(=B!=1W:20`;?$##4!C<-4QM'(1'
M```;C$$@!,'=K80-T,(SBM@T"A[@\40Q@$`!-."+%<50+,4V)H<W_@\XAJ//
M;`570"8UF<#E7=,ZKJ/1%``0N(&1'00?(-$K[$5?5$V0Q@`]2,8(K,-!+"D]
M00W43`R51:D^#8(+S(V5?@8:J``+;"F7XD)QJ-EJM)DF\,/$,(`'4"`*6$WI
M7<$#4A\W:N6.-&4JO,%/_0*ES21TQ&1,A@Z?4IK[N9_MR`,[M`+_._"">PBE
M%5A!J-G?_9G:`9A`'BPEJQ'@0DDE#RP``EIEIFKJ55IEX&"E`C[`&FCEX1W%
MK,W:!*9J1TT@@[#JY$"/A$Q45E4/X]A!$GC5BW@/A3T;L[5(BK2(8:"@76K`
ME*A#,[B@M=7(D#3##TC`E``)!8A#1XB#_4A)D]A52#``*5B-$VB."N!5D"!6
M$5[/$28A95Y0&)S!"B2`,MP>9Y:!*(!F"8T09DF#O=HKGA!!"=S!::*6H1B<
M`HQ!`="F'P:!'M2A'!ILR^E!'10`;N+F'M2!'-)F<+(*`C`!K201K:S!K4R`
MIOP6J]1*R)**%D5!(B[B!Q1+$)"%,SC+_R1:HGNE%R:.)])Y"Q\A'1^U)[DX
M`[F(3+O$Y[S8BT/L2RRV8H)=A%P!C'Y-!$4<6$4LI('6!0-(P`DX&(5)`"F,
M4D>8FT8V!(*.`1*H02VHQ!/PG=]MZ-]Q*,@XPP(`1:PEQ8G"F(JJ:(LVTU;T
M&@-5$X]EDWK@Z%K<0`$@`2!X$]1T`21@P0E<#3GM(P"4S2`LAA-$+F(H!I59
M@STH`0YPZ9;"@)=2`BY0`NB&KNB.+B4\0LL,GT(IE"9$0F`Q@`M$7P6L*6#4
MVJG*6O4%11>`*0(V94K^E#S\`I^V5)^Z7SJ\GZ`.:BO('RPH:J@MJJB]`?0Z
M:BI(:@BPVE1:*O^G9NJ.>.I5?JKW=B^HXHA?M4P7B*IR$$57VEI4M>JJ4N#S
M1,]9IJ56"1N(B(CY#(*NVB_$S"7YR.5=G@\`3$,T5)M>_8C^G)L--HF0%.8,
M0H1('!`/:L`5&,$"7`$-E$(#&$!;S1ED_EH7%`4*W(!DU4(8%(!FAE`(>4,*
MTVN?$$$92,,W@((_@$+:@$*^[FMJ"HIJMHD"#(`>MEPRZN8>&*P6P`$A7HH@
MN*:C[%"F8`HG;(#(ZM;&23$"U(.L!$*H8%QO85P6:=$$A((P8&<924"Q>.<;
M1&(DOM%[5:+-JN=XF@NVY"QYZFS/.EU\'A(B8<%#08F1Z9<G!8Q^"83_?_V7
M)R%8TWX#17B=@`%"U9*"K@:C@_9+MGJ$$P`"&T0"$CA`+<R+AJ)M+-T2B>4$
MB$+`&I#HXL'M-B+3#JBRR]1M5Y"CC!Y!(?!8C?K8C;I%7+#!OM"%-23!"B`N
M"I#>.'&4:>P-52C!/%!.-$S%'3R"YWII:70NZ4YSZ!:!*:C9\*W&`HS#&)`"
M1(&3FDK@\K`I/BI(FR)(<BS']N[N`!Z`,2R#_+$#.QRO/!_JIX'`.S,J]/H?
MI$KJ`%JO`08TIKJ:51(TIWHO0G>O`BXT0S<T0XLJJ3[`X<%`5T+.@U0`JV(T
M^VIT\^0:#"16$=*J`ZWE6VJ$KFK`(^_J_@(K_UB!%;+]`(WLCXV<V]06!H`1
M24C0H+5EPP,W"6(.D`JT1E#X%0X0"058@[ARH%=TP0:0``HX`+J6L)^PR9AE
M`1=$09R@T`B)@C3<@RPDP%<[`KUZP[Y^`**H9@P,``VQP0*<X:.H81A6`:G`
M%B1@L1<*R/#E]1I\RA=04:E\P1,Q`6`3T1<@@9A$5\=ND:W<UJW$@8K@7`<`
M0+$8RQDX@S,$0"3RK"=N]GG)4<ZRYQS3\;G0!![3%RU0@08LI@;$XM;UIT$T
M`UWHU]("R8!61"$/:)`LZ30D@@8PLM6"5<-TA!(\L$=,`S!^`!L(`1/X0BW)
M$L@\=]J&\LHPU<N4*/_C;:-3L#(`?:/O;0F,EF/0Z&TMW_*/(0U9.``01$(\
M\O(6+`#B,ME?.!D)A"X+3,4(#,(\W`%^-\*9L0#HID#H8D+H`KB`%W@*8$*!
M([B`VX&H*B!K+(`(<,*X55D%@.1CX8`08/CF^$57GO/U+:`"%O1"=<D!0&^I
ME1K_26J7B$`!7J^K86I!QWCVSOA!(S1#)]3X.K1?[7BHT@"/E^\"0O16'EX2
M4/2I8K0X:W2M<71&-PAHX$!O/!.'S"\,2(`'?`BN7KD$O"7W7&VP_F]+`X`P
M#'"0O,`:8'!?\4`#Z`_]-`,#2,$/_,A<(>8/SG2V%J/^*$00RH)C8A4T=4'_
M$CAU(8@P"1<".(B0:&86OOG;[94![:7(#VAF%'0`%R"*%&1!":R6&\3`'IAA
M)N"0#KT6<V4<$U!0J"!!/111!@`!))0Z%"G1;FD<$@1"H\0U''""&&2`(>B`
M%X1"*$2!K\M!%A"`',@``+1K&:6-,DSV#>##,?B<9D/`97-VT*UQ:'^BSO(L
MS^;2ND!=NU"!8%CM0S32;?NG;&>#?OF7D=2V;;]BPH!2)358#'S`"VS$KC;$
M2GL$UJJ=P'J8<_L[X`4\RH1,,9`R-\H,S=0,%KC,&OC`"N0!?^0?"-3M.$+F
M-(D`C=:HQI-WC^V'IC``;-.%`/PR.0'&.`E!$8`N_PR,@%3D4R-T0"/DDQ)0
MA@H408(K.,[GO,XK.(,+SD+S0/&1J4:J``K8KH:3`)N&)/4A"$GF^#I3)>$$
M(%-*Y4+MK@%NJHP;M*9J??8&#D(YM(_C.([[N/CR>([S.(ZHLU8*N41+-(EV
M)5E"CCA/8%3-?51%59._+TB+=%8(FXFXI<-<[98+OET6OI=_SP^0.9]?@57Z
M#P9[`%W!=I/,2!`>IF$:=9[+U;1M/@.H0-`P#@TTM1`4@`5AT`U\D)O`"57'
M2130"0GY6[NZ:QG`@^YIYKX&G%67P`RY00EH',8E%W7Q$,;%UO!G`G`%UW`!
M/\;M2@]X`:^3@`[H`!NP`?\7$``@D((;9+\3S)X<R($"2,$DE``;1($!:*%J
MGF86-#H1Z)XR`(%W'<LR\&P-:+NX1#NUOY=HY[][RA=]`<2V(<>8>/A@0`(#
M:]:F5:,0#2(%AQ,E-JLV$6+&B!`G-FNV<!I#`!+8G/CP08($#1)(I73"0`,`
M)P`T,&`PC0%+4A].+$`W!&BQH$"'""5Z%&BNI$!!$`U`8T>#!FNH,H&TH$`!
M$UM-&*.RM5"(`@L6K/AW%FU:M<&"I;#3MFV*N"GHVA%QXPQ>O6?R]N7[]R]>
MOGMO%&(2B,%':]D\\.`DY`H*R)$J4(Y4!!.E1];^17,QZ,Z(1NH&#5+2X05F
M3*O_6;=V[3K-ZC1V'JRA00/2;;(+(C%0PD``#A+#B1<7?IP$<JE3N]R^S0-Z
M=#P\R.)90)W'].O3HW?W#IW&=_#/G9>__<`\#?3GV:MW3Z-Y\P==YJ.O_V#^
M\@9)DI.H\%\%`P084(`7#'R!0!44_&^+*QB\8@L&_ZM@01P>*<*.NNARBZXB
MDG!"@D%2\D`E#T`D,2655-0`Q1136BE%&%?20`-99*&`@FF<4*$")PY,C`)A
M@O2(`D<HN!%)'&T\4LDDE[21#Q4XS)##%+K88;@];@BCEC!N`(`(&60@@LPQ
MRQ23"&_43$!--6=(P)$$$B""BV\4N%,!+DKHH00%2D`@_Q`DX*@B$""JJ`()
M)":H8@PLO/!"!QUZB*('':*8A``"LL@BTTVYT/,$-J)@@XT22OB`BP^R``1/
M">YT0P(9``!`AC)LM;566V<%D10L]MC#@1O0<898"(IU!@)C(7@CV0`@<#;9
M:*6=EEIDD566&Z%RH66;;FD9HH`*=GI!`R48LL8AC31ZZ*%H)()HA'7=O<BC
M<S_"R0E`##"I)0E&BI$FFQA(9*%F&'!"BIW86(&*HH@RRBB'AU!J*:0>'@*"
M-:::*H]"\LAC+*Q$7J&L\JA:0ZV4TWJ+K2E=SC`8$4P@K"_!]O)K,)SQ<F"%
M0-RPIIELK!G$AS7&0.&*I"-Q,/^2$S"CY`$G_BE-"74::82"=4H;6K768L,D
MMK#!!CN-LLG^`QKT;,--MP->*9>/%X0KCF[BYIY[N"2DVF$]\L3KCCOOI@N/
M<!X(+_QPO]-;O#W[G),/OLCORV^YX8Y+^K\3%%2AP!<\\,`%)T37P`G217?"
MA=0-''#S_R!\/<(*(EP0A@<PU'#*1SX/48(35_)@)1$]$#Y&%V%\T<45IUF2
M`H-_\$B89HID$LDGG:R>22.#W#YZ87X08,,J,S1EAPV$6&%+,L(X(U9<T1P3
M?C3E3$`:^N>?WQLN9,%3"E.CZ),+2!C#&'0P`,CH(!(QX`<;=%"!4'%A4B7@
M`B`V)07_*=PI)0IPU0;=@*=7*:"#'J0@(*1`0A*2XG,I]`""6*<"-*A@"P]8
MP:_P88QC64M9UXH6M*!%+1]&2X?8@D#$ML&M(9A@!P;Y@!-^L)#%5$-=490B
MO-HU+\6$!(LXD<`'V!`#`T@!>3&R"1^:N`Z+-",1`-B)`3ZP!A-<3&(2BQA2
ME$(QBA4C8U'9P1I"EINB444_#8C*&O;8!92I3&5PD<M<PE>7N]3,+S?+66!R
MMI="[,%GBQ$:'[K`!"R<0#)+JTP%^,&#9V"B""\8@0#X()H(1,`>(SC%(.:A
MA`<\HVQEV\79TO",/SS#E\,(AC:,8(12'),VM;'-VJX2`BPX_R$1#'!!W>J&
MM[L-9V\-H(]Y#.>=\'C'!^#IIG/&21[&+<YQCE//-M%#GRXTX`':#.1^&F`W
M!U%(0)YS@4I*UT_3G:YWH3O=($Q'NG^FS@4":)WL'-2@"6T.![:C4I6*D$H5
MNH1W(U(1\)+'HN,9KZ,,N$<TGD2](Y'T2$Y**9*DYXAF"*-[+X6I.(1!4YI^
MSV55X@&6-L`$?(2!#!PX`ZMDH(`L<&%3GLJ"&S8U)F_<3TZNP%\6A!'"+)0@
M"C'X7PD&\($7N*IT-:$1C4"D@!("H@3].ZH4CGK426S*@[,"@"C*P("ZVH1&
M$GB!@$Y0@:3A``:!3<(CDE"/1Y@"L?^FP,5B&;L"!SP6!,22+`YQF"QF_1"S
MU[+6L2#`#6=H:PC=$@@D3K`3#]SD7-FHXA0S$B]Y6;%>/V#`#V1KC41H8"<G
MX%<87V23D)S1(S#9(A<YD8<X0@R.$UL*Q98BE&(X0V,:DPH)YKDWC>UQ8]%%
M9"+9DB'OOHPN,J/9S<@+&)M5LA!``,0T@I:-'S3`DZ#$G&5B0(-AH+("?)C'
M*3K0`=&,(#1*8($M?8F)/_QA%P=^!C&/61NIX,!!"GJ!0%5`%1JL(3>&"P$G
M2*$$/FA`.%@@@8BIV9_BP"!O4GEG%PS)N'(JSG").V=ZUI-.^1BR/NY<0XZE
M@F((`VA`GSO_G4$-ZH*5B,Y$GW,!Z)B<PB4S><FH$QU"J5SE%\RC0A5@@>RX
M3*$*P*`(XJL+#"I@``'M3@(HXFB+@-=FC;Z(H\B3D2P@0F<[D_1)1I)%,US:
M/9K6%*:!%L>@"6W3FM[T!>&C4H9XT(4-D(`)6^I2&`Q`*S&Y00:>BL)2D[HI
M(D#U?MYP@R@ZJ*<!#&`,IT9U#&)0*JR^6H)9`*%3GPIJ8<#C!S3);5__"@/`
M!K8!CPAVL/'S"-OQK0B/&,4C-A"%*`S@"U_801(8R]@"/-8!(%C&9+E=6<Q6
M2UG)HFP.N>$.9H266P(Q`0E8(H5R3<-<U;#(:EDK17;)6S$"\\U'_]QP$#:P
M$8PJ>E%-%C-O>MV6%*0PP`O&4("@('<H$:>C<IL+`:A(!0L8;T#&,QX5J417
MD,PYY';3HLA@3+21;A%!(2!Y7I=7<I)Z*0P2V`"`:@#-&B3P`2=`^8H3-(TR
M)^!$)W81#!CP`0TL0$/2E9[T>=220A-V`A^44`T`=X#D:KF#!@RY3-PLH!.<
M8,-L-5`!O5%WQ&BG)MZP25UM[GC'%^[;C.GNGMK8^.[K7"?EDB"<""_<<Z,C
MJT'[J9+0"3G)3W:!YSRW0L<;R`.=.]#C%0^Z)5\>RI97W3P0]!\<.'1"#&I`
MF#>4H2VP4`#_>>&9TYR\C@J<1:XWGCB0Y/]21P1:IH$&M.X!;>AL&!KXO?>>
M`+Z+.SLXF@1(2!\'PH"",HA)3&T"]?395/TV1>%32*W5FEPA#5=(=7["4$89
M5K(3%9S@K[^&@50>(>Q'!)8%+-@""Q1$__IK607T9\$5`-M^VZV!!TJ!!^S`
M%/``#QCA`+.B$`JA`!80VQS@5X1EVYCAN3:+LZ9%LW)(`R7+LSK+6K@A6[)E
M*;H%"U`B)6YBMN:-WNI-7CKB7@2&#P@&C4C"`/[M`_I%1@@.:!RB(JQ!MH;K
M`X0`$A`A8B`NCBB.N>KH8:!K8S1NGK`KN["+*K*NY+JK],`K!<1KO%HNYB)I
M,*C@!FX`"2)!`MK_RQHJ@`:``/U0H*^:Y@H4J$!<8![D\.GJT`X_@P^L#L#N
MH+^H,&4Z@`^FXL+6A@9$`!(BX3?XH`)&;./JJ9XR3NWJ!L7<3C]8;#XN[#UH
MK#S:R3[B[A)Y;+J2`T!.0/)4B,DD8)]"!Q51)\F<H,D<[_$B[T`.1*$VAT<T
M9Q$+I',D;Q873\DP[_(N;\(N[^D4J@)P0,NZ[!B3`$,6#0<:[W-0SP#0H`+0
MP,QVI\U^!\["*/;"2!RD1Z9>*O=R#_=H*AN$[\^^$?ALJM"F(=&N<$H<;0.P
M0-+(H!:$H`S:Y*GVD?KZD4V485;,:M?Z"@5P``>6`S\>H!04,IYD)_]L_]$6
MM6S+XN\A'W(+Y@_%!&D'F,`'F&`/LJ(!'?"Q/G(35D`+3A(!5@`!5G(ED4`+
M$``($&`/@N`,EN&YBN$FG2%;C(6SQLTGN0%;/$LGC\6SLL4H1`L=4""L7F*V
MJNY=6)#>J@BX0((/!*:)A"$G;-`D`N[(:N('LL'@<.0C;DL"`,$D(L$'',8(
MBY`H[$BYE#`7\`@J]&@Y,BZ;0HZ0UJ#K?,`'S,(/_P$N8`;E%`T:"F$+:88+
MNS`,Q7`,`.'FA$8`.I(?4&!I?JXR3"(1(&(=-(`/.K,S/8SJ[&$=K&$$L.XO
MT6($UJ$S2^/#8.!DV(8&R&(,8I`/#,#M1&SCT/^NGB)Q$H<C(_4CGG:,/O3R
M[CQ1[M1#+]=)*OC#(%$@<TB1%!&$\;#1%:=,RDC$%%5H.F>Q%@/D"DC@GH[Q
M"@ID$1O@[PZRGBA$%V=QA>9AA51GR89Q&-\3=.1S\6JQ02)$/X^Q=L(L0V!@
MPK*30`P@0%SH!*QQX3[GHSXJSF)$&8(D>GP/'87A'(//'`]M0BUT&CR@^,2'
M!C8`1!T@##A`?=1+`62@UMC$&XB@#`*R+*7@)$Y@7W3+K[;`(`'+(%G`UV!`
M1]OO$1J-/A2R"(ZI"!X@"3AG0.CO(@U2;W8`"#82"#J2+_NR+U72))E`"YA@
M)57R5WXE"+QT#V32`5S_$@(GX+&T`%@L(`P<(`A$%*A``">+@0(_*R<[T"=]
MTEA`<"B!LACTM"@I\-S:H(BVH0`,0&"<`"?B32)6,".B<B/HY8IDRRH9HBQK
ML`9O$/88@`]V$$=P!-]^4&%.@`G<X2C6LBV7ZRTI[KD`:3D\;H^HHDH5T##Y
M@DO\X#3?POC`*V9FYC`A"6=T)C!N``@"`1`^(AN4P`.H0I269ED_(![.X@ZB
M800`;%KOP%KYT%I-,RWZBUNY]5KY,$JV`(9@8`M2;Q`M["H6@!-FBP\$@+KL
MT@D9L>V(8S=13&^6XYV$DQ/A8SZ$4SGKZ<<T)Y\:;Y]$IW=0$6$K3SL?;V`%
M_R`Z>40]*P!I2.#\5.`*&N#"#+(\O>S!KD!!Y@9`.&<6KXSQ?''QX--D45:?
MAA'+>,0@82=IDL!VW`)`,2\[5PA!]B5ST$!&S>P#T$SV'%0LA>'VQO%";:H9
M)-1",[0=/8#TQ(P`L0!$EZ\6?&``M*H$)F$22B`."%1G9<<@`TML8<!'?;38
MRK9L\4,$OL`'KF,W1$`$%@`/I&T'ZK9N@0!OL70%9JA+@:5-'^MO'Q!P!_<!
M\0$?V/2GVC0,PF`/.(`##/=Q*^$)N.0).,`<VB!.XY0"0_"YA'(#\[0HB_*S
M/(L91+=T<=(HE4(@MF$'2$%@.'.V>#!=&-5=U*5='/_B(^[%&O1-8$;"WWS6
M)6BB)J8A&W@P(IK'MD9BC6)@#1I&CN!HCMP2+I7+&6B`+R%A;U<`)`LA6,Y@
M<6NA%ARW$BK!$BRA#_K@--MBH@:S]%8N#+EP"WUUO$S@,`!A,19C$#92")!F
M676+#1)A!*KA%`9X'2@@6[NU`[`U@;_56JEU6A\8P%R`;($-!SCG-6U#PSA!
M`Q*!#SP`!_1H!^PR">Q27M%N;G:3GN;I[MSI[NYN.9!QX0K68$%DGY)L86-1
MGU;(8?')975+./[#[1QH*FJC0)>#!BI808;#\S0V=CB'<P#D0-QS9:L,&%.'
M/D\6BY5,H3[O99'1(*D+0P#_-/-NU@.D0(?-K*^68$)\MHS1K$54XD%A*FF3
M-D/KV-"F01BF01E^0!D(#4-M:AI<X'86K2Z@XM%$U`^8KP!`=`,N80/RH1[R
M@1&*H`&$(-C0MOU\C;"&S79LAP=,0>^RPSHZ9@$+P006,`P%=P^T@$M7DDTA
M\$O;-'`?RW`-=W%'U''%]PG&EWQ[V7'[8)=[>9>'^0F*V9C](!W:P`HR-W,I
ML$YUDAGVM'-)-W2=H72AN4_[%%"5RUMZA"'T#5WFQ=YJMU$?%=]`8G=YUR;*
MDHMDE`U>0`K"2@?G+2)4`7EERPE(X=^8EPK8\@A1-56GMRA0&2^X)'R?H'S-
MMP]L_Z`/+J"A;<"A(SI]6X:0OXM*M+!7)>F\6BX,]X`)/B`DA(8!D@`2L&`R
ME28R^.$$$F$08"C^Z$\)3H$"('@CJ@B"'_A:N?4?JL%'2H<!UJ$:7.!D;`,2
M>``20@`22.$'E,`)+M95&W&Z'%$W26`24?A>50PAX4DXA;.>$M1'TLP4&6_R
M:%$Z`\_R1`=!SB,YKH`'ZDFZI(L&_"JBNB`Y(@2&%:1`(!)`CO'S/`]B56`[
M339`L7B*4388X=-SL.Q&%_M&F;%F,^_);MB,5\BKS(P:EV`X4``%?C9%6N1!
MA^3VTG&F*!30ID$<I@&U]UB/]U@91($!9N4'_OC0:,IIX?_1NW9*:@MA1(/*
M`3)@`C(@`WH`N%DA'WA`"**`JA^!!?ROHGB@;1?@8TQY,6GUEO'A!@SW`64Y
M"&+Y5QP``6(`$-!J`!+EIX"*`]+AO"NWF'LYH?O`?-N[?-T[H>>[?(N9`Q*9
M1(%J<?\"!*P`3I=YF9E93N4T6Z(YFOO4FHN2P!,\FXVRP`M\P(5B4+?!`YHH
MG6?+&MH%1\BYWC0<>:_HPL4J)UCB(+S(`'#0*SF57=RE7J*)Q'^.$PX@XB*F
M*8Y0>@-Z8N+[O1VZH<\WHGO\QR\`HM'W+W.*?1UI5C,:YN`W,`H@$/Y7:(X5
M![Z`YZZ`,J[@YW3+#2H@V?`C!1K_8!`>.('[\#0[X!N(%O?R^"9PHNL(D2P@
M@1]^X,,JH&X)*>2B8@,P+A+KM>V6,Y#>R<'B22K*;/$F3P!P5CH')-$)I$`6
M;D!<@`$4!'@^#,L,B4(.4F/\HX5$-J\YQV.W&*\1!+"1M!0-Q#WE\,H\0(KC
M$V6A#*%<O3[A4_-.%H88NXL_#QK)^&8]9[*EP$`J>U]0X(M:[T7$84@`K4+I
M^!QK:OS<H`1B8+R1@"57$@AB``!:]`<&;;8!V0D&V?AVJGR"Q1[)P`%8P=S/
MW=Q1X09FYB_61[_#X*=J^7`%EY8/MY87E_ER^;PYP)@KEW'1%`*!I1;ZO9@M
M`:$3FJ%M_V"^[;MRT9L,'EZ_SX`,`(,*:E+;0`#C^QL$8,$*.!X6<L&_<Z&_
M!5QS47<HKWES`56;!QP$!]R9G7EB1&L(%*(9ID'.K4$)I&<CRGF<YZ5Y=)>V
M7I<F9*(LMZC5V`@E:L(FS"A=,J(C;#XG<BL2=L#ADHNY4%4)<3P7VH"A+\`2
M>%S('SK(OQ[(>_PTY2)7+5HNH.$`WC>CX[=FP#`,TRL&W"`;A.8'*F`-F$"W
M+`/+48`?$J)TS`5=1N`;[N`;#O\TH94"-&`>/D$`T&`+DB`)6*P+EH`!IN)D
M<B,V(6$,V+4"IF*/ZC;D&E$W4=@W4]_MKKH2'^P$RGH75T<7`?^/0#Y@/6]?
MZD!GR@P$KXTQ9"F$1YR8T7FQ<SBOK-LSL2<L^5G=/H-QUJV8RF9=\YI?U6N=
ML4F@(,<3LE4(A73=US^GU^'Y&CL[)3Z;M"U4&5Q%"L9[`ZXV!J1@5L1J5D2!
MMES[T/#XM&W*!1[`M@$B13`[0'9L*'`#7Q@R8?`Y?!BF8<*$^,XXC(B10Q@.
M'#M6XE#I2<A*(RU5,FDII<HG+%L^\4,FIDPRK6KV6[;,1*H\A0J=(<.!S)DS
M-X8:/1/FYTPRZ<CX29=N&0@05JA:L0(+*ZRML')M]6HEE]A<Q<@6FU4L+;-B
M:YEQ4_MV;=QB<>?255ML2-DA0[:U&:+_I)DU!C^F6?M1C4*TQ8JC-6Z\V'%D
M"M6:"3X\C<%@!@`T>)8`&M`'`S%.G/@`6@,#S=D23W9<V=IF":0^Q$#!J0#?
MO'KY^AZ2ZS??X'^#&P>^+>6%/C:6.^_CW-+S"]*A0_^'/;OV[0-3V$GA';QX
M\7:,%"IZ`SW1]>K9LZ>B/OV90H$B29"=S9J`-4P,G+B"0B05G!#)"8`D(M@/
M"C+@F0<>2"%!,]M-N-TW/Z"!QBAH;+'%)5O4@T<J/DA!0@-KG$@##9`LL``G
M2O#!@`H-?$'#&CLT<..-#32`Q8Y8E`AD`R20`,.0#12Y8Q([+KDC"2H(8,`+
M`@@@Y0M13EDE_Y54?J#E"UEZ2>4+'DPYI0I2"O"D"FF2R6:87K[I@9@OS!.G
M"W6Z,*>#+^#)YYYW[LFG"X(.:F>A@WI`***``DJHH%ZJL`4.DN)`PJ0H5/"D
MF`YNRFFG#I+BH!0>@"K%"Z5*\<$''DBP*FCB4"!,,\*((\RLS=`JS@]E`,"`
M`E)DH8`$98CRPZRTSCJ-,LH`\(,RTS3;F1LO0`I#$=V!]YUW/'2Q`Q8%.'`#
M1D!Q-"Y0YG+@!T?I<"222"BI!&\?EO1!;W3TJM14*V<8<T-/>12`QPH^?&$C
M%AN0(`0*I1D0I94D%,(4&?(9M51,?CP%53I/:&R55EQ]#+)78K4Q5O]99*&%
M5EMLT:6RRBOC=5=::?66"SHF+`#)-,T\*QM^KTD&-&-`4V:9-<^NQD<BJSGA
MA!M.2`!(;1^P<0(;!JCJF6;6-$,!9(M5)EAF#-#VP0E"8`%);VH#-US;Q[W-
M=BXD2U?==-9%9_<%RU'(]WC9?@=X>,&(<$!Z\;EW>.*&+X[$&(!DDY]^.T#"
M!C\H\%.!@`4"PNR8`F#(X1))[$""%-_P3>$W#(QB2CU)C+[##BN8T$\A,5QA
M(HHITK``$X0I84`#-/A0HXTX'M^DD,H/B8.00):(9`-*+HF#"E=:^26677;Y
M9O?>@_DDEF>.[WV<'LPC9YUBHA_H^G@JZJC_HO"W?VBBC1J***+W.UJH_BZ@
M&:E)54I22[@"#K:`*3)IBE.@`E6G1/6@&`@A!J0Q`(1``YII"`-6M,K&K&PE
M#&4T2QFTFL8TB+4K"2A``1\H00QB,``A#&`,`YCA!L8PA@TTX`%%L$.VP@-$
M.W0!"%A80;@8,JYUN62)+H%7O%0B+WDY<8HI><(9?&"0(56@`EAR@1,&H0$^
M**$1IZ"`.D;@CQ%TP!\=J,8+"O"$7Y`!!/IJA<4N=K&,026.+?E%*T`&R$!Z
MI2M=$<M>@H.6E;4,+W)AY,O.TIN\Y.(`3!""U:I1C9XU(S_5&!IL%`-*3U*@
M:+)9C=@8!(#02$%J_U9;&"DDH)H?;,TUD7',*'>V&0"0P@!L.-L*=N,;WO@F
M.,.,FS&-LPWFW*UNT&'F=.J&N@EUYV_C\1LTSH.>Q"%NFT5A3WJ`,`8VX,<:
M+MB!#TP3H,QEKFJL&H4[1_$ZUWU!!'@@P0RBN9T[,&`#J0C8"@I0@$*8X`RM
ML-T)=G`B%$&"!SAS@C7X\`(2X`$/PUM#%]:`/!TE;TA%JE0#*-71CT(/>A4P
M@/:JA-+OJ72EZ%-IG.@D)YCB2:9[JBF?X/<G_BV*4(#RGZ!\"M2?[D]_1!VJ
MH-`T*0'BX`I$>L0C8`"#I7*1>UX2E:D^Y:`/H``(>T``$AKW`2F("D*OJO_5
M!W$EC&<M*U@*`(042L"&%\YP#$A``!/V\"UP.:`0X"H$0/-`32`&T0Y?*(@1
M+<8!C;%$8XS5(U0PML<GS`N*3CP)O$XB12FBP@-*6,<Z*#`"--ZA`VOLP!WN
MX(_3AG:U(U`'!4[Q@D(\H15TK(ECGV`.)K+$!D_@+3M`A@U84`,6V!AN<84K
MR+$8,A>ST(LBG^NRM<@L+\5`1%JL:]TA'`,++K",=[_K7<I0!I.)Z61Y05G>
MHAT-::O1``"<0(JHI6IJH[&:`5ZI&MEPK9:P\:[1EB8!VYR-"8<(YF^(Z;8$
MPRT7R6GF,Y>SS+LM$Y_:^2$U`_>=8!BA<(LCBC;_%>?-&\#G!DRHSR:--@@2
M0*)`Z+S"?ZH&"`&8PA0G0`,*2(`"%/C@!L98@3`HK)UIQ,`$;WB#"7KBUSVL
M``L`^$#NUI`B'D`B!)``!!]^X`(2L`@/Q+,H1C7ZH^5]5$@=+5)4B61F(CDI
M3&[R7IN_A[XX>^E\Z5N?G=77I_F)*5"&VFF?>2I41C7*I_N[7U$+C;]&":`"
M255JI6#PB![:@0<-P)0*,&52*IG/JE(XP0J&HA!\[.&%%A1KL6Z5K&8UBS-N
M^`!=@8"`/>"5KX9CCU",TLU^`=0.U[(PMK!%@R]\X;!"B4E-;-(.G+0##&\`
M@RYT<80C[`2@A>"`NZ!8_R^]:7O;V[:!,:JG@GFX8!!*.,4961M:=;CV%(UH
M!!_>/8A!".$,)L!#'DS0BG0H0A%/P$"_7<);&P2\MS9@!S;800V$KV+A#%\X
M-59!C7!$?+@A*Z0AK3O=1\YLXY',;G,E.00>:`"3)C2,881A-,,(9N7@K0PF
MQ0NVGJUF-4I[KPIKP\N<U_=J$G`"`Y0P2_Y&)C;_'9L$J":$,:R!NKM!,-L.
M?,QCML$&=:,;=9Y3]0LTYVY`QLZOOUY-[URSUF1'G'SBHS@2!R(&AK&&$AB`
M`CR,@1\$4F>!^`&(&*1"'V](=C]:P0YV**(5/N[Z';X1C1^`!E6F06<%A(`[
M3O\D5$4I8E$D'JH!'."A`'E8P`HH:KP<,6E('&5>D2B%@],/L%)O7JF7XOS2
M.-4Y]GMRDYW\A'O^T0_00N6]4`E=OT3W/JB&,FKP#3VH>3`ZJ:NO0!B=T``1
MI.((=CC2%IXTC^R3206IWZ&]SZ,0!Z!@`TQ@`A$C(=<Q("#6#@!7&,*%E*/$
M/]?93`\V>U(`@?$@&.0!^]\&P@,\4![0<`30$`P'.$T)R&L+"![;0@,K(!W<
M)H$3J&W0D0H2\%I\,`B+!@-,T@"CH`+Q)H*#,&[9-P]74`CRP"U=,#P\D6\$
M)W`"9PF\-8,S2'6_P`X,]PNKL(,[V'`.%W'"%0[A\!7_%C<60V`%D20S2OAQ
MB#`$S4460Y!=25@,[J`!S>`8S;`:O-(9&.09O*(@"F(T8ZAR6W,913=S[04U
MI!!7,=!*5C,:J0)+#*!R7M-?WK5>J:159\,)PB1,PG$<4?<V;9`<*5$O]+),
M>&,=#M8'7?</OA8>&"80&]9AV<1-'N9A\.%AB[,'3!`)6B,.2J`"/L`)C7<Y
M!1(@I*``&^`#/E!^0``$C3-!@*!>[05?I&`E+<94)(`%/>*+O<@))B)Y"05E
M*;(B"S`&#``C%6!O_\(BPU,\2](C)=(DS&.-9]9HDM)Z<)(G=88^L?>-[+-G
MM6=3NZ<_/<53_D-\QQ=\P(=H_^]X:/8S:+TG5(O6:`.$`Q7@`E?0!7@@4.W0
M#F\`#0_P""S@5+A@"D700T:`!T8@`L[0"NE2"6'P0CDF!$``4`#E`$-1%$DQ
M?T.QD?:7'GW%5WSU+1E9""NP`C0@@($C6(&U@`,ADY%83?P7=MC"`\$&@=!!
M@3VY;7UP!@*@@2+H`B9H@BHP"A^8?24X"/.08@5`!GE`(ZWX>0%E`DPA#Y(5
M@S%8@P+W"U_YE1CP"XH@EF+)@S^X<.&0ED3(%<IE'(B`%D[XA'/I<2`GA78Y
M!,:P!I\5&3O#&4TC`6Z`0:#1&:J1AFE8&-,0.8?97H(Y-:7Q0I'IAJDB!4Z@
M`;+4#/^=!!DP1TK6H#0:<'21(`1"T(=KLS9.5QQNTP;40`WF():_`!,RP0'*
M(2^*>(@0MC==YW\W*7;81'9I=XF&,V(W4`">Z`9G:`#\438L=@(54!HG4!N1
M$"`!\D(G4!H?4!M6P@_^T9Q7`'E","0_XHL\T@#!*'G"2(P*Q9(L$@M\D!FC
M>`"%D`>=MP`410,7I5'+@R1JAGK9."F9(GO?."<Q]5*:XB7O@Z`[%7OO*(_%
M1X_NR(Z%=FCQV*`,2H]O@B8J\!\&]%'9.$`"L`5=L`#SF0HE*@)%\%0LP`(P
ML*(/$(`IT@7W=@8:<P8E<#6DX2T!Y1/P1W\CV2][Y5<!I9'_&>D``+4"!8%0
M+NI#?K.;@O623"J)49J375``$>B35VH#K5`!(\BE\:9]U')`1HD#")$*GZ>2
M&:FCW80Q+-&5,LA;&$"69(D!<PJG<_H+9HF6$P<+1.B68D$S>N&$P5%=AZ07
M@FH<95$,!^`!=B@8`#:8@^DTL$28[F68LF%"A_D9M-%*DJDP5X.='A!+UI`8
MCR%>WV6I/\`@1W<".+0#?EA,Q41,QK&:KHD!-F"GO]`4Q;80UD8WAP@=-G`W
MP'H!C@B)43J)''9VEGAV(X:)RKHX#N")@-`S2N`!DU,VC6<:+,8&;.@?W(FM
MER*=F>.=W@F>K_`CYLJ+XVF>PHA0_^E9C)"@(E3V<PRP'SP1G\ZX`,1#`P]P
M(SVBGY5")/WIG_GX)@(JH.9C4PF;H/-S:.,H?!!JH11JH?!(CSP%/AI:`5=@
M0.%9GD\&93C#(@NP!E'5:$G@43P@?;KP!@$``7GP40B4)HQ&`J]3(M]'%"LP
M7RY41/]T'MBT5S=0I$$*4$R@DN5G?@A1I$"Z`CN@)FJRHI#&0PKYI$$TM2[I
M-W:@D$7`0P_`M3Q`/%6J-SQYI128#B0@;B3HE.)6E$ZYM@(@*21;`0=A`@4`
M99QGMSK:$Q/S$T_!IBIA`XI@JW,JIW1ZIV1YIZN``6BY"D,XA-M02,#AIX0*
M<MD%-WOAA/\FP`G9(#1].1B)X%Z/"KJ@X03O-7.)N1FHI`&.:1LO))TQ@'XQ
M@)VH,H?6T!J=9$N)L3.H2H>&L85'AP*CB07NL#9_Z'2Q*G&_('"UZF\L<3$S
M,10;P0%:=W5U`ZR+Z(A-&G9V,';)VJSUU[W=BQY'Q@3A5`V1XP%)4`"D@*UT
M9QHQP+Y58YV60R#I=`61,*[?^0JD-P;DB04XP`E8L*X[<)[N6B.[PR('P"M\
M<+X"=60',)];EB+&LR1!TCP#VVA7H&ERDGLVE5.%XF?^XV<3.Z'MR*`0BWQX
M`B92TK3-F;$::R3#N%`A&P*:,,.:X`XW?`@Y?,/N<`CN$`)K<(__2&($NA``
M->`,L[`5>8`#98(F&7IIC)8$4#91/K`!"D-!%ZF2>)4>>]`315J<KL@$L?,C
M4J4F!>!A>^4`*V"V14F"30FB+1JUD@:EX9&U=?P`IL"U!.E41\*B',)]-,!E
M8#NV/FD)Z;`#`F""36F4BXS(W,>"*U`(!44#YI21/(%DAF,"W40Q,;%',[AO
MM@K*="K*=LJ#B>MPR4`-J#R$L+`-1[A@P`%R48@.QD`%A:`&)D`%5-!C+Q!*
M_!4;NNM>@!FZG5&ZI]I>[P6:HD$UDGD;L`LAJP1+LC2J71,-8#,-H#FZA)$(
M,/(T;/"[8Q"\!@9,4`<<;1`.M0K*;_IO_^N"1PSA86%0"8B(F_-"'<PQK%U7
MK#29892X.,GZF\XZG,.9'N,;"8*1'TYP!05`->SKOI>#`MAZ`O(;`^MT!;=C
MO_8K!*^``^`Y!KQHKJ_`(_[:(\%H(YS0KL0(KY2W`,@@`=R,`SQQ9`U<`%N6
MDR<RP<XC*?@X*0;$:`94/0>JL#OEL+KG>Q)*PA-[PA([?.^CP6=R:08TTBK"
M(B%0#II@PS?,#=QP"-S`P[[0PSS<PV'-P\*KPSV\`!V:>D0B/3QP#1#@#&GA
M%4K<M)>F`FBP17>]1084Q6O@`TN60T0+"4)Z`SR;?_F8*6K;*+'U?D6*5SZ`
M`VG;E)'=QD7)??^/$+58ZQUV3)#6QP)J@LCC-@@:^&ZBK8&C&,@1V!R#/('I
M\`B(O,A&B<AE<FE;X"TV80*=%S"6C&0QW<^:_+Q*H3%_F[RA+,J#:\H_&'&,
MV\HDXZ=O$ZAY@0[17<N!D`F1H`.1L`>0``DHP)>:R5_C-8:,69B'F0A*8')%
M-[I-@W.1:9V1:4&#Z7.T6UZ,,4K7'#5S6!BKX9B1,`9G0P7#*QQ0!PO^YF^@
MW%N2M41!(10B.2_5:XB5=;U3F[W;6W_.6G_,^L^&0]"7D0T:4`$+0#40?0(/
MG:UU1R!78#GUJ^(83:[YF[\E\HLA79XC[:Y09N,QO`#EP`8`P`<>#M/_F6P"
M1_;`]5DC73#!%>R?/)V/^;A%5')30NU[Z$AH\6C")8S4B?(H&5LBG"#5"T#5
M5NT.7%W66BWFOJ#56YW#::[F:3X$;%Y@.=SF;7X(FK``C88DO-/6SI`+5H`(
M!\#'4!55434*.)`$A`X#2M(C.[```A6D>U41?G`&4`D3A5`I6W`%6^39KCT/
M-/`39^``>`500'"VD,W&;4R4V;<%4Y)]\3;:K4[:H0WK\";:H5T!/A`PA6"E
MVI;:8VL=?H`',!!N:6N"&1HI2F)OR]`*_8`'DI($_9@'!V`"_')D/7L#F9P>
MUGYV1R$3,+B5M3JX=WJGB6O*J<RX1-C*S1UU_\5`'Q9@W3K@[CI```0`[VX`
M`"]G2[7D->.5F6$#=&/8,_]NJ4L3J9H:5^T-F3PWF/F5F3!7WTWV2H01\!H`
M7W&5=.$<2:\:A<%!#?^&`3;H\6YJ"2T1$T3A5S<`$BO!$1'1?GM`K/VGST!D
M!'G0VYN8'@+MSY58[>FQ`H$P!L(`.6ZG`G)G-?!K&G3GOHVG.2.>]"K^G1M-
M>A[MT0T`TO];GB>=GC62TKRS`)KP"JK!!P;@C]4.Y$'NP!!<(Z/'/$G%:!EK
MZ0ADV$,M:'QFY2),]T.EPEJ>.\<8`E1]`%5MU7^O"5^]U6!-^&MN^&/=PW).
MUCP\!&/=^%_M#G\?`O\TL'S1TP6$L_?E\`;.<``!:`0+8`0!Z*(Y&8`!.%'U
M60"9[%=>G!YD8`Z0_@N6X$<S/5$4Q;720[(X8`QM0`8C=MMF&]GC!MK#;^KQ
MMK;-<Y\X`-I#*>O-#^NL'F\5L`*>YP#"&K:JS6UDX`.OT]<\4112T0ZM8`7)
MO@S&T$]=<$``U('?-U!T-$<>EK<YW\_N,12<W!);&;ASBKAHJ98`$4[@MFVY
M#.8:8C#A$"I[O$3204`'FXDZN$0$Q&":M6K1HE&H!O*C1Y(EHX6L5JU9,Y4K
M7;ZT-BV1!)H22`'ZP.9$#)XQ3K`Q\.&#%`D:BFKXP1$D!:;-$@$0Z@%I,VO_
MS60"T(`3Q1@A6(X-*38$[-BP8<6VP6;.W!.V-I[8L&$)KERZ<2T](4/F1J%"
M#L[<<+`)`0(DA0N/&?-/\6+&C5.DL/,8LF3*D*'E^7M#\^;,FS53\;P9=&C-
M>P()240UFQ(/>#@!Y6?@YPG:M6M'JA#IRHE7*'I?T:W[E1`2KTB,P8&E@7(L
MS!MP>KY&^O0UD-;0P`YIP?9R@9PPX",`CPD3-TP8.T^^4)X\"_!@[]*@`0D2
M..S;OX*C@OX*_?U74$$`%P9TP0,"#31PP`075)#`!A]D\$`'$7SA!0%4N.(*
M$I:3C@;MMEL@!!$/T*1$3=Q!T9U#5%3Q$!=7=+'%_Q=;9!%&%E,TL9P#1`01
M1$AX@,1#[-9@@@8FK.O//AB2:&"-$-YPYI@WI#Q`A!"ON88<([;D4@01KGDC
M3&.,@>6,`O9888\]"KB!#`R>^`4N#'X!81ECWKC&2A[V?*#/!HX!(=!CCC%&
MA`;FF<>%0>891%%$+ZQ@"QPVQ&*'-7:@P8<%V#N@@D'X^!1440?YE%13036U
M@A46**"0/BZXX%589Z6UUE=M@/4N8\PS(8\"3.AGF4)6P,.'+[H`8H=ZZ@OP
M416V:,`'7_,H1#-CR`@4!//V(JVS&S([XPQ\PLV+C'3@A,L&#-95!(-5WJ5F
M%8$$@@66@A#"=X@V"@ED`/\=(OHWX'\!<2.1C5AB2J6E/**`88='8NJDI5":
M>*5I&*")%"EP\JDG%'@*Z@-2)&"@9`T8J(IB5:QB@!2AG$BJF6Q8QI@4-F(0
MHBLJQN+9K+)R:<./M=9*-RZ[XNK#AJ0MN2L=,L`-XX8]-AAC`"$&&``%K`=H
MK&O&(GL,[,C&GLR.8?+H-FW/1EM[V\T*8$((-V2VQAH/:`C$`'X^J$TGVB+Y
M._!(4+B"\$B$N`)QXHPK#@OC''=..4YV@(ZZZX0,<@$:M@L!$E*48,"#+@HI
M;]<QT^NU/3QXD$Z^#>^S;S_9__-/P!<&O#U!"1WDO7??':SP0A4JR(^^RJ_[
M,$3_$4L\Y$07?3D$F11AI'[&&*]?$44320QAQQ!ZU'R!(&D@<KHCSU\AS0+6
M+\"!]AUP8"\@DMRP@2Y"*,8@9HIQ1I,P`WA#.:XQC&&08Q<'W(4N`@`!9Q2C
M&%8(!P@*P;Y6G<$/[?K%G'ZQ"EA881G+@(`N1,`E.Y2"!W9HH`,;Z(QKT$`_
M."@>?3;0@!W4$`C(`L(7ON`#'S#A"TQ800&``0-2H:I4I1J5$4UU!3RLKQ"6
MJ!6M9!4K6.%J5K)ZP@U\A8<N[&"'/J!!?.ICGU$T:QX"...%<)`$&N!A6GRI
M5KC.L"O.8,M;I,%CN,*0EW2<ZPGK`B2\8!&.;=CK(/C*_T4QU!`(+PCL7UZH
M@A>\P(:"U2T;'?E(2I;2,(B5A),.:U@H.TF51!@%$%(0R@=Z$H-(\.0$0B'*
MR7Y0LJ1<<F+6F$E4-%(WJL@$8X`PP%:Z\I6RB*688_%#,H76EKHL[0)QH6)<
MGL"!IX5ACT_;PP!BD#5M:O-C7@-GV"0#MLH\YC)X%$UH[JB9=98';F-00#6L
MD0UK.*$>D'CE3_1&&[_=I@*\R0UP!)JXQ"V./E@@`4*7LQS)18<ZF%L`#WJT
MO$*0HF0N:`#ISC.F&]CI3B8XP'9X@!WY-&!2^)D=[?ZC@ML5:$*]B]!+"Q0\
MX9V@/QG:$">D\Z$0F,@=W#@$-_]4A(Q#0,]&V'L1]6ZDO>UIX@#>^]YV?F0=
M3D"'$UBX:G.P,(;F(`$(3&""FO8`OQO@`Q]A\`,'.%`)2_1ABDJ[@1!48!_Y
MT"`/^4OD+'(Q"RLX$`)X"D&6#*B+7?0"`@QTQOX2*:6-&@,$L(@7.ZA1K[XR
MPQD0"(`NCD`.`G96!,XPQC(&1:7W&(N'/DA?^GP`!-869@,;L-K'>(("((`!
M!RX0%:J4:"K>FHH$[+O!JX1+1>):D;A3?)4?OK`%%33W0@+8`AN[*)\=-``&
M:'C4&=&@`A:PL8D%\!4<X;@M8X2K%:U`)VD<T)?VM3=^-]CCN=)ACE]L<!74
M",<@87'_D(6@HP"9:*07,E&%3!1X$4'(1"0`D8BJ5"5A*J'8PT0YX8>9Y",K
MNY@$<"(4-MQL)S'X&!N$,C*2)666O*28530LXI/Q<F;6F*5-;I8S++@#'3WK
M&="4R8$G-%-I%X!B6X$,9*8](1W4Y$`Z_/"T`FQ@FZM\,CB]1DZQE:ULYTSO
M9[),FO)HQ@%[B`0;5D)/#20!$FP@Q=YF0QM^!"YPQ,--<!)G',8YK@&O:,`8
M&/J<YUBJ0Q\J0/<.8`(J4`$=AQX"+7QQ`E)XX`4DZ++I/#HF]*S'/>2K[GQ@
M=P7:#<_3`!*`[GPG:@F]P-$6>H$*3I`?G6XN1"5RQXFX,6L7_Q%51C4Z:E)K
ME"(<Q5H3Y>!1D-8`'2P@CC;_M.D)"$=C)(!53?"S9BTJP=:D1=':UK8$%OI#
M`AA@Z@!X/:1"BH$(O^))@.7H10`6>-@&6I:!B'7@7AVXO\NJ6]V]T`66]'V`
M/`R:+^Q;P296P%H@(.&U6>N)`4HPE"Q(00H*@/C#/R"$-&PA5'S`>&XS?L3>
MDH!:;(+B,V<5\BM&\5:Q2@<0[+.%+41J>)'"`<N9*X!'L``-:%3!/)J[QC:Z
M$;RM$J]XV>DM<'U+C^'RLOO6I*8TJ>];YH+3+^)ER#8<!!UJ@`@D]4"(.G2=
M#K6HQ1X^H(1YKH1B%!.)*$?2$0JK_?]A5&$``#:<$]FPLB>O'`I-3K81&&\D
MQ4YQV0LL^H.#-3@1<0?FX;KBCB$P`\<)H04(R%"+R0M-+L[$E:R4=K2[L,7S
MU+Q!`9#`DQY`.092[IHX55_.%$!#!%L.39<W(WO9;Z80D!A`)%8R3PU4H`!X
MI\T^_=;F$P!N-Y&(<X9TD[.$8E6G1Q(?Y]1P@$+;N`T$(21!VA".6VSC%MSG
M/C6V,00L')L$&IVCG>KTP=/Q.Z)A=%U]_+,%3G^ZN9X60$L1]*`#6<BF&[H.
M[BB16?NI7<,>&JD>7$/`[/$U8),J\M&T^CL!O9$-94.!KL`"('HV^`J#M6*:
M:P/!$`S!/1#_@OVP'QXP`7`+MQ44-V<(H'1;H&/@!F>800:2P6*@-V>(DC!1
MCPE:G]3:!"9H+8.S&FV*`84K`2F8A(=3@(>3`070`!G0``#`"BJL0@!@``5`
M@5W`@8O#N$9HA'4X!3`,PT90@D;8N$'8@DT1@4(`@>%ZJ^(:,BC*/"+SP1]4
M+;#Z@DMA%I9C`1Q@@0NQ.19H@$QAE9\#.K[@#'+YBS,@`V5ZQ&3*"TA\@B7;
MHSV2&B!"`"9``"#81"#R"W.I+VJ@AC9H"!V`I"H@!#J0BS.H!1LPAS-P@JHP
MN[-KAHGAI%SL)%T<B5ZD``Q["IO(B0\P`-/#.Z+0.Y29IXVXI%M4_XEID(!4
MDH`?(#NJZ*4,`X09XRIW"`N$:(,V($527#+*2ZL>8QHK&JX@8RNFZ;S.8PNG
MN8$5&`/3ZPG4:PPJ&R<KBPPC>+TLZXQU<AO-Z+)JB4?$&+-U8``!R(-((,8/
M4#/;.)SAX"HL&#8/T8Y6H3XJL#$0H(5$0P=:0`<J0(9""($"6(`58((U:(Z<
MH0T!&`,JH(9;^#Z9E,EP:(,=0`%EVP#RN($Q.8-E^,DSJ)/V:X\A<9W[\(^7
MN[^E9"G<J1`,T9`F<341*0<3.9$3F1[K6<`%/"JFVI'M(!^5G`\2(*@,R1`:
MPP)/5)_X.:NTXK%U3!JWFB*3BR81M,M:N?\!+)B4)EF`-\B?_6)!1&!!?'$@
M;C@&=2,4].C!.TR?("PX@SLXK0&9*%BX)70XB(,XH[#"*62`,M``40"`,J#"
MSA0%!A"%TPQ-"3B!9X`!-'(!1%$4C%,"/CC#,T1#)5*!+N`!:-"%?O@QD8,B
M68%#*GJ5X'R"P-""34C.P1B,@MN`%?#!]`$O$6`!G=N/'?`!.)(C<DFF,R@$
M.2H$?#"'<;DF#N0`/P@#?'A$:^*Q#IPFM`J#]=H#)O`J+#`,KVJV-/E.-7`(
M+]BZKV,KHWD"?#``L[NDLPN)36*[3@J)3O)%A@$)N`,`#:.[&+@9$.N8H)""
MD7$"69H9NF&)D%C_"0!P&9'9NX-YL0PC!9[(&21`BS8X`]`XDS1IDS"@O%HP
MA[;*O)/#%:;I`W8$4G9\1^]<`2$H@2-%THU1`'MDC-4CIW*R@WZ$O=D32-@K
MA#VPSW>P1M;(@ZNJ*K""A`*`!+XX@$(8-.I;3!\,4TB`!+!2R>8@`<3)2=KX
M`,$S-2?`4S[0`(PS@$*H29F,R>_+!4[X)PTIG8X:DV6HDT6U$_(H2O@S*1A:
M*?M;RBOX,Q`1$63H*:RTM>I)*J6Z'A81JA+Y2JF:#OE0#OJ@#^)H#K`*J[%B
MRVA3J[6:MK8:KKO$U5P%P3!0N;K"`[\LI%S8+\`,MZH;3+`HAC<8EO01_\+'
MI)HB7*4DO4PF-`HIM,*X*TT`$(4R,$W3+,ULG<(H_-8R^%:,B8%GJ+E/P*[M
MLCDT",1/F(=/Z*TC$H`DL(-4N('@)$Y8.3D>+4X@<XL@$#@$6(%.)(S[#*(]
M4,0)6H$=PH,%X(OR>!K-R`OX\@,C<P#X/"LRN$0RX(#T/(,DXP`'\-A:V*./
MO5@.N(%:.,^//0/W00`LH!JJ$0*J&0,D0``M&+!,6,5IBTL;J`0'B(0?R"2$
MP<6ST\6D!24(39B5$(:2H5`#`(H+O3L1$YED9(`?2`F7L"6+B<8Z+8JDX+MK
M9``WL!F<$8(Q0$GZ1(*MZHH]L-$]J@5SU-<>_?_12NBQX@S2(F,+O2@$)DA"
M!:`)-Y``-YA0)ET,?-3'*T,;*O4,VDNO+JN]O3`-+"@*!M``#1"`,B6/0CLT
M6F@#=$"&!=@#-F73E*RJK'J%W9C`.W4"V0S#=9#=4UB'1J#=,B1#,W0!/_W3
M6PC4FT2!"D`!2"N=\@+*#_K)0&D_DV2=-9`/I`00`&'*YMJ/GH(`3>C*7/-4
M`\P>$^$1'PG+84.HY&@^+`@$9UL3LCJK#GS+#YQ+787?^`U!/V""#<&4OBR&
M>A'6@B#6<"L(@C"(;;B^@C`!((`M(XR"H"@!RY2`S(3"*;1"+`1-<B7-;OW6
M"Z;@TT1-!7C"SOR!,IC_I=+TS!-(`UR8`Q-F@3E(X17&A13^!!;XA$]H@188
MA`C`N#++@U1PE;J-E3I,QR&#ICYX@CW0`N9LSL(PV+%J'\!```M`C$!`@&=[
MMB`@XB"(&O4\SSV:)H[M0"ZF)FOR6''A,3+`X@Y,J[/:8K8(@[]0$[9]UC%@
M`IT%,`O(!`<X*QZ["WP0`B5@.[3SXX1INUTD";6C@-T[/+/-B:GMF%8Z0E@Z
MBI-!F6;X")<046M@`&#*.P90`L(C/,,KVQ5%6Q1HI:F5VAA``/CBV'*T51\&
M,KQ=1W:,E2`ULJ<I!"!P`PB.8"I$7,5P4M8S)RE]W-@3YH#TC&JI%K@!`A%[
M_P&^N8)E@`7?I4EH;H,"8(,[W=-&L(8R/(4QE-TRK%TPK%W:!.=UF$TE,&<S
M/.?:=0+>C>::S`4LV`T42(+B_<GC/0,/JN=&Y;?WH(&CK+_I94H<*`>@LIY/
ME1$;\36GTH3NB2KK&+;E4%6M:HZO>E7X65\/?%\1S&CYY6CXY8`5J)_-24&#
MJ)?\"E;M0VD!)HC_+8AICH&':^!PE8$J%$T1WM8RR&`-_@%1V&F>/LV=!FJ>
M9@!E`&H0!@`IB()M4H!O_>`/CKL3V`5*F(.IINJJMNI/F(,8UNH6F`=3T&$'
M"#*1$\XY[%$@<RLB&^(@U`).Y$2!4Q,V\0P$Z`&`X?^"'NB!`7@(+\!K?_&"
MC%UC:SK9([,FP<8'/ZB%.PX#*V:+D54K]OS8]G1/]N18P%`3@RVK(!@#";`&
M!8B!F]V#((`?%&``IL!%B4':!FW00.;%HK6*#).Q4H:R"60#AW.!R\W:ND%M
MLROD1'"#AG0!62H9/MBE:<#&G<B9&"@!A;/:$A@#O[91/*XV?GVF'P72XHQ+
M(%WLIW&`#<CE7-[E?U#<Q=U':IE2QQWFR;W2%2B<X*T`$F@'[FMGF6P#2"!#
MV\3=W`7G^A9G)6`4<S[#UT24>5""1AD$):#=02@`0(WO-EB#X!U>GC3>?#:&
M5E!4Y46/?0XCYY4_Z0T0Y^K_\.9:`.=!P%WCM1)QP`60#DX@R]T0WH*RS[!J
MGXMFJXZF\1JW\0L88OM=@_'(WT&BET("\ESX7WL!<H(PI&U8@`^@0G(-S6\E
M:I_FZ:#>::*F<E%0AJ&V\A]0!BL'X42P<IXN@RW_`3>P`+,*@P$(S0\>5PU8
M35S0ZD%H@:R>:JR6<ZNV:FC0X>#2UUOYT2'[USZW"TO@@`+8A/2%GU89E['Z
M%K+*A!X@@$>']$B7B$?2`34@SY,UV;S@L2>(F@[,6/1T@%FE)J;)V/>$[,;F
M,0Y`X[C5C%KP`['SB`;;/5I,[01%VJ.-&`I[T$&.AMV[F`G%B:G]L)X`BJNU
M[=N^_T76WCT2%;%8THB+*9GA_B6>.!P4$+&@`(H3V`/XNE&X/.M_9<<^3\<B
M$](D(P,M8`/1[&Y=WN5>]N4H-6\\JCV"K%*"K!83,.8"*%(''UYG@.];P(!H
MGN;\_D*,T[F6RSF,\W`8:("Y>H"<PP$8:`0<.",8@`$<4`$^&$,*0,,$C^^8
M'%3VAK2>#$I%/0,*#Q1%9;]*`TOGU310R[\*L1`!H'D5:`!-$"J$CC4'A$"R
M1+;"854@>+8[SML;-_JCMW%+*("%$NG'"@?\FA<C!_(C)_*5;ND"4'(IYVEE
MX'IA4`9A`'NPYWH0KG(JUW(MM_*A1OM9,GL05@`$8,\!D/\`G_Y@;@4``]B%
M1XA7&=9X,!S#1I#A"(B`'(AS.[<#:JD$<`=WLO[9NZB$<@F])7Y$P("O;_$,
M"Q`8`D@$28_T1^IKRHL?#A`7,+Y$TE>K:5)C]^1T#A#T,+"$2G!LMA"[=9@&
M54("N)6+)T""CA@!>8H)7C):B0DE6\=UI5V8I`6)E8D)S(W:V/:)8D=&2$X*
M7LI%"'O:KQ4\6;+D6:(E7,*8G$#;&.`PH>AL&[U1Z`9.(O-16^7SZM;1S@L#
M),AEPG4#S/QNQ26;_'<];@D-@"ATP\2-@@4)%A1X0^%"@PD+%5A!`@6*"BA(
M`*-V"\.MCAYI%6JTKE&C08,$S!O_-&_+O'DP8+!0,:C1%AQ;4&I@(4`%#)8P
M;,*H4&&+"Y*G&BF!%*ZC1H_AM@$1(I0$P3/&SK1:=F89"!#&LF[=:LR8B0-Y
M\-!8TZ`!C@HJ5`AXX<$%W1=V!518$&+!@K0-.#7`0@(+%DY,(.TIX`!?F#"U
M.%2R9*F/C3X7+%_(K'DSY\Z>/X,.+7HTZ=*6"NQHL&,-'A-6J"5;E8Q:N-I/
MMVV#A7LW[S:[\WPH(TK9#V7&A0E3EEP8/./*E0V';OS'\.+5B2LK4YR!<>W:
MH2M`$(;Q``G"$XFBS@"`@6>4*,V)_VD.BT_UYW^:ES]"_/[Q\11R1F6567)!
M@7T42*!D_Y(]\00''#Q!A@-A^(%/0614J-@-9R@6QAD.[*$#%P202*(.)Q*`
M8HDG>@''A&$X<$-C#IS!6&,WAO$@A)94PD$83U22HX,Y1C8>C'N,(44SU5@C
MS`_K11*&)6&@0$$TZHS0C#763#.--<TL24$U8I(YYIAAFDEF-%9:N>:8:T8#
M)P5@6L/`>A*0\@$;,;!Q0@Q_QN#G!Q]((8$$&MCY@Y?9A!EG-'0F@N>@'TC@
MA)W3,%`G`S]P::<"I/PYAA`Q$%JH`C%,2(9CD$E&F64+PGK9!39<!BN"!DI6
MR1.;Q*"`&VXH$*RP"@#RC[''(IML"BG8L2RSSD*[K!TB)%2M0?\,7>M0MMD*
M!-$*0E14$0G.P.(11QY10\51ZR@QB%LIK22`"S`T$-0@ZU00TSQ\-*+"%OKB
M@$-+*K1D$A\CC;3"4AXYM0TGX5)EU59=+=.*,14;`P)7RRPSE@EE+8"66B1<
MX99==#F1LA.#N/!"`VNLD)B&,=J8XX-`MEJ:SCOSW+////=12&H[T-!:,;)1
MLTHXR=BV33BZ.0WU;;T5$)QUV"F7G'(S<$U$<F5@9UUQT(U]77%GAZV=`DAP
M@`\^`RB07GIE,"`*`!_LLH\MMNAMARVX_(V+X+BP0#@:_L6'2RIO&/-$@8\S
M"*MD#^9H"3YD/"A0&*K><#D9-]`HH4'_6DQPH@XD`E)BBBF>OJ(77F021&.,
MJ7IC+3<^B#F$1?[X!#X0^LC!#4$@$0FI@&@PS9I@,J\!VP[$T.8(<UK#Z9:,
MHEFFF,V(F:::;$;S9IP4D*_*G,UT>2<@@/1I`*!^GF``&X2Z<*B=F6ZY9#6.
M/MH,`Q(`X@,&^``I[,<`)21""5[ZTC02H0$)?"`&D1""$$J@`0!@4`ICP$<M
M=+<CRM1J00CJPZLN@Z!66>95#`K#&+@P+$`H(`N`R$()N)"L&R*K6=)R5K-Z
M^*Q@B`!;UFJ(MA32+8<(T5M"N`)%+I*1C73D7+=(UTA(,@BX#((/\QB*`%B`
M`[BD)"XI:<0I_US0$A=H$8U\,(D2E,`'/IR"`B2!1!O0Q;`VK$$J%:"*,38$
M@K!\16-=$63'/`8R/*B%+14X@0I>X(*5:4`#?&``'S30@#V<8565B,R"?N;)
M3X(RE#QSP!JP\#*CA6,5JX`-;9J6&]P\Y3:WR05N@.,=K&5-=26:07:P$QWI
M4"=LP`1;=8BIC+51;@,*(,YW?E`&#7S@&ET@P09(0()+;.`2ETB"-D>1!%R8
MPA:4V-L^**$W4UPC`(PC0R<E0R0@-<A!-VL,YL(@(U5]2$9G*`2-/.0`+03B
M=0(]40]T>3H4'50'L,-'A2CD(YLU9IXV<UQC=)6C6OP3`0/X0/*J`?\F\6GI
M2^B3P!Z$(`'RC6`$X=.2E[STT25Q+TT>E6F9Y,0F\L')HUI*Q/\D%<$]!>I/
M>YJ4H2*YJ45]M$TKG88;\L2&`7K`"8A*U#04]25K),(-$`S5&(*3B"?U(`B/
M(<-C<$9"R;6*5BFTU8%,R*-=14$*Z^,"%TI@URC8M0<XW.L.^QHM:5&K(=AB
MB`F..$3!5DL@!2C`'D@&,6<LC&$="0<Z$-:(-<YDC?.`"TJR6+`W\JN-H'VC
M&]_(1I*@MA%,J*-DI[B-/)[@(@2Y"E>RXI5!<D5C8OG8Q_+0%QHT@`1M@8LC
M$<4':RAA2R0(`ZU$Z=SG0A>ZEKC!%U3#F@/_@``6JU1E*IMV&]W$$C>^P4TN
MJB8<K!4''L(PG1AT(`8"S(`(QD3;V'PI3&&FYZL`F$#G'#````33F<Z$YC4,
MD*EI0*<,90"`#(`EA1)@001'N(8NWI"*`UCX`-<XPC.&<0/'=9(Q#>H1/#F`
MN2?0TT<UPF>,[.F``ES.`0&%W2(R48775:%UJD,HZUZG!\;H***4@Q"*A=RV
M&^$#1$FRAO;4-+XN36-)UD@>]^*4TO!E@TM?PIZ98"I3[I$IS'(:LT[1ARE#
M`<*I07V?_`95U/OE+ZEMLI+_2)&G0=7/J)NJWI88R(`'LH$-D<#"&&)`G*PB
M@8/!V]%D%&0)LV;&_U6M:BNM)O/H,/3`KB7`*QMZX.E(#"#4>\6A#I_U+!_V
M$(B&/>Q@$5N((\*Z(!%9(D6N@)&F<$2*U*!%:M]X6248Y13"EN,Z1M(N/K3+
MC"TIV$X$L`48#`+8TE8M.EK;$3SJD8]GZ,JVMZV5?FR;D&,A"V]]ZQ?AFNP%
M4CWNFSQP@P)%-][RGC=ISL"$M<`,N[#HKBIG8QOO.BW@Y,6->='F'&',0`SM
M7;@.P-'+J]'7;/:%N'1$(84!D`H`8!,P=@`@A6NH0`/BN(<W$F#RDY_<``]8
M>1%*P0,1@"$`:=C%,S#QC`(0.9XB=N?-V@8\(VW.`85@J(;LF9@P!,$"+?]:
M1!WT`(<JZ,'I!S4HZUCD!2T(*7A#^IV/DNP`$.U!"PA``!+*`V8WD:\:8\)I
MG*K'@"AK:>U6OG)(L\R\F88IIME+4_C$-+Z<G@^KZI/"4T\`U*#.KU25HJHU
M&.71-9F/`JK0$@`,18H\ZYF2TU"@EK&JU0@*`0G%<PX;@N"'A^Y.,KAZ-&1<
M):L33B:%D3XA!Q`0`T_W(-2AGL`8)C`!"UA@U#?T:ZG_.BTD%B1&AEVUJXDH
M6(A`8@-,1(&MW[`**+:V#<`N-FJ/0L9&R-'[<E3"/#J[;!>8)/VH+;9E*\F$
M:EM[&TQ@XAXW1%LR<`4KN-5M(4U@C#>411Z8&W#_-<`57`$C/9*EK$,TC$`C
M%`"\T5L$2J"\]4$8K(!J=`$/Z%O2J%+2U$8K!5QXR9)X+4!PH)=R@$/"*5Q[
M20)\@0,&P6!Z3,<)TA?9B`TS`8`"`(`,CHV`>1PY5(`33`,%P(,,B`(\>$,2
M)B$12(`*N-$+:(`35,#*K=PCK!P3?%T6@LAB<,"4="&*U0SNI(.+G0$'O%CG
M))\61)W4J8A"F4[5)535O4X=V`P9Z,H>&`"B*$$S,,KUZ,_^\,^:I%U-24\U
M8(J=G!W_7!GUB!2:P-0CXIU'-1GY@$_:H<^36%X`/=7[\(D!#!"E&)"7S-3W
MZ)1.V<E4;<K]7(KU:%F7_U3>GHP!$C`!$HC">B#`8P@9B,'*0T4&9B@("6U&
M[%6&&0Z`[XV!!?R>!2"!,C(C$@A?LI2:#J':J:D:$2F?\RW?JS4?K`E=(4@$
MN#`1";Q!4V#?N80#LJT?2<C1]XW$.AY%&[E1%'K`"\26$!#&&AS&`A3`JYD`
M%:`#.FP#.4J6_$G%1;S!#?Q1M[7";56,5FS,Q?@?``9@R*3%R!Q@(SU2IC#)
M"CS!!'KD1X92'Y#!"I@2S.0!"%!#2JJ2*MV"OWF7".X&+>4!(`28="B'*N@8
MB23"#)2!&VB`&VA<#0KE"<Z@V(@"#PK3#U0>.1A8,SC"$<(#/!#!$7I#+1H*
MIO],E1.X`"FD3!1*00P,P!AL0*B)GN@Y@(-,3N6HBHW8".AL2-N<`2XZ@!YD
M`AP0E(JLR.KDI>GPI1<$`1T\P1D4Q`9P"O/<'27.V9@)XINPG:/XSY\Q0"+.
M79QXE!]*XDR5F6$^8DQY3Y>ACYT8BA3HB?OLB9_L29L5BJ%<BDCAE%)MSYGP
MU*98U:8H`6URR@+ME!,H@*"-`1-H`1``Y0`XP.UH$EH%3R_*"H]TDNP=B&3@
M`P(PHS(N(W12Y]@AP#,B"_']%0\%D5MVRS7RT_,EWS9J8[<P%@D4I!/!@A1A
MWQ1I@+25ECR^@`%8A#T2!A,PP0KHXV(=0"'P%A4`Z#__H@,(T`(M#$$;A$,;
M"&1KA</\B8L)G$&W@8#%>)O%:(S%C!NY]99O\0`-T$`7K`6Z$=>Z,0`3<`!(
MHFB*DL:KD$$!6!<-'(`Q<"!+7A]3W$)MA*#`C5=YD4(Q89!P($<6D,BO`((;
MQ-<."H<,)N62#F4-XI<R<$?EB<`'<`=Q"(,XB,,TB,*"5=X'+-$!]LF?Q-85
M1,()G,`'E`"@Q(!8AIH6*">"[(C6^9R)-48M%)G-.$`0P($7](#I]&E.[B7K
MP*%"7=T>\,`#=($`))7:-2;_5.+WI!V<6)E'_9D0BL]D+D_CO13>?50?\N&G
M1J(C,L\A:I4FR@_BQ8#\#%!J_TZ52U694BW/DBQ/576>EEE/2_49ES@0^Z``
M$@3""@0"&[C!'CB&D,&*/-G,9&B&K<A*<M)>$$"G!52GM%KGV$DK=AY+-/+0
MJ?W0`BR$0`B=8(&G=WYKM_`3-[[:K-&?06I$KK76&NP`8>P`?D*"?BX6/_:C
M/Z)#@6X#+=S"-MSHC7Y@.*3D4TQ1P$96_#$!"5B$MH7;MEG!MGU%_FV,__U?
M69A%R'3H&B02R2P21DK5"I"!BI)LR6J&['&`BQ*-#^1!,7#@+:Q"KIU+*P'<
MU&Q#&RR`%'R'*%P0V,###"A`"<`0('"!&R3'4?Y`DS+ITBIMV3"``H@`"I2`
M#HI",_^(@]4JI08H``11'PK`#T7$0!-50`D,RB38%5BR*1)PDN0\2&0$B>,L
M&ABV+3YD0B:T2"9$7=UZ020`JD$AE.EXP01@`4RPP"!D`Z,V:B`Z"D[QG2!*
MJDHQR9]U%*Q>6?_8G:@R3Q]FF=TUHF8R2OI47IJ-YE.59B<.2@&IYJ8X'B4&
MXO8X9BOF*J?(;I_9'::X`>%%PA@@`!,@0"3T``?9R"8Q".7<B+)&VIO"VUK5
M2B5D5+52Z[1:)[8:BW9N)[-T9[B>*[F&YW?&VJMUHP,4EAIX(Q901`547[N:
M"_:U`2WX!H(2K(TZQ13]V_PFZ/S:D;7A;X/2'PEL2+>1`;?_60'&4$PA&=*&
M+@`/=.@#)-)/E,R(.H&)FFP$I^BK]$$ZH(9JT$`AH,-*QNSUL:?`QA*..HUO
M\*AS4$=T(`<`_`I0[J#6U)=SP#`N,6U1/BG:_$\>"$$/%&T98"ER9&WE28`"
MZ(F:2E`1?P"Q2`$7H&D,;,`$#$"O<L`)P=ZC#>_D_`Z03)3O!($>U`$^T`$=
MU`(=U,$69T*?ZM*.K0Y?1L(KL$`;#X)D+J[B_IV8L1VL4N:990KE+JZ6;*IF
M7D^N9L/F7A5+I8^=5!XIB.9H\DFJIFKBL2H`[%FC**[D@51(;4E+*0KGY6I(
M80H`D`(;A"40:`$3Z.[L/,:"$*_;_X1!)6#&ZMU*I!&(@2`(TE5K+4LK$E`G
M+DOO/VCK#DUC,!A!>89K-RZ$\L$:N'KO,9]K`2R`]#61.)(C>W($P6H$_0J<
M;1PL_FKS-EM;@X++'OE?A/[1A$YHN+6#MUG%N$EDQAYP6H#H6@3,Q\K%`X^L
M!-MS!&)&"E5"(<#K&M!`'BR#*G%$S`YT>]*OS=)"SBHI=B2'-T3E<7@#<M#@
MDM[7"U=TV`Q'W3``W1RE!"R``A"!?`$81P\8!D'0&``!`@`![_)NS)"=T";Q
M@T4!J=C5!$C)%$\:@D3&D.B*/.',)OWT6_5(+>"#%GA!W^X87^I`#^!`&V_!
M(%RJ'+?N^/_0E&(NKB$N7I4YRB)^JMYE[B6#]0)E6>-Q22&#)IX$T.ANHJH.
MBA04T%05)F/&<9QLIIE!V2'>#RMJ:I/4R>W"8B#P;B"X#9`QR-;EZ6)4PF;H
MM++*7F,SK]A1I[1*=BY']BY3[W;:03`+G?)QMC"?JS&7YZMEKV@S%@517_7Q
M0GNR)P@D+#>[]FLSS`=/UL(V+(3^[_^V@K>!`+AIC$,6\!N8A6^A15H\0(@*
M5P.?#!"$P3TS][PQYQ,4`A"H!LL:PW9U<-+H&L**<,#E0BZL`$W.H#*(@S)$
MM#>4@0S(0+!D018H`-C$\'N_<`_B4M("P`6MAUL7BFA*P$A[M!3_R(`<R$$&
MZ2`D7]!/&@`2K$"")_@>)$:,[$&OR)449$$$G>T8!(&NK*UR[F*&YPJ0Z,B0
M?3AD](@:P($9#^D95QT;-+4;V[%4MVYG5J+B4JI41>96\T]EUC4A@W4KWK4J
M(DKEE>H'I/4F=J(C%Q4D%Z96*ZYAI@]0&DJ8SD^A6,H/@`GV7/+_L(\0H/3N
M8IVB<9)A[\$F3$@KOU4^9X:R6MJ4:,%DX_(M1S9E[W(O<RNJ!5%Y%C.X?NOS
M<>]GBS:?DV3)H,`2D$``X%HYMF?ZNNNYR+:AI^^A2]:B=T0R0`+#H@`.W,!5
MA-M"YO:$+D/$]O98+(,)K+-O423'I@9;_[3%(L6%"RAW<[OZ<S$GC]P`O!)-
M'AB#=LWH]27-P2[%_")H3$*"%,QW=L00>P<+"P?E1!.'?#NI#4O`/`I0:`9Q
M:F[*,^'!H<A!L'A<H2S8?N?@!Z#`!F!!/0`!$'R!#^Q!YQ0`W`C+@Y4`QH$E
M`BS()K5M4"<9UWTXB>F*B#M(C^B(OX>!'N@`&Y2(&Z!XBK!!&[/`4[>XBSLJ
M3>U/C%-UG2Q>-BCB^&AFE5^R`BE*TJ;/DZ@B)*^'$TB`6P\*Z9(F6Q-*42%*
M7#?\2C6#,'0R^["!?99[O'HMI3A!<HF4G[F!GD2"Z+'TA+`*ZXW'BVE!$.`#
M*Y\Y)P'CF>-*"/]!]F13*[7B<IN3G66;VM8;GV;S^9UO[V;S>2&(KV>3-DDV
M4?65"Z(;NKNVEJ(S>MM'T=Q#D6Q_,#5,.D5$#!FTPFV/<VX)$FV1!;D%M\9Z
MZ#L'%PXTL`$XT@Z<P:M#_B=AQN,@R`WX``;;>DHFS>;3:#77QK_&TK^*UPI(
M0'B/=W;T;-T<Y4(/97A;-`W_F:$82GW7=R35=T8#P+77(NUO+0S^Y+0;@!`L
M`0K\"47H[M>51Q`'<="FZ9],0+WO#F3<3)`PAK^'N([@3&%3CMN`"`),P%&/
MR,&3"#\0+@OP@:.HPY7$2?KS#_O_79?1<1QWV0\\D`1$V<5OCV%><E7_515`
M_&`PD"!!`!HT,-``P(D;"8!(??C`Q@#%&!4-2"0E0<)"!C^L-6M&(5I)D]$H
MB&PV;1H#-Z0BC<$"9"8G(#NP;!!RXH,+`'RFB;3&TB4I-BB0!$J*`%^M2I:@
M/@F#[T:034'PA>ESX8*E2D\L;>7:AZQ8J);P(;"```$2MFW7PE4+U\(_NW?Q
MYK63@N_>OBGV!DX1S$@APPX*W2B$&+'BQ88A'XZ,>'*A`BNP7$&AF<0;6!AN
M@09]B_3HT*5/8QAM^C1JTJ]AOV8->S;I;2M(H*A`PL09$+[)@`#1:KAO$,O.
M+%MFC+F)-R9,',BS8`$/&FL>K&G0@`2.*Q5._Z@@Y0++&:[GT:=7OYY]>_?O
MX<>7/S_^5K)/;C#9L6:%"1"P8*$FP'"HH8;`<)()1\%M%@QGFVW:>#`72!3X
M01EEQ,%0&0LOY/`'#S>\4,012=QPFA!'_$$4!E9DD445E6&Q#`M_<(,'*0#(
M40$%<@2`@1Q_!$`!*4HP0`HI)-A1BAB00,(`-WK,\4@N)BDAAJL<<`"?K,+@
MP$L.GOCRJS'#_#*,J;;,,H@]]F"KR3$&Z*&'"73H@8`[\<R3#18>84&%04P:
M(1IUHA'TI$--HJ`:11FM!J5'HUFTFFJ:L281)SJ:9M%#*54II&FL`8D!:T8M
M:*"%$O)Q(8XDD$*B#_\PBH$-BCX@!<F.$AI5I$T156F:1%SZ("8@:,II`Q+&
M($&(G0SPP`E=*QTJD59+&#80(/8(XZFH."`C2P?V<(".2L[S*BQ++A!K*W3/
MY2"(MN9:*RYYU4+"`@N:S$M?O/[JEZ]_^RJLL<<2DXPRQ@I1PV#(#C:L@#VP
M0&$S%$@X`!;:4LNX-=96PQBUCEN3[>/88*,&DMQVZPV$X%C^[3CDECGN#&.@
MHSFZ/*9;``\:KMN..QQPJ$`%%5[P8(,;Z$M:Z:69;MII=BTY8X4U\#@`'5C:
MP!K`<&#AFFM8&`0;P@?)EI`)"6@<,4,:1>$0Q0M/C-O"##.,>\1I+,0[1!C_
MW4:1QC(T6*"$)(>4(,<R?A1%\1^3-#Q*(17(@D<`VBX#``G<4)*+&`;@O$DL
MM3SS3`Y$/W-+?++<I$TDX.P\BB)+B%WV'KP80(<Z\\R3'Q9@8($%/D@Z25!"
M"47T44HE992DX!M5="4&)""%`4V#+RDEH4!E2:"6!"KH((,4.H@CB"1BXR)9
M#<CH@UL]`BFDZJV/5"1A6H+>_)FP4!:%$TZ(@?_T,T(*#2A!*$-IB1L`P89(
M)`4(6L`'![9E"2^A#EQ!T)99MB66='6E+&%Y0EKH92^XV(N$)<37OE#H%\#\
M2S""(<QC&H8PR11LA@<K`,$0<YG,2`P'G;F8:D`F_YJ/"3&(&PL9R#0V&].P
M!C<2X\T9SD"&*`H'!%;P32MBEASF+`,Z790.=:R3G1ULISM!"\\+2"$$I#F-
MC6UT8WVZLD'TV$>.=*1CN<)P@`,<XVK8P$8;`*DU00(H%V`S9(3&EHM<G*U$
M(.*(*$Y$-PU)\D0:FJ2&*EE)$:6-;<I8G.4T@$`>#&Y'.SJ<Y1B`.,ME3@H*
M,!Q',E>"5@*N#(B#7"L_8"4#R$YV4>#<&!"@NC5MHBUPBD$,>"F[7)9@F<QD
M)A=RR88)6,`+=<(=GKC`CSX]`@V`*HF@#&4HXUGO>B)I'J0HD)))56H:E_/`
M]!R5*.QICU0MX0.P3/4CA?_\*"$.`<2K+$*1BJQO(QPAR#2R,9)'!<]1V/M1
M`E$0"2Q@00@H2%^M7B`%4GA``DY`R`^:48UL#&4H#'`"D188"`1D*X)A"H.:
M@N``#JBK$D\ARQS9E2Y+A.%=^)(7"7T*5'M-P%XHW)>_5`BP@#'L,0IK*@P)
M]I@;VE"J.A1"!9QHL25F3#1"=,U611:RK\:FB+<P1VQ,1@+-X$!EQFG9&:P(
M,^30S&;0P1EU=K:&+OBLC!40F@%<<`4'O)&PA5U:'Z!BIBZ)#DQEB6-.UQ5'
M._;!!D_8QC&.48P`F>,)Z?!#<(2C2$4.0;2E->T0&.E)%AWD<H:KP`<^DB%+
MRI;_DI:<[27G5B)E`,`-62@!&WHP!B`P8068^4`I)T>Y5(KB0H"[')0L!P#+
M$8ZU,]*1%``!B"Q(X76RS,(')K%,(CFSF<TD+S/%*TOO`F)*V`4$%VCGA6K>
MC@WT90,,'H$+%0`O4(,J2?$019)UJH12C$)G\H3"!P!L1`,@710%5%&I#^63
MPJH*7_@P18I_LN$#%Z$(&YBI48YX9%0AX57\5"(,QDWD!,]RP0=X4M`1(R0A
M?+#&I"AE#1T?,(%":)(6;N"4LW0+'P40)C[(I5,.A.4\9&'RN22(CZ!.&5_3
M1`)1L3R&"8S!J/I2X9=7V,+"X+"&#)MJ`7(H50=,U3*/_\%,15&P!!^.K*M&
M).+(0G-GC6%,B:XA61,K((3>D('09VC%%;,H,^8TIXLWPRO/UJ"=GP4-/`)X
M@6!M8%A-:QJQEGA");Y$NC1]BX(4#!V8H-+I#=JGTXA=]1/"P8S,YN(,!;@!
M&3C[!'-\%@3H$$XQBC$$8`L[%Z0E;3&`(`%E:`!6Z3M!1B0`O8]<B+;45IMM
M.Y1M9=22MYN+`5&UX`"L;&F8"&`"`G(B2QXM1'$68F[:VK8W>*]HVS\HPX:B
MZX90#FF[W_TN("8A!2X<:;L#!Z]ZB;3=(TE!X=@=TL-;64K"<2$2$_!"#^A[
MNTC@UW?>].]_Q\F\=*HSI"$U,/_S)"722D&/51]A"=[P>2H*%R15^SR(&UQ5
M/@-X6'U'&O%`?H!0D<2O)`U=R;0`<4P#.`&D+7$!IIS@4800!"39D%2TCBZ!
M#H\A$$RP8"4Z[5)P86FFZUHRNC1H'[1#!1^;(*H%L'QE+<]]RW6G>Y?U4@13
M/(#O#^C"`[:3A`8D@00D2`(0V*PPA"W^,&Q.\PT7P^8"Z%`S%;A"Q3Y#9ZYN
M7C4>&ZO(O.IGT9<,,UC%02&@N#+5NRPY(-@B<V[0:.G@#`_6Z1D9N_,=%0B`
M%"@HP*:!#Y]UW50]?:C$Z$IW.E-KZ5MH9E.X'-`E,($%*H\=_EG.`NMB9+88
MA1B#</?_@'HR/$'7?O`#.HR!#F"OG_W`WH$&/(FKUE+N0QL2AHADJVVWK=*W
M<AK`VX'@+58``8HK2TXG=8``"81@`%``F:1@(:1+N=IM1E2KEE))1ES$1R(P
ME;@M2AR"WQA.X+!KX`:NW[0+N[8+XI!+`=P`2APG2CB0WLK`#0@`XRY.!R[N
M%1XAO_9+>#XNP.+GZCK%Y$XL4:ZNI%B%Q+P'(2Q,GUB+Q%*%(1PB(B9BH#A,
M(D3,<(!.QTP.4D9")%CB<LQG?SS`P9XG(7*%(&Q,QQXLQW8,>GYK#)!@#YHB
M@BJ!#/#!*F(*R;A"@FQJU2CKL:"B$AS`7NB.[OYO`.!D`OYO_P,8$4[P#B^X
M@SL*3UDJ"LXD)@90``O8C,R8"LVJRC+6+/)(\88H3V(HQF(X;Q6+J&-:T?.0
M:/1>8P%RXPJ$X`W:@-!6!CA<!CE^HSGJJA`.H!!R)J_TBJ^\XZ]>H`(*`%V"
MS[#4CDP@J$R\I$NH;]5(ITN4[UNR9`^"X&&>;Q-60!Q5QP%N`!_.H'2LT1)L
MP-7.Q<D\#19D;1F&H`!0('900`Y7P!P)S?S\0#C0`;/<@1N`S1UDC1,`0)/\
M1K=$Q'(BIP2BH`<&X/]$B"VT8!.T8`4N4B/'\=P2$`D"L"U89P&1299:R7`0
M9T561)56\@)M20.#)$@>YW'TC;=.\/\F%8Z]'FY'DL0A>.MQ?@1Q4LG>]$^W
MA(0+V$"^O``.QF`'^X0/^@O`C&=Y4&)12DXE0NK!3J)10FHH6JLC?&0@GI"U
MGM`CGN5[5*6U7`6]U.=5;.7GML?$TJGHKH=^Q#`2EB4&7J#!D&?E&$`)3.4'
ME,#$JK*`6N(AV,`MHL^F$NNEUB2F("A=:BK5SB/3R@(>TX(1-3,1)[(S.[-U
M/#,2[^*82+,T3;,!-Q$4/7'-<NCQ6M,435$4T>QA*$HWY"P5,N_.=',502_/
M1,^K:J.L7H,:%F`,3,\8TL&S=!&TA$.+F.,,3*"N;B9G>(8&LH.,@$;WB.8$
M"D"#GE%IKJ__#SZ-&DWG=-#$U-9QR*2/^;($',EQ$^!S'/=`"_:`(R</%->L
M/@WP"8:/@U+-$JAA^YP!!`H@$B0BO&*'25;`UL+@LSX+_9@#LYS!'9P!"^"/
M(44A1V0@"[*`"Z(@(O\O+H)@1`V0/:UB`)N$=1CP(DSRX31`!F3@<2#013P)
M6$1A1G"T)6G)(S2P1R!P)@TG<S1@)R6N!8/41Z7K`NDM;91!(>E'&*`T2J?A
M297A_L!A!J/`XBR@*?/K=^!G*^-'4:(AI&3!*H<0*R>E>D3.*D.%Y?1-GU!E
MG\*'"9G0YDR*(1Z""B?B56HE"P<";[A0*Z\RZY).N'+C`Z+MQM8I_U24`%2L
M`3#7T.J6QPV)XB78(!#H4,AL`"KPL((6<RL^;<F:+%W<L2N\(@B0P#-5=559
M=0!$TRYTR31+$S4E!@D@;_$D+X9$4399<S9A<P5V0#.RZH=8L5CK##@U[XAD
M\37.ZC4P`Q7?`!M^85K3`1L*S66,869F1CKMJABO8PW&"#O-B&A48`\R[3O7
MPSO7`]1"K3S3)*9(C1NA;TNF#RU"!_J^I3XYDDW0C#$08P\VX=R88!-\``&^
MH$DV8`.0P`':4:<D"RK,8?LRJP`&8)<^@+V.A+VL!`E6X-;\0->DB`K>`+/>
M``LDH`-C5$@Z5"+O10M&U#S=-7788B)CX/\D%6`AG,MR5$D#;`F4-K"65B1)
M8X2Y6"1&0L1%;(F?G(LLH^1':1)*HH0E]X9$[@]*JW1*HU1*H71*N39KK?;^
ME`$<P.%'W(`-G/)W0$XJ"VSH1@+!AC"A1FI7-N5+TRG'$J&UGL54PM+"6,M.
M(9!5L(M/-4*CV,?E0*4+C6XE#H@-9,(FA*!9!B@D=H6==$S'^$`P;VPN4<(P
MD2X2$"#ZELS)I*(;L8(.G-%+;DKM=,K)$"L,4K5587=57_4?9/68:)4!46``
M?*P369,47W,V+0,V?=44UXPVKVHS2``WC36)>K-8R<K/MBKTAI,63>\&Y&%:
M56-:L8$XH$A;:2;_]KI(&'$F#VJ/9_8*]Y*Q`@S@!51@!9SQ&>&17;^$/^<(
ML;)"U)3O'&^@/<6-3<0Q(\UM$QP@'=5Q*@3X!FX`BF[@809P'#528!%V`W2W
M`97N2"0B!IC@?2^3LJ"B&)SA&);!'I'I5;"K<5Q)`3IL`_9Q_)[`#\X@]IA@
M##9@+5QVW.A`^O`W#^'SR@8@"B9!`6(4:&_T1EE$<8RX;9`8B<N@;8JXB552
MGQ`G1A#'WNS-)>%4`YWV1SG019!X0S@$:['6:\5XC+MVC*/T0A*A(6NI`W/D
M`W!@![WT4!1%%K"RC@D,*T,B)!+*G$X,?E*B33$G#;UG3K_'(^@44Q3`_U;T
MM$]/\N=8@@O-"2N)XG*$8"9V8`<VP``ZXB.XT'DJU\0JI<",<)X4H@3FL`ZA
M8E-%[64OZ`)`C<G4Q51-M=/<3E4EL@=B`)=UV9=T&9<_-`9F]WQD-7<E9H)W
M-_*HJC5W=39[M7B1^3YU"`=T@V+R@%AW$UF9]YHW[WF7]<\B)M!,(!VF]0DP
MP`:`Z!>P@8JR%?8:C1B]]5N1D=*(Q@#<]XV\(E1=*BOP@0RF8BKT-TNZA#*A
M0OI09W_!A4T&D)C88@`!]OGVP%>EJC[9Y`;"0!=IH1!6X$T0MF)ER7`2`I(^
M1"""#F\```G(Y7W[$+&>(!<PRP3V@((M=GV.Q/^57FE'<@DI]H"BQR\=R"`;
M#]`J-H&'>YA*2@D">7:YFEA%+.3>&(`A1:2I[^T'$D$4$H$HIQJ*!0)'D?:)
M58F*W^UM\*^2S-B,PUB,P[A*O]:IMVVM+5!G>Z0%%>"?8.`!T``JMU(5RLF.
M^])3FB&AK&&D="RATO1+K8>=+L<)PG+FP(>?;NXA\E2C+M;G9"PAW.>.P;!^
MQ#`&9")_+.I9^.`O';4O/UE1'DQS"[-RIZ4'`L&"0K<KQ,X`1?4"(,C5-J@=
M6PVQ0&TBY427C\F7NTMVN*`$)H$+H(D+LB"8=^XT41%W%W`'5/.91[%X'P^:
M)Z]XH;EX5P`(CO?RJEG_\[09FUW1B/A,K$BFO*FA`+#`]$R@%<SA%\C9G,TY
M>].A#82#"L`7.L1W.O!@`2"-K\I(]P1``.J9:>17^M0Q3?+7U.;5&L&"$-&$
M&PMAF%;@H9VO`+[Q80AVN`:6N!"`6)J$"0H@#%K8A0OA6II$=TN`QCXD*(3A
M!UI\E12@!%AV#\XN*CSM*\B/I:&#"80`F6+:X3C"E2[G<H9T29`"`?K5`8C)
M`G2[NR+N167DB-W-DZB\J3<I1:86WD($1_%-JEN2BK-\:E&$):JVK,?ZS,6X
M2M6\24<DC4?DWN!\C5,I`J/+`ULP<R('$*R$!`1`"1)E3,<TKR77CO^Z4D;*
M_Z\K)=$5BK"=IQD4XDT9`%CJ1V\)N2$X@G"Q2\1D;,1\9"CZ.M&)@G$TC!0V
MX@26Y=FDYY-!98\I9:1`9;`=!7YR#%1^`!"X#I4YV!+XV0!;^97E:-565Y4=
MP)>(';A+(+@9CD-/,*[92W(`(9A]*;DIV'918`&%0&&9N?&@FU>9V5='<7AU
M"&6H.3>]FWFW^16EEV0ZYJQJ8P'26V),`!N>X!<P0!&`"+ZSEQK^R/6@,SJ$
ML0"HHSJ[`%S%]3OXYP7<=^W.@DS^<%3[H!K/4_DH*,G1[!O]=\(1^$P(C0/T
M6=PH.H$MHTV"J:$!=AP#5H)U5X*G?9<,``G"("K\`/\?5D=%2P#/WTO/)7(B
MWPX!:AATGV(\I[&F_``6CL$$"H$).J<DUP=C3U@#`IDFB42S%S`*D$0&AKB(
M582YOAK+083*0:1O2.2KW:;KTT:3,NE)T3SMSUS-Z0=NU/K>FDN5N,VMZ_RM
M[YP%2TF[B/M#HR`2/&`:P/0+[1B//_W3]?BO_WK5Y7;D9)U2?@2Q306?$INU
M+#U)-H*]%/E66,612>KE\,F?DG`@2.'97J`C"*A3/GD(=RQSDZ=Z.-?6`^&!
M^%-T.1ZVU\6FTDZR$,O)PF`,8L>X&4Z[5G#XB7]V=RY69Y5S)&99;!6&\+.Z
MB?<^I5OZJ1OZ]V`'X*R'NGO_>;^;-X-SK&*19,X[O0.M$%HA'3BKG/%=->);
M-:@!D%P/.H91O_M[.["@AY)1!0Q``)@`(/Q8XD"00QB#8<+@2_C$DJ4^%RX\
M+,C!`;X;%QUHW,-QTYX56C[N\;CBH\8;*!W<L+CR1A@R9V`Z6($$"Q(@2'*.
M&2`D!HH2'Z0(E:`!`(,?2'\,P/=P(KX@6A!L0H!DC`4D%A`@T!(DB$9\8!4F
M+/B$8B6*?K`=.U``B!`#,3X$!:1`@MVZ;HIJR`N@KU\`,OHR*".*L&%EB!'_
M2*QL\6+&BAD[3CRYL67(TX0I$Y:9LS!AXCZ+'OW9$>G3J$=O7CT-LFO(9925
MF3T8_T"9OK?_^G7#N[<;!;\59!&>A0N7$B6BL.G!?,``!=.B1:.@BD(SZ\VR
M:]_>;)HU8=:^A_=NS3OY:=FL::\6K1H%"M+A-[/&H"@#!HGPW]^O%X`3-W9)
M00HI@$@A`2`2&&C7@OX9-<V#T^@'P($#DB(!`P^6QX`$I&B@`1_7N5=-,]ED
M0^*(\UGS@Q+6B`@??-)5,YXUB2@0B19T<-"')1)9\H1"%H51"41]5,)C1!=`
ME&0?-NSH4$59#*?`E,!52>656%[YSY9<=NDE<@:4$$,)<,5@ID\H\"0$$@4X
M4$`AA;CI9IQMUFFGFP78F:><>>:YP@XDH'#%$D*(``(&M__<@NBBBC;J***/
M)@HIHY0Z:FFBF&8*:::)+H`%"A6@8`(9Z?SRRQ.*8&`#!JJRVJJK&%!#33AM
M&$,%6PNL0`,-:^S0P*\DD(##%16<8``39X"%$5CX6*315P<UQ&0?"AETTD9:
MK+`)2"!YQ)&<>_0I4@$E`0$$`@Z<P8$?M/A!A0-,Y(3$!@/$((6'1ZG7W6?*
M'%4&`WUE@4083"9IR5D(,1O60@DE1,=!.5(D\<0$M;'6"D"8"910!M8UX80R
M2/!Q47V1;)1M]\7&`&(KBW+9RY%!5IG,EK66VF?-B);S:!0(DW/./?><LVDW
MB[99:Z\E'=O2_][FM&V`_<4;`+[_]89EE%P49QQR443!7'/.33"!!0I80X$L
MU:"]'G?9J8>>>7"7)[=YY7G'-GLO9C=-@_OM!X`&`/L'H`0*$"B@@*0(6!=1
M>8D,^%$_[`<@(!^<\($3/W1WWP_>X:O$-.Q-AZ*)V:$H]P_95".B=/&E2)\;
M/011BY%,/@DD/ASP6.1#22))I,$/51(&$E7[!MQOR&>)I9?,=VE`F#%`+V:9
M:`HA!!!O.D`GG7C>N>?W?88?_D=`7"&$H"3D`0LUC#;:_J3N1RK_IIAN"C^G
M]>-?`!:AHG``&7XPQR]8M:I7%?!5L$H4-;:1BR&@XQ@F.$`(%@")7:VA5PW`
M`@E6H+"+_S3K60[XEDO(P(%T/&DA3\'(#<YP@P*,2R-TZ@A-Z+6!>,EK`V,8
MPP:`X`"'G.4,>V#"&*JR$PG,R&?"*`-O%,"%'@S`*@CH"NXJ\00J6I$#E<@B
M12)&L2X29"P3@X4)"B'$,05E2D5QW-_6V!\VKI$!HGC,8V"6M#G.+&:MZ<QH
M?N:(ZPA#%GZ4A3!ZYHB@B89H1"N:9A:9--C(9C:T>5IN=$.UXF4I2E@SSG&Z
MQ@:O?6T`3@S;`,0VMK%9@&R98YLJLY,-\$#H09SCW"MGF2&[J1)%]S%*+AG@
M!*.XH9<+*ESB"E0@*2!H07;1@,CV$Z$)48X-0CB!!%C4#(#9Y?\^]&$`BU)'
M`1&M)W7:&<_GFN$BUD4C10^20"34@$6(/.0)9`"+18;4(R7Y+DE-<LB.GH"/
M'A0/>4LT7O*H%)SF&11,"(4>]5#`4#9M#X9UTI[WQ!?1/(7+A18%%`IPL%'U
M:2I^D8+?^^(W4OSA[WXFO<7^*A"J0I"J5$_`@"(.Z"J:PHI5F-J&3H=`BR$,
MH1CN<(<FCJ$)34CP`-H#(4>6NBV.H`0C+'0)09IUAEJ0@19G<*&\$``$)E#%
M7#KLB1F'HI?[E&`%//(A!_"A!210!0D3&"44M<(5KWR%60W#HEZ]R->^2LR*
M3WB".?P`Q`W$97$?6Z-?^L/8DJ%,&2[_BUED[`BS17Y&CSKKXQ\'*8O.4D"S
M?31-(A5YFM5HII&),0PDH29)2O[32@H`!"8UR84H)*<$/?#DUYH32E'&E91B
M.Z5PM3(!0,@2B3]CV]S*PSD,88AS*II&4B*'E%FJ1U_;H5%]C$*R-"(3$(E3
M'"D*=Z##(?-O?0,0&TX0"12\0`.9B]""G``X[_R@1>[I9C=5-Z+^AE-%G^.F
M>U@WHKH!P@+X&%(^!W*[,#RD#SN"<$24I+L>^=`!)=A-U8Z7/('"UJ#-^P!0
MR$3B,,%%3#X9P`9\D#T\\8E/WH.QN,3WD1V<[PHH2!\(5E&I'KM/I""EWT<E
ME;^4FI0:!6C`_PD$E0<R8".`IJHI`J?LJDR%XQ8ZW89/MUR,(;@#'4$U`;@B
M"D,WA:M[;1H7/DCH!S^T@0QDO&&]XO(!!4CA;_A*RH-."X`8!(%W.SJ+0N0)
MPF8IS&%A>%BB#>)7BB$,804Y2Q:S6$4C.42?EQ9L&/:P`38H8"^-#;5CVPC'
MF,WQ-:C9&<X^TS-9G*VSL.ZL(P"I6=*JYK2HC<TC(=G:2>KFGP.ETFRW9EO=
M[I:WSNG!;T<)7.!:P)3"S8H%HA*5'BC`*+*$T'=R5K>Z0<BY$8I0Y"*TG_SL
M9]ROM`;I]`8P@/WG/\$<IC''F[AZ'XZ\#"(9*=B`@O:>P`,:N*XUG?]P'^G*
MS6SZS:][5&DB#=V7G"]B'3I+D(G9/=@&EHCG5^B05MY-.")IG9:/J.B``;B!
M:BBO)&\DL&&`'@\X(&8>F>0R8A.3*7K50T))LE?10H"/HC.>\44Q%J@;Y\$*
MG*H4D8%,9)`.N>E&CGJB]@<J%.0A)NDHU:E2=5.;WG136=9I+MJPY;(/@0IQ
MBA,(TQQ$!*Q@!6Y'`!-PLH$-(,$!#0FL'VI1@+=6I0>/0]UW$),;-P`B.6QP
MSK29<NF12TS1#X,\!Q[6Z+Y*6J^3GO3!&C\M"0.O+.DX@P.08"^[*%;4W77C
M&VN6F#PJ`[.9;49HFT'KLW%6%H7$_=ED+_O_HID6M8DI#*]7^S2IJ;SE6))M
M%F1+VV(;^Y-.[.THF=WLZD,[VJ=$0%;@H`7N:\$";)B:+A.1[5J^4I;ZZ=O)
MVKU^76[N*-INV]Z\&^\"?0"\AS.F4(AI."G$ED.D\`'\-@;6$P,>P`#7M3?T
M]7"N8PWKD'#Z14ZJ0TX4V#;9=%^J\QX$UAV)$`E!P'$=]R/RA#ONY!`2@22]
M4X(^]`0W@``IYP8R<'(R*%``U6$*$'->0G,BMH,U1V)F(@1UQP0KL"<^]V+?
MXV(8=5$7-3XKP`E"@&.$L@!6P#Z*XF-,=S_TTSY2MX6<$@YYP#\M%1-MIG5<
M]W5F>"GAH%.TH&5F_U=V5-`F&N%"VN)50$`O/D&``\!0<0$4,>`#0P)A`X$/
M>R`O2#``=!%;@'`<N.4<5N%67'%7!%%%5;17E5>)CJ9%DKAYG-<43N(0@546
M"4%H!;`)AB4%)^=&J8>*I_<W_X(8I+$S.2-(UA%KM"AKO"<,B31:J+$:2L,8
MPS<;K`4UKH5\P4$<PZ9))5!;77-LR.9;OV5]U8=]TBB-V@<'6K$56A`5$V`@
MXN=^Y$=+TG4?YG8R>_$?RK1&\,9R)-,W\==,=U%>X$4YE",7]%B/]L@&'V``
M;,`&,2`$6/"/@?)>^A(A@-,BHC,?*<(>$.=-ZT"!U6`B#>=PX0%QYC0?;O\P
M!G4@+9=F$(8F)`;C>2F(3YT86`:Q!]>&<C)(-==6@ROW<LB#@UVB@_0(%#PH
M8G"!`D!H=TQP9C$6/MV#9DEH4>3B%H)B/E)(#4M'4D'6=$QW4ES(A507*E='
M!E3I!Z5B#JE2AF:80)D2=FQ(=F5W"";`+>="=^>S,<LD2SLS#>(@`0CP!#;0
M.S8@/`X`%5&!%=BX!W9E$0NA:`;!1988F)&6>9MG:9BV))B6:229,"&T"3F!
M`F-2`H<X:JJ7>JDX&"O#.4B$1-;Q:K$V:[JG>[QG&H*DBZG!BZ_!-,#H-,47
M-7T!;,&V?%BC-8K(-;D%?:"4F]-G?=37;,\VC<#_&9S#M7W=EXT64`)3<H@L
M]Q=]TS?F!C![03C2:1<`,C@%0B#4N8X8(C>)X$S#9(\SN8,R*8`"V(^1(`1C
M\(__N`$H8``:H`0%MA\MDG#AQ$T+N5^LI$KEH03Y8C:A(QW-\`X*D`E"\F`^
MPI$6P7%+\CN]TZ"9=J!DX`!98'PH*8,APY)6XP8PR27W!Y[B*1<&8),^47<[
MQ`1DYI/C@U$J&I3A@C%/R%!+((668H5,"75"!G4X^I1=F&0G$"HFH'=5B0U:
M-T!;6660@I19UE-M6'8FP!%(4`+P)0X_8QV>(5V14R.RI6Q[\`3N!&%%`FF*
MUC`YLFB3)YB51Y@1YJ4A__D[(0=A<=EX$!H&*S$5A0B9D^!_>`$8UZ8!G^98
M?JH7_P)'2/%ZJ]9JM/=9M`B:KJ:HFX6+JG::N-9(OQB,OO::QQ=04_(;F'2,
MBLA)S.@<H+J;T&A]PEFJIAIMUKA]=)6-6E!<QA1;=8$7(G.*S/D7\58X4R*=
M_U=,!3*=;P0A!S*/<L$&)8"/QDJ>R+J/.(D$3-"L2(">ZQE-E\,`\H=-`F8=
M$ZAN$@A.W>20%4@BX:$AV@0Z`]8ZL6-QM<-@8:$C$L&@2D)A/?*))80/`X!R
M@7%R]UI)+!>#F)H\&[HE02$4)2`%05&P.CAB9C(`6&`N;G<G?,*3*:JB2T@^
M@?^"8U>`!U-8A4M94BA5HSKZL5&)`H4`ESYB#@"4%MCP"ZM@*D3Z=9?BE0T$
MEF9W#)"P!PC`!7Y328<72G-55T&"14;2$$9R19!F%@11M%V$M(0Y)/HD8>ZT
MIG*Y(_AD"1CGB3Y2%AHW$U1AA[:E?WA:)0#P:=<F,GVJ6'"4F9H9&CK#69RE
MJ+A'BW\TFK9F-)(J&W:[FL#X:\`&6\-1'+29C+=UF[NEF[[%;+T)C;]Y?:>Z
MN(RKJJP:%9*)JX<(JW1Q(-.Y.,%DN75!;]?)J_-&3*\Z7BQW(.&)C_4(%,3*
MC^=Y$\V*$\TZ=QM@/0SU`1YP(?K"7.KF(BB"'?/9D`[_B:VE4X'7%1[Y<5_S
MR3KQ@)&YHSL#L59@@441T23VU*#OVB/I@+7#0TDO"!BPZ1O_^@]2P`4!2SGB
MZZ$W-Z+,6A*%L$(29802*Y0J6A)O1Y0,A0)'J71:R+$Y>J,?:V1(N3\GL&0%
MT`I4ZXE/T&9I00VKP&,\ED#M@Z3;T`;;H*1+>G9I%@A7<8VLVA7/<FA@!%B7
M![28-\(A3(F21FF6%F&\4V'36S!P^HEE01!D,&@?Y`";L"UOM1.0:4:3D*L2
M$#)4LQ>)14FB4!B.H1EJZS.`A*B)>C:Y-VMQ"UJVAIJIN6O$)XP:YF%7LJFT
MN4G*\7RY*7W/"%R'ZYN*V[C"_WG&C:M]UX@`WI>-Q44E=$$@A1./^@<(>)S'
M>'S'7JO']V?'\EB/^`=>(V:LC'@56>%W\B*$)<$$@=!5S8H%/1&B``=?ZC8C
M\^E?,M*MN1L>)N)-$BB\KC,-_/DYVAHZB9`))-B)'!!/"\&N(.FN'Q>O)=3*
MF^!:EHJ2*/G#+%<EWSL77JM_!@L4T),F:Z)S!7`#Z<`!M8`/%3512FA10RB'
M;A$JH8*Q28F%0\:__)MT_<LIVT!U/8H]9W"]&&<#@94.*(L-"JS`OZ"Q]).&
M8==`%8P.9W`['81"B$9Y.0*87D1%)#S"E69%0WMI7LJ@2!*"91'##4-H03`2
M4^%W=?_G'&>"''=*)8%QDB(C`R93,O\"`*(`1W$D#H2Z:M<1:T[\F;M':[W7
M>XI$Q4KSBZNU&_RZ85/2MYQZ6\O(C-$'JLLVJJ2JQJ<DU*5*U-$&;48]C7"0
M%<5IG`*RQZ"KQ\2$Q^7Y1*"$CU/MH?<7@('<H3S(!I'P1%:1R!O<%=GB=LVJ
M!8R,,>8R=S9F.41AK>J1'B&R7YPLO!0@-Y\<O*;C;7,3.:8,<:K`!8%`!Y8F
M$:`8%O0DO4<RR]6+V,N<#A%*JWX1&"GWPQ4Z-;WQO?X'S/87OO9X<SRA8F,`
M!'N@S`<:!A)E)]$<E$/X$6\GR<2"8SR0L2-E/_*CE-_<O___BP4!C),;@`#)
M?+T.@7$'W&;8@`WKH\"QLBA("<%K2,$5[`<(0P=T4`O]7*;:[44'\<^7A\)5
MI(D/!K5OZHD2$XHU?,,YG(<Q$`4&X'^$,R54$Q@:8-FZT4:4A)E%K!A[)(NT
MZ)FUZ&J;Y=*F65K`)]-7_)K(=].;FC7'L4FX]7P][8Q`'8VEE,9#G>'2:$H7
M?M1%C7W7E]3#J7W4EHULP`7&E,=?'0,]P.*@FGU;015Q-0"1P.(QD+H?2I/$
M:B8]$-9/E'UUU15"/N1[D"U>];JP;4-`\(]O(04$9[P-EQT0&+S^.1_9(!TJ
MHB\H$D[D=A]*P#F?PP?;B5T]4`<6_]<4B3U%"-V@U'M/S;O,9T#9N]$7,6BI
MEO0;WPNZ'*/G*$YS8F+,SF%W!4`&<-D'/Q*'>B*4TQPN+4H^YU._&(N45W@I
M.5KINWT+LH(-;7"C7QC`2Y9B.G<#K1!8!>PC"`P+RRTKJGX+X2#/6L9`0P`"
M%=P&2/M%9CHQDE9IX?U@O_,[5>N)`-W*0#(3CEFG8W+1=Y$7P'&A0.RG&]U&
M)I,;_^(RCP$:K$9[L`;@GN5J*HU[MRA:4RRI"+Z:=J[%.6V;$DZX/TU*A@O4
MOQF<'*[A[X[4B2OO\"[O(2Y<'7[A_/[NU&B-"#``Q(H<B!=*IH2-0EZ7=>D5
M9GV7%K`3H/_$XSS.B'B9C4-^\1@/%45.EFB]`D*XY'5W/@8`<%!^R=I!GR@"
M.MV4'A0P`C+B'>L6GWCF'YN#?H$=H!;`3B9HWLR2.T0BM0D-<O<T8229#F%0
M`G(^YY8*Q"FYV?]J9[&5XOLGS`2;CPDK!"JF8DBP"3?0$$W"3]W3VBU*+B(Q
MOS@F*"B`!\6`E$M99%EH4N9PZ9AB#@50%4A@"1@0]U<6#H7@VP$<F080!3$P
M`*%.Z.=<.PC<!NL3#K.2AJ[.AA7\4VUPZ_\,M$V+@K,<ER('H1DQ%5Q[I_ZW
M<C)P;2&SG*1?WR5#W_:M^G]!&Y'U`Z$Q>_\=X+0/:XXZM_S"2*[_,:GDKK?\
MNL69E(S+:&R$2^&]6<;!%>_`&>_]KN'*/^_3R/P9KKC2S^_)7^$6CGW:9P$#
M<$I(4-89G_$+S_#A7_[F'_Y<$1(@<>2O^W8>_RG1(Q?WP@<3.2.E\QY;+B.I
M\Y!F`Q!WHC538LU:LW7-#$[3X,2)!(@:&#"P]N,'@T0_%KK1@J^2I3Z6;%CB
MP`$?OC"5^ERPL?+"A94V7KIT^?*EC2<<TG%`H0#`3Z`R@+J1X0:`T:)'W?A4
M\,_I4ZA1%4B96E4*("E9L7*1\J%$C!@H!@@9,&`#$B`("H1Y,O))+7P.'!28
M6V!/`;MY]ZPHL(()$"%7*J"X0F/9JEN)_Q7?PK#8,>/'D25/OA7NEA\U01S<
ML-38\JUM!;"<.&$`A8$2)3YD+6%@`))--\@\`=ERI*4G?JBU@=5FF^\V0]KD
M&D*\V)#C0Y0/`5'2^?.2E3A(IU[)NJ6/?;3#M-G=YDI+X7.:O.%@$Q`D96.4
MR))5P7L%$MQH,"H!@`(-]S4(!9K_Z'Z@?F*@#`9^$$69'Z811Q@&'7%$&`ID
MD27"""6T\$(,+W2DF0<9]/###Y411D1E2C31Q#)*+&/%%0$H8RBBW)!Q1O@4
MR`*0++C@HH0H>NSAQQX&"#+(L@:8P$@CCYQ@22:;7-*"":"4<LHHI8SR2BHM
MR'++*K>TTLLLK_\4$THGG43RR"+33!--):?4T@($X$1`"SKK#$*+(/+4<T\^
M^_3S3S_QO+-.0NE<00N_$``B+28:90(+(0P@Q0.(G-`H&VLPG6::!`]JIIIF
M0@WU(%#7H6"$@:R9YJ!L1DUDHOPTR(^/`E7EXZ($$V$CB%JRNR`\#L((`Q\.
M0'K)$NZ^FZF[FGX=#PF?`C0JP*-^,NI:I=R(:ENHXJM*@JNH"C=<K\`:0"RR
M-G@-K4T<F.V)W,(H9*Z[\N)KA;WZV@NPP2I8PH=BJ%FL,<H*-M@Q@6]).#%S
MR`BC%C_,24Q@RPX8S8`3UOO@@RS@RVJ2&`9`(#8RBAWI-I&>,&=E;';_RV4X
MY&)>3KDVIIO.NNL^`@FD[9!=J5EE:PNI)#+B,@\!)#90-X8H2IB$JO?H<\,^
M`"4H:C\`H_W)/Q<!$.7K'Q!49L$%&9S0$0LKE%#M##,41A9A.@1Q[A%'//'$
M%/-FL45I9UQJ*1MMS")''9OV$4@AU51R\3++=/--+K6L<G+)*X_\\BXI_Q++
M)LELG'$DU4QSR,1))[U()<>H$@DY$9BS4#P%!71VVF,?%';8YW1="R960*!1
MM!;%`@E(#9!"HHE65575:6B]2-5/HU<H^G6B&0%5A0Q2*!M.&9!5UHD86#7!
M\,,?HXY>D0V/)&%30I8[FI)5UKN0GMA)"RFH_]7_IZ2J-4H!&7%+@%*00'P(
M"#523`4K4N!*N<PE%K-,X"Q(0,!FR)`.>-6B/'BY2P?OM1>_\`L%A*%!.Q)&
M,,A`IC$$8V%B4'BPQUA&AI6I3!O"00V*T3`T&R"-`6+P@4E@Q5M+*:`42H""
M"0"!+F&8C4A0)AX,P&MEYH@8-;#1!BQB,1TZ"T\?6O(S[]#O5^*!%]&$9;1-
M;`()Z0&+T]XC`_S81P;^F0__`"!'K@%%%`3:XX'"%C9A-,-#S9`%VB;4-K:U
M#6UO"Z3<Z,8@$MU-DLK8&XNHY3<9O:=C@\M1"7;$H\,ACDBH8]SGG/2X-U%.
M<ZNT'"M;^<HPC>E)IO]D4I+.A#HUF4Y(0.)E+WUYNB2I#G)Q<MWK<"<[V@7J
M=K$[)J%T5\QB'BI13"`>%L:P`2%@$P42T(`25H6IY3$O?!H)%:A&E8UJ5*-Z
MW\">03`UJHD`(%;CU,BJ7L4````B$\02&FZ")2R5_.Q]R7H?T+H#+#\X@`O[
M`X!0A#(MHOAO1@+DEK<*>%%QO4=<@/B`#Q]8EG1)<(V;*`0^,!BO#=X%7W99
M`;Y:"H01HF`P/EA&,B3S0L?@]&`)$U@.9Q@.&?[4,ML(QS8*,8;2^-`K4+NH
M?+PU%2F$[`OMD@T':!,>F<3$-D^$%[Q:$L:;C%$\TB':/X<EER#L81.N2]K_
M`%`#-0WXA#YWE.=#^\.?`+UH0`P`6XFF,4@*O&UM;2-LAC:TH;@]DFZ11!$E
M*6E)OEW2;S7BI(X\"4I?)@Z7M.P<EB#WV51:SDVNQ-PK.;<Y,:76E+=<DV9-
M]TO8^C(*/9@M;7^IV21U24O0Q-V=?&L[X/ZVF<-])C0SX3HXR:EWOZ,F-H7P
M7!0(`04?D$@S-+6\\4W#FP61'J@R%;U3H2H:!F&5JAC@D.\QH"`+J0BM&`"(
M2/#*5_7[YW1BLJSX)<N@8\S)#4K@AA?I;UK6\I]2`$C1;5E4P1`Y(%2]$@6P
M1/A<8RG+!L:PQA4XP`]=]0,^.,C2EH+P+T*HP&!0_U#"A:T0AHOA*<(4-C$:
M!K4R0-W&C(%:U!L3=1L+P`+&?%B"JUCT/O(A,N"F\I77+/%=(JF-S[;*$I:H
M;WUC'<\_C5:`M:Y1/:G)RD4;:K7Z-)0^<]1?'O$I"KZ*31QE(R0ATU98.$OH
ML(U4+(@8*TF]M2C`=LS6W^!36<OVJ+8_PBTI.8M*T$+.E;H5+2L]FSG3<DZU
MJU52Z$17EAY,8$B;CNTO9_MI08=:U#X*)3!5-P;0\K:9@V+U<'-')V@:UW7'
M)::<`C&G1BD*"=*-0<;`@H(8D((BV0TG=JT!*E"URKK6,%4U*,!.5%5#><V8
M1B*<,#4).($!?-@4>57U*O\WQ-<!O0K)&*4SK&+-Q&=!"Z-!29*.,/1@P/N+
M:+6.DI0`(A@J%UWP4XNH`*]X-,+F"EF1U(7A&V`0-PG%RTI!N(>_R%2FA5G&
M"5?,XA>WN*>)D?&-:8SCC^L8%ML8.2QR08NC^OJ'0O2)U>P3'_U4R^4:D(,4
M0/8:(.RAI&0HF<*[N#YX.2P,Y0F"[]"SY:?!9SYR9?I1J"8#JMD10%Q#\]=,
MY*'#JF*PAXQS81GIR#I#TFZ2W.-C(=NWR?X9T*`<-*$W:THR(3K1<P\MW45;
M]]+*<I:TM"6;+OW:3L?VT[0%]:@-QR,>[>B3ETT-X@7=RS5-`-6[;9T6C.EJ
MS!?_-]8(H'7KY/1Y8C)7>)`ZC0%,;P`VE.9X!5+OM,G;*G-Z:E2?HH#U!!(-
M"FAO&@R0`"D^0(IL)R]3!U'5#]PPAB"H@5C9"8D_`1J__+HDJV`]%KS",`"?
M[)G>!(9Z)K6E[Z<0&>;QF5I\F@K5U!A@M@,/2\@@*`0)JN4,)[5$&.@5XI9&
MO`(G&$P7VG'#R6BQ%\NX&)NQ&/.XD,,QDEO`DH,%D^N-7(C`X:"%`@""`6BC
MU5BP`HJK`HHY.[(/?ON8#X"PD-D`D2JFMEH/IY&"]N@8^+BHJ:FK_;`:`)$G
MJ>N:`3$0-9L;#KF01.JZ"_FZL%NL25(1L^N:/;L6&E$[_\+YI,<3)<7YG"^Q
M.RJL0BNL.U6RDDG[G%M"DUPJ$DX+O%X:O,(SO!Y)O"A0O,O2$39L0S=\0\M*
MC5*+O%2CM6(B+LO+P\W;0]>!@V+JO&)*KCAY$R3X"R2X)NDR@(WYO8W!F-]#
MGDYY)^*SKNS1GFK(%&>SGNN)AE1A"%)0Q`^@%(E8KU8YB$0`@$C8`_L+@V+Q
M(G,KB93XJG6;/C"B/IL8"0X@`R0`!(9JJ*`H,"4$OZ<HOSN*(_*#"(MBC?13
M/Z9AOPL4"[$XBTTH@-G`"3^P/WW)/Y@Z`8GK@F6`!<40P(T;Q\J@&`3,,04L
MJI$+AY'CC9)SQ]W`H2FB(C*@A?\S.`,'8((QN$`@>X\"FIJEN`^@L`\QJZ.?
M($@"*Z`:8<$LF`0@XX))>,%YHRMJ88K_")`!*0-1L`@3^0$&83-#<@0*P9`?
MA+.W$22X&<*ZP3/'JJ2ND99LH:S*\B3#:3NW:RW'8;0KW$F>=+18XJPE82W1
MT24Q'$/;(K51<SS'*QPXA,,F'!PNX"2IK"RJ;$,Y'+0T.;7/JC7+X\,[W+P\
M+)0_A";0>Y-!I#S662/G`HN-F93>ZXJ.^@!NJ@AW$A5-V91NFP9E.S9-%*]H
MN,3=TX#><X'@HXCO6@@&8(-`P(=:<`#W\1GQ"!;[FHEFN2_\HK[Z(0,M*`%?
M9"ALD2C_`/H^870YB!!($+RC\BL@K/`*'D$-IH&P'B"X"2N+,0""%9"-KB*#
MN9"FB",-_ML!9P!'<O0I`_0XHD)'D2,Y&^H-6-B-<+@B:H`%;)C.Z4P'<^@J
M>,$-<P@6?'0`+6"C#SC&^:BCTR2P7MR:\\PCBCQ(BB2SO-*`JM/(L/&K#PFL
M0JJ0D@1""6&DE!S".RM"E]2^/C,RP6E"MH.\42J+4CHEG>1)!]U)2),TH+2T
M+PS#HCS*HS1#I6P:Q4O#IG3#'('*J1S1P5$`'-DD30J<3:I*)\1*!54=UJ&\
M6N.\6:M1&X63-0J$M"C$6]O#LD2`0*"\("7$0Y0N8%-$`H((_X@@!=_[/0DH
M$(WXKE&Q!O5BO00)E6S(!DWD1"[%+EB1B%LA/N*;!@`8`^4KC_0IMY`@*PZ`
MOG6#/ENT"9+@@#V(@9<\3_,,1F'\!VP#2/F(JSN**\'4J*Y0C<9KC:_X"@@C
MP8^"C4*X('BY1@?8B][D/Q1H@&\\1TT]1UA@QW#@#7:,SN9L3BO"(2M*!VJP
MSG3P@W1HU57U.3+Z)WS<`Z2Y0*J(0?[9CWG#FJTQ"O]03QL,U@#Y5?3\B1<A
M$!>1SXWT2!$9)$,ZI/S4S_WL3Y5<R;O)FY:,+&N9+,!9439T/`3%R<:IG`9]
M4'.EPBS<PJ!<U[_#M%VZ4#(T0T%#0__$^U"GC,H0)5$2Q1$5K9$:`1P_`]CW
M(-#!`81`XR4%E;QA`KW00ZY!7*-#'(,+LS")/0LL``(F^!T@#<1:2RX+8!VD
M<9U`(+TC_3W@XZ9L@P@/8%(IT+9+$951N8A[FHA)#"\NY43`-(CRB=+#K#8V
MJ*`;4`,'F`YCF;+QJ`ECX8[IFQ^PRDP'&``!_<6&PI:B\+X]_8<_Q8^E`\'Q
MI`]D'!?58$W40%0?6E2"$PLDN,V3>@+=W`LL`#;?W(%CL`)-[=228T>[=<!X
M;!D<PH9?6)E?>(+`#=RN(EP,<M5T*!EA@<5AB0NU0IH8Z)B)O,AIX9K)92A@
MM4&N\0\"61'_`PD;<1`1<1"D0)*S-Y-619(%0G($59BSQ;)6ELPS2\(K3)+)
MJ&2\)R2T!)7"TSI7WWW01RN3OKLT=[50V")#PDO*,S0<Q;/7-LQ7?-77J10<
M?ZW>?PU-[XL1&2F*JGTH;M6D@[U)U9F`&%W8A_W8-;*FYQJ+]6T_%(B$Z)+8
MX4$/]+BU(*TUD.U1E]JU"$/22HD5P7Q+X).(;_H4[Z)2]YJ('\C2=-K$F[U$
M;S(()5`O=P(G54%%-;B!&YB7Z6@)R,2.Z\"O@>(.]8G3F6!;?!B`.SU/;-%3
M801(^@#4&*:KTB34'&$@K_B`'6'-QD.-LOTULTC;&Y`'W'@+!T`"_Q0@C;#8
M`6.P@N%XXG8D5=U8&97)SI.Y8IS(XK:`%T5X@BYN59X;.@?(DRQCH_6@"OG`
M4VJI034FUF*5I\[U(Q'YJ[()K-4]7=1MFY-$++![)``U.Y=$N]!D0LOB@MS5
M77'M++G;2KL[R]_MR;@37G9M5WA-7GDU9$.FR0\E'$Z.7NDMT16UWNHULK_!
M).V-$>[U1?Z0@0!K$59690-[CT!C`[=;DLE+2XD%*?AEW^<B"[*`Q@MDOX&+
MWVLBGC7"V$19%!W%6`38"P0X4E"D%&X*'UE14E(@((GP%'-2B/)1X$GTRVJP
MGK_DE(-0'G=RI]U3`$AP@$(H@"#@IY_QHO_FHXWOD`D2AA^F!2M@"0,DP*M>
MM*MJ"<VKO2.HHV$:[EH#4B`&8L&N6&@@VYA#3;\>,9>S6`%(A9<;"`*ZN`%6
MK.+KO$ZONJK;P.*329FN`F,RT.!Y68$L4Q=^9(_VJ-[^`0I\ZER^0E8-*(/-
M[0_-[6D7F0CY]*NRB1M14=T\!L(]5DD26<FQ,\*]66$E'&1-FLD#A4+1@;LK
M'$2M9F3*>V0K5-=:\L*A?%?!L^3E75[$\Z1[U1$1_61.4E$7%.6!!2"Z+F53
MUE[NW=X8L:-7+@-6KB3`UK,]JUKPW9':<JT88(,28`/75+EA/A=?%H(Q4-_$
M5D358&S5`.)>SB;_B26>R9Z@WW$I(6#LC4E2)P`?:GZ(WAO@!2ZG=**V\%DO
M5FD&"C!@"@AGW--9;Y-$\@HWN=`7?@H/$L:.<ON.[5!:?)8??7X"?KY</H,H
M[\TW8:3A@G8YZD9&0N6*K5AHKN"*]L@*96S$*/`ALYC&"[($/TAOJZ*-DGXB
M)L.-(JZR,_IM9UZC?0QFIGFKCG$J\P0*`<V/FMXK9,4G?"HSO=)(!A";L-D4
M$$%)-XO6H^800>KCU_W/E@1D[5/"3)))J'2\MBNT!662NZ.[&15$LTPUGG3D
MK_:<QA'*"O6T'RG#4*/)U+#7$(U*3Y9>Z@T<N:;KNIYK&M%K5!;RO.[,_X;R
M:Q;YZ\!>\B5WD>@N[!KG`HX2%PF@%'&!R[A$/8$+BP$8GFN*A!]:1#%O1"!^
MW\VFV,DN1`1H*2181"954D@L'R7MO;FDO=M6B!^88'*>;6L8+]K#[4NDR[HD
MK]T#A$!@*2;8`X\HVE]IOJ1M]+#*+WN.T\A$@"P($(>"25^<+`"XVC^-08(,
M]?_`-H5>Z.W685./2JSX[BP`(J?Y"A0``I+9L`NB/Z!CVUP4EALP&KEX7+8Z
M1/70F.]FBNZ[R#+C:3P=D*K+2([DJS^:!K_Z*P]179'<.JX[ZOV4\,3R3]AM
M+-E=X0%-44";99M,T-Q2Y')EY!G=ZJ[V6(]5\?]V/U>PGN2QAO$,';5,7D.U
M!M$<U]<=[_$?#]C:)0H`JEJ]EH'NW>M,9^6_5G(F?_B]H20BD-U*<BA3_E-9
MD2?OP2<`#F!PD8)KWAC&]J%(R";)!K:VS(K?.R#?8VQA_N41*GD+0P(=_3T/
M,.V&&$7MHN8YUS9T^O/L:9Y.H41THHC:SL2_W.V>M08W8`-*;115U!GM@,R0
M@+[X>=-E,6'[V<RH-?)JX0\7!C^#M@^#%/6GVBA3OXKVV&[P7OOOQHK5A/6T
M_>U)W6A\*(]>]W4MN\"F`;*XOJ@Y^DQA+=98>>-A!8`"WZN-1)!$.!%I9Q!!
MDG"2M/:C%BRSJ5:QFR3_BC]6M"/0`NVD%J5EA-U=QQGQ$Y=1AC7Q=T=]=S]+
MUX_W*^2L^Z[WX[WW&>_[?7_#MOYD@/=Q@:]=.$KXO$;X(>?>5.:?8UT1AX=X
MYL=6Y[_P%<%PSD=\!18?B\B(;KZ(;O:>.V*PD/\`EQ^XC<$*<`&7D_WX1@S_
M&`#%162#L-@`)EB-\Y<5;:-9BX`5`%!M4M``3P$("M4H-&MFS=JT'],.%LS6
MS(F&==6:58MFL1I":]DT&IS&QTVD0$"08$&R)TPE2WTNK%1YP>6%F'ULL*RY
M\F;,G#IUKGS"(4@,`$*'$I7A1NC1I`K<*/CG]"G4J``D3!5*M:I5`&XTN)&@
M_T"!E"Q2`(GE4G:L6+)CI8`="Q:L6"E2)GV($N.N@1)V40P8<+?$)+E?F2Z5
MT-5-5Z)(AVH`P#5K8\6.A39F()0!@S*B1"G[H4S9-&'"FCEJ)JL@!5G"4LN2
MQ?IUZ]BR9\MV=%J8:M&Z=^]6)LSWY^#*R@0G7N8X<J))$2/^FD5!EBQ<INN-
MTL-ZC^S9^W(?,.$[^.\6)E@H;[X\`@OI$;!GK[Z]>O5PUL>GGSZ^^?OX]Y_O
M[]]\>."-\5UWW/70EW8))FA=%`TZ&$4)>D7(10G3F66A6=%IN&%T7WGX(8B#
M+868#$N5:)0;)Z:8(HHK&O7B43((508`9<A`(W(YZO^X(X\[#F?<<,,18=R0
M0B9"1)!E%*FDC@HU(\Y"44HY#954(D2E0EE:IH$&$DA`BEP?B#FFF')YZ:44
M5''IE11C@NDEEUUZ^4$,D2!Q`BEGQ@F`$PSPL9`U2F#&P)I?,F#-0(E6,Y$U
M#"C$D4$O.*&$0-E4I$XT&!VTJ1+3,"#!!Y$(L<$8)J%DB4J6U)3J3GW@I.I*
M,M6T$ZU//.'``)+)J)50N\:(E!M1"0M55HQ1AA55"GCU%5MK`1+66G$I\.RT
M;`'R5K,>"O8A6\QZZ!53$AC5J[A3R4`5NI-===1D[4:&F6:?>1;:;@619EIK
ML-&V+[^RF58:;P'K!IQPGQ'_E^2/R2FV'%.$01<==1!BIUV!WGD7H'CD];=>
M>QU[C,!\\KEG7WWXW4=?R>C]MW)YY`5H\005#W`@S0IFA]V##^I%88458@@Q
MAQQ"%Z*'A#7,'',HPMABBRYJ):.,-N)X8X]56^WC<0@3AZ220BJ#9'!@%RQV
M(LHDPN39QRU4D#5/VMN,,&UG5.644OXP**%RGNF!!%*`F:>:<`)@F1->\NVH
MEHUUZ7<,0@B19N$:Y$WHH];</2B7A4OP`T4"42`018UVVO9$&OPY4#.61C-"
M-`8Y=.7=H#8^1JDGI>3JJK'J!!-.-*E**_`L67+K&+L"X.M0,B:E%=+#.G]5
MNL<R_R9#8UXMZRVV:8%U[5O8AGB]]<I.I6RX`"A0E6%<-;;5452=*YEC9<`K
MBF>>B<,;W+BMMEJ^_?J_KR-489O1.$)@O"%8P;2VHQHM#&F$>8Z&,%2=B<VL
M.S'#F,LV5I^/=6P^(&./!T,&GQ&6;&3ET4+*4,:?E;D,/!>SF,QJ9C,&72=G
M$IN0SWZ6(:%UZ#DA:MA21D2B(;J(146$T?&@=CRI'8=J5ZO:D'3T(ZU1L6M`
M`MO!#C8VX8!-;%_[&A'*)B0&4*D@HRG(-%(WMRK]0`D_>&,;$7<W3UW.,H[A
MDF6VI+?`20`SGL+CVBA2D(E@9DZ1V$">XH0W!BAA4P<1%/_FNN2$'U2$`A:Y
M9#0L%\AJ3$,)G9M(,RP9#8)LZ@>-^A0@(C&`#0AA#+:;B:OZH"H;Q#(G.%D)
M35XUJ^#%Q!*5"`,2X+<\7JU(*UP)EO.$U:ZJ*&XRD3&,LKB%/6U1<YK1#%\T
M$V.5<W5%7.@Z%S@EHX'C,&`SY80C<.A5KWM1@'^N>>?__*<_TAA08`@L3I)T
MQ,"%,0^(SHD@=2)$0XI5[(+@&8]_1L9!!&@!A.T)X4(Y)D(1I@>%%569?O3#
MLI:-YV47C.',;':=F]D00CC$T'2DLT,>#@U$1A-BTH:H-"(NK5=+9.`3<\HC
MKV4-2%<DTM:V)IPC;9&+G_%B`HW_&K8D.2EU!HE;-J81U2A=B6YTNY+E8%?'
M10YJ<,WLD@82XJBV.60B`_D<*)M1R!-(`(^'.HB?#L4VA!P*;X4[E"@Q.<I-
M#=(@J`'=HE@WD=<-2@*`B,$8A("",03A5+BSR4MX4I-<0I:7M!I>&!!@O.0-
MA5V>;5$RE;F594;FF5GY"IN(IMION=1Z3.D2]10CKLBX2W[E=!1GZ@<:=8YF
M?^W\7&Q8$\]^Z2\W]>S-;WXCG"SF,T?*Z:<__ZG2"DF,#1/;SH$*9%#QG(=D
M$6U/0QGZP?"2ESWAA0,*+?K=]Y1P/QKU#P8_"E*1WJR&#JK.SB:DPZ!MJ*4_
M#")S%#!3_QC)]%?'ZY6-:M1$G>XHBCWU*16YQE.O8?&H2]VB%\6&U*0J`QS!
M\;"'N5@V))'1&G%SFXFCFA$5B^,@@%+QW%R<D4W1#8YWVRIF!O>G0+[-7@(9
M9:::,0T-/`HS!CF(*1=%$(QXQ".1)&.B?FP1@YC2<TJNB)"K?!&V>8I0I$"L
M$!"KA5K<3I:1==7O>AG9,\\*)Y:-B4^TH)C-+H:8_0RM5&A[QV.5=BO1[!Y;
M^O;G/V,3M>0#EU=X-90\UB@S\M.,9X*37/R51C7#'2YN5$//XXH&.,HM&(3U
M2:,&-L=A$%0IA;C@(#;8K*`7.^A_.*B%6=.ZH;:F-<AFG6N/H?]WUQ90;P<;
M6A\1FFRC`.HH@>1;(!EJAX8E-6F$>K9?_@[-AQ]ZJ0./N*("*W%73'0B@QV,
MG"GV=$E?%"J2TOTUHE[8PE]\MU(WS.$.T_LS(`XQ.$!,[Q!;N`R)8,!H'"(.
M@[18JGY-X^N<FO"%NTYN&]D(H*B:D"F]$4N0LA?$36ROBF`2L$=&#9"#/&,G
M1Z[$;0OEE)60"&N(TG,4^",#FG%)1G79L&S8``IB,`#;H0JRO]/=+2>[RS?+
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M`>M`1U<-N.`#?60DHBYB.4I>4B"J8(`;^O2#=8R?4?_VT@F,00P80"1H@6/!
MBDT`'9LA8$L,7:OLSD]D`?P(D_(PS],]Q3*1EC-MT_5$4[88VC4=!6V)0CEQ
M1FXIP_T(3`&5_P;`M%/_7%ILX`;`N%URS9O<'0=."1-T.4RU39=`U1=!]1W&
M()1Y(`%X"5X0:$$2*N'@-6$3BA=Z+9[B]9IY52%$;9#*L!"R*=OEA=3F,8A=
MW!>T15L.I11_09!_71N`9=NV+4TQ*1$3+5BX84VHO1NZ!0GN^9Z[Y9X>^AZ_
MV1N^Y=N]W=N^$9\AYILP$*(A)A#`L8V098,P))Q3V<OS19]#7&+T0=_S49_U
M;83UR5A&3"*220`;H$`D1$(,?$#,<=PE8<HH)4HTN"+KK,XK@E*CX%';U%\U
MX-66J56?R(W,31E<>0D;A!D!:@$=/($L!9WNR`H#KEDSOIDLW4H)P/^/ZA43
M8MS9!?Z#L72=!J+/5!R&L31:O'2&<(B=:/"6:+1@IKU@#,+3O@A0_M33/270
M#<[=/CU7@#6'<TP+0$5;@[1:@0Q("W540BG>K"5A$"@D$RKD0C+D0BKA$CHA
M11:>XHG7QU!4RIQ'!H5'7UC>LE70@M10#-B00$F;SX3>2O50M;F4B#B0@"$-
M$NV*$@T%CMSD$\&>[$'8N7T1'_8>'_9A'WJ#O14E40JB(AYB\0&?AR4B(H*#
M,!!E5":B,,!#(OJ&5$+E(H98(OQ`5#U)BE6B0TPB)H[E6/:8)6)<]&VB\RG<
M0F3<Q;G8W6B.!#@!`*21^,7B^%W2^=&B7J'_7RV.GR510"Z.7S,X!N=4@U<J
MV2@)&0.00BFF8@&>BDJXF9NI60.JRN_0!-'UTJWDRM(A106F"*\LQ39R(VWI
MV:)=!@.)@ORX)OUP!MA]AC"HHS``3"C91K\(5VNL8V_=)@WVX3WF(ZD%V-T]
M#"#PC-Z-%-\)X00@`:R=!Q)`'N+1&D-*Y$-&9'8V9$)*)'=6I.!=9.)U#'ME
MU'\$R(#`4!<J"!@Z2$DVB(1$&X6H%-"PE+6YI.FER(BXX8'59(W<R!*U7HZ(
MFY!`F+FIFX:UFU#JH5(*(E,JHC?\QB)&*/!1:(2"`SQ0*%5J*#A<*%5JY8:*
MAE:":(?!`_&=XR,B_]PD9B)99B(FLFA92E];`N/TI<[#O<Y&8)Q<DI%820Y>
MZI7YJ<,(?`/Z%6F1$JGGF%\KSF(SU"6/6D[G"%(S)(("G``*G`"=(``=W`YD
M1>-+X-*J5%9GOL03X$.NT-F!+0_#(,9I&DMFO&D9_$"\F*!N@8:=UF:]B`;<
M_!:_"-<`61K<M)W`0&4]XI-/B1IQ%B<_MI1:4`>%2(Q=*$C%$.3?%6%^--[@
M.61V;JIV/F1#0B1$,F%W4N1%DB?*O!>`0&>RJ6=(LB=)-DA)2HA)Y9V%A%YT
MA`4:WB=^C@A,S11ITAE-3HV`YDC"($Q/!DE0REOO,>AG>,,@+N568F53.O]K
M5!+J4U)EAWWHAH*HAX*HMHI&A$XEMVJKM0:?0E!)5'WER9WEB[:HB[Z-6;HK
M)K(EO<ZH&ITE6CHFC_H8D-*BD1HID>[ED@*F7PI#5_B)0OQ)7QD$`'S9`$H!
M&P3"`3K@3B`@+5W`Q<:*EP*/+.%#,+&+33&=FIH/,EW@:\[I;-ZI;QA0_MP+
M#/:FH!K0RMJCV307#M*=#K+AAT`06024WD4!JP4A=US0@!!A?QCAQ]3:$G(J
MTS:MIVIG=X;J=8(G1IKJ"G%D"Z6GS/2%SKFJ>\+G#<EGJMGJ2H9%2]TG$.6G
M3+[A\1C8C"P1N`TKN>&A4-UA@L+;@A8,B!WELSK_J/!1*/%U:R)R*-_Z1H=*
MJ.""Z(B*J+:&*U2&*U4RKN.*ZX<NI;R@JXK&*XR^:[N^:(RRJXQR!%O.Z[W*
MJ/-)(C">7$$`*::@WS>LS@@(:?KM)?K)+B8U0QGDR>!@QJ/8"Y608@R@@`&T
MB04XEF72RF/=A,:.J<9:`C#19)V-"S8VSS9^1E?:J6WJJ6C\5CO*DZ5QF@TJ
M$-WA[`1F6Q#=G11<B')6A^8EB!`6K<:4QW3:1^15YZ<Z+?[FKW=V*G=.[436
M&@==+4(]YW>D)T@B"`+W0/O6U]?&)X2L;PFH9-"0GJZJ8:DU31'UITW5)(#&
MX;#N).W1WD_F;0(YZX,F_V7Q8>CC2BM6`A^X/N[C1JZ'ANL,,R[EWG`,3Z5N
M0*X.1RZXZ@944JX*U]MN08E80I]:,ER,5B(2YRN^'O'H^A6-FFZ\/A\%L`X:
MJ6Z__N5>6E+L#NF09DKK3,.SO)_W!=(T3$6="*]AC0$^W$[&!D]F8BQ+4-;&
M-F.L."\"#%/3V1ESD.QI!LQI5%IK_$L,LF"@^B8]<IB_54VB*D<VFF^(A$7/
M^BQ\9H?F5=#03L"`3.=T6L#\SF]YFI?28F?^GO(I;\)#JC+_3FUXAI?5?C)'
MN<R`:.U\M2\NMR=\QB<.I>1*0@<%JQ:V99NO:C!G10U.??!.&NL=YB$)<UA2
M&O^?AW%HB$ZN-<OP;GBH#@?QN$9N$/-P$-NP..]&#I?S#I,S$%<NX%ZNP45B
MC^&K(ZHH,*HE],5KC#JBYKX-6ZZEC)[E%!?FZDS$'*VN7A:I11`L)JG#-]BN
MO22"&[!!FI!1EDU<0DP%G2B6`7#%`-`!F3T6+S6@\LJ*+1&=+''`)AC8-38=
M!@>R"Y;=I@4GW!EJPB!J^;+AHGJ(6.1TSY!A@UB7`FLR=]1R_,JR0B5MU)JR
MTSK`0RHU*C<UIV*GJ`[>QZC')T\G`:NJ+7>A2"HP@[QG&(8M&4:;!&\(M*1A
MT9SUT3#-$:V>38V:!\LM3TJ8,V_8LB80OQF?L\(PH9+_JS??L.#2,#;W=3C[
M\#C;\.3>\`\GME_3(.2"<SIK9;V=ZS2T6#W#*UJ^CE09W+S:LR:Z*Q/CJ^>F
M98U^KB.>E902BD0'8^SR)1>S#I&FXS2X00E\`"!(SO))"0,`P@>P0>.<@`M8
M1@^H`0=40BU=)D_D,<::&66-J=$%P<@^35(TC5:8YC8>5Z$61]HXFG.-6DU+
MLFKE-*KQ=`EH1_MJ5R>31U5C%*9F*OXJM7L'P7L[P'LO)%,[=?ZJLA;@=WA.
M=7JD]W=@-1=>G@)C\E?#JAB28=[5)TOZ4`6?[TLZT$RU[02^[5L+*+DQ5]WB
M85V3<(-2<[@:[C:'>`VG,P^/__,W*_8YHSA@,S8-MG@]0:Y6KG-P5(F]Q$T9
MT;-:(L3`6<..XSAG1S$4(['#]7-;MNL4GV6B^"YFV&4:!>-!MV(LMJXZJ$)5
MN`%D?H`4^&CJI!&7HY*8Q$"68P8;U,%PN\3&CC2;&?<#BG1+<(`#V)GT/@WS
MD.R(G&8"B4+:\,@^<7=WPR31Y'0EBS>L*G#73BHG/Z>EBO)Z(R'3,K6CPS>D
MQS=]1_JFUK=]/^0>!($J;X)4\[<G@_)5'_H`C,'6BF0N&WB!CR%*AAY9@#?I
M<<]JK6%,M2%I@JS2`6@'PS5/9CB2R.:&"Z4TZ[550J55)FZ(*BYOE'@VNSBS
M-[NS/_^[`0EN<@7?9%<BE#!?92=QM6>V/X/N%&=NZ*H1/RMQD2/Q:*MNDC,9
MH7C)7:)<R%W20K_NE/Z;`GS`;&<YYS1$&B'$#QB6WQA`6S%`(@!"8W%IT#T@
M<L<Q`I+TK:"(HJGI'Z\(=9LL/DXX).^@@VO+Z(6%6>RTK([4`@/U1Q+D=(X!
M*,<'T@:>$S8ZI<LW?+LWS+>\S#\ZI5_Z'FS"'N0W`'N,$9Y\R1.PJ&\MS2QP
M21;]@\1J6'\>%Z2OJYLM&L9ZVD)X=/.Q-2;8!\\MAM.M,S_S[R$E4IKHX:KP
M7E-S-P]VP!SVBBL[M*\]V[OX#+A=#"_BY?:8E=S/$[_S(_+_.)=O;KGO>[@C
MG(G5*_5)L;R&NR1&J>^""B#HKE6=43.HPAC79FZS05Z$N;WL>&U.PYF`BI=@
M!B",&0?@SIFC>66*J66]BB7@0R1+^,CN(U.TJ3[NX$V#"%KDM(6$]:"7=W9U
MAU"G=U$'GOU&;:6__,O+M_$[0!T8?_(COWLG/WPOO_-+NO2G\D+B_"9P^LZ/
MS*=#9RVSJH$8B.9IGET8?1C&Y_IVO*VVNEL\?>G!U+9A([#JRG\J\X-5$<+L
M'M<7HC+D];0"A#)AX(3!&UCP8$)O!PD*6^A06,2'"B5&M'@18T:-&SEV%#;#
M(T:0&T&._!C1)$J2%B<2%`A.F;)$_\JF36N6K5E.:S5W9K.),R?0G,VL"<,Y
MS:?/H#>',K5&--O3;.*>4J6J=.I.ICB?2MU*U&E8KF"9#J70K-I0!A]B1&(#
M")`$!1+H`F"0Z$<B!G<!`"K!QH`$!C_&6BT*0((;"1^D2-#`0(*%,!PL]>ES
MX?+E"YLY;]:,V=(%&Q="?^YLVO,3?`K<R'#C!H!K`*U?UY[MAO4_W;MY]ZZM
M@#5PX<"E9#$.*`L7+B66ER@1Y6^4&#VF]^@Q`'OV"6,F(+'@W3L"\>*U("BO
MY;QY].B#M'<?Q`%\!_/IUZ\S_WY^!_?I\Z\??S[YX!L00`+?.S"(3?90<)--
MM'"PO/'$`__O.PNXXVZ`";+;\+KI!I!.NAA`C()$YTP\,8L24DRNN"P4R*(X
M!0`9CD;6<+.QMAQADTV&V0#X$4@@>RP#@#*,/!+)))-4QD@FG2S#R2=C@E(9
M(F*Z$LLLM;P2)F7`\0:<+P=29J&7$%JH(8((>DA-B#J:**0XY50IHY1.NK.D
M.T_*DT\Z][3(I#SI'(E0E>RT:$UAO*Q2&0:$:>JF:8J:5)BGRFH*IZ.RJ?2G
MH81:RAIQP)+4,*6>LJDG5"L5"ZQ,6;5FK+$L16NHM*8AQ8`8##@A!E[9B`&P
M#X0%)!$`%/C`@!(:8\"F:?8:K"9G`=!@L0\<8\"-2/#AH)+,,//_K#-P,>MC
M-,N^12W<<TE;S;;7?'3W-]QPZXU>WA1H40KEFC,Q"C:DHP[@`:[;<+OM*@Q/
MPO366W@]!-L#\+_Y\.D/OXKWB_B_^^2+3V.(!8QO0(<W">)!]#:1<#PD$$`"
M//`*QE###;&+H3H107S..>A.7&ZY2514T;@7I9"Q1N%N#$['I&7;,<BF@202
M:B65%$5)*:&\FE$JL;1RRZZYC*E+F-1<4R"#7*JH(303<O.BABZ"<\ZX]>R3
M3[K_[-//0N_&\\^][084\$`!-Q2C,!>M$B]8(9W&,%);A;2IKB2=7*A/=3(J
MU*@XM:8GJJ(E-=2NOI+U\5B3\LHK6H=*_X2NUC6@]G7$/D"!!-8_^(NQQX`2
M9B^[?IA&+\1(^<"#U]T`!)]:*ON6^73#M:RTTDYS?C-++`F#B]MR?!<V!;3/
MK=YZ<68#X.H$ECE#[I#HKL*542:/82WVD-]AC.WWSS\')K;?OOXC_MA`"%I0
MR=#SOI6Q#('?>5G!T+>AZ3R01#;3V8E,-`DN?,`XQX$1T8I6(WDEC7L]<MH(
MBR0#J!5):BEL4AFH9C4I14EK5^*:UVAHN#$]Q&P(2=-!V-2VC+A-;D&\2-T^
M4B@C]LUN@I*%WY;H"$<(2G!0Y-O>_,8W*?;M;0<Y7!D281-,\615C'O<I9:R
MJ5#51%2S@ARH//^WD]!192<\B5:H'H>Z5X6E*Y@#B^B:,HT?/&LO&K"+'W?"
M@,<``C`QR!U2^EB3W_V16@HX@12<L!<WJ($.W5)7\\3EF=&$1GJ=9)YF+G.]
M$K#&-1)8VFM8,QND*2!\]6K@A0P&G@F][SP+2]`>VL-+]Q3H?AG3G_[J,#%C
M2NQBP[S/Q/+WGXT]#)H.DQ^$#*@R!'IG#$A0GX9BAKX8G.^!U!F1!$UT0>;D
M*PO(00[17-1!HR$M::]9F@A%2,(BW5.%^622*%R(M2AI*88TI*%#PJ1#M"&*
M(5D4XD+K=+>2/-1O3[1($T$B"T<(8XD)6*)%9W!1CG[$HK+H*$95LM'_)RZQ
MHWP2Z9XD6D6\'5%04WSIVPPW)66H,2=S;$:SD-*I-8**)^+PZ4];-3G.3>YS
M<PQJ3^JX1Z=FZB=%20I4H&*IH\9Q+W1Y3$V:$0\%L*$$-`N,!@C3C+,,Y7,,
M$-XDK\6`((2A$LOSEO-,TX?HD8:3Z?K,]:(03]C`*T?!B26]QG`P"QA0/0SC
MI2\/!$S[[0^9Q[R89/FW/\CR#Y@A.Q"$J"DA:UYS?=ID8#<=.(!OAE-$J1U1
MB298SA:M4SA#Z^`'_3H;V=ASA&4P(3[SB20F80VX-J520`5:W,.%26P)%8B9
MSM8F(#X$3G!CJ$:2:$66?N2B*<TN23TJC),*_R,!V-5N2C<:7D=P](D2;2)&
MR0O>B*#TO-K]4TLONMT\=1>E+JVBG]H4$R)PT8N-=-P9)T5&2&GJ<T<AJJ=Z
M>M6>&A6I<:2C'5UE1]$U>*=1&>-0K$&!:!02,G$1I%K9\"M=68NL.$7K'R&C
M@!B\H*T6V-9<YTJ];\DUKZ*\<1AZ8"/O`58&B<&-L>0UV-[`+W[SZV40&.M8
M^D#VF%$FIC&+61_*[D?*5,9L`-\S,@)&R+,'1&!W1MM`%)C6M#0#D6IO!IT)
M-N=VY^1".F&4SMGB2$>W\1%N?T1/(J$0A;U=$@M9V$^;;DEK,S3N<6$RD$:?
MK4R*@DB;)JT1Z4YW3O]7+$E+3>I=[XXTO20UZ0PXBE[MCOJ\[F7O25F=TO!F
M%*.MAG6IORO2DY*:U'AZ8DI3RK<EZE=/6EP4E&P2C;/J9(YIG!Q5C&)@#D<J
MCJBR'.2Z<A4(_R#:T?Z<5DC7[595)553G=59*3`"6V7U`Z20@E]H1C-A;156
M`<YI3=1*+5VU=0!JH`PI;8P:NXHF-.7J=_7Z$(8!$-FOBG$-*X%C9-YH@62+
M_>7&K#S,+.MO?U6.[#`Y/N7_X*.9]M.L>T:FH)*][[/7O-``QI`AF9TVS303
MIVJ?T]H385!97$"G<8HSHW86C;9Y_BN?^_RC$QHIT%,S$M4([4(L#7?14?__
MFI<D;:;"(72'0,3(I3$]1)="5+XD!4EZ-QKK\8ITH[F6Q:MOG>I7=]36:%<[
MW$]-WO226M;?30#<,?IJ]\[Z[JDF]=OO3E+VDG3O,IWBI+OT7V%XV-A!42I1
MA%H3,Y(%<CCQG$]VPNRRN`I3T&YCA)/Z@]]-OL)?Z0FL*A6ZG3H5\F>UQ@BB
M011Z2\#$OXH$S1JC`4DM15+"B%;O-."&$Q#O,7UQ`!V>0.,</X\TI>0DOSE3
M2@X,(%X_7GCV;^3PW6#LXO@0O\6-*66+8]SC';\L_T8>\2^#.66@9=D8-K"=
M!F:G0S)/;6IK7B(*E@"#/D#G8&1&AF:#7L2=@@.>_[8'-G+K:8R.MWKKMYHN
MN+2&N*!.ZFH(;)I+TB*"N1+*;:*KZSH"IHI([#[MTP(/O3"J&>[.HC1*%<@N
MUS0*[^BNU#YMU$2*!L\K!FN0UM0.[<`KHT@M[61-"-E+HT`J[V9P"-U.U$#"
M[\(K"2OJ!/,KIGAHV'[@\:*!"\]JVY@MJ6YB5:8-J")L52)GC;B"\_Q(CMCP
M=P;C]$"'*IK*51CI5&YBJLSJV"SE+-SH)AB`%&)@#,9`"-S-]SP'>"Q)`OSB
M=DAA+JJ%+M1*`A``'S1IE&R,,VQ`^LP%7<!%,ZX'^_`L1U0)SP3+^_Z!_,9/
M%;-,_);)XRX.F42N0-YC0?_F9V%0!@C$#('H;P+J#T,:".;T+T3&Z?],1``#
M\#AB!+8\Z)V"3NCVC(2B)ND$C="HIH4L\)\R<-&JCALIS2`LPNHB0NM&,-,"
MYTY^K8EL307-+K[:4>U>;=3(*PC7#KOD+NU*K;S4SNPVJ@A]L._8R]9J<`G[
MD:/XCO`",O"^R^[:*[Q&:J56RKQZ+=C09%'^BT@2H1G4@0MW*@Q]0JDX!_0R
M+\,2C%/(B`RY`A&MX?0>B5E:D@UU*E:<2G'ND`R;H21G12O2HAE^8#$B80/H
M+P:DX$>.YR\B@>4&$2D+T0#F(MT<@UK&0-_J2L?T"I2FLL9(PQ*NS\<^Z,>R
M3SC_3A$551']Q*_\R)+\U,]BZH/+:-'D.BME=)%ENH.6[@_-3JO=UFRUBK$$
M?`89BV-H_')&W$DNG#'A^$R$HH8:K_&%HN0'L#%+B$L;NU$R/_`#GXL<Y6;6
M4K"CTBO4V(XA"=(1>I`?,0JEWB[N?A`?-2JC9"'NF+"C-`HV6_.D5'/5`A+M
M9,T?9=,V;VT'`S();U`*R^XW:VV\B/,$8TI-_.O/`$`@(F\G3H_S.!*,F"TD
M(07</-(FJ//S5`RM'"Q:\@(\G<7TXI!RGLH\12=3."6I"BPG*$`G$T$#V$((
MZ(\0!Q$)`@$!F$`+F"`_6>8G=R_=&$,"G``Q>N"MEJ?Z_S"Q,S3QWP2ND^8J
M*P<`.(@,X89,%!ON%%?Q_+0,L]0R0`YD#^9G?AP$Y>!2F];G)TE+"++CS.PR
MS?`R+__O=@0P7WIN1GQ.MFCD:.!)>^"%Z*(1T!`32:SQ:AHS)F;B`K5Q&Y=+
MTC@0TCQP;2Y3;NS$[SXJ(NLKUQRA&<K.U-`+OLI+U,"4'EFS[^)K3%\M`?+N
M-@>/[LZ+-5%M'G]S\&K3!W&MU'R0.-W1U&JM(=W13VUMU=JK'_5N4%AB3*;D
MSV1C*(3O<R(EJ>;P#M.P&9C-C7@B+$!%4K.!\Y[3]%KRCQ)1+^(P=+P-/8DB
MC+YS,.[B]"RE&F1O&A`#$&(`!?^P`(&`@#]7@#^9``DV0`@*$05.[`,`H3$`
MP`D`(1`JD:X4U%MP#/K`I3(X8`+@R<=Z5`$QU/LDR_S8#V3<(T1-9@_,(\SD
M+YNXPQ?O[YM:](%4B^9L+LYF%``'L.?NQ44"$^@6D`%C0P)^]`&/9!I5B$A%
M828"%H:4U+B:M`,C[6R8=!S%4:&D-"2RZZ+$*]0D"DM3C4Q1DT_YL09W<`:2
MT&-'4S6)4&/?5&19DPA54V/=]&)1-J1\<.U6EC55-C;13J/R5#;K-`BGT!U_
M4PA=#?$RBE`1LB3RRX>0JTJ,A)6XP`U0)<%^+ZF"2L.``O2L:J<VCZLN;RL4
MYZ>BPHW_WM#TV!"0/A7U2H<LUO`[]4*MTA9:N(K#_FA:)$`*A"579'4`>A4%
MA.!7Q:K=A&58Y6(,@L`2%92NJE(J12DKQT!>MI*59`!'%!`LM77D>`D];!%E
M4FX712M%S;4NVTU=282U]/)VI"#G_%)H$K`9X4G(]BQ?]35(CJZW_I4""7:@
MF)1VN1$<.Y!)'59*(98*/PH=12U,21-XQU1X3]--^RX?\1$?2?-D^5$UGY<U
M479F7Y9Z679FFY=ZH[=EWQ1ZX=%-]P[M7I9.338T45,>!?4U*VKO_)0A`U6]
M6BHEDO-HB<0UN&`"$,`-I(H-*>5IS:A2FBUU@,(PA(K;5D7%_\9"=3PECI2`
MD%H2;>W"+M9VP%C%5)]S^'H',MR@^&('+[X3;)F%Q0*)+J0@;H5%;MO-`/C6
M,5Q,"VJA$P7W,C01KZ8O0>T*6H'C-URC*UEI1Q^76YEL/4XF7.5/FWBQY>AR
M<SE77?N/70$0`&NTSD@W,'/TG>;"7O\J,5C7`8^.`?RU&@L-:V9"=I<K)KBQ
M=FL72F]W'(%H874W(K9+HC;3T\K.(?F.[^#4B58SUK1W-OGQ>*%W-6/P30>9
MD+4WI%3SCS66!LF4-DW6>F%6?$WV9<]+>AGY8@>Y9K6W8\-W\&@6"=>48U$3
MO.:.[-Q7:(?P!.^$(N?7E:(@"/!A#/\DP%&-0G.T+5I.I]D0N%.:)54HKZ<V
M+'76J%*C#9`$*?F>1515Q:I*KYCKC2X4@!3DHBX>XUF<!:E0U9`0PP/@%A#8
MHMW8P%KD(A*"@`,$=^#P*C2H9Z\X`'%Q>`'?N?M.43R$^("`0/[J#PD&()_I
M\LQB[B[93$1PIAB%)0L^8!*$-8J!P\ZHV(,&4\B$S%T0`QKU%>EZJXNEA@&<
M1&"O!#(%RHP_N@/E1"#<6$XBEM.\J[[>.`79L>[:D4M=L-7,=#9Q-C4-&7L-
M.7LK.68+F:>SMZ<+.395EI"AMV1?MF1%-C:)$.\N.:8O]H[!5]0(#T\[MDT%
M\I2'U[WL1&S_)K`V['<^!J"+)$7!L+-I)^SU+$6`H>(G_C>/@KG"A,(]CZVJ
M_"B$ZRV;U1:$/=B1F&7X@D>MIF6#6T<*AF=HZN)9.OASWO!9C'F$/X!7Q*H$
M)*`$CM5<S%F=KW*3T/GZ7.1&XH6'JQ663O&:?G)]5@X89\:?(8C-FMA$1!=&
MX!5'"S`!._NA_\I=>J0!M1B?(G#I+CI)1,&W&Y-JC'2%^$E)/WJD1_HBDMM@
MVYBD+R)B?Q?4WFN./6V1T2X&11.C!+E-=="H$=EE\32D^/BG91:GW52HWY22
M>5JG?3JG<9IE,9E[Y[MZWY0TIQ=EA1"H)1EE-SEDY]&[E=`?P;?M_V9MJH-V
MBMA$.74+-[*@![2`#O:@!+Q(F1GU49%*4Z5J*4SU*+2BIZ8*5:C-V3"E:YUE
ML8G5F/$:D#`X55G\1PCT;1%#+M:-L!TQ7ZD9#E<2;>L-L)W@6+RY+2(!`=0@
M<"U;G4,I7-(9,\(@6A.7ME[IL\'R_EHTS?QYYF)41I5E=.M,6&4D1AA:`3N[
M-B`:,89NZ'3;=96$`9CN2(C;2)%TG^`<:S(Z`Y$[I-/X`Z/TN3<BI?O<TPP/
MU4"M=T5-!L_KI%K68F&ZHU3!HAB=U1B=D"VVJ.,[>]-;OGNZO3-]J">=OH<:
MDV\ZIYEWIZEWO6<V3>.N9E6!P&DV[?YQ-_\WUB#[KJH)=0:#31R[A%]?(YTF
M@`/P`0D8@,,PYVGEB%([12@FQ?6:12FDC0Z?#2A:52=UXCE;/&VGQ=H%"8(%
MR;#_VIC?5I"<@+%E'&Y-F&]M?,3V8L?MXMS3EEJ$Y9L08`\JL;*-W'F0O(:=
M52O=67$[FT;`\K2H@W-AU&9NCN!I5.>08]U<A`#KU9T_*'5W)%]S6[<A4$C+
MP+=_>\U9*!$`%F"9Q$ACPK@S>N.5X0<*]HSM'"-R=\\U(F(Q(J4]K;MJC;MD
M,[N-4$YA\'AWV@;#=[P]G9!)T[TOO=/W&Z?A>^A_6NB/GKX?&=.5_N<)>:KE
M^ZBIMY-?'3@%<I/_G_")0OGOJ%!0DC,1_BLV;H0+>B"3'*`$+B4[AYUQ0(=Q
M6,^.!CAT/CS#L&+#=*(IXIK#XJA3>?S;B56#BR\2GP6P$2.P%8-8KQTQ[J6;
M2R!9@M7<!0."LSEV5EQV8@`)]B"3R.6%Z?W&GH^4>$S?/YOT'?<4US5G*.AV
M)F'U<0XP-PC,==2*'=Y'([[X@$3B^8Q(U*KBC23CJ>;WR\!(,YJ?Z%R,Q[AK
MH#1WF3LCE'OE7?[/31JE87Y+O6M+-[/ZB]`V[[@U$3UF!=EXB]K2C5ZH*]F\
MBQ[IF=Z]*?V]C9[H.SV^X__H-;V^I]?G@?ZZ`?(>K7Y]`4+6#&'"9L@B_R@K
M@4%'!H4E$":0X<&'!P<2)`A.F+*-93H"<*,@"Y<>=/I4"L(@6[.5V::Y?`G3
M&DR5UH19:R:N64V:S;+9;#9-9\]I/F\&W;GRILJ5/84VHU"-0M)I,G\PN,I`
M`P``$KA*4"`!ZU8`&MR0Y:I!@MJR;+M*<*-6RH</;.@:*#$7$%BU?`$X`7`5
M<&`-"B)IP5?)DN(^%QH[?@PY<F3&CQE39FPI#!<%G!6`].PFM&?0G17\.XTZ
MM6J\DSZ4D,(%MI0LLV<#HJU`KY32O#M_#0TW]-N/93^.-3LVN7+E90`T[P@]
M^H\RHLHH8U!=F?7MVKMO5);HN_CQ&\.#)X]>H_]Z@LHN7FR_WKW\^?3KSW=T
M$7]^88[P^R_H2#,0#2B+0`7.X(B!"1H448$+)NB@@0TNU&!"!28088$:7K@A
MAA9F*`N$'VHH8H<;GHBBAAZFR.*()J*XXHH<SJCBB3&^"&.-&S(X`X8^6@C1
MAP@>R"&&/1;HT$$1(=@0A@4E.0.31N)'$9,2/3F011F!`XXR1#0G`T@B]<!!
M'WUP@,134JT$4YLQN22.-3DI!91./Q$E5)Q`R7G3G'7RM!13@JY$`51)66-5
M(F*E18H4;_'UJ`1.N)%6<!IH]==?$J05%R!SL6%`#&S$0*H!=7V@UZ-::1"8
M$[D9ID8M3UA2R:R2W8K_*V245>98)0YT!E*PGPG+6;"FJ88L:EG<=EMNN`&R
MFP+1]O:59V\%9U9H7!FW7+?>.L=`=-&%VQ%VT$TW77?;I:O,#\J(@AYZ[IH7
MGGKMP7=O?/7!)TQ&]OT+\'X$_?<??P8?E"!_`BJI2L)*.J+*PTI"Y+##$SZH
MH)`B;HSCC2&2V"*+,N(8<LDZFHSRR322[**-'8O\XI`2?BBCATPJJ:1"$%4Y
M(40+#6FE054Z'/23%WFC3)?0B38F'8U5@@\`@[[T@YMMRD23,(#^-*?6>=)Y
ME->`LC1HV<U$=6A568'%MEQSH;H;I)M>>I96?L&EE@*-SE5"#*&2.L`8`PP0
M_\-<CFX*&%<*L#&`%FK044FMM9IIY@6[YHHYYAQLTMMHP'D^&F?)CL[9M)V'
M[CEPP$D@0U?9?@O[<\Z).RYTU567+G?671=O[QNY6]YW]@Z?+[_N3:,>\@3%
M$W#S].DWL,'^-8/?Q-8W+,O"_'T\),05.RBTA<U@B'V%!99_XI$H<SQRRBJ[
M#W_\\KL<<OLCUJRRQR,RJ../!GJ8I!KQ2$,%01+YC!0B@S1)00-1R$2&Y#.C
M#61+'`%3:$0R@#(QIA)(D-J:@#*-1%3-:G"2"5&4\I.BX"1/3;&32H*2M1<.
MI2<VB1-5J"*,LA6J&CI)!*2D0`JZE&!4ICH5M+ZBJO^S;"IO?%'`V_H&N#%@
M`0E4',,81(4JM;@!$&P(1!#P00<_1(X#'$B,#?I@"<M=+E=D#$,8RI2YQG!`
M"UDHS;"*11K4C2Y9>/S-M8BE+;.X3@,RL!OLNL4`Y\RN7.421;C,-1U'OHL!
MVOF!>=J%R>]<TG?BN23Q-%*\]\@GE,XKY;_T0S#JY9`A`6JE]AYVL^TU)$01
MPQ@$D80S5F;L?R+RD(=*=#+[U6]^Q"RF,5$FS!3A3YDLFY'_G$2DA`0)EQ9B
MD(]N)I&<[6R6"F&E`A.8L`<QR6C"\$8YO;0T,7%A`$YK3&8&P``*1(,"PG")
MNZA&0CG]B88WJ4F?FH(4H_#_<T\V,2'51'B5,C"@32NI1C34$8UF_&!5<9E+
MJ/Y&*E(9\7"JPIO<I.`V4,4@$D(8`Q*8@`"45G$`D1C<&+3@`#K4@HRU(N,3
M*H'&G*9Q5QN,W!C#X(`@"#4(:[Q59A``+-`9ZXZCV2.RL*6ZUAD'.5(])'.V
M\AS:U8XZMJ-.(LJ0N^Z8!U[`XZ0F@[>13X:2E/%!GO),"5?WH%)Z!%)8@.J*
M2U<Z#'O]X6O&L(<]!NT,1(3]V(8@!,P502B9[SNF8Q_K/L;FJ$7+=%'[5O0S
M#87O0R)2'S<KDC.!&`F:`AGLS8Z$304.+4ONH2`ZRQ`FSJR3`Y9K3!_V`(AF
MS!.$_RYIESU)>,)](@6&+BQNUOC4)DLFDBP@`81>P"(<`/R`*3R\86#XXK8/
MD`H%D4#!`%"043;@10J`0"(3?_BIC`IA`%1<P1[>"]\].""F,Z7I$\A81L58
M@G*6L1RMGH"/^<XW"`@HL`4.7(DX7B`,2*BC'1^\U,XX534`D,%6"&E5V"4R
MJPJ%#KD>61VP<E5=P4L$O.1EUO&81ZV?#!B_C!?7Y^V'8`:K,<*HITJ<9;9B
M$6,@T0CX,8AQ;T&&+3)E(8OD8X[,ETE>69/?M^3\T6_*TNS00E3!9/X!R7K:
MW/*!$@:T*ZV6(>3,2-*TTYR/A&2=.+7M!=!4!D']MFH_H/_SU>+D-7\V!88I
M_%,-#?H2L7"EN8`8XD@'Q[@Q3"`&;G")@*A[**MDI:+:C0$*2EK2P`DA$J4J
MP1'W8EY/972[[$6"%N3K@!N$H19AQ&]-;2JYQ?!*,4\`JA9N76`$6$#7%J!M
MYBR!#PLXF#<19NJQ)GR:#'=+=K3[<$<B*>+LB/@\O&L76#-I5GH);ZTLAC%[
MDE?/<+\UQ@&;JUXA0KV&-2S'!/+>+6E)9%T&B4$0FB:]9U;D:4KVR?Q.<C+M
MQV23^>_(!&>9,*/LS/O-#($QX]`W43L1":G6(3Y#8)(<HD!O5J2U_=K(ERI\
M02Y,@+8\Y0`"IBN5EX@P$=.HF@C_Z_PF?\9PGWSV)TP4M=PM<H$-D9A`(!``
M4S4$6*A[$*J`'8"``0`","/,X:#4=BD)D/<NEA;"!J1(122,80.<+EP)2"$M
M:4FA!*8:=4NEB("B.P`?^'`C&?V`7_S>%(V.N9QB.("/(-Q:"[E&`!)Z'<<^
MX&,,S<+C9_`(.M$A.]G+X3!T%"FN1W:8JY&D)'?&*IZRFG5>X^DVB_<%;G*+
M?F#-0)BZO5=+"`HY8]Z+$/8H)J%Y9PBQ!6\1,/N-^R8CG'X'9V;*`L[8RBJ\
ML0/\7XUNY*,@)5]'@^TFD20R\8GX3"+>A!A%L-2OCG_)(^H<>=W5B(\!/$5`
M![5DG<W?_W(WM62%P]TSH,/UD2V68``6\*(#ZA`&.M#4IQRH+W[U7PM`%02!
M,``E0"D,4#5.,14M=Q5I`5)TL5V7-@!"L%Y"`%Y8Y!H0."H9-8$F%0@K$`2I
MUG9N1((D2%/[-1GN9`D<0`8.@&L(``>ZIFL)]FOA-VQ)=4>')V&+]P]:Q4@^
M2"[1D1WA0F*\`SR4A&V<I&W;1CQIQ5:CU&+RP3RC9Q\'\6BMA%=!HH6YQ%?=
M(PN`E2"!%4VMAS[H0V5&EGMI"#_[AGML^#(M,S_"IS^]MS\#5WS9E``-$S[?
M%''?1'VJ%7$4MR0#PEH8T2]=LGUN$%LB1W+?YRL*P!0N(4+MLO]R#)`(+W=^
M;A(G-F0G-6%/B;`56\0X%J`%(0A&^T<KBI$8-W53/D4KE4!&M<!V#K`'@6`!
M5P0(9C%"2:$35)-(4?>`<S%JPTB,@+->)H4$:8=J;,>,;&>"B8&"W_<8EG!?
M8:!W0)=K"%94D6$)#M`#-TAL2A4Z/-B#DC=YC/1AMV-YO#-MX.$N[K([NY-B
MZ;%6R,-MQI,O]E@?R#.%5%@?`D(0]*0P=M5NL"1DU"<AK6<Q0$--JR<SA54C
MMZ>&$TF1%0F'DD6'P^1["C=`F)5PT<1P"1$^/$,QT0<T&#=]3#).A6A.7%)!
M9<`T7&`!;>9FC&%R#)!#]30="66)/6G_B9=(20C(<B[!)S9A$RX1+LW5`SZG
M!76`#[6`4V:B7ZDH.:P(BU:)7P%(@K.X!UJ`!(3#!GJQ%0M%E#:D-@WH%<%H
M=BPU@6UI1<A88*B6:FMW`\SH=I.#*YA!C61@:WQG8+KF:YC3C5&@%PYF+#B(
M>,>&;+8#25QU.USU521F'?1R8O*HA&CEA/92/-PV'_E2'\S3C_X(,#B&A0."
MA=:SA>#S,;`'>SH6AADR30(',A9)F[7I6#^R>TZFFP8G9<'T(I=U?-$$-!:'
M0`QY<=5$$7_H0*RT6BE)3N74<:\%<@H@DS3(4Y;#`3'```)B%>`"&!WV2-_9
MDR+4)N*@<A\!_P@]0']Z`$91*954F1A5*3FU<E^P&'=;.8L!-F![4&""TP.>
MQAECB7.5J$1?05[":(R!8U+(2$4I=6IR.5]UV78SE1B5HRNU95O5F'?8:&"`
MESDGP07+TAL1ACJ*MWBW8V*71V+A`2](6%::-X^=MYF>-SS?IH_NX6VB64IZ
M]4JK5'H$$F3T1F\]!F]?:%A!8H8O`DP<8YO\YH9-^EA/>H;_UILT$I(?R7"^
MQ#\)D$VX9#/<(UH#@9RI]8<5P1"L]1#8UR](`P[086&RA0`)=IV.X0"`0!#3
MD#C+!7_PIQR/A(`PUUN)I``]8`'LB5-GU`=G-)6+RJB+.BO4.)]9*?]3JT:I
MS+B?6F"+_ED"`$HI<)$;GF)H''B,#-IW3/"@1S>";D2A^[6-UZD8Z1`&`>:7
MF2"#@<E&03`;G?%<.LBK.[AXX;$[E`0O9/4NQ6J9*;9)WS$-F3FC[:&/-_IM
MGDD?H:FCS4.:[(::2G)+LD=D.`.F1EIO*,*D1B:14&JNYTI,3ZH_&TFEOCE9
M$&=\$:=9$L)PL12F">,DR=DC*7DE*CD@.L.2&(&('A$F;L`%6D"3CK%3EJ,%
M)<!REZA(R@9_7V6),$FH=0`YE:.Q.H5&C>JQ'_N*3]"*]IF5_<<!=$""*&NI
M045TN,9WMS9405!T[W5K\1541[=VSOA&D2/_:Y*Q4QI+:QS0E[GV1=L8&7/$
M+."(>(?IJ\A6K**0K.-QK+X3M6JE#/H82M`J2M[&C]4J>CAF5S^:/0%BA4HB
MMB%2>N5Z(@ERD.CJMG#86&_[MG)8I5,&G,,G-)M%$2+Y90WB,TLR2V$62P\1
M)626)8;;6ETBG6&2!5E`5&Y66Y=A<ES06\F1+89T2"#1`T%`!QD;N8JJ7QT[
ME;.RBE4ILM0(LOI5NE8)BR0;BV_$:EKI1FU'N\UHN\VX=CF;J@%87SQ+.7G9
M7Q>01D%+!OCP@H=AM)&!#PC0N)VC@R5JHDX;HS`Z'M2;5LO*K)^DM>`&8UWK
MM0'S:!=AA:L4MJZ4_ZWH1K864S(E0B%:-C]J*[>3%;_S>X;Q0[=6>B"X^9&;
MU;[9-)P&HEJ9M5I+,C%1`B`&3+AJ"ITNN7WQ1YT.8*$7:CEA@```T');\2AL
MXQD7MARA`0CKA+&7H4:4LU^C^VIQA\)R9U^U@KJI2Y6L6$9C1+*N:[*U,%,W
M;+(UG,/^YU.^&[R9TU_#2RM"2V!\Q[D*MF!(D+0A\;RHHX/D&*/H$;5,>+7W
M6*/K(:W'(PS4^KWV`9#"0$]WA877RJ-DBVY<EK8L4JYL6TLI,J[T>YMP+,?!
MYZXKLTQ7VI&"92$\XT`JPB/X*GT)U$U"PZ\JJ7$'S%J)W))(`QX=86%B4O\2
MD(NAD3MXY:)FI>%'PI$M7S$2$Z`'<!2Y%W!&PBN\M.:Z)1BKL4J[J,R"*'R5
M]+F*^O6HJOM?I5O+K3BRN.Q3NAPY-Y6*LF8#2'PKEH%&]W6-F1`$MIHK@C<!
M(?I<2;6TO0'%48R9,JH1R[JLH!2%^/)M[L$\SMK%I?3%-U8]Y8M78ALD"Y,]
M8PMD:'A8X@JN\0._<DS/]0PS&FG'+*,^ST0_ZN.E`+P@Q<D0H[5C#9229EJX
M#22F!_R<6](E;>K(%P1'(JQ&CP$U/9`X:O86SCL:6<`&A)H)"4O,:B3+KY;*
MN(NS*:V[J?I&*,R*5MG"+BS3BS&5HDO3H2S,><G_`2Y88,FL8'W@`&,@HN#8
MQ-+,@]1,'DUXM9YW+V_%S>&6HUP<SCE)$`!Y$`-)SCU*3Z9'MNF6OO.ZQK:'
M9/-LSV5MUE!&,L+'MS/"O_,:/CNS3>"4M]4G6G^;<0E]IF2V<8DL08N<-`U<
M8=399I=SG9:!#P9HN1O-&<^\V%%`J'K@-/V5J'J)J*IX7T*KRD<7@GNP"5K0
MV2O@V9O`V>^%JLUH@B[=RR_MRZG+L8J:4VJ$J!J;TS\--=AXQ('G``.P+$K+
MT:4QS4A]+]:<O2\&A>%FW!<!FEL\U?,A('?%;N4,W<U-OME*/5\((:6',]@M
M/_#[QO4LI6<]QU/*FW5;_TT<(A$(]"-'0F2GE4!V[;?7-V8)37$(C'V%N,!G
MUL`@$06_.\D_3!EA8`$EH`!JABVZFAL[1W]'?!D[)6M2B4:2@U^S.XO["5]\
MMP*YM@D8K@4K(-J;$`0%$(("9KNL['8M748B.RNS7-,W'<Q%E;RS/8UTX)<^
M'4>6L`<]$**[?3K0&[T3UCN@E-1-S;V?UU9%KMS(O=Q4[<4#6<[D?,YF;+;K
MO,X*B=VQN;[@#5G?C>6V&7`;F<]H722&%9)]/#0`G$!]^TT4\1`.)"6QE"5[
M71`)S-<$81%KJKANZ@99,``4S2O]?29!H'2YF!O.XES+\L$7&\DCG%.54\*E
M7/_"8]1&$JZ?%'YK%]YWV/BRH+T)HFUT:H>S`0;J=LG*0@MKLHRZ>HF"+P[C
MTTC!+QM3-:X%4:#C.WXZ@/#;XJ'-OI/K-.K4Q6T\4NVU`!F^5_C%JF3LI&>^
M!+(P9/QZ&E+E#N)7[QPR9+WEU6[M=?SE^U.'$K?'W1YF6`:2HG4QF36XQVFX
M06/05RWG]4T0+7F(Z#0666`!%AJ\_EUWOH(`F\$%4<`&CKVI7`#P;#`!6I#H
MEN':H.M?_$5KKWB?DJ[9,MN5"`#:&T[Q?GEK';[IH5UT1!=4!9#2H:[*;D=3
M]A6ZB;KJ2-P',IYKI1A'E8``GJ;C1`W-OGW4N+YM]'C_S4Q]I]TL;DA^Y$GN
M'L*.'\(.QJ2'$.4KMCAFMEUMW4U?W:MGY>Y#[1!)]==N]6Z[KG#;Y?B#0`CY
MI7P[UP;RMW"]G.0N?56"R(B[KWQMWPNLN-LG`S+`!0B`&9-<D\.\O#W`[SW`
M]WW_T3V0"75@G8K.JA6]L`O[GOQ'LF^DRI-.=(]/=*)]:J(]VJ=F^1U>=)P^
MLR$8XBL]@BE<H0TNR2<O&:U.JT`71Y/;N+S]8$:]>#<?W+$O'MBK\_#1ZUK\
M\\`>[%7-^U@X/57=Y%DXMNB<K:W7]-,4]6ZL_&I\]<T_M_+;KOW3S]W^,0$G
M)68^)>*NWOO*0`\TB/3=$(;,__;L;M\4!`[;!Y,EH`6AO$9\7AES9`%\'P51
M,`!]OY2<2Y,,/KRO37<`T>>"P($%^_2QE-!2)88-.83A0"=,&'P5\3FXZ$!C
M$`<</0;9`Q+D'I(A28+<%*3`2(X:-5:<R$'FS$H*+?6Q<4'G3IX]??[TV0>?
M%@0(+"#0`K1G&"1<`&5Y"DC!5*I5K4[]EU7K5J[*O'H5]C7L5['*PIXUF_;L
MM+-MS0H3QC8>7+K"YM;%FU?OWKS-X/IU!-BO,%EP`Q]NACAP85F)'3,F_-B1
M*EF5&4^N3(%PY<V6/7\&'5KT:-*E39]&G5KU:M:M7;^6E<"R[,JT:]_V+%OV
M#,^\9?_Y3L";MF]9CF+7WNR;\`Q'O)GS%A:\>?'GA1,0%@;]^8SHV;U[YQX>
MO#!OY(6!4X:>2)DR,@!$<7!0)T&"!7G6YTD'00_^`WH,&&`""^J@HQ*!#KHI
M0?D6/%`G2^P[4+Z;;$!HH86>8$@FB1Z::"*++LK(I8TZ\HC$$4M\"2:(9*H$
M0PQO:M`^I6:D4:BB;@P"/Z#PL8`+J+*8"LBKW+@**ZZ.U$JMLM!""RPEF32+
MK;:D;`NNN>9ZBR\MM\1K,+H&`TP8S;!C;`;'%'N,S&8:6VPRX\ALK+(W.;/,
M$0KJQ-,SXT[;$S8__P0T4$$''<TVW(X#S5#;%D7TM]MH@]3_4>IT<]2Y,G7C
M;;KJIILN.N?`X^XW3[-KCE3NQA/OU%/A`N>\])1A#P``>L`G0AGG,^B^GOK@
M`)],^)M`0`N"J,/`G01Z\""$E$4HUUSK@]:@91.J::&&')HI(@XI^K`BC+RU
MZ%N+(%J1(0N7I?!6&M=5JI(@B-+BJ"#8=6`,+GR,JDA]I4*RW[&<A)(L*-=R
M"ZZWI,Q2+BX79KA+,0U+3)@P"].LL,"@@XS--2-#+&,YZ61L3<8^Z].TD@E%
M.6655V8YM]D^8S11W(B3-%+?A,,Y-M^,8^XX2J5SCE/AENL4:$V;*_6ZY;*[
M+E54Q\NN/'#04X^]]GJ@XX('(=3U_UBE#JJD#BW@R,2"3+0HT&L8DVT01FD+
M2M997.D;"$$$$[S)0',QK"3;,"0"?"*).A0\6P[,K6E9==EE'"@.M"`JDZ+F
MU=&G(`;P$2H%A-3WJBSZ1?+))944G>"##8:+RBSM8OVNAE^OR\N_9I<X,&$<
MN9W,AS-6<S&.-P[9N,38I+BRX3<C[.26EV>^>>=7,Q3FT&*V;(:8AZ,4T9Y[
M+FZWX7[K5%+GKONMZ4F7GL&Y[9H+[[FGG7;Z.[J\H9J(1-ASHP<.;(UV;J\K
MUTG?Z$`'?-0!'Y785=V6A:!G=0U7#7Q@`OT7(;LEJ";7:@C?KJ5!<U6(:P!L
M7`@K,12BX/_(:T#1`N8`P87-*4`JG;L*Z([TK]*1I89,B@OJ<G@>NB@,=C_\
M4NQL-\2(Z8Y-V$&3[X('/.#%J6/"FY/P/D:R*1;G>5?$8A9?0STN2D]FAP)C
MHWJ6O=O<C&>(BA3YK)<I-L:&:.!+7]),Y3[ND.]]4(.+JLHC-6^\*E8R&``"
MZ::C&$4+A'5CR$\:I"P%-I""%5R0C.AV0@<:<B`/4@@DUV8WK4DRA)]TG`-*
M:!0$Y&AQ.[&$%GJ0!7P!"4@OA.'F9-B5)OTK8`![$NK>LLL>UN4NK@,BP\`4
M1(G-KHB%.9,1C7@FX'&,=W&*C&609[PY@4QY6L1F-K7YLC"&L8O_G[&>]K(G
MG.K))CK'V=/-*E.=Y10FG$BSWG+4V)SK!`=]ZZOC=K(#OSO*CX?T4\_]RJ"`
M"3"PD/_CF@0/&10%*HA9$JI;W:R5.`9%,D:G!*4$*9E1C@:%A*-$RD(O4`DD
ML.%>KH1E+%VH@%EN92P#2XO`2L>6U4V)5;W\93"#.::ZX,YB?BG,PY+(3#3Q
M3HDAR]B<DD<=D'6F,R6[YC:E.M5`1<]E7P0CHVQ#LYH]JGITVLUQ<N;5<X;*
M44)SHW;8YZE2X7,\3>NGJO`B-:IY93T`R((%!GG*_BV2HQ7:)+.T)E@8'6BB
M#'G"39QU48QVU+&/==R[;@0'HUA@?QL=_VD0>E`"+DC!*2U,:>>`U-(DP12F
M`*/IP*34JAVV5J>O%6(Q]6*QVQ$U8L]4IL:6J<0U"2]YTVQJ<*VH)ZH6U[BN
M^6:CE*NHK[[,9NL,Z\_6>9RRGA$[X=P>T*CC/NNXSXYQ!.\<[QB_58GGG_"8
MFC+64P8N:,&B$9P;8_<JTON`[:'W56!%&<DL:ETK(7+S*V,A.V!0<D"4D`.I
M!1#HN`%$@;,GC0KG5`H(TF;%EC?$)0YK:E,>IHYUK(4MPW"7.]D6$YETT4QB
M5'&8%2.1F3\MZN]8/&.@0J:W3`59GJIZ7!XOSZK*!3(WEWM5W&!JNFB<;G#*
M*%9I/HJ<9HVGSO_0&ASPZC.>='1G'?<Y7KJ4%RY[/(]Z8%6&'N0(67+KVB3A
MV[A'[O=9_+.H?OD+-L292[$,]2N!]:P4?+QKE$>Q@(+;-8`2//A'4PEMYYY2
MX7\XJ8:.-BV3$.;AF^;E2B'>DI<T;;NZ!+5VM;NMBP^36]VE";=&A1.GZD29
MZ::39WN**G&#W&-:$RIZS.VFD(?<FZN&DS#9\U[YQ!I6C$6WC>P,3M/H>=WG
MR#&\5N;RT_+X3V703[WL*7,G`^S)@_9US8I<K"/%O5_^O7F3:\.@@00[WSWO
MN0\'1G!1`,T!I7!@LYPM`2M=*"0)7P66C'ZIZ!Q]0X+1Y715FHL/?8G_:2WA
MKHBQDVW$S.1349NZMC%N3.]6_&(DKMB*.V/U9F!]9/%1<;B@B76M56Z:Y`(9
MUXT"MLZ$'/.9,YE2Z61,='V6'>H<+6A1OO)VX&H=IID*KNF+-M1F4![S@,/:
MX%CO`&H%P9]L35W>!B4(+5G(<G<]HLHZ[`4=ZF;,MINC8?#S*"47Z`7_Q-Z%
M+D&$G[+26/Z(T3$-.*1'AY;41DF'JM-+3JW$<&&.&&)T@3%V1)T[R"AFMZ'.
M6#*+X_&S>ARX'G?3R$2>*4FE?.6?9\W+LRH:JW)5R-C5GL^$71UA4XJ<UR5V
ML..YFZ(C'8[B1?JH^+E[I4_[O.F%%1&D?N9%_PJX60]4\U\1BO6M(W_YXY;6
MM)KE9@&;G<WPAI>\C=)VGU3BWO?RT>;FKE)$`USOM=P[P?UN\%ZVBDJ")SSL
M#.^8V8TZ\8T7:J@U,U3%;-Q-(J<\,Y*4Y/@X'.N,LU*G/J&>TO@QT-.F!12]
M7=NU2%$]X,@-"^2\0_F>=C*VM'(CHMN>4A$5H&F:H&NKMNH.\^(]+_,],$LO
MJ&./":"#]](Z_TFH/&,<1@*W&_2DQH*^/-NVLK.^3WH<!`.IRK(ZG^"`&'`P
M"!L_J>@WS_F<"L,[F:(AF<(P]@.\O&"M++FT^".\,!D,GKH_)+HX4BO#RR">
M[0FN,](\ST@>RCB9#/\TCI)IP)-I0`=D'@@DLM'3M:V:F22#KD;9DS1R%-EP
M!.DR)]>CIQ$<'S@J'T^Y/>U(P12$-M[#([GRAE/9HZGI(Z\H`\MJ&W$[(?SH
M'P>BD1$*@B#`!SK8'_G@P;WRP1G9-B#DMB$,H3X(`R.,-^U#@$-ZNP>;.\UY
M)=$J/RH\ORK,L"SDI2IA"_=C/]:I"RH!P[PP/+C@J=PIHOW#BZ`:M=Q)(G"L
MN#1\0P!\M<[S..7@-<P@'](0N3XTN5G30]AHP'KLPPB\GB*3%)AK+D:QE.E0
M,D=I)YP!2#KQ-3M2,H"TQ+4R0:0+CZ-+NM[S#A?LH_H!`$&+F^33*%-$J%S_
M1+M5;`D'<$5"JB1W8R@;%$)<[`E5Y,7)NA$'F)&W`[\?@<*J2+25RH(I)"TL
MQ"4;^HIIB)(LK)(-D\:$Z;"%JT;8"9-BXC1.(RJBL2W[N[C;0IK+L+S),P[,
M2\<<XQ0YI+Q?4[WIJ2)=&\MY!!31XT.RO#5>VT=UTL>PU+EP"BOP\2K7^PRF
M(;KR&1]Y6AHU,I6_U#*E6<$N&X_RX,2Z:)56`2CU`@`$,):XV9KJTS8`0T5V
MH0,M`$G,7$615#=9_""S.T64E,PAM`0"6D4C1(H2DI>LJ3<'>[#,$3^<E,T@
MH0H*0T8KY$G34C\=&A@=`B:D3,J\R$;:`9-OW+0S_Z2MGVJ\4%,BQGM'-AP9
M-CRCZ1B9R;-.NBS'CZ&-`V04!:3'S\M#K'HYM/0B;C)$)%,GZ3C$0R&GN51/
MC!FCH?G`[$J>O8S$]EDV[;"R\$!!\NHRIN/$\``SNGH5(G`#]YK,N/F:;PO-
MQN&`TP1)D&S%1"+)A%+)6;S0E>P(7H2<&T&*()C!F&S">Y&"N:M)ND.TJK"[
MV_3))K$AH&3&N%`+WIQ&WSR+A!N\WPQ.8NJI+ADQ,OP2BALB<&3.B,$=-UFQ
M9ELQ_[-*)*VFIVHC[#PG?L2QEWFJ>,RU/`S/E=E2L2Q/>_12M?0B"EP]070Y
MZJI`<V*RUF.RGT-`\M&4>O\JNN[HKCQBR/<9S,(\3.XPS)M2S/0B`@5`4%N4
M3,^\.@<5I7=15$5MQ</!KPIE%_J*U`REQ3Y35`[%3,ZD$0YP3:=H)="JS1:*
M3?&[.QMR49]4$A@-B[XK&+!`G=3ZN[V@1AW=4;Z0';X8DY^Z'568RG`\THM;
MTG/$F)'9$W/$3K0:0+`B&E932#$ERV<EO:E*KK6LN6KU)B]RRS/E1T4\Q'9:
M3[!4TV*SCG7B&>V:/7EJG]K3O69S2!64-A5DNJCATZ@QC_-X.O7B`C/K),A<
M4`O5%4GEB1'"3,U<5%8$G%;\&V-!LUT!V'9K6,<RL):$G`F%Q=9\3<]*47X3
MU13_%3^=;"E4+0N07<;3BK1H/!UH[$)I'#R5K55KA`M/JRT2^[0B$M*9';$T
M5#PW4;'PF:;-*U:0Z1G@JDXY4<?@VDY$F=)N:CGHB5;2F%9H]4,))$\SI=+O
MH;FYQ*Y%1#*[#*LII92!7+9+@;U482<MXT^'W*>V&DP!_<^ZD*L.6TSTR#8&
MN46%ZD@,K;K+S$P()=@(W<P9--2!,#",X#Y*/4F@>-A="8,Z(!%6%*Q-A3L(
MRTG9A*6:%))%8U%3%=F8\@H8!<I5U<U6C56]6!VS@+^6Y1*'PXL1BYB',\/$
MXS2+88YF>D/,0!I5@%,V^MGH%"[R:4?JI$[:@"I9.[FT_\0JI24RJUK`(`-3
M;3W>>_S#MT3/([-`0*P92ZF.G/F>['W/#TPV3_E>^P2O$[PR]E';2L3$PI17
M\UBZ>O5$X.N!^(`^OBH[=EL77AG82]U;"(U0C`#<-5/%("A<PYV/BB7-^P)8
M#B@TI_@18J1<?\L"*?#86=K<"E:&SR6=@(NT+&E&:#1=U`&FG/I"U'48NF#=
MOH"XFQ5'P_.IG54FBHM.I3JKV@6NY$`KZNR,3(F4SA`]XYA:YBW/7-/`(([:
MY1W/Y$5BEW'+<%K/MPPV;JW>E^&>@HQB$'2G3O&N[E"V=ET:]%W;N/*]^5D5
M%R2/]/"&":@5XIM,C;3!BTK<G?^HA/S5S/PMV#K&B%?T"3KH"'P@8$4R8$IM
M6`5>8`8VT8VE"LUY(:@H50OV2<_MW`M."U85.-YLQKQ8G2_445HEX1+#'9[Z
M42%B3EYM2J@,JI_"F-_RF#@,'QP6+J:R777$N9'1C<U04S&RUMA@->>]5B'6
MY5[>Y2&^Y22.'N`@9D&T6N_]-3<=H_7T74CDWF2NI_3YC?8QV_RTQ"U+UR_6
MQ/5M7WIE.H!Z033V*P7]ME)$7.=+1;ZMXSGV6X+ES!BQ!$NEMSZN+X6E9\8)
M@XO%EQ8JQLNE39I<9$9^T2K4X/3;8%UBG;?`DAIM'6G4Y$TNL=9=W<$891*K
MV>3<5:G_3(!T?%)9N,K+&%:PI,XH3=JE^L"A/4`\'%/DA4<M==:7;FEXA%H^
MQ%WG`B,+3#V['"Z<WEZQ:M8GRUT[&D$MA@XJHZ,['5]MUM,O&^.)_`ZI,0]K
MLX"LR4A2Y,BZ?>/YX%\YWNHZCM!6O#,]YHBLOM](99'$O3.5[`,Z&.3,><*-
M+4:ZP]R=%.C-A=&!D^30C<:ZV+`//DJZ.%V(-@R]N$83-N&EI"V>M1A>;;P5
MPPPXJ<_)@%.!I)/;=64YS)0D/3):SK%:1J,U&:>3H])>-F+HC6E@CMXBOBHR
M'3*>/L3VE+D.5+(W^EI<]EXV\MVB7B--N;(M@RN(?#8N2]]N_UZZ/8WJIHM;
M!`C1;4M"`%*SJ\[%/J-CKO9J=F;4PPD#$F%-LY.)T0P@1R7"RR)K=HGGBWV*
M5W*EE4IDG#SO@*YK5,7@5(UD@L[@O#8=OAX\OWYHP>91%"ZQ_T::%1;',OF_
M9PI!\-G*^@3IZ<S6&6ZR<X+P)<LY/,&UD3OBT?YE:@UFTY;`"61+,B4G80M+
MZMIHK1V.1$R]HJZ45UNC\YFGYZ`RM8UF[RA!I%9J\@+0;Q8/,#MN/E(&+:`W
M-;:D2:4D[\YC_>5J@IWN@J7CS9QGLZL$`AK@'<S%D53)..:L#VBE8:0[E*+-
MCG7O]R8+FG(T#,;@@#$M:NSK'0*Q:/^\M/VNQFL<,4X;;(L.DVO$6:2!/.>$
M)Z7*O,BF[#(IP*I<JFF:2^!*`.\4LD+<1Z2]C0-LKB+#:9Q&,GG$<'G$-4@A
M#C(*R/,\YB?#$W5D8NZ-[67>E+*-Q&F^XBKS[13\;6P6;E3I4]];%6^V=3YR
MND00X%J\E<J112-?ESA&<G7NVW9>U('%S*G+P8<`[QH9[QR\T#`@-/#SK)RT
MW"*1B@B3@C`7\T8NB\\%RG#'3=TL'3>_41I=63A'73JG';XXTA:#,2,UTI=U
M3H^6X6D*5@)/JJ"M97D:UPCO=[`2>&DB4T.IXJ5MVB3N<`_7-=,3G[FD7G%2
M/=FC>'1B8D3_+#:<\?>]W.WM@/'TH:-H3M=K!NY8?]M-)`\^+>[YJ5>H[D09
M,*51%/+*/-QR7A?IOM0E3_)A7U21%*$"$I<GOV=*M80@&-$M!]78'$:ID."Y
M_MAN'VA(#O>`.W.UR.L;:O/U6_.$=N@<A>CA;'=.`WLD8H[:,BHEA6$%)WM"
MIY,X5,.>92I5-LC=;>:3!AG;.,>N0M-]1,3:V/1;MMZ6TW#CO71NM;DD^[61
M(PYU$O5.OVVP_+44[*YIYIFS99I4<3:R-?GWF76G;MMO/FZG<SHWB(^9QSJ-
M<K[Q[A7]'?8E;_W3/*`0RN[^W>Z53.NA'S`>&>0(Z]BD5^^.=7H*_X9Z1KXP
MJ8=DJX_1&=4AM;B+#5-W_JYS+9GW43O2LH^\M*=+N8?W9H,C&4[25]O*@RQ`
M1_?L@0?++^*\@F?+JN5P7OYA8>8UKM5[Z1JNYZKX)^X>^(Q+<UHC@)CA:(:L
M&<(2')R!$"'!&0*%*6RH$*+!BA4A4L1X<:-&C,*\&?0F#"+(D25+?A0&+B4X
M;UGP];D04R;-F)8NT,2I<R?/GC-[`NU9"5^0(%JT&$V*-*E2IDB?(J7S,^C.
M/D2+%G7`(6B8KAPX5.ICJ<]4JF;/HDV[DP."*"6X?."2!5"6N0KL`E*@=VZ6
MNWGY<ODG>##APLH.(TZL>#%CQ-.$(8;\6/\9Y,J'+6.FK!DSY\HC/U,6%J_R
M:-&F5WY.K7HUZ]:N73M2'3NUHV8#8\L2EANWL-B^5?GN/7*W0(+"<R-'KANY
MP.2Z':E"6%`6=$<%!U(W+BO!=MW<O1^4)9Y[<N[FK6\7/UZ\=>X$TZM?_UX]
M>?CTU<^OKS^^^_OV$[SW'GD`WF?>=@29AR""!Z8'WG;803A=0]0QJ-!T"5EX
MD&[%$8@10PP-]!!'%FFXT4`=C5C2#"*1-%)%+((D$HP0K>1-2RI%`9--.=VT
M(TXQE576CSD-J5951$'5U%--*<E4)49>P($#6.%#1UA<39F5`_B$\=634((9
M9E"6(-!#"6?*11?_77JMV5=?>BF0EYIS25&8G80UEJ>>>D)VV#1^:G;99H)F
MYAEGE$TV4FBIE:9:HZ]!&FFDS42:FW"V"<<;;[MEBBETO3UTFVZC,G=;J<T9
M9]U#XI%Z$'`7GOJ=>J229]VK`JY74'T+ZII>??#MAZM__\4W;*[B\9KK@`4B
MVU]Z`:ZW''++0LN@>_UE*-U``([ZX8;<-@1@10455Q&`(=[F4$8CHM@12BNZ
M>-)'!LV;4DHRJF3C`%+5U.],0)HE9%5BZM0''4HNF7"32\($998Z"EQ5'QQ<
MA1566W+)P5@$<VQ6)1/$X-9;)?`U9YQPLEFRFW1E<:?+>\(<\Y^!*C-9_\U]
MXCQHH9L9JEIHB*HTTDJ/H6;::$5+FK32M%'*]*HCS:8IJ-BUZENJJ8XJJG/(
M09>`;;=.FW5S&[;W'GH;9@?L>NBAARIZT_U*7K7."FO?L^J]/9W:OC*K-]W6
MZIV?KPLF>'=_!!Z^H'?8$1A1N-Y%5!!$(!I'N4$,E:L1B>QRWFZ]+9H4TKTI
MP3OZ2N!8$`;`,_58I.M&1@RE)?@H7#O"1CWUI5H<8,6O6I8,9;'P03A0?/'X
M5`F66$/APT'L'?,T%!(]B,Q%"7.:W-=?<J[,EQ2!N6QGS..//[.@-.^<_L^%
M]JPH:XLN';_\D$8MC&T&S;:;I\,=1ZFHFCZ-4__/2=5UQF:IX%QG:\7)3:T(
M<B+V5"X^\^$/WN`C+6H-RT++ZA6QXH:?9@4.@WLS$`D9J+?I,`YN@7/$=]S#
MPFFMT#S=.I6&SO4XASB$6^!"U^6*@Z+.;41%)*$72NPEDA<1T21*K)$W$$`'
M?T&Q=:_K5\"(!*8^U"Y)1UF841SPO)Y<Q0%/A%(E#C:\,VH)8_C(DE:^R+&)
MX6,3%C"3R-["A335)7MY\8M=I`"8EH7/,.0;)*!F]J>9]2E0B51?^MXW$J()
MXS%!@^1(1G,TT\PODTFKC:4Z";5/2@V!4\,4I[0FMDTY:#G=@LBF&(>VYBB'
M5?=Q(+(8Q#=9P4=8!"+_EMU@.4%;`G,_\$'/KM0&.<!I1VZ#LV5[8`@M62%.
MA9&;W$1T]2V',+!<$S%.1#+"$`UY\X?MXDA'AABZ(\H+7C'Z#+Y$TA(M.(]'
M\B22&Z%GEJ)LT79:3)+OTM('?-8A#%<,`QH+6E"MV+,JEN!`&*9D@0&P(0IU
MM./W2N:7O_@E3BH#Q/<"*4A"@M0QBLD9H4K*2/2MSV>.9`W2'J7)E]+FDS+U
M9*>"(RJR30VGUSGE`C6T4ZOAICBMC&`$2]6KY9QM:^3Q3JXFN*``&<@_RK0;
M+S=80NI8]5@E)%P"<36A:TGS<"H,3WBX":%JLG*;WW1(B,R5.7!MQ"(G`J(Y
M_U=$+]*E1D:BFU$[6>*-(#S)1Q>0(NO\F="@U$$I^\0=[J!R%-VEA0-;#,(8
M86=&@YYQ*<+#!V0)MKR&:N&A`^@!:2-Z)C3A$7MW.1GVNM=1CPYFD#\(*6,.
M>;Y$GN]/)_5,2C=3&LJ,9E'!/0VC*@G3X\XFIL(`CDP?>)RL>:H9NV&NU(A#
MG'19K3?,Y5IR4!7+5'8'A=#2I2SIHZJW196JY-V;L)A:+;,%KI:(4U"%`"<=
M7#5NF?)U;WAE1=^$B(M!U^26Y*9IPXU\LX;K*M$XS<DBN\;K14.4%SI'UU>1
M..!*A068%*W(DY_4,TQ(6FP^'0N5$,O$`4=!BD#!1/]0S&)V24%HL6>#9X$)
M3&``HQTM]>IH/;JD=F5[.9GW^#(7\,'V'X,L`VT':1F=0?E0E4F42E<#O]0`
MU[C'W;+]A-/E^GE9@#8%%?]L&JJGX69_``R.?TTUP^4L4#NR`-L&C[J>J<Z9
M;G*+ZIY#J*P[`_J6?+-/,RFT+.XT$SMWXVJX[`Q6]P+(/0DA5[JRB5VUIE6N
M$9EKB"AR(LPU^"(J.N+G4#(CTKF3B'N]%Q%T!,6<K&Y(0D*QF"K1V-N5N+%'
M:5AD\QD$?%R1=S!&HV8MMA6K<#:R1$&`!2PP!F?K6,>D[4%$?<P%*;1V>]KC
M"Q^Q+1<DPY9\HFAR8\PWJ,C_B%214-:9^]C-[N$.%S3&11J7XQ>;IB7W,P?4
M=T[W+4I.`3Q3HQ*JB_@72P,Z4#L+G%;EM*/*!.KMX8=&+W54P1Z+%YH]\>D:
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MR.#L@Y4U%)D>E'\=MB=3TJ*NJV[U&7_1UE</]M<-6FP'7"`,9B>+4-9H%`0P
M&[,UVQA,``%*&X^Q00E43UP$66OEG<H`1M])X`128`5:X`5B8`9JX`9R8`=Z
MX`>"8`B*X`B28`F:X`FB8`JJX`JR8`NZX`O"8`S*X`S28`W:X`WB8`[JX`[R
G8`_ZX`\"81`*X1`281$:X1$B81(JX1(R81,ZX1-"811F8`)````[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>f39432a6f3943217.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a6f3943217.gif
M1TE&.#EA40+K`.8``,;&QLK*RLC(R,#`P*:FIKJZNJZNKDU-3;Z^OKR\O$A(
M2+:VMD1$1*NKJ[.SLZ2DI+*RLK"PL(R,C*FIJ:*BHJJJJJ"@H+BXN`("`I24
ME(Z.CH2$A):6EIV=G9R<G)&1D9*2DHF)B9B8F$%!09J:FG9V=G1T=(*"@H:&
MAGIZ>HB(B'!P<",C(X"`@'AX>&YN;GU]?6MK:W)R<GY^?F9F9FEI:6AH:#T]
M/6)B8F1D9#DY.5]?7UU=75M;6UE961L;&S4U-5A86%145#`P,%)24E965BPL
M+!$1$5!04"DI*?[^_OW]_?S\_/O[^_KZ^OGY^?CX^/?W]_;V]O7U]?3T]//S
M\_+R\O#P\/'Q\>_O[^[N[NWM[>KJZNOKZ^GIZ>+BXN3DY.?GY^;FYNSL[.#@
MX./CX]O;V^CHZ-C8V-_?W^'AX</#P]/3T]S<W.7EY=;6UMW=W=34U-#0T,7%
MQ<[.SM[>WM?7U]'1T=G9V<3$Q,W-S<S,S,+"PM75U<_/S____R'Y!```````
M+`````!1`NL```?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=C4I3
M6H)>%1,4#P\=)3$Q,&U_2@L/%&:";GMO:DU*GKV^O\#!PL/$Q<;'R,G%2E)9
M8E]D>'=1@FE^=F&"2U964=Y14N%22X)/WN1_4%UI9GAT`7=T<7B\2EM83KS*
M^_S]_O\``PH<^,^)'3X7!+"ITV6+%2KH?BUI`D5*/3AR!%#[HR4BP8\@0XH<
M2;*D229MV+SZPV3,E"9+]/53@DX)G`![V-B!<X:*3)-`@PH=2K3HQR5<S@A"
M":9*T"=:R)AY)Z`.%*-8LVK=RK6KH"9GS-S9$\`,E:XTMTP99>8*$Z]P_^/*
MG4M7TQ(M=P0$8*/F;-T_83)F^TNXL.'#1:_^Z4+'RD]C2L9L2:9$'Q@[8M8B
MWLRYLV=@3MH$6-GO28`'!O1L3.8D39P``<B\_4R[MNW;@I0X$;2ESF/*;0R`
M,:.E2P4X3_I%80-!@);DN*-+G\Z5"9@U=G[S0WKUC9<_3O`,H#-['Q,Q=/)\
MI\Z^O7N"3+"\22!'L3\G:`0T(60%.BPR!I2Q&T!*8.'7>P@FJ&`O2Z"11P!I
M^.?/%;@XM8@3=P`@X79U!""`1PN&*.*(BH0AP!U<V-=/$V\]@<5OE1G"1!9O
M-;'?3%-XP0L3&Y+HXX\(?K':/VHDP(4B7V2A2/\7`XBAG3)8K*''@$!6:>5G
M2V31AQ@#,7%&``!H<2,B:!R9"!-;!/!%0$M4`<<:>%AXY9QTUF4%`F@,I(4<
M"ZA17B)H=/')4@%-$0`?9E!9YZ*,#J5$%>0PH>),8>@A0!B**A(H)&;XP<63
MR$Q1QQQV:-;HJ:A^)$4<?O38CQ-U#-`'B(ML^H@2:"#@QY#]4*'''E*D*NRP
M_,3!@1FN]L.$%9DV8BLD3G`1`1N@(A/%G\1FJZTG2UA@`@7!!L0$&V58\FPD
M3XCW1K/\5,KKMO#&ZX@2?0BQ`1BT\N.&`6E,&LFYDD31!@%C!-0$%P0(*N_"
M#!L"A1DBI*!'M<I,X:__)&9,=@D4["K7\,<-2R&&'@?ZHT06>5RAB1((W/''
M$GZT0$\E40SP8D!6H$$QR#Q7284<5\@)4!-J(""`T)4T.(`?`=2@P`P%E/!"
M'CL;8@4'0<!`1T!/V#&`4CV'36<9`##-1D"/`@#`%V-:TL0;:LH!`PXA\)'%
M%02\H('&C4`AP`LM4$##"FS'9#(<?(21K]B,+SA%%'+`T7:[`@R@,B9-6/0R
M`C;($$<Y`,SA!@`L*-`(%1#@<(*9?YA1@PL=Z,$Z/TX`($"RC><>71-XQ($.
M$U=4+8P4="!`QN23*!'%'&@PD48*)2P0[E)X*,#"#R@LTH09*[0PQX9/0,`*
M_P%[0"'\+[`B@(7N[$OWA!H+L.&$$UF</PP67&IR!0)<?)$!$GG`EB`*\(,C
ME,`*B[``!M8`*B6XX`@#6``:IK>/*?2I?1CTC!*@4(<\L&$M3YC#&^S7BPV^
M06&8`,5NGL`%"<3@`4I*1!\V,+4JF$,?T0J3$AZ``QE\0`S8>EL*4!"$/D0!
M#G-@0Q1(V(DK^(&)&8QB8N"P@``,H@L+0"$_P+``.6B""FTH@!BZ0`(D+,`0
M7$!``#8$AAW@``$+L,H92$`$(OC@`@2HP!0><(`'K&<):="``O+P!PW4@B5F
M6(`;I,A(88GA`FTX4!0*$`8H>N(*):O$N!R`ABH\@/\!#QC,()Q``"(<X0<E
M6,\@H"`'%]!@`310``?2H(0VJ(`%(!!$&!Y`A`=4H00[6("%)'!(053A<OZ(
M`/(:R4RAQ"@*<E*"%Q!@JF00S0X=DP04X)"'.+CA`C8(`1C^A(4%X``(!WC!
M#A@`!!&\P2-U*`$05."&,-3!"TUX0@TR,`@F?*$%+(``V`1!S$,HP0]EN!@Q
MR!``9#;SH29A`Q^0IX:)[D,)8C``&QR3"3,4X`U66,`!)##00<Q!"#<8@@?$
ML(00TB`)#$B!RIQ0`'MQ(0V".$,$TC`'#)R@$&>X@2$*>@A?)6!QP[A"22'*
MU(\\`0!]F,)/E-`AA0JC"6+_T,L6D-J(*A0`!SN0@!S.L(`4G,`.*G+"`E8P
MA`.H``^*ND(%<,``!:"`!CN`PQB<(*DK0`$%!3R"!@HA!@8,M9@RTHSYFLI8
MV\3(":Y2`ANX"HPG"``!^;.$Z\PH@AJ4P`4K*(`ATI`!'0QA!P-XTA9J\`,@
M&"`,7MJ@%=8@@1&P``,ZR,'Z!B&&$1RV$6"X0PR/H00M(+"QR$4&%9"86;1]
M80T#T((`(U$')`BA"`1XP@-,$`/Y$8)X*="!`E+0AXXQX0([6($%_-`$*D#A
M"GAHP`J.H(,4[&$"1E"!```PSC_T]K>,4$(7]OL%2U;"JV!(KH*%L00U#"``
MNSU$_Q@R28PH&$L#B[R$$CB`@1O@`0TGP`$!)K4%%!S@!S28P#(%0884O"`%
M5+"".M+`!3<@801#"`(!]$&`!U@'`8+Z;R&(&N`Q9$`"?JCF,-)0@.,N^,F;
M:`(8!K"'=PU""6DT,"6HVB<RN*%R$8Z$$I[08`88`0-(J`\AEA`&#]P`"`H`
M@$*5D(82\(`/78/"5;3PA1``X;8_`,#T(E"!I?"B##H`L"*6L`4$Y"$,`R!#
M`I1HC#%`P,E0SG3RT@"```P7$9#C6S&VEQPR*,4+LWO$%-@@@"G\D@$=4+(6
M/"`$%AS@!C#HF!8DX(,45,%E2J#"'>K0@A$D(0@;B`$[5__@Q3\8H-"$@,,/
MXB`T(B-""P#@@Z"N,`#PL`$!U"J&&[K-LR5@@0M,"X`=ME"%;&JZ$U/@@QQP
M5P@M1X()9:A#(8)&B.54\U'!*X03X&``-53!`$DH`*]"JH,W&^`A(4C"!0[T
MJ`X,80":"_8?I@`!F`)!>B\30P^&H`,<<`$"T!Y$&!3004(8$A'*$X`P]1&%
M8J)D`GB8;B_Z4`![5^D)#I#!"39``@M8@`0::($,**#*=W>"";N92".6H'-?
M,.D.%$2$&I*X&RYD(`<^V,!NGR!1-LQZ!R#(Y!4B$(0AL*`%:"".$K@1`APT
M``I/X``-0)`&.XP!#)]*`P%PD`3_!7@@U9)E*P-T0()"N,&W@]""$EY^"#WP
M`:>+P((<"I!J7R@A)SXG$4;3^P4H,.&807."%-SP/PZHP:I.OW<7$*!O1S`!
M#1D.ACZ:8&5$+`$*5D@`$3QP!2P8H)=,;L,6UB"$O?TD"@`@P@V,<(0A*(``
M6MB-$IC`A3*4@`5#(`%L_X`%9E%(`3HP@@BV\"0GT.$`1_@`82%OBP74X'-K
M%@1$#'H(/<."LIC`!`B`6-G2!`_``UY$!B20`BT@`1^P`2<@`K4`!0M0`BNP
M`)\6>Y/0!4D&";FR8IN@!*,#@G]P#X<0`"-@`GLP;X+P!BL`!!]``#*``F<P
M50N0`[9V_R]?L`$C<`.O%&R9$0%$@`-FL$%@P3$)@`-&8%=+E0@M@`,`,"9"
M-@A4L`(HT`;D``5T``>*(`5VH`A5`"$`:`E1`'N-D@4?8`)RD`82L`,$,`!F
M$`9<(!H/4`-K,`H)$`(KP"]FJ(&$X`16\!9,,(94B``9V`EWH38UJ`AIT(1_
M(`)'L`-\$`=\T`92X`1:\`8;D`0J4#"K%#.+EP)TX!=4P`<F<`,,H`()$``I
MD`(-A04JLP1M,``F0'(P(`=*A@A.8`8T@`2MZ`?!,H5_$%(T$`!R$`!]P`>=
MI`C<I@A-X`6R,@RAER!ML`,>L`0&(`0.,%T!@`-S\`<!0`0'L/\!>0`!*1`#
M#I"+?D@(3/`&<$AOH+8`HO`+3.(<C:`&33<(6Y`!"@`$1&`"!<`'?:`88?`!
M-&``4A4`.S`$0R`!7V@(]+(!1X`!&Z`&?P`&3F`X?$!X/W`"!*@(<?`",;`'
MV]<'+A`#>O!X7V$!..`!Y3)W:^``95!UY,<'C7`CA#@)5?`&P[($`D`#$4`%
M$O`"'YD."(`##J`$`S`$*_`!%5`")K``#B`!%T@&[J9I3W`&:R`'.C()?8`'
M.0D)YL8&`_`%-$D(^`AJ>L`#/S`$,C`'=Y`'8)`<44`'+O8"(Z``-G`!O0<%
M=Q`#-'`!70`&<%`'#+$&3N.#/@`#;S#_)DY`!FS`?OV4!@\0`PTPCX)@!1Z0
M!!R@`&&X`JZX>@-`#4S@!:.A"%A`;I^0!G(@F9W@!'S@4(SR!`;0`YX"`S.0
MCX+@!!U`!'8`!FA``RP0!"[0!U00`#Y0`Q/@!ZX$`N&VCF$``.I3"4]0`'TX
M"5VS`/CW"&E9;TR@#Q>``4G``B+`!@4``/4#"P,P`AC@`8K0!A\0=K!``'6@
M!FRF`4.`3BNP?0;@`QGP'5A01D40`WE`#5I``3RP`89@?#QP!".@`R<0!`&@
M!%JI<*!V"*D)"?3B`&]`89@`!GJ`*F:P`1)`!@`0`P70(TW0!C+P`A(@`Q)`
M`!Z``R/0:R\@_P*_0@`P@`(&0``2$)5P<)9-Y02C$P=C(*1G4@".F`E.$`;7
M60C=J0U9X`=](`5XL`$E<`$(4`(W8%<!('FK-`<;L`%X1@A0P`8M$#U8`(M_
M(`7I0@36@TII0`54D!QFT``E<(X>8`?'V88;L`($P%+]Y`46@%)"0`$-X(I*
M!9<=D0@!X`=:1'ZJ^0A/T`9)9`5AR0A(0R=_&0)1$`&2B`ASL`([L`,DT`67
M^`12T`8H``,;$`(Q(`$%P$7=0P&L:`(=@(69M@4"D`69:@A>``"=\`1F\*1:
MITI4X(YQ:`$OY(E10`$X,`1(0`%<$@8*0P6#)P*T]`=<P`$U4`%IP/\E3+`?
M7/``0F!]XTD$%5`%>"`H9!:L8T`15&`'#S`",_`%'K$$!1`#UH<"XS1F7N`'
M"*`XVF,'<_`3&3H)3K`'<$*"/+,`2*`'35`#*Z";@F!.-O`"9(`(7+`&*4`$
M(B`!LI0%=4`!(Y`"YHD#0<"3R;5]L!!Z4/"KBF`&!B`YEM"=5*0&O*D`#9"/
M2[``1W`$0,``'S!@UBD(%B0$$L"/&?`%7S`%8,,$()`$IB687<`!0JL`$(!,
M9E`+`1"3(_`!%ED(;#`"ML4!9(`.33``7W,^V)*PE"`J$\"%FC`&1>DC4Y`!
M,>`&=R`#)!!F5`@#/(`#&G`62^`&QXB,FK'_07;0JAMPDA]P`5<P`3'0`@0`
M`#```Q:`!TRE!&4P!Q(K$EI0!?8&!F+P!GS`!F[P`#N0`5W@$5D0`3X@K2?`
M`40`!#M`"_Y1(!1P`R\`!WA`!5&0!@.#!&TE`DZR%%\@`?!7!`8B.8E":V?U
M)Z;!5D+0`G'P)TB!I(?0L2=$2!N#F9@0!0C@B562!C20`5,P`$@P`-/E!KY[
M``%`#G0@!#2@`T?@`R&@`"X031W+`T+0`2AP`P@@,!R0BF8``31``W>+01CE
MFID0&9K0!4FY,A6@`6H@!0*@`,CK$9)U``PP!!F086=@`$"`3A/@7R[#&P[0
M1UQ0,Z8%!!D@2H2@_P<_4`-XP`V\,``WX)'8<@8X0`0LD+\WP@1KT%R5,`5J
M0`&Y]`=9P`'F.PG+(;Z4<`8`(+/140`\8`!+@`(X0,-7M@`\0`/WIP1A,`,E
M,`<PD`()H`$F0`($L`(P8``:LWUF@`(FH'0YD`$`4`6#!P,3P`<N``,$T,!A
MHP1@D'N=H!(:Y@9Y(&B9T`1(M``-(`$],`-;U6\+(`,L,`(;P`4>S`4B<`!Y
MB0(I0`!H!0M>9P1#\`-$T`)C0"M,D`)&P)<&L00G$`,]X#M_R`>;.`0C<`=]
M8``T(`$#<'E87`A;P"<7H`H](`(T@`*I-0D!(`$HD`#V5KX_H@03X`/R8_\#
M+2";N=$`--`#*2`H=H`#&8`&."`"*B-9'?`"$S``$D`#%'`@*$$!-1`#>$P#
M;$`%%Y`"/-`!<J!WA\<^5;`&`1"IFM`$#I#,;0H`:_"ZF;`_>N`%[$P$&Z`'
M'F$&Q<:4`J!S3%``$UD")'``*8``&=8@-(`!$F`J2T!I?_`$"C`$)A`'NS@#
M(W`!F.;$G3D$.``!.#4%2P`&!'`##Q#!?3``:)`%%J``--``60`%@K,!O8<(
M63`#,>`!P%0NEE`%DQHB9[`"&S`%#K`#!9`O9&`#.,`##;`$4Q`!-2`'2D`$
M!TL(L5`#5P`!!$`!*:`"#H"978/&,+`*&4`'6!#_`32P`190`*U8`0G6,TZ@
M!K9#NK[`!.KX"6`P!SJD"4_0!R&5`AM`#TOP7&\@!7-0`@UW5HM#2@IP!#*0
MGEA``38`J'5`#11*E07P!=!\DB<P65Z@`3J``480`U%8"'>@`F]6`@2`!E3@
M!5U@!R*`!AF0!"-@K(G@!E]0!QF08DLT!7H``%S@!72UL8Q`!G=5P(@4`R70
M`.)-"6RPI.[1!OQL!0,03-K1!CW@1F>T83O`!N89`R=0`)J!C3T0`"2PV"8@
M`@]P`BFP`*;"!'F@`:NP`B80`GB`-R:PAPM`0Q``N/)2!0+`!V4`T;\0!7>`
M`".4"5%P(U[0`C1``']R_P4+$`-`D`0IEG6$4`?S=0`3@"UL``.MFP>2J01\
MH``'L`)[4-H?P`,C9@4T,`0P0,6>%`1&(`0?T!%A4`8#0``!4``'D`1]A,6/
M\A9*4``VD`)%2`AM<`)",`)(8-Z)L`04P,]>K8\$P`,U``%VH..,\`5/M"!-
M@``^$`!5<`([D"]0X`!"$`,F4"Y?L`,?X`4B&<<U$`1(P`%;"@-LT+KDH*\U
M@`)K(`*23@>F4KU#U^A"K049P``@```LV0)KL*G$$JRC*0Q,<-6+H`5@7`E6
M$`#J8P>6O`=%U0)!BP)7+0<2@`$L8,A7@.1V\`0AU`(;H,B"0`$,\`,-\!A;
M8/\`Z'<#(O`$CD$%9#.A?P``U3<SDL`$82!!59`ZR'X(7S"1(W`VBB`&1R`!
M5J4$$8`!$[``H`T)?G.([.$$:<@3A.LJ3@`"-!`$(1`\>^#D`7"0Y"`%`P`"
M.5`"'/``;$`#HM5O+F`"6&8!,V`""*`YZ;`&:;@"*T`#LT2HT.,`#X`"*]``
M8S"-"E*?)CYU>-#KSCA9G9!O7H`",4``(#X(FHD#'W#SAJ,-6W`"-``!*5@"
M:R!`2]"X-BX!`<`##)!RAC"B1```.#1X)(>C7B!57G"Y9A`L,9'`>A-P`M\&
MT`@X2PYSM(@#>_`$-/&'3?$'`T`$,)J>A4";)=!+GZW_*U=)"'Y@[>P!!B8@
M`5FPGE9D"$4-U3P@6E"``#=@!DP`!),_"#\K`UA`!D=Y`699#@XP`GN``#W0
M`Q"`!R6`!`;@!HXY`4BP`0/L`G%@!6`@`S<PMQ]P`+20^#]B;D@L#%'@`)#P
M!0:0)YD@!9_R!V.`[0:0*5O@!SWM!";;`0"0,O8@`B/0WS$P<$'PW^A0U"++
M!U^@`-1W!`=0`G3@+TR@!B#``AOP!%`0`$+`RA@`"$,D9TQ3=!=K.!UA?V5=
M?W]2%B,-64J0F)F03%E2?U%X,3AXFDYP9D^:43Y%`0AU3T]L/$9">A<-2Q!&
M#5>7GP5(-D\!%)!*<`Y?OYK-_TM+S='2T]35UM?8V7]*`3P35Q0K;]%+#D$\
M)@%_5R4E86L(.S(!4)=/(2\!*1L204@X)0:`F5&BS8D29+H0P&=@@HD8:Z+\
MDB+@0XP5+F)T.%/F@8P<$QI(H.%`"C-M*%.J7,F2FI0Y`+RT5%E&'38E7ZS,
MA-3D#A\S4S+$>"`FDQ(I$&Y@$%)!9R8Q%&A\<%`B1@@]8*!8*0+E#[$3--!T
M24%C@I,_;F9XN%&$30@D!II@4K(EQ0L#=#P,X'$#"(<`"PY@N-$B08<<2H_H
M@.#I$Y<V^EY0.!M-R1@^`;+T`<CGY)(T*Y*PB($&&B8F>UR\<""BB`\)7P"D
M&-(!DO^5##LH3"D00P(;2'F,89I2YN3.X\B38ZM"8,27,1>E51%Q@`8,+'_0
M$'E0IH<,%$)6""$R04`*"7N($("TY`,Z'`H@?`DB'%.6(!"4<#$!EPRS)A2\
MM@(#*-`QQ1<I,(5'"@I,@(=<RD4HX81*7,)$5Q-6`P`3U3@A1AW)/4&&`V9L
ML<`(&5"&B14(C`"$`D+H,,0(`&`WUQ@,L"!"$TYP`2$.C4%B!A`_K)&)&QE<
M$8<-D,!Q40!XO&$!`Q>408`)&+!P0`E7K(@#$"-@\,,-,7@!@P(8,````&B\
M8>$5&MQ00!9&:1%``5>8X8(0:FC"1!HPL*```P<PD,0)Q67_XD0#+-P`00!2
MU//$`NME$L(/+Q2%R1SU&76&&AQ.PT27&99JZEPQP)`%'4(T$&0F2\0@@Q`6
MU)-`#W,84,0`D&Q1P`8[A&#!`GF\X(<F5*P@`20#T$!*)G3LT$<$.*P`00,I
MQ,!&J']@,<`&/;Q@0@T=7)'&!#'L,$`%,_`P@&FGQBMO,V,`0.J\FDAATS1E
M+!!`%<<I\48!;TS1``XA@%%*`3P`<8,$9?Q!A@1]]5"`7$\8@`,'8%3AAA0+
M.$!'`R.H"$D''&CBQ@=7R!'#7'/(8(01*53!`0\<?,#"#WXPP\8`88C1@!$T
ML$&9&A(`H0,1$%!!QB=@F($&"CLL_P!)%GSDX<87,L20P!2::+&!$$D(@4`4
M411``PM"A/#T'UOT(,0`,CFQP`)LZ*%(V!ZDH4EPTE`AQP)43&/%`L;AJ[@V
M2L0A`P%>+!##!2;SQ$8/->P`P!-5',:&&CODH4D9,W20!1X3\##'V^LTL`,;
M$Y3@`@U!A`#`&%HXL"L')03P+0P/3`##"@,L<W4<(M#@@@PX4(!&&`6X4,($
M:Z#@0@)?0+CX]L<ML04=,7&[_2G2--'%'`%LH;U*5!0@0P8-L%'&&B:HT,>K
M^J9PPP@EQ!&D%'@P`0-N8`(#F&`#;XC"'YH0!2_XP0`L8,$0UO<'`EA`92S3
M`P_$IP4A%/_@!`<0AQ.:P`8-Q&`!6H#$%:9PB2:D(869B`(;5C`"PA1`"V%@
M`L"F@``%F.`!?$@#'#J``P.<@1DX,8`";G``"+C!-$O@@A(5H``+<*`&%+C#
M+_13@!&P``,>")L%6`><3OE)?=N`%R:B``"`<>^-UDA`$0HP!A68@!'1Z$`0
MBE`"+OS!"S1`@1<&L``:J(!U36A''%:P@1,$@0@K0($=K$"#%%PA!AMP0QI(
MX`(%$,$%-4@!%Y2EP&VH003S4`,(3&`"O]D'`B?``0YV8(*NB.`'7=C"!&P0
M!`G(`8[`1`D7UB2&Q"T.`'C4Q!G6,(<N&#,;3$B`#TX`@1(0X07_-C#!+S4!
M`!/T)07'BH83V`"$(^#`#I_1`A/`$`<$X$`I.C#"`$Q&@-H<B65E\($*DOD'
M$[3@"`:`PQKZ@`DW$($!":`@-63S@R/D@*!M:$(8GD"%@_%@!3&@0.$R\002
M'*!LNI&&%$[P@Q]8`(9.`%$`8J"`)!P!"$20"2:T,,:_F5&D<W#CC6P4S)[^
MD00T:(,=9/`!G6;""QD0@A`R0*<"O"`"`UA!!B00`QKLH`4%*``,.@`!&T#`
M"M]#00UJ@((0+(`.-&@`V/ZPA/,A80YML`(!>."%DP0@=&UP@`4;B0`P0$,)
M66!#"E9@%P,000,H@$$%#D/%JI5!C3[M_VF/`!``,%2.>T[0`YTR,88`S,$+
MJ6C)#(4P@2I4@0)5Y<-&>4*'%NPO!0!8K2:@D`!'$N`*3NB8&9S0@24.8043
M6`$0V```,V#A$@^P9T%9MH0S-*`$!#`#)%;0@?V9``'$C0,>`,"&`&S`!07@
M:35VLX,;#"$?;]B"%-;PA0D``5%(5`@/1G"`#(A!?'/IB`)*4`8[4*$)69C"
M'$AP@R,0@0,D8,`&]"``-W"(IF3\0QX><(TEA($/<N`"$I\967Q-804U>`(`
MA&"U:&@!!K/D`!.8T(`@A,P'#M@&&U!@@Q58]0$%V($`-%$'!O#J#QU`@6P%
MQH,T((`"'P@""O\2T*4ES`$_[K0+=!WP`A=L!!-0V$`&4G"`!IC@!:$UV#N3
M\((&]*G#P61"`!(`APY3P7^:($`%0CL3!1@A#TM80`JV`UDNB,!%0B``AJ*!
M!@GLH`$K5D,5"K>'##``"#B8@%R4@`,G4"$`>0!;<E4&@GMMX04Y((`35I"%
M"1QA"#?(P!I@D((V'$,/08"!&3BL"@OH``,'D(`7EC"`&MA`IIAPP@!*P`(&
MM'(:3^#-"]APW#^``0M/&,`!?K"EB/TA`A-0@AL*\(4_0%@3G,J&$PCP`/RB
MF7M-:!;=,F""-T`6&$2P`0T>VX46A.`,U;3V,>"P`SN(@0XC`8`?(2'_A@^8
M``T=N$@,>O"7+IPAX7F`P0;8D(?9S5("(4C!'C30`C2P]3(G0`$;')`"%2#`
M#7^P@A&HL``;#`"_4"C#!`K%OP(<\=SX>L8VKJ!08"[!"<9Q`!C6@`<ZHP2P
M?ZC`SH!0@TPS@PEX.($"@!"#?TD#"G<8R0*NH`8I/$$+NYG!#5S*@#ZHJ`:>
M4`(4..2!E!VITYEHPAD>4`,6X*`%`0B`$(Y`;0*@80UC@`0Q#@B`05.#"EPH
M``YT<`0&>(`,Z]/"`O@R`@K4P9A+\$+J4)"&P*?A"DR(`P$8P/@C:.!>`ZC4
M$KJR!1&`*!.`LX86V("`-M!AT$LHPUIQ+B\G_T!@!PD0PP9BX!15B"`(`-$)
M&&C`@2_XH0,F@,!F_T`%%[2@#RMX00QXP(,95*`+9:CR%FBP@?FU``<]V,'P
M7("@$YCF"7DX?P?X,`41]$"VGPC"`,@P`!&LX`0%8`$9%03Z%@UR]0)&\%L&
M4("\-R%8X`>&UX"9$&-05WS:8`5O``#=(@1^44HK\@!!D(`_$`#/E`4A0`,$
M\`7P,@5RP`%)D`1!\`)$,`0]8`$;90,>"`D2@`-G\';W,A=X``,OUP5T,``D
MT`,_8`0<$`>O=PP&8`,2\"S28&$#<`5+4`#FI(&:$``P``1`8`0V8(%&D0`K
M4`(+$`9CL$4#X$4_4/\#./!H)R`'9S$`$Z`)7E`"!B!;X48-4(`'!<`&35`%
M=S!H2O!9$G@J3O`!/;`%9W``)/!NW;*##-`!GE``1$`':Z``P+(#XL$!6/`&
M1+```P`$=C`%83``0J!^/$`$`X`&0(``E,$$8@`!2"``97`%(2`!QB$'/=`'
M6K`'M@8YO]`&06``"#")"9(!,U(")V!4TQ`%;8`"0Z`T&J""AZ@<=6!SM(9S
M>Z`*9P!94/!N2P`'"P`'5O``"C`G)^$$%W`#YF4`8G`'+%`"=94)4X".#Y`%
M2\`$480%5U`!(S!`#K`%@-4`0/!H%Q,#K_('#P`"4%)0<!<X`G!#2Z`$TS'_
M!$LD`JD0!@JD!%.P`#W@`5L0#5&0`'.`!62035]@,IGG`CJ@`TAP!UY0`0H0
M`97S!JGR!CRG!&>1!6*P`C>@`RE@!CR"!RM@!#I``UM`AYJ0!1ZP!FN@(GM8
M&6X``6Q02E&@!B:S!\!VC1%2!SD@`2S&`W<@#6@`:CQ0`'^0B#00!QF0`W53
M/33P`BL@`W2X`].W#06@`'&P#370`";C!`X0`V8``8@5`R@@`(6C!`1``Q.V
M`RH``S1P`$(@`0Y``3VP`!+P`CWX!W0P!$*P,2G1!1E``S-C`@X0>%ZY$J%B
M;FC&!'4@7M(0!7[`!PKS!V-`1"90`*'R!'8P`'<P_P8-8`,@H)K#L0`X8`0C
M\`%6<`6I@!0750=+8`44@`,:X`52`'67T`4>T%!$(`(#5U`<<`!VQP!&5T'*
MQ011@"0_.!QQ,`!J8!Q10`!!P#8B\`5\L`=A)A09$)[U,@!<P`95\2Z:H`8P
M<`"U``!6P`2Z5P82L`(&D$("^@(#4`5-,`904`5;8`<Q\(4KP)N9P`0#8`,Z
M,`)(8$;?M@E/(``WM0U<,`!S$('-8`81MIH[D08WH)@?4`.NU`P0,`(R$`2^
M0`7!4@4GD`&[]P=,$`8CP`1-\`0N@`*&QP0FL`-6P`$C8!<,X`!-H`1+@`*$
MN0]F,'HF8`..MP,O4`8HD/\",L$$8V``#'`"$V``6=`"%I!V<3`"."`$VY02
M2B!#+Z`##&`$&7!S-GH-3A``=+":6">C5X<%3(``.D``@44#->`%8A`!?1`%
M>6`$$@!#F+`$?,``(_`#&*`#*A!:??D'51``@P($$I`%5>`$$O$'4.`!!\D"
M'X`%D`A8&C`$0U`YFP8)43`'#=",)%D%D+@-5.``1F!>6Z=&5;``0R`";$0X
M4V`#"L`&YRD%,P"L&``$+!"CQR`&5C`&'P!3!Y!`3["@4]`$5X`"?'<`J#";
M<(`FR@4)*=HM$2`"==@,:I>#T\`%W7:H.W$%'(`#I_`"(."H6]`"1=`#&D`G
MK!+_`60``!M0`G-`9WW``P10`#;@`CAP`#BP`1"`!1KT`&:P`R10!@;0`D$@
M!#)@%W]1`Q;P"U$``</C+T[P`BFPD%VPKF=`!@30`A[@!12P`T)@`GG)$FE0
MF@Y3`A#@J`:[#KX3GZOI!/[1#&WF#'S0?7N0!K]0`6`R``G`C,8)"4Z``#Q0
M;)Q7`#UP:AF@,$J@!UI0`31P`F%P!72B!%[P!BV6!`J@`8]@#62`!`'@3)A0
M3]QT``M@(T^08=2P!;OW<$+``D5@`%4P!6C0&%H0&BU`!AO@<OA%!AF@`$.@
M+F:``JBK``T@!I11`"7``XC3+5BK!RGP@C0P`.<9#5+P_P$:<`<>N*]>D51M
M8!IU8`<<Y@1C(#YCL*I5NQ)24`(O,`:L8@#20`;C<@`$$`5,0``^$``&@`1[
MQHGJ8@4`@`24PI=*0@$D:P)%4`1Y<`$*L#G$J@<B\`)T@`=ND+GKHP00P`-1
ML`6B*P1Y0`67H`1HT`,)``$*\`(^T`'_%`0^(`)-VQ)1Q`<UL#0*X`#Z&+VV
M>B=A<%F':$PEI@E/$`,L<)T!```2\01EP`?3=@$YR`1L\`(,,`0M$`>3-@;N
M-0(*L`!64`!"X`-WL*1N9,,(^`,F8`;+ZB=<("A!8`%5<`F,&VRCAP8(\`;\
M1P94"PEV$)Z0D`8AH)P]0`=P@/\`:<`AGR@"&+`#MWD,4T``!S`"1F``([D-
M<E`#0%`=?+`%#S`"'0`'A?,$RW`%=%RB!B";TR`%&H`!.&`#<"`7^ZH?/I`!
M<>``1`AXU%`%;&!X@@C"*H&*!0`%'V`#-;H-$"`*-"!=7M`"*``'C-054+``
MX!))&X`'$J`!FJ`$$L`#.K$$!S`'TLH!*B`&&K`!,O`=<I`*3D`001@#)(!B
M1(`#)V``(!`#`!`#*=`56!`#/]`#,3`'&:($;6`!/("1+K``"RF!2J`%`&"(
MHMP,)VP4<6":"K`"'Y`UA>L$:R`#,!`QT724(S`#78O"%%`$?.<":N`%B[E`
MOS<8&W#_9M<@H"9P+',<+/-I3TM@`5+Q"+!I`'G0SIH@%M'@!A)P`$,0!"=`
M``)P!QM%!886`:QWNC^``P0`B7+0A4>`!`^00E+P-F&08'9G`$^L">>X,5T!
M*"\@`%U04W^@)P$!"5"0!Q!`!D?MR8:W!`0US]C0!`Z0`WP@!A)@`@>M*!8@
MSB4`!@P:26$P`QH`JG"3`3A@!5A@!C4@Q/#B!3'P`6]``AJP`B;P`7<P!=[3
M`B4``#"``@2P`=SW`B>``!E;0BE0%%V``!K``S&@`230!RC0`2/I!'3``TA0
M`XMJ*HWCT4`@!"\P)ZZ)9ESP$SWGE=,9#?5L%&K0`2QP!".`_S?<Q4)_\`4$
M\`(<,`,(:@(+(+"8T`2\B`1-\P=90`5>X`1J<`*[#:QK8%1,T`7-:Q1E0$24
M>AIHP"`9\`!0(`<K8')4(`9VT!558`8"D+;-8-+1(&![]P,EP`9[\%ER(06*
MG0(BL`.D^@%P\-I9$`%"J;S8\01>\`4.P`,ZL-LN,,F9(`5AT&R8(`5Z8`(:
MISU-`)`A\`!IT'HQ8`%G(`5LP`A,X`4`$`<<IM6P,@Y>;0U?T`(UDP>'YIIJ
MD`-%L`-J^0<-T`-Z$`<)@`,B$$Z0`))\0`&AQ%*]@0!6T``'0`<00`,```84
M``-%0`0E0%47H#9\@`D^W.4&P`93X/\#'G`22I``0>`&9C``+*L&30`L/)`!
MRFTJ?N`>@IL"`_#%<*2LV^#5*&[;TA!:59`"/Y`$#$`!VZ59D##'"L`",28-
MA5@#/0`!:D`%C[5`<M`"Y;0"<Y`%6&!-(M`5!K%P*S!K?\#4<8%!0A"NX9$"
M9_`$=3``W&H4+02):"#&I\$>;"`:++";<9`'=G`,:I`"1W``>6QB&L``'.`%
M63`&2L)`%$`$+.`#((`%=B/8>L"J#K`#HD``.C$%!L!(_+0-?/`"NRT$-'!"
M4U`%>8``O+Y%B0/CH2KC,SX-7X!)4F``/0``B5.W+X`#/K``3/"[B<UN&X`#
M06`#,-`'8T#_+=Y%F*>(`LCG3R7P!J6)!Y>0>1"P`2$P4-I1EARU`3#0!&K`
M!C)@`G%0Q0L$L@4@`CD``T(@-PQ``P7?NR;6`"!``'60I"K1!'U@`3LP!#X@
M`X_[VHMC!7?@![-ML%(`O9EPVTM@"'8@=R$0`P0``J1*`P6`!G+]!1^``P.`
MX3P!!B!`76D@=RJD!BJ@`#\`!"?;5EY@!7/PH!*@`R`0!BSZ`AN`+D<+*U90
M`3UP`PS@?SZ04UB3/B4(`&=`0?1]&D,7!5*``/I<`3&`D2'@!U*X0`L026Y@
M,D?!!X'$SEX`!5A`!5(P`.]T!"6`!QS2!%80!AN0`X%=`@@0!FS0_P)E-K,O
M%W=]<`)(``0FD`%U;@91\)MF0+5*4`9[8!*98._L@>_YK@E+H`<Z$*,:L`-R
M':IY$$(C$'A@4`*M!@,2H!-CL/`K0$5%$`8[H&*<59F0@`4W@'*9<`49D`&^
MX@!M`P@#6W]_61\T9AP,.#LK(S8+=Q8[>B8IA&(*1S0\<X2?H*%@/#\E%@<E
M<UBAK*%47$ZA2PY$!T-($W5*K;R]OK^$`VB[P,7&Q\B$4G>M"Z!3:`MI7AX'
M#L1C*PI)+P%13%Q2RC0]"%!_2UX<2!Y=?TU*64]H)3\Z0S\_*7%C5D_O5.YT
M>'/NCQ0+-VA,<54@B!$&*=P1&A,`0A5@3?\0T"%&"(W$/TRZY$$0!4")'6@(
M+2E09,20!E[^6-E"[,(($694SMDQHDP5>4N4<`F`X\@/%C^$0+"SA$J7)TZ4
M2(A#I4F;/V]HZ"@02@D9#DET,/!$"`J9"'2*U3%`!105-@55ODE&MZ[=4%@\
MQ&C#ID2&*ZR4C#F!PX:$*4[DY*@@!D>#N$K"S("!A0N$'6RR$%NB9P<$/1M`
MT(AAP4P5*&9J9%A08T*#%#QXQ%A=`D0`$R*N*`%38,,.%QDLR(EA8.&4!4@.
MI`A3['B0`GTZM,@P@4,)$F3:^KJ2P>\+"V'B_HGB1P2/&T4V(-"RY"Y=)E06
MHG-/OSXK*@.:$;+_8F>-F2\6T$``&*`HH48*1HU`0P%LS`$'(4ZPH8$)#H3P
M0@=?L&&'$E4X@48+1MR`A`%I!,`#"S>,,,`49T!A!1A=E%&&%A&LT$%.H%R1
MP'DWX?&)%70$($9[Q2P1E1)1-/&'1^]HD<<>:@A@P@8`_/.)%&PD8500*O2Q
M!P#R5='`"BTXL,()#=2Q1!]W--&%`$(,<40+>7SQ@`(L)&%!D%-`,<456)0!
MQ0,GP)!`%*`\`08*"@SQ0@3:+?$%`GV(8PP33*`CA1)OB2>8?:"&ZH4$,:BA
M1PX>Q,(*&2GT@(,#4RQA``X"?!%`$`.,0203`RA0``0RI&!#$#`,P`44_PL0
M,<`%/110@`D[<`("!3)$L$`."2C!1!8%I$!#!@0$@`</!%CYAQ)7;+`!%W`\
M<`,`5E2100Y"J+`*,$QH8`0,:BSQA!L5O)"!`12LH$$`\K%21@@2I)$%&QRL
M8$$<JI8%!@%!%,%`"04,&6HO5;S!Q[T?EUP7?LU$H<8:;)RQ@`D?E*'D)UCD
ML<,--]3PP@@W9"``CLJ8F(0';%`AA152Y&%!40QP0$:F\2RPPST&F''&'P$L
M,44!+K1`A[E_3"$'#"G"X`?87;A1,3),L'''%GB,<84<?(CQA@8QS&$%*$O4
M\8$""ARPP0$W!&'`&WL3$M(#.B!A1Q0!/"$%%O]RF)`$`T$@0,4N3I0!0Q(_
M!.&&%5KD!(<>%#`@`4V?"#6!$`H0,4$6F4*H1A9$)C/%'&1DT8=XYYHL/#)H
M*$``$QSPD`9'H`C@PPL\`$`(#B6$$4,/!QRPP@XM;)%O#6$(48(7O.&@P`HX
M*`=&"B]D83L!.3P@)`$T:-%5$!3\<<8`0[1@_R<.X($:6H`#%+#@"$-0P`L.
MX(?:_0(*.?@`'AR0`QL\Z`]08$,&1N"!/&3@`!3('2'ZH(`&A*(+`X"!#P:P
MMO'HX0-&4``2-F"'X1DD`!<``_!LR,-60$$.S"-$"`I@!LCI0`1E"&(!D'"#
M(7``#$:Z@PQ8H"`W_`'_#E9\QQU<H(,\_,$)!#C`#Y*0@3,$\0]Y2,(^GE`&
M+DP!(1MXP\P^088>W.`'1WC`S#+X/_<L@0L`D(`(`,"%*-B@',#CP@P.P`(B
M!*`M7HB`$1)8@7>P@1A9<(`"-/"&)V@!1#]`@A^T`PHL?*X!3<A"$Z10AQ8@
MP0&)^P03'L``'?Q@!%G\PQ7F4A\IM*$!'4!4#X?9"R9,@`8``,,&8-!'OA$@
M!CE8P1>8X(<5B"``+R!`%[PP@`W$(`8F6,$&UD`#BQ!""5NX@P(F(`8J\`$'
M7P@%&V*P`#-`H`,^Z```+&6&&4A@;"6001(.((0/#$`/((@!'TBCA2G`H0A)
M_UE!`(JA!#\000<C4P(*9]`"`Y!A/'#@@`DTT(`/E(`#=(!"%!Z``SJT\%Q6
MN(,*8-"!/H`M"F7P``^0H``7%$!7H(K'&]8`!V$2\ZB)NH.E0(&`!0@J`T>0
M`!MF]H0$Q.`&J("#>*JP@!@P0`%2U4,`SA`4*T"`!CX0`@:&,`,R@(T04S`!
M!ZOPA3_.`08Y$$#"T-$'%=R``318`!]2H!X[```/#G3/%?Q`@@Y`0`(+Z@+S
MZD`!!>B@!PZ(B2S-``(B+*(#*#"`'1:RA#:((`<T,,H.+C"&5O2!`2$@0QRX
M8`4_$$`(!/@"\[0`@1[HH`@Q*``(<F`!--PA#Q>I3_\3R."``BRA#(#1Y2"0
MRL,J:,`%7V@##RBPUT]0`;5"L$"F]'"``JBA!P/('1/LT(('G",$*]BK$@"@
M`#;TI04QP$$!K(2'("R@`$*8@$Z#4((@/*``!S!`'ZSQ!":DP0!!X%)[Q5`$
M/F1*"B3H@0)"$%U@#.```:!#"@Y0KG>TP0.C48,R"M`"S*YA!CT80?>`$88&
MT``'>V#%%09P@B$<@`<2:"U]GA"``<!ACM2E;A/,X+X_`.`"/RKR'&@0PPU$
MR!%)V$`=$ILH%!SA"$10`1C\P(?$/:$`0,``'1PH!3#4+@P8N`%EG*`%!?1`
M#TC^@QHV@"<<R$$*@%%"`&;_4(0+#GD/"!"#%2R0A!6L(116J"P0$AS+KI1!
M2PJP`!%>X``X$$.91XA!<@FQ!2'_00)'4``?HA`%37K`U(1X`@+L"`01A($)
M_N*"!X30@CS;10H)D$-R'2`$/OS!#!]-LO#:L`(5=&$!Z!7A)_)@@VBMH0E5
M.$09MK:#/!@5"O0+@`=,``-.A&`-6=""!F@0!P[88`T06($-BL`#$&C`!@'(
M0`P>U(0M3"`%.,B`","P!L?E;@E=Z,$"KA"&.N"``'50PPEX$(0)O)476E@!
M&<F`)#!XH`8<T,,WKK"&$FS``02"`AA"8((6'.`!2_W%$JH0APV8X`$R:QUJ
M1&`^_P7,``(=IDL<VA`592M["6"``P)<D(*KR7(+`0#``Z9V%`64P`\OC74!
M8+"".7Q`""D:2![HL(6@8`$",0#!%[8P)ARD8`%58`("=M`H1B"W0&80@0YN
M@-XZ_&$+4HCZ.Z-J'S;`@;(UZ,`6S#*`.#QA#&$<0GBOP.5/I$$#1]#!`ZR`
M\`?T(`4&``.BEHS?`5PA`!+800XD<!4JF$`!0%#`#B3@!21C80TX&(+JOM"$
M*T@!#WS0@B*.(`;Z[&()5N"($_"0`H.EP>@EBP,24)D!&J2D%6O@@1"$D.,J
M--\.$G`!"B0``T,YH0H=,`$`:E`">Z:^"#5`7PO8`(,23/\7"PC8``U"X`&_
MO8`+H0`%+&!L62`""G!MG_`$$Y`#8"`!)F`"$K`!1-`#-+`#"%!Y7;$$6K`!
M$G!7::=99Y`!X10Y7]0MWS%=#J`#)N0+46`'>6``%R``;M`$2U!S*Q`"!%(@
M>.`!+Q`B)>``.]0+37!QT$==7O$".!`!OG8N=1``!:`!+%!"T@8*:L!R!L`I
M2E`'&2`$0$!/>+`&<J`J8)`!"E`#+G`'2E``*_`"<?`':7`#2:`!;T4%!+`#
M0T`$&<`&JN(&`[``&H`$+#`$">`>>[0`--`"2?0)<^,;0W`#;36%BE,`#/`#
M,`"`H-`&,!`$()`'F@4%`R`$T9+_`4T0!B1`&E'@!`T0.@#00G4@5T#@:&Y"
M!4]P!PM@`-K0:-V%#%-`!Z/&"LAR`"]0?$5('U!P`C%`!I5C`97V"5O@34"F
M2@-03@7P`GFP!6S0`BD@`1I0`C$@`F:RBBJ!0D;`!ET@!1F@`KVH!-EW!GDP
M`2ZP`R)P![&P!'D0`PWP3AN0`S]`!#Q``@7`!RV``@C``Q>0!5U``"R@`V$F
MC+S0.6T@`3Q@!$?P`7VP!%=`!R^0`A2@!DK`2AFP`A\``$V02A>P`B5@DF;$
M"U>P`/67`0D0`&M@`,L4`A=`9W+@`B7P`"K6.E-@!QF``W\E`06PC`%(!PC0
M9,-(75"P_P<G4`)L$'.MP`1:$`!FL"FML`0`0$`9(`98H`3_D`9S4`)?E@1(
M8`&&]P=/8``ED`)FX$#S``,U<`,/0#(@H08D`'N.P61>>0$4L`!'LP%'T!.0
MB"\N>`9L9TUN<$9S\&5"L&6\`'DZ@`$:$`9G]`YC4`-#L`#_8`<<4`,$,`4<
M<045H!5"8`9KTP3=DD`EH`9/H`1I,`9TT`!KX`7DA0$%`)7'H`1BD`==^0M1
M\`8Q4`(`@(%)^0OI@HAHL`,98%2EE%\[8`&QT!`+8#/.0`A-X`=KZ0;N4P0A
MP#Q*@``Z``8``%HE$`)L4#MZ0`0+,`$[``,N$`0CT&PXM`,-8/\B!,`A$-`"
M0;`#,F`*?9`#"!!K6T@$+1!TS1`$"@`#8[`&+O`#-X`"K14%<]"?%-!:N_$!
MED`Q,L$")V")K?`$D`4`6T``*"`"'+`!$``P-(`"1((`S<<!7!!$<2`!N<<`
M+9``1"@3E5*<U+4%*O!PH%F9K*"!O+`%(H`;>],%9[`W48`$(_`#.+`!*<``
M0%`#`R`&)F`XE>D$M@@#1J4$!D`#+``$,.`&3U`%31$`>7`'7R`?'[`",#!1
M=/$$`C`&"/"`.<8+4$`"2"`"O0@*`X`#-+`".M`">U"9J)E[-'`&!$`$*Z!9
M"K,"/,`'<_0%*,``+"`#%!!/3D`%:`#_`&SP>%O`!54@`3+``;A)4520=8'Q
M!UA``*H!J3SZ"W*@%**I`&)P1DP`8"M``TET!0Z8!5\P`K`$"E"``C50!Q;`
M`09@C`2`!DU@!;WJ!BG0`GJ0`3:P`CV0`PZ@`C0@!M5Z#F[2`33@`A*@C(V*
ME"#A!8Y$!6X@`2E0!G_P!3?&`&OF"UN0`2S``,-Y3E=P`4F``3H0`7M#!0G@
M`S.P!JVE*#!`GQN0`8-)"!D@`4W@`$A0`5H@!5,P!A$@!-SU&MJA!%@P`.V9
M!\TT'GX@`T2@`#=``F;P#W0UJTF&!B(P`B0!$GHP7<:@!'-P!\+D!*A&L!S2
M!$P0!AZ@`R,@_P0)<`X(=P('H`-?M@(9(*^LL%XJP`(F5`40(`0Z$+!)8`!2
MX`1G0`<%4`$Q\`93P`1>N01,8`8F0`,!(*1\HP69T@1YT')0!`I1<`<,61;0
M%H\`,`9,D)8X,`/0Z@`3``=<EP=QP54\H`%4,`/Y@`$;,P!_2@A88`!Q8D9I
M$`()A`$8D`%X4`5-(!#YUP%QH`1*X`2QD`4(H``;(%G`T()9<PQC\'QE,7<$
MT"\RRPL7H"Q,L`(F8*#G1``^4`0F0"!X\`(G@`<MX`*,(`.6^P=B``,A$``]
M$`(.<`(S@`(G8`(E8`,B@`8!)TQA8`'U]P`.P`4F@`)OI0=#4`=.$/\&@OH&
MN3,8+6`'*5!N#+`",N`J^_8+5K`#/[`#:5&U"[`"H40!L1`%`W"2,$H(*W</
M$$"4*I$$B$(#;/`'8$`'<D`38Q!<39`"*YB``V`"%V*@@O8!2``$0F`"'8``
MO-2[/;0%/#A(/+`"!B`&`2"KQ1`%#=(>3.``0#`$."!:`P"1+'``%O`1GQ`'
M*?`#"-`!08`#3JP_\`4!"4```!`#82$!"Q`"1F$#!1`&!9`#1R"P+B"26O`/
M9Z`%:Y"1R<8+60``5<)L);``W@D'DGL##?!67H"M&H``:KD##)PI$T``Z.``
M,2`#A_L")N`C?Z`"KT<##*H`#Q`*3)``-'#_`G(@`6:@`4+``CYP3R<R`C%@
M!GN0`40`NDD``G9P!5W`!(#!!9Q``3DZ0HT7A+RP!&FPD^>T!0Q@!!R0B[,J
M!270`TWP!3>P`)`85RM`!"B@!$OP!C>0`&0P`@``!7.@`$7`$RJ@`Q4``0R@
M"^<2!0V0:5'P>#O@![)@!@JP!&&0!BB`!&^P.>C0!@>P`&\0."R``4(0!'30
M!6!`!!00``=`J8M&N3Z0`L2I$FCP`T:0`\8,"E90`1AP!!H`11T)`4`@`3KT
M!QD0`!N0!`\0!GG&!$:`:SE``DDA4AC``B3@AR*-`JV@!.!F!"F09TK0!`,0
ML'?H`+A#P\,C!?PC_XJ$L`"@"[H*``%FD'RYJ3A.<`6I=01.BB<$P)Q=8:T@
MT0`Z@`!<,`;4``07L`4"\`$8,`(L8`+,00AFD&9R@@$_T`DZH`,LH`%=(,D6
M^01[\`,QP`4BI`13``!`%P8TP``<"0K@$`()F2<W``1_%@I3@`(9/21/<`5*
M,@(VK1)X,`)'\`(Y2`@:T`9RD`')5P:C@09@8`5?(`16_`8%8`0_P+(74#M-
M0`&SG=&690`:D`0WH`!H4`5*``>)H[\Z(`"D9)T78[_)(`7PXCL1@`.@.R<$
MH'F\7(1F(#%7$$#YX5H4V&U(D@$[\`9U>'T@$0<KL`("X`55<`-SK!(9T/\#
M2B``<T``_I22?S`!/7`']W8"+K!3*8`"`\`!/2``$X`#$Y6YB[0#)5`#]?T"
M>D!J*4`$0M`!$0L2O3T$$1`7`3`!#H"&@6$`^N@#?!`+3S``*1`$4C`5KEHP
M-@`!(E0"^;,"H,L".*"/.T`$/T"I,V`!OB`%`A(*4:`'`H`&J,=(/'`"`""W
M1&T7`!`"L/8'=/`#2^W*/5`":Y"JO,`%`V`&&00#/P`$DPD,$I"G?\`%&N`#
M(Y`$,!`&((`#D(4!1+#!BD,'`%`&>B"6[;P?AIC6$B",6N`^4E``.S`#_Y,%
M<S`'8.`&Y88`4,D%*.`2,9``KZ`!+L$#>DP(:G#_$@MW+F^P`&V@!0?``:&@
M!CK`"J`<!R*0.*@I`R,`!#K`!GY``R6@`D,@TQUV!F#X8$:0!")@/UYQ`FNN
M``[08(3@!EC@!AN``RQT+F9P4*S:"TIP!K2$)U5^!-4I!AZ`NSSJ!`'@*WG!
M`.J:@`N@/3$@#EC0<@Y\`'H`-E.P`C/`!1W``30@!`80!JVY!85^!FX'`T5@
M`020H'FP`C$0!C6P`4JR?#C``R&0`0TP!3/@`\G-!&#``&#P!&(08%J@!&@0
M!#6@`XGH"TU0!"Q`M:4+!`R0T0Q`D%T@;;L!F#\0JE0@`SF@!"'`#"I1!HQB
M`-/T!U00!![@;WCT`P>`_P%((`1@8@$FH-6@P*5&$`*?L'P+X&;G5`4(1J4\
M4``MW^0\I`?_7.55O@'7'0J)40!;\'B]"0PJ8.:$0!1[()8:<`Y*(`<\T`)J
M@PY40"1+(`5<5K$,<$<?`-A!D2D.?$0#@`!>(`8:P`",&PIA0`%),`(*,`"V
M9P*Q]QR,L@=[PP1;,`Q[D/)'``*A(`8,P`H:8`8:1)=,``(?$``.:@:[<`4B
M(`0+<"^L]@E0`#Q*D'%UC0,+D!)JNP1+X`8Z4`.MY@<7[D,T#O9+/8!<?VH]
M``=@L`-0WPI9(-Y"L`&#0.@1(`?I30.'Z.A_8`?$<0$',`$7L`%<ZW8?<,0`
M(/\$#=`>6&`!U0H!(K``=;`#$\`*%``(1%9.5R\P:4M_BFTT#78K+30\*Y(X
M*52*F9J94!\M8)DB"AM&#"E%+"Q!*'&;BE8/)B\C(E8+27.N8P\E*PM_9QDK
M'VEL'1P&`64$.#!3KIE2,2D+'YE;:4[037PJ#$E"(&:)T.7FY^CIZNN97T,8
M\/$81Q#DZU=["&3L!0<#VHM`$#&RQLZ`+DK^+%EP8T<8=EDH"`'W0<L44`'\
M6.E!!,4,&A2>;.KBX0"+(@TPN5(")\:1(0VJ-"DCI0P4/20.),%PPX;(3&)&
MN))@9HP+&`\S&3@Q!$4:`7&@*$JSX@8!=DO8P)@GQ(__(B\>8F`X$.4*.TU-
M%,B3!Z3.V;=P-WE)@:*-@!<&K*P<`R-&$0]5G"R@8:"`C0(#,M"PL:*$!QP=
M*-`(H`C+'1$[9$28(X?&@"::P,0@\*2+'1H9X$A)V&0.C@80<C"F44/#&RYW
M<%@P0&,!F@(Q6(SHH:$+.B5NCFY1-.:#`AXLA(AHH(+##2-#1FP0H"5A)B59
M!KPHD8(!#3;0E)R!T&+%@"\!*&QPL:&#!ADR.`R0"FT)FA02;(''"6$P\8=W
MYDRA1P9(,'!`"WY@84]<%%9HH1)]C+`6!B-4`5<38>SAQQ@(FO/$&B;`T$<4
M?YBA@0]#!#'!'7G0H048`R1`_T`,#X0QH3E.N,C`#0?,L<<87'SA1``G`*$!
M&:`IHH05`_1`9`9M&+A2&`OTL`$;47"!!11LF$&!$3HH(`$.2?#`!QQ0)!34
M4&8H(08).!@@AB(-S#`"$B8(<`<?;FPA1P(+S&#"'2JE8T4#0AQQ@P9A_<#"
M"WI8",>&&.A@AH6@HD,&#Q1D`4$0>90#0`XUU*"'$E-\T,,7$_CP12914&"#
M?M@<`(HF2K00@Q-Q4+""GIIT@`,:)*1P0@@?O'""`6J(<(`=.[;Q!QLAK("#
M)3C$84`,:"BBA@D,"-&`.GH$8<!/5AQP0!`_\,B!!A!\8``!"AAA*0\3<%&B
M(F[`$/\$`P0,O$D:,+S0`1Y*/!&&&6JL=@X3>?@`@2)ZZ'"'ENLXT0`.0"1A
M`P%FA:KRRN=HH:$\2,"A\#IE#(#>.GKL,$,;;7R@1@E'M!G!&Q1DP.(?6W!`
M@P4IJR-&"-\48<`?5Z0@!`U-*^*$`2^PP,`&RY4#A0,[[)"R&V>,H84!#+#@
M9<HPZ!`"`@AX..<F1&6"A0IX7>'``FP<\0,0$JPA0@=E:"F'#290QLX`#!R!
M01([_`*JRVO%8!S++%-1``]KA''?%S_^044#0?00@K9FP)"!%@04D65H.%#0
MA@$4X%#"`&$XP00<*V000`D;;+!##SQ\H$<?)Z`@@`P?@%'_!@(GS/"!"!D\
ML$4)+8R121-U6``#&6*0<4``$B800P\VL`&0.500L$(`B4`QP`$O$#'$!@9D
M(,(#&WC`_RCPK'X-00$AT,,5?N2%`LB`&F&(DBN8``8#S&`#`S@#R,Q1A0ZL
MP`P`L0,,XJ*$+00`:@H(@@K8@(69<>Z%<5'#RS"0@@*L@`-L^,E;G,`%13RA
M=*ZP10Q,H(`5G*``)!A2#R1`-S2P:`EM$$$,(O"K=$2!#2?0P1`8\`()H$&"
M2L#"`$QP@Q%(X`W\<446$+`"!N!A#%3``Q2RX(8)($$'1V!!`3RD"`B0(`]A
MV()(P'`#.FD"BA\H01`LX8$%X,!2_SO0@`ZI!@`8;&>2YQ##!$JP@"JX4!U+
MP,,#:`""'\1C!8V"H866\`$A=$$-,9!`.;S``0;LP`1Z$4`.1-"'>^T@!08X
M@R+`$#P$"*$],H@!$6)``69,``!YD@H<2O`")!3A+W@0P@5*A(8#7$4A"KC`
MT<QU`@K<80,AL-H&2E*#$F@A'5GX``]NI9`.W``%0&``!R*P`0)4P`4..,$&
M&I"!!?#O`3=@P0^2P,EWNH(.,EC!`\0`Q$Q`,P8-\)XYO+"!&+BA#?N@F@I`
MI88,!"$)1FA!`IZARI;"90ETH`$&6!`V$@2!`VJPD!WZ@$ES<$`!"P!(%U9P
M``P((0!TR/]I)LKP@A@,@*7E4`(7V%`%)FC@!TBXPR:4P(84&`$(1[!&.9R0
MAQ3L8$5:JD-X;/"2`VP1"1;0RQ\,4(%-]($%8YA0WEQ1!B2L``Y-4,,`##:$
M'WB@#*YX@!`\0(9/_N$);?A4J+KP`!R<@`I,D,$\-H`%EU9H"7;@`0'.4(`=
M`.!]F5C"&VKP@B*L(0I;\,`*YF`!$^AA`!_8`0YRH((.[*``(("!MJ1*!PGL
M@`,%,`,?</"Q[ZC!75D@`PE*$(<L>&<*.PJ``0!$`@FL@`!]<$,!"".!$K#A
M#1<XP`\.L(,(2`$=36"#PSS$$A/(BP6ULT`*(,`!"U#@`Q5H@0C_"-#/_E(`
M!1M(`@N2,`(4O,&3P%)#`<B#@`B.E0P16`$&2826`+S``FR80QU4H@4AF&&#
M<"'N!A2P3`[0@8^>C;$YS(`&",S!.TJX@@-1T(>*HD,*@H7Q.90P,/#10`<,
MR,$>E^"%9S"A#B&(@0.RX`J)`<`/;EC#"E`0@!)5(0`UN,$0G#J'%KP@`$*F
M$@Y<```K1$$)8&!"%%PS`@:T8`].&`,$D$`D"HB!KIL`@P[\<#-%[!4:5%!#
M`M#PWD?IH(P<:,.$IK"`$C@8&E:(PP!H8J$GU"$#,5C`YAY[`@A(4,;L4,(`
M*C>&V/5X@@D(P@IB4*<LG&`%:`#!"G(:_S$[;$`('8"`&`:S)TU8(0@4H`(:
M++`""%A7$5)0C!V"FX(#>*D`6;C"!YBKM#?0P00E4`$*3#"#%0`@`QN@IQV"
MH``DK`'%T+@`#1`@$B6T`0E$&`$+FNV!#!B@!"((>`/T10$50&`&&<@`,K)7
M@G[]0`<;*$`:%;$$*J`H!1TX@PN78*H23"ME2XB`$`@0`*HB2`M&,($'9F>A
M*[Y@`#L"P07>B^J::ZT>/U)"%YAM`6&FV`D)48*/SR&%`,3@!D#@<@#F0(9$
M/($--&C!C:7$A3VL@0MRD$`-!!"GU)(A!`H8P@%@0`<21:$`2$B!6_ZP!VH.
M``YG2,.>EI"&#?\,X08T2$#7%0(&#>AO,1381%"8\!/0''H39)A#`-Z<"2:(
M`01!&((0)I"U)7RASA./0AO6P`:+52@,H/X`%\@Q!:G\T.9G<<`!XM`$&L2@
MLZY8@@78+0+C,((`4@#W.!51!5Q8X0(3.,`&J*P(*EB%"T(HP0%TYP,)7&$*
MJKN"`CQP!3`L8`<C:#@#1,"%'6R`/TP(@P%P4(`P3,$`2`#(`GB0NB\X5A$;
MJ(',%#&`I-]`"#A@PP<RX`$.0"`%$_``O^4!'M`!&0`!*]``O.$`#_``%J`!
M$C`/!T0:$T0&%5!$85,.36`&'9`$-``#0O`#$@`'$*8)6\`"#3``,2#_!'@`
M*DI@`@#`!70``!V`!!2(>C)6#.8P!@9P`!I@(590``(3%TR@!R]P0"7P!5L`
M,DT@!R50`[>R!@/`!5H0`SO`!U"E"$S@)SMQ!!*P!-=U!FZ``/M&`SU@`!ZR
M!.0`!3&@`RQP/C2W55]``BQP!"`@>$*1"7$P!R>@+="0!E;@0EU@`/GD3=[1
M@P<P`FGD!4.3A7'Q!!R@`Q'@!IO@`(Z(@^>P!2E@`D^P!T(``?#V!W"``@=0
M!`^0"`9@`PX``!:0`3L@`1&0,FNP`P.@+!E@`C'``\)'`"30`WP@<@'`!$Z`
M`+)``R50`@XP`$@@!_8`!7>@`P'P!$S0`#&@_U&9,``T,`<#X`$$H`$I\`$A
MT`.HL7NSM`(JH!)7`'8MD`0,8`'LT0$=X`$-L`%^Y&\S$'#<*`$$)0$3<`(2
M\`$:X``?$`$RH!9'0#C[L552D`?>1P#$EQY`8`<%T`%"0(G0D`4\`&H20``I
MX`(>(%EO,50IT`(]P`(Q<`*MZ`(:D`?DB(DLXP0#(%?ID04D0`,D(&1G(04`
ML`9M<&H_QA\+03(CH`%XP`1>@%A_P`0&,`(W@`"?UAN.^`49@'1G^``C,`1&
MX#-+\`2=]04X<`,5\$Y-\`96,`5OP`'ZQ@`.X).QQP5(`#::<#=20@8[4"I2
M4@;%-E:;HP1CL&(>*/\"1W@`)]!#.K<&`H!:<9$&%O`"(K!W0$$_+ID.9"")
M4N`!2!!2KH`&0I`"0!`'2Q`%(8`#8U`!,2``$X!_I+@!#:<&/K`!/;0$75`E
M*S`!#B`&%4`#8(`@3-`&[I$(6[9!3T``06!]([`#,7``#\!2"+`#>&`",M`'
M!M`#,6`$1#4`[_<'96`$"Q`E7J``V'<I*$``P68"%[`F^B<"%C`=-7`!DK$&
M),`!D;$`-@`!>U8`&D``%D`?$J@`$0!O2T`&#7`#,""3FR`445`%&M!#T*`%
MLH0%`M`"!P`!?)"+:[<.9F`$O+$`68`#6%`&':``&L`'']"4D0E#4]"2KL#_
M!14`!`YPG>4P!7$``01Z#F3@!9H@!710!-D!`UO@!P:`"4[0!7X0*10PHTW0
M`$"@`T"0!["7!0[P`P?D8$[@`@<@!U2P!-J@!$[0!">0!#J@`P"`D^>P`B\1
M`@`AEXI0!D*```M`!UB0``$PHYMP!0,`+&[P`))S!!X@!EJB!%)`!2YJ#E;@
M'!I:#EG04R7*"0:0`WT`!AN0`@JZ"5!@4XSC(62``Q(P!@_467XZ6#10``@@
M!3#``:C%$B,P`%K`!AMP1._3!<ZB!R>PB9*@`0M@!><"`VA`'FZP!R<0`PJP
M1,>8!RL@`O2U`$9P`#[0!N_7!*[86'_0!)`SG4``_TP@T`$$5@T/4`$ET`$H
M0`$3@"\2``(&``,=$`+<"`+5(`(1`$PA(`(&\`'`H5X_8$9S,'$'D@7CQ3\I
MXP1L@`>%]`=.(`&1N@E9D`068!Q+4`<<4`+WV0(;8`%P@`Y0H`$YP"4Z("]'
M,`%-5P4-,)(6(`$PH`$`$*B)JC*PH@$UH#TD5`5S,`=I\'YJ8*.;(`5DHP-(
M(`$5``$!H*!1L``OT`*2]@==\%,Q0@&."![*LF`TT`%?@`=?4)9.X&LZT0.X
MMPY8T``KH`%EL`4/\`(DP`5AD(=_@`8;8`,+P`1/!@$%D$K0($9[80$]I@1J
M4">A@@<?D+(E6+)G`0(\4/\'6L`#&\"6?X`%&<`#<$5E<G``!=`$/L`!;)L%
M/P`&42`''$`$!A"'<!"A;]`#,."=N)@`3/`%,>`!>C!R74`'UM(#*>!Z!H`'
M2$`"A9<&'=`#""`'5L`#'``:2N`!-"`$*^!00V8"*1"QBM`!0+`"\PH"%;`!
M$Y!.>S`#)$`!'-``+6``()`""+!_!$`!`>8`(N`"!?`!'?``_@8#!C`!)K``
M$F"M)2`$\S`".9``T!`%`J`!/=``5^`'<6`%>1BP`ZL)`7``'!`.-@IG"V!6
M"^`!-M`"_YL)`5L"(>!]&]!:1V`$F+H/4U"_14`![!$#(ZNW+;<.2U`&OP:Z
M)!3_!@$P`$,7L[-D`"S`(1[P!6NP!E'"!<*9`0B``X_V`7FY$AW``C)``6_0
M!U`P)E"P?DDP!$<0>"L!#7A`!"U0+IE04@S`-DGI`:2"!="*"9I7`&EP#FZ;
M(`"0!Z-&(585!-R'#HA:LGT0!!ZP!`_0`VPP,W<A!+3[K"A0`V+@`!P0"2&P
M!B+Q!.LG!\:CFC%``SC0`@1&+A*0`\;1!)56`S0PD@+@0199?,L%=%(`@4*F
M!`VP`[%U`C8@!"&P23O0&Z%X2'+@+IG0!CW@`S9@!*,A`A+@`"#03"50`1I`
M`1VP`0L0`A9``##P`!)``B1`JQ+@7R[0`1\0S"@P`!OP_P$-<`(5$`(DT(H7
MH$P_\`,,<`(",#!/<`4C$P,&D`4*H#4)Z@K1A@,LH@0+L`+#[%!DX%THL$F*
M3$\*(0<\L`/S.2%94`$KH``ZX!AN,06RA0(>T"T20`>I#,+G$``@J0YCH`$O
MX`'`^Q91L,(R6PY<:RE(\`!["`#=\0=0P#9>R+::,-$X\`%ZT5E-D`5:D&!'
MH``64`53,,`@X&038`-%$`-W`!I;8XQE3-(.0*97B0(X0`!-H`4",``;K1`H
MJC=U:@Y-$-7L8`?"LI;IL``^Y]!_(``[\`"P0`-]4`X"<,@]L`=-D(XQH`8[
M+0(G$`0]K0((8`%%``"*8@=_X/^D&X`#)O`!'_`&S*;7F6`%RM(&4N`$#-`!
M38`@4E!P4O``)W`",A!Q@*J4/#`'Q^@!QI,$/\`#-+`QZ+`$`3!YWN$&WJD`
M/V`"!.`!*+``)Y"/ZDL`(A`"$2`!S00"Q-P!(L`_&C!@]:P"_I4"$8`"%M``
M&C`!*<"-!J<!'6```7T$1W``(=!<2O`%`N`A@]@P/[`:3I#.FO`$%#`O&Q``
MVB`%!L4C5J"&>T`"+5#/&[`"I<($`-`#/;`"A+U574":!\``)M`!6@";!$`>
M#Q`M*F`&@NO5T``%!6#5Y3`',-";%>(%<M!3+`PL9_`&6\H'E``#3$D#-=)T
M=QD)!1#_AP[,D$3@!U0`55M3`PJ6`I31!DN(@)PDO`BP!Y1@`0'0`B6PML!2
M!Q+0+V9X!!K@F6B``'APB5*R!Q2U"6&,%GXPU'%!!200`R2@5.@PAB0K8U"P
M(XT5`QM@XIE`!1)`!"_P`6I8N@2P!30@2Y7QSBE``?NQ`Q?P4#HP!E7PQ!F@
M55-,`QX0`,X2`SY@DWW@!'40!!J0!CR`.!>P`BO``SP0`C2P`7?0`_)K.B)@
M!$A@`U*N1K=&<U#0`$GP`@R&#"%POB4``1D`C["H`@H(@.++B[!M`0[@`K?M
M`10``@A@K@M@OK_]@-`L`0;@`A.@<!0P-SMP`X*SF2+`!BAF_P62<0)\T`)E
M3`8N,!P%``9YG`%Z8"!-0#9'I!=*\`8CZ0$6(`0CP%X=(*9\-;M"L#^B-K@2
M8)/;90(3T.0*#L8.;@YG@`+DG.#'X04#T,-_<.&/I6@:4=0H4&Q04.9`P`,E
M+E4L-0627LZ*$`4C0P,C-N9>D``\\!)YM#MF,`5Q:$-F$`9^X`1GQP(VD-^9
M4%P,%@.%9@5OX,7OQP0!L`8E\N2#NP<)T-4DA`8,8@``+ZE\(.8E.W[&L5V(
M^@4G@`,^,`&K40`X``!/\`(9(.8`0`1@8!DQ@`)VH$-Y@`,+```N<`(T,!XH
M0`=/L%P1\#D00`8&$`)$0`3'B`,7P/\&2``!`'$%":`!R,@'6H`PB=`$C2P$
M%9$.7U`"`NM#)Z``)3`$1/#<,#`!K6@`]RD!$G`!);"])-``&QD"I_ZP%"`"
M%?`!!)`!M=P"#S`!TLR/O5P`,-!,'C`!""T",X#Y_D7J\W`#$L!RFE`&!F`"
M+``!<:($:7`P._`&3)`(;9`!,G`"=-#8M@`#.?``&<UV),`#Z6Z#::0$:,L$
M"K,$;FT"(Q`$UR\&,T$`/$Y0)H`"73!T^4XA3I``&T`#<=#0YP`%*@$(2G]_
M:EY_2EEK`&=R*RX%2X.#3@D_/SHE`7!Y>)%*:"<X`0`F+AU>5'U*2F(!"D`_
M+PD#*RP_.`#_7X-M5G%-?79P)B\-49*'6QH*0S005(-*<`4!S\?6UE:"@G]8
M`X--:`EFU=?EY4P+-!QAYN9R;.WQ\O/Q33!V?TX,NM=O03Q`Y/RQTL$&&3\#
M8/!8HR52$S9"%CPX$*.'"08\`*B9($0.!")DE*3)0>-$#R0]\&3HL>58&0T[
MFOSAPN-.)$E.$`AY`@!!BQT%_)B(L6/!MG9.`!!Q(.G,#APP?M#@(\+$``T;
M#*B8(,'`A`-S4$AHT+6%`0@O"GC8\(##!1@$(NR`($+"A`\!9&3(0Z.`!10=
M/N39(($/#0(=7BA@88`("R,_8LBY<O/8EQY!)BQX)6/)&Q@2V$@9_Q3`!XT+
M9R)E$7%#A)DH;1340()&TA0[?R5LR+`F#)-K2O2LH"'D!@DT4I:@P6&B@`$D
M*020HT>]NO4ITZW_"4-D11LGVB4]29`FRA<N5P(LH-)&A1!XQY:`@3%$B`X%
M"I+,8(.FI:0R2!S!`Q144/&;'W3L\,,1/MPAB1)\,)`?!VF$(9,82[C1`1)&
M6:,%`3<P@,0#OTG2Q!U':6>&'EI<D0<493C0QX,/ICB/$ER46-T8!83GHW52
MG"!(%C:,8<T3!-```PXAN?'"!G"HP!8*!QR00PAR@(##`!O`H(L8#9@01`DB
MB&!'"#"P(\D7)J2P1110C!``%-LH<08,)?]TD8$$)3S91Q1+1)'!"P'@,"4/
M1K!0Q`D"R?,$"#3$$<D2`8Q@@PXZF+!`!APT\($!&8@`P0P-B``"!%U)``(!
M&S1`0@8$A$``!QI44$(#%(C`:@6$&9`"`1:00``*;6E@``H65*!!DD7L4,("
M&K05@PY'Z""$!F0\<8T9#XR``0Q@-)`#!`M(0,,$OBW11P<FJ!#'$TI0$8$$
M"@A1Q`9N0/-%#!L0T$`%?A1`0@DPW"&%C4KTX<$*1/A@`P1C.,%&!BE(0,$&
M)7#@ADP_=FR=&@-`T?$3`Y1BA[;A37%''@8X(``85<20P@4B2\)$&"H<,$11
M3RPQ0`E`,)!"'TW_=`'&30.DL((>=URAA@L*Z)!#`2@_"*`.%'C!!!E,W/$!
M#19H<0PB(@@!&0YA",($'&)[/,@7`120P0!L5#')`PIXX,0`1`AAAA(2$($#
M?&X?XP4".A:N^!]3O&",$SW,<0P6*L@`QPY[*$$'#A38\<('V6P1P`8]O"`!
M`7C`H,$5#[JQ&195#%!$`79+$@8.&9AA`04KQ`""`%TT`<<*']!A@@=Y2%##
M#CU(L,`,)^2Q@@54*`%&#"QT!X:-UBCA10@MN"'($Q`H@+T.,"RP@0<4?/``
MK!VHX$`&'1"0P0,:-/!7`QK`2L)=!+B8I^['`:Z0H`$GF,">*L`!5-%O_P4-
M\(`&.C#!%+BO!`_PP/UT8X0AA$@"<IB"-;86@144P0@`L,(?JG`'#;S@`7&`
M@A/4X``<2``!8]!"!D9`!!!T81!,6$,-%F"&$[0`!#&@P!W,@``9G(`/9[C&
M$\`P`1S@8`>',4,5OM``XB'F,&P0X>+&^(T^]"%QX1'#`FI`@CIPS#I,N$*I
MU,`$!/P`!7`HT1+`=(`;*,``XAO$$K00@1[@QP)F"(`<QK`$)6C!`#&00`84
M8(0#+"!?W;N`#RA0!Y7]@0X&6$$&VJ`C1R*`!CI@``@H\"0`>.$.`ZB=VYP@
M!@M,(`LZBL`02C"$"P`!"2/8`18PM8,9C<T)3/]8PA0J0QTGY*$-9%Q<%8[P
M`4&480<2&(T=>F"`*$3!!G]X0!#:P(8##``\Q^!`$*3@!C;@(`6&D(0#>B"'
M"_1-""^H`0A:4@`A!&`B?+C#`W(PIA?8BPT%8(`>)#$&`Y1@`PB(@Q\4.@D<
MQ.`&$!B-//H)@1)=`0<]2($.BB`"!88R@H_@0`8J<,`6>&`"+]@4!PCPJ1)D
MP`.:ZH`(VI>`%E#``#0P@`4X\(`-0.`$((C`"RJ0P0Z@H`4W@`$"3#'4":``
M`B;80`%40``)I.``1^B;"C0Z-C@\``<Z(((9!C$%"&S`!P\0Q!+H0($1("$&
M0AA`B:0@@ABP80%(@(#_(*#@$QJLH0EX\$`05J"&<IRH`T(X@`UV0``E+,$/
M&<!!""X``AY00(S1+!P3"H`/MRGA`B=(0\=Z<8$]["`)(TB!&*;0@0,D00$0
M`*TUHN"`1!V@!&=0#^O^(`4'*.`'(<C",6KV!RA0RP1PR(<%%/``?N`$`D)(
MPA`L0(9!Z&$/&O`!`!:WA6ED1PDK2($9_`"'"]"2`7L8PAZXH`0YN"$+`<#"
M`21$`R`TH&KTB`,<N!?:\$1A!S:8`'WAX-4.U*`"2V!$"IS%AC48X$H#V$(D
MIA"!$B!``BN``0V*T#P`I($`S;&`"0)@AP64``<Y>,$,'L&GZ/[A"60HP`I:
M_Q`',J1!`6M($>52<(8!3(`'(0C`&E(0@RVA\1I6,,`+#NO=%^"`"$"(`0%>
M18$,*!`%7/'``U!`TPI8(`43.($'@D6!:'G`+I(D@`@J<#\*G"`"(="5"`P0
M`@L\0`40R``(+/"!%!`!!A1HP00XL&80&.`#]3O!K#PPK!``80@Z&,$$``S$
M.AC@!D;H00'*P`0L^($#);``&JH``!WT(`>=&`080E`"-X"!!@BPQA5:\`(L
MH*$/;UB`"R20!RY<(PII,,#R<%"""9C!"F;HL`0TF`)5Z[;`X9%"'@+IL26,
M@=/:64(8XM8!'S#@!D#@80;H6`XEE`&F&6A`<81@@?\^".`.6A!$&!Y0@PRX
M@0EH^$`,9H"`91I``><VH@3N\$9NY.%2"DC!`,30ABIH(0!56$,2#H!.MVE!
M"^!V`@]84"\[*$$*.^!!!5B`!"($H`<4*``.SH"!#,!V`T.H376D\&1L:R<*
M&I@""C@GPBT,((H!L`'!3)"#$<P@`RM``@]<P`$V#$,`-)"`3."0)`:L(`0J
M8'`*E"N)`*0`!6=P`AF$$$^<O.`$;?4`#%I``BQ(P@0M``#N1/#5'V"``:.<
MAQ1D$`-R?)H&1M!!""+0+P*D+P0>>'28)Y`"/'O``2%H``J(VH+YG4X"#D#!
M3E?`AYM:-0(GD$`%3`"!H9+_Q0"[<4`)'-`6V",P`XQ7X$LE\``)A``!64$!
M"X[P`SJT8PHXP$`+(MG8/VR!`BX801"0L#I)O"$'!'#"'180!!6H5A(A,($>
M4E""$L@``7L[P0NJ?PTI)$`"^RT!"A*@3/7)P`($.,$*O.%S'UD!`3_4?];A
M!@&0`!UP`S\@`6UW#54P`3&0`5&T!&5@`44P!#C0`&8```%@#-Q``$1`!"\`
M`58``"U``P'`#2]P!$*@<\<0`"N`;CQ@!DO0!%/P!`(P`&N``Z"&`CU''5K`
M!@2&$T&``U4P`C#@!!G``GT`-U"`!"%`4@O``V*``4LP`B30!T9P@@*XA<Z'
M`C?6_P8$L`(B$`"C<05`T`%:H`$RT`%*0P`(P"4]H`$?4`!>(&IOY&T2@`-8
MP`4$$`1LP(&#@`;G(@<4H%@X`$,UJ`>4%0`QT`$0P&16Q@%R00$..`!-L`1D
M<`!&,`(;<&W7P`1LL`,34`U3$`('\%I!<#JG$@(9X``M$$&GDP$&((<&<#HZ
M10%)]0$?8%44,"L/\"E[`GL6(`(S=3HBL`$.L!OMHWXSH`$P,`$3Y`$SE7D=
M0"JA4HAD,0$/$`./I@-)0`,W``;FL"\V-P5BX``RT`()T`5I(`/U$@$:!04+
M@`-T$`<E(`$?`&,],'OCIP$%\`(&\'$3$P,1P`7A$@,A(/\`9'<,46`'!(!@
M6&0`O-`&[$)I&E`"%?`=7'@C63``*M0QZ3"*;'`",8`&2[``)[`!=6`=3M`%
M`#`':M!PQ]`%%7``*(`&-0,%9W`%'+`@0$`$$<`&?0`%F/@`/.`!1C((4<`&
MR[<#*2`'@'AC=``TYM,T?P`'8S`'!7`&4.``CT&&/Z($<;`&W&8.3$`#+:`$
M,I`"(L`"`+`$>)`&2K`#&Q`$(A"%;D"%(^`!;&`$>T`/8/"6&QD>9T`#X"0)
MJ_$",."1'&`Z:```*Z`!1Q696"<">\0&/0`!@*@$#O`">U``,.`"!T`#&A``
MO_$&%[@`1&!+*U`#"J!9I,,'FD3_94U0`"E@`A^``@`P`#W07<YW`C00!`00
ME><``3S`!Y*P!25`!#;P`SU@`1ZP%2KP`+NB`K`2`KJW`'#Q`1*`9X\6>:VB
M`1+0`<@(`AQ@`#``*B%05`;``:`W`P3@`1/V`Q8PC"[&`2#`%HJV)PO0`J%B
M%RA@`&\V`"I`<BL`!&M@#GQ!`4K``@.@+4[@8C20<J(F"5>@6&E0*"(@"&;P
M`3:``S20`A0@!SE0`2F2B1,P"%@``3G0`A=`G(/`DRN``TAP/)*2AI'I5BL@
M`<8TF.V0!@L@2]HQ!2RP`XS!``QP`#U@!>CF`W^I'4XP!C(I"7Y0`C%P`7_0
M28S#$RTP_P0,@`.N:00E``!8X``'8`)V=PU0X`$'D`$+6`<9P`!`L"5PH@1,
M,``%0`"JE053``#\@B(^$@U!:`T;<`-SH`,]J0,?`'P*@`!)T`$*T`(G,$YZ
M20)WD`1:&`]@<`%IZJ/TP`040`-X=@U4$`<2\`(4,`!^@#$$L`!L2%02X'1.
M68+$P0$(```HL`%YT`+X\@4%$`-$L`/I10.XN@%J$@7A@CMRX`5F4`1OD")>
M4`(40`8(X`$[D`$(D`XT(`-M,*AOHP(HX)M_0`!"T`,CH`.2=@*=@@(-P`$<
MT`'GJ0&K)&DBD`$4,!8?L%-LP0$6$!B+=IX^U0&4%J`?((OK`_^=7=55/!`#
M2#"C.6`!O#<#)C!F%$`"'E`!8T$"7"4!%ML#0\`#^*0FV$`"*Z"%++`!TQ,`
M9X`W/#`#7;`-;_`Y5&`8;V`-8X`#&F`%;,`!/H``&#((5,`!--`'*M8J9@`'
M#1`#'"``9`4-4U`'??6A*8"!6?`&0BL"185FI.2IW:,%G:H=95,`#0`'%?`%
M<C`$:<`"*#`'2E``T-8&81`"1*`#&X"H4_H@==`'2?D'`(`!(6`&,G$%4#`%
M`X!*(Y`!:,`$4Z0,(Y`$1W``*M`&S/4@M<0"$N`$32`'(0!J&)`$'M`&6G`&
M=[`[(A`!NN`$D2`%!="P"^")U[`$5W#_!V6@'5>@`B,@`5>@`",P`B50!2DP
M`B*@!3W``+["!B4`.'?@!22P@.9P!D+*M>T`.#B@!U`@`>W`!0*'`GY0!^H'
M`GOP`"D@/R'``!)0!\E(`Z9A`AJ0!BD0`K(D!0MP``2`DQ?``WL["$_``VB8
M``:@67Q0,[XK`VN0`R=@`B#*`@P0!"F`2?%0!B6A(PV@`S7``CH0;YD7*V[5
M`0]P`K7H+RT0`1I00.R*`A10`9FW`1I``2'`9_>#`J'':#,P`+QW++6X+#,`
M`2KE`.DI`?Z9`A"@`D'@`R/P`2$0PC5@/QQ0`"ML`4)P!"5P`QV0'8/`!1L@
M`P'X!TGP!%L`_QE$<``^``+'L`8]L`!/$``5\`($T'9+T`(E8'4P8`)"(`0B
MV@5<<)M94`,RH`9KP,8<0,<48`(E,`!-:SLBL`(\L%BY\P=@@`+I"`$?$)EE
MP$S0^R/9];AKU006$`1Q@`'#!P=)H`<A@`(!<`0T\`J\)([M\`1V@`#^(0='
MP`PG&%PG<`-#$`.Y=@P/40(_P``4$`0U0#B2\(\?3`%<$*=&L`,@\`*@A@0B
M$`?JXRU'L`-K\!MNH`9XX`8$@`,S@`?Q()8#$`<P2@^2+`F18`4X`$V3['-0
M<(^C`73R,`5FL`+F1`9S`*8!<`<P$!$Z1BAD0)=2X`0G4`)9P$QZ,/\$;S`Q
M5)(#?(`%3"`21K``<!`$];FP-A`$!:`'0M```X`$`;`$3F`&/P`$0&`!X3PV
M"24`Z.0$+\``/8`!0N``:38`H2PW!B!I"Q`#`,`!*@`JPF@`+H``B;9H$``#
M%E``LT<6!*`"!6`*")!@%`2Q"P!V>R`#HG(Z(6";,#`')>`!#<`I)T""9WH#
M3";'K_4#)X"IW*,$9J``%L`Q37`!#'`&*?`"/&`#0C`'',,$!A`$<$`'/-`"
M*]`#*^`#)Q`'<=`#(K#1""`%5[`'*2`$?8(#!F`'.H``->,]":`#,R(%:)#/
M!3`&"%.J)U`$2_("?T,%?O`"-E`'`+`#.T#_!ZZ[D3[SD=5Q`R,@!@I``^/Z
M`P``!7RP!28PP0&0JY5"!TZE!3I06O&`N8?`!&?`2S]0!#5PKC@`!Y-[#$[@
M`#NP0@1P``;0!5@P!6Q`!'CD:2P0-`I0`"*T!&9P`TD`!#K``D,P!!D0!/'=
M`F/P!4[P!#*Q!00P`BV@-=:P!%^P`)*+;4`GLM:1!5_@K>G\!"(0`C<1!=9+
M#V4@`?S"!G2`)Q2@!WQ"PC/P`D"0`!8``B5``S40&H)@E&T0`C@@MC!`!`Q0
M`RAP`CL@!WT8!S'ZB#5`&(3(`VW#!C10$7EPM\=@!2&P`M\W"!TP`CS``)H2
MC/L*9BNLPL?R`&W6_P`@4`'#`GOPFC_1D@$K+`$<$.'00@#YMP"`\8NSV`$3
MT`(8^P$>P,%R7@'5M@'N$Z`JP`$.\"E>=0+4,@(W<``ZC@5?L`55$P$Q0`?;
MP`0;8((\8%&1KN.#X`:`G051:!1-X`<:$`,TL`*:D@<+80T`P`/\1R8=]P=-
M``!"$`<#@+5;P`4HL`(G<`=/M@1WD`$E<``Z8`$J]`9"X"!_(``E($KWZZ-F
M0#/6$0,B\`<J@%M)8`%_<`5KE<TL0`?$K0!L$)U9H`,L.`]:(`!ML`1[$`-#
M$,T1<-W7P`8Q(`E:0#I(@!]Z$`!]L@-'X+G^\0=G``!W\*OWCH9_$`4%</]<
M1-`!8#`%7S`%7/`$;R`"-1#@0$0&`T`'@VP=:,#H!?8%@IS.\E`'.E`U%'X=
M>L`#"N`'7'!P*0`&:L`#2$`'QI4$]O4!-\!T79P"8\``',"!3A`&@4-$52`'
M-+"0@U`%D@0%5C`!+C<%;\``AFEL'8_,UYT"1_!W=Q"9`^`^*2`1-&`&MYD\
MK**-Q,H!*5``(A`F%V``/!``%,"N)$##`W``!AB@$E``8!,`.]``!4!FMIIZ
M=K`#%E"+$#L'+@`#`0`V@>8!**`'*N`#=X0)'$@%<*`'SRH%&C`$#-?06T`#
M#U``0P#'06`"S`4&#-`!2V`!,2"DL*L`9"P%C7G_!CK2!.%U]+R[`FR]3$Q`
M+U]`.FU0`;Q[!9`O!`PP)P@S!6O``#^`!`2@`P70!+$.*%;0`$/P`./,A5?0
M-M3Q!D"`!D"@`2.%`'T0(:/<E@V0`AL``"-P!R*``MVNW#?B!'L0`5J@=J]!
M#W+0[@]R!0<0``8`6V4`"$U,`3TK7$I_?V11B$UB6(F14@A&0$,-8TQ,?Y!1
M`D<5408"4)&FIZB)2U8G!WFIL+&I80-.LK>XN;<+!*91)XBZB4QF)R49>`@E
M)@UL&C`M#S`N%'`$"G)E?RT@2Z9*;T(!=186.!EFD6<K*!4T(2D["BP*01Y2
MN'D*"ZE3)T0L6#`PH8&`_X0+(D!`B);A@X$9$#IH,+"!`@<-$TXTX)!AP@82
M$E10?.!!PP(4#3)L*-#"@`45!C-XV.!`@P4"*%%XL!#"P08"#3[X)&'P0H@;
M.DPH</`D%9D8*MJTB1-G`P,8#XP((=+C@K<_2@CL8&/%#X<8!2`E6I<A@(P4
M*8CL@-'`2I\8&=#LD!`&P88>"FBXH)&A#PX.7Z$,*%&"BI(R'VB@L)-J28P8
M$;HX4;%C!D$M?\1L*+%)F.G3N%`H:-'&1`\?*:2$4&"BR8$@*E[XL1`F0((H
M'[B@OA(@#YE@N,P<<$#%E`D223H`".`E49,"1%Z`$<;$PPX,1T244>*EC'<,
M,__*5$$=R0P,&A&:L+\E10^`K_/S"R-`PU23%0"PMX07!O30`AMX:$`$!6^L
M$<,*#E!P0`T_C`&`1#NTL(=C3`PPPAQK^%"!!@KL@$0*;`2``P%BW<%)'AB,
M,$0!MMP2AP(WU$#'>J<T$08)!]SP`PL\+%""!`B$0`!&'+@@0`@]:4#!1!2D
MD,<'&T``P@,A1$!`"0649,`)$\!0000T%)"!!`9D8``*#R@3`04AM+G`"20X
MX,($#VCPP`=Y;,!!`3&P``0.-[P!BP`*)%!:%`W<<(<5%F!PPPVDJ*%&&1*L
MT,4`/J"P@PTO[#`!%V;P8$$!XECAQ@0[U+""$$%4((#_#P@T]4<39A!@!!MP
MG%&"!34FHL0:0F#AAAQ>@)$`#3FPT9PI"VSPA!LK:)#%'UY\$`,B3K30@'[D
M?J$&?K(TH85\3T@QA7Q.:*%$%T/4H00CQB*"'&I;")!'%OO"0HP).Z2AJPPG
M"/0`&'D`,,44`4!`@!`2R)N+$EELD(0"0&CP!@M##'%`&/,Q(<8,0:1%+BQ-
M`#`'NBO'C$H'1P1@RAP]V#R?$@&48`,%9$!0@@L%^($"#!)\8,((-P3`P0Q"
M("'#!B:L0,8)-%R1"!<&F'"B!'2<D$)S2ER0`PX%Y[(`$C?`808**VQ@AGP]
M\I$"`S_\@$0)'S2@`@0B?!#!_PP/-#3!1"!H``$,/+DI^`>";U"X!`ZHX$`&
M*K!$P)H32$!2"QYED$$(%9#>@0H5M.!!!B!43L`$/`Q!@Q`Q"(>*$A+0H$TB
M7M"0@A)+&,`##S)8`=84`#`@`14?'/"`&6AT+<0.*<"P1P,OI/$-JR3_T0,%
MI27B!`0,N!'!:"^$($!33!"0PQX9X""!"<QL\<8))GB@?2(J@!#`#@V@&UA.
M@(!$D`$&Q9*9,)8@@#64@EQ82`%H8A$`/B10&&&8SK1P\885O$``?WB!&T0P
M!!8<H`-U*$`!ZI`(*S0`!Q]02RZXH*`CQ"@%`6*/$M30`@AM4(&)Z,(%U`#$
M(IH"`O\FH($<:J0$.93@!'6(PGRD```-O,`#<;C`!EZ0@`$\H`0@$$$(9+``
M/53`!35H@`.^\*4OG`(`1&"#%L*``QB`P0H(\$$=T8"+)X@%`"APXQ+8\(`7
MI,`,/#)%%0!P%"#\8`0XH(A01)(!$<QD`2'@0)LF\($.?.`$!@!!WPKB@0Y\
M"0(2R``J";`!"WC$)1)`90<RH($*R,`"'&#3!QZ``B6EP``/8(`1:C""#6PA
M%6/XP`J("!8[F(`"6JB"!'RP`Q1,JPE^X`$!FL`!UHPA#&4PPQHVP`((O($-
M+;#`%IP0#"EDH`1>((`QXC8'*BQA"KD+6PP:H`$A\"`')TC_0`MJ\(8,R$`;
MDU"F`Z;`AK-P('HKZ(`/!`"S<2;"#C;`AQ%U$04YK$&&^8%"P$YAAA7,0`VZ
M,HT3Q%`*)8P4%6,H0`TDH``0T``$$KC!"'9``CR<H@T<P,$%L/!25"Q!#S%@
M``)`RATN<(`&%7#C1O\0!3XP<ZHQ6X)C'+``,BA`?72+P@*"$%"FJC0"9`7`
M%U;0@P[@H0`^`"4,</```N@@#'7(0P96``&`)<(-..@)$GSP`A\,00>0%$$N
MJ+!%*4@!!5<%RQYZ4(,%C"$55."`#T9@0Q@H\R03X(`((!`#`DB#`"`XG`@*
M,"P"I*`!(.!G"`*P`@)08`,34"4(_P+:`A0X(`:'<TD)[,:!!H3@`6QZP$HT
MQH(2C*``+W4##S90FB<,@`@)",T*B."#`D0B+$&H`Q;4P(,(D$&`92B!!N:@
M`R"4H!XI>``<WF""&<!!"!M`PPD\R(`5/,`%&V@##$LSA0_4,0,%L,(+8!"^
M1-!A!&BX0AJR,($CX*`$.#"K$EJPAD28@`A2Q&HNOE"`,!05B`$@`@KJ`#-A
MG`$/*97%$AZ@@Q),$`PP4,`1#N#`4RBX!P/0:"RB8(=$LD<,'5!`!6*\T26$
M6,3DDH)!E#`'&"CA"36)P0*^`*\`[-4"=9C"?!;9J0D(H`(S*$$>$&`!OL6/
M!R:PP0/BL?^#%7R`#0;8YP=@``<ED$$"/V"`$`K0X,K(`0<LX$,6I-"".,#L
M"6R@@`E08`:B^G@`$AA"$HX0F,Y1@`"[Y(!%8(*"#!BD<`3H``H,\`$+-``%
M!K$`G0P0@@]HR2(>($`+0*U**7V``\A-2=]*0(_IZ6&D34B`#P)`MRN`(`9M
M@((#;-"#%W0X$6"`4AN0J`$:X,!W`@@#'>AJ`!L$0`P#^,`.HD:$?:Y!`1+P
MPQO*\`4'M*`'"Q"`&V@P+E,XX0([:$(9[/"@`%QA$TZ@PPHFX($2D*`'!^`,
M`;9U"B;HX05,D((#@E`"(4-9%E<`P!U^.-4NY%D"=;A@+J)`ACS_;"<7`K2.
M'X+`@AO$(``>?T(<)*!FDH,E"@W"PP-/PP0R>"`&#[#=1I50!:U]?&5<&(W6
MNL"`="3B"2E`@@780#<H>(`!+?"#F.=#A18@@0-R`"R^W6``BA&J!P90PQU>
M4`*SIP`,,=B`?)0P`!Q\F.(ROFX!T!"$%5R`YQ`(0XOY?H`7%,#IIYC"!A1@
M!`Q@0`,S*0"P35V`';@$!@L0@4$\4``:=*#-"_!`!'IYZ`DTP`0&(,HSYA`#
M$DQ@X1F(0`9:P%H0%.``/W!-#U3^AR=8``F0!^P,J#J!`^1@!T+^P@Y4,(8,
M^,`-?[A""/S>`R(H``T/4(#Q(C&%%<C`_UA'N`/PKO"&``C`!$"`@`-*GX,M
M!Z,"2)!#\X?W`B/$P`"]HE0;D`)>4`!!(#P#``MY@`0```4J@`-A(`$>]W2Q
MH`<(,'X?=PWZ,Q^VX%+SD08X,`(_@`)W`#-F\`,:<`I+``<+T`<G=@MA\``'
MH`$ON#)*``87\'(4R!Y-<`<XT`$A-D@Y0`J1<`4+T`(Q<`%A(!]5L`<:L")B
M\&2G805Y(`%:=CTP8`)SX$79P@$;X`()D`$[0`5B``8TP`%M``84,#P9H'2I
M4`534`4H\`,2``=/P`1IX%H]\`-$4`*656A1$`</$`,A8`=6$#!8,``SD`0_
M<`0C`%PMT`$4D/\!%2!J$I`E$D`!#2`!%2!Z))`""Y`"%,!JR/4`(K`!;:)*
MF2@3%N`";\(!G/0F"J`#*W`#!C!VIK`$=2`#$G!,?S`(.%``3Q`&;,4#%)`8
M:Z,'4&`#(K!!2C`&!J`#5+`%`-`#<Z`%7W&#9_@%B2,#.*`"=I`%3>`&)K`!
M`4`8Y\,"/R`$(4`H,Q``,=`"8K`$7<`'$A`$)I`!%M`&:?0%[[0!,0`'MX,%
M,%`"9@`'/?``61`&(3"!.Y@*6U`'3(951L@W:%!H',4&9#!T*D4'&P`$(T`#
M;.`$3*`%$]`#27`"D1`%:8``>&!DPO`$<+`!$`)X6&4%;V!6#YD+3.#_`$(P
M`!QI<8<!`*6Q!%=P!R%06V;@#5.`!AQ@`AP0`,2'"TI`!79@A0\P`,KP$P#@
M6H("`T!``Q*``RE@`C$P!-SE`Q;@D-^E!AO@+>\H`B\@`@#0!$XP!A?0`&HP
M`RS0`A%@8J?@!&I@`"Z@`0C@BZ9@!7<P`PQP!$?``BFP`1(`:KG5`0V`6Q^0
M`9O8.1ZP`#!@`!Q@:VXB.F-"`3/!21`@6AEA`9YD$$8@.PR0!S$W#`&0`QV@
M45@P5GM@<280!#M`A+N2`32`!ZAR@&>0C0HG`@D``S#P`D60`A?P!4P``#)@
M`"%"``!P`CN0`STP`PV0`AZ0`#&P9$R`!7J0_P(X4&H&0`<'8`-ZP`9M\`5B
M4`9B*`9MX`!$X`!P40,;<%FH``<G@`)I\#\+4`K$B`<UN(-*P`0N]00)NC)+
M<`8B0`,6@'VGH000$P!@,)6I(`5T8P470`,,,`(>T`"UJ#Q2-09SL`=6T&*X
ML`1J0`+`!08/FA],X`U+X*([B0LAD`->\%).L)PCL`#%,B`00`,\H#-_H`5S
M,`/[P*&XD`4%\`(*$`!D0`!!``-D$``?$`0;X`$F(`,MH`-&0`(M<`!R,)NG
M@``'4``!L`$'8`%/4`4#8!4TLBLM8`)ML`=&,`(K@(&^T`<9(`0RX)^YN`4.
ML`..>00WL!(XL``6X/^='^"9&8``*1`!(X$"$+`!*(``MY0`DVEK']`"`.`"
M(E`37`(!'U`"1T`#![`#D64*%,``>%`:3D`#-0`:$+`#/%`";1`)6K`"''`%
M(M`#,7``*\`#*>!&$-`#>D4#:``&`Y`"-H<#@0$`',`#OPH6;@`!"P8`[2<$
M<:""+/$'=K$",#`&4W`%8G`&=B4!.;`"*H`!+&!]!<"69B`$#>`$,NA3B1`&
M2'``,4`9.QH+2@``.?1T6M!V$B`@6+`'2J@+:-`%O@``16!Y0P`"9H`<7*"3
MN2`%*7``$$"Q'X<`$U2PIG$'P@J3IW`O=;!7)""5QH(%`+`!,M`!9)`(4F#_
M!R@@`R+@!Q.I"U3`!A(@`QXP!PD0F1'`!@X0`A*0`C$03@/X!2=V!1GP`B7X
M!TY@'B\@`0"@!2_[`AJ@7F*P!CC0``BI`Y)S!JC@!%Y@HNWHAG^@58O)64<P
M!#`0`B(06IMC2C-@$)33$1*PM[_T:R6!6J:V:[FT.17P`41@!"\P`BW`EF+0
M`BW@BTU$`Q-`!8_%G1)@:4O`!SM0#2D0`EE@!0&@`3%0`R60`B7PIC`P?A@:
M!SO``6%0!6U`!'UP"B![=[P06`F@%D[0*05%=S%``T2P`1&P!]X1`2_``6[`
M`400!`H``=Z@!60@!EH@!4O@`37`!CBV`389@06X_P(G(%4H&YAH0`<8.54#
M0@`Q(`)L>QI+D`4"$`!J4(-V(+?F2@`N8`>"\`6&RAYFD`'_MP4ZJD!4T`<%
M\`4)G+ZH0`?Y^<"G(*7OE8"1`*,-4'B[&T2>V@-RT+ZY0(\7L`(X$`!X(`)(
MH`%:,`9(L`%W$`04P):F4`,@P+)80`<Y!@!*0+/LZP$'0`990`,;@`5\L(XP
M@)BF``5$*P0?X',1NG&+R@"YMP(#@!.7TP`M$`(+T`,.$`$:\0$3T`(2,``O
MT`&@=0)(=`)Y4`,B4XL(P)'`*@0/H%%\)P1^\`=9H``XP&/(00`,4`=7<``&
M($!+``8@8`/K80`^P%1XH/\`?'`&*2`V/%#'_WH`'M`'/"")/3`"KL$!:S`"
M&=`%1?`!4\`$9U``/"`$*-!*Y(4`3!`#/%<"71`,5'`&=?`&`\``.C``#:`#
MH7`*#(D/49``.V"A$.QO%&Q$8=``(T`LJ($Q?C``-HD*$RL+58``>@"HIB$&
M,-`5W#Q5;K``(YG,N=`%'"`$;K#,+?L$:+!%;I6-4Y``)O"9)J8$4&`&:=8!
M2SD?4:`'6=@!`O``)HP`\+@&":P$>[`<(JRU97`#&3`>8)`"&D`%?+`"PH@`
M0R`$&J`#1U`"$R`&`=,$5D``+[`!"5#-^`P`U.J81O`!,]`!$Q!;2B)/!;`!
MJ37_FI+HBB$@.;&D)!-``T!P`#T0!%2+"E0``4&P!U_!!<+IP`:P`SL0`_F[
M%H9D!6HP!THE0T[@`#60!Q8@`3`0`T)P`@NP3D=Z!P10!`,P`(,Q/*I#`U?,
M`WZ0HU0``$B8`0\0`'9``W,@0%79`C-@!69``38``3P@`3M``$$+`#3@`5Z0
M9`00!IM0!7:0AF+0D)%P`2?`LN;\!7[@5Q^W!%C``2M0`=UC&DIP!;B8"FC`
MOZ9`!5G`SBW+!I%!`%50H_FA!&X``'P@4N:,"U)0`B_0VJA!#!I@`A+@K[2)
M`C_CBTO0!E:(`M4Q'TW@D3'0`1.&!3C`!K>@!"M0,VIJ_PIFP`(Z\`*B0@)7
M,``[X%T&<+>FI`$\D`08L"+AK,<34`):)H6JL`<A8+=)`0(5H+QTTK06T!`0
M\$L&P6H4``*D8P(/T`$\P`)"H``Y(`:P\`$^L+&)L`4O8`+KL:M"4`(8G@AU
M$%%=H`$R0-8TX(=6(`4GB0`2\`)F,``>,#LQ4)9!<`>YLZU5P`>J^Z5QL`<\
MH`>!"=)_(`5KD`,(L$&AV]Y0FP(8$!U%$K1LP`.%'#_[<W5E@`9P$(%2$`=]
MH`9F4`,='-R1``5V,`!VT-!%I`1]``,\,`!!FPN$K:;7?`I0\`9UG@M3X!T9
M<+(B)@5L(`!'C>:QL`078`-_'?\S2B`%=#`#*2`"+*0*5%#">[(MLTO<^D/;
M+:ODDUP!RGT'XYT(:4`$.-`"+O`!O]TCUO<#;U`%<X`'<%`",*`%::!C*?!D
M3X`'/7JWM87,D=`$7=!FF3.!2R`%!;`T1_`#0'`")V`!J[.)F[,!_%1)$G`X
MJ=8""R`!26!S2C;>;(!T=@P!/C```F<".)"0=%,%_`$``P!<[@)(,6"L*P`"
MBU$!3$1%56H%3F``*U#-7W"VO6(!._`!`,`CQ*@";``#*Z#?/M`#7.P'QF``
M.```:N#P+4`#/XH*5D"39;'8_&T*8#"Y32`%8L`&),H&;.#ET\*@R>P$7S``
M9$&!`S+_/Q8@M\SQW5LP`!P>"7F>"%G@!VM0R[<0!:*M"@$`-PLP!;I-+F=@
M](@>"TTP`#T``484NB>PR>B;Y-\I`Q,08E&0!RW0M0-,=`/0`CR@%2#`W$N,
M!!A`!''3NBT@`.T$Q)SU!DV@!&9P\$K0!A/>L*E0%3ZP:97EV5O0`56S!L:=
MY!<``SK0B*NA$:_5.9O:`2)P`O_U`'3R^#=`&T0P`"XJ?2!@JP;P/G\P\$$P
MY\@A`D*`!WHQ`:;`!*77`5H3`[5Q"G2`!&:0!A[``>C-;(GP!3(<`&4=`CV`
M!/QYOS2@`6`06$TP!0.``NMN`F3L!S2P97`!`S*@DU2P`BG0__,\,`$O2`>Y
MGPAWP`+HW@7AI!9AP`9W`'DH>Y1KT&<V+P`NL`)Y;$!'``@G4G^$A8:$5&=*
MAFA=A$IO`W10AY6$%CV.A%D9-!QNEJ&BHX5294^DJ:JKJUHM/56+K+-_3@D[
M)0!8A4I8#0<?<DZ$4`$[+7Q9M+Q.#3@*+$4%8(M+"$`"61H]-`PR#R4[!@4\
M2#U[72\\)@=H4`9'266RH4QF-C0823`#595+8TH0F8!GR2$E[WJ,.')$R(`8
M*!)L:)"!``<8`4ID6/`"0X\@.ZY8FF)`!RA"6TJ8N/(DP@$:+ZP4^A(DPY,M
M%%:@:5*H&0X_(F3`$'*`@ADG4`CT2/\3(D@`#C8$TJ#0H<@6#D3\*;E2`0>,
M%#/4^!E2AYZ2*",L0/FR00*"("!T##!XB`F"`PBJ/,#QA9`42I7@C*A3R`L-
M%FQ"*6%"5\R``'V^C-E"Y0F]9;.6M+D`!K-G)5MJT%B`)0<&#$-.IF+2I\X3
M/&.:J'%`ABZI*2M.MV!2A\,!!TP\TUIB9X$7X<B%I[&AX7+R44O6;(CA05FI
M"2Y6&$#U)\J`%#$XC!$N9<$&!D:$<,"S@(4-+H2\/##!X(")%!]4X#B"0LL?
M)6`0\`43*1SA0QNK+('&##NP@($)!E!AR1@9K+""'#P=$H4#,P#!P@]%;/`!
M!3`8`$(&#FS_0`$'#!Q1PP@M9'C(%"[$,`@A=10A@A-3:,"#$!ML40@:.T#@
M1@@KU%#$"RT,(`46$M@0P`H2M&&`!CL<D$,*.<1@1@HGG(%2`S"L\,$#95#P
M0E^&M'&``%M1P(,?PQ`R10,T#"####Q@<,,).,AA21,.[-"/#"9$00@3"\QE
MB!(%"`%`(78@069BJBAA11AUF&&'''OH<=0CSXW21!C.E3H*$PF4<,!IIQ&!
MQBI8W#$`!`-(<F,J5Y@`ZP\QT."!D*JFX@08P16KK"5+Q('$'K8M&\H25'2@
M@`9O`/;'$FELH(`!9/#4"P4C>*#&KL-AX=L!21RQP`4*E,"&A$VX_Y&"`CS$
M,(,!73S`0`9U3+$$&3=@4(*,E9S5A1AD?.%&%T]$`0`2K^H`L**'R&8#$7ET
M$>U_5V0`Q`U'#/'"&BYP8!X%)#`P1`M'%)`J@"]04*<2!BC`AA)<P'2``:44
M,`099`0A@A1=M"!$"S0(<:T:0AA`5YP,E%'%$B9D$.T2:B@`@!AF4+!#`ELL
MHD07-&1`Q@H'["!#$$$8UX4).0B`!`)GP!##!S18=T@5*M`0A1H'3##U!`8@
MD.P?4#300Q^$+$&``F9`D<+.J:ZB!%U.!)#K+HQ3`<7'SZ$1P!6+2VM(%+#"
MRL(=I(?B1`$#I$Y*%2.TC@$0(JENR$T%I/_A^_!_8$$"#AOLL/?7L?L>100M
MK&`!=YM08$()`V0H!00PO&``NK10`8$+2.B0@P<%;)#R&(N,80`*V"OZ?`HJ
M&<%"`:-<(8$,$GC@/PGP(\$7E+"&%.Q@"$>@@0%D4HDO9.`%\AJ)`4R0A"3\
MH`<:R,`$3'#!&!Q`>)5@PAQZ`(%2B"`%"!K`1V(0AT(\008QL$(!=A``0UC!
M`#A8@#]T,`&$*:$!2!C#4TKP@@_8018(<`@.X=<#(9A``G2H``\ND(<>.*!X
M$SA!$`ZP@0U,P`$TP$,?:J`"$V@@%'W``0FR0($>U!!'=$"!#@NAA?N`C@HE
M<$%?V``#+J0!!7/_*-5BZ'(&.?C!D'%H0QFFD#E:@*$/XR'>?S:@N].P8`&D
M:,("]&"(/O"AD86@PZMT%S-0/B<+`)@#&_PA26EAH04E*`,8A&#)(=R`"%XL
M@!_"0`7;*<L*`^`;;3*T!"Z8QP1X"\X6`A""'!@`#-2C118"<((A*$`(&G!`
MA3SP!BHHX0P):`$RW;"$+.QA"#H`0)TJ\00`T(`$:P``'Q:P`-HAP`,Q,$`4
MGG`'#@"!"#'8@0?"$,U:6,D%&PA`)`NQA"WP`09#\)`/@I`$(?"@!+.J!!4J
MD(,]<(<+].M"%"X@!"*D0`V/`,,+2"`&)I1`//1X1PP"T``0I(`&)@C`_QF6
M@`4+K(`-&DC!`E+``QSL0`)[,$`,^/`!+SG!#>DK@@Q.(($U5(`&='H$%P`P
MA`"0X0TI<,``:I"\"##0$)V+P03D4X(]/"(`!$#`%Z90B#J8X`-T_<,74@`"
M(65A!A%@@A4BD((-\*%LQ>)1%KK`A2^\X0YZ*,L?GE"%RBQC"<%I0AG&H"UE
MF0$(E;3D`A#F0C2$P`5F,`088+`!/Y#V$6P`;6B!$(9E*4$*9Q```,B0!5.V
MTC,7V(',"K&`(806`S\P`@Q:*04'E(`&#UCG'\KP@!7D@).$T$(%2F"#"11T
M%EDP@`M8<`,3D"!]-9!`)+5`@13@X`(9L$!>0_\Q@1ULP0PQ:,$$0N4`"9!0
M"AMH`6"@```-L.`(.+!B9Q>%!P[<IX65X`)VC&N@"80"#$'0@(P`P(`"\,:]
M`[G1$B[@QC><H`02R$`)2O`&KE&)#S@@`!X:D((B*.\%/LA`'XA``%9RX0%<
M(L`"RK`"#["RKB,X0Q.HL`$9M,$V75!!"Q)``V^Y*'IB"`4*8I"&.O3@`QG2
M0@=((`'5*($#.,A#(>ZRAD6P800$>)0=2.""$F"WE5HP`QZH\8<IL,$,7/"E
M8K:`!@$(`(2);8,&Z%/)(TA`0H9```Y*0(=0S*$%-*Q$`XX06AW$``1^*]48
MUA"`-QSYM\L:``T*$*W_)M`A=\=M`:K'L``)C*8-&6+"%R``I@)P81%G0,`'
M7`"!-`AZ-5U`0`L8H``<B(``(B@!`>Q@A26<P0$R^$$$$!N*%"3@#Q*@P!:V
MX(:'86%*!9B"">1`CRH`(`,'^`$-<%"!+TBW%G!H[P;F0*Q",($+=Z`='"Q!
MP!<0@(%/>``-`+`$.-0`!T$H`&"N0``:Z&$/-1-`4$*``AB<(#P/(4!CYH""
M&A0@`%G@00,Z*X4"Z(`+9@C`"U#@AUALRPPT($!&2I"D'*!`#V!X0PE4H-0(
M#``'UPN+)<Z`@@TXA@8-\+$#3D`!9!&""QV@-"&BD($8"&H)$+#!`K[;A#00
M_R`%$AB`%YJG+,P2H@EBJ(,=_$"'.."A#EO`PK'_8X4RL$%46X"";V?QA"\D
M8`(X:-=ICK`!12WA#1PH`02T`$HL7``_=D#%%$[P@U\E(><)@(,WGT.MO$HA
M#/-%M;0R("9+0"$WE?P!2E7_!S=(8&]RL(T2``!+#[2^]AM8`;:^RPH\J*`'
M0-#!!PHP@1BD``&#L`,.:."""2ST$"M0QL)Y_@$4C`#J'MC`$AH``5]6`0$V
M(&\05G"'F:E:!@WXO;%F&$B_J%@-2K@`$79``]6,P00KP`0.<`!X4`A60``Q
MT`!D0`55D`23<@@9@`-6(`<($`,2L`":\`<$(`1L@/\))1`#/<!%\4<`1!``
M"Z``-80&#[0#%Z5`%.`#7?`&^?4"'1`*QF`!3O``.5!I_Q$&#]`"(B`C7+`"
M)9!76.`"+9!E4,`W&34*`V`A%-`&@Z<Z9S$&;7!(K"0&:1`&&',(3Y`&`[`'
M9L!VR+$$7T`!!X!`%%`&MN8!>^>%>Q$":L`!R`4$/D``_K$L4'`'<X!HM/>'
M+D0"2:`[1"``8T"&TK($6E``IP4!8D!,9#!!:?=K2N`%"%!G`S!`F/%O!>`"
M!Z``._``$<`!-6``*>(%9D``+[`!=)"'A7`F3+`!G)8$&Y`"+&`$"F`$(*`$
M(L!JH7`%`8`#-[!B1>``\W#_"%!@!OC$`:MD2EL0`B9PC$Q@!R^0`5.`!2)`
M,12@"4L``#Q@`%?0!C@0`-'B!2J0`690``7``2NP`6Q0-F40`A(@!R9P`H2%
M`R^P`QP@`!D``P)0`B%P!DY0!@6@10C%`7$``K$D"TS@!A'``&;P!0C0`W?0
M`2\``S0@`*\5!<V'`%[0`DY'#`EP`AS`!Z#S!PA0`PZ@*$UP!PJD*'"0-:$V
M"DZ0!I*X!EJ`B)(D"U;`!64`.E[0!W!P!EM@!5,`!5;06[4@!E@@>,K2"P40
M!#U@`-S&"F<``3LP`@]@!E$PA:JP!%.@!?#Q!TW0!5+@E8`X/'A@!*Y#`3CE
M`&/Y_X=RL`+400:'8``^(`-460AXD`,[4'7"P01L8`)"``0,,`%KX'T*<$=*
M80()X#<`$`0#(`;[H0\]<&4I``;X50:DT`$[\`<6H`,[@`,9``>^Y`0$@`,M
M@`"05@EJ0`,AL$X#0`2C!08AH``]H#7$L``[X`=F8`$1.!IFL`AAD$>J=@(&
ME`$1N"\T<`)T4&02L@0+L`)[0@,2``8FP`$(LP0?L`)D"05```&IYP5!!0`A
MD`))P`)[$P.$40E:@!5:0`8X``(9`@7!E0+D^`@1T`/?1@B1P@>$$`=!\`!H
MR5`+8`,I\`#REY:6\&]FL`<(```!<`=FT`:_U@1[L`9O0/]\PG%#+R`>R$$%
M'H`#%-":PK$$59`&:)`'"9!:#/JBE7`%)<!I&Z`$3T`&#4`E:Z"4JF=M`_`"
M)^``8L`YN_8"$@``68!98?`=*3``8:"3#2H&";`"0H`$0G`"-."*?R`%>-`!
M*Y`!?F`%2D`&*U8`"-``&B`!(=```A``%L`#["8*;J`"1,`#,,`!9\`&SM<"
M/+``G:$A:/``,2`"`7!63!`!&6D02J`%,``#:=`$?,`#\]8&R?*1)P`'!&`#
M%]"!.[`#0I`"QW,!$T!I2M`+<F`!.]``>)`&6]`#:Y`Z5O``!R`%;U``,9`!
MS<@X!7`R8!0#)8`#1.`!>^`&<V#_`Q;P`25@!A$`),*7>H]`C1TP!1T@)=4@
M!AD@`Q506X0`5B'@']]4`AL`"E/P`2^`(,)1=MBV`0B0DS`J"DOP!%.0E$H9
M!6Q`!W6P!$X@H68`!EIP;ZF@!&F@<!/`)LEAA@:0`P]@KH3'!75`!P$0!V"0
M!5$`I>V*:DU``$G&4#VUB@O0A:H'!0,`2P00ETI`!0YPD0:05U`P!RX``QZ0
M99AAHR'+`,G'`7V0.DM@!22P`BBP!E+0!!#0CAE``@U@$<BJ`6=E"6AS`ESP
M`RB`!0,@!!'P!!Z@`,$B`3!K"`WEI1N0`$T@!1-0!'$@"W4``RH`,1,`$BO0
MF@ZG`=6"_P-P4`WD>50.L*1"(`:7X00[<$9U0*8:,`<80[4[T`<5D@(KL`,Y
M$`)\X`9HUH%"8`9/$``M@`-"@#PED#XRT`4.8`/347[_(&EK,`424`)V4`AJ
M$!04X(IP0)J`\08KP`'^<04S,`-V^1RW9:LA0``S6;'0<05A$!P;T@$:H`$@
M8`#O^(:%0`4M<`)#^I1<<`(HH`I.H`6@DP4"\`9C@+R\^Z+.2@QX(#)F!8@&
M>P,MH*V$\`1V8`$W0)^$X`1?,#DOT`4%BE9I8`$*H`#F\$:&,`5FL`(C``%-
MP`1=('=V$`=H``8>:PEWH`!K\`1,Y@0?<`!M<`4M^P5HH`,;(/\$.1"7AB`%
M<:`".G``*W!D91`UE(4"/,``%=":"S`"M:,F)LHX)M!C:T``(5*[C*,16W``
M1:``)@`!(2`$$!`&=78&02`!6"`%:E"U)H`"-&`!9>"KK:E9'%`$9&`%'0`#
M3E!&2H/#AM`$#Q`$<A`&:3,(3N``DM,#"-"%"*`#:)`L9H`$#L`39U`X"_8<
MFA0".A`"2;N]JL`$4*`%9?`&"/``(M`!>+,MHL`$6O!:JK($O9,P=%$'!2``
M6NK'F#P+4D"N,U``??Q;2G"R,4``UR=F5>8`=1(%">!\$9"!R]`$#>`J2;`#
MN%H)6R`!B0L`'&H)3B`V;S0%.]#$4$#_!SD@`E$``3P@`%>0`SWP`A_*P860
M!BEP9!80!$<4`(09-P9H`2]@!FSP`1+``RWP`.W9!CP``A,95#&@``R0`AZ@
M%!Z``#S@`*6:`/0C`A5B`'K0`Q%P"%*`0?C6`PL0+6CP`AXP`2W0`C\P!#/P
M`F=K"5Y0`BE`!0$0-4K@;A&X!',@`#T1`B^0M1S``RZZ`$&P!D^)!S/@(E*P
M!`:P`S!0`9&<R;2`%$I0!VN``'D@)F?P!;S4!/,[TU=P!IV"!GT0*GMP'#*=
MU,(!!7"0`D``'(#(!&40FHUG"%!@!RC```90)Z<B`AA\:C/M!E[-;"^`*890
M!7C@OPV\&A=Y_U98\`,&`+0,D'LQ$`-!/00>9@`WD`$*T`*7O`4B0`E*@`0I
M<(@#$`3KO'9;UP,F(`4&<``!L`9.,Q3(DP1MT`$'H`@HZ@<KT`,/L`!N$``'
M(%F1XP8M0`*$P`<*\$F&L`!$8`9K@$XE``-/K2@!,`1Z(`&..@`\Q,""A@<'
M``%+H`%!,)8)8`0F4`.,40A=D)LWP@0'(`$BL01)@M2"A`<*L'BM69,$``0;
M$--*/0N`/`Q1$`9L$``(8*8+``!^4`;)P@1.X,B\T`1.D"Q1$`<7YP].<-YO
M4)15\!<_'=X"7@A5D`%DE0?:*RU/P!'CG'IAX`&K>`&`\00.X*L.`/_>FEP!
M,8`$0R`]`_<HY!D#^U8/^TP!AT`%$F`%=98%<L`#J>L!/H`'3&8"9%`%#T<#
M-&!]A#`&''#5.V`X5'`"!\`#'T`/`!`U44"$O4,<$E`##9``4B`!.[!@7(`$
M$LX&(A`#8U<(6?`59O`5)Q`"&X!B?@`&T0,')_`"9Q`%!,`T0F"D)C!&'+`%
M%B#B-G!G7VP!-,`&82#B\$$%<6,$/)<L2Z!"5^2?WV@08R0")YD<8R`!L(9<
M@E()0"L#$#;@I;($2,FN4=`&<9`M_Z&99C#JHU[`$+L(3W`&5B#?F-[JG@$0
M"P`#.P``/OV'4@``_D4`3DD(73!4-(``M6[_!=(QE5WI&<(>`D-`!$)@+K8C
M!A$0#G@@79`B!`5P;U-@`VIT;G%#!010`]UD`C*`!6YP`,:<!T<0`PB;!6/@
M`0L,'&$P`T[C`"+6`$[Q!QIP`N!M!3[`!U80![[A`91'"&Z@5F3``QM`N310
M`P,P!6XP`RH@!_H8!@+0`3R``EDL?'``FT=6!0*``RIPQ1_``5'0`N"Q`EY<
M".H"MV#``R1`5U#`!QA0`$!`/\'!TCG08MMRY`G`!$K0!CTP/:2G!2C0>:V#
M`J`$!7?LZDJ_]$RO&&&P`3G``9/^AUKP`$CP`7P@75^@`37``6\@"U.0FB&@
M!PD\"U1@`<^@`RM0_P#R>PAJP%TA``<#"?4+2@A6<$GOR0-EL#8MH`1H,)5*
M,`=#D`"+,`7CDP(NT`,I\`,*,`AY0`-!8`.EBQ*Z[04`0``24`0A,``2P@1'
M/@$+$"(`F`-%<`(&\``]<`$/4`2)H00/\0)"$`,K``%4QH.+`@$WP$`%4`-F
M30AL4"04\`$F4#(;4`,4T+VUAP.QB9>5E@43</D8@``W``,HL`1B,%7$,@4H
MD`-U@JH*>Z(-T">5A`0!WO3F?_ZNO@1FP`$I``-LP.K#TP45<`(K,`#%OBUO
M0`%UA@>5"@@$*2L(4DI_B(F*BXMA!"5#!S$>7DN*36U&/"HI"@Z6C%,H4/\F
M+F-L/`]5`#<1EF09*R=D37]<$!([,2%P2P8X.#9?B$IG-AM8%#@$&3L,,246
M'D5K'31Q?U)Z(CDY*!)L$2]TBE(`/`Y130P93H>(2Q-%6@$I(AXE*7A/3`,,
M%R%,S/'`H@6-!TX8_0&``\*3$"O\_&$"XL@<`Q@0W.A01LPN+(BN[%!QY<^3
M?&@4JESY!\H1##!C8F`QAJ7-FSASZMS)LZ?/GT"#"AU*E)$2/SUR#'#SKFA.
M,BF(3$A3BYB>`S4N=$ETAH80`F2"@IEQX(`.%'ZH*)IQY5"#`J`63<$1Q,"?
M+SKR,/DSI<(($&^>(`H@:<`62V,T]/"P0<$.#DW_"2_`$F,%*"H%A)1XX(#)
MBA2,Q-QH\\3-B0YJFE:18.++AQ@ID!QP4&9)E0\OW+C8D:8#D0P3B.Q8(<1-
MD`Q-)B"AL$.-PB8.D,1)4^+$%"5?<!#!$,#!D0`/IB`8D0<1DS4'"B!Z@^-#
MW*$47LH\,L"I_?OX\^O?S[\_2R5W:+!""V9`T91_?RA1!@4IP%`(*$KLD8$+
M(=0AV%T6F)`"'57\M(0:!)@PQ`@U4(#%7C!X@4@%<"E4QA$D"':%!RZT$``4
M2U#A``HF3)`%$TM(^(($:!@(@`Y(!%'`.U&\ML<?(7``4B+%$-$&&`"4$,,"
M5EBBA!HQ0##'"B'(@,,*_R[,<04>,7R`0`T5D+'`!T$H`%L,(+"!PP-J_8'%
M`BB<`$`<5O30@!8OS+`""FDH!,8&)8BA)P$&IA$#"]OML0`06#R100QP'"*%
M`2\(\$<3<^RPP%Y.1;&!3!@04!6"M-9JZZVXYFI3``J8(,`6!])JAPT[1"#&
M@?ZDL$9;B-2Q@Q`('`N4'"LH`(0.%IBQ`A>(3-`B(U>P<$,&;$2!B!PTT'"!
M%X=XL0&V;23$1!YV-B!$#0R(D<@7,ZB@!1Q^/$`$`674\@0`(PQ`P`$;"/&"
M$$@88,8`0P"0F1Y_9%$"#RX@H<`("0!P@$2)4$&!`ELXX00.!AS(A!](S,''
M`O\:``&$!3L0\%XB9AP`PA($**"B%&%,H,`/VP4@`!5@R``:(EG`$,,A4(B@
MP(7V!8"##C$1H>O78(<M]M@\/2&'"#%D8(8[MBYAQB,GL&&@>0&(@$,&:0B&
MG04OE("'(3XM4<<$,>B@P!$/7+$$BSO[F4,"4A000@T$=,$$$W)08,()@2F1
MQ0(;F`#!%4Q000,#/)P@A7F37@'1!!+P`!L,#1CTA@LGJ&A%`!_@8((''I21
M`0QN**(%`3CH,0441A0`.")2J+""%A6D$`,.*,QAR!,/Y'!!V@8P<$,(0<S1
M>!,$\"!'%2^T0,823CQ`P,DL!($!%U,$L,,$M2@1``__!*""$L:P`PE,R2E/
M:(`-`J"$%F!``6$AFP0G2,$*(D@*9IB`"S[`!RO<B@EE6(`)0E"`,R0B"F^8
MP`I`$(`.-8$,$7#!!OC`A6#EI`EB@,`*#J"`AFC@6\3H@PF,8(`O,`$+=Q#!
M"BRPAR@X00T1*`$(%M"%)8Q!`"=`0@8VP(,<$$`+Q(A`#/CPA11(0`Q+V`(`
M/F`#&'#``'"(00>R0"4K+.`&5!@#&%8P`14EPET2B,,]5E"##2R%"60X`0K8
MD((3#.!302!""`P@@0TX(`8/((,%8N""$O3!AE?H0`G,<(<4<(".=+#`!BP0
MM!^D(`55@$`/]B`8*!1@!1"(_P(3!+#$/CEE-2YHE"TRH`=66?"8R$RF,G/R
MA#F`@`$AZ-"ME!`'"C#`!5M0Q!/V(`%)LJH)9B#!#DI0O)\HH0TG`\(-A)"`
MIK`A"`,(`\YBP`9$6&$`&SB`!0YQ%`_XP`5::`,/=L""'?0@)>:A00K*@`8B
M%`!KB#`#$LY@!>JL@`[&U`,1Z&"``^#@`#FH00I2LP8A%"`"2.!#&A!@`SO%
M0`@'6,`>;C"'"XF'3@[0PQL.\`4Q],!J'0`C([(C@ECV8`Z':,((&&:!!C`@
M"5^(`@]6L#I$I"!2$YD`#>Z`'S#H8`*^7*98QTI6L48!#QY8(@"F<*L7&L`$
M/P06(O^B@`8"K$`$`3#7$\H010TDP(\]>4(8Q"@$!M"``'WPP`%6$``I."$,
M#D@!"AP0!MO(P1H6T(/*P-"`&RA`!C2071L2@8<2B,`+?;C`"C:`@#,<(@H#
M\$$!*+#:%-0@!QM8@!P(0(,!X`,`81"`EG"P@TXBX`$E,!4BN,`&J=GA"U,P
MZ7NH$($#M&$!&?@!#&B@`AJD@Q%/R`/+M/`I,"P!"B<P`!"0$`(+&"`#<?!#
M"1I`1R501P)MZ4((4L`N^S`A`C@80$+*2N`"&UB"3X``"H*P`&FV;0X?Z($$
MZ%BR`K0@9Q>"0@!0@`,/U.0G3O"#"$8P!`8@[@+=O,#JF-#_!P[@@!>(J$)D
M:0`!)I`@!V<20CL2L8<1(&`))Z"!!6300Q-D```IP$$9%&HN$)F@"!*0``G"
M,(,9F"L1:=``#+[0!"VP0)A4VAP3&A""%KA``GA(Q`ER$(<@>*`"+#B`!&A0
M3X5((`=UX$(/0K`7,9#A"!^XP0%4D*TH7,"DB;@`$1:`"#L4P0(.+HH2,C#*
M`UOZTIBNE1*@H(8,V*`#>;V5$]Q0@1IH8``.GH(=8N$!/T#!)&+@[9$/R),F
M>,$!//C8"PBP!@[4P`-TX(<7"F`"%$1`151@0P8**H0=V````XZ"!FA0!CCD
M8(Y,R$(>#-(@")0!"`NX\A^6D(4,_Q`A"E9X`PT*4))$T.$%$`#`-W*`!$&-
MX2@K(,`>=N"!/5P5!SY(;PD^0``AZ,$,G"@!21222!"X(0$T-A`8<B"`(X2`
M`0<@`!NR\`%J6X(*'I"!',Z[`!L@8%9$40(9AL363+O\Y3!W"GEI`(/RX&H*
M#:!YC14!!Q"\``5ZN,P$3&`"`(B[)Z-*P0U^<-@X:*`$+0#`(1*\@A(08$HL
M&`$/<$"R;)3`!&08`PX:<*`F&"`&7FA"'71@``HC`@`U6,``7KD"&K2@`:_>
MPS(,0(,%S*$%.!""#\R(`PH@8`<)N!`;3B"#$Y"@``C@`1C4K8(7>(#6B0##
MBS_'@_(P8?\+%U!``#`@@6=PP0LM2,$[N(""&DS)`SRP`W[8D+.6Q_SVN,_]
M391`!32@K0-W0#F"G@##NVF/&%18=0Q($(=70^$+'=C%&L*Z$R>``0+.`$()
M*L`'$IA`!`!X0A.Z4(`7;*`%)HBLODXE`!P4P`T#F(`//F`81$!!JWP000EF
M\`*#<B`!<2`!)0``9?8&9T!L*[`",6`"+;`'(:`!ZY=&?@!7<*`%6=`#?G`@
M6N!B;[``)6`$*4`#&Q`#="!\I\);?5`&+;`!66!?-P`!#G```'`$&K``8U``
M-9!X"1(`-L`_?V`&,I`!D484Y28#:=`XNI>$2IA[V*$!(Q0`N3+_!B&7`@4P
M8(B`!A(@"[*'"%OP`2(U`!#%$U/P`"^@`RS`1P$(=38'!3=@`G7@``]0"TQ0
M`$4P`%-@6R:``PQ`!"@P``@7`W+@`B8P!>>Q73Y``S/`*%7F=D[0``U1!DXP
M'ENA"%`@9$]@``V0`RW`)="S`35P!SO`>$<@!!M``V:@$$J@`37`!=HB`N8"
M!1F``0VP`$0@`#_0`%+@`$$``/#@`#L`A7^@-2*`'TJP`2L0!DN8C,J8A%-`
M!R;@`VO@0;?R!'@@`4)0`6,`(52`+CW`!WT"!6F03Q#@6C_1!%FF`PR@`S#`
M!O6@`!HP!`10`QA`''LP!2>``UF0!D"`_P!/L`16P`<[0`0N0&-X<``.D0A,
M8`5!)@5+($I:<"!VT`,!@`8?T`$H(`0>U@1*T`?I@0<L8``(T&R=D`%T0`0=
MX`!#\`6($CL?\&JAD0,<8`XW@`!,L%=9(HMTR`9[4`4;TX)_0`6EZ!Q-``%"
M0`<V%!1+4`9#@!#+V)1.&7-VP'@2\$FX`@<?L%IK$!=*P`8;(`,;T`;\Y`64
ME@+U`11<4`$[``1#8`\#10!;T@(^T`,?DP)78`<\T'6(\`0G(`)=A@`*8(>*
MD`<Q,``%4`(KT`,X(`$V%UL.@#,+4`$PD`/#,0,P@`,)\``[\`9S%0`A0`,H
MP`%^T`$O8$L2UO\0QJ0(^O,`3P`".#`,6K`",E``*8`!$;``'E`%;(!)K%(&
M+Z`!J\-Z,=!N]E$!/#`'I_F4R)F<!+8$7M``._`":/`\M.(Y`V`"@TD%<5$&
MN)8"T7D(6!``*\`#>^"3/:$$5:`')Z``&?`&4Z``"1`%)Q`'!J``AC-?.V``
M5E`53N`!0L!-1"!X!K4&65`%%H`#9D`!-N`';%!Z*T`L*[`#<!`+W)(-??`!
M/``!`:`%9D`$PZ`(HA`#6&"70=`!/.`!01``C?,$FX(&57!5':(&"\`",9``
M)8`!!E`D;T`$GX`(=+`##H`(!*0")B@431(#8*F<2)JD904@+?`"&0#_!KBB
M!'"@`3$0-XM0#R8``FB$"&H0`B\0G\>I$_9%`CB0`@G0`BV@`VOPDPY0`@KP
MIDG``"4P`'+P8@&0`Q[`!+"U`3M@)S/P`;RY`0ZV!1-0`A-@!TO`15:("%_@
M4%50`!`0`ZS%*IJ'`MCW`4*``:5@`M07$K"A!`.``Q.`"%U@F$D0`X5Y!&V0
M!2+``\[Q!T[``32@F?^U`QAS'V1``Q^PJ$K:J[YJ05&P!W9#`J3Q07'`6R$0
M!\\#!7I``C'``5%U*FKP`%[)!E5PE+M7!P\P`RGP`"?P`A3P!5!P!@C0,(4%
M!$&@`000`"]0`+.R.T+P`7"`<RE00U12!CLP_P`AI`$X0"#7L01Q\`(5X`=X
MVCM5-P,%D`=!V`&VJ@:?80(39A1U4`(><`9\T!"'<`'(LP)&$'<B$`%C<%43
MZ@4",EI1@#QEZ13@)`2J^:LN^[(5Y`1Y$`(Q(`)NIVD5^@(J`&;C%@`M4+-"
M]0=HP&$HH)E`@0<B``,;,`$GD`(=@(Q;0`$N(`1!8`(6$#M^,"M+0`$P8)4M
ML$,Y(`+.\003L`,(4*`7T`$I<`"RLP%2(P`2@`-U@`A:T``IX`(98`%X0"9-
M8#<A@`-/`EX&D*]E<%72^`<21@,E``0UP`9,D``\D+)HT`,4D!![Y)OW`04;
M@`.`!;.>^[E@`P4#P/\!,4`!<!"&_K$$`4!;'\"B3`(`&5`#&:`&K\@&:AL"
M=W"M@5-7*:`"%!`")=`!;1`%98``:\L#<JD`+A``8^`%*%`"?B`!,#`'"6`"
M24(#&C!M`B"KH\4$8+``*1`$(C`!9*!#IZ@(;;`##Q`&?0`$9O1S,@",BT`%
M#(L&9!`#*G!T-G!G)8`$(F!'-`",2[``-$"3?\`&5ANF0K$%+7`"<`"Z$!S!
MNL($K1H"">"2MU(`9W(H36$%!M`#+3``5]8$O)0"!K!^/\$'QV`!'?!B`U`2
M:6`]1=`#!\`"B-@!?=`#'Z`(87`"-F``>J`$,3`#0Z4#<H`%PLHR$_H'88#_
MOQ_\`BQP!#R0`B:`A$V#`DI0`#U@<XH0`Q)@`R>0!EH0`CZP?DW0#*?(!(,;
MN$ZA!&;@`P0@P7(\Q[5R4WQ4)-BJ'T^PNB_P`7UPN%30:R8@O*O3!&R`7"1Y
MN+76!Q/0`B%``EG8``62!@GP`D%`7!Q@!B<``MF4"$\P`#2`!WQ0.R4:!QVR
M!'30=P60-BB0%%Z\!@CP`JJ4`G"P!C8P`S)`=HQ`PCFP`&=``O&;"%L0Q']@
M`QH0`7WP!C8@`FRE!'8``Q(`1EWJ`G-K'U,0`3NPIG2\S=R\'U&@`D*`5PK<
M'TI@`$+0`H6@"&.`J1H0:@E"`0PS`#?+$TM0`')&_S-!P`%T,`5-H`<Q$`,\
MQ`-'@`/1^`=54`$*(`=T8@`K@`,*<`,J<`$-,`)T``$^0`[^(P,R4`,]0$].
MV@06T`,,BY>),`4.<`-WP`7;Y6!9,``VMP*KD@`]D+)L4`0>L%PTA[I"804A
MD`/"V<U`'=1#89YY0`#S7"M/P`8>T"9X8'M9`&$K$">OF%@KX`%L($`^8<@J
M)`$>T)D&4`=2D`:7Q`-!8(8Z8%L2\`8OT`$>M`1B@``K(!40,`8D<`(FE`BH
MO&AF0`<_0`(-8D9EH!!=\$I=,`?>94Q7H`(+@`"'<`9A4-<(%044$`-XH`1+
M$`$Y``!(&!1D8`*)(]2@'?_:-M$$53$%87`(5D0%_5A]&DD%6#!@3J"[BJ`$
M;,,23P`B3BK"Q"`%=?!T(G`'"?$$7L`W$E``0Z@337`+-O`!%O`!IG4C6E"=
M+T`$.N`#!C`&0A`!$+4$`P`$G'8!;BN@F5<"$F`-(7`$/V`"*Z`!6+T(<2`#
MB>,``8QR`1`FZQ<&,%`"_<5Q)E`3($T#`I#'0#$QO"K:!B[:&9`!?[`'0)`$
M*:#&1@`$\HL32L`!"-`!0S`$*X`(`U`"06L>P)<34K`'660!&*P$6\"#?TD,
M4Z`'*L``%J#(/`$%<L"?'#``**``!1`%X.@!CB$#0<`",.Y+>4`$<>`;(+`#
M-T#_`X6'!?:\RBG@Y`>@`4(@`$C(!D00C:U73HE`&1M`!B#Q!C?@`"Z)KQS0
M(5N`.T=]X&S>YD1!`1A0`DK`?P3``FP`!!D@!#BP!5Q@&'WP26)0!@&`!7KP
M!>]0!BM@!B_E`*]*!6)`!66P!N?[!Q90`INM$$_D`30``FM@>U``!]M%`F]@
M";9&`;++!P6>$TP0:U[\`"HP"0'P>05``S:0`T#``D.``@60"W&``B[0!DPP
M!0#@`I<,QGFP`_0%O*SQ!C:T!1Y`!&F0JR%@>XC@!'C@``$@0`20F5,W``RV
M%SW*`4/JYN1>[CLQ`4%0`G^P!5,0!SK`*VMK/2R``4GP_P-'8`'U?@1)@-YR
MD"`3``-.H`,_P`"@,.L<8.\_(%1<``3'?1-(G`(,X``'T@7B)01L``I2$``:
MP';CCA/;J`$*H)@2<`-9.05F(`+/8`.C>`%7D&^+V@0]YK@>>>S<``)5M0A7
M0(JB>P-^L#-;0`!.,`=QH)<FL,0J$`2G_0<=50<'0K;8<$X`T.\\T05.D$%#
MR`32M`074.!A0.WF_O7*N`17E0BY-@4F$,46$`2S]`/G,`-'T`(<,`1V``01
MT!+MX00WX-`[L!<&P(=```8*8!<)H@-<59Y.``N]N0<8/`5]L`&6]P8)\5AH
M(P$G5XYN,'0J,`$:X`+`%@5G,/\!*;`#.6`#&3`"*1``PHD`-$`!D'("&#`$
M,T`##1"F2I``[C<%'+`"/'LJ=-`!-_T$:$`#$G`A9``#&4!'6:`")B#C6U`X
M0-`!:(`!0,```LX(#C`#,S@"0O!A!OT#$@`],2#C?T`MU0_VYO]RG=0M+&#<
M-R``^31_>-$%*^#V`[``(S`%-V`74P`$<0P(;D]6.F-_!D0;(TXX!'^/.@B/
MDY25EH]*:1,R)F^5=Q\K)V=*CV(9)2MT2Y>MEFX6+24$&2DE9G]G#RD[.#L_
M.C5S4@LO%*)8$",MPI=-%SM^6!(V8I5+;Q\1;7]L1`91CUPX*E-_8S`F799[
M.GL:2`/_1EY656@$$U^W6`$6`P(@W$R:(<&`""DC]$SZ@$'"HR4"KN`AH*'*
M(R9"U+C:R+&CQX\@0XH<2;*DR9,H4ZI<R?*1BQ)_*ARA\X<,@R@(1@3YH`8(
MEQ<PC@QP,&+*#0-_HO3PT,0%%B\WLOR)D&A1HTDW`JAD4N<%C0:D)C61@V,%
M`BT/P:2@,:$,DY)+TH2P42%!J@5>F'#90`-&#B`LA&Q`(.2"@!XF4)CX<FG+
MAAU;^B#Q4&I2EB\-)BQ@\N2#CW!_E%RX\49)$ST*#%2N=&6%@B$$)&#`@`/!
MD1M'CN@X>F3$D1\_<&"ZP>9/E0^%'N'Y,6+#HRY'*/1F$>/M_Q\+)EIJW\Z]
MN_?OX,.+)^G"!)-?07#442`$"(T@$M(D.?-B!H8!$&Y4.?J'B8@34"1Q@`XG
M/&+``2<L$@0%'J@A!1#KL"1'!BML4`<KCS2QAPHO:&!(:'AH\$(+?IR$A@@P
M;."`!B6$@,8?:E"P@1!'),'##49LL`$!*X1`Q25E\!#"$P4HL`:&CSS1@0<2
M!#`%%ANT4,8D(O0@T!\$]'`'DI5\(400"G```0P$L-!`$E[$4((20%@PPA(W
M/%""`DDJ@,4?;FQP`QY)I?""CH]L$1T+:#C@@T5_#)##:N,UZNBCD$8JZ:2M
MI`&'$@7H*`(67[S`015ZE/'$'4R88?\'`E9<X8<2`USQ"!LO7-'%"R)@N(4=
M8/"A1!M=`%#%`$(TL9T3>RA00P!78*B$$P[<\`(;YBC!1``]"-$JHR$QT8</
M+P1P01`Q"&#%$D[480`+=#CAA!X,+'")$@@HL,<4&01;"11LM+!!!G&LET%E
M7JP`PUM62&""JZY`H,,5"0`AQEM$H#`"%C'`\$>;"C1Q`P0E'/`(%0=`,<43
M?RB@P1][S(;!#7?\(2@%(X3AP`Z(!K`#EY3FK//.//?L<TI2E%#`1TMLT,!W
M>FP0PP9@K$8%`GX^L,5%:$A0@@9VG-2'!!4Z$(()(K31Q`,X/,P!#;A8,L4#
M*_3!10DG2$7_B1(.&$`!'W%`@`0`POZ!!P\BE")&#BK\N-$"291!@+,H=*$#
M`0M7?'$'&1]E`IW]C7!&!BTTH<`#4ECA00LC\&#-&$=8<(/,/%@AQ1\7V/#S
M[+37;OOMCEYA>$=*:&'==Q#I8`,;B":IN@1FO![:&@>4$(`5)\5!!`X!0,`#
M$B5$,44(*!0_2;DTK`"J#NY2HD43#N``PQ142(!#95$XD$08?RP!`!#%=51%
M"1C\8```L^E!'I!@A10X1P$5V`$3D%``%`CG$4BX0!2.@`$%9(&!CP@!"!Z1
M!188H`A<*$`)!O@'%5``=RA,H0I7R,*0A($/4\!9>)K@AU!HX`R__Y,"`F#P
M`@^,H3)Z<!\(\/`[D2RA#R`PP0;(\!8J6(`&)$A#%:1P!3N(8`4N6,,3,D`#
M,JRF"7#80`1"0"HOT$`$AL/""TS@A/YDP`97\H@3`*`1)9Q!#E-H0A64((4?
M68$)/\)"$T0VB1"48`E>"$`XMM#&/T`!"I/H0A.HL"PI,&$,6#C`G5K(R4YZ
M\I,[PX((2F``./2M44YXPP1H(($[0(^#?B"!#1K0!G-`(0X$\-0>]D@2;1F@
M1WO`@A3H0(`-E$`&,D@!`020A3I(``5IF-L>,K4!/4QA#SR80#AVU0(+K$,,
M(8`!&!Y%!Q#L;B0"X``HU\G.=KJS)5Q8P/\*>*`:2$D!(#O(P"8_EBD<5``T
M3```"(3DA9,$X`,Q2`$:BO@(,L1@!Q`@&26H@((%%$`J&\`!8_J#@!P,X!%Q
M\,$#L#4>)I`4)"9]ITI7RM*65L(+")!`"AR0!H:&!PIRD),(7#D)+>B!`R:8
M`!JDH(0HR($`)LB`KTH"A3<8X`0PR,`$#&"`#IQ@1TRT!!8\4(<H@$$"*DA#
M*;#0@1CT08\SFP-H5J*$`/#)I7"-JUSG6A([H`(%:)!A>*Q@`!.4P`+>XT(&
M8F""/%@G"A!(00HH8-.04.$.<X#```*PSW=IX0EG`%QEPE"A-D;!+\IKB09B
MT#*ZFO:TJ*7K$KK_D(`6P,`!;CCE>*K0!Q+$0`1QV-T6`A`"&1C`#)YE`P%H
MT($]A/8[5%@`#P#01B7L(081B((2^B`#`J"%)4K`0PHD<-W4>O>[X&TG`%:P
M`A&0(5);0`$-4)"'4RKA"S"(P0?DT,@I@"`'(4``)+T3A1#X($).0``#/KH$
M-@3!`MN!@Q`RT-CP.OC!$)X=$]Q0`!><`"\-[HX2KA`'#I3@`=":Q!@$$((4
M&,`.K+@F!V)@`3J8HR5*8(,-*'#=+LP@!6500A9$\`(TR#8E5"BK'3(<X2(;
M^<B.<L(:<)`"J45*#"U@)1M^IP0SR(!68GV$%S1``PVD:R5+V$,/D-+0_Q5H
MP!QC.($+7LR2*:"@!FE#LISG3&?P,*$,$!C"!E[YJ"NP80<'D,,IEY`%`!R`
M!QM50A7N4(,(JJ0!(XC#),XP@@*PH@D]:(!$69(%(73@N'4.M:A';1(G0(`3
M$ZCL>.*R@1=(H`^-K!\;3%`##22Z#A^@P0;D4)(NF``&AHO"`PZ`"R<4B0_;
MN8`/AD;J9CO[V1V1P@`^D`,"4!)2<&A`#5[PA5-&@0TDV$$(Q,"*]QJ@!"40
M=$C2\`)]/D(**<C!.)=0KSB<U"1+,,`.`J!7:/O[WZ2NP@1>0$I0CP</)>AR
M'5;CA#FDP`0/N-)TK:8!,_1[$D3:01XFX8=OM/^1##;(P'Y9`H<5M."<`$^Y
MRD7=A0:4X`4&>,*]O4,L"FT@+Y.(0@%"T.X?AH8-7-R`&5):"3Z&``=W*,42
MZ+"#"(@#!Q(@\DB4X`4<?,![*\^ZUN5\A5QN@`\_%H\2XE`"$X!@G&)!P`IF
M4($(H4RQ&I@``N(@AP%0X`0T.-+'E'8&1U*`V-IA@@=Z<-ZM&_[P1Y89#$J`
M@&L[2@IZT,`*/O"%6%-A`"AX`0'&P`HF%*H#&>!`!D0@=\,I(0PVV``7_F`%
M9A2>)5&0P+,03_O:0[@.*1`"`;X@=>X\P0%("`&R**&D`V3`#P8O^@!VL`!A
ME0$'&=BT2G9%.-M;__K_W\7#`UJ0`@%@X>+=D4(>-)#4-(P\"PN(;P/*0(5-
M*^$)/CW!#`*PK`'08`$S)XD3$K`#`X`?^P`8@.]D!SA``P;`!;VW'4^P."@@
M!WSV!U?P`<TC`@,P!P"0`!R@`#PP!Z7P!!2@`*^W$E#@`2/P@`)X@BCX3G%Q
M;BFP2_G''5,``.IE`6<0:T]`!@$P``50`),5!DKW?"$P-2WQ!2L@`2.7@DB8
MA*#$!&"0`%WC<XZ"!79@`2O@`7>0?'/#!S)@`7*S$M/R`H"EA&(XAI[$!&]`
M`D*0`@C39P.0`@HP`6Q6"6:0"G3P@B+Q!/JF%62XAWRH0DQ8`#F@`6O0A8U2
M_P5Q``(RH`$/X```4#TD<&,+H&HD$0:GI`4;L`)A\']]N(F<2"E+<`<<0`0?
M((GBX01IL`<)@`"J&`!AD1)V,`)(\`AOD&E'V(FV>(LZ<X._A`((0(B1\@1K
M=1)3H`"S`7,U4`!AAXO*N(R/H@5()33)"!Y%]0=?D`(#$(<DT0$J@P&$PHS>
M^(V0T@1B@`)(T`%=H(DK@05=UA]AT`(,T``X-Q(#L(VS@6#@>(_X"!Y>0`$U
MX`)Y@(Y:$P0$X#U:<$5"DX"3P`9#0(_]0P$`F8\0&9$>`05D@`,*``%68(<C
MT00$P`!N0%+O5P8MH`,&D"P=007$R)!'H`(/*9$N^?^2EO`%904#=_!C3P``
M)O@15X`"+J`1''$&)$!P^.<*3'`"#*E[M0B32KF4'($%=)`#0C`'OO,(";`R
M;N<12P`&09`!L=814'`'*G``"\`%.*,$!/`#VZ@#`9"43-F6;FD);2!Y,S!T
M:(D!0U!/'F$`/L`W)%&0)9`""'!*=E"70W`"!?66B)F8EL`$;=``*8`$V_@#
M'X!R:D,!,:`'+5ET9V``,X`#?+`%8L`#_=,!GJ"8IGF:CW`&.L"0@-<*6K`#
M'!",*'$&%I`".L`"ZH::NIF82Z`!%,20.G`!V.($?Z9-@?<%FW`"!3`&T;B;
MS@F159"2#%F/L;8$%(`$I>F1'7*0`N45@L_YG?E(0PL@`C0P!'6I,D>``[PV
M!AMP`G`@'DM@!A%0`BU0`)0)GO@)CJN%`">@`#CR`RRP`#@0`I$2`"_P4?F9
MH!+I!%L@!R4P`@.`D-NQ!-*GH!8*CE3``>JAD1?:H1>J!40@`;[HH21:HDRP
>!CG@`,U9HBR:H`NP;"T:HQXJ!2UP`CDIHXD9"``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>f39432a6f3943222.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a6f3943222.gif
M1TE&.#EA_@$B`<08`,#`P("`@$!`0"@H*%%14?#P\-#0T*"@H````.#@X&!@
M8'!P<'EY>9"0D+"PL%!04#`P,!`0$"`@(!04%#P\/`H*"AX>'J*BHO___P``
M`````````````````````````"'Y!`$``!@`+`````#^`2(!``7_(":.9&F>
M:*JN;.N^<"S/=&W?>*[O?.__O,3((,0D#"5`0404'8'0J'1*K5JOV*PVZI"(
M&@V%P:``CQ2.1P$L)INW\+A\3J_;[W4`1/3`%!0*2WU&"Q@.!WU_@1B#>(Z/
MD)&2DY0^`B*7&`*9F0`!&)Z<G",%`*:5J*FJJZRM/9F)@().A8>QBXTC`*Z\
MO;Z_P(Z9;&-E#1@'&&AJQ&['2<'1TM/4U3)(3$5/&)^@2QA-1MC0UN7FY^C4
MXS"[Z>[O\/'`[?+U]O?X<O3Y_/W^_S7V`1Q(L.`_@083*EQH#B'#AQ`CKG(H
ML:+%BW,H8MS(L>,/C1Y#BASI`B3)DRA)_YI,R;*EQ94N8\HT"'.FS9OX:N+<
MR1.=SIY`@P;[*;2H455$CRI=ZB@ITZ=0MSB-2K5JE*E6LVK%@76KUZ\EP8H=
MJZ,KV;-@S:)=FU4MV[=0W<*=>U0NW;M`[>+=>U,OW[\N_0(>?%(PX<,>#2->
M?%$QX\<0'4.>G%`RY<L`+6/>G$\SY\_R/(,>G4XTZ=/63*->'4TUZ]>]7,.>
M/9&V;8*R;^OF44K$@0;?C`38M289,N`F<N^&G&#0@4W&D6V"T.>!`#48)&Q:
M]P*`@$\.&A@HQ.=/@@4&&C@(/S[Y\O<QGH_29$)!@M^&#'BZL7_0(`.?`-"`
M?_Z18HIR\"V6"?\2!62BRR<//`>>`@(\,\-^\^T7"B;SD8!@@H<YZ(``W&%7
M(08+.`"``RA&%\-^"P@QR!_(I$%(C(RX!^*.*F12A@EDB&"?(>HM$1X-^Q7P
M@`*[%-+``@J`HH`:2C*I(X]8EG!)`A`$X"6*7SQCP'<"%#!B``(4H8.%[&3I
MYA!^'+@+-@D$5\HWO?407)MO]NG+AWX&:@.@@A;ZHJ$)RO<`BP:X"$XRW(%)
M!Z&(CC6<'P\HH:8(!0CAX`B?QD%II6!=:@23GZ!IG2<'1'#`<P\4$BH<HY+J
ME:F:>))`E`D(@"$R(NPQJU2V[F;JKI[LE^LGEP2@0`!>#*M%K<5F=:G_DJ9`
M:*:OS&*P1P+1YE'M;8HR"ND##9"8S`('G/DJ>1F-NZ.O;TQ"K;Q@)1``BY7<
MBV^A_OX;:,`",P4``IO68,">5!!<L%*`B"F.$:`(D8`0!40JP@)L-OSP:PUR
MB0F3`I`<P`+H18G?"0(@X'(W4SC\L5`',"F!ITN4"<Z*E^SQ0,(D9,SP53.O
M]IVSLF+BAP`'>(=!`XBDT,5U0`,A<]$\-<=IN/09D&D#$'0J@:,D^'IT%5=C
MC9-^(QQ0@''&Z>J`$'ND@*8$$(B6MMI4+0`S"@X$H+'5?"<(D@%Y"_@WT87/
MAAX,"T2PB:]H-[[1@4-?`PGE,"R\L!5[6PY$_Z8H7L=P`Y^,R30)$GBYN@WP
MXL'Y"U/_7+GH\H!M2BU_(\[L$G4K'>S;7R0`P&]+>,)B`N'-'8`0R11WQ^PN
MF/VEQ[C#,]ZEWT$P#K;@Q9J+@\/M008`$H0G1J8!-`!`!&DP*:PF#OQ8!_4M
MW)WW[=FGHV0!PVF0XLZ@GU2Y3V?"XX;R%I`MI07N`<-)U2XNP2T_#$X+^&M!
MX"[H@]#U#P>JPQOJ$CB=L64"5P[Z%H5`T0VF!:`4$50@?4A4".;9(8,K4-WK
M8O9!>'`O`(N2%`L-`<%/M0Y-QOG.$.D'00KMAWOT>18.MS#%%'S'%%7[2`_?
M42<1*($)I-`&=S!W!O^,%0$)3UB8Q9:`!&Q\[H9$.<!P`)#%#F[Q(BB;1A51
ML`#M[%`*'KRC2_9X`BM=(9""9`DAZ^-'LA$ND0`!(#P660+]8)%_D.Q'`]+W
M#DHR`663<Z06,^D/ID4)15#C6+M*IA](=6P5GK2@)>F(25+>(TA>R)4NH]2@
M`NPA1;V()3@2-T+LV1(??12`J^C#S#`LX!+VD58JA!FYR>GMF/FHF]>8>8GV
M-,@0"HA=*X0)CBP@$IL\<`"\)/!-^BB)3$B(0!U10<X#N`P!BX/".=&Y!275
M0P#\`AT_'T*B>GCIDB[X&P`X=J.-X8@<`V7-,Z'3@EU]J@^""X2`W$<CB$;_
MM!_Y1$4IY$32DIHT<X?@H`D<I"$T<2B!(]WG1X&``%<`H`(#R*E.=\K3GE8`
M(4"\CDY8&B"7:J)#NIBI/VK:"@`,X`)0C:I4ITK5`2#$>B%%P46Y0892@$$)
MI_204OO!5%8XE:IH3:M53>"`"$3@9B\@3Q\6>HSSD`=E0)/I6'E0UHD\-:V`
MC>I:39`G&8AR!7K=JP[ZBI2_!A:P@VT;1L7).,7:@[&I..MC(2N0".R"2P$%
MI&7O@5E4:':S:(TL.,B753O>\8LDN-@(MB$"+]EVGM,H;;\<B]JIJC8[PVD5
M;G>06,8T"$WC<)8"D@'$/'I1#Z;(G#5T2XG3]E:J_[\]3\E,4UR)'(\$:>A&
M_+ZA.LE)LPKM"1RH^,#,T#(3'`]X`!(`(09#L/*H`J`L*JAK+]Y>%ZJ_)19B
M"M`Z4J@A/+U4UGIU8<8WWBE."-7!)N2Y8`D`(+X0<%0F?%D`#LM3:[S<<$%;
MP5])6/>_%PCPM!:S*)@IBVE@()N(@=@T"3R3CM]9E+X"`+\=:"U(OIF.T]XK
M/&4-9Q3.]-%A*5'B2)SXORI.J4`/LR\%"_"9:**KEKY@G+P5XG\%[,;U=.#-
M1D0O$$AE9J\P`2Y,>?,2?NM%DR'QY.L&.*BD,^9@)`>!L<UV7ZI,H/#V%2QE
M96I1(ZR9#YXI7_H@HJ#/V?]?V20;H>Q89V'602("-J'?2LSY$77N;8"Q6LO!
M:*A.OF)2KQ:J82?0BX'I0P/J```(`\"/EI$XKR\^W13_0ADA;7WK<,O"&.-5
MS`CN<P*A2Q"=!*@'%.QJ!_+<9UN9=1H8O,9#J%&KXL+J>3<*ADJV[[#MS08X
MB(=,4*<<40CYY-</:'HH.L9MAW(_-L`*,.^2>=!=TC1K'P`%1R[G;5-?VQDA
MLQQV#OH]DG4GW`E7^S<IPOK&<]`[#P87-<(G]\I'C@9#U491$?<=AV9!`#KA
M=L?%)Y5Q;B,$7?F])FE^-813=O01$G="6`67CI5GI.7F1LBSNM3:'C!<)"#W
MDK/_]Y9S3.QBR`1O*M#OC9"W/4?A7#D-AC"'*Y7&H=WK`&!^I4L-G^MCZH$-
ML!P/6NK-T)P)-A]X+Q8QW8*C&+L(63L$W*M/K7>+!(`(@/>`H8"PU5WJ=Q>L
M1@)`<F*3QN&$/;HR).#U<=H]\2E&R$1[_.W1UB<"E;>)O=..<%.$?N&>7P&/
M3Q^3T7/6!!.=7.=/,V9KM(KU+7&]6H$JOZ;-GC2UMSWH4^'NR1G_^,C?#IW1
M_GHML2C.OQ]-\(6/>S@$@`(,R+[VM\_][EN`8+I/+;`E1^'H@V;ZPF_\'`)`
M`,QG?OGN5[&^L)YUV*#?]@A0?QS8'W_P,W_W)?`LT`)7_^;W&?>7&LLD"?R'
M>2K&<OU'`HB3'9Y0=/PV&P=H#;:F?UJP@(G7@#_W@$,``0E04_;#0_9'@=60
M@9'`@7?G@6<'@F>`3WI`=D9G@2B8@@GH""R(8BXH*O\G?I-B@_9@:V%U!SOX
M:_#'@)0B>2AQ@>=`A#K8?DJ8A!VXA$)X#UQ2A'1PA`='A2WX<GPG6B>8#[ZD
MA7+`A1KGA3PH=/K6=L!W@^=0AG:`ABZGADA820="?X-RA60(`6:X!708=';8
MA95T<@M`@Q4XAOW@2X9WAE)8A8.8AB6P*/G5<:/T&DX(#XR(B%,0B%07B748
M@`M`'1JXAXKH#W_0B(#XB%\(BO^"6`(%\$R6>(FLD8GR4'B<"`6>2'JN^(FP
M2"%PB'JG"!"XN(HPJ&T_6%5"UWLUP$!20B5+@A!,2`7>1B3?$#AJ$GM_1`FV
M6`_%F`6[V'R]=HQ"\GREV#:4TP=V)2-7`A$20@('D")]4#-Z4`*XD@K=:%"Y
MZ`/A"("@EHR^Q88MLPDT`$5'!5,'4A'I\3<G-":ED#"FHCJRDFG2$2NE`P$1
M8'W!6`XFU9$=J8?YPXIKV(N\B(=R4I"[0"#LY5&1\3=B($`2$$ZA8BJ&QWAI
MH@SW$2PC,'B`N)'3U5-`&903X),A28[U!I!X!P27@A[JP1Z4-8TQ\S=_$%]M
MAB+K8"K_G6!4$?0LN;1<^T>49>=^!`"6JB>2=SB.4_@1&`,UOH$<+/D0RH($
MXO%-\O4_)("52)`I`/5-W^(%)W.&9"D-"""6@6DW9DF(:`F))7`?-;./]2<1
MC;(Q?K``C?8'^',`V!"+050AC>8NQ:>1_#"8F#>6_'B8DIB8K3B)7=`^;G@3
MN@:8H4F8I6F4&&>4$9(^A<DG07&.5Y"/Y2":B4>:/="/0/B/1CDF]0.22,*'
MI"6;PVF:H8B:(YD$CNEXB@0*?G0)E@E!D^";T^6</$"<RDB2XC@"D1,AU6F*
MUQEN:,`'83B'N8EMX+D#XAF0Y.F/L+@`+G-MB;B>3`(`>8F/__'Y"\!Y=\(9
MGM#YBM)YEN:)`.AI=MTQ2*!P-,GPFO`9FZ,YH/:8H+ZXH(BI"^GYF"EQ">&&
M0/4":E`9`P6*8@=*GQQ:DAYZFD/`<:T9$B3Z-VEP/#J3`,,7%2OZ7RVJ`_69
ME,:9EB0`<\Y8@!V1#,8&@5`3')L4HC/QH]<5I#DPI(IWG\4)>(+GG0&Q%-_(
M%%3:6U:*`U@*8/YGE%9WDTJ*$]>!!2US3W(ZIW1Z3Q9*H/,II"]:GN2&E%FZ
MF*]"=R:H%')H!0+``)C'`'>Z:WEZI7N*G\AHFZLYBS7(%`40`93Z"HB:>(K:
M<XUJIH^ZI9%JI"-PF^K5ICNA@E1PJ/^)NJAR]JDW<*;O5Z2*"8$`-22HNA/O
M4WTSP*J<ZJJ\,*:H5::Q&JKC2:NI25C*N9Q1<7M3X*MWUZGS!JLV(*L]2"M^
MBJ8F,"`/8&$U6A2C**4P`*TH)JT61ZTU8*UI2JI*@P`IUW=5$:8_0*[_9:[F
M(*R;1:S5:JSVB:S3>9<QR2[?:A1^&`7T>EWV^IOH6I#\2J0Q&IT>\F"Y"A2^
MQ)\W<+"]E;#?F:&SR:Y'29OC46`3:P/M%#2YQ&CB:@ZJ:@F;&JW`Z@KX^ECZ
MFJX-^Z</JZ"3*0%NE:G]&05CDI$!Z`4+90@:.@VV]IX7V[+E^K(DMK`SH*Y:
M>JQ>A`#1Q%W_AEH"ZL$)@L>KZ>"LFMJJGLJQSTF;#LBN]1,!5+NL,F`:GQ(D
MVDDO14L-PO6UOQJVP1FWM56SVNJO#`I>)2B&JPJ/$U9!1$80\HH#&(M:&EL-
M,1M8,\NP9/N!'KMB59`)F+E@.8:T_F`=/)"XF[6X82FV"!JY+SBYYF0%=!(<
MXP!;"E&H.>"YCP6ZN>6T,@"U?/NAM#(6!*:AL!M8LBN8M!L#MGNS'2HJ9+&R
M-M"[@/6[T="X@/6X3ZNWLTJ\,&J\0%!\%FL1!N"NB*NT]<JTK."\:06]M2N]
MURH5V3J]UJM/>/L/7EL#RIM6S!L,XHM6Y"N\YKNNM;J^5M,-[Z0&_VCRIJH3
M"/*!`%S[#M"2LIK@O0@+OJM0OU1UOS`PO*.ZO[E[%=U@);3&>,C0-$*0I`S%
M$(<[K@R<L0ZL"A`\51+\`A3<IZ0[9>Q+0I>B/$6T"XH&$6]*`_&+5O,KGZ+K
MHB^,K4$\LFLK9L>`.G\I!F6"+?48$:X;`SM,53V,IS^LIT,\+>E[OH,*!)'Y
M!2=R,D'D-4P"2LKW$)?*FU$\55/,J%7LJ%=L3EELA1N8HEN`O-53PHI[PJF0
MPE*UP@F5OU';K_H@%6IK$&V%>VDL56O\JFT,JF^,!>$GM?S[%G/[`HD<58L<
MK,$[P8!\NS)ZP5&)7ZLS(O>5&%",QY^KQ__[M<DLW,G4RZ<"%LJ?TBML%#QP
MZ9&XG(>@@LJQJ\J>QLI__,B'%,=!V##,@CGM@A$($)3,O%-#N<M@.ZV-7*S"
M##K$'"_&K`FW=8\2P<=1=:"7#%69#+/`7)2F*[D6_`/J5272B#9_)P*GFAW=
M#)[A?`'CW+33O*_5C#;7K$_/@B+L^);]6[A,<V&\V9RB6\_W'+[ES`(M_+'G
M3%Q_YR`Q-06(8&R.8B8\-\\)S<N^Z\M,UM!EN<\-T\\Q7"`"S0/;>\`)X<U0
M!<X>O;P@/0DN?0%^;,[I7)L171;@(1Y/&04\>M`+4=,P'<WGFL\T2](Q8])`
MT*3(TXYZ`@'9J\S_]!S3\CO3DD#4[?O0.IW3ISLZ6#T06@W-=2O-=]NQ7HW.
MR3K).Q"N+3'6F&#5/!S6D`#7H[O30HS71-P"[YL2=JW0=/T(=@W$>HW%2MVS
M9.99,?'7<BW%@>T(@VW%A0W'ATU<>I*#;UW51GVO(JT"7%VV:9UN._#$F=W1
MFZVP2`VYDPW)3!W+.5!X-L'8I[VQ9SVVJSW,E6V=9LI.L:W997W4M7W7H>V#
MN2V,.'#(-R';O\W9J1V]Q?T1K4VY-W"T.*'<+FNW!KK5KES!:PW*-4!@/'L2
MUKVTV,VBVOW<'13=7VT#!;L3X_V]Y0VDYWW;UHS>ZDD#L,T3[]W`\5VE__,]
MW'D-X'L]`@T0`0J\$?MMPOU-IO_=W1`MX%O\(CVJW[Y]W6:=W6CMX%VMX>L=
M`W9<W15.WA=NWAG^K]QMXM[]`K[4OAP=W("]X,/:X"C^X!P.R;WZAR!NVLN-
MVL%-V!!.V?1-BRXPPNX=XO`]XO)=XGU+XS,NW2Y0R4*1X'D,X_DJXTN^X4W>
MX2QP,"P]$E*>RE0NLU:.NTQ^Y5JN`D&M%%_>RV'NN&/^R65.YDZN`A6[%&O^
MT6W^O&\.L2X<Y*[%`O$EID;.WTCNWTHNYZ!=XZ*]`G]PX.(]Z`I>Z`Q^Z'".
MY69NXV1QYS*=Y^.[YSC;YS]>66*AZ5?-Z?;KZ?_%"^J*+E#)U^JM+M0<0>IS
M;>H1C.K5J^I9;N,(T'V\WNL4P.(,(>N.3>LJ;.NP;.F(KNN='>N0/N62'N.4
MSN=Q7NFG&]F]K>,6#MP8;MNACMM^7H/6/J7-#N;/7N71_NG3+NTK%NXR(>QJ
M_-AXP.[Z_.V`I-[*WMQ^/>YL7NYB?NZIGN[HON[+CN#ZCN?\[N;^?NL`_^\"
MC^\HX>Z*#.]W(.])3>]78>_I1O&E[>*-_>[$WL?&#JFX?ND9/_!4C>TBKNTD
MSNVK'N`M[S$:SQ(0C\D2;P<Q7[[VS6\8+U`W__`%O^D'K^<)?^R)GNLE[_"/
MCO)'KO))SO)&3]P63VS_/9_T'#_;C&OR)O#9:OWTE3/U)#'SXESS=>#UP1SU
M5K/S78_U%@'V]BSV=$#V./WRAFWV,%`UNP#W(<'V"_W`:G^7VSWRR>X#;S,L
M=]_W+;[M"VSUH=OCDMWM]4WW+5`*GS)2[H,`!'#YF)_YFK_Y`_"?N?SYH!_Z
MHC_ZI%_ZIF\*EK_YJJ_ZG7\@$$`!JQ_[F$\!B7/ZMG_[IY_ZLA_[K8_[):4`
M`[#[LC\![N/[QE]2#3`!PA_[Q,^ZSWH"<A']NGW?_#']7VK<U8_]V2^BU'_]
MW._]WP\%A&_]S!K^%V+9V@_^W5_^VV_^:TO^YY_^[-_^4C`LCLXI.G#_?I#_
M_Z,-`I@XDJ59%J>ZBBG[DBX,RS-;VRN>FSL?_W1!E6]8-`Z3AB2SZ7Q"H](I
MM6J]8K/:+;?K_8+#XC&Y;#ZCT^HUN^U^P^/9PE%NKR;N^KTIS^?YZ3D$*"R5
M``#\*38!!&`<8#@F%2R40"YB45J2)2PH)))(8F(T$.Z(WET&'#0L%`P&@([.
MOE`&)`@D/*P.$6(4!+@*R-)&^1H$W.:.00*S(K?20B(N\#8T//PE%`84(#H>
M$!>/CR@`1V)4HO(X(ALDK),[.38X&)R3&>1V-Z0H%`,PI\Z``PS_]@3,X^@;
M!D3R'AH,L`]=/!N.O"T8!!&*HP0.%,`C`RH9J105^?^4,AF)(+H]"I(U:@B@
MU*>-#QTM"'D21L=J,\79_.%HD*N<8QPL6(`,0R=?LP0DTYE.8M"J5J]BS:IU
M*]>N7K^R\18(K#8`=7(`,$2V%H"Q9]+:3&"6EH%/O%A<6IOF0*Q"+_*>**#`
MP8%*>,'6;03XQ.(K@@D;7M%8#M^`:E5,5B,*W"-2`>RMRL6WX(+,>K=L-K#D
M`+)NK`X(*%#*`*M`!_S<A@2I%&@`PT:G,WUS!.?=GY'!3@"\=)7;(G)WYAU\
M6*,&P>-LAJ2ZM>Q8^UPW<%MF,T69"P`4O`4)Y^DQFQT&4-V@D4GGR6J(8K@0
MP/GTRM%%=A5YCNS77R3_L5?_17XQ%9A.>;<%Z,9F^\G'GP@D*=?-&MV\HLZ!
ML9R72%\D[=1>%I48T`A\]<PG23+)\%6"`XGP=<XM(,(7$(E:<8@41?#PE^-+
M!%HQXR/=$`BDAXY`=:,<*#:R'XLQ13(DE6H()M$_+X&D`#;AI-.4AR:"45<`
M$(0WY(LD8?!`)Z7%$\P#L7&YS9>)S%?-F%AE*<"6A-CY`)@YZ=F2@@O,"8Q$
M@88T'TWXP&$FFDC9M:8(#PS"#1QGD;D&IS9\JE>H7HRJ2*F=HIJJJJNRVJJK
MK\*:23#W!&`=,-;!$FL7N2)3T"!+#&)=+;-Z1D>M(OQ'%C!*W?K+L7R52,6R
M2Z34_ZP!U8AG!Z^?8?!KM]S*T<]4W@Q"[E!`Z:I@MQ8ZZ6&$)XB;D5GWH3?5
M6O%V@UZ^&GT1[XR*DNO0(N>J$Y*'PJT1Y84N_F)4NEI0$I**+35P$`P*1^)B
M?-%FA3&;$IGRA<<:*^"7J3DM%$LD_($KQTOH=/?+?`]<]K`5`-",#F'IT>$@
M#"^+2Y)L$"RZULL7E2*S"`)S`;1)2!.G",Y+#'5`>@"L9P<K:1%V2]>Z('*J
MS3P\$#:(Z=!WGL62S??.*@Y\?>%:6Q/$ET=V#^9*%W3#8_77J\RG2-GS6GB>
M(Y^\VX9<<+TC0N.(S#7VS6$WE((WR*+;!R)+)&!(X\BNM2CX$I]_'CD7HC/E
@N1^?_P%Y"G-=_HOIDM->N^VWXYZ[[KOSWKOO$(4``#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>f39432a6f3943219.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a6f3943219.gif
M1TE&.#EAA@(C`^9_`/;V]G!P<&9F9FEI:1`0$.KJZO+R\EE96=S<W.SL[/3T
M]%!04````&UM;>;FYC`P,`L+"U5554E)2?CX^-+2TB`@(#\_/]G9V=C8V,K*
MRDU-3;*RLK:VMN3DY,;&QM34U(J*BCDY.>CHZ$5%1:BHJ+2TM*:FIL+"PM;6
MULS,S.+BXA86%KJZNB8F)BDI*:RLK+BXN):6EJJJJJ2DI/KZ^IF9F34U-924
ME,C(R'IZ>I*2DIR<G+R\O**BHL3$Q"TM+8*"@AD9&79V=IJ:FG)R<HV-C7Q\
M?(6%A6QL;(>'AUQ<7!T='7AX>'1T=(B(B&-C8TQ,3%)24D)"0C(R,BPL+#P\
M/!L;&R,C(X"`@,#`P$!`0*"@H/#P\&!@8.#@X-#0T+"PL._O[Y"0D%]?7Y^?
MG[^_OW]_?]_?W\_/SX^/CZ^OK_[^_OS\_-[>WOW]_:ZNKN'AX9Z>GL[.SGY^
M?HZ.CN[N[H&!@5Y>7I&1D6%A8<'!P;Z^OK&QL='1T?_______R'Y!`$``'\`
M+`````"&`B,#``?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PH9?"UI@CER+6UZ(
M7EN;65F)7&+0P]C9VMO<W=M?#%T!!,B,#XM:TX=96IM86(E=%6+>]?;W^/GZ
MEUKT?UOG&#%`I\X0.W?P$*7;Q["APX<0>W$9.,A?``9:E`7`0N`!EXOMM'3I
M\@>DLH6#+E;XPDX+`VA<7*XLR='C'RU8P@G:0F#FNY@,9N[L^.5+!0+0O@2H
M<"VBTZ=0HTIM=+#0E@I@1-Y\D&7>%@;PP'ZYFI4DRG_DQ'!E(`9+A9+I_[HL
MV-J57C@P#+YX2?OVG=HL8D@*ZMK%2X4`7[UD80"FV=3'D"-+ME>5T`)H>V\B
M>_>'(@-EE_]D/MOE&I@L`0=F:995\Q_.GV]FV;)`VH,O[[#<%DTHG5%!7<2@
MGDR\N/'CMBH/0CEP(6Q!%)G+7EZPZD`N\C!.?RX[)X/O67Y6"%I.4+JJ[Y0C
M7\^^O7M-%`7=ENX\+'3SZIH71*FX7><_<H&Q14C3<)<.9X,@"$87!/0FC7_I
M^??>A!16:.$@"_B318,!D`30=O;]5Y*'YYS5H6@$6.<:%@2^%F(Z8+SUQP)>
MO+,%/!,Y.%$S6*EWX8]`!BG58N(00,]>#S`&XO\?'8F(I))G(4D`%BK61$"+
M!D[S0`45M//.7EH<YF!)/9WCHY!HIJDF9<8T5:,ZS/PAC9SP)"0:E3LY)DB-
MF%V3D!ABU/A/,W,F%&<U8B@S)Y]6.;9%HJ(UM>:DE%9JZ:689JHI9,]HHDPC
MBA:TZ:BDEJK-F9,$M`@8\&PAJ:FPQBIK+:A*$I\B",ZJZZZ\?D*C(#3RQ$``
M<AZ3$*M`$4N(L,KRA!1(-PD2P!<E,8"444RYBM9,-QY%;:_@ABLN</08-=$6
M8!#`DA:9S;C%2*@U=6ZZ>K&5KAA@B0@C5F(0X(46!V+AQ4M+O4;.`G.-J_#"
ML-+V1V!<E,/503/YVZ/_&`G_$;%\LPF618[ZKC9-CISY)=A*6!!;*\,LMXPF
M%PTN@$Q6X!T4@!A?G//==Q+^03,#X=DI8G0%)CE0R;GAQ]G*+C?M](1<$<#%
M7L*=UTY68A![ZR!4LQ/TGD/C!]`6X+CH(H(!%_OTVFQ3R&([P\'\('0+/0!-
M%LK*>8[<,0JRDF=>R)VRG$?7B47?`W.Q=,]M-^ZX9.#0`_,#!*18U0(-^HP1
MT(-,7KF67+;39)@/3(P1`0/U>R,\6Q)`[.*/QR[[5`(+@EL6IW4J9U/AB?K'
M[:=I#*BB.&(Q%FL"!UJ--"-;,]@TNL\N_?345V_]]=AGK_WVW'?O_?>T?"L:
M__/DE^\[^.BGCXUB@+W31>UWVLBU^?0/$C0636VQ$1;"K:;^_P`<1!?.\HG]
M;:1_>DH%2]IGP/($<'L!`!C`7/6J2$QK$Q=$!(O$]QXP%083^MO(^7X1@!+"
M[X'3$TENOE8)`O)CA+^;TH5*TY4`?&H17`#,`1U2HYO!$(4N(R""O,!!12@&
M/WH9!$L(D4,FBNIC^/F=[RH#14%,;3V&V4D%A,8U5IG0?T_Q@A=%>$,@LDR(
MK?H.2:X#I8)\A0$>`9BUFM&%[YB)<L/2&^J(Q84DJ4LV%X$C(7C61VM1"V"9
M0TYIK*B;:^#-A\;)8<IN9D:&J1!I3&J,NLXCPULAQ?]=6IA+/_82N`I((R^+
M(1Q+4C<7AZ4C+S/2DUJ^((:,!$"4-F1/'ZVX(&/\\#@W1%<9*SDK+3Q`@BX:
M#DWV![#*Y,R*2R*4*56DH@6\+R>R(8#,"G&08VA,/^[!GPCW!+`$3DB2`7`@
M,6&%1O0<#F']RIK]>E:?:EEK;O]1D3&1>9[Q5$!/[/"#%LK@!S\P0*`$+:A"
M%\K0ACKTH1"-J$0G2M&)EB$`9/!#&!X0AH:6P0)CZ&A%1TK2DIKTI"8-`Q;0
M@-*6NO2E,/7#.BW1SH!L!&;IT&9YE+F:^ACED/A4C7^:4XZ3^.\+.+&?!?Q@
M`35H]*`62&A,ITK5DYXA#0'_&(,:1.H',YCAH61X@!FX6M6RFI6J82!#"<E`
MUK.Z]:T.G6D+1<49<NR%6ENZ207*2(Z8#*A`5-KK8H*JMO_4,H=O2<=,,J14
M/Z3!`F&X)5.E"M?*PA0-)4P#2QL:A@JT=:%FJ$!&+4O:TCX4#6880QK.8-K6
MQE2NE$#C/]0('`ZI:B=V7)(?>S34PE[':,A(QQMM,IBE;M1:+(VJ:Y<;436L
M];,,]6I$PQ!:RC+WNF:]ZA@"L%GL>O>AL)W$%\KH!<<0D6O4.F\ACO@[9917
M8Q\K+Q>^-3+ZVL\QXQU?(;C0W3*(%`W0_6YIS[#5D7)4HF<8@W*ORX'N"ABF
M:4W#_X,G+-/P1H3"WL6L=4=*AJ]:%*2L;>T'1E"Z",`!PU0U0XA1W%H+VV)C
MU'D$=PC!8M>F80QL=>D#5BQ1-51@K*45@1'0L(4RE"$$6`!`C5VJW30$>,E5
M=7$M<C4=1RS-$%#.<D/),`:2DN''K2UR0<GP@Q-H&:4`/K-;I4P)YMW)C7@2
MA#7>^P](S3<\7,#.!Z/X)OOAKR*KD]/OO"`&9&C4#&5(LYI;BH;M\CBF%7BT
M1*G[@-&6E0(1<*I"M[#0R)IXT2=5JZ1!;5(V3P(C`0`3.<CDDFF,XRCP6$KI
MY,2E+BTF7_AYTLQ.%^M:VR=,K?9#ZPBP85)/EPP+R+%9U?_0Y9(F>,$Q_<``
MGM!63C/T#!+(@0*,/=(SI%;3W"ZIJ6U%+<X\\P'-V$AG>`0/J<WH-%(;F-FH
M<Z(/(<9G[8C-%O^3U/>5H0)^.`,#BAWNA9ZAA`2GJ@5&/=$S6&#A+ZT#"+!0
M;&M[%-H%[_$8@)SQB8X[$M$YIDMLIQ8J08A*5PJ3R>]#Y71()U*^/#F_`2O=
MR7;<HQMG>%G+T.R3EN$!(47I&X1@`(AR0.=I4,.);Q[1!`=`YS?_."2B<\U8
M8^0!*T_F%M-3):&Y/#^:$[D[9^ZBFF.\X\BV=&G/7E(R-\$!)/V`$HX@42-+
MM`=I6#K3'QJ&&R<\XU)_!$5"X[/_SFA$8#)ZWV\&W74'A68T,V-7XG\-6"X7
MM`)_!_49,N_6C\+4#%8PPK8G2H0H0+V@=I=H`@X`@KU+M,.N5VC@'4$1LK"(
M2=:0X6&^`H_#@&%BO<7"K\2&%:U8\_?M\'TG021PM0X\XV'@O&79GM(`K"`&
M$X!H&18@?3^\H/O,[G[LF3[[1L1')=3Z2@5&$L,*+``>1LDC-64819/$T'5O
MP=;[R/X./Y"!`1;P`.*'8=3U=`*&!DL54PE&`$5``PO%!C'@`FHW45O@8!-E
M!G,@`^/W4`DV@>%6?IK`7L'1"F408A5@@6IV<*?76F,P@'5G`15P`065`#80
M`$_V4!9'_U(9<`>CMX$,Q7/@]H$@B`D#4T(,8$ZH0`8$8`8+`'`^N%P.5U8^
M1@1#L``KZ%`Y2%*KUP-/V%!7"&5#F`E941NNT%4@!FI8!64X5E5L8`*4TP`%
M<%)*UE)DX`(DT(5>Z(%G%H;>P&U<YH*N=09.&%,L,`>L15U+<`1S.%)H@((D
M15TAD`)XN%!_2&I\V`VD!H1JMH8OE04CP`/7-@808`1%5U$\`(A>N``-,(D+
M=6-?*&"7R`V+EF`>IF8;Y5)L(`91X(@!9P$C0`$590*HZ%#;-XS&5H`W.&&Q
MN`UJ9@8V:&QFH(<4Q0)/$(0/]7,'@`$4:(P.E08:D`&L6%!GD/]L6K:,VJ!E
M/,>+6K91R=A0+)`#6>!E%7``7A!18E95D74`7Q".?L!LZ@B+YH@-?H`&RH9A
MJM5Q-5=19L`!)T5=*T`$"8"#W!A1<,>/R%AC`2F0/@9TULB/<-59[3@!.]""
M+A59!$`$6#B1$H4`<<"/F_=6.Q,4_]A0M@-4L?5+&L1%&=D(!?4``SD&AS&3
M<'4&[0AJ9C``$L4"52"-)C6.-A"/"W6/;V4&$0".'GE6`V=D8^"3(Q5%^34)
M+M0(5+:3/.D'"]!=S/9CKSA5SEB4H'8%",!W`L!Q5/51W[AI*CE183`&>5"1
MK&@&'?E2!Z50@^EM4M5A4E4&9K`:#Y#_*/G59X-6:(9P(\UP#)(I/+4S7[@Q
M-<;C(H_B9X[A9F0I"&-6BP655@OP`$YF66C`?3Y(!DK04`G@BF_E8R/0!WX@
ME94U`3%P`R(0CLSFEA0UF'Y0!@00<`1@`03@5.-@`<^G!@#8$>"1#KJF5ZU&
M"..@!?X";+"T)92#6%N2FM_I%D=!+.FBG<V`:J-)FAK%E9R5!@^0;,+9E/-)
M:A6``@IE`#D0`GDY46E``&.0!/U940[P!"#@@),8650%@`_'`%\E76C@DSOF
M!P'P518@87BS$.E0;R4"#_LW"+!T./TF,`%A.GG&.5SA%J+Q&0LA3["TGG^@
M4%;8=&;`D5<Y_U5D<``%10$N(&&F15T$(`!LT%K490-^>:,HY:#C,%H!V*`%
MA0;P^56#&45?=Q_U-!CT!%B#P1&$U1T)\4H`<TPB`J,*108^*E&850%C()03
MI0:FB8<5P`-S4`/U.54U8`$NL`$*]0%'ZE8']Z9=>`9L&E&#"9\%!5)>]547
M$8!26E!4ZC56JJ58.B:<03EATJ5I(QM@(3];0Y8*=0;N25',]@`&6'UG.HD&
MH`06,*3,Q0$V(`4Q8`%54`("4`%6``2+^%;;9P+9-XD)>5+$*5IF.5I.Q0`=
M5:%^0`"L14L:F@6/UR!7^CLRL@60FAXEBJGA<3*D!%]CNIX+=6"/B/]LJOF*
MC3:H':<`,<"?%B"#KE4`4&"#"78"5<``$*`'D04!2="K9L4&-[`"$7`$4Z"G
MD[A]=5I0Q/EE_E<!;KI4!)`&2OA5"E8&.($3,3$;Q6<6DNHWZ61*/D4..8&M
M.0$&!3-`SAHB9*I0#HM2?1>?!0E6S\B*8>`"'E8&58"@S,4&=.`Z:54!&H`!
M#E<!`EM5+$`%464&$!``0B`%!0MJ87"6P+I0PJH2+/5_:MIE8>"<&8$OD&I_
MT2JM>51/=31!*M(=\C`30)$1W3J:!K<`+^5M:AJ8%,J4&Q@&9&4!#$E:&T!9
M%*"JW45=5*`#`/!O1M"G+94`9O`#EC:.%O#_!@<YB0%PJI8%H[[`4.#Z4FFZ
MI@IUM>9:<`8``B]`C%-@62AP`+58``.@L`X564'0DD\``<"(BVGP8Y_U;Q'0
M`T9@`C;K@\ZUM*4FN;S`4!A55:,:`&H`6:SX!B$`MTSU!F]U`4]`;07%!B``
M9DVW`"VP`C_`C2S@`F,`=6D0!'.`!D<0M#[8:&O94K[[NPO5:&<EGJO5A9%%
MEPYU!BYP5F$``C.@4&R0!BL0=!)%`D$P!BO`%BC%`E(@@!0562N`!0(P`A\`
MOTY;6>F["PT5JE3E5&GU`!;0LC?G`!I0JA(U!EQ856\0!:7H!Q_@`M3'4`B@
MPB90!3]6`56@`B0U_P$:0`!R.[\6L`0](`4'<,(;J%42/,&YT%#$6UE7Y7[*
M"VH[,`+B=P8_0%480+HB50!F0`4YG+D6(`$RBP!W``>Q>P0125$+L`3GJU"M
M.Y!`0+Y(ZE)D4$1$/`LX-U71%U&8!70#VEH&G,4-Q8DOY8PAQ@9%L(3U2097
M0`1U@`82@`4.$%I%H*\090%FT`)'`,03I92IJ5`I``)GW,8+]7/#%,>RX%"#
M6)+=*ZI;R5V+Y@$V(+_=5LHI502N65`PX`(SVI!F<`5$IP95L`48`)0FP%!P
M0+[&)<`M.5$?(`68QU2=5J&\"V5-^\P-A0:>)<JWX%"8ZU((6,BI^;Y+UO_(
M('Q2`4!W)S4$+6!I!HS`;2O`.]!5/R`#"!@$.\`&#G``05`!4O"Z"3B0%C`%
M/@!1"3`.9[K/"H4&(Q``8QQ[K2G-6LQ2UFP+#N5<?[RT&;S!#%U6?/`$N8I2
M"1`$/5A184#%!44#.8##$P4`1Z`%A.M1#Q`%";"7`A"X%3`"*X`$??>?-0``
M!)VP8V#)?K`!1UNW8"4%5AE[>WG1&^RH#TT+#V7!S'55\;G$II5@S,N60#!2
M`$";!<4!5_"R$64"0?!P5F`'D`Q6#UD'1H8`45`!1VL$#!E92[`$G#7)[;RC
M4@!Q#+73G=:6XT>W,+5QLK?4<NQ0$7R``8#'U^7_`$3@U3$5!DN0T!#%!CM0
M!-T%`R&`UQ&5`9?]`A)0`3U@!D%PH)-F!BMP`Q%0`5`@`]05!#E0BH+(@6,P
M!22`!*CK4'H=B@CMR6#5<Q4FV+$`5H`Z4:BEJZF\N2_5R$;0R1<H!!*U`7,0
MEP5U`5"PS!*5`=,M`P*`PS\G!7S0A&S<4`!P!TOH!Q[@`:PE!"W``7:``0YP
MVPKU;\P=R115!E(@!'40>XGF<Y7;V[[]"GSGU&@:`*2E!DWHS7#%`;E;5F$0
M!"OM!R<P!0)>4`A`!"L`N0XE`D]``"```CI;I@0@`3&`SV8&WG2P!*?,`Q8P
M`68&!W)04"`@!+#<4!8`_]T/Y=X.Q65QP*HWI[DE1<UMU=^__5"W3%&81:1D
M$(`<K(!'7%EI`*@0&`'=Q0'<VXYE8`-CP`(/)VF(N`%I8`5'`,EP$`4MT'H*
M5=4O<+=^0`(20)PUW@819>,/]0).$(=,Q^,@;0$H".2P`%%F6E%%_M3P28XQ
M5<_^:UD<!0!)<(=D,`>26%`8(`%X/E&:;0$P(`]_-XY5L`%+H:<`D`,M$`)^
M4`!TX`$*@``E4%`?<`1RP`.T#00`OE`6X.;R75(`0`1(`-D%=[5NF=0TJ>=E
MR(&OSE!_GF&'+<0H!0!```5Y/%%D4`564*,$,,)^<`$"<`52[0<.<`<5,`0@
ML/\$%GZ-^,P!`1@$8_7/2%``6"`'&3`%'N`'<[`#=G`E.7`%Q_GFLE[C*%4&
M4W`#.I[KA0Y1@!U7OMX*$;7?#H6`&,9SI+H!>G?2C\7'524#2\``*V`&(Q`"
M%6`!/M`$%3]10K8$.<#A_TY1:0`!5K``$>`'6=!EB'$&`#`#'N``;``$VA0'
M$&`#GO?F-&[;+J59=3[R#&5YX#7PK!!1*0M11UUC!,X`4,"N32=6%SU28:`!
M#S`%!S!P'G"'$,``IYR4`%H&5Q#I)14&$O``-N`'>4#>=ZBC"H4`*3`%#Z`&
M\C`.`0#G3'7O/`]3!4#G!8?PUVCP"T7T10]1XXCT"Q#_]6Z%FE20`TZ_4`!@
M!`>@W,=N!Q``!"EP!61``GHP[0>PP@M5SQ9``D)`!=<.WG,``737[IJO4'"'
M!WT@!#">`S<@NQHU!FQNVSLOXS$%`&,@!OUN;,.^OIX548*_"A(%^`65S6<&
MU0]0!-"-TBYPZJYE!@1``ALG`WTP`05`X5DL`@U`!=R^!,$]40`<``YPARR0
M_0ZX`UJ`!&@_^Q'P?T-^J!(UXV].53O@`O-<<!<%"'Z"@F$6:(.(B'^+C(V.
MCY"1DI.4E9:7F)F:FYR=GI^@D8FC`62C?F2'IZNLK:ZOJV<!%50Y#P$'(5NP
MO+QF#`0M9WX7-BMF8:XT21!F_SU78\.]@F`A#V=W?M(B1HDL##9[5P]EIQ:N
M%FVMY].K;#%3"V95+.WV][QDIH,6^ZVA``,*'$BPH,&#!UVA&8.OH4->A18$
M4R*'A8.'O108<4%@P9,5`E8LD,:*QH8*"VX\L%"N78H0%39X\),`2`=!.C`8
M,7`D@X8*#Q8PH))@%3M6Z=8]9+.C2AH_9K2-T8``HU5[+?V,B?H*H=>O8,.*
M'9O0U8.K:!T".!--4)H'#)Z@T*8@[:@4!TRAL6!#`KE7#K0\@"&$@+]I-0B,
M\$."AZ`/TM+,*`#E"(,65P@0>+'@"@5SZ*HB=5@@RIAD?H`,*C,B"1N[L%F1
M80B+K/_MV[ASZR;X*H":06&RQAXN2(8A1&6VA"&SP,6(%KM@>P$"YK6?.D`(
M/'4UX8@5$!N6,(@`IQT)*F,N\(!,!TD3$C>TQ9"0HT4$$R$LG"%3(<"+!T]\
MALA11HEF%#YLB!&%*H*`D`@9]!!'7!D/H-;5;AAFJ.&&N+U2!FU^+&"AA':Q
MH,%VR$6GS5L,3$$"6@KD,(!U?M2P0@`CGD(#"?T]L\`;1)!!@``%P))!?@,$
M((`?+GCPA1\`]-%'$5]8%L(.$%2051AF7''##@0@490@!)JCSFCVQ`#%;XDX
MF`B7&GQ`8EIH]-<+AWCFJ>>>G,!2@2`!,#CG512,@.,IR8W_(DL%5P!A(#Y&
M_"7("5/H]\H&5UC`@10/<````'`H$(49!(!``RMP=,%`#EZD84"1:-#P!@XQ
M?"!`%0M4$$-(*")RQ@)4'&$$`3>\5N8H2:'92Q@!<#6*FXJ.T>N@^!2"ACZ\
M\*GMMMSJ"<L8:)0Q+;4.(6&$H(EXX-@J:`0`#A:CE'&%$A.TLM\@",`DW"H.
M2%$!!P(0`(4?/100@!]E7.!'"A9<L<$I`31S!@!1^!$&'SM\-H,?#DR@!`$-
M"+'"::U0^`,+#;]P;"(6/(IL+Q/$0`9)SY9\!A[DXM,/H.BNTNW/0`<M%BQJ
M')PS1C)HP"8K9>P;;P40N!!`"A8+_]'";"YP,(H">R2BPQ7.LA(S%6:<%`4%
M1_A1@@-7^,'!$2]FT$,%1`[B00C""#)!``8`P`$26=2H!`LAK,"#!<?!PA\(
M/$`=FE*OL#$$$.6U$O8J)\PQT]&\;(7(8:P(+?KHI'_"RUF<XX.&/+`T#4L:
M59@QPA(B#;(7%`K[$:,$=0RBQ@,DNW+2&"=HL>H*$'@Q2)%^8'#P"T58@,02
M('APP`\-:""!@T+$L+P@"$AA@QI+M+`T1&94<$,58B+E,B(D$/`*&E$X?<KE
MK!#10(ZI/PCB-*4+H``'^`A8_*IG_6N%`P:0!YJ5S`00L4$0M/"6*T!0$&IH
MP0)>((&E4?\J<:V@@!0L8()<J6$!-MB!!D""`9OXH0,5RUT&$)`#Y%U!`>7X
MP*DH,),=("`-#BA,$6J(OUZ<P0)4",$5<C`FEKW/#]6P@(I.T2YD^,*("R"#
M`1*8"`KQKS8$#*,8A>8A,Y"AB%Q,1`$&(`7[,6V*K/A`?LA@@3LXX`R".@D!
MF+!%.$2@`N=;Q0?\M0,B$,!99:A`"#00`AO,0`6G*M(+!$$#$#!``Q!DPP<>
MY@><I2`'?C``$YI!AY$Y\!Z)M``#5E`L)R9"#OKR0P!&L#E?&6$'IVQ%VJ91
M!A#088M<K-,749'+08SQF,CDDRO"L`"+H2Z-J_!`!4#7.CBN0BC_]?"#&J@P
M24$H0`+18,L*B'",82)"#(<DP<CXEX8A_0!J-7#`"D10ERPLX0$7"$.1"K"`
M$_@A#7)P6P9`0``)$,`&+$$+&1C@&R0RCTQG$L0<-.,K"W3A5(*8`1-HU`MH
M3:,.9TN@M5C!S'\D\Z0HW8TK`B6(D4!S%,RRHCT\T$UTZ,`"2JB<&7"T@P,(
MIPP6"$%$5\&"*HQA`R-$("%F,0,SM*`(#G@#$I3``"9@0&V"*(IC[C8!"02A
M`D4(@&'0@@$)6$H09+C%F)+%HP-`X9FKD<(&6)`7?%"S%P(@PD-SMK-6J&%<
MQDRI8`<;EI(YBPR`3>`:E5#,M"QN"$,J_](1*C""BXR"#"L0`C`3(4(+O"``
M5P@DNX+*@C%4H`':J<,%Y(0`!,2!#@/S0PP,4)@TV*&<5[G``;0$TRX5*QU'
MH@(4EG!78A"@`AM+'1I&H-F<>>X5P1L%8:=+7=ZPXG]G@"L7V4`'+;BQ%ZXS
MX!A:H(-A32$'8:!!#&X`@-ZNX`B;3<``"$`'((#-G*=00P4T`($`=``93&C0
M":!:%S_$X49B<(%+K6*`)JP@L8+X%17V:X40$.!0HZ#M",X0AC&,X*KV0.,T
MU!"".%!K-A#YGR*JR^(6]VD59MA7A=+XCBG("2-ET!IX'["$/'2F!J\I@`6.
MT-Y$_&H%<4A`#O\(8(0CF-(>F*("B`%`@T,,0`$OP,,)^O"3"LC`!EF2`(@=
M8H`AK%,9(("`!::0J6)RP`7"66YQ+6<5+HF(1%[L11I$ZP<7^_G/E(@%_M(P
MYT'Q$\,XMF8K6+"`Q.2`!0^00)&X%`++=A$N"TC!6[_+"A$@`0)E,,.3&O#0
M-@AA`ODT;1DXDH,W=,`(#.#D*1R0`UF?`@,K4:JOJF`!&"B!MZ>0!1K_6N0K
M7D78Q!%F.Z(;6$`[^]FK8':$FYFZ2FJ@L:A4=+"E18@G+"$&(*#>J<XP!_:>
M(@TK((`.[%'))9A!:P60ZAF$`*7V<B`!56B!&0Z,HP#`P"((6,`#2I#_B`DD
MP0J[E8*`$)$`(H06,'>@@@S"G5@5$$$`^/4#"HRP<%>(&!^L&0)L1MH.-.#O
MV2@'-*(2.^.<J5=2:4F4*S+0!0P#P`@/;HX)9F$J/Q0@"2:&:0"0/(WAX:&F
M7KBQ'Q!0#R2,C`-!.&L&1""((B`LTG/QPTD.$`8'X""1>;BQ`6X`ME<L8PFU
MAL8PMQ`!78^B!O1^Q<<;0@8!^!,M?;5'`!R8\KZW&#2K*$7..!`"'<-&YJR(
MPP8P"H`;!`'#%)(`REJ@XX7D\HA3X,.E0N""0V0@!SYX`PW"0/`S^6`*(1C"
M`1@`@@SL8&-#>(T(]$#O'@A)``\(P2$FT`93_QR!5`&P45M:L:,*C.%K(+S*
MA_B,B+F_5"O.)ZF*_4[]Z5[VNPNA%@J@(.V8:QMAPM'#$LZ*"'1#@0,5D+3%
M`A#24>C7!I7+L`0J@`0":&T''*"!`<"P0#\,`(8,L`-490&_D#91H`)"T$PI
M0`)%X@%G<"(UH!H[\`)95Q42P``)Y0IRD"DD,'_,QP*+X1!D``5OP`K1YQ!T
M]1`HYA`QMF+5]X(GI2AF,2<T4`0+X'96@7B(D`$#X"QA8#7,MWX54`)F(&[:
M``5`4&S-UP+>DP@R\`-$D`"M5Q08`$I:YP?E\017,``_,`5C\#L1L`,,4`5)
MD`$G("!T<!,9T`$JX/\'-%`Q3R!??I`!!T`$T_0*$V`$5#`$9/`#:$1;`H!M
MO4`"1Z!TS3<G99!"(-=R#M$K,/B(R*1W06@5:!`!A886.L@Q8Q`\`#`'^A8Y
M[C(",#`&#B,(9;``]M-A4Q!TF"(,?;,P&5`D".`#++`D>C`%4D`""P!"F)4#
M4'<`%_`"5P4`,N`'=M`#X%,.S;0D.<``,E42,>!NSS!\H]`#`L!I]J``0A``
MO7.(@Y(&`N`#)5<!&7</D'B.8805*H86+-`LY:A\*A(&1P`%#$("0=!]B<`&
M-^`"8Z!.!44"%B`!+;%3V90(>X&+#Y!-1W`!`F`"*(",'%`""/`"G'(#2P#_
M2$('`51@!Q``!%"@`#5!#"\2(D]2%6:V8*UP$@M0`B/D1C.`!;ES>%,0`S1R
M@E?!`48@CK#@`)T7&^CXDP'4?._X)W:!`-PGB':1*!,``C_@0?F!C7[``E1@
M`6]@0E`Q3G20?E?580IW"OQQ!5408`,@""]@`$[``F?0`0=``#$`!%;PC(IB
M`160!%3``$K@`&WH!\I3=7Z@`T$`<ZP@0@\0`W]47#X0#G.2!C9`DU!Q-#2`
M!`=@::L``%-PB?8@#4"9F:(#'$8#73C8#C%@`U!Y>%O@`%,@4P8P?Y;)!K^V
M`PUP#(C082M0`V:P`NOF!V@@!5;76P0`2A'@("#`_P83\`(R``%L!`'46#(0
MX(QED)<SD`%^(`&Z@UH0-@@>HQTUX(Q?I(TH22+,$@)<DCK;5%.G$`$VV0O4
MIIGJ^3.#8`9(B4&=^1"$8YG#40;L0Q(SX`)P>0IL@`</8`;G@8][(0&C.'""
M0`%F0)Z#P!93T`47P0%L``)3,`4>$`4P!P!DT'&(0`%58`,DT`9\$`9;=`'E
M<`$Z(#7E>!(!<`*X4@%`T$2K@8J<\RL64"^(L`.CB1$[E4M"L(Y600;EL)Y"
MJBV#X*.LH%WW<`%/H`/O"!L3@`-G(`%8T%XO$`+=253\R`-0D'Q>>05$\`98
M]T(9H`0(1"$6\`$O<`!!$/\"06`%AV&/IC4`>_4!"[`"+%``%9H#0M`$?O`&
M)_!!2)D"([0I$&!U!T`JK>0'/G``U2DA=?`!:K"8KQ$'7F@!46"(PY$!2/!_
MB-`#C&@7##&DHIHGP#$--]@0"$`$4?">L;$!4V!99$`"U@"5&?!6S'&'L,`E
M04`$=*`8#'`%,=`%`Z"A:$4`$+``0-`,%G(DQ\$E%4`'8R(%#&`"2*`!9<`"
M!N`%",`#*3!_4#E(%?`"A@0"(B`"'U`$12``0;"'"X!H.1,S"U!@9C``E:(*
M0A(!>0D;#K!Z5$`'4IH,'K`"37H/:G`&HWJP&F)7YPD<3=`".3IR\H`:(M`%
M8^7_"FV@`<1"1`,K"!=`.Q<6!OHE`34@!5_$):N4=0L#!1CI*V-`+&Q@`3>@
M&(%C!`<P!@X0!(?T"@D@5@U0!`1@`;N5!1E`!*CF<TH``2W0-3/Z`RCB`(7Y
M)F8``7.@A!@!`,F*#/PA#U*@!E?PF1B!L&"K&]6"I*^``E'0J!*2!M3((_MY
M"NAG!BASI;`@0AA(,V9`!3U78$86D/[4`_HY3!3R!`,0`O'S+TB0`C$`/"EJ
M5"<@K3Q4`QX0!@F0`:+B`QI0!4JPED]$'%R":#7PG\-$HU1C%2=@`2C))0]0
M!!5@`3=!(F'[NK;Q3_<@MZQP`5T0!QN;%GR0@7.8'TC)_P)FM0<:`)B\D`!(
MP``K^R:DN`$<`"Z(L@+0@)1DL`0A0`4M\`940`51P*6GT%D\@`0Q`9U+L@$)
MD`1^L`=&,`-?X`%9,@(/^Q!U<`,H22FTFPA$P``X\!#["FR)@``0,)LQ`$02
M`KL$'!:R<`]D`"^P<`0;UC^NBB)M<`?\RPI&&1-,L`+TF0@)X+,YVPI[,0(;
ML`!Q-PA'0KRMP"4$\`#IEKRL(%\5L`-+5C&"@`'K]@5A$`0-@`=1T`,<.0`]
M``%>NQ3PL#1R$`$F/`J#%!3OFP@`8`=6`&%(,`84H@$9T)94BQ8!4,!:?!!I
MP*I&1@4>\H7]\P&&(K%/H!VO0/];[Z6Q[:"/!,``^.B5Z5<#,NH'10`!&6QD
M-J"=KK"S5]!DZ08#-F`#!0`'4!`&88``0"`!AW`#(S,`:N;%#;$'L3,(^UJQ
MK6`P]$4$02#)@V"U-V).B8L:F!4%6/`#Q0@;8``&6]S*`F&DL/``0Y4('/")
MJ6,`3R`%#`)9[KH*?3`DZD1^O?`!=<F]RU2;1I`&%0"0%2`%`=4.>``!\N,*
M+T``8R`#5``!:J`&10),])8#S7Q5^1(,$SP<"`!.%B(&RCH_5=4#*R`!GCPI
MXX=M92"PL1FU0F`&36(7?]`%KOS/G_`%>3P*:;`#I]!P3Y"[:+$!0,`@*'``
MQ@QC5@#_:GY@!",)"PG`!`]0`020O_8``%2U?A!0`&E@!4E@HZ_`HB.Q,I:L
M!)X5``]P`!CU`D4"`S/@1[]!`\46!A%`>1+"%&G`("=@5JS*+$M@!4U3!4H[
M#7*)J:-`IC"U>FX8`V)PQ0WQ!P'`!0"]U9K0R]/P*XE@`#H0`4N,%O,&G8+@
M`!(\B;&P`"$`G6D`!:/+"OH(-CNP!%-,K*P``'1`-@^@`_5B`1H``A<P"[9V
M"BI@Q"W!TL9+`#M`=D80'("2!!V@`$<0`T/P!`J@&B!0FE*```EP1#^PU&E1
MA7OI!XE=S@9D`0IG9Z<-"RQ1`1$P9FE<'V9P%`4`!&7M,U^P_P5<_=N6T`4/
MP8@U8`,#;1<[A1IGM[!=I$ART&$:\,SY*)4+("<9,,U"(J>O0`)+T!86,`:L
M=`Z_0P<78`$_<-AI/0=!T"O'XL9&$`/9#$H7X$^26P`.P`</(`044#%/\0$9
M4((\\`2R%#&KBA8Q]<GJC;9^M5^0(0$-$'^(8!)V4&SLT$Y$T(VML`5G5B9J
MZ]$.L0C^#-PB#@E@\'V\('B-V[:#LK-M1$D@8`7)N0I4YPKM1"1HH`5U,PA[
M0`57,`=2(`@W<!0H_**K(`<6`',6$`%TH$J#0`9SP`'Z)05*U\3]E2,$PA0*
M%@<_P``U2P!)E@!XT`'%_0,_G@&8&_\#^H0$:E,7HRL"*E";K/(07A`%"P;*
M7IV/>P5C%Y8`JY8#>NLV+?#=03"20CYT-X#AB9`%",4@Q\(L51#$/H/57C#B
ME,X(6?T0]`,$,4XN&/`$#^4`O`:5%V!0AD=2`6`%6J,&53`3;#`'#"`$.\`%
MEEPFOW(%TBT(`(!:H$.`I?(#B3`$Z$4JIH``")5+N)TK/(`%AJ%?&E`"1WX`
M+]`'L8/(J'7D#'!&:(WK?!,?LC0"]M<0/#``*$WL$;VA(V`XK]!A5U`/::`%
M54$#LV`*8[`%00`%7D#K2(2IN(RK_,`N6B!R^+`(O5WIE9[%#O$.#`#I=@&R
M,^X'>4@%EDG_6U<0`&,0D$X=EV\=!D7P`A40!`5``G/`!Q1``D"PBXA"-\Q#
M`F_)/^?080P0+6K081?Y7>?`76"U`Q7PC$[5`'@3!%)P!D9`!E9@!!O@`H.#
M.!W'!AT``"4X!SO2`/&PN:R`1ZW+,?7!UC0!O@&PBU$`X:/5VD,0`U"8`#!P
M`S0P!R"`6=.<"/H5A8*P`_K&\GXEQ>:X"%E,\"(^\`V1!5I`!K[!.3L[?)6T
MSJZP`\=`!U.P`CE0`B@QR_E5`4HPE6?0!FF@`/60`7(2!RS]3TL@!%9:3$?!
MTF00`<Z^N>T%L_UQ'G(;!JNW!",0!$=@`PN`!%,9:F!E`1`@`$B`_P&T5O64
M;_E^<`-TX_6QH`0R!0!8$`3.-P%?8P3";P5`$`/V(9FKP!]Y,`ZB`0`Z<`$9
M4!1`0+:"T"4YX(6@+W=*,-?98O=:C?>_+0:3?@\L:D5E\./D4@<@T.*"H))(
M&0<H`0@D-A9E80$K,4TK.09^CH^0;1H5A0E^,VQOD'X6FYMA#S.>D)V.%@ZC
M?F%J2S*>"4`$%BT6>PN4J3(_9A80(!5#`P1DCV%C$`M&%1I-"46JEIB:JF:+
MC:E>`R-GCR1+8]RICFPW*V-O#Q9HQDLU0E9V`.)^'R,M,T=]?@A^%%]H<$S-
M"U-A6JI2\_R<Z;(`34)(?R*"`1.QHL6+&/\S:MS(L:/'CR!#BAQ)LJ3)DRA3
M_@D0\:$G-&G".2)0QZ7->6QB7"'F:(.4!V4>^ICR(,Z!"CP=G;$0Y,:8%4>N
M03HC8$4:1QU\^&'QB&>!%@DM>)B'D$P0.ZA&63@ADYRY,V0(A"!P=12:'#'"
M.")3`0(#,WHWH;'@HL8(`G38^,FZM:O2IST\*<CA(J@C$B$(/=Q#Q4*1*!74
M0!J\A,Z8)3'D;<)P8!@'2";\),C@B,.,*V'YB4/XL`R0(P5<6F2ILKCQX\B3
M*U_.W/A-/R\66(:D9,/SZX\*#`@0>,(1*TGG%4$:9P7@46I:""EC`8KNVB[&
M1%8`*8"?`B\2?"'_\H-`V+&[3;7`%">HU08:"Y3@P!-`%1/`$B1X`D`-P'T2
MTSQJ_`!%%Q8H$9PC]N&G7QROF?'``3*Q5I<?`!C10GBI)&#B#CI<848J9+A@
M!`</1.`%)!LL849L5[&AVCX@^!'##!7X1]9[:EU'00XI/&31%LUEJ>667';I
MY7$VZ:'%BINH\01V+B$0!1$(S*&!3!M4P-U#.ZP0P`93+"!3*F:T<,0-ZAF`
M`12>%9"$'P,X$D$8EH2100X56!`"6&0!>-`F05;@XR86\).`"PQ$,,I2(<CQ
MB`Q5H("F(V&840$=$2R!Q`*,JI+!#K%%X$`31I"QR`<'"!"8'R18<1Y._S?8
M^`(58PP[2JM4X!%#$',`T(<4%IC*@0-V^`%'DB2\<($?'EAA01>X/4D6FC54
M4:4X7\8K[[STUIO<0W!$,*<XE*XZBA=1K$#&#PQ(<,T&@^R9R@E36,#!`0VZ
M9,P*8N0!P0JB52F/`!TX0`0.KMPQEPTY!.'D;I9&20H$0$R+1%J<(,`!`6:<
M888$&(Q21@5WO`#%C?X^<L88#`PA!`1WA%Q&"A+X<<$'%/#@AP-+,(#$-22X
MH.=#+%"Q`!D+:.;2T$L,H00$E-2\3P+R`#""'T\H(,`!$$CQA!45A-7&NFB>
ML8``\-HK^."$%^XEEBV)T\$`$CB4D'1!0V)`#O_FH0&&!",\5804N"3DP20D
M*#$,=B=`0/,98,@`N!]L\.&'"3MX8(0`2QA!=PL%\*96RI[H;H$0"RRQ@QD0
MQ!.S!8O\>(8474#Y2!H$'/!AY(ZPM\(!"[3`P3-%!#>N`1GP<(8:.2S05`@1
MS[.'!`_T`!J,+KUA>AI2^U&#'P'LX`@.'_@1PME.(`(#+)``W?7.>9P*6AD4
M]@C#.?"!$(Q@2(CS!W&\P`6B<0D9<D`]/Z1@!0MP!0<RD(!<T<PE1*#+"R"P
MK^?X`(0B)&%LIG:C,-"`!1`8`QI<8`$R/,`%#_@/WQZAA@I$@4<_\(`%EG"!
M3CT@`\<0A1_*T`+]/>+_!AU0Q1@(8)T.[H4`3Z!"!:8PO0&("0!=8(,"KJ*!
MT26$#4@8Q@P@<*SG;&`%6M`"&M5XE03P1`H9>`$#`A`#"%B@B$3)S1"#MH$"
M060X$HRD)"<YKR\@KH*>0$`7@&:3,%`A<G`(6PTFEP(<R&,./VC60W@PA3&4
M8`068.!#$$"H45+)E'Z@C2.^T`<1P%)U/\B@'^(BQ`!]P@Q4,`$9X#$S`JQ`
M`PP0`A\LL`#=I"$**"C#`;CRB,%HP%1>;%4%MF<R&CC@"'[@0`=,`()=+:&%
MXN!`"P+PAA!L[3H?^`DZU<E.!^@2G"F(@`7L,(+.^0%ZBC0F]7*@!!$TT")8
M_Z"D1"=*T>-LX0L5\40&EC##YU0S:&9@0`R*P`8#E*`?V'+</$Z`K8<9]"8&
M$,(5$G6#DIYT:NA\`0DN<!2SF:=WQ;S4J!9`A2V8@0`/`$($7I2&1<R@!0+@
M1AD(0`!=EJD"`I@>]?SF`A($`*N+^@`,#KJ$6'*M,V580/INDH"OJN$$!PB#
M6/UP@H!`!P<.N$(%M@`$*Y!)(.I2*/4*^="*@"$+%4VL8A?+$<1F=!-E`(%M
MKD.&OUXG`""XQ09R0($!A.8A#HA`!4B`!;]BQP!',,\`]K8#-N1@`K1I'8MR
M0``CU.`*X%`9RA;IB3(\0`HM@-2QC!&$&50#"@O`0O\:1M"$(T'"#$L`@58C
MMS,HL,`"%8`!`I)PE.F(HPVW(`'EX/>0.A"A=HY(P`!H@(`2(*`&<`A.!Z!@
M!2:<%YZ/,""G$$B*#EY``@&PCR,NX@4Q,/;`"$9P;Y/D!S4(\R%G""*:$*"!
M+2X@!BLP71U3P:T@"`$(.7263<I#``ET00ZB>.\-!J`$KC0@#E=80!I<0(`E
M6#6!E>+M*.)RS]%4H04M>$H$@F(`&J1B:`0`@6*HEP$;6+@)%6@!72#,!*CD
M@(4B?HA;M'"#(Q3A`2SH00(,(`<)@&`.`J##$I30@R8]`)Q`)<O>!#OA`TB!
M&YS$"$83S.<^4W+!7?F!5ES_\H`LOW$'>0A*JQA`@-PF1`_F*,,@5'J3,$3@
M`1N@0!C*T``.K("T^^A``B@@@1(3H`(,F`'T;J#;@_`.QZN2PP.^^@0UA&`*
M,BG#N'IK`2DXU%\QC:HJ`@`!*Z@R(3,;0PH:)LN$)&`$5WC;?7(6!`\H(0HD
MF`$`,A"$T2JA`D'@P%'O%^?=S%FHJ]I`91XAAL+Z^=WPEB"@BV$&73TD#>05
M!PN`8-=^*$%L\X!#%"Q``B-`8%(O>$Y,"1``.(3@``>8`"HXH`($Q$`*'CCJ
M$-(@I##XS08<"``5X@!K5^O8)@40P+[Z%`4R!$HA3R""H0<FA.G:9`8@&%8&
M)*"._X=<@%!J$$(%I#"%L;*5".!1PA,*@`<H5$$%%S"G'HB%!"O$H`5"\L-@
MJK"',80@0OT-++JO@X(H<-(16W!WO-?.]B]EP;&)@T1D/7&&`SP!9D.U"857
ME(`XYAL2#@A`$&+0UR84H`,70&H67%(>)*1`!*RF`!O@8``[,,``9>B!Z##;
M@AY/L0)*X(`%IF`I_9+BU6&_#A*@H+`S2&#PU8A!(\H0@:AXHE5)-K)-6""%
M^OE!!$_X;$+.\(1[4"X-D"_#%6QPXU2XA0'CV@,&4M`#&G2`!E6J``B`\!<G
M5.#8CBBB`&0@J7=Q(J%C[R04GI#EM`^8P&V/O_R1<UB+>/_"`SI(11FJ<`3G
M;J+0#Q$!$1`.$W`#-&-HD```=D!'-;`$!(`'!1``24`#M:8I/Y(*8-`P/B`"
M-``"&"`$2/`%'I`%"F`J4W`%$-`#%K!6D)`&5G`',5`!![`WII=?J)=?UX$@
MW@4;[!$"T;$"4I0`(.!^F^`W5_`:"2$"(;`O!0`"'9<0DV,>6[`"(X`!'?B!
M2*`,2H!WF[`#7H,&KD,;;\`'$3B!9U($!``!+X`M._@(T#4`OY!5YR=G)X<A
M.I0*'841]3=_?-B'(Q%1]@=9;=B"/S!UG@!B%0!GJ:!2+T``GI<*>K`$"_`"
MZ=``:L`")F`"*G`HCF!P2C`!FP#_!S8P=%/D`3?``V60*#N``XY0`!(P3@_@
M1N)@"!!P`T?U;T'5:@E!`4?0;-43%'QQ`"3P`"&@`HYP`5'`7[[E`OTSBS(Q
M`XWFBX_@:6,`8Q"`!F5@BJBHBC!@!E:0*)MP`0\@4G[`!ZJR!6]PB9G8`4G@
M`"NH!GKU=ZRR1;;(<#5H"N>FB_.@`V0@C7EV$6_GAP(YD!M!07'W"&4PB)!@
M"''U"!A`36I@!51@!/Z7`1UU'PRBD)"@`DKP`!R`!1!P!0X@!/VS`RF@!E(@
M`?<C!$8P!C_@>QBF!'Z@="EP`C()!S'P`F^P!)NT!%<0!W*"@"]A`1'@`423
MB^4V#P5P_P1XX'^]91FML@(]P!=ST`A#(W.CP'$@H'O=X'M3<P``]UU@&700
MT``T:9/>DI,[V049,"``P@:_0`8((`27``(C,)(EF0(DT`(,4`4R8"Q""5D=
M@@,+P`#HIX^C@`%&T$7S\(\6P06`2)"229"1>9#5PTW#IQ<7<`>=4P%MX(T]
M(`\4)F"R00<58%D2@@5!D`;%L@(O("FN@``#8`#6@0:6T`<%`@(6$`4[,`4N
M\`5MH'M;P`?<L`,H0`<J(`,,,`8G`$O2F`I%I`0"0'J[-0HQU2_B0`9WN$K>
M]7$L<`@D-T50,(B&4`$;8&0>,`+/T(HYL`3RZ`@Q)3!U8@5%0/\%$G`!PUF<
MQZD"`$`!CM"1!Z`#4!4&'4`$!F!79?`!L3D`.S!(6*`US[EC6'4`(6!^!Q0C
M7_409H!??*)V$5&9DQFB\P>B\_80!J`(9!(`K^$W%7`$]T0.#!>8+.(-`3`$
M$&H&5R`$#;`$=[`'2G%324(!0.`'/@`!5>`X8)!%?J``._`!0U`]L$0"KZB1
M+N&-P&4!S6<*KX9:+0`83ND(--`#8_!@";$%;>A;$O":-@`@:3`&F#D5LQ!@
M@=&!!PB%&&8&.F`.:'!41(`'*T`$3?JD?E`')1`<+*`_-V!(9Z!527$&)""D
M56`!-?`#+/@<XD1?4."?%[H)YF4C)?#_I:H``F-`I9O@F)`DHJ@J?P:)27+'
M8`FQ!W8B8F&@%P9`!RLH!?[9-6:5$-Y@`6"P@M-A#`R0`\J`!!<P!PEG`CX:
M`WAP%.6@`#IP`HX$`"(P=7*``:_X!`-@%1W$#GYQ!UPH%IM0'O<T!3E0$Y#`
M`7:0`3*Z"5N`@-!S!R10`2%`&X8P!8/V".=T"SCC!QL08Q%*KC(P"-/A-RM0
M!-70!(OG!T8``G"@`$9``859`G0)`D/@`+CJ4/*0C5I0`3*0![(8-$;(``P@
MAZ0`)6ZA2FKP`#L`BI`0!R!`:2Y!;GZ0$2":JCCK9R0*6:[:F`S0`$NV"13@
M`D`#/0\@?`,Q_PD?.65#20501``GL#=@0``&``4$H`0F0`,[4`?<8`/T$06Q
M@0`!4%MB8`[M:A,3(%IDT"H00(2<8"EA\!,GXPAIT`*Z1`,"@(37X;:W1VQ\
M<%1TJ1`6P(G^2@49=%054*FW]Q,;,+;DY5L6D`+((WDTD`!<P`:,AHMT"0<9
MD#,;T`!^,`9@(`P2H`,Q&DY0$!J&0``W90KOD0`/4`5SVRHMD!8)$`&J@AU$
M:+,YV[OOMK.0@`%ZVYAX$``MD'#%0`3"LI`/X@KB```[0+0T&I@#,P!Q='<[
MH`>M=`9<H087,`%#FJ2+00(;4`5C<`.P)+.,](1*80%KJJ5^8`!,4/\!>=!*
M?3L`1:`!I"H.CC0/I,("8S`%79169K)AQG`%C&F=WI<&Y;%AGL`7>5`#0:`!
M1E`$',`L88``;7`"1O8,(*``;*`_>/!])V`N$7H3T7MV6P=.%K`W"4`$5W``
M\T1W2@`$1!`%)SP*AEBS&'&SOOO#B06\Q7"V:-`C>K""61!3&J"^[6L!7S`*
MWC`&>Y`9)RQ..;`#2*4937`#)\`#4)(&7_`&L%1/5T"FC/0#CU@]H.>.'E`>
MF!.6Z=HP`8"NV#&K+K$S=R!ZS.<`2C`&3-"_HV$!$M",XVHG'&`#:?PLU1`!
MVWH%OGH-%,`$"!"MD/`%#_``?_-2D1/%AB;_?KF#`,DB*3WG"3DQ>FD`JA#F
MH7_0!4#<RHLEQ+]X$[XR`";`:'C0&T.GJ1Z4&3W`F?M;A!)0-4%$!V<'GX[P
M`6-+!PU``$)PMBY!`3]!JBY(`$'0`B&`%*GP`1)P'FHP!3$0M#>1D#?AC3F`
M!PP``6"W;_T&"?!X`#GC"$-A`3+`/K\\%5.`-AK0`1HP=3D0&9"@`!@@`,#P
M!`S@!%ZTRW#L"="U`DOP`%.`M)OPFG61!@]@QE6JRC[LRAH=005V$;W%MPD1
M!E.PG$FP`DJPSGQ"``/``ZD;#"=T'0``8H"1<'#@`2I@`&B0!Z;R!'70`,/J
M!.;`%&`7-,@<LAS6_QI"(`5T!*^/R`LY_`@O4,^.(`(KP`!/D`-6(`"HX'H'
MH*0+60U$P`*C2`)WP+0*=V7<$0-^P`.WF0+<@`5SX(I7NP`YA%T)O"I?(-#O
MJ1"W,``A\%//(J?,FP/.[(88O=&(+4D!&8BM^AQF,`=+80,IL$5>F0K"*@&L
M`'XW<0)>LR<C0`)JH`)AD!_T((D20`LK:@(5P'X+0P5/(!6>L`%8MDIV<D>)
MO!60$]BH*0YF6FFCNG5E\!0`TLV#.#0,H`0\$*O8P0(M``5QD+NG$@(`D'`7
M@`7?8+P6`#@T(`,5,``(R`(KT`"H/`-_(:-L\`+FT8B:_0AL`#;--C1L,__.
MAYW8]/U`7.`%'LVS-K$!N>T'.7#<TY2,#S$8#.#/SQ%:#1*>CM`'%W@5LOD`
M,9!"Q)`D'<"*3<4(&QD!@]0G5@0)T+RK*]4P'@`Q"JD'4;#;F^`#K>42O?T0
M`-"F,O$$$/`$)$"4J!`&,@`$%PA9XSB\-N$W!,>*Z829-``&:/=+VZK6CB"\
M?D`$5``$SM4&0.>-0_T(&6!/$=HUTA$V"AD#F/T087`$R*NA\UW?9AY!)2H.
M)"``2?%S0%$-<Z#:$8#2Z(%5-I<*"F@%;^,`,^``*;`#FD!N8<`#AR$!!F@&
M(C`LH.P'.1<%Q<4BJID&:(`%.!`#W\83%)`'FCS_"J%5$*7U=R^0!H4-!SG@
MO//0XL][`T@P'?E$"-Z8!#7P@J@0PCT+"7%!!'0,A55&#(N>)"H``GIPH&"0
M<A#P`,N<`QB0<%IE!&<0!4N@"=<9N&%0RS\`=F6FN)L@">TC!"\B#C>`XJ/`
M`;?]7&5^YN9>.&D.Q83<!D\@,,5P&FD@!(N`RJSB*@%PYX\0TRM``!>`"@F`
M!C.@/Q&``$V0`VPP`(/45`SP21UP(UOP`N]2('G[`#^P`E;`%2!``@K@`'S`
M`1!@`P)@UN*P*T&0!"#&H2SB+ZV"\H^`ZJD0`[_F!RB@MD(S!A70`U<&Y5K7
MWU^]`D"0ZYXP.1"P*`\?__%^H-58D`(L$`00H`PD"P)\@`%S`#>.H`$%X.]Q
ML((0\`,I4/!$N@-M`+E/8-2C@@0K<`.4X\".0.\A'0"(WICE?NYR[R5<D-^-
MG0II\&!'L-1#N01B&@07>61;5.60<`)EQ0-$H/1^$`$LX`%!I,%2[\A10`4,
M$`0[4`%0T`%OHP0MLM8'X`=Y``(J0`(<4`@>!`7'Z`<]L)SMFJAC$"0@7JHV
M4-BC,@:?F`HN_]649@1U*IA7\`:W`"`Y8N`"L@)W_0C)O0`7L/F=SP.?'_HJ
ML/H$8`*@@A3TZK("X`4(D/A2P_@>L`)G`/F6T0"J8GDL#PE)P$)O`$*RE+;W
MZ/\2:-``@3L*IEH1&3WW^+\<L#Q%M0X(?GYQ%F6"?A@6"V>'C8=J+4(<%E%P
MCI=^919*!8UA1BXY-!PQ)VE^2!,QC``)3Q4].A5I80$M'&9!"VQ1?@)^/B1^
M`WX3;'X>*6%^'WT^`0L6:)B."%$6'`T5AI@H$6;4X>%P=CO'CEO<C0!`4(R"
M&55C[]1D5G8<#TH.?F%F$1TPE:D0($$C%4A<&%+!P4^O7\%0%7CR@,4=`F3"
MC'EPA,"#&WZVC"IU*M4J/P#ZS0B8@$0("_3"79!0J,L#=8[*:"`CKJ<C-#G>
M8`(GZ(_1HTB3*EW*M*G3IU"C2IU*M:K5JUBS:MUJ%$O_TDME0#CR(>64(`0'
MMOD4$:&""SHQ5N0PX)/,D@$%`-BQ8J8`.`1<:.0Y1)>-C14K=$`(L$P0&@M0
MJ$AP(?8-"\)^BGQ`\H*""3\<;DBHH,:G@X0D@%@Q>ZD`"#.-?<H6Y&7`Y4;I
M',FP4%K0!RDW32^HL,2$$RM`4IX9P]I1F@HYZAC(L2)-#T%04OCIX\>R(`!F
MEDQY$@3V(4TC]"QH0<0/8,&8_3R1<\!`!!6O<%([D[8$=9Z8I#`'+;,52$(4
M%#A"E!]<->C@@Q!&*.&$%#KH%5)@B27(!0<P)H@!0E3G4P$-+`$""`0LL$0,
M9JPP1TKB^$/`$DHT]D$&?H``_Z,?0@1Q0Q!0@'$%3)BH4<$(A$!QVPU2-#",
M(&\88$<)`RQAGCAZ\47"$F/$Y@D(>-!5X)C^:/#%(;D)PL$""R80`$:F'1!$
M#*I9`$L`2Z0Q0282Z'A)+8@AL<P%A]3@!P]]I,2&`"F2L,(BF)!1000]/!"!
M''X*TJ,?'8B!C!P+$-`<-08P45T<*WAX"3EOG#/F;&<L@-<A"U9HZZVXYJKK
MKA9^E9-8#BA!I!\&Q*5J.#2@&(`)5T"J20@O+!"$,#W%ZL(,)&QA`(Q;M%',
M'@]8(`0!I/74HA`C,.`!2K3RM,4$(#`P3T\`;,F<"])0$X,-T[SJ[QF*>!&2
M(11(T?^E('4`0<"5X;`#`1-Q<,G(0%)L8.<&@J1!!;6.`/S`!C,8TDLG?HC@
M!`<N5&&"!,&%XP\$34C!P`7=%G-(!F,4$("\7F)B`*IC_#BL(PKD$$),_LY6
MA@VSUJI4%KQ&+?745%<]%1>^-A+6"U3TY@<%*^1;[9`93*%6(V2DF(\$/0M4
MP109?"9(#$.4,-H.#2P\FP,$,'!#05T<L@`7(5%1B$]G+,%;J%X[$H86#"?]
M:AG7I@."%/WZD<&C2&-RP1(+>'!%RX>D0<`3)%2PP#*UC*%`D178@#$`.9`<
M@Q00D$"`J+.A`8%:='L`@@^"J&#!D)G+%'89(Q"@WR$\N`#_H.3^DG%%"DXG
M=:'5W'?O_?>V@G7%@GZHP0#'?MSFB`BOR`!"GM3X,VT:<HDI3AI!2$"#'S0T
MD`,#"RB""PYVE@'L@!HSH((9B*"#"R#A"WDP@Q(0D`,@+&%Z#9O#G&8@'@A4
M85W.F1?UJ)>&!_Q@>@E`PMG$X8"T<&`O&/1$`"H`!C-0(3E^J(,3TO"Z2YCA
M"CI@@P<ZD"P(V"`-5CC6!P2`OD;$H`5$Z1\%TK`%,A1!"DKX0>/B)X06S"`&
M%;""#2[EN`!$;H1D,D(%#K&4`(#OC7",HQR?,A0)X$@09EB`%>B0DAD\P!')
M6D(.4G>L_2P@!!L(0!!FX)-:5*`&_S^JP!:BD3D056<!4SA!(TK@@B"<`0&B
MP=@'2I`"#X1@86US!`#L888:+"$*+."!`UI`@`/P@PTQT,#ST%@@"F1`(U'@
M0@)R,`N?9"D)/>!+*AL!,"V<8`Q+$(H:/A`%N3D.FG0`PA6T$`4(#,U-&+%`
M".XH"$>-0`(>>($?=J"#!1`K`QTYXR4,``(HDF$%05#G!YX``0%THFA*Z!PO
M9\."*DQO*=N;HT(7RM!<00U#F%A.%QB1!BUL0$5T\.0A:!"'*XS!!"T8FD_*
M\`!HB5.=U;(``U90@0I@<`>I:LQ`-$`\/U@``ET`P0>*$`(UR&$$1`@!%2#5
MDRTM``QVBO]#$<9P'T$(``(#L$$,!SJ;`@R`&&?I2"$Q`0`Z+"$`<5"=0*FA
MABM(H0=7\`@$@,`$"?`!$X]A0!"HL,()W`"5@C#2';1CTR"`H`UU\,$!"@"%
M,;3A32(4!]!(8`,+(*&G/R5"%,*SD5U2U2=H$(.7EK*%AGKVLZ#E2D+_((XR
M:*$+(I"4!LS`@`?<D0-#JL%HMBB;"[2``0*H007&Z1,C$8"<815IQFKI``L4
M@0'11(`7PO`"'CR`=.&00Q4>H(,N8,0!%]B``E``@.LL804N6*NK+CO2$*CC
M#88;:R->H+@-2&&%!<I`W\H5*TG^HAX5((`E_,"&&W#.AZ<K@`7_I&"!%H2@
M"IU`P0Z&9-E&>*"Q()```-VS7'5F`0`96(`-"%`$\LXF(-0(K8A'3&*J@.&A
M1JG+"'YI!@@H`8EVL.$08O`#\AG("DU8&15D8(86Q$`V9O@!"`K0!/B6D0I*
M6(&/*V`$!YB`#L6DUW/20`*^<$</<AAF$P"P$RA<0`E&8`!?/2R3!:!PAK3]
M$RA(`.51S0:F>#U/!?+`CS%[P@P?*8``H'O-$`B`,D]\``#:D(0+^@1$#R##
M#J#8`SEP@7`F*``0%J"$!?``8`P@<T]@((&QEOC3H`YU%L``T9[X0PE+74`5
M8+"``*"5@&/*0`@\*8-U`2P$+!B##:P9_PX5+$%OB+,`%:9`(R4P@`%;Q<26
M`L"#$*R@#`FP`PMJ8`(.F$`$2#""P/9@A06,H<$>IL``5,4&'8S/F$!0H`R^
MNDQQG&`*\AHK$H&0`0DT41`IL`+O1FJ!$5#A"G8X``$@(,]+H,H,')@"%1A!
M!@6\0`\[&,(&#J"#&G@`91O1-#5X<``W-R+4(`\Y:!-:H'AFX@$$P!>XJ?$%
M`51@!GP@@P]<$(("P.&]=X"!.,EI\!7`6C9&VC`!A(L)65M@`QI@0!E*4%$*
M@``!Y9/!`@[@YRA4H`D!6(%Z+YM"*;R##22@PL^I8:\36(#H/LE`%%J[\EHL
M00=,J-$A^DN`9/^+0U(H3]'6!<&"*2Q`!EJP``G`\%8A<`8'.9C!`6*^`P@P
M``1Y6*/&F6F$(K2[*$GIK,@WSWFKN?$HLTE!$-!0!C6480)DF.J(!,"`'`P"
M`==F@P@$P9/P/`$$%;B#MQSA!`AH,FE)][@CY&`G&3#J#MN!1P?$LH$0!,`0
M0(``%N9`\,L/M+]34,<>#+=R/^SA[#UX;YI[$BP&P`E6=M(!<Q@Q!@*@(&EA
M2%?W<6"#!Y#@#BX-"0(PT,,2',$"9A`':,$`=#`&*V!CFF8`:6`.LJ$4G]=Y
M$!B!N/*`I.43$U`N@N```G`=K[(#!"``.Z`"<W`(1<`/)B`61\`$WD3_`*]!
M`%A%*Q:P`DGP*A,P''QV"8QB!AZH*B5P"!10!@<P!=/0`7@05VCG86\P!0M2
M@_GG$WK``'DP`,#V*C?@>`77$T8B!22%!!8`388R)EXP&I(G#DH@*D90?8UP
M`IU`6%`@@H[Q``S0:9-W"$Z@$`6B%*,E@7JXAZ)5:N(P!@@(`@-@?8<@!S2!
M!BJ@3ACC"T4@`@I0!`"``+NE`4)0`19P`'N@:R#D!V90!H\!!;O7$_TU/F%P
M!PW&`2$P!GOP$@-``B+P`PY@/T00`%G`'2ED""^0;DTV>05P!"C%7S?P`%<(
M.Q"@`GYP`',Q&QXP!390`3Z6-!^@4K3W6R35_U0^$4C@8`'B@%X!P`$VH`5)
M@`(=0`4TL`4\0"@S<`1?H(A.503ODP0[0F9AH`0(V!-)\06:QX?ZN(]6L05?
M`'H]L0/N%%%FUA-ZQ@`']`3J=`;:80`&``>=8`-I]0`YL&^2T@4DH`_OUXFT
M%PGV@PDL(';O8(H!\A(LX'(CF`%ZP`$&P`%(X`<!,`8_)A1^8(PXD@$C```M
M8`5'L"<>-@0O<@@A251DTF,[8`!E(`%;0'X'H'0<P``:$02\UA,<<A,6(`#\
M`(!*D`)D$`1!B0EL@``;X%&-H8V8L(P6X`%*\`!+\`(7!P!'T`&7(2[[M)`X
M8@!<`)%A<$H@,%Y49?\&`;!WF)!Y_\B/AGF83H&/`!D.)'5Y99`#,>"3'5-+
M&=`)```#*.$`.^`%:2`$!H`$!R@&B^$E_F`B0T``=R``ZN`/]7,)&:`!AW,(
M)-D(>E8!(*`P!*`#"E`T?C`#K[,#LT@!'^`'7H`!>!`#(R`(GN('*'`&Y+*(
MO,0&63`&7M,&&G"#8[(<*Q`'?I`&(<!(E^``T9<&OND'?^0'C\%;XE`'1"`B
M-E4$+OA'`-,%&-`B=A"/4')L-E`#PVE3X9D6)!``$+`"&/!^)#`!)B`'BQ(`
M0E``$W"9F;F9G>D'/V8M#3%012,!W1=B2$&!B/FA(/J`XH`#HR<;X@F=YV'_
M`:<C`'(P`U#'(R3``R&Q`EH``H:3/,PT!A60!/^C']K)G8)P!E%P?HTPFWY`
M(H)4D02@!$+@8DWPHD53!0<@`E"P`G[G`SKPHLAP"$SP`B50!8B$1BSP#8TA
MI$0:#@7P>Z7U`#;@`;6@GL40?5O9"&9)>[G'<X2A`S%U"!;@`C&`!)DF"")P
M`S=P`2K",1@P6V&@!CH*`<-!*!FH!%;`!-''`$]@!P1`!'?P`G(@!R?0!8M@
M`/Q$!5F@*3%Z"&<P>WY``OFC/I(3/:IWATB1AR!:J_LHHM1``UTS)F;0`/QP
M"&BP!+C``#.0`0;P!NTQ`$HP!1``1ABXIEJ@F@)A_REPP`%H>`FSZ0%<4@8$
MA@;+40$LP%J?@093P!,(,`6*0"XN(``SX`,[\`02L*K-D38!@)\%L@,@<0C6
M.HR'8`+')@IU00!'8`"QL@QG\!(XZI]W1@`'U`@8D%Z.4`BJ<Y[`&E`#@94R
M<(`]<P:20@!6(`8OX'-H\!)G$"M0]``0@#$L$!P8$"YCT'Y=D*RN%U!5\%8]
M(`RF@P7[XR^UP*\-V*&V&K2&B0584X&8,&[^@@90<`0[H@E1H`&']$M)\`5=
M1`8"`$5CDC8-EC9$B:UE(`)W\``R,`!:I#6;$`%60`4$\`4)T`4M8`)/]($A
M4@,9D"!X@)YOX*`H(`0?$/\&8423!:(&R5-O1]@(<O`20T"/2T`".^LR+<*=
M#A``7<,/>$`'?G`$*&``=9JC;>H'"4`$5Y!F9FDZ?V)&86`Z!Z!>VJ@&'K$"
M5<``=RMG+O`"+K`$0?`!">`"5E`$&X9K`CH$%$`7(!%I?K`!)\`/=M",%SH;
M!H`%@3E02#%J0CN]?/@%A4D-.["YKZ(&6O!6AY`V2B`#.%4$+1``1Q`$8P=D
MX,:1F(`!=7`'6K`$0X![!0<$#``!0Q`N4&0#Z!L&FJ`!`H!):HH$8.`#(A`&
M++`,"G!(/X"BX<`"$C`];3`<W:>!%3"V0R<!++`>RQL.UF(%!Z`!$V`(%Z!)
M"@#_`@U`!8SY`%)P;M10I]H+K$L;`EKJ"!^@N0"J&F9@!C%X`'AP)K[``'M4
M`1(P/J_+&"2E!$"P`A`@`XYP`B),PB<`,!:`F3XQ`R!`B++:%45+O5ZLAP'B
M`EKLN!*@JOU@!@0P!3G@`C?P$ALZ%#\6#NS;"!0P'."%!,R26(U0-#V%QG3P
M`UB`L&A3`0>PEE*@2;\D"$#0")=!4E*0(-3``B-P):7BGN*@9QP&G^9Q3[E%
MQ!@@#NS5)0:@!W-C36C0!S'L"`_P?N$`PS)*#;/4L(V0`5I0`2NP!$R@`UP2
M&XL:`"BGHCN0=3'P,>@:$Z:S`*ES!:PQRJ5\""00AY"*_PE;H`713%5`^\78
M'(&7X`$ND+!)<P9FQ$RA\CNQVCM$;,4^A!.8#`Z/`0'.0W9'4*I!N@`,\*QW
M!@%4QP`1@`5[X@!9\)*&4AH&T`&F,P#]B:I0^P[3X7/6ERP$@`0Q@"\QX0\,
M(`28>@?5+`@;T%('``9A(`)RDP*T.`,3X``Y8`4]80$U?`EU.A`+(,\LC0`9
MD8$7<0J:,*#>/`$Z@`=DH*,$8`/'9F2"4`L$,`(Y``$N4`,?32TBG04D[0`P
M@,9$`&(W8P-VAT9'P04>FLU<'6HL7<Y)4P8+\(N90""\E`8FTKBTH@YED(I>
M4E9$8!"-X`5'P(`_<7FQ4G]-V?\>')`$.+(!DN8';=!A)A`"-*2O"Z`.%P`%
M8B,.]&$!)RG4\YR6,P2=`&`$5$`&`T`.7T`!/[`N33!D&,`!H#N&+[S2$:L@
M0.27-H4`X&P$7%-(9."1CI`!3("B9Y`&H;(`.L#*EP`P$F`#"P`!;^#9H"W:
M'K!3?J`$8^`"%VH`,Z#'Y'448$!J77W=)<8%8F"T>!0`FD8&5=#!5*7+P^'`
M'/E3C:W:.B`(&2J8:WH%59A)1R`P%"`"G3`!4"`?7,"%6M`#5<`:8=!%XT>;
M+N<^\-,3`W$'+-!O*9!`$J`$J+`#P1L#*6`0&-``=&<&6Q`$*8W:=.H(N#<&
M5."JK8W_#$M0`0,@F8?`FD#J`"_;;FB0!A;0;7APT'*F`25P4SU@X4Z2"4<Z
M#`BP,W$#`AGM84=1F-B=Y"+F1HV@!JG,=60F`02@P1;P`,O;B3T``6#=#V/0
M`G9@7E1E.E)P!)/R8W/0L"B@'1K@"P7@`I.2(--1`?4(2+AG!'1P!5>-"?1#
M!!%POV<@!PWA)`E`%Q\@![.7!2@+IG:2TJ&("=JKHI1B`1*P!WS:!@I3&F10
M,01IU5#@S=10!KX<!"\&R7BT!$E@`A6@`?R@`C#``4]P""7B`BG2Z!JGY+9.
M8@%`.(Y1`6.,1GQ+54HP`$M,!#W@R9Q8!F80.RA*RF!A`9ET_UFUP`!`,`#(
MY@%#(`A*D"#&R`(G,0`NYG-[QP;O,P8U@"^>[FX>408L<*$%0!=S@``#$`,7
MD`/P!@(JY0+%U>'B\.A$$"(Y<`,5$`6,H-)5KL%G'*9@45)X*AN];,L'$`-G
MHA'(=M1)4`-ET`%+*6LV``)04`'NS4NW'O*@A8]#_0#G[F%E`-\#!3`K<`("
M2@8MD@1F0`*1("E1`",!$`)R'0:I:Z=/H.)HQ/)@,`;-2H(AH:9-X`(,$)OB
M(`+XH@9I,>`-0^UDL`5([P('`).^`:A-8`3EL1SNK.^M_!,6L`0XP[`M$@,6
ML`<$$`-I\P3[$RL'`"-GD-_3*`34P_^Q[;<"1'`!CQ$$-@#4E^$%:4$&XS+G
MFF84*";RC!]'`N,'!3F'EZ#;I#Y"`T$$"RX!)[`"];QV#]`#-D0ML7(#-7``
MR<.:<4Q5`]$`1$``4?#JGUPR>&\`#7`%6\X_,@8"+H#XXE!E9@!"(H#W?J``
MY_`$/?`""Q,'`$0/:&#:CN[A?%HDD>#D4<`!\]64@C=#%ZH3)D`$2##167?[
M/1'CP[$`Z3("&1D!Y>$$+2#=DF\46]WX\M\]G#@&DA\.+V`&E4]"*P`(0CTK
M"S<V%F=E%E(;"S\;?GYD03&1EI%G"P]9EYV>GYYF!%$D+4H(D60(`RMF8:"6
M-"`$9B8N8V?_L+!R%A8I>`ZI""`&9I8"/Q8@$0]EGA:Z?A9MNM"@9A5S,00!
M(%4+B0]0+!95,!.SSI]G%C89T?"19686#!!'4B$C%NKQ_O%_LFSY0["@P8,(
M$RI<R+"APX<0(TJ<2+&BQ8L8,QY4\^"?1X]%!A3X^"E,@!4N7%10<XE,!20D
M'DBA4&:+&2TG/I5Y$"$G25!AHBRI82;('``"*H"#Q^'*`A(2^)&DH('`C$A>
M7OD!(<2!@!,'6%5HTF`%&5#68%E`I597F#%!EDBIT$_2BB9\(!#(84Q7F0I*
M4/PLJ48"`P8K\'P8S-C/GP!<-$J>3+FRY<N8,U?V0D!KX\]^U$S1_P':#YH%
M?3N%$46D"`$IE=XN\/&)#($(7DJ3"9'&@HL0(2`T@P=#PH,:4"J<_5A@`(&U
M`YKD.9+#``4Z$L#XX1!AQ9,6$!:LJ($VVMIJ\,HL2%.R"H,E0%:TR!TM#8$[
MP3X[.%)%S1DR8U1@A1)B+%8:/'^(H=F"##;HX(,05L;%`P&@<2!H9@20RX7K
M+'#%"0$P\$8D:%A`!QN>F$0`#XTA<,`.6JG!``'+Z4)##C26P,``GOT#PQ(N
MA.$"#I:(@$$.?;S@@@D\,!#5(14\\<8#"R3PC'G4M#48`$0LH,@#'D@!`0?P
MO+5"723Y\(0,GIR1Q@($/$#&AAQV$N&=>/_FJ>>>E'4AQEMU-F:2$",%>LE.
M51!A@184I**!E6U:$`(G'QEP1(U^Q+%"`#V"LD$%`9A@P0(Q+"$$I/%\T0X+
MU+`P`0D^D'&!$$_XD8$,(53!AQ)T^;':%3&X1$0=EZ2%%EOED32!&E#T\]<#
M;U@@`0;PE!C%.Q\YD`.9T:#1&X5J='H@G^26:^ZY=XK1Q1]^<&HH8Z>E@>J[
M9C`0P`L5Y-%H-']%`(<_!L0P@H61>#`%(DR%8`$+$D!`@C$P*$%`&BCJ4D!2
M'851@@R"\9&`"@9P<,89$5P1PDGL79+)`V"8L<(-%1O[R7E:>G2&#2EW\L0*
M@EQ!Q`7PJ%$!?O[_."#$`73Z4T8`#SQ@!IJ?H2OUU%17'5$6#T3F1QF8ODO2
M;@2_>P(9`1!P@VL#S`M*&BOD4"@L0M:(P@&]1H.!!!6\0819%TSH1PITX+&`
M"RR`4D`.%9CA@!%<^'&!`"EL)T`D0N2P0AXACB&N/`],,8,%+$MC'K(S>P1`
M&NY^<H.9.[A,A`'PF&&%$_!X0`74'H6A1@!*I1'V8`%8+?SPQ)OK105>$!1)
M1UXSMEKJ@9;A##M7[#`&`5N4.08$=$3CF<2IZ;)W&D!`\(,(GKBXG14/&&@)
M"000H($?6)"GV@M;]`#!"@TL8<'OH+!-!%A0@2E48'3HB8<!GD"":/2E_T13
MB,$85E"":,#A!PPH$X?^$Z`%S(DD)BF>"$=(PLQ,*`L%B<086-(\QISA!D=X
MVX6D9XF_#(`'%M#`OG1A+=(9(`DON`0/IJ`Y>&S@"F/PP`@8@`00^$$/?7!"
M!_S0`0D8X%]^2,,2BH"B`BB!'VBP4A]R@H<+X"$2(``#%"R@!B&LY!^KR9M]
MU-:):>@B!/'@P!.HY<!+J,%G+[#``8#VB1A4(`TV`(4#`D`;KWE+$RO<W"?,
M<(826O*2F)2(GPR2"IFUD"2GJT'%#E0&;EDB#16@`PDJ()*@M4`(N9&!#?KA
M@07\#QX?B(K>"&"J*RQA``J(A`QKA(;OY($*<__BEA,I`(1(L"$!!A!""P1`
MA!:$[Q_L>$`>KJ"#":`E2Y[XPC>B<88`7!,6YS1#"VI`!I\1RQ*:"@`';+"`
M3P`!"DEKX3Q`%P`6PF(,CD'(%[20R8(:5(1;6!<G?44`W'W2(VH(0>%(F3W5
M7.\&1D@E'4.Q@BH<P1(.H)L_87$!(EPA#N/;6@4D\`8(V(`(6QF"`WY``?0!
MP`\L$(4K$C"'()I@#WZ(@0EJ@`8$K&`%#T!"$'#1F+^,0`KCF1DX+4&57KW3
M$Q]H`/1BMXX`%<%EE3"8!3B@A.%TH@PK?"@H=O<`"Y@!@))P1D+$4($O'/2N
M>#W7%[)V$$L$`*!J=9[_&1XPT<_4!!0EHD(-+CI*3W@`"G\-`@D```0KN"(:
M==B;&9RP@B*>D@!!&$(%0@"&#S3P!'?P`Q&,X)0<1$(.?J!&+2<@`1A\8`!!
M6,`+%.90DAQ!+YWSB27L:(GF,"!G`8C`#OV0@"-<Y2-.!(4B/`>G"L3@#A/S
MQ`NB<,[`J@9`5/*="B.1$"U@`0L%\4(6(O,'];+W#U]`85[G2]^,<*&N"#EE
M`'KK77B<80L!H(%A*[I6P`22"C*TA!!NN;5ZC""?G_!!9S=P,+CZJFPE,`,$
MYK`#V%&@`%,8C@(H<`141B(`P@P#Z")@`^5<B`(K0)A+GG!5XOKA#00X``'.
M_SJ%E)U@`<$D271A89L&6.`%$-BJ'P"P`,_VU[]DT(0%-!10@TQH0@0!PV$(
MX`4MSRAY73C,`_ZP2<[4UR#JS8*:O\`%NU[$"\F;#)P9\@4W,XC-"\$S1.8L
MWXFP+"&6<!-@G_R3#@#!`XWI`!]U@0T\[.`'A+($&*(PTE2T#7:@P$`$+*"W
M*U0Z4A,;0P@X((LEV.&C?BB"#^B0@/PTR@`Y@``3C`"!RY9&!6ZLRZ\J(0U4
M4*`<`EA"UU(!A0C8FB1]*%.]$'8)`(A!"?PE-"C&\*T`@,$@`/[#`Y*G!06)
M80O=3M`6...%^V8!#`3=P@+.7!`L'.8P6L@"02]R7O_*U%LA[E8H@^*]$'Y#
MI-X,H$@`@@=H2ZP0PM+V1QJ8^I.1Q>,,8W#!PR9V`BET-Q*K6<%S+Y%9&MW@
M"L>.AM`$``8")-D!$P`J3$EP!`Y\@00@6,`,5A"$#81@*:4Q`!-6D+-.K"P+
M%LA`L*L0A)!;(@$#>((99C*8:.M"!A88=L+KTX\LH+<@7;AV``:BB2U$INOL
M35X6*K!>!G!AD^S^P[T)(F^,K%TC;S^(%J[M('^7M\\.B7M$Q+``+3Q`"^;%
M@IH]8_2IPS$`&B"=TIQ>PW*XA@$-).<")!N)"=R@%2!8`L,]8A@+\"`'A/1#
M`6)@@"!F``4L@(`%BK`$!NS_X$+QE*0E>&#R((3`!<SNQ`2P(`5UG$$*K?S(
MQ;N5@S3(WO`IJJ<E$$*`=Z_;"UJ8$1B@+_W';!F%<\=OVM_>=K7/_0_C!C\*
MU6P0+)A7[0'HP@(B<_;SJQW=`WF_%N+_A05T(3+G;?_5V5Z!+GBA_O<7$&"P
M`''F?0%8?]^G=@.U!?47/&JF?I'!;P#X7G\@@?;'7N87@%Q@?P&`7NBU!0-(
M<`.%!>''$%QP;N?5"VWU`-1&0\CG$6@P`K7B$640>?Z@`"T&!630-(4%"SL1
M`B!`"#UP,(S7"1>`-UR#!0E0!*(W197`(AD0`A5``F%&!"XC!)@&"@B0A:`P
M`X=@_V&=P`&XAP12Z%"9,&P[T8/Q,'R@H`)F$$0O^`^4=`D'@35JE@4!ESQ>
M$`!:H(=\^`7XQ6_J0@!I1Q#<1U!8`"H$D`5=,!`$L&Z-V&X$@`4/(`98P`T4
M\@=]=XD#P0!:$"+)XXF@R`7<T'=JAP5=\`"42'?@%R=90`!=`'AJ!RKLM063
MN`#!`XN@^`>BR``+P(F7V'<$%6^D&`"F6!#$"(NR2%>4N"Y:8'^3R(L56`&<
M2(JQR`!XYQ"7<!H`$@`J.&5F0`9E`(9QJ`9C4(1;0V#5@@NK,2;V`02-M38Y
M!@0T0A(T@`6M4'GYX3BF%PDW0`L<$`0!D`$C<08$T`+N<_\)]\@`5)"0E_`6
M;Q0-!4`$%2`#E]ASEW`QA7=*@[:&-*A\<>@/Y60G!A$`"D(0"P`&F\1W*[D`
M8W>"V`A?!#!OV_=NV-AV9*=V?N)_#U`!?X`\!;$)[66)ZX)N9(9_Z,4`R2.4
M2JEMYZ90VW9>X?9_!A%OX/8'I.@%J%A^Z_8'TT=P_,8`=C5_ITB)6,EE\::2
M!+%MR"@0!)658C!^6D"*!'%^`4>6'6B4I)B-#=$)QC`/AU(&:6`&8P`ZO6`&
M9J`&98!PTF8&`Z!XTJ6.L``'YJ05`/`$#$D"`=`"'!"/*1(B-T`2'-`"4F`$
M.$!J!1!$,F0$7K@P(?``[&$_88#_0^(0>GY0`DB4`D]0`42@-CM@3?`@"XG3
M%$H6"0G0`$K`F)T`!TF08-?@#[4D=2'I$0>A?0G2!5_0?`109]II5P\P(Q5`
M=]18B#IYAR=(4`$7$%JP5P.HE(18$.EIB.C5=ES`=]&8GF%9EU9GDU:'!6+`
M`-1(@?%V;P.Z?_`U(_[77N87D_B)0N=%H/*VG^_69P6JG^#7!140;_,&<!7H
MH`]JH1$!"E3F%M*#F+94`:."F-)S?%YS!D]P`)!Y5I+I"0XP!T9`)R2P!)RR
M$U"`0X3C7Y*"+;@4%6@``B2@``[`!P4P!WXP@QH0A4?68D+@!Q&``$W@6CZP
M`]00(DU@_P`>$!7W$CFJ%03#DBDML'FPT!1C4`-$"@L;0(Z?``!V`%-]U"U&
ML#K3&34&@7=MAI7K11`GR%Z!.F<_:6?L=HC2J)Y_P`WF9XP&$9^GJ*A^AP6_
MF*CYV:&H:)[UQHBP6)7]J9]QMX<54`&D^(M,::$/>G4::G5=8)YM":&).'`:
M*I_2R&^I"J(0`10=:3-EH`:(^8UC8`9I0$-HP(71HP1%8*R',J.=P`("%@EO
M@'M)PS9"X!)08)O250%0(*2?<(2@\B\8,#F.8PE/T`$4$#^T`@$,D`<1X`<(
MT`8?P$)SZ`!PH&%!(`5-"@`-@%.:8P%()171``.]@!P1V0EL0/\I@V&._,6&
MD6!*>=H8$K(%/DF>B)J36]EW`!9N!9&3*KFIZ$D079"4%MJ@5YD@6GE>8D>3
M'7J56?EV8$!WV#AO.=F@9?F6!,`%5CEO8E"`.7N6T(="X$:*7R>RMHH%>KF(
M$@$+G_89:,`UA`DZAX%[!V`&<;"/!Q(&1``).L&L?M`'7@)26E"P#QD`$)`$
M+O,$WN1`L`@*1D``1A`&#G`!N7`!^)-(D<`#`K`C0@"@#+`!#W`%'&`E;/`!
MB.8'2>`'"_!19X`!N2$!3>H'*)`30>!BT0``>$,&1I"/GX`!/X!BGV$&$2`8
MDP0+,X!S#^L/;_4)E8&'\4<0K3M?B!K_JTCK;EGPGX::B(FX!1[[D_;'`"+;
MH9:Z7K"(H:<H!JJHBIYJC;+X=ME)J7UH+]&'0C3[H,HXC,+;!<3;ELI+4*E8
M-L/XB?<)O/FGC#$9HIU`!G`:/8)I!K9T!;C7!49`!QQ`D(T1`]?J"8>UG!&0
M.@"P`U3`L.P@`1X0<0ZKJ[-T"1Q@`6/0`!^`!"]``2:P'21``3T0":DW!CO0
MIF2P!#E`0$$``P=@``<P`5PPI2E0P7X`!9&3;&]0.)JRD9VP`4M0"S:`II;`
M!G@`!>G[#P!P`\T9"I\@!U"`D:=+3A>W(-U'7UOPNE]`<.9'=P/59BIKB.>W
MQ/`5/`/5B.@U_V\!,)8$T<7PM0`+8%=6;'X&^AAV-8'@][I>J04!"&[G=6U<
M3,:ZFWX!",;U-\8EF<87B)5B/(!8B;W?5H%HO,;P95YV]Q"?B7QAT*N_:@$$
M@*+&Y@1\X`/."0HDTZ7+VFQ8(`$XJGDLZ@<\0`77<P?1,BW5$J1W0P"U,@#0
M:@!VX`$?(&`7T`8'8`%I$`5BNQI+<`,2L`1YT`%O<`0B8""A1QX\T`<`X`-3
M8+IIV@(+P#``:[`D@`5BRB%<0@?/&@G7=#'%6<2ZL`"21!!U-A#UV;I6U[K?
M1JA;(`;L%U]8$!G&:ZCD6<]Y=\8.`H(^F[2>,&AHL,/>E0ADD"&]@/\8WR`$
M1V`")Q"C+B@/%04`=%`%_<`+#*8+6&,!?!`!H+("3-`#5P"C05,!#'"XW'P6
M6\`&`,`M&`#)>2`4&\D.KL<[,>`#4^0',^`,42!ZD0`#06!6NG`W#[`%)B6=
M+"`$#EDG9#`"+U`QJ=$<&@#0X&P):+"TY%6!?Z=M/1D\6J8%T5@V%=#5%=`T
M`3&J&<J+GFC/:'W/>(*'83O%VN@):4`GXAS5)+*^A?F=!&`#$A``=K`#9?`!
M;,`%5W%8,O`#.4,!&"J=E^`%&@T$EM,79D('5ZBLJB$[1B`"T=0HW10`"L`"
M20`!2$`'%6##^%L!4O"=0(`!4V0`D0,`3(#_``X@,8IM"25%`'C0!`RPD0B@
M`4[F-:M!!85C##1`!P]`U73]$W6I(/1)JEO7QKR8/.-YLYH(!J_(!5X0<$F<
MUMJ-$.2WUB1($26QC0P+SHT\#^QK`2*M%U1P!TP@`4K@&4Y`"RS*!D70"C4`
M`;UM&OZZ`1/42+H`<0QY`4S8`3<``B,``2/@`0PPS=WB)%L4`/NZ!2SB!P:P
M!4D6RC5@+R>P`E80HT$U`NA8&IGP!#D@`C8PWL=-G>*;H5R-0EZ@;K-ZBJ\(
M>-38?=CMUMN=XY84#VE@W"G>)KUJ`1!P,"Z5#PR0`V60`4'V"7OP`V.@!U%0
MT9Z@!J_$!Q9PO_SR_P`C(`,M0`)V4%8S,`!6@"DD8`,!0$?&-04PP`$%@``I
MT`<JD`8#4%:Y!PL?L`\L,`!4D`8]&9K;.`:SW3PR``%=H)P_W@D^7M6V&GA8
MT&4,\'<Q?EYC]Z!J-F\WKN.8CDG^,->'_@]E$`++@09CP#L,<`4/<`!MH@D]
M@`0M$.B^HDXWH`-W0=GG:P55,`!ZT0+R;0D4/0]7`#.6,`MI@`+.4`1CH`1^
MX`(ID`%TXW3AFC=$D-L90`0B4$O#@0%*`,,M--Q?V^G5XKFZ8*'JPG8X>VWH
M=CP@BP6`2,[J9>F*FNGP/D*8K&L@Z>UK*`6%HP9!8`(N4QV7``>L$`-ST/\*
MH1QH$R39*^`$M&X)J^$DOD@G7E&P$$<%P%X/$6`V%U#!P61UE@4/F<5S-;`I
M'4`#$]`!"C`YD$P%-F#H+:0"$V[O;E'OL&"AU[W$I&I_8'#5H+(%OON3UK8)
M-C[6]!SO1#\UL`#N\H#B,.\K8V`#.%`B2Y`$$S0#````L68&,;!4+/\)/6`%
M##`%)"`><>!?<+(!`M8<NWY63;,'%F`J#-#>?L`%.O`$^!W*,=!91=`"55`K
M.SLY',`"#O`""X`C$7!3WL4"E[ST_;SU`>5OMH@],LD-/IF=2H%>@&@O[QYP
M]X7C1=_YY'+TH1#B]HX&$5`)5"X$)3`JHZ('927_^LQE4FI@`CUI!)_2F^DQ
M-#9'VBU1`0=0!5&@!PN`C1=@!5(."A^P:3Q`D64P#'YP`@7@`EL3%63@`QZ0
M!PS@^HQ!`TGPWHI?'XF^?!&A7B![DIY?_B2DM%"C^]T_Y5'P`JO1`EL0`3=@
M.:[N"6R@`R`7"2(`!CT`"&8K.VD50@9^B8J+?E\5%F6,DHEA9@0V*RL+#"UJ
MDXQU1%=J.BL,!7!2"0`3?@H(1F)($Q$,#PN1G[J[NFQT&KF\PL/$Q<1E`<5_
MR\S-SG]>#`$!#%[/U]C9VMO<W=[?X.'BX^3EYN=_NF')C&%C8<;Q\O/#E0%A
M9V,,$&;P\34MQF2(D6@+_P(,"LXLF+(AP*!/!000(!-/X9(5!/KQJG/CBAD0
M*\8D$)&(HAP$0/((@`-B0X4Q/:A8\$>/&`P[>FKJW&DLS`)CS;)HV09&RX(L
MS1B@6\JTJ=.G4*-*?;:+'2,T5GEJW3KI3)D>#M"<D9=E"@$EB0!X\0,@S(D"
MB5XPL$'"PA0.DA80P#%OPJ:QO&J$[#'%0H\9<'G,\`-$1(X09`#X$<#@CI0*
MP;A*PB#$A^;/6WW2'!9TJ#BE4U.K7LVZM6MGN]*@Z0JZ]E8:=!K$HV6%S)`7
M(#P4@``@.%X_=2Y3.Z"FPA0$BRRD(2!!<C$^%18\X'7A@84=$2IXPB(`X9-$
M$?\$:/%3!`\"";6DV%X$0(,%P//S%PLPVQ@7,6)P(5066'"QC!=8!`B-%V"(
M\0>!!E:#Q1?+_+=%A5]L8<UK'';HX8=3[7)&&OJ5N!4/$N#'2T<'5%'?"QYP
M`,`1';#@AP4%F'!)#U6,$0`5?)C1`D&)6.#'.A5L,(P#2CP0B9&?U)%#!63$
M<,48//AA@`%PP*5!$T(8"80?&>C!@0(<0&&!!'+,5P8P)L:YBQF>Q/-`!0\\
MD$4%?"X`#0%W#H5%G@0$P.=0#.!)@#5Y5A#`@WA>".*DE%9J*3:\C"&BG)Q^
M8L\%NY3QP!AGB)$("GZ0,($)<K!!T!Q!C*$&`1;T=X;_71N,,44/-RIRZP@>
MZ`(`$%:06.0D;-RP`IVCG@&``SMXD880?L1`QA@()%""`@KDX,<,"OAA8QD5
M1+"69E\$8$:G["JB!D7QD&O@`EL0P$4T?X#1Q1]<*#5HOO;V^P<#%W81@%#\
M5B`@`9<V[/##K_&BT2=C]-=NNV=L@84#DZ#!P'E^!)L($R_((0=<%$CQ0`@2
M4"E)<P=P8%<%C#0G`0:,3'#$$O=$)\D>M\R@,@&\^B$$"5GZ0485-?AQ@0]B
MJ-`#=(HHT$0"Z@8QAW4[(0#%.Q>'+8\96#"#\,`5@D'-'UB4?;92J`F%105:
M:$%`%F=#K/?>?)O#"QKP3B*:_]CMTE"#&%PG4H8$%MA0A09^'('$(A<,0$`1
M`60T&B-F6/%$$@1,(@@1=23BTGV20)G("2$\T$,$!%00P@X6+'&`'S6\0,(#
M2$BQ0QX,$'`#&XIT(!DB;/0Q&11+V)&X/#6,8#'AU$M<]C)O_YF=OVZ;!C?V
M6F`1?MM>Y-WW^>BG#QLO64GB3O7LDB'](F<0<``1%5!A0`$P%#!!"AI@@!D>
M<"45>6H,*Z"9X,9P!1(,`#.?@!(;0$"`-/"`'_"P1`V:\P0/F&$,:$&"`)5`
M!!>,(`_),`,%#-``CB6B#4;P0!!L0+5XH&$,@8.??M`PO7BD85]LVX+WV/8H
M@;7M0?]#K,8?MM`%,0`Q"P(RC?JF2$6]"4-3N]B<#DNTC@-T0!'NF(()A&0!
M,/B`!558``>>X"1CH$&!GW@CM71AI!>T(`!@N(6*W!&"*3%``'Z@0!HW$($'
M!.$`+ZB`#1*@`!`T(`%8\`,7N."'%]"`!&IH00Z>MXL+@&!B6\Q/&&92DS,0
MK%Y%6892Q*"G3;"M>ZH<V`+`4`$-G5)AYJNB+G?Y(6&<08NA%-L9).`\1:"A
M<3*HPA3R4`$I(&$B\U!=!&O(B!U0P`+>T4,A,[,((1"``"\8`Z!>D#F*N",(
M.3!"!6Z0`N4EP@LG\,-Q_)`$,P0!"YQD1`)`L)A@ZL<=P#3_1KT(L(7L<>$!
MTEC4$;/'`"Q(8QD#O5`N>4G1BJ:&*W7R9XG4`(7,-.<*29#"#31'CP4`(9]%
M:H,D:K`$<4(@#0U8@;$DX0,;]*,Y57A`#DAJ3`O\X``'@$`4V(`SY/B!#G[P
M0@TPX($<K&`))/B$`9I@`T1H=#X`Y8E%M\I57G(%*U<UD1D"(+(C68(!J"OE
M&"J0!!I,P@(J5<0)IM#&2C#`"M14!`*P4()%5((`"S"@NRH0!3I8@0I5<*L$
MX(`S$:#@!7CPPP&*<(40@*&:+<AA6#\S2L'.HZN@#>WYAG$&STH"*P'=;&@$
MD`.:G*&'-2&7$EP8':K5`00NHY\%_[1``4;$H0%Y)48E'H"%'1#@"'!`0@9>
MX(<!["$%1LI`"C(P@!7,P:U>`$$:4JO:G51L*Z(-KW@O58_VZ>*8W.WN3M#`
M'-`\@0`@L$(Q%6$!Z,1@60$EUP#@X@,IS)0>^:#"$<P``25D@41`8$,1X+(6
M`-3@``PH0Q%V8%7U:F:4L*W)>#?,80X1`XO#0*^%+6R!$52@!P0^0BMNA`")
M?$`8TX&"$M);C#)88`$O6``5()<(%PK`!P]8@02:9-H1U^28&=9PAY?,Y*@0
M(PU%ED0^:&SD>9PA"DK2R@)&$(,'2*$'"T@2BRT0@.99AP*/7(0#%+`.X1%O
M*V0@P`J<X/\"*.PA!_)!@016(`4@/(+*528&&J"IF28;^M#G(,89,EJ/[P9:
M,PJ)`DI[8@D=Q%D),,C.`YP``6#4#E1*NP)?*JD$M_KAF"X`M5;L&H/I#(`-
M%`@".*L`P4=K9=":U0JB=\UK;V"U5K;6##*8RQ.%5&$#9EC"#);`@!$<@$]V
M($$+A`"/2HPA`NNJV17VRQ6%6$`)+;O"#K10@?\&NR9D"$"4E=SK=KN;&?H)
M`*//O1,*F('8.Q&5%#A0@1CLH`7]6`=4[;DUW'%S$6:H`!W>K!51D?N;8*.W
M3LB0[=J\^^+M+I&Z);X5$E0AR?&(,P%:JJ)CAB"<4-W"P>DW!A?_#(\KP`,V
MQVLRAHI;'.,X/[0QS#MS3IU!"P-8=1I6[H?F6$`'%H"O,&Q,!1OMQ`<'B'C/
MY>&.-/"<*SG/.I-WOA-`3_T39<!%B31H*`%,6A%DJ$`3&!X/5ZGXZ_-P1[KU
MH_6Z;]@8:IAW3QP-]WFD(0(I^*<X=V#/J/*B$N5F^S#*,(#@]KT>:/@)W>U.
M^=#VY.K"E??CXQZ`)X!\*TZP0`C>L(`?&%Y$"W"!TX5Q@II[??/LJKSLN1H/
MS!<#RK"71^1SK1D.G"'M`I#!RC*P]`=$01@9(%7NA2MU$\W^^10-^>>7/Q\U
MC"$&IOY,&2)AUP%04`"TG81@0O>)!`2>__J"KE@8>&\;Z+N_BA4QMTZFC_Y%
M<"`'YQ=V,!02`A:4^?2+@`!C8`%O0`6?H`<+4%;UIPMJ<`^=)2?O%X'I(P\@
MQA-F8',+N`LOD`,DP15@P$VBT@5Z('K$EPBA,!%6@H%'\@2@E(&90G^%)H$R
MN#=CLVYN%%@NR`MA!P)G)U`9%F?!5P%=D`'*8@:LI'R,0`8XF(,=LPC\T2DS
M&(4/HWOL1P_K('],N`AD\`#8QQ-;H`Z9`P(4M``S4!C<!`!8X`)$QX07J`A/
M"(52&(>5,@^V1P_6]WKHYP`:T($U\84B8@%7$`2PDVL7\`-8F(619S$XU"YR
MV(@@0H>UX0YZE_^%B@``0U"%PU`ZQ=>"?@`'#2``>)A[8T439(")^>&(J.AA
M\K!]MG&'E`AVLY1];@2#DJ``1B`!M(A^D9<9I1@VJ?B+K!%,5?>*GT`&-M!7
M\;*&NB`#1Y"+Z#>*6GB(<0*,U!@B_J0&-IB#ZQ`"KZ=RQH``1-!;Q+@(8==#
MUD<XU9B.3S&.5:80IK@(WD@,T,B.1Q(`6.B,[:>.^H@.-2&-GR$K]$B.4I!E
MO!"/NP``UZ*,3"@65[6/#ED.-5&'FJ&$V>B":7",!:F0+W`$\\2.J?5+\/.0
M(AD._5B1JS:)XQ@&0#`'134)!ND^9_!%`9D/[#=*H9B/(YF3VU!*_AC_D'&R
M!04G"2^I"`70!<U'C/804%D5DCK9E)AR9!BSB#X9,B-`D(HPE'Y@`A*@D-H8
M94>)CDX9ELWP:#;&E2Y8"1'`AW[PDADP`N^8@2BI6F(YE^E@:PDYE:4%C[F0
M`A+0,_1XEX%&EV*Y$R8Y'X#IDPX``F&@<B+0!6G%CH>Y"W$)EH+9E#LAD7$2
MF>R820U`!#]@EO6GF;KPAL%4F4ZY$WFG0THXF=K8AG\Y!J#I!U+I3Z9IF3JQ
M#J&$CU,)>]86FTKSEKY8FSG)$YAY,=NUFTQX!AMG#+T85L(YG#M!!KH9)\I)
MFLB9>S=9$CU9/<\YDL6VG6*S?M?)FVD`FW98_X$-V9T/J17H&5:X-YXSAPS3
MF0A@U5WJN9X66)CA69YDD)WP23UAX)^+4)_V>9_[>&M^:&%9,`V^^9^$8WW+
M.7^2IUX&6J',\"BZQ`5;,`T;8J'9D"Y=``9-`44>6J+I@Z&\Y`5.)`8=6J+I
M$@!;8"`F.J.&!@8B:E$,XJ(!L``*XA231*-`RC=($5H!,"'=F2$R^A1<H`4M
M&J1.FHY>L*%-JI,:&@`4HAI=<*5/NJ4/F05BH*4/*08'PQI&RJ5F2BE)NF$J
M.@T:0HTJ>CUG&J>&!D1-]@5B"J-3&H%V.@U?*J=^VF0LRFM[.J;N1R!L"J8<
M<J-_NJBMH:(YAP5;@/^H&.<%10H&:?HA6R`IC+JIJH&B&)<A`2"C/WIH7X`%
MTR"IE;(%#L*IK!J6I3H-"4*BH%4^D&HVE]HP^M*JNDJ7M%JD12H&0YH^>-,V
ML`JL>0HQZ;*KREJ;Y<,,&E.I'R(@60`&<*HQ6``&LEI%R;JLW+H4FEJ-8D"L
M;6.JX]HVP8HW>".J>!.NY4JNY+,,7X"NH?4%?M*M]FH.-FJ:Z"JKTGJL2[:D
MMWJO`NL-GCJP>\,%71"P!KNPV%"P#-LP"*NP#SNQ$(6J%`LB7N"O%_NP"+*Q
M'ONQ$$.G(-LA&CNR"QNH)OL:5IJR'YLA+-L:7?"M+TNQ#CNS3Y&I-NNQH9K_
MLU(AL3PKL/GZLT([M`1+M.B0!25KM-R:M.B`($S[##[KM.)`(.%0%'`J#C[;
M##Z+L^(@M0VSK4H;MMZ0!0P0K-_@"-I`MF;K#0X5#M]4L]VP!?6Z#7*K#74S
M#FK[M7`KMGSK#'D;#FV;#7\+#LT*#@U5#G?+#8F+#8L+#H-+*?3:MQ,KLU"A
MME^@!?52`12"!03P4']`#9KK"`P@16S3N8]"MET0.Q2RI*-[+UI`(3"Z1/0R
M%$*T!:V[1*,[#1>:*!<247]PN;#[*-/P`$`T4*&J!;?K!0BEN<;;#*!+(5KP
M`,B+H=3P4-/0!01##?N"NH!B(+Y[N9Q;JJ8;%0`K_[D/B[)2H;9D6R@,T`71
ML`#86U#2(+VB*T7O&[_KJ[U_8#><.Q0$-3!#T04+T+8.=0L$$PT&+$6@*[\+
ML`EX4[;[.Q3(>[A+]+:<>\%_D+IS4TMOZZP))<$,H!W5``;2L`F7*PT5,+K(
M&Z_!H[U<`%AZ(2`,,,/W2S!*FK#FR[&KFKYE2[874C=D&ZH4T@45D"\,P`6!
MBSW2P`44XL,1'`T.(@;5L``'D\)_\`#AZB]*U%!2;`UTDQ1ED[K+0`!=D+=W
MB[SWP@QW*X2?^P#[6P%(:R"-2\0/(J+D]B!E&Z5&+!1N[%#ET\,VG+JVZP7]
M@JW2\,="?,-9F\/+NK=+H?^^$%PW+SS#^V(WT5NV2<POG=N^>(P40`S!:BL&
MX:,79%NJ6JQ*;8,:C7NXB?O)GBS!I!O!`T,W5NQ0B?+*S="X=YNW@S+#0B$H
M2@')2.%0#E4W#96WD\S)3;&D3\O(NKK#42',LDRI*2Q$%3"N"((:S$#-!&/&
M6I"WEAO"8M#`#$/`J-%0@;O*9=/*WQS)L.P,=SNZXPI1FU#$NCP4A"S+:NM0
M7>!0O\PVP0S(P]Q0Z(P%#SRDW$RYY9"ESMS002'0$9P%"Q`AIFHO6>"^F2S1
M%.W-_2*\J/%-=@I8`#W2`W.M#/"EHPO&GWO$_6+0#&"I7]RXLBR]?R"FG^L@
M;=O_N)F3P0RSRV4;O;C[SVT+R8\2O20,14<!SA-=TDRQL@[]U-)<-]&`)X!<
M`;%3T[:PS8F"4`<MR]0PO<N@%[][TB,=N(>+4+%#NH?K!;%CU80</%;]SLV@
M%_UL"YR,O9;\!W1M-G9=U$.AMMB+4#\-S)V\O@A5(-^4PG^,%%/-U4OA!1;[
MU)+KM%*+LQ*M!3=:%`NPN@T<%`N`V="`!=;`M>(#IUD@*:+](&YS/08=VI=+
MNJW]NPU\I44!!CC+M<P`OFRC!3B,Q+QM(+K-#$6!PSCKM`B[V09MV65#V1-"
MQ?#ZV2+JM9>MJ)+-M]/Z;GL"16PLAXM<W=SJR$V6PKXL_X=;0-W>O;#@S61O
MNK8RJ*KG3;&1RK>Y^MX3V[%BV\STO:LBF]_\S:CH*[1?@-_]W:IV2K3E.^`3
MF]X@&[$(3K/=O;$,WN`3>]TYR\P2?K$*?K$,?>$4"\TLZ]0<'N(F"N(B7N(&
M&K,FGN+WB=LJ?K(";J_FW>(#ZZ@R7N.5N=\VGN,ZN;,;6ZHZ_K"C2K%@:[-(
M(:WRRB_A>JQ,_+L/S@WLK:1@^@5-_N.\%+D_&]`S/,,)HRBHBC#?S!3:G+ZD
M^^7A@.-4SC?Y?.5(Y`Q=`$18,+>E4443=1JH"-EGWIW!',M'7"%P_KD\2KOE
MLZ`3+3Y7*CXW>JV8RR]=$#[+P/_:H,TV18':O]T,]`K:44KHR["CHMP,&C*M
M`NR]$HVA;8HWMGNU<6CFW;KD1)OG0>'&V#`HAB+!!%(HTMO`13PHG(L4N5L-
M74!<#R"B_N(H=P/`U!"E!/#FGDK&Q9X%,'SK#Q#KN3SK`4"\^ULHU[R_PVRJ
M*>V(&<ZI%K[J>)SE!AW+S?``FROK;PXIL?0`UI"K2J0G6N`@=JX4<,PV^_+N
M!%*OBDJIR_#->\(O2F'NNQWM6+`OJ:0%IVO/V8XVJ!C?`[OAX)X%>H(WY4/N
MS!`WZ`Y+:)/E*:W*7IHH!;+QX,/PW_P%P>.^S8`@R(LW233R:DP@L$3F2O'E
M1Q3FW&W_ZM\=V3;+ZLSPPL[;H1B/[0N51.A*(1[_(*E[[PR/,$=/S45<(8`U
M*"P?2T'_\D./[;%$\V5C\W*(ZKI*XA$?RWIR('N^#&._Z=]\]6A3[X[J\:G-
M]']0[P5/\M-ZH]I\-G"</6<_YC"_YHPN\?LKHOW,\*CXW\J*XF++\\Y*4'GD
MJ7,S-QF_YFCS^+5$]ZR$ZY,O[+K>[UGP!<?^V5H=`"N?/93/]U=/;H82QL]^
M[9[KB`7.K2RNM$,QY(W>N3C<#&^^H9^;(1>RK:91VOV>Z>=^/;__Z*:QLL.=
MID+4-F#@^XU.+YYJI3B;K/$^P'P.HQ>RZ:G8[6<:^W>./F0N_Y(\KJON7>-2
MKNK8\`4Z[Q09"P[AWZ4QSJCS7>/^;O&-KLSEP`6/\OJO#@A8?X-_782'AUM>
MB(R-CH^0D9*3E)66D0&7FIN<G9Z?H)9;H:2EIJ>HJ:JA6EE96H]:8*"O?UB"
MC[>'#*N]OK^2F<##Q,7&Q\C)RLN)BUM9?ZY_8%JXK;586EU<A%D575Y<70M?
M?UY;75E;7PL!X@O<[+*%%=FMT]6#7`M=`;A_6Q@(8K>-F<&#Y0XJ7,BPH<.'
M#[N,(K"@T#,"6!X(NJ9E"\9VA#P^^*)%&P$N60@$>%6/@)8`#PP1Z,?`RP.7
M%2I<S+B1'T9"`1AHX3*S),2C2),J3?_E!=;2IU`?B@'WH,*?"EX"C.)BE2.6
MBM,.M?)R\D]';X.TB+%EZ%76M*Y@Z=+ZARO1M/_^\-H"B^BBJ(`#"X8HCMO@
MPXA[?7D`9D%-`F892.;%\0N#F7_AUK*%9?,]7;6\9&,0EW/DR9MU$>*E^E[B
MUUP,OYX=JC#MV[@WJ<P6H*):5]`XF@N04VQISIZA@1Y*,6-I7;^!.U4]B+4U
M:+D#>UF;O3NEV-[#BQ^TH&,`M85P9>((9I9>XV2YG77Z6="KS16>"^JBGBBW
M!7GMU1<!F8V7E"$&)JC@@KAA09H8#)23TGF&5/:14W"991)*]"EGGQ9>,'`>
M:2EMX=R$VFC_&,!/J[E3%(:T?0$<8.XP&%Z!-N8(&$E<D$0(-04%\,47F0`I
MVQ]"UC5..40.DN06HS3)URVS]./%`J,8J6078HQ"B!BP$'3D8-LM4($VMW2A
MQ0/58(?4%^[I>%N2<M9IYYV?9+'``V+@2`@78'1100!^XFEH*1(=JN@QYT"B
MB"1C?F=)7I!0BHAH;D*UCVN3\)7.HJ!ZTF6HI/K29"R9-G*E)BM9PLLDKSI2
MP0.I*N5-G);H.4^IO#KJ9:_`#L.I(YM9,JPDL4:2+"/++K7%`V-^,=6:U$H4
MJ1>"_JJ0I<$>M`5WW8;;29/5,(!@0"5E<2HL'HGXQTU:88$1+ETD_\2%%@Q4
M\(5(0U8@E'P.(MB%0+S<FV\Y`1!7",$`$>`N4$(A^2]`\B;$4!<%Z8/%-^L@
MDH48,=7*Q<981)J,,.)ZBV#*+.<*B[E@1$@6&$$=QPL!8F3Q`+8Z;0P&677%
M"O+'Z7QCTTI\ZM5%S/O2BB^2K8QCU@+J.'USSCN')-`6%0!I2]<-[8/RR`]L
M8?(AKW#+Q;/@&-1QR\J<"O?<D=3"@'SJ()C?9KPP(`87BV`CC+[4$))1.8O<
MXZ4_>N&=:(C1+%+X/(_W_3>.O&!I#F18H*P0%V43\D4%X$JB\R$H6>QIK<5P
MX3G=P\@-^^P>OPQ7:S;_`:&Y')J&9.?_</^5[RSWL..P(*^VXEK!@D9\S_*Z
M2Y9Q=69A9QU#H[O)E\62/"M;2A21;IBNN!JS,NVF@H7^^M'87CWN?`^R'>G8
MX`(&FZD&"MD]@V;!>/+WH=XXP,"7ZAGP/>80`^EV<<#K*>19%@/9V1HQ#MD$
MI(#8PLA?>*8M8O2)?;TH&0C79S?-6(4+)+)*%G@!K=_5;S56"8D@4&C`NYD%
M>;<S1,S,,HML&!`+.F0A-QBW&B09XEF^(X07"O4+"1("8Y78Q_G`0(!R8&AD
M,[$7R2;(E-*-\(M@S)/[[E&5G&2!*`]P#)+.1"#+^.,?>SH$6;0PJ#^8B20Y
M^0D`R?*`!["&`#?_@<4]^.C'-6J!0`SD(P-Z2"D]#:I\O<"884#'+4>`KH,Q
M\T<+_\0UUZPM)DQ,Q>O"2,I23J)1N'@4%W+VJ"^4+)58^`N4I.&DUXG&2Z()
M!Q;6,8I4+B*7N!!#GP3Q*'/$$I8XP@6F!D%+1M"L`@OXH"KNA;+%=!`2HW//
MQVZ!!6%.95;2'`1?=!(2+5`-&#4R)2?NI<YV:D)?MRG3(T]ADU^-CGN1N-\7
ML/4`K0!'#'LBE+3.I*TL"$J$T2C/-4^A#G=J@AP.C2@BN.&*<S#@`?+K)4`6
MP<5&X((;Q:1$2!O!C49)XIE8"F4E[AF2D53">QM;Z""`!`V6F$V)@FJ;_SFZ
M4+:.>F*4$G4$G8(:T57-LA6&:1(OA`2&2L9B&AMA':H>L2K92:),_91J][1@
ML6SX](G@X(=/R;=3C,@&BY^JRQ9%251)X+.MZBQ6L1@X".I,*JK&TNI<-T&S
M-(XT$DX<!!2_TXY+6H*#P\%,(LX4)Z[IM!1@T"I<)]NKH,#3(Y<%617Q-0JU
MF$N<#LL$O([*V3\H%4E<T\D"`B>,)OG(+&89G4Y>`L@C:<,001F*65;4PM$1
M8!3P<JV_@!H)K+8*$H.M2](H4<]L;F)D]8C-QM+*3#K>%!_GI*PJ5*K=.WD$
M#"`+T184)J]`D4X,D+DH&'2"PBU0\0O9NL4*M?]2DQ)V)%U<^IT^.$>:Q>BE
M*<JC%3E7@X5]=2U%=/3:H`+"P5I\0V>0K$1?4SK1?`R")#)M1/;6^U9+?+)M
MG<05?,W*3#5EN+N;@!**296H:4QE$/H"8C0P^IX(`00>[J%5_=!2B)S9KA6Z
MV$)%:$4(?95'F)FXWCSL:D/-`:TCFQN=8'W</B_$<)^@V,Z:6F7-;L!3I"/Q
M'B.D=1XT_2P2?#FG3>6X(IWR\[HKYL2WXAPJ3N%N.=1[52VH(1G]I*8S/\Z"
M+E!(PR=R+0`8&X62/417Z"WOS[6X#XQ*`2B>?AD@6:.$!"6)"+9]2PR1%?2:
M3AP-$Y<ZNG]28':ABU#_.5,6'72N,W9$<QT\U[BZ9/&QGZ<#Z/<`&1?]A!$Z
M2$/'12PZB0ATM/4@#0M)RP\5$`2*;BF!L2N]3F<B!!D9B!-+8VJ$BV\&G*`(
ME8@^_LJQW'W$^8)JU5@;"M&;6Z\Y[F;KOHV"/Z<CBI]K<I724$;0N""9'/OX
MKA@>F\E..B)&4\07%"ZB:Y$>"K_S6XJ,3#*YD*J&8<O]ERZ,P0\@]P,9C%87
MD)'[$:R6;A;11L>_S=2<DG5$JR7:;G?CB8\_J8I*3!._?-TD'(`D``'4)2+Y
MYF16[?/UQWYKVD4BPB5701`OT,L71A=Q<WXDWIF<OB*DN[$6O"T+*9(+.B]"
M_Z*Y^4%$!>NB!3.$_.UEL(!KV!9S=`/D3)G*X,D-"N65DCJ,[+`YJ6ZICU%%
M`QHF15XN+]R9R`+D&5DXQ\=*JE%%K!(:A.XT-)Y1UY*K(W"9^L<R`2(M[;G\
M\28U4;J_HQ'1,6:E^HKVG_@AOP>0X>VX]P,:7L_,\D3X$-0X)U]"]R=YU4M^
M/(5SW8+:E*\*/EC-(H60Q8-A+W?8$=L+K#Z(?Q4TY#[WFI-CMNJ6_(2*CY-X
MUQBJZ6R;YQNJ24-]JM;$DN)1"`E*#OI])U1,BNM3@J7BM$F38'&<)CI@4V1E
M\'TA%P868#\ET6TI=W8P<3E=H$&)8%TA07(HUG[NA_\GM?!7'G4(,G9UEP`=
MP.$%_M<)S00*D"%GF88D\%`)DO02B*!/%Z8N/'-[N7<&Q#<.82!RWU`.'Z92
M9!-+HJ%8W5"!"$4-QR)'#A5.'7@G<X6";D5K#'1&W<`]5'AA5C@L**%$'?:%
MW?!56*@/V%&&8B@Z?Q%]`SAM4A1%&E%/G;9)76`!9C`&92,:%6`&/PAR:)!V
MXO!Q<"=WV+$Z:&8TJP1->9=3?V%0W'<(Q!6%DC@8M=`*7^`P:O)#.!000A$@
M^()1H",9F3`:3L>)^?!K.A-:IN4P;'((EWA1W#`P?90[NL``C@$M.N-'(X)1
MK]A")7$932$9FD!VCQ@)U@3_@&#%#6(3<F<P@>?P`&-0!F;@4J"C@SLX!E^F
M*Z3V"HK#)MJ"5K,V@4?R-I-8CH=1B7I2,JU8'^]11601(']310UG&5\S,K#@
MCC^!BA&R0G;D#D9!"-'48Y>X-B3B%-?#.[\1(9?X-_D1D/EE3C=D&3$W4<ME
M6@<X"?>T/:@#$LIEC0LXC;'45"ZW&&J@@"&'!C`2;MA4?C8UC@2E,7&H#Y&X
M/B=GCG:"CC940.P8(31&1-1C0.&P0\OA7_J%B@;Y!V51.(0P+VK2.3!&BXJ'
M#Z>3;"F1)H+$:&SH"-4W4Y?6/3NC?>9`?*.3@"8Y<@42`"5IDGX0!F,P2A%(
M53!1_S(C-G,M*4XDMVXCU&(V>9-7J6=7:1K$5E<!`A<&XS`\ISR"^3Z]=FM)
MMQHE\1+P<Y2U6%WQ4SU"41+K@965X`VJ(X"2X%489Y&S5@'>IY9AX%(_8GLF
M>9I>,CH6\&UV^5@D97)+1!RR.9?C4Q*K%4:&MY=\63U)^9>U2)0^294`96R'
M29Q1)5]'&9R[,$EB(`PZ)IG(PPV-49FM8$-UH8D(Y)6948"3($FM5VX6,SIG
M8)K$!R98`EU\B'N[YQ[/<IYA0`:@]'+9]0AL\P7015V)I5/P58SKHW^^N2#H
M"!)&H7'UT(Y@P!6#^3X5X2"'B90+FJ!&23V%]8_D,8KU0O\@*^0*)P$A@.F/
M5$:5("%C.^E3YS%)'#D)9==EAQ!8,@(HT$B6[GF`'A<&S1B'7#,&Y^D'9?!E
M6&`!?1AR9&`!V<5WVY@N=[<KA9=^_<@GSC>@4EH,Z/B*1A$S,[&)DF%A/SD6
MK$AO'P(06[J<B\D+O0@CKXA(`P-(T*"+!_F)O4.5:9HXC.8OD"`.*[-Q&%DV
MR"A8!7$O"S"-X*`G%I"6(*<&\`0Z:?!V89`&_>0%U&`!<M=Q@OA]93`&T\9/
MI^<(B$4-`]929>,.1;AZO4*J4RH>/6):RB@C3K%/2Q0-\K-$!8(=^FD.T*"?
MKYJJYB"KJKI$NHIX**B4?U*&JGK_#U\(K.^!';]Z8<I8AK6:JUJEI]FSF;&'
MFOI@839AC46:#CDHC;UE`1[Y=O0Y/8/P`(NJEGYPGVH5DU3%$RAQ4$?R"BIA
M&'8'-S5WJAXX:<N`,SIC=HW0A"2H"HO16-;JG5XU<*U9`30:<F6@4*O43?%`
MFNB:!GFQ&.CJ!V;@%"A1AO5J22`##CQ3D^90`2K1B$J:,O>*KU*HK\K0+N0Z
M58Z0E:'`F5_BF9@P%*$)@/=3FM]W!IB*"%K`LPIXFN4#$^'Z=F.`(*-C!F:@
M@=Q8=]IP1L9G,>XPM1=6?MT2>,S`3=PD:/4G*:&P>,0@#B"".H^GLLL@9G[J
M?'A:=IW&_U4S]0!#JH!GT()`L0`+ZYY]=S]I]#,PT9X+.)[/PK-J8*2TBK6/
M0%:=!`V.MS9.FA506JK3M@R3,1D0J@D8BG(`NPD=6@P0@IKW$APLB[;H%(-L
M-Y,4N0Y]9S@"&)WH^H="*`:WX`6$>K2P.P@@\X,^JQ/;T4_GN7M>DKNY=ZG$
M![F;JBKCM[C:0D7!PQ.FRB`<N`RN,(N")K.Q,+IH0QJD@!)1&@J7RTS:F[FD
M"PQXJD0`^@@#VZ>%L#*^FA%I,+<AIP;4^`!F4`:%2S7\1`9]2)\)X7&X%P9-
M6S+C!+>%4*D]NZ)D([*,D'+HE1>@@Y>.E8(Y$KT&\8\.DEM#=/\PJ(,ONF44
MHZ/!\N(N?N12EH4PB,8`X_59$@-/)"$O&EG"&SPQ!J-;?$$<,WPD-_S!&#+"
M),$F#P/#XWL*TMJ5=5.M!4))%Y9&>V(V&1$`/0IR]!D/#V"H/HJ'3%P!8U`>
MRO@295E'D!@`%YL&ZM-2QX=R/G,O+603\`!=)>&-3VLH]_*\P&#!%^48SR`B
MK6@X&)&/L-!'\K):MC@PSW)1KH3')X$OQ'&9^XC'S88:I!$0*P(C%1@4&[''
M<C&F>YP7AR0O7.4O.TS(^+(G]<7(06P*`UM.$EQNKC.YIB66$NL'.2K`,^JS
M!>$-0LN,,!$E?U&-%QM#3W2N)NFHR@C_)FGUQB@7.CQUB89@$Z5CO`;UJ7("
M40U!Q\8&1%81,[+Q#4BR<.RR"/@C(JG:N=#4=,-G"Z/\S--P-_-%NZ0A*-&`
M*]J\#B&R%A`B&HMD9;A%8_-&SS7QO=$0OBK4SM>LG:7\"1Q6LU$Z#MBR;@`8
MG__KJ(3B/^'GT*NIKN-UL4EKAE)+O_`+<AFM7.][J7V'6)9$*RO"=.H+DYWA
MKCH2?PM!Q]61#2[A1VZ2+W1$&6&R``[#'-+SS]`@$#%M%!#:H8>T)B2BO43-
MLD`-OC5%&I=KTW;*U#[MSYUK%$0]T]I;T)Z@MNL;16)5D0'X%T':T41ZD2-+
MUF_WAT<,C;>\_X`6(`SW<X=Y"#(\ZM:M-<5OY[,]Y6TS)SH`(DL$C)]!2)L,
M`@:IG`PPK1?94`^SZYC<I"%$03JMF!7^<L<_C0L"(=2\0-2,'4N=F]3F<"1`
M+2%([=2OTHG4\=FFG;VBZ]-TQ$URK-6'L';*Y50+S*>\9SC3%@`&K(!J\#IV
MB-8^"J282;M:8`%YRYH!V(<`7`_GH`5CH`;RZR6V_'W-_5&$#;3[HCLVF[CI
MDI_:E=@"L2+OFAFM&)T:LD*S@'<Q*!"=2W`QPXWF[-/D;5#LW-3^`QD5>`AI
M=!7PX"Y!,=_O`@OHK0\`SAK)4M6-G-_E+=N:\(9)_'<&&%E$C'%!B_^N49Q`
MN[1*OIM[]$FI/SBN^R0H.OB'V'&C'FXT`"=+<HNN%ATR26A$>.E6R6?,;27>
MG9$O!.#+YNQ'%0(BE^')(3(K_75161`S-\'-\]VA*T2R`8W?*Z2+(GA17"<4
M[G*Y#N+CD&CEHY@LEN$T"][D.^[@ES#$AQVW38/#8&U:YI2W(3>-$4L&WBK+
MT?CFN@4Z;C>(LB`:#R!W0M@.:ED&N0UCPNV'6,%,D9=02$4K#-H)Q@M?T'P;
M(-@0_.>UML"XYH1/V5`0*D8-*ZWH[G$>DJ,-(#4*7KMXP8<XW8;JI(X(V?`/
MK\Y,L-[J(FAAEBYMYS`*K"[-9(Z1:1>`9X[_::YCNA%NEQ:@XG48KA^]LPOH
MJ(.Z`'9H`0B2K72+C?BD!4>;>V;@11VN@#\JA/UD!M*.>&:R#N=;YCPA:+!)
M&W/6Z^[N"3985ZP<"=46FC3+W7U8N&/!4_I[!@VXW-^WK?N4Z!;9UKA7!I.F
ML.B:M,,,L<\R!FV=X:-CJ`TK"WQ*Q)\0P=F-&+#&$/L@S1\_)E-23AWTF$PJ
M?=@K/R=O#!U60._^4@(8FG=:6,7X+)2:>VA@Q:MD3NZ!XB;YHXBP`%1LW<3'
MO211J-9->Z9E`6E0!B,WJ,=MJ"DZ#:_\=FH@CZ@YD2[3"N!]&`**V))!8WYD
MB]DK&;,0,Y+!/97K_W059[T0,N/HQ++^_/+(E3%NRUP77[1WSL5T&P`6<"0`
M=;'R6X.VA]8\&+Q[&#(YR*BN++3W&WF",HW"\"P=7:2N-+GD2`J.^`PG2SOS
MO$)#(M"S70&`:D=`KBU`;64\/E%NDCIR)(2L0_"'H--V*S^&$0ZVFFY#XHKX
MM(48NH)H\SW!KK)B(SJKZU;Y<=!_DERJZ>*9HC-N+JXM9(_KN3%F\,2&WK^5
M6O$+:OWV>X`4??!XN*`$#P9"FGO"')JNPQ0\)0:0+N$*$=O#T+E^PV#7+A>0
M40_$&M.X"P@,7@0!?V`,7UH/#PP/?U\$#`R%#`N16)&%6`Q_7(P,8'^BHO\,
M70Q9HHH$"ZH+6Y*@7Z!_`02C?Z:3HKE=I):3FPQ:GI*.FW^;I@1>7)&EM]#1
MTM/4U=;7V-G:V]S=W9Y;HUD57]I;#U_G7+?@HU\/?O'R\_%CO8]86%Y970]D
M]/6ZK/.4QL^9,0_$<-E28<R9>&0LE..B)0#`@Q6V>-F2SXLH+`_"`)QWYH''
M46+&B)QGSY,8:86\8>."I0*6+R"QK)/)DYL7+3V#6LO"0".#?`PNW=)2`1>G
MI$EWDL(BBB@_H)C^:&$@QM27?ED6/*V0)=*6K<@XB0'UH.FH0UXJQ-SZ``O=
MFEW&`;6I=8&[HZ8V<ET;+BF8!P3&9=Q"`,RF+,?_DJT5LQ9,@`HGA6K>S+FS
M9YE?R(XZE_F:F`=<NBR0^NA!J%LUS:RD%\9"S'-JU%C0DL5+@`=I5H99<.^=
MFGEAS-3=I^C!L#]>_(V,EQSUK2P6IL]#8QWV`S,/P]1-%$Z:F-*?_S#L\N5T
M`/3I9:9F'9\G`0(5CFY:P$CJVD]_)!6`+J,<5=4IKVC5BR)_6,6%%UZ(%2!5
M#$;&"7_0L=9%4QNF8HM6'S(3&E!=`%442@QP\>`?"[A5@5^Z'*,%4(_0=(J%
MZ^A72CGU]>CCCT!&<PZ/M#R731==1!B3..2(\IL%#VRQT`,.(1>EDPO,AL88
M&='T0`#*E3<.&M.148%`_^Q44(9V\DAT2US_:$>&28\TIY!Z#44Y#I'1>/'2
MCV!HL4`6Y^05I#;S'>H-&`0P@A07AZ`R"EU/%>+<+08V>(H7IYPXHZ99A`;+
MA%IAQ8F,-$)3`0%,"5)J*C0R)@E0KQ"5V3&3TOBI@:AVLI4DD)W*R82#2.*7
MHL@FJRPVI^V4VCTS::'3E;>HTTD78\1SAG(ZG37&FF6(EEJV%W';8&^BG#/;
M=&/\*<H7%JP+4&TQ>9%/;R#)!I!RZQQ&9G7ZA)8.G=5`^^-56V0QXVO+LJ,%
M?`U/`V&`8"1HU77(.,+7IP521<NP#P3VJE45N':,@9]:.#+#LL#"U:NO<KI`
M(O]`<5&*6Q]QLA%%COSQ`(Q4]=H%`5M$JC*I"VW%9\1,-UT?DLXFI$UT6X0F
MZ2BJ#00<;7,F>=7,G6RM71@!&/P'`?("Q-W2IX$WDGAB5D!&&5Q*>5J5`:4;
M$CUD-/I%`$96$P!]/GK13]4;EA<QV$Y7P^HF$`*6XEE_$'8F+A4PNF2`T@YX
MSV4]?VI5)10]1:&I::5%$<YK[?0SS*)S-0B-;6U.E&."K/6%+"_QRLF,JW,Q
M8+"I3U@3I*<TKOSR05&TY#L,7R/P87QR0=R[%L0Y4D0>C[*`]MJ-T?TN8Y`Y
M7;@\/IG00@T])`\:HJFWM[9FV)3T&&98X+%J:9OQ,)+_V4A'LFAB$WO9;UD!
M6!KS1C&@9[!($IK0620(4(Z6+0-3L.C.(>8"%*O\*C\V.UWJCE&LEXEB$0Q,
M$<<^U0Q)E,Q)L[C%)_Q"C$;D*&B<,(6T7`B*HQV%*,58H!"':`VJ,4F!U#A+
M>[HCBG8\H@+F8].PL*:OZ83!'J(P7$688X'C\(U.!*&.<MZCL"[Z84[IB]>\
MNL:%+Z`+%^2B1TNDIHW-(6L]`TL2LA)(Q&A09A1<^"-T)(43(D%F:5E(Y-6@
M$\/==2(+*A*#E"")+D?N8Y!9Q(+B&D0D+D#2D8_@D;UZ(ZE7T">0=^H$97:"
MKDO2)!1;4$AO+GG)!GG$7JGL_Z,NAVBUT3#Q&B!Y%FM"PS`L6(1-<'L7%F#9
MOGG1,33'B4A>#"<W>?AO'?`"'T1"]@7?5&0GV&+3&5/5H.S0)B'0XX8=DQ6H
M09W%4$#JPB9WZ:.OI&B(64`A/??)SQXID8&KT0;4*@(-ZCEL`6L:"1JT4![5
MJ.$R.FEG0OVPT/*<PWWQH!M#"0BEF(0FB@`I@VV@(89CLHD,QV*@&>-1T3UU
M`PS16Q;"PJ*%F'Y&DOT4BO48YXX%M$@7)1T-0Z.!1&D4U4GKG(8D7D.YG#KU
MJ=QH5A.OEPU/Z(-:OAQ(/T*6R'YH$WX3J8@\PF`FKW7!`FFH'X]`DC:#("04
MF3D,1O^M^"&4+&"N``%<O]JR`#!0<V[DL-8WDJHLPT7I*QF)ST:@RI-?]6P4
M^9'$1%@EBD-(5H;CHT9=JL&Q:[RQ>(P-K6BQ!BTG8N,=58L?:;46IS*PPJ^_
M"<X9T1$V;<9#-X/:"!C`&4<KXNPC9A!G195YGC).E"7W4)=;,_(3DP0@H#(Y
M26J<PTUE$5`?-='):)G&*3$0A4B\JY6H:,0*3FTR4YZ4RCYVDBE`0A)6GG0O
MG[PP$4D=X[WO6AJ/0K7=_C;-JN[(G#8$]D]`+L"C:J('1C1B%RV@*33'#2EM
MQ;$`<<X6&M9;J=J:)#\UE)6^7ATK';&UKN2P*D)F`TT%XJ?_,-XL"X^%@IA_
M?70Q$ZIR'S<J&8UL@M]42$(?$_1(,"CXJ^Y!(BD>84HD''%D753B$IE("R.L
MT\!"$&4K99%$BF?,Y1ZA]BT<Q@9II#H*(QKB`2!%CEI5E69GSK<"LIT.OZ"C
M!2CE=D-D6!<:R3<;D?+&-U\*4R<./*\YSE,F>VJQI*AY:)ZX\:@%%12A'+S(
M;GS!IEV6!E&,DEE:V&*W'(,*`:3R"MYL:!R]6$59-"F,J[6(40OBBE?`(B$&
MD,4L:)&,['2$8_Q4YC(R]N]Z,[T9@655&W9Y%C1Z*;^VSJ,,Y/Q#@L=&+<AH
MTDL!P*L?L/A$\VE42K$1R9RM9]+M_]3-D^CRA&W%(P9B:H8QZDU<%G^C79Z,
M8P%8X(^4L#'3UWKC;\3&QGWRDUE9="_4A"#05,ZFB:;8>M^D&@4A'I$*1S@(
M0K6FD#&$M0[GM"Y`"7M9,B#=WU=(HM':F*),>),/Y@UIM0(5B+2@\?)4:)L>
M8*U*J/ZJT/B=HPQE^(U"SE$^ZN@O75I(\T'6=Y:9UY9-!W&7(7K+4M>`(<P]
M>>Y[H&&ON@PD)\&N!FD`F5W"2<.PB$OL@%,:\&HPRE%I>BS,='&IC@7(91]+
M"BK:&W%8@4I4DB!5RH0%JV#\^&(E9'N7FX&*LI@]&RKW!LL[';%D3Y6PTG#)
MEV]!YJI\Y__F?E!#DSP!)E8P^#NS4<.$GSN;ZI!1$;\ISVF<G1RL^\R+;`J`
MNYA!I2BB3[`]L1Y37)%YL*?K3&&/AEZCP3X]7N.Z!JRW-7;;]FM,+(9.&O52
M=BQ"NY="D>^J!=`P196JC>P4)<.=X%&WB77,Z#&)Q+&DDH:(@"N,@>7`Y3H@
M!(:70`:;?O(:PP(9I?$%``@=MX0%DC)Y#:))3`-`3815TG-8M@<U@S8C4L(0
M>",/<X)-V2,/2Z<1[E$&XQ9.VQ,RS'`U`:`2XD0&F24V5G1@>F,!9W(6%E`&
M'6B!S4,MC.%\0H)\53$CE99Y$)A$DI8-,(:"U2<4CR,(B=!-MC;_(SS",1NB
M.>07/.55`2]Q*4<A%8K0#`O209VR&FB!,NS'%09'%.W6&!=S/)$2<(.P2(/0
M%EBQ"(2P8D#1'+/`"8RB!1<D"GTE;;V@>[/3&%IA;5>FA<OB$@$VA-2P)S77
M1$X'87Y0>SIA7/404!\U+_4340[X=&SB6JKB;!SH)@U(*"M615;24%ER6Q;@
M"JN@))KA;B@1*"ZF:4+X+H=##8S(;Z:'A))V%H.RA#S10+U@%28'+'[W")+P
MAZ)`<):%,K`0"@3W%K!0#K&C,#P40J]B(8QP09\P:A<#1(U0?:\@%_W2"S:3
M,88P:NLH*/(3((=8.4MB3%SP0NC0<N]P_XCY@`7J2'D_LGGR0W+58A+!]";4
M<G5I]F%?L0@><U$G)7>X4!#B-`9V=!C9-AUI8!VI\3T(\0!G0'08!3^A,"X`
MH0:E8%H]`6MFUY`HAS#SMC[+YAH^D3B/!PTTE3"_*(G)1XRB($BI04J*M!.@
MU(#Z=1,-J#@<04A(*0X*F%^/%$F3Y$D>84FHL%Y-&4CZ$)69E$MP*`:K,A"6
M<2I4<7_R6%.D((_"H`BIHC#:>);.@1:3=PC$ERPN]9._9`UZ583OPF'*-1*X
MQ1KY1(HL]5O(<(-CPVWC`"7=0B41UA*@6(F=N!&"H@9I,'K2<4ZIY8C=0!K&
MUR="9W9HUT2?>?^7WU!VV,!HC,8B!.F3&":1K@F'F:$%YX$?$M)R9OD[DO(4
MQO.)4Y$3>=@%_<B/Y<<(T?8C8[<+:#(34$-'0I4^K9A[T0,&%@!ZA<DC''$3
M8?&!FJDWX;&19+0`9C0<'O4`N#</#'EM87.>A5DQ$Q84.H@G/L@.(+%US(>:
M\MEY\A%C,Y%=]I*2L4F:TA.@2]@5H]"/A;".N$DCOQ,.<2&/%Q1?N=(5,U>7
MH3!YEA1Y/K)\OH)YS'=80\5Y3%0!%B9Z)Y%(9U9T`#$G)Z$:9:`;?^95*\$=
MY1$`:H2>7*5%:-D@4!2*!(,])TD.^BD?,A@-+<8>TE`H2#0ESB<H-]G_F90V
M$^<0)?SIDU>':00:H.8%'61Q&F%!E@W"H%J1.0XFCR42%N.#"9"1&'CB&'EH
M;8>1!6`)2#W)$\J611)H#=!C;+?`E[B`F&5B'?`2`!#%1<<U;EH07"!X;C5!
MJ!QF@B/A9UQ7`=9)'9@!#?FR$CFXG,$7,EYG5/*&B[<H)"%#59Y!4U@*#5T`
M.'GQ3IPI;#[UI%GJFLFHCHQ0"_92EF):$:R2([XB#*P!%T210DW"@`,29G&1
MJIVJ.'S*;X'UHV'C,7Z"E#Q'#\^%33T*$<CW5ZYU#]%A6P9A+BAZ0A3))L-8
M9FC&)C3ZDX(2#H%$)?;P$QXZ8.+B'A`CG)_:_R>ABF%JIUC[:AYB\EJH2FQ@
MJ:RS&J!4R0VC&B0`UAGIA'2MJ3?"$SBM41Z'008P>I696HG<=@YMYF>](0;+
MU)=MAASM<AWFQ";^(PZ]X8>`BG.C=V!AL"U>=X_OD:>6-I`T5UV<QPSV>G;X
M^40&2PWM`3@S,B.ZIT#713A;,$^J^:^C]1/0=;!4&Q0+>RCQ&1171R1#*C@+
M8#AFPZ=_N5SN>AI04AYLI1UH4*025[)6$E,V"JYY`QV!M@C9AF<XZA'JAAP;
MF1'-*A,ETA;]>AT+4V;N4BB.R*1>L+6G&3()@Y-;T`_V"4A5JAY21Y\V@1/Y
M&EH%6[6>&Q1\I"S)V?\3P.>GU6`]`N&<>M.B+*A@W$(?6$!UD:IXB4J*)2%[
MBW!GP%%BSS1M?@"R!F0&0?<<T+1ADQ:Q1'4>!$5`#T<XJXD+..EO25HRLFH>
M."L-@<*I0M6J6\8.2OJS3R6UU?NYY"M$X_"JV)`UD@B0F7=8>6IYUB.[:F8V
M"Z"H<C)ACL%,&_@^C\J""^8E;C-<9]9F_\L1Y;&)7[1$XYND@G(BU9(?!"!]
M9&<3VIM%4(L+%9R^G/HW1^L<\B055^>(86&(8D9I2II3G5N^*IQ3T7&Y5<6V
M`BD]F6.:RHDUY:H=:6`VJ5%-([&1`Z$%WT)OD"(H$[5GY.:Z]G,6%:`%V#G_
M/R.Q+8KGQ/+@PZ:+;`]POM.@C1$,'^SSM<5W0(^@>-F@>V4F*-3G#J=1;]'!
MF<_K60*;B[LDOBL\Q_UTIXB"57\[?>@`?&$C=81*F&.@B3,RC`2DBMOFK9E9
MB1MI5M^!$*QE17,R3UL0G6IKF#9Z7/&Z68`K3^\Y#?94"A#C'.>*8>N!2Y:6
M*G&!OF1VCS>YM*F9.&TL1%Y*Q[3<3UWKR:H5B=>@#M=Z"YN'$QG83+1!51"Y
M8)U`=$!W=$\481!A`>RQ#X3DN]H1>25%F*HW$:S:5?Y`+S&\#59URV=7"SL"
M#596(B@7**N"O!_!,*-LA*/1/?;"?)5[NMGU-YO;_SCRNL"UO,]-P[C6$(F6
M=R1)XJ=W>1ID<)E)(E$BAK8W2C\'M`6$^AK^XJ.E@04W_#;XUD3Q9VN&S($<
MN35;$B414A1Y/&!14L760!.1,*HP9<%18G:ZIX39$#B/Y4G]:'Z3DAD]DRC3
MX*I2RDV?V32SS,]$O4O=3%),A-*9=V`J*3^LFWJ[H<T'39-P!,F:7&850)@&
M<:E8O;^KV)>$BAAEH(%S!9F4"(*_\:SJ[,MDX70RP1#"\!J;`WV8B@KMA+[>
M0R06IPC+E$B80`!Z])2I<"W52U-XO;VH.)_)DL]%W=BZ1&[3H(.].!,4"+?/
M<<1J@Q`B>!YA8[_:\4O1P?_,VQ$_#191=19A).F=U+'(BUMG:M"ME96N?",1
M`=V95WR]+[45&4%YI7R@5P.3U2"R6*,(+])N#5(791$E#S,*%E>G>#JT%%93
MBJ8L0^W8UDU$'"J)SQ.BIT46_MQ$$+BWVG$&"R!U62"_]*`<1!5B)TE;1TQ6
M*-B0<2)Z:]70I9@7."'88SO%J*'4P,0;ME=FX*<-_/!P6<PQ@EUFA_-XK)Q%
MC:)[79%^@L)[T,(/BR+&190X+GDHC'W='CY$-6=F3X2\0\+'IO4`HBU'4N<)
M7HU<651G/W.5L34;'1B9S9Q;O_$SO!6*%A!360T0<^3"V_`SG0QF/^-3@'W8
M"G[_'Q+L*QZ3X)C;Y+&]$S]Q)LZ19+V`8L["U=Y<=]QP7?;LE>E1W1]>YLR#
M6LTZNJ;1WU/;&M$#@Q@=$[:8T*=]3AZ#P'1S)=BF!L2!K>PI#QJU-`MPT3W\
M@AM8&S?!W3)QD-$P-(2"'[S!$%=+S_<A%0()Y3^HV$[]%C\U-$.C:H"$&,[=
MB,>)**?!'D';&1UNYJR^//<89ME]#4@BB]?!88\&P&F33+2@1B`KWU5G44FG
M8*%I""/;;>+$Y]"@!2EN39>=#T,'Q&5`HS3L#57,,X%$-%D`.!F!SBA74!Y1
MRLU:%H=]US@)QN^B2)7&$$3##2]7ZNS.5;W-&63>ZO0N_]2EJB+^C6'2TM2"
M=59FH-GONH'P(RF0RE)U`VA0PB.S9T5KMA1N*V(,<Y5G);?<%AIS`Y[[@!@#
M,^KM2WG1L1I#`]'V90G+M"%2[LN*$R@$<+A?HN0-8LXT=R9GG+PAXYO90&;N
MW@V*1NY!L>KU_O,-`X%3*N020X&5ULN8;1!"["V6B9F$3C]4S4"M*R>9Q1!R
M2U$")C\(,4W]$&>5J,D*B:/\P<'Z;%2*[@Z`31'+<!X5P]G1D>0;,KG*AY/F
M?*V8GN%=XLMVL<0!D`^L\#,9V.V1S:DY[PV,!MS>,.]`O_B'TK"MH5IZ2@X&
M96#W(-Y\^R7TI9Y>P)UC4U<GI/_51NP8^?<;'8T^'W&CKE53`/RB/"C%\>`_
M8!L4):T>1//QAJ,0@013_:<BGN,8@(U$@Z.O)W+WSY?J+/M9ENO-!+44G]%U
M-['@V^#SC#_]`8E5>S+91JC`[$`MQ2LG7(X,3R]'%TDEH.?#81,`:J#9JO0E
M[E/C5:U@YY:=/,(_0)ZZ@B]FT'J@C0$)-04(8G]_8@M>?UYB6V")7%L56F"/
M6EF#EE]<EII_7%@5#Y6;HJ.<CUV'I)9;7:FC7@];HEJMM+1<8@\!7YY8F;6X
MH;7"P\3%QL?(R<K+S,W.SYM?%5^J#[Y<75V^H[C8VIK28(->%6A^Y^CI?F$/
MU)<59F'_ZNCL@G]?#Q8/IUM:8V7JQGR3!O#<F0`/>OW9DN_!@DQ<'IB91\],
M!52#P"R85P^?N&58M&S3U&7:%@);OH"1E$5<%C%8!F4)($YEOPI;;L8:YF@?
MQF/]N@03]25`,6GN-LV"-HJA4*<_-WG1$F`DTZM8LVK=RK6K5X88`SS<U&U4
M-BY4-X%I9XG<&8KT8`WJMV"+HPICWJ9#HV4G0W-^R%@0FF6!!37K%AC]LQ9P
MNC!I<D7]\X`,W'0+AI*SC([OEBS3EGD;%=&:&)0!JC)6Y`5,%B];L%3BDCJ3
MI`4$L&BLH'!8T*'&"D<BNMBWEJ1*O?[)HH72;U'`E$N?3KVZ__7KPD)>RT8*
M-/*(6%[MK.;K2Q8NS/]11%/A8Y<Q8<Z82<@%C)8%!=F[PR4O79D%?7G117,?
M,=0?7&0\(-4#!\(ED$Q88/&%@)6%H1]#5AD3D3W1[(--;BDQ)M0@`8A1R6>+
MA`@&38-@T04#0G5!@"X9=@?@1\@(B-,E"Q13%BE+*:?C9S>.0U6-V"6IY)),
M-FD6*X-$--XH^.Q4I33`G<6)/Q:=DD47%G!V3AFA193&8Y%YV44^QPWRWF5G
MC&&-)F!8T.!Z%8C"D!EZJ<-.3`L]H(8:%D32R2=>B(7D,%52.6-IMRQR2WU;
MB)&)%W4-(H8DD[:D&EH$+``&%@2T.?_,D,H<VHM(Q'#72I#2>8%%0E^4A!!P
M3N:JZZZ\,K7A.SBFPL4"72#5SW>*C5,9.F44^MJ:9)0Q7R9?A(G@8%9I,=%E
MYP0P5)U]4J0&6X0T9^E">#GFQQER_?'>@7%6,""F4"KC75,,I.20&-]@8^DM
M*X'Q+[\0=2&&%[=\L<C`!#R`"R2X"LO+HK9`)0QXM<`ZW2VYW,<;Q;V&+/+(
MO3::46C#:,'`2W.VU:XTZIZ#AIQVP70NS-SZD49Q@SR0L\YS.K)%:_<5I$Z"
MOKP;QGSA+:?%87Z02<VP`7`DD)3,@#4*J5E\46HC"[=XRCTY@:%P?6+8(X:W
M9"^B<*`,I*W_Q8X\69S,<ZF83,L#?5TG1@73<!S`9"07;OCAU-T[5\O9]15J
M-!6$\A><`6BL1<P</1#L'[.F<2<Z#]X#3QH69/:EM:"/9>;1\E(CH!9C1R1F
M7&*$PXRBHF!C4KXKUK329R[!)!.+*DFR$B*I982%72V!!N("%9SKVSX1D]*)
M)L)M/@A2*5-H5ZQ'OE)-L8B7;_[YT&CMYEC#G$55NX&ZL];GZIR1IR8!6&#T
M/&BTNY9#=IE5`,(5!@L`:G)C&D.`UI0&-1!K>ZB;1[-,98D%S$YFL``#RI(Q
MFMP]P!JDPH*).%$;QN2D-:^)S6Q*:+R68"(V[@A`TT3UHBZ`049-_QL&<R@A
MC`4@9QPE&5J4//'#5QU"52!K1G0&<3]+[+!ZZ(NB%*>(.TXDBR<.:Q1:C/(C
M0FR$6_KAA!BH8AXP7=`/820$@]9%LYZ,P1SL\LL:ZR>G@ZEP>^7(&1EZ1!(^
M^<<DC$,&UH@B+]TIS'@J&M$?2G2B+*2(&C?\B`C%`;R<4&,F%<C$VDHU*@*,
M[51!;(4N4K'#YO1%8[28&_G0]<FK?.%(ENB"4;(0H7.A:HJXS&7Y.L@)^-7B
ME2G9X"(+N0E/Q(,B"9K:`])P!D)1@D*>.T<RW30&/UDD/,+AH;O@<YFE\=$2
ME\L9.\;CCD?D)3#6T)(R/#**+#SJ@Y'4E/^D+"4)6V8*8$.SE"-5@ZE8X/,+
M^B36I4H2O4E`412RH@]1BH@]0(&S&+-X8D;N<]!C>"(86PS46G`Q.$3,JC>Z
M#*E(G31(T544>X#\SGW:@19]&(HAYT1'9*@EJ'3$*X`/&`.`($*5RY"A`CSC
M7#7U^$U-00TN_=L)0J#7-.8X!%-!/88&&;J%?.$#%)9*1+\,Q@6`K61@4,+&
MT&X!&X&50G4T.8\UPD8(P(E0"[ZT!4<)1TJ'#@*5KVI+*)<SH"DE`Q^J458L
MNC"6I3AE:A^EZT@7RUBML#,CY!(&6&8U$O&(;EELW!%=U%"&JRTGC_.03T+N
M@0K9_:R)+0H`_=#_@31.A*0N.B+#G<*X1=:V[BQQ!4H@+1$``IAG1KMPS=ER
M8@\7'4)A;K.+P-3&-N2:+18"`]0-9W%(%"WG`3/:`O2D)]E],+2==OT#7E.A
ML80JQ'M)),5%P1$:5XD7>\V1G+P4V]CZVA<94[5$%VM1.5[BT1W2D,ACKHD>
M+`1`CJL]1Q@RHXDM#)5;H4-/)3@:+M#U:YELA(6LX-$?P2CSC&JP:N280=@,
M8:,=516A/7IWC]\=CY;2I0EZ7"R.1"UF5,QSC?$8DY;E+,\++1$0C%:1&_IN
M`C2@J`4MDT,,O'(L=A,[2BY&<JS/9J%K[XW&FG8BT?MZ^<O$P%`LOW$Q_]QR
M:"ZF8LA;QL!->B1H<Q5(L,PNH@FTO!$N!;RQ1!!B*9@:;<&+J=;LEO:Q1UB@
M4-2JP/[FO)+("O*!'K1&`!BPDBL+;(6JD<30S`8;"9%((2TTFR,\O<BFT;@J
M*PH%(Q?2R;Z0JI6MJ-0MNQ/>\0)I.$V!G7QAG8KU:J*+HW(1X+XG%3Y3:\M@
M3K:R2<*^C&*Q=GW[=<NV8"?6SA$=#MR$1!(LM18UQTM/0\QCVF4@!3,-R(8A
MP[BL!-IY_)3,VWL`YM0PC?T>HZ3LU49):M6T%$D"DHI<-8K^+2));HH0-CD8
M7W>BB!X=K)Z7$I6F_E90B,6Z7N:MT9(U8>M1//]@UD<N$H\93`K`6H4[B0#0
M!^^S*5Q(?!-(1)[#TKOLFJ./:B[S:RL\PCV2U$N\BRY#@V@;&S#<):;I:.TV
MY2&8S,1VSJ%XE[OG*RM2JSEG)?KU@ZWM#9J7?,2B<&<O/I@VV]A0C(MH!,3O
M<<]-Y1,]6^!GV_^=58*):&`!J_M6'\";,>;V'E$57%0V_E#?A#7*"`UB)KX4
M;4W,ZH=HZ<6:%-X6[<*B5CC)D"F.B'B;>QZ7)<42,;RCOBB-EKU(/]K'$2&1
MSF;>/OA!1W][>2;_*!"GA9K:`K8N0<UM@@!R1J,VHU02,>ET*E$UQEJH*F)M
MN!V@B.`7\>URBY:8]1;_6QVK':^O78BD%6QF]>(A$O$9M5=*4]@]\':W4918
M>]>)M9[>2.["ZR%^#!&*O\?IP7'Y]K1"51L&4I8`>[MF9)]W@"4#=@M!0;6`
M(=K!?SLQ+)\0'O:A/^I@!JR",^;V,5\B$8,1;V=D$'+R0UH0@D?S0^^!.9U1
M)G!E`9EG3(IA6<M@;V[B6V+G(M2B&UUC%\0E-L=5-F^S7)K27$`(7<+#&,23
M(BVQ'$?(8L6S"#6F,C%29%]05*047S[&9+101:)`@*2P>:XE+X[V7Z7W?U`!
MAB&':UZ(@&PX,LNG7[LE2H;@7O\%@M(T7[6R+&$0.@C$.J>`'JB@@7"B,8J6
M_S,19C-`]C2+AD[CAUF$)B$H(7K+0(>6,"PH!B/',RKV$'<N06-,&&-&9WU0
MZ%$WMCSU86DC1!N+$1N;ED*R04*99DFN(2NE$AL$X%O$H",RI(6ID`VO``L:
MUU>D0("`-5\-U@ZS5PR_L8::<$N,IW-M&(U*(F9N\G.V(%`.LPGJ`QHQ,T&O
M43E:L(G7)BZH]0<+(&[=U"Z`6(5'Y2>05BUI4`;OY@5/=P[3(CHQ$P:]Y4@,
M>&_9Z$$BT5LVH5SF(3!3(T.V<4*<!D.?EI`Z]D*CY"[]ADB8<$.*L$@C-'`J
MPB*<DY$O\0GA:'&G\E';T''N4BR!PPN$0R'<A3T$P/\`JZAKG*,%`F*-Q?!$
MSY@[489>TMB3V*%.[I)\UG-Y<?6`@5)AG2$G/Z%=P<<>:K%M2-4NQE0ZSU(!
MLA47[*8NWKAA<K**\C8/XP)0<2AET.@UVK``#L,V$GD(_J8B/D0B(U0["W,(
M&A$*DT0(K5$IBW=VA+`(A%`?"V!/#,<I^A0;$>=/(<%WE?)!T&@]<Y5EI.$P
M;Z@*QJB3"?$3^!`>QK8<T*,-_[@,0\*3=?:8,>>3IND5TC>`5KAS[:$X8Z9?
MU<8M:6!76?``2)ETY%((0B$X%99&;Y)`P&A,93`N!6*;ZR$G->$+\S,/,T6)
M4B5,`T@`EH)=YG<N\10IC$#_3X;)=O[D=HVP3P/5G73'!5HU4/^200+357;G
M+P@CE^GI"`"",)63&_81/5[G%.,E)=1X9%C8%,;X>)7X4?A0.[[W#.85@)KW
M?CU1?Z?9H,V`#YM`9\(P5?O92V?&`#^31E>6B!;H;D&S>V<P,W(!4X#A85NR
M+39E;+&10[,B9_;S$UUP1@(Q%>%U##2X$)'H29AB=-67$H*@5=.GGM8G"-A7
M,$.3"&5%I(5P*=_79SDA-B;B7&<CA(1`/E)JA-*%&U.80\+096W1%R6V<\C6
M3MBUFB2"$JX)#8*'AO"E37CCH'"Z#`Q8*_+'A??0>'-AE3ZU>J\0`/-1+)@W
M.YYE_UKH<!#T41@K=RF811&$-A+5DJ&9U(R*J&`6H`M_5PQ`21*^!0:>]*2<
M,S8`]1G#=7Z?^H/)M1IJ\XI2*@Y4ZH1*&#R`,A.^8SPUMHN,88K-,XJ8TJFO
M9H!Z13=8XEY4LY(((8"<HSE[]0X*,Y;;`Q.*\6/&L'GV,7R7,*;9$Z?8:@SB
M\VN-N0EG08F*4YOZ,#3&="<8F&B.,4&,($"$$F@UQ1&1(8!<T&Z780'(L1G<
M,DU3\4&G$*C]]UU85*-6]'$G@2)0Z!(B-!<L(HHO=H1%=XJ:5@DV-A>*<(HM
MD8K)8T*MV&F8EI`IL9`2(@@R1)<L(6JG$0E_0W+"D"BY$/\Y\.,1AT4:CYF9
M;4&2@9(H[*,G^U!^5U8(O.&K3A1?':AS+/L]()>M2`M>Q:0],)<L!J.-JW>4
MZW!-"H,7>L&'7TE'F<>0GZ6"Z9!UES".'&%`XQ`A1E>N\W"/!'$.A)(9G.I(
M8V@,P.0*?/,A*R)="OD%"E,[)`1J)Y02L!&17:`09>-($.D.@\N6%%D?`>>1
MCU1P+>*1.WM)7;`3RR,.=J28#(&GMC`KO#&`&^2E4`L]1<0Q\>F<\6:LE<BF
MPI"'0[.9=19EI9FTM#L\1R:4IA<+VK4)R9@_=S*/&D%VZ)=@WA2AP<<.F[,6
M`T01<203%<!9-`,;.=4GH=,8ZE#_!A^T"\RJ0]"Y/9XD@;+F"*LTLH3@2`)#
MEV^Y2)^!EPMC&^E[N7BY=E_R$8J`N91R,W*!3]^YG558*6DSGHG`3UP%,'.C
M&W-#;)(U7Q4*1'3#?^"(*UUWJ8K34B[H5\RXLEMVH'IBC()7N[0+&J(0MW@4
M"C19B>[UFQ31+%98"$VI(!R7>NK0/Q^!$..Z@.JQ@I)S;8\(&_=A!F0;*)_3
MG#89K6-Y$M-)DY<[*9*@$(4A#MAI?@K1OV(D"?LK=]3W?'IGGNJ9=\X75I7;
MGDD*>&B5$F3%5MIU1/R2&U^2&U['')26"AG7(N0R:QMB.TT1M?C`&:(E@#E)
M#$C$NFBF_T@QZ\'8F@7Y`CE%Q!!)$20EA6$YH[*$H%KY2BZQT6=%(T%E\IM[
MC!Z&H0:002YB03_S:!ZH$`!ME@YL]BN3F+._1@!FXTEK,PZB(J0^ZE%0(B!V
MD0A#ZEK?@,M>H#"PX:DX>`\Z.*J6"ZHY(2K*E39#6`E7NAK2-2+5Y4A,>&,R
M(A2]2@RN^XJY@PMK4J,!6)N+T+TDPBKXZ"=I\A.BZ1OS);HR(7+N3,@^B4D_
ME)G;L%^&H'\X4A@_@X'C<&6'<DP>"A&[)X_M;$9<1WOH[!.)`DO8P'N]MPD,
M<"<%)"&<JR$])@HRHC#`-30Y<<RFVC5&]]&I9:IFPZH720BJ6O^X*+UB24BK
M/G9`P\&P-18ARI-CYENKBT%+&ULILP$]*%L!D$P+B?*2N%9,?*-(,+?1"TQ\
M]=(/7HM.?C6[$TI1KIMX='.T\AR-M"2)`0I47P)O,J$YT-G)EX&U9E"LL&&U
MJ'QAL].VSR(1.Z5_)A@8/ZQ?5:-'&K,G_=$_9)!&?_5W:&$:*+$VE>!(!^MC
MJ<JJ+9$3AVW3"Z$;$.O8R'-C.6&QEP:+&9&WG58KM.&W#YE0,61J)5N1`>=I
M;4D-5=47_="/_^<)#-#`-,N91[TX71>9XU%N8.1D=J-#-\*RQAK'<;S57!T3
MKZ"Z.#::?;8R<NQ=]4@[PVM;Q5*!G'7_1=*`CK:G.>@!8/3*J`R@%A80U7Z`
M.VNA#^&!"V-`;V@P+D#;'>3\"@^!0R&2*'CKT7I;*5,SN)GPT;`Q(7&'N(2[
M"(;K"&J9N*SV2(RK:H[;%Y!$<B+4-<=13X?0Q"WBE]II3_0[3^AQP*32WGE*
M`+P!H,V8?V(!5257H(-PCCE#=,NCC3*9BXHG0%'1P9T@&<3-AH0W*PA,)0ZS
MI*!!6$/EC0$M#YY!39_CC;O`S=S(+>R"'%B`HGC6+D!V'LS1CO2`M?+PR8.#
M&_K#RKI%.&8YV+K\&0<COC&D<.YIG?FLOA.6I.[K#O![X6;GQ/6KQ'K)G;S\
M=N#)&#OR3W7'_T\ELL5D3I[K:3#M"08,,"MGUEV4`.(,>BBP@V\H5<^7C$SV
MVDMF("WWYT0BQQ,3,\@-5IF`?./*1GAAJ+JB4TYLT0\WG%D\V!"ZE]=P<0:!
M:;SBY&AH$7OK$6U[@A"#\]SU8.1'PP`?!SNWX^5S@1+PK5V(I>%+O'@2]\3:
M&<5SI^=Q=YB"#GU`BG]7O,O8MTAB!<8Y(1+PR:2`NWUJD\_D]QKTQ,Q5JD':
MX,K%0%D-`TD4Y4'!5#W4V%+>U8$7-%.B@XYA,(\CWL`7`Q7QW&7Q3.I>9NJ4
MR6L&M@VU&:MF;1`6L3D6]#-@:PEZ>AGL(4G\"F0(O1<HPQ_65BR'XO^G^;M[
M%'$UG_EH0GD:K]P.@K`+@3;+8_X2M@Q$0Z,PC8V8JE$4/>_1PCP0Q<R#16_2
M4QJ.S7RGI]JJ1%BRGY@1Q$-C8A<1)NFM4.+"3B2,>-1HWU5%:QLUA<((".$Y
M>P@E&J2";7NO-AMFSIVLU?HR8\KP7A9YJ<",I7DH._'<9Z`Q&0]A_0(3."70
M?Y3?0^5,<1U-"8(*4G>]SB)A1[2HM*,W.7*I3!V)K*$2P2Q)'85<(BTT#/?Y
M0(C2#/>*B!TPM[J)"^MOL$KU+I$:NAH`D5HIRG5EE#VQJ]'3&!N+DQ9,0SR4
M'()7+/D(8EDCPU(OUFM38Y!Y8Z0%!R2VU[O_6QT\>O$UW'H%C#+7DG8_4J\P
MN+1PK5%B-\*=6"_3-;ISE>X8:%:IZ><]O0E-J$D9G-_&4[+.O+7.Z?S3%VD*
M"'^"@X2%@U\57X9_7`\/7&($8@%;@EA867]@8%N<F5F4@F)88)I9G%N?EX);
MI%Q@IUNI?UX!6(*HKU^G8HI<MKBR7F!?7JV^MEQ=6\M9D5];`8I_75A>?YVI
M6U^O79E_MHK9G(I@`>8$NP2WBXM?6I6##%W7AEQ:CUU=7(N-\=@/PO@92'!@
M&#.)"'T)6+#A0#05^"W:4H%>NW9>NE38`NE!@'J#N&"I@(6?R`?6+JI<R;*E
MRY<P8\J<2;/FH0I9_[*P6YEQ(Z$M6KP)ZOB1D9@*#ZYU66!F@18P(BN8$6CP
M03PP%=`0#$.FHC$M8\R,6<!O(1F'`\\$>/!MT(*S:`N:$5,H@`6X?B!">V1S
MRX-IA1;NZ\(@RS;#VVA58R5L&S0LOJKQD[7%6+%HTR1CZV286[1OU:Z-$^/E
MU8)I`<1DZM6)M":D6;1@0?F'-"<Q_+(L^(:E4^U76W#36E"J-B=(7AQ!8_"/
M)2+`@K3$EEYHJ1<M`=HA*@YN#-6X?M+L_+.P#'@_91+6UK*@^9_I;5O6>H#;
MK]!"]NM1M&BSO___``8HX$Q^*:+32U&5-`A\@]@WC5\5+$#0&6/X1-$89?^H
M@1,K##FDA@6G[?(-(EJ==X86A;QUGA]C[*.)%D%YD=$#::215`!DV12`%A(%
M1D``C>3CFFJIX,8%,_6D=@UK8`@'QFF"4+*:,4U.!J5(G4`"G)-=E`))EKAQ
MHN`7[1G%B1=BC+*%4\4L8^8VN*$))"VI<0&))W&*X:(R8CCR2SHO^072("B2
MU\4#7B[PD57M@/$7(01\%Y<:CQX)V8QX%40&7\IXIQ9]/1K**(*S6:/;4X8`
M=1\8[,4WX*NPQBJKK'U*="!,1S[`GV(^"3)=<;%98)Y!")4$QB5)+B"I0^FE
MJ,:*88S*11:E'4K&LGZ$H:@E#'VX&Q<5:)%1%S;_<;$`N1,QM]`":?+SI"^]
M015F*[D19U0G:$Y++WEEWED9789E-QQ4_GY!%YKH9L01)*<TR0@6"2]#YE)B
M.`Q)CK4X5AEEEE@$32K0O)+F%P0,]JA+.X9*:$A:($7`-NJERM=/4IT1UZ9E
M/6"&&DY5MM94!.%H$HT%'>31H/,)%ZA7/;GW'HS?9-$%/+-6;?756%^D3X^W
MRJ1J6UZ4*E'3@GQA[59=A;KFBNA54$@64F'[T*A^X0A/5$!7%4\78S14Q@(5
M^6-3<DY;0D`6)--3<9'D82&PU%!!8Q@GM#A>-B5>0/-Q)2*Y^`7FT!@C2\=E
M58PX1[+0]0?$UWQ,#%1-_\8SB36N?U%*DZJ;DPDTGI3B##OFE&)[%Y($J?)%
MRJ!KR#MEPX.(85I`1\C693]@`:@7VES06&5E->$85J'I45/H?G'7S;J&FN#Q
M*L&W?B%D*V85^UG7;__],.GS]G@R,3A4J?5X7]($$H8*#"H+#Q@6^DRR`$=8
MPR]CT!Y!]"**#E$(>Q7`4%<R<0\S."1:O:@`=V;RO'9H9#FCF)/!*F,[T17'
M<:V3!>*@PK'5%04QL+A=;RR!B??(8A,Z5%TT?+>)3OAN%*P@A2E0D8E:""PX
M'($%8IH8`(&A8AC4"@X'JQB);90,0?1I5$+@9KN_U*H?VV*%%K1B-%-I05C9
M.O\7AR2XE6+I:QHD6I%X)N(5F$CM;G[A'YT*]3"2T`]_B$SD_2!FB*[5)'ZL
MZ",C\O,PE(Q*)];`%%J$1IX'P*4K]``*A@:RJ7KP;5EM'`:R&.%)AZ#!*EB1
M7DR`(LLH100+/X*%)D*QNAX6T1/OX>4H;A>+Q'Q.B!73!2H440O@R4(7O$"&
M@JZX#6-`AA&:^6%GCB0-080&&Y[81C>^$0YP9L-LZ0##.EZRD,)A@P#2$52M
M]->/4=6F0P0!Y1?,!J-X8,$"<B.(C0JQ1F@AZB*LV@U,9E29V4@/7*F2I"(G
M2E&K+601CAR<V!8$M08%Y1O[$9\:/B2=^>0M#"WRE??_"N*MG#3P`3FZ1P#.
MLRGH8"%3`TG/7@[9$BSPZ"($`,,)Q?#,P\B"F8O9S,;V>0QL*H@REC%&-\'Q
M5,Z0YDA=R$Q*B-2D:[PK2K,@36O<!:75^<8VP<E-ERQQUBV5Q5Y?PH<Q7O82
M,IJ0+"3+!SUDHYT->=,[<2F#!0@I"@FM"")U68`"74FUU5D/):'ZHSO;<1),
MV)-P[5#5H"K*V<[V1Z&-%&2Y^E047TWM'Z<J#JL(\*R'@(\CI#5#&`%"QX*4
M80SB*D0K5S0&U94M;OG,1XYHDKR55&!'@?/FD`SC##LA*4I799)PUH2,5"!G
MK-BX4KRT=!MWK?5+8,B7F-[*_[G%Y2M@_/!"OQ9G,"[(*;U=,!*1G$$+/36"
M1\2K969G5@ASD2MY,FWG?@&C*+:!EA4+J&U#2BD*9.GF?`VA(#7ZEBT;E580
MD'3)45A5B5BN)#9S\JR(1_P2MV%4M/YQT"`8NF*-<.0]78"P'SYUBYS40PP`
MU2/_'J#@AJ0TN\L@BEH6H%Z!$7>V*B$9*0"'!2==B:CR`HZ"=,-!**/)A^P@
MDY?,"[!H8)@X=EH<?<,6,8Z@J6%TZ1R&EY&YC8VN<V4AQ>E$YT^/R5!R\S!7
M4E["27N,BCZ$>TX[SN@K"[#-1B;)2:[&4**&F.&GC3!#A@9++6M1I::L].""
M=16?]_^YA'!3VQ69L+/9>Y::Q*A.-6$)`0I9^:^0"H(U?*U"E3"DIA`$8)M.
M,4PM!([R@VGDVQG0\%I(Y-F>)!3AIXF'">*=HQ)?L!R,(Z<-RI'Y<BS<!L?@
MW+ALTYETY#&=[8XT.AO&L!/CCEV#=_=#VVDB3;@XAP\YL8GWK`(;MBC>`W[:
MDN*ZPZ^@>%Z!3.@B0MBEM6AI46ZD(MN/!&NQ/TY.IHB]D:B,Y:<2!X]@E3<4
M2O8[(H7PL*I4A@B>IOKD%%TU(4`N*[/9,U?\.5(?$R20^!9B)#C5U)ZI80$S
M@,BE%D!XMAC5P:(A9",EM`D^8MUO7'K#Z?L,[P^C=$,9GN+_2$2U1-4YHT-_
M]A"']3:'[)280QG:FQVM("83Z?3$9TJQ25MT9F6(88Q>=#%Q8'2GHPY5"2^$
M*]K\)81,!\&JC_;D6D5+HU^^LZFL'IY265YI0\X@VUL4`\.2!P\!,AL4_=8E
M/GX)E8=9K7*4FYZB#*"?M&>5M!ZI&!>MFJ0C%@#[5H5-9\MZM$FP0Y#;PN/P
M8=!0$W=;$(ALXF0UP4+J27MJRE+D*4?9$"S.&<SBI.EVMCLJ>6Z-C62^3OO-
M9`SJ=M&DR%1UJ5(U_V0X(T[,>#,EXQ"G4,EYS4X\()V28*>R)\*7^1S*WX:`
M69:08W]S-R,!--$2#SB"+8)54J/P_R`%!1[:,D*3`"T6H#JB<T`=I1(]Y$W#
MI1`&5!TC='HDF$@,8&2&4"964UD@\6J2I4;5P&-Y42&P]0`1-!`_U@@Y=T'_
M0FKDD7D#H2$&$W@SH0^$9!^NLA)`8144<5SB9QF/H7[&\2\R\ES4H"`5`PM7
M987QM22\XV1)$E94XF33$"^U,0QII0G?!67<E89DLH1H0E<N,7J&0#V#L#5(
M%A@QPS>35VQ^<3T<Q(?@<08+P#\5$%`3@GS8)&.3-RI842,5`1T91E#78"XH
M^#8<9R@EN(F)U$^498=6$U(MUBOR\V(/AG"4!UE`80$D\5N+U1`'80$$U6C!
M!6#E0ANKEO]:?@0X%=,R%O$+T?6%DY%5C"`EUU4EV04O8.)6:KAE^#(O8[)>
M9X(;Z#4<Y44.!Z,G:[8P\T4:,*4,@.(2H=</V"%XLO$.[D1+0T$T:'$0I"@(
M3'%HF8A[X"%A:P%3E>9)DB)AB]=[E$8(M\=THI`=@J,2#V`()L:)"IDU/()L
MA=`GD_4JK]9Z_V-(O((786`COH5YM-B.(3@(.$*+8W$=ER@3`O8'I<=0)@>0
MS"94Z\`.5'8OX=5E6097[`4PDU`V8(8F>%(YY4,)7"`YJ/`P`O,YWK9M$!-G
ML!`R-<0ZY-$*)7,/.]<22\$^R4%[AV`5@K8(A.8%C-B.#)`B:;#_(BEC%+UA
M##:H8)@F4VE!@WAC,V1@`:BA+`Y!(>_(@AP2E'ZE$JO&!6&YD(!I-2AB+A_8
M7X>B-!;%=R$!0`W21P'Y'0GI*W0I@42W(]X0+&J@+8L2D2VQE2B)/",AD"LA
M$B4C-25C;8RT?=FV.0_C.6?90E-G0Z6SE#14;C#TE.@&.UG72Y^@34'$"O(V
M.49T=EOP,E>YDD.11LLC0F+S'()"<(2`!6/)6P+C!8BC#/J8<.5C`6E0!G:4
M4`J$:*R$4Y1G2$`1%"8AB'%!(26Y'UOC*)Y'"`?Y$W\9F/8)*X3D***YF!9Y
M-2K9F+M2>%5V-#]&'N+@$3T&$<,WE@58_QD+H"Y[21//N3)**%$L(7-/@4O2
M<750I'77`':9(':6H!J:0&^S(**U07;%I`IHIZ++1"=HYW;DUPO%*'?#@$[$
M\$4N49`R,PV0@!2?PV_]11L*@:!Q`4*B(!6XQ1$'*$%(^H.T"$K6&6,^YSD5
M\(IHXY!=,)WGD0:9N([9,8XL(52"YPCW>:8#0EA$T7S88*&SXFDO<F`N%P\4
M00"M8X/@4Q\V2(N4H@AY]#T/@!/J:!,CH3*EAU$;*([X(`L5X!/?9TPV5QO)
M9%2)D1$Q.GZG<$W*<'Y1Y7Z_4%73YQE390NB06]7]554E5_%R9D@F(05%"JS
M,2[:84\^)1N+UO^1K[0W@#5C>2IS&*(&C>47'1F$(%(,B%,]PSIYJ[:EB.@'
MG,0JCA``"%0)H+@24TD-8G"H:+JM,4&$`$&,C1)[6".*IM58=`(J3],R)6(T
M#O=&:H`&X@D4P]JGA%832P$C(Z2M[N!BNU@!1*4%/\(/7.9>S"`175@;S&4D
M7#@DPJ@)1`9667",TZ5=8(*&7.*,428FR?$(D3""*@&?T#D]^Y"'(.BC6N!!
M&:DKUOE&PT)!EOA!E6>=JW1/S5H&\SD(6"!T[3@JUAFQ!X@M*(4N=A@`AS-X
M+K%ZU$`N^LJM3+L2]]9(B=I(IY4U"04V_/H_*-$Z9Q-<CH<%[#(9^%3_B_14
M$XV`@5>[(QZK$@&)G&NV#FL"3]45L6*%C%^%)1F;AD*%L>*U+UKV)E<6,%^V
M9=A87V469D=!%OGU$O5JCNL@$65[DCV*8<1'2A;@#3,R6+XPN0[1%0=D6.>!
M6"!X@VBAH)%D!FM1$MFS%417CAQ2#`[)@83D;TO;M+2["*\[BI/UGU?S@A7)
M=*(X'VGP'8*UD<F!+2UR'2C&3@ZY/DW#MD:ALB\1-J5)&$FE&Z7`DXP3;8_3
M)4$9?Y53E$`IE&^6E*K99M_&;0:SE*ACFUT2E?C@O-6Z8O/3)UT"#W:U"#XE
M$7_*+&Q2"%=J8/%1'C15*1J1M>#9$$(X@+5F_V'#P!YJL"E]9T^UDG14J3QE
M2Z&UF\$7>KLKME']$)K.VQ^0!',MV%$TEU-8.0@ZXZ06(`T<7%?PY*HD/#7]
MJ:CWT6]'D:'PY!LBH4)$E3E2YQNR&6ZT26X*N'4YI`D[Q)L^Q'5*+$3!.0Z<
MP!S'N:.LNYS00;0[%;(`D:PL-1[@TF-;D49H<BD:D7/AT7^[):52L\8SHYXZ
MYPW1EA*>N34#UV](MA#YJL%\/)K8P5-XV0\>MX(@W""Z`AAS&DGQ%3V&\K40
MA`9GH)4Q$Q/ZD12Z.!&L2Q$/6U<]`Q-^01]'`4LARDN7$*(F.LICAWTOJA/(
M!#O95ZG`H%305'XURO\8Q(,X.BH?'#RH'%(+A1D2>:@%S3IC!T4+$>LHOP:+
MEU0!9$!2U/*S!/%C^YM3E#8?R=4(7(H6-CM"2L0(?+6X26:N]XO!?5S.AG`4
MK$JNF'S#54/"'$4=&':Z[H*O?J$&Y=EA!""HBH@@^(`=0MJ\*M$(.P+/RS8_
M==4R:1*H];$+X)=4E'$DY*>IV=08ES&J6+@)SE`:7+A5DW.J1'9"6\`<^N>J
MC@6KXC*V@6&N'(+&#Y$0RM!S*GN*Q>=7_=B6%0=!/H=V#^#%Q+;/FIMP&^DH
M,L(H*+T2GBFFA#"[YIS!<-H.K]9(3I&VL?(U+?9RLU$49E,!/5<&&9+/_GK_
M$B&<E="FF()7R,LS*@OQCA<:FFP:@"VI!2>X)`GK7+_8A9#0L&M2B<8XMQ.K
MC/)BL=Z%L<A!`(^`2R2-R?JU%-`+8!Q\O[]@>(<2O)N6N7@1E[MQ>&70%7.)
M+>59$CGQ(&&+%F3`/P2`I3Z&+K5Z+H'*#7PECE/99P15PTL]V^Z<9&2]"),X
M*Y=\KHAYGB]F.Y=`"J;TI2[AF;RM,NJL"<C7)X"7$DNS*RPAO5U"&)7"AO.2
M.T(!7E<F)CHIN/_B0]5IDSUY;89"O\HPR2L!SNN(=NQ!']NQ7_6P$`RZI"=A
M!MJ#,YVDL^A!WZ.@()UR'AF9PH)PB(>E'M:9.3&&_\9(V@@*LK&NRZH@R6_^
M=1$HDMRSO=14K;9K@9C]9=96,\(>+CX>`3+`O)&>O,]8Z]R$%WNST2-CFQQN
M^F%1.YJ'&PWPM+W49J(^B6W=6TRM&6='.;Z>(VZU"0L!ZR<O4=2'H-*(T`GH
M'>&VDGD7I*?7,R=PX\6\NJR:UJ4"WJ8L[0>8!@X]]W.8\AVY2A[F.L%/_HD6
M_,*?R2')>^$:O-N4Y>']Q7Q8L[8`.BC3@DM%J=(PT>(5"MTP5A$LLQ,7#!0'
MUIE7Z]I:,`I(43%4EQNFPZ'E5D4?ZIM*['6]:42HW&"W(U3JDCY6C&+&349(
M+7ACZQ<]UD:#D%,R".`5T/\0`;"K<;&`>>$4"Y"9T*QS!*2>/7TM!YC9WI,>
MC:8/?B"L;%,57`H1K47A=2&D<K[4N1U1A/X3AXPU:[KB!S;A/QB?*J'D%_'4
M\&-/[ST4$>+F`>C!+1$;&Q%]1%4.\B:IJJQ]K,P*WO?*2,4.1(6IM+RI1(O+
M)7D1D(L?A8'MRO#+Z^A;_S3,%O`-`Y$&%%:/#]!::&`&U](5HELT8T!A$&$>
M=IGQ:8F#@!4M.[@6P4L&9F#?8![KT>)!LC7,$T1\E-)HT(X?WCKM?:SG'RNN
MB$K0H9CMDOD4CD*GUPI&)MZ9<H3%AHS(!T61.TJ_;0T_;[T.EI&IOO"U4X@F
M5<C_'YJ1A<V%50;+L*TQ(\L!X;^E7SY5M>!`9,H9&,7<2;KVD6$@$+*5-WZS
M4CY'!FL1`&?P(7#$[*04Z\02-W%Y/9KV2E_NCI(2*7-S%AV_[#DE>9LB*3>/
M'TJM\TV[[>TSM1C1Z%8SD:5L"=+.3H`.$RKH48`AZ+BP$<%]ND?CR1\5O4XG
MZD1VU]CU7+]@77QM)7Z-'-W5C$;1)X\0\(&"XMZD/+H1.(V-WD:*/M>0'!9P
M/==B872T*=H3^<'%:#V=!IL"%SXG-UQQ7),'A!^TTP6Q`&,)$6CP\I+?\M_1
M\<MR^=5QV)K/QZ]W$;J[[I`%"'^"@X2%AH>(@EY=%5N&_UD+B9)_7@0!DY)>
M%5J-@F(/7()<75V$8A4/6EM969]=7V(,75F8A%E=JK6BIPM;6`0/M%QB6V!>
M8G]@OH)?"V"48LJP?ZV7?\W/Q\JME%BO%5VC%5^Z?UB@AUP/R(/J6U\5M(=;
MZ->X8E[T8V5^_?YF6D+!0]/O3(`'9L*0>3`&C4$+8?R$0>BO8AD+%LJ<(9/F
M3+\Q8RJ*]/>`GS\T$$=6G$A&8@",(!\\.(.RI4J5`19$E+@@@,I$6A!YB52N
MJ-&C2),J7<JT5A8M6N0EXH*E`I90Z<X%\-)4EY>#5P=A>98TYX.P1>$MR.+E
MG)92HM81ZO*@4Z&GEB!I(>N5KO\8K+7H:1%S2@O1+P&V</FR2IDCJ@$$8MGB
MY8NQ+<7^0!88+8ME,`RNR@2,B12B+P\<#4(-!LP#<H=R8J571B$X+Y`LJ/$W
M!BX]@BO3/`APILP8"VGZH7E@\^:9![O]E7EPL^+"G33]+!SC<>3RELN3^U%#
M`"*:"L"K^PL#TM_SYATF^`-*OZO]^_CSZU>ZR.[4+;<E`F`77.UG"%5G<97%
M`P4>-=8PPS4XR19:?%&A*%+!PQ<74(V32'^8$=`(:9,@B(6$DSS5R"=6J1;`
M5LDHTQHM8`1`%A9BT"@C&#0FY@D66##P#CCEJ,/.(\!(!<8XGY`HR@)P_4'/
M3OU<%%7_?V-4P,Z4U9%1073^$)!>=0LTUP]#W:ED1DIAP%1!0F18L$]%YQ%4
M!GJ\A;10FNI)Q-Q)%9BT1@$V9#`?(D$A:N"BC#;J*%)?G>5D(13.DLA343TJ
MR(!>N':B410&2,\KDWSBA1;64/K::JG4D\DO6U7U:3F<EK,(`6,M@.L[U`3`
M#F%@</&.8^0L@H4GF`G[119@8($8`<OB6HZ%JAE"3V5T808**9.Z,T@78U!)
MYQC!4#-(`.'VJ<8"(OU9W41F]*,&1L1=E-%([?EIDT)HEK&`!62<(9Q'U_4S
M47)KBJO>>6`N!-P:#M00@0>''OB`4(EJJO'&'.]G(HJ/++!7_R)?9*LQIEG4
M6DL7!"S0*52TH(P(*5X\0$"U8KD*CV&3(@)A`%TL$&`Y8,!LZR^S="'+,5SD
M$XX@7?SU1S0\_B4L@5#C,_6"KVTAY+0>QA;0()6XC.II%9#%14]]GE%!(5J8
MU.4#P*%1AD-9DJ&P']_U,[!V#*&!1MX&4\1WH"/%N8!&:Z81T1@Z*0<P>R'U
MZ8\:>/K]`)4)T''"`C)43.FQA^#2\>FHIYZ4RA\R@G,AD4K]:,FIR3Q53U(:
MQHK))?NGV5GPL"5K**-$*>4FQA<UZK*I2.64R;I058$SOT0U3#Y@2+W%`N0,
M4\PP7"@C-1A=T`-*`-#2RF`ZIK734__-KP^R)&Q3^]3G0H58.*=*!8>QP`)F
M^)<:PF"&-U&I3A^IG'0PHH8SF.$!%JB`3=1`M^KXRW[*85>5T',PR_FC8`G<
MR00`<`0B9&$,!1!=.RHP*4RI[H4PC.$CC"8)Z:'E0.>8E:-B=XO4I,.'@^@A
M9?S2M(,DIBJ8N9`H1B67<]4E?D;!5-I<5Y1%I*9G\]@$,2K0"6VLPA'5$,0M
M@L48&;V#`.&@"_TP$8"Q60QG[@@>(NA!&M28"5]/6U`$7Y&;.X(D(BQQ3]YL
MLX\U$:1-\5+)&;($)GEMKD\360F>]M0W#_H!<CM!9$5F$(`4"`$,%ZB(Q?A"
M"'B<2H:H3&7_ZF@'14((ZP%8F^/0'&5#Q*P#,%\@`"G)=A!\#(\:T3@&`2:5
M&5'0)6WV`=&I<(5%'%JEF7?AQ!;$P(FG?6$RE;E,,;$0F6N(X1=_&4WTVF<(
MU$`O>!1:XUR>1@T@"<^`(O&?->C1'2NQA2YZ.P/;^`:=D1#0@&HP@][TU38"
MB,0,XJD.`A_2$PM`,`QW&I-ZY.D>=_FA``;`@A(Z8(*1%,);Y?10QE1)TI(V
M*G;07%XBBK86C0WHF@FBQREB^=%/;&5`M%@$*:XXE0<(39U-:4L%H#4JD$F"
M=9@H&:[(A\8;84%'Q5A%,A*SA9OE,GDU;.(C/!2I@\#"5:[$W::@_V.<*^JC
M.Q-1#1924I%%-B(,:6#@!B4J$B\=-*'5&0,&#4:N.UZN@IC;C4$(H*>96#*0
MRLF<'V@P`!/L8```,(!'R0;$0K@&-B,UJ68W>Q\;0M-VA[A%+C3%TI0-%384
M:ND\WL*L-O9"%+_,'SC`BI^?Y=*GSL-$:6V%OJ2AD5?&VE2RWJ$%:(%!6KI`
M32OI2(AS%,]GE047E0PBJ=0&`)E_`%=U'&C8DSQRHA40R70&JA)-\M.A&:&N
MXZSS2.%D\D\YV=M-SB,WA_E#!#+`PA$D0(*;K"8>\W!59CE+X`*O;I9"H6*"
M>?HHT:Z"A@Y&1(2S2%/S+0":)/,%D("4(_\G`>@U0BS*A&LA/>JUK!5<&`;6
M1B&&!3"HJJT,;=@,$332T$P+I`NI/-:FP.`,IVE2>0!>;Q*`1J*$3][IIQ_B
M6J9_F@')[YEK00;Y0.*P)W)_5`YT*&?)\52P'P^DD@%",(87D,`$-%C#3Z2T
M*AJSDQ)$,;"<YUR4W;Y*4CZ+[0ZS%6)*9&M2*#U$:0N3JK0PH@M/904K?*&%
M6T8S*L=U=%\8')A-8,;2PTC&--41$)8!54"T?=+%VH$JY<ZQS>KPZT'C+(CO
M5B=A5:H-YAJBDHA*!"0TZ2LANT/??H#0/0^$T[^28UX_1!2Q'G1OGOPQ@3XX
M80Q/.(`!UD#MGS3_Z4!B_5:,Z<SM;HL1%]O6C$V-NBD$,ZJ6O22>K(R*(!@]
M8J?A/L2I1E9#`'6SE$J+3`[)G95GED-%#Q;28GR!QK6M3Q>R^>$W)04_>'QZ
M:JXJD^7T2BEXJJ0W6@[``[EC+[D!#I!"7DD!GWP1"&;N)?*5B'`\GH:$7F<Y
MC>Q3EOV4R'Z8P`8>$``8,-`G<A("?OD;M;>'3G2R_7E"YB9$I7*[J%>^8M_E
MIJFJ+"5;IF,B"P`.(A9$9IBG*CWK/T]W5:6.":1.0JE/95DO"!!.-V+BN8?0
MT"[JDK(VNYDT.4'R2J`T5H<Z`D#<68E<#I<>Q6DD;V6(+S]5K9T*I*LB_^BR
M7!IJKIUTQ1=S=+U)FS!8$V9S(0!*>`$5X."&=UD@QZ4$NR)F7/36>]NS*:)A
M:$6V2T8M766@O8O(JK6@ATO"0H`9E3$442-_4Z*RKCP'78J6*:+ICK?@J-%@
M8%4DY!/BLDJOD'/3<38,;<HP'B^<6E/BP&>RE!_+44V<Z&H<@`E,H(G-?$4F
M+Q("Z+VNCRR#&?:?)3E]W))1%G_^L`9%(`0R``0U0`%JYAS,$6#JA!J^YWH2
M6&!.QV_,`#WRIF`-1GNVPTH+]A<LA!1VQRUY5@\<XGN<<EOQ9@O@5B345`$,
M\!81&'2U-U:DT20^]W.5942PI"!=`##>11;:M?\2"T$@HL4]GN!J([%(>^4'
M%7!_@A=SLP:%*+=D9#4O!-`2F&1)O>9KW>4'#B`'(8`$&C`'=;`P>&((UY9Z
M,SB!;LA92S<)@=9O-W12KN.!E``6W7(.(6@4)3,(VY-40@<)L;<)<U@+5J08
MC#(_,\,`]Y9=X:!5L@4;:X-!BI-3=&$&U]4](7<3<5)H4]-C\V4!(I$3\L<W
M0`@X#I40\[(X*Y$O^7(X`[0`HJ@>Z^</5=@/7E`%,2`!`F`"`&"+7U8()*AT
M!_>&R-AM>E&#R9<@/E-4FE)+1"1N$1):3V04Q#`(+F,+BE8(DS$(H59.V7);
M.O1V>H8?S(5MD;$\.$;_+7.D1*DV$L:1"US`"L1C4=7Q-H2@<?=C`8<45R2'
M$>%'>)H#2%["<7WE!\]!;(;C96B`;)+W75SF#W50!%(@!E/``S2@'F%6,1R"
M>H*`!6Z7C"1)9R!2=DD'B+#4AO8!(4]G%06B4K9P(CF$8<@R"`$!(:@")-?E
M:%F08UZ'B.@3"6:'=&3'%#4F;\@7`$+B<(BPAO`PD((D=&+4A!<7)5_@!0B2
M$"JA;`N)!JUX>!+T0=TU<Y=C`8OS$+J!BLWQ<HAC2;'807Z@9B@@`0U0!4P0
M!_*15Z*H"-8'=R49F-P&>Y)@9Z$E>XZR/+@'%7SQDW/G;K\7)6)P7;(0+"&9
M_QHV@QE'0BI%XER?@)AE]WQ,L398Q0RJYW#7,C-1H@FG:##Z2&JN6%YGP0P,
ML7MP-1Q\DF5=6"5]57XYP2;[5&O'(1(+D!Y_1$&MN1(64'.5Y`<34`!=$`(#
M$`73]BZ=*$I.Z4J2*)C<*6<_8X'4T(()YCN-@C)V=I*.^76<F0BH)A.$(9(R
M,1D)PC*`097_9@G?9GTILGM*`5+68G=L=DTCV0ZS"8@:9)VJH6$^B(_\E*!?
MMDA"QB_[<!'V@YR*=!`MH1&%PW@541(5(7$4]6M]TIRVIF9K``)'D`<'\`)R
ML#"I*!+T\(#ZV9TT6F`RV3J4!CLUJ2D@,F$E!I)B!/^:I62"-E--GK%]`$(_
M0)(4#-`.I'!T?4&>M2!'A_`)/7B9.G4:E549YH`0\G4>\@`N9="*.740ZW4>
ML/$)"D-`"%$<^V<2(NI/Q6D1U"%SE:-_"(41?V*6(ZI8U[$&'-`!?N`%(2``
M41``I:=0BE41#T0B6,>2-1JIJI1[=-@SW\FC.<1*Z@:DJZ&!JM(@]"`T(FFE
M5SI62:$T<<$.G\=,G6E\N@6@ZQ0*+`4E1H(VE*@%<I(@-L4GF,.)>%56CW$.
M/@4;TM4E7T(G2J@2YX%DU\5X%'5)BZ-_7%0;%F"5<Y,>\34H#]`'8"@%3W`#
M'R",]P<2_PF>DGJN)'621LG_;R\5C39U3<^4GA^2;N6$9\2W84$I"@EG%*09
M%')'FY=VE/]1JJ#6+3CF2EIB:@[HE_LB'#<5.+<I$"_:5KU$8]8J$O2W'EY:
M'1;J!P^$$0$3;.(22'().`[!H!PID;3HG&<`!%=``7Z``#_P`FR@'KDH>/%2
M"/N*KCQK8&UAKP(BFM;8?(_"*0`R&"0&=<E7`0$0@;:T@F_T!ZJ@1,DP8VIG
M=4%+=7>GE#A#+8^*""*)%5&9.!8P"Z(5%@,Q4:]%"/;7)\H&5P)UFX&'?SN1
M+Q`:,,(1>+W6G.ZUFQ.G0(&T!@,P!]?5H@;0`QNI>;%()ZGHI*79LY"K69<J
M"<M(_S(8Z"CF*;3K:@CDDPI`TAI`XF)=P(Q)A5U0`1AK"''U*)ZZ4+FD!HJK
MH4MLF)JE$R6N<8H46@A/"$D/L$NHL3_XDB[G00:)%Z%Q`KQ95K(&,W(;\2]S
M:FLA9%\>5+(,TP\HP`!&T`058"B\JVH(U`]Q`;61.[XR5)2PXZFP0Z^SPV>L
M&WM$ZTJLX$YLL12,*`@C58R0B!7JX&**&*6.`'2KE5JT<"T[JYU'XAHIYQZ9
MM;'S-5K,!R.YT4C/VK$2467%\2]K8C^=YXECV:&95*U6F,`BL<'C@2=G4``I
MP`!V<%T4LS!*AG]\<@W81;XT7&"4ZDQUV(SER"BQHZE3>O^Y^I&.]AL7.:8.
M.>:.A)FT7(2UVQ>>J9"E<3=:(3EDWN$APX`CQX`F59RFAE6$F"A!85!)<>J%
MW%$<O+:H-\$`(E$!$1%EB]NGA?=($R`%&)#"0!``2^`#(K&`4C82-]L/]5O#
M@DQ@>#BP`AMUYMJ2F7J.\RII^)&4A."OE>6.8F2UO9"2$L:ID.A*W#*CU,!Z
MFO&#C$=!G&@&95"$^:`%P+L0Q"J*_C(RPP!^'Q$Y%A1>C,JA&RHO^U=E'+2<
M7;8G>1(&:P``8M`"%_`%*DP$%:#'GIBLMU:+"V&3@SS-,'2([ZBU,_2^C6*T
MF/Q12ML4E7@(>S%C7SM6!0*8QZ7_6BD"I$9LP*QQ:N>,J[!T3Q'*7@*!CW%B
MMAA,+L2C!9375EG"%WYSH!Q;I^XA)_+7>1,1`*?L4'03@!X$:SQA/V"`!DS@
M`@CP`0Q`N%?@`7P,>;0L>%0,$M),S2:M.A_COE@;GE+L**5EF)N[%/X)-ZXB
MQ/OJGY4X8ID<=&"G7(&LLVXTML9&>UMY!NQA36A<);2'&SN&LB)Q!@0P"(XD
ME62Y$R^QG,4A5W2")]5;D-]K.1.ID']2``C0!1Z0`RV``1>`O<J<!1_-$[7(
M3S%'42==UP1FOC^'OGF=HXSB8#I-N4*:7*H'-X!1C(!)R<=7+<C,UUK'AJST
MJ$+,R;;[_V6"-"+;@[1L!H4%`:!80,7XDBK`X2]KB2^1(Y<'>09N91/V1<'M
M(;U@?9V]%@958`)CX`-&D-9MP`"::`,\)WBJ!KT::Q-V/=R;!=/RMJ.5RJ/C
M"*5G!\2O&H&)PB&IXI_9*<,9<D6,W$XJV2`UPR"0_%%:Q27E54!K!`\B?#@2
MLB#DY4^G5VX.-2=WFTGY0L)5(I!LZG@1H6PTY['./%\6);U,:0)YX`&WC0)P
M@+US$$I;'7->J#"[2=P0;E)_?2#C)B#=G!\V)%0Y+!3J6RKA&,G7,,DS'*,J
M23^!3`\(EIYANX\NPW=QU[OG$M*>B'J:@,MH^GV#(51/]M1`)/_>HKT;_Z1Q
M[O+5(YPE8^(O.]$W;ZP>P.U>;L`#""`!#-`#3^`!0$`%?=`!$%`$#O#1%`S2
M"O/E$3[FZ<K<I[:>G*NYVPP.C)%T\.#-SI@(^`L4Y9P,=I>Z>*XS7V-GCNES
MQ3/3ML!Z_5T1O:H9OI"5!\&5^%<@TL6F)P)X9QRFCS>5`U4&&FJRZM)C9%`Y
M=0(OO^QJ[>$&?$``'J`!#$`&2)`!0/`#7^``8\`%="NGM:C?*D3FMOY"22QA
M@2U&M*<QI27`VRU+1RG=NM!HH.HJ/H>_<^YG(^+7!\&_X4NE_TDBKK'C_(,.
MJ&$&:C`&JO`S:0(0]_C/7L)'C19!W1/_G/Y40$AF`9JM94`>4.UW$((SL7VB
M>!+ARVM@!`-``#ZP``RP`PV0`4?P`!E``XD;S/Z$LGP*OK?>\.5[X?;@R<PN
MODWAU[07V8=)M*@Q8$!1V.P4SJ+0?:LGL)YU*S>3A\/1N]@7&Q=&FPYU%8`G
M49`C$(H%H7^A#P$$%S7#>%:B3DY=BN'G)1R*0.<1`&1P71@1QDFMN`H496Z@
M`%8@``20!1'``$,0\'90!0@PE^N![H`RUR"\9@X_]B\4AYG0X=[LJG:8&JC!
M`$<R";"T":E@(>40W2*/TS,*[!2FE1)258P1CJ0)B%KPCSWX%/=RU&.E=XZ^
M&)YAFLE)!JSV_P=L;*<&0P;:7L$6]T'^B.D)!#CM[MN`0A!K<`0%$`0"``$L
M4/4U$``><`0IP..JAGFP7QUD7_LOY+I3\<T?!8V/0A4,4`$:#DT#QO&*`L`R
M3$JCP-@LW4J&24?+'KZ#H*9U5;;W!!7C)\+X$\G)V2:O0P_6'D_[A!*F3#B[
M5I`A7#@(PU:6T]4FNP89@`$2X``K,`"H?P`,4`,-X`&"NM52"0AD#V%^A85H
M%6B&BX9_CH^0D9*3E)66EYB9FIN<G9Z?H*&BHYA>715;F%L575Z56UI=6:29
M75VK75];#ZV56I*_FEI?%5^/7@1@DUQ8%5A<DZ8/6]"265W370M>6O\!E,3*
MCEUCC(ME"UK5CF(+Y>6(D6(6:NZ%9]/K%18/`5ZK8XH,A7E`YE`B@68JF"&D
MQL*^`(7&D#MD@4P8B?7<J3E8R,R@-6M"<)`@8L4`"!P.,*CQ(@$C,A8",I)(
M:!%,F?5HZ=S)LZ?/GT"#]F3F3!VE+%JTS#J:=.E/+K8>@=&R(`LL69."0=**
M*:DQ2%.K4L+E2A)1+&4C?6'0"M\D,,4>:3&3T9#81UL6G*DKJ*R8+EB^F*I@
MD1&BK^,,"<J%U$(9/V4JT/,C:"^C,&0JC+%L*`#$0I'1#$Q3]^4@0QC]\/CR
M@P.4`B91WF%`8@VC-*<O+_B\R&/-ND*#"Q__3KRX\:!<=O6R=$U+*DJ#G_/D
MXA92\RU9T(63"TP3%P+/)EVK'FFJTK&LTOZAOH68TTB[U'UY4-H/;FA>LF1)
M_@"@.S/IK#=7&0TI1=1"A<!D#!?=E%.&!5J`<<88%OCGAV]\T;?(`@%5A@9!
M]:&V0$VC^4'#%Q;`\``'491TTAM/"`"`;:A-Q,@]!<UD8VG']>CCCT`&*91R
M[T6##3708?%`>+2P5XDT[9TB'5>.4&F)%DJB%4T`#XAAU"-?',G4>>[M\I4D
MMGS)98[NC-&%(W"9X5$KC4T6T9M_>`&B(1.B\L<J#@5('9OE3*BA8NV4AHAA
MF@5@01BAA>A'&+L9_X)&17ZLX40#(DT!1@0)K(`$!"]DX`:-DUI`USL5/+;(
M0*N&*.2LM-9JZZU(G6?)65\^PH48_*CWR1?.87*6%\T\8Z65E53@""YG0L+,
MDL(ZX@677DX2IA8/?`%LK^OM]DAVL7AQ[0-I_):J-W_F1ID%50V6AAI+.D(,
M3GPFA,5ZU7C1:GT/X-009^Y4YL=&^RQ`+SD&AS@0FX@H`D`&`B`1`@LV@'%`
MJ`VT<`%(ENYI&KX?$EK?K2BGK/+*/46G2GJO\!(M)\3,?`FTNU0@++.3B,&N
M([D6B1<K-J^G9#^2Q!?5,M7MLE=#54T;P%[W/!?`B`Z.X=RO@3T;<%V42O_W
M1W:EA6'!9V>D808:#SKVWVEF/'H(`Z1=K6Y=B+A*V0-GN,&!$TD,,$`5,-BP
M@1()+!$''(SB6PAN=T<L:2,L5V[YY9A'@NR2X()%E=#C-M5)S9^$954L3O$<
MR=6]NBR>Z),H=Z8MW.RK;05..:IN&6/@`\L##\P"U8Z%+F#[(Q7<76CPJQ.D
M_*33@$980XZAT3NAJ:7FQX=J7$1\7?3*I+L?:^51Q``"7&QX'@Y88,#(;8YQ
M=\.3^Y'Y_?CG3^NOP5Y"KMB:DY(FIE*T38P'.]KY@^H<`94%]$\2R"J*D?PD
M'@)@J1MZ`B!>NL7`Q+CC#%S:CB,60)K2I`%/CWC_`(+J<1A'<.D!"P##@0B&
MB%GLC3-](@,(^2$(NI1(>J(167T$02*,K`$#6V#`$XJ`A/2Q(`1\>((#WM<;
M=PE$5>6(V_-.IK\N>O&+P9'=)5RWI2YUSFMGY(0TQ!"F"BQ@5VX1HUF44ZT\
M9<DHU.F"&`C0GKCT[`'5H$X),Q(&`D2"A*5AW7K$@`4O_8-@">(@%RKEASZE
MXI$'X^`?QG<CCYCA#&I(@R(>IIA!<&]R-"E$B=P`@P/T@`%C`$$#+,:!$+R!
M!V[0T0>%&)'O30Z,P`RF,$41M$OPBA+3TE+2`#F=+'TA6;V:CPC'EI1IXN5S
MRP!6+Z19)DVBJ0OJ\%E]_P*`POU,:X6O<I.]+)"&,GBD'U-Q6R2A,:C+Z(L+
MY`*G.'R)D$2!AC=VBY3#SA:R'+TA``>8`0.4L*G!@4$"*$`5]`:Y",F]"EWU
M*\<P-\K1CGY#3+NBXRM@]@ARIE$4..-%6KY``'U"4(#BZ4*Q8A>+8IA)2>!B
MT,_LI9`M^D&=[>*2@8`U-8&XY5XVD5F85&@!?1)#;Y<1!`"[$*N,D,&?E20,
MI1AFQ;K@R!"12D`-:M``)9A@H4EH@``L\(("&`93Y1`$R7B94?MY]*YX'>:Y
MLF6)JX`.:*);FE""YE<SB=0LT#22&9?)/ZB@4'/5R0(YJ0&LS5RF2^O(C?5\
MU_\?`L61;^YXD%+R\Q6D>I5*`9!?7;1XH0<D;`$,*,@8L!:BO)7R#&M(0`K&
M4`.$GE4)("!G!#[`"($R`D/FX$A=%Y'7YCK7B\FLHW42^-$*/*`X2T4@`Z3C
MUV4<-A+1+>D"'$N=XZG%C^TJ`QKN"8LQN`H-,_7@(G;XC"Q@09E8D%M&SN`L
M2&#!9.48R'/R,PM,E@,CWJM)``C0O07PLV`QZ0S67E`%'XQA!PA])7`#P(0Z
M2)1^B]#>;9>KT>>:^,28(\L880K>+AWII#O9:QNE\[^Q8#-VK+@&.+%$+`T^
M:Q@EU>^D%I,?!^YC00VJ1QC2H+/IU@<>D""&9=U1PV?_*81+6`@#U/16HA\>
M+!&DE!3D5(D1&B"``53`@0!V0(0(O#(/(,`!`!C!R8M2M!!V(W&)4<SG/J.L
MF);8')/6XY9C#B>9SY1@GEX<TYE:`Q49)-T?`RG?E\!K9G0]L`CU9*>"/<`5
M4`%>/QH#U2]_);\DPLUF>$<0013D4FPBHFTEI3U2KL$$6$!S!@:P`R$L@`1*
MW(!$O4=EN`I$Q'JFG)^7S>P@7<>81#47>:R\G.%`2YME,70`I]&K!:Q"%Y^F
MA&`%69HR4"EYI0$J/K-@KE,4YKC,U%..%I.%I<Z;F7^HM&(J5(:TI6$O%OWI
MB,(G*;/%ZI1K8($8<L``%^`@_P`]"(`&7L"`'@P[TP%79::3W>R.>_PX4#KI
M*OA8"=,5A["\<(J*$>L,]2CI"V#`-WBQY-\[MVFG?XCYE"]S-IX&(&ZR.-!O
M@&I:L&KG7+R@)T8S4H8'=-H,DZ$41(@HJ9*!]2`.```1TL"$AN^Z!U>0P`G(
MP(:*.MW3D$1$IY/-W(^[_>W(2>PW4`&[1OL8*-D%=,[K#A^8X?0/%0#7?``8
M\U*G$T^`*@HL%@!5`<-)N><HUC_B9CM8.,X>8T"O(S8>8HJJ02^D3&5ME4MU
M/5BA`P&X`<-=D($\F&`$!SA5<B]?YT)LY/)LMRO<=\][G:S<.IHDXTL7.QP9
MLSB[E/^8"BN`AG.>GBDOLK!W@#'[!V#5)#-TZ@*F(K.472C/4*GX`KN]YM,$
MF1?PAM=E&.(&K]ZU2NJ3DZN("'%F!C@@`'A8?0J4,`,0$(_JEX%L>U-^'-=[
M!GB`H&!R:*0Y=X1,R2)=/I%,]L4YUH(M7U)>XW)^[?(5PW,&U@-I7+)"\/4<
M^G8P\,)N`1`+7Y%G2F8&;P0)Z(8W?I0?[99I7;9T]Y`(7R4IR+55?C`!<9`!
M#,``(D`$16`$#-`"<A`!"#`!%1!BM&5G!Z9:N9<3"'B%6)@)Y`(&\8%,T392
MU28<N)`%7V@TU&(OQ2(&!A)X_A4@A$919Z`O7E!9`1`7.L7_=%H3"5CP8(@"
M'^BR10KB0JH"(2CXAP6U/6?W.*;T+[1F(V&V`R$@A$0H!&*`A"W0!S%@&^XU
M*0Y&98DH$)14A5:8A:18BII#``P@!JH@,Y6@=\*!<KDP-%T`%U^@4W7X*R@D
M6/,!8$.6=/K!0)QG",SS"%@0`.4G"/0D4T&G))]T&\PT/'R2>=1P-&60&8I@
M7#0A?PZS=-LC&7Z@`&$0`E.`!D/H`$00`V;0<`90=@=CC)EF7!K'BZ*H;*98
MCUF8)G+7BGRG%B`U'#.6*UO@"ED`/-*6"EB`#9LSD*K(4[AG"&9@7@-9'T`U
M-K/`C)"$9^/U![L(&5IS29IA&6ZB_W0`%H>*=U][T3!F`Q%C5EO&1G`8``0\
M((YKP0`=T`!#,`<K<`(250&,:!J1TY/SZ`[V.)17.&[?!1TL!D$62!SG$AA8
M@`ZWD"=^A`7UUB4#&6Z.0``7>5G35(?RF)+VP@]8QA\6,BE`E07*54F]XR79
M\0#.$)9K]RJ940V%$(-?)7I/1GJG80`NT``8\P`4,(1PL&9%@`*,H`8,Y@XL
M6$H-&92Z1Y20Z78,HH%_@CICU(#+D"40.!1EZ`A8(!U4N1YUF`4F-PY;>0@S
MQ246`&G,J"Z.EW,<L63!4B?T\AQ.XP[K5R^0X"^-"3U?40B(E#<&%W^@U4LU
MH0)6@`1/9/\#'S"$;2``9^!6294&=^:#SDB`01F9VNEQ3M**U%4)_(,TZ!&&
M8<2*>7*&H6DM,H4=1Q(6AM="#+(JZ]=RE05PN$-^<95RR)*>M><.%O`>Q%!^
MCL<%*5@AO1,3.Q@BK,6)O.$'';`$`<`"5<"<0X@`>"!1/R4_`W%1`(:7CCF*
MVQFB*-:=*T9!?66>KZ,KPP%HN(`5NWDD7X`M8(`-L19N\A95Z9$75($84>@@
M%B`V\U$?D2$L<+%S9J<,@Y<@!+"(O7ELCLA+#K`$`P`#53`%]:<"LJ=*H:A9
MWO@J!/6A/"*B8OI<[L$)VC8F?Z61_2@<KN.*#/2`62)9_(`.T/#_5!G1$.>7
M6O5Q0I'`#Z>Y-V6AFJC`!>Z97,:`EL;02^_2I!HW2+.V"%$J`!RP#P@``3.0
MI94D1&E0$`0W7\$(IH4PIJ**5Y+6"?Q!GB]EHDI)?&S:@,*W0:U`%O46EKU9
M2(>4?DE%3_?E2/WA.`!"3W.A2O=D;V6`&Z[0A7\PG,CU9"+3J1+E`!6`!!LP
M`BZ0`!0`,@91:FBP``!H*6D)JB`ZJN(*3*4*"MT5:)B)6&=X:%\H:+WB5X"&
M!39W(VY!6J9@;#.1D;M8K"I5)ZB!)S?Z$NFQG]FB2!H)(@+(=,JUD@[*!>P8
MI4B@!A(P`ABJC8Q``%2X;XP*JN/:L<"4_Y&TL(70IE)@N)D](4;\@ZI;F%T,
M(D^LTGT*T3L!2:._<1%X@I8X`1.R,!B9MY!V6@]X&F5:<2^P0IQ#E[%^0`(R
M4@A1&@`O<`0B<)T!M@!=ZI!=!:[AZK%:RVRO&CLIIX\J^HJP<ZXO"H)+<@V$
M<9B:I`TUL4-B$$%KTW2V>;60@0ZSX!3S4:N&Y"MQ8296)RDLF)*+L`8ID`%`
MD$M^(`)+(`0P0`.Z-'UDP#LAQH=8VW9;>[G-=J;B\9V2,&/%T::<^Z;TR0\3
MB"#W$2[?DYO]L`6VL!3]>2/]18Q5M4NI<"VQD())P05%5S;:DZ!^``!;X`)E
MP`,34`@%\`,=@/^IP\DJKJ(A15NYLH*YI)!K0ZBJ7X04HT"H"I2F>&$)]P4)
M#)`)J8"]0'*J)MNUQS"63.FJ4G*!T48D:M@-(IDAZD$VY1:[#*0%+LLHLQ!S
M2(H%+=4N?WI9$`.4:R`$+L`':A`!Q?N-""!1OFL(G?I3:`!KT"LITCN]LD"&
M!`!CEZ.[H_"]M>@_"_2]CQ"^F!"^Y"LD9.N`BF86G1D<X0EJ^0BKXL=WGP@9
M#0J<[Q&P]8",+F1=N3`8)D,OQH"LU*&*6)`.5?>)%EL(U,$"))`!+$`CV&H0
ME]>M!T.U&WO!&1S"QQ,\7Z`+B_0<7%,66Y">2U&+NAN08Z-,X_*+R++_%,C"
M5W-L+[J`MUSP*V9\J/IQQI%@7S1&E8[E!;6HQX`,+,9PQ^N0QN;%`,AB#",\
M-F#"`/JA%$S"R,<ALB%%LF.!HF+XM7]"4M;1%*Y3`9P1!FEILT!S7P'))>E2
M#BD(K*LB6F``MX1PNMI0#3V6;W@2(K=G"`QK"#BP`$8P`C!@`%9L$Q%V8#UJ
M'UIYP;_TQ:%@PG\0/-SR"\!3`=Z@!16@!88$P.!L#"BL%&@Y#6!@002@'@R`
M0>HL0TL*0WGRS@KT`-RB#%S``-11`03@#=C;SBGXS7L+)^T,'CE7T`$PA$L\
MD/BLSV[Y`!T\A%J`#."L#'7(DX]L7>OL&1H9_[M:,(1HR9-O1-')\"/H"Q^6
MB:8G5TUP<F-E&Y!9,A6;^',7-;=JX$[48I'_:BV\9$G)D10!``VZ6`Q)_`A#
MY"X)ZP<OL`0"T`8R,`$8:A]7:YV]X1`#+,V62\V><)#Z`<`*I(K8RP6!!\G5
MQPWCJPSEK!][>QX^`[[&(,+!TU_>`-=?_0?%N'=PD2?Z_,_D[`IO6U*I,!5U
M+5G?B\G>,!5ZLGF7;-?[,A]_H,^`]\BIT`4!,)#5]U@JW,%>$+YT7;XUO+D1
M\B1)&1QMNJ85V"5SR`MY`=%'*H@UBQNKJQD>X;/?BA`5($*,M$&&3![I1EO+
MRP@3H`(AH`$%P`$\$/_5"1MFDVL?\XK5>Z;5G4"]#'#;VVO7WPS.`\G-KK!@
M+IK6Y-O.V0R^56+/'XT,BY7-'UW=CAT`C&0[YOP+*.R6XGD,.OK8_K4O2K'>
M"VE?!+#8Z&W)P6#-]DU-?[#.WB;>WUW/28'"09(<I(R4UKN;Z2K#B;57%ZB9
M5\$+!%&-=EB"D=0*XE<6,=>;\`4)>0$-LXRHD4!(H1C!A;`&QDT$!V`"&S!G
M%S6[!K%V/W0&6.7<60O=F2#@U;W$]X46IH"*^]$,#+`OWAT,2^[*XJU`@/&]
MV<$`'1P+15[=!:XGS^3>BXW"1V[)4L$`Y#W@GHG?L[#.'`31WNS?4TZ5`?[_
MR(#U!]ZVS@CNY%*>Y;6R>-QK-"\,7C$L%.9KAG`LB]+@'.VM=,T-5E2B!;C*
M)_C0Y0?YS6^R"]6B9"*3<8M@`#O@`!DPO`I@&)D6S!6%KW3KX_0(Y)H@Y&Q]
ML\DA#E@@0Y4YX,%#OG:.3U%^X#FGO=21'<^A#+H"&,[R%XY0#/_\++`N%\H@
MV';N+84]"\(^-M=US8NMZ[?<7X`!OL=:Z50;"2J,Y];^9^AP=[YRE'X8B\1Q
MKM!B#0]@R634!8N.&CA'#,U(9?>Y"V!`FN"LBK,\"?:N-S=1#QB0`R@P`6\0
M`XY;4;4]@(US7/*(ZH^IZD%^?N>QV5NP"DD\D%M`_TXZ5N"-U-_D*U/9(>>C
M#`9+_!U@D,[^<-M+K.6XH-<;[RS'?LUBH/&/L`"S:,_YIA18\I3<4&#+QU(F
M;\F(N@HF_PO<G,Z/'$-^LMDO>,+YCN=&W_(I$W(WD](IVN<\P<ENF@U;`TU@
ML+\'!K`.%"P&5DK&D"9A20V")0GE,,'+.KAGD`,A8```4`9T\&%?(\O/#&*'
M0+G.+?&<P.K=1P`D1PP,X`T,TL[0D$0B3[Z+[X:.P.`)W;>&;S73;0RZDL_A
ML`4$$!<SC_@[Q5+]["R1CT_@<1Z<+P[@30W?O$F9W]&L\,BY]C/4=_,`/ODN
M%/LKH[G6$+HO_;DPY3HF#/\E_J#:V@=@`T';KK(8-RQ/]S%)Y434T[;B276T
M[@`2&^`">F`#7+`&`&#C'3'5`ACWBW`H$,\(@K_^G&#G'?5[$$[N[DH<Q[0Y
M7`)>T+1XK&N(VP,(6EM_?UL/:'Z)B6466EE?70\/`5Q<#X.$AEQ?#V"$GZ"$
MBGYC8V&)80]FHXIK:SQV(UY*$ZRD8[9^J62VI;F*`6J_P\3%QJ'(R<K+S,W.
MS]#1TM/+7E^?7E[4?UR/VM*;?U]9Y%G?7EAB7,A<8EC?VZ%?E=?Q]J%>D=#9
M]_WQ8%H69&G&!4L%+.N2M9L$SQ]!0UVT<2'P("*R+14B9EF@Q=VD`!7J&3J5
MZ\S_F`<-%V#Z$V!!MY#.4%D(H`C-`UZC7/D!0&($BQ$&`+!*E2:736&C4JTB
MIH:FL:=0B3F<2K6JU6E8""3$@H7:1`9=NB[#LN5:O2Q:_FAAP)9!URP4*SQ(
M2(A+!;D$ZC7;,G"9([3/NMCC$H#9%RU?^"XC_(?KU<?(LG01]#!CPU`0^T+&
MK*5+V$*=-7_:$CK?)3!9$@8P52R-6$)=!G'Q7&CN,S]G;M:L@(@5@#8B#M2(
M\H'$&E9H+.!D588W<MW&'D2=3CW1YNO8LT/#XI:0XVE9'C1^G6P@0C&$`#L*
M50%31U"T&R]XMMXON;3.&-@#[*Q^^;3?:7>5:5O0I0QI_P(M@Y86G@@H1@4,
MIL=1@Z!LQ&!!!R5$@#%DH/1'%ER)\8`6E_S1A4O0H%%!&8IT>`8K:["PPQ<@
M%*&'$@6X@9QSMG1(TFZ]&;-`D-45.8R`2":)'19::#4>-Y.)A05`F'RQ0!?K
M=-&>8U9B6=`ZD/PA!FKII>7?A^*E1QX#"7$QGSA7KI,%&">^%%$ZZ`$DUE]I
MS;;`-5YLT45?6W3GIUZ$`/1GHIW-UAXY?P0*I19O678H?%L&4*=W$2HYF$$(
M-2,99<KDTYYV#WQA*B:K&ABIEH-@%-&#9/S(2H=9+H":016`X:9@T!@2I!D6
MV'H<&U%P($841G"@PG&CN)A+2_^V^M$AD<604921W.;BZ;?@]L,5I4]RE-4@
M#&@1``->3#196@\0$`!7$[5D9E<!?1A`7^J)AD5AY:4)BKM:`"AO15M0]`58
M?,E[D%KWJ;5``%K!M2\AZYK9F9.$?"'O`A5\R$!+"\0[[UMIF4O`%@FG&A#%
M=)F<50"3-/9`5J*%*XVLER%#H*O8@`HT50%B&*K1KB*M*!@&F5'M&%ZJ^PD8
M(5FRDC,B_N@+C'[0$($01V@AP!RUC$)LM;IL/4H:#Z!-3"K=QCV*SG37W0Q7
M<!74%99/LOO'`UF0Q@T!7@#&%9V$H`37@V9]<9:9;>D78"C\@2+X1.@(!A#$
M?_C]61;_(?-I%\9\A0R*?EXX2>J'Z'7.DEC[`HBRB>LXYLCH+*UDN.;P:H.X
MW=,HFC,[0BO#!40]^_-%!4GSG(EEH2P40.&3L5S!&"^&,3$W)68RU_(4.D,;
M*@]LFQ,"?MP@00Y':#"#'#HEHG92Y?>"2W46O"AWW,#WW[_M7.E*.Q9`@*[H
M!V+?X=-XN-.6@:PE?)]0CQC*\:3_(".!()K=>@Y8'_WP*0N1PT+E"*$?_DPN
M"S3SH&8,-[L!%A!B(&S+:UCXH;1$#C_^B\:HKG8@Z!TH-%4!W#(0U!?A7:0B
MJHJ$&+90LE,MKR]N<@D84@4-+I#K#WY(SG)&<888R$`.8[`#_PC&<`0V*((H
M1GD`4LYH@:54)PU;W%^1<DC'<#G&8OBZV0(,2`A'8)"%6!@4.6KGM\B8231@
M>!.4/C$14$P/@W<\I.LXY[H/`HX<A<,A"6OHG1D2H`MB4&$$9<=)$F%ACS"\
MI#E&^23`,*`<B*JC,W[6#",JPT(0C(<8`,8,"V%",MVK4,$*9)``Z`4FZ"B1
M)O813!5A2Q$)P$,7"J`!!)RA!T))A$WBN`@>*2(WW(S*&18@QV[)\IQ(2N`+
M#_@9#@:N3X1CH>#$U"Z*`(MRDF0DQPP!"B%&BDV7(UPD.<?.2L%0"ZE;!VI&
MZ+J$JF4ECO&"?CYC%\,51G`%A9A#R?]4IE:FI0(#\4+KT/D,HR6O0M6K!JSN
MX07;/(.67J"9.O`!D@6X(Q(%(P")5`(;OCUC>7HQA/Y&H:,+D.``#QA`"EP!
M+3\TYYG6>L!0M>E-([6MG$8BJ58W\QT0=J4"5^J..PF6%A:Z2TLL68!$>]:O
M4$0"#`D+7\*V,,7"D-6C$I-H>AR&KX@5C&*9#,7(U+(QNB3,("645VA6=M@1
M_0&L7>A.0+SP5\)%<&4#!=6IMAHL'ZKT$D/C1O&H<::2%J\@-^N92"=S,W9L
M+UA4Y%2UW``#"DS`"#6(`!%@$+]$2,L6`2C6K2P`5>H$`ZMSY*QRI\*R3\1&
M')W9`KXP9I;_.(GCHH.PTI^LJ(UT(.,+A3%F]"+[PE!D!2P)Z=(ZF@O>&AYF
M:E<T9GMG$Z'V@D(,?3I1+`/`(+7^`2!\ZT)X!5*8P\0&9?.8#`0%S%Z`,8D\
MRZUEP887O=&R`WG2V*4]G%>(C,02%&=J*0^9@067SD8PMLC``.*PA1S$X`XT
MZ*T?@HNV,,PO$6QS6W70<#_D3B?"0`ZRD(=,9%!`(IA#].Q%@#A+E]K#E@L:
M'C\_\<1HQ(=[K<O)#F(P`":`8`0<2$!3T]9C^IE/$3>.6P5\3)TBNUE4X'$<
M.Q#%#PK_-+0$^;#/3LJ,<&C'SV^N2DP?,%-FV+(\$VI&:?>3TE=M_Y8E6C!L
M;)UAB9%R8B6CV$`-,A``([B``V:D7SBU.)0V(G<,Q66SMP+-ZM-)8RV3,20H
M''-`TMI95)J,7F$F!PV&)D,Q_?!UJ_N!VG>(JM')6)4R-"SH2!0H4@8A$2]K
M@V=YK`YTB!I%`,P@@"84X<S:5*-1JHH;Z&"U*:J&RK#7+0TV"=N\$)[&HOU!
M0_#D.AGS9G?=./S90A,O0Z!H:;4_!7!E5(#/`P-)4#T$BE8H00,.P,(7W##F
MI^;BMT!2]9K3?0Q]+Y<<+2D(8AK#*"S-2:V7*I0(`92);,CF2O,B>6.N^*$&
M)6;F?/-C0L1@#>M:J5.$D-245F>B3&UJYO\0O!1@Z"NE1H$N(I<*%&F^0"5&
MB85E$9&-@LU[128U"$__I;F^HTP04)WT>!7Y1KZIPN]9@W89D'AT6H&FB`]\
MV@UUT%&TKFJ+L]WJ$.E>P%0YOFJ/<W9F(UH`R%P'0I(5TXJ%S9@K^^C7*ZVS
M,04D=,=,!\H'E5@PCN!I0C_VT3URC)/I6A<\9':P7=^,`*)Y6<521BG&%G!B
M+3M,8>&B^!&I'BXEQA>EU/-ZO62EQ.ZH`,4&PC#@M];PXG"V,]K.F8E-^SJ'
M9N2#]KA0$$6B"^$[L3(4`8``L&#,B:!6+M*<8XYKB_!2@?Y63_DAT^E'/S%_
MG6`<2ID2VI#R:-'_2&K!1T(D4I]@62$Q0:64!6(@&$ST.RC!`->0&JSD-_[$
M28$4=G_C._>$.P'`%VG!-P'T)I[@"/S7,"2D#8[P@=P0.H,0@$["47\34@]B
M'H+A-RR(._(W:/YV2Q,V1#HU8INQ0\G&-`$$!A\F8LLP"CA``T.19KI0/ZQ0
M"CI63G`#?[\@?_,W.ZXC2IW$27V#>@#H"/A!:Y/D5EO@!:8C*!"B42%S8)&S
M$0R`9)-'21@X.S<402&T=&)`0!+'`)^D@A$S'OSA3FO1%IR#%L)6:Y-4AX?(
M%EK(2,&'<-&'9)]@@LXV<%1!2QEV@<G0"GIW1N8V"J26%#.!A7[`=Z@X_S>1
MB$X#U85V^(IFZ(CW84)\Q(BCH1*"44S\Q3DA<7"!5`[KM0`,H#O_9X<TY$JP
M%$&J%%BFA$HQ=1<'U4F%2'D=04'KH8CW=H:->(S7""FM.!I*EFPR11=]*(D%
MEQT8(EX/<3,#1WX[LD:D2&[@M(IPM(JL$([G](KW9R("=!!=<8*,9T/K`%(P
MN`ZHI!\@]5\=2`"ZPCF"LQZ:(A[SQ'/`$B"TR$H#M9`&&'0Q&#$%!08-HD(G
M6(T0\QDLD8@(Y20L2`@+22<+F8$9E9+Z.$IK5Q>3J(9`0WW7P40(0X%UP8`@
M$RHQD0BAZ`=J0&Z^)54[PB*KB`;DA(^*4)-UQ/^/C*=88;$GA360CZ5X!JDQ
M%,-'FG4U\9(EDZ!3G`,&\C(XGA$RBH<S%4AYER5=LS.6(*8N\51ZD25QMV<F
M:E4P73![FP1#6*F2A`58GS"6Q01[C5B85$EETK<7=S%2R)!]V<&`3%(P!4,6
ME!@*%Z>*9B-<>Y=JZ28=4FD=C^D_#=9':E%RQX,)E]*:[7486R!?=N492]2:
M,P=AM5D7BI=(+%$/(P<GBT)?X=->^,&.L/&!V>5@8C<IGC";T=45`"8GB'$I
M]I6<UU"=P7E=T,EU3=<@.,2=J8D--$.4R@`0/WA+R,99O;``;I-F/G*:,R:/
MJUB>^)F?^IE#J#4]"L'_/)4HA$&7B>YY1@M09J((;K=0A817!@B*BOL9H1(Z
MH4DB*['TD.9):*&%-%HEBEN01A^:%!-#GZ-@FE))H2B:HBHZ%63W7XHT,).8
M9!9!4E7V73`Q,);X+5V@9RO:HS[ZHW2S*@`JHWQFF?XS17IF"+%4HW0#!M<'
MI%`:I5**'6KHCKBV=D280\MT04Z6*)-&-Y8PI6(ZIF3J#XDD/908=P+Z*F]G
M-YXQ-%<V&EU:-_Y5IG9ZIW@:/4-:&SO:#(.&GA5V$)UY'6[RI-P3;V^:0V)`
MF7G:J(X*I1@J3#<I6@Q!I-^BA-]EB85:1U[PHH_ZJ:`ZH<!9*BNU%TBT#.IY
M_VN/P:1&=J.,E*/],Z>A.JNTJH]V,7#)!*C_L79'MJ95H:2_]J7BL)#[Z*NU
M>JS(RFHV544BXI_,H&RE4HZ;(2)#4V*N@J0T>D_)NJW<ZF:;,PT0P:-!8Z4*
M$:-6$:?PH:W>HXEV$V_=^J[P2E*6,*B[JJK<T*Q\QI/Q8$7NRJ_(D*CQ&K`"
M6Z8!P*C4`*W,$*X*LI[V@*GXH*E7,K`2.[%0^FX':V$^R*N120W8E@Q`%3VP
M&@_C,$B"I@WS(`UR1K$JN[)>P7!3L1`SJE)R1U,:&@V$@5"_-IQ4UBM5\8AY
M031]%0W<H:XL6[1&&PH%"QF9X:?!MZ$EIIRE4F("2O^MH4`UXAH/]8&N]\!K
M])%+1_NU+&NQ+)IH?8:OJ!H)>U0.Y."D#\!3RJ"U6]JS_))?7;>HLW9%>N*;
M`M85:3@GF_(K,OAT/<<W)T>O8'NXGSJOVH&P0W2J<&>$`21">.:O;H4B5Y&U
M7:$RZ/)<WI%Y$\17$A.8?85XH-<9W9$)%`$7[](8RL>NB/NZC9JT2,*AO50P
M7KL-EQ8]$0L9/ILEM6-`#5&`#5@I`D@N?L0[$[$.8N<(`94YL/N\R"JVFX%V
M,4NJ,\NQKEH7(3L5WW@B]^J'W,B-'62+"(0RY'N)&41Y7`N][)NGBALNI#$H
M3)N.-DLSEP$^V.$?'J1'?.3_:NA+0N3K1^9;AN0AP.KKKNV;P&0JNW2#2^WH
MK)2&$09KM=E1'ZDS2>W$'@-!)Y_#/$Z"2@9\D`,(8N\T..B`P`J<PA4K,';#
MN`=2,B)D/'1"KI8CJX_1&5Q1$5VYE^$[EA;S,)4UNAIDN@6<&I]4,!6DPDH<
MI79QM>!"NXOAI"2BF04S(C&<#$>7'?RUF6`RG;IYMV*1MU`"2H-@3*OY*_E'
M77#"-\VUQ&[\HVE,1]1KN%6TNQ[W!7MBK&^\QS[*"5L5O_9JL]LK9/PP,!11
MEM1PLGR\R.4IK.CDP/>`OY[R!08;#91,8O&&#CT8#9/*R)[,;NM+4JVR#27F
MQ%R%_\+.$,I?*+>?W,I:Z,="9E+1@!&H[!"*`BB8\`X_Z'7>09M6`C"W3%GK
M(<9H3!Y,PC=,U\N"\,L?(ADHLA[JY<K2W&HI.V1H9U/BBD*5>AT>TQ(A4XC+
MLR7*QYBIQP"F5Q8?\XN/DGGX8GFO<5C;H[F=HR[F?"Y9P1&'5"\<,<W\O+*!
M@E/J,BXD`GX"PH";5(V.$9,W>`V4@3>M(SE=D8,>W$>O07__13M]P]"#$$#B
M@3F.`(%TW,\B';TDZRG:['^;9(9BR#EWE$)/\HBO1,!4!H@6X4+]NQZ1:XT@
M$H<CW=,^33F?%$I@"-'=.$DX+4)!3=3?.(B3$XVAP[]&;?\>`:33P5C2/WW5
M(AU1)20>>I70-AC5"Q201(V2E/#!KR&2FY11[K1`\&1%)4Q/6!W7_'Q8%8`Z
M(T.,-@,BX\Q\<LD5="TYEU2804QE?;G#8M777''$^?Q):"77CNW*_)5(VC!U
M:=&I&]TIVED(9=Q?V<!3W'EBN0E??&-@TJ6;XL4R_Y*HXJ5=IOS8+!LYV?NR
MMSL6*Z<\5^L?7##;XG`-N`B[JNS:[?M*Y*`/5O';R8`WVRAOJNH?O[U!*2HI
M'&L>A1#2SS#5P.W&C'A`Z*`9T@5%(G2R[<`J@8(>)W8.VF`-W'`-X4V-9446
M\G!SZQTI$J$J-;L%A580BE@7GG'_WE<<=!K*+A)7%Z%=GM*K#&8(M5,AW->-
MW9<5*3I%`)Y`,6LQ$`]0`03`F)*@?*P;+R+$%F*A86@%G!F^:RL'0EI0`90Y
MQ7]CX21>0PR$0G*1)I)``,0:0^]`$0Q`(2\^A_&2.!5NJ.%8X,?=OX_1VPNN
MP.E2,-W!)>+A(?,".O\4,;?*)*"1Q.&QXH0Q07W"/,B=@04!8GD2,A*E-POX
M!Q^,&ES]2HD9T0[(PALT$%_9@JX[=DJ.">NR,H5@$#_K,1G!1[:Y%K)A,M.6
M,(,U@&`!&VYAY$<>W/^"YVHQ(FO1,2)BW7X$(4V2OO66UF2HUSF506@!!N;,
M0T=]P`L(_Q<%`Y![HAFVTQ>,Z-P(9.F,F9H@E'S_U2MB0`"8ETCS@>(J5TGD
MP`#N@.L*UH9U48QJR=O@)X&&@!:*ONC0>T`BTD=9&='I<C.01"E<<<)W"&),
M,B^2@^WO@-RUD2XD7$$A?$B@$T#I&XM!*[Y\C4#@3MVM=N4--1!<(#F%@19J
M"!M\]!=IHI"3C4.YG3C,I[R2,0AZY>PJ7&NGXK:>P":O(R@NR8#`DAJ99<P!
M01IIT8#IH3=H(6<)+Y<<_UAX3)V'M#P=\\\3O^9_('JX_K_N-/)`^9@F66*0
M&$GDJT+5>$`C!!!L\>Z;/I@*C^3BV&%,DQ8$L$0%)%&U^4I,C_\19&XX=?HA
M!01\_V0]'L\@@/,@Y<[T("$F((7$E&(7`3!%YE",H:3J:H41`,;M]TYY3[^G
M5%F-AE`61*V-7ZCS^-&/8.C@6@[T^1V^0__LH'`JZP(3A9(1#ECM`Y$P>#Y0
M5E_LZ$(H%[[1M7WXB%(?"0,3EI#T&_]*RU/H"<.P5I\Q!I+V:^WX>@Q]")WO
M=V]#VM!:>K])E!%KZ='1Y*R^FM/L@[_(JT3RUUV-)DX`K\\2<='O@Z@?H!XO
M`D\1%P[XJ2,)O-_[>PS/I@/<T!W&[\!SD`+=+`,I?.MRWI$H8Z))>#PGTCW=
MT(8.U'^XDSKP)-89"-?)\<`=E8P9?>__#_#_"=,/"'^"?UA8@X>(B8J+C(V.
MCY"1D15??PL!DIF:FYR=GI^@H:*CI*6FIYU:68Z%HE]<J'\,8+"-65I_MZ2M
MAZN1O+'!AUM>C[6E`0P,%<6;QXI>6\+3U-76U]C9VG]>6+ZJW%ABL%QB6%Y<
M75W%W;ZO8F!_6V*#\^1?Q*_ATH?=_.7\O'@9)X_@H"\,5@$4)-"@F`=?;F7!
M4JL=HG?QYC$4QR7=NH9<LGBIQ*V214%BM@#;)BH`249@#)VJX&M33%NX6.K<
MR;.GSY^/O!#00B">*J$/*N#2HI1`%F7G"#R8]4?+`RT,`CP@8"A`A0</<GW=
M<E1J!4P,S6)*_TH`$Y:O7KR"/825P1^V;N$*4J:J@M\%W(86I7LUZ]:H255!
M??O`"P/'Q2J`$4HTGE>_,H&B6DG*;B?.B'1I'DVZM.G3OPQ]":L*3)<_7.P^
M_B.F6]?76UAC"H`+#"X"L!:`R4)`D"HL@+GD))1<"Y@*W!AP02X(N*5X@^P^
MCSX=\"!=Q+DX)J0Z["`MNWL[?QV;//.]?]1AP=5JM2Q8%3*C;N3R"V\&TFQ!
M0%9?^+6%2@1\D5-_`70!(!8,O/9',EK`$@`64G%!X3`$$"!-@1[^X1]66Q18
MP8$8?@&B-*+MY^*+,,8XC55:8%650F`D<]=9Q;0"CBPWNB?14$QYD_^3*C_2
M51,OQQE"7(WY'6(7DQ/I!UY.=M%HXWFKM*(+%SE.:0@O=CGF5%57824::#+>
M^)0YQ1$@1A8/W'*<9$"ZR8`88E30!1@)YI:%.FAF44%*#&3F&#S`G;7%8V]B
MZ$6-$^'I**3+M:GIIIQV2E<7A1A25@4+E-G%@%4&"20X7O85:A:B(5D3EX-0
MZ65^A<PJIG&I?H>+:%F"NA*K3FHA%*F[DBG(`N9I(:R1@K`IHRITPK>G>.YA
M@99GU$)WWXV@PEJ<<^YY)L@6$L+J;1=SFI<L)@4*PFZ+GM9K[[VC+<"/41-A
MTAX_SUHBC5!!MAJOB%[$FH6^\@["<'QB2$C_27W>?M$,?!$+,K&5OV(IL"#8
M\2JD%MK"EJQ,93)PYL.3K:O?IM1Z+(8R74PW)LJ\`LMK7<H4;(BY[@FR)K1`
MMM)JM$3CJ_323%NSA63SW?C0PG8]T*Y*"T0CF;,^YX++66#4J?#3.2Y'-F^.
M;>%5T&#7*65T:D.WDJ$1>4QVU+2V.G6IS-D&WR51W_UU`("^K&G,\''3ISDW
M)XYXGK(J6>XAO"2<4ZX>&UTLTO0V[?GGH'N2#"4W<C%5``2,5$%6N7`U(0,5
M=JU+@:PK_#KI@XQ>B8"D\T([6MF=2T#O^G&AE,ZWOR1[A:>G3ERH>X7'Q9FZ
MB^@7J/4^7K6%T).)_XY3R*O2(&Q+=?GS(=O]0=-LDNFLN<F1#9=IZ/37;__]
M^(^F_81-#>0ADU\1F\=NA!37$>L/4CE$4I0RH>&%16=B^)],4/<5K^7O@AC,
MH"*XH#R!2$(?GA`))T"H#0\*@H--(T8THG6N<\!F3K`Z(1;P(1!^R(08^SA7
M,6(XD4.4PR#VX(8-7PBKF@1QA1I,HA+M1R]I#6,52=H$B3@116RTXC6=6Z(6
MM\C%+DXCBX^H(B>DDXI9;<,N8/2B&M?(QB2F@UR$@.,,M5"B2WAM/I6`533P
M&"UGA<1/T2B&;VX(!COZL`L+V%VBT$>R$W:AD;!YI%'$8,B#+(!<;Y3)?/]J
M%LE&9@$[.)1',;:PBB)FX5%&XF,;5\G*5G[.*BEZ"^I6`;MD+`!#I!S*J6Q&
MG`4L`#I]PL(#NB`@B%"K+5$J4HC.XRS@;$AH7'F`(2Z)2S2E2)DA0V`7DN&%
M+DCS`6`0$'(P04T/'8R,\9$&`0!#S$)0J)?,<J4\YTE/&4T/%L.A"2%>PX!*
MT)$\X:F*2KP!G?;,R8+@4`7V#"70"2G*.O\$6@"D8;SXP*(0]_R#_*1QH4'$
M96?T&`EU-&I1]SC//+191U+4YS<T%A1H]8RI3&?*$GIY1A?<,M_0,)<X=#$P
MH1*!SP&%=KGSG4<9/2O'`KA"KZ%N1$TSRP\'5;;_CA<NU1#L*ID@5E/(QQ2G
M%6@<($W'2M:RGL*F1(6<3HO*TZ*=A3=!BMRJS.<KI.7).#"$HC1OV52ZGG"=
MPBSEJ5X3%[]8\Y;RN&0VVS*?```&K!:\JUDG2]G*0D(H%GI:E_@ILEQ!-"9$
MR](JR!+703D).D[%;$.!AKT)Y0E4JIVH4T5#$Q?>`@S8D8V\#!&;!SSCDFK3
M`CT@BSS+&O>XQZT1ZKIQEC/E%*#KW&5;[>)-U"TE:\?TBJC\:IQFP@)HQ.'-
M:TCE(%&A)W6IS0I4OSE#KEQ2?0LHKR!62KF$S*P28`U`<9'+W_[2](W8F0]V
M%K2[$ETHD?(PL'%@X\M"_WK-/Y48I"!<DN!#(K@JB/`-)Q74SDY:IL##(!D6
MXC$?F6@8%AQ62;0D=)`**>A<TA"#%ORS8/_:^,8X7B(X<\SC'ONXA!<S!0H_
M090?&_G(2-Z%X4:11DG,,,E0CK*46;%D431YREC.<I2_$-]:;-++C=06(I_A
MFPM_61Y<#D`Z%G#16[`(%VM6GI;G3.<<3\^QN`CF,`D133AI!7B."8!6:).?
M/2L3/7M>QBQUH85+6*?.D(XT<ETSWX&4$A=N&P@67N.;[U0`G[2Y=%6&BT5<
M4&73MZCHA/@AZ5:[>JP00NIHN\!`H!WMA*M;@"]\6KZ1Y4DBBD%JE5]-[&*O
M$?_5L)K.6TU-N<T-HAQ38:Z@>WVTF\I*;"(TMK:W[472TF92H_W:*EQSZW#L
M+-S+DT67]&LLZPR'V_".MP:GIP[H5'<HA,C/B<J-0$$#Y][4WAP#'K#HI9PW
MR/).N,(_QV4$<Z'!WBEQA6EL28=#?$(@IO$LR$5C`"_\XR"?+$Q#3O*2DW7D
M)D^YRETY[)6[_.4PC[G,9T[SFMO\YCC/N<YWSO.>^_SG0`^ZT(=.]*(;_>A(
M3[K2E\[TICO]Z5"/NM2G3O6J6_WJ6,^ZUK?.]:Y[_>M@#[O8QT[VLIO][&A/
MN]K7SO:VN_WM<(\[*DQI2CES*F$Q'`7>LQVC@5P2/6;_S$01$1ZCD"1;[O-$
MJN*5T99G:"K6*.]$,O@BHT<MG@%L'B-4"A^RIR@C\(AGX^47[]M.09X4JT.J
MXT]C^='/+Q+"AE&!,N/YA(3>E:-?_.MC='I1.$;QV3S-]'*O#%9+(O8NLCSM
M97W[5B)5*36:BN*-7_D:[9X3K5<&\%#3^A-]4OH#WP3R]S-^!=7([LWWXO@C
M^7PNEDKQWMJ/@U1V#.,A5?R;=]'ZTR_/_5L"J>@G>*#W'7GG"`GS#"$1@(P0
M$0JH"`.R#$A%>(F0,(O`=R<$*PVH"74Q/Y`'>GJD",@7$:OW;`7H"%D@9R*X
M@(>7"/ZW"(8W@OR'/_[W>XLT_Q]<<P@RUFCG8GUBH0RX<PB3AU3;5Q4UL@4/
MAWP"XH/*0Q8UDF&IMPS!MP@(`15(17W=14=@X(/1P(/2)Q/*H7C+I%'6]PQV
M8BR+4!?QMU7.XD*4\X"P(V?"-BE"F`@:HGAJ%F)-""C*`!'D,X>(D(1(%3L3
MQC/0)R+6ISSIH'B<%(,8U(*I!Q@SHPS/('T1!X"+ESJ','^+MWW"QC/*$$Z7
M>#&]=RZC9X6)$(F/\8@@J'U/.!U(A8K^`G[`MU5(E4V35QR+H(E9\PB:B%0)
M(B7:YX;Y-PBRN(?U]7FD9SJ;.`RCAU*>>'^U5Q/*F(R,>$$MN('1\7G`""#1
M\GR7!_\\M7=Y%^.+E_>$=E@K]Y<6H_=HC("&\<%XJPB!/D@(WEA\]#AZ\9=Z
M^E$7+)8(V1<A43@(6>AZV[B.QWAYF0%YPNB#HU<+PU>*QC%ZN<!\$Y9[+5>-
M3=."O:>/WQ&!W8A4NJ:)RS%_[<,S(0-_N"6,=0)YRS&*FN@-[[<GCH!4G`:`
M+'AYCS5ZE9!ZK=&*\D)YV6&/+KB0*A,`A)=Z'A(V-KD7SX=;3^@+#UD42DE_
M'ZE]@[)X\`!^NU:%61"$:/$?/MB$T<@02`5.@(B+&&D_&IF.\]>2\UB5WJ$^
MZ2B75)&-B\24RM`,D/=I\S67H_B`<<F3ME"+)C.,0;F'X33_7(H'DW99"ZVW
ME3TC-![)"/_HB_1P$*](EL.H>"0QD#(I#Q0YA=QXCQ%RF)_IF3(Q?\`CF(>Y
M?-I(&TOYF&FIEH:)CI'IF4=5FE49,II(@I>)EYD1B!VI?;9I+KTGFB'C%>C!
M'ZK7E[!SDWEYD/W(#:<TG+97F-<9:VFX")69F2C1G/-U%:Q6EL^&?.^'4E5!
M,U59$SQS#.-W2A>#C:UIG;YPGN79:`,XFTNSEI$9&Z])F%5Y#*.("-TP?GXX
MD4))FL4),I,I"=*'4D$(G>A)F@%I211Y%_E7%T.X"-V4>\TP>=L)G9R8?]*W
M?;%V.>"9GLNPC4O&!8"8*>])D=(W_YWZ>3_\:2[21P^B*:!SJ:#]($R+%YS#
M.)95N:`^*@G^R3H,^HF(()P'Z8%>L7@U,7G>\8`5ND$/L8PJ>GWSV:6!&"KS
M`8]'NJ4LZD.4I'ME*IG_69LU2IMWB0@D:9N0:(Q&6J0G%(1!VJ4(>IU'VGL#
M"@F>F7M#N']_R@W/>*&>5QP[N@E>$)/-`I2,L'[(1WSI.*#R"9R#$$$$J:=$
MVH)M&CK7"*F)^G]*:J>FBJ>89Z!#>J&CZ*<]"@F]V(Q-6IN%*HM#<:&RH`Q?
M$(D3F@@1L60\$Y'/V0B2FG^4&IF6"JFY>I>!.G"LB:EJ>IV>^JF?XW]).J+]
M9*4'N:UV>?\BW[69J_J:?5JIK_H(YNBA:5JGI,@7\4"DPGJFI:H(D&=WO7>I
MBU"L=TF3=%=$IDJF78J4+F2O,;JF;TJM]>-_K9=-[_>G`]I[K3>.X/JF[MJJ
MZ>BN7(8%1@@-QYJ@R_HR?QJGT3HKD4AKXJH(M6<X$3JFZ#)B>MJQSDFCW"JL
M,+IY-,AJ`ANNUVFO@O9D!LLT^_<%#XB6WRF/'-BCKAJ9=BFD$LNJ?IF.-/B;
MD">!J!B%-)FN_>JOH%FR4_B$CI"D[`@;#V@>K?<2[@BMT`JR\G(A))&LPXJI
M[OJL+ANR/ZDRVPBS/>LI7QHJ,5FP(I*G,>NC';@LJKJTXDJQ2)O_>GQ)ER$J
MN)*8"'4AM(3ZJH]+#D^)",+(I;DY<-@QE4I*@]Y!@RR&KS?DG;6'%FP[LXMT
MLD/;MLL*CA39>I?9>J9XMYVRL5^K,9R)"`V;CI[)%9X8NCB[)$V+M)`G33Q3
M90^X>_/:LF/Z.GOX%M,'IXKWFS"QL?$)DM`KKJ+[5S2).I-YNF6:I%G1BVD8
MM,@!*Q3YD%GAO51)N_ARK+^8")HHM/W:>^I;CR@UL'QJN.9B?Y=WN[3(IGVK
M#+\9N4@;K?!'G,RXE(ZPM]]X"**)IBT[?I"W>"P&OEUZJ#XIK++FKJCHM^Y[
M+Y0Z8]P)DHFPNTC[CW4RF?HKO,3;HT![_XD!&+@."*D&/'*Q>B%OZ5&^&`E?
M.'HT6IFE-\&&&:L#QZ,'?+-W&<.^6+/U(*7N^HX6',)*`Z9@6B*-()K4*S30
M\QU=##*KXSKDP;.OXE&A<C%50GM?S!"G0E42V$).-%`)F2NAL<:U,B!X8AL4
M8;G*$)>0L`5+Y8-=,(!4LPQ[W&S>@,AF1!8^>,A<O!(#97QEK(8T`PL#E4U]
MHC)9H\<(EQM[.+M4C#^>^<;]E:2@',I3A[8\]K"H?`I^\,JP',NR/,NT7,NV
M?,NXG,NZO,N\S,O"MZ=VBURPX`6(V\JNW,O(G,S*O,S,W,Q^<!K/>*7'5<'Q
M:LRBX,S8G,W:O/_-MWP:O=BK_I5]F&C-I,#-YGS.Z(S,I[&7&6A<M1>&Y'S-
MZ3S/]%S/IV$;&=MCY2`.I!S/G%#/`%W/:[`&M#S0%V`&",T!NNS/81?0#DW/
M!`W+`^T&'""$$=W-#/UU#[W1VSS0M.P&;E`"%IW+&:W1''W2SCS0%^T':^`&
M:U#1VK?2M5S27L?,!.W1KRS3L^S1-RW+*BW1/LW1:\`&&7`$2'#42#T``S`&
M3S```G``1\T$&$W36V?3/]W3MJS26KW26NW26XW3#^T&-4"42+4$8>#2[P<!
M4TW56;?+8)W3+/W3N?S5L?S5/*W5&[T&"!`$E%H!=0#2:;W6;'UU;JW_TWM@
M!&;``C0PUW8MT6OP`7.`!6D``'2=UR)-J4MP`0[@`%#`>((]V%67RQ,@`@A0
MVJ:-``#P!,HP!@"`RVO0`5L0`R9`V3M=`\H``050`#L0`V00!CI]R[^]TUGM
M!R:`5'/0!@B`W*8]`T@U`&>``"KPV:`]=;7<TFY``0<``9<'`6`@`,J0![0=
MUQ/]TS.@W4$@`G2]!D-PVPG``[>-!A=]TS@]WGC]RBZ=TU?]VU[-W`P``6)0
MURT-TUDAUS,]W81=RQ-``^>*5!#P!MX=(;3MU2I]WVM``N;M`#?M!A*]WOU=
M`.ZM,E]0W^+M!Q(NUQ'=TB@.U!.0`08@T2"]_P;%W=\Z4-<N+>`!0."T;.`'
M+MP`@%1(T`9GX`5`#@<`\.!=T-KW+=XMS=(&@`(4@`%L0-`EO@:VW=\)```4
M\.03$.4Y[=5*GM\G+N&P[-(D$`,X$`<;\,I>X-0"(`5(%0("$.=Q_@1/?0!*
MH`11$.=$(-TZ_G35[0<]K@Q,L-6O_.#@W089D`$=$.5KD``ID`%]0`,&@`89
M0`$TH-(&``-D4`,<0`>W70`*\.AH0-E#_0$RL`-D``-MH`)P@`%>$.H9(`<`
M0`,(L`$RX`$3P-)UL`<D``9GP`4[<`0@T`0ZL-AZL+%E[0!AP`4:X-FVW.>A
M7=TT@%0Y(-\>;>0`H/\$$``!!Z#2`@(!*Y``+[`"$-`"!3#0)-`"8,C>)T``
M$!`$%,`&*A#(2+4"]DX`!W`"V[X")A`%#P@!&B`'-=`"VLT`*S``"'`$=P`"
M."`':Q".Q_II`QW8SP[MU$W+)"`!$H!4+G`'=W[G+.`'V/Y^4*#258[;%LX`
MY^T&18!4+1`!%L#@"5`&[PT`TN<"0$`$_ZX%=K`'BU<!(T".$*`%*Z`,*[`!
M(%``2$`"";`&)X#LRI#9'=`!G:TR?&[Q2U?+9G"L0"#R-`,`)&_RGVX"%XX`
M!9_T;@``2,#>--_?7P#3$'`!;L`&.P"`-/#TMPT$!3`!55"6/@``_$T`:5#_
M!`B`!R_PREB>Y2VO#$*0Y8Z?Y3NP[1#P!%F.`5>/]4E7RS'@%PP>!)X?!"NP
M!5[/`.`=]@-]\@60\D'@`'@0]4T_T#'`]N\=XQ#0`2[]`DCE\'C/`',P`0-=
M]580[V[0]@10``A@!AYPXBSM!B1PVWC@TR\]TKB,^5%WRQ.`5(,^XJ-_Y.^G
M`1.-^JJ/`*J->9<^T!P.`3-_VU_@`("Y`2;@`LIP!77@]+>=`2J]\0P@`1%]
M[!T."&M^@X-KAFLR#`P0-X1^AQR*#`&"@HZ7?YF:FYR=GI^@H:*CI*6FIZBI
MJJNLK:ZOL+&RL[2UMJ:7EQ.20KE^`HI=``N*$FYN_P`!BA`%)!`,06T#BE4`
MAS7+"67+:&LFSY**%G)N:R?+.(02BB.$6<L%EH0&'"4<0`0$04T<_?[WDBCY
MPG2KH,&#"!,J7,BPH<.'$$\-'+1+4:]<P!@((\8@!(`V2B0Q<P;-P0M)+Q2P
MN6`AV[9%<FC(F<+@BA0)2%X`>&0.G;IBA'($,!/!B[Q!>B1=,0#@`LUP4!F`
M.#HPHM6K6+-JW<JUJU>)$RLRN'@IHS`DDK0$84``'LD@#@"T7!1"PPJ1VI9]
MF=&60(P>6\AL,5'&P)JDB](-6L>@G1\U:L8L*).&ZCM%5VCX\?(TJJ(5"*CZ
M^DJZM.G3J%.K?CC1#P!>OO^>*!H#X`0X:D3@?2NY!LV5<!!"P-NC%ZWG149H
M((;@P1+C$8;*E+%`X$P9JB]KLMELX_@B/-M;#UI-OKSY\^C39QUHB,V,&D.^
M/'*T)D.-&AEHK,%P!$D.'@H@L$,-)DR@0@]#D#"!'VZ$088`8PB1`0(Q[*!@
M`7'4T$,=`!RAB!56+&'%;3@4,,006]11R1Y#U)"%(6J48<8899!AB",B'*$C
M$E7T^(2.0`(9`P9LE".>'^HEJ>223#;I9&N6'')4E(7P9$@Y;-QH9"5KE+-&
MEL?P]$@YY;#0%A)U<!%&&&C<Q0`/QU1"B!N$&!*&&6B<848;-\YY)0G+Z"#:
M?'W6BN?DH8@FJNBB#+5&IY1TUBFEEI-V.>4A5DJ9)8/S/*#(``ZPP04'PM54
MQZ.36FEE&7L42I\AB7P'I:M5,6KKK;CFJJLFLZ::BYSR!%O(C5P..VR4AM`@
MFTCA5("#:*BJ.I^DU*[QQC(Q'*GMKMQVZ^VWJ6DK[KCD6BD"$B.*U((07PQ:
M[J\.D$#""RJ\.QJX^.:K[[X'V>OOOW6&\85T)R!@#<!0(GPOOPPW[/##H"@L
G\<045TP0Q!AGK+&W%G?L\<?;;BSRR"0_"?+)*']<\LHLMYQ:(``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>f39432a6f3943220.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a6f3943220.gif
M1TE&.#EA^`+>`^8``+72Y24T8X]4,W:(K2A$A"(N6/>QD:UP35!4:,W/U?W^
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M2%A<7IJ^VB@I;P@G3D9`@"E,=#LO<PLJ.BE+B2I,BRQ.CBE/CB'Y!```````
M+`````#X`MX#``?_@`41@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*CI*6FIY*"#ZNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<;'R,G*R\S-
MSL^Z@]#3U-76U]C9VMO<W=[?X.&WTN+EYN?HZ>KK[.WN[\CD\//T]?;W^/GZ
M^]3R_/\``PH<2+"@P6'^#BI<R+"APX<0GR6,2+&BQ8L8,^:;J+&CQX\@0XH,
MQG&DR9,H4ZI<6'*ERY<P8\KTUG*FS9LX<^H<%V&GSY]`@\:L*;2HT:-("1)-
MRK2ITZ?FED*=2K6JU7@]KVK=RK5KM*Q>PXH=>U4JV;-HT\HTJ[:MV[<=_]G"
MG4NWKD&Y=O/JW3L/+]^_@`/3!"NXL.'#W/PB7LS898K'D"-'MJ>XL>7+'PO8
M>,.YLV?./"@3QDRZ],D?%#0D6,VZ=0(6$5+0JVRZMFV#3!(HV,V[]^X*!63W
M'7V[N'&'3+[LA@&#=W/>P(7#HWV\NO5W3(8H``)CS&XW;KK_CCV;^/7SZ.]E
MWRY>@1LHS,=+?T<]O?W[VI(O?ZZ@^?/HY>$GX(#I_*!=?\^%U]]OP05(X(,0
M=K,>=PGZUQ^`PT6HX8;53-A>>/$I@.%TYG%HXHG#&,B>=^Z%QV(%Y&6(XHPT
M`J,?@LXM*&*#,M;HXX^VW!BB>[V-2%^)0";IX_]C0K((7GPPP#B?._4I:25=
MDF6IY99</O:#;CCZ]ML<74(6%9)7ILG7'`\\5L`/&]0@IYQ;S&GGG7CF.2<(
M+%3@YY^`^LE"G7=N86@-AF[!1#E5JNDH5W-$&ND/=%1`00)>S#"#%5YTZNFG
MH(8J:J80_)""(G-$L$4";H2J::<SN-$`F^$T^NBM546:@AP@4.`%$6[L!H0;
M0(AI[+'(EIH"F8\]H(5D-7B!;&^SBF,KKN!$*I.DM!8W!Q,5:+!=L=L!2^ZT
MZ!JKK*2OR!8MLB%66RN:V*[#[;WWFJ1MOK<]M@$%0!`1:[H$IZOL*E.V^<"[
MOOD7;[??7%OO-?A6#''_1A;C6]P/:11+!!&\@0=>P23OMFXL[DJ;KKS@2#SQ
M6Q=?QS$10!3;'7_$CERRP:;2PC"Z+$=,[\M$5Z5&#2!O-\,8S`U)[,X\)^S*
MSV(&NUO0@Q5=SVA:K#+T1W?<T;5A,;>2P@_*]=;TVDU#C>[!"9/YP!8J`UWV
M-BYK/4W>$86-V-VKS$%WPVPSQ[3;TZX;,ZU4YT@MX-GP/=77/DF-TAU_WQUI
M`0R<ZUSA8S!=^.BDCZZXW($S^V[HK(?>---8=R.YWLJD&K@KND+^4`3<LM)L
M8]K&,@?:T\+@QL=`B%[Z\J,K\(6IO$/,9LH(KJU\<[$G1KE;VZ<4P0:$SDF'
M_YURZ/X0$S7T4`,=[+,_IQR6[Q4\+'-L("Y_O1U/<\V>(^Y;`C^X`+/:);BZ
M]:9FC[-6]XZRP*.DH``5(((&--"I"<(J`5LPGT-8(#!->?!CJLF@!M?10(+,
M[P&88\4<$"`N8X&G6#.PX`1G2,,:VO"&%*3`!C97@`*H00T][.'1$A!#'%*0
M"-G#6PF#,KN8I$`-%1B7CF#@,1"@[AA+Y$8%K.8;&()@62-$1Q8%<L(4MFD.
M(+C?D%JD``U48`-P1(`<YTC'.MKQCANH%`724`(*E."/?OQC&EB``#@:<@.%
M-&0A?\"H,?K$D11AUR\DZ3L(]B=GPH)A#<*("T@^AO];LOE=,U@0+"ZZQSM>
MJ,&RO!8;X6@L?HEA11/S(;@6$FXW"=ADF7:Y)16ABP',VF4C:<<+<L@F>I(2
M92\N]L`H-D=GO"'")K'XBP*\X0<_8((VF8!-;/)H&2Q@T;F>DTKA2&,.<M!F
M-K?)36^R(H4G3$L$&D>A^&B@!LG0C\W65J1O'HF8P:"5I'SX`SD8]*`(3>A!
M"X#0@LJMF0B"YFYF,$UOK!`"7_C"$(8``8Y"``(4P(`SPBDL,973%05H`$8U
MNM&-9K0$"+A8/+4RML71DY\:R"`R]%FX(L6(1)0!""1[,=2](6P.:F#"%EC`
M@#^6@`90C:I4H^K4JCJ5!3W_6Y8SC6=*!5"4D]'@10-F@"PDCE2<)E7E`[+R
MQ"@B*Z=R.R=8E5'47<S2%[UKQ=$,R![^P!66MH@G\>K9-NC\])];$^HUZNH,
MWCT@J2!(PQ`TD#3_]>8+;UB65B/:U:_2=1<IV,(,:@8L!=%,`PT`K#!(NIVT
M'A-A:F#!/C_7QHJJ<*[)8&PN[KI,?CV@@,;R:P9=F;'B^E:?82HE@U1[)H#N
M0EM'`UC^7`>UY]3L>9J=PU8EZE7;:H--:"3K#*!0O>.A%K>Z8&W_%'!2KZ&S
M`O5LD3VGV:W@F?$J%5/AX,0D7+D95Y(6<P5R0Z3<'3%WF,[%A:[DT``P/1,*
M\,$?_[I&-P8@?&$#IX(H<[CK66Y("@1D;9X7DE@,];HV=>\]5G-R*3W[=B6O
M^I66A'OSUV,@UVHCLYJ1J*3;6T5*#BQ0V1C@0]N"D<YY&.:=)3?<6>]F0U<@
M9EJ$FP:$$:\2G&CU37LE)0?XA@E']ZRO).^KE3&O8J\Z,E:-C:&BTEZ2BU'R
M)X\3K.`YU$!<R>,G&TE6N&)]@0E@7#)72]I=]+)R&+H2+>N@T((6P``*FDJM
MH6]A8BVKE1!M)2Q.Z?M;,S^E6XZ%A=]^^ZXUTEBGJ]""JE6-PK"-NM6NCG78
MQO8E!1!!=%"`9I34P&J@TOD670:9&[S3-)$ASKK.RZIV.?]+Z`YO@UEC[8_R
MH%#A&:1VE%GN37M_F^DOSY=,`G5Q54KBZE5L08W'@NLJ9,WN=KN;%<0+7829
M-K(XH[!'OY[%M[0S!@4]FJMN&*UE@0"!S+8I`MNU&KF<_=TVC16!)FW`60FM
M;;7>3@X#6"]O:MP32J(E*^=.,V\@7-M)RR+>8UB:Z$*G@#'LN!V\?4J/8[E"
MW;!N/\&:`0TJP(*>^_SG0`]ZGQH@!U8(6F<+=S)1BRH&!CC]Z6EX.@-BBFV*
M\V;;JRC`%J3.]9V_@59RU4I/A)/=5P!WQB1/Y17-MJ5V:8EX1"BLVBH0S#(A
M.-_Z1H!N#+>?8GD!#>#]+XHEY8__HRM\HDK71@2"R'C&S_P5E:YXPAH?Q!\"
M<7$F'\CC8Y&5CM]K$-S:+W]7C`8U@/&_J)?4!I3SL=:[GF8,"([@[VZ-S;LB
MY@*Q_7/U'M&:W=P+=#"T,M>:\&8G7AMV!\;7(G]UB[NB66::3$_,.%.[ZO[0
M$HFY-`I0J#RA(0U6F#&.O,``/9G__'=J0,\#!:@^#0K]/0"!#6A?C>MC7WZ\
MIS*%O#,#-`PU*X)&)*U5:&MU"YG7"F!'9FL%,55""+=W,<RW&UB'8JZ`.9&2
M%:-6??J&#=KG@*^@6]*@!6^0`0!@09\R0ZLQ`Z;F'.0U`ZM!0:,2@S+H!6WP
M=0JU4')0_P-$-(-CT`"=)S148E>P(#&X)PQ2480("&,(DW]0TAP>TP-UEBH7
MXS<:]DR$)DULDA522$EAPX6UL(7S@SF%($N$AR]9A$S/=V6MP%IJTQS;%G@P
MUH4>5X!>LU8>V&G,HH&M4&X?2`ZC@6D7*$L18$9H8H:BMFZ=%SU).#^$`7JR
MP!'QE`*\9V3(TE6692S8]1AC8S8+PU?'`AL*I#U[0X3V]XC=<X>/B`T7&(E,
M^!S\`050.(1]Z(CO-&H!>'BV9EN@-#VII@5C1GU[*%=YI6I@Y(?(I"N:-7RM
M@(J"B(S+LGAR4`#.*!QL2%M8=XP0PVJ$)TMF1PC$^$F?YUAF8O^'@ZB`?8@P
MTI&.]V>'OC..DQ$XTB`-?!@X6C)`*I0ZB@@68[B'M_5\"'`@EQB0Z()==0@+
MHA<RWV$UH#@O2D0O\C!&?H&$7Z%\/$$+?_B'7\B,;=**R]%:1!"+MJ"1Z]8F
MMWB%%350X1@!:H!4<O-J#)B(93@(*[F2=,@[*IDQ"7&'QGA&Z80`-0`"ZM=S
M<+`%",`$Y?,8U;@?['5IGI>2-[DO/3%V!<DFK/8FB/230-D`6@D"(%"4Y1-,
MWR@9\$@>'2<(+!F(['A_QX1-5UD#B_0#IO<8?BB(;0)&/4E'&^!09@)>T3,(
MOW-,8#>(_0@6D@B0;2AW`HDX0V`J<TC_*P=Y2PK@@Z$8.2*)%=!0BI6)17=5
M",S$D0M2++#82351A0)(+EBXC`B@E:JYFEHY?V8'"]S'FJP)`D5'?6\@FZSY
M!K,PAI^$/A4``0E`03/0>C/@!0DP!`P``AOP`'#`(FVXE*_E-;>)FUJY!8S$
MC<<D#;*A!C]0`RQ0`D,0G)GB0:^2`!3``"S0`QN@3>N)39OQ!G.$*`V``&!A
M`ZJ9E:Q9`YV7A]W9``Q``>$Y00GP!1#```VP`4?Y@'7Y+=[YGZV14>=YH`7@
M+&18@-:$`&\0`#\ECZGCCX99/8B9F&Z#7;X%7H^Y((4EF0S)@?M8"Q#9@8UE
M*T.3F71Y>SQ!_P@G)(E[)R:@"9(N2B^DB8NGB3`%P`(:0)[DZ07J-I*_!0L_
M4`(=A*3#67!UZ(MT(Z4>A%H%N8Q:^``%@``L``&4I7%:-@1P0`&6&!_;UA,%
M,`"_\BJ>,IQEH'3)A$Y@>BFCY3DA&G#&V5)#D%$9]8(P"`1IP$BJ]H^OXD&P
M,@,E4'1Y"*9B.IS'4F4)4`(UT"!1*8UV&J:_4ED'5&4%B@"FEY81@``#T`"(
M(@);`#\5V*%F\X\-8RP0-V',4ZO-<SKL$GHR1F'DHJ(M4XJ<AXIH\J*7>7TT
M&E;!NCT3\34XJC&_E7_'$IKC4`M!:I+=\D0<)'+1M`6/$39=BIVH,?\M"8!A
M[)@"#0`RH=,_UA:=-KHL&\`""9`TRB-M\9%KTS5C:NI\L0%%XLII;%<_%3`$
M(&,XOM<Z1+:"!9,&HYH"&P`FQP(!1_DM#?`%GOIFPT9=VY$`1"<;W+(!%1"O
MSM%OK,-WP@(!-6!ZY(``!EI(-E`#!EITMP-/[3*)`<DV(FHRC%2BYN:)^7,U
M!ZB9>,.EN?60R]"B6/&0?".LCX>-^,*$Q@(%P5=,Q%&M`SBD'<<"P\ED(/(Q
MW%J`WVHVX9IG:W1A8/=;YPH$PQEWY`4#`G-MLO!$->`KO.$ZMJIGS_F&7NIE
M:[1BFQ0\XFAG%%!9K?,ZC'8]-MM%G_,<:5#_`%W#L+J1/$M#+`&C`!2PDG96
M`M*B:4?&/ZAE>FS"!"`P!&2E`!!FN#9;+$`P!/C$"C9@H.#3`%N`2`R@4UEX
MB!OIL`2#L"`J?I:UF,48"XWC&U9#8I2I0,-*0LOHHK+8$,&#+X[;<@366C,0
MM9-4AR59M2>)K7$W)/%!!%U+&#%S-A2P'WHVKA`36@-[NNN:O+[S`^$"+.1K
MMPA"<M4S+1/894I9OV&6*H3Q`_!J-?QD//"+(]V!:[I+NJ:TN`C3L-!+9$SC
M'94++GM'M\P18<%BL\<#!"RV0C2@,M9S,R#:10276:?2`(5JJAO`)W*P=8Q9
M$F,'J[0JOP,H;8=S_[,$F9,["R^\0;PL2G^WMT08:83$0;06^8$5R8VY-;3Z
M:#'/RV1$DG/!QTMM%VIL6GS8*U#:N[O=^T5T>#O@.KY:O&([9#:BI<43E41G
MPP"C!1ZF&Z(LR+O--Q\05;]ML[_&I`8@D``UXS#^@71*^BL()#`U'#)04+&\
ML;BAQ,!L`Q_>,00]$$'?,;*%!2(VNS]O5`,0@&/,,5X)TA\1AKA>``(D*0)P
M8&=3IW[UPP"ZV:2W-0AW,'9O\`44TK,M\AX0IKO\TV^U+#*\+#)UJP"EXK6"
M2:$YS,O\X8H\O%C`R@P-I'W%6AY@\0:'@BC3'&0X4DHC,P,L<$C<W,W=_/\&
M-D#%CV7%IIF]:C``Z4M;1,#%X(L[XAN__&&^9!QB(>Q5LQ*^0`8RP/)O_J'+
M[B$P%E19`4=>R()U<\R]?(N6&SD$W''+_?PT--B5/@D"#```I&7(#>R<ASRA
M;:+(A24>,P`!*G@SP];)(=-3+/<%:4"Q(1,KIGDN`R.\ME8"IM*F<'`!F%P"
M)GL!3*#*K'R/V/D&`HNP[R'#!T0SR'.SP,Q(Y@%RGF@UAP,#R5Q[RQR24OL5
MMJ>/6GW$0INL2=S5Q_!`#::D-80IH!DZX&&O[N%2@-K6;LU2;0T!/KB-AF>M
M]-BFZ:R4Z\RN/]UI[US/N#3&OE/&SS0DZXN=:@#_!QHP+.[1-CKC!D-0`5T9
M1S4`!VW@!<96T,Y'DFZ%T&TD0MT"1>CJT"UG-2;[`\GT`-W)`(M-,Z.7`!4`
M![(-!WURL@OLL'P,'\=S,V.0-!J<!EP)`A];OPO"<@)3,T_"&QJ<G-[9P9;8
M<A66`)D5`2)`=S4`4RPP*RH[?S+5+D)-IE-TP*X]PR+Z/!?0CFQWHL;"`C]K
M#!)9Q,6$U72UU>NXFQ>)),?J"Q>I#+&%T<N!:VEM(>"=+D00>[='SKMAM5Z*
MSL%E:SK5SK?UU\<BSV9$V(W-'];6O+%A9^)"!%/V3`/S!?.)VAP;/3^P!30P
MNIH])9;T5J#-"@@@RT5-_V3'LQNJ"VYH.3P5H.*Q^@4]\$."L'@3FBK/FY`!
M/F0>SC0?TT9O!)>3(@(\.VPZX^&:LAL:,'5?R9UNQ5\5I@$(\!C7+4<LH`:I
MR03JQ]%)"`MB``$!$S"O%RLBRUW*[3'(PS]V?N<7_7IN_GH0P`0:\T.2PD*V
MQC^M1^B1V=[%\-XQ:M^8"4G'FM_$X$C,V!-J$&W&<FMKD]EJ75VV%GMJ6-=7
MS(YX/7H.KM!]K2WABBP4CC`6KB#"DN%W:`,0,"X09L'!0@0EL`$TJ:##0P//
M'<<H-0`J5G+S,P"4M;W/L>0)(*K/>('BR#$:YS$,<)T*\UN\\[RH2RZ&$RLE
M[?]5-(``7VD[#V`#8.Q"KF@U5UX#Y=.DRU(#/$Z^8W!/;<)@LZOK1S,`JBSN
M6M@MMNB3YL<^/6"D_1,?->,%%=`#ZH-^"H\GPNUT?N+P3U<!#%`!;JGPKKFB
MOSJC3>W"-JK?PYJ(7$V.Q\N^YV`(*+8LV9JX5(3!%_QH&AW#Q09,GX[@N<@F
MK[S@XZW.(@3A'9KJ$S[&?J,%(+8@3X*ZZRKN.&]K!DR_-.#G@IA"F)8".FB_
M%G?S;;I>WQ8\!5`";1X?2EXS%:`&-1H]RT('N/T<O:W!JYMJ%D@F#8M`3Q/"
M*<=>+!#N_!N5(F!UA]D?0P`"J.VU:W4V>CQ.:R/OJP#_9"OKG0,04TCOJK#F
M^(L8*8)..).[P8@^/-JA/VZ.W,'BZ<)#\D!XF:+YH\E;$_N]=/9=H\HKB*;?
MB%4MM7XX/?U]F+W-\J_SZZ/'-D1`=S]]O=$T35;/X+?DO:;>8JI=[L:RZFW2
MZEQ49=?6+3&^'25]^PHP!%]^]SD9&ZB!^^UE]5O^G&'&RK$LMLT1.DA-!V)O
MQ)W&,466<LXO]N4(3XX+]Z54P%2T&U]`F[^[APT`"`H*0(*%@E!0,`I$;0AJ
M*0\1D@^1*0400(J",)R*&C64$7,%"`TL+%L_<Y&1$92MKW>NE'.UK[</M7,(
M&@IN;H8P1$0*&ENZN,G*RZ\__PF^AM$P%060S-?8V=K:D]O,LZ'@K;/BV=W;
MDNG>X=_JX:[GL,OE\O6OD^ZAR>+\M_GC]-:Q`XB+W#EP:AH0(Z2@TQ@@8\9P
M$O3+#:>'T3(6ZJ1I484Y*<`5J-`0&#!#1$"LFE1@`+&.*(^QHF7K3J15/RAH
M+)1@PZI7*;;,"%8(R(P&]U*H(5D(6"="QB)8:_>@`(,Q.Q5XJ0%)W<A-&C^M
MI%3C&2>+#6$`T_##VBQ9K&JI81%,42<B%1X]N&.35HH-9GVY0701JQ<&;W[Z
MN[4%BB"&:6&,<0-$@P@>BN6Y*E!"6B>M7&^-*E"@G+M_N'39>J6KAA<%$2$;
M$AN)K_]M2K;YQMK7]Q63(8,D-YVH@-K4?0*3*R\8</F\?/&<[T/-C1YU@N^D
M7X.^>!WU=."B>P,?'7SW5P4:R#8$!*+$IL`P9LU(7!`1!H]$DE0+#:5*6"V]
MI!$1,H&S6B@XZ016-#UE%M10&QER5#AS_`"<9XH000,3Z$3"P$D:;=452TS!
M5(A86LQ20R\MJ&71+X(DT!8[NK4RQUST(>(+-<G4\E<"$U7$T1A>&-?5/;C4
MX-@@FW"D``0-5#../YMU1I\B(J(C26;BY8*,:+6X!MMZ)X+22F^X[=6A;Q<*
M)UA#@ABGW9S2=9G<=>8-],US7>9ICYW*X'G:==59!\]!X4W_=T]XWT&7Z'A^
M+AH//JXD5(8&"62J::9$0.3BFP]Y(>JHI)9JJ@8:#%#.5_R!:-]_LP0(9T8$
MCN7*@5L^D--&)C:HSX-$%3*AC0B\AF$Q!<Z3"SX5N!I-EEZ5&%8-8SV`P#,M
MN@BC`CVI(<J9BSZ@!@,:340$"P7,E`Y(@`7Y"T=>L-#6B/6HN"1DGR50PR,A
M^2F))59Z!MI4A$;:I6II>CF'F.WM9$QV>KY37IZ_;8+5FYKP&"B2$-,Y)Z#>
M@1RR01*;UIQ`B)[\L:33&3IIN'H2.G([C6Z7RP\((+!!SCQO`(=99U4$#%XU
M%&WTT4CW@'0-;\"#WGXF19/22INY_S2KU,ENJ=@D*>S:)(,(."A4L((,>RL(
M.VDR!!,IS-$<I9$TFQ6T)"X8#6VSO($M?]`0,@,+M4PLR@9?,"D-LOJ,PRZ0
MBFR;UA=,N#THQTH^1HA%$Z7Q"-7J`AAP70-3J3)R+4>0FRAAOK;>9P\#Y"]Y
MZZXB>3<5-W0QC!FG&R@YHH_NL3F^;P<[S%1*2MZ4L`S/\GF1[@X[/Y-"__SN
M'>N#:,?7(]^\H1`_K_SQ-/.^C&I_`2<<C)-IA4;P"JN&NGXE]5<($=3J4P`+
M`M*:->JL<.VUDSP)6S>`%2%A(8457RF7($H@A[8=BE$#J<#%0A0:TVU&6AG!
M&R7D0`%/G?\$&`W[@D\<F)T4R&$`0VF/"BFB@"\@H'>+<Y?%8$`!.<RN>#.I
M'`Q4B#E%Y,46V:M2N;`4&M%)K'?$H\0><&,;U"W,6'692.LDIIK9P4X7X/E)
M[=R$NSBE*T^3<]WOZL2^TCE*/-+SGF:Z83*3'=%UKW,9<WH'/N:@IF8Q\][T
MCL<][>GQCP^T8_=(9HL47`LV6-'1269`A\Q<XT`XK`K4Y%>V^B'0:B:R3[)H
M`C==*2B3W!(@U\96P+(=<(-I2,OABE,`]TU/'A*<6P6?9K?9U,]TD6B`%R3#
MD/<0@@@E")O;.#<'.32@%\&9"!"&5H$?&,]'[6I<U!110RM"\!7_.FQ80Q+!
M2N1IKRJ?XU7HU$'..P[*B7/(31.=N"(,27$+HLGB%;.(Q751@@F%4^6;"L$C
M0#Z0G%H:8R119K#FP4R-`_F'S+#CS^7!D7EL5)X=^\BQQ!'DG-BKXQSAZ$]&
M&:QX?#S>+IX1$1A`P54SZ,%$KVA-)R)PDLZ:P2VKEC^L56M9;*2$UP26@+#!
M8@ZDK.51W*93G=0'+&X`'#(0VHU8[@1:M+R:+7]R!Y!<"P8S&,9@,M0>(E#`
M$=:`Q!R84`$-`*%3D1D$,?15SW/\2(8F`0($;!C1B&63(7S[R$RF="B`#1$T
M;WSE7@$BN5JHDR]:6Q@R><6Z`J4Q9=FC_P4^O[9/+W(T.^`36<3&""C3T!&A
M%JV7>2@5T=+:Z9R@E>CKC/=*A;HV>BQ3K?18>TT_QM%X):OMGYX'%VN1]#./
M44!*?_+8D)[#%JQJG-3^<\F:QN0X-R'JLBJD$VV"C9ACLPM*D3(+&T!`GQ$Z
MUY>^Y[0(.)6"]))D+4]4()N8D`5>."L1>NA+(@R!`0VH0<Y`4`$(&`MS$8G(
MT-#5+_*LPI",JRPAYBK=RY+%,3#9%H^V9I!_<>:O6PGL:E/35E>@B29A6FQD
M&DLU/7(4D),E@D2$9HA^WK:.&G6H0#<[,\$*DK4.!J-!<6SBZJGVLPP]66H]
M.N2"T/9M0<;M2O\WS-<*'Y82AP1N0_S6R-!BYW3_6$5RY?=+2U)"5J"LU5Z_
M=:A:,$%!._'5)(`Z%.U*Z)0/L(%13:0((%3`AL3-K#A8,$%QTNW+&+Q;>RG1
MM31TB@A0"/!3'D.$&8AJ!K(QJ4.P<A\.J<L\"#ZJ(1C<T`=4KB@OLNQ!>7?A
M*P'VQ-R9SD\*BYU1B&)%^!H2LDK<4>>!!S"+"!IL.N)BU&9TQPO]V.@6VEK8
M8@?5T;-Q\B!KW)5:U+3)UNT?-UI0DIFQH#)6]I$=53(JY0;*SY#J#H5;Y2JZ
MDJHVZ4MTMAQ3YGX9DP/:'YEC=^;Y])2XE,AN_`QXBUUE4A,,P/,-ES?_B_.*
M4Z9'`O1Z!6&,52!6*@_80`G0&IDQS&`,%)=&#P$(S#=,M\*BR'0FV\/I[=EK
M(\OLSX0=F2@YA/-K6?JLS")0FF^9^^:[Z`69AC'KM@ETLIE0+@L5P`#=8=:<
MP]/LC$7&;9EC#XFYU:B>VQAM;>N89#:>&!U]7-H;]TG'#HUCC'/K36CC\#:'
M%#>59<?VFR=#W;A@=S1F(!/TP%M_@9/%:LJLAK)4UA#WQH6^^6;*?J=2TQ.A
M0%NL&'97&/QK,JU'`D'9\+W(0FL2'XH;9I`(2>_0#?.%#3>;9%+'`"$!S>Q*
MX$#N6TT/0JYTQ>.GX80YRY8'22['<!&W;2?9_Y$C<#@/4P+D.XSB#^/T6U!#
M2W.515N#IV)2]L7%BFY$DT]]QMA@>F2C?D1F\S[:W[>V\VP]2$41K]JF_35R
MQL[DNMKVC5LO>Z+`SHZTPV3<1*##LVF\??4&:>YU]V[.-3_'X#:]%3BTT'<0
M\"YIYE.,T6;[5GBO(`?[01]8T5-'LGV3P&>F%GGG,'EA(1.ZL24ID`(VP`!>
M8!(<41_`)324001>``')IWJ#91Y1-BMU!GL#MU&SMX*V!SWAX%>F%G/AIPRK
M-PH(4#1T<#0]@`8]T`,(T`,-P`!IP`!6>(586`'Y10=<V(5>R(5*^(5>N#0U
M\#,C!@T29G1K)#B`A/]]RU`:!+5D!&=MS"9U'75]U.-\H]4G.-0H)I9JX7-M
MY2=:XG-LM'5B@L@Q:2<-OT0'A[)1#V4/_B=TPN)N57%WRX6`L]!@0`4<1@%*
MW.(3@@>!A"=<<#8'($`FMJ,5Z'(>2B8W`O-GZB55[.5PNH$,%0("0]!#H^<0
MG7!213$#$,`"D1,2NI-L#X!@<*().<A@PO-@C$4<+N9(XR"$L;A[=]@CR/`&
M&:`!634#X)A5C=8I&L``/Z`&Z)B.:E``<J!\9!5?C1:.X>@%\NAHXFA\\2B/
M7I``"R$9VP(C4-"*+D-UT^:&R0"'RN**."9_U2-_8C>'[!<0;81$$@5U=LC_
M5/VW6WTT=8_8,F3'=:RGD>A418L8#&OG37EHB)/(98M@B6J`B?YQ4](5`3;`
M`F8%$9T7?2*$7:2X78E3+%<R;D/P0D:$'1,P!/]&1".R&70A;@PG@@\G"K?"
M!#20@H2@"4)R$93A!E[P!110`36@"AV39^KP(\O8)"0G!S<F#ST(0!6PB6$D
M%06``[KG%O2'DIP$$F]0!D3@>@US'WH!8JHQ%\0P'X:9%5TE$>_1%%K1`(&D
M9$JVAV4T)Z01,1/YD1K6D!@U44491I<&?Y!Y4>7D;+]VF4W7>(+3F>XW6[)U
M1IF9;;GB6^#%2\*U/@QE?DDF=[-"/^(`9@/2``B(_R#B@@`,L!!N@!71%R.B
MV`WZYCBF2!.Z\EW[U`F0AA<-%"[UU#9O``&N-Q%TPY2UI`EX8Q.Q20I5>1:%
MX`440`-M0`$4T`8E8(6H@`!B"5UG5)8WR#><`'N<Z0Z?]AG2Z#0WE%-S69>1
MF#+/82U#H&(C=VC4MWI.)`IR@#^':5V'21'M45*",`8ZPBVPDGY0UWW!]CN5
M68,@YWWA@EH[AI<7^5&!R'WL<(?<=I^*LIII)$9&%GYCAZ.)<Y=2QR?@$&4K
MB!$R56$P"G_,`A8346<?L"^79T(5`"$<H4*`F0L(4B$U<"%8`2/.R1/+Z5X@
M`(%<Y@7`B0P)T0O'N8)9U?^8RJ<%-3*2"$`!M><9E0$*G',_0:<)VL16>^4V
M:L`$+,`XQ$$$PV@#!1``-F`#/,`#`>`*)6B7!K%J>>)>@)&G)[&?<P6DV`1A
MZ/EZQ:$&8W8K4EDEJP,-&89LB]$7$'HK&^")>=H1OU1T;8.`#_<`%.@L%WJA
MF<2AG$<,:T.:(2J:2D<G)6J(5W>D*@IL55=1:Z@R'$ED4==C&75L012CKZ5;
M2]:B%FF'@]0/'GD+0KJD1%H#_W2D[S>+=F$7@U"DZC`'NN04P'56+@02RR('
M-5`"K[%#%Z$(HW==M4$)#2"F(&(493I,NF(E3A$1@@$,1?(#XJ`+<K`!985(
M25G_IT`$GN!5)IQ#"6]0`?Q8"!>C`26P`:T$7:QA3^^P&HQW"[C6"9>Z0YE*
M?M`8&2!$"#_T/%L#3@+#L&82B5?&2>W:JJ\'0$QR']7P+9;7#118F+G:M$-D
M<8W6B@L)FH0XHAY3K%<W6\N&H*B6?3!F;"O:FEHKHYP)DM=CHS=*M=%ZK:K9
M20G5=<SZ="-UAK294H$DK;9U0:0'7'1G8%N0@F?H"XV6!O3Y`S90`PR`3";5
M,&D*BH''G/FS72`A.631"Z''8CPW`Q30`&\@!S0G!SA3`5]`#"55L5Y0@`#2
ME)1'+91+"FD`(8QV5N;H2MWP)<S15I`T"RW;J9AJ0S+K_VE+XK)UQDK+ERBE
MQE@\>X@=`Q>K-Q-"2S9%*ZNK4:NV6@%,Z[386W%68%\.J)G5IKP&B1['2&3%
M%9)YVVD.MH:E*:W<BFP5F;60=:YL^)#75I`YEK5Y=*VR-;=I!1O`,%Q-1K;5
M.'D^*%QUMR5^%[C\001?4`(E``$?*QF2<6CTZ'HQXE.0BX,=\3='"&B=LI45
MX0L7)P@Q2`,54`%I0`$?.[31]QFGJXE5H;K3\B4(,'&2<3%G!01>``=5-)(0
M.CNX2'.ED;N4L+OZJ0C.V(;`N[<MUDIOBT4Z&XU8`D^T]K4"2KFZ>R%ILPBR
M>@N(9:5+.V(K.,9D7,;N%"HLX/^[H"E;ZK=TT/%%CP52OM:MM8:(S^9^:UMU
MHYG'8HNL>.R9W49:!J6LX`>^GMFB)L>_P+7`/?!/=;RUXE(B!4QWCG1F5^DD
MG`",[(&3+7)6$""Z@1M`V)4_3L+!HT"O.C5QB[!,O\"I%JQ6:#5?Z</$+TQ4
M>NN4W,*Z6F:]GJ),*@0!($"&-;`%9+@%QJQ?",`$YZ@+0XP+RNBR7U-R/[K$
M8IP[D-1M!2K%6E&`Q:NUJ]=;SSM$PM#%X:!NQ62]U5S&ZDS&&**P%!`Y9%F'
MC^*0;OS&5J:_W)JL!0F_/*;'+R:V,@J_[UO(UB-V0Y:-2+I'AXQ^^#NW4J8)
M1&";YYO_SW53S20L@JP1L`IL4N`H&>`H$9*V",&T`:G$H='WN+>R!<0`KY\Q
M5#-Y*S5LG"#-$2?ULB858()``5\P&38]Q1>+KJ`C%C[B7>Y1QD:A`5Z`U*B2
MU*."*DXM*JB2*4-``2Q`GZUDN\FXB$LZ$=+LHCHTQE[48+6[+%&\MSZ]JE:\
MB9(#%^63L2-FM`139N<\T^M<UV!M@0_Q!=3B<^358]]+8\KQ/4;'1T"&DI+Y
MK(<-K8089`-=9&MKR,;EK>K;;7+(T%FGK5\KH@2IV%&VF'4KT8D=4L=&P#-=
M-HX5<I9,631=&/51CFWA-2"](&J6TBN]<8I@RAM;"QO0!B_Q_XLYV=.EW5-P
MP-,VK<.L:T&S"!\3P59#_5V-EI.^F+U/M;EXAK3)B&L]E!98T=6;60.]S1$G
M00U8K%!E+<;;#,7Y"P^JNM;_(K2+K-VR*R6B4PL4J)C2/1_$L2U`\`4J46!]
M#:+(:&7.P52#_=^NB:.;V=C05H=TO.`>E="D1=E;"[=UE>"6;:0*'>$2_M^H
MN;Y;=T@*RVC$P$AWZ\CR3$L9.K!G)8*UBP`08)R7P])'I9Y1DHQ>HXH-`@^U
MH-*P3'M&`3C=TS82*V)'-:3I8U\J`0>XNI\B<D,M`1DA'".Z;$+%.0Q!XS@F
ML2UTYA".41$YS'#R`E`_TE5XA7%/$O][+\;COJ"G:*4QGED:V9P1A-#D;$M8
MS)<.*;"=;HU(9Y47QX%%K;04`WC?H+,(E.$%P02J/$K9>QA_<SPRXD$:^RS`
M$ZZB,N?7#8782IS'&Z[IY&O@.KI:H9W62AS0^"R;UD4(?D.NE0[0YI%`<F[`
M)>8E:K`!#+#"L3:H"=`&#5",N5!OAG-=$>`MHD!*%JK#W&5L!5`#:;#"6>&=
MP^@3<]`LJE@9*G%#<D`N61$5JO$&:8!,+$81SK+(*_C;_"$,(RXO.)75SR`;
M*@0$-<2CH[4%JAX-#$%]''6Q//!RGOHPUA3JQZ/G.Z'J@#FK-Z<4%$KH%TH$
M";"YOH[(F^[_OBI9*&A4<W\XQW^=K)!YV&0WZI@NR)<^Z5P[6IK]\18>O^X+
MX(]NZB=Z#S4,`10``4,@\Q!0\U\``:PNP,>:'@EP\S4?\U\0]%]E\7GR`S70
M7PD`N(PV`QKPR<G\)7-@`P-0\S(_!%9O\R70-!&P1+FP!3+O\S9_\Q20?*Y5
M&FUCK_VE`9UBH8N@`4/``HDQN0T`]E9_]1#0!JR^%YO1`!#P!74_\S;?"%<]
M"S_`]RFHY2WLLB[XC]G-T1<H3-T@<50_^51_9^6*HR[N\W]O\U%23EHCE54A
M`G]O]S5?`GEOV!UU>0_P!FW@U)N"*0D`^^:H!G)0^[9_^Q(;^["__RF\W_M.
MO?N]W_-?N05,4`T.9$$HS]@=[_D5":3L1_2=%MF>?W3H:^K"6L=M>/'H*_'R
M^\CZC+\(+?$L;V,%\`9O\`,;D/X;P`3K;_XUE_+%!AXX\P;JK\SJ_P:M),C#
M3@EJ``AO-0T5%0P,%2P--4P%<X\1D1$/$39O&YB9&TR8!9%[E'-RFC^<&V^H
M`922DJL1CX\%3%L5)1`00T.W-"Q;3&HI*;$_IY>:F&\_#P]W=Y%SQ,>HR`64
MRP^/:AL@-%XP"C#A"N/DX]_EZ.!0X>QC,V-`0"S5K6I,3,:F/S]O-IZL`",M
MBU#`V#%.R5P-%#BGU1P;QS+M>Z-J(4!7`?\!.ILDI\:6&B!#@@0!<@NA0RA1
M%C+42Z3+ES!CAD3P"Q:D2'<P7K28,:-%GCNO"=4I<.@U@CUW*IT$M)5"5DV+
M$IV4%./4I#VO!M0Y]:A/JUFM7HU*%6I1LUB=?DT;MJI0+==L/DA!-NW0K7.'
M!J/;D"%4HZ_4J'DTEZZG@9X@82-<F*X:J:\>[0TVIW`HHD^?(>;'Q(8-)G(B
M[!UX#>XRFW/H#FSVC'#E8`^TF%[H*L6%.2`2A!L3#HB&!,`U_`9.G+B&&3.^
MP6C1`@HX=D`4E&#R4ZCJQM6WMKHN5_5?27V1+NX^NGIFMCE;I[X.>_V<&AK2
MH=.P)77CR7$GHY;_+`S6=:^5B8665Q=5]9U;!(9E%"7_V&6>6@5"**&!;+$5
MU8-G.;C4@4PII!563?$D((=U:5?AB1-V*)"*D<U10(,;:BBA12^*IE-X';H2
MX&FP<"@>CGVM`@93$<@AAUPS$K51*Z]8!QLV0H5G$6H=;K0D*SMBYLQ<T(`P
M!!&[C:%``G"$])%,)K%0`01>C#$&%&ZT,PX$U(7W3X`PXA7C0E2BJ!F6`4[X
M85+IJ;>@3?`]Q\YN1"A`7RR39!E4CYKQ&*15.&;(I#5$,NFGITZ5*!5@>;:E
MJ5NA>HJ9AY^&V-5YJ*9(88XFK@A9A:+6FFN2?HIX878R=FKA*@EF!16._P0F
M<5A<&C73#$8WJ77-E2\ZPNI%F5YKJZA$P?(/6,\T^]=&R[Q!`Q'Q`$$$NAJP
M`(Q>>MDWAQIO5.!%/&ZL`P,\"D#P1I`1"EO66K*&EY.VD8:[U%&[#KQM)`6$
MMB!!C\"WZ,5B:E!#M`@6>R)0K@[X\:I<#9HCJ;8:*^NMP+*(ZZYBF0PBL3&B
M2%O-INJ9LJ]C@>K3@2,&:U>2L/H8JWD7ICIL@J\&A2524MZLM,.A=J4TSP2?
MBE2GRVQ`03Q@0@%%=!7\T!]M'H[W"!T)D+-H=!0PX2)CX`:-<\*CINRTRERG
M_7)`WT)6V7M>@&...(9K3-K(/FNMJL<_"RM4K?^.V[S@-34*_.G4O\I\Z^>:
M0]XK@2$/K37368,HJ(B@-KRZW7KGS#17>'&+UM2:YSXS["#GBC"M'3M(;,G@
M_O4A+!N4X(8"RRNPC@)#4)<BQQ2K`4+AS4.G0!I'.L+8[9M:CO7NFP?UH>C@
M!7I:#87+E_@6I,E</.@QN^XR\+&CW_'ER]1(5O'VJYK.<N<Z_35N6YX;5HI,
M!KFQ:*5HL:L<D>KV0%S-2'P#-!K?0"<H\+5N5:VBW>ZL]L'?$;!I+TK-#TJ`
M+C&9@WD-R%3M`#('KS'/#<MCQS@J<"09SBQRDH-@^>87OP.:3U<BFD,/VB>?
M;SR*4T`<6`"]PD`C:C#_:1X\&?]>%$`$RL^`"**<!!DG1MU9*(PS+*.F?#6K
M@)G(50G\X>GBB,8"_L^"9:0C\986PBN6+&>5`4%\@"`F'(Z#"#5(P=;*2!<$
ML%!=V1.'QFQR-ZH%JUA-*]_].`C&R!QKB>Y[7V4V1T6099",<L3=Z/B'.7IH
M$G\17*,8>Z?`5]XO1'T46A8U.,&81?&5L+,9B6CYL9QM,E:H#!T(@=BRR>GR
MEYDAYLJ.Y2(&Q(,W,!`;.=QU':4DH2AJ<&1TB)"],32O!&8C3"5'9SPWKLYR
M5)N=_8A%N"9*LCX^-!TG\UC+!_Z1EU]A9?]*%4N]=3)U"+5=.W>YT"'>;GRV
M_UQCVNSV/Q&>4'7&W%`7`5J_=0I0=J;LE<\PE$HW`E!J&;WE,E8(A(O!:7D)
MJ($<GF2-MQCF#7"``+K0%:?=C".FJ6'*E9(YP,5Y$([('![Y]L:*;VVIGNA8
ME*/P^4OP=9)D&"V+0ALJ/(%FSJ,%.M\\L9K5:9:U=&9]:(DJJ,^0JM*,"J(9
M4]\:4+3U#*Q^7!G,.'A**V[0D@=%(S)Y^0"6*N!-BW)#/+Y0`03\8%EY>8!@
M?E`#%E!@!@H`P@ST=8Y#PJ&'?>MK8.$JJRG^KH'HB13[#.<V'3Y*AG;LJAHC
M:$"DODR@#_BJ1-M(RD&=C[>2(V5?C_FWV;).F&E<:/]=BCC&Y`[V=$?[B28S
M>2HZQI*-(RTF0DL+3*M&H`*-(@)GP]$\(B2@!`QH``C.5`,0L(`!%$@`9@_[
M#G:X`5T*F`$#S,8*<@T7C)C\)U.M&\]E?JR>B%-4QJC:0;]&]*\/JZHSCTNY
M!>F6=/YTI^[&FM8]$9BKTR6L6N&Y5!"7%)>SY2U:.:='";=L@RCV\(,-?%;>
M)=0J6XA/3R_6V7&X809>\()PO-"H<F1SO/CU0MDX]JSADM:=$*5K1F,,4&.M
MML?@<).C8A@U$QY5P%5.G>><6=`1MC)_'^;C@_'HY"<[U[J8B6*:;YN_-3/4
MDK:D,%[/V#H-E]G/;L[EGV?_S+<'R($!C7(#-GGLG%`>CL?G(,(0&L#?Q$B"
M-7Z>GYU'O&E]1@X;B7*T!AKPBJS->;N=)NQRB7=F.0/:I!U&VUN[N%$5>[=5
MMP9I`K%KT&"6U*1Q?K4#C59`'U&4A"F6)G!AC,3?6I%`<V!"!>)SV/%>3%%8
M=FFCQU2!#0RF1PO!-*ZG7-4/+I"!Z%[=EB)0`P@4Y]T)T``$:M!&/=>[P;G>
M,(3YVM":#G2Z8EUVKCU6:[!^V**;UM:+!SUH7C=7I*HLN)<=K'!3^_;@50QQ
M=4_=$U$T(`'1(0<0<,CCYS0/''$RY"$30(,:>"\QETIQ;P\H\3L[N,\969(<
M$("`_PWP_.>9X/D/NOMK=O:ZW+T='H;_?=24AEGF:V9KH#VMZ4Y+5\IX9J;`
MKTM@W_+9H#:G];['C70[GY3C63Q,`1!0@3+,MQR+[BP,0HX.('@!`HU5!H-2
M7=RQWQGA4$=ZH>85H/UD(^NU=/K6^5YBB0X4[2:.*.2!6?"Q#]OJDY_CJP[.
M>$&_6N-E__K3'=KY8Q6D`?%]NZ/+082[,Z`&_I"B>#+OZ=%'/?.%BH!@U$,I
MG`QUQE@L?>>1IMO14S?A$!,^S5M<>X:KCJ"2:!"'9?2MRJ?EJ]-O\]0[K/C%
M-U[T`J=]I`KP`P2```ZU&`*\B0.!-%1`O321V#)^WZGB\_]]%=*/8V`S-UK?
M-21S#=$C@=-]PH-<RB=Y\<,@`Y@W-[<L%>9K0P1X1(=!9!=V71=L`16!4$=K
M-#97!EAO&X6!MN*`&OAYHY5O#N-6UQ<`EB`&+B@&J.""_I!_<;2`%@AG@(<8
M5"%VGD=B**B"955G6%>!*4AY*F)_]R=^!"B$!SB!0^.`T/=<I><['&=]$->$
M;.9\?A<ZR7>%"<<SS?2%B9=G2HB%WF>&J6:%T75A&(=JC*>$9>B#4Q&%RW9'
MH&=[MW>&6YB&S(=\37AU-Y=4N_5*-HB'R$6'9J>'1@=H:FB('YB%9"@02%B"
M_"=U9D&"?2=\8'9_#08C>Q>$`D/_>](W?!!3?3:'AD9GBL*7?Q62)YB8>/:V
M.32(;T3X<(&'?RB(%:^89T17?998BXB';'989<AVA9,8486(@`!1B<J'B)O&
M?]Q7/I`5C7[BC,_XBHWHAM=8A'RGB@#W@>+G/Q.7A[;HAUZ8$=[8>>+8C&B8
MCN$X@M"W:UBX7*A8CW%8CP=H?U9XC_BXB/VX9M8H7)!(>G]HAE/T>01IA/\(
M.#9(9GCF.]^7B#4C@E%8-'L5?<QF/'NW>5WH@9&W(0&IC0PI.T?4?+KD<.5(
M;!)(5!Z9D`6F:J5X=`HRAL:T1YY&4-Q2=9A7=*8V5]05DA_)(?'X99!(4/YS
MAX"SBEIH_TL-"7XB66XY29,E6(^ZA8EW)85-M91%IX-[)HL[TY.!]X@4`HU/
M&7ZY^&39Z))H=Y5:"8R@R!8#>!B[)#_+2#5LN)"*B)=+67D-PY=BZ982J97B
MQX]O^(T*28IM&8EJ)'%Q"(B.^)=Z29C2^!T<)Y<JDV8K:79$D8R0)U:QJ%V!
MR(LTAY"PAHUIF'PZF8J(QXE':74@J)=>J8-I"67YN#-0%'6\4IG!2&B7&%S*
M"",%$`!`&9J:F)EY.)PN&9%=29K#MY*7IWUY"9@9Y'5OB91[Z)2P&9V@J7S[
M*(&_4F/I5I"G!$#;J12NB)R1*9G9*7FA%YE2V126Z9K2R9OE>?]`0*F>YWB`
M3X&3_KB>61>>S'F*V4F7D*F+`;":A(B757B6`=J>84F<VIF42>@I5LF'BS2%
MG_B81;61&2>0[NF:^FB0]'F+O?B@PA22NJF`#^F$N86>#3JBYLB3!3J8_EFC
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MFW<XG*`JJW%ZJ;Q)K!<ZCYXSE/BXJN+)JXS'GS7:,"Y*J8<IK0#IHF-*KC5*
MEL5WJY':$U%XC%NCHJ-Z(E"XI(CHIS^*FOH*3_`J'AT)E\")D,B90/5J07$I
MK"A2+;I(),Y8*OCGB58CK@E+A]1JJ6@1D+_*JI^RKO_JIK#*KM%JL8!:I.T)
MKT?)L:E*$`5[?>?Y8'(YB?U:>X2*?3THL2J;:@'[L(G)$]X:L\.Z(MBG1P0K
MD2\;L(9)%3#K_[,)BV?,B(Q(:YD*:UIU6JU*BXPT>Z<O6Q95N[$-HK`IJ34K
M"ZM9J:)H.K*R.7L,J:S/52VE$K/82J\8!;40ZHE)\557FJY^9;0(NHS(B9[F
MNK=-18=DRY1PNYR+I!5V.ZS6:+0U6+&6"J5Q"ZV$"[@BRZ7/R*T=:YY%:C^"
M&Y,=.8?_X+5Q6PUQ9K,Q>Q1Z2[)5R4<VRW3ZZK,@ZZY9>K/41[*V"YR(Z`H-
M&WU0ZXR(@:](*[M_TZ^)>ZL5J;MM$:+F.KN)R[NUE+IERTXV*XE%Z[Q\IK?(
M&[WDT[SU][36:SKHF:$\>;5="[QC:;YH6[[/"[0%HKZJ:2#N2[L=:_\RT+NY
MGDN-6RNV=>NX&AN]L0NP0BJCE;N_@4NWU[>LMDNOB^N*`DN(?WN[!UN-"]RN
M@^:V$;RP"5RW?&MG=MNV&ZNXZZ2T^<NR[JJIMSO`YUJMWYNVNG.>W(NE9+G!
MI3C"\EO"NIN_HMMI53F)L4O#39O`.:S"5#N<00RP=PNR;)NLSF=_$XQT.=RY
M-6S$]^K"3BRZ"VRJN"NA),QFJPO`$LS`+!N201R0ZVC$&8RF47JR'NO%5T'%
M@:N+5AF.IEFX7BS!9\S"U?C&9QRUF=N_<(R^6MS'>-R,-)RLI`NL][O%B"S(
M,NS`"JS$B2R[@'S`9FQ)1EF_VGN*%[R_#TS_QG&\M*L9M5H:R'`,M(M;P!`"
MQ7I\QWK3KX-[B!79R(H[P?)(NP_,JD6\QB>:.:<,PA/K,*JLLA8\;L>XF0(9
MNJ#\L[49Q<)+N:A<FSY;R+R,HA"'S&64O\:K(<OK"=%,L9><M7GZP^!\B4DL
MQ"3[13.\I94(I2)\GSIKOSK<Q5T(LM[YL%FL80MQQ=>+B>-,H5Y+O!G"P_:<
MNY\+H/);L5&9SO-<@`HLST0YE[P;OQ`]P6),S+G<C1W\,Z(\O%:\R:29SQE=
MA%X+G^_JO>HHT8;*R"-+P#"*H'?ILNMXR[?SQ'TJTP$<R3>*TQ\M,R\\HEU,
MF#;=RO>\R"3,E1@]_\GENL+QC-*3"<Q#/;<NJI/'!\KXN:N:*+D[JJ,M/85$
MO=6/BHK_2\G5J:3M.*`I:[!(K<MJ?2+"6<J/NU`#.Y+.?*%M_-2:LKRF#,D?
M8M?'#,8QF:%H=[)^FJAEIL;0F<S3^]8?_,K3R,ALJ=.32L%WS<%94]'.*Z^.
M6BNC6,A;R-<CF%4MJ]C\IEU9S+EPM</!>X1&F;R87*#_^K<]0\VU2Z%Y?;1K
MS<$D*-@H3'I![<?+S,PS^MICZ]HT'-;-+,@9Z]`]6*I,#5SY[,^LO-O_^=KW
M6H>,+9HFXMDLN<(A&B$U,L+\.]:HFI\J?=S8?(\E_6>W3+$YO4M=BZRERO^.
M8TG*=8S5VZK(G9R,O>W+)>S,/<W2J/+>6/C?&@S<Y'S98IU2^RU+-RN^">ZI
MS5V=8`'>S3R'"-ZMT:W([2O@N+G!!!K7Q!N?]VG@[2W:OIW,I(JT;5W>&@NZ
M.NVTXAOA#I71@^+*':G<\?R]LWNAP:F.__C21XW`DUO6<]W418[!=@R0NMRW
M"\G97,N=+X[1)Z[,]GFY.'O;W;KC4D[?7JGB>?S*-QW*V^S!:XRRDHSB&9[+
MZ2V-U<WB?[Q]1E[@27W"4:[4TNVA;>ODORS9=Q[&=,SF[`WF2<[23J[G<OW,
M0O[@"JUI(]P73,SA/(XBPKG?IKO@_5V&D([A?YW_C[X+TVH[Y(;^R'UZX4KN
MO^8\YYQ>9I"7V!]<VS%\TF9HV8Y<F!E>KD!9QN=[OY3^P!8NU^%K<S+>JW(>
MUW0<ZL-^Z]NWVFM*Q*%+[+3=R,@N0GE>YTD)KIE.N;MKYW+>WR9]ZK"VUM<^
MZE0MZ@=]Y]<:S!B1V#N\XGZ]2)0ZQ>Q]X_R+VMQ^ZGD>TE.NX6N.Z_`LS-9;
MXT@>T:O<KA@;R:VIMZS.M]J-[YE[P^X+\-MN\/L.O/<>X03^YJ1>[^3>OUO[
MQ)-\C,4WQDS;[S#,\-#^Q0//O:\NQ"+OTIP<N.Q>WQ$=[R3^XA?=T0[\S<%>
M[MK.W=Y\YFC<\W=\\_1N_]Z(KO`#?^BRK/#-_O,+3?07/_15:[*07LZ#3/4`
M/C`>K^@"G\EAOO30WN:#C/1ION-)&_4#;,\`'N(=>]$'G>UI"WTKKM$F795S
M?Z9SC[M3O+!D:_?AO?9'7\D96KP*^/?LN^EVN^+9"\D\?O>XIK[R2A".3]_%
M*_G='IP'JO1(3N/";-/BV,$A3_,-WN-GSK.J&\$.S<=]'JEG/^C+*)Q&+?EI
MG<B0W_@VZ/9:>_G/++3NWNR!'^;56\/!2:56']Y6G[G_W;`[K/="+\E[_[N&
M+-FE3;`QW.[@K:YQN?/6.\9DWN!?+.(>[N^KK^:KO/)_C+[:S<FA7_[&/\P#
MU?^W[Q[V\/_\N37Y)([[NL[L"9_^+P\($0\1$04%A(B&B8>"B(Z/C(:,A(J.
MDHN/F9J7FH6<G04!D9.?DZ"6F8J#E9Z?E*:OL:FCB["=E):VI+NNH*:LLIZ-
ME<"^K[JDN:>$@\*XL\'%RH*KMYBRK-*0R9"B@IR]S\S!A=#8DL"VF[#9H]K2
MO^;IX<OBP[OWULRKO-OYB?H@H?(735N]7JJ$\5-GS!HQ=^@"QB/HS-D\1`L!
MROM%[UJJ6NLX,B3WT*.KCK>X53PYLN#`E?-:EKO6#F0NF2_3W;29<MI,<2P-
MNHSFLY5#CB8A[NR94V5$GNL\_GS(3BA,DTO)126:5.3_4:8PD7ZU5_-848E%
M^T']R+-DJW8RQ4Y5:]:A3[=U*]+D5?92I57>!,9:*)?66G^$\<6*.?:MXIF,
M-?%K]#8IKF9/MSHV;/$0X*JY$DO-&[$90<)2#UWZW!C=8[PH]6;NF[4A:;JU
M&#VH]J\R2:.4`J><)*K4P,B[,4X^5M;B/:L)76M\%MFV=*Y_"P7&[/EJ\]3"
MIT=GJ;$4].[75V):?A;@=U\!J.E3*3M3DOL%DMB&_#C"??NAM`1,$N_-$H`W
MIDG4GSJ9F=,63MJA-U%6Q>A7'H(!W99A@/+EAXB%VS#RGU:O8*A972<9R!"!
M(%KF2(N*Q!927O[-<A%%X%A5_V*''=I"H(@>DF,AAYW<9V1;X^B%WW:IZ#?B
M4)L$)TIR\!0VDCOS`86E1,+)=9>7B81W8X8AR@@<F988.6*+_+7$YHOX9;-.
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MM&^D+OUL2,BR`BG2'*-+8Z\9QTP5IH^@/%^CDWC:M("ZY>:BL-BV_%MKA5;<
M"L,_/2E@2%OZ^]]_7AL-I3YYDS@;?2`CT^7+2L=ELU&CZCV7R:@*-3&.3EMM
M=)6^J@Q/E%SCJQ18P68K,C(/4YOQ63]&A.BP6X_EL%TB`9SZZ#`3ZZ^^YB1H
MKH*''<UTEMGZA:5YPQ0=XGY.U:8>T:+CC&+,E.D%W+I7\<[_^9<R=ZW5HFGC
M7(RXPP^F/%P,TJ43CH.^7NS2-\:&4%5>9J-?<DS'6*:&LG"G,+/C9\)PP@QV
M'S)EI=D=R8#WM0V1CV;;"U_$$N<YYV7O1(`;$[!JPSRI%`=3?P/=I8K5N'2Q
MSW-!R5SO`(:C<C'001WA#8V@]QS2.((]TJ$2,EX3)=3\K(71ZU'*0.,?N63$
M:2$4DM)&5I?]O>YRQOO)_BKE(K@)8PX=,<5D?GB^V>FO%%%K7E@P4A<96JP`
M<W`B$DVV.*Z53575H<>ZC,@*-H;(C;P)H]#&)T&\U$*,9;N>^#IG%1G638H#
MK-(9HZ8.%M;/6=DX4`$WR$@N/B\M_S*C'`S-Z$@%S@2&EI)?\"@!AD6"Q':@
M<9W`_D2]AKUH6/MP#"&,J!W%U>YK3YF20FSW@%]%`(]1\@LH.BF>>SAI'+HD
M!_PZ5YEUQ>9FK!#-<1"6RK_PBWVT:TIVT$@LSZBP7E',D?465HX/&I`LNO`?
M*,?UE00)LC_`O!]T@@-+8U#I2[#<TR6?N)I6XF)_`*06)FF""AMNPYR(P%!"
M@+G)`O`2>800:/_>:0CX(:Q?L_H(#P_!2G96]%DHZ^-*XG.S3"@3,@LD!N$8
M`0;P"<*)/NO3@0:A2(4,4'NZ606(`B`'B[G4>42DD&:,-(EJ@`:*6<0<(<!0
M4@!"#!50E/_:D&!ANU5^DI.WS.$,`=6G`FT1&N]L1)?(B8L\5J^J?P0K"1M"
M0$@^-&N\L-!RNM,0(U$)0[_\T,RLV4.,E4.F!/7$'-8JK$ZQ***F^1A3+]E4
M6$TM=,GQ%)74](@ZY>=]XJ#B+?&9*7=%U!XLK9Y#HQJ+J2UG$'$J`&O>ES?\
M^,2N`&W&R^ZS&]#V0Q&0HESSLN,?1=5(K2!UE7)<L5<KE@=3D@+MJQ)DPV;<
M(2,`19%\"NLJ7E5(;G^"A=SL<T-$QHZ'"*6:&=6)W1.2D2#%Z9_:J@HT;G@F
M!0_8@Q;6ZUIJH/>N^P#M`U*PWCNL5PN[>2\BM+`'];9V'/QX`'__[ZN%.H%H
M-P2^;RU]9%_\\@;!][W3?-'[W^.NM[_J=;`C^JL%"H,R+Q9V<(?QJX@4O/<I
MK1V$:5+<O!2S&%003N\>-C'?`JOWQ+OQT&[VT.#;K,;!"$Y.D%N+W_C6]TY:
M,.J!Z+2'UEKX`7@;)C,ZW`P$<_B^E!!P@F^\XAUWN,E%SI,UU5``-42UQ@T.
M<W+2#.1XW8G-4$[@"Q^@!C5XT7KOZZ^67;LRRF28O_"K,7'3JP4CSC>]=\AP
MEPEM8RHWX@%O3C1[I\C>T/QW,)!NL(`#25N":-.!U2$+T+`Y'CD'2Y3S4Y`W
M:(L2@PP453^(]0\"<(7XS#@)!ZIUDW-L_X-:"S@)5\C/%:X0:S(?*`#]!?9]
M?E#F`ES!!@4H\)3W<(4W6!O:?]8"L&M=9T.H0<_CB(^V;5!L_$+V"DFHLQJ(
M_8,ZZUH+SJXUP6(=`#44&-?L5O>WU]M#94!9V48R=@'Z&XIAV]D9M3Q0NZ<<
M;QYHV=FQ#E"9DXQK43#[V]\VL<]RC6XRQU3`:OB!M=^`[@B$F1Q[`/8;Q/`&
M9/-W#P$*P*P#Q..*WV?85\AX"D)1JOZJP08K?\/`.1SR'UR!&H-@=[237&M9
MSUK<M(ZXL(M3[_ONX0=`MW;.36[.2:1`#340P0`P(-J$T_KF5_!OO--=<6^_
M?#?K#OK1.ZR*CO]>H0$B:(`-^&V-.R1!Y&]`@`V2H-Z4+HZ^2<CZ&WJ=X:('
M6[ZU;/>L!?%UH+/<!O7>0PKV0&N#%QUL]*7V?=1-[X-'H-Z33Y#,95[V':O\
MVL%N,@?1%DV<[NO4$*H)ASI*:F+F%!3(6A4\A;H>EXI6#0W(0`EP@(,2+/\-
M_!7#`)P_`.BO-P`#R``.]OX&'"A_^<QG@/-QT(#^UH#YS7=^"3*0@0E4N@#2
MST`=YJ]]$8C!WEKH/OC'/X`&W)_"N'8':H`!Z=<`]G9<#S`!ZM=\Z-=\&5!^
M>W!^ZC>!&8`!`H9]$TA]#?`&]M94C-!]#>A\[-<`\]5]&3``>Q=G^I'_?]/'
M`&_06GM`@"4P``%P`7N0?.`G?B6``!>`?.G'?PU0`TMG<MC'?LRW?@,@6M3P
M!B)0`O-7!QG``!B0@OE`9S]0`]E7!V50!S.(`=]6`^.W?.M7`_1U?N@'A"]8
M"+MQ!U=P?D_(A0,@!NJ%`$CX`_BU<PVP?ABP!Q=@`PR@?$>X?'66?8!XA`[(
M`#9P`5IP!02HA?1'?@6@7PBG!0B0`0"0`6^@>3^0?2$X`#]P`7.P!=KW@]2W
M=_P5`%@H?X]8`TVF8Y*!?&4``)Y(7Y3U##:``0SPA">(`-\&"N]3`&_0`-Y'
M?S,HAYNH?09XAQA8`@T0;6K`A*H(A3.8B6_P_X<+>(3*)P+V9H:!R(`(H%XV
MD'XH2%^)9@/9-XV-]P99J(L#@``ZE%VN]%7[A#FO,1)KU26>-#O;XTK^TE(E
MDVK_TS``4TL,\`$:````\`$`4`<U<`$7@``)^0$?,`!JX)`%4`(*^08/&8L(
M&9$="0`,T%\8X)$?"0`8<%]7,``>N841F0%[=P$UL)(1^0%U@`#T10B)]@89
M()$TF8@%=@<CJ9`(*9$=.9%\V``\^9$2V0!:<`$!@)$(R9$260?-B%ZR4@-U
M0)1%:90/"0!$4`?61RM:(`99"0`;H(C\!0<:\`$9\(E[(`(S&94-N0<#0)2Q
MF)0NJ'DI<`4X,)1#"?\!GYAD-6")"CE_"0D`3%ED$6&.AVF8$ID!WP8"9<"3
M1-D`#@D"APD`+"F1$`!]@W`'ZMB8=1"1%`F3C_D#Z*4%:J"27/D#ECB390"9
M:K"3F:F4=?");U`"'3E_=UD'>X<G+Z0%/\``&E`&#>F0-J";)%D"G[B:0JF4
M9:"1%[")=[F0+6F'CG4(0#9EJWF0)(A>*/4?`2`"DTF5#5">-NF!27"!#9"5
MA3E_$CD`_567-"F=#Q"4`,"#*8"5[SF:2[D'")"5=ZF5"5D"%1F3S_F<&."0
M;^"1)ZF(R!>1T=EA`^B>6ZB%\:EY-J0^F?-59N-"9V,\&<04V020T<,)!T+_
M"N$5(ENU%](!#('QC%B(D%3)@0Z)`%)IG$VI!@4)`)_X`PT``E@XFB#9`$9Z
MG#%YB4$*`DS:`($9@X=9`G30;L&XD(D(DPCY@`@PI/%I;S@)I9JID`V9`O9U
M!7G7`'`PFF7``$PJ`CQX`4AYB7!0`TP*`AOHD`'0EP!0`C40=ADPF67@A2GP
M2?Q9!OT7A'8JG3C*EH'Y"OE'FV=Y7PV`D`Q0D=-9`Q5`HQM8D3>(D#C`I'!0
M`G?)`*C9@V\`A@C)IYG(H*_Y@&]PA;JYH.\5'ZHQJ0K)`%,:C%OXHPC0G@H)
M![SHD$E:`B"PI2J9D"*@7BDG`E/9CB*GDCAPH`D)_YD7`'*L*9\V>*H,4*`@
MD(E[8*<UD(=9"@=VFHS,^@%26F=7.']NR50W.)FEZ9!JL*7;NJ<(L*HI$*</
MV*='RJGXR0`U\*Q;6)%\-V>$T)0_``$?@`.?&$9PQ)<?8)P.29\-0%\>US7Y
M!Y75MP<AUY[8^@,:RX=Y^JM\Z)H*67WJ.@!4V8-'FGRIV@`8$(0I@*5R:J?E
M*IT_P)$`@`,U>`$0&XO1R:!EZ8DI:Z@:*B6ZTUV:@A3-PG/G@`VAXQZ*Q!IB
MQAG-L@TI&E!S)0D7I!V.DAZFHQ+^F`T\(%HS2[/4ZI`;:9V7V)PX$+'2J;8F
M"P!QJ[8(R@!GJ[9R6Y:5JO^W%[`!+/"),#F9:4N7TQJ)*K::"TFDI7F'9ZL&
M;UL'9^FW01FM?JNV!5"O;]J#QPJ6BKA@UL2?:7NY$,FH%Y`"265R.KF0GTA?
M6C"I>VJI#DD'J2J[^2J1<*"V<X`!9;"6<%"19PL'"FF9:JNX]:FWR*>?8<0(
M^<>WLCN=3JJV&T"D@BNLL1B2#KD'RHF]^:>I?"B]7MB5Z$JPJLF:<#`'I^N0
M09F[EPNG"#D`>=N#[LF^Q<N+@ZH(<*-MD2NXZ'6VQSH`>JL%('"R[7L!J_L!
M%?"\-F"`\HH``^!].#``-:`&861BG0H`-5!H454`/!``ZWD%M`D"$RN1QVEF
MGV#_7[!+MWXK<NAKF@N9B;9JH#>:D+>YPF\0OWNPK1]PG&J;`D&)O>V;LWZ)
MI$3ZPL)*P]7KD#]@D]6J/;0R(V>2M>V1+Q"50\>63GW6%"ARQ0#Y::>GM;]"
M2N1!1#D2QAS286@KNUI0`['(A0AIF7OPMBJLMR`KD4E\F9[ZO'E;`PJ)B>T[
M!V?+QFPINTA)DVJ`NH)@`SM)E1CIN29F8O(:N9.KMJ\KD9;;P\7;HYL[G7WY
M`7!0>`#Q`&1INNU;NFUYNN4P!X]*DU=PNO0%NS*LMK0;NSU<R/1K@ZS)G.E[
M`11+QX3YR0YYMI",NJP0E))[N9`LM`F9Q$$)P&I[K#C`_X<WJ)"Z[+<MC*`R
M3*'FB[YG:ZO$>[FPZ\Q[2\UW',Q)I1O-RY4.Z[_OJ[??JI#)VKX(>LS6/+/(
M5\01:9,.:\!969IAXL&J::MM^0992:K!?+]@M(:OVY$,[+>/J[&Y*:9VFY"!
M^KSM&\<)R<,3_0%]&\0T^L8V6)"&Z;D7@)F:&;[(/$YRI4&K0\9ILSX0X1IB
M$ADP+9#Y8E:&83\)]3)A>Q31\AE4VPL=EJ1I6X;OBP"2S*,9Z9"`/)T8^0'2
M"<E@"I(#P`!679IO>:N6.@?J!HJ!3+AN.9Q+^0#5BE[-/,V(Z9`/4,$]N,B3
M^\B5O)`,4-56W8P6*<>;#*<2*?_#H4'0MVJD+,`"T?N067G*U2!@?ET'K6QB
M6L"LM#RS^TG-P(M>A0R_>KNH09N]=8F8>0N1"!G5@`S9)\8,SKFPD_W(HLW/
MRTS)(PF2;NG7:<VY!,S43;W1V8RZYGO0"_T!WXS:%XRMQ;O9"SF#-;`!6\T<
MZ06[;PHW-4:?SFS!<5H'<("F<,`"/$B7DAW,\Z6W`ET#U@8"?'JZA_!U=7G*
MYUPJ)J>XFKF%(*"NKVK"/97.-,H`#8``/_"]9TO0BYN0'6W`"DNC_6??9QO:
M/=C)QXFZ)N;95&W5]&VI&Y"J*HN)#7J"HTG2^IVE_3>EVNTRD2`V8<((6X43
M/P0/R%+_XCH11`@1&"'^-_X##`D'XCR]XBMS+%OB._Y8#EK0VG4PV6N<D"`0
M@?RMCDL-BNCKF@D9U3O&NS,ID1H``14)N2=;L@TP`%0^W8(KR(8ZY:TJN!2*
MU^++UV"DRC\@R>;,7W$ZE!))!*=\`07@Y;N<I#O>Q*M!EFAND`KYIH)\RJ/]
MJ`NYV.L%R^3[`'R\LQ4)R&IPKMA*7P9,FU%MN)P]T:S[N:C+W`MVL*4-Q(.Z
M2I/.SQ*9B(RMX_V7?650!I>LU`#`OO,%18*@B-A,L(/*FL1KP7#)VY`=1@*&
MUHD>1O+]G&NZ`4?;"NFUV8*+3_S%F@S@D!=VYI1)!!4PLYM=_YJ/3&3&V]\<
MJW$F5\F>"[J4(9S'FI#8&J"R^`-^E-Z^6N=E\+N[K-Y3^:8S^P"VZI<+R<"V
M7N`93=M&O>2<*;@_\+Y"+GX`T*V++)VP2)0\^8`5*65M`J*64UWED3IE'!RM
M,WSX$TFJT;4"I$K+`^,4'U`6WX^\,+8Q315@&N<=MI\):9FS&;'B![>GFU^K
M.\>('*&:&>J'BKZFCJT;,)D\60:3FZ1USM'\:V+Z?<IU7`8\R`_"V9?TS##)
M79B'.@`5T-YXJJ<97&B;!^?`.TO@OJ=S70%S?>5@W?*>P.>*?;I_7KMH*>@*
M:;EPA^A\J.@ZN=06>ZP5B^SS')B[<?]1S)L$SOWVK+3/?OT!GKY>K;WDAEJ]
MILZ^#JL(Z]7JBKASL*[6Q7[R,^NPMQZGV-H,ZU6-1'J0>XWWVE%34%[#)I94
MB7:LQUZM9N[T=`VPI_OL?*AA@G#V[XL!K_J]*9;C$GV_"+('X9BJBTP'8)>0
M"2S><E`IX@9VN5B2LLC-ZZ7(0EGWZ"6O-<``.GN8Y8?(7V?@3$T-<,X`<!#^
MTVVI0DR1#;J6MUG')-V#U8_/44YAT^&/*=JBFZ&B^\A.QT#_#]+QB00($8(!
M!84%@H:(A1&)@X2"D(N,DI.-AI>+F`&/BI"3GXR<H*.,E7LU```9:A=:*0\U
M90!P%Q=O=:G_N6^M#P\I-AD?`+LI<Q$/:@T`'PQ[M<^U>PW"):P_#0TXRV4;
MM36X97!P&<L#SJTI6G"I=0UO#>0`YA=SA0\_.!]UW?3'TL(,6$%[%D`;``07
M4J3[Q\Q9BD^^Q-3YD.%'K11[YJ3PMJQB0BV0M+R)=Z65%BW*`.!@=?)4JE4F
MU8CX\&'>QE-E]%F,-D!8@XWIWN0\6`NDH`>+'D"Z(Y/FRH2>)CVPA0N`C8]:
M,+P$`4<6`!'G+JCI":!9PGK'(IQ$19'5Q@(#EOV\\$#+GK@?&CA[8"S"GF3"
MYBD]%DW-FQHB<`FKH1!2`#G(\M5Q:^S0R;AEB]J=-NM<L9N</;Z"_U3WPH\!
MLF@"_*&EUX,[=S`L/EM)J3)F:O`!9+"LQEY$CS9>V//C\("J^T:WXEQGYRM?
MT8IC8."U8C&U:K1]J%%+:2]4\@0.-+ULI9H2-,VI"59F%[2_AZFS^Z%0*250
MF`YUJJ0_48%-^B'BB23Y11)@*9T40DB`]U&227\.0G@)@`8.V,@D`2CBGX68
M[(??@1H*&-4@AJCADBHLI</6/!>0I4LKQ_P2S#`)'?)`$K<Q,-XS""Q3!T+/
MO-&1>PA,!%-*`.@5TXRYI"+,9'0)HL45P=3AGG?2I&+60&\9!.1PM]`$0BT5
MIE#D!]7L>`%;,/%25PHC">/>23.IQ))=X/^E>=)8Z86E&YKBW>63%JV8%L\\
M1JE1P!ND%9`$GCX"N8<O$?!@(U6I6*105N4XDU(=W"5T"DW-P3B'%FI<H886
M;(HWEER;8B2"7,YHT1=3*2'*5R'CG9D7F0H6$)E.M?15UQ[YR*/9/TFJR18`
MH>[AUST"J8%``PPHEM=42K6F%;1GS5%/AGS.4LL/)>1"D4721F`,&$KQ(-XS
M($0:I8HYI9E0"@7\,.]P*95!WRM:)*%=J(-%H%5-80WT0[[.P"$,0FI,U%Y"
M)@[T:J90(8B?*,#U5Z&&EXBXWW\@6A()ARA#.#+*41'(((,+4FCR@"!70N*(
M_RW(W\OW>1AT*/__J6$B>#"=Q&JGY\8C9\>_3$3C0X>HL;"^>_PEW`\S,K"3
M+1WMU*I8O'U0AJ2Q"(,##G64D.YLKYQ*I3Y7JL5L">QFG36ANH%*J+7:>73!
M@,?DZ5POKJRY#-[#&6VT%NCZ)%QV3-MU8II[;"8,'*P0A]IBA&Y4KI+1W`9J
MYX8-T$!=`IX4)P!X._,7!@.P-M4MJ;C7"GCSJ%&VE4$.57NM:M30`"MA_GC.
M&^A],"9=F]'*BR!_Y5IK+V\,X!LTYWV@`<(]8\<`L?S.X=I=J0Q05-:R*8L.
M-,#0Y/7>Q0_`2J"G+5,!*XRDD`P`/TH(7S[!IW6=*UU,\U\!^O*0!M1N_R!A
M$HT_>H0FY_#+@?2!1MI*E8X4&*PW13G*M^P7C3T0S#032=,/:H``9_Q`:MU(
M`08;]@VSL0(I(R(9:4(QLIAM@A,7BE#*9I9#!0$Q0I'(&1)Y!B"7K<Q`#0K0
M)F(6+,<0T3X>XEG0%D&(:_$&`&5H``)V0D$69>E%#XF`C)9!#+3LX5MU@`,(
M&B`.=]PD;6BJP0^NX2.Q+4X@7*.)1]!7$W\9[31J^PWDJN0><9UD&OI0'3;@
M,(`-N!`]*L%&!123`2#QI3(V8M-.C**6->6D#`R8I`,1L)%Z`5",",`+C<`$
M`LRTHP:[8%8&&L`5<OCD'-:"1RI*($9`OBT<-?\P7C`:`!5)1(\:#4@F:@0F
MDAI@1AYZY`AN:H&[L@CDC+"+IC7M)):>Z`,$AWE;J<1BO+=E``0(4$,:-<<P
MDX@D%7#`97'PPC@MW*$`EE(+2E*!$%O91YG"R``+6<(9]:'C.</!P%"(*4TP
MLD)U_AJ.Q#X`!V<(PG\]X:!])/&LX45NF&_8"%J.\H">[!(!;RC.^.0QAXZY
MQ(#TZ,4T=OF&-]@``9A44CJFY$OP?<='JH,#-MS!MWS]"X5FXT=/B.E3&]0@
MJ!YED(62T""6<6B*2IFBT(0VLZ$9T8H]?%`/=49%4=@,B5U%*Q1-YA\0O0R*
M0W044L8G#">!ZP(4G$O_+7RWC*E]-'X?:*,@_K<,U=`D2<)Y8S`>6X>J,$YQ
M;7D&'LTCM2_5@H(74TH*`GFV[OB"(8YM[%S0Y:349L`]S^G$`Q"0$Y&2AE6I
M<:P&:C)8O&B@M>T@%%U<U%API6`=K7WL+L432+,Y26!!>IMJ`*`!4#7S$<Y(
M1FY;FZ;;J.M7F"5A+9`D7IE,5K?B9=YC@1LJTPS%KV6X2K?4(#%Y7.\!;X#`
M=+55@BO=06<BF0A8H#*'./65)A#824,=,M*I6&TBCG4**V::`;>%#2M[L,%$
M;`)*R\`E)_HH`2XJO(T:R!,I`;J-,+RR&M,B8V&B$=8#,+#;%8.X)@)Y4T%`
M_W@=I;`EPM[#0"TV\,?QD)8?*@9C<<6;,)G9U4%9M(2$;F8A+>;U$/DI65I)
M$2(J9MFN7F[0$<6<1*UZF4-G+@"J&E`"!@S@S0Q@@'O>L#8@;2I[)7A@,31R
M!1&L35/B\K&;!Q!G-\>9E0D!$YLA`($Z9&``Z!0(GL4K%A`4VJ>$/MY%-G*-
M0X_F@C@8P%7H8KX(U"#4`\#!H%6-Z&08>M#1_)I"ZI$(_*8:#@40H(!L7>@X
M$QH'7W)U!AC]Z#=X)@6G[G6HKW(*7_LZUL*M10&P->@!E$`$;CE7+3-0V1+`
MX0TL.0;,_O8.$3L:!^[X[-K>3&@&`"E[.*A!30?KP/]E/V,/>*YL!E+Y-=-D
M(P-E:!L<?A"6L;1YT&[.]5`+D.SMM089-8!#"1H=<`:`X'#_K83_QN<1D-0C
M&]5.)4L:'CI:2PE,`^#VN=-MBY1#H`QE(*9S]L294%$M*74I``9PP.TR['*/
MU!Y`2F]^C!5*O-&,UIY`'N*:-\19T\;PQ0]J:6Y'5\#$%T$<CN+<1F%%():]
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M,;Z@$([C+PVC%'=@'W)0`!O!%E!W*K)7%$!Q$98C'+1F".&7?D:C>^2W?^(Q
M5/@6#&V"8I0068<T+['W)BBF1A<!@M/G';U@-,G7#R[8./LW?95A-UFC4J70
M$K"'$35(>C6(%KZ`*L@P$-&'@-`06T&D17CG57]'-%UF=QWB=U.H94\F1(*7
MA:*P_T6+5S*(QW<JDU9F10F#@7[D=WWK9PSS1G[B8AD#\7D?I2;%$FB)HR;4
MAWY[:(?%)RXWN&GUL(&CL0C1MB,:H88#H30F>'R'&%N3<"IV:(&*N&E[5HGO
MYX</]TD[0GVEH8<CE0F<AXF9.!YL^`R!]HEW.%2@6("5Z(FDF$8QPGK'P!>D
MV!K&D'$%T(!J$3EEP!V7V(FG>!$_4Q=Y.(F@J`5PX1,7D8$[Y('(.!J>H(KC
MX1H)PX>#83Z'R"5]81FHMWEJ08JEV(S&\HC#R"77@2!.9H87$GF"5X:'QX4>
M\V5+-`I7.'@D@WA@-E<M,T1Z1W<$(H55N&NQ5WF?9XP%*?\'J?APG]<7=M$:
M>]:`1VB,0T5]#>D:0%%R=(B0MQ=U\F>1[A*'1_B'@(@XN'@)KKB'N*@1>!@K
MZ2!0_`$BVOAPG["#KEA\ST$U*JDTMG*0;[*'O3!KE1>`K0$)GT=]=O$9GR=C
MX5<?A4@@&=(+B;B''3F5/>E(MN>3M5B5YD.5];%KU]=!#=F0GJ@T=5>`M6@?
MXB(<L*@4YG,'20!$)A(Y5C)K'.F)KD&2/],7X6A[0NDNU-=_O<`(RJ`!XM5A
M*W,L36F+'?22:7$4LWAZ>^8:BU`?N)>!=?$FDKF4^G$LQ;!`@'@4KH"+%CF3
MKO!)*S6*`8@XW]B0X;,SG<!548C_CU"9(61EC^U(=R?C,[A)"KG)91[S5C+C
MF_ZQ(&%H=R<#AF&X15%1#X!8CEC4C8\9AVAX#"8WC2S%"-29%(\I"(#8"%))
M&JX!F>(6`-0)"9]Y?(.)">.9G=J9FNU9"EA4CVD)$?99B]9Y((,YF/G9@)9A
M4(P0GH?`EX,Q&(;PG<>@!BQY(;[`G[U`C]W9E;NR0`LDC=.X@._9G,XYH-Z1
MBHC9GFX9FHM0:M03>#MD(\7(GSDDFY/0>P@@`@P@;Q;J&GU!H)\@"38I@]DH
MG]XA)?QI`R*`4=/#,_B9%J')4@E3(?;`E\]9(=&9@9TYGI<YA@%"A_:@HJCI
M+MDYH&RU_Y[3V)[;N8[NJ(_W:(]?*(]]5R"/)V4TLYR*]V1DB*:1!U!1)#11
M:8]*6E;,B9UUYS(&&J4Q6:2$(UMTE4/XV3.`.C2]2:1\.H8[1)Y7^JA\=W>4
MN8^6:JA2F*1%)*B8^J@E$Y]/Q'AV%8J0^9N,BJ=1\:=4)*DVHJE(Y*JU-I#)
MF99LF9F[-B)-!H9IT:K<^:A>BA0>F(ZK>JOTN5:J&C.$8Z*.IZ)1M(6[>JB=
M*JN`IZD?(S)DY2!-=)QT!64`&439:H9K^H]7B*AU2E>V67B$LW@V,X_^N%:Z
M.66S.JCNNJ>-MWC#"IR^J7?*:I]R^J[`<:?TJ:B3JHZ/H*SM2O]EN=D?8'4S
M8+:>S2JO8K6M5=:I^KA61#2QP/F$4;9W6]:%7>@@2?"8WTBMF^H(3G2?BSI7
M&U@CVKJG3HJ<>7>J!HJQ6!BS&GMX8?8R!1NMN'EENPEY[2BPDYH)9\J.-#NF
M_XBJX&IE.'-$')NTW'F/=06TUIJR":NP)QN0876Q:4JT61M$E'"F8J8?$3N<
M[&JQ08ME8L6F]]JL-/.O7ZNMR>FM9.NTNMFM6$B%>KN.8@JV\BBJA,=#:-NR
M9KNL0?F5`QL!0&2W'X*W.E2`:WF=A7>P/7L@BUNU2R2W4HNUMZF.]2BUM@FX
M"<*UQQFVG+NH\+JM?NNX`:DS@9>K;[O_MQ>+HFCJJ/]1A7TK1+9KG.&ZIGEW
MM6R;CP\"5T'[K8ZK,WY+I>0ZIL,[D,/KIEB6O&R*N<5K"1%[HS$KO-!K",+I
MN_PHO5CK1**JNVD+H2(BAKK[KEKXM\/IL&5*--%[LU/+,L";NE+FO,V;1+R[
MOGCGMF3:,HD'-,@9DRECG-S[N_F;L_T;9?`:M++:C][[(>T*MKS)NF/6OV9E
MFQ0ROS#CK;S[577K,O-KIM&;K@$04(IKMYI@I_];12E\L@0<ML:K(6]UN=B[
MN<KKPNO*C[CKJ!@"1#QPKCX[MGGU0__ZK,AKMEFVJP<LK@H[N0K[P5#TA4*,
M5Z%KN3F\K@O[_[R,MZL_!(8U?,76"H_P>V7VVR'H6V;)N[8CG+\RK)P`%;K=
MZ[E9.\,3`I5ZJD/8*L6E@*B.<%<Q'+Z]>L<F>S+A:A\S7`D+6[8B7+AJ&C.6
MLL0?(\9P2[_TR+<7'`I*-*Z/_""4K,G^V[Q@:\%!O+V*=[;CJ[^F'"*9V\!?
M'&9\.[L)_,H8+,D_N[>TW+N!NA^9;$1FK*?`+,9U*[8%TLFG"Y6E;,EOJL2]
M;,2U3,#\V,O)C,':NW?2##*7C,.R&\6AS,6#"L"W"QR1C&;9["$^8[T[/+5?
MIJ0VK,G8[,:;"QR/E\N0W,ZUG!_".;9)J[U9=KU-C,M#_&7$W*;[O/_.R)O/
MV!K%CYG-$T+,7KC)!OT?*#RF$;O#&\S%?IR/CL$))^QU?0RA/>/0<I7"5A:_
MFO#.?XO2V;RN]UC#!;S2`SV%Z<S0(:W&!*VW_"PA)RS$_UO(RMS//!VKC#?1
M@8S/"'W3KWG/$T+4^KBXY\K*Q9S45+JV$`W3`LEX$%W4]#P@T]S!,OT(Y!J\
M65B]?PS*Y8S(I^N%(8R^9+W+C(#"6#UE+GS$H(PSQVS`;ZJ_(:.N=QV_`YS1
M%0S0<*O..PO88"VN<(W7)MVT`TS2XS+,)KV[G"M%<LS-Q5S8+AT58/6:$=V.
MF1T)05S)G:W/[[K!H;VUG*S/`.P)'5W65&C_ON8WV6EA,Q>-UVZ]S99KP^8+
MGB^\ST2#UF;-UNK*TSY4MXJ0K:>LUN?;SOTHL,T=O8J]UW4-S=0,TD9MV:N<
MQ!Q,RX\<PV8]N6!]U*N,QLT\9BU<5[T\VF0ZI^K\,QGMWM0<R'/*T@:<KM.+
MQK79IN![RFQ=R7M-O/D-O^[-TCBLA1L,UD"]S)'`5>N[Q&)(W\H+Q6J*SH(\
MWAW,MG/]OA/NX.CKTNLMJN?<WJO=W<:LSM<MO,I<U`*=R56&U3\DQ\*LQ>.L
MLQS-W>;MXA5,(#S``[/]XL;-'S4\X^9<XTV$VUHXS83:T8CLS)P]X7;,VN?Z
MQ;+\SRG\S@_-FS>^_\?+*:Z$D-D-33.!C=0OKL$('L"(@.2W[,[AC>`3LM'^
M3-D*&\3,?<!1;.6X;./+;-F0D`1\SN5X3C)?6,HMZU8OOM'YZ-1B2]<AS>*@
MN\ETK>8;K>#?K;,H.N:*SKU/W=%R&\94K7CT;>=)#2"T+<QQ_.AHQ=9%+M4"
MC>;`C.G';.(2;;.\:0BA[=K0+-'8K,RIKM+^L>-<V]N*O.9^M]1%^[V^#+4E
M'`I(+F5L[L>-Y]U^3*J^.^IYW=``2[ZN[L1^_=9,;;/'#NS:K2"U3ISX7.OC
MV\_CKKHGG=;WJ[A!'+*,`._3+E:M[;NX3KI3&\8Y+=&6<JSN_>WUVM3IGO^^
M/\S-**[LQ2[A!R[2"/_K`OWJ#N[K/=SL"Y^GWOS?TRW?=^[CG1OPDIS0W#V[
M`RW6393/A=?M4JO*&;U$SARH*5T($C^YR%[B>[WL?^?Q&Z[&.]W#..W==EHS
M2JS0H\N_>QWRNYGE+Q_2VQ[@1?WSRXOAXGW#GKX)\-[G@@ONSZU52P[P1+3R
MD>W*1L2X>)S30%,S*BP);W7P:ZS"-=[JK6SV7UO0S]VM2M_Q(R^FKUW;A+[E
M&OVOR/VYV'S@5>O.D3TR.PSL;OSW#6[J@EM73:O8%[OS=KTS]U'RVISQ>XN[
MHEZF]FSOPVW0D_R.C0[Y-`Z%^-&TNVWP8^UX2K__V$/.UZ/[^+;,]-I>O(+.
MYU;/YW#.V(,7UO&,^3*_QQ?]\FG6NH3_\;L_^=AK()!?N(=_WUZL^'V;,S7,
ML(7.WE-HA1T"W(JLMK-9N6'(Y'/LR`1_W&5[P31/W94P[N.?[1*^G`L?MZ/<
M]U_NTTZV^+?M_DTNZ1(,"`4%$801@@4!`8.&BH2'CH./D(6'BY"(C8P!DY>2
MAHN5@H6?B:"9GYVBG)^2E0$\IINHK+2KE:.NL;:-JK.LO8>OLDF)21%)R*F6
MK;>7I8X\LK.AR]6>P=&%B92@H=S=O<ZRF*#?UZK>XM+/S,V^Z>*+S]/PY^&"
MPI2\RXK-[>'?"+&+!,R=_[M?MZ@%3&7.&C6"[8PAFVAIHK&&JI`)2H*HFS98
M'7]=5/;PG+ED#R,\.&91%+Y^$).!D2.GP$1(Q7#UXU@)C$UBX"!I!,>3Y"":
M,-$YY&6(9L:)LI*F`XAO$$=&K:2&HB@J600PI9(90S0VPIQ#+2'B(W23+<]6
MC$Z^C:!H*"6O=`ERXS@2*+5QQ,8R@^EVKE&60]%=Y"K'+%B+<M\&0'9JED:L
M;A&!,?K0JR2N'M&R?3E9\,:;(2<1<]0OTX-@"8-E\O2K(4:7"FLA=#BJ-^Z7
M>@MQ/-7Q'O%YF"[Y1GYPZNS9-EFR+%T8+\)C&PNKI+MII2,YT+.SMB1PV\IM
M0O\);>YX\5#-4<CN)#O[GN6@LY/O%)H#?C*DS;[9LUE@VI#GEED1(+7('-<U
M1=-[!<"BG3[1<5>`4PQ:-!(C8+SV"D0JS<$@6#X=:(AZ:*'CU(0UC>33:=B1
M)0A_-?T4$":+;2B?(#4Q&%U!;5VHR$I`L6:,?BNEEIM^&HT4$CG*J;32B@^@
MYM`B_26Q!UT\`$@6?#R)Z%02=^C'329V'0-=;TE0B5@!8(@X1TZ")(E(>M\-
M\@"1C=CYV5!R`!AD?J/L*2*.27@G2(G8$>;G>)#J1!QM!CT7%"[_&-@;*9%\
M2&E!]@#S(6N95(99@^90V.EOO:$GDI/NQ+>GF7N^5L#_`RG4.J>FPK4EY:DG
M:B%L!'MHX5U>N&JAWT%W[.%LL1X6L$<*>R#Y2:*YRFE3LRNMY*RP?O+3%9G0
MBL*@2F7>8>PM*>1ZHDK.XOJ`&MU`MZ$HQBKKWKG;EKFG%EL2$FVMA*BK10J?
M[$EMF5(:6\B>N*P8WQVX1J"&O.<2LL<#RAIR[(5H4?S`EKJ,_(#!^3K\*[$B
M'QM!F<X*Q`.\L^2G[,$`JZ%2<39NG&ZSPCILITI:G+4(Q^OJ>7++'(?[S<95
M'H+?RTA76RO(Q$X++H)*5RMPL0$#&^.>S\9\B;]$*RJE&OZN)&+#`G.\,2JS
MEEGDR/*1JF6WX#YP+IG&$MSR_V6UCAQPDN$M!PXPNFD2)6VZ';3IXQ&":$MS
MG_HS#GE*$J;,;?18PQ"FG-OPA@U7I)ZZ#39L5P#KJ-^ZIQJPRRY=`+`'H`5V
MGYBN>@"IJW&PK8A<<7IPAKQQNNJLR[-Z`'//D83J9@FB[AX!O(%`#36\<47,
MGOAEU>I7N$X)ZU<$L&<DM;.%?NH__+")RO3@$H'J5PAVZ"#-)O'&!!,0PQM^
ML#X][8%V$\#`!&P@K8Y=(7[>@]T5]$07]$%L*ZNS0?Q0=P4;S&$E',0?`XNE
M!9<<*0FULQ4A>(`ZX.%O=05`F`0Y.`AZO4]XHL@>`QTAI>F]00PU0(`-+H:X
M1>@'=__H<V'Z?J!!G>7.;XOHH`UX<#4.LBX1/(@&50H@Q?)A110L%.$/&I.@
MY26B@\?;DPMA]P,8NDX:(GN=]KKW`S7,K4YWN((%Q#`!!+RA.Q$(8P8M((?U
MP0YUB)SB=H#'NB3LKGJ^H\4>IB<&!;YA9MY!XB%M`+Q;&>,\-A##]KQ'P=B(
MBU2@"E4_."&*1W5B<@%23N(>D9O=<`,:ZPA*IC!R2\?5(B6Y24PX;#"`#)0@
M`\@T9AU*\(8+[`$!.$`F#L1PL#NHH9@XL('#+E(#8Y9@`#:8FR&NT(!DFG,`
M-;B52M10S@R(0'T(4HD-HEF"$N`@FMF\P`/:B8,!?&]/Q*S_PP!^@+`Y:"$`
M&&!`!LH```#4(0/H5*=P3%B`"3#@F`QXP[JV\X9H9@`'"`A<`43P43$4ZPK8
M-"<.&H``VRFI&S\H)C(Q(+Q)Y+$&Q61H&>K`@!K\@!`I4`,"BEF'G2ZS`070
M0DSK><QS_D`+:N@F1&.(D"N0U)S*Q`%!V5G/9-:3`1@()RF(955DEJ`&%KL5
M.Q]JUJ8BLPXUT,(;DHG/.M!4"\249@.@%@$,?'0"'US$&TA:U#+LM*<$G,7(
M,.#6>V)U`&JX9C1IBK#[D?2L%?.K,;&:`;02#"4UB*8(:GJ(*C7@H8XU9@T^
M*%5SE@`"S'0F!CSJ5M5>;!4!&.I"_P%@6(C6@&.$B"H.ZE!8GM8@LN6L)PZ:
M6H,]7``!6.VJ.W$UTF6N5`VY>D!',X#4L\QKL#B`0$,?VH`W.`N:T2T!7)\5
M@!HP@+@ZA:@8+F@OP]0#<ZN2Q^8L]Y8-P?))`SF34K)2BH+@1"MJ,<5@#))*
MG@&G7HHI,"54<H4,?*"A'\@P`"[<S`O4H`P9_L``8@@P!G`883D<0(@!T(!A
M&2.F&B[JAC]0A@9$X&!S4/$'&(#=\]S*!AG`\(4!D`$;.%/'%\:`<^5JX0P0
M=`XI",``0'SAG<ZXR/3S##$&@&$64U=C-=AP0QE`T`NH`0<7KL$%+I`$"U^X
M#C-V*%(?.?\-]+Q!S!\HP0\NP)]&D)/*O&4H$2"@T1*>5LQ6YK"9W2SD#.O9
MF0UP-$']](`KE$##>/Y`'?:\!RY7F;<:QL$;DJ2E/4R@#AIF0%(CH>,98SK#
M&'@NG+O\@;U>X`=N_D`&.LS.)!MT7G[5\$ZI#(&0'DL6#7!UHS^@@1+8\=(:
MV&NNM&#I"[<8TBMVM08P@#0B):JO&\8!=EE1)1$,6<QPO4`*(CWD$--X`\X4
M09S=#8"X?BP2&)@U<8N:87$+ZP<B`'2B-[V'9(NYH?5.@8<;C?`=*UP-)MYP
M'1"PY@>$><<QW!-T-ZR!1$?;N0B8=[NOS4X0.Q2^%QY`Q1Q,&6G_P$,JO021
M-\BQ.%B2+A;(^V6E)*P<`&M%YZMD!<]#!YM@]'PJ+9=&P@IP:0#@@'L-:``&
MCKOF-\RZH4IV)@,:VDRC[6&N76:`<X\Q+Q4#X*QO.&V_]QQ4>8O8N=&*[!O<
MV]`,^%$-SH0#PL^^YPM4.,]XIQ8&Q'Q6"#9@IT9&<87J=`4<-)S'[E))R!%>
MAN::.>)J-G/3&;"]<HJY`79<E\MK:/:&EJ&9*DQ"OC/<V1]LH`;BI;@6$(!J
M7=.Q!B4`0#/5$.2S@Z`&46<IW@ONZ,`WY<8_R+W3N5<#$#3@MT?><&>UYVD6
M1P!ALW-[ANO03*@*M0&_W[I#X=#\!NQ9_PUSGS4Z?^#<Y'=Y`,XE?N45_O7:
MPS5^/^AFO;=6X+2#'PZSUE/`1W%[X'@```(7`#!0A68LMF9[@`%O]GR_AP$-
MD'BDEBCL%&X]Q@IY-%0(5UZ!9W`E\'S@]WS#EVRZ1H)1AP%[MCN@<`=@!P`#
M%5D_T`"P-7P?=F%H-W=!1G'H-V6\U0`;@'<+UU#D!P*_5P/P=GGG-E#.%'(B
MAG=XA68T)H0_\`8F-@`*!X5U\'S`!WQ&=@%6=V%P4$=7*`("53$!412<P@^>
M\PX$L28Z!SF3TPZ<,CEO,6#`,F"7(C93X1*3\DJ1LP@:TA8$4A634$(6!@"Q
MMF:.N&:S=W6ZUO],G:9H*%9P#:5\IZ=/-]9K```'SG4!(+!ASK9F:N!V\,=G
MG1(!D+9A#*!PD*AW>P=9MX9JI2B&;D:+COAU&%``ZI81VZ`%879R#A57V16)
M>[=K6G=A%*=Y:>:(&:AI(?5(GE!IJ$9<#05ZD?<&F]=W:Y9_Y^=ICP:-/K5H
M#=6,C^B`*%B**?`(0<6`F9>.T?=VIJA\JJ9/(S-7FC9KUP8UL#B&XYB.O/=N
MD'AKR@=GZ78!D59YIFAV`6F*W7,P"#,.%_-PN?<!F0>+!=A0\;B,#9B`$"B#
M1)B.BB<PT8@#<%<]@Z`%8CA>WK@'PZB+Z8B)M2:/:Z9X*SEYROB(3*3_<,EW
M85K%D^6X9K2G:=[H82"6`2,ID%RV=[9F=3(8?^S&?;!H9MU#E!LFD^D(@7G6
M88YXA;\H.K91,X'H"U\4):-C<W`X"J.R*3RC#:6R7Y/0"Z?@*B^W#[AQ2W0I
M#5[Q,VWS,L9`,OM`"`>UB*#G+)$%BY&H:T&V8\YE=AU&"#\`CQ'7``DX,FH`
M!]:FCFD6B@^`BF.G%PF(@@SPB%J@F6RE:6HVD.*F;BBX:3;)DOHT+D,2`1$'
M`DTI=D$E+`C`4`^5E<YB=LVH!DV'CHN68?"G,NRQ)R&)3G"FC+,S>)KFE8[X
MC[47C[#8+N;(8H@96:&H!>N(=\235&=V82#0_YW8Y8">-@"[:(\/<`'P(H(@
M@&I.=IFX4G6V>)2P.)``L(0^J7P#\)Q[!H$).8;U9I/5Z2$\))L0MV$=Z4P&
M"'IJ4$?<:)Z0&))Z]BR)F8#O`B_2*7:<^#?O>6<.-9(/.&;#IYWJF)78%5F)
MV2YV(CR3)U#L5Y60F(,,29)5N0$@5@=+^6$.95XN:D<-J8/7V$P_`)Q,&)7R
M"(M0F*%#ZHA3:7Y01I+O,'H$ADHZQT.^-(>F4H?5L"D2$B#W@`EQ>2FIP1P)
MU@GL,`^[T2FG,#%^*2SIDE9"]S!_YU`#P``,L%S0)VNU5@.S9EY-28E[(JA$
M]@-TT%#PEUV9J8-3%_^@3)J`IZBD38$OT?B*ZI8K7%8&O]=0XK8')M::UX2B
MINB=W_DV-J(24+EI;Y"4>T8T8L!0`U"A`(``E7BK]?B,T"B.PG-OWV9VS65V
ML>8N[-::E]DNL`BDNG>3(E*5O#=>?'I/3[>B@#>;(#-)!LA3?'I,<36/J?A,
MLZ9F"#-)P@IQTGB9*J%P8UB??/:LM[:(Z)@"[C=Q9K=7-:"::W9QL,EG=O0L
M-VDA2O.>Q.F@CB@L9R:M?5I/)H>`(%EE)<"G%P5Z@>,(B7*B]%@+''-GFC:2
M^S1>`]```["G68>)#F5/.*!0VN@RM_*J"/=1Z_>=[#:.*5"EF[J%U_BC"!?_
ML2G[365V3:H9:0#`8VJ`:JF(:[R:@!+II`QU=A';IT%9A+RU3#$+B:="2XAX
M8("X)L!1'E<B.6QBA[TQIF/Y16W9EGP(<Z02=*B0"&=J%#!';<$WMW0;?+_U
M&F-*)DB[;$!0`418E.<YBCL64USG3`=C;@VX!T>JM$";:2GGC96:L1$B"_-"
MF@K7+I5ZJZ)J;5BH:[[8H)_H7.S$`",;LNRGJEYQHC*X9JBFJT&U![/*G720
M89S7E,WXDP=ZLX=GE-CJ(P601_2Y9^S6J)7+J$LF)V:Q9@;GHYLJ)R)R`06P
MB!K@;B*VHF=G?!=R8P&@?-1+!.$JBW4`!PW``.(%_P`BL&0K<077*+PI!RT"
M(U?!JV[.2Z_R>K-`UK$<.W&#EY"#=[U660&E:W[MP@AC*@CMJ'R9)R\)RU#T
M]H$WVG`A1@1ZEBL7LQ%[@H*I^!KO\2]B(''>^+$0_`%`4(HFZVHBK)3P>1\G
M$HV81F1EB&T[%GC.^ZSMDH/,FX!%2+TG!E4FMFE%6X5CF(J].9TWZ3"WHG!`
MVKT?T'=`FVU$1E/8>@T%9@UN*P\%#*=5,15:!!";,AQ].`I;;!-9K`\P@6#D
M,0[98"&X5!DE41)SF<;!.(;GIL,A5@)4!1..%+TZ.+=P@`!$.(9PX(PRN(C=
M=\`TUF&:R6(L"56)+%`BJ_]\L:5/&)R2E5"\#J=NQ0L`=-"2FA9-1/:YXI>*
MKZIAO&LG3B*<:P:$`\"2D36KU;L'N5<&QW2.NYJ[!M5I22F>V8L8'^I<'.NN
MF4N+10-%UP>>+HF/8E(3[;B((SBW2TB3['A\2@7)P0<'`X``<V!F30G!GTB$
MT6F\8BB@^F0T#R`&\5NS<D)M%E8&%/>LN%:B>R!O9S=<"8FH*`QQ1'!A-#:-
M)!%E"+QF9O&.F5C-DOJ1P@BRP8=.>&<TK?2QCOF+*Z(2_,IVN2*T`E6Z#-``
MV6RR&2"^43<`((!W]'!`.)5K")>*I"F>VJ(GK`5B9<!VPM*_,DBW1%BJ`+!G
MPPC_47#&GA?`HT2<7711$QP#I(X<=7``!R/)52"F`92W5Z\1*1&B1;?1QI`R
MN5[+&E*MECS1'ER\0DE1Q8OCAKAT<Z'PU6F,"FGZ''WR"S#W=7O*IR-;`14@
ML0`\LJ`',8$T/\1IH=6YJ?`K8@JW`9+8K`G8FPTE`MMSD1D0`)QIOJ%(N#&L
M3Z")S!WA+):[J:6:HT+[LKX(S7BG!LZW=;JV9]'RO@:*3@B@7J.-CT/,TZ.\
M=YFWU[E[,'L=V5"$#WO0>'6'``C@=NQLBL?:=V[#($/=M)'9(P4@/);&D4UJ
M+-+)CE-R*Y/)U]6)N4W)75/&J_DRF77W>P6M9B54)T7I_V3H?"Z5MLY=!V7O
M?-/'B7#UO+Y\!GR2^MMTQ@COD0(\\,\((P=G$:&/*-N6F8#Y^@'(NJEK=A9C
MRIS@/)YU,HRP62M<28O*JITTF8KIF#2$X8#HAU/E"YL#7I_N\C8GD@)#7`>^
MF"LI@*C]^H@/9W:<5GJ,RI)[FWE&(R;7-\0%[JSO:8I72'?2]U0D(0R+4RII
M#"5P*Q5N"J:+U]6&D$5U4<6\1"I:"I?Z)1MM+,4UIZ5&;C%#VN61)2('U&-%
MI+V+^*!%7)1PD,WKMG<`$(:9R>9[EZ./^I'*6W><-MG9\@D`8W`,P)(#W*F9
MM[>9&'A<:)P75Y_1@@P7W&5[I_^OA:VDN8IPPUF<U?D&$)!F?6,AX@H`7\!;
M;([4`BYQWUI0KZ,[8%=K"O<NG&20Q2B/<A.>SNHQ/X!Y3=IVP(FN>69D!R.U
M<!Z5[:@GX\UV/G)C?\=]\DN_#=5WS-KJ\9ID/-ET"4S&@T"O%TFN_"$(!MB1
MFVO0($"[V<SB-5L<1".=&;S2-\:%@0=LX/R(N!*Y/,WB?H,?[U%',SF,S9JD
MF&Z?>4TLX=RQF'S0_FZ30/O256=RX(SK/-:[<C!$P@AB.7[@<T#O__V:+<@S
M8/T;4LP+0W>V9:P(26%S&4&'E.#D7>L,?`@E-(?R;2K5#S8I76NF+Q]@WXZ@
MKKX6QY#_1X89?U\.9<*(:FG^C27`U`T5AC:@?!!U3^]U\&9GX;/.HJT8A4;<
M"`>4F],"HRJ6HRF^=[?XDUWIB*/\X#Z2"`_`W41&K>IEJBG`L4R_B+0LR,T%
M51TE?5)(*I$ESW60!F;_!1\``7TWW6=G7GX350,@!MHL<4+Z&NZ%I$$&5Q,^
M+P=#?*-]0#Q"G@QXGF9V0%5:JO3H?HEJW6_&L\N%D&]0LV;Q`$/\:+\^&>K,
M6Q37+G@5RTR\S0G9:>-E><[XVQRZ&Q%?[?*;W`60[?_==`&^!]T^M,/GHOO3
M%.KS`!]J1VK@%,DMT1Z\J2"LB\YK9JCXJQC#+\^`4QLP\YP,_YO;SDP;,TDX
M]?:RYE"D/=1VKJ%J`&5!%7$=5G!"SZ0IL`4;5@:4=4`(``@,#7,7-64?)3\7
M>W.-A&H-`XH7E!<8`!\9BEH%`06?`:$%$1&=GI^CI9^EHJRMIJ2OH9ZDJ*2W
MM;01K;B]L)VKN:*I2;J[`<*SM3RZJ+"E/,S(M\$%S*.F`=>NN=@1<RDI6@^D
M#RD7X5KJ6L>CQ1$_)1\`=1DE]QDX-HL(=1]PYQ;5`*`!0)D-E$`<2E3IPH9#
M$!3M&3"O#H,!#.I@*O.&TD0`].S=JU-"S9X&)332*R%I48-Y-2JIH0BR)"4M
M;_P9'%`#P0!,==ZH(R>'1X$]&`Y1F/^$+N>'.C$=8F*@IA*"0_,Z7OB1H2(.
M'!E``LB`$-T#9WO>A"VSY>8%-17F-=A#*2?(,BP'E*"G-5[%$G`:X`#944W7
ME25PE,@PH.I)L?8B9T#P%L??>XNI+OKY@0'="V_*U*S*%69#-?(`#*#[0(V:
M?H@VJ2GPFD'*FB40T%7[H0Q3WB"C;NTZ#T>--PVZED%PCIRJ6#SFQ,-40UVY
M`(,!@/#X-O7V12`N9QB?H88::G("W$G2`"1)S/;>[*FQ^"[+CO,_?&A,:<XG
M<VJ(`!1F)4"0P1LIG`5*`0]@4!`.#=100W)R!?2#3G7@,(!>?*7%0%A/W4?7
M0.X16$<#6KS_15-9;S&@GVJ?S30//0-$<LA<%UPUCTA@0;59;PR`(.$`.D5%
M#2C*0+--+=5LDPTSP@AC2BKMX&(+DU3VDD24I5@YY99,;IF$,\XDJ<TTJI!Y
MC#:I7)GF*4C"^4HPO3QGCG,/D`,,*FH\4-J,8CVU3XZ'\!?.#PQ@`@!":KCX
MSV>4&/:!!MNE`(=^+X*420V??33CBT^9=%B@=4AT*0#"#:=?!E5%B@&(%2F*
MPR9I1I"$HW!`VMT\`U"RP52MJJ@H96^-BND\#"!(20ISL)+$'0-E$BPE+\7F
M40W^`*K?K#>],5BF0%U1+*:8S,C08]HJ&I,:EH&JJ6^;3?59"NW)_Z4&':LR
MY9)^)11P@3I[Z!B16;/5.P^F.)8&P"8N*=I`0"F\,0!6](@%`7,7G$6+,WZ6
MH,$'U;'S@!8_6$;I35J@)I='U1Z+\![L.+->O6)I&I06&+C\%+$UZ*=9(ZND
M+.#!\WR,JG7/17!)S9JJQE0*V"JJJ;3HE@O3B%+7O%^*,@*@U;].=4;((AM\
M^^D\&(Q(L:+Z-=`PTQOA>!8UPY2YY)1IDID-*J%LN:?>>&,I>)VXC&G,D<,,
M_@PO93HS^)IGMEE-*F?6X@HVJ[C9.)6CZ$D+FWD6(-A7#)2N6$LX#5`>(7/D
M*?%%BLS$TB0IHH,!`\;M,9^&N.-P40.3G/\S!WU?%?]58Y!HJ!CN_&DA&`/$
MGJ-&#;@W4-4Z:OS00$8&,=:`#:RMTNP5(GRUP3D08Z"7".!(#.'U39TNU%O;
MFWX1"/(MZQPK$<R7F-L9J]T/]-(2]"$G`V4H`TF`!ZD4_*`&.*B#`C,@@OQ!
MHG2F4Y[U^&$\#'ZE,*/S7>D&H*$?:&$^'[)>0)*'@PHBP!Z<:@AH2#@`'F2,
M'!(#S`\2I`J?'&]#N:.?[ZHBCJWH!7KA6"'U5$(2$2"@5?QC!8-28`.]X*`C
M,=M%^9)UD[,\CUC32XP'B\<<3K0B3V+`'0;5.``;:`$!)5BCAK3BK?==P#],
M"L#M-G01V\PQ'';_TH(-U!=!T5C$/,L"AP.3D\`,?>]?$.3C\>A8/`]6+T4-
M8LPFS+$[XX!C;`_,B&@R$*%6O0&#&#$>&'V"P.X-('\9ZY(4;S&+P`&#2="9
M1N-J-29BU&UCDZ,3X?*8)2P%HY=MVA@O:&F46*@IE\-89B=H*<U0=,-QJJCE
M,PV'#38Q*&6ZDV'&`G+"/81C#J[)DTD"LHAPWC!/Z#-G)2"E*W0XPB2ZTU7M
M/`*IV@%,GGD:F3K^-911>,0UKG&G66Z9)]T%JQ'IV.<B$OHO@?*3G0F5:"68
ME<QO[@&?Z/OG.0:JA8`XE*++2N)!4<K/AGR&I.VLYR+\><*65N*?\P+'_TWH
MV<!TA+.D/&SH9Q3$H(3V<Y\/^&@7SZ%09IGC)@@U24,4]+C^N9,=Y4@JS&X8
MCH#2!69[T.I-D1JX<4AUG@/]5Z=TM\^/?J81W1C95F6XU?V5`Z<(W><X'C"V
MMR!4G_G<Z4;!NM::5M2=SB%H)2!JTK_2]:Q7E>A'';O3<60N2V>2DS'HE"0N
M_8U.4RH3FMPT3"EY"9O`$-,T;7799.HR<8BS`3(^<3=@\DURN+V2:+O9S"KM
MHDT1**DX4YH@=J9@%4^%F$29=8NGIG2XBVV$'.0`,79"5X;P3&EST5$)JIK#
MN@WAH10?<(=],@NN(]MH$9=EV0)(U!'@52\/%_\4@3R1-*"<<.]&OUO?X9[7
M$0^`+CETZM\DQE>^UZ5$0"'6B)$=V)[@((=Y^4H*XVH,&0]&QS@"<J?ZLM,1
MW\APQJK1C/I.6!7.30=^]=??!&.U5HI,<'B-VXC]ADX7`8:N.'SQ38WNM[YY
MZBMV(>9?`D-7'<;]QAS,"]%F12"^YPRQCM$1CB,/)6^<VQLK>AM,S9$83F`R
M;2>X+,S2'J.WV63<+6>9-#(UPQ.;W>WEZ+OFSV).;UAVLYPHITOD?O><COBD
MDOGJII$9^KOD2!`J`LK?)QL8T$`K0.OX&NCD,C9!`6W=4`B="G.4U#ETNE-$
M[7J,"-S!Q./`I4`9G:?_^B;-T/]M75>[.FF^'<ZJJ<;2@D']75E#>@YR"!KZ
MSDOI24\:T:WV]9^+BVF^?K>BC`9RJSOG87$@F;FX;'9S\0MJ/POTVL[Y=#G^
M,XY(2SK0BH1HS&R="VD'69;?R&JKW<UJ1B,YU]?\A"*3N&QB`YC"()XT__`4
M46L']+2=^^XZ7DP-1QMXU\;>=Z43!(Y-XVFOI&C=EH)L;A,_.M#?*/:CF;OO
M/P/Y35G>Y8)T2V(UW9:TW9@SS$L+##2OO!M@NF4OO<0XV+Y)F6]^K3#Q9NN4
MGR(6NHC<Y1#>.B<K&:Z8HQOGLDIUP4T[%<8VIG]&`?5S._G?=M+3<UK7)7W'
M_YS3M2[F:H\4C'DW5W$,0CN`MW[NHN/25B>WIN4"&@Q9;]T1!9ANL"4-\&:!
M&+FJ./R@*8S<9EWIX+<@.V@1#V3`!S[+76(\DQR?'@:%O4L"]X\GR,YV8SZ]
MS<WP<WUM<>>X@[I.C1>?V`MW=+B"'L1I:CHJH.[JG9]6X(0CT]5#;@MRC#[K
M^H[TUZ>-"TYGW$Z@?W[BS:UZ)?_>\4H6'\C)_=MG2/'+;8(2F_.8>IT7CFY!
MGWII#9>$9M[62@'(>=!]D?XLPQE-;$)ZTH=N6]1J64F4(WYK=B1L-WE19WP"
M2`MZ0B6>TSFWU&EY]@F=UTV90PNV5V?/!#C8$`VU,/]=\:9WMU`,8?8WU)`$
M.^<Y0O>!%B@X=*<YGF""N"`+G(,FKD8FTU5\N-1R-9AZVP9],U<KKI8>R\`#
M-9APCF>`K`<G9F<-/`@=DF8E9.9ENP<T^;<+O;5,,;=R,WATN>!^-_@-`XAT
MN<5U>49VC!-LI"""](=;;79;0#-XUS1^JO8<XH-ESW=+_I&`P#5VE\=0W89X
MP.!X;_:$0&:`(/A]5%*%3$@Y:J=WMQ5F:5@`858Y5AAG-"<*1K$W5#(FD6@,
MW$1,6!)G<))O?Z-,,WAGU01GKG5_L]5:I8>(.?=_H75TK*=;M-!+RU0,V)0W
M2MB$0/A^Q)0EI3AX-^@F)CC_A@5X3'+&>KYGB[44BLJX.0^X=K;H?9(HB9P8
M@L=HBC''9H83?R.XBV[F<AA8@3[W65+B.*LEA9<#@[:"3"VG-WHG35V6<D@H
M@1(X>,88B]Z7)MGH"O>'#29H@G&&#1-HCYQ3C`?949$HB?KGCFDVB-](CL%`
MBX%7>P")663B-ZN@9E]6D"[H<BF8A8]H9LBD33](?YEX#;"%"L=89C)GCOXW
MBGFV)',"C*=0D,ODB-'03::H.2+HC@39-V+2-Z5@`^YWDVP&C.\XD&!RC&G(
M#$49?ZR%B[@%DM4(@*50%(PXD&/H6E?2C%5(E$XYD&FH3<:T6<J4E$HH)D+9
M"659_PQDF89.J0U@8I>V0I3@V)1F69>I)R=.$DTY"7[&A%IK.0UCJ828(PIQ
MZ92#8R9`1U]YEHP,:85RL`Q"UYB.R5K8Z)!Y>9?B=R9%Z7]\DY8(28E[PI=J
MV)A\:91(MR6H28MR<DUJ291G.0WMAYOS^()PJ7\L1Y-UUI-B6"OEB(6PUPP)
M>&N%@R2T)5M(.)&$(Y=J9I%U4YG,:7>A]7/A-YBF5XEQ(I.KZ)9]0Y9R*7^:
MQ9N2>7-Y"8Z:>9M^*9YHB(@^F9[.:&M`-R8<>0I^,PM<^)+I:`J:Z9:ZB'Z&
M"98H1Y=Q:9O2R9X(*I[@.`L!&I?O.)[`5*&]"'06J8Z1D_^5&<F<V:2!JS"4
MF^F88Z99X#F9,3F?'3IFDC.@$CJ4MKF>4_F@C&F'6OB?B=AGI?B"GQFA>2F5
M0OF6CEB++&>8C/F41BFBV%B6#`JC!.J,R;",H[A+9F9+LL"%L)<-MA(-'JFB
MPT2?OUDWW'!W:M:-SV2%UW"*8BB==_:+_-F%TI!,2+J?`MB9?TEB7-J7^,F7
MV2"BZRDE5/F-U<1GHQ";%$A^(:H-F1BB.T=TPMF>"[J*H*4+O22=,:>&$[J7
MZZF?9_F42!JH@6J6`"J4$!I,W3@G9IJ:V<2EIDJ<@<F&>,9:HNFI,+BCDMAS
MJ(BG::HX&_.J^/D)+\F%V=!S5*G_<S?9IM^9#(?S@/WG<C`HHG7)JI]ZEJTG
M16[9>IY9HI/J2^X0F_O944&'EK_UF(-8H"D9A\R:H5GZC.UW-[6HG+`7I6D9
MF+YHC9D#BC%'B6S&"YWU@,K:>DJG"N)IGJ[V@N$8HYJE6IQ(D)\ZI_"GBDVY
MI53IIM,ZG.]XG?X8.%`Y?M;4+&49BJ8(G4OW#J8U2[BUI[^ZB,(@H.[9D,N9
M6OLILKK5EQZ)LN^'3,50IPXIE]34)A!9F,ZT=`+[K/@7J#-+I78S@URR)KGP
ME)S)<MVXKRG7LR$HBSD9A=TZ@FKYL@HJ6IX%@DGBHO*WI'D)"C87F5_;9S\W
MK_NWM-:X_ZR!<XGF2*!"^[2IQ0JRU9U8:F;*VK-:MHYB.J9U%KA6N(&MV%HM
MZI$1N&4;N$L2*KC.R*,LFJ+99#ECZENQ^@(\,)7;2`S`FJA!RH]<B)>3BXW?
MES1#&JY)=X6*6:C`Y(1F&KA,&`%@P)5:B(Y+F7ZT&)JMBY\?BZNJ2;/(()V-
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MH*7$V1F4`[G!25**5BH-HA``!ZF/B4FK,#JQ:Z*++-K`^6BV7SG"*?S$AUJZ
M]+@@\+J&2!=\H<"J_UG#>Y*AQ<1CB&I_SWB^V`N_+HR_4A<`2&G$'?4+46RA
M'VRV20DE=G:=LH#!K<REN92O19>>7/K_P9U\A6PICU(\A.DYR-M0.9H8S%V<
M6>77R??[DR::N[+[)(A9I^T66NP+G,.*MLQZG<')GU<9F]P8RGLVR47JRM7L
MR%?+G2;L@M0,R\[D9K-\EBRYA='@?L(YSIHXNJP<BDORS]RXH;MLP6]BT&PI
MAK-X6;Q,T/Z<E)6<S[Y9FXJZS;-5H>3,.?O\P!1<)W+YJ,!@6\AD%.E+<U9*
MC]HTF&ILO6?LRLX)EBB)M!6(OJ'9SZ;LOH)I6S#MS><;S90<S-"`#4@I9CQ@
M`PPL2\RY9\"8.;,<?C-=ROP[B(P+TR;\EZU+U+^0?\]@#4@YS1VMGM9`SK*@
MU!BM@8FC9\D\_V;N:LY:"%OSR+N\M:MIIM:CRUNS)9QH.LTJ_)UJXLZ86:AH
M;70F2HZ?D],;6-@%B)(HV6Y'N<V4$]9;N-4H7-9+IXA)38//##A6O8A:JB3"
MVM)[!KP%<-2%"QUQNGX`NIZCC"4#ZLWCZ@R"'+?!]\Q#;'>5J,S=<)XMS=?#
MRF?WRV7?-\B""=S_AYI\W:&D[=:'.\2NC--'#-C?*=-!S*]Y6[?07'2*NH45
MZ20__-#J[,OIV(7VC*/19,M.+*P,7=E`S#>;#;*OM;I&1]UP1MX`>9BY])52
M/`N>K'^]>LM.',PKE]&QC'^AF=TIRI^GL-FYI=^[K9U3<IZO'*5Z_?_+Z`?7
MH>S@%H[A^IK+NARPP>WAXF?A->W6X/K=_EQ^`?U+/?G:ID6\T1FB!/Z)SB!;
M.PQO#QO.P#G$$9Y9-\U;AOM^(ZY_OOG=>SW1+^SCZ(RG&BW:NBR9N_#*VEJ1
MV<W0JFBAB9B<0:S8\XS,4(RA6_XYV2W-%UJ;T+S?4TZ$4RZ[/JZRLAW9L5#F
M@DG)OMFA@VV]T%2=XNK-?>[542S(&=ISB_K8*BO8;=[9+:G<J\SFT6W$*BS/
M51["O(W*/WVEHRV`=AW41^GH+(GI]4?.^SVY&M[`J[S1_7O4)2K::)F=JCWD
MX2=^_^R<A+N&UUBC(@VL.$S,G#DFF6C.MQW_W&_^?[P(F/#KS?\=SMY-VHE]
MM:B@TX`*DLR^PP'MG(/M)@P.F$ALM@@<@`'9V!@JQ0%-WDSXYQY:Y8Z-P//]
MYM3^XSVMWM1D[KI,KX!=SW,VVM3>U4*<P?'>DE)J[/<>L`S>9;^-Q%]>S]5=
M?Z\0F+\>PMT=P6-LW-INUOQJW#MM:RQ)[[1EDW`M=43WC`4_SSA*H`E=[X!Y
MQ-7YH7X>Z&T]S-6ZXZX=@CS6K8+\CZXX3>5.6F`>MRC\H5I9HJUPRDB2X(*<
MC/\\S(<]X9J^VC[/Z6>F\26]VD$].;K`UQE]PJR(G#B>6UCMW'""O]L.#90M
M=:2`Y90(Z@D8T4FX_[IPG9CV[MQJZIU>G^3];?;Q*,;*WN)(`J=J>>%;YO#^
MRZ]%?ZK-C/2JG,Q]_65J?MHAO.KA;,RY;3<LS.P^"=U4/K66SH1AO)LQK?9)
M>,N;7]J,X^!</[M9S<+VJ=Q3W?1C&=:H7]R\>S@%O*GG=UJ5B.M$W)LG[&5+
M;G]OO9A(_.A=OUMC5N$^OR89?/1:/HOQO71CG=%=W]+PK>#?7$M*I[)WO>$*
M[H@#;\M"3G[%'=94*^S>KY4J'TWX';GH;\S"+8_)'JYV@\OD[M3%/]W*BOX;
MC<N?-0P<#@@1!0$%!8(!A(.(`3P\`1$1C(^"BH6(@SPV/(:'A)"*B8J.D/^2
MGX.6B8R-G(J?EY:8HY$VDZBVC)JLB*ZOH(Z&I92OH0&YD(>ZEY>9DY*ZA:>*
MFK6>G<J6C9^_O-#0Q9O'E[R$RJN"YM[DV(W4A<*IY.C;WK"@U4FGI`%)QQ'\
M_?CV)6$G[M@@?[LB+1)FB1LR5J9`<:)DJ%6D7[8DTAN'BU-!<<%NA4*F;5,!
M9A4]Y;M8S5XWDM9.TNKDL=E,4XL:TCSW*V2UA,5JI8.UDZ6J=OJ`F7N7LV*^
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M]TTRGW(ZQO(BC-;TD]Y#:`$X#'3YY4CD5QA.]U!IXQ$#UGB&B<,;@0!)5T`2
MO,'WFS^%\+9EER..E0D/_PX!-Y1^,.463GVMF69,!)D@"8^="J)2)T]X$D51
M1$_IR=A@0/+XC%L$>G,:G3<=^&"@?;VS&">+AHC*6(@FBLE-075E:*%-<5-I
M;/5=ZM58B7#4J(,U$54/7ZDIQJDL19IJ47;I5-HH=K)E&N692E$C[$MF96A-
M+@\4H,F;<8478D''@@.7/JB9-9D]$:DBK:4T9>54GO%(RPXPH#F;:FW)J,+)
MI*0<RMF`T%I5X)5?"OE;;9=\N5E.C`C9R6*S8<E1<I[F%=RWT`8HI2WZ&3IP
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M>D+C:$=7Y`KMPKOJG'_.I&K"&B3QX'.O?B*;?.'D?-+*^W0[TH-GZ"PM0+X)
M9^=H5SXUX^CM'*1X4^W(,27-);@>WWA;\TN]W&C+R-W_OGN,OV2&O>'$BR4Q
MTE[":#4/:;7*5U8AWIE(Q!Q<1<ITLTB%[(0DNB3-[#TE@0Z'YH:J_V3#*ZUJ
MSH"&\['YO*YW.T)/S@S20%IAJ7'3^0_M^,1#&*JO?::;UO)DD:8<:L]B[.@A
M\?#4&Q+*1#6L(.+N1M:^14V#%Y_8G0R#F,0,LHE93&L=!;^!Q7XTKT>Z4\RP
M_-(@*=T,,9W*(+D@@L#LJ&D\CN!'503!/\4MHH]@^@Y\LFB@8B!'A5J36Y`*
M-CL@WBB'2JN)V0@XG<B4!U"PBHN"%.8LFG$/>*E:4D9NM9+O^!&-2%/;"'W&
M-@ZI)1VK#)\'5V:J-SIQBS2Z_]/T'H&OIM$L0JW897FV]XRPN*E"X-KDS/)A
M2YX12'=&6Y.CW&BP\.D2D@3K9>X>"926!,>1C=0(>9A%,C]*CCI08^3>!D@V
MVP`2$E?*(R+X$:MP($<K'*S&F3;)3\>H<(ZH$@H^V3,CJ!7I?I3\GR#8U9ZZ
M?>V<TZR:M'+Q*GA)[8+5`%B!*BE&L#RS%@7M4&]\IDW8=?%I8@FB#(_&0$19
M:Y+0_`CYQ!DPY#&E,ZF8U0.S`AYT"28S)*KD19=H38_,BF7J\)48+T-&%(H2
M2I\,Y8(86"Z>>M.:-MG6L*S:MH\"HRRL\A.V8#8D(=K./=!DH?$DNILF<HEP
MJ_`0)?_P<:&)ZNA*DO1H+_^!&WS\XZ]ZVT5`EK,9';HE0>FK'M**HJZUQ>>Q
M+"J*</(S5IEQU'B1"][7?G*>%.6,?9-SEM7HDR.2,DYS.--B+G$J+)Y.KZN:
MA5<46?32ZT#0M&E]EVU+V,M,?:4[UT%J:S<;2:CBL'#H>21F9V;,:_7%&;:\
MB$EPE[Q453&FW$,LG!!V+OB$\HW,Y2>T^!>0PT*OGOKCY0V;5A#9]4FY9=TA
M/,.4M7/YS[.5[,_6V*:H'6J,<QWRX%&*>Y:6_BF,_GF.?)@*-9\.9I!3%-XU
MOQD\"+]6B^YP;E:L!B20=+.JP(0F9B;C7G,1RT54:MB,'IC_4*QV173[A>R`
M!7.(-$D&@A\R["6MQU36]5?##1N;14GVRU$^C9=Y9=*&V-BK0GX8-^/*IAL-
M5$IW&N0WY;4*<P%X,87D3V;#4&W3,`1/C7'Y'U']%C:B)]D2XU@YPTOAJ::H
MS>DL*V?"Q//#KG)G$VL#I])#KGJQDYX.%>6F,&HH&PFKT/"X-,.\9%?RRKC+
M+*;Q%4N!LI2)9\?I[*6XO0M4G3%-&'.%D!L=3<2GY1QJF#Y7@R`MU5C80\)A
MN!=VT0WH'-6(:@]1IHS;Y+68*>T\`5FBST(&-5E-$4M"T'.#@<8G;_X*D,#^
M%9^T:6*.YA0-+KWBG6;4"CU#-.P,_]^:E1>!HI]VZ.C-0F^A)C%SU61=4NBR
MZK/25&AU?V*9*'-OW;^ER'/UFR#UG$R$7)S$:3IY&Z4A>M:K,W$]:F53935C
M6T'S).P2#HFX,CQIT'Y-==`47TD69FVQ!2G)L[U=2./7E#L)QHU/O,;J1A$<
MWV#8S@#*Y$O/AGQ^$74=?3U0.DUT4.2A.1A)")#Y6HH?^#C,"2/8/4Y\*4!Y
M*T5@!0)7%+]T2_E#I">BSDUOG4J`6(-?)ZSV0F;2BMO!-4_<5:SJ$@]T'65+
MH>CL3EO\O)J"GW:CW+M<MQH*O*32+1O+UOQ5'?$+G_TM9UFWL<>4P;3@1RM5
M+':Z2?A$/O_H)"ZUX($;7(CG1JM4RQ$QPHH[M+?SH)Z7>*,#CR_^G.>TD5?T
M50KGG^1JWGNP*BUK6#9&T4O>7VCV%IK?HPJ!TXCG\!SL/*4WY_S0E2D]R<E@
M`9BEKG(DB4)$Z7[9HAG3Z-<R6^-7ZO`3LZ,8EYK/_Y#G%CZN0COS3N>81FLV
M=7%BB!2Q?R%>*+%YV"14W^)YVJ,KI<))(X4?"%-_,#8:[0-,^K,JO\=X'\%^
MR'`7*C=H%`9+.18W@(%SX'<DVS%<OR43XJ)?;I1]*!A5#+5B%_,H1L)=,X)Q
M,TA=(B=5L-$?$%@EQS1\Z2(/,Z5X-R9_6`)UUU8JU)8C_9$?^3+_3_<"35''
M5V@$$22C03B7+WCC;<&U#S>5=^$Q423X<U>$:`KC-F08+!4!,`\E5,Y1"M-2
M%8;44^IG6^0VA[1B`8=D-$8H/&U(@BL(=!^3=^3&*+STA(NQ'L.7A@T&?F#5
MAV?SA0N#B+,@+GTH-O&F5VQ$?\*3B7?82]W4<9PR*#)!B#F8>L&T*)D&,#KT
M(_R")$=%"HOX2TX34RMW9S?81?M"B0$S;TKDBK#U8Q[V52OW=G/BAY18%VSE
M1;,P#5`7?5P"'5UB=6#7?N=#+N5U??MFC7<S?7,E=MDX'6@6)@$%&).`5W(H
MA\#"$3="(V<(691W$QOHB'(B>I,#=&WG_XCVD`FFN$Q[1T1&\B*XL"N30X0H
MZ%'?H5'1Y!6)."AAN%H%B63M$XFHQ(]WL2LZJ&^\R(""Q)`)AD-=U"U_N"AA
M(T!J)X0*`Y)]1QAQM!FW5PY`UX\I@7Z,B"(14HL-64<F*4BPZ(_I0A64%QMV
MXQFB`'>ATA:*07+*J##M.&KV@X_V"!B-@GQ^YAO+I9`--G:1`UA7=U=<DGP3
MV!-5Z0]3R(^Y8S]V:).)^","II;=-5.G,6!'EH&VE33]UF^=%7S1\4%JQ'B/
M<8N,!A*C)4<(%)B"*2):)2!Q11O6H7CF@7<&1%$YYR/-95\%Q9AEB#JW1V0!
MV%O2M68!F)C%$?]ET&6,J"E'X),H'M>2J*E&97=0=ZD-,Y%MCSEW4$4;M!EI
M2$>0G'@B@"E1=7=L>ZE2<!E%>5EWC_26<5>3L*:,8`=U5F<EVB8D*S.!6S)/
M26:.\$0<H_!6\Y5@)!EEGW"6:6B6:75_>@)K@%F9#@E>4,:>FP.!&L@::MF>
M@N0@$8*-ME8.>-@(#.0=7M.?[1F5'9@U-`6+-+)PJP.?QVF;&H07,`>3L\%V
M\GD4T--/D1%EXV(;&)H8;B.$/C*B'CJ`(C&,1L&9;+4IVY(@J,9R?O.?#`5=
MD;2A/<&AC($@%R>@_6.@8F-O'&:4F#,,R"$>*&9^ZG5[_=,4IHE8Z]G_?^49
M2'#R3E%U,UE&=NZ$93BQ/V;9-TO#9`3QA&4FD5;2)<%#BT?W.C2J%;&Q3P3#
M**IAFOWI?OEG%^9S/2K8H7`I%<H"BI^HA=ZE7>;W"8L82:B#?M-PHX*Z*G[Z
MD$FJDYL#&RIWD_I4BII`<,$U(_KG61,D74UZ)WNWJ9=TF-IRGX%9@ILZ:Z')
M$J:)?B-H$ZBH%T,)H/'FJG>!C-\5H$KA"(VYI]OBAFND+"18J&21J<@X(@L2
M@Y=ZH<I)J+1`8.Q2JLI`F3W8@=_UB56SB#XH+DCZ%V&)3`)CG<*I-7H$AEOW
M"&%9+Z+@/#U'7,Z667<R;N0Y:2G*IIMY-IO(_X?4X)*/IRV[ZEM$:@%,"8<!
MPE`4U8C'9@&.]X<Z^HP`FU/T2+#VH%%]^K"Q(+!R%JD`RIY^*`H"JV"Y*2?"
M"9VR0F!K^AF,%TW8P)`'>1W`(FPB6@P8:T%E,X!QY*%U)VDM:Y\X9Y#7L"D0
M65\+F8O;E1OZ:F/:-8"5PH#^&*R-%0OFD',="[2:IY(O2SE">!$L>7KP`*#-
MV(C?<6TLV"-T`V?4(X5H:Y1Y`Y[I19TQAE**<"7%(S%ME48%6']@&V"!R;+=
M(Y^]6!\A9$AH8F+^VI3D(CQV80,*NQ'Y)7A""DEDN7+&]C:4X9:X\:Q/>23!
MF88NMV:".ZJVMIC+N?\@L#%3)S:R.SA0\3F15.:?\+<5&TJ5AQL:@AI_@1*F
MJ)=?05I[3[*WZ/=O']JO_V473<M(*>L+<<B8MXI_GA:D6+<[WB&,[=1XT%FU
MGL&W0U&YL!)B$N91TL=*W!ANELE"P200K-&=9BF6DOI''S9L8812Z3INV,F,
M^0<XDQ5_#W:;4*0B/)96C4"LP>.<%;%1^%>G^EM&4NL-KFHJEWC`:,5M\(._
M+.H=#N*2R1BI3N*I,?EG:#H>G/*E1^F"W/,>3O%9(*PMSWIW1.I`/#1^4!&3
M]+9PIZ:Y)3&0(WR)K(EZ2M:A`5R_@;.%5;2L,I:MB6(,CX><&PM:1%P_'HC_
M%K0JPGCFM<!%DKH@Q-PKG-^HCR>,L]S";'2S#/472]G9%]?WK?N&LSB2/(K4
M-RHHO^;X5JQAA1ZH$-OGI:EW+*8X*B)U#\_R-1HU$$XJ?3RX#W5VE)9!L1[&
MB2?!72*8D8Y:KHW13.Y4&Q3+BJ:82VXAR,Y&R:6(5.CDQD:#&G5(BW.,5R86
M6+*#"VMHPI35QT-X9S?;33K7QP,"E)>8:&\K(`OT&<[*1)CI6]R@N+`:8&PZ
M=HVF7+$0B1V&?W@5RAOHCU!W&G(+DW7[A8?5$0MUR6#HPG5Y-P$A"](\7A-!
M3\\FJ1`Q6&PL;L`!6+U'P=<A9N/L;4T[QO&+GG\4_Y;))K]_%%!R#!NB"+@=
M*\BPI951*(5Q&[?=Z(ZN"PI>Z%*"E5L_&;:G[,ICPDFIN\U]B\X"C2@":C=U
M+%33:&4(&ZGX7-&=Y:5N&YMCS+AIJ\^>$[OB=J7:F=(T#:,H<\\M+=#]K'TV
MC&$I5\W^2J+UT=`(O77#^*.-L7TU+4GG86W,Y+828=0*C8>;;-")("98RH6(
MY%/O2C?DG'@JHQ_GJE9=&DV\\:SZE\@5W=55F,W>RT=TI5*<Y8&?-"8N@<_B
MMI39*:%8EG,AO<]F[=>O0QE*N*XN#8;GJ]=DDM0AC0[QX8739Z9[_9T%(=!,
MD]5H&[4S>@\CVHV8O<U1:_\.>!5U"K$_$(W3>HIZT?<:?_UM\428V[IXMZ&?
M81%82_P-B_>MP@'97!<V[@=4+$':49U@6R?/F-IK-(L1FDS(2KL_S3R->'LC
MK5TRAYJ.RJ,HX"#5:T?=:B2_2BC9?C7)`?+-Z$J'WZD>SF;4WAQUFR?9W&>5
M-6@0K@#=%"BN_J%'E^K.LWS5\R6O5"D4*#U]EZ$WD`-UZ^@<O#TFB+C7UZ';
MP2#9YM16U"IK^)Q'1NW22)R=!36-")%'"6TT?*4)>G12BV-#0",,7D+"SPC*
M+5*N`NAX1IQ$S0QVDJ#/4BE3C$$FB]>=HF4EXOG;),YU/"37SP4P^,`.(Z[@
M"U7_'X/TXTB>&2..V'TSW4N8CVQ9((*@6C5NUOY@Y.)AICR.Y%)=4IE1W9"=
MOC-NSG_MX8=`"_)LS.G(X"[^KF:Z%6?=?QJ>CD$EW5^F"L8-./B3)9[!B/@S
M;77>U6!B0"(6`'QXHV';"=/(G9`^$(M!/M.HR5):M]8X4G^$O&(Y6C[9N-Q0
MX>!(Y$>:2\5S(L159IU9XY40W@+!YW<=X'>9TKX2S1Z3SJ$8MW^-Z_-'R+U(
M4]7,V[I%R_Y9QV:*UY5M(Y;7K]L'RN<KI;2,6&<^Z;,>QX<-#])GX%4-V&QA
MU_.$QA1RS$U![&"W>_O0Z9%-L,2EOB<H5K3L6^YPZ,Y&_Z-!2=QU'I8(^WA_
M]>H8E#=3S>MA0EXVLN[1&:.A9);&<>C7.!`"6ZWMF"?7..#[)',3FGFUP.W!
MTK9;<M_A@<CQFB_KNLGV`)[WS`S)KC=H%2&:C-[/V)8_&FLB7_)NO-ANK>O"
M15PF!U0\'^Y@N-U#Z$;D?>0\T.O-_+PB-^^=+LVKL'U"*Y0I_>;D_<D@;M8I
M'\X^J.WB>>'/+K4LQS"VG875/-G'IDL+L:[)P*,(+=BFS<P`8N`8\M<=WPA1
MOM)Z@^D-:6UJ2O?Y!=2OV_&P'2Q.7]/H"_#)<]8?#!YO=>DUWAMM[0O/*NDT
MIWUDAQ)-^[GD.$#JGI^:K/%%X?]7]HS3B3GSQ\S#4>@E]TV7YUZ7NH-B<XZX
ME$]==-GI)7_9J:O/R^WJ=3Z#WYS"8XK1:2C(YM[A'A,FZ7W1,TWY^^D_<*Z%
M6HDO&(Z$'1],K"W1W(O:ZCSEJA[3\3'>EIG>RF_ZA*RVEJ7Z4OJ^GO>A<0S6
MFUR-2,C3JSG3)ZWE"DDUZU_,J\_DEJO\WP8(`3P\`84!!8B%24D%AH>.B8X1
M$8X!21&,$06+G(V'C(**C82(B)R+AJ2%!9BLK)JA-C:'FI>,I9.5FZV%-H2#
MOH.#D)JFDZ"?AIM)JZ&%A+:KF(*OB\67GI;9BK#`G].'D8FDS,T\F]L!DZ.$
MM-VNBLS_T)2TRJ.2E,+N]\CCZ@7DE)6#5&[8)T^LRB$:YB\;*V>64`D:A,M0
MOT:^+H6Z"''9LV&W#,$*%VJ3,F4C+19DB$S;*G8/"8W$YNS51%^?!FI\.6@G
M.FD`VY'\1>IG1(0E%2*C^8RD(%FT3"8;.FO@.'@6(QE<YFGGHZ+VPCI"!8R<
MIJ)(06[,YY+@QZ(CC9H,Z#294)>_N`&,RK,JPFPM5X'B@7,70GI#G4I5%]B5
MJ5N+#EN=J#A3RY[E;.&2!VS6NDZ(P*&,;`BGK+)W+:U[C+!EI]+ZHO&P19%3
M*V.W1`,M%(&'!74SSY[+-4_AI)32DE`,X!D<4^`BXV(*+)@W_W,>ZS:.LKE;
M6\*.;)G)P@IO^+3A@&]YH@A.TWC1N?:1.A^1>LQP&26J#G6L>\YM8/WSGCQM
MV31?>J40(P\CLFC&373*T6+<)9@(E5!1[+%U7W81(5;--I%!4X`-O\7'6%?T
M\>+.0,E)P]P_HS!5'E;A<!@=-;W90"&**(9WUD'(M",5*X3MYV)Q%LW$526#
M;5)D?Z+<.$]7I6QC"C7*-7?886QQ&)E7\;2RHT>S*4D6<(2Y@IR(W(AYUFDX
M80,9)[KLZ`AAPN3YR#>VT1EEA]8`%(R60`TSG2V@H</B0>Q=-UA$S?`6%%:1
MI0.*9R]:HM))<Y6I822[577=8A)MZ?_+=P^V<XY&F)XJV4LY&9I/H'=IM"IS
MG@&TI$#W$,=8)?7,PHZFU3G5DHD_64B)J"!E!I@[;>YEE&#+0BKLEN$TXH]H
M5RJ;1*X,E>00K#)IJ-N)KI;$ZU1G<H@51<N<2B"WNFSH(7)1@>N78']%-0A]
MSR5GZ(M2E=I:216>2-EC109E;#^%JJ84<L?T5"VHI8J4))?`+F/--:VEYV<O
M55$'#3<[GG?:4L>$MJC'Z>!)5&77'!,2DQ2&*$MA`U4H$R,?6]-GG8.%VZQ"
M_#@<<%.O#)N*D/V:(^QYH,J'TU?S&?<B(PW'U9%6!C4%M"?AB3><<K<F!4LP
M>`68BCGH`;O_UBA73_0SRF!-J4B]XS0[MT7BCDJ?E=GA";=B"\F4%('W\/O1
MG>4*=!)[DXVVK$&<33LD1N:-JY(\5Z]WT%`8HI>.-.?I,VQ+=(?S)+XJL2,D
M96?.E1AI<F,%E:8L/0LO0^?R%Z*0G&5+[CGW&%702SESU4]*.5?<65LXQ_.*
M:,*X`M)QZ>RBGR.S/-X5-J$5LR34AMWY"%1T=KY,RZSI4HRF)`HHK+/FW$E;
M^,D-]*2@!6)1V.(6MH1D`R0C\H6OND([_F"$?S3"U3^*Q)&GO0T5N\L6.Z`R
M"3Q1!VM[LLEI1E.::PE.718DQE/:$8T28L=LFX,(L%0FE.?L["$-_Z)'));7
ME&F,,!PM(5&9<`6/JFTD,\)124H,=[G[(`4B\Y"@8'!'F%9Y!FGJ2][:(+A$
M"]@`AR94S$;X\Z8:8F]`%,Q,)4IWH=U5*11X`B/UU#4[[*Q-60=\CP3CPD!@
MT:1N'EM-^D;7IH_9#1J+RHKU.)2:?ZSE90[2Q75Z<8XC0D:0QV'&)4TD.0XZ
M;#6GN!+D#B2W/<TP0N[Y8K6X-D+N9#&1VEO?K?+#'`N0XX,6S,99'N)%'`[1
M`K:4$(#R5HE=+DM8$W$%,.4ENE+NR5;VFV"^O-BA`P(K-4["3\G8D\#P?<^9
M*!E%A;8I(1*%SRAA<^8BHL@L]`B1-[`#I_]S`#@)3_J&A3<#I^1<EY$$3I":
MBKJF.@^6J_<`!*"U@(0,JS><ZW000]0DI/H2B1>3V)*5_PQF>4IYEP2UZH5I
MZN#NEG:2A?DKFO/*$L^.,QU3H$@GG\FG('`WPWB,K2EVB=M4QD)3R1ED.>7:
M!?RN9[-,^E%VQ2S&H4"EJMZI+Q?RBJ.-%BJ4*@*G>+=@R`-5<SKU/86#]C$;
M"-U%F;<]8SPR388)935,9U)3(D*"*KB""KE2[DQ"<+06.5[75KM6!3$H<=0Q
MN;I&;-[$.V_3WK4H.%5P0L6EWJ(@`",(3JNZS(P8X:?$]"D4]CWJ2`')2#QQ
M>M93X6L=D@5>\6K_\CA<F0<\F<7@V?3Y-+2N4RCC),E?FYE.\+DJFX72USXB
MY<PJ5J-2+O5/\YZ3#W\83QVB6-HIPODX9AR7:/X+X4P_IHFB8F(=W'/&E!CB
MP4K9#)<DA`0ZRBLX4]PSE;ZL[J(H-"H8&O**3UKA1XSX'5K*BQ/_^]_NH"8_
M\:ARDF-+[3:OUI-AX2*!K)J-,48EJ%493J$+D^L$_<(J4>7GPHUBFERQP5BH
M-M15(&83\0P<DULVL8F<<[#XQH'?J45X?5]T&KSD]R9M-"P3$C1;&7'Z/70`
MD)7((TM!#\Q@5:@WMR)%'CH\V2#.S3BI69IEMGI\3%_.#)8])@LB+R%@_\]8
ME6DS].&O/)D(OU!PDAE63W)'5RZETC=8V!Q);V"$+V,()R80M!-/*V9*_?7I
M%&.+3.'X@:_':L;(:^1QQSYK-+"@6!56E:U5@O>5?:'X?IE>;;D(E%@*_SB.
M7W7*7:`D/O%Y,'E?O54ZI]5:"MNZ,!+LVU@XC6/Z(6]K!I9P6<URNH6D*UVU
MR;6HH=5;!SML=:[U\4^_TTC.#`:9XZ&;E%OK2K,V\+&W=M5J^=3(UMU6ECC>
M=@$;6U>,8I1S&`J?62Y354RK`MR&,_:ZN^JTV$X65YZN53>NF;T*<^UD^29(
M)R:$DMM89F\6$(,8O(FJ\7VP%#DKK&E5E!6/W?]OTHA&M$L+9RQZ95!1R.EJ
M/;;20I,8=&>X5HNJ1"O%UP1KR6P[=^/*FT`6#GR=;CX-PH>^0E.<7#\&CD@5
MV6?2F>O(/1H=F9-R!7!LB^IIJ_H60#W2E]D8V-%O+J'$S`E$B0!=Z3O#-#+K
M.HV(HLK''PZ&VGD'FRM%-))3][IKD4TL"Z[S[M"SKVOOTMNG0">#T'3Y$(5N
MK;KL\9BW'-]3,)AV65;M=;ZY%I0H#UVAW]NKKXNVS5V.*9EA^]=^3SH\>^6H
MK\>IOG>:VL(0)9)>9?(4T]B$#<2``0R(P>LA(A;7U?LE]0R;KDSBSM45%/*0
M-VTM6</2N.').BS^2:O_HBG:&E_OV84Z"9AEZM7T4YW*7RU4$."_4.0*SW1/
M0C$5I]%-ZB#'/G\FK*S/>.O`?;7]*X*UE,H1<4]G)?A7&K94?HNB%FG7-(AD
M-['G?U27.[7T6I'30"1326E$6GMC3JZT&/WG=1GH3"N3(OG02'%484:T$4MG
M&"'66U(E52J7:C+2*0^H(X(7:<P@@!DG$WMQ3?)B:T=52\U!($%B2H3Q&S"4
M<N"C?THS?E6$"E[44W*C-WPQ'[=G2/0C!A,P`6)P%-9'$UM1)2[59G4#*PH'
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MV"Y99D#T]"UV&(#>(&(8B8+<DX$"%X!E:"A$6&'`(?]2C/%3FW579Q4/FU)_
M:O9-5X4G&;0]:Q%DV1&/**18GD@[1)AT&?=7?N1#92%60Z)AUR-88\07<&()
M>0%5A_=7N+AGNW9,*Y-A/J5Y@]4XJ`-P/_5Q-OE8+9-L-70*YE1OL<(H]U,Q
MI2=\/D23&38IJ60>BZ!';)*5/4E*Y%@?2=1G"94:VZ,T;B)R>928E$(-==)2
M52*)RG@U00,L@38G:YA'Y0A=6J5:B]&+@($+\Y=3OQ)^?M0/_C-FI163'U8/
M>S-<CB1?&P2!LC9'?$%'3!,DGN5!GX)=@LE6-_%QF>AXPO2&'<6;_70:H`([
MK)9(+;1"$?80VG`9W/&7M:'_G"?64`WX-HN&+R/S@GZ9&`BC2ZM%;S_8((P#
M6/Z11/YA58,%#LZU&SRH*GO8FO%I'):"=/T&*F3'(*B'C,1WB>M26IQG(M]$
M;;CY'/`99+]HAS,!29#Q2<"8%(\A<NM$,JZ`*#I$EH@T5![3,0_8(<$S(F@Q
MF9M96IBV44GT&!;)G")#1>CS(CX32S:Z*;622$Y657T72T<I0T"#@_C'@]L%
M(`+:+&U%B^IE/3)$G<Y`8@RF="<C46N2CV2D<FB3?(IDC"]#<A.Y4+[R0<$C
MA9&VFS^II?+CH8GQB>,H<!T33[;SHS;I9&>2F#*$</(C$@(D42U">'3'4YE!
M:F[8_T,F@Z=CX1`)*$T%FEC:AD3"$XT%=J?G*$EZ,:4`=JA5`C##IA<N$W*7
M(UAB&*B]13YR-J:Y97B05BN9HAZ:Z8["T&2(B!>L:E3@AS/>XX!T9I#2]$:S
M)SXA06"J0T2?4CBS0V3%IE\Q!C#)PI9B0P^X%2&8>&"Q4U;ZT0[Q$88F]7]C
MYF!BI1<75#Q;)0[W*)ADE%UBUFEUD1#=^B-7JHOM)WMCQAE#E)S%HW>5MJ;'
M03NG0X]3$6_S6A_K<39%@C)^-'L_5@ZKL5]+)#$.0XJ:93O/ASED^2Y8XH`F
M:4D!FU/D.CE5E4/R\'R4P:XVA7_RVF;_NBLH27Q`PPL!AO\3YH-Q0-,)AL.#
M]F@=99@^H"&HS7-FZX(YR^(QK(JA=/-#XEB?4N8]OQH^];.R'DB?KE,F+?D3
M800UW[0_LW1@!U([JTF0"G*"@J,4'L%WXPA;7NNR%@I-U?HS.GLI)X9?6;=`
M3N,O>2%";=M"(H>6/'4/\W`YVI>ABI8YSDI=JL-Y6R4<B+:0#6LD216*<6)Q
M^_.G:BL^&H:4'[M4^34,&WLWOL$[^S)F`]D-Q).Q=&)/5Z0='7::/M=OQ!%T
MW/D?GY2E;VA6IVNR";(B30A;I&4+]0=[(I(L`BH0R.4Q[X6"9C<V\:.TR`,&
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MK(][*FC?QV2&;,+=P\=(`BMH!82IH!6+&GW$O'A3FLDL\18MHE8>]FNW*<=3
M=!N0K#C4-)!CPG%2-"5S=@CY]L5O%[U*_(&X03`H^L5V\UAI=U>?6PMA3$Q/
M(ZB<6'KD,)D9>T"-LKWN4A#-&RZATZ52E,)H5WC([`^-@A/S-D4%&)`0";L`
MED&Q"KKVUG?KA\,SJXQXEHSSR1:3`TC*"F>M-K>(830,;3P-F/]."`26^N"9
M^W9$N%H3*T%31)K2&W6ZU#NX\R4[5A@X+H@U?C,6^I4<XV-EC-H1:QMME4K-
M+`TW_6LA5L:2"//0RD@\B15LP'L@+DC-#J34C%D[=P1"?/$]J,8;K-HX;H3-
M#U;*/154,\LS;$L^Y`RZIV*6K=2]&,>R^6C6*4DP6?IHZ=Q@]9P//[2.!Z=O
MI);$;$QZ<06*(-$P>CD1MM+23$T:FIMW>)P4K75MUW+*`-)/XK*,!:1M!#:G
MOG:.!Z>3EV*9TM-W"Y-9,'%NQ,QXKD&$3?>GB6,Q.<+3N2UC>+H86L74;X=T
M>T1'JQ(4+#2T/[W0L0S4T)74&NF^#)3_6JX3FVT9:P[=S%O%.(SM%L3(FIAF
MRVMG%^9])#^4++2!/#\F"D\BKUL6O(_R(W&KI],2K`?A4O9;&*$1JOMY,\23
M'3]DAKA2*7+6AC\4WC3'5I-YJ&K3@[V(V3"=+<9K9**$,-#JFWMQKB:F?F",
MJ^.2'][=ICJE04_C1.W5GEB5/!<^9IU5XAE*;0,X1EE<:,KVDY%C6BV95D,B
MK"/.P(0:+@FZ*)YD?9RHN=6Y<S&)/#G4.(RFE[@MW/3,/O=2KN_-*P%+%X6[
M2E?A,[':AGK<W0YQ+^+QY=JR6C9,Y9S-U7A+X9&</*$W.3.)R=X!-N9=YK[;
M)`#C'`1^(!:>_UQ&ZT@+GC72ZV.,,:%9DFM*M==HSFHLP7&[6PENY-_]S8R^
ML(!8Z7!0;-Z@A#:6Q65)'*JS*JAMU'DYAB._V!#2L1+E\M[(UE#U2(1_QDEH
MG5]^;+0%`^5M^@S1T$\-(].WXN&S#M)IR;FSR8CR-R_@X',.97\+::$UND!>
M_B`*1,G';A4,LW[L&#:9_F\6\Q>UN\*ZL8SOX6B`@T].0H$2DQ=XAH!H@[9T
M9B"$%;*8(%P@LN&H+>W<QLU__-6JT#<MICVKED!$(MHVF0RV@UK.6TS6?C$Z
M$18^VB4+:^$&?B:T".CIEK_]6^?)<NF=8[P'S,`C\<9^O7(=BSXQ^__6GM>X
MHD#.`D77S+UCG4GQ?5*'$(%:P81UZ\7#[#TUVR$Z%3S@JA,SZ$JF?K.]29V(
MBNT<R],^`Q[;U``&K>>;35R=*K7%#1$XOX5"V2DH@9DW`&^2"2C(0G_:6,.V
MCI$_XR5W+_`6D?`"6&5)4V@\3^\W[:0I5S!;>/K3`U:3#>$P4G^_:C1[\OH[
M+*02/'`%BZP?&BR7*XD6AM]K63^W-#9`S_RP)MIM0%_YD49M;5;T$-./-:,H
M+&XH,.M:O40?JK*),$N&&>:],AI=15B/!MP75R.1R(4KZ==S>7*;+]OZ-$@3
MP@VKC!B\V6%\+PW))%(BE"QALT9$G_1`1U/_0KUD?R#=L70W3K-0&Z*Q,CW'
M-4\;KD6ZT>U#"##JM:1@$.P#/-_L()W!WJDOY[_=B!HT#$($A5[=L+\>6O(&
M"`%)204!/#PV%C81$3R*21&&`9.4B#R3AP4128F7DP6@AH@6/(.(-J&7+Y^&
M-H*3D)&*G@&:A9<V-CP%20&Y`9&7MYBTEY"<KI*#P0%7-E>$`8JINP75CKN2
MMJ>4@[V7W(._S-^ONL20UKJ'M=&'W)'CUMF5Y]:U$06YM+:5BN:NHE6B=$[;
M)D28!`T2E<A5/%>\8/7"I.O6I4W[*.$CU&^AI'SL&($"U4M7IWRB-+8S1C*B
M+U?">''D6"A9.X$)_T="DM0-)3M+"=G)#&5AP@0QM4318A5PI%.='@5IXEAI
MZ2]"0F723%7KECV!GMAA379HH<.7H"Q%M/!/ID9<V=@E9%8SH*]=21S-$K2)
MYUV+27<%XR'+`K"_A2OZE%MQWL!A\2R8125+3+*I584IU9A/U\/#Y_)9L*RP
M4,IW55,.`U,@B^&Z$1O"ZEO,V-VY>15B*QF0DV5A"^4*CRDQDSY2@Z[PE;8W
M'4_4\\("F\?+4=)<MFR0)OGMI_*\X.;ZJDZJ,T1K;($/;!5X:5J\TJIA!_E;
M\+#-@$5I,J3)$66$])%2&C&H=:=16G9-\Y)4I_0VT3M"I=1-.;T\DE=%>?^E
MIY!(W&VCGC'Y/)7:,,!I)A$AP174U4@AFC8A3@<.$E&!L2Q(8&I=B2,&4I'`
M(M%;*SXEY%`M,<32*4NMZ`TH/CTGU"8&I@,4;\#T&)Z$C/W#R&9=_557E1:%
M5=LAZ1WCERFYF$4<,6RBYDMZ6T)G&D*@_$+2>N$)QY9"J\BYH'DKJI20DXDH
M)&@T=KX))I=N^F.82'[%=M:>5$DH:"L:AL+3EHD*!99*8D[223]^7H4>7HN]
MM=0H&VTFXU7(!-FHF^#DXE!T+%T(38:E5"J77^\T--)/L*ASC9:##=>F;"AM
M!M)YELC8'3B_$F29F1!*B2%:(_EE:5C_Q!*BC`?_7902AT[]*-V$)BZI44;&
M;`42/VZQ"=5I01)S%D*9&>K),$QN0M='0S)"TU:GQ7LA14T)Z8Z8GCX,8H8V
MF"+@)XT@I\^D,,DU[:*/&)M46B%?]5*MO?[*RT-JWM)?>1&,>C*$[WD":9HE
M58-/`&+TVHDX`A9853_SV=AMR/[5>8[0T.VTYY<8)YWQ-4O_JU2\"U;XVLY[
MRO+?Q=4^^5D!<F2TW#C2[-K)H)D1_:BBA>R']C3HV43<.W<^W<J_@'J-8+4W
M\G5ARKI$TUEY&]?Y3WCWS<8)*7^'4DC72;`E*4&K3BPS0M$`39@T%=<%85=N
M#@OYX'%CA7C7MZ6$XDPR_V4R+YA."62*&(;QY!'`.!T"+W#I\C,3VS2QF6-^
M&'+2Y:Q5^B*5)LW:=E'!FPR)I3?@U>/05M3L+:$WW\,(U-Y_$])IN#6Y1]N-
M.5,4E]T9?8RQBY<6;BR:5#=V]2?=YW1*=8T97T-T5I!_Y4<X&.*&.E#QN,(M
MS&/K&YWW+L3`\2&I/:4S1:A<M:`O44QG$/*$C"Q!JT3]`@RBZ(4SSC&62DPE
M>]^RBPE1L4`"_J17@*%5A&;(,.*L@W]<<9UJ-M85.UWP8V7Q2#':EK4F-H0C
MC2H-8Z17#!G:Q%:Z68=8[A,VB*"N@R?S5Y!X`1G7C4LGIAF$!3`P`1:2T4<L
M2?_-^)0!1<;):$0Z`9*TC)="Y6F*6DW13U_:HY(A/65)[AC(3G8(DT^@"$>2
M$`MM"O+(Z14*([/0S%4@]+/(7&9V5`*)(DQ&I],X\'%/JLETY&$KD[D2%_,Y
MSGFX8C[#B&,?%5$-4/Z'24FZ[)8^:V4IP/B,5E0,:/:@!B9WA:2"F(TQ#/2-
M36B#EY-DS"1A*=S,M$3!F*2/9()YR3Z\$H!57,$3X_B@(]GU"*]A$77J$!4-
MZZ88BY`'/IUHS#ZFI4!U7&P_8OD3<Q3X%_:PBF0%B5TI'K(?MM@*@,<D(:P:
M)(QY-90RXG1E,G[!'HN10F'\*<QT'+I#=&XT(/%@2;?_IH>()9$1C67AP00P
MP$;*Q.D5<4R2[%)(31%"*H/-BE'_^!*=67[CH?=YJ8$TPKT.361X.07&PA`5
M*H%IPT4>N>.;%,8YD3E&6+SI!WN4<XL=;<@ZMR2+J+14`,OY1(OFP-U%!D.-
M;,!$2Z";RNARZ8B>#<LA8)"@)"Z)EAZ]"Q63&,TQ(3,M$L%I8Z5P$;5N,1J\
MI&]+SH!8F8CX"GQAPJS@V^DSR02YXQ`F+^>D2"BT<\R<A6@=+DH$W7XVD:MY
MQ3):Z88X<:H7GR'.6SR1;97`DQU[@"MTV.@IQ+1C`:?<C4X_F<;4-!7)8+JU
M20>QGS'G<X5K,>,GL<%=\P(:_[91?,TN;*,(I8(ZEMI@T6M1`9SK-(C3YQG2
M)9R8*0:0\CI#!">(6%NGMU0:'+G$+5D5':3*=H)%%M7->`?S+(H<1I60T&48
M]`T.J!8*,(#EH\*^"]2',"&@P2B$*N^1*O^T`Y\3Q2)62VUJ2)]:$C%J$$$R
MO!2I2/<+8:6T20MD1/5N"*KI`.4*NRK'C`01+<FB!FL@X@9K4905,*VI0P=N
M1"D>\(#8MD49`&OBK.8J9(R<0S81T<0#HO'@=.G18$(^3;B@9"8FV\G).;%G
M2HU9@#47(A8KM=_HTLR5;EV'@:JAA.A2A9]X[$PC75OS))K$'@7[#F^.N1P/
MQ%N=A?_"T&0)$PN%CNJ[TEY5&TTFD'LPX8Z*`"A[W;'%D"I5"^V`=L+&D5XA
M']:.VX@POEA38L3D%RA,M6-&9_XD=R1X2"P/2CI+;J&)`4PM)9;FC:Z:W>SN
M.161D+5%SIO#`R+@C!]<XR78DU$:O=$7LEHC+3<IB7+:T1?P"5JZ]O[<:^0B
M2BT2JUS0<\05-K8(?4A5.(%2Q'=<RA4P!)84K(D%0EASB#X)KD'[(&%_\)&/
M[Y0YR[V&7K=27"`,>VTZD9O()I2C!BZ#[A<12H(:.+[GCWMFW;50@TAL1:Q!
MJ$'GXLIK(0Y"MTP8)*6[Z2Y2]B!-3J'WEF](DYY[)#DUI-C_T0RV2W;"&9>Y
M)H&LC'G#&SS4T$=]^$_6"4`6`@`&3EGF=^J25*^RWME!(8KG^Z-?3=KI]*2H
MQ%<;[$U6[ELN8RJLT/[-C\-V.(L.5?=Y_#SV@PQ85\XE4G0XQ""!*4P_<]BR
M?=D#Y4K7&DV>.-Y5&IX='P$]@0$P8``-$,.6!M'E&@P`!S@8@`U28%KLO:$!
MKA>![*$T;AM@P/4,$,$N+"LJ#(A`!`V@:1LCT&7]'6KE9U$.YU1RDN,8RH'-
M$(0-<```!AQ&PQ]YD*W>@('HO^&GTWE,I6HKJN>Q0S9OPF@S:M"`_C=`!!@0
M`5KP>_\7?>U7<&I@?"+P>@V``'A!_S&+Y"^HT7<+<043(`(XP``8<`5NAV@V
M,%,#$((88`/C1F\1(`8-V!5T=@7'QP`:"!K290/^YW]BT&?QD%J+%"\D1%3J
MU5P14`,04`*[%P`#``$-T'*4L'"]4`!B4`(X('N.P0@RV'\#`(!B,'`;@0BQ
M84>#T7;X`3[LAP"+\`!$J`$EP`-D>&)542.WXB8.AT*B(EZ8Q%N\E4I]9"E<
M(1LE84M"%$*8$4<)H6[(=AB4,WB$]U4.,A2HIBK'YDCRLUYSHC*#-$1_9&!@
M,6CV<A<1DW=-U1*=9U+U91I-88A@42:C1@B+\6NZTX>61!@V(`)U4`894`<`
MD`%B``GC]O\&#``````!95`";Y`"Y#`(&%`"LI@!LE@#!;`'^5`#&0``91"+
M#$""<28(8D!^`!"+O%@""/!S:@82T,-NR\!ENR-DR[!RT%!O>W`''#%NL7`'
M`0!\&%``.L>,YE@CX#!P/S``O%@'&+`'>Q!24$)]D2".!O-B7#9(J6=1DT:$
MT-B/1[@'#<"+95`&O`@`;Z`%:N",T%B1T(@`6L!H1Z*#V50:KVB1LP@`W#AN
M'B8&SYB-'U!^PQ<)[%<"Y1<`PO@*-6"3L@@``]!G%@$)+@F-VE@'`_!^U+=F
M@!8PZ28NR[`0C(`!,?D#%Z`&&?`!(O!SC#!NYA@`#R`&'U`&((G_/9N``;08
MC6=YE&[19UP&%=_X8O,F"`^0`N[X@V5@?BF@D350`0T`E`2YE5VF'`/Y`.QX
M$%529AH&-1$"B&RB07C34T($+T`2&&Q":<7B8,I@(R$AB,V6/J?`<*9P'8TR
M:['Q4:X3)BH5)HXS>91W(URD&>C$+AW5B2^U8?LTF]IPFC>Q6D$C:M6CFC<!
M9J)6%F]4"!/Y`7#P`V]PE0/P`WDY?A_`C3\PG=[("#P`#39PE0PPG0/P`1EP
M!1J)`%=9`C4PG6^@!B%Y=A&PG-%9`[97!M[9C7N@#G`)$=@1D-?RE%?P!COR
M!@$`D,B0!'>@G.=)EZRE!@"Y!]BA!0R:_X!B]P8<V&6Q^0`_<)4?\`$#@*!,
MXCPAL@<)B%%3L9\[@@H`V0S/<#.4\0NYV`!UX)WE>0%[T)UE``?NZ9YJ<`'B
M&98-('8#4`8UH`4%0%8=I$H_-26F40-EH`')B0`0@*$M%R>[\(H,4`,(``<:
MH`$#L`<IL`<UT**\F*&\9XTM"HQJ,)T)"1*U@``MF@'NR8\8^@`:^0.VYA#C
MY@P<6)!,EPMB5S$>NI'0^`9560(?T`![H`5TZ0O\R8%WD`)O$)8@>8])@`$`
M@*%O@``,$),UH'/7(797D)`!R9]BX)^S9Q91]Y]JT)T9<)X(6J8_H*5:,)^V
MYI4E:`/^V65BI_\5Q=>?5Z!S!&=GK+")3:.)4,:*GI=C,T%!71*(\P<E6P5.
M;CEKI`8KH``&&L8;'B-CR/8(6*);RT,CPN9-D0@BU;5DE7=#G-EL?T=1AH`<
M-69B\M(M',5B;"8Q*K5%=$(A?R:%W0D`&W`!%]``'U`'5"F1T+@!>^"O_MIE
M4@@-2/H!"."O;V"1-5"5`)NJ`(FP='D/P,"><'"P>T`'3<H`"(H!N8>3#U`#
MN3>=#8`#_8<#=3"E20"0NEB1LB@"-O"J*#L`QU<'&;"!.PD!3UBH>W!\&)`"
M,(H``X",97"4T;-0"-"/M?@&]E@`#:"!_'>$^SBEMH<!93H`9YD!4^K_H0U0
M`D?(>RLK`EX)(`#Y`Y>:H?ZZ!R+@G52)L#!ZJ3YZL%4Y=O.Y4'_2(^)"5YW1
M"Z@ZMW#@G06@!5WV)C+W`PA:E5>)`Q[[!JY'BP/P`!>P']U9`G.+L%S9"`,G
M!I1[L&H@J"*+HRGYBPW0JFI`L@-0`\<GM>*IC1FPHPA:`]!(E:,[J`?[E0P0
MBT:9D0/HJ!>@!>PX"%S*BQ-[`1&+G%H:`+8'`=!XE(5*M<\8C3`+D%=@>[XK
M`BQHD2HYI6JP`7```C>J!3\@`LCXLIF:`C^PLOW'`!`PNZW*="1KD4O[!M57
M'L@`'[F")GXW.@7V:W5#'ACE1;&C/U?RK-S!_V*]-$;0*E'5<$C^Q2O$>5^.
M05`7!$2=ER^#5CVJ!CVW04N&IJY"4BQ+\BNMQ!L<E0FU)2V(A&JR%5D[\RN?
MTD*C-QN@<`4#H`%ET*_*RXN`>JH!VW]\F9$Y^0EJ`+`?`*@74*&#ZKBU2(6I
MZZ\F]@#9R;S^J@:%6P94V0`:@)$7$`$X\`$X\'-VFP'(&)TV`*/..``@X+4^
M6;N3RK-?BP//2,8WN@>76@(':P-->I?&*`([]@!)W)[/2*AU:K?PF0'3>96T
M2,8I8`,,.+;9*+4`*[!-3(N"O'->F0)J,,99^K8`6P8@8)ZXJYTWBK$9"V_+
ML`</8(^NG)"R5A9$*/^W_EH#/.R<9/@D<YG%)8"EEIN7%-J=<'"C7,:>Y`E\
MJ6NH+.D*>Z"F`-``;RNH)7"C.TF%%IF5$AF3WON/7=H`(``'M(@#!7`!N,S%
M@8JA!ZNF==``.PD`D/O#/3R\ZFB[`/"P.#JITJR\%4FCNZBY37Q[T;>+=SNT
M\&F4/"L&#2N+1UG(U7RY_&B4-ED'->"A^UH')="B8@FC&%"1;CP`9%N"Q')J
M<X>OSS%>)3<0@.,8=S2LAZ<5V'-#",=P$KS"#JPI4(,/M?.;D400U_$/)\*)
M],IQ!B)"J[4\D">*>">($_%2C1-&QK1;[_$"30D^D_9!J;1@U!$E;F8B]#C_
MD='\<V#]L)\<EB5@DP&;D0^`5EK0L,VYD;0HS6I`BSQ[QSAP!3!J#5G09U<<
MRC!ZG("ZO!/[`TDJS3$:G6_0OC'YL%J0!/.[C[5(E?9\A,CLGR(`Q'7[`0SP
MU]ZIJE0:`7-0"*SQ`%=@DQ5=N&4LC%=PJ4;ISGOP`V,*!PV8`G/`N`#9L(,M
ML?(L!B%9?:C`>Z",MP1+D5_:Q$TJ`EK@KRE`EP\@;D24O315H]+-?^>9:04@
MJ0!`OD*,SKN\'[5@N<<+`0A`VW.PW$+LMKG8HAC]R#CP`X@;##'[!BU:`3]G
MNX-JM#^WMKM8QN8<DPS0?T$\OT*,R72@`9B<NX;=_[;K;)&!_:?#^U0;:9%'
M^<XE@-=:$+=N"]L?,+&OC:#/W**$^@.D:P,)6`/_";#`"*=[4+@/;<\5_0-C
M7,:'70<(\`,-*]>":K&O[9PB\3_&,B>7%Z[=*FJ)AE<XHPVY$<#E5-78$WX5
MLCVFXM1W8B,F/*_&L#8:+!54!L`BXQ_')N3<`1[7"N8T@3/_XE+;=1DX36]1
MX15`D7&Y4'0NEF[767=%1G_%HEN&.,)B\0!O(*C96`)7"<:YNYT?VZ(9"J3X
MP'3'68LO.;%J8)&&KJ9.JNAR$`&1?)4=>P%;"M@PVITB:[L`K<?(Z:\_`(T3
M^ZJ_YX)K2I4($+"X>ZEP`/^Q##Z\E[K9<[WA"!O++#)NDDK@V0B2GMR=;FOJ
M+<K$"&OC(3C&#CN\P3V1#RW2E]!E;9O*VWR7_O>PA/W$P^NA978;'?W%%WF1
M&A"3&1H)<6/%8ZP!%)#1`7NC`N,3!;"E#0L"_CH'H4W(Q&[,>R#?R%G?O(@!
M#)JOZ^FE[NZD62RYK@>?+0[K=*L&"`!\7NOP3XO.N6OO&IX!`P`'Y*?K/Q"6
M06P:]-BP#QF=<ROBWKGLDSKK36Q[(`V?]FZ[98#LR=W?)3`';\OB-XKBJ6R[
MF`RPH6R53WS8*@G.5$F7SU)%D54Z3B8W<*5@@5%`MJ+D]/5K3`YKR`HU1.(2
MWM/_#1(,BHI6.RT-%&^$1;HY/GLTFOUC0#G#.\6S7?3BU!4V*$'32JVD2$S>
M1YLY14W#6&J!$FYV%S[WVF_LSJR-NX(Z`&\[N!?0EL"@D6\`!S3*CX3>HB*P
M^"8?D-!CQ9J.MUH<EG/K\S6PB_M,ZBQ_ZAL=X4M;M2IYHZ^.R:2^S\L[M[=>
ME1:)SPFK<_G`"#H<D[EGDSYIN4+<`$9K[$M,MW_^BY)_^_XJJ6QJC,DKH4D1
M"6-<NI]NRS!ZL#\0L@?[JEK9+*#P>ULPW=-]GBU"?0GXQN.;X^B)N.-V$10*
MB]'L^:"@D?N^I5I@`R#NRU@)"'M:!4D1A6]U'V4E#`,U_VH7%WL-964,#24`
M.)`U'W4_D1=J()67#`"?%QL`9:![)1\-%S]E'R4###@#`Z`_K`BB`3P\$7LU
M```5((DED+,9MKB-`\`_`Z@-E!\U%\>MH:$@MLY[<!\9D`T?#,['J>H,>Z+0
M#?+6M<@E;Q<I$0$%!0+8L/$O@,$`27@0)"1L&(\`$0HHM&#C80%_PR`F+#B0
M1T"%"`4B3"+LRL,D*%.B?)$R(\J,PBH>?!B14,"&`P_^2P(0($J!PV3V[/F/
M4,*'&2\:BFF!Q\N'!A5:Y#D3*DJ`#6%2_2@3*M&J4(4=Y&D3:\.8`[M:H#B0
MXLR1*E.*??HOHEB%%:=^+*C5Y__0KR0#/-"RI_`/6`,@J1DP3A3C9K,0(+"A
M1IZD/8L!H!.%6#&#=6H&7;SX!AH<><8@?$@<24VF#*A`B?H,)](/11N>Q8K4
M:7.G5&H^R[J`H%;N"Y\9<(YE6<T/-0]J%BC-JH[U6I`7?S@=ZD>B?9$F-?Z1
M00.P9YH!0-;R0"+`RC9PK':F1ET&V:'V?"Z#`/6/&C;X`U`$-3V0PH$()OA`
M>W]%<*!AB,FCQ7\U$//`#Y1D4(-E>T17C':L"4+>:O:8%AJ!_ZB!R'R5@7,8
M<\:HQ\DYD!BF6@.<Q*8**Z[`(HL:)DHBBCVL[#-(10LB@`P=QGP``!R*P0)E
M>"V"P./_<MP4!P`WX14F#COAV3?C9A=8>=\%\,@#Y&ZB./=&`XDP<&!`HTEU
MT5$WA>3026()Y!9/+@6FD50H5O333WO&I>A1(_%PQ4@"V7`14&3=Y%!%>Y7%
MTTL5Y?37IWLZ9=1'>!'$Z9X[Y=D755D95"E.0GW5*J0.&?175$A!)5-':;FU
M%UQQ44K20@$5(A%;F%)%4Q(R$5CLIX38Y=$5-=3P`QVP0("?DK'\8*4&7#;`
MB@V%O5'#!G0,H`%_X1T#0`/>EK&E%J(-6)HGV<"R#BA:1"(N`-NEP$]PJ]FF
MR#[>;?>#-1]H2YPBH`1'1&W$`0Q*"I^5P)N3<&R`P``X,FB0_SIUO%'8*!^`
M*PEC8`K\1BWGI;`'8]JJ<<PVD6@AKI/#+1C!,*0-4`L$\!*FCL,7+!@)`M``
M`#(FX'JH5'0&1I*"%@+SLR"#HP5PQ1L(;%`#+&>N_`$.!:3PQBF>.-+``&_0
M:P,&#4!3!P9O*&9.'>?"L2XP*;0G:01B)#*<U>QIB>,/&<]8AV+.U0+'PHP]
M3MRZ$?OHKR)T//=Q+RD#LT<!%:FA!K?<E/,!FYV48>WI`^1FWW,UU`+";/B:
M"W<W#;^NACF0)<P+`JH-((\Z):A)CV,X[K%!\8';51=0#`%-$DP(162#!0A)
M=3V?`^WE3[(-=5T2L(L>U9)3*IT5P/]:!>%:Z_4(#740K^Q#2VJMV=,_DZGO
MR\E.6%6KG@2F@"3!"E+$L)!7224IFYK5510(%9I$JB.E>HM/T@<3B]C%)CR@
M"$ATLA,(4J52H++(%4Z!#`U`X#S]R@PKD,$:-/$H<%9J(01JT"]Z60,`ZV(%
MCI)&J@C$!QE(+`,O^!&!!UQ@10`X3@H*<(KAO$$#``!&?32@B`S400-G0@#$
M<-<`@6D)%`](3FNN,4,`8`!%_XC/.BPSBUH,8`XSFP\_U`:S/6JA=LB```20
MP:59)"(5T0%(^*[`1B`^20TI.-K%!(09!&3"28%\0^`DXI&:--%G:B!01$8I
M'=*=H@P:T(#_/OHUBT'RL!NHE%<2>6B,#,@2&138QQ[>()\VUH.)MHK`&P;Y
M2_8$[D+7J$0=:H&#.3S,80LJ@+I0X45/0$))#G,-F^Z!Q4$"H!>_2($:B%(`
M0-[.,8K@QN^`6`9O5@,6+K0EF]Z0B1E"`&%-RP`"M@@FFT$@B*J\F+A8XQH-
M_(B-$)`7#GX0/8DL)%+LZU.K;.(GF<A/3R?Q'K,:*%&DH&]1PF#)"X;!DF`A
MZZ&SLL@P-D71F#S$4*]*%4A6:A1<S24A7>G(!+-B$9^`I7XAR4M'_@*HO(S$
M@/RKGT_O$A:W!&4A23%*^H;54T,<$"U1:5:D"A$8O[!J4R,$2`UV_T&-RA2&
M7IAY4R/Z(XD4_&`+.+K:&W;1`&L)C%Y.5!%=]\F>Z(10,.7$0+5J@(`?6(8]
M!=#"FB"3@CF4LP'@J0^\6C-6>%'(F1AZA"@0`%F!V6RR*>`L>#;[M@%@`)(_
M(P:&&F"#G(FB!@U`P-4X"XHY0.<'=*LM'D\'!T><KFBMB9,\VE/`QU8+!)U]
M8ETAT9[WI<VM8P69M08CH#[U1)0W@99"(M*`1L36&9%X`P`<E@(>9$.PU1*L
M*VQPWL%.]P%[^,_;OGL!Q!:$='2+6T,+,!@,@6QAU1(8AD[[@#D$SK^0I1`D
M%"P)T8;BL[O`FV>SP=!0:@^_D[5-`S"P3_]);*"[(.OP+-Y6V#>!)[X($,$`
M1(``)SZQMW!S:UV;\Z9=:+:^)O8L9V4[B[%>0K-72ZU+8P*ICIR%@C80`_?&
M]]"IZ(H@4;%516\ZU>N5%"0@30NF+GH0@-`T56CQ:$1V6CVIU`4CJ$+)^-R2
MEIWP=(`'A(E4Q;(]I)3E*YXBBZ"&'$%%OB4A%!D604!BERK'Q2?2"I5!X$<7
M^Q7E)X8Z5E/^@=8]9(T]302(@>@5"L4ZL;$&QC0='V#A"&"MOJS$:T22TD1P
MY*>)SC+G'N80D:KQ@U[]0E!]L^9J7A=88(UU<>#F8.N<H177P*R+I;6V:4AV
MVC(ID,-S3JT%QS;_$=G/QIHW$(!K(RXY(*&Q6H)"T=@"R$$B$.%T8<#!(.TU
M9=6=))VG:E*^BPR&W)L6UR\/!%]76\VQS@9']`;#:7H%F2B2,E#@L(81>Y-Z
MW0)7D"@'LVQR9RUP%S]0SCI$QUOCFFL9:>*E;8WQ_%S<P+P&!WM.?;5<)TC7
MD5#X,5EYS'LC;C`M-WFG^R&,23'P(MNS`:#6`F5$70I\4.X@0?Q!D8O\U<MB
M$,.CTE?2A$R=63RH>EQT):JC_X-/)QD53BKH9JX2(LT;?/.FKA=T128=542!
MNZOV-Y!A%>568KF)7.2W4KF<A%'[&R&FZ&1HE<1]?A<\NEG(4K^KEDHF_X6X
M]H'PBNY/+@C8@3/='(@]2IP?DTX$VIKG!P$T3@KFXF@-I5)L<(HSF=OA/I.\
M;</=5ZRU7/3$WCRMFTAL36,-TZ1.M2C'=_JK)1(ZH$;KYLT]#(6W1P[IGOS*
M-\EZ`(!I=)ST2C%L;SJ9)S*88B%XAVSOUU!5\*EU+DI6+M)705BZ)P-8*+.+
M\?+-.ZL`SA2WAP@.WQ[J_8,.1V]A\4FLQ&R7QW/_,!@+0G/!IGO$)GH+8CK(
M9X"7%QTBX2PBUU<'"&J>-VSC%&Y^I(&UQP^V96#XAB`>\DDH&'H?%P'0\7M4
M<U<+^'U\IVC#P&AL!WD0=2IU@6Y[8E$5%'0?%?\L)S%2?[<H4'5^+H%NF>)3
M3Q5E*$06:68K!Q1I%`5EGN)02&$JAU=<'#$10A<0D`<M0'5W>9)5V2,250%4
M9*<^-I$^4I42EF)FHY%^0M@^C\93YC=`2F%Y/U,1]P=[J\9?S46(HV069FAY
M@B,I8@@1+/B!2P%E=-,?6E!*#4)KH!<=XS1Q'Q1-"6B)`V*)!`>`U+-_`B$'
MSN(1B,4#<@!]!I%IK,@#8+`UG9=(-@!;FG0!J>5E%-%$/"&!FR@=9A@I2C$@
M5/,SOA)"4-44>!$6>V)OGF2!`?$&N1B--;%\GQ(!]G==V&6(<M!3-@&(Q.41
MQT*.G#@4G^10CC@UM/C_C?Q%)Y[(C>EX78D40L3@#_^P>Q\$:PE8B==EC,,7
MD`."6*%H(-;XBHDT&MPX(%/3B?ZHD.[F$>_#/<>2%_S#/Y-29YRR=%+8=`&@
M9-TC0L-P=1S$/D>A=<$"0,TX%OZC%SEH*'G'D-^SA&Z69B0QDUM8"!,9*,H"
M=V4V95AA5"B$%7Y!5%'6)S`)$@:D)TQY%877/HI64QD!AH_V$Q3TA$?&$'<G
M2F_V%0A7%*7G93TU47TXAUX1D]EU+`'P@(518/"6B!$!?6EI%@JD?D`C+>OX
M*Z$H*R'19=E7ESHY5&?(B@$`!L;BE00"'1+B4.>F45[C09D23*12;Z2(%U_G
M_RDKR15&98;96``O.`@]%P&M>&X4U!.C22=W8BM>N8/$Z&5))T+%.)?.,BOF
MTS7Q!IE#-9MT.9LV!99W%YH?<7CFHYK%J)HH!)R2J92F5YNH&8C$.9EBF%/+
MZ!9!961SIX=<IH4&D7Y4^1(DJ1*!XBAP@9(XY9H3,`'$\A1[(1="I9)WAR@6
MZ9<\]1.)-A>_LCT4Z80V&90W*"ED@4%SYV@,\2F.9YT.,1I0.3]/J1(OX#Y0
M@68_X51<Z)3N@Q;-PG9>P9]@,)$0(6\`NI)*IWY".!0AQZ$HD19)$2DZL35E
MF61>H2RD&3Y%951NEU5;&&]U1A.(Z'8!@E,H&IT4)/\,37$G5^!4!<`2!Z$]
M2T=JU-43S<@5+K5Z#`2.G"2&[_:'/ZJB?!=HP\(6.BH6*,)`NBF,9O:-E\*(
M$C&E9W93;8>,7HJ&4+I5$9H7)-HH@<9D4761!P$_!"('1B:5=NJ?%[1E=D)D
M?M*AEKFF?2<05Q"46L:?O9D3!**,>2<M&3DX`=1F0Z83$P$I1&<5ID<2;C$^
M4YIT0`@5?`IH5Z`H)/44Y,F@&;4]YVDJB,(7\=.,7T:E8HAX/;F$O5I5S,)F
M0H&A6F%T=X@5(@FJ2_4KQYD5?X)E8[8^Y[.@#'H6@`=X6J@KCS:9#<$3D(<1
M;09"I:>E606;)MJ;,(&?'J'_+)!R!8\B/S:0!1RQ=,TI/6W!0%=1;Q#%4X(I
MJ8&W*^HZ/6>9J!<TI"JZ%.9'$D7Z<P@K9<7%G^:6?I.9HDDF!NOJK4AW?B@J
MJA8+*+F"/1;`0';94RO)J>189U<9%8+V)X*"I)IJ$F!XHH/WC'VB$"+;BIRT
M$H[RKEEA4>%*0F860B!I=(9I=<Z80:0SI+^J*T07/S?UF#:5%KS(B&_FLR!)
M*V[F*4`QHI0:>!T4LA3)=O63J%)QA\I8JZA2$B8!%ZTZ4M^I*`WZ9!8P`6)P
M5$16I6\&M$HUL4IE=,)P0C@596^8M*=JHXO*E)2:0!#U0,]YA;1J0(J4K&%G
M0#BY_RAQF#[E0S^-IJ5OAU%C>X0_`2L#1#W+>;:]F@4'*K/5>8,_1S^$X*XH
M<05UY[&H\J4].!"/DF06@*0I:A%M1W?Q:0@YX:TBFV1-)I$2U11H.Y7+$E5U
M]@*Z*P<*^[F\&&_,-PQF2HXENA8O=;69JY0AE)^&NK-8RX.ZRQ?:BRD\\`:#
MPQ6U4GKB:0A%2A#&&Q)7H`(N*Y'<^Q/N^D`4"Y8Y@9_GYJ="-[V"YIO^ZV17
MM[@X&%(&'*QLF,`C6P!@H(P309'"$ABBJH.&.[`JQ2M#:X2-XA1^0H[9RC_?
M$U0BQ+U!69TV2D#8.9E=&I(%[,!)X*Y#6*U1P18=>X9-*?\2UK.&?J%H"<J3
M/FI"_C.\829G$104?X)D-6B&.%5`QCED;3=!7CM5!+JK$&2?$*2<->L42HFM
MHQ*58DLJ#'&'",L]VXF%64MT%OG%,#6B54C"0(APR-*54'A!9H@73^%1V1-T
M`D2'C#)T]/IU2\8H:"G(`/MW8$JX>4FZ'71WNFMDE@EIB)JJ[LLI4+B1(C1V
M7SBU/>A00O>'N=(2<*R$0>5F^RL7R=@5;,L6DS:%,UMG]Z>,9W>C[/FF*EIF
M&VG"/GJ9-H6L7AJ5W;K!/77`N]JM9]<K@T;(6%;"QM+&:VB?`J%D@UQT*CK#
MT7+`=A<8):6=/>L43-9X0\EX3#O_K#>9=RNEQQ;QMTM;%`C[L%P<=GYK4QP+
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M+#R%DMM<_\)*RIGZ`Q29^1=8IH0Z.D)CF;:-IW9@%9_V@W;I2G183&=-]Q5(
MNV<=Q'5$-L^(_,S7N;.@JRAI2<V8N723/;R#RQ2M:UVE75R%K(XR[#XPJ79F
M:68IA;ZA*\2B?=/_0W;X3"FDJ]QA)D`"'79YVKEHC60E&[1]YST.^LYR/<)>
M%V87*&^(>GY\0:-U;*!`V"@/-<CO3,0V:IU"*"P:Y1(E2L3`>[2"6]QGT;M!
MP=8]F\WN7=W4/9,-5,]*;-]!!3X$;99V>Z:GNH6VRI2]J78=S#XE2ROWW8;?
M8Q(H&:?;;=ED6+86=2OM?'0TL6K,F.'O["K1[;YZP7>_:9F7[/_@C.83EZ*R
MZ'S@0(A!IHJN%VF36BQED=+36%6K[MLU`]*E/VB]93;06*:.)[HL694L#\11
MS*V9V]ET2KV4.H76\6W'GOTGUEH].J733%VV>PU`?&K<"B2844EW[/.GX?O6
M).3;+G6$S#NC0?5S=@[3)-LI$>7A*'NP&Y4]X*J#03YF6VLJ;2:J*VTG@F)D
M*3QX@5[?=*Z\33BC(\YJ1^$0OSSFVDNE0DK.LV*70MG+)0S4>?BG&#H6E=X]
M!CII7;T^6!X4\&F=LPZ40&&WG'Y`)CY53YZX^E.4+J7$D)MW*KJ$8D[*!]YE
MI\XGH2M4O]F5J1F^38:&->VD&813"8K_HG.1?A`%U#);Y4:,N?\3=$,:='1!
M57L;[0)$UEMQY8+NY8:BU\9R/4J+V2BUK\:2N%><Y?3=9$(9G84JI`5\MN#:
MEQ49[+1ZU80>$&P>*&^]/U28MR<MLDP'0#)JI^LZSI.2MQK/V!KIAD"E@[RB
M$5P6H08KJ8_>/DI<MDJ%V7_7YYC>=8>\V!/.Q/X[/?M[KM0>G85]E]GNR(W>
M\H36S<,[Q591TJ:R9J*BD5I.48RFX_SI/5A_=DJKE`0B:.0(RH[:XA-)TV1.
M/5;E4L_==PL]9=(LAP2J)_C#57JVGA8\EF9A074FU%<Y%9#VL%X_Y#[?LU/&
M>)VBUD4'Y"@J_]>)"E4/OA>"?-OPSA1N/:AW>[!+L91*-].5@I,V7NPL;70X
M33[7+BB$'&?O6[AI/-<*JMY_S[Q[3#[,7/1WDK:%']Y,>7A+G]8\R?.2CZV"
MQH-TO9F#[[,2Z=*-C>[&FJ%Z2';+_).:J<V\[_#,#?M%]=Y:,<X46O1)/K+H
MFQ<`C3U+#*<C?606ZK29/?TSH<PI_%,U1=K+;?LCO:O-C'CI#0@%`0$\/#8V
M/(.%282)!8R#@TF%A0%)EYB9@I2%B(V#!:&BHI$V%I0!CY>DE8:'B9BBC*B&
MITF"EXV+C+>&J+>AC9ZX$9^<J0&FM3:@!9S,@H2OEJ&NILR&@X?,TO_0@@41
MC-L6-IGFYM^^%F*(RZZ.R=ZAFKZWUYW4NHZ;S+/,$<6H^1($;5*[?HK:I?)G
M*0"Y`,4L6+!4K]$M?<BD5;J8#*+#B>)`5D24Z]4^78@>$6PHD8>XE,D2?9J%
MZA'&53$OK>,1KN6FAHLVU:3Y"E,C0>O*)3&%#.;&>+XB..LD$Q+)`M<>*2,H
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MOEBH4"^_I7::36@EX]U7&%XXH%\,5A4908W5,J`QR%0"UCL/`D;CA;3YA5J.
MG*#(#&V0&%(9=*[8AX\_01*$#3P^JMB55S4)TT]G^-@$FX>!N40=-)/E=]>`
MPR'49#=`F029@:,]*513WFUCGYTE(>8/55ZJR611W5`6$VOHF3?7/G&&.4IP
MPJQ(#21.1O=H*O&1_T@AAL>H\A)L'#D'#TUZ\G.D&!.!(Q2@37GB22OC*/3A
M7H_\QZ"`^9U3:$F'L",->T5!)@LD_+SXY:H'P0?8H0L!PXA\.W9B@Y?L"3K0
M3&@M!DV3IR')5XD+I>972$IE(R2!J"C2$E@G^J6@(O`T&",FC'%[T55,RB9D
M8$"%6,TZITB"K[K=D.A1@YPX$N^(0E73E;TY.;9<?A\IU%^0U#FLVTOYUK.M
M0GVB2)%ID3E663W@5C5G?5")D^IL(\;&+8HMRH1DPQ0#N"]Y$8K[B96G^>:1
M+J!$/(ROCO%\[$!<)7*K>3K7-<U,MCD8+GWR!?.*)Y1R)-E7(+&;J7Q?(?_C
M9;FW%1F+>G;^UZ1PN$G(%'7G3J2;BE,&[:QVOQ@*C#LJ\MJN//+E2&0SW6R'
MIH]M`5/;;9&@9*&Y:.IG3TJGY9G?V$VC)E$2AU&VT4MI-M0G=DNYQ(.N&D*6
M9W8R^7L04)&85KF0`!&79SA$>L6-;,.A2?+:D\C($$Q8\\YN4Q#3)FOK82)2
M#-;:SDBR8YWK%>S%L/&NUL48`S2CDR$J,DA+WLMH,E-C`ZNEDR[#9=<_UB;?
M.NN%S&EEGP,/>%A!<_.F#[)T&X[K#N>09SV/3*`BG7E>L)IN\0])2V&+UP[Q
MD^"H9!*_`0LI)#,9L2A#@9>@%>&V8;+E&*<1.WG_F+[&!B02HF89=G(.;3)3
MF-:MAC4!N-725G$Z;FSG:2+#Q6VF4AE*):\](&%($4>QN'G`RUD+84IL@"0L
M,;4++_\0DHDR4YI23:LN?WN/^RJ4F`$E*#+!$Q_&5G<JSS4&4,3K2HZ,M24'
M`2<S(1$3Y39SQ/<<\7,%I)$5K]2Z.5T''%#94A+D$A?,I.1Y<M0(S-($03P6
M@#W'2V,DJN$-BT!)1A2,RXV",C<#Y61[+F1).;#2+[LTCI-*.:5^2'F(7C`)
M+T.RI0$C`\F!N`PBHU'=W"`1&_V)+%"#V*$YKG"%.69-BPX1`\2><2T,F2,Z
M49+,UO@T%6?U*Q=>HTSO_[`&-K+AHE']T@H[D!00=I$D3G4B!#OBU20HTE-C
M.6(-<)*@S)A88QLUJ^/B0,&JK`4-H%CS)6PD8YT+EC-*T:'FEI2$P1OUJF+)
M>5Z)OK*C?H1/.I/[T$D`BAH2<E)!.CD%(N^3-[J%R*2E$1/O;*<N_71H&:68
M!L!(AJ>V:.E%NTHHUGK#IN[=RQ>='(U""D$.#4F))1.IGC4^QR-G=8B*JC0B
ML?#ICF=@ZE4'E%_AC.C2DM:%6B+YC>58Q)%[?`A$^/HE`#VE%[<BDUU[\HTQ
M_Z1(0S705\3$H$1(-4<6D05#E/H1TIA((%H!!(,,^N;(4D,8_)3S%P]]B+A,
M0?]84X&J29$EH3^WTR\=]>L>&/I,(7!HGH^DHB53?4Q\F%A8(X(-H&4:&>>B
MT5#>[.E+*'FC+1+GJ8*Q+$:5'<>++M,SW53H0:@UY5?8$4+3U(-59C731CG4
MJH^5JI0<#5MU!31&IIH%LA9ZH56/53BN,HBP@A7@9$P"R&CE[+VKO`Q?!EFP
MH1VL+M7`#7SI251:D/>(L\I'=P5KQM8)Z,'"@BTWQ@E?UZ*,FB^TFF;_X4Z0
M^61GV'T+G:8$3E<8CV'0V2IN8HG01[7VKVWAX(%,4:./6I0^9+TG<&QCPLNY
M;%4MFD9OCZ$XC#3#I@\1E2'@BXL*G>ZTY,F@YA#Z0L?_E$6E_@(*,_>)B;)@
M``/KM)/X(-K$:,`N&"\HP`L"Q:H:"104\Q*JG:)1,`-7&2DWZFPP,3A/?VTT
MH<]@&5*B2ARDD$I:U%304/ZR#K(D^71]SE-X1?PE<O1$##<Z\:%3$8Z[W+*D
M3<DTIG]I:--PTJMLVAD%/R+3+?%+D1VQQKI>P0]'/^N8_*K*+)U<9\@$L&A]
MX\:I#U)28OM#G99Y(ZGX9]6G32,UL"G+LQJISE,`U9\;,L9&HDU=5M(GUX3!
MIH$/W):(]`,M6%DV??3&S'R1=5FEI"(8'V>;3F@VL8(`0V/%XJ29">-)UKG)
M9>O7G\(U513_/2:1GRP@]L3S_V`9]&&+)?&K`%RA9;FPP`2^#.:,Y$Y0CT#/
M9WRKS6YRZK^_"$A@5\P)3&9'0);Z6!TY2JR#Y+HD[ID%PV2#.U;YT#W)$,-Y
M41*NK<1K4JLJ$7W+,FH-P8G6K&;=7=W*&+,$I$*#ENEPM>C"I2\[36+Y<$MX
M(<,'/S@IG.O@;+Z;E#YI9^D^%#I<N**\^]%-%5JJ.=<(N[\1W4^4'$*FK`6\
MRL()II5HD;2<2\HO,V%=4G%1RIR*:Q+.EDI*3\E*NB7O&"<3J_'$?$&A0G[R
M9FKB&\:0N%<PLP]RH>\JI%CSW7:C#Q-=N2Z0\I0L4,)EI,J%%$C,[Y0`7$"E
MT_AI__\4<R(NWAI^.E_-=/:[-,3`<0M<).`8,KUK(I'FSY!K*$LA;`][JQ<2
M86/!"4RLA9F;'VF?I:ET$VU[X=79`AJTT)<!#9[^28TK>_>5IZ-U6C<KF+)"
MKC5%D7`=EI!_T8(/O*==<D-/S?!D9&$6+H4G$65$8V=W-R-SMB9K7`(+Q<!W
MK):`ZT<J[T>`^3(,4K$3X!(>]P-IF!%Q9")DR+"!RM`XK+8M>C5X_[17C)2#
M_B)W$>%%#T%"4"(/TF$EE[.#T;2`$I9B<Q8;F-:"U`5O2>$S68=UBO,::K)/
M+Z!OH2![Z45&/L4_@Z!/6`83.%%[M1(\^C(FF,1;;L@*M,+_"O8F>:J1-A&S
M,TAA./%WA,6&2:NE?9D@>J)W?ZZR*A,P`=(4'^&`0S?TAN<@'\OR)I40#M-P
M?.7'"YOB:<9"5X<"16'B&S]WBD5'7QF!:F!"0W3C&\/%(Z3C:0MR(75RBS-#
M7\SS0M!3+]"0?YSXB<.@16NR?S-5)\N64QN".<_&?CFX)E?@<OH''(D4(M@B
M,A)X?!9U-3,76Y)25!0H6(*ABO2SB-Z!C2O"?C]H1,4E4G%U=.+(,F_G+W7V
M*G>5&^,AC]CB:\WX%]#A(?DX)U)A$TYU+)@0AF)X%(FD0-"S$)@G11V!=\'"
M/*=".MO"5(7W612WA_NP%DG6;RX"_XL-(D^Y4EH()4+7H'2U0HF("`Z49(/G
MF`^&P!HX5"@ZM`ICR&D8LQ<:,8*8!D'S@'D=1(TNY':#YA$.9Y(MM`QIEQ3F
MPV$N&$TX4XHR1%T1L4ZM430NR$JB58PVQV)]MDW5!1Y7]FR>0AO^IQ4E`D[$
M\WME:7;%MF2N=FA/1Q_2%D++UHL+LF11%4T($P^/@';B*(5QR5SAQR"<!IB'
M"0Y,1QY3UCP5=GM88HJ<\Y82)V_&(YD0$5:"!4PX8XO%PE1)='MUA"3^-Y@M
MM"YM-PE"1SJ`L1@DR"OC:%95%V$OHCB_`Q^9((8_@157LT_5L1$3B20FDB0P
MEWM<>!%.Z?\6J82;7S-!IJ8/`=4.C<8L[/!J-.="WC25>I.(JA!]("-LFY1(
MAG@>!UEBHE,TV:")*0$CH`8L:P)&TA4M6F4P_VABM@"/H`%&ZZ`K(R-S-/<;
M/*AD']6:$#$N7/(A/J&?9UE2K8E]#E9SQ]<^1)%M3(<0.;$Q"HIE4=F@:6B@
MT4`QRK=DNL*$20@D0O==QY1_UF`:[A<\JBA@2<2<?&6@03=M/VA:G>5K;&9O
MN7%ED_51-\>9&=BBY]9MHP4]*<H;E,6BW?6*NV:-&B=-2?(W$HHZ1[<<_3AA
MDN,CFL)/HD<@@?$TZ1.1"=0)O<%$=$6/V?8>G)AZ&/>`>,A1CK?_)O#2@!]I
M8BE:6AB)6N?7'GUE*^CA6S_&3;M'5U\J>M.A#Z?F2+[CEAZU(7LR+QF1>X!:
M6`<"A:M49Q?E+N-0HHBAGA6&85>T=KFB9TVE,GQ!)C+D00[V&UF82>)"@<-)
M:WNB6+%J$?="8VV2?'LY7GP9:D6T8@.S=#9$+QE4?\3I47G:==HG+NC%=/GC
M,7&QAJ$I5'J401\&&Y6&:4YW-__)<K=G2*J&964'2-N&,X?V5,VUK;0)1CMR
M+G*W1@TCF&4'1(M'K%TJ+KQUGG-"4A"#5]6A$?8Q&QZWIFT"1#D%L%RY&24V
M&#E6+M8H6JL0$M;%BXVIBLUVGTG!6JZ!_QZ#FF4(]7MP5A@0HS=NJ'`XAJUQ
M5HR:P:78)T)<<6K(E@MYA5$<(IN#)TGAET1YM),&TK.."45<D1A)I(E]`3T.
MEI<QDGG7HCW-$8219+3W($(.<YHHXI^WU'ZD\ID>]+0@,3KK(IQ*15(ZTU2P
M>7D>J!_<LZJ`.H]J04_"`8^;D3,Z2V1NX1-L"21XM0E,6RSN)DC!L"G64F5S
MT9J#\25/,7;GM*R&2W@XTR4\B78J86'4P:^I5GFC9!POIAU`1TP7`UY->CS[
M]A0B-3^S]$X_)SM5FB6?I6N7P4??QWZPE12D=23%AEI:PGR>V%I]]$]:,W^"
M@(@Y9!0:^8I",O\R)P5.P>4G8L*.],5#[3DM0%97K+HV4L)TF?9[.D..LQ-;
M5E,(#WJ8REN'2I2!\T*B%O5H->A#8\0-H)&`E"!WIHA2NW90+-8EH)*%Z?9=
M?Y$71I(JMMHH_AF.>)1ZP"&B8K:_6!J9L-"JN#)(.D43H'=T:N-N7M$UOZDX
MB)"%<F4QAI6IGXAH%3RJ@_06:7=RDMHH$T`F]A(B%=4EXR(D0W6G;*=2ZL)0
ME7@:<JD7TW0\82,EJA."ZD>G.)$7`6<2259B-=%8KG*GR:@^(%BWO/*9EPHW
MI\`4AE`-6T:-Q7L>;"-WOFFU:G>(BCH=V$5CQ6:_)..)?0-?T`$L,)+_38K;
MBP,S$;G9Q-@D9K&[)97DOM$WC(97)UL50E^XPL;V6<XFA65D2P2K9'83FO5K
MJP?L<[-!%5U66CX17?9I11*W@C=5>:>(PA%TH,]8BT4Q8\XR7@2;+IFQ-E)C
M0\E7O](3K]E5C=Q%BL55JD_5O9@<P<;HOA\#5*KK>&YA>+-)H^EED#*4#T8A
M'9XW*:`K<I"3()"2%OL)2A2QB^4"=D.#*T&"'!LER]1AAZ[BQ&-GJ1!53X<F
MRE7;;%-)(/HD"8@X'1FW<1.AB]>"7+6BJ&OFA63QMO(7/G&8@*PY3V3D/[%U
MJX`15R%J@Y*:O?[X;"A&)F]%)-CQ$\7H'H8)_T%)&&I8HV@>Y8MW0HU,&4[3
MA,E%FLX%+6N8AR4?1='?U,9C=:9S)&1*98JGAAP8R+!$)R(RT1*/$[-YBBU[
M"+]"R%SALR3CR#$__1(_)RRNN=#&E801*C.YF)6!DD`8.E6;,C[#53'*N(*X
M]Z6BDG08RKQ@^LQ9C,,Z.+#CS`O!24@4V5Y9D[H&O2L7BVJX*5H/-9)6;1TE
MDX^Z<0^Z,D/+=HZ,H$^$<I#^HA4;-P)@YCYP5\/GD8CT"#V8%$#ZH2%D98(Y
MN!.-TSO`]457@4]1I"8S\8E,:ETS976#4!K5)&2;0CJG2;M]93MV?=:4P:NL
M:0&()#M1^RQ"*9.2VO^S$`&D824+A29NA06M07>#UEJI*]I3[A@,0M<08AQC
MB9F9"SQ?9A*;HQFV4?1=LS>*]<6AWNHPF0"12*4F&02!V6H9_'.^AG6B$S)J
M]\-*SJP1^#TZQB*8_!L5EY@BAE4;GIBUIUAR_4I,<0)1S&LPW`*]XN/<$XA<
M.!F_D))(YW@9M31R9(0YW@*2P%D+^DV75N5PYP=#G])!M_+%\4!]DOV("825
M!AUR:Y9FKVL*$R`W9KM'\&%FJ>T;R4@X2$RP0#,V$1MG4^W7CG,3B4>O?GTJ
M6W<FD03#/?/1"5O'G%J#5-*D@]$<4&05B'!Q(J0O&"/1N/0.QDDK?#3B!&/_
M4KR=$7`7JAE=);@EO4*6O?V572G\OS9R)U,8O_AQC?Z-RTQ-1^25;:G1:?`+
MO@]XTWW^+]=30S+IY.LX$]!-T!6BJ'A7*(1@YK102*$`!M=D(RM49$ZSEGC8
M,_*7TN1$Y@[;YGL9;$&;LJXWDNX$2`;WBW1)G>L4WU9R5KW#?#N4$SR`SV\M
ME5A&J+E`+N[$M.IJKF]6*Y9TH<+Y4YA:RAE1:R@<+/`KIY(4`(0U/D4G,P6(
MKLNX7Q1Z@#;V<K'^0V)D:.7@6B)6RPIKQ)7CET48*30:SN9;H/6>&ZK&JF+V
M5IX3)'>Y7_>>BS9H>!PB4YBF5_;3-`</(:XSRFR+_XTC32OIBS05LV<)\B>>
MG,K32&<R`\>:O,_\A:$U'5=`"EE`:_"_<,;FN4;A:._48)/^L&$OHA(H[U*$
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MW^#$TA8E-GO$+`((-F(V`3R"@S86%C8\A8P%!0&2DI&&/)6/A3R&B3:>C4F.
M`:&&DY.AHXZ@G)L!D8F*A*X!GTE)5[*=DIZ2EK.;O(ZPC+_$JH6+O;*^FIRS
MPZV0M4F?PLJ-S)O:J8:*T:^7U,2>R\3,M.27M+'$!:'$[XVZZ(WHW-7OT/>-
M!3R+2=U<^5/7#AVO5_I0\0(X+MDQ5:32*8O%#Z%`<]5HU;-$BM5%11;X'8LG
MK)[_L58OFC%*TH_=2H:@-.XR=O(1S)6:AJ4217(=-IKU5,8,\*)H45OV0EWY
M&2SHI*(\EBY\!$D2*G^>%)TRY4U0R)?<M/&[^HD0TGP91S&T,,B6)6WPJK("
M5558P5YBM_H3@VA0`4]_%WF#Y`YN2%LL"UW!)=8MHQ>(]S'VB+BR3&T4D8D!
MZ9`C4DF0>4)$BGES-)CN$O'X;,H5JL*,%HKBL3FQYU)N'3Z\AOORYGT(8WI*
M$L'>UMB9C&EU',XS.N(,9XT:6,IB`*V5_O6S::]X,+7T-J6V(`D[S(CAKI-'
MK[?;ZO#+MQ/:OOH=>4C^I(-+-*F4>O`'#51`<<GDTTAH_P8YQ`MMZRDEG`T#
M4A-2:L:HQ=A*+_C'%@\18/+,)1&<UU-B-DC%`V2U"'*)AR1UJ%I5%>)E222:
M7-<63*G`(\XHUDWR22NHV)*26B],@XLK?]VX#26.X')8(4C2^,PBJK7F(Y5L
M%2C7CVJ10F4]MG$"EC*,8(=,;/5LB0]XP+1#%C;@(=6)5YXLA4Z6:=(H)BBD
MQ;9(80<BEF%42]D9D9V0"1E*,@N&E*!@Y#5#I%%RVL"<HO:!-!]/&2YU5!)#
M0N:.509&(Z!ZJP$9'90S(2D@0S^R-!"!ZWG6U(>NFI63F[2]-YA&^%4(CEK^
MD3F?A):JEXM9Q?JX*6X('030/_^H1O(G?:RN$T!Q`LI'3BK45BF3M>_EN!XR
MZFCT26A_TN*7/?UDD064P8:C`@E7O!#!"U(5=&,B5X!Z+V0O<'%%52PMA"VH
MBRVF`K@!4X,`$W+T<V"1LA#UPKTJA*:C(2J$3'!MU.!!B!Q`BA*`'!7/:%$E
M>>4SRCRR52@K5<Y$E%%5HW;)F%)7$-6?<I&B]RU`08U:V")8[>2T3_X4J!`^
M?1[MFE#@V?73=)NUHR8C?*:T6%0G"LJ)H9790@Q?B8@A"CGIH*+*-'W&4F.B
MB&$5E5F@$HJH96(]PHE+WM!#E)"?.KCDI[NXU&HO08.*=]JD[FK*G$SI&N"$
MJ/ZRT;?_-':RC4<J<V)??<W`=>PZ:(I9S'03(IOC1JS(224OHLM::X&"$.+=
MLM5$FXZ8-\-^F%?%,!7[F3]&K0XS!^GRBJ-PCP(5._($[TO4KGB%6$8>X4?1
MX"$-N5A*WMPBM4P->TI4U.0P0=G&OD;*2E4LYX]RE,J6!;;U*C`)'M0Q&&R5
MI&?8:U-06N&3:6V*%@%["YA&%22EX.1G+!D5G7X#,[`Q4%6(L1:6G)(U9!%B
M(#*25J48>+7J4:(CS+@)+'BD$&=4;F^1B\Q<2)6V"PW#`D';'I>D(\$HP2\=
MD_-8H>H#JIS\[3-O81:>VG9"0B2.4D4ATZ0J)3IKD"*'B4I<_VO$)`NU>8)M
M"1O$3+"A.C3]XG:R^!T5;<$62^U(%7,YB$%L:!\JSDR-QX@B<C)&QHP)`XW4
M^`U)"ED]M7D#-QWQ(S(LX)AED#%GR-K$84)$/F8I$H6"!!M5Z+202M91("0S
M3HD6L\J0%8-IGPA6%KR"#3P,D#X\""#8+$""`.:R*"KP1@"%QJTS;HH_`NOE
MH`K!A&8ZLYD(V((T>X"`#5C3F7)`WJ(.L[&'T:-Y!=&%M`9GFFV^IQK^*\MJ
MIN?!24!";M_CIF=HE!M%^`56XZ!=E^1DFG.80F>_*0EEI-1(JVB-1YA8D]H&
M`8Q-K!!,3<0AGU"!"[1)KC*T(<2<'O\9EF]ES8/":5.!4B(DH:FFI`0+0$4A
MBA1':>1T_X&DH+!X.)6&+5%[(L:&*@%&HX`F)4"*FD/0XL)T\"("`F)0+_X!
M$+ZX-!Y9P8@'<=*NY6`E85F"AUT\RHJ,K(0V;G-@*IP:N?U4+Z>^NTZR=LJ]
MID[`I=<HZE1-8D<+3&"M]]F+U&[BD1_%L@"*H",@EQ,`I_(-GQZM:"\L%#$+
M[*"QL3N$CE2*B^$5DA_\0>J["N<NTR`I?\Z\Y@80\(9V_@5"!4``&U:K`Q94
MH`(RH,$:9KL&&>A`!R>0`0O8T`-G$N)>^%+!%3I6I+R2K$J)!*3.R.%2RV)C
M/;T[W3O8%I3_#)["D>\Y$FM,T:8<>96-!B43TUAHBH0V$A:^"(7.6'B5)3%)
M=:E02"RD,8ZCR6UOJ@(JH28J.;R5`G<C;(U$N*M.%O:.&)\:$D,2!9J2-NQB
ML^"<=KH*RXC-]"@I2:E1?`HWDV1F78SKTGZ!01';@2U3SSU,//;D"$?M):P&
M6HCS)ID>OTX5(VCD#69K42UNJ8XIS^4+ZNYD1YVX"T*+_-:>#"'D]BZI=JCJ
MDT%$">`LV:9ZIPW&AC+(R%UQ0@QW5>^4)5'9@*G'PHNY1<-"AB]97($O>4!<
MR(2;BHK:Q\(U&EWSF(Q:EC%AM%L`00-<RX)";X&T/R",')CPAAJP_T`)M+V!
MI(-`Z4HKX=)*"$)M==#;9@*Q*%?@)8,9D<U5*K"SZ_$63CJQ*#62Z"=BB6*6
M]AD9(9U4'*@;4G]T'#R93#9!N7#*?=VH$4V6TQTD`AU+8)BQ#J8%$YJ,5(L]
M^IDR\U`38SO<A7%:IJTR[;W#D\XWD]$21F0[;0@JJ;;[9@@[]6<C3RJ//.1!
MR6UO&''J5NF7^.DG!&^X<BN%&W<Z;!6EK@.NB<R%BS<:#/_EZ).$;5PN`*F:
M;IB%X-P*J%J=UCN)ST3@URC0)*=T0MA-/%)U=-U!6YI7K1B4EDV]CVHPYT"%
MV2A5WUY%DVEFFBZVB6]*1=^GA>2\?HAA@/]R^,$;EKYT"$VB80-RT7S^4EK]
M_7EB/_CS!I[)=6?VP+4RF.T-:%M;W>J`MSWH`1MT(-L@H.#ME$:!`2H=A+F;
M00D.<(`2[GZ"LV_]#:OAEZB/0HO2AB(/U(/CJB62&HKKIG$XWYW`25BYDW9J
MR.J%C<E=N)U=,-$NX7+:FX)!U#KV[)OJN/(Y@G.74D$Y,ZQIMZ?,AM]U]Y=2
M2M4R(G3EK+0TKG#;JWT821H*O(GQ;'2=CFSDIF4[WO[>@M(AP=>[%ROZ]&I^
ML[%(0+[<AEK\CQ-7N(*,>JRNVECAZ/]].5ALK.%YE&8*^M)6#Z)J\H\CH,BS
MT?@=WGOOST.IB13_*?K09<LE$3XW&/F75<92.Q;4/G[C*3Q@2WY637_V=87&
M`B#0`UMG`TQ76APH!M)T:"'8``T@32#06H6&@BEX@2BX6FS``C(0=FM`=Y2&
M:92V!IB6:2BP`'+G=G)G`$`8A$!8!&:0=T;H`">`!+PU,>W&9KVD&59$`L?3
M-9]34'-3#:X#/S0V+=]6(__$,"H6:EFC:Q'Q<6L"+"]50^[Q#N)F1DTS;'"T
M"K=#0NIT-5YV0P.&1T;6)]L@?24R%AL6B%`Q"..53\U2@*E@=%_!-%?!2I&3
M86D3?6G3;NYQ#=>F-64CB!J68817(C-!&D^2<A<#B<%G<;R'/>;R'DUF_R.;
ML7#I%%5CU364$!BJ*`8<HG^%<X`:15AU]!(BLE.X>!CP8RW]]G#?ICMKY6I>
M83?*<B9,5F_7\59WH1QMH7^LQCI;I4C1&!)\LG&`U19)(AC)4B5DM!P!J"/!
ME"_%Y68@@0<4LVA"H':X=0)'F'=]MP(^H`-(<`+\&(,YF&ET9P8T.)!!\(\&
M>6EFD)`*Z0$>8`9%$(1%$)%`^'9O-Y%R]Y!#&)%F,`4>X``Y\)$<\)%(H(1"
MT$Q580$FP(P`DQ)&Y5)@50O3PS7D@503T(J)AW[H!3OEXEW9%32:R'PS,X?8
MAQ%#TQ!X$5ZHYTZ/\@P:%1N):#$>95"6$`RCPO]BB9%P>Z)!M<-@9793FF@4
M&<4H[W%JK$%PWE:-^P`D*45[9Z%NH98^UU%=P_8_7_EOUI-%3:$KO0$+W"@+
MW-:300D@.>DA2R55AY`JVBAP./96)&>&J@.,<*E`4<0VE#`CL)(]6=$6,^9E
M"R((;[5":P0\P+=EJ-<HE*E!&2,Z)`82Y6&+[==P3I4\$X$<W3!8KKE&P-!B
M'&0Q,:&2GO`&[L@$:@>#,Q@$9M"1]9@#_*AW.9B0=!>1T!F1!!F0"6F#-7AW
M"0F="3D%4X"1&8F1%"EW%2F$!J"=Q^F1(,D!'#"2;!"//:`-5R"%+N<5D#$X
M#95<,&9#DLE<\ZEQ.87_F2L1'#+S?%ET$>61&5(9;`NH2DAIEO?`?<ZC1S*B
M&X#24)53$F,$*<K@>9801L+@;HA3EQG2->:XH/>UGWBU)D#%2F534\J7,9]A
M"V_V);^VH`4JHO=F#QFBEX?1><7FB;E1'\[Q(+IP*:H44'GT/U[$.H<@C$P%
MF^5`93A!#]/%"+$I(E4B/5/683(S26?D:@/!'"-7*F7QHB;!4#90DTRYH0%H
MAMQG.$>F5_73/=23F%*:E\;8-IR#8#\:G'XFCR>0:1#)D(1:J(0:G8A*GHJJ
MJ(BJD8WJD(\JD4(HD11ID4+X@Q"9D'F7GAQP``?@`P+@`SZ@@113"/BR%)S0
M_S&+@GXO-HZZXA!U1*82T1,^P3KC$7B>H8G$HE%=8TCQT!-9*#@/=%`$EIO.
MH%>'=85\`FVJ8J)DD16<DT=E@Q1=J6TX>CWV="X[P25RLRM-X3B59VZ!DD7^
M8")MJ11,LU.6<8=$HC&!V$3L)AK16A,\4FR1TVXR4J"VDS,/89GYIQ:]0RZC
M@8MHJCW-I8U]M%@\,5WBV&'BDXS#V@G$*`H:U(H%&Z![J8WL9$8#2R<NH4>`
MT:;(5@B`Y!^E])**4%G?>G'*97*CP"@5TJ2]Z@D/PY+SP01BX$P(``(5L`8W
M4'?E"9V$RIV(2K30N:CD.9Y(&[2-VK00>;23^I"5:O\`%RFUF#J$16B$.:">
MG;H"`A"J*\!;3``)1@&71+E4A#AY`$N-[Y$8Z>,+LL$Z:%4.DR*(S]J+5@(L
M_J%`;+@CH4-L11DC<!.KD>%"]0I?;)*'L_,6+H:*3:08V69\UUH*L!040#5@
MB>$(2"J:89-])Y)A![<)2X%1-(%(.\%^/_65I.$D0&2D>^DH5\9*9FM]`B88
MJ'-226$/?_4?Y79B:$&921"KI\64F/2&X1$4Y`!F+&M',Q(>(+LIL'2ZFT"9
M1X95J%5Q5$$/PH,ZEF!7E!2.,X,39-1"FI.'7U:-VH2[G?ERY;LFW8M_B=D(
MB]9,/8!;,N"#DSJ$1ANUDJK_J%,;GDJ[M-_9J$'0OU1[M4%[P.%I`%-0=PL,
MA!QYA%N[M0?PM0)`!0=P=KWE#AM#`NLTE0_4#6HJ(>>R.19:+R:77E)B5<!8
M2G5I++((3SR13FEB",.RH`3F>^=HOK-:E'WXK$/!&S[L1SKT8#S$B2(J2'ST
M/LCA-/!CH8X)KRIE;LQ2*%J1'Y5B+E%)K%^HJYD"ETSE"Q,[1B42FU/\N=H&
M;*[1-!!1J\81QDVY3G)[C7;S*GNY+-Y%?\X;+LG`$2UQ3F?[<[<K2M12QU8E
MOG0;FJCE;0+X;2;<I<4ROGT$B\VX<3AR#,@T90OD0<L!"P^S&)"P:!OP=6L`
MP(L:_Y'=29Z2&L`*#,"NC,!(&YU!6&F7BL!'&\!%,`5!.)Y$F)PAR0%4\+54
M0`4K<%MLL`&-P#',P4"E=W&.?"XBMW#-H;A(TD`SYASN&H@25Z1R8QV*=[L$
MD<??028IXRR#H<2Z<C-N=**^5Q++L'EQTS<KU6`ABJ-L3)OM84-FR(S$JR-`
MLU)1H6^+\&#X"A,D%J4Q\A2JVVZB,V#-V\Y/ER6%XBDY.B?']!(U([AV$RT?
M)'`(D7@NJ56A6TF]9I9Q`W,C88;B+!*#XZJ-4B">052]YS7C&[HTID7))G+J
MQ'Q..6;PPQZ])V'RA\,#EK)NL0%;P`)M<`.M/+54&[2IC/^TK/S*5/W*N[RT
M=/>#%2FIMVS+E'J16;NIG!K,&`S,&7QV;^`P]>D)\B,=.G&9!^VR>:QB9MG-
M0Q-_#8+$=ML_#6(*+(ES^.P8;%K3@<LWQL)91^2+W5?-6R42F*B40I4]RM`P
M=7NM8&D6S,I[B-5=ZL&(MK"]X;H70=,0Y#%C.$)4NU0/NJHQ'T6B_:8[0EH^
MA,<FC[1EJ/`"Y795H')KVB56H)(;S.(G_8&*`P)6OW<)QBL0,.U"B'4L^:=-
MWF@5_Q=NK,<G:1I6M.0.9N*R,<;2/6S<7$A`]Z%>3:-J4CE>Q,(77&.+8UQP
MNE&'H-U2)J`OA?4&%,,$;!!V-\#_@Q2Y`/[]WY4*M5*-J55=X`8NP$VMRE^M
MRE$]A,B9`YNJGCD0S!?LJ0=`S$AP=@@@!P#1,--HNT*2!WF@`JTV'[<V"9Z-
M%8LA-!?:4O^B2,5W?5G$DEC">P2VS3;3<,J3-(W=,UWU.`IX',3&1<9`K3T<
MU"%=)SIBV8)8+"2=-/ATC(F]D\*@&YDB$<#P&RA4)3[%NG\8`&"0NN^J:U'#
M%PPUAQQ!62RN,4W$&.M`O5P1&SD4INKSN2LZK3*Q5;NJN`WM)["V)548M\SU
M+'VNGP7A#.R$V4F9'5U!<&'J+.#BE,^J52T]E4[Z0+(QAU=&)?<`2Z($:X(9
M83R0!0-$_ZZB=#7QR05<0`(VT$RCK`-*4-7_[=]3"YX(;,H&GNL%+L!.';6Q
MW)W].P6;Z@`>(`4<8.Q40`8^8.$7CN&<1C$`TTM5LTI"LABJCJH!83C0]D49
M02FWC:YU,C8K7L_:S""5F+<-@40$!5X.)V:2K">G3M*2%+C5Q3I`U"6*42?9
M;!!C0U6#@#9,WN2`Q)/+I\8R1,U[<A:%9:5N4VSCDX='@16Q&BJJ2U+HP#:?
M<#N#P2^'I6`65!^2]5>LH%T0(7AH3*X'$J8[&BNA"29LO&7<`P[H8TF8M*7[
M`(4B=$+ALLG3P#QZZ>_U`\CED9JWTW].H7NRX'+WG)I#U-AR;?]E$N(KSDSP
MVT=L*[H+.?MG+."S`#SK_4WK4QW`NN[*_#WVL.R_K)R1OR[+#"S64B`%6TOA
M&&SAQ+P"Q7S,S50GY"J4Z#H*,RH-?A$8='HBZ##/VASJMP!QZW%OG#B]?4EY
MN]":2DH6'(KPLRIF%7<<'TOH_@0KB+*KHAMXICX-LI>M.Q'P@<C&W"5_S#>S
M&%WTW=K$1N,X%5?;?(-33K(9CYC-_X;RF7D)'MN%9#,YK)T-!GA.7V$#*=6Z
M48]2Y+H8R;#RNN$2W0C3H_FMPO_IDZQ'IN.EW9`^%KW2V]3$[+0T?7PTX=]'
MA0Q'Q`LN_>1S9IGP!V<UB*Y7'M?8:#'_(9=D%AL#"!97`4ER3$P];#(W"R@H
M!I"."Y..DHV/D)&.FI6=GI.7E:">I)69IP:8FJB01:Z1J$5310:NKE,>#CD<
M'+M4`@)4!QP'!RM4*\DZ.FP]3'(\`2\J%C;6-M%)`=8\VC9B%CP\-A;AWM?=
M/%?DV`'2+_`O[DG>YMOEZ>6#TDGQ\NK?;`08%\W=O('7+(@1:-!@NWO8'A)"
MR,V@MFW6+#1TQZ.<N8[1Q%4,4$";.((OZ'&LU@Y>OX'KKF33=J5<1H'RWOG;
MR3->QY$&?TJ$2&YAPW'H-B845VW;0G;HEA(D1.^%M9J"K%'E:3!G0FSCQ(!C
M1Q(A(7E54\+L_W:/1P&,%-<).OL37DT;*KF2&_0"J5:3'O^Z^SMN9;N*[$R"
M%3?89KN24Q%&^Q8.+L2@[`H6K99M8-,"!,?ADTR1I&ANWL:B[MMTX$ER&MN"
M;DWQ8<>QV=ZV_@DQY,-RA-3)%5<`=K4K*N!1TZ@-$1L6:TH]LG1I%*;KTK.#
MHD1]>_;OJE*%/_5J4R9;YV7E<J`KAZ]@O(H92Y;L`!(=0H0\`YW%<6>M;S'6
M$6=(-=9-$NM<I9,_!Y'#0U\V#(*43.+(-)$[$,+FVT8JL>-1019MPY9C#&%V
MS49"#8511ME`A=2!BJ'C#T"H:2-/@A8V:).$5PS23T]`SOB48,$E5?^@<0)=
M=`Z!_UD#CDC1*%349`)E1I!*/3JX34P+QJ/32F,Y)5:8;SFHEDKOH$1:@!%)
M^5=?,O7C()HIY:36@TD(1]MAX"01('!Y8N,G;_6XA1F4@PG$`SAE%8A1-[,E
MF<2<\Z3(EE:+,I=G-0449TX]5%74F6.A*BH66Y%=J0T^G49F8F62W68H;Y&J
MA(]BL^J&'*S<8'5%/)_Q\`8;)T0G2BB=C.(=>,RBL%THSR[;;">9F,<*+>*1
M]\IYN+#7'@>_4-$+,2L8XX,/]14C1#.'5"9ED1J!9D,6<I19V6PAH3I<G3VM
M:D]3]=A00`2/'G32NR)N]&<UMU[4X&0LE1C_HU;NL'EB21:WXRAEL$Z$E$T7
M!A"3CRD%JB`_<,KU*3E=!MG3BW,Z_%5KL)TXC\G&12/O-V*\>(]"+%$YH&<1
MCIPD05HQB*'#`S)5CEB<)1H-O_!(<P]'0_E;%%Z`S?HIABZ+G)2GZ3!:6FD%
M%5AFDK6U,VDXL\4VTE0@"B;8:8R!MI!NE16XJ:(3V>WVHY]FNFK/)@<7#F.;
MAD-PC;7I_-/AOC'DLT.2<E/2/3)Y60T]%N21'(1N(0*"$JE$0DFTSW:'[+2?
M+,NZM-.>,IZUIF0R2RVOJ,?>+L2$&Q]]*Z!;WPK`K,`,`F_42Y;(&LG#C3CT
M3'5.X#WV>"%/A=*$_Y-7&H^&]5*!;A0X2Y^97QAE%).$,]N*1V0HYA69+%K#
MXP?F,8YX&I1@2VKAQO2"PAB7!8DQUQ@<18`V/@&ZK4.!^0O[&*65"88#4QX9
M"#BRXB.39(DA=LK)^#[V%(`5#"T7\5*O5'0XAAU-$-+#AEI:EI-^".<O+?0+
M-CY7L.>1!5<Z'-60VK2RO@$*9-<+(@31\3&&:(DW/[L46`0(J9\E4$-8"PG-
M@,.F?%'**8LCXM'"%SYSR`MB/1K="WR5/16HH#"&Z`$+:!"$9#5B=M*BG79>
MYSH\L@YVMF.%*G+'.UK8XA;=<@^XJ"",^##R7/1AI`#((``?+(,-"&#"2?_&
M00+DL$91HVE:]0XC(X>)L&J4(M([C".6LEQ1@B4Z"CX<]!;S)5`L#)%94E3B
M%Q!-S)>>B=C@2*B1Z5W#1VG*DH7N],$72G%J!N0)<5;4L<&HAI;%N8E2GG03
MOWB$,PG\YA3!&,P(S<2#Z$CA1=XBA@FX!6@D*A38=H(AZ%43<^_J):A$:)&7
MS`-"40N<DQ;2PD09:$`181M":^1-@B:!@9%ZE(9H!<9TGN,;$[``/2AC&D$$
MJHF.RA,N0?*JC&ZT3V3#F4U$TXT(9.HT'7*222?%J$U5KF89(4G<<IJ3!)E@
M!R10C@DL((<XZJ".T^GC[.SX'63ET8]0M0ZSJG7_'6UEJQ78J@4N/#"%*;!'
M"CDX`"-YL8MB4`&2\IDD)<MU'S:@`0%E*<?H2$""MD6,-A^"(9IX.1%`P<5.
M51D0+ANCI8<\Y`6UO$T8V=*0394P29N#BJ`4$[&)=&I%L6S,6/Y&-(3]+$L/
MNI--[!'`H/'#IH6B9S09%\2@.$9\#13(VF`FJP"X:2%'<E+07O0DH.')2S!Y
M7L@6A0$,#&FE#BS(C_IE$H,$B",ZW*%1WF:U+F61)M^4'&=<2%B_38ZCEQ%I
M1K%12YQBZHI-2<RBQ$`(CFH#:N3=V16#"3'"ND-*JV+;!)Z"*O1.T9@%^0@N
MW\N<`+2SIB,D2XI\*##;_Q+4MG`S<$:1@R&D74,%%#E$#W1@+#L^*P0@#D'K
M2,''V$DUJBBNG7C"DU5:F$(6Y,%%5[VJ2$8VDAAB/2NZBN$#,E!RQY=LQL$L
MX$8WPH-E--5H`11B*'CRQ90W^^O5_%DGB=H#*H/9$(IJYJC&1HJCM<3L3`Q3
MF*-H4RD929]C!GL1K`#*2[Z:&CH#ZB4UK6-J-'P9B/"6CO`]"44$NN^((L)-
MZ?(LH:>YIDB^&0XOU?F#93&(!3`@`A$8]T&,0\B=\^R/EU3-8PGTC?YJ\J!Y
MQJ,>@E"';_M:V2B6TT]PL=)*13-8PAHVE&Q^$4OO!Q:%&,4P%$/H?=,W/>02
MJ/\H>[.UY6XEJPY!++U<ML%^V1;JE;2&@=?K3;05,@$;Y$2'XSL$$]B@`QD@
M]5B3"+&Z0ZQ'2S3UJ2B.ZE173)[TO'@*Z9'%C'41//GXV\;($*M:=UP,^KQU
M`\_HB`F"2@_M7>8R@M64PZ)\*P@?J"M5&T2DP*T;@UYV@941E)<=S#/&1JYB
MUJ9-;,<L9H+H9H._+A)L?L6T75KM?]"41]7446HM<7HG9<Y8`D_::A,Y4.9C
M:>6`@&;,-+^K@F+8!\9=\H__N=8"$ZATMQ?$D4&0.H1*>T=U&VC"@-CS+//T
M'X%&*RG,9JZ5(H55:C3ZT%]+2=A$J1NC/"5WFN*%Y"W_G*A(?IADDDS4?929
MS*E(CA4G)C!4IXH[B,@)>)(C5#/I%-.(DGW?/_/,FN@3E`Z+6M0-]&`+(*C`
M&A@!K>VL^_7M=E:)91_OVJ^..]\))"MXERTSX!L%AYQQ+LHZ#!S[.\<"]W$P
M"DX\'8#`&47]AB<[E&PFORWTYP2L5:[\M;07IC@3V&_46L60>V6,9I&FBH,W
M2)M>AJAF]ZQVI4(]RD6W,Y<@_Y5/)@3-KO<HYXY&.O(43?``$FCR,V9C3*/A
M3^`V)^NU&5#G)%72)EMS7I)B)VDG48ZW#1.``0T&-L)!):86)%LV>(WR$XK%
M#US'.>,@$X1'327B3<5&,V:3_T_P127S!1A7M&A.5(,]`WK6\#>/!R\\Z!>@
MIWBQ<8.=E7G1-46CP4"4QS'M)4R3)13<A45;`T:*]R1":`W/8`B(P`(RL'JM
MXWJOMVXC1F*XAVZV5WNT-WO6`@OU5DBI4`2^AU6(M!Z[<`2\$!_'9U9J]6/E
M0CS*T`P(ITFPH0*'@Q?K%1*XY$0=I"1M(3W=QW73)`88,`+&)5MEHD5[]A4;
M$F:4"#5HPT2R%#3:,#$/U#9CIB$EIWX)03*)8DY4X4'_9VI+HQ@WUV@$B((A
M$T$VLQ3I9RD.=&CL@PU0,QI@@4M,-CEI`5Q?4ANCL3:=LEP0`FDI!"1B%T#_
M!6IE,_\D4P<3%/)!MZ@U>V(/`^9@'^)JX;1WBS)>;=<WM09/37%Y"P4HZ\42
MH%9^/J@_.-50!=9.^F@8BP@ZR=AKBR-,D2=AJ)@XMM5MJ;%!H#1+WX1@6,<2
MAX``8G@#K*>&9ZAN2T4**R8=;5B2DB`=N_<(+=8[O6,&V')(1;`>#M"'-/F'
MR:=\D$2(Q6-)S`!]^1@T5A).L*(/ZN<O/3=9#3$CLB5M^[5?.D,:[=.$!H5F
M9P9A0U@IZ#,1HY04A+!3"N098R(_TGAQ1%,1+A%<`*0T57,CYF`5,K1:'T(/
M6G,%?V9T0Q%$9L<^3V,4K-1TC(:4N,@A2\*%&/%Q/B$(ZQ#_(GDV$%830T+3
M/<7Q)#ZS<V46(0:%)4SG/E#4--0T8.LE4%3D%-.FF9/%98E&4)\9*."$00(9
M:<&63PR3CHOG=HN!=1EU(:AA>?<CFXB#$.@3&UCW))"A9D;A%_/8)RN"<V*"
M`%O0``S0!D,`8LBR8J#PD2(6DDF%'219DK;G;M2R>ZFS+>BA;Z[@DGCH._Q6
MDV;U;U1`23A)/,QG/,ICB-=`BN243:&V:$WA%6V)9`[C:<K1:PL!6XX"*WCI
M1,IE:R98=Y*))I9R(=&%(6P2-37WCNSEE4CD02SQ9.YP%XFY7.$H=F9"&@:T
M=$$8:ZOFH&DVC$()3J.E&N54:&"$_VW9^&G`)0^=<HPV4T_EU#E@,X)$DPV;
M.1?0PS4LLR7"834=L0\4(T(7!2B-(P_`(3()")0#J380%IO+YD0A]V?1%5".
MLE`'-C[MA4&QT4M<63!6-*;9%AK@U81VPT/X\([_PAQ'XE?_\WC]\'_-P00;
M@`#/(0,T,`0)X`77R4<?]I%X9!ZX4PIW5(;<B9TB&8>Q`)-:-0OH44BRX"W`
MTX=FQ4B?"@RB6DDZF9/*P`QLP"Z'(#\!=2*-XS0;N*<DH$89>`XU,1:\*&F@
MA&GY:2$DI784JD.^%B(+935;63_THTK&*9PD)UP9,A*C-&N(!8TVJG.3.(EJ
MZ1/AY*IT*?\(1+I*63%YFI41QX6K0\0QJPF!)!-VT5@6F-AM9O<C&"8V=V%=
M.E=GBS5E2]JA(F<F<%(A$F*9GH%G#B%,5%$7:^11ZMB*=I=0#>%K)))*_\*%
MFX-?C^(J'(-;9^9SX'41X,4R6+H9C_6:/5A@1'=?5=(Q/`.,NP$P'`4&JU13
MUJ`"5Y`'5]`I<H``J;<("\!NL?>&/7N&BTJI(^FHUA$M0.N&V7%5<PB3^C9C
MMP"36_4[G8IC`"=)P.`#DU1)\KF374L?]M&3XI8D4>$V+V`!)C!X]"<RL]H3
MC841MXH/0"<HECDA,I28MB5U]E09<IF/6`9L)5*`*A-:J@@_G57_G`+D:[F$
M,XS1$.R0(R0()"#AF-LS3PAT&W]W%\?1$E8C6<Z59'V)N1E+@2.5N-KT:3S:
M%0:!B2+0`.('0!B6/4G#(*=4@*]I%-?8<)]2$[]23]S@6]@EKN6$0U!T9X[I
M<G$3/W,#&_?W<A90$K1D9;`8+V*6/P/V4+<)$1-CH)3B'Z`)-?V`;3X4,1='
M&%_A2LB6)!#E<ZTEI07F(6YA"%M0`3>0`&@8>Y$J5>`)'MZ!M)&:>ZD3"^?Y
MM*[@`5QE"UVE;S))D\8'<*+J`[^0M?1Q+J:JDP>P##V92>2G#Z<&&#_8B/9B
M9&MIH]M;EV+WH0CY?T<&2@WA9B"TIXK+_UDIHKHDY&UHX79;MC6P]H"OF*P'
MX1HK]7/::+NAQ27_I!.-JS]Y*Z41$B'\-%]_`H$1*R5,QPW)F*]W89FHB[HJ
M*`8-T`"5MHEF>8TL<Z^UZ[LX:'V\\4D;U98H(QP'5CEC1UBM@2#ED!*\&[S'
M&VPN<G4UTUT%&AMP$:;5-EM_;)5$0Z:VM8&S2&PN=&W(Y4Q28QDPB!DV87=K
M9SD44VS(D03+P1D%$(8WX`6&>JBX5V+YZPG@6;1J"(<FN;1,FV^R@$@)W"T>
M<`L'W%4+K)XY%L'`@+5<6SP/K).$B`0G<`)BNZI.O!,!8T6(\J/FT\8,,Q?T
MI+#3O&G2\RL=L?^+)\/-"',_##-YWB2NYVMFFQ%IMR&9&B.,!)04M$N`GZ8F
M6A*`$.(.W&03/P+.4G<C1K)=`ZJE#XA+C+)TUS01_\,7(9H3K-NZ\-K$,M2"
M_LJN=T)*OF6$T',%,(S1-N)I'9%1QZ$]_$0XN30TG-46CAO$BTPQ.KC)-%BG
M^/?'C1-0OEFG]6A]!1.MG*$U$H$DB5+3A:-RAXP1"[A`?Z=->.<JX"P-*D`"
M-E%43``=T8FTLD=[KN.S*:;*JXR2K`P[4@T>JZRI,R9C8<T>F&K`7#6UZ>FI
MO7RU6(LNYS*JQ`RVQ8`$='T?.M`#"/<#9^%H'GMMN"6*(?VPW\070/?_$=F%
M9Y.[S7^C5[NX=L`)7QAW&C`D0GG:&0N$8)?-''OAN>T\0.\<319!.FRI?Z=D
M8>3*7C9RC?5JK5`QITT,-;AZ03#W-%4RVR%RT!L10AV!`6`L`NX46T7##>SZ
MMIL,#AH+#BDQ)]M'<]`<3#*!7Q-W&CM]QS8E#74A,P#32TT2--`KLPNI<B(U
M1FD*;@;Y@R7G+\.%CX%1-Y5%=/G0,WP3:=O'*W\,O:'6W8B3>,.F?@.!!XVV
MU"1@#8;`!H-Z8JWG1R"9J*;\.I6Z+9R0+=@".R8FX5\=?+I\UKI,UKYCUGJH
M2&K-UC:FM5P[JJ1*/*;*?/9AS&V%!AN@UZEK_S46"U&UQ,4/BZL@=*]BTQCZ
MZ$\4,XYR@=`=2BI!BFQL84,>$DLTTCXR!U%D%Q%`R$/0=6;#G91<P2"DEEJE
M#3(+R[F4>!=K*=0RRKRQ+=G5`%^G+1&J&<2G%$P3`,9;9\E2<F<@:C[^MYL]
M`\X`46H<C('@.@A[F5D_4W;`\4FLW6BVPC9"KN-W\THL0AI;&3^J@L/6!HJ'
M84(FO5#41BHK_4K/=A!3&DSMU]YIWDTUG224^"``+A-RL`'08;]=K535>;]!
M*^L,/L`.?BWEL0GC,9*V(U7SMLK!A^%;9<!D[57><NSNX>%^".(4G+5:VP$E
M3H@G+M=U3=<]N0%/V?\53-U)V7,YH47E]X"K^V"C6V)/#^%/GP,2HU5@;'D<
M&\%T6A[3WQKDKNI:66CO#"8.D!UF1]ZN@3V"VCBBFW84OR99XE,]QU$9-\QT
MA?:`MY6R*WMW$?N)2CP0:@$<TN:!BIG.9K,]_/0/YK0.89EFY&`"O4F4@?U)
MUJ2Q=5.5XZM__]%HEB'9:4/R]BY2Q:F,_Z+)[6U%MN'7?\=D#T<8+L3>/Y3(
M)&?/(4<SFAS4DI4V?JU1%C?TX?-!&AG508M'TCD[L@Y[:QB'M#R>6<4[NQ/+
M7\T)N4-(`;SVNS?+ZC$+%T[L#B#WWM+ARFZUH`IP;UU)<$V(YO*UZ>)O=9W_
MS$45Y+^B`D.E.+`2TC'D)H>%@0F)BO=*4D=.&R"OY34NF5,J3HTI-D"!\.=L
M=%'COKK5=ER6@6)'Y]K8F,O-ECFW*-VX=-1LW1F1(S-MYK?$?K,FT!*94.[^
M$@"AC]J*$UVF$\@FTR'4PG4K%T;A)D\C-_<DHM2<):E&,23B,:W!NV,GN%8W
MO'&%??$#A'@.ZHZ'TLYOZH1BFEJ.4(:]L8H6_N7$:\^6W6FF&1%4L,OFVB##
M_EH$"#:";PUM"2TAB8H+C`N*(8Z)C9./DY8+*)F9!IR=1453H:*C4Y^F'AZE
MG:NLK:R?KJTHL::EH*B?4Z@>#CD.J`[!OL`YQ3D<_\@'RLL'5,[./CX"TP(^
M*]?8*P<KT=G9S,M(XCIL/1M,3#PV/`$J)`0D*B\J%A;K`?CY^%?U]0&"[%[D
M>Y&$AP5U8NRQ&QC@B@U\]019N!)`(#X;$:_P2)(/HZ"$`0IBM.>QHD`>#NU1
MY(C/($:0^=2-7!C2H!@Q#TO^BTA3G\^?0($*Y,=#(,:`_W#ZBZGR($NC]NQQ
M/!C@YDN9/'A8M6H!I\%Z";O>VRGH(4NR]FKZ$_D07Y(70_OA=,BNZ#R34+/:
MT!CQXP1[-ZG6ZYDO21)^;?FI/2B1)+LD!70"Q&LQYF29DY/8"'R/HTN(5#>'
M'MUVY.0`71,"])R6K$T+%_^I?LT7L?5FU6UC&SZ:5/:]DFPC<GRI>J'+`II#
M)V3'>V1+A3805!@RHP4B1H^R:\=>"=(E1IIFO:JE:Y?Y4:<\2)'BH<@J]Z]B
M&3`%2[Y\^J!NI2K/*]@O_\7\9TPQR1Q0H#+.3$.%--0(X(TWW7#C#3@4ZD`.
M&N;(<=%>[N01SQ4@5O16/BD-]L]#<!7V`D8.>5613R`6E!!B"T$5D4G/.7:4
MC&*`.-8+,CF46P!9R04;<L%)Q5$!+G4%&UEEC174E%0"I4Y1#>T56V`+&78E
M/U=4IDY496$F5T[K;/;11[")Y:24'@D2DD4N[25319\]121B`$5)DT4GV<E/
M5(S_W136<JBU!A28%3'ZUI6WE1723D\>E2*.^*185Y3W?'9;`,AY-)R26L$V
M:EVQ];5A5C?5)"I9K#WYE7&@F;@3JV(\EN=G1'8UZ66_OF2#9SG!U.NPD5$U
ME5,%*5H`:H-L08,74"`B"7>)6&===HU4,DDFF(3G"G[ZF6>N+J&@LAY[MI"+
M7RONPC>?O/;A)XJY`/X"3"^^"$/@,<@$S,$R"0JP(#714+',@]5<8\TW%"ZL
MC84ZH($`.DR`VI`%>1#T`HAPI2BD6,/9-5"S4?6(:4?LB'5:7/5HA&6O_6R4
M:*\W4:0/B#'[)!/)^#!)Z)!U2E3:<O<`6EF53/^$D@JQ_U%T!6>=[3,146+N
ME=J=MSG)M6H1X?927\8U%:9`'(UL@@4$Y9GIQA/)V6M*-5K&%VQ3K^/D5CW:
M=/9/0*XU:&%3!8;3K_X(C6)E(3=^$DF3J<GC0WEZE)5:9MWJI9\A;6;S33P(
M;:I+E]-L\XXH#[8;3AR!?NR&ZV2U;$<'(7?BC2@_Z_I7D)54^F#/'H7<5S8P
MT<.TUFJGB+;;>KL(>.%%+YXGY('"W[KKJF>N>MBG$B^YU']/WWOU<4(N*NGV
M%XP4P^S++X`"QT_P,\]$J+#$VEPSS8/7+!SQ-M>@6#F8((<"/,LA.JN'"@*"
MDK),1#-#RM2*P`:;2YG$(&,B"?]#1A(B?8S$5CB3R-H(,JI!;80E/P,)"C^8
M.9I=1B$V.5S39B@4@<`%@U#A65]JUY&]T.5%O5J;6$[T&IZ4A2LX45.B.&4<
M%FEI9ZDIC5-"1BE)T<F!-;HA=$C3#R=ML85.`\AL`%6X?DC1+!@$XD`<%Z@H
M_4IL+.Q<6ISC&M#HQ8UEY)1D2',1%=[J*ZH+7E^BU)HTWJDWIRN-:=X(.0>.
M+BVSZHW&_&$0`CC$>#3P3K:RQ3SF>2L2DMC$)CHQ/?/9BS_<PYXJ5RD%9&2/
M%.*+I;M,"9]XH=(_`&H?+@=$H(`9XT`(HI\S(H8-97##0?PSIC;^U[\#4`Q#
M!#2@:%+_8Q$?D:12;8$:4^(F%9_`A45O\LD'=38I0*[C+*@)#%_.:"<)IO!)
MP0(AD1K3)>)U31]+HR'3J+C`@T!%3N84IP\G$K)2"8MKJ2'3.UVV'#.IKEET
MTX=-&J.SQFU,(FK,$HTPU<`Q%45-M?'*#YGVE96X4RZYRF!;/F/!E;VH:+F1
M2&`,8X&_Q(9RCC0:[<Q($YG*\%.1.5R==GA.S7"&AW4*#$1@<J4[F@:CH^IB
MYCZHPD\EAW)#TVFL+,`%$O#`>&M``;9"0"UM0>&LS;M$*`T0!/O,BQ3I4Q<K
MY[JN(]B5`^Q!'WJL)XI:D"L4?C7%O-SS/?/X1PK_81\N<PDP_X!QH%\`6P8P
MFS%,<!1S&Q%Z$/XHM$QE4@P$/<B8:'+VED%!!Z=_"A3H>*/&P*4,GLN*V\PN
MNB,/?B17*#,-1<3T6HG2\RQ8413.BJ.0F.ASAI>*R^FZ&2>JD(BG@=L+WYQJ
MN%S)Z3:<:15HXC0LUQ9W3R,C+4?DH<U(YD.;@Q)$>7.DEU3)U*,CHI)`[$$0
M<=;F(*^)VAHE&%T\#1)Q#L0J4:=B`]T=#CA:*8ZK<AK"(CVIFZ`SJE.J\A<E
M+?&#S#'B1GQG%1G)2@P5[BGD8.(U7BVEPPGF001X,(&_<($B&Y#!$-3JA>9I
MZWG0$VNX@M#6\)UR%-NC*UWM2N3UG/\+R'!-,F!ST=?QV7(7P9"K>@+D+U[Z
M\K&0C=]DZ==9B`%0F5[^LF4?YED+L6`+"'B#WBIH6JRB]D4W'-LA5V8:/S8J
M(P&QT6E:PJFT&#6)%?VGDR0J5=_JU"WS3(T<442DX^Y3:;'!TD1H9SD@VK-,
M(S%4(U]C%;0<*BJ+:0P:L4C$=-X(GYIR[LI*I!%"7^$M2_G@8'2248;@`VHI
M"I09MW0XQ`!1(+B&F341M0\.ZL5$MWD,M!R<TS%-0(90^LT04]S#(AVX9IMI
M\;#2MNM$.66BFTM3IT4C;FWSF6PA3/>HTDUNA#P;-G+HP0V\0PGE74(3I!3/
M7Y.\/;FR4LO_KFPED8O<[WOM`JY'ABOX^)J>5/""/=@S1I4'Y,L!]0+@%'H&
M9YLIYOXUD^.<[0:85T`Q<IP#'3SP:D3DD4:`-$X%6GOP2GT2-MP^MV;UA9L_
M;)BD!!9+-87Q-'YS=.ISTWI4%)7C;@'74D<#+E$;`=F+/)*6RAS1*W,\%*83
MRE.J%^<T3Y7;F!9)*<B9C(KMP$L8^U%.C-QYZ:3#[YZ]:=&?A%W2.9L:/&NM
M%Q`):9&Q];.IEYHK?7A-D@;%\(ET\F?F*+B/#V[HFWABIMPDN"W3AGS+0#+1
M2&VH9IUKE82K)AK'"R:)80E`O&\0+DO0^SOX'A=]^&T>(:\'X%H>_[@SCI"]
M?A<\KGI5^%[1U=>#>Z`8$>?EQ'G)?-S_[_D24V;'H8]9:S`C&Q9B0SEZ@`"S
M;^@B%3V6Y-)H7%.+QH/]V*U%GMH3E)CP;9-O#=)KNO<,JEK0.L-2G%KM=K+`
M>;].QS1$P0\V1"0--!@Y9WZGQ0^'@A(UEVR0\E^\,79N-$_)=BP_4W6,PT9I
MYUL]`RU68RKE1(%SAVK\9!F-]"*FU2(5]#:9,BO&QAM;918?,TB.I!PX:&V(
MPD(`\2SV9$1&E!!EA#/%Q5UK88#<97^;%WF1YQ44R!,YPCF5=H'GETZ(0@]@
M!1[?80G2<Q^S9W"U9WNM%#\#5X9V]0Q'@/]7>>5[;'@>2K8+N;`?!J<O[/-8
MZ\%\_;)\%(<,>"@P$3,PS_=Q$--9$2,.F"6(V/=,"'`.!20T14$")%!?3M45
M41>)<%$0%4$<M`9(&I%S@`1/<?%!_Q<I8S=_0N@632)<</-$"^$1(,)`.U<2
M-E1W`3@E<#$HT':+A#(0@(0T`&$DW$4<-Q)W:5)IQ$,F+4$U<A-MN"9!.$*+
M0Q%S:Z$"("(/Z,2#I1,4%M1&&I$9.W)Y(5*`>'(4.V0B\S41@N=K58%;6O%L
MB$(\%&@5G_,7WDA?J/$7SY(:<%2.HC@5]#@6AS1$__!ND`.$)*%"">88SX%Y
MA_-G8=$8UR01SV;_$B:``#T@`UOX+=%#/N5S2OTFAF/(`68XDD?P#&3@#&K8
M>VW(AF^("ZAD6(=E#.R#?!:7+_QB95C6?)-%?0"T3!.R#=1GB-'P,/Q3<F@`
M37(@!SB4<BG29P\6)IB"BVCB0I/V-K(6?L=(&#)5*1$Y:!P1>'\2)&*W(>I8
M&57'(FN43[4X)5-#;)Z!&";2)(8#&QB4D%;1)Y]V&3#U0@69$]=$;(DV&,WX
M:_-@,CCB?JE!$0:Q$DN3BCV!=OBT1AXU3ZWH9PF)0';Q./?0&A^($&M#3LXQ
M004)%JQS>=M%><)X0I4#=+U8FAT6;9S98B(XA34CET+5:=$F)_SP;LJF_SH8
MUIITB9LYM0[N(`9;,!U;*#VE)$M\M0L@&9(B29)$)DS.0`8GF8:KQ(9&MI(%
MUV^+Q3YWZ%@`XR^+A8?'\$M[N)-_.#`<YW&$R$P'(`Y(P`V954R):"'0Q`2)
M(0\?4R8N$3@S,Q0L>!&I,A$]85K^=$%=%"9GP2<Z<7GRB&B%AG[?A3B^MHUC
MY!':U'1K.264J&HWI1`BFA!'58SZZ!4`@41[%XP*P194!TD)U7Z$P@/:)"*T
MDUH=H4Z28A@[LQ<E")E!@1D6>%-18T)RXUIU01/9^(DU84(K,J*%IU*FL2F_
M,1,@!D]R4Q+DEFCB5DB^TQ<@%J5K03J>%W8S0?^D]A2FF\*5Q6(;]_5=>T0`
M*B`&/<`"K*>1&^EC2D8*80B2R""=NB=,UFF=5)"&*0F2_L:=,`EE>'A[`$>>
MC(6>YME+ZDDA.^F374:(^;-,ADB?]7F(`30.VF<.^IE-?J<1,/=1>T>-/*,R
M`-5%+7%G.%=0<01%7XI5FA9TM1J%<L(1WX2.+>A-'G&.K>:"'?IT(?B!`"86
M:;0WOLAI8`.1$=IH>SEA#M1IG2<WQ,)3^/2)2`%_3=&0#(&@AEDE0!([;HHB
MPPHKS>*7=K0QY&25Z8>*5:F.@R:A0G5:O?EIU\2F2R6"D/=]M,9U1E-($[8U
MF"A)?R1X7H0;;->N?23_!CZS@XRA*!:P`T9``&*0A8T@+N/QA7MJ+G.%>]%I
MAM1)/P(PJ(-:J`'WG*K$AE%V6+@TD[]$LGP8(,20DSDIJ35[(!C'#(!(3)EJ
M6>&`!,HPGPQ"E"O0,/9)<MD'`B"``$HY$9`H#R1@`5!#2:IG`23`@!:P&P7K
M3R-"KH=)*$\B,G%C>0R%`1)+KZ!G&8>V4SM'=_YE%JQ5:\?Z$R6"@.@7K9@Q
MET4B7:3I49$B)V:Y9I,Y)H$!>E0'1N/DC*5'%#7J:Z\103J7-$SS*#)%.5#W
M.HFR=-'U&CJS48;6,SED-8K97+J";->D;#)E4X.7%#9PCKQ2.#83D;_B;DRX
M_Y"K`WHH4Q?WM5-*I1D3V2RM6(PGU+G>NE-^L`-O(`=,@)$YMIS[MJ?`)V1D
M*)TGFR`JJ[*%BITNFYU0MBXSJTH]:[.&RH?$,*GH>9-^:"`5-S#O&XB/9;1'
M^WSV*P['U"`-,W+WN7WFD#G^D`54811W,QCQ%T%,*D%@4G3G"(4Y2J)`ESJL
MLTUH*:^.H99KI(Z+B;=Y"R-I,J^9TC5WV:51U">D66(W.'-H@;Q)@1-JRF=D
M)[<H`BE(XURSH7/%%54&6B4U&D("&6NMP2BY1C,U):;QJFNV$C@ZHQ/#"$-+
MD8$/(4AG0H1CAZ:=8BOW%3I0$L0D)D59,288&)BJ]O^B,-I08N>F#@:\<>M`
M!&`/QB.]'4N]Y,&G;4A7N4>2)YNRT]"]WON]6!:^MO>=-&NS`5.&?/@?D:J3
M.FFS\!LP@7@`OA`.01M]^6NT]%D-U+"I2ON_Y8``-J"4ZU``.]=/EN,FBRLE
M.MQ^N[HGZ=<3F?:0*%QT9)Q_!5JL`IBE58<I&KR6(/.)BL2`)(HF!E%A?_$9
MBQNMN[&+C59%(7RM[Q:K73PI(=@GTFB@&F&O5\.MND4800J\8&&V*T5?3YI%
M%B$C]&A&Z.1=@G?!IT9K5;08(.1(__IS!78K%.I<78047<256:?/H!C/%F@B
M@N0[PD(DPJEJ"$%LW`H[``'_O75Z`^`"'A_+9&#XD?\&<-I+G7WLQWYL,"SK
M2^`IR,P'GN<K,("Z>VD(68M59?'3AS=KR)5,M,40R?_3J=60M)[ZDY<5G^30
M`Z0*O0_A#B3`!2;B-5&$3VTFHQQD0:V<FT:SN"`:;7CRP#U,0QEJ+&K7RTY7
MK,>H-<4R-F*TE49T6\+"HRT<JT^J-P=UQ)*R36-$(EJ#=15[$/RP-IA3;+)6
M:?I$5;!A`[`+'$3Q(H/9$#E#85]K@'$FB@M)I$B:#TP"$R\:.LM":X#=MLD&
ML1YD++`Z2>CV9Z%7>#>CI$P58#LE/"^\$:;9N3'1*J)3=!@D/'(@'?/6>J/D
M8WSU_Y+.B<<HG=(<G;(>[=$@K3`O;;[LFYXP?<B`6I)H^%@W^=PQJ7S'+=/S
MVPR/-=/79TP4(I\'P"`Y'0W[4Y\@-P[D\,D7\P]7X`YA7,\/2W15"3-+_'E5
MQQ+-=5.&@B@K5(&5*0BMQM6$22F9:"Q`FK<.D<\HJC<2;#1)@,H2<6Q);7@'
MH2BLT1A@<Y?"-2N"ERH/V4`<!#3VP)]9TC7R9*Y6:.&#M'.,<FMI9Q3KD!)7
MVLPT4Y:L!<][-AOMNF<OVK<%BU/*8CKY6#,\VKB2.*6F#<]1K'@AJFID4^2V
MPBO>!J>,T1;0RP)#L`AYJJ<7+89YK,=[#-S!/:@-0C_*\/_2O>18U(V^T[F]
MPI23[W.3R$>S>7C<E&K(\U.IVGWGS,#=/M`!W^W=F45FEX7)`F0.BX@.27GH
M@'W,=\+.,AH5#'IS"-B4$3Z;V*54*+AG>3$9`XYJ/K,4#NS?7=V"\Z5I>-G/
M%2L(]+A:.?%L#WJ:$13+FVLTJHSA+43"**I2#@AJ*_ZDFC9;YBHD87J02H$[
M+'(I*E"C>>+6J'-ID^*D[R>OBR'#I^%0-`%)*(:0!UL[RQNB9@&QE]<ZA;='
MTDY?!2V+I`-N-Y-.PP)UD:U0-V6X!<`$5,XM5SY8%KW;O*W<7+Z]'?W1?,R_
MPWT_9S[P9'@`9ZCF*,NR_@$,[F/_GGK(OC']L\U@($2;W3VYW4+9`7P.WM,P
ME.!-E!&B3$@@0*,:6H:.#HH6X_O<./87K\`<JW?T775QWPI)@7^R$\_.H28H
MF;$X="YUK%.S=(8MP0W$@B?<KYK62#-*:'$;L:*VD'N66^U\6T`(UNJ`UZA6
MZ7NG-!J,RA$N!GC@16?T?\>N14VL6TO19@J*)2GN,SD>;0O1SVK[8=?&NJ>6
ME40(VR_DA&<J:["CQ?V,.)4BCU-J?[*B>%*Z.#;`!K6]/(APY1Z)[ZJ4O<N-
M\-30O?Q[/]L[Y@3_I]17J`BOY@;#>PL/9>O#2C;IYN89\5H6B!]WYST-#H8H
M`!K?(!Z/_S`[S3^=Q=U06P,UD&;T-`\DL`,B?&[*6BL&JBF3;5_8RH^OGK8>
M;(OY-#A,7#<?;-CDW,#O=N!C,VARTK`Z]?(O.*&Y-38AP<,9_N0M\Q`-2R8C
M\_58HDU=E$12`FS/N'ZD>405]LX$!0@O`8.$@Q86`2\V%E<!/!8V/(N0DSPO
M+U>0B8^-A8Z#CX>@AX<\CA9B8H<V`4FGB$F+-I,6IJ(!-JH\KJNUAJFKA+*.
MB[:0IL6OIH^3K+C`L[NOB9F1DU>AR*D\!0&]K"\\)JK1H%MK"0L+(2WM[0LH
M!BCQ!O5%]U/Y'OM2_?[]'`(&/$*PH,&"5!(J7$A%@,.'$!U2.?\0\,"!%1@Q
M6A3(T>(!AB!#BAP94N(1#CD<J-SG0:5+!RQ?RG29(V7-FP%Q<JSHL>?%C!97
M_`RJT2(2)!Z/7A30H6D'`3Y\0(Q*U4?&JUB-(M'!@H4.-FQZ(-B```$3'F]4
M^2(4*IB@09D.75&12!`M9VQ)!<.%"I*FMY+\(KKDJ3`ANI?>#L(D2A$CPY`C
M&ZY6BYFD":IT'9ND=I;G7&J/@;KKJ=3C4*?$F%@[BI2I0JM218J=6<QL:[J2
M#<JEEY0-NHD<J5!!&/@BV9<QI[+M:E&C%\!?!Z@&]Q;?2,`T[=8^3#*/UVU]
M9;,Q`5:L6ZB]V1;F[/LKW:5X;&M^:UC_@4J&$'TZU6R[)%U),`9.)E>\D(1\
M%A"G0A;BF<(@'A`Z8P$)*I"P`R(\R/$#`C*HLPX[[4`!10OPT%.//?E,P=(_
M_NS$P4$P$D020Q%%5=112/E$D4!$134551$)0,:01!(9Y$,*(=F0DB>EM%)+
M3[($I4PUS723`S?AE(.+.G)`E(Y8%76`4F#ZX)1#9T+E4%56416F4#WE>)0.
M7X4EA!`;J-**(-^Y1IR!T^5!PJ!_;D>*)^&9HJ=ZY`SB2GC82":I)W:)D@2!
MDV;JR17DR,:7?+:E<LI_MO52"V]]24?,+-810XE<U>F%:"^J>H-*J=8<%QJK
MW^F2C5S:M16)_R."#$?88H]HIA8PG3`"7'"$A%/?8X4D>\BBIQ1HZUR&`;K8
M=+64DD@N-L3B*6^_6-.*K:]UE^AN>H+&"C/^2;),*;R(Y@VKSI![H&P'-H;I
M%=JB(@V^UXF+R6J"H,*$'')L4,$0ZH0`8@M0P"!B"R&8>"(^*O+#HA0[Q8C0
MC"COB&..'F$EU4-`PFSC"@E%5.3-1D:4I`!)*M2D2U)*.=/0*]&4998"U=21
M3SSI^%-61CF-U`IF-H7FF4_)7-6;3B>%(YU@]2`6$V0SX9DIQ+TRX9^7!";N
M?K(40UA?UXI1VBJ1:IHIGW+'I;>F5\PB!F;1,`-:JK+<BOALG:DJ2?]_GSB6
M*E^"!=[):+X5<@7AF#U.ZJUGT])K>8$/V[9>TET"')^E@%:J*HUD4YQBK?47
M3B&NKW>=H9*Z!ZYKPD##ZE[#D-L**NT%(_HHV0W/W6:+]K5N,J]*1[=GI'3B
MW#0O2-^<#8UX)L85201H@0FK1<+$!CVP,;'%\+LC/\?PV',/R"N.+)#)!J$\
MDD<\:EE59*8U-E$!(VXZ(%.:@K,&#@E)'PG)23@@A2AY($5!FU+0@#8E)QUM
M2RC12=,V,L*6<:UK2IG:`A=H-186<&8GU-'7Z$3#L(EE`V^P00$"Q)A#4(AM
M"0,'YN*#.]DT8QF?R=O?]I:>22Q14MCH"VC_'&$;'I2'/&*@%ZK(49EF>`9W
MV,/+O]1"L%N82E6T6$M;LG,J1M`MB[_2#.G6`J@TOD9UT3G?+K!(FE`\)P##
M,8S;A,B6QR$G<Y2KU2#HXKO?E0)0I/"4-\K3BF&4SC?9R$_U"!%)2C)J-]%8
M1=R<2!\N2H<SE$R"!3#3"NJ$!UBU*!]O,C&^Q,0E%7A@0@]8<(,AI.,&\_@0
M_(89@OH9X'XI"ID'1D:R_?'O9"3IFD<2@D"IO&Q--F(3FZ[R,JM0;85"<N#-
M)&*1(X`$)16$23+O5X1]W"^#4QI:2SYXM)TPK81$@=I%9,BRI3@E32ZLT=;>
M1-`O&>4$6PF;67Z@_Z'$.4-!AAM67ERC&+?IR3*?,1WMGABMR/TN$:MX%D<U
M1PM@Y,8OM<G5X0ZITK<-$1+EXXMLI%>7N+C4;?$Q37D6]SER6`,2VZ";)6A'
MF;44*BZQT\M/>9`)Z0PGD(!<G0HBD393!$PPE``&-5Q:"!7TR1DV]05]E)J:
M-DH($;F8@#;T(Y\K@B>-.?6I)E`#*E:@ZT`3N.)@KG,<_53B<?D9A&P*@*#R
M;6X">1!48ACQGRVPH`)K6,,-@J"$RBHA"`:H&#$]9,PBZ$.9S`0(1YYI$&F2
MT"('I)HUM>DFFK56FU,1@!!@5LV,^&!)'1B2!'!&SH$D9(+I=,`ZV9D/=O^^
M<Q]$*QH]5:(T>P*0)]0D*)SV^;2H]60%+/RG=ELHT&V&R;0465F=Q%(6LS&A
MJWY\#'!4H)=.%"MNBWHE'4<JF;?X[3H\$*EA]#N9*IJT/(_KJQ';J+B]O(<U
ME$N&93BE54$TC%:$N*I2:7,M6V"G/*RT#!N/09@[$B@^?T(J)M93#%Z`KQ9O
M"62Q"G$L/@6'K(PBL78$&3A330Y>?ND3,#ZW+E$B[R[_R6NY##4+(O/X>TQ%
M7F"JF%8`;X=7,IT7\@Q$5R7+BU5Y7<9W;+"^]K%`!FNP;&6#$`04?&A^%O/0
M/.RGC_PQTT4O.@B<*Q)`D-","K>-+FMCALT]NTG_*D_Q9LN")$XR\`S.49J"
M9XV+3$43%YXOZ>`'L01"YW:$(06M+E!\`B?L;O?3W.WS0/4)WC&)]RMB>QC$
MY,`@\.6A0,5J2WX5$Q=99,-:^J)O9(X5JR<K\HE-%=^R;H/%6WUUBW:K*.JJ
M96-8U+553!T>&G7%+UHJ[C-UD^(L`K<:1^27OXZ4:"CLJ@NV&,*N")Y=K$U!
M.V&9;I6V.=ROO7V-WB0/DX;H'!5UQXN+ILI:\J:<OD"U1TEJ(XOJ.=6`%^7%
M78PQ?)),S7JDQV#!B0$/>M`#'K;0`Q!\.;)D)G,PSXPQ=\!/'?/P&#ZDQ,Q*
MS_GESD6M2-[$IH=D#2I6_]'!44[`<YY;U@$'6&%4QA3T?T+$@5`AX94NZ&A&
M&[?IC<[@DUY2)4J+$.81C"Y&4EL4H'3]NIUFB@0D`&JC'^G/WA33IJ5)IC&-
MMVP0.D2AU#9K![-7,*T8=]UVL5%='X;7L4(&8_U>NI\NQZ<E#4U@+)[K`R^#
M;WW=(U8;$YRB+@->F6GCY_2*5K40;C,2!61D$G5?FC;2UKE0E7[YY)ZY814\
MOC%V1U^#U/:6(S_#,%]H-C.Y56)H</J!=S1X(VU#*37RST#XOQ4G^-<_"JZS
M4=XAQ9"'Z0Q.#%O(/ANZ`N8;W&`=G`W_,-N1YA*=J!YD-H/ZS3`%,R`SGE:G
MI__\Y[P13NL9AGZ>V<[%K`09]/P$E55T3&$52.``)R`$G^802`<G(;02Q>5T
M]W-,$'@/&U0TD39/],01+I=UF/8T&N%U'SA=8E)T8U=VH18DW51;4#."7>(E
M7Q,6/4`VD9`8K@()"D(7=]<=FS!@U#)[?O=4D_%(P]!WZ_540*@YE%1D*U4+
M$U<;E-`GO6%NOW)Y$D=@4+@7[0)A-7A]HL0J3E@-CS`!QW$;EK!(X$8(824N
MLK,?:L-51RAZE')K;T,O;74H^V$*2-4,E-`)KS0]HE!7@H49KM%7_+((K$1%
M5P0^H^`,P-<P@NAC3-9):P%\B[`N@&4MO[`KB3<X&"#_`@W0`([5?=\7?IR5
M<J2X`),5<F16#RGG,>=W3&V&7$3#<BX70M#5,@M1<ZRU`DC`<TAP%3O'<S+@
M?_Z'4,9X`D&')E&!!$IP@*"F@`WD`QM1)>P'=4[WBA.X<A6H7!Y43[;((PHA
M<PEQ$6FW::0V%$&1728($3?W0C`4@M/E-#RQ<PG%!F;1#6TC.M"A(*_2'JZR
M8YDD&48XD`1)D%V%AF8T8Y!1D$:X.4\H;->B4B9519H05HZS;*``#:AP.;9B
MAZ_A&Y$08'VAD8QS;:]2-^20.E$E&;>$<)RB'QT55J%GAHC!>IKS2$U%'\,"
M*H*A*G$Q'.*R/6J#+31U.#56_S<VH`C;T(;!T%9.MCO[]E/70DF`J'<@N4I/
M:1ET%QZJX%5ZL0.I,`&YI$LZL`8CAW*LN&:JN(KR8``B1XHG5R*MB#\5Z`'J
MUW[KMTR4EC3-!7;>M(L9H7,^5UD(M14X\G^(F9A%YQ0^`(#.F(#0.$X301$I
MX7[W\#&,AHT3J$Q21Q-&@S0Y<6GCR($UPS57$10FA(YF,G9D9X(`)6HX]Y?E
MJ'9KUQ,!\35H$(-G(0EX0`F)\%0D@$BU4Y3'H))=Q9#(.9""E%-<=9S)^9+Q
M!@DV)61Q@Y+>(SF/M!AI5#NZ<CF5XI&+J&V1E%*&`PR=4PP\*2I\\BQ0!0JE
M`0T,YO^>JA,>2;E10,@Z?_&2235D3O0I?J0;")(?X,&'IO)B>B(M.N9LL;<*
M'VDW8P14^M9$T(-P"6='6Q9+`'=]S?=DHN.56?!M1_@=&:)+8)9RQ^26E#5F
M:RER9WDQQ!27)NI9,7&!%V1<Z@=_6.(E/>)=1H%`0A&,8N:+P5B8O;@5-&2D
MO<ASB]D4/L",2E`UD!E.8_=`U'0`E7F9KXB9V?A^4+(/G"F+W`B:*"&:TY2+
M`F":YMAIIVD1J\F:K>F:6B,SU=0F64%J);0"8+,!3)!+MW<)344=WB9PP],:
M\Q95R7FHB!&H']4]J_%KB+HY*65K@DA)K;,LL01)J.-BAH/_=[B`&?=5>6X$
MDZTQ4PH7J;B1;<>0509V&.UI&%($;U0(2(G2=XO4&KX1%WB8D/T2+)K@'*CA
M&+'#;-D3`-V02;D'J^N2<(*%5K50`-T`;^(9E-H!.KCC26:$%]"J>'I$%PP2
M2+[C587@K`4`!@$`,62S2V`69I:UEM[7KFLPC#*@!&9&<IM5BB;B6<FD04RW
M3BEB!DI`:4>A6KLHF$'ZBSJ7I(FY,E-C(UM!%73B`T(P,X#&F$A09CJ`@)`I
M%62P6U2*9U3``3"!I5EJ/Y@I@8_&$HKVI2TA-!DH0CH"$F<J72"83VOJ::S9
M%&^ZCMTU:G4J:*56CT)0-G+0#8`T_R%J^)$]J0P",F^(BJC?DE^]UI&-1)/(
MR6`%%GVW@G@EJ8BN@'MO0V61Y%>W2GD'EB`NEK4G%8;7$B[A\CI^P0IT\Q?%
M\H9W@QN">$?0D61?RX:U^CNYJCL2FI2JA&#,0$O=]E&;HE2,!*C]:4><1*$P
MA@O'8:WE)@N5`CF?XK5X@4KI0PM&&*Y$.PCBZJQ@4+IRP&4]X%@5,(QKH(J1
M%5G#>`(T-+L`6&;"5$PH9Z(FVV88E$$8E*]8,C4""[$1FW,(.V:$B9@(2Z1;
M,;S$*XTZ0#5"035W4KW;)8UE]IC;Y1#8M;$<:V@OLP(@*[(C6[Y:RIF]"T_(
M91/L&T+-I?^CD[D0$40S,ENG(`@G;5J")>B:[1A;L5F_-.LT&`$V/?`&&4*H
M<Y6%=DBHO\.1K-JTR>E4P/&2OJ9ZAUICEKIXO$&)J<I%8F0KE?`6CK%CQ4,:
MGY"&;)$[5VF=IR)@PH.UU&*0\FD!&(`!Y4(>8E@.>6NT"!89!//#G,$*N,H?
MO,-BM]0Y`M*W3,E(AR(MNUHNXW9KS#!E[S&&906%N,<?6%RVWW&4YV,"WS$<
M84P(XPH&M$JZY$H,"-``+$`#[1H$KUN,LPL6:%#'/8`&=`*O2C"*<JFEC?99
M^*J^5+(E1'&P25HG=-*+\+K(1.J+)F1;:><C.,>+OQ@458&QVB7_C9>EO=JU
M)F+WO0KX%`?@`)99!.9[RN>K3"KK@!W$7!\$CA,AOQ<Q$;95OS)+CCA[L_Q[
M@CO;6FOJ@?:W:6%A%J\0G.T!A;S2;K<PQ)X`P<GI;8#7D4\F4H^*DL*35;51
M8S",8+W!D938*'FG5.SV8,!S#/_%*H$SD3G&&<V#D*10A"%Z&2(P`IEW1@+7
MP^:&D,9P?<-S5KOJG>[95M$9+&^5J=,@S=VC'=)"41WY&-+2&;_`>W.UJMN9
M":M!"EE`(5D@P^L%!N-Z+,Z:K*#P'QCPB0QPTC1``Q4`-C8$@ST@!&+3/F"A
M`P#8NBSJBO80!%O*F:Y<$_V4%(,9<LTX_YC\]W_-.Z?:I%J0O$W16TV3'!6=
MO`(`*`,K\(Q'!\HLM`(YX`'DB\KF2US)Q-,P`::?>74?(8[QZS*V[($$536Z
MG+-1:G,_XLL`_,BGN0)@$;1,X$-I,P@,(DJQNDC+W)PXZ,P,*<&T)RZ?"J*%
M/9"<8G'+X1E'R4;L]DI4&(5,"3O1TH<3M;;.<WC]6&QIBT7`)U+BC$<J=BF#
MDU=Y);:4D$:LH)R%(8>9%X9V`Y4+;!C`I[;N^5)X<5].%`[=!JZ*T*CD;"D-
MS0J\@,0V,`Z[(`YL=0KH8P%9D-%7,"@_]%1VL-W;?2QV\%0O$+K5,MEA6=*?
MV``@4`,U$-/LW?_>:,`&>2R*I7@BF(7*(--F/7TE*K$R0;VB*1JD0MJ\^3?@
M6R.-!S"[WS3)WW0F4AT$3H`$U_2::#*EAL849"#*(>O5(TL/IFRRC/:ER94E
M.?J^`<$0'V$5!X1G:JV"D#R]+I/+N@RG-M>.WB6]-9NF`4R.83$+)*`ZKG(V
M$FPL=V<HBF38SER&_8F%1KB/C@V2)A6JEY%Y-PGEWV(J4`:M/9@PP6(HJ9#.
MC#=3AL=&DST!J\&';?@;^^CCF<L;IP14NT*USP(8J8H*Y[D<KWU6K(%&T-/:
MO;UX;U-Z`R<70Y5)D#)$MW<7%BIW3V4O4'N&B2&N`5"Z1.N5C&!3A\?_VC6,
M`7FEWF51%AM`%I\N-G7L<:M+`Y(U!"^J9O2PBKIK/T5PHV6=)2?@`)=%9F(6
M<O1MZY9%I,Y+X'LVO$HM%-&K`S[`!@GNRREX`BAP`Q!^35?#CEC]3UK-U1VN
MX2?BBA`8BRI"-/(GIF4ZOQD1L[7,XBQ>CC[2`6ZZRRT4:C'SZ]\%)B*(I_9X
M7E'U.$\HHJQJ2P)C@V,,YT9>D#XI=WQQ.1=<G8<G&TC%1@$-2V6X*M:V5=U\
MAXG#S4\>&-9R2&X4J1V</:K2S8GQG96D.T5T>`VOG%#%":'`A19W.+$-/".]
M2'>%PXBDAVR5Y#WH'MOC1YK4@]J&.89WDA62_]UU0:QE/`AV\"W1$M*8L]J9
MWO1-GU>:GE>I\`94_P.?O@%H``(>)P.F?@,)X`4;8W(GU^JL*$P+8`#Z$%R5
ME=\JH7[^_?;J]Z^%J5K6VQ35^UH#Q;-AXLMWKP/D^)?X"Q52K0XGX.P!A2;C
MY$*CK&C6GI9KYL?W#77QM+X9Z+X",8Z8%NZU);&SR?DM;K,W"]=EQQ1'4OIK
M\N[455T'=0)LL`'NP5ZPPRW[=?*-@1_.^>\%64B!MZBR:BR&.AW@TPP3B<[)
M<@W"ZC>*H2L8(@IAI438(_(QYL%K=,U?[E_1)Y2"D(9I`QU!*2H'HCFI,`Y9
ME&)'"*YT&+:V/;G*Q_]5KS%5\1'$^)%&G3#$!M9ZP)\]E](+2=4;60@(62H!
M*CP6/`$!/"J,@R\!8)&1B90!+Y>)5S:;-F]B8A,3&`TBI0T8J!BAJI]O;S97
MFIPV/3HR-#>Y0R$A+;Z_P+P+"RC%*`8&02B]+;R\*!X.T0Y*0=9%9DK49F9%
MR,C6X=QF4]$Y.0<'*SX^`AWO\/#L\ROU\S[U^?KY]P(^0AW\Y6.C`\F)$TC4
MK5"X`IT`?TB"W-#QT%V\=Q4%D-FX\2$\`2LX>/#VK:3);\=.%EG)<HI+EBNG
M2?-@+H<#!^=RYN3`\P`5*CY_"J6"#Q]1@?L6\L.WCFD[INO>29@Z]:)5C`'_
M,VK=BG2?PG0,U1U`XN"$#C9,Y,BQ8<%"'A*,,%4BU,C2%3$6$K6]@HA2H[^`
M`PNN>XF'X41L+:AXT5:Q)4)^&070Q&-6VT\6/L6RP+>Q!1N5#'FFE(0'YL97
M*%WQW#>1Z+:@#6W"_&G39QNTQ5C&FYGW(46>KPQ"5#FXWKP!,O]6Y#KQZ>5U
M_<I>?5DW6U!X/^&=W'91ZT0JJ%O"'1MV8MO+Q2?_/'>N\M3KE1ONC3IP(DPO
M"NB7^P),`4C[S15>++.!(DH#")Z2"BH3:-<*)_`%D$02D\G"PBZ^A##,`KPT
MTZ$PQ%BCQ(@D(;-,"%_<L,8-&HXXA3?%G%12.#"9_X%3#CW]U`X\0@@A@(_^
MW$-//F`EM520Z[@3Y%/L(#&B#`B!)>5"2#3EI`P4;15/11QU9%%%!^0PDHQD
MEND-3&@6X1)-;-[DYHTWZ81C4.D,5:</5-2C3E?Z,`05.TOILR-55WV4459<
M)0J5D5(V6B0;/3#!!%LDP+78)2](!MX@E:A'76N#A2JJIH548H,)OR7&PR.#
M:)I);`&0AYN#G"!F'"6O=:<(==>)\9UGRRF2&+#H:6?>9_3A55RO%C3H&G"H
M&588L9L@HNJSCPP++&?MN;;7L+79$(J#RK)E0U^<>JMK9:!1:.ZLR/:EGKFX
MAM8<<8V)@2JQPOUEAQV82O\B,!B8J%!`97WQ$(LFO872H!BC)*C@N-J]LDDL
MB4S8'KN9L7"B,QH*@T(X(QYTD#8.=(.,F@:,[,3+-S1C#0K#&*/2%".B'.><
M0@EY3Z!&ZE#0E/WX[,-8#*V@0U/^G!"$$@<AD5`Z7B'1I`Q8MJ/5E@]U289'
MB/K`@0,EEFEV26FNZ<&::M_4YIMRYG@`!T%103<[0M&]`DA)^>G4HGW:(Y4$
MA2+Z9:**&MFGHWL&R0:DDUYQR:699MKM?2^(=AQTHW;^%R&@4G)M8H7PU5ZU
MML*FG'*A`8LN=;"M!EIRIT587&/GBIZO=<B2^VYOM-YNK&'R>I:[NO1EHBNN
MVJ;_>MDAZ1[677>RP4ON;<O72TA;C-!K*O#;"=N6K;-??GH6L6:AOOK?$6S)
MP)$\DL@DJO6:G8.KI'*@"`W44`,"K;`8+.9"(=<T@@0$\`S$9$`S#8TL9U$S
MR,E&-+.4K,PEX8#9%V8`!6+0S(,&4!--=L8!J2&!)R5D'*.D-A86@H6%3<&'
M.IXB!"8UZ2#G2`B5HM2.%3@@"":+FM"\,L,5'$0'6CN4X332);!E)"1C.IL4
M5P83EY2#36MR$YNF<8X;G:,G<Z.;4.KT$Y#P9&]%`912[,$/Q1'-'80J%.(4
M]<0VVE&%(*':67J`B,G%!5.N^H[R?O,IR&S*<Z,Z3'L*_PD[]C!'6.6+E>JJ
MLQQ\/>]9K\&,A`SA&VXQ)Y/(P1>M9I$;9'V&-A/@S"'@!9L^9LYUS#,6M!!1
MB$'0ISN/4-BP$D:\Z9E`<@P[C7;.!9MN.4(%W4F,]C@Y/$DBQWO$JR4C%I$N
MR5S"#G,1&";@5X!(E&X^UC&0P\8I"@SXKP8/TQ^$%M8MXO%`?6U!(`'FR;XL
M3*`"4$/(U$QX`@IN"&0U^X85O6&-7"0`"E!PX#7*$2<4@K&%2,BA"2=*40E&
M,(9_ZI$/R%*EI=!#"0:P40X0HB<8XL-I4).:$(4F-3VM8P4&0>(<N<21K!CJ
M(53(P11*8HP83?$;:++B%;<8C?\1S@0G;MI)3U!HIZ`(`"@^`=1#C/2G-;*Q
M2$R!8U7DN)4D9F0>#UF4&E^JIRFM`*I@.0L3#DFYR>$*7;@:GS/3Q59$=LXU
MB"CDZL+GG4UH#S7/(=X@]](Z65(G/*Q1A"6+*;U1KA)\QZ+D)VZG+1M4<W5Y
ML=Q=>*>LP#02.:YI9&KZJ$M5<LMZV7EL)"NAJ=<<CWG508^N5!5-[W"*4Y?P
M#_PDD5N"R4\_!="8^/#'BG*2<YP/@@6\SJ5(A1'H7%D`5J5X4"FXO-40/1#"
MXW1P`ADHHX$=RA"(CJ$F*])DI\6X`8<T9(`1>1%'#HTO3[IX$WT&\;[V/<$*
M>O0.']'_PR`4=`!%#S"/`XPH&V71(1*6I@^#+/@?/A`:0@I2I31&F*3^F"D3
MR8"H)0K@`&1#24\M^-/R"E5M:R.JVZ;1IB^"D2=-+>-/[(&/L":%;TW9APRI
MYA2/$*YP6BD:.RIB-!J/M:Q%JA/5%API.2BV$8"4C"+G(IX7'+:6=;5KJ$#7
M%PN@:CJR9,XFIKFJ%PP+%HE539H1\QQE[<HXI9+=;&^3F]W<[SRH;4PO4<.6
MP7J25[V"3V`,L0/'L+:1@C3-(?;"2=AH1G:/'/0BH*78N/9.=9.=)63H.C#]
M1.#3$>BF;B4!W&Z&=F&V^00Y]2<*BHG!%;.PW937%]W&F&!?_UFP%&#`<Y]*
M%.`':)#!#1+@A18@5+P@TQ`Q+FA>+'Z0&-J(KU+E*R=I<.--$7QPCX2@`VMT
M%*--"L(PDJ$$?A[$2B1#B#X7[-*C(6';4^'VR\RR-"%QMTH9GFE-M821HSE`
MQ",F\=E,/%"ABK"H6UPQ"5]<MZ$<Q1]$`:M3[)ACLN:Q2/NP")"_*G&P+BF)
M1;$QC1?"N!>:I<G1I%Q=IDQEN;*%FJ32LN<,R4S0X*8W$8(%E#_Y&<.LAC??
MR=7LS+6[H*?96I,D>G5XDYC5/*Q<BTYELWS5'`6NRWBB001]CL<J3ADB-9IB
ME6B;.SY%:SV<>^GYI%<^3<KA55VJJO]L-DM=`%#;_>Z@3H)^0L.)ZKA"._E#
M;L4Z$6N,3081%)J/`O=E@5SK>M>8"YA<`J"?#<B`@P@]-H@V9+,@F)BH'I""
M`Z90#"5\T29O2BJ.<B)ZHR+U)CKT60VYJP2:/:UD%<:'$C@4HI1:U&H;M899
MV%$0[JX;4#Z8R@]^(($-Z.`&7W`"O>U]D`,0V>-:V?>AFNB#')0HX#:3(L%?
M=/`4CS#AJ9\VW<#B<*%4I(Q(2E+()ZYC*NDP*3NZB)+":C0+][\??*,U3#$E
MC;)@;"`$:^47F)(IPT%+[6%E+L<]=,&`,C<JH.,:>/$NV($7V=(ON-*`Q*$M
M$?)*N`-IM,/_:-^C9XIU.\VR:+H!6>;"3)AA&;/B9CQW2\@!.YJD",_A2=$A
M36$'.L"2&A!(2,O#*^-#'EWW9*T22*T175E0&89$"?[A:7AWA7>W=YD`"OHC
M3L>%7*[P!K<!(>:3>%E@`]'E,+[!7#'W.90@:@6P@'*A'SS``EZ@`%"0(<3`
M>;D0?@3')E(0B($H#7!B?EN$8D;E8F`Q-@[``8JC`[OG0,40#D!$8,&G;+VG
M;B;T4@BQ;3UB"VL`)>>&#T(P%1MPBG10`=`7?6;Q4C+43]8G<EY%4QSV-8GR
M-2!&$N#G4P-712\R5*"78JFW,_"U5'3B<!5Q5E,%%0+Q%%=55B5U_W\OA556
M<7W]QT9,HT;:R(PXA60D]XU'HP,;D!9.5F:`Q%H/R!VAQ#UQ48%WI0B,D!G+
M92"U$2O"01?1\1V(]BPZ*`:I$4RFU#IK%BL.8AZZL8&ZD75U)CNF\8+!0CN=
M-#O4`0IY(1K-<X_1L82L%8^^$8^9]2GR4R&KH7BKLBGPN&52Q@,'`US^@85W
M5X6A1G>)5X.B8`H(8D[GY#]/EX&PL##LU$Z&`4_;@CNX@0KH)!AO6(7_`0GQ
M,WG_,0%ML'D>M"&<YU/E!8B"*(A>M`UF0(DM,4(.%10RY"3'P`U!8",=%7S-
MT%/IEA#X$`1K*2(CXF`M-7M"\SAL@`8ZL/\B3B"*2.0#!R@$&_`#&P`":4`!
M7Y`B,I![@-)/.2"`]L`5-66+B",V(;:+`B<C:?*'H#<3")=^Q4@W+S84(G<4
MT[@W&/6,WT@EZ$!$"@$V'_%_1V9D?S.;>],5&*<4[#`66R`&:6$8E[(8U417
ME<8=H(%,T-.$[FB!P&$"!8D;4F<=_>(JQ`DM*E@\O6%S":DMQ+$Y$HB!#Y-*
MOP,\1+ETY<(;#EF29Z8M;-9)OY$KBL$JO$87AY2"SV-)K7$82&AH=.$=,!<7
M5"@P5HB%P/5ID2!J_D$AP>2%JR`"`S``_%,#./D_8=B3$=(MIJ..7G9KM[8^
MA0"<E?`&(E`&`%#_!@P0'0'J6Y)@"0O8".HS`3B0`#5C#%3)>52$B%F9E7#2
ME<K0"S>@,_#E*`GA).HE,C2#`N4&82?`>^NU`")R?#Y0>^4F-`?03_V43^O`
M;6=QE]JU!D,0?4)#?$=$!S]`!W#@!!"0(HJI`S74F$'@`+<)@-G71#,5$MV`
MF68#$U147@<G5`B'?JJW$V&4#F(D8T/1#D2AFT:FFE1#<CDP-6)A5DEB*/\G
M*'^BC2+'#U,5.&N$#QR0`RRP!9("G']$5V[8<NOH&,LI*L5I9;S1(/8S3,SY
MH7)70)MU*_%!/=B)2YGD6`6"'9Q0&75&/;"T'?#9<\"B+_D)2XU`3>#Q_Y_I
MLCN@44B=\EG"T1E81WD(JA^1X))WIW=)$`$38JN<@#\.@T[Y@P&FX#_&XI,*
M(T@2(I\J0`*W!BQG&$UO-X6QT@`,``$:0`'(\1^\A2F1(1C$(P8E$`+AUS(C
M!E17N44Y*@6?6A:U5PP+X`L+D$_])")))25!$`)Y*`S6X*3EUA0RL%[CI;%2
M(Z83)C2@F`LJHE\P)8YH0`=,L`%P@)@I(GT'2!`G4+-H``<RX`0W,`0)D`!K
M8#5MB@].H@1H%%:(TP$<QA480610Q+!XJIF;V1(O47Z="3<Z$98PUG[N5Q1`
M05:,0G)2\E`O-#70.&19@7S;J#CX9YL"$1;MEO\.4J-6<J`"7,`%<D%+%NB1
MJ4.<JSH8H@-XXBE,EH5(A"!WQ8&>J?0LN?J>UCD]EV8LV$.>">EH3U>1QW$=
MHFMFZ'F?IC$!A999>Z:"TM&<@H!EB>N>L],:GU5=)%""E!<!8."MH+:[61A<
MNY)J!K(@.8E.[*JXJ%"A.N=6WK-IC%`I\SI/'XJBYK.`^F$#"``"7P`!>``&
MB?`OC<`70>EXNN:4/-``:X`V,-)3:--L68E"@7@.D<@A>4BR0;"82O`,*5$$
MCK@0*.`&"66D3Z-/X4:R!^%=4+(&*?4/QD=O(``"J@A]N8`E,(4$>3F8J5@"
M.HNT;*JE:!"T1'L#,+/_!B?`#AK5)-7`IK-(M56[-39E8]X'<`%')EN[$@-5
M!.<%C&V2B.HW-PW7?D]UFH`#C7J[?I^*#G,S-3SA0KDI@%55<72K8_0P0Q?G
M%4B6#F>!!Y8`N*8Z<XRD*T!XN$@)D;0R=6/FN)?+&3^'"-CQ&;@E&H6DG_EB
M2H80G<A2(#@HO!19:?!Y'4B7+Q,0&YK[G@H#+)9`NYYQ6RN8+,J",']!`N3K
MK$GIN[R;A;"EN.6T()J,KA5S&WDP@RR'C\B42NYD&+=K`8]'O?^1'W#(K0,3
M*]B;!@FP!8KPNO-D`H4&%Z[4HM-T"#PP`3*@BR;"OC>J-N]+;<O`(AAK#2WB
M_R0B\PT.D`XY<+$>XB%(ZGLOE0-FL&Y((`,KD@!]^6Y:>A8/C`80C)A#$+-(
M5*4Z4+-T<,Z(Z05>L`9(](DN.[18XK+]YR1!8#4:IG$L[!%$EHLR/,,JL;5=
MRS8Z;%0UH7XH],-"059&L3=Y0E:.`D81M7XNM,2/:E8S-,113"1)DR1\,E58
M=321FE8Z(*I)L&M:1I`?V1T?FF5BO!@GF)W+95=X!2[A<P7UVDH),TGZ"(..
M=F=$5V<:Z!MXI7@*9'-+]SP,(Q^6QKK6N1GP81AXECR5\"^/@*`':J"CQKO!
M]1_L0ER:S&JNY@G&<C'P>B]!:0'S!,D4Z9^ND6LV#?\9\O,">N?5\'--V)0%
M>"`&",``&C``I+.<AV$###1%#QNQ\L4!I(<":S#9(O*Q3R-N>O@T.`$6XJ90
M)#.786I$)7-$.N`$Q";",H`&W%8!%:`#='"*AJFS$\RF=VG.%3"T,*O.3:%=
M+HN7:/`S]E8-P#='6M/"6Y,HN8B9"VL2-<RU)Z9B8.MB\45&[8<G$:>,@=(H
M+_:I)71"1CQ?2*PWJYDT>,LHN>E1NWF;JPD5!6@6"/`#]U&J:'Q8\0$J-8V4
MA7P_JZ0;6G88D=L@5Y`$=T%,B65)ZD$<BGM*YW(]DP2#US''CT%-QC-;L)H9
ML*H7OH'(ET2"=V%*IM-TQ//_6MU*R5<HH+M+XJ$&26*(O/K3A0$T"Q8JOHE0
M:@6$U:<L79:2'":`/IQB:O<A:KGUXZ,V"6``OL_;!$V@`EG@G!,P`!K``"II
M0`3`H280UW]!L&]E`]T60FIR)B=A7H[-$T>`0CD@EUA3,A)1#2$``PK@!B%P
M`QR;`V?E-$^C4MXE$3<P?2M0#4H`)>U<VHF9IDZ`!DS0`S3@!'"`BG"0!DZ`
MF`GP!3(0F`1!$%B#-:Q]EP1QE_^@79G.!D."4;0WW,1].%J2;QZ!B_^6$EG+
MW,W-IP\;C%RD5*$)T1$'%(!"!7R3J(0*%G-RQ/"5$]+<14A\#B7W%9(:.!AW
MTDD2_YE5O#B-<A:#&8=01H'O^,6*42JB7-,7"-/UF!R-B\9=UB!"K:%N?(/1
M$M7BOAVR(NX-8I'``^"Z`CN"M@BK\7.V\>`6GH%PIZO6B1>`AAG4<8^MX<H"
M`VISX)*2D.+LHL<,.DZJT"`"-$"7,ZYU)UPK6&NH<LJ&0!PHB@C^P90'JI3>
M"PGS,_+>NPBT9KLY3I`-4`8E8#%ML0,3T`5=$`,$8$U9!LG,Q08@Q>4WX[['
M?`1"/^:?FC-8(WS\K.8(I0#S?.=)NE%7*@-]WD\LD@#Y_#@G$(I8\L%G>K2)
M20$-L`$UP``,`-MP4`%ID*9?D``44`$@@`;9M5V8_L';!O\H^HP/+LM@[=:F
MH;["`@VU+6PX[S!D7G4T'E#0RZV^S9W0"_TV@2K=.4*V.D)_(KU^88(.OIX3
M."$UFC_L2%QR:GO>B^.-1++L6@.-(AVI]0#M?=2.=H6=H2L<77??DB%EQ&(:
MWSYS_KU7DZMFN(-)0XAI96Q*!6E*X&.#R-D8MQ4>C,<6SG*Z:[A8/3?5]2J^
MAQ&2`U/),1D!<W#PGT;6%HX*"J(_Z/ITL!:LVIHQ>[W7>0>\Q%-K;;$^)$!-
M>3`*(A"JN8,)X[I;NP4(=G9@@V!9$Q-9%A99C3P\*@&2DBH\%F(V-64)%0P#
M6Q97)CL[!"0JJ*DDJZ>HDP5,)P;_!D6U4[5%4[H>NQY2O\`<1\/#'#D.)S(R
M:PLH2"LG2C)*-]75RDHG)P<^/CHG2-\W:^()"3<T+#T(+&TT%6AH.C(WYE\)
M$`UO;PT-"'1PTI0H06'@)P0]&FSIL:&'D(<0(W;KM@*)Q0,6D1S8N((C1&](
M9.@0TJ%D20$"3J+T@;(#RI0O4W9@N3*F@`-%#*#8R7.6SY\^<0G-:>N6KBD>
MDBI=ZL&!4P<YHN;@L)$#52I4-F+=2H7B"A\KJ*P8N[&LL1P'.#B5^M2BU*A5
M<VB,JA$CU8X8ZW(<RW<O7KYD5PB8V#%PWP-D$5=$PF9#@!>07Z2:3)DR#TE7
M%DFR9.%R_^7/H$.[FG3EL@TQJ&V(IKR9AXU%/*Z@%A/J,N9%N#<'X+R(=N90
M8B9<$L[Y](39%E[;.#V;M@U)DG&;L``Y`*I%KX=;V!V\-VX>+W@GWUWI4:4L
M`0JH+Q"AO7LP\-W+G\\^POH"R_?5P("A@8C_(C3`7PW'H;;/<C;8ED02ZRW(
MH(/W%4!)*CR0T$@6K+`FB0D#E*&!!@P@($D!\*D'1F3PE0B&A"M*,L@D$X@@
M1FR7J2=)=F+L,`%__30`1P(S)$"$!A#(*`8&7701`Q^K4!;9))6HP`0;:P11
MU%!%)07,+\(00\PQ2BBQQ@T+W'#"-T&(=*8.%<C@A!,W!)$--_\6Z?#-FC+<
M\\470Z2!@`T-E$$!"'2``(>;]R3P18@;[K@%"P.PL,46-2#PQB-XX+'0!DPP
M\1`;*[#!A@Y?320$&]&`D]&J&OD@T3<CF22K2R_11&M+M)Y$4S<Q^9!#3CKQ
MA`)0Q,Z"Y95%(<744D^]-9555I55%E>"^2`68&11%=>SQ[`%E3%KP5751E*9
MI5A&TOJ5F+J*<<3K7X4EAFU6VK#!!"62K?:9=;]%@ATDD4RH[\"3%&R)<ZM9
M5]YMG05@@PEB3!?*;I>)M]TCNUT",6[+]49;:LI=0MMQKB5GP7'837C%;Z&D
M(AD)'L>,HW>[O9:%;3:F&-]\\^W,<WO_ZB4Q"0_!^3?`T0R44$&/&-0@QH$K
M3[+@?0\"?9_""4]6\&,OI%C`%0TP4`80$(C(GM?PO6`=#XK<?/($`8`1@!VC
M[<C#UQ_SAP&`(XR@MPA)0Z"!%3,``001"3"`08X[6("*VM"))D<L5N)R5"]:
M;MFEET=0<00'T4BSQAHR/*.#$D&<*<0&:,!1CSD+!(&$-W9JHP,(.CB1@!=[
M?I$&!A;4@$,)#1A:01H4])Y&`\F14`4!662*AQ[4VR&'''IDD7VF/8@Z:ITZ
M9+0"1'>RRJH.KD8$*TFSFE0K2[?*Y)*N*_'ZT@$.Y"3L3L42>VPNEPN@4I3U
M%*@X*RK02J!6_[8B`&H!Y@!H(9=4SA*5<!VC6<\R!E7>8A%M840NZ5+,`]FE
MKE+!ZS`B#`M&3J".YPQ,0]99VW1,LX@7VA`T-#R-:D1#"8QEAX:X^4X,`\"R
MY-B&.R.;P!5>XQJ4I6812VP.;9*3G2#NT#-!=-PD7B"RWB#B$>+)PG/28R*?
M_>R,*W+/@VJVCS<@R`9OJ$$#!I"!.I;`$PVH@1L/-"()!>V,$6A1#Z,$FJV5
MR$$,,M'4DJ""'3&`"$,P6]HHP8I5M.T1.[*`C0K6'S'40`0#`.4`>B0@O?5G
M``R`@#F\,`,8P,!P&FB`PZ;#BD94LA70D<3DJ!0$,QCE*$K9$I>LPO^YSE%!
M+6'2!CA(=3J1H$$(\:A`HKS@A1OH8%3*T$$\V*2[(>$##F+@SAP9D+029.".
MHXR8":K0!1,$8'*=PD,/\!!//%Q(#SV@@9TLXH!P($$;C#G5/%3USVRP:GSJ
MLX@/VC>KP>#J)>T;S$0FNA+\Z606/>E?4(9B+&`>!1<#3$H!*WA`:*6+*P((
M"U:P98RZL,59%L0@M";8K;=H"PGBDA:VUC7"%);*!R14#%C2@I%K]H`)<F`;
MP/2U-53\YC']2@76;J@O2,@F.#L,#21(`QN'=;6(GF$8%,&(&]1<HC-5+)!P
MLL,<[?SP8%-<:A$=Y]2SQJQB.$M1>^8P!_?_]!60\F'/@R2T'-1,8#\"TN,^
M$%`#.`P`!QF`0!DR,(#%/0=C`4C"<W@&GZ96!K-;1)&*P`#8^;R@:%Y(``CP
MP(@+-4*J6RL`#_A3V.#L")7]&*6/2,E;5#(@#:I,@!6@``,H>($(1"@!`G8T
M`1,PZ6:N>)+"()$%)G0O3+RX7#"%24QB<"4K2`B3,F0`T#NQX9EH`$$:A)M:
M+PR!!:*J``4J``)#(0](&BA#!1#`MN1,P#^D=)H;%=$$=DX`#PCI'@L6O&"%
MV#-Z+*#!F585OHQ<\U0LL!,S-:SA<$1$"/M<*$-E!5&5R$]7$TWQ8`[@@9_P
M3Z.TJ(6QB`+``&HW_[M,&:E-HS6M[V9E*QQ)RU2$?$$#7O`M(TW@3,/EE)O2
M)80[C3*\NK$1BOAT+RLNBX9[<#WS$*RI1-0,%VNH-:H.[#+#R6IHN-JPLQ8L
MBU=0F'7@G)RK+N(X.F1.<,QJLN3,!L\8LUB4,B8Q+2X1KPDBHU__ZIX'.)JO
M?/U9`1:$&0198!]B8.Q^3%F#2C%VG(_-``Y""3PPCDAH7Y30VE`!QH!MK6!3
MFW02`%F?GB4!<M;Y;P,2`(0*,"'1Z2&CT+PZFTX#3D#'66S81@F'9@_`L0$B
M)2C)60(]>8&X+:#F#"!0`]@\3M63R9#6)J>#-6!.F,'HKC&_VY%HD*YTS__P
MP3_/FUX6Z,X*YB#2%CC%#G)6H`(TD&P"VG`0/%1!>O3L%!,2KO#L9:$)_ZT`
M.$*G3&5LP9YX:)-%M)&#-=E)5$?M`7PY)8$?L.Y.&I;(J$ZP`I.0H7TO+_&M
MVI?BFJ_8#!C%Z+"*A8N-UO@6EM/%SY6E%!U/T*0GQ<JTTB45G%:0R1:\8%,0
MJ.0C5]#)%X%RE/U2%A.ZZX1_L3)>_JD#3LEAJCP$,Q%G&`#<.#429M:7VF(S
M`3474@5"/.L1'P'G(181$[^1C7"ZHQSCS*9CKODS;?:>14@`K#.E(6.MY?.`
M.3BZ\I=_0'L<;9]$#EM")7O#D?A3(`.)7M.=[O3_8?=SM'[(<0`UB'QZ".$:
M,.YMK0ER]:MGK[/2_JRS`N--(P,T!""P0`ZJ)N)K$/&W:"O$]0C(=.K'"0?>
M\G9`>QM`"2#PA>%"`0HM",'NVN"8SI#`%!>JI`HB\P)!Z%(./8C&4]`]3'6O
M>ROM%A-Y-5R1$Z"7FPF@`3.06BSP!M<C!S:P!;Y%3BR01VYD,XV@!]=C75O0
M(PNV!8G0"%M``Z23$1.6#.F0"!DG<01E._]T)D>%`%N``&K0@FKP`V@@`T-P
M`_N7/D+0#=]P`"X'<RKA/K@B*Q,A42HV&!R`<SOW8C"V41^5"\=R8\Q20!B4
M03QV`$IG+MK2+4Y79$]G_V1/808&1$'@\H4FQ4$AY%-2UG4HM%,ZY15BD1?7
MM`%G]T*OAEF_43'3$7<WA#&8(!J9$1M0Y%4-8QNEP1ML]PBEX3&GL1UGA1Q&
M9%;-@58FXT1C5#/8D6BN=A][97F8]VB,]E=_E7R[,33Y(7JIUS2>A@"HF(JF
M]XBV)1R2<"06(#06(#&CT%RA$"-BD'RX5B(DXGN!U'LDDB*0@0HPPP@`PS4%
M(`8!\@4*D`:=IC=,,R"IAP#],4>P=XIOP%C52$J<IE9&$S@SX`8S$`+D""1>
MT`#,505&4`E;E#;#J`I<8`+TU#U(X`#T)P4)Y%T^=BTG,#I5D@VJH@P9UB;W
M%O\D);`%RR<<>(`(R*$]U*,'IE",CP)P'(@-:Y`.,\(##=`&Y"47J])Q)U`!
M%X<'(%`!%U82J'(G"W943+!O+6AR&P`"%+`[YW`";/`1WJ`$2)`29-"3L_)R
MN>(^#!6$-6<_%8%S.9>$0"$4,?8_3M@4#@"51J=D2&<62(>%WF)`.M:%WV)U
M6J@M%-1T98B&V)(N\$*6B7$1@%&%104"CB&'NF=J@'@=9(:'JQ%HRQ$:F6$"
MTY%HV=$:@P@>;5=H"Y-X'X,)L'$R(X.8F*!G:T5%7<1$?<B.DM=HFK>)F8=&
M]F$C)=,<#PA';71ZFF8IH=E&;_0*5J,V$A(C&/!&8/3_FBH`BZ^@'KXH'SHC
MC%/E")'0-2NR'M41`!B0`0SP!4"0."P0($T3?:)W6-O8(P,``JB8>ON!6#S2
M--!H2OX1('#``FF@`5!P#@D0`EZ@`%X``DPT&@*C`N(&=Y%P@$*P`F]1?YMS
M?SX&%OWHCV=2*O-``S)``]4P!'T"!UM@5EE@`EE@/6R#!\$Q*0RJ)#L@!EN0
M2OZX!F$2)C1``PBID6V@#4Z13!N'!))273T``DR@!A(@`1V`*J,CD`CY!BMH
M<FA`!P`!)U^06DXP$A]Q.CMY$B,6E#TZ$[QB<T;Y*TI9I#XG%$_9%%"IA51W
M%@ID%L]"+E#A=%$8E5!GI5/A_Y4%!)91J!=EN'5FN1=H619U\14H`63AH$UC
MM%1Y:!L/HT4P<P5V654TI#64<%6O,2.`:!NL5AG%^(?$-AQFE7@><WB).7B-
M^494A#.9R(F.E@*9=WEJA$CM06G*)WURE)REN:FBQXC+42.25C/GQP?3(08*
M\0-,L`$;($?0V3&KD%F)9$:EQ8O3Y0A;M2)>XYMK8P%Y0`*F6@%#8`Y#4@%P
M``*EB`%G<`9Z4P/U!0+]L*R=A@!A4U\LX*RZU2,BX#?)RA^@U``L``=?\)W7
M9@7#=8YGUP@$`#VM8*>>I0**@&#=\PW/4DS#L(]*%Q+OM@9K,A9LTI_IH!`#
M"D:-T/\$3?`(&X!-RY"O,M`#C8`'+#`$02`G`'F"VK!?\,<"Y*41X7,F&"L#
M%<`"T^-),MHZ((`&P!HD3K`TK,6J:*"J)EL-7_`Z%>`0$,$&8=)R/^JC/0H6
MNU*4M9(#.@$L1JI10P%TEK,L(H5!#D"5&@2E1X>56QEU3!J61=9D4FI!9ED8
M.M538RFF[2*F@C$8ZR(7]I)4D,$%K.9E-J09;?>'D)`O<PIW<MJVD[%5OP$R
M?':,Y0$:?'D)'>-GC^BW<,6(6?0O-4*;D?H`*;"XC,MY9S1ILD5%G^H:HXB*
MF$J:F_I&"0*J$5!Y5D,Q000Q8A"1)O!?`\$`;1"L&@`$0W#_5(\@&?71>[;I
M-053'KFWF[2)JU!"C/\B>S:``0Q``1`PO(23!L0*`J:(K!C`G,Y:?7.D#W\F
M1SA`;>3$``$B`HN#&GEP!7G0O?^52A5P`T$RKJN$H<T5D;J7GL38)*,Q@3U0
M84B00/9*!6<J%G:2L+&S3!IV7B'W*'ED6(C0!__%@4%0)>,0)]EP<='#`!`;
M!"@@)R)!L7"``'+`#C?9`>33GV\B`R"KH`T@H_4UHFDP!*QD!>^%![_+`/05
MHP&1/'R"#VZ9JM`4@[+#/CK;@SDK4?4SA"P!5$3J8CLW8S`F8S$V8T&7%+Z$
MM%"Q%E9!=5(X4]XB%U%A!DL*A08D_U('Q*1#MH7EHE-=5T+RLBY;RW5F"19B
M'`Y'=79<@+;EP:8#TR]A1E=Q&QID-EV9T1P)<C(-8QF5(1FB4%8F,T6/6$5\
M-D7CL1Y^57ESP+B0&JD\8R.0ZS"@N2--\S2:NZF,A;F?>;B;IWF;N1N-,(M\
MV;>.4#!7$)P`\`'(Y4V\]@4UP`1\^@*V";DVDK9*=42T^<F[NPJ6`&PZ\P(V
M,@'!.[P40`$:D%Q+8ZP$PGR=]F\5<$<5T`8L\(S5*`*CADH`0LG/80/-E0>D
MP%PB``'(TUX#6`T)0`-ZJIX$X*?LZHYK4UW6U3VB`A@I-A9=T4!=L0+?L`9.
ML`8A8"8C,?\JHB)0$7:1'BLI"+`(&S@.$ANQ$:L-(>JP-U"AV;!_X[5?/*`I
M-#O#+#"3Y^"Q#.H/A<(IZG4/Y)HX8B`'8O"<=-`Z%4"CY@`!`X``"F==:'`"
M-<Q0$/6#$44_M?)31$D1/^P305S$0PPL0ENT9K#45+PL2_PM3MHM38Q`2&9D
M.;#4:V'%4('%80F%6^S5"#26A@'&8IRU09:U*+01:`S+I_".9A;'ZQ=5A#2G
M<IH*KS$:*G#'#-DQ/[09%$+''R,<E2A%A856B<:Y?,7(BMW(GAQ8E&L;E(L@
MGD0@_5')H?DTH3F*IUD`BOMH[@%Z%K,(-R,)O;D>UD$".X`#'_#_`1_R(;UC
M!:X,RY0@>08#FWU4'R2RNQ4BVK8!!@ZBRQ42&T?R6`-Q1ZE4!@R01]%G6YL6
M-O,%`6V`NLDM(&?`?-B[(ZB!`?NP."=SW=V[`XNS!>?DT;L#!3>@.Q!P<;/H
M!WZPK@4#&8)$'NJ\"`PW@37+!EY!SQ,Q*BPP.KI#@QZ'L6,"H#/HCQS,!-G3
M``7NT`4,D#J@#AIHDC?Y$&R2#&]2`37@&@WPTB)1LG!``5X0?NC0``LY`,2*
M!IX"!TZ@)\)5`AG)K/95W&E``S@@`G47``IW<F;"/CO=XSWZ$#R*8D5I/_@C
MM$/[$T2<Y%BB"TOMU"0UU23U4E$>=4W^_]16G@-<7=5/W<1):V0>M+4CI(9=
M^[5A[G5?'`YL0-,`X]8WA!EWJ`(;`UMSG`IUS!M[%LB&K+=S71EMQY!X5D6=
M<1F667F+K=B:2!_J0;E+]`8[TFF<6IJ3K<FF&6>UYME^E'QLXUH80R*Y'%B3
MYC"H<04D,`$9P-J]<^KFT`"_-HN-$QNE/"([$]\":QZD35HF(B&1L#*E$<IN
M$R.H=#2C9(J4\C0`?$H,$&%#0`-#0`$1Q@!'90-KK)[\H9A'DMTBPQP!L",`
M$EF)0L)0,`1.$*PVS@A-\IN@82%;1=J0\PCOR@2I6-.=\F'>PP;(G@#A1SHZ
MT`,]L`;7%CL\(?\GRJ0#&,@"X;D`!A\[^@HK;#!/68``(!`1(RJ#J44!RX,(
M)EZL)6NR%&`%+=`")KP%BB`"<""C.@`'\K4G]C``I5`)$-HCP\Y:6:">)(`@
MUO6P-[!0/&X3-RPK0#X_*D$88^$5*P&?4Q`41[Z4_X.D2TUT23MU49Z56OET
M;^$!7EA!3J^54Q?549@648G%-J5U\7+69?VEAH$75^:U!V`G7`8):\P%DN'&
M"?,">QD*<CWG3K6'E=!6>(NHCJ.VH3%W(H,:=Q,`B:RXA=ZXDHK(]D$QEQSI
MB/6_EXW9F&V:R]%'$:")F<D=B&`"FXLSG2YIG1D<V3<`$X#:&3`DO6/_#OGF
M!13@-,'13@$3C$#3&F+4^98?`0PR-*]Y"BMSN(G^7P`"[-+(G*;$'UMP;,`*
M<-),`R'"!!;`QE>`"-0^H!":@`T@^K_+(UN``YN`;\&*L@"Z!>DA\S&_9J^F
M"N='`!)S3P=X@)VB[_"_#H\"XM<6`AQL+_L^`^$7.Q<%"$HG2"<R6UE;;3<R
M2#IL;#HRA2<Z('@\-2PZD3(L<!5#7EX)%`,38B(5%2`;/V@5%`E6LV4865D3
M#35H<$X4$,`0)2(375TF*CP\-C993$QZ>K<6%B;4S`@@0S=H0M[?`N'BX1WE
MYAW?Y4+FY.$^[_`K\#XK'$4&!O?X^_S]_D7W_P`*'%C$C)DI"#U,*3+%@0</
M#ASDR!%Q(L6(%3%2-&/1@4&)%T%6O#B1@\F)($UR"`FQ9,D#,&.NF'F`9LV8
M-W'JE#G3)L^?-5<08K.!"8\77+B\2,9#A=.G4*%>4?'BQ94=.ZX$H&9A:M2O
M8,.JL"#&!H\`-L10$U.6VH13U)0U%?N4QQ4+-@+P*!#AP8,4@`,+#NPW0H'#
M`1`K8V;C#5L$-2(C>/,&<@T$F"-3%O.F,67&9Q-'&.VW=(HY<PKHS=(L2S4Q
M)K+P'4V;-N(`:)FQQ="@M^\!P+N0V(%#@X8$LHP?3^`%`@)FQ?@DQJV7J3(5
MU,&`F:T]`/9D)&Y=#__P8G:2)*J530#.'HX(X`W>BQ#1`,,IMM=J,&B0B`4+
M&CWXAP`3-BSU0A+4\?=&`Y.QL`4##$R``0Z]G<)?<41`D<`--XSBQ`T)1#@!
M5CO$UA1Y+^!6%74\W$+"BS`^9<>,,ZK0Q"UXY*CC,TS((0<36S1`@P:B>'$#
M#31LP08--R@1Q`(H1!F$((7(T(,="+#`A@1<,B'$?QS*4`$+"%BP11I.R*`F
M'"!4@-R;%5S20!IPH&$G"&E0\(4L,Y31A8NY?)(&`_1ML<4$%F11A3$39&$'
M#WKHJ.,$>+R%%S-OU("D$%Y^LTX'[9!SCCK>E",`.Z>:*DX\\O@@P`HYZ./_
MSZRSRIH/00!-81!"9BA4!$0.8>20&2`]-))&'Z'4*T@4=21212I9]%(.QFH4
M;0X[]134MC!INQ.WVJ[0;;?B]B0N3B><P`83Y"7%!5-T@84;#]8XQ0,U7L6K
M[UU<R4466V6)\19^\^Z;C`4\D#;8PG/8=MC#RWB&66:155SQ9)1EO%EGH.$V
M6VD@-YQ>%LK,*]=LM=6F&FXV6"!A;QC$+'-\]%7<`'`C$+##`&4`8!QR7U#P
M"RF333"""!CL0`W)V1UF6`%@F'S=4^1M-]MA*<I%PKUIX?!!&<!!R``.`\P7
M,\#,4)/'%6D-P!\+/?0``A,U-+#!90&P;99J#3"0_R4("%"PG]\(X-#&`#6L
MQT(;&@"AX1"A&!E*&UM0\R)VU.FKXHK>J>":"02$3D"BMY#LHX^KN9Q)Y#,<
MV0;<%<BPR28G*"%[(6,BX(R2:&Q2@0XLQ/+%#4Y4<.@6%82I`R]IO"D+Y6+T
M#3@(GY0`3`(:0##`"#$8T00)+A^*!^G1)*H"`8LB^D8/D/CW"`@L--##&TS@
MT7(-`S#0`X^>"A&._Z(ZAS<ZA8Y/!;`#9!C'.WJR0`Z8`1^VHI4$!7*KA>"*
M(0J90K4VV!*/$$M8'?R@!ULB+91(9"70.DE).'``#CA`@QJ1EDIT$BZ:^,0G
M-#Q7#8-2PW/EA!`GV%]3E/\"+WV!A5_8J88%C*BO:ER!;7I!BZ72`C"U%,R(
MX$O87P8#LM&L;#I>5(UCZM8;BUD,,QK+&&/,DAB4@:PPAJ&.7N02&C"DS#9/
MRUO:!"8A#+R';$BSSUMFQIO\92`#(@!=`\KP,Z!!;@C'B9\(1M`%I7E,.T];
M&1U+YC'N0(U%K=D:U7"SA3(0H0QBXT\-`+:9@0FL1'B)WA:RM`$0,*!-:6A`
M[BQ3@S?\H&\(J``#MC`$R@T3`0Q`Y18RT;<$`&$,7H"<*&XPA`0,X`VX.9\%
M2*`";D9%CBGJG%-((+HL$.`64)$C>%Q##=%-0`0E\,(,9@`#X@V!3'"@4S>\
MP8;_=,E@#:HX!!-T&3LG%`\6"?B"0M.PA;2XZ09U:I,3]L0<*T2(+&7L6PE*
M@`,&#(`%O=Q!%Y;P!P(D(PO2D)2.MDD`$^2B`;23Q.S$M+\WC,^E^=L"CSK5
M/W&8BE2<VL`ZA.`#58%*`&1`U:KF`2L*2C!***@50/9Q05QI$(;)\@A&#$(1
M8(4P(@9)5@FMU:P<L'`E+VFA0X#E$AGFD('E\F%.WHI#'IJKKC@AA`YZ8`.J
MV&LN3(P*O9:H`B0&%BS5.`N_EJ$6M;BLL0B;6KR68I\"`"8U*`LC;>;P@#E<
M-@`"BUE\W-;+#:11C6P[B]/ZLD7"/"".RKB%652[VCOF__$*E:F!S';+FYJ1
M$6:"K&)HWS,`'.!@!-C!@"FM((M9($<#1$@`'!"@EJE<02[BD<LEH89)Q##E
M15.CCM/`L")EB`"ZQZ$`"'I@QAH$21?X42(/Q(`X!$"``128`2DHD(8*P*$!
M(*@!"'0!&594X'4)&`((D-0#&@R!`:OP#P,:!\UM,$>AT1R`?4Q@#6]ZK"KA
MA$J,2A::`&A'+BVC!H=#=SD5U&@'\$S`#+P`!2M4DP9U*\$JNK&!'LB@FE\P
M*#%JD`H9."$-(&C3GA2:``@TX`IBP.\JJ)>G/6D``!3`0%.4X;(18$!\>,B"
M'.1"@"4L(08FL`$>>K`%$+R/!?\@V():K#$!50P""7C6`2'4Q(8!Y<@$T1LF
M'J*AAV<(U5.B2M4`GS'44@G`5>1(8%*5NBHJY&`*$LPT56E558`HY"$%D8A'
M/-!54FLU6&`-JQE"7<*0F)4D9UWA25!M$;36&B8F.0`5=$@/;GT+*'2]*UYC
MHM<>Z&&.V3QL5*Y0+ZM00]E0<6**TK(6A('V/E8$K+Y>8((16*`O!3#47E@+
MLH4]P`9^]$U\=.'+'_R`,6WD2[D!4QHOSG&3G;1M'O62ED'>;&QE@UE]9'89
MW6+@,I2Y%#.>J,=,O6<"><,`!(@P"RO,\^)`\`)(MQ!<M3`-/=HYC':B-D=F
MG`@[(7__F'?G,CJ$-:!Q1-!`?R',@@$(DP$E*(.3!:;B@3&`!@R80<R/(PP*
M5`#`%4OR93:P@0.S(,%LD,$-EI2`"M!`F$B:`1!@,`,+$\$+7SA.`Q"6#*>(
MDRZ<DV.+V,D5UFA[*4]I@MQ-@($!#$$!4("!%WR!X[[MF.EHH$%"WX2#"60J
MG\6C\I(5"@$1[$`,-5`%"RJ0AA(([0ME*$$#Q,"'*OC!F]@==#180\XF&&$'
M7P[2Y&6G`U483T?(@X.>@8CG=*G+SS>M^Q8&C=*=>@K21Q7`-QA=P'70`])(
M/6`YR)!`<5"!`YC6]`0CR(^J+D2#`,%(J%$-PJU^)*S/&DE;_T_8PI6H!(4Q
M;+59?UT3>@A;KCB!?[;>[RV=%((-EY`LM*DVV"36"]K5@#E;T5AE@1;_$A=G
MIR_#80/@U@`XL`7RMC"GX5FGP0/O-'`'=QDV\#"UT5KTUEEA=&\EEEDI4P#+
M8`$9$UH3H%OT41^],1\8&#/8)EPVH!5R=!Z(<1@M(S".)7%$<'%C``-C``1`
MH``*0`/Q@0%B8(,CMQUJ%UN<I'(B%TYSE%V=(UX3,'&D\`E#``&_H%#51`0`
M``+OEA?HYC=I\'4_F%!!E@;]Q28!1@<(0`>2@0!;`&=MH'$_I@,TH'%.T`9(
M\G1;UW44$`JD,`1EP`)X40W64#KI)/]'"5@ZDIA=^C=.Y,1BW&0!(\``=^<&
M"F`%,D`#%.`@#,`":$`'=,`+PB,+7E!X9\@`;`('<!`+V)-@#+`#3F$#60(A
MQF5SI(4`)E`%,1`#QZ`,>(``;,8&AF(H878CT?,[FT`(>58(#I(CNB1[,44)
ML\,&^S,^9($_#=",XL$CAT94XR!\B]8_1'4`R"<.S)=4[\A\2"6/]B!]TS=5
M5-5IN`(1'I!]U8(1'O!!JI9JHI9^XV=6YW=^KJ9^",E",9%K[.A^PL9^YL)^
MY#*1.Y$NZV(4[[)_Z=1_8_%L1N0=]](53O%$/)AB_4(-R&9$2P$Z!=!9$Y`!
M$"B!"Q,!\S7_,"@8`'U!&#Z9`ET4`4X8;TZ#&BD#2F-T,\9%*+XA6F6D6_6Q
M2IS!&$_T1/!V'H:!(";3,GUD'[.%&V_``$1(!&-0EF[P3#"@`&G@7M4U6^*Q
M-5%H1P]C-2((EV=1%060!*.1!"GB.??"`EA&`;+H!6Y033,V"EY`!"702VI!
M`"(@#,Y4)-M`)[)XBG28=$@W,1OP=&KB!9W)`FM03$;G3%PW!(4X"D/P!5Y0
M!L10(B;@82L"%C`2'DP#B23I.8QH#03@36;G'190=VU`!)ZX=TX0(GW#`JC(
M"Q6P>%:@`1DP`A+"`A"F"E6&'$.PEB^B,P)C*/;!&6]P7=<E.H*D_WHLH":J
M`'2[EP65$CN#$(UYM@G5B`=WN$_\-#NSLS\I!GGS,0$VT@2[J0R%]@WMB(Y"
M4!3?P`;>X`-(<`#GV*#A$(_O*``'\$"W8@!1Q0]18H\0U&D6Q!`8U(^_@A`:
MX4$>!'ZC5I#,PI`)>7["TI`E-$,/Z9"NHD/R4)'S-VS!5I%X!A/%QI$>^8C,
MMD0OH$3ZTA3,EA7><1>[4194%%GA91?;UDTJT(`B(`<V21@1,(!X$9-7:I0J
M8T<I`T?V!DID\3(PV!O`40%N$V!F-!E\Q*1LY#$J\T7)L$;YB0$CX&43D#"J
MD18,0`1`0`2"*IQ%:(2"Z3:NE"A[H9<A-_^4:\<,;H<;F&08W3$OLUDZ/-``
M;S($<"!/D%-1\@0$$%`#+8.G&/`%"A!="=`"S+4(,M!?=/`#:O`#=W,S;J-*
MF+$%"=`)N_ITH)D`C!.&,!!=TC0*>X(#8I!-O&DOW=1BO4D==B!.+Y(4F!@6
ML;6(8@"<,V"$1K(&3N`@_G$GL0,BR"$*`[`#)",&TDD#>?(+%-`&1X<`?A`%
M5:`THY<%)C`I;*$CK($\T#A[,052.;(%-$`)@U`[VD@)239H<2.K:C"K&Q`)
M:Z`F(/4&>;`61&8*)"!W<N<YO<=3X^`IY8B@0K`")\"@`^J@\QB/`E"/^W"A
M^`!54*6AUB<0%N3_*U?%CUO5$`%)HF"%H@Q9:RMJ$@7IHFY5?@X9$S,J$^XW
M5Q9YD4_+0SN*:XW0`SS0D3_:FR5YDB))%W?!829YI#RG%E1T%MIE%]HFFT^A
MESB)*!&`&G![&H&1I:)!;AX(E($Q!TT(IH9!6WQQ&">8K7Y$'Z+5@H1K,[J`
M<`EGIYS!`^CQ,#@(2CLP(MM$`N!9E4JZ&V;C%AA0`5H'J(*Z=0H0A%\P)C40
M&MPUE"8C6R4SJ7-Y=CP0'N/Q`MUQ%KJ:8#>@#:-0KA?G!110`P4@!S=3`PF@
M`,@!!1K"(5_`7!70"N[VL+7T"?ZU3'8X!#+`!A.K`[O:A]4DK-!$3432_X4`
M4`(8H&*@(SKFLSFW`17FA(G+&A6TR79@2Q8B@`,0L*T*8"1'PA\_!X<5,%'.
M0P'\218NTP"3-R;\,2`$D@4=NPQK9B@&+&'[02GJ^1\R99\!.[":\`B/H&>;
M8)Z6$"D(X+#N1@>@D&")]YUK\4X5L*<<VP0V<@O\`T#_\PTCZPTFBP2NDK(.
M&J',YP,NZP\SJZ'YV*$$L6H>^J'\R(^>!BPF^A`D$;3F-[2VEA(O&J-)JVOA
MX$.M4G]1BZ-O-2X\B@3KDFQ004?*MK5#:@WY\A5;P<9<@2]LL8,J1G;*1C++
MP!=SP`-X``:<!;<4>!K(QEI/`[>&(0>-(0=S(/^I8&`'$!,]O009;/%;:.I1
M+0A<B<,6;W$*-?A$A345XN4TY\&74607;,.Y$X"Y-I`'LXD753DAQY47`0`"
MC:-?P*`!,S`&1O@%238@:[<8)G<B(?<T=-DYFU1B39@Y7/`BQ*2_/Z9?%/5U
M1%*ZSY`\%?!U7S!/&P(',C`+B8>*L3JK5$8\((`&/08Y.K`&:Z`#0X`D1I)@
M">`&,*!W-Q`+Q_$%````&H85V_04?7G&:4L7TR`Z+6<!E:+),C,"^3-A"@`#
M\'Q/?9,!_45Y>O(%P+`?L/$6KFG0*N4,")`C55"O6\#-DF![M1,$LF-L>,``
M)9TN&(P$:K(%D;(%L>K_;K3:)B0])F'F4C9`JZB()U8VOG!`JFP1C'V#`:W!
ML;/I.<@8LD+0`P7J#>R#H#Z0+LC'PRK[H"U+?18*LQB:CQ#4#_AX*P$Q$/GP
M:0^A02`J0JLF0B+Q:E9\0M$RM"%!M$*+:Q`)$U3@#C2Z0&#L:SD:?\.&9P@J
M!^YB%5!8B?OR?US1QLQZ,/A"P$[Q+XEZDM`F10SX``'0QYPEE)Z%&@4@!O;#
MDX5!19#A&SB0`3@@`O"&%HZ1"Q!"'\!!7&YS<+S1E)'AG2BX@TL8`*/\VZ.L
M%P0,I9]<E;RMR:>P-F>!()C#-IF2.+?]%BP``0G%7WHR`VXPG$=W*([%1G-)
M_Y?8-1Z=E,QF;!US41YBD%_4)`-M,`,V]EQ>8'$:L`H]4`&(N2?ZY00@(`2]
MT%]HL@ITP'39D$\)1=\-=D]K<`/IO`9/1Z[QS*VF68OX/*I/U"+_-YN@EP5.
M`7=/@>$O(AYGG*WS838R*"$04KP:$L\)4!_$!2%MT`8EL!]RYEC]K`QB8(<1
M[!_^<2@<-B%!)@G26`A*8%"[AP>3A\&=L'IB(M/R&:L;D(JJF%#%XR!9D*V1
M4<YT``).D)K8`P`/R!5&/0RDH]27<PO("&GOX`T]]@A0[0-$10A7C=59'0Y!
M/%49BJ%W;H]E/54#<;,8M!"@UBO&TH]N;4(HT6H..?_%"@EKL):T,T0%NK;7
M`K!K=O5H\A?&@$TN43O&E,`I'&YV:*QL2.1L81L6%J`T2C05:]&=UE98RH8;
MZU$#$9`"?.S'H\%9IU$`;Y$%I/U:!>"`)9`!/>.%PE`"UR1%*]@;<``AL@@'
MMPJ#D2$S$T!='-/)#`>Y>_G;WJ$7=S$PF`N>U<8,>9,+J8P85\#*T7.KF5EW
M;C,`)<!XV$.8T21/%3#"<D"4Z0%8)C/>(9<YYBV`4(,U3R$&-$`$84(#[EU-
MY6IQ&O=S+"`*V^`A<"`$:&!0GQ`+@AE@`88`O#!15^<@@A>*"<"'-\`"GXJ8
M:1E-A:@!7%X&F[?)$_":,1+_+QB>3C-R=C!6-JS.21.0VL6K=_).*),4,\NX
MC)>P@R,":'>H"J$XL320)@WP!BV"`1DP/!/;GA_L"^&(".9LTT+`!OZ!)$ON
M&FV&!FU2`;W3(?HE.%LP7]++"J_P(4RF`92C!RI6!50_`&)P"V3N%#C2`U?-
MP>6I+D3E#0=P`O+@#H\V#_"0U3\<*](WQ-+'Y_C8YPSAYQCT?1^D*\+RUF6%
MD`B)M'AM0@Z@0FF5:[E&!:KO?':U`H_VM/175Y?^+;5'"3V@%5G[%?VWQB89
M%N!C#?@"98.$*/Y^V1(G`I8U7S'Y6O7F,A9@8@TS&@&03#HWX24P*![52T2F
M;K:J_VXQH[AEQ#&HJQJCG$>AL6Q6R97WT=C*<%T>\[!7,"&FX!A\M!X]<_W[
M0488P)3O#@A?"5X)@S=.@Q5,3#P68A:0-CR3`95@EP69E0$JG3R=FP%@!6!)
MEP&3/"2K)!851$,),A5>,T.W0QHS1%X@-$,LL11?7C<5(!MP5C=I3L0::7`L
M#`T;&V@5@A`0##1>-!6R,K*Q@[D*"C,)$`D:A5X:U%N/%I.=]_B=)/F;]ZMX
M>"RP(C%!!`9)J2IUFH"CQ!!TZKRXR2#"H(V+3!!L8<&BP9:/&+I,F-"@31L:
M-&2L62-#AA,9+&I8L(&!`04G-UB>.*%#AXQF#2QDF5#CA_\:-3^N5:!QXU":
M!F)(@D`#YQ@=.,.L6%G7`*`(!BQ`@*AZ0U"A!`S>-+)@H@J&##C$9,G2I,E`
M%4VRX.GA0X"`#CY\J@RBA(T0'T*$K#BQHJ]?`3XB2Y[\N/+C%3F*&-C,N;,!
M%*`W@T;AV4`1S:<WIS9]NK7K*5.*3/%@QH,#,V8<W+9M6W>.'`Y^!__-H7CQ
M`\</(.<@7'?QWSF.,^>@7#D5*@+(^+W>>(5WR-7#A_=.OOR*\>?%JP^/9"<;
M!#SD?,IW;S[]^Y6N[+#0B2U_%5?@8X\*_D'B"`883&#!%978=]^#H$R0P0`%
MI,"#&`%$,,<#'$9@PP0FJ'!)!"3_/A```P!\00$$7T!`01HP,C``''"(T,"-
M.#:`(`*25*)&$F(D:,,F!9"820&H7&&#(R88>,4J`%ZAI!AB7!25CE<DD40!
M4O)@`P(U("`F"`S(:.,C06901@D.)9#&6`/4T,``TQ3B#@2QW)#`&`K0`$)'
M]/08P)%(*I3*)T022DJA`F;A("H-$)+`#2QX`<4MDR:PRPPL5#"$#K$0(PL<
M:&P03@5P#`(/`S7\&=,&(%"P"SPG>;$&"[*P$((,-W@QA*\)P``#$0G$`H\&
M\'"#@!QX*)@%"03L`Z$*+^3#"@$$S&4?#Q,,,,%:!EH0+4-M#.&&`E!XX84"
M$%34@$8-_["`$DH5+,7`%@&),8"+*RGAKQ(GM!36!!^R`(=8:`@A6`5.-,Q"
M/40A0`<:.H#@4P)6M&"%$P,@V``<'R.#1AK#%&)%&2+@D04&<8)0`8Q?Q!PS
MJU?PD`4D)DS`0`83S%77/JO0U<1>.O35@<)K-$68#H<AI@-/CODUV=2166:9
M#YEQIEEIG(W&]=>=I>::;+#)1EMNM3E`&V^Z#><V<<;%39URSPD7'7/0S9V<
M==AI=QT5Y?7E@WKIH6>>=]4AOM[B2#2N0ZF,9*$"%Y1S49^#TZK`R15-]M>Y
MM?-=`8GH5(YD`2J89TY?`!8,,$``*41PNH8=\K!#B"-&P.$#//\P4(B*%%!0
M@O`93.@QCAA4&<`;R1>I801!BJ'E]%M62P*XI8]$)95YY"'Z!&)<<>05+(M@
MPY8!8#!"30"44>_!9);90`UOO-%`&650L*<M%4P3IPAT`H`[AH"G!,3L5TZH
MP<Y$(`8>5&))0J%$*"Y!04THA!^54!08JM4)&VP!6;'000+<4*Q,S6`&;J!`
M!2@U"%XXH5ZE"D>I*$`$8K$*3`PX1JIJ.`,(G*18N%J##G:UAA;H*18P&`.Q
M8H&L=Q""!4S```-MD#E6/&@3=O!'*T30KJB8`%L$4($#6[>-&2@`!E"`@@+B
MT:ER-24$(<A)2]9``3AL02,X&`).%K#_`*7QI&(@^!8>&H"&'QCR!PJC`4YN
M,H!'2&4L/8%#&F*AL2_@``,6P$`)&``'.M1`DB7#&,HD1P(I`I!-,AJ`CL)'
M@KQ`8@<Z`T!0A`8E$@@-#UM@6@=VR09>W2`(06!:8H302Z95AFKDD8S5CLF!
MK8%M-*0!FS2W-C:RF6UM9YN-;FP#'=\`)V]RBTYU\`:=<GYS;^'!SF.XDTR_
M%$XYBEO/X0KWSL6)!PD'0((.V-`#)DAN<I7S1.H@%*``<.X__I$6@.@3KJB<
M#G524MT5>0!`&Z1@#@[<D.X"L`,_4(M$)$(%3?3WA1+`*'@0*('K#J(D1X#O
M#4.*7B9*\2&"_]D@?*$0HX&V%Q7PH6D'.^A>00YB2!N\H08V:@#!+#`"&T%`
M`RE5T<'@`!:.Q`D#9=``$6"0`">0"BLEN)'K])<`%?ZBK"N\`1I*D@$&B$!!
M$ISI*$:QB4/9YP45)`48ZNHH%02-!UM(`+&\`"H2YDE3NY"%+-3EPI^4*E45
M0,,0B*".L.(P&G`H@5EH4*9;!.,&(F1),<H:+!BX`5CJ(D0MH$"#'HA@"Y+H
MJU\'HE!JO8`3]&F%0%9!``LP@`@,$`HIY[(*"X@@`Q18UQG5F(#^_2(G25L`
M"@`F`R4X(0T5^`@+TN`2EK!`!D&0P4[$LH5&-``9=&!#3UBP!DT9D/\:$Z@)
M_(1`%0H,01!;P<&W]-5),C5#9@8LP5O#J!\$(8@>DW@2`>H"B9$P0`,#$,K/
M6ID7!N=2"!+8I1!\"4RF]4`(3.B!#)@6M<?XX'#*7*8[L_;,T$ASFJ@96]F*
M0)O9>.#&--[F<(`3'+SY6#KBI)LYOVDWXZA'G28&W'<Z((!ZVE,\Y7GR>AIW
MSWTR00Z=J)SEQ"C1^_A'<P<-$(2`2@(J.7!`8NXR/BI1DS>DP$(\T&@$"-`%
M$@3@!;J3G<>>6M;@M:@"\QM2`>80`2TM+[[)<RB##-I0\(U.=!>YJ?(2'%^8
MQC>^KAL`FW!4`SFITL#V0RY6:EA'ERT%`F7_"-,PO"J$0Z)A&`(>0$,&00$:
M))<0@B!"!<2$`"F.H(&+*A1NO>2H#.IUKK?EQ(#NL8ED!T`,$`!"(=A[VCS=
M8%->&(>>:N&%+[RD5&A`A'L)&-96C64J51E>F>25`/:"=@@L.0N>B*``('1;
M$+50U0S6P`8:L*!9$PA(MOQ!K7YHD;9S$=``B%""-T""`":(>+2,BR?EPB"U
MX*#!&BKPM!.L`9CB;8D3VH"O3B7,U0W+2?^Z8MRPN(P&<-`!(J"P%0H$16=@
M$1E6[FLG')C`#BL[;V;9!)<RO74"(^@"'VK&BKDX/0O8XH,1C-"DD0P`9?RQ
MRS[JPO4L7#C#1SN!_]*"<((>]#,C_4O882HSS\943<4"H`*+G?F9:+[XQ=24
M336M>>.^\X:;W8P.<<ZYG""3LSG>[/'<TKG,Z_1%.R>6,N&<#&4H4UXY[=%!
M/S^A94^HF3X\^)Q_4L<#!HG.$?48Z.<]\8*:("`"*0B`#?*L@AB$2!0DLH'K
MN`@$8GTA%D.HQ@^8,`="(ZFE03KP&\!G`R5!,"H(<G2B"B*&3*BA`/;K6)`,
M,@`99<`=)F4`"#XY(P!B"`0LDAEV:?0R5`,`&26``#(,":L*#*,,JM3T"6]`
M@1OD8JLGI`B:D'R.YB@.9`D4A`F:(""(4@EXE5<7]&P00"RRL`;I`GR]PO]#
M3N`KL8!"7M`PD84-(_0-+T,-0M=)R?`RFW0,--!NOZ`#31$,A3`$LH(.]]9"
MJP4%-\`&)]$#'A%!]E%;5J0ZMF0!#0!5\R!QT:(Y*M``%8<.7#4(;5`F3O`X
M:$`Q'B=>27,#$+`%;[!=&T!_:``"SC`$AU`!1R<"J/(^+J,G&&,%7Q`48E`F
M('`556%?&*,!^+<#!.`E)`%`G^93$E8%77`&9V`"66`#S?(1C+@%$[`#1D``
MMP-+(H`#LS1;>%%A>3$!+"`$NW0T,/A+9&=VC&`#(L`"'S9,4A,9*$8U4P,>
M#D!W71,:T&1W=Z<UIQ$;U>0!L>%WO7%C.Y8WOW'_`-]$-],A9-W4&\'A'.AT
M`-=A8E9#!I!W'NEQ>95G3_$D>9BG3ST@"5E6'ZN7#U\&($TB+6F&#Q8`5^'X
M(#SP`MU2`WEF`Q42`%6P`YH#!A%0`',(`3@P@4!@;^V0`#2``#^@$55R$1:0
M!U1B8)V&:#R%D(_P!E0BCT=2`S@@`IT6)G*"/%*T;C91+R^"*F/8`/:7`0WP
M`^AG0!5`!T9A*C3(#AH`!V_@*5,Q%B0#(_=%#3MS0B\D`_IS0K50`B"``-MC
M(`Y$*'2%.G:E.0@X"A9T00*%*#;P6X3`$C.@6I-2"T2@@X3P*_16##<@`W2@
M%/PW50=3+V(QEA5@4FFP_VZXLA0)T&_MYG_"H%SJ,`@S``0SD$:7H@-KT`9L
MT!%RH!>(6%O3,A#9$C1S$5A#(!-0ARU0H@(84$#GPE5Z,B'R<@Q72%\Z`)=V
M\F\B4`)T0`>^\")I8!;,T#$D,3S10!7.<!9CH`$L,!+QL@4N@U(L,@0J-0%=
M,`([,!<`T23"I0=.UP154`5+T`48\!&N,F(ZT"DL,`]L80*4:(F(B(E-D"U-
M8`0$P0)L\(D*,W8G@`8(\`8W<R-OL`BIB$S>X8KN.3BQJ#6B48O05!JR*#9[
M1TVS`1N^V#;>5$[343?&:'C=U#:!9V35\3<F5F+2*#7T9(W:*'F-@T_JD7F;
M5_]ZY[B.]W!08%:.4;*AG7`%5;)0&LH/^H(!!?``'E(D)A`#63`H$1``.H,_
M&M![1#`&)U1#S04"-S(//%4Z!J8C"9(]-J`&^2A["/(&#%(`$E("-;`O*\@J
MUB`G#%`"!\,`$-`,944C[%<"654""``">C1_]`<'>"((&K!K+/`%:U@O:S@S
M#;`S&N`&A\!$6J%&P:<61QD*_7`H-E!L1X()>W4Y]N&`H6`'!L4`'U"5)W!"
M9W$#NG"C^&8L;D!"7R`#+2ES3L`"8S@5)#.6$Y,&)4`#HPH!_B:0WO!=V;8&
M>B20RD4$[N`%]%:I4*`.*@$,*,$$N(0'#?@@T!(MAGG_.37P*RP7<5^TA!-0
M+B-T1IE2!M30EC0R%:0Y20.4`/H5FC;IIIKU.U^0`9AT/Q10DR_CAGE9!D'A
M)0@P)Q50I6#A$0JB`CO0FR[*`WJ@!P#Q$0!1`X]PG%1'DBS0$SO1$RT!$TE(
MG4AWD2;0!-BIG0MF`MX)GJ$8!&9P`N^A,B305&(@!XO`!,/4-.]I'JYX`/'9
M&?19GV$CB[@X8WMG!OS9G\`X9.$D3G)#3OZY8XHG'L^XH(_1H`YZ`%$6H4#+
M'A.Z'@%[H:JWCAQ*()_C5_6Q#XY0HOAA7`V0HA'@*!\B.?@8`$ZX20GPCT0`
M!#AJ1@H`"X"&(ZJT/0@)0<TG_R4U53\_8`-(]2[U8U1?\3'44`%92BI3JFG<
M(">"M3'(<`UIL`U9-00]0`=Z=(54L7ZGB::LT@#-97^:"0)I0`@,($7?IP!#
MT!)MH"E6P%RPY2600"4SD1#&5D$&)T8#L@ES=0H-\@DD<`4#H`N3(@.6\JB"
M15F9XG^"14)=54@_@`TR`#]C,0SH)4EE`@Y`5"S>X&^^\@L;V%[H`)"R2@2T
M>I4JT6XRT`8]\!%RP#K"!33!"B$WTRPTQ`)B<*R1J0)B4`*%<"[I@#$`$%8D
M@RK2&BL!N2(0<"-WFP858W]G\050U0`F@`$X\"8N<U+MH(?>,A?-%R0C$7`J
M0YRJ@/\MA`@^N+0%;-`_S]D_C@@B#@L./:%/.H`$2C!BWHD`?$"=\6HC?#A;
MK9287-`$#JL#X,D&22.QA8$`*B.9WI(*&;$!(;:>KMB>R71BC0&+I5&R+G9W
M>Z<:8\.+-N:+W*1X=W,WR1&SB!>,/9:@?X-DEB&-VN&@YA&T9IQ/$TJA[!&P
M",`(1QN.K"-ZGY-F-@,@X0.U_&`#<6H#')*.[UHD!8`![6,P"5!OO9<N*%1M
MP=,&VR"4/\`@26!0SI<E,JHC<U(-"$!5#5`_8<(R89)2Q0L!+W,P<9I5YAHK
M=;0!1_$#=-"X[H4,.,%^,,)^3=$.#"`F+J)(=5A?E34G3T7_!*#5F7L"!7SB
M!='I:)#``T@I;#:#$*8[*!N$"1>T;*G`E()\6@EP`N8B*7H"E%U55K<@$>%<
MA0DSFF-8%2\#(V+A!%G*64[8;K'``B<AID/`%-IF+A`1J37D!FG4`O$&$_S&
M$0"1/`G'#P<'F5#B=&]``QH0%.("<=$2+7-8+&*K`.JB`4(IN0=SA7`0,^WP
M!>TS/QQ!(Q0C`V91"/.+`3>#`-/`)O'G0VV``QVS`X2(`2'R"9/@"'BP),<Z
M=3G3`&R@7C[!$RY!L"K#B?42,"UQ`NW!$R#P'GP05#1M(Q,01JQ0%\\RPQ:@
M7C?,%#JL`SPL.071!:EP4Y*0$40L_QGM.34@&QDB2W=,;'=-;)_5!,6N<6-3
MW)\\]AQU@Z#+0;,\%HS%Z,4Y&XUB;&)&K#@0>L;;.+2,0[&;UPD<I*$1A0J0
MX#D"L:%B-IW_@<=,V0`E(`;%9P(C,`&:,V@6P`YK6,CH,`9N8+T*4&VW4`8`
MD`$@8$@PI23U$Q55TBT=HVGSPZ,@4YZ=-B<3@``EH`$MLGYK*3P4H`$?()OV
M!P?6,(9N:E\:X`Z1Q13I##^9]06\>\O(72PK><Y?$)OM<EQE0$(-DPMC,`8P
MD`[H*VC)9E?V?92+(LW#AM/,=F=)B5N";&^$M0;8;`7V-0--)`/UC(=WN0S&
M@`9C:0U5P?_1,(((W+`-\@P,_K<%Z]H#Y=(&85DLYG(N"+X+-62]:126F^N7
M@3F0\84'B.JKZTL?P.D-4#$!?<`'?`"LK1`,OW)&4:C<2T$!8=$#8Y@&!H2F
M&B!+3\I))>T$N;#`-B<4%H`'-3`-93(C'D$E!#!U57`&(X"(!#`2Y7,C(G`&
M?9"=!%`3,J!/WM$33U,OT=DLA(0&0:U>SOF<'*'"4ET%5&W5JX#5)*#5ZO47
M1R-BHA@$J`@0\-HQGB`NEF,!ZID8;%W$W;'6Q*@9<>UB)DO7>=<:*<N+?E>S
M/"9XIN[7U,$<-?N?PD$=@..,.<NS.ROKD*'6BLW8]X1/NI[&:CS_93+`!CT\
M.7A<V9P3(F+4)!E*(*_4V5`["34A!B3"FQ9@!W90`'+@.X`&%M$6VV.01NAP
M6C[$(J*LD2R)V_13/V\P`-Y:$^-7`1FP20<#)J<(%@I4!ED*O,D@,UIES+B2
M!N=\D]ME%FG*TJ),@Z12O"4$#.5IP*(\%NM:!M%]22.P+R0T"_ISH_`-!!40
M)E2R`U32)%3$E(K"*%'9WW)%"B_`07.!K!/H!;LB`[5J#D-PE=AK#+1@+#-P
MJ>NGMQM`FA,C20*<I6E@:TO1!BP0/&1"Y/;%(F3U*Y5*!%IA!5IUH\*BX32`
MP][96ELPD!DA!L`Z4:K0=#=C`2P`87C0_R0\/KK[\N/HD)4".<KBB@@>C>`E
MD"`=62].@-WM8SQ`%0,QX`>EXZ,'V7R_:@)=P)P<40&S\%W^AB]ZH885L!-_
M!.?KA2^XQ)*KO`$<\5T"@P`DP`=YL`,QT%1=8-431F%YL1&>>#0;9H;`5'8J
MDP5\8!&6#320D)YF)P0?-AEN=\2LF,2#XP&BP4?2M>E@0W>@CHNX@4W`:*!$
M!K,SBQSEY)]P0QRPKJ#9,<:S3NN.@<34N-AGO.M4ECCWQ!-LL`$#LF6'`E`"
M)5&A5P]QO"#X<'JGQQ]*N8X.)`;Z50"V`P@$*G9V<@T:$'`,#`T00$0*;C`P
M"E!6"1`990`4#?\L#'`_HC]O-35O/PB+"!@5<'!I);(5%0,-#"5#3C4X$`UT
M&QMT(!40"0D:5EX5;$,4KZX@('`47U\:RTQ;$"4L<&AHTU\)0T,,;P4!`6(B
M`W`5N#@XC#$C.&5N"2>P$!]`8V-@W&"Q10P>"S9X!"A0($D2,"\"\+!AH:(-
M%1@7,F0(I@`8=2HFDL"(D0</%>IL,)CA)802&3-F)/`RY(:7F#/6W)"A@YQ-
M+PF<N'H'1]H[5Q72:-!`BT(%&HLHI('PI0(%;N.R?F'9PHT;(L>0$?DWQLT0
M%FO6L%DC8ZT.%D.V,&&#!Z5"%4U(DB"1I>+>)EFRA.2!(0,#/(CQ5*G_8L*$
MF`DB(`S1X$:!@B%K@-*H4**"41E.CGWQ0L27"1)\,`R0=94;`Q$8)NS`0MO%
M2!YXMFR9L*7&E@8%+9AH@H<%#9XZD.A8?D+&&AI;$#>`PV:YC@HR3N@XH9V@
M'CP8$*C9HT84"!I?=/&L08`/GQTQ5(\01*!)D[TD[`<NSD9(APY"L""9$]RQ
M@0`>31`@@@@V!&"#"2=9L$-%%HAA`Q-,]*"A$#ZLX,.''GXHXHA4Y%"$`0:@
ML``*-Z#@(HHPQBCCC`84<2*,-A9AAAD>].ACCPX$F<.01.;@0`X<)'G`D!P<
ML.211`8)99)4'D#%E50((``99&CI)9=@<NFE_Y8=KF"FF4ZFJ>::!R#!YIMI
M(B&GFBNHJ:1R;&S`Q$E<<#&822KT65(6)Y%DZ*$\F&"!215:<$5(&%44845_
M'FKII2&M@T,##YH@2`!@(%".5;X@4,)8DTSBAA=?0.#J)FG4P$(9<)0W2BEO
M;%##(J8PX$0:18%`QS"R&./%#34,0&LXL$@UU3%6S$!##[X2!0X:Q5B#20,(
M;`%'9\'>LE4"L3):D1BF(*`N`F^P2\(9.-1!!!0W."&+!D#(Y`4%(""@ASHF
MV9"%#2.A]*="ZG34D3H2`7KI"R@QK`()%@R`30LWZ.#%JD`-09H7--UPU@T)
MD#S$.,[2DD92OZ:11O\U3KU<#`7HN8J)JU-]\3(-$,P+A5<R(:,!$6Z,P=)9
M--RPEEIKL-`,"SVP,($=/%C0UWV&$EJH"EDD6-$$&4`P`1X3>$H``8'9L,TQ
ME2E`#DL4X&++.TY<DT`9B`P@6Q=G=(%!`X`#IYO5%>VP@Q]_^#%!#9ZPP`(M
M#$#5P`16;\$`+=Q9EYP,-U#``F(8@!`,$S]L\#AV,M`2G0E;;%">,&A0$VW)
M,H#@AQ^&[Z":""9,;!]^^F7!GW\`ZC#@"4BPT0.")(P@@@4!2/K@A!2:A.$&
M/7`XXO;<^[#D%"BB$$00-)9O_HPY%C$%CS_^*"61',!/9?PY'!`_E$.^CV3_
ME59BJ2687PJ3F,8D@#*9J4-LFA.<%IA`!<K)36EJ4INT8R`^E010??+38#!U
MJ48IY$$64,&C5"`I<X50(AQ,(4HLL*`)R(8$+XA``!B0@,<E@`(($(/%_J$`
M&$"!)A2@0`8T\0$(U``$$*#`#VQ%"@28HA@0`,$VOO`-!(A"#1N``]YF,`9D
M-0(.&XA=4J1"`6C-H`((>%PX0``.8HQ#`PD`HPWD\(-=70X>N(``(W(HAL:0
M8"&`Y$&[:I##,X@@`_-:P\HJ4(9\S>0+#>C!8UPH!DD%X`5@Z`A#)&8HAS%,
M(YE\`<0&12B,7*$!"9@!QGK",59I@"4=2X`,:*`+_V<$D2I?:!E2:)&4IKC&
M56THPRUET0;(P>%QCO"A5XA@!2L0`2='&X(.9#`$-M#2FC+H03&;T8#<3"`P
M'-S+V="&$#$P0`-;J)H%Q-D8,:QM"#/H(4O<@(@2X&```V!`&X90!@BT81$L
MB$T7NA"#'>`A"TS`0P]TPU#=8``#!%4-+VDA@UG2@&8-,,@MP(&=:5:T.:#Y
MG`5,H2=1;``$+^O<RAK@J2U8D1C0*&,SC\6"&/#A=GV8P#TG\)?[]!0PQ=&!
M?X0@!!VTX09KR-SR[N,\,:BS:I443L$2PH0W8$@(&^)>`;EW``?<"$8H`*N+
MQEJ^L)ZO1CE:7_M\A+\B[?^/?D.R7UN-)*2WILE_6P)@7LD@@3#]STMG.F"=
MUJ1`!AK620],;)L(F[D\;<U0&KR@"@\%0H4(9U$AJ=`53G(%"DTVA0&X0CLP
M$`,3@*H`("A#!6I`@1D,@"(-*,,8@#")'][0G@/`P0<2T"\&#`$-:L`B(:<!
MAYYI``XU2"(=2A>,(U8``$LI&0A80`$T_&`8Q%B95IB21F!)0W1T..<'/E`"
M!$A$'6\`7&]THZXWV&"SXD3)%=Y`W]_@<0#MR,`,Z'71$@``"#29204DN:A/
M7E*4$@F,@D\BRE!&)"(@N92!&8:!5+8@`3H8@AM@.8YG`M%S3^%,+%P6Q$5.
M="C_BDBBRBYWN<<YCA:GL\I,(D&T?,V`"$O9V`TJ<)8,3[.:L]1F6X:`1A8@
M0`YR"(P%SO:[@G7R"C:P6`,L@`<3[*`Q5GY,"=Y6B9\!00-ED,>"%M'B!M3`
M(`0PP6(8@Y@M.,XX%7@<#5@PN2K;(PT5S8Z<FN.$N&W!`G\;%AHTQ`;LH"X-
M(A!#%B;0`#:*$18):*;.1#`!`FQA`"Q8V30J0#(K1'<`?6@/'TR@4QQ@H*<$
M^"EQ&B!4``G!FIAIC@Z62@(,)+IJ?1%#5$F0P9%<P4(!8(*Z-`2.[HFH@!SP
M@/G&RFP:F?6LZ9O"6CU05[?N+P?4CBM<Z5IM)=WU2O\3_R"7)-!7<7=)`('U
MT&`)>]AV)[:P;Y*3#MBPI[NHX`6"$N%G#Z4.#Y)04>?JHTFNT%E*[1LC>S&4
MK3&P`QYD$@']=#.K:E``PE!@#`HH"TLPP0!;Q%8##=A``RB@@^"2(A7?&L<,
M&*"*-(B"#BPH@:NH4@UKL&!78/RN-"J`#&M`P,B,>QP<`#>`#````!G(:(44
MU2`>;&0B[R5X'G8P4,C@(ER+L&<#1E`"#;CM!MPP!@UH,).0VX`B`?=+1@)`
M"#M$."-P-PG#1(E@@!6J+X`N`Q&`@I8-@^P8.*F7*\8.CQ%/]"A#X>4[&$#G
M:;``!)Z8+@.F.V=:%B,!-/`"$/\JDZ^EO-(K-%A+6YH&E[>HA09,FQ8-&I#0
M@SY6+_BAF`7R4)A$+YD$:2:U"P<@&2]$`@9C*2(.,H`!,;1+7>I%S`0&ROQ;
MC/WY%=7)G+^)!Q'@`'4?50YHG-"&+2S:S*,((PM`4Z\TL!S0C49I5=0?+2M\
M06^6G@>*TZ"MI?@BU>TQ7-%%@.I4V\<^%N!F_4%4L+8&2*`=RR,(D#$!:#=)
MCA(H&<0%!)`'(J1KQJ<N&T!4QN8#Z.95*<)L9@6"9P5M:25M[C-7\L,!#C`%
M1T(E2,)M;N5M3@)NX29`Y&9N8B(B(8(F#;18/NAN:J)8"U0G\M8#&%(H^49P
M!V<IEQ7_(5A&28["*(T10DOH9"JP`R/0!:8%!EG@7R*P!11`!"[7$6)0`D#P
M"+8U!"70<;#1=14@<@P`7'-P13]07,Z0`.?P.,&`4L9P%5]``4-P0S5@`RS0
M!K"0!F@01EWW3"4@`IPR$>:$`PN"7XYX9@@1&`I1`&='$6+P-PU@:R.``6>@
M.W4``"OS"I"'1PUP2`EP&3)0%`P``;24+Q6@&RXT`964$`V6#@FF8+=!$IBD
M29M$$CR@8,9X$CPP`1``2[/42M!R"7](1L)4`A10`BX#8[SD#8I@?D/7:)Z@
M"'%63`+B.&=1`5Y@'`G`<X_`$G`T-#-0#J<7>L>A`P.!%FS`_P)*DS1K40'%
ML07_$@!X81_C=#;XL5DV\%!E8SC+UP6A:&O[%$^2P$6E,7P88`-OX&:/PW@9
M.0!=8#B6@V<5=1PRH`0W$`1.,'W5!PIQQ@9L<(!(H!,WT`8-D`5B`#B"MFFA
M<0D4()-_(P+$0"[34#>1Y@4:T`88D(R@,`PDIBWCQ0!B8!^-@8N'Q'^XER#W
M\7^`L07,0%2OYELWH%0'E04[`!N-,DDC%(%<P`=<\`+OD@<6@2%7I3W<LP(<
M<"(@^")D-8+FDSYIU2-%`"3YTX),DB0Y(&V#&3_WXP%%@IAJ0H,!!"8WB(-;
M=6P%5"<\B%AN`D$0=%@/%"?P9EAX@O\`2*A!#K.$).$@?41"NF8!N$@A!2<<
MO6.:AD(`,=`%6:`.#0``#&!K>-,`'E$`%L``9S@O0&1^\C`=IJ@KDZ<&<[A$
M/U`!?Y@&"=`&"$`,X``+N01IQE(!;Q``;\![NFD*+*`)95`"9[8%"6$#R=(`
M]$5?!*<1#"$AG;@@@2,"BR!F$Y`'-<D)T'"*[U`"^)0!7K<OJ:,),^%[YGEV
MFV424-<PQ4AE!?:;F001#/.@6;`7@*(.+[!))J&)*P$R%04%00-X&F`-/B=S
MU=@9V$@+FT$4Z5<+9E8,4`07;2`@-``"Z<@"3$$#&E!&SX0->W>'<:8T]CA+
M;+`3^,B29T'_36LQ+8R74)64'_9Q*210-1.0A0,5&[+!=!/``&7@>ST$!;/U
M!4-D"X5(#FVP&4_A3\57D^!2`7U&`4CE!'FV>BDI.J3S`VA048'8*@-0(>U@
M%+Q41C/@?C_W4")0-_R"+=40%C,@-A,1J-0``6703QD`H!B0!WO1&#M0DV&&
M?P.)E22@E0.(53QV`TKP$LMC`4U@`HZH:XY122-D*"00FR80`YI:I28A!TR`
M/=FC@2/251]XER(8/GFIEWQI@M)65T)"/U3B`-GV5H39;56")30H;N06F6%2
M;EWR(06D)99YF6V2F9OI;N7:F4%8KFN"@!MP8"61$!@16:;9*913_R&5I`*<
M"'"*(IMZ\0<Q$`,D4`!B,$2Q(0(EZCH=08B:MWDR$3<,<)RY"0'JX@K.&5S)
M=4-E1)U95!16X03A()W7``$]H!%1E@$#P#B`@P&GX"`84!&C]0.A90,6:'Q7
MH(FP$5L08`O?A7A#]T00D!1IT&>+)'.[J2Q`X#9"40)EH![[@@!,0"'&MYKO
MV3`;D0X*P:`\P!=:$S&9Y!%OEP6.P0-RP`+/)"T:\T,@<Q-AD3*7\PJ`4Q2O
M<!3$,'E'5(TN=4[Z5$.205TW``+.0*/45`XSL7%>$'IG\30ZH!;.T:1HX31G
M47J<TP.SQ`2\44J&(I"YQZE75A%*6!*_YO^EE!&FE&`.PY>F24,.:U`!W'$#
M-\`(GG!'?>8J.]$<X3@`.A2'P8`]<$!+(/,%9<``$Z`:`Z!S[U!&-V$%/X<8
M(D`!K[AIC0H47F"4A&("PKL(^/6)^3F0G,IH`%`'`(NY3/9_$U`!.N`#1!4U
M-9&J;?$&2Z8@(E`#PD$YLVHHE,*:6,`'!5.,PK,N"+`AKP8B.3"L*D*L>'FL
MY6,C.&(C4[#`;/4^S0H_V!:M\V,DB\D_UEJ#VYJMW*K!9-`!6S4FEHE`:**9
MZOHF9S*NA`5OGQE!\H8&#0(QB>)4$R.O")=")#!"K&D"G?48(?1K]:HH\ZM"
MCX5[_^H'(U%T#7#_92+PNS\0`1W!`ZBD``Q[0V3FNF7`6ZI0`<XI"JR51*["
M`C90`+(2BQ5PG1``1Q"P!7*P$1&@0Q79()^DB1E5&"<+.*;@B>U`::O(#JH5
MM\'R#K&@1XP#`=?(1AM0A\#4#CVC`!GSDS<DG35DB0$7O`_U4&='(12BJQ$#
M*EUK=Q:*'\7(&TS``C/P"&O`2B+J=T1Y0]$P=,1%#(-'"S5:##>W#6F<7@D@
M"YBW3T\Q!#20IL:Q&1<EN#1A'&O0`S=@N&T1>D7*-&VQ$\WP%M6$%@LUDWAG
M-@29%Z=)$IB,9:0&ND>;*F8ARS]+4:R;9T[@!-P`.(R'BAN01F.7`+GT_[LZ
ME`%PFP9M0&)J6P89`!NK`2S`0`R`F$HT(0*!T:7(12KC@`S\C%^D13&39!`'
MD1"XUQX$4`4*B0%UD`'?2P!&$&KUT01&T`03X#@?0E1P,01*4"`'<A\M)!P[
M0(&=A)KG,@'XFS45TIK&!Y<:T@,MJ00"3,#%>CY?%6T,#"0.C((P**W6-C\S
MZ)C8JL%2G:T#Q(&`)5@G[)F'E=4I/"<D_(-LLAP]L`&0B`<"!S%6>'")HL,6
M03GJA,F;I=;Z%B@NL`1G4%IBL%-*G'0<D0XU\`52O&%!@4<=-P#0A5R7\P/D
M81XO4T9I@``,H9Y>6A33`6-J/*$5]XF`%%H$]_]'-D!TAH&*C.,.<)!/'H<`
MH@4LO=3*5K$40W!$06%=X0>=Y!"@E(&D6U:H0[E:+M23^"2)UK<I,EM)"*,P
MG,2@>W&,H")*!2`'>,``;E;*1)`Q&J8`L'0,Y9`&0@</BC!GDD%#-$-D/+=:
M6]`&,BDK0V#>-\3+%5!,FV%-<_8<M$0#3G`#Z&M-:H%4UG2/TYR/H_?,0U8=
M]FT<RJ=HEX)W8+N]8G!EJ49"AS0TE@$#(2`3C!<YM+`<VV=1,N`J@".3AVQ2
MA:AA,S`.1?NSQ;N&4S$T5@``99!HC>`9S/(R@4@:&F#0Q;B*N35$\N>(`M4%
M3Q`#!,`HRC<V9HUE%[W_-QAP3P#KT490!>-D!".]`R9]TB!`,@:H'2V=!;8&
MOW[420&C:V9=:892<#O@UHHB!WJ04/U+5"<0!$)-K"CR508<(T9M@@VL/VY%
MK=N&/Q8\)N8VU5,]0`0$(NK&U2B\U7"B6%XMA`TT;^PR-K!)JPFW;XDB'*L)
MJ_I*A4O(`TJ(;W5]!F=PI0-0R:J!`UM0`$[\$6+@")L'!3H##_.P&D.3!B"0
MV(N=7A!P=&F,ZKRN&NRYB7('!FX'G+9P=C^@G@L2&V*``,5U3]8(#';L1)`7
M<RSWV0P0"]\`#.%%C7B3`*;@#(XV#22F`6?1``+J-C+P../03)ZVAO>$3PL"
M_QNXR`XX4`,&9HP+=A+JL!&9]'85@>;%5`'Q!`081@/Y0`Y)XQ0TPP*8QW,7
MI0&TA'D(CWDT-&>?H)&QZ$^RR&..,\MM`-\]0#-/,_+2M+CZV#31?*3W>'K.
MC,Q.HS3-H"&?(P<(@7:8O"@W?P45G6J`9G3Q-`DS002=('1PH#GD2TMEE`"`
M\[,(,`Q)P0`#+<]DNB"7>HH"?0Q>8`4?4`:C;N[<@E)]]D9+T<]ETUD,J:6M
M>799X-%18->Q40J>$&=O!AQ79F6ZTP5*3IM+$`5&8#90WN2/$R(^W0:T@X`(
MLFBC[ED7)'>LJ6N4`RF953@[L*E5FAAFC2%LH`0@N/\B!"PC<$[G=;Y64J+4
M^6-M42(_3^WG40WHVDI`DWE`A,YN[19OZ+KHA^XDEREO!F+6BV)E\YO60OP8
MCN_X%0'$):'6CP(Q7/#I9^`\O[T@\U`#$3`'%+KJ4AP)Y*)/EQJ+S^0YEX,`
M[VP*MP"@6]#$',$#L`&?F\1V=E``73H`W=(`HF!]HQZ\XV\*&:#:)1!RU0D(
M(!49964-3"P0:2`;/VIS""6%&I0-"#0W(&AP%104:11>7@PL&1]`-S(5#%]>
M,V-6:14##1-B%C8V/#P!O6\,)5MBMUG%*KT!!05@S&`!*CPVQB34!+9R-&TT
M,PI`7BPR4&M#0RP40SIM;2S_&A05[31>G@EM0^U#VNM;6PVD^PP0*FACL8Y%
M.8-L"/:@0:/'$!D.6;!!Q^(&&QD6&;)9(W$-&QT66:Q9.'(-Q!L2A_38T@:/
M'%L68N:R,&P"AILB:NV(4<4/'P(8,@`@H@`&C`0)B$```:=$!1!0T0BJ,&1&
M`DH#1+2IT`-$&G+SD"(UA`%'F31PF';ZDL"*%:4BQ$QH0`M.FB^>/,FJ,6$$
MAAU-FF0A08!$%@MX+!0C8"2*GQT81,!AP:*"#!DG+JOZN\-6ERXX!G0QTN6)
M$0(F"#`V8L1$@PHZ?*SHP89&@AM!E.CH@4?PA`$8+.2YHJ(XCRR[;`RS,&'"
MKBS0_VC2G)!'!6$561*;,&&!!Y,>.H*@&$^^_'@#Z-&;5X\B/?HB\.%/F>^A
MOGT'^!WDV,]_?_[^`.;`@8`''$#%@0(D2,:"#)(AP8,01OC@@@E6*(`//ERX
M0H8)RK;""@>`6."())9H8H%(I#BBB@<@@6*)(J*(Q&Y,,!&3!2:(04)QUO'H
MXX\]%A>37,W=8D-,5US!"P]`-@G-+L5Q\<<22XPP@@@X9``!`*'AP$`-!43`
MC`IBE`#$&&ZX8843;4``00DE)`#$#!109@D"?(F1QQO#V+!,,E?<9$,2!00@
M!@8(O/&&#0&\04$;-?13PP8UP%$#`AN\40,#`)2```(#5/^01@DLU$`''791
MX*8&:3#10`(5-$*'5'``)%8"#(!`PQ><R/)))S.X04,#.&C@S0UN?D$$#`HD
M``<=PES1"P\QF6`+GYPV(`:C`=CA+1@O(+/+N$P>T\L+Z`80&1X$Q0,#%#/0
M4($7,L13P0W?T%!.&R@-08-!;5"0``1#R$.!O*1\2M<^#32PQ4(-;3512FRP
M<4,/(I&TD0P;Z6`Q94-<U-"_/:SA<4@A9TR##$)P%)%#6^#1``9RW=2`"`,,
M@$-H#&2`PP06_$0-"1/@,%11"HA"A+,5!)06'%+=V]877VB0P0`,5+")*J)6
MW98&5@VP!0-E0-VK$VRYE0`+.W3_9T%D(L3M<)$6$%;%$D],@,=AS?&S#PNT
M[%2%-5A7P,()B&=V604-=!%#<\WA'$,?(RSA@FJJ&>'":5O0L*''/5"%FQ(G
M\&9"%F(`E\=P3#ZWBUS"[6#"DT<.8[NT2`J7!Q_4\"`'$QN9)WQ[Z97GG@'$
MNQ=?$?--85]]^$$?8'X>Z.=?@!QP4.`*5'`H0(,+2B@^A!0*T$$''7*X884>
M?ACCB26RN&**+LK88OWPQT\C<]S%M*.3`#0.#^1RJ%O<HCA)"B"0QE4<$N!M
M"3D3@5`*40<&>*D!86)&`"R`@S.Y00%0^`($R@`!!E!``T08PQ<,MX5<7"$)
M,+R"<L20_X5NJ0`##>`3`AHU@`SDD$\8*`$$+M6&7(D*!#_X@<)*``!#(*`I
MBVB$&O:``$^T`@@40,`6$H"6M'2B`G!0%B4T\"4X4(`3$/@$',(X@W@12P,@
MY"*PT&2%I\0-`Y"S!7=D:`,1`*"%`7A.,?Q7KF0T0QF%LLZ."C"!-FR!#>M(
MP+MF<`.JJ,(+-UB#%U:&DFRPX%^U80@^:%"GR@B"`5M@00/PP`26;.%W`H%8
M#[0QL8DD)"066<-(+E,RD%&F(9992$HHIH.1?%((]>K!#?[E+Q:4P$L[8T#.
M:'$I30'#.9AK3=$@D``W&&4&HEA*`]RA"330`00,0(K:K-8`%O_`00><J$`%
MG'`5L6B@!#/K!UI$A3:V(`65$^@"T(K1O\,H)@N!84UC)K`/?KR&%`0IH;8(
M4`4<4N8RB4N<#FH1`X$VYV8QB,$9%)K-S1%@;+$!'0MN0SJ(X&%O>*#%+90D
M2&HU9P<DR`,!H'&D'-F.45>@R;96QX6B'@-X,@@"\H9'GN(UU3W$BX\!EL>\
M(MC'>=6#WG]R0+WJZ6>K^^$`$K07(N^!ST'C&Q^%SH<^#&5(-MYKG_ORA[_[
MQ8]^*$(<7N\ZHKFFB`4@J,FVMO,_`%+#1TKB(P$M(#OB*-!'0[..8ZT3`RMA
M*4M4PTO.&,<$940@`$7S`A`^"`,OC`7_`H28`1`>PCANR:$`T9CA%0K5A1&(
MH0%(5`,(2@""&EP*3R+`@`UJ4((TI`$"EOH4#AE`CB%\B0$TH$,2?[`!5'%3
M`TBA``A>]12[R&(37W`+)2J`@`:D<8U@Y$35-%`&@'R`")24%P54"P0%#&$6
M(@`:"7@QK>B(8&`@:*$QT(4N1!8J.3<J*AXF<`8;X*$-'JO3#=P`A8/1((WW
MTL9#/OG)?U7&C(9;APYH4#&/?!)C,F""'1K)`B9D000INQA&2@81DRD39+=,
M2$/60.(-D_C$\J1Q;3S&D8I\<@T58$B2&4**`;```<OI#G\MT,/\-J<*56@"
M`40``0UXDUD)_QB"LQJPCAJ4TQQBL8(H@H$!!D!M$Z!`2MH`(`+5,&<`;7BF
MSW:6E1$XKK8CR,-QK"67+6AQ9B9P01C"P"Y2Z.#1B;O,RE@P@1@TK`92T8%E
M9$"9$\!S"\WQ:&0<E^7-L09SJID`"W2`AH\D1,PR>#0:$+"W+>?7!L1AX"V:
MDR03M.Y&MZ`)[J*\K<G&!`$B4>I2A\>>\S3[>.]Y#_/FPSPS/,\,^/%/?LR`
M;0=P.]O](6M9.736\(4OK1-BZ_DNY%8,64BN<S61_$ZT5_HAX03VWFM?X]TB
M3_?@!S9(35!-L*/#_DA)0"*!8VT*M'(]]N%8>()E=08!JE$@9TY!0/^8"I`'
M#`P`C@H(N1M,6X8,U&$HWN!T7-[P@]<R81B+RD5?AH$#.%0W+1N@U*>VNW(A
MNH,..?]!`S+`7"(0`5)4\6*OY%DPL:CR5T-8(532:86VE($%_`!(%WM5M4YA
M+0&J-2U2B!)R&N`I.,^(B4TPT`4QF``#9:#`!ICP6F6$ZQG'N5%,QA6`%ZA`
M#GC(R24@4DJPWY<!;7!")[3A#@Z;XY>:KD#GN,*Q6>H8Q3W0PX-;G(4MI.SS
M)%D(5U`R,814))06(S&):Y,0CLF`(PRIU\H\_,M/MH$-J\`#/]Z`1X*CIB>_
MR4!P8H)0+0^]##,P2K.JQKB$S4H08DZ`*+S_H`$<S`QGZ"6E/Q/07@R$M*,B
M8$'<K(2!,YA`IR:H@@E$BD>&YD0$61,(`S"`!1>X8`+0K4!&,ZJ9";BF`4"7
M<W2@`ZL&#JH0,S?U&<&U`U6@.21%`(&1'931:AZC`]RT!IFA`[26!5LV`!.@
M"T]")KOF:SB2)$,R4U>P+1L$--+!*$Q"`MSQ!EN05,LF/$[E;$\%;=)&545@
M;3YH;?D1A-_F;=T6;OMF5F=%/N@F`0NB;A;";G'E(1C";_&3/_=3/_F6A745
M(O*&.#JP`=32-D&%4P`T64U"`D)EA@^G0'P@<5>")14G0@Q`-J@4)E=P!F?P
M7R$7<M[`?1D@%$01_R^`TP"3,EV^M2AO0!<8$`#$!4:R8"F1LEUPT`#XA``$
M8W/3]0,@4'&N0`044`.)T%VB`D85T`IM804V-XK?Q11I@!0H5`(U@`<\E`$E
M@#5M0`@D1`LX('W>0`Y?P`TA-P3;-0`CD$<PX8(3($0(4",&M1T$@!S(T`O*
MX`S/\'=Z@&>AMPX](##W]4DAM@YMP#&@I`_H,&*IU!"4L1`>LWH0H0=Z,(=X
MH`<3@`ZVI`,J\7H]P$LF,1$<XQ$6DQ`>00,!21E%-GO:\"_R@GLL$#ILX!`5
MDS(,@#'!H#,BD'X]00TC@`,B(#L3@&55$`,2E!3,TBPW`"N@^"SG9!<E>?\5
M&N`%$%`+U@)_)=`F90```U-"P?49CM,_1-(<B?%26,8:9Q`J[E09L?9ZRR0,
M?>!QFO`1!BA/JD"`$P`4.:0&5OD#J`(*3G"`>&`".[`#`D6,.W`:IG9J$-@$
M@:<U:.`QD,12NK&!33`"'L@+")0C0F4!0867.'(CP\8#*6A`W8%K?KD=%O`&
M"*`#2E"#-JB8.:B#/!@?SL-MW.9504B$VV8]_"%NW(.$#;*$$M`!Y-.$Z/-N
MZY,^&\(A'K(][U-7[V,_5TAO6]@B72@#(,`$RM$V?-E`D:5`0W-`:ZA(0&*&
M?)"'(F`E`$$U)<0I^&0CE=9Q95!?(3<#^%`"TE3_`G#D!FL``CW$"%#A6X9F
M`XDH-C:`3J#P%+U5`Q4`)QD@,#;G"6BP`9N@BF!W%;P"8G;Q%.?4BFYA!5]@
M"93X%&BP"7;ABH:0'#8P%W+3,`Y3`X=B%L:B`<TE6B$W9K4@+=-R)#>R!;L(
M`AO()`'`#(4B+EF`H190&)VA!PV0,B.19+-4)X;S28)P>RS*HB0C,2%A3`NY
M,@O1D"3FC@JA>>502PGP:A@S$@Q1,B3&$1]C$.#`8PS!$(Y7$.B(CCDJ>05Q
M7ZN`,T,0-\$5&#Q"`B-P-1/0&:EA'6V&?"/I!6(V+"R0*U'C!&*V7F7@@>D7
M`Y%A07,H398P#";@$WRP_QV%1AF"N@JU,#@$,`)9XTZ/]FB7`:?#8A.$B``]
M(`1"D!"4L96J,)5G@`%O<)7Y.9\W0`$PN1-A.0`[P`>:4Y:J$1AI&:"@8QLW
MH`2Q1FN%,93.\0Q78)?2$53!AB-[)$-(0J8QP2/`NATF8`/?(0-3Q9A,93PZ
MN(,["!\_:&V4N6W=!E8"(FX(4B%)N(1H)9KK1II16)INY3X?DC^M^9KV=E>Q
M26\9^)U9L$<T41U?6EA.XI<J,*R_:7`-E&OE0@*559QY6'%N0IT`X`ZV0PT8
M``'0>13RDA5T89T*<`.;``!P@)50L0J0N"D-`0*J4@%`YPA8239@4T<;H"_O
M)/\(%*!X^MD6"=!;;G9.`;I&<?(6K%)-6Y`3\000````$."!-4,WNA!;BJ(<
M`]!E"D`$HM"2T#D$L\87U6(MH68+$\!E&R`'_(4,T&`8,M$ZQ=$+8O!D+%%B
M&#,R(S-,MF0012I+X;@1'5$QZ`@1I"!,>B`'/YH%VD!CRM20%F&/^9A+*)%)
M&,$0/,9CT,5A/3"W^G![(%`0J)1D;:I*$N4PK](`TN$C!-`%6#(`LU.BJD$T
M9.,%:8H4CI2SH<(`3A"';G(UC>,X(94CD).S,2,7@+:I=,$`FJ$93K!,I<)8
MH>*J.I`X2"`#2K`&110YD]((WR%/7[&R-(`!F9M#U:7_%@)S"AKP!?/GE3&P
M!#&@,QC`!^"K4`JE96\'H`V9N$,0J[K!&Q;0!+\A7+L@'4/B-OVSEWB9KS=R
M4Y.E<,.0!ZG!`WIPF$&@;..Q`,VZ'M"V/,I#59))K97YP-AFA*KI/=_3F9Y)
M/NHVFA7R(>/*/F]EKB&2KNF*5UJXKN@:(RE"@&C`!`%``CNP+6)`AE_*FT)B
M`]"PAORZ7P+$(WP@E\7)922$%V130@@`@AV7`63GL("3$PU#`:LE%6>11-,[
M`-1)LTL!`@E``=*5B0B0!I1@<8)``SD7>:)R%V[A!5_`H6`T*P&Z736K%#7P
M`\HP7*&2,WE*3<L!C0<&GGBB_Z!TT65`H+0#DQ3UY05ID17M=XR[$``V`'=P
M0&O^<U"+'(W/@'>_XP_K8#&TL:)M('HWQ@9KD[87HS([]K:U`1Y4*DQTMP40
MP`9RD`7)I*-*>A!KHR^OYR].RFF35I"75QF=\R];T0`TD*>IQ``.8VC_P@0O
MM05E\$H\L)M@Z7$X\!=7%@-^@']EX`4A!P.4!`&.)!<ZHR4%2PNU<%.L00W*
M@4/PQSCP5YSD!W^XNSB6L;M#\+.VX&0]\'P$&&NZ)`/J`&JT@`#/]TEBAL9.
M0`,;.1=0$4]K8;,),,U\X`=^(%)8,@(2;7^IJE#JQY2MU@,],`#D,,`N5:([
M$%RX9O^_0V+#-$&8QPHE\ML<W?&E_<,=T)`%WZ$$RK94!KR8SGH\"ARM\='`
M6N4`0QT]W):9(T(%W,.MX'/!$I+!3\C!4.ANZ:,A&P+",)+56%C"\R:;JGFN
M][.H/7`<L',%>5`W,_QPPZJ&AE58U$(<]MK#.N,7XBR'A<``&E<`7)`'9U`"
MHLLL=&)!Y(Q#2,&A)D0':D!=250#5%P&2LMJE;0!B7U*)I19>($&Z'DJ`+I&
MK8@4'V`(D3(`:>%;="$4[#4`4$8D,!=SN(9KO1!PD(-#A+A==$'%7M)E1F=/
M,[`LAKQ=PH5WM=.3(M`.PL`++P`&(7H<Q4`8)>K"7<!*0:;_HS0``B63$!10
MMDBJ3"=!,6G;R=*=HW"+W:I`=V(``3K`!#SP,1@A$MIP`YEDO-JPW@)AW:@W
M$%+:IL:,>-*$=?^R#[K'`#04#5F!')VGD;-36"0@4%26`?G5-H>5!UP&1^\"
M!4BQI5MP$\U1`_R`,RPH!CK9!;8[`*!P`TY@7.<PS>G7!3ICE)@1O)<!"@#@
M@3E3B$FD*U1!#@-#,UC#V:E0BFUA%<YE"VVJ>).Q%M)'"<*7!U@0!7]P!F$Z
M`$&9JF4Y.+^!6X8F!C`V!$H@JZ;3!'U0G+XJ;`,D96,J'>5B4VW3&=V!<##(
M'7K20+Z#,3=P@TSUK'8^5?`A;0T,_X340]1#"%::R9D,XM020@90G3ZH*=5/
MF"`<C-4DTIH@4E<E+&]=G5<IXFG"D`LSA2/_8Z^&Y3].XNG[]3_40IC&T4!#
M.0!X:!9N4D)E0`\:U\)\S0`:H'QND,5MH)$Y0XEK@VQI@-B)+;*4R(DY>K$_
M@`:B4ER@D%D,\`-,0`NS@FEN;)->4`;6)Q>1LL0ZXR59(0S^QQT!D`16J08;
M)`:^50,W@>%#=S7G&=IS:!<`P`UMU$1>D$*&3`<-8XPV(5"[%A"VB0MZ=R.%
M44C/@`$+*0B8QVGJR,HE5AO>'3$=(1%]ZQ$LJO`DMA#[,*7+R!+#T@`R@`_\
ML@:/XDE0:O^C.,:D).]<CDL*#D,0JX0'OW`(N_`;6\`+%H`S&%`,TMP`"`X9
M.;(S$W`%'$@`/[$#1YL44``%1T$.^>5VFAXIP$"Y.6$EM249J^`)C7H#(D2G
M99$U\G)1\\P0&@`!6T"="$!=E-(`:8`OU,=]P)$U7I$`3L`)%,`6,U!U#*`W
M6B$+S*OUX34&'X`#9U`86$`:88H#,6`"42#EJOH;`W`IB<%E#_%H;$"KAQH7
MU6(!*I""W6$MQNI8S^#Y_,-3UF&L;1,E*I`+&]`Y05`$-;C3S';GS\K`DOG`
M'C`%UXJ9!&(@W:,@W;J$H!F:36@^&MQN<$7!%L+![6.%VP,_]2;_/R9,Z?=V
M`J5"=P=J`@-'K_>*X/[CZ0UT<,;&'5ZI^5!"`GDX`G@X`(50L"=$]EBK`GS]
M<4ASZ]H0&CK#";`B,WA]E<(.""44:0D5""QP&QL@('".:5^1$`T!`5L##34U
M"#4#$``:90T3$S86/&(#(C5BI&\V-CR5`2HJ/&\3FV(8#2(B`PP-8K`-926.
M()H@#<`5)64:1%Y?#`P:,V,*%'`#`QBD8A:P*E<VNQ006UL3%GE9I[(O8/.5
ML@43-&PU-#TZ:ST5^,E@@:`-"S8WV%1H`Y`?C7QK#M[0P68-&Q;\6+#H08.%
MD(%;VNB0,80!BP%M;K3)T(;&0I<4-#*L_T"!(S\*+H=H'/+09`4(&M691(#'
M1H,V6^3(X?%+#`\>$[HYG2`"!PX\6:@.&$%"!0D".WQ-P#`@@X@)7;K$\,/'
MA`@("8B,@0(C`84A(EJ1PE`UPZ`*--N,,F&";(-&%9PH7HR.P80M#.`LZ\%D
M`XN`7A(,(9*@`0,*AQLX@D,(FP8(97`P`QSIT9<$":S(9A`.<@72%"A$BFVE
MS`@^!+C\,7(&0X8Z79I4,>*BN9'G39K$Z$84#PD,;8;(T'&"#5$"3;H,8&?"
MPA4>%G98L$#*@@D>MN#;(&5B1[@K5U38,)''O85:`(HAQAN'*&'`@2B@L,`"
M"3;HX($0-@CAA/\0%F'AA468H:$'9GC@H0,>3.'`B`[D,&(.'*1X`!54""``
M&3#&V$$'$M1HXXT2D$&CC3IVH*,`,[HH@`]$^K#""D7Z(*2+21IYY`H'1"GE
ME$=*B00245YY999:6KGEE%-JB80.("#`1%;L7)''#GD`2$Y7M9``9RWK73&G
MFW>Z>46=>Y:7!0]9U++#"".<<<8`=90!`00EE*#!$"`LI4(>AVJ@P*5N).!$
M-=T$PX(&%&R`0`5HJ*'&#Z9N`(<@=['`!`(-T+$!'8TTD@8$7VB0@1@%%,`#
M69CPU2D+6SQE`@F[;%$#JFH$4(X-/P30JP6$,H,#)IKP`DPP"'#"``3_MU60
M1F0->%8"`\]HX$9FZ,P@UQA.H+',!.>9T@H&(V#`"UQ;X,%#`4D4`$8!M`"Z
MWGJM\,"$#&QPQ$9%/;#`$`LR%%1!10>U<='$_SS4@T$.LY&/#OG0L(8_;:3D
M1,H95--1`R%MU!$;D$J\$T8&T5!21RQ0$,P6$;>!@`UXB!&,+#Q`AH$%`5A0
ME0BP8,``#ACP@`>^`_C[3GE>J>#6M=7BP,`WQW9U'0YE$*$`#`IDI@$#6_#E
M"PO/4"`#8#<,44$#PI80KA-##+&&#(33-,D6-,!!QP^,J^I$`C-D1H0&%7Q;
M02.C/8Z-%0EH@,,$#900R=^O=1[Y`'QD88)G_^B6D0`$%)1P+08F$,`'%G[\
MT04&)0`P`@'/->?"<T9$5T53ZX6'0P(W*''R=^&)L+1Y/.QY,'UZI@?.P?+5
MEQX\9N<AH!AX]"!#$.@;D."""SY(H?L4'H@AAAJ:,<44'G:H(8DEEH@B!U%B
MD8MT%*,8X>B`!X31C#H`)`86B4E&2M*2AJ0D)SWI`%4"$P;#A"4Q<>E+&O12
M"+FS$3R8\#[BRX]7G@(G.;EI/6Z*H5?R1(*#^:>&Y7F*"K!`J#/$0`2)PA5.
M-.,J^%!J``"XE`+6=8/8,:`;HM'`%[IU.519L0;BR@U2Y/`#1G""$2#XR6L`
MT(!>%2`"/&#&-P;T"O][6*`+A5$-+-[PAE9LH5P8"`>^I)8!.!PF&340#1P`
M$XP:T`TP@)$,"-#EMV]Y88E>6%0T%``O>:GB&]\@Q?;$\),MF,("-;0A*$GP
M%*O!#`\:X0A%+,*&B3G$(1O1V,=Z@)"(W<`F(AO(X&1P`QJT80TFHP$.7.(2
M5AR%#4RP0$M`T(;+M8$!"S&)3I[8`(FIXS$&88(>\``9!,@A`'CHQ@304Y7Q
M0*6<%LB*OL;)`P*\(PM9J$37WB2WLZ1B`.$@C!]R-P(<0."1EYJ&!DJ@K'+5
MP%8W<`(-9$"#&WR!`I@8@-\J<#>*+E0&BGE-)OR&!EHY@B9>F`'GK."%<5'_
MX#8@D%=BOF"%%LQ@!AH8`'LL)RXGZ*9S&CC-`)ZPA#SD@1>_$`'?)B`@/)B@
M"FN)PA_&P@``B(``P!O><\`3'0+\8@=0-4(,EG<#])40/%V0GGE4$`![6:`5
M]P$0#TPPOH/E!Q7JZ4\IO>)3^YPB"VQ00OH:Q"`&24A]#OIK_.17!,):2$,6
MFH+^S,"_')CH?U(2X(L*B,#*XLA'/5H@!97D0"<1:8)*&M*31@NE$())3%CZ
M(`BC5-H#K#9,)SB!#BB#'@&MYUAQ8J$,50##W>9V3E=@ZY[44XO]F"!0*N##
M$P@5A1%D``!#^`($")$`&B``/ER83AF4Z(89#,&)_U!L@`82L(DTP,%4C;/5
M763:JS?\(A/+&``.6K:%,THK`E?0E[0`-HLK!"`/(RAG("^GB3NR3A4-$$?E
M$(-21L"!`K"I@&7T!H+%H6H#SFC4MQ+@!BB4A`%E\$(VO'`;50PC%O#AK0G&
M4H$$P`T#.ZB%+,@Z#S`$X%]R8`$#(E8!53KL8VP`04U8L`8A4(P)'0F93EB@
M$YV9+&4M<0E&--+C5`Z$!W)H@$[.Q`)P/9-U00E)`Q`P`3PT@`9OD$,6\/#$
M-P`*`V(3@QT@@P,1O.,75./MO9`;PUFHX$\`(D%]=G"&`(O@"A.8G0A&L`,^
M/*<+:-,`$"XU@]>4(+X51O^#2A6#T8SBLRH@4`3CT*`SR+DK`<0J@7G#^!<(
MN^NE;_/,=#--D]=880Q$*`,&!"VU`3BC#`"H0P8@T#(,G,$79Y`3#L]:YC6W
M(BTQB/98RB("X`#/"%"E*E1',)YK5V$`S$.?#'I@5.5(3X5-LZUM>0L?]]2G
M"^$0T)[$4)X<`BH+IN"/3_VK,'\$(4)^#:S`!3M8"ET(L1G:D`<:^U@`!K!%
MDZ6L92>N0`DL,$@/9-*1/CM!C2/)@E!JK6E=VR62H[9+K7VMEZXT6R:88P+'
M\EZ@\T2G__AVA;6PDUN_!Z!\_X<$3UAT%,[PW.A"0&<:8`A\2!"6#+A!B=Y-
MP[C_NO&+G"8C#2!0PQY^L($:#+($B]K"?0N``"AJ`@$#ND(!Y$"P`N07`U=(
M0A)ND:T)^+2<Y5*<J#1QT')U`P,V>,-H&GS0+';.NI]*A"+HX/5O`<!O;>`P
M%!*@*,AE0P&)J,'2YHV6`.<+`W!I0"P"$#""!0"';"TS$Q!'RXR,VR0]L$@/
M:E(1(9"L(2*#R4,>TA+"8>1B`Q'9PV2P!1V+K`(60&5+MI"%+8"&!3#3"-J9
MP.8&Z.$=#9`C5.;;`*M5Y7-V$)8(L))Z$P"HK+609YSD1("CQF`"!&#Z+U0A
M@B[4$(@9V,H.YK2#;ZGK4F,`.4`!#+%"!P:(!A6@$3>0_U`NE@H9L"RS`@(2
MDP!>P#FO46>JADCAHALA)1NQ]AF2,4AI<%->,#D9,`(FT`060!93<RW!\@UX
MX`)+X'G',A;Z(CWJ,%1=<`9I,1;9)P)]0#SQ!U5-D&UDT07>)@)#T#PG,&[E
M9@2+1CU7T`KND29/T2>$L3UG16_Y9',&0QB$T2;QP03F\V\(,G!HF"`%-UCT
M4S\=LG#\<R(J\G`#5$`P,G&6)2,7AW&?120?%UJ@U22DE4$CYT$GAUHKAR4B
M!T)(<`(;\0;NH1[#-2<DH$(O9'.^I4.V0!B@=##EH4*J(P9V<FPC@`5G@`,`
M4`:1D!U>@!0\T`0DP$-.IT10\/\%4L<I#)`!'T`Y((!U%Q9(P-`H+&`!8!`!
M28!&ZO`#9M0K`:`42O$KPD!'-Q9(?)-)9<$+EQ:!",`X!`("J+@K;R`NDK$!
MC/,#=,``(W@-0]`#(*`=FO9U?D,!H`(';7`-4.`%93!L,\`V,%`!@51G>T0?
MY;$+L%,#^0:&A`%5)/`G8C!F/^9Z0I"`/E8";*`#$[$0`4%,&#$0/*,Q"L%C
M`+$W!B$R+H,1-&!".M8&6<-ZU*<'GH$':C8!U>`O3M,R$Z`"B99_=R86[["%
MR.5G,K9T6=!^A+$#.^`'"(E4,3`H5O$-ZD$5:#,`^[<#T58%X@$!_T=)D(-J
MS,`"%6;_@+2R$[!!!!0@!B+01[9R+I`@&["1`((A44YP&X/D!*4C&S"%@5@7
M1HN"*V-4`JHP`C$`'(4Q`LOQ!WP@)RNV!$M0:+^@#B+H$@%A$M48`UTP*`U@
M%GT0'47X%515A.+Q.\2CA#>P'0QC0M$18/^!'NTA;SKD;OYQ5O[%'EU8"W^2
M!>/#'USP`EQ0B:]2$85UAFDH<&MH<//CAOL3AR4RARP"<7:8(WB8AYG%0)I5
M01*T)(`804DRB(080E]RB![T0::56B2G`W!0`UI3'K<U5O-TB3,T<S+6%=:S
M'I)(#@)B`S?V221`BEB`!:BHB@_U3Y-@`U[!0SB@-IBB*6D@_SOS!0!`0`27
MDX";D"UX5`-,(##'&`"/\0-S$`$%8`J?Q'90(0R!]`8_\`:9L`%T!#H94`('
M%1F#I'<(@!C/I0$-\`8C&&J-$Z,CF"M>`"E"E@;O*"[0)(^%0`,46!?5\$^7
M]P5^Y`UB8!^:M#L!=AO7)`:D-&.T4`F^XI5()C,7,6X!(3(140*[QU`)2`,Z
MH&,]`$UH8!*M)#,:`3<V8Q);4`&8T``10P/LP#H-D!7!8`-J=A0-@!5;@`-M
M(`*\54XW61CZ$B@V]">R0`MX(B?N5F_NH9!RDF*UT`>526C?P&U;T9!F80(!
M%IA@\199"0,B-@/!4`V'88"+X$NPD?\K$,`7QX`&<(`N(P@;'CA0^Q(3C8!1
M#F67F0$W\Q>,L@--F#`!?!`#GN<'3)<6TDH*ZI`6(Y`6(@!-@&&F&$4#T"14
M:5$89RD"51`=V$:$FDD`TR$"T`&%<+$&3<@&Y=8$J*EG$V`?A/%6:]6%\7E;
M5*A6]B(@N,4%7G%69"@#!@*<P8D@PSDA\W-P;@B'C:6<DM6<=_B<E:59'2=:
M30*(0M*QI.6'(G=:W=DEWZE:)J=R6#(2!!$+[&$"\:EL,11*\9%;\($?[18.
M4*$>U;-6,(<?]6(!A38"41`&(N`Z@8,.H0`'^4$"Q#$`DG8I]Q@[&;"B:7,I
M,<$"['`?LU#_/0'P`B\@=U11CB6:K35`1W1$%@)R#%U7GN7X!B"`E5\``CQV
M.:+61:P2%Q7`!!4`*>R(&X#Q.`D0"<%``^8U+E0&"1'691HP!E;P&NY"!).6
M`'2[#/A"*(0B/43U%%IJ>O6`,,,0`)[1$+_W$KM'3!TQ,_G`$:T'$&W`:A+3
MJMXZ`,7'`,N@#I@P>H6Z-'Q!.[_"?4U3%I_S*U.#J"3@!T89?S<W<YQ)`'U0
M!=`+O;4#3\L;:)3Y%8)VEADP`23@7'QC3A;0?J%SM90V`VX`%.B2";!JD10X
MN%\``)B@@50V!+QJ!3`5#&=Y#(-$`0[%4CGU3$BQ:'[0!82B%EB5_U7!$W32
MXW4)2%$C<0,1$3?8*@*#%%LRT(2[I`-V>JU_4&CY-P%5E6W@057'4VU9-0)P
MT3P,\P8F\&AY@3#LL!\V5ZD[D!]`*P:5*9_J&5SJP3750R?'L@./<0)FJ#[L
ML[`-:P`78E@0&[$D\C\.MR+,25D]@K$W,B,ULH<=P'$0U+%`TG$BNW%%HIVE
MY9WBR4%FC(AHS`8H^J0$8`[A0'.\E9HI1DK%E1^OB9[HZ8G#0`ZUX`<C\`18
MX`(C@+3?)8]E4`$V8"=&L`3@-FEK,P.#6P9U4`<`\`&3M@W$(@O':'HV\`T!
M8&.[D`O+H@9E-P!G6T>],#2\\W7^R`F:`/\'6#D#-'!F%``"9/L#-?`9N4++
M3,!DBD0::2`NKY$KG6$9)S5(XD+,A[=A8R#)XQ4-0``$7L`S53IZ]?`4`8M6
M3PH.5!%]+0%E4088/),1-&`9/<8S0/&FOJ01)T6G$MDOGE$#@&(4^'1CA?K"
MZ?04<&86IA!4X[2%8B!#ZA=HV5:41ED[\2?'?38+M#`G5MD6.R"NWK`#`U`&
M#"`]]_)^(M`&_\2/D4,$0Y"KQU`#LH*`]$N!5J`!9#1@#1P0]+L;D30*^L)(
M8!<)TL4HV0H!\O547T$8>O%N:J&8,TC!5+90%;`&$$P#TD/`0J5I(T$X4JT#
M&IS1:N'!.("$12C_PD48'7WP"WYPPAFPA$VH`PB@T.+!#K)9#ER3'CWL0N3@
MUD9I'C!T!7;UB7MB"_ZQ`_#&!'D5(>L3<&@XG!;BL!G2Q(S%<"G"`<LI61%W
MAQ=KQ9>UATO"A]2YL9LU6MDYB(EXB"2KQN#)G6/2`QO``X+VK[X%0RXDLW&=
MQ^^1;_1V"F<%#[5``&<@R"[P!$@K7?+X-@@`2D80!6]AH#```Y/#TL`V22--
M+*^PR'",MK&P"[M0`A:F"6^P"714+D.S!:IV4F`$C#]Q#4#1$HLS*[F:I&UY
MRSW#"%(GEX3`.:&P!2;**!\E=73YO_[GN,,,"9*K-C-``099#[#P<NL4_S>9
M1%0VR`SRQ1*+@A.7X942>3&LVTIA1`-UZJT&$3-!<13]@I(-(`?7)V8\8`<6
M(%_%PA09D-7']6=-`#K2`Q^JXTYV\&<SSKP'0P#N1I72J[R^Y=!=&ZE`K@+Q
MUP<DP*D[N&CZPC=AA1KC017<JP)P%F*7HJI;63F7=H"D$3BV%@K2(P(H)8*E
MTSGP"W.$0196X8*71`K4UI0"0HT:44T9C0$QH%2'<AM4)M6$0P'Y1\"8`)9H
M\'LRL$L44&<3$`.%UI0CS-5$2`#<%@-.:P1=P`!+J`1W\]O@$1;3PP[H<0K!
MQ84J9,.<:%?XX6[T]HE^K&+L<0;O088Z$`0HH/\^1BS8@QT_&&+8;GA8B7TB
M4"S%RRDD=EC%DCW9&NLBT^D#,T(D#!2(?BBR$,39JI7&9CQR&G0ELD5;LFES
M<`T@O35#P/6:0FP>>`QSVKQBIQ`G,;`$1:O;4L3;G5,"2V,[/T0!,[`V;-,V
M`)"*P*8VA5`N=W2G&@TM]S(,(E`""+`!VFWP8P8K\[P%JBAA9!LZ\D@$G!$0
MMRPOJS)16)E30X`&:^H(3K!JI+$;`(`#ZU`#`Z]J[7U3$!`,SR!2A_L%D@O)
M0Y`)`C(6FE3S-7^#OU"U\R4VYS)E$DA+&Q'A&M&1&%E\+P,T0_$&JR<T((Y*
M#/`&X'29^`05N0@U::3_"F0>';F%B6Z2!4UP7%`U:!,MQ!.]'O`$]DW0XS]>
M2KE,MJ!$JE5``&$E7U1SFSOP#*,@/3\-9U@YY9D1.83TE:PVJVUI%KS0`("1
M!C85YJDA/9=K*)IT\Z9``I?);=?B"[[&`-[*`!Y=`BQP!E'@K'^DS'@.&,2F
M+YA0\(US&4X0`@[U.B+@0X5VC8F>;55UF@.`A,^A70D0!(3SV\43%B,P/OCQ
MB6"HL_C1VGM=P[PED&.E0M=#.[;`!`<K(0HBZTC,A@]KG,<IAQ3KV+^.Q<%^
MQ91-[)T56LCN0%V\[!'4Q:/UV=#NG>%IQM6^`<DD#C>W[2X$"%<D/!:%A28F
M_Q8V*BH\B!:$B(D\*B1_2TMA2QD:7U]#$`D:$`UB)G]G(R4S"C`P"C-#&1DX
M)65$"AHL(`P5<`PE)1DE#1L_"`T-;V\-<'"^#2`@#=`5#`D-6PD5&]T((,YI
M7QJBV\`@:,[2<.*B7FW=+&F^ZQ44`!JC-3PV`388P!@(%#B@`88&MC00H?`,
M`A$@0!YZ85!*C(4L60(4""!&!`,<LVCA*)A,1`T$`U@@DT9C5TL:#+94L,:`
M18,V++9LP;.%P1LF/-X,&,`C``\,;1K8R#*!088&A$1D8""&HP@1$XIF242"
M@`D2*@($8,2(A`5).TSLV!&CBEM$!`@TP<B(AUVC=O_Y7;%KH^^/OX#_JE'S
M8_#@OV)(F!@P@D"7$2.N[A"#`<..";,F3!!Q>83F`1D2`%$`*\$,+Q585&A0
M`UP:"@EBBX(@(@^?/#M`9X``8=A(@UV"QXABA(2@"94-8A"Q/(.(!@,$JIXY
M4X8,)S>^,,#0100<.N#345]SHP*$,@:?%OZ[`03L%E]N]!9Q)D8J$3A$F&@2
MEX`1N?S)U<4`&/AG1`P#E)&`#"?(T(,%1C2QPU5B6*3"%1:=]<A>>RF62"*"
M6)"A&)I9P.$55QA28EDVX($'"TH8@,*,*"Q`XXTXTFC`CCSN6,2/0/YHQI!$
M$NF``SEPP,$!!RQ)!14"1"G_`!E44BE!!QU(H.6566[9Y99@:HGEF%)V((`/
M:*:Y@@]8GADEFF>FZ<.:;Z*YPITK,*DG$GSVZ>>?@.HIJ*!],HG$`7SJH`,;
M/=A@5Q8D<,$%68P4<B$)F%9RR*:-3,+#%2J(^$BH:6'*!R9AA($#``E\,H0H
M0PQ@2A_V,:`!::YX00%!^(E&1`4@T%!"#73,Q```PVY00P,4(2!"&DY\U\U?
MO"2D`0@(0%`!'6B`8%X)SWS1JA<:]`(L.W"T!D<)GN3#P$DU1#<`.-:4@`\`
MLHIH$65;G(0``F_T19E396A`P4P4>/'0:1,A8)0-^HK!+"T#/#=!A3:\(<8;
M.M4@_]"R%="`$PN]L)`3"P-LT<._,0'%@\=BR"&'&-%598%4#$R0!08XY(?1
M8QA`\FA18HE5"0&8\K`5(FO%X+33DI@`(*5U-9)77GWY%5AAAG6]]7H3%'(5
M'\'UX<=:^.&`P02V/+?V"%T0<'-H;I#FAA>GS</``,Y4\%H"K`*N]@Y=G''?
M55<9)(8-)`IG'W+0"43#Y!"T\1&!T45#;W76W0#X`-T-4,.T[54@PQ!>B`L`
M<^H=TUH%7U@!@Q4W4)#!`!/4E\I(.S3QGW\`RD5`#"(TYI\?(D`PQ`DZR+!3
M?U<9$H`%%YM0H8DH7IB6B!:0=<5E.X@X@0DH@GH6]6%3*O\B'CVPL(:,,N*X
M@(TXQM]CCT$"6>3^'AR90Y),4M*3H!2E*I$A2U@"TY?$E$`O?6E,9&H3FLPD
M)RE)24YPFI,/XF0G/`T*48`*H9\^2$(^[4E/BD*"#M[`ERPP0E)DL12FC-.(
M\YW%0H182_<^98+QQ3!L)#`"JL*0($^XBAQ4L0T6SC```(P&!E!(``TJ4+'(
M#4$!%&@?!$#P@PW0H085*`$#I`&[-,3K"W`PAF!^@`;8R:8"6RA!&L#C-SBX
M1ERFT<"YUK$.=HA+'P'CP00&,!*2"42,!!+#9<9WA0#((2\1JPQ^(/"!!%#@
M;PO#&REJH!G-4&86RNB+6.QB`>C_;`$@'XD)LTRFDYH`C`G,0H#,F)`2)OB#
M9R*`!,\(E"+\8"54GG0A(\8R3&+R!6)K:=H$NL"6M$AMAE2CU-6.R8^O=<UK
M7[/F#THT@@&0;01\P)0)I(*#L-D*!PU`S@@0T1U;X,(-=SM-2P8"$MZ4`0*(
M-`AD#!>#/IRE,@?120,0!QD1I$0UDZ.!#-9``0@TE")#V0*W0*"#F33("1A-
M@-JB,SHOT@$.3GB5%V)3+H`4`XP($Y<59I"`W@R`GV?``"WB]KNX-.&F_"&>
M"/A@H!&$Q@D-`@$>A!<9BQ2%1(C`X5XTM*'L$<*3FS*1BC`@AK)4(@_6PP,;
M9!`$'N5H_W[UF]']#``DL@II?T4ZDEJ3I"0G#=""58(@!+W$0`@>4*YX;1.9
MTF3!.E50@QC$4YX&)<(1&@J$AR*AH49HPL4B`00;X,L,)Z4I"X"E+(Y(A`V%
M]HA"["54DS"$!?R#B2B$000*@L`1$T`5"_!AB2*HPT-<D0`G!*,@(M@""[PP
M!`34H`T56,]?$/`,=A'A"S5@P1?0`)CVA.,+EQQ""60"AQ]X"P3<\J,5K&`P
MF\S$CM)H1@D2\`$`L*`OA2#106K`7H`%K)&"P%0>,E:A&AS$H"7`P4<R\`'4
M^.T+>!,7$8:PA4#>A689P(#`*+,VGCFG)RG;`@*V(`(\,($);__8FPT*P(.>
M-``/!9A`SZ!B`4+BSBHBZ`(DSI>1HA&34DTPBP76HIG@L*4+,4@+TC)%%DI0
M[5-9RR;7N'88P6!3R%^;P`@L@`%OQ@!NA.O"<@@T2'R1""LF\(Q,3:,`>$)A
M!C/0EGX-NK>A%&1?$XC!'_S@M`F`S&]I$%GE"(3C$=1$&CHX@9ZM(X,;:&`(
MR6@6>#:`!H3R=@@:4)M4[!@R)[Q&(3.(3P*>$AWJS,0)%%`I.6X'TS.`Q'C]
M$9Y<%',5/QCA/UT(S0T:Q`(\[(<`D0G:],*&B$\5)47;2P0CRC=CM:0/0Z8H
MA&9,T(CXYN'8X6,"&V*THZ^"-4=C+8+_C_2'5B.I%4EM=5(%I42EO([)@=\&
MMUP%$,$V71!.%OSKG0(KV,%^L+"-1>R?"!5">JL0LDS(0O>D60CC@"5%F@41
M4TU`2O+%T!2Z[HH0GY`)U`)`M4-`M`:&Y5HL+$$JLU6`%^0#`088-!D1[U<O
M-G`8PA"77:VJP1:6^Y>/,B`<%(CY$!C@V^](([OL\%4"B)$,Z%0L.@QH*`30
MB9QAVZ"1/]A(UJ[`N&4:+C*L47DSHH-(8&C`"YC&XR6_L!`$..J&)&(`;3K9
MR0HAIT+/R0N%\2`S,0AD`M-+'@[$T.&>B8`0R\$`L:?W%1*X^.^4R()7V!(#
MLJ]%$G&16A.B_UF7JY5/R-<LLF&0O+5N6+Z+@.D(]0:PEH+FIPM%[T@9<@89
M$Z2"!#*%@`9&TV4PSWPD%R/1!"C\89Y@`#*X?\XSH`6MB,\\G55X%G44I><&
M70=U+.!9,;JX@?;1X`9W\\('$BP57U!``S>`5@*\,`8K;)_Z()G'I?^HD$33
MYVE,K$,#%-Z?FXZ:``:-@8&Z@(,$W"#/*I&:8Q@#L6&#Z%.D<GB84CYFD1;;
M8R)/-3[(@3V4<!8D@!M@(0=,H`-!(&W.]FPW,E8\4@1F("34EE;7QE9*PB1K
MLD%PY6WA5E=A(F[C1FYF0FX<A&X8="8E&(/M=B<E5%B.E5B*%2@[B/\$S(,M
M^29,F>)9@W`A(&(*/C9CX=.`P<8(-F`]%E()I\)P8>!3`.`)H'!U;5`#9X$*
M/O4!0/`*+3`$PI(?`M$`L,$:?K,!>T`8[+$N:3!>$I8&D.5;S0!S#9443&`#
MSO`OZE(!G``$K%405&4#6S`4SY$,_>)U$),U1?,#&K,L)5$0$X`VX,)>FN@M
M!&%U1%`[PA)S-V`%N0!'6]!)%L`,^8%>=J$"=C!*40$5!6`##8!.&<$S:D,(
M`]`&N(-W:P,6/'!983%,,00QZ25[G71XB8`1E#`61H,TE`*+U01YUT1DE/<U
MEI>-VJA&DIA+--,%?N!YG'%LB=``]U0\.Q#_CC$P3AD`&[C096Y`!*PU$A5"
M&0,U`*E1`6,&>F<`'9IC.M=Q`YA6.>DT`&G@#'"`!FC0/"S@!/;'=0S@4P,0
M'F2$.G<#.&4P%.!2`:TR?@FP7=R5,SPC1VD`+9DF"D1`!&50/&>0CCN0?CL5
M:L$38[`&.KYC!/0W!#=@'17P('*!($$C>^%S(J*B%MU#@!IB"B@B6CUT=L66
M(H6`&WGP`HW`!#W`54%P@?-#/V*E@1X8)%.`5B$(0(-")U'2`=V&@N&6@@N$
M@F5REG[E5QB$;G+9;CD(;X7R;CIH*#F06$!X`FP0670Q@%,(<"9B/>%3%^=S
M(3.F2)!0*;IV-$OP_P1/$`:>!@!EX`FAX`6D\(5+,`(XL'JO$$4PD1^94P)>
MP`(;L"YT`(?#90]_HQ31X$7L!0[L$'.L]08<!D::$SF[`0$#@`"A]P;V%3!+
M)Q8%D)SH4QGLI1-;<(\CMCA-P1#@(`WKX!1[$YH*4![VT"JQL5(J@0?\<'3_
M,!**0'=V4$RWI%]P1S/`:0$!T!0$8A=%IPA%413%5!:80@""MQ;<T6!K4SU"
M\W<$^C".<C742&35>(V!L8T.JHV`\08BL#C%0S;!,0(MN1S,@5KH,5J0T0?=
M@0.A\(ZDH7%M,`N+"!H=%S+*XQS^R3?)\`S7@5'6X9"X8Y#810<_P`1H,/\Y
M0W`:,P`$)>!3)>`+,R$/J$,$(P4``("&[/(%!PD')[E2,X`>:H$?<G223(H/
MM+$<(]`TW=2DO0,\."5J/(,!-XD@$+"32N`@H]4$P3<"9A<VH,)T-X0(PKA4
M4>-C*7(QU.,9^)DB%G$95T!9/,`$"+!L09"5-[*56YF!T?:50!*6^S.62U*6
M&V2"9%`F:MDE"Q0F#=2IYK9!+RB7<2*7'>1!/8B7/$A8];8GC<4G)\`";'!A
MK6@6Z6,6`D<^Y\,A3+EB4\@X'T(`7!`%E!D&",*DG["9@&8*6!`%3.1$I`$%
MND(!)6!FS$($#-`>%,!%$<HLP8!/68$,_F*=`U#_`N>Q.@$`!@5P#$.A')5Q
M,?V0=U=1`S;P`_ZP#,N`,?_`'-$!`II(B<^P-\R!$`SQ#/3P#';'+`DP!I9$
M`Z'@"4X`8"IQ,60'$$_!8/!)3$;A4^C$#WD'GSQP/48A32^VGP1PB82S3,L$
M>GHW/A?1BD;S=QN!%W8A!W^Q#-E$&$4F7`S:7`\:M$'[%\QA`V,3'(F7&[10
M&1FPDH3SI3O@&0.0:21*&C.P*]=J$`T@#DY0HYA6`L_A$3,A1Z;3M==!`PY9
M3@,``=]!!]9)`S_*,%4J%45J1[OW*C/0?1JPDH/D4"59DJKUD3/P`2LI?\A#
M==9*L,Q!.$-1'T\F`@"0_P%=X#LVY7[\00(#,@(W^0?)LR!(`$>NQA\40B+[
MMI2/D)@7$B+.=)1UBCZR9Q%+A68F0I6@]08(H`-KT%6-ZJA<V97X,ZE`X@'"
MZP$@Z#]D>:DK\"3KUE<N**J?RB6A*JJ<FFXRF*ES:9>*]8,\.&\DZ&[RII=^
MR3P]L`&.0BH6H:OI16R:,H4)^)@\<!F.`I67:`)<X`*4&0?$4P99Z"HCQ0+.
M"JVH]40PL'$4,!+OR@!$4`+?L$6N25Q^TU!PL&$_0(D`"P+GNAM@^P81``9@
MH`97P!PFXF*-%`"[=#O+\"\(<!#),!2WAQ6#-"_6&</F409/X3$'BUW&0`?!
M</\[^`$`7W9)[3`N":P3,.LH'>$<<:=@'&L5:U,4$'-913.,F%4(!K@VP<$=
M11<^>&H!Z4D6Z5DT>3%*`8!DTQ)Y#"JT:)S&#OH7!G$%R_%-?<>.Y<0V&D`@
M7XJY73!.YU&U"K`0,\$:"."V,UJCL)$4,K$:#8`&7L0"-+`&K\)U$-`=V@(.
MP>`WIC$#2FH%*REV!Z.0[!!QIC$&&B"Y)E"+\Y`&H<"DHA"YBG@&<;$#`+4V
M.X`T>4`KA(0!3G,0=2"YE%NY_4$"""("I^8"1C`";?`%0.4\H0M_+FQP-?0(
MG@*,9Z%#N\9#%N&4AS`B$^`HBZ`"N,$'%L`^+*"[-<+_NX^J(UV9/QU8!%,P
MO,0[)->&)"*X),E[)U1@@LQ[EL[;EG)55_I<JB[85W0YT&HB6-GKJK'*O0>`
M@X1UE["J`R`0,"J0!9.A(8<PE(V@2(G)0V%#2DB%@,B4!UQ@!/?[!R.@OZZ"
M.JPU/G\0!1?G$*TPP#>`2`?\`1"P+!"`!H=!G+^`KELD!QW\`\P"P\T0#0C`
M`P4`!G;PBF+0!5=0`$DP/9-Q,7G09"@*L`BP`;[5&BM\RU?0%,U`#Q7\#`D@
MCPV```PP!)!%.B"`KLA",F7@!E?[:!^Y741``PB0;UDC(@T`G`$C!B.@=]!H
M57<A%DM-E?QP>)?Q-MQQH9H1_S[=\YAB3!:P>*#3^+.8C7EJO-F</2T_<!!?
M+0)^\!B%$]@:NC;'PGE\P`?V404[('9EX`6L!P50<%QI\'+$$AZFP\@"^2HY
M,0\(P'QTP`*>XP4C906KL[9&6I(5X)`?2:U0L)+)0YUWJU*#BP-QLQF'=!Z]
M(4<$\KC%XP=Q$0.-W06N'0/!@1\8BMZX.+F_4Z8[EAO";`3$/`(4H),R0`.E
M\&J1X:>\9CT;,@@%=WB4`"J$4(\ETDBN2SV0@!'ZAAM88`)98)4GT&SF?,YB
MI2/J[`%%X,["&\_&>ZEZDKQ/DL]]M<\/Y+PF3KUPR5<QF*K>>]![Z:KV!JM]
M,H*(,O\37F<7/=19`J?%&4)P,91KA_!_D4!:#&>L&;"_$9</TW4*41`%JO".
MLY-]`[$W%$"(R5`"(#`8MDL-Z/H4&P8&$1`!M&BO1X<B/]`/'!8JE;$X5Y`$
MS%"PK%&+SO$QRH(M6LU>"%$&P876+X?#?X$&<L1UVHH`+,"VW0("J"Q'9?`!
MQ+"+1``%-P`3L`&2L0`"\>I)1XP55+5+74`U,QL`N(H(RP09P1$<C^T5<A/&
M8NQB');9LM[9M%[KV0@8-2`"-K`93@,9A*0?]7@S36K%+6D"5JUZN``#]B>/
M1IJCX`$")G,ZKU(N6V`YZ,`.,E`!-V#<WEDNYVJM1MIGL;/_75X0W4,Q%=*`
MRH%K!40PRI_W!R;0'5<!4/.[`Q;W!`:58I0Q%"5SI!/#'+U.2.YM(`'2'WU@
M4%5P:D;@:3H)A#J``$/5!`,2-'L1"9)@(F7!5&D!*JE[/L,FJ.D%516O-*6B
M:WJ@;&M`(Q>.X;X;)$3BX2!NO&PE*'CR)BN0SRA85Y^*XBU(0?CL\_@<]-@;
MXX>EO;!Z]/1F;WS"5K(JOBX#V499%N`#%@58NDQ(/@>N5(BP<$^@Y%F8`/<D
M"A2P!6+P!RY@K`.0[%#T!<&@7\"0`,H.!QX!!P"CPG#`PD_-P6#`$7`W!Q$P
MBT=7(6+AQLQA7X7Q!G^XYU+Z+B13_P/H0@>^E>ZF,00]L`4.A09,$!CN`1MX
MTP;(P+;T@LK"\@4V#1T9@#<RH`-3JP%Y.P8P$`(ZX*=W00(&M0_/68MJPYC"
M&!9,5CR@YVMA,UJ[WP2O^.H<)A:R?L;9F-7+C\*V_OQ#:PP;,``BDF)_\!@&
M%93QBEH)-FPJH&23))K*?@,L93*!#A[990][FP\TT!/H]`P4T+6CN%T?F0`Y
M`3O4V=S9@>F<"0@##0.$`QD`9749$!`,&%TB`T]11D9=(S$Q$U5-?#%+3Z%/
MD0T-+!4T,B=.3C(R3A0#CS$C`S@CE;D$NP1&3021794N9SAE0R?)&WB<D`T6
M5R0$)CLF%O\6/%=7*E?4U!8DVMS?$QAB/`'=$V(6Y>?<*A8F\R99/#97`28B
M12C^"P`#!O3GSX!!@T423IEBQHP'APXB2HR8HV)%#@<R9ERQPH</CCX$B!S9
MH:1)DQ)2JERYLD/*DS!CEAQ)DJ;-D1\/<-RI<2,2)!I_"@T*-.//GD5['D@J
MM.E/'3V8!+C&@QJ/>"1(5%/!M=T.$N#B[;"@XIZ8==!49#7R9,23,$L.??E2
M!D("+T,:B.GC(LJ9`1H4P(`!)4&)PPQP0"`"PTH%$2QJU,`P`<&;R_@*%``#
MAD>Y*YHCV!#1X(T8,5=L3!!Q6M"/#340_'CSXT<-!HVV-*A0(4W_!1"Q$0PX
MG&!&`A!;VJ2ATX,.'3B^&0SQDB`!!!8#(,`!P9MWFA(0-&@7@4.#FQLT#A$9
M`V6,@@1L;,AO-V$'!A$BWGC&3WE"`Q%=D,"5'5F(D`%K-J@00`!<,<@#.@P&
M`&$`<O!0VX489JCAAJ]MX"$"((;H7(@DDNCAB2BFJ.**++;HX6NO#<`.@'^,
MT$4F]ADR0!<89)`!!B3,LX.-Q901V&#&>:$!`RR4\)MDSE4P1`(:#&'D=0PP
M``<<W3EQ5W7%E2'"%@R4D<:6O<V5@!5$6)=!`^6,(`(#A8B``09;B#%/+0.,
ML`0?&`Q`6BG_"3K"H3'\Q4`#((!PRBJL_\A``P0X`'B)(;CL4DDOTOA"0"W"
M&$&,,4/(H(0,RYC01`SX01.D/&.5I<T5\GBS33BT5G.6&/)I<]8$P)Z&&JW?
M7*.@#?>T<T(0!`DD$$$H'(100M0V!-%$$UG$`48:[=111S>))!-,+)4DP;CC
MVC13N.R.Y"U/2BDU%%'Q&C5OO4X!I2\2;/0P'PD\U`KP@_,$3,\U`H)ES37R
MG$865P2`,DD4.``P%P!V?9``"V+P$85?`P`@&&$)4$`!!#X"0`00,]``60W(
M:E;`/9?E`T8`Y5A&FQH(5/J&#:<%BH$-#3``7`5P(+!!B`U0H`$`+#30!@5P
M;%";&C\T4(+31/]XP0("#%#0*'<04-#;EPGD1:9OOO56`05?B`='`S@D\)X,
MNR4PQMX*M"##G5L$:\)J!R)[9SD&9C!"%ERIT*.,"T8N8382+LCAY9AW>"*(
M2XOHW.<@@DXB'9QOKK2+J*?.XFLB3&"!"",0T$6`#TZ@HPEB&-/`G;-/0,($
MBB7`V&#4+5GTD['50(,&8%(Y!`MS=L>;E]5]064;@S+@9`4E6%^=!N(9<V#K
M@P,[01>N9X''#F<<VI:=&)C"0-O@E0`[!F?<AT$-(&S)I2LTX(UU8'>I.HC`
M")K*!0)]T00,W*(245C"`(ZABA/T``^JV@%^\F"#:LPC+;CZ8#6V<:O_;]A'
M#!*:#SO*80*S6,.#L;H'K:XA!C;(`%HH<-8"<!BM@U`K(0ZY%K8H<A&E>"LD
M[1(7NLQUKI@T<8DT65<':I)$D7SD7?6B%U*8DA2BW,N+^7H*&RP#CJQ\`QX6
MV$$UH$&LL%1%C1;`!]!<)R`N1"$440A#R"X&@2]01T8DP()?1%`&!8S,.`#`
M&`3*X`4@$*$-V`&!#0*@&1Z8YC(HQ!EE:E`"$&!-,I:QP1MJ@!_+[*8!:3@3
M<&I@"NYI8`:\@4`%K.:AYZ0I`=:C`0@FU3\T;:E[X!//%M[``EE"AP*^H0``
M/@"`QU1L!C=@`70T``2^08$&YD#6@E1@.UD$_TX^IUE-GRS`H`)E``$RF]P]
M,L?.#9EN=)^+ISQ'5*(/G>Z=JLMG/FM3"AO(279=X(.01H`#'*`O`V*JCS6D
M,8)%#&$&@X%!VC0`20;\!@UT0`,<*&`%ZUG!"EX0V_'0E`:[?$\#91B`^3"`
MFY.5H2X^JA0ARU!0#&3!`F>YSYBVL(41G.$,3UC"$B(!@HQ60`:\H<')*`4G
M_$BF45PZ*@T"N+PR-.!&@4II%7;A`@7VPA==Z!,$APJ!4B5C"PC8:A7DQ(YJ
MQ.H*V<B5K1HGUQT$BP<O"!@[RL>KU)R%&F.YBGSTBCLFL&$-`/F'LWCHPQ].
MX2$>\,`0)7*1;?4$)/_@JJ(`EKC$E[@$BB91U[J2>$4L9K&+]M*BO+X(QC#J
MH%]ES(H\$@:6^EPE'O5AXQ7L:H)\\.`LL>("%O`8!A$``)>*9!X#?&>$04+`
MD#!0@!MF`+XR()2:1&A$!1I0`YYV%P,Z>T,[[$1,"-0`-N=%[R@)M8$&!!`.
M='C1!BJ@G"\0`9;%K``:T$`VLZ7!>GX4&W2XI,K^@:<X&J`!6K56`NVQ#0(`
M0*D@LC.#D(('NVY0`!0H$+AP`HN@`T#`:M81+)R:0$#Q(,0/(A"`VESF,NV\
MG(L0,,]XUJ#&\JSGBDJGSQZOSFK_N<)]_'`).=UO=\`:@`&%I,;9&0("7AC_
M3&&&D-U3_":C7+H!+M=D!0V48'?1Z\V!@PF``\5@=O<A!'Y(0YD=Y"$&BXB$
M+!`W@"Q5@`$T8(`(?@H*$6QGOSJ`PPG^1X,I.2(2L3D1"%QQ@R'<P+YB0C,A
M<1"#!.JB$DVPW0'[$@4##6$-KD!.I3^ETEJ5,1H*\X9NP0)#&F)#'O)P71M_
M6Y^Q9&4;-FB8-?2``!;<0+&+A59CB["0QT8VLI,E8A$OF]EPA;:S*'%BN3@[
M1761%B?OXD@6\<7%H-@+M4=92KXXL"\=Z""V`IIMPF`=#6]8@RNLAD:MJB$@
M/H1B"6$8P7'I4E8O>*$-6R!!<\_0@`Q`UY!$>!K*_S(0F#8QJ0*G:'"#02`;
M&R"`-&(@)@M`T(#M`*?.'(>#]GH]A*I="#;<LXL&O'`F9$*5-[_TZ`PH@(#;
M(,WCT&&$\"`@2?DX$`(-UIZ/2B`+@D)@!BWCCGV)X(8,;VQ,:"&!&"8X@%S?
M!P>RV"97?HN#!JBA`!8_48=B//86A8YT:)?,C7%,.A&5*$0^CKL^8;2%`5QA
M-9F0DRU$8((\U(J019^=&DG0H_!$MS`WF$%>LE14[OQWRW=):7U8M35&?.&X
M9:``G0AXHWGDM!SK^)4Q8$<*J*;RJ+#(P(XNU0#^-NH4.C@!`"DZ"`;(YD)T
MD`$%T&8%`*S^$C[JPE<WI?^+)FA0!#&(X%`SX.A0;T'X3:@%6L`15X,!-F'1
M2*.0'I9&M`P.&_>@Q@3$WT(V6O\:-LA"%A!0@2#H<"`%F99"%H)L!QR;L@ZP
MB+:8W>R;4-LE+/%$TB:`4*1$[>(1V)9M.K$".K%M6_1M31$OX19&JX4$9)$5
M\'9&LB4D)Q8DL<(-:;1&N?(5!-`^;S$"1O)2?>1O$-``)O`'6+`$&%`"0``$
M@J$`>$$!1"<=*Z,!2$,#\/4V)5`&G;0!;W!Q(49,-^<<5L-^AV$7$$`'(%!R
M&\!?T.$DC^='UQ%`O00"_/4VWI-@/#4`O]%+=Z9,X,,`;T`K9S$(@D(HDG$:
M!%7_`EXP!D[@2BO#,E`P!#7P,P^2#:]3%ULP%8$B"[F"#0$@!AE0`6H@!PC0
M`%9S<K718W#W=O!$!U#"=O1DB7`G=Y[H(C!2`P.`4\CG!X=R!G9B'[!C.S2%
M`=5``!:0!<!0!X8G&-3A!@F@/8O2/VD`-\Q#)1J``ZZ(9@R0`8>!&'`0&V*`
M`9A0!9G0=SI5"-HS)V)2"SB0C%A6`;&G>PF04I?BA<RQ`=P!!S*0`#?@-"V8
M&&^`-:^Q2\7A!>>8`+XW.\"G.)8V?+O@!Y%P!J"P?.9H;APW`GS0!&%E#J>F
M#0U#;R24:A\D#E41++)V%0$#+&OT02I@`_1@#0]"`@%@_P,](`/OEU@$(2WS
M1W^2=7_YIW_:PBT;D1$A\1'.QED!Z%D#&&V@-5HW@8!6E&T,Z"T.J&T3&&Y&
MX8#Z<EH_44:-HQ8?Q`,`TWW<!T<"H@X[<%N#8P($0`M/$`<]@E)]%!YXP0([
MP`=8@`7%0$V&A(MID"6E\#9$0`1I``*I9#50=1C)Z"@M"#940P=7HP;B.&8)
ML!W:(8YI<(=;\GA4D@:LM'&-8H5@:`4S`'!X<!J[85':@P.+T`@-@`#"$D?R
M`4XD1AFHR`"!43(TD`;"HP!(MS'=93YV57!?EB<3<"AW0@@80$X6D`%I\`,%
M\`:1.(F<2&._&9R>(T]K%T\T-O]/EOB)ROEC/R`<>@(@?#`[8$$`#E0I]N$C
M_:$)$\`J&;![AJ1A,P`$N9@E%M6+)O4%C$!T/O4$9X!F@+,%=Y)3AS*?_%%[
M;;`U0S`$-``>=D(G->!Z:()Z7E(&A[(H*((&W*-EN.0%+3@GLJ%1Y.@ECME1
M\C@`[7,)#&!`?C!\"H1`?1`);N$6!F*.KA`U(N`'JR(+2`F(''AK<$4/@;4-
M90$KP*);95$^KJ-7[%`K&ED67``PAH58.Q1L\2=_Q\80DI4M*:E_EL5_5X1$
MHG42-#F3-$DNG*5$,5%%'L&3"M@M1(E:#KA%0KE%L964"D,6`2,PJ?:!0<(.
MVN`-GN#_%G%0EACS!5/RE6)``"Y`EB%C@VX@47FV*(2R&,O!`A1`!VJ`-1M`
M!UIS9R4``+;'`%^`!B?'/SEG,K*D-2"P`5S2>+UA4F40&47#*&/#)8^:<"R@
M'[E6`RQ`)_]!*&@U'V61#?A@&O$C9X50-PI0*J69`"RC-RW3`'E"%4*F>CG5
M'[%94"*`#5F``Q2@FQBR-)B8B9OX=IUCK?9TB<Y1G*)SB=BZG.`J7\U9:H<2
MG6<`,+^S=]<I)H_0!?2V`Y9I-R/C!D!`4>1IF2B#&,)Z)_SX,9IP%KJQ9G."
M=;#C4Z77/TG%"EKF>W4W`!FU7U^("C?@)1I@)TX"H)_J;UN6_U+DP2B]X0I.
MX%%64!V^=Z&U0%.5UJ&Z\"DRU2<C:HYK0`/8,0%-4`5V(@X@""N]%0XWJD8*
M*:/S-A8XJWT^&T?$L@ZX<V)E00)<\*,\@`>^-A#/4J338FS&ABU,R@&5Q9(+
M>$0Q*:5/1*73]G\%2%H>45I<VBT,N&UCJK9KZQ00.)1(@6Y)J0(?E!5,"5@=
M.%M<T0T'DS"FF)5_D4B7=Z<)4`%BL!:K408U"`4P$%)Y1@C<Q0!$<*A-XTDI
M<#4_P!U;@S$U("6R`1M<8JIE`QX,P*I)`XX:Q3UQXV6924H#@'..:CT<IIG!
M(@:A)$>#-9'H4P[<Q3^E0`B6*;P`(/^>C79YF><$(%4!3/`@N893#@0YUW`%
M?O=Y]I`%V;$!!5"I:M>]U=J).X8BG)ACW2J<X!NNX,HZM7DH`'5F=Q()\(,#
M=5";5NEW!``\=I%A@X%P^4H:<@)F8S*1[M,6\=-QVM,&VK-(7S8!(.,D6])+
MLO<*<8,#=<<`\:5HJ$`!(1`"2C(`:U.87X!,4$8$%`H`78<#)7!Z1[5[P`@^
M!O13ET)3-*NRFT*0!"M3=C$$K0!Q*M4$'SH"#S-#IB8.'JA]MP)7/*J13-EN
M:K0P>I(@]*$GMY(53=L$6<!K+""U\-=#C55L2(JU69L#V\*UV0:E4<I$342E
M:"P3*G&34D3_1>%RMJ5U11NA;<P6IEXJ;FVK6D$1%G4+;VE$%MG'6_`&1WU;
M/BC&!8$[IX1D,8A0'+GH.R3@"0T``38X!H^+'G129_^A`5_`<3+[`YE[-4Y8
M4N8E-;(AA1U'NDM5&EL0&8OJ>A40'D````V`++^59F18"',3&S:`!]#``W*@
M&:E!'ZS$'Y01*$9S8Y)1>X+*`,5+'4A5-DHU`Y6+'(&S4H:PK%9G)^>0#3R@
M?I6,`'/@F]WKO6UWOJKSFZ+SO>9K(NC[B:^Q.T(F`GPP).1Q"^:S#DK6.N<#
M+)I@#&5`!",3741`A`RP!7F0!P`[JEL`OP6+'Z1JJA0P!-:3J8E2_V<PA[!'
M-;'H.`@9@`:+BF5.,!TM`%+!2!YG8II?X!OA@73@XWN!`G2IE$J[MW()5V9[
M]E/W@9U-0,.8U@4%90N"`F4)(`,Z`'&.L`OX@1I@04-*NW4BM+/10"Q_BV+:
M=T:YYC`XA19JD15,^Z,`(P<]<`,;G$-;/&S$5FQ"I&PKV:1NVQ$Z:8";!;9I
M/)-@6Y-72A)25&T'R*4^B<=B*K=9Q(`3V,<H]L<]^S"LUEMB06]]:U=A00*+
M3%860Q</Y662[`DS2-"&!$UI*;RD<5S(`7$_4,X7<AO(]*BQ<;H>\E04O4AJ
M^%NEP#\<QP+&D$@,D$D2(@;_80["(A\4PO\@-'0:(#(9\=.JJH<!UN!`)>!Q
MI5H!&4`G%=.61YT&B30='Y4`PKJCQR("C0`L@;+<Z)!^66`'6P`!6Q`!W(O.
M:-=VRUDBZ>S.[\QC\1QWM7$?W'2B^$R;[7`X$R2,@F>5P/!2!!U1"D`$0Z`]
M2*;,=D8#;;#<:G0?I,J+Y^@$YW@#)3`"A<@H(MT#+.`*:?-0W)U?O<0E7N(%
M(QLW$%!GOF$]*^T]'_4!\YL'!H(#YME'$=:6-(5U/O53!B(F/RTJ*ENSEGGD
MV<$\:W`"`:1GJE(+8]$P>A+$AWA&VA`./'J!":-J;C21XX=3['`5&%A'>,L$
M%9``(4"D\E>25YO_+2HYQF2L;>!BQE%DURBAQG9N+F1;UZ%5UU4$V($MV%[$
MM@^8+WZLV+(EM"3T0589)">6#?%`#[L`5'$@@Q`V%V7PCA``)`)G'PSP`=]9
M&/>)=8)"2!J0F;VQ`>PX&[MQC.9E`UM05%+H<=Q#`771`)14`+[MJH2"9.S0
M.'D@)^9PY1QTA)-$`H=2-`-PSAT'<[L3*`Y\A6>2<@=B"-24`$X`'@"0GTXS
M!#WP*[=;<`P01^WPVP4\`><]`2VXO9/8O<"1G.`*3V=7WSIVWYY8&Z*X6\A'
M"^[JKH%2*8N+`WE*`'Y'#3/%=(Z+<+DXW=EC,JWP"A3@,O\A9[TQF!3P__"M
M,"46RP`8Y1QH4$Q?0%U?T&409TQ(,SUK,@-=]@$_HC4`AC0LG/)$D`'"QRJ6
MN0C5Q0@'TDT[C8H9\`$#H$!=I4`UJV09H`C&D#8W$`1K<&<#P`D$90ZZ`D($
M\T)?P;/$LD8HEN@>Q-AF\2NHH7U@?9%A[;1;0`-I/K4]]$-K?6Q)2EEO#M=U
MO!$O2>=\GM=WWL8M@<8O08#_)RZ:M9.`;L=X#)1@^FT5Z!1T"V\`HQ:F!NE:
M,7XH-E>T4A]9T059*8-RL4C%H7@-D!4$P#Z``5V/JX-ZMF8#70'LYP2(FMIS
MLC5$1QL(\&=SPXL7PP"3A`Z[21H_TYGIH"=F5/\+=@(G*Q4H>F$[!*<E:E>J
MIIH!74<W%O7`\04'A]%U!@+J-R!FVXY+RXMDU>"[.-`&KI-3^&$(PGC>8D`!
M+"`'W#NMP=&)]_2)\GZ<Z6R^]JZ<IV,;H[@/`04((SLJ65D8.#@B%A@0&1A=
MCQ-=,2,9$#,*,#`*;D`:#`PX#34U<&E.3C*J3A1M`R(B`PQI:7`@+#*X0S<)
M7@-;);4@IA5P%`E$'PE67FT,$&D5(,,5%%_+R0`#.QB6M*@40QI>,T0:&2)=
M!-RRH!4-#1@3\P,X`V?X(AD?`P1&_P`#5M&7H4X&'&42)+@1Y(:,4%6:')(W
M88>%*U=4J"!A88>)'1;_2614T=&$21(;49(`:=*"2HX6Q,B<(`9CQQTD<F;A
MP:4GB2Q,6"P82A2%40,&BBB=PM2#4Z<.HD;-0;4JAZL'LAY8P37K"A\"?(@5
M$)9LA[-HSTJ0H':MV[9KX;J-F[:NW0YFR>K=RU>L7ZZ``6OMJG7KBL('D"#1
MJG@QXJR*(3=N[#)GSI27+5LPX5+C9A,J=U2\J.*C2Q,QGCQ9LF0`@`1#%'K1
M4&:`F)QY8H@H`P1(IF8,!@B'589(FAH52FQ0\V/#!A`5TI2`4&(+CP`_$`PH
MU@#6*Q$8+"1)$N!%``L3KA0H$."*C8Y=)I@0$PM\`P0;:F#`T'TX>`L-2`/'
M_X`-3-,`'`P@\T4\U*&QP0\0;@#'=!`(EX$&1'Q!`04E:#".%<RP\`8>//"@
M`@]BC("#(_.(1A,&PG5APWF@V``AA`B0HB,"//+HW(]`!BGDD,[U:.212!I)
MI)!*+NGDDT#B]Z!V8E@@P@A_C!`#`29U48\($W3CR`XQF$0`"1,@Y(5OF4"A
M@!<TA-(`'734,(PJ,H`S!`-;B%#"?70XAT8:X2B$X9\E4&`+H4X0V@L17E@Q
M`PT-X$#=-'!4<XT51!`!@`@@B8`#*!`H]$49J*(S`BQ/8(&%:/N%.0$>>-!C
MSPCXJ*B-"4T$9(0++@!$4*IE>`';#:G(0,,$$F70@/\8\UR$T7L@>639%1Q]
M9%%GV)+P44N6;6122SQLAE)).7'Q$P\V9,3#!!4,0=0"1J&05!%3>#"%4OCB
MZX%44U5%%5:#';;55CX`!M9>=\DUU\,0LR7Q6PU7S-?%9/F5<&"!#68888\U
M)IECCY6<V&)(5&;9RI=IY"UG+K^\694=?<:9!03XH1IKNR5P30(:?````PA8
MML,($(SA&PS`"1?<`(?>0K0:&]!I"H6*!*`U#PC`T<`;-H1=8@#KK<<#2%<D
M44`$-F``WJKRB-J="`@T1PJ/I#0`RA99#),I"'3@UW4)%7P!*8-$YZAW-&GX
M_(JERDC#0FR12EH!`EMLT47_%SN<'8L-Y1(@*\T6\'!%%B*T4?>-^>E8PY%0
MQCZDE+0G"7OL2<H.I90_2MD<F%?`XL<(Q,-2/'AB8F!"%1_%T`72KQ&A@`)0
M)%`.!14P``<:-01>RH#AB-/&%@TX6S5TT0$-FS@0,-`&!=%4('\:O'@!J8>4
M/B--=$Y\L6FGM>G"JT90CPP$HP)7DD<?_G`&`@Y@"02H`O'@-@'R=2<1(WA"
M%)[@F@'PRE?`"I81NE&',@"@5#.`C0Q.H(HU=*$)$\B`;6)2I7+%Y%LD*-%&
M/F.MC7A&)O.Q@`JP)2YMJ0Q<+R.!N@K1+I]L@09#J==1EN(!?N'+#&;X%\`$
MEH.K_W"@,(0YS%<4=K&&18PM'3CC7-"RQHJY\2P8TXM8.":8@WW,8(B9C,GV
M:#*5L6QE&MFA1V+VK8Q<P005,8FU^/"$#"ZA9T.(#0`\U(8:I"M+&2#"TJS0
M/G=4(`,S`,(7O,:"&N0''K$8CABTIC4PB*$&5XA`!-9SGE6RAP?/F\`;WE``
M-;P!%J^K`?D8(((:",=.MBA2CAA0AD^(@0408$&@?J`&YL"!.L@@`@-J(!T0
MH`$$:8``_"C@(6*N*'(@8("'9@"%=@Z!!5O`0T?D80,"UN`-DAB`##&P-??P
MH`$0J,&-[.:ZV^GNH,JTG4)[M"3>(=1)#*6=<YH3CRNLJO\*SQ,5#KK`!VCM
M0`S,',`$)_$1A&!H>C/@A7$:L!T0W(T.U+B!L30``7A`0$!I&`(J>F&L9=34
M3]"07P7ZMPPOS.8<LI"AWJQA*`^A0S@C6`(68N"V$52P"R;@DO.>MRJ1ABD6
M#&`!"Q@0IWJ(%%<$+`,.JA"0$`+K'UW`00E/V`O8)&L--\!`$W:0`0:(004V
MD(D%8O*9EY2K)9P1"48.*0:/2$LD+\,A27("$I68A`N$L$`3,?N&"D01!?2R
M%[[V944/9%&+7!R8%[_X&#'.$2P+XXM=U$A;B*61+F]T8QPS]I>O;$PP=0P9
MR?A(7,CX\8_A<IEI7%:S$QUR6XG_)0$!&KF:W6@@-@F`@(<@L(6-<($/9\"!
M%98V@R&4``<E8$"'>J.!"EAP"W?;)49X$($Y@$%M)L#`#QX@RP#L,B8SNH*L
M)M"`Y?S@=;O<I=X&0(H!'$@8@?(;!0!`A(!6(`%P:,X&$$"-4JV/3].9AOP&
M5`V%E"`6$"!"`F;1AN(`01,*H``"F#"V1;@M$3/1YP`F4"Z99"$`6R@#")@3
M(=>]KDD/U=U"';IDAR9Y=TW"SXW<Q@.W3:(+#1R!'V+0G1$<HC8[.%-F>B8]
M&%3/>A08:PEL\3J8IN%GV&7!A&QABD;QHA<@&D-``7K33!'*?]B@S9]@E%0(
M&#J]P9&'_P-%<`8^F&!5F:,(!D:P.5P]TL&DR!0+*D"#-L0)`AALX`!`W86V
MNC58,6#`7%'EH87@%:\BX%(&'$&`(4*K2F(`34YXP!&6'-=FUN((ML85W<QX
MRR(D,8$+?C+8*_1$!4$)K123PA32YNM?J.7B:KW86C'Z%K:QU<M=:DON-N;V
MC1F[F,:X,D<Z@LPPQ95,O!5S7$!B)F;K$.(0-S/8('I+W])=@B,K<5U3>6@(
M($@)'V(`M>G!((6&AL`U.@4$XPCS/C]8SWC(4QX[V"$`1[-E`?;PA@%@P`;X
M#%,\;*`W.KD40KM$`#3+P`"6CGB:S*&%-8A0ABV`8`@5@*F?B_^1!@_YKPT!
M2@,XE>[G8W@A#6[3+@3@P`*]A9*="D"X,#$@!M,1$!TSR@*!WR8<#&3!#A,H
M`QR(W)PZN=V@3\:=0J-DN[@?-'=2?E`-1"#@=#B/#WDP`1_TD8@)Z&,;!.@#
MF38W@(1@`J6]^$+V%.5-JSE!(5:XQB?&6HQ,R0^[F$_`4V=-=&OXSPICX/FL
MXX'6"<I#GO!I9"JUM*I85'T`;4C$?G(E@@)-`P0ZT`&>*M"(5^Q'GQDHM1&B
M`*PPA"&$1MA!XTU8!G$8RR%KP.L`!KLBY5T$/32I$LL4&9*4,-:QUY+923"3
MF<KF!`L$V,E[?,+R&TA[BM5^BOX#IMK_;2.!M043&.DV%@*`%P4X;A-3;K1U
M;KD51^OF6^[6,1TS;Y'A%5V!1XE1;\EU;X%4$D-T!9LQ&C6#$AM!`(^T&N&E
M`0KA,T&3`"R@,KKQ!0[W<!H````P`TJC2<9A0340`+)4`(MU!:QD>"IG`VI0
M`#F"`"B'`&[S+&]P(.E4`3KB-PPP!%Y04\\``@-5)]'A/[11=4`G=)F2*=;@
M(9_`8;1@"]"A<]8#`;&P#QK`(=6@23.P"5[@7A.`'B?7-@94`V(`"?OA-@=A
M=G:`!S?U`W(0(4G8/4AF=[*#)+,#=XXH=U'6'-DA`C)Q)91@`MUR!O4@")60
M`92V.57@$8SP_P6/IP#E!1L-P`(TL#UH\$V%@WE64(,F)P+:XV=$92B<!!YA
M,@`ED"C^,XQ?($/,9`_;0`)]X#QAT@5B4"L35#Q>I3@D1@,0X`S(TWMVXC?R
M,WP0H%;@T07Z4`8C\`_,YP+.!WU^,'VHTDPJB'UXQ0`6T`2-%QZ^%BV8<1,G
MD4,Y,3.2A1(\@%BZQGZ9L5S_5B+.ID0\T`-K$`+31FW7IG]0$3#;YD7#98$"
M&!8$R#`(F!8*>$8,B&X':(`:J3'M%H'>AH'%58%\E#+(96\MHUPX83H!N2W!
M1H(D$`57PAI0XS->J((5('XK@30SJ`#)\`&]T1M&Z00@0#[P-1,T`?\V[V%X
MX2$+&_`&K_,#;X``NU0#K?@ZFU8,OE,#)4`#-)``;N""-$`!@/--Q&`,*Y@`
ME.(,#1`-WH0@AF:&#%!!TP$'=!`@T8%"90`+#$!A-\5,FC0&;O`F+-`#>"`'
M579R8I`!9?`L>0B"'S$"#3`!64`2.)`&B'@CBQ@X##6)2M:(0>(C$%4[JNF(
MK;EA$_5+>7@E?6!5B-1`L>!EA#<!!"!FO=D-7^`%BZF*D9<]K_A-M]`X*^@A
MVL!2#-!YI_`S0*,!.(`/E58/B#`JQA<W!Z%/(]`'7`4+L,`"KT`\3R!J`P`X
M=/!-P5<!,G`,#'!\(N!2R.F>,G`#-R`.`)#_"&"B#Y]BCNCH?,_W?(-70B8T
M22HX!'B%GS0@!J@#``VP$HD$1$*4+=]2H;RFCXF5$IMA$?OXDIYQ$EQ``%72
M+I9A`T$Q!/9R%/?2%!(YD?WG?V#D;F3!%;+E1FCDD1\)DB%Y%P>X6^N&,"@9
M;XQQD8F11QH(DR2(&5RB6?R&+BGA,EBPDU'0D\,8-!JP+"Y!`'^``12P-)M0
M<1]`!.7@&T!``9D##Z%@5O>T2X;7`(&5GEX)!Z0``I@V#&W``@A0#7#P(-6D
M!@CP#.%@+)O69R)6#,375!6P`=D3('06'110*E?HA#6@7J``"A2`*NWC-J/V
M"<@!`6L"!&-@E#10_W5Y&)F'``'\A")N$QZ+50A9P``4P`2)6&1O5YJFR22I
MB7>XZF2[RIJOF60(0)H2]2"_A`$D``OY13Q0%8B2T'T[L#G2B@$E\`4:,)PI
M!#040%9J2(;7H'FT<5:X.`NL\#,V*$/12#SR$(CR,%AB4#ZO@*Z:F4K;$:DE
M(%+YT'N_-PTZ<`)$EUWQ8`^FM`%,(',T<&?C``#H`":5\"E_L'P!*J`$6@FH
M\AJMMA#X>0-H^J#;]Q'S@!$R`8*^IC(;P1*<T2TY\2WKQS(QHQGK1U@XJ5D,
M&00&8"](8441^112$:-7\7_#Q3$;\UHW.I)U86ZWM:.VU:-VL5N\=9)UQ/\Q
M']-:>21<CY&D+]DR_=BA@W63QN8".U.EKS&,"?`!7C`$6["E?-`%);`TTV,.
M--4&R-`;"="4T@!0!B1#IO0#Y"-0,N<W=!(X>B-GC;.HU?`@&V:G\G,,E/-I
M`E)YZ>1A,Z`!++`!+)`!+!"+U!!.S81A-@`&)3(!^C0JEXIIGF@I&7(,VI64
MTG,#((`'?5(Z^V$IEGD(,K1*&`&KHX8`M4I0=Q.LKKFK&U::M].K3@:)D.B:
M=!)1$_4#%;4J!.`\*K(-W(`!HH$0)D=I,1!F)M!XR(!2US`#%6*732>V'K)C
MR^B)LV8)AM97QH,K5?"^??`1^U%[_`$/V(@()L?_([\'!ZNPK?L1"W5*#6)%
M`TY``T-0F=WP-1#"!'3``G>F(=:J*I!@O7ZP?%$0!1(;!E'0!]T``";D(9""
ML?BYL1B@5GF(2)?9H1[1$A^8+2OL$HM5DRU1.E>+DSFQ#C_4&4-D`Y2[!D%0
M+S?K+_OG`%)@%17)DG<$@=\F1V`!1T1[@!/#1DC+HSFJM$[,6[R%DNR&@<'E
M%9"!&"I9M34,HIB!2-`%<%V[!*NADPGADY-4MEM@`]+%!SO``!_`"9R0`!Q2
M<[CG!8RY!6VP=AM0(*.V3?G!`FP)R$SII]7T`Q-2`D!#-(CL(,A!.&2H$#-P
MAWH#BRX'J=8:A_>!`,XI_S^S4`+45P(@(`8Q,`_A!S9O8`%YT"Y7P`=?ER&0
M:CT5AV8]0*L68%7E@HOAP1E5-0_\,0$GT@`]-P>LT[NXFJM$$F70K)K!6G>H
M*:S#RCN^P[Q\YS8QX#PNL@,:16ER)0)YT)M<PCR--P2/YP;V`QP'A""1^C,U
MB`Z3=CSP$`_P@&L30#R5YF7\0:]5B#W;JC=_$L!WB:BF?(OI.0WXP0:XP`N:
M!QZBX!Q"]V:2,@/^H[":"+IJ%0-^P!H7_%91L`08E0$VB*69G`"HD)]#T`!B
MUPCR@1.$52XMTCG=0A(F*T0@2%F.51F\-L8K8QJ'!1J8=05,T`,R($6B)<1/
M(?\%16P57;1:2*S%?H'%)'EN4VQ;:X1;2ML7??%;[A:`7'PRB_%N1QHR5EO#
M+8L>(6$ZR.4":JQ!E;""IS(.+6T#*2%]&@`#BPD%0%<!P]$`7SH#C0D*U)0=
M'`8*K0BJ\"1.!@8A@6,,AC8$X^.*=/`#:-"MFO*M=%H,@8*<T`')&:*%Z\%R
M*X)HH(!I")!K626$O10`@47,&"!J%S($IC`$UEIQU^J"6\"9*5(E1(@M8C"_
M7X<#9L<#6[`@<T!D^4&LONO,P!K="26)O3-W=M<CQ`HD$+)W?0<26(42>4!X
M9K<;)B>MFP.ZKS$#;K#>T^,%VQH-##!KFDH=J7TE9P#_TG[`#5X&-YSJ'ZG4
MK>!#`3O%EGH33'Y#=;@@`VD``"4`(P4M)0UPL`JAL2L&(_?A>=$)(K5(&SA`
M//DP:X\0`P#1F^98TC7X`1_@(<:RTK#!`K12`HZ0!RIQ0R&8AY`ELD;4C^+2
MTSX-U"M3$AF1!1^A1">"U$5ALTSM`4YMQ-S6LU.-DJ]5U5>=6UFM1G!AQ23)
MM$,JUBI9@6%L,B[IXRP;,^]1.A@!62QC!*RQ&D]P(:;23&4+I]X%S@#`UYP`
M=.39>_!0!C,@A9Q&!XU,37LJJT!3`1/@::+)C8FR(36U!7JZ`6A`)P<R5-::
M77RL/?NJ-Q`P2=MD`W@`+2IW_V0R`39">`5<,A\3P)7ZT1_8:2'D<`Q?H%W7
MI<XNB`#@$0#YQ:E@`HBL'+UF)W9I)@?,S8C4[<R_VF3%OE"N.:RD&2BPJ7>*
M`,XQ`)ZZE@<JTN&&IU8AO@-]8`0DP`C%P0G#203FQ<?9B8RC`"V;T\T[<`;_
MW`Z@,!WW&HX.M*^'RFFLN`4,X%+=LYX#C%TT)8AS\DV;Q@L@`L$+VWO1<0I,
MI>$?4`=G=0:&MR+I$!"]V2M&\+PX4(-8J@$I=`-XI1`,0"O,A*SJ(A)_Z!&^
M=@7EPA)MW2W$-E@O(>8`65@X;0*8Q34R,"]35`10L>11O6T'X.072=7LMI%F
M`4<X6O_E#X/E/LJT)0FU7&[64ULR()/65QM(&U$B)0(Z*+LR7!`%<?`$81!>
MK^$S"5&V+#`C&^$'NV'G3.,$@.T=#5`",[!-D]S(C9Q.P2AY>."*$3(,PR`=
MXD0!."`&+*>>,#7I3O<%?Z)RL@#8H3#Y#H8`\\`\I;,V[.&NX5?/_!$<!;+J
M8"52=?\!,R#WF2).<SBW3##</&8!>``CF#A8-F"R@L4#68`'<2+LBGADU6SL
MNDIWRLXDUAV\#X7=PAN;LT]I!/`(7%5[X$%X.&'.1L`'X(X)[-T)&I!>KW!E
MOR@"O>TVXDGW!S(+_*.QA3?QS]EYF.*>UOA.^@X'#@4"UFC_<#^5GFA`?$-P
M"LL`""U67PDE&"(X#!5I%$Z$5I`:&C@-9R-=$X@`&5T$1I^@1@0$50,``!H?
M&EXS"4,W";$T>%D#91@D7%PJ-F(373L\5R86)!8[R#LF)"17*B0FRB;$S,\\
MS-C9VB0J/,_3%ED6)GQ</'@R(0OK"R@&!D4>'@Y2.3D<^/GX!P=(_OP`#ZP8
M.!#@0!\'$0I8R'"A#P$=(DJ4**&BQ8L8,VJL.+&CQX\-0SILB'"%0((H4P9<
MR?(DP0/%MLF<R8R'39M7KLR,LB1.F"4,`,3Z4B:!EP0,W@10H8+/B`QC%"B`
M,6,(C0%8&31(HX%"C09MT*A1\Z/L_P\0#"B4@,"`R98*"#8@J`$"SB(*";Y0
M:,`C0`TX:.C4;0"'`8186K=8$//FC0@1#3!@F,#XC0T>67#:N&*C\=P&H`<P
M$#%93`,<%4#46`V"<(4!CS-HF$$AS2(`$"AH`$)[BPT+DVV*>5S,UP`<(BP$
MX)Q%'(,V3,B6G8N@NO4-V+-KW\Z]NW?M<;=;'S^>._GSV:]_[WX^/!WL/]XT
MF$`"0Z=#B`9@FC#!!(8,&5S211<Q5+$#!A`,X84;"K@1%1`:,,``#ACDL<,(
MCXE6P83(C>#A"*"!4%<%%<C@A!,40)"!")DH0B(<(E;`@B-##!'A%B4,4`,=
M/`H&BQ4)0/\`01DB8-A`!80XD<87D$"BR@`QG(%#"7:EP8A1K,Q0Q@`-C'#&
M@`V8<DL3H1A!YB@FB'#*;%ZPX@HLLM#20!D-Y,(%"6*(8<($.V`S#3+1F*`3
M-\/L,(ZAV-A$DTR\7,&%A<2HD`<?1F2!3@CJK.,./%/,4\\]^N3#CS^D\F.2
M2J:N4)(/JSKT4$@>;23KK!A%),%$''VDJT@"O.I02L"BZI))+:4*4$R+)DN"
M-SQ8X"RC7$3QA$]/X%"&!@"4450K%"`0P%(DG%%"5##``$4";>"@KE9P:##$
M:@S`\8-T/R``!R-IE%`"$TPT\!X"=,`A,"-??%$"`@44$,!;%0C_G)4B(-A@
M0W\FY#F!#0DOQYD-W]H!7&@-K+8:8:+E&!D&`U"0FL`"$Y9&!EB5\`41$`X!
M@0:$X&P%#:!=-L$(D@T0X'Y")Z?"8F)D8<,`;2!`[P8[DK?>U%2S9UY[Y8&'
M=75:5ZTUC]71$1Y\/T1&PH`$_()?%VLC2&2!%A#0!)XE%,4@%%`H0`126)V1
M"0YUE-#PO67`/""&6-E5(@TRT'!BW0RT"%A@<BV2@!4USM#&%HK0@89=<+!P
M@Q6"Y$7D(6D-DF\LEUM!!``C\.&'"((S0D&-1LV@P8JP?2B"*1HTX,DG<I,I
M"@%JHD*$)#,<=<,-0P2Y!1X8;)G'G7SD_VF".,H8PY\TR!XZS3+/*%O--A8X
MJ@(!%5N@`A=_F(`'"YBRLVD1\=!C3ZC[\,-!J0))U4L$F)"$L.I5$5G(1VC%
MP(SHZH$0[`"O>M6KD@0K6,-"2;$"@@1DF>^#,^$"%I[PA"B,P%HXJY&--``!
M$/3E&3'`@0;&4*YS0:`$B>!2`P#@!3:(@0$RV(!9H+8(?6GE,JN!&LON18$O
M`(`!<IA#`,`0@.&(0`R+2=\5`E``X$P`91C`6`#B(QD,@`8!-@!C`ZA$!Y'1
M17$28D$#).0:@;6&`6MA`2+*0#,GD$@W&D@`!7:&@"U@H"_A2!,.)F"3M`'M
MB["90'-$``$Z//]M->CQFB;9P[5,ADUL4OO.UL:V28"!C6O9*8MD2/`+`NR@
M$WSH0PP&4`<*30`'`&B`"?H0#6#<<EM3@8$"("0AK1`&#FMA``M84(';W8`!
M62%1"6I#@Q(H@@9#P$L;#I$!?_7H<TZPP@R^<!@('*("?XG7O:)GA3',@`A$
MZL(`A)0&&9B($*W[0`8P8`0^Q$`$&1"2M@"4`77!)D,#P)`,-2`"$Q@O%*,@
MP`BT588V:8`(SJO1%X;`@BQ,(`,,$`/[*B92I@`J&K\P@0IR<K1`@8,;()S)
M-;!!`#[`5`Q;8$$"ZM<.%+@C'E((:JA:4BIB:?`D!E$505BE*@$T58+_$-'5
M13K0P*I:Q%81E,@$27+`"WI56!L,B`=C2M9<N("$3\"0;#9:(TEPE&//V,$`
M9DA#*'B!`L4<S0ZAH`,QX""(/\".8.["%F\5((UU5-R&&J"4C%7Q8A%(PE)6
MFH<KF`8#$MJ"&*RS&C.&"38#\(T(*H`&$86H-<A$3`]8H#(0T,$L"*C`8:!I
M+2(HX`8H2D`@9]!.#8"`"5],FBM',``,6(`_7PQ:03&0F2VT\)(U\.0FIWN=
M4682.Z1,SRBGBUU3JB>5-<"%"3HQ7@(PHP_YF8`%3*$?M@U(&?/\P@S*!8.H
MT&9"%6A`C-)``QE5X'DWV`OGXB4B'A4F+;'`_U8#$.':>S4,25;P`LZ"A($1
M".Y%:8`3)&8P@PQ,@``8F!*)4(1/"4\"`U^R!%96_!B@/88T&/(2RK(EO.&!
M8A2B<-NUVH115\0">@S`0Q4R4`**Y<E]S3@&GZ+1O96*SP3F+:M,;C)3$O#!
MILU"@$YYVE-X>""H4A@J44U%YH`4)*FG6FJOFAK5J,;*JG"N558[,L$#6K"K
M7P5K6/LQ5BE_4!=+2"MI9+A1'P<R*9/E@YJ`0$,8W!6:$\(*`!0@@QJ@IBP;
M:",(FBFD!DP1#&``#I>BRQAG<7$IR_&%#2*0,![X0@P88,P<H7G&P(I,1)L>
MC<0&`*,TP$&_=/GC;O_>I=,*"#'3=5G27;$B&P4D`+=XR=T8O%"!-_#@BT7B
MY@!V0)D\B$$9/V-19B8``7F9I5Y8DPMWURV7=+<;E>^V[G4U.9Y3JAL^"##N
M>,<Q@ACX(0;8)LV,!P#E46"#DA#P`A1J2(09E"!,6L&UXEA`@V=O=#*)0`"F
M-P`"F7T!MX2`S`#J@I<TL(`!NFVG..G4@-P,[$2/B,0`\F#E$V8@14,J@Y#2
M520//2$&?4B;P(&&LM%TX1)/^)(MN@GE3[B`>)Y(6P:R)8F+'J5-(8#>+*H`
M.`Q,`XN#NL(QN-TG:)0=&>.(<OG\G`U%88,/Q.C,EC/59:#60\Q[!@@2DFK_
M9J,NU<X/@:J;.Q+G6=E*SK>:LT=(4D'`6]"KP^I[F?7>9[8G"]"(.X.88A&]
MH]!`#(F>*!#*I0`OW$!=!I4A#)R`L@K0X0UT(0P><_2&`H`:#`6`];P25H!F
M74&R`0@7!MY@EBH^QHQ!0\X<6<":&DQG-170N69'"R.R=;P$2P)"`D0$@94U
MLS:&\0($F*T!2NO`+@EXYPS.M<P:]-Y]5YA`0G/BK`I/H++AR(P8!/<#.<`V
MNNB17>PV->WQ;MT%;_+F;J5D'6TD-O<F1&_@=1(U#462'T0W&4\Q`!,0`P/2
M@2)0!@HB3#``)!KP<`/P<+@F(C!2`;$@88/&`'&Q_VEW,11.``O%A144H#)V
M<1BST7`S``&DH2_ZE08P]P@:\#9G$"6(H"\XQ"5;L`7\$0-+L`11<#R9\&(+
MU@9MD%!>DE::)R0B4`7#\W3'(PH[@$O7TCP-AR5>L%%M,`%-8`M>AT5N-W9[
MHEXYP63*$#?5L':61P)9D`UWL@-B8`-,``([17<^Y65"I0]YMW<K<2J1Z'=_
M=T`)Q!`+5'AQIG@/%!*.AV>J\G@%@4%GQA(=](<@]#Y+D'FF``"$T'F"Y"U,
M41\0``13H0!5H2^)`#@?,`8W`!HLH!J@(1F486T)8P=V<#20%0$1$`#C,`U,
M<6TL,A<;0!:KT1BPMT8,4/\#G#,P<%`#R$88$$`$1`"#A@$"@546`9,&0O(%
M@21'$)`&*L@`:4"/-_,%$U('Y?<%3A`]-,-HCL9\#8!%XP!)MG1T.``SRL$#
M-I`9%H!';W!)#`A*#SB``XA*G:0>"3AO55-O8+,=\3$?]0%E'H(((X!2_?%1
M`2(9P*`,_U$&,R`5CO8%XC<A,`,":)"3I85@.4,A(L`"&X`&*6(;T987NL4`
M*),!ME$!*-)$&B!.5E`&2/E%Q92#.3=0./`A(_`$2Q`#9D1T$X`'>/`+4DB%
M+K`$7?`5HD&4>8%7,*9T.A>&8TB&P^,'N*0\%[4W+?@*%+`%3:`F#>4LSL`,
MTF#_*,>0/JR$`=+0AWYH><T1B-S`!:Y4B%LP!%RVB':7#T?`#U30F6%5BL0R
MB::"$*8R$H*'B82GB9N(55FU59X8BJLBBGGV$D<%$ZCX0<]@0L1U!A_HBGE!
MDX)4`^`2+AE@6\)T+FIA3;CT`>,4(@A@&=^B,`&0!`GS`@'``P=2>QD#:^HE
M!GF0!YEP,4<2%ZM1%HU1`X9!`]S(3`VC';EV,T!``PA@&&@0E(51&[+UFTC!
M`FW@:[91%_=""/@X(0D`!%808'C1<#0T!O(I'V4D&;A$<-SV.U<$:\:5&93D
M-$.$26'321;9D?!V-1D9HN)A7=PUD1292C\@&18`#`0P_R`<.*&P(1D`@@$&
M)PZLA`.'88M4H5M?`!D@A9.>LVFZE1<W8#"'`!BR]6!,PCI`HH$`Y7TD-ANM
M\'!$=QP$U82P$1E=L`1A$`8NX`+&<`C#N`44^B%3""*@<216$F`H@D,]UP4`
M!81BZ'1T^0E_8`M%H0JSP3I'42-^.5$#H!R"Z4K*H`QYJ">'PB?8,(NH6#[-
MP0RZ\`QB@`=;<`.7^5-?!BI'T*F=Z9DM49L!))H"P2JE24$C,7@4,554I9JR
MLJJM26=U!IL',9NC2(K$4GFWN0W/,$)/D%"4Y)L%LPI#L`7>P`P34`(?8(L-
M4A6YH2\`L*P)H$-X\"W,J#`KM?]%D@5K8E">9($!-8"-^58D>,("*P@C.Z(:
M<-`&L<`"6]`&%(".YX:>;3`$[MB7+%!NI;4(2WDS3ZD!<-%,MB$P%;`6UQ(A
M$S)I7T`B:9``1#`&-*0`0\!8#'D9`9`''S@`#<EM0',:,,-(=C`G->!_F`:`
M6?.AZQ%*7=-NW:5=&ZFRI71*#C@V*XH+:(,VS2!7'^M7=<`B'4@@(28DQEEZ
M>1$91.9:I74O0Q%(01(9++,A!,,ZL6`([/,[_-I$NH4M$(`#6-%B'H(?]F$H
MT2"%41`%8?H'!V*U&^*.XU<DE@!LT248<&!/,E`!-+`E'M(%FF<XGA"F9`@*
MLZ-S_JK_6T=A%*Y0K$W0!66``Q;0+(>2#%K4#'?X)WW2F'\8C<:@#4>#4Q20
MJ5[F`)QZ`$?PJ510+*%YN@;1#Z-:JJ>R$+`9>)EX5:WJJ@S$B;+**@R!NXVG
M9K)Y9AC$0;JZJ]G`%'Q`0BTV=05CK[/Q5N4S`0Q0?F[`(&Y0N``2K<N37YIE
M`9O1"X68$_17&M`D1-0('_)!&L=EK@WC@!SW1P[+`,Y%`:^%;`)C&$99!LM$
M`4IJ1P&:8%_`?"Q0!O@[(FOACOJD+GPT`T>:?@\K3&[`49KE"_RA;6HS&0:I
M@0%@!\X%`B1K:P`(2M^%LMZAD0:(@*0T-B][LBD;%][UP4+$_Z(P>G3F-0R(
MP"(_M"7VT0550`YR);1ND#>L`QMM4`)(6Q=.X*2Z$R`38!?[A;4)1B0[P`=Y
M("6Y$5`J0F0YU#M<N018<"%E]$4+AG14:`G@ZAI,B:#U6('?V,%U,2,W4*^3
MD+?_I"XC8*=ABF-&\`=/(22GX(Y7UR8UT@`>M;43P!EVV#TP!0W(M0S1$+Q_
M")EWP@W:6P-MX+GQX`&<.KJD6[HL852C8HHYL,E&96=/)4&PBRNT6WBV>XE;
M)<JBC*N_.RJ,++S+LCZ^<T)[7##IAQ3N\PSR5P;#Q""X*&$`<C.J0`.M@0$Y
M!1JD81EOX`N280/HB9,B$A>"(38@(/\:3Z@D("!$\W(6C'`S1+`70:R"BK.#
M_,M\`^MK(X*UDO!PT+>4^9(B%,6U.NH%"J`7"0JQ;@`$$VM(Q!C!I)$G`LTG
MW-8??2$&%,`"&PPUT85)#2B`(%RBH?1=).JRX9&`7H.B*1H>/Q!>>R(@_68)
M)9E0\E<'VU9P3(9P,Q"]]WR4(B`ATGPO<,(DNJ,?58`!,!(FTX1/DK`B9W`&
M24=<H/48)_-B6\F541`E)0D:SP%2(O#3O,DEJI&T)5*WS:05(H"NV5$#,@(+
MT;,['I*$Q)65?4#'H!`%?]`%&:!S9;`F?>P%-2(">&`"`,)(A2PHS6`,3,8?
MRV!VNRS+#*G_N8TK!C30`IB2*3\U!:"+#YB<R:%*9GLW$/_0#Y!(J@_1*A!!
M06]VRG!&>*WIFDR%N[WKRD=UBK*<+$ZQE0IU"D.1?E[0!J!'`GV0";XL%5/1
M"NF2D*GP`?'Z.YNF,E@1KHVQ8!.P,,$((VT$,$H,!T,2,D/@!,?&<0,CH'!-
M<>56%Q*W)$]I!1`0KHO@6F_$"&W]`71B;3:``$)CQ5.2")$!4!5U6S20S^ZD
M.RQ@&3?A/4`S#K"F+LEQG39A!_O'`.>&;M6Q(Z<$T1%]@%E#T2%:@!M);Z8D
M,N]Q;_4R`LI0)$='7"L";NJ%(!22MS`ZI[LA%83@!>Y[<C!2)4U4_S"0``$C
MT`2N-$?#+"2Q4%`]E\5_P`<O^DC)9=1;N00_+1E'\D>YP1;M+=6!@0"EQ085
MT`9*0DZ_LXU#!`)XX3Q-!(0>\D\%-0)_X+=A:@154+9&$$-E4`?:HCPM^*<L
M,-?6$D;?9@)YL`R#0@(G]2>"H@+3P`V6:WD-J0V-BP>%?=A=9@"*#2H<D,F:
M/'F4W7>E,MFC4MFE^HFHF9J<;56I#!)<Y7BVJD&E:)NG31-90`!I14(GU-:<
M-P3-T]WKXP=?E`',J@!0,`1M`$VBL=8?,`1L<()"U!HU(!J,%8%<8@,L(#C;
M7!9C$5O-)`E`283O\3G6%*`Z,[&%@6L\LO]I,G,Y)=@`6R"#7U%$0W(*%.+,
M6["F(F,=;[`#(NYL"J);,S!M#KLYE/%%AX,5%!QBR)$^XY`%'B,A3+#0H&3@
M'HS@"7Y=&+G@)\R1!-@C/:+"Y#L9$F7AOO-AR?5%*C(9RF!P0:L!P-R";7!R
M@O-R*UZD.)"$\\ZU$B(:[LH?76JVQR-T1/W2J%<D@@:NK$&P=9LO)9`A(>-:
MV`$"%!<][D@DB`".@84&2Y)^@^`$;5U<_090`=+E7UJV41#F3Y>GA9.0U])C
M7M`"KA!D!&`+%8H,>?`,2%;GQ;#(W[`#YK7G?M;GV7`9#VG8];.(A+[8^(#H
M9L9!D+CWD]WW167_$*\2VI-NRI5>59>^*R/QB1<DFP1D$K$LRW$3`T?]JW4@
M%`D`@FT"`5L`#7`78K9UVU:A0R(72&S0`!D``F.!';WNSFO4-,7&S6,!>P6;
MO!70`XOP'INF@ODI7Q`P%\$H6"-R)=P=1C90+R>X+OI"9%J!7/Q1B'T1`-S;
M62=T,^J>3?)%%5Y`!&UP,GQ]#`!U2,=P""@6)@UE![4`'?1"'7-AX`:?X%I3
M@/%V\/*6T1W:H10>@38+#)=``'$."%T#&0,8&!D9&`0$)GTQ,2,X&65$;@HS
M7EX9#1@,)0P,&1"C9640)0,CJB-=&!,3#2*&$Q9B$X]+2T9^KS6Q`P,,_Z00
M#`TC(@,UR@AT:"!P%4YI%&4#R"QT=!L_&RQM0PD)7PEE(L@U&\_37U]6,^(`
M&H4CD)(#,6%A<4M1449&+OZ)J(-C`(XZ`(AD"@%%'(,)!$0`&"!&S`X3)%20
M(,'#Q`X+)DQ8V`CRXL8=.S)JW,BRI<N7)+ALY&$C2Q:7*BQ4",$SQ`(4*`P8
MF.(@!X>C5)(J/<"TZ8$5!Y`@83H528X<4YM*W?H4:M2G`@3X6.'#1U@?'=*J
M[2"AK=NW<./*G3MWK=V[>#N$W5NVK]\5@`'W#0R5<.`#(V$J7LR8)8^1D$8\
M.2,B`P``X89D@B`BY,8)#+PH4`"C(0T&(AHTV/^"H8X7'35*R/@Q1PV3'V\:
M,*A0`G,--$/@_."63C4#"A1*0&@#@@6+#>EJ('A6@0*[!!!`;`%6@\XS:-,2
M$&'PA@?-W-94<W)5WH:%+!8LV)C_!@$&<RP,&BPC.@&%(>"\`\YX",1'DWLF
MB%".!3N\8@@&!PU@@ATJB-`&`FH,QXUT""B3#0(@(@#=!B*.:.*)**:(8H@B
M@C@BBS#&*&.(*[JHHHDQDM@B=+AAT`4)772Q@RHD7'%%#(.(4%$)Y009)#UG
M#$)))6X0,4,B$U2&R)8X%&3(&6<L$<,??&R41P/6C*">.5W$T,42QZ0&`@@-
M@%`!#3100\Q]#"@#0C;_SK!`@SA#E($:#GUF0P<<3FCF10(W?#$1FG.F@=TZ
M"5AA10*7#7#&$S%$2=`984011S__N!`0`2,0@LPDF7C!$*0T;)%%%X96A-$5
M+'GDZTL>$:"19XT5*Q-'\]W44DXL].034`84,84'1G%PA%+8.I455UI9A556
M5W$+E55@C47666C=1=>Z[+;;5E[PXK77O'[5^]=A71F&6+'\\FL3"7^H\D04
MK6H@3CA>S%#-!'E\QD(""KA1FG]>(G,&#EZPT(D3&]0V7(8#I`%!*0WTT(9P
MW'P'QS3)M<%`#XN*2,=T<,`A3#A?I*$,,@-48#,H)5```04-O&*T&!;P$$``
M_U>X9T$>[DWP()KJJ=:S05U"H`$,[Q@<#@4RW#`&!5LX^.!]9>#@R@0H>70,
M!A:H$``&$/20X7`;<.CAS#.7>./?@.-(HXTSV@A=X8:?F/C?(/8]>(D_&`(D
M*UV,T(=%E5OSRD$B/%*%'S'PL<,`H\Q@I1M`N%%-G.:(L(H(72SB0CZJ+M(@
MF@P$$S0$&<`>)#(U_UD#"#I4(`,-X)`M0@E_:I-W!<>%PVD)N,^YLA-.W)#`
M#%9\H8$\&`1301HEI"%RIC.\8XHLDU%61P:DFAI%&*FN>@@.(T@9:PL-W=#&
M%A;H0@9*0(N;7&%8%T%)2WC0*Y%LY%?]@LFQ#J0LEO\PRUD_"8JTJ'64:V&+
M"E[IUE:DTJVK?"M<49G*N%3HE7/M!5YP88N[9LBN>-E0+_,2BUETR!>R&.:'
MATE,!(?H$INH(&`CX,?%-`"`<23`"PUA0!<2LP,10,P24+!"<E`C`OP-0`,R
MJ$$TZ'`WO,$A:$QB``(8`(=MY(TZZSC%%N3P`]6`B$[08-+W^O0&&TQ`#%O(
M77I4HPPQB,0F\@D`#YIF"T.@21:S6%X%YD1).&`-!Q#X0OH2,`3D$,H+8Q@"
M"[:PA8K$QP(0HHA[=N`CAEV!!RK(@@HFP!PZXNU#>V/&X@+'R\.UB$4Z\N6,
M!#=,%>W2F(W[T"]Y5`,,D&#_2$_*GS4,P8H))(EMCP!3E#)``2)$+&*J\Y0V
M=W`&L[FB<F>(03_\<(:J`6-ER($`#F`7O@$$CPXU@,,)HC&.&4#@/AD`P8CH
MT`#D?4\<9=@$,NQT&6EHSPN:4I@L!D&#"HS/.OT<@Q72)H)/@6D@=1A!%'+!
MCW^8E``"G*>4-!`K3-R`:'BHPD$F8`,2*,M7"EP)L'8@+!*$1(A$=$E-8&*#
M9O5D`3\I@E(Y:*T/)L4I3,%*"JM"0F^94*HII`I36OB4'88E+5]52PQI2%:Z
MV.5=-\1A#OG"E[&8"XCZ`FI0ATB`F/!!8$N($F:DIP$B)*`$&!##1OPP`@@`
M`09N_\CB%[8(C&,`H`0(:``%0%#&'X@1.2*C`1.VT("!U@R>DF*`#0I0`#&D
MYK,6+0$BU&@!87U$#(&5SWR,=(6E!<`&C<2`,H9')V1\`@0UL$7(X$"=SX8B
M`YCDCU]O``Z#;2H<(&""TTH2/B79HC+S'.W25&`'/)2@`C:PY0\ZE$P9]?*\
MB(.1,(&97K^9EY>$8T9WG.>\O,'-!/2`1!?QEX<\["`&5324,9QTABJ*8@:C
MB1@1-,``:CJR9RRP7@G:4(@)5$XU<QH>:F4@`PJT01:@:`!Q010-2YF."&50
M$_.:8:<T.&%[;MB4!C;1@/%YCP+\?&+Z-"&"";0*`N9S`O\%I$<$(DS$'![M
M0F6J@0M_&&$11FA"$V1:`G/@H`P:P$0FH,!<%N"A"3-U3TT]@I*4Z!0G/N7I
M`TURYKDNI@$A:,%14:#4(C#5@Q^$ZE2O$E6I6J4H5J7*MDC8U:VV50!@74M9
M%]VNM+@EK6I=*[KZ(A:X!L9<^W+S7%60AV,\04P2:2*`Q*.!_PF6!'V`$!$0
M.['E(,H:$H'`\":KH91Y(CG4LP$>&H`.-'SVC!#H5`!(6UH1%"/#RJ!I`1@$
M)%EH%[<5>848W',?/H$`1,/[A45]IAH<I*%FX[.HS48A"2PKA*_L8(<7*D!*
M'P5):IJK2#U'$&TQ9,$.64!4%L3_2UYF.`Z8Y^UE>^,+\($7DT0"3V8V#O<B
M#)@`I4:H`N6$Q$K754$B:KL('Q[1AU8-&0BC48@&J@R,`<1"&!6MV310X2,U
M62_"XV-!=1HECRW\5CH;H(.EVO$H)KJ.`<"M#@6P]X6$I4\#^---&0"`8TRE
MSTIJ@P0BE#.*+XR"=QW-GV3.H.1)#,`/?W#RDPD0Y2DGJ8M8UC(4AW"#"GQY
M`'6@Z7L8T;9B(1`CS\2("MJL:9?`6<X^^4FTIB6%#CJ5"GHV2E:C<L)PF1!<
M.1!A5PP=EG,E6M&,SGQ<'`UIM4@ZAY1^*UE$;QBY]MWN&Z',UA4D:@!]CS.G
MYD,7<.!-_RQBQV7`,,=EME`#"J",&]XQG]#@\`8YR`$!Q(5&S6Z-BC<48&E@
M"(#4;&">I=%$::](T`!H6I\.K<GDL7`%=S(\)Q'SYA2<\,0DT8`&$8'`$_)4
MC@:`\(YQ>$$#5L@$$6I5H)H6J8HC@`>X)36K8!`B8`$!D`7'@0?\QB'*I%X!
MAU[II2,0^%X4.$PT$C@*QS<,YT88P%-=T`<H%0,;@5+`X$QTLPD6]B0Q(`)#
MDP!NX`9C,`/?`UA98G+#<R<54"<BQ@`%T0H8]B?I4`+80RA$H#:@T!W.P"C@
MT`(]!S[`P`)!8U%.T$_<,Q&M@`,```$6A2E6,(/E0!FI<!\E9_\.E!,#<#)/
MJD`9$?(')O4/9!=E`M$[D9!VL=(_;M<$`]$`"!(2;(9Z$!02=<5WIT<"?\<3
M2*5!'B`%A7<$>(8M(<1X5$456/%X.0!H6^$`#C!H6]44.T1I.*0NFC>*:-5Y
MGO=YAV8N]P)$IE>(BK%W,0$G`M,JHA8.+%4-2',2`U!["M`0RP$*7/0%'\!K
MM,8--$,^5E<#SV<'`5`#P9`:JJ%;"#!:T6<'/%`1PQ8!S^<>MH!;&*`;(K`,
M)*(,WX@FP<"'8G!L/D-)/2B,":`QF-1&Q.%K:2`I):`<"#8#0^`]!I-EF$`#
M",`$M6!A/I9[#V(TX3-/",@#+``!""#_7GF#;?^6@1$(7XCS(A1Y@1-8(W[#
M./[6-_7%(Y$#$6UB!$'"$M:4"B9`-^5@"(_0!7S`DO.76%[@/1#`"<B@6]XA
M<Q$&#17`.TH&=#R2#O^A&4/0!@F@-CVC#-4A?`G0`F-P?^!3&>7C,_68`%E6
M9``@`G^`).]SCR,C*9?1.^&3`2,0!BZ`!4,R<7S@"&SH.JSP*@/P!V07$&,7
M9570!*V2"G#W1'=(*Q.@EW5`$;7@*[#(+PC44Q#DBBUQB(&G00[`B$UU>)%(
M:'RV9U>%B7^&582V5:/G%_,BBA(@0Z2X:*:X%JAX%CKD5811%I>V`JW(F(K!
M!5BP"F=P"`;C_T3?8RAK@Q(BH`$14QI>T$GW*$@),4DT@#(=`@WPQP!BL(P1
M,#<8T$=*LS2U%0!VP(RP)0;#]GQ2<Y#65`R4`ATS8XR^X`DL`")L1%SU]7[6
M83H/03I_H@X4X&+B00$W4PF+-03?$U'OP`+KT05L4Y8/$1]Y$!(6\0H\D)T-
M``%SI"$YAVT'5Y&`TUX8J3CNE2,W`G`>J2A\TY'#40.Q8V$HQ0H8H`IF:`BB
MT`"M10"0$`.'$`\QZ%?\60U=!'3SY6N3-&3@D&++`P?-P`(N5H6/<I1#H#;+
MLQOF<R?@8`50,`8:4`UH4P+@81U8201`\`'PTX*M@P,E@"BYDQJN4/\9`Q`'
MIT(``9,F(W"B<`F7<3D(]Y`J;RB'!'`_^6,9++5E7D`!M=($*24&>&!(>&=!
M@/@1&F$2LLD2#;``@)>(T1*9C7AXB)=X4L$!6U&)5Z&)@):I6+5X7?%6H)D7
MH^EHI6F:IVD7J2D6\T(8E488L9FH+L$%+O`$:W@&&<!$!X.5>V)A:]H`5T23
MQ%F<EK%_=L("RE`UT?@&PQ8`8+!L$Q``<Z"-UI<TW*4"8M``8O`&;_`#:F`#
MAH``VAI9S?=^RD!<W=$A[P<!Y$",:8`&M;8!#5`"US%R$\`"7P"DT"!D,E"/
M&D`,ZEID-U"%?94^4*``7M``TTA]*O`8#3#_0#0%6]-46WO'75MPDQ"I2](Q
MD1U)H1*XL<$D.!AI@1CJL2.K<+IT(N,%-SL0._BU7R-P$6PS.IQQHEU`&4%R
M90F0.N]``8^"L%T$7,W@##96DU&:&E2*!A6P/0'KESV7"'3#=%TX9.@S!BC6
M8PJ2`<*'$)CQ/9O`AF?`!U@`"Y`D)!:0)5TB`F9:!28H2/F!"+`F&6]*"#$`
M$*L"95&&4LAU#%>6IU"TIVW0``3@!Y(0;662$QM!B(3:$L'R0`Z4J(O:J()G
M9Y+YB-FB+2@T0IBJB9=8B47!F9WY0ZZY`H@6+Z5:JFQQJJF*+I;VJK#:$ERP
M!+3J.EJ(&>#P1$/0_V!L$R>&%9SZB!SWV!L?0`2^%V$=$ESR4;86D`2DI4A2
M8P$1\+S2!S>GE`6P4`.Y40/#`2*U5@,,T`;/82??T1TDDD?B,0/I*33:T`P^
M:2G/=9,#X'L^Z9,"2PQ#5F3[V5=%5K!><&VV8#19@ER!9;9J4ULV<6\3``$#
M(%X_@$OXI*$<JX&%LUX9&K(2C$P0'"+X]"$H^P8J*P(7@:(]E@=2(Z`#(*5M
MX@="8@(#@!F5<&X&8ZR#0%S.P'Z6@C/D8`W?!0)I,`32(+7YUU=..S)*&A[X
M-P-9RAEH@BB_BP@%<8)5A#^HTK)CVW5J^&FM@`QU4C,RT$G`*`*T6CG8U?\%
M<BIE<=@$+BH)JK"WCP)%,X`<G4$`@Q!<@ZIIBYMFK!M4CRMGCBJY'42Y3Z45
MFRL5WW*I17$"F_EX(Y15@-$4Y^)68#6ZHEFZI8FZJ5MYEV8N=YRH#!03\_,$
M\\1Z\_H.J+`>NE-[$S,$HR!_P?L%+,`&"1L`T'N-8E"=`0!;$]!':M"MJJ&M
M;R`USN:,P%4G)I(;6)8=!54!V/LQ/Z##\LI2%8``-)`=.HH<XY,IKT=*YF,^
MX+8.3'0<FK%@R$$)"C`&8X!8-*`:I20296L-T\8@;^/+$Y`%`>!=)?`#!0"A
M\X5/')*1#\R1!I>!&UMP_M:1A'/!)NLBD+,!#I?_(%T@<3O0!WR0!Q""/UDR
M$18!=H^0)::0LT!09`!2#/'(?NP'!Q30GU9@,*@@/MLF`TYDBT30.\M3!N6#
M*=_3T=4`#//$2IQP!FLZ`7A0METT`)_F#PE2$-#8O3+-"9.A&T"7#<1S)S1P
M//A)JVO:168IIP30!/\@94W`!Y(@NTNWQHF%'!)"`@K"HA74=X&H9H=[>GF,
MB(K8B([H5'IF%5/A>-^BB2>PUY>HN9?J9YWZJ:!G%J(JR:1XJJB9NCXT&+#9
MNHIA'ALAJV'P!(106$TTK]B!&FO:)6F`8*/A!CT'`$OW`7VE`2S0`]8[6L]W
M(-1G'F(P`A/@C#60(?6!_QNXX0L]Q@.1)6+L"1U64P;T!Z!<"*%+6(_7<<["
M0%SB5C-6JJN\IQR3!$>9Q$1@Z05^E2<)D3I04"4O4QXT$1_5]4>OT`KW<;86
M(`<*2`'%A\\SLUL0V,_^_,\%34P:29'S[9$8_(`Y-Y0.9P&PXR8IP2L7HS82
M+=,^`B9MPDK+,015<G\`4@+;`0%`.M(5T%R:LF`-%J_?-CY5*#W;@W2NT`FB
MD$F<(MJFD#LP/0(F`!_DU$IX8+:I,-1+<!_0R-S$:0U/T`ELA`8L5CPR@#W9
MPP!4K61H7#]R6':+D"3Y4PK.%8-D704D,`)E@-:,"4&(ZHI_UZAQ;2U^C'@<
M`/]5X6+7F]O7>ZVI5R7(@]RIK6DOD%S8AEU#FX?8CYR:]A(8F2R;_L<%44"K
MN1=LUX&54<I%D7"/GCT:'4T$'Y#HW_,!,T`#HR0U9:-;O#R`AF`#NH$.R@`=
MF1Y9[%P#:5`!:+`-&A*ORF'=._K,R[D;O-$.X0#A\;I\Q&4G5EJ#JP$'`[3-
MS?P!CX5)7@`$>RHT?64)3JX=98.07B)M"&H(LH"`64`Z"'#/>'.NN<2A\!VR
M\KTX%6B!][VA,*+??L/!'\$*;A(Z#:)DFI."'^@'?#!V&%`&`.(&F*`!_.F@
M#8`#<+"$3"H]5K!@.'!RGWY1WB.5_>H[9'B/;?"E\[3_&F;+IB\[)*UC-8C0
M4>D4)?TN(L4M#4[`.VN:.T";#?D*(."``U3M8U_MAK6CU4@>$;VS30#04FX0
ML`_!*M7P'K+Y*P=*+&X=9W.V07)]>'5]B=[B+69^B6:`B8ALUR/$0H91+VT>
MR6].0W*.JJH)>JSHV(J1&+1)U:I@&>SP/7V5`*A1"(-0`L#Y3?2WFZ-=9!#@
M')SE@Y_0`&^P`=JZ&GU$2,@V'>L(!\NQ!2!PK[6&3SH\,N+A!"!0GZH1Z]!@
M'2?-8&\0&SN8Q>>GKA\PY?*1&UZJ6@/$.\BU'_B[6)H$!*E3">]8-DCCV@8A
MO;5@"--V?3R0!0VJC!"*2_/U_][5[DOU;:'6;CB/,\$6V>T?NM\\X@HD8&%N
MDL:I0-Z;LPF/@(8`1C<`8B4T*+4`:D]P9*774;6].@!!8QWQP$1E0!"MHPIG
M<Y#1%M3(,$\TCF$-26YI,@B3Y-300`-.L*^2(KL#(")XD^^>+_*J``A=&`,9
M`S$$+D8$BP1-C",9(F<B&1I>"5XS;D,T#!,$764,%EDDIJ>HJ:JI*B0F.R:F
MK[&KM;4-(2TANPLH15-24AQ'1U3&QU0'R@=(2#D.#LX..=34)R<.9DK3U=/-
MSTC*SN$KY3X^Y@+JZAWM[AT2\?+S]/7V]_CW[_O\_0(=ZGRL6X>NG,$5%FPI
M7%CK2O]"$EQ</!$Q8L2@,E^^:-@X(T&%`0,&E6!0!HB"DQTAC&0``8`&(!!8
M,&#QHP:#"A5*P*FQ84,#%@ALB&#0`,2/'QN.PKE9XD,"$#4H5-A`!PT(.%C3
M?$F08`8%$&D87&U`IP:<"A02;-0PH,86!C@:-#C+H`2$,AH`E,!@0HR8"2)`
MBI#;`,,$,1<U$"$RA`($Q4`Z>AE2PX8-"Q;\8L`!@8'A084F!)##@X<=.UL@
M-"@@Y^@/.G00U*@!&X'MVSUSZ][-N[?NV\"#"]\M',%OW!N0^R8>O&QM!+![
M_I@P@<2.+C&Z=!&!PQ"!/#OR3,!19H#V,S'\$!##8`B$&3/_B&B@,$0#`^X5
ML%9(0Y]K@@\`F)<=!MR582`$".(@PH(5C=!%%7WD(0:#&&#PTP`,9(##"-P1
M!8)M(*!1P0U.I%&"A@/@4$)^6%U5`0WTW:#6`-P-\,91&X#@A$8:J$3!AAQ6
M2`@.9Q!@A"**-+(("5UTQUT=&LS@129N)-`)!DU4D4$)8I3"T)<DM#*++#N$
M">8MN>P20B]%>"`,,<4@D\PRS$B3@S-F6%--#DIH0PTTWC`#33AU'K#",BN@
M(Y``Y[`#T#[Y1"KII/;T8^D^CJX#$$'G&(3.0V>&FLH5-I@2T40-#@!``ENM
ME<!](8DP$@0FP:"`%Q0P<!\<&-(*_\$6:&V@!E5TY%3!;`U0P,(;+,$AK!K0
M_@"675NQT$,:%<`&0G[;:L45$118!4=M=.A7`H^_XF$#`D/=5%<&=ZDD`@:"
M4.>7#:3^1=T.DU2RV!<44/"%%T1(Z84&+%2H,'4#0)!!`YK1.$%FAV5A!QXQ
MR=':4=#)1EMLP2TG\LC)%6>R;<<5U]/)QI&\<G//V4:'='\18,*#V<6`P2&`
MS=MD&2+X<20C8@S@GF*+8:)!!0UP=E,:3@C,ZD:15$31@AC2V,"\._![1H,C
MG&&A8`LR0$$;;9004@-;P@$"'2"P`(<,3I1(01EQR5I!B#.#P``-0["JT88@
MO4$5'/P-W/]11AF$/2^!&HYP))*+.$(`"3'@H"&\`,Q@Q91N>)%&&A@<J?D$
M7HIJBY@F6,`ZJ*J3@(LN:[+IYC#$R&G,`1S4V<P)=SZS)Z!F:#,-H'<V,Z@X
MAAZ*:**,-CH0/Y16;WT]\$APZ:6.NC,0I^=\&GOL/)0*$1>H5C1`&:RJM58)
M6Q,X:ZVWYMH='(4-0,076\#Q5;1(J0%(!E`"#90``0VC@VLV4`,0@`4"`1O"
MWM+@++@Y\"S>"IP3K+(WJESE+`+;2`5L4#X;V.1^@I$+`MY@`9N]P@)7<`AB
M%H0U0I2!"`I(P!"VXH7(=(4(%<"`&%K'@P#P0`0.P\!E9E@A',3_Q087:\,`
M-+9`D$&G!L-QF19S(YR8J8R++$,.;EKFLBYB$3<S2PIB3'"S*G1A!":X@BD@
MD0&^B*`\,<AC'KLP`18,X0:*F=*4["-`!-%G*ZRB0%AH1)&*=`$6!+J:)&E(
M$9#@;RYP8$$:;A"P+Y0@,%O"22994`$=R,`_'VB#_,B21CBT80B!XV0"'C88
M!("%`IS\@A6LH`&N-.YK%6I:XR;7!,M9C@15P$$=G)@!`!#!"EUQPPQDD`81
M'*EA&,@"%\:GD#&Y8@>7BQT!9L<+V[TI3KI;1C-^%[S@'2\'V#">,Z@Q3VD0
MJAET8H:A.@6][E'O>@"]GCOBL;WM?2\@_^$3'S=#%<-3<&$)(WC"$R;QF*FM
M!0(T(E!W2H!#D\Q@"&F#E5RXP@802.4'>U###Z"%@/T(C`((V,(!D5(NK"#.
M,8YA`1[FTA-M8;"BHD`6T[""(175`0!U$`%U#/,7,;S!,F]XP[UL\!<,5$0N
M(-B"7`88F+J4X0-`F(\.(?"%--"@*Q5`@+Z6VK!(5&@".SC,('"@1#!D05=,
MV%@`KT@;X&SQKR\#CA59!L8PGDR+,(--;)(CG3=@`)S8N5EU3`&8D$P(;R/(
MHQ_X$`L,("B04UJ,:AH`$ETQ8("6G0`&OD8A"U7@M*]M`X+N\YD!L,BFB+M!
M1C10A@K9A5M8//_+62]JU;@@``TWE9$7H)D`(JAF$+:-6MUT:07/60$"(XA"
MV+ZF3!$L`DE#8X011+!,0FC@`[W4A!N<<)\J-(&\&.#!0A72-5IXDR';W"8)
M+,""%M!N`0LP0)O.205T[HX#'-B3@N')C0:;@1O)>P8WPF'/0AWD((ORYT`#
MRF%*;;B@EOK'I@:24(3,5U0/X8)V)?H$2&@@(US92&="HMH&,.`E)B%"`BC0
MB0$V``)>*"FV5JK2E6X`+0'[%0(84`.DY,A%_&E,'>T@!K(@Y8,Y>0P`'G:9
MV6#HM%R=UP38:`("7*$`!0A``&R@6K%92"X*&P`%9]/`GY!25W7XP#/_TW(#
M!-'@!O&A`)P-LP/$G/8P)L@"&S%C@HD5,0!#P8->&<C7D`'VKXD-8V$-^T62
M-><VBVW941X+BC)K1Q!6I:&%((`#<!Z)#[#V[%T*IM[)T&@$A=;7&\7,H1HN
M"),X<2DL9SR4$F"+!M@*]E8T`@`AUN5#*V,!O+AREX>-8``LT"17;J#<@YVW
M#85Q(@-&YP09[1(^UWU"%)8PT6N7I\Q'2L30FF"$]VH(!P``T*K4>X/3=J$)
M9ZC#"$B0!=B=V!06\.8+2X-P4Q0\Q5R(.,(K0+M=H$#`M\N=,01PC`-48Y["
MZP:@MH&-!GL#Y'?R^/*4<6$,3^^?V>NPS/,Q_]!V:*^@F3IH^$Q\<#"E&`L5
MD>@(\)V15B6@#;IJ`'@P<&,BF*1*%"A!=YS(-@WHH`?[$99K:H+D$I2A`7A@
M`4]Z@EP,"NP+HP`##T`@@BU@F3,```!=)Y89&UCH,'[)@][S<(4`J(`'N?Z+
M;"Q$P],VX#`3J(O;YB(7N;U6F?FVPE;J<PDO0($Q6(1AF`*0>!&(@:H3Z+5H
M[&!$%02@`0><M,QF8^E+(U:P7C09<XS#Z<".[--83*.HIP/9,NVZ.R.P%YLS
M4,=38^<Z\'H/E0Y6'I#X90);H^20*%*AP!3E@CBA`01@N650EH`"3F!:`W`"
MY/]H0*FZ2B-RO=61P/\!;1(5<((&K%`B&25@EQNAZV:V1.ZT6&(,.D8D1@!1
M7[,^./`)\38YC5!OD``298!4^^8&"B!!Y@%PD4!PJ=-SIQ!7L6`!L``J#X$9
M$"=Q/&`!%*<FO8!Q!)9.">9.R/,G@#(-\>1.$08-)\`,PH,HZ/`\+J<I_3!S
M0+AA\F!S\P!B_D!BYV!P&K@0I\)B9Z`J@J,1.Z8K`Z!:@0$`0/!TDQ%U*1(7
M##`#0,$"%$`'`/0&-O9])=`&6\`#,=53+>)2K-(``0`&`>!8ED08</9478`'
M68`!6S`!-H!F5R`A$K(#5Z`")D`@!!(2=/9FI'5:\R(K#*`?R:8K)3`2&?#_
M51UQ`]KW8IB@8S4@51,@"(*0(H8QBC4B&BJ0!5E@>A.@AJI7::WG>K<'>[*W
M')RF''Z%BX(%:K27&S\@!N"41P20'1R":Z^P5)DH`M@1`WT0"R:P/LKG!6[@
M!O)!(]VQ59HS`'+!$IB5:@-P%CC!'V:%("U11VPSB6^3(XX!`5P1=U48&`VT
M'Z.S%;LT)0D@"2+@+5*Q(URQ2P`2$IM1!E'720D0=[Q%(V>P;MNU/AG0!49B
M!"XPD9/#@`K"'1K"/M280Z_U;SM0"!BXA*GP0OLU)G*$<)AA*A&W33R`!PQ0
M<2E8!,$`)^G$._0D8=4`/-?P@MD0#3B)DQ068>1P_RB$LD_FD&$B!BE`N)0Q
MIP]&R`\'Q2A**)*V@#Y.J"J>&&-E,!*1N""THH7N@70@86/3M`%P``%DJ%(,
MM!3\(6@V``8V4!@?!`(8XG4`P`!B4`!@@&9"$8J681E]EV:&80$T`E55A8>%
M<6T84`,XL!-EX4!8=18C82&ZPB)O@P!G"4$I`@%@]5$T4`+MHPE>0!2GN`.8
ML07=(08EN`-O%7KS4D1B`&YZ]0.K-U@H0XME5'N\D8N'I1R[V8O041NZ$8P3
MT`3900#7X0>;Q0?<,7><@0%\8`1\\`<[D$?2&!].9XUL$4D-@"RZ8E-I<!>?
MU%5F@RV2J7T)T!('2`GC`O\;(A(XF<`J=PE]X5@!.U1_NC1(0!,#2*1(Y$96
M]V<%1-!;T)4BQ.<P3G1K2S`)74"`_?*01D*1\G8D``=\S5D'F""!5J`K(]`$
M?.!$>7`95)D0K=`U#V&BJC""+(D'-`"3%P<,4J!Q<F*3PZ-@#@`\,9@-#X8$
M/0F#ZT1/V)!RA<)RZ?!R2JD]2\F433F$V?.4WO,]/C"55+D*#Q51$W5'6>D^
MA5`8-9(!.*0`H=,8/48C7W@#=/!C9$A3W7(N&5`#<U@`569X61..(/`&`5``
MIA<`?Q&(:%8:5_!YG!=Z<?$&MD&HB-F%2C0(%X05<I%)658"LY$!%#`N"X0X
MLP7_+R^A8T/@$E%B,'5J&3P00Q:``<2'`18PBE:E47151!90`BPPFZ!FF[>)
MFR+#F[,:,K9*1KZ9,C+C,:PWG&_P"3$P`@3@!UU@`@PW=)YG`^MC'HZ$'<Q9
M!D`F)1VA%@K2'5!1%N/'(J-SB8>'(0Z41B#P?5M1;<7U(2("?N66";QD0(B!
M`^J*+5(CH#.@`77T!Y!05E`C-><%("+`GQL25X17&.B!!5B@713AH,T)D1(Y
MD?*6",;I1!S"3)@P`PI`!)TP`E7`!REB`B(ZI:<P"Z^3"BI*`E35HBAX<1EG
M8!W7@@OF@GVR#<338/#T<3@H@]2@3BQ')T6:E.]P<TN:_Z0`)81%&'-..F($
M(:4@BPHJ%E$+>D<`L&SN@U'5AXU?"@,?Q6.F14`=81404`,J56=9AE%V:@=)
MD`03`C&?9P&@JF9^IP+4$8AJ$`$\4%6+Z5@T-!<*1"Q4@44"1%=V^$%81!7T
MJ!%?5P,0D`9)<3CCN!6]@H4)(`/:]QCP`1]BIUH-8B&:HU2190'BL2`8T'=9
M@`,,P`1;1ZC!*:NT6HNYVKJ:YAN?%IR#*VK!:C,C`&O800"<-0EBUJSIP0=+
MH@(8(*V8@(\:\3`8T@!H@`;:4@&D!#!V,2_I1W9G$3B)="(5<EK;PDETHUS5
MRB7C`0'!YBWW-P-`\`&>`%$&"O\OTDI\D0,8&Q(%4?`'?7!M%F$8,7`&K#4"
M"NM$#%N1$>H"'BJQ0Z<Y7$&-8Y`K(E`%!#!T@*BT\Q5.'FB:9$(+#:>2^W6R
M+CI@N*,[1T"C+RMA.IJCT%"S[90#RB#"0NIQ19E/!N&S/RBT,LRD17NTWP/!
M4]H*$!$%3[`$83`)1Y41@2-C1(&J@_`!)Z$`F_B9XD8!EX`&-5`"()`<C%>7
M#(``::8"!1`!;,:G:&9$)*1F*L"?$U`^/U``CL54L\$=#6"&SH*94TPL<),U
M8K`%&<`T2;%2TF)L%)`7W;DB/7%+^9$&,[(^SO0%I)2)\`$%UJ@LAM$Z)#0A
MGD$**G#_JJ;)MC9@>CS``&VP`;&H6+:YNK7JNJ0<J[/:&[';JXR5%(ZU"%T`
MO&_4:[(,?86P`WW`!WZ@1W?DC@5S"6G!)4Q7`<O+O,CUO%_0$E68O-4[!-^W
M7/[Q=1-`"/Y9`3+@O?6J`3C@%_B&+5%CCU:0A0"@=/8["5D#9X@&"?%K!/0[
M=(RT(!;J(!7!71L2D0K8L-<$)$Z$`[U$C3"@P-4!":$K7TL;LF-6R5V#"J`B
M<190MVVPP2LK)T?0.R[[)WOR8"6GPC7Z#3?(H^]$*#G(@XEB#MX3PS,LPT1(
M4$?;#@.!PTL;$4NP!`Q)'E_`/FIQ"?`S`9RU`R*`8PH`!0EP_P-I@XDN806'
MYX<+XQ=^80$!8`<J\'>G:@,1T*=^\7!]MP/!5V4(<!2A^`-1]09_6QER40,L
MP$IKN1]V\;5;4`;.XAIP@S@9@2">=Q,Y4B)N@Q;_40B8.@.<V!)$,`:VX@8T
M@``B.$2(@2'401V4,`!BX+9-;0=(A`!ZA;JI.XNBS!PE4\J^V#+!^;JH7!R*
M]8MY#%>@<`C#RATC<,M=DP>D6@(.HAW$V`69^!)3(GG'7!@W$2)HT`/(U1^L
M(@I;,!18D1;@-P3+M4L)\'67);YT4V[%NQ@?D,W1#"_L*ZWFN!>5]01A8`11
ML!T6P4>-QLY.ZP)\,`E$@4GG$A;=T?\%7S.L*4*L\2:A"FC:3^A$[&.Q$_@1
MGP#;(G"2`[V!L%#!)"#0Y[--;(L`%.!?O.`+;D*3R(!@#FZC,&AR@'("]=23
M%(X$%XWA]%1/('T0(@;#/XND)=UA)XW2-OSAZL#2(!MQ/+QN9T`>`$#346)`
MAK$()C`"M'(24+"%)Y*)+@&&?W@O7^RV141Z@"=$=XIF;S`O%(/8B=H6-="=
M-Q)5"$!:&0`'")0?3784*M4`_-$29;`%:0T"*B4BYDG(+_8%BCT4VS*I9O<%
MSXUZ&9`),@`"J&>Q?ST$=MX`%7&*IB@&F#$(GO>G$Z,"=O!C6Q"+D[V+E?V;
MEXW97?39G,W_J[$JG+LGC*``D3ES!CLPW@OR1J5:9HQ``.'[!8OAURG!C>.&
MVU5AGX,TTY^$(8-,;O^X2U90'MP!`.*[KXA$,#W2SEN3H%KCAW]AVG$@;_S)
M2%N@JLS8P]H%$HMY05"#$Y$3SQ-+K-]ESPH("2+P!%VHD2;A$2%!`,DT`"I^
M<"7ZWR3@!ZUSP?I5X`?^7PH>HS)J#!&-8-T@<C"H!"17PL#S#<5#X?&4)\^P
MH^O$LSNX3TFI81\VXD*;TN]PP_W-M*F@8A*UH(9<!D-<K^`&3KI+JE>[XT-0
M!L0')8HQ`&+N5`$0U6O6MJ0WJG*E=;+1U<&Z(*J)`8LZ&X_YB`2Y_P4-8Q30
MHI8V9HZ_8A-&00?\`0?(!9IK@9>;,1)N\U,'B=<W-`-.P"OO`0.V<BLL(.:8
MH6998&.A6\EVNQE5:.AI_:I;5^F4W>@O\^BD#/>I&WM9]!MRWS$H0T;$68P0
M>1U]<#E^D-API3F9I4?9T20(8K%C,`93^*U?H5A@X1_X]S"DQ:W\X1]:22,$
M%#"=A$AJ(0ID`Y'&IQT3@`?P.P!/$`?S^P?;X6-P8!=;^@3#2G70816FY`0R
M\'@-HK_<L<`16I$*"-L#,`E.]!@:((%>\%H80.[=H7D3[]_V56:KP+8U,`0(
MOB8JR.#'<.\N6\)\<CPY>M'`(SPVR*-!$/\$!-^C!\^#RI!A*@WB35KB#A]0
M(9[2F7+N!Z=?J,##/0P(2R)U`!`)APD:90T6)`1\73A$"I0P;C.*&1EE"3,,
M6ULU"#4U;Z1OJ&]B$R,3-B(#&QNB/[,(I@TB6V(-%14@&S\_:C]P:240&E];
M(A0;Q!L@<"`-:8D092*\<`C&<-]IAHF+%A8B)<`U<`P,$``:``,X)1I`5E]E
M&D0P_%!>+#4FK,(P`<,`"#@(=IE@8N"``1-XV,$#@8$<.<)^(-A(I^/&C[)"
MBAQ)LB3)C1L^JES)\J/'E@@ZO@2Y\J2LF#`YROKQ9@*!'5U^CO!#HN@9$2)B
M^!E09L"9+EUB5#'_0:!!F61$9LQ(0"'#@`8,TH"@@P9$!0J($FG(@)1!"7`4
MT&HX!&_`CCX[#$+`MC<#CH<-<B6-T27/CA%(133`T&!`!@8CSIS9<09Q`U(@
MI#FAD"8-`Q%'_XKJ**W"C1L4KH*.''I`4".P8\=N$N-O97G)$DPB4H%!`P)-
M'#,D4+2X\>/(DRLO2IR$B1TFBN[8T>BX#1M;AK1H$2+$`@-%I$@Y0IZ*^?,'
M.'#(D<.!>_=FVIMQ<*)]CA/N[SN8?P))_1QF!.B`?@,B@01[2!R@X((K^""`
M#RL((*&$'51HX8472J#AAAQVZ.&'((8(HH4;8FCBB18*4-UR++:8'!=%_ZWX
MQQ-/+!'%"!D`\$5:BC!"`A]\_#&`%Y10X@81F6SR#@1;!*8..R4,4,--N8R0
MQQMP-$!'9G2,\DT-()S#`AXL0`#',VJD&4T:<7VQS!9IT%'+-R#4P()<APS`
M"P/?3`-'!6SNJ$$)8@2@@ABP-%:")GSY)D\"0$!!03L:C`&#`C#,0$,N&'0J
M$`9[86!"%EG\5,XJ%DB$1PDEZ(&1,*.D-!-*)M5JZT@HY5022UWFY*M*-K74
M*P*R[M03`29T84*R,<0@61=(C="%8R)$1\"URUIE"!%CC*$!!1"4$-@O:/P9
M3EI6K(64/)T%JL%<\&0@;67K)H;4+A;D<90(7?^,,$*GL"@66#L(B8"!9"+X
M1H<L9<'AA!.`4I!0HB@Q@08--`R!2#:5/1$:#J_))AL!5>"``XVXS;5;;R)4
MT80(&6`@1G0NUMQB<\[MP(=T.^!<U'79;><="@9,(1YY1YQWGGKK.:#$@/M!
M_=[3)^`WH'ST6?W>@/45>,"!.22XX`$K-`AAA!.B:**(;+?M]MMJQVWABC;7
MC1P7,)*PHA%+V!C%&3FFY84BVCP7E0@:%)EI`A7)0X@B6Y@%#!RLEO!+,,R,
M(`:6%4P3T@\U\'F0!@R0Z4R:M60&@C40:-P`G,!(4V<U.R:20`,VB,%`!6C0
MH0Z@ALPU@`V&7H&!6W__/32`8JS@D`$$0'A1`5,:S``#%%!HBB\/`03`0PW(
M8%`.*P.,8$'W*DB41040X)%1+5/*5-.M]->:*TR[_JI_2_FO-),L"PN&#7R2
M+*K$`#$XX)=D8D``'`T``U")X`0:L!=(N4$!&DB#7VH`%C^=I79?L`(1LC&!
M'4S@''MQ!P#*<)6_B,!?'EO(<SI%D('`(H&)"<QE,%.!(>PE2K!X#`C*DAD6
MR.!A#_M"S$2`@QH(0Q8@T%@"AA`7MDCF"0<TV0@(8`3@B"PVCI'60TIPB$FX
M@0:?B4$31@`R"T#';G`T#LZF0P(56&!9-/L9=A+`G:$9P`-2X`#2E$:%(S`-
M_T#S<9J`X!,@)?0G/UJKVB+?8Y^P*8@]8U-0V59`-@=12&X9:EN%WD9*4H(R
M;G2+(QSS5HZBN&`)80C#WW`PER%HS`M<T89S_"4"2%$""ESY3"Z<EP\0("`-
M%2`&*:KQEE$T0%QO<`LPAH&Z=92``E\HP033\(QBT``.ZD!+(JS`@AZD`9P-
MR$PO`I6`+^!`##RP0>B,N4YP'8("#5C%0B9`BENL`@&KT)<\*$`$Z3GF"UZX
M7@AFT(8:B&$5!>D4`S*PF$Y1ZWQ9L(`*[!"`,DW@5?#;@/R`5;^2XHI8^TLI
M1X8U4EV=U'^]ZE)*/B>&:T6%``=$RAE^!)4^-*`../^05@R@0Y4)X&!;,_#'
M$`JAJ,Y%K'8)2%<)%((!6#!@'@P80%8)<H8:Q2$*45A"#/[`QJ]4U61^`<T!
M`8,9:1Q1!NR#0%MVUSDT](`%%<C8+2'`P28^D7([\H(7O@`NIW0U!DP,*A]@
MTX0O&N%E&8"*5?,Q"2!0@`4M:P(&$N+&-ZKRLS]ZXQU[5AR@\;$["R`:()&6
MM/.01SWLV5J`#)#(^;3GD0XPD'NJYH`BQ"=J5_M/@@RD(.*2;9-H@]"$!'!*
M49;RN6XCD01.62$!Y!&T<:1;6&,9!1'H"`)0I0`<WA``$OAK!-`#@@*`28,*
MZ!`I./C`F<+R@Q1`HQOG[$W_`BJP`1J4(!A/)$T:OD`#"K1A%`R8DEG@L*4T
M.$%07\AGPKBQ@7(9`YLK%`'W>&"!QF25'>Q8GLQ,T*RI!*``*!X@*6C8@.=I
MP`OG!)<^!.N&!+!@,1-8R$.9.`$+B,$")Y39";5A!SM0<`L%R(A(.4)2DSHY
M)2J%R;!\Q5*93)E8_6.R_$1*4S'0)@9&<-90@938+F#`+SYQ!+),8-2]Z(,(
M1+CG8K1Z562P\"H(6=YYG[`0QN@0`PZM:F(0(S"G_FDO%"B!;PQBN3Y](V)Q
MN0H&=J#5!O2NPA_\PFD89U$%L\F6"?""%>[Q!<CXZS9>\8-C9\/&$2QA!+CI
MQ`6'_Y`+,,=@>8V8SG6Q6S<_0.=4I-6;#5AP6N^`9[7E(>1ZU+.U_2S2MOAY
MFH$,U![W*"%`V+8M>Q`T[6X?=Y,.\H&X)21N4(X(NNB.[BBG2]T.6)?7\(Z!
MC6(Y@C*X:8J'&()O?NRL,Y0`"$#@1P+6P([$'`4`%6`""YR`!M0-XP=@048"
M&*!P!F0$#9V31AI.`X$V;.$-+*A3QLV%S00`(,&K^,I&I.$6;)9AJIUE,V-D
M!M$=Y$$%Y;U6$PA@@RO\('<&^8KR-%&&#X2++@EX,!`2T`,F>$\%5["!.3@+
M40S\RS$XB$@`M@"!!B0Y(U>FU9-/FN7[1?GL,!V6253BD?^1!C`8JB"9K;N0
M*N<PL5IB.*K!SAN56Z^P'G">8M>K*@]-&#Z!$)1,W^(0!B.8D(E9G8?S@&CU
M":ONT4XXS8X88!#.^.+R9WG7!VA]:RF)U"S8'/44=\2OKS3@P3?(?*C3E8"F
M-*L5504J`UVPZB9$0@1/@+5C0GW!V[G&"$L90'6>LVMXWPP+O_:QSK@03Q9X
MH8_?*0(@!=G:UE)AV3GPK=.NG<CW\-:18-OV"<@?!-IB.VSVZ;;8QH;<LHW[
M0<R-6[KWSW]VM[L#S>=\=N,'3Q`%]&8(.Z(QRE`"(C`!=40".\``D\`/7G`#
M_I55Y5-O-+`!U0`"#J=,;L$F&PC_`@P0#-%@3'20:65P8#;0&)<A4N`0/!"`
M`3W'`R?T$.Q@,B$V8GAT/B@6`+GS4'F0!R1@&%(1`XQ!"ARD/`_!1#E"!!#`
M`L<0%TZ@&[>#``5A9A;%%A/0A0QA`D#V0F*0!0$@!AG``C\`4O@S=B:5$S$U
M*SC!=E$&94PF=B^U4E:&$\924WW`0(3A!\C"!_O2A9L@`KI&%020!=Z5#S-@
M!5!@!8/S&<MS!IU2408C!B9D=>>%%(%!9P3#0I]A=0-@.7CU:(`R!()B%^A%
M+@SS08S#0DX!"YFQ<3?0.J$F6#,```U`:3@0%DBT(Z.6+O'@!U40&="B"2'C
M6+3Q%XCQ_Q`9$%7%!P?\8@1_``LSPS,!>"T">!QY\!P_QF:J=AW6QQVI=6SC
MD6S)MA[R\32-A&V45&T'4B#KL7[M%P2U52#;MFWS)S;UUR#D]DGNMF[2U7\$
M:4K_5R$!N(TUPP<U$DM/D!M?($5<P0@J`'5Y,``?$'"9,@1M4`+)\T(00`$(
M`"=P\'`9`0+7=$T;B``5L#"CD!D#,(7XP`(V\#TO.`OFTB@(T%D%H4,K-@&H
M8`,521Q9<`7=4P`!\`8S)VC_T@5YD54[I(2=F#";8'2`,F"',`->H"D!45,6
M<!T-D$"N,#XRTW-?R3U9@`,58`-R0`P:X9+\PX:WHC]6%G9HI_\_(8%E=(B'
M=1A`/,&'#`0)_I*!+[00CK&+T[$#5=`L(E`&:`$#EK(50P`12#&$!;$%5148
ML+`\+]2,Z@0'`R"%?*$)RX-5;C$->%4!MJ,!.``4&0`,&]$#<"!.BK`7#-`O
M`^`PD&A@0_`NH38#93`".P`SEN-@-R`H5C`#']`4?O`WDO4\([!JL;$4"=2,
M.$!\"B`]+V0$?`!K7XB-"KD<Q`$C#8&)=]$'/E8!U[<`Y6@TY]A]26-('@`U
MV5:?VN8>8,,!7^-L06"/4I./`+J/FH1<GI0V^E<B!9F@"%HB`DE="1F>+$(`
M-!)+2Y`C.I)O7P`!$#%:PUD/_<`X;2#_B:#QC#U0`YUADC@9#MC``#8`<>#4
M$1P$*->4H37P@QS$&#@X>5]1$-+28]QS8E%W!3XFE,X!AA9P"F_@3`]A,F;%
M"@Q0)]0`I7_B%\Z#%1IP='/A)M+S`SS0I:="07*U"K"60(5B*#BG`C'Y!FT9
M8'O)$G)I/[]2ES1!97#H/W$Y4S?!=O(30%@F##459EV$FPD!)";`!WD`,QDH
M5%*!`5?Q!0H0*;BD;\Q@5F#Q&(K!`D?%A908&(X6%L?`*N#2`!,PBITS)1L`
M!Q`P8/>0`/+R!$\:#16P&<<I0N\R*&86%C>0=.X2C*RZ4V?V&#/Z!>_P`<M9
M/E'P2L^9#=+9_P1-("1!M2\X``!><$%GM#Q5T)T)`8$THVL0JAPPXF-=:`)<
MP`=B4`,RL!VI133N.4B%9!Y'D`/S*1_8=FWV*"#5Y@#ZN2"(E&WO&(]ADW[&
ME4G)53;+E7\GHB'KIJ`%V0$,RK`(>TKOUJUVTU44R@``L$+Y9IL-V"^,408:
M"0->``%H%#`C0`_&!"C!$!._PR8LU``\4`#J(">ST`#6M**%PCT#E$.7`6AB
MT',F4`4]\Z-(Z6,/51`E)$,&(0)*J(0L%AA.FB598DP@$!=YYF)0^`W85#M>
M0`,UT"GG51#.4SA#5I:H(A'-@``@M61QZ*9O6G92YJ8UD79Z.F4MA?]E8A<3
M5;9E>OD#8O!8?O`'.!5!RX(8K2`"&JH41*AF$Y!"63$#-<8XN<!6$=<YZ_`\
M+B0/8>%Y;@$H>-9UP_FD"_,#=&`-AV`%X,(63S``0S1@7_`PI?LN,Z!-D0`!
ML2<#6!E566$%&3`=3O@\*91";`%!-K($71`:32&=CV4$3!09\)4/U$H!RP-F
MD8`!.;,#X"FQQI&X0,80),`%8K`%:T".1*-]1X..KU5)SM:._KEM5Y,#EY0#
MY,>O^4%M!0*P\_<U"1(A$$(V!9LB!LNP":NP`NRP_@=*$8N]$=J]%"M+C8FQ
M@J=HXF,!584C'^L%DZ(\+U0"7@`,%5`"77+_>9WA!`@A!BG6*4JJ58N"`PTP
M*G=T1SW;I5)W!3+<I8&;46+@<SS1M:20*#37&#7@.S_\DM1`.0PP07PR%@"V
M`>$``.*2`260#^+%`%_P+EFA`$,``OB"<QQV=Q8@I'D!,&0J$:"R!6G[AG4(
M$FU[AVC<IG#+QBXQMWEXI_?3=G4I4R+!$WQ``'X`B(31'$95!Q!Q9EF7F(1A
M9GWAN&[@!A2`1@$A`M-`&H#R:,>`$`@T`)_G.[Y`#XPC5X@E)5MR88:@>G4Q
M+9G,&6R2E<JI`0/PLTR1J@XFK.\`9P`@`F0%?!^3508S5!-P0*ZV!`B#`X"<
MQ[U'`,N[+Z/CN%;,_P(#X(=!513,=[W8BS/E\!Q\P`46L`4W(+Y%LWWL^EKJ
M**_VF1_;IAZ79`9*T)_R&W_^*G_Y*[!FTTGDIC8/:TH"C&[_=\`(S")<T"^P
M%`44A+$K=!6<UP@1A0,:F9TA&F)(40(S4)(L4`(H!29_<KHB8`,1@)1BD+0Z
MI$,"80&D0APG%@$7?04_1K0UU84Y*PJHX$S+Y"F\("7JQ$/L`"XEP`P0T)*G
MEY.*,(J4D@"=47);J<@(4).GDG)BJ4\$<4)_`4]VL+@-D+9PS+9IG)?SDZ=K
M:-5NB(<OT:94W:9T+!-X"G=]T`1[3`+]0C,FL+QY8%1L88Q04043L`D0D/]4
M6K'(;=")GHP&>OTGYH(,1;Q99Q(2X).A(1FJQ0C3UL`9J=>(5A`/TQ*2R`0H
MM3,#1+!TOU$%AIMH67MGA;#,RQL;7^PIR-*%,.3+:^455#$RLF%>S]J,R3"M
M"K!?MQEF"50<SPR!GH4</O-9XUD<6>`<?L`'UWP#W6%L'L#-Y@M;\N%;]2G.
M`T+.^QD@Z#Q)^EAM_SIMQQ6P]K=)R^5N`(DA"[JP"DK`TN6@^5PS@O`$8>`"
M9W:Q%\L)+]>`U.$<`\`MEV+!:(2!CI%!/T""*<NIH[A!5\`#-OQ0/2MU7WD=
MAF*FZ6.4*,8#J_!0C-&%.R8E?3H*I4`*7_'2F8'_`,*@!AO`/H+2=0U``;RS
M.HG`&1"PG*#YQ!D$)NR#B['-`IA)0UUX=P+Q:\[<A:EB!V*@H3SP/KGB.W8Y
M=GKIMG@I$K2"MWJJU7:\MDN>4F'-$T31AS@U`D.U$/WR+[^*`7E\+8FHB&60
M`0G5`E``:NZE5772.P@@#7!``\I0$07Q%A4VFR%I.X2]S`:1N1!#NEZ0/82#
MV87@"^RD`1\`9Q10`X>Q+L[C%TUH,";@0$O@`KQ'S`_D+]!245U%(TCH&,O<
M6+'!1:'>!58TF,\(VQHP/5W0!U6P/,9QV]RJV^%9#BI``G^P`WB`S<7]'8`4
M2(/T6NDQ(&;`W.F<'_J9_Z_RT9]!('ZQQ6WYF"#K(3;$Q4F=Q$EF4Z#C5EW@
M/9`,6L^EE+`-JC8&^Z#G71PW`DMAL%DKA`^<,"@8\*,J0,P>J@`S,`3Y?55'
M]2TI(3`;75%`60X>_;(1H`87'0`)?AT\H`*_'0`35`I)FJ3+E`OY)`:J*PO]
MU.:Y&>!Z<A!3\D0Q@:KM5'M?40)BL3JI*MGP<%40L`F7Q0!H4=G=D@#<,(8_
M:@,&$<%NA!3BTSW>8P<6,"E9(.1R6-5.9H=4/:?[`Z?^\\,P&L=R+"Q3!F7&
M`HA6'NF)!1H0M`,4SQ811!A7=Q4)Q0^$===[,@U#U.9YI3$9.E6C.@T5,,5W
M+O]8Z<*:4)$C)AXQLZ<54(@!5?%#>W%O9?`.%,4*H'$MA-$I9\`0%H`'FU4^
MDVX$T)<P`G,0%?%"FRX9GJY&1D#I7T0`I!Y4O(0#"'5!1+!5K`X+UFO;=(3;
MY`Y:/M-*).`"?<`+Q1T"ZEJ^Y>'-U6:?DV3L"L(!\%$$]:IM`!J@8'._9?-M
MX'9_W2TW'A+`!.SM'#*0X6[>Y<XB#*G>87`&T6IO=Y8`XF*61<&H15)C"7U5
MFZ`,(/"]-=2SY="E`9`$+U"1/%\`:5(``X0!JD`0U0$(%@T,(!N&&V^&"#4B
M##4(A!L("#\_:I`E)64`.&(-$`V&:!5I%140&@FJ#(/_)7"E("`53E\:&@P,
M&1D?MW`50T`S5C,)+&]B$\G)(C@#&,D8.#@B%@$V%CQV/`PX>)65DI,(=.+B
MA^?HZ>J'D^0(X>63Z>7SYN-T^'0UC_?Q]/#Q\KE[-\[0CS=]"/2)08!`EQ$#
M!DP@86+'#A,BZ@SH<J:+Q0G1`)3Q`J/%&"L)AC#`,*!$!1!HT"``44*5S0PB
M&E7PY<1)&B<)K`A-H"'#"`P9$J1Y1>'&EP0SHA(!M4-$1!RZ,I1@$+'!L@%/
M7!@96V7$B#-GEDD[NR0*EC,Y]\$!P0#"C:T#1#QY@I89CAA&7`C&,K:)D88Q
M=(DP:W6(%S<*B*3)6<4(Q(DD_TBH(&'11.:*GC.+)D%@M.G3J$N/MD"""Q<2
M8EB$:!%B`0H#4Z1(.<*;"F\.P',X<&#&C!+CQ8<KSY'C@','18)$+Z[$`7/A
MPZ]G/X"$.1+GX,&O6.%\O(_SZ`4(Z,"^?7L)["7(GT]??OSZ^//KWP__OOT.
M_[DGX("AH6;@@0@F2((1>X411@P#B`2!A!!DX$PR79@P`00*P`"#`AI`D(DT
MNI21``AB;&'#%05$4,`U`<08@`HTJF##!#6\4<D;-32P3P,-8("-&"(TD`]!
M^]!!5S$UN$2))6JH\0,<)4!@)0X3;(&#C[)00`$IM:CRA0@3L$!!&DO)D@8%
MM6BPE?\N'T```@)P`$/$#%`00<$66V#PC!@6L(3#"!98L`,&(F"PPP1FF6"'
M'"QD,,$W/\"3I#_KU),I0/[\4\\[Y\03CD!'=OJ/.$>26BH=!OU@`F(-==%%
M#`Q5-<T$(N"TPQ\--811&1D,`0,4,+B1``2.-+`5"/C4``<%MA"E01D#0&3*
M3F#:)%11BV%5`IIL/N5%5-3FE.BAY@8Y@0E96,#,"&&X4$45)G1AKI\#0%#&
M2A/$L`1$D<P$`AP]H3G-&6?%,`)678P5[U@0\Z$05A'E-(!CD.EI%6!=X-#%
M9JI1=%%FG2EH\F@A9\9::[!5$,++"QA01&X<\':$;\!QP-S_<,4EE]QR'"`A
M=`YF&!!$$-1EMW-V.@_W'1+6?<?=TU*3=\!X6)^W@GKJ#0@@?V"'+79^_O7W
MM==H=R!`@2>W[3:#3T3QH`B;3"@A!2N)L8-9.S``A`*`$W%L!M)@!<$'<-QH
MP^(VO`&2&(OGL8-J8@S@2*AS(@*D&)XPB\\&E<A2`05EW%(##13048G`SJ(B
MX18(B,"L*7#P])05(7I%=PFQ^#)Z`A]\D`$#)>``0`);H4*$&QY",<06@/*@
M`@\W#F`AYQAVP=+U,3:0P1:4_B#.I9AN&BJHFIIJCOGHJ'\//N[3TXZJ2:8*
MJJL2^Y&0K*)-8#VA9UA+1SHR@@F(_Z%";9B!`H*!K`'4``-;00,=T/"*IP0%
M=V40P:$B4KLU?<$*7E`%,382@QWDJPQ6^D(94-@&KC!#!+*:UPBT9Q8,O7`)
M82"+O8I4I!I4(`%XR\NLK`<'?*`A%K*X@1,H8"&$C6!O6!F!$:(0!;%`[#"&
M>:%5(@*!QRQP"`/PF!'\-P*0C:8B.R#915+FMM289F6O$0,#7E8;F=&L-SC3
MV<YZYC,S*,<Z>B3.T8[V,^M<YSI-R\'0HB8TJ86G/%@SCWG6D[:RC>V2F,2/
M@,QFMDJNK8V@-!D7EA"W,/AA!'4`@+X``(`O4,`9@`*)"2I`A`X!+D2$PPH.
MVB"9-^!!#/\L&4#M?+2(!Z;Q"I5C5C^<58C8X0`#<H3#DZ*DA@U0R4I#:(,L
MG!"3@;U$%JA(@"H;@(`&S&4G`_.@!G!'@0;PJ24,(,42O]"F$E@N`P#00#M/
M,:[FW<"=$]">GW!EH2XDPP0(-0&B1&""&&$`%`&@%*IJ4*KUK0-]GV)'_$RE
M#GG``WZHJFA`!D*0]PED'Y<Z$NA,P`<2\(%7LGH5`?:V&)#H8E8Q\(-"R50E
M&GAA@408`@3:4*1X=K,"):#G!37`B1$THA2C@X!CO#`N-V$@!AR!2.&:D1,,
M.?4)_^J+57*"@0;@H`XXP>$?8F"5(FZ@!K&8A0Q&]TP($8(</5#_$AQD<(,A
MB',C3QB!PJ)(Q8==L2%&>!=$\M+%&4`F`<QH6#1$H)G3H/$S.Y!8*-VXFM:X
M1@PTH&/,BN`!W?3F-TWC61%Z=ISE:*<X@R2D(0V9,T7J49'=P2T2./!(YWPG
MDI$\#R4KZ9[_9/*X_!F0<8G;GD]N]KFB:8AF_`#6,/RA"_A<I2K*4((&`,H$
M,3#!`!0X!C>,09]<"2,.2O`!"ARC2`VXU@",](9C)*-Q1I+$.>`0SU.4P;O?
MHH24PD$3H0IU8-P<Q4XHF(8PJ7*^9OJFFBA`E!!6`'(\>,,`*)`)+W%X*PU@
M1BK+4($:L``"1"`"%*)2C"T<U`06L`%+_ZAQ!0MH:%W38U<`"B"&##0@HM\H
MAT`\Q;XBRV^C'E5$DN<WD"&'],GC$#+]4.H.?;SC!V)H*0'^8`2%.74Q9CE*
M-/["ASY(S"&Y@D`:$K!`8[40`PBP7%P]J%2A9-!/@Z"`E2`@+56\TEQG\0A-
M,6#0*NS@(>8R%P>!U*,,U&$K>G$J#BH@07P,3`9.D$$:*H2!*D1$=4RHU"GZ
M*E0(`/8L"S-*#*IH12,TH0D$&,L(<`(7QH[+#6[00`,V4I:\'`@T:F0;=-F8
M&=>0``%MH$T=26O:FQVAMJI=;<_^J!PS%,%HL4V.=G+`6YUUVSN-'!IO#Z`S
MJ@$WN#X8+G._EO])2R+W/L6=S[J;ZUSHVCLS?-@+%3LFDN,])7<V"("&,*(!
M("RO!3>@`0M"G!/C06`1%`!!I4#0(P9(LU*[YEPD*D%-!)"B2AF4(PUJ`#HT
ML``FSTJ`!6/1!HK"Q)MLLL6^:K`%9;G"%PS8-"N+@H'%(6.A1PFQNHB$%0!X
M`0(4ML6=E`H")F2!!]2S`##S@KV%/?,*,>)!`.Q@@>'90`[?"`>5RU=D]I4/
MR9WB5$A%*JKY2?FDJKJ')'Y@`S&0IC*];L89+'(1\1K%B04D`%(`D`$-M#D!
M-*!!D,)8NUG0\]],9<`9:#78K&1EOG[*R0B6H-,\>`+S0+**-*JUV-K_61H$
M-B<%5QD_S$M7H`U#&,*T&F!"$82=8!=TI3TWOY<GA%$$D[_B6&(]%NP"?ZSX
MU`"NO<""E?1A"59!$&@*5;+3$#M!A>J5:%YC@2T,@3:VP4VS;0:<:B/-VGPT
M)&QO<WY"^O&0S'$.<WB;6_KG5K?S[RTDT\TUM;&G:YO4'\G%;LAU2<45'_/V
M?_5V;\-V!G$3!1#"2B9B$Z"`#3:F`A-0!D#P-RW@!"RP<!C0%YNP#TX`!U%2
M*1LP""RP!<_R<!M2`980=BE8`AS63C8P""BW$WI%83:Q@JSP.3ZT)M("`5M0
M`"^R!<2S%<2C"SC`"@;4+SN0!U?0/W[R#+A2_W1`,`2C\P6.,16UP`(TIPS0
MD!<&M"@1,0$VE@S5D`7K]75A-PEC!U)E9S[R@'9(IG9,!E(C)61YJ`_UHRKY
M,'=8UA"5X1!',0%\<"B$YC\^9A%^8"]=X"[<509$``0PX`5]Y0Q6D7,T:$$K
M!"Q@9A9GD'G3X%2*`A*`9A9EU15`DH3%`T,+8W%(Y#NH@R:FABNL0''O``*:
MQF>Q!T:X$@ITD@9.\4$MH'+`PGM[X1<P=$6"$1BN%@-Z!Q',D$]`X`8S0`,5
MT``$X`(080*;@1IY@$;4-S('HGT(DGW2)1KMP@;?9QLH,#/C]QLYX`'((1WH
M]S/"81Q!@`+N=VWOI_\=XZ9'X*%'00-_C<0=^E<>7-.0:@.`:%.`$KD?RI6`
M[2%L#!A*!$!*5!2!JF037V!/T&1C%I"!&Z@`'?B!7C&*V/4!Y%0"3K`!<R`E
ME5`#EN,ZT`,!%0`ZD@`3=/`L7V`E(G`C+(`/<W%$3$&!(("$LNA-0LA4)8``
MBW,,"Y5YF`<Y-990>?`&4H<,NQ818)D!E*B3%"9[0)0`1%`"-8"&%O!T/(`1
M(B`&*F!C#Z$]OV<"V6`]8E``;PB'%*4/Y*!1<]@^=FB'>,ADII(J('525-8L
M*/67K/(D8D``KP9K:*$:8Z9!N:)!.3539((4=0$9,#`#-]`&W@47AO.)%9+_
M%Z$(5E'`!PK5#`QG,:S)&,+4`*CW@<2#"UJ1$[IP+7,!!RQP"A8T`+%9"*)0
M`3<`%9CH!!`P*$7RDWXU!!3@&"T00H2W>6B!FCC1!7[@C-#8!'XPC7F!`Z53
M2V[0!BP@`I6Q,!.P&2MC6191CAB9&;UR?:MA`=IG;%F`!RR0`"T`C\RV&S9S
M!,(Q!<5Q;44@;=1&';%U-`MJ!MQV2..6?^0&?X9T'8T4-`NY`OS7D!"Y;F%#
M@!-I'_1AD>X!D?69D2:C&@00`ZX9!0U0-Q84DGF!`?62$Q!@<"B9<#3`FHLQ
M`!H@`F\P.B!P@N"09WJF(L+DAP.C)(ZG0@S`.3YR_P@_N29\I@%?P`!,\`:[
MA@M@F@D54@*?.5"`$G`W\B<Q9B@/459%@@'[@`%P<!7-D`&HH*5[=B8_1`1<
M>@V%@E",J$%B"!*_9P%V8`?>,P%\"0[^`)CH@U%E5YB2ZCYL1U*`2"J/Z9B9
M6A"@,XB5Z1!GT%(D`"'.$"AU,"AA9BA.9:=E()HS(%2L\&5;9#%DL@/;&68(
M`R3J12)V.@T8\"^64SN]4P$TT&''<A;KA4Z2$%\-IG()@"4LP2Q)Y!0),"XJ
M5Q1'(4RCXV'5:@6"DYU+L)W,@!,C$`7@61A]$$8(DQ<#<)Z0`0$L,`"`\00>
M0R.D82#`QAGFN%GJ6!K&9O\#>,``7E`;MS&@!<H!#N`!"%HT1J./Q&%MT3%(
M?/1^]\=M`_EMBH0=&>H=&MI;60.B_9>`(UJB%(FB:+.B+)H@(?,'KOD'&)!*
M4D6!\Y4HN,(,E>@A7B!4%A(1$`$``^"EKH"DE<(4>M8`/,""AJ`/*/<3]`0*
M#]2D$_=Q^00`#+`%`<`#G-,C\"5TSU`H^BE=/$!W;]`G>,:USS`(/@)7O7-/
MQ'.G2W%->I9BH-`GR7`11'(]A9('>4!]T:,"=C`!&8`!B[HZ?2@J@ZED[G-1
MD[I1))6'?^B'CQFY%!5E!O$&KV(87886?H)H!81*6-('>S,"%0%!&<!+S`,%
M.?O_3-JS`S^'9V"F>9JW6$#RE;FP0JMI%5J1!B[1>+^C`5[P!1B`!2U!<DE+
MG%JJ9X."*.94`KY[`]2Z3D+!`""!`U#U$\OINRGFL[MRJP.@$>5ZKE;$#!@@
MJWRF0`HP!+O6,/0Z`I55&M>7K]7W7.BH,EO0!@,;?E-06C7S&U*PL&80!`UK
M'-7VOP:`;>[G1[156\!!;N16;O*G-/`W?XX4'I,$LB$;;^Y&LN]FL@.R@"E[
M,NMH!$O0%E%P!MGU>`E`+0O%*(/P`1MXB=ED3Q&!*`!0`CP2M#3Y`SX4+J!@
M`S-Q#J,`+E_`"9`S=7#0(Y8C#9D@`@@`.0&`#2\BA7K+_SF`\L0:(BNC&+ES
M:CD,0+,LX0KFM!.U0SS<527Y="::D`I:6@L,()50!W57`)IB4&,[-`%:%P":
MP77=!62$6TQL=[B(>YB0BKB+JSYZZ+A_*+F*+'>@8P.7>Q@*8SV#(BOK@A2!
MNW<FT"AYD"L)U"''2`%8$KI6.;.XVPQG,;["A$05$$^HHR]E`)U(1SLQ40I`
M,0-$X`4B(+P,P"H41`JELTZJ8!2X,@`54`MG<KU"00SL:4)J-@ML4F$IED&Q
M%JZCV*Y&8:Z"\8R!(18+LQCFDA1>-`3KV04NL`2^9D:_9A'!-FSKF!DVX'WW
M>QNE1:"\T;\12L#GYT<]`\`%7/_`^8S`%NIM#>P<XW8`V+$T&1IN'8H>Z?&0
MZJ9<QB5O(TJBF`1O'"P@'OS!"J)](HQ#4;`#^%0&*&QJ;HJ*0OHWEYAP+I0H
M,_IP30*#-#D3SLQAY`17-0`.LD"#I..S-F"$R&0506*F;]#3=9<%52`&.S8C
MR$3%(.$G1P$7%D=1&Z!7C<<50)()IE`*M<,49:P)1*!/OLQG7E(,3,#4RV`A
M=;LP&X%U^NFW-K`E-B!1?MD.AGNXZQ,_YV.82';(4P:9FMJ84OTYC?S(!'!*
M8^49`X===<`8$R!XHBL"5N)8PY*S$.#-B58"&;`3NU8E]D2;OE`*:U(*-+!*
M..`'H"G_U1N`!K]H$\\*?0X$E&K&9]5JRQ#P1")`@Q#@$T[@5U8P!D3P`0`@
M`C/5KIVH5)^($X!!17QQ!M;<!524S59D11U#>DY5$U[P-\4`0^6<%WD0C@ER
M6?J*LBTJ71;8``E0&Z,US^0G!0NZH/P\L?P<6P&<?HADD-Q1H1GK6JZ%D.#A
M2.?VH2%*7!H\T1=-7.*MT:>AG\4VPAV)`],R!%P(JU[1M;@"`"]L!11``UT,
MU)]0!H_@$E'2DY_-)@,02R%&<LZRRKI@3Q,0`&"0U($R`3:0!#(2`&R=##4D
M!L>0M2C5%1/@>;<]%[$`)%M=`78J`C5`/"_!*I6`!ILF(K5+_P1?X",58"*\
M@#NLX!7K4B@U"R@4,5#H(B10%Q%QW9>+X'9I=SY&5LAH=\AT/5)]_9>*[-?A
M8!`V,#F&4=@S%%XD$$PSA!4XBB@[$"BKB@,)8(F76*P-H%!`L@6HEW,[T7Q/
MSJXY!PM*4@I)5Q0Q@`%M($U3#0)IX%=H:1,X4,U,<0-H(BXSX`786A5B>28>
M%!2^301E@`%^L$76DPEX\::T,L*D%*Z2W##8#-W2W0Q[4=U$`1D:4`&+X0)1
M8!5\X-V<)3*O0NT)CI_6)QH6\`8L<+^VP6S[^VP>L*`R`\#M5QS^;.[_^\\!
M.7_>5M`&36VSM1P5RZ%3<S57`UP^,/])%CG@FF31!9XV&8W@".*OHX1#+O`'
M$2+2QV(EK*"FP(1BM42:&CZKD*T!<V)Q(0Y7KU`EE<TBR*2\L]OH.1(C-6*$
M3PPYC-.538UG_(`(/3*L<.`C&(`+OH-..`=R);YA150).RA.;W(X-5P7)J(!
M4:%/+(`'4)<%[5*S@XY&.&X]&J0"`<`,;\#'E@*9ZM,^D3JI;IZ8;KZ8??C7
M%#7GF\JIE3"9>=X'@B4:8Z8HW4LF"O5$;-J$;#;9JQR7RILDWO393^X5P<HJ
MA@`"%+#;05DAVF-Q5TJ=-.!7PD`41E'S>BI/XN(&7YT!72!XK^XE%J0*TZ*)
M@_*(01?4Z\+_!S#JZV"%FJ4^157D(-E<?-)P[+=-%!.?!B$F&!`1`Z_1HI<U
M4_NZT:9!WMM>`?$L,^K-&_4X!==V-`T[2/[\O_XHL=,VH=QVH?'WP`BLWX8T
M-(H4'E5C-1ZZ[Y'TT)7D[__N'P$O\`=.\"A3;%&`\'Q`-ZV4$@X_PXH8#1HP
M\4.@C6`)"`,,91IP;P-P&QLU#7!P##@X(F(!E0$V$PU;-C\V-CPV5Y5-!"J5
M!39B8F^LK!BO$V*,((J+CG`@#2P,#`T8`R45<'2*/W0,)1!E90R,)2!T(&D)
M"10E7Q\9R"4:`+T5)0D:,U9$$#5B&%VPOP,8._`F\CL8(A@FIA@X_V\!/_X;
M"`+6H$,PH,&#"&HI7,BP%L*'$`M"?"@Q(!V#=`9:),BQAL>!!#]Z#"F28[$?
M8@@T,4*`SYDN?`@0B#%"1)<)`P!(&K&CRX@)?F+@R*`!"`PH7FX,88"A`:*/
M=-"PF`IA2`((#<0(0K.!#IPTR:A]H0`APT\6%2HX^>)$[9<$,V9X28!C708(
MPF2LI3;#C0(-`V+X$1'I+@0(;7`P&##@)^$1+HRPC.'+YRL,9\XLB;*D\QG"
M.)Y$&1VF=.G11J(,"/VD)@Y"1!00H=%`1.0S`[IP(4&`A._?P&7R-@&O=W$2
M)GK_%NY;IO+E,BW80$`C1`@4*`P4\2!%RO^1(QQR."AB('L0`]J#G$>OGKWZ
M(F;BFW&0HSZ'`P?"T\<OGG[]^/[5)Z!X.2"!'Q(YW+<"?OBMX(,/*T2X@@`=
M5&CAA1A6*(&&$G3HX8<@;OAA!R.2:.&&&::HXHH5"F`"<##&*..,-,K('!=_
M+!%&9"-``,`77Y21P!<EE."."1/$,D!1"KB1@!.\+#9`!H0P\(8(N.0B0@,@
M7&9!)2J84DDJG'CBB04\J)`%/BJHPLH&K;#"B"]B-,!`EG"DI>=7$)2`@1@,
M4,#5#VKX0T<%%"S#S!8B/.,5!=6DD08V$$"2P0<)P%%#!1`00<088Q`QA)9B
M6("F!2*X8X%O2$[_D(=O:9(0P`09U%"`'/\8!-)%`3F44$(-!;O01,06:RQ%
MO"+`44=0D232LR/5$)`_*9'"DD\UB3!"/2-T(4(9[C1&7+==K%9&;##,,$0;
M+,@R0`70<`1"!314-00$(DP@`@,@@,"-!A0,X8475HA3Q@AUE@%!&FE-FH`5
M,X2:@`A&T!KI6E]H,`X10)1A4ZK;BI"J/1C$8L$.(T@211B2$5"NMMM.*<D9
MG#W1V0BKC1"%"SR;=IIDJSW1FKGCP.`&!;6QC%L7S=7X'`'QJ$`"/%2;L&K3
MS3$''0'2]4!!"`M@5\04W7'P77A3E(>=>^NY9X!ZZLGGP-P)<G!??G7K_U>W
M>``62&!_=-?G'X,'1.B#`!).2"&+*8KH>(B01_YXAXPSOGB*`F3^8HV<=\ZY
M<[YQ882./&;PXQ!E`'!5+['$8D,#&B@@NQ=0\B+(,@"44*=`"(A1IG1@2FU*
M`9>LPHKOJO!`PJFOO.'/#XMX!`(<1M:PRRT@:&0G`SZ6D56@=/PS?9Y?S*!Q
M"4X%DZ<P7U&0<:7):&S-$$-H0`3$HK*050$\F"H&8?G:@;YP,(`)B"(`PC,!
M5@*`*W_H"B0'`0BP&#)!8?GJ6!C,H$4.LBQFC<2#T(**1C:`$A-8RP@^64UN
MB+,#$V```C@0@[ZZ0``3^,$((J!2;!2@KC8P9?\+#*@`&C8"`DA1XU[V2-7T
M($6!2<W%"A`#P"1$H($RI,4)>X$BQS0P@HKAX#!@A$`=RI*!#/@"9"Q!4@/(
MU84JX*$!!+39$HQ0A2XTHC8-L!,`,D#`;HT@,SC#@<YZMJ/21$8R.;09S@8`
M`0UX`08*&$)MHF"$&&BK-\^)42:'TT+?"+!J-M):U@C@B08,`6QBXXYWSN8`
MM:VM"$$H`GG>%@0SP$T)M92;?^R6(+P=X&\)XMM\"H0$!\AGF`*BCX$.L$P'
M1:A!A\N<-!=WN<:A2'+8+%'EMEFY:6[.<^`,)V]NY`(=A2$*9RC!CY1QE4IA
MX$LNE"$$@$!/*]P@2KS_J"(`(%"/&M@@``6(0"6N<$`$^D8%/'`3*WX0$%8D
M217I$$%"HI*+6SRB+'E,PS!(^#P$(*H,%,C`)!J0!C2@88D,FY3&-%`"CR`C
MB-.K0!H@\#Y+G>L9#:A``NYG!2=5H`86@$4LVC$!XM1#!#NP@`QW0`(56"`#
M`[!!`QEJD5T]I"&]LB`%-3B19!VK(LI:5K0^&)*,A#!:%R&A&$Q(QTJ.X*TP
MF0!<7^@Q)+TU*#3!`3=DYP8O+$5:^X)&5]!0@?HYLAN22!5:9"JI+Q3L840`
M3$V6P3`GN(\O0&#I&9X@LJ8P9@"=/<,$!`@R2K)$7R+K%@98<!B;="$&^NK%
M_T5J``*T-+$$4'WK'P,I`DKR[+<\DXP11F"6..`LAPGP`A04D(`U+L$%?G@K
M)CNG-7B8*AXL_.;68.2<5##`"Z@T`-E6^9T<3`$%87ME+,F3R_/D4I>[Y*7=
MPI,#9`K3OL:4VX#JLTP&28B9#5*<`![T(`I54YHG.M$UL<DARG'SP2R:IHO$
M26'J/H<+7#"G"V+`@!\%Z5X4Z`4E@JJ*$G`,"%!(0!O*6*2KI&X=#>`!#P(`
MAE2\(117X`%!"8J3!CC/'V^HP8W?,(%7,((%_7)$]KR2%A]!8`L-:`,<"%4H
MLU;@+641P1M^$8TT\"(MEZ4&#3SR17C%U&$?\$8)R/_R@334M@U>(`(48``#
M+]!@"S690"7Z)[()J`!JZSC#+R2!)A4H!DT=30A9KZK51BN"J\CB%4>,)1%)
MFW4@S7+6KIX5UH3\X`ULK0(!HAL#Y^00!W\J`;A$8-08N'H)@H@=G;W0AI^^
MCC8$00,<G$"-AUE!`S@X`Q8&P+`\6?8M0]JI%$O6@+M<`]EBJ91N14V`*L3`
M9IS9610>,YK.Q*`I<*B-H(?`%@:(X"4-*(&;0P("'9P`BQ0(\66*K,+GNF!'
MP'7!SLX@2.,VA@')A4)?[?'</W2!AIX3)7*29#6J?9*[X]P-="PP@3;,`&SB
M5>5WP.,!5ZX-/=J!3WS*4\O_N,TM<,',&]\29$R1*S._]A4<?Y'0WYH;2$+1
M=%"!,U1-$W&HP2&ZD(>$CB((7RAS%KJ<A*FIW0H[/3C3]<W*=C28,GP!`/1;
M!E3?:0$3](\!L3'*#!*@=2I1"0`EPT"0,;"%MOOS"JDHE8Y_40/H*6).TJK!
M`'P,1'AQ5`UJ.%0:EO'D+62@`L":Q;PRU@T&](Y+7Q&&3)$M/U\PL@2.8$`:
M+IMF7N`64V2AAA?&`,D9.(%1&.A?D@;XCIL<G-Z28-.^Q,"#YTF0K%ZM8+"R
M:D&NYK[38?T]0@J2K`Y>>E?'/[Y'$+#\\(%Z):(VP0AB\)N7)?6+M1G!BYP3
M@]7(_[K.%&"7WOD5E3P9T=?9P,P`*"",-%C6U]0`]@1B(,`I*>,P&2B!N4$[
M@B<8@11]$!2ZM0XXPT<CX`=1$`/>@@AH0%N,0`%.`!8BE0G!``)HD!'M)@,W
M`"1?P$^OT`6X04!GD&^&I&^5)`E+4!,X4P;*U5?NT`62L01GP`<6%B.MPD))
M<A-%A37"(7'C9`%O-`10@''C93;@(05I@QU*6![H(7*VA!UP`R`GER!(P$O!
MY`%TTW+PI5_V@2#TP0$TMTS]13@,$DT%AG0MTG,8XF`D`CD9XH81AH:8<W02
MU@%RZ`--]W1ZN$E&8!I_,`)U("2]MD]'PC5P-P`SH`"0!/\#5<1'0U%&`#``
M0>81.846FN(\;X``L<`#3:$LO8(`\X((R3``;P0!4P9X_^`5AT$6WU,!&S`O
MPN`5:Z$!"0``;:`),F51;B$.8\<""&`#>=!L^;=F8E0'?)0J0_$!&B`,W&,_
M'$,$3E`;2F4/JI`J7&<JID(`$]`%.]`$3:`"^D`)ML<L%2%!NK=[YPAIP%<L
M%>%5E59\QJ=\'_0LFB8M'&4#*R$9)I`9`I0D<_5%[Z`M$_`22^`MW!,QX$<#
MON@4#1`-:G$#O0877B!232%3\>8^]D.+&@`!C=%_0O-6(@,S!Z=;Y/($@L:0
MFJ!W15(")/,+=W*!)Z4+DF)94B3_5^3'46BP>5\P!-8@2$M@DI\1"5TD7/DF
M&=TW`)O5?]^B`6/@!C/``'@6@T]`?4X#.LLA0/(0"^E0,J.E7<K!!7G@'*:R
M`2R0`.%5A';C`;)4'@L0-FR)`N\U2_`!2TIP<G03AH(#<PZ`2^]U3/,QA0-R
MEV%(<V18.!*R='7(.&P8="K"AI:S<RV"(6BX=&G(='IXF<L!(WPP=2Y`7#]R
M1&4`5:5R,KX#.T#@%T1`)*"5*JOA#6]@)R34+R#`"R!`*`A@#T$U`!>X`8!7
M*+.Y>94B!EM@BAPU/?UR94/B,:^3".,S/9M'#0"P*%NP?G>2)V#Q%AJ0#?ZD
M5`/T69_E_PLX44:T"&8`\`&110T4P`(38`.O$`#]4Q-=X#]-<0]B(CSZ@`']
MD(H7L2P&88Z.!A!;Y7O[&8]=96GP&(]GE:"<QE'^8`.\(5PI)`D@F!G>4@<,
M,%KK,']5('T,D`$(F0`T0!L(H`\B$%-.`)'QUS$!1`_<`R0`H#%]8FX8T'^=
MX0)YD`<HHRVO4!.,`3.?L24@@``]<)Q!5`'>J1@L8%&+516--``NU`RV!P=6
M,1<A!EJ;E1F@,0)_0)3`900N\`>,D92<50=P(7!0.0)5D!I3^3E1]QLLU(^M
M4S)8R5UYL!LRD073H5,8MQU28#8<@(3HH81*V);F$1]R*7)*D/^7_N&%<R,?
M2J`$MM27QV27@+FH_`5@9!@AB)F8BKE@(&)T/,>I/;>I22>'$X:9EZD<JLJ9
M_*8Z"9!UH@E0,F0#-9``],1<%0">9Q`RN?.:YP!X=[<O#<`(!&0!#0`!M8F*
MT$,'+$`6^H<'>'`GRI)3PR`-CD5V#%`G%6`2\W)LW5`K,G8E1;(-8;1UZL"-
M.P!1Z>`+7)DRII.:;\$]H)=<[9()";4MQY6#`(0/5V`!O=$F9I2?AC);TI(L
M_NEHYVB.Q#)I&!&/PL=\F69\$*N@%/L1"/`\A=()*I"/,[%(!X@%?N`'VI@!
M=9`OHC8<EC04'%-G]P*5@]8PEP4DY^/_1R#)FJ`%6D75$UWPDYXQHZM9&Y%`
M0.>*&WLG/6G!"W#``D*I#Y(@6!L`!R%Z+Z:#`T7F>-!#6`$39V-7%HU!H04H
M`C>4IK]U&I%!&)JA6QE0I@K0!G(5`VI*E30B'*KJ&R<##T6FE:L7#UE#`A@V
M3G@*`C<`7@N@'=UQ-DA('DN(7H1*2V8@2X;ZEX`3(,;4J'X9-W[YEY0:("F7
M`PQ"F,QT<P1VAM-$A];DJ8X#JI%)NI*I=`A6F8=S='F(JN(TM[Q!.AN&`ZY*
M#<N`:F@B5S;P!A`@.[@*`ELP?V=`#V7TFH>G!A?P/*^I>53"`)Q8!K1@*!8X
M+S2E?Q/``WFT_PC"D&0.TX$LX`RX0%L-XR.-1PF@4`^V(PB@12<R5&JF8@-*
MA0!.L9HB,Q3VTT1X86(`,Q=`A9OV8`,[(#),=3+;@B0B0T-.Q9("2U40R[`1
MA+!8Q8Y@%7P22Q%DM6@<5(\*FE8G\3PB_`/*0P`LX0<OT04V-#(S6D8J>'"N
MIH",X06RTT/MDIL90!8OND_YQW]"HX`Q8`(1E4<DHX(D*3)YE$>.H!A2(C*K
M(7GKDQ;)X",9<+P$=+'+>F49,P2J1I$B`!!NH13PUX$O^!(%&!A<>F_G)!DI
M@P$I^%9IZP5`H`#\U"TQ6&I5R1S,@8.P8"I)0C5[V[<$D`4\\`85X/\%+4"$
M9<-QLB2HBNN6ZW6YF"N%_2')C7NYE#N%4V@@]"4@-M=,B2.ZT52J:MB&J&O*
MW329=3BZI&RJFB.[>\B#*\,S6"`"`)"[T6E&^$`/TE$"<ZP`=E8!YI8M7?!%
MS(<#:;`!*9"Q!>!110)5F/`,BN`5T"`-[H-1Z]J?\])86.9/-;`O4N)Y9)%E
M.?C'L4!D[!H+."IHKV`/'\$HC!$)C$$40&`-+O8%[E<--5`/$25CJ)6S<'IJ
M&%`*/,`8M3>.$7S!_RDL%GR@&]%!D296FQ:QRE>.(3S"&%TH5_"@1H#"3$4"
M?)!#N6'+&5!D,-P'?3`3D5`48^!7/K0%$17_M)'`"_:P`S'0&3M22;`%&JLA
MT^=FQHR1Q(X@S&#A(ZB60^QC4C%%`5541?FR=Q/5/HXU=AGC,?7@")L'@6\!
M104#+J\UDC)S!FF<TY)1S"+PQL3U!31L#FL$@Z-#0SZH25;)&\#1CW)JMZ-%
MNQAVIQ:P!4*8R"@P-HLL!;.$'6UYV.81R7(CA5+8J([+7G'CA/,QR9I\E\Q$
M7S0'A@=2((:Y(`Z"F*1\RJ)MA](439LZ8*Z,8$L7N["<<%A#`OI&RR-@=3L9
M)&6`/O]$`C=A`P.P0^I2`O(<"?50!@&<!G2@K,:`*"$U`-)1HH-U@5X!G+?M
M"TY1=PSEG!!0BZ[)_S\4QYI._+Y_TG7)00([=@5#G,1(_`J",*R8-M3F1AB=
M4@T48)WA,';FI@H%A%J,@:Y6\RHY.@&^$0"IP@FV)Q!6-<&\M]`2=,$1P>`%
MBGP>#.$*@=$4/L*]V9MR$``DT`<L@1S<^!N[:D"TXC$M9`)\$+)U1$!E``2A
M,A?XLHVNAM?U4#*9T1JZU120)\R:=QAUL!.$H7^2PC["C)$?0+4Y5+W^@`8T
M8!7R/8%`"@=O,0191`U6X#TF(`)-)%/'YFOF0^)1\`0'ET-U,)3`1=:C@X(V
M_AI%408XX`MB74XP$=<0)]?-\4GT,`$GPXVK(@]:XS^'G,AA(TN%RP$=-_^H
M"P`VZ?4VL@0?C:J%NC1RZ-&X["')E2US_=&%S$1,GHNIB?/9J'U@<CC:VW3:
MIFU@ITU-I\[:K?TYKQW;+H`%L_V9J!.:#?`)084!KR/'LE$-P$U`C2$"6&$#
M6_`,ROJ*P%DIZ[D%(*$(L*B3D7AC>C<``W%F9,$,M.>>:!)WI2)#KM.O)N!J
M()BNJU<;\0Q:?X(!BR&;NJA_K0D$"<`^U]!(`\,`GR"--2$&-;$#[DD"Z1"?
M&_T;`0!'%E``!:XL!]Z?C]9["?YHP"?!Z_CP#8Y[)%$0$U[A%B_"O4DH_J`&
MQ,,#,^&VR/%'W`*2]Y`3/OY:KC88C4)/J4D#;9[_'*/6$]GBG8TA1_0VK$EF
MD=;0XTZL;DT$![K&,$R=G1G0%"WU#X0%D1I0,(=10#4!!Q0P%UBTU5P-`7B.
MY3/I/HX%,6/P`1Z3!UC0&=YB.A23;\$5@P3TDW\T`*E#!$9R;ET$YWP@Y\$1
M2L#1*JLW#_/02<UA*M1Q<8O+IW9S7H9]Z*@4^(Z[E\84Z8XK'[)DN;;TN'_9
MV('C'YK+(.(AAF,88#@WRFFHNBRB342G(IGSNJ3:(J8=VFD((:B^`JJ^ZC,R
MU[Z1&L%U!J;#@6"4WT4V`L(>.[+!DS3@G?7`D;1*`2"@K-%]S4PA"]`@/N"0
M#-$98Y50)]^9Q"7S3PBD_P(F<`7$XYZIH)5;.5=;\BR-P!A2XA3:<+3%9I$B
M]1J><B^'\9EO40&O.0`R-`E:X0[P4"Z2``AB`2HD)#P!$SAB!3^-/W0("#4U
M=)"1EP@;FIN;F!N8H*&8E9:1I:)TDY2DF9R.K["QL&JO<G(%`0$\/#:]%C%=
M77T$629G(SAU(C%\$R)=`P`B$\%^!"0$1B,#$$0S"4,4$`,872,B(@,X&0QP
M#0,,&3@B9SL8`P-P<!45:?[^)2#@&&&"&QPZ&WYL@#,$`H4O$`2*P""BQD(G
M0YPX^6*EHP8-#";<JW#CB\:2"6:,Z0AA`@$,$2F(*P,`@(8/1,H,6!(ES)*?
MR/]T_C'BHJC1HD:BX`-Z#H=3=`,FC#"2],D.+EP*%;JVE8!7KUVU%MHQ@6R7
M'19(F"A+UD0A"S;PL!C2(D0(%`:*>/`@A4..(B@6"!Z\`(5A`XB+F''@P$P1
MQ&;,(`[B6'%DRY$;+];,.$>.SIX_@^;``0D2OPYR'%C-NO6!%;!]^!!`N[:`
M#KASY[ZM6[>$W[US2^A-NX-MW`)DW[;-O+AQY\97O)Y=V\<*MV*S:]_.O7OV
MK]][NC`2HP2`+^@CRINX8\0(&S42*%!`Y`L-!@/2D1,!@0'\$B"HH<8&=(``
M1QI.R#2`!6)L,4`#FM0`!P,E9`"!3F_DDHL-&#10PQ7_N%PA8@"X8!/##F*D
MJ***%(DPP@06W#,`"#706$,#^E1`(0X=EH`#`Q4<U`@()5#`P#80:`!$`FDT
M`$*25GCAQ1`/3L##"!A8H-\(.YA@PC8BY&&!"5V2H$(B&`3PRB63D')**Y_`
MZ4DGHICBIINHC'(GG)K($HN`@`8JBX:Y[,(+'B)AH*B+75311!-&!!/#.5WP
M$8.B0455115^_/%'%$MLD\$,I'H1$0,8`-/`JBS@4$*0#510(0[YZ9<&!6GH
MDT8_7Y210`9<#E""19J@4<$7'VD`41L3B8#C0S<X<4,"'5GQ44@3,$"!1AI]
MD8`&WEA!1`83.%,A30F4H2X$_R4P\$P73\2QQ!/S#I"!"'P0=9115*4#U#&U
MMKC#&51%\40,6(G%%39?-;P=`3M$'+%;9%E`U@[7F,`@`U[855A>?/4EA0&#
MV16"8(8=IAACD1F`5Q!!3%8$S)%MYEC-+&\FFF>H,99:#J7Y9=II2+!FVFJP
MO1:;<LFM,)MQU#$7W-14!\<;<K7!QIMUU<W&='--K["<;3Y@Y]W9:'L'GL(Q
M1%'4#@R<EQZ[[K:XR!L0`*$`$%_L"M5^993P7X"/H`%"/^(,6T`!-DRP:@/H
MH+-JEKBH8/F&8EC`@XA7C)GB!,=@4`,";Y0NR23OX-,`1>WF&.0^_3@!00:*
M9@!@*_]T&`O!%_?:J^00++!``WI>S&!J#;O<DZ((9&5I`<2*.H-/ECR8@$,#
M/*P929NL@*+))=_7B0J>EKPYIRM^R@+H#X+&<@LNNO`P)HKEGC-"%XM.(_$.
M59A0!3`QR`958I",:8@``!"(G*2&<@9X*.D;:<#/!";5`#2DPD#\F%"%[B4&
M#.`'!&A(R`8J(!,(T*`-]^I".B)QN),DP`M62$"Z]E."?\A`6C*TP@R(`(`!
MB,$$#"C#MF0RA(\0X0,?2*#T@H$.!LS#1>4*QA/B)2^#B6`>^=+74:CB@C.(
M`"A3=-$9`#;&*%0E!MI96,/6N,:MF"!C%R-3N:AA@BS88`O_$.C8QXHP!;YP
M0`J`*9G'"J.RR"C!##%SF0%BII@B8,9F.//99GSVL\],,C28+-H!CC8TUSB-
M-M816W*B)C:L7:UJJ,0:<4`)-JUES95,6]IQFF.VM-GREFL3BQ_<Y@(^1$-N
M$6G7JJ81@#G8H`1$F`^3*H`/?*2C#!D0`P(8``*%U$B#[&K`&Q87`<9!#@$V
M@$LO;%`H`C3!<KBPP8H8E*BR]*%#"&C$&TX'`@.IXT$B`)(^0*@)$""(`NE:
M70D`5*-C]0V@94`'#I3DA1/N[@M>\$8"&H"`+8A@"V+`TA7N\:(NS%&%M)J`
M(;*`#Q[(P1&?V(`J5F&^.8EO%`AH_VDH-I&^FJHO?1KRA1@^>@X7*4I19]E?
MEX)!U"[$H`I4,8)7C'#%`9"E#!`H1PR4NI4)J$,#7M!``L21@0:H$`X@J`2!
M]'&@"XVC@PR`D$+0``<GR#`<][G?-@STD&U-JWA:5:((A,@/!'F+6CN41L2X
M$9$A#$%=4)W=1-0Q@C[TSZH#P!(&1$+4)_2D)T^XH@C\H,4M4B54])KB$B([
M1?MU80DN,-@9%K85K;#QM0YC6,76DJ@SQ``N6Z#+R1(3,@=,(3"&6<`@4Y:7
MS"`2+Y.)6<V6F[-)4I*2GGGN<T7SLZ&59I.M*9K39`,;IT$M:JD,;RI!&37G
MD)>\H5P!<O^HXTK;Q"9KM;RE?-4&ENSX`;6]W"LPZ381&%D@`#9@`!'TUE!F
MWC,=%JK!&]QQHP:PH%8/>D,2-+0X^;V!G+I0)SD)<4X2B.'"'S:=.FL@.C'L
M0`05H)&!]IDC"OD0`Z\*(?MH@89;>:L,'I(5'-A:5Q*FJXD)`((&<M4`9.X0
M"#-(0PVV@`=$B(!!ZL@2`2Q@@3SXSZ.%L%PZ+'#21L1II968:9SDQ*>7GJ]/
M-DVS+&P@!T+I@@14WJE(>HJ.<@1C`EXBD\3*=88N]-FHUOA*$PC`V:3^P1Y8
MR@".8\#H&'QJ"0W$`0"DY`6(E``#[4DQ*<9:@38D-BK0:$#N*@#_CH?(L-+C
M"`8#&)"&&B+H6RJQ%NVT!-78_34!'P#"N,:8GW-02!Z]#H87,["3)1S5JD_L
MT*I=-`*>\,2+\YCJOI!2L!%8=EY/R`^H,CN",Z#6")#FPW=<"]O7,@QB75H+
M6LH%C`F\(;=U60!B^B@%*4S!9804+LH.DQ@S'#((_(8999:;&<V8@;J27$QH
M&B-=GV'2,YS4)&NZVUVD=:TVX@WO*7?#2MZ8-Y3<I?@KQ<8TY8`<OO--.7W;
M2((_X/<E=0!``B`2D>O!Z`H3$$0#E(1D"AB85OA(1@-P/KK1E4Z<&-9%%@ZQ
M.!M<V.FERYP-KF`FQ\73RP22Q#X>!(U<_^W3(@C81SS85;L!).01]80#0+6J
MDW>4`'9@/9"W`#"/$I2!"`D($@VZ000-&`\./^`!'BR*`3%<D4?/DQY!#D&(
M+*@``XK(GI=-P;TW<8)/*:73F=7,>5@8:A>%"J><6\3LGDYVCA(C:J.->J(W
MQI8`7H*].4;@!RQ0Y1H$<`9-(GN_+A&`#WVX(@"0#(XOE*`!SJ!F)2Q(APH,
M86ZH4J&3#.I7:F6UAQ%C``1V57W`6N$#Y/J2HLOP_&\!0%UTY_4`SM"'M8`I
M>E4X\3RL'05+;:-6#MY="?#1;7I-:BF=Y5E1X![;EFTB$`=QD%GO,AZA(FX*
M0V[EEDMO1`(7(_\2Y9(BT8,`+)``=8%<4U!OCY$R);-OB)$74W`9P#49B$1P
MD31)QH4SHN%<J>%P$.<7'&`T.2!Q%"<=2B,;/@@VT+%Q&6=*T,%QHI1>3M-=
MM$%QRM%=UL%=Z'4=*C>%W,%&),`'^-5%&:!5-)=-__4"^',%\4$$9#@$!M9,
M3J0,C?-?BX,+5'8(@T`(9E(]%O`#;X`'I1-U<X1G(P`AFI`[*Q8K,M$`<I$K
M"#%C/U`#%#([V((/E*"(_4%"R:(3-V([$)!B^V!J&D`.VD<$7D`!-"`..U0\
M1$`!DX,!6Q`C^4$K9V%5]Y(%`9`%A9`%=@`35H)2EL`]WL,)O-B+Z-/_><!H
M*+E@.6-"#8OB3,[B+)-%%M00147E9XT6:(_R*%2Q*4HU*<]``%VP#B*`!7EP
M>WEP#8G00Q/0!TKE)7T@?W<'0Q\Q#E+1#LQ7($X00]:B`>,0.;'"?1PA0S)$
M=XI2`LMT*VZE5>*RB=00.132!NWB+JL3`]F&`T\0!I^5#CZE0O8"D5,$*NE`
M471`5@G2:D?B'D9U?UU`%/H2!OQB!']`@/.R!.F`@`H(#)\U`@[H6A`8@:SE
M1G-4>`QB#QU"`S/0`A]C`'WD`2X37()$2"7H2(^!;\A%&33#@L_U@BU(204'
M&@\G<9V4-$JS@^]U7N!E2E53A$2X2ECS2>E%_TIBXX19,QTGQQQE@Y-R.9=T
M"1X$P!/C04#*\@6&!551H3D:$P!B``$X@7<T\&#-A`_$UCB+T(9OD',V8"A9
M,)D\8%579X>14#HDMCKW(&J&4T_UU%<R)`)XH'UHL#X$0B1E\`4^5P-BL"H=
MR0]]I8DX]@8-8#M@=3C5]P&7Q@W%XP0T(F#>H&M?P`(8=0AB0`Z&ER6R:`]X
MID(O0@!G0CN2UPCE$V9BU@F]Z">T`(RQ((P:<@6BERCN$3GNX1[+&#&K-WO/
MV"@!5`A\X!5^8%1>$0/H,`)>(0)U@`,B%0/V(@*XIU3Q20@'Q",B&0,\\0<@
MY0V59B0-8`-P<Q"5</\XWL(11Y1`7=``^F1K'>$MUC(0%&$A,H$>W_(M'Z`,
MY\E^.]4AT4-ER&9M/-$,^O$@6U`"]D@KW6:?M!)6!:(KN#)07G4_H<)80\%%
MTV8$3S`"VQ8J.+`$81"39V!&2V!4-]D5=<DPA;`6T9-S,;(%<]&!>,%''A""
M@2%<)T,8Q+5(B)$R*4,SCR1)<&IP+GB5-],96!D:0>,:GK2#Y55>S_$<0LAQ
M&T>61+B$I20`LF2H7QDVVZ6$S1&7=1FIDNHP=XF7#71^SV=8_8%\;Y@$%K!0
M1#`&7G`#^)&8R(`#>5`N3B<)HG-A;Y`B5#:9L7)V$0)6DO`."I8.^D`'C4#_
M"YDX0Q/``A0`!YO`8@"I5120BCC"5EY7`1M!HGFW9`&!B<YJ:E8P!`JE`5#@
M!(9#`43@!F[@#5^P!>%D`<X@`N'D+)FS`XQV!O=`;"*E`M8S=-HS9N#CBV?G
MG6IV!8>P.<.8I7,F6::'`7UV(A$C*8PV>U/T!'WF!WP0!9^"H$:P*2)I*4VU
M`R00`QF@#(4`>?R9!;GG(I/Y%>WG/P<$+/=3!=G0!!F+#WVW56W0!J`&)#5@
M.&U5H3I$!!!`B!C@#_O@0EYP:@FU`UC`!R.@:.A!<Q2P?^<9D7$0!O$Y*=86
M#.\Z`,'`$SL0*R`4/&@@`U_`#_LW63C@<_N$06D0_Q$1P3SPDJ3JL%E)9:3\
MDEE18##UXJ0*V&=+D!3T::5<09<DD`?G]CP,\E.%1Q9;0`-V05P"=Y1)21A*
MN;AL6DB+P5P,QS(YTW"0I#,.YQ=`$QK9=8-<R82C=!R`FAQ!F'$8)ZA`J*@@
MEU[NQ99OR1S7,:FT&ZG8,"]SVT#J@AZ&);/(%TX3T`L,8$1X)Q!`%UFN@H&3
ML&J.F(>O*@:\X"2?0`F?<"!PP`(9D`$U8`,B0`'5%"@;<#CBX(X:"@+ANP]A
M14+(HE51X4&ODR,;(4,:D%!BP"'K,%`EM"ZH@@P```-,0@%E`"YNH&L@L07E
M4"Y4)@+9.PV-%C'.@`'$H/\"%I`?-O`*VOF+^FI33M<+H*<AF\.,`7N>]\,6
MZ,BNPM9GYVE4T-@IGE)[Z8B-S),'VW@O?+`#`U`&.("Q)P8L)`"R%"%24X8!
M+R+$*BPI!3I!`40`?=`'?-!`T8!56]4?Y9(/-NNLMP8N"<![%+)J(\J/'X$#
M8]1M/04/^($.]1#&H74&(D&1D]4`KD(K4F61![$!G]D/P;,.Y?`C%800'=EJ
M:$ML1@44]S15;[LOX-9L!D,OB'RWWD85P="W:^.W?'L-%H,_BK(%7GH#0[E(
M`)=O)F,R:'H8B;2FA/0RCT1PTI49EC2#,KAPG<&YL)Q=VL6#(O<UYG5>N_$T
MND'_J*I;J!^'-(TJ'5J3EM7!A&D)&ZY7N\H<@=C@<F$0!5YT(17:$*AB`07`
M`X5W!;^T0PFP?U#A(NN0(OE`Q^XP`!5`479X(WA@`TXB5KTZ0@,%30_:O6C@
M9352(VD@0U)<`P-0`S]P.&EWMA\A0ZCBQKEBMB7@+5\,O;)X#S\"#P_M(<ZP
M4#`0`OH``2^$=]["`)FC.;%X?SPBBQE;#UJA`H['`U=4P8BH$/F:P9RW"Y-)
M9>8*5&O<7ZB79U["KM3`>JK':!'CL,`P1NV:#B.0!V>0##ELU,DP`#4L(QB;
M!R<F`OU3!=!)$4*,8`/!*;[7!0N,#H`V0.D``:1B'_@A_P9YH+6Z:6KR"W[/
M<"GVLBXTL2XE4'K^1Q:0(U=42Y'X^#A;4$\B,%#,1"L(-B.@"3MI<!\;BVGX
MD!"TL`'Y#`[]P8JG%2I-1<A)9<BAXFR*;%E)ZB(2BZ1=`,GU)<GF9C$[@#\(
MT`!MD``H,,HN<S+!-4B.6\J1>Y3\EA>.M%RYW7!6.8/2Y<H/1QK7I:>ML5U^
M2KI,L\NZ+)94D[J]_!PBMX06AZC3,7+![(36D<S+O-TL!VYA$`98,`(0(#?>
MLJF"8`$C\%][E4=$<`,LP)E8`@VT$V`EP#YVN!!OASH^9`,L4`&,+2`*X4]T
M@ST>Q*,&$E9$(D.!@P&V2:P(L?\0_I`D,D0!&"#!M[E_JU8D%P)-[V)4$6/6
M><"BD_4&[8$#9>`&7@`"<Y$27K`K7\L$YFJ,0QP5)A`,C&4"/""'6A9-KP#@
M+NT(X*D+A2(_+GK5Z"G$R_A#.Q"?EB(I[<EH59".P,?$5'T.=G:1!*O`.E'#
M"IS#-0PF3-P'*N2,8-)KZ;#44"$/,3!HL%?CBC9_;_0H).`'ZE`&,<2:%-!5
M5O5V!R(.%6H3/339T.843N%,DV4.]-(3?G`I>@T53I0?^+.1(!!3A],/*58!
M$J'`KP('.A":MP)5YX=IZ#!Y<."AWR`3`^%GD'9X9Y!%`3@>`WAMBMQLE#T"
M#OE9E7+_;F"AS#:I%OC3`S20`'?!IF8J;X%QIK--VY%[VT'`E*<<2="5<)C[
M,Y44&D2CITFC24E87KC<`<JQ2K?,RZJTR\TANDTSW2>'A%Y)':&DW=S][H7@
MW>.!`1EP'D.@X',-(^UA`P5`[TE2BN^]I?;05=P+`72P!S[.SZL&3>0J+(R-
M=O64!I;VH%:%$.A+SA*?``!0`IALSJM@MNN;=QAF`1KZ(P^&'PS&KHL>`WY`
M`B*2JBTR.=D&`5``!='2!MZJ`47RB0:\C)IS!<@`12=&#AI3,2J`S1!0`VH2
M";WZXS\0/[L@>CMUGN6"*84'J\\C1^W)>BHKGRSO!YSB18RB_T(;NPS0`$V8
MUD#WXB7V.0#,0`#8.'OE^13WMY]C?"^DU]:-1M621@X80P";LNA.L85:U1!=
MA5;X>R'GA[;NDJ)C-##Y<<!\9FTBW(>0\S<XT`8_,A';T`ZY"3LEX`1G2XX*
M/,?6>;;ITBXIY"QO8"P44'[B$D._0@_>-N@T>=F&K`VRGJ2TSFVW#FY=T/)M
M1+O<<=H3P`9#X`6#4:8>@Q<H(-N.N^Q(R:;%A<IR*H.]'5V5>W`[@TDW>`"D
M4=S6`<S1;<L7-^Y!Z-Q6<TJ(VE[M/\Q\JJBBRY75W?ZKX>[OOMUI@87/#`@N
M,3@`95]?9649`V(!%A-B!6(9$!I`0_\5%0,B&)P3.`PV-0QP:A<_/VH_("44
M$"5;/`T,=!L;:'`@N$Z'$`,(8@TU&[5T(!5I%(<`#&]OLPP5<)D,)1`0924@
M8E4[.Q/@8F\U#1C@-E=Y,5WLYC4U&`T#\_,C`Q`S4$Y.;339<!1F5'ACH:#!
M"2-PX)A@P\(.=A-$;-J11<6$,@U0_=B02J/'CSP"\!AYQ4;#@F+`85B)8<0(
MEA-V%#2QPP3-">QBK.L2H\J2*D:,$"!@Y(]./SOL#1BQ`P..,CA&Q!"1H<Z`
M'3$P#,#1A687$2(FK)38283+>76BCJ!:1\17$3@&9#7GEL##GG_\\+%)P,0`
M``,P\(S!AT__'SYP2VA(\&4(!1P-',+%D:$R91R<6G99LB1*%"Q-%4IDH+#>
MB#-G)#8`P1H.G&IMTF3`##>:M-85*"1(H$$#`X0X:J`2@J;"%R]>-$"@4&9`
ME[7'*`RY<2.!%2N[$V00P7G)F8091O`)&M2%>?-&7+B,LN1)^Q&<GYA=%W1)
MEQTDANK/K[^___\D!,@%%T,AQ<<$,B00P@(,HK!`"`LN@(*#$$;(8(,39J@A
M"@88,*$!181HQHAF.&"B`V844>*)+#J0PXLGKNAB#C.^^"(2!QS``1(<Y'C`
M"BOD".200/K@@P`"'(FDD4HBZ:23'439@0!25FDEE%$*4*231:YP_V21/GC)
M99!=&DFDF&>N8,)_;+;IYIMP#F5!?DN$$88@?QWRQ34E,.)(4SR(44(9EB10
M0@D9,+!58%M98,,T/Z2`BBJL+,=`+#7`@<`MNA"3FS(0,-#`!`W`00<J=,"1
MC)X8!5"`!9TPH*BLBHI03@T3Z(1?`+Q>$0Q,8KGTW`#"O$,./4L-D($&^CB1
MP"N9?#%#&EMLL5(7YH`#ED,C3'!&%Q-L)8()*JA@P7:3?J3N%;V:=%!9+KFT
MDC?>3%!0O3BQ,UA/!#31!`%]``544$/U,<(B9TQ51QDB/*0L#F?TT=12]-IS
M;43SS";1`&6TU<4\S3WW4F`1J60"3B>/0/\N?X4-9=,.5#601X`T]Z7LLE_P
ME@!4+9F%[4JDAF7!<YS%N];&6Y4!``25B8":/:2X)C4RK@!0`CC5@%#+1B#0
M,$0"-[C"0$L#U)"JLSDG@!QVOHD%2B84W/`%=M?UE@$&6'@60T)M_4'>>>>E
M]\0(GKDGG^$NQ7!&%$9$\40,`?;'7YR2"TA@'W[$0(!%:SQX(8,08OB@A9]O
M.*&$'`;1(8A%K)ZBC"BJR&(.'-#H8NVSVVZBC2_VF"./.`JIXP%AINEDDTL^
MN2205&;9_)3/7_G\DDQN:6221Q:?/9%<_HA\\5VN2?GXY+]9$`F>F>>'"``L
MC<TKQ(+35$'W?`'_A!?+E5`:)UN)\6@:&U"#*C8"!VN\H@$-:0`=%DB,:20#
M5`B,"`-`L`$$@``.`T!4(OP4@+Z0H"G9`I<)+'"%*]B$)B8PB3,0T`EDE0,2
M&"`%:VK`FF/(*AXXT(`"6K`&&E1`:3I+0`4@88-R\2HB&!##2TA`$PN@D`3E
M(D$,)\`#.?Q@)"+A01:T:(&4J*0L9NE$MU#(@SE]4%_YNL\.@-*O?PEE+WS(
MSUJD8H3Q#(5].(A!'LZP%9GQ82J!R<,WP`*O38BF`90!``ZT@L@ZC.`K03L9
M!FP@EJ%UH0K@0H@)($D"/M"K7A"1AQ@$N8,SK&0MBP)`;_"W"#'P@2EV_U%)
M`\`R2[`8C98-R`0R6D$!"BP"+)5)0QJD\1ID,.8#$$A87#2R`1"D80A>P,XU
MPO.Q4GW!#0EP0G5V4S<&X.$3%!"F,G*F@1G,0`,?R,`97!"&*.R-$!F(P=\`
MAYXEP"<,3W#/`-QCS].<80E!Z<(9(K>?R8V/!`,:$`%T,D(+;.%S%ZJ0Z$@G
M.@QM:'4&"$*(.D2BCIIH1">Z40Y`:CO>H:A$O/L=CSC`4A\!27@_LAZ3KG>\
M(T%/2S]J'I:@9Z4IW;2F8KH>DXXW))RZE$A*`E^2AA0F\97OJ5`]WQ^BX(*B
M-$!I$$#$*T0EABM$A(3W2``1O$`!_2EJ$Q')P/\$?M```.Y!%9YJQ348(88M
MF(TCJ4I#*W*6@1H4H``VD`<Q-S$/3MB`5RK8"Z\62TIZX<2491$&`B8KCWF4
M@`&>H(HT=.F:"@QJ'CG<H0Q8\,,R]#(9#2#(3+R1D,PXD9";*Y=L"1"S-YBD
M(1.PUE@*2\ALU:0F0_EC3F)`K_S@1P61,X()=-*O+B@$`WL90%O\T(<^$(`/
M"]W*0`7IDF\@!"P2.1H.TG(T;(QL40BA2TQ&(`8Q8,`F24192QZ2DLR$Q5PU
MN8G(OD(;9!5V*PQ096/:<%DQ).4EG:`,84F#F6\E91.EJ@"M&-!+5P0&`[-Q
MS:D0D`RO'2(\?!0!URK_<(VOU4T#``B+"`X5-R<HPSKFQ,X`G,B`,CCAF8?H
MC0:(0`3`K),]>_M+!KHP3WH:P9YURN<2EE(TI_W3!5%XCG4C%T>#QBD_>4AH
MYD9H`S$,('01E>CG*"JA"V4(=1C-:!!2)**.DJA%N],=29&`!!BAE$<Y"!Y+
M?7>`X+U42$C%'O*F--0GA0EY2.IIE0RMO$9K*7O@8UZ08NHE,QE/2V=R*E0W
M3;GS8>%.+N`#A@%PB#)L-3)>%8$-"M``"(AU!J&J%5I%4`<,J*$&;E4#,8Z1
MC`.^@50-0,!&R.'9:_ABU7^5!"&=<5L>_#4+`--C"4MH8'"(Q59)#(:H:`B"
M_W>`H`&Y/-0`ME"-S>J"#L6Q<"?*0`0H+(`"-*!$SG*6!G`+YCXT2<A"+*#O
M$5@`N313019VD,%%E$,>M`'6"5^FD^%6P0\FH*Y^^-(7=IB@DW"YBA2K@H$`
M.44$>?@C:O##1PPH#EM@P0PJ,\"PM3PE,&;9BK:"=;(N$`!<6>@6K"9@@H9I
M4BPG:R\GFB(&%4CR6]\"U\3H83133D:5JMQ9">AB*QI6(`-IZ"RB2@"'<HC`
M-L(4I@_;,`17_P;#(K#%1M#@A,4P1G].&T&P0:";+T@GFE;PP@P`T(`^4*45
M^_B:=:`P!BO,0`0W9P`V$K&,1)B:`:>I$WL^-ILS%/\9<(T;P1/PZ1Z7-!DU
M78#RX&+0!YIAU\IQBN.`L#)"/-A@"VT`\^AD/V:(.LBB:,X0B$:D(C=[E$:R
MTQV,9E0[&AG?1L1G:?!\%%.7@B][CA8T]93GO)Y&O]%")>J8*OTEIE9/IL<;
MDZ8Y3?XVG<\(H#X0(7K!IP'8RP)Y"``8)I"!+^R8`IH@+/_JT(`"X+HCZ*8J
MO10J;U```?`&\0!NF[`QMA()`:`"KA(`-L!L`3!M7>1$P?(2XN`,X[`2E?5"
M7X<;Q"0-BN<+P0`!:0`"S$0':7`(F"5='P`#-Y`)RY(`,X`<:6!;%2%;/$!P
MC+`60-,4CW1Q4$0"CZ!;[77_,C&!+X.!$U50!4[E+__R1`0P1Q=W,(M$`GE`
M%2#'1/:P`SR`7%\A2%01%7SP%I3!"7`!%>)U-YT@1DG1!;`B$UT@!B:@,@0'
M#OZV$E?P$B:``04!B(_09>#0%200$Y@#<4,1<'Y!,EZQ$J@!%U3Q`;M!`8I2
M`[!B*YN2*IF@=4S#/U&C-<WD0[KA:G?S"0W`*17@8L=Q3E]@%=\Q#\D@3FIS
M'5:@`7?S2I108:ZF`7HW`U8``8*Q"5I1&5M%C.;@$IMG'_SE')>''E"F>>S1
M>?#A'6;Q+8TS>CO@!YN6'VL2(-Y@`EE@`4R``"R@(!8B9A$%.F1F4:;3(6OV
M.B?%_WL@Y2+R6%*\HSNW4WPT@E)Y5F=YQGP"Z27>EU0T%7U2,CTZ=7U48F@%
MN50VM525%F@2*28U=9!+-7[EMY'Z<3[LA!X3$&#L5U:!81`6$`""XFJPYE_$
M(ET#(`H,$$`;8'6'<@T-$``1\%<V4!88``SM)086$!+(-1(%D).4!)3BX%[F
ML)0B0$&HL&NK@7"0H151DPM:4P-4@PT,$`QE4`&UD&[[8'\0`$S,<@,LP``9
ML!O(X04E@`"/$!-P*1'@4)(J(1K'I0)-8!,S\3+ZPA/W,0%0*#YX20"8I#D$
M$"Z!1`(<,P`FX%4R!XXN00"1,T:%V#`PHP@88!<2P7)J*/^)Z35?"%$3E[0.
M6<`.5<AS3)$'[A<,>9`2`0`.OD)"D.!502D8F\,?4@AP>V$"F$0RWJ`K,O&'
M<;$LRY$&U3`J7Y>*MG`+G54U&%$%`T`+'&$+<*`G7Y`&<8$!!*=`QI%-O*`V
MYZ1(SX$#RY$)JV(=8P`$'U`"1(9AIG8-2A-UIA9S`[`$!/`'PV(6C_2;RHA/
M/#$9(T`>Z8%Y0;$>[6%/(N`>WR$5`'5D3)$YW%@^DQ,@$M-0>-`#(+`&7D![
MLE<A"T)[9F8Z'-(A'-)F;W92+$)2(;4[M?-F_ZB/_TAGR@=3E)8F,T53/Y5H
MB\:0T;.0,U54C)8E-\H]%8D\6^+_D&K"D4K:'^?#!782%`1':N]#D@SA"%V0
M!6)`GC88*O0@:XM@`PA0-A;D&M&I**EE@"J0;(]PDDE0@24A6R3``W;``[?%
M@37@#/!@#F)0`P-@*K:`!JQ1*F=9&0V@;7"`!ASQE``!GQFP!0V0`15P0960
M`,)T'!#0``D!`%#@!3[$`-)B3D"0``U@+4M($UM1%B#$6ISP;^7R+SAQ;W[Y
MA-C%!WDP0DPT7]<EB?C1!94Q`AZ'&9)YB`W#`P$R%2IQ8)*X%CM``$ZA<3V'
M2LGXJM^@G2)D#DFA+2ESAAB0!^]U!6%!28Z20B>#6UTT`5D`#CP@%L'Z'T;0
M!\3%FU_Q_UN:!FT81I[*87<6)A:BLD"UT$S3``&JI`$#4`5?9S;II@R+L2>S
MP11?YUDW0(MK8P6`\1`ED`#AY&+5H0%6D)X:P!7/\749T`804`<9H#\0QD?A
M`6I&P$=+\4@BHXQQX!W\%17/6%6"0S@'>CC>D3B=X:"$(3'<B'IP$B">9%T%
M@0<LT`;HV(ZSYZ$0%:(7%02JTR$F6H\@]7L?!2.]TX_^.'PN@B.UXSM^-CP$
MZ7U'"B58@K8\JJ,)R6C+@VC*<VA(`J02V22%AJ1)NJ1+VJ1/*A2M!I^FM@A5
M"BLF$5:AF@9E>E9;@0..,@'P,*J3Q8%74`!@@)<06)2`!90%4?]&DHE<(B$6
M;Z`1XU`#"'`L(N"HT7!!KH&H:$!:;5`((B`&(D`!*OB4-J0,[9,!X%8"D8H,
MF^4LC&%(93`&0E0!.)``,(`<,_`%"&`#6=`K`:)O(M!%A(0?`1*&4-0$Y=(7
MG4L"51`#?D`"?H<9$[!QX5&KM#9C5R!%81&&I:DR!.!$+_$5CP1,BX1*S1$1
MD'-S*F,N+S$T]J*=2I02W>(2Z840UY8'W-J:$R!(7?4-Y7I&;SDT53`T\&4!
MI=D5?%`%!!!R0R&%V?LQ/-<73Q@#@(E)"I$!E,@8KL`"718-9D,'F](U$#`$
MB3"65:`5KA$05H"PO2&Q#),'(U`'`!#_=JZ@-GIWBSC@22+92^1D';=X-_8@
M`E@`;+BDG9LD&D\0!W82!4KQ$FY#&X0#>O80%7T@H`1J!(,3'_G$'0CJ-)SA
MH%T0(,MEO9(3)^$8OUC*`&H3`BW@M!#EH6`6(;>'.AJ"446@456[(HL<(S*2
MCR-5(P!Y(P?0.SG"9T<5)CGE`T)BD-.7/)^\/&*2)1:):4`%I,4CRH4&I-PC
MM]''/`*@D7I+?OG1!$8P,,S*<C4\39#!<W$*!CP@`@!+!!K0)W&!+)0Q`2AI
M`U7T5V[**VBZ.0;(`ZC`@?[S!NU5$`T!%IMB"Q84E13V&Z,0J5LC0!O``JL"
M&.X%&;N6!J_0_X+6H1RC&@UZE0L"F#:$E0%$D`#10&%N-P,)``<]L`765A-4
M.0%7H!7/!451%'`?!`XFD*X*H3)^,;&'2!D=QT3;,A+\9B\U@41DX1+DZ7XI
MAP.#5!9*-,=&IYW$6DEBH91(U`E!0RH,`0FP$I0QP:T!',`&31,8<*Z9"0[G
M&L`F8`<>1#,U0Q3]X5QN07H2IQ]^<#.]L1M?TP;FD$%:4POF.`37L1N^T$*N
MH4TRX"QYMQN+$;M7Q;O)(#>\,0-$``0:T#`LJ\O8,!MQP0D)49]01EQD`31I
MM4_N$06I<1NY@*&9(!IGH&1EW#!%5AXW^P2.PQD)ZCAKD3``Y<5,D?\?$F.]
M!E40`/)!R[JY8L`"0R#(@,R.$O6A"W)FAHQF'H("(5*U1?!1ON<B,3+;+>*U
M+_([-G+)+360DT:09M+)U&,F=NO)HCS*4U+*24)49.*V<RLDJIS<*X`]<5NW
M2"++LPQ562:930`4574&3Y%50U`94Y="8!`!<V`'!T,H'T`!]``6]'`W*'D%
M8#`'<U``Z9`'A\4KQ*H"7G6GHHL`H5NZ>=H)JU%#W=8`I.5J;3`!;W!9PB9`
MP[:HU_`;X:(UKU$"PP3/O-$&6^!ET')!M"AC9?P!'R`J!?0!,^`&"C`#-``"
M(5X0)828!*QOY0NGSV&N?C&6^($!(ZLRL(+_&418,L2:KF%A;2XAB1];&6,A
MB3`]+G?(+4/CJU[8<9L4%EJ!X*3B@2E1#N;@*PR1$@/7<>P@18`XA$QQAS;1
M%3@QU`!<$4W`'T%1785QQOH1+B,`A59F!#"S"!#P`8O12S2P!1;0`-J```O4
M`#0`Q<B1`&U0#M&)#&DPUB&`';NQSX'QJ*]``W%#3A]`S"502]R1&N`U'P:M
M$)O73O@I$9Z05IB1$Q\3#8@*`CJ@`Q5``YZ.,(J]*$16'N@QH"Y@3XO#3V:!
M3Y4=`T\0%-\!7$SD#4DM)YZ]B.I@F./X!B!P`QO:`G\,(=V.VJFMVJTMHAQ2
MHKW7>[[G4;.CHB&%_WPNXB.6#-QDHLG<]WS3E\H\"CU%U;9QVR1TZV@O5=W:
M@Z31=VCX[@/:O=WE,S,!\MWI<9B$L,OFW0`FX"KJ/7^)1`1#H'^GKKN!PLQX
MX`Q$9%O:'(860"R)^@/??*<U8"MB02RYL#4_P*>>JAU))"N)RHF2FK`E4`.R
M:S;#U%G`*Y8BT/+9L!J[E%6]@1E;T3X,P`(E\`6AK@!NX`5IT`-O,!(!\@BD
M$4;IQ=#EL@.4X:M^P3`71ULF/9FQJ\#/*A9Z2!7A039M(80245]_.$EBP0-)
M1`),P6\GXW,1D>2=L*=>%[LO#0E*Z45S:,%WB!4V)V4NL4D\UQ6;Y!5O>?^N
M/&$33WC&0K&(_?+!8K_G#T==Y'%=>:T8=J?KA7[H$[1`Q^!J:FDW5PVIR*!-
MUF'6ZPD?S[%XC+%X?"+?\/$'0R&$CZ02XO)/2^"N"`YNDU6&F\`.0PP!D0JH
MT^`U90<5_]1Y#X,!P![L537LTLA/!CHXI['L1O`<.R`QDND-0<L?0ML'F>\H
M=<4`T/3'W6[:@@SNJ&/('P((!BB#@P9FAT6)AXN'#HL.D)`YDI$..3E(EY('
MG`<Y')P<H`<KI:0^I:BIJCX"`J6N*P(='0*MM*ZSM+6HKKBYN3ZMP<.VPKDK
MQ;')P,?`SZ6RS28$U=;7V-G:V]S;>20$)$U51B[_!#L#`!!#0QD9)0,8%B]@
M$6`3.!``1!HE#`,#1`@<@6.`#3$3$#0`.*`!`AMOWH@1DX6'B08U-FC46*-"
MA08,,HBP88$!@QH_U*C\40-."0@42H@0`Y(.'1!PX(``D>9+@I]#&DP84`%.
M4:-I*/A,H"$#!C%O7/I+4R+#N@001(P06*)?A1(ERF@@,L,+!1!;)DR(X2>/
MF`$B=Q#`@"&+"A(J\EH8@`/#%8M:+?`@84%$EQUK,<03B$$@CCH#)FQUAT%R
M8WF5\SRU($^,WPDB.&,P(:)R/`Q])WA^ZO;IF\J>)UA0/=O$CM$3Y'7I0F`W
MGR==_(R(T65$E:TF=A-0_YNEBXGD%F[;M4VMR38CV/LLQR&B2I4^1JHU&=^[
M8-<$7X:TR4J3`0@T.-,,^9G`BX8/6177*4%5:7VF'Y0A0@Q++!&#"`.$1,$_
MI]&U58%/1.%'%P@V0)<(.&2`PPAG$-A80W34`(*(%9C$P(8QC+!?3N^!0(,3
MZ$%01@8C+/'$$F?`U1=VY;C@`H_813'""%$4N,2#43PQY!E+8*>D7#O$8$(>
M?.S@1SC@$&`!"5QRF4<,?=B&!QY;L#"$%RVT$(*:(;2YP)MMQAD"G&XN@,*;
MA!0BB)Y%F)'(GWTR8@8DC512R:"7))J))$AT<HDHGW1B"BG)H'(**\$\8XPN
MN?_L8@LSGFK:#"S+%.,#*;,L(TTPJS;S3"W`4-/-K+36FDT>>833A!_E&,%'
M.A"L`T$).&QH00`1V"-&!F4``,0,;?RCE58C:#C1`!F!M!"V;_R`0%I93-``
M'1N0FY(:':6A#P-O6(!#"72DM`&+<"AU`P0#O%'#`!H5M5.]]&%EX0`45(`3
M4OYI`$`#-O#`PQLBN&,B#B8UL,,27/4#4@G[>#%$>B#@(5A>*ES1``X-1"?"
M!#R03/(.(^R@0A99I#@1!CL(!-=B`]0!P0@4\B6""71)-@'1T4V01Q<37)'9
M"`C-U!A-*UL(VH5^!7#%T7F9,,$..W1!0F[)=6$!TR;_C'#T"+:-P,>$?RS1
MA1$CW%@CA;9A0`)B8T_0VW-JWR6>=01@Q\?AXE6C@@D%F<#E-3P&/<!8&D"0
M!@T-\+`%`P;#D883/GWQQ5@?]!6E"'64(2,`&FA0ANH!#7GC'V`K5AK0B#5&
M[9`C-.![#34H5!4\TQ8+1PUTP&=43"50("#1*&_T`PCSH4>52$_<>`:&-(+G
MHX]`^CADD1"*$*&2P\4019(#DL!'##MP&:5<7G;991Y@$X#'!%LTT`:::0J@
MFMZT`#G5B4YVNE,"![%`%!C``'^"8)\40:A'.`)1DS!4HC:8J`-DPH./ND0G
M*#5"87!B%<ZH!3,^=0M>W$)5_SX(E:B0$0U,N4(5P(B&II3AJEW@`E2RLI40
MAWBK7(D#.S_*@PA>%RP(O`-E8N`!&*9H`P8TBRPE\!T&SC`"NKA#-1F`@TH0
MH"^`!&]?#5"!&!@`APV<2PT_H$.]G)@O'B0(>6@PRHC@``$-)*`,?1$#'!"P
M`1`DKP*?\XD?&2`&&]2``?SQ2!J2XA,`.,5K:J$+!LB(`8S4X&O;XPL`_%$&
M"D``"%_PW!!J0!(+$"!,:2M(;N3A,A588TB2`9IC:+05')2!`9+1V==6EIO9
M3(`$A]',<T:#@1'DH8N%P1I=-/.4W.0ND\<:F]AL>9BS`:YM93O;VG;`![<)
MQPC$*?\GD6ITH-J1P&M]ZXW?=E.%:CRG&N$11Y?&8YUW\J4+?>!#'\`3GG#P
M`4$,8-T7*$"#-@Q`#%O(``40%CJF$`$``]K!'U!3!ZNH3D,-V>*-XA"%/]`.
M-:<9$E\*PJ&M-,"0&Q!1#5B0!H\0:Y='^5=28O3+VYSD!T!%0`42,`-^Q"0#
M`ZC;$[:7H0'U"'Q/I1N1R/<$\]EH2#$@$/O.P*4^[,!QYX"?_<8*#K7@`:(T
MJ(\``VA``Q*P@'@B8)X6^,`@).*!$Z0@(BQH*$M(0A.6V&"CD""*41Q`%".<
M%"BB@4)A%(-4L,`%#E4EBU_,\(:,G>PR<IB*4;505+A0867_.Q!$(IIVB'S0
M%1+-,0(F-E%#*[.`;`/`@XB5@0A><$]E=G`&M<#E*25PP@\N`$=O&<5S^,H"
M'DI0`3<"-8\X,67!Q!``WVT`#1XQ)`@JT,<_H@R-R).C1T#'E#)@(``!L`$&
M0N(/BKT+'I51R]>.I;4K>,9W#6BI"!):AI<@D@A?J``%O,""+50&?B:8#4".
M9A>\E%4@7?@0('5'F:L%A`1T29MLY,$93&+8;+NM3#-G@YFO8>`PLD'(#HPY
MFQ5W(09YJ8+9[L*TYASM,$1+#@9ZPQN</7.98W/;D,KYXHSN.#E[\YM:;%D=
M%8Q''/S$!G:\,Q?#I)8`UC%"/PF`_R%?^O$+ZP#F!*S(GY>$SB>`Y%WVAO2A
M@*S,-F>XD9$BO"W\)L@D`^C0"`#R'N6Q@`8%XZY34,-<.*!!(_4:@@86JJ$(
M8^NZ<*!!]68P`_3484/98RID8O#4'ZW6"%Q<`E6MJB01=$C41SI#.`A@&[F<
MXZMDS1*K5=.#H::I36MM:YS>*E<%,C!/#GR@!`$5*$$-ZE#'!FQ@(0&I2&6"
M`Y%:P6%)<=C%2JJQCC65,XXA6F>P4!D\O*$J:O@I5IEJA=Y.AF6!L6Y?T**T
MIXUW-W)5#1(8(0K?PP"S(`!F)T+1`EEX3G69I0$OI($%`3E#,W.#LC<0#`US
M2,&YYF5*?/^1A'/DNHG!HBNZ-C!,7(34KE',#.8&1(UB#8"#B63TNLBT.G=;
M`!Y=@/>&*US!:TQ3#4)JT!A(%DLKHH0``V#R$L[Y!`1,`'B69H.@NEB@"EF%
M7[6<`IJ(/;2+4[/`"*(S@K'YA2Z<.5II(CP;$,M&+0AYCFQ:[347R]9L2`Z;
M"G;3M<-8)\+).2;:1G.;Y6!@:1N^66XBD^$A"<<YSDG.<\P6-@L(CE;\))P*
M<M8%@?(!2`7=LP@@\('*4<"A8M!ZAIK81`;XCG<%B@(66E,0@;B>6DNED"=%
ME),2^;QX#)ADYQ"9,`B8A@'FNBZ,O%!I"KBCBP/0B1-N4+T$6*'_TM[ET%+W
M?.DS=)I'WTMUD6ZDE:N:FD#W'M(W","'5F_)-GWH$C8`;H,M5.!,:V7KK@MX
MP+<2(H%XRI.P'4CL8A<[$L=6*)K`03G`"9-0@-#V*-0V0HF5#)WU"NCF6)>U
M*3,$*C,T;N&&6:WR#-[6#,,`*YKB0P(`;_)6@MC`!UEB2U'0*S'`+*(3+!G`
M`!A@`P4`!EX3`!C0+!HP`Q20!K#5=/@@`B9S%FIP`1-7+S%A$#Q@7<FC$X5$
M20L5&:#1`,[5$6#!;U^0`1-0``7@<!IR(B=",?]P-%GU55<0`%P8`+&1&_*%
M2YJ'`<!3`R#!%TD5$%8!%AYA>A7@1R#P_P9J$25^X#4($C//D6``1QHK,V)T
MX31=H`)/00+&D39>,X.YH5ZRP68S&!U7@!A)TXE>LXDL$P,3,'<FD`6CT00C
M0`#'H0*Y\3C%X1W%81MZ-T^+AS]_-W/X91)M\$L!X1DB,"&\<1C-00V)]V+6
M@!W6P$_B<!>$8T\$$`,!8267=WGA@1U=`!!B$2SI40*5\7JQHWG5$`-Q)F<X
MTDD,`1!A:%4Q@!HZL1,'TQ\SLC(8PCF&=ET5(`,W(#I9J#8#P`(V@5T4\!->
M0!8)H`Z[(0(E(`-.L)`W4!_/9P4*$QDQ`!Q[Y@[6]SV>AI%"$B%&LA5A<"1:
MH55"XDQ9\D[S]?]..Y!^LO8<%F`#"&`F7J!K;85`!#0G]X=_^4<(^S=L?A(H
M?7)!A-)7B6()F:`H2+`)GE"`#"@IDB(,TB8+-H0IW79#.^19J3)9P_"`%*@J
MF8)9RO!#+P1:(CB")EB6V8""]58X/O*,OO2"_A89+?,<!3`!&0``'T`$EE,L
M`1$0*+4U:2!&<P!4+%$!3F!*.#`!`:`0;E0N\$&8A;E0)J<8+$!(-Y$@S*(Z
MH8%>:NA2%J))3Z$U),`%)(`K-@`1?H@@YU@:L@$2.@$\_T*'S=0`S')P.`$6
M_U$":2$&":876T%+)$,"66`!LM@%8F`'N>$T6S<DE)<S#G(0$W`0H8?_$&@G
MG`D&-M'A8H[3!3:`9!,@-DR#8?'#-FFS-SO&3<;QC,[!B6@G8A:R$`CB#\S"
M.A8U`Y5C(0-2'/*$3(XS&HM33^(!95%F#>`Q4"9@!-1P'&[SGX7#(P0Q`!PC
M%GX$`2:GG#B7-X;13&JF)/CE.PA"F,'"'2HU%0?W4A5``Q#P$\]3+6TDF"`0
MD%Z0`)\G$Q0B`GET`R_J$UZ0HTP!`<XA`A0@`PIY`PUI!0])GY&1),5A6R)P
M?9TVDD8"DD6R%1QR!NLS)&"U:F"S`]_0!_!S9<)I`4SPDO\3DS))?W,R?W`2
M5_FWI@ED`$$@"!*$"'DU*'YR;$(Y@`2H**%`_T(G-&V3$@TG=`S;]H`V1"KL
MID*/12F:4BFMH%D0N$*CPBE?N6ZA)4-D:9:8B@W@X`+X1@!^,`!EX)8:TA<M
MHP(!,`?N4@=$]07$TGJJ62P'P3D_$)@_\(2%Z40FAP"&Q**(5)@!F09O4``\
M0!,L``?GR"`FEQ=XH0(\T)(3(9T3T2Z\=08*!X?`@P"*P2`%T9E$D1-&<120
M)!(`\1)@81+!$B,4\!``)ULJPQU*DRM?10VR%0ZVM&<(T:.)*`]_*!O1$9VA
M]S6W08QOQP-\\S6L*)QZ`S/&A$S'-!I(XQF"$2['%'`OU@6=Z3L,02PA81)@
M00&MPQ0Y2@1`4)\-`/]UJ4@<R!0#&#:*MB0.D&,$`<4CB0-E7-($%#)0!,6I
M*_B,`<$`K5-*QM<`R0$TP200VP*;3#*C&`$"*3=>%&!*(J$8;8!(%1`\?]90
M["`@5;!>(%"K>20?.3H#5O`%`C)XA/D30BJ01*H.>C,"$'`##.D31%I4%S4`
M.X`%!4(A=3D`?Q!5G>8"0_*D>U8@6V%J$0)J(A`_:2F<^1-67R5;-/.2`Z8F
MM^969HJF:6I_OZ9`=N*F=H57B`!!/4FGAG"G&118!_@)T&9M)R1MBR5ME,)8
M6BENM*N!,02!(=@!FO64Q$"5&$@,.-1NJ8*[[A8J/C26[Y:IREMO).`"86#_
M#GT`JC'B1&!Q7E,4`:CJ2V7PHFD`$--2&1EB`WG@$2E1JW*4%*8D@V(@AQE1
MJPU0(J9$M@R#AFK8`(PQ$6AG`P$@.(0A6VM(%^O;F=1Z&P,P(@B``'*8$PGB
M#Q9"C_YB$SQ1`G5@M`,@(Z;7`&9&'P7VA_&*(2YGB(4XG?@[$S:@&KF!O[)U
M-+4!'5YC`XAA8YP1>F(3-GL3/U]#`.(IGHW('&K189RQ`\')AKFA,_X`2541
M@WAH$HC4//1!?,_7.AK```/2!W,C8R205=I4B(=#C04U.#7;C*QF`JB(`V?@
M![R">4T`C:*D.NOP2]W)&(U1%<EG$K`%-`WJ$46!_TB7PV\`4`9",0!M8&CQ
ML@%#Q0X+U087*@(9P0+V,A]>0*2M,P!5,&:/N9!?8`5$);;XP1MGH*K:N!1,
MX3HHLCYR@R%E,``K^#VK]3U*0HY/,`!V(Q!GT`5-LCU<M;@H>26LM@.AIUPO
MV9``5+GS)R>\5LPVR4!VTFM!L,QO*KI_(BA`>;I_E4$$V"C5MI0->"FRRRF&
M2I4NQ&VH\(%4"8&-VEE3R2J0*H&=PBK#:X''^\[PG+S+J[S-&P;/>U!E,+U/
M9+WU,`<!D`Y$I0%I\'JE@1H9(`974*SR0GOHBR\\4`!7((<8L2TF\@\(4`#,
MR@.TA1!Y8'/X\ZR(L1O%8?^M9,1S-5`F(848^_52.>$[1A$2EO04#@H'YE*K
M+1HLTQ(Q^+(0!/<L7E`!""`R#L,#ZE40.-.=N8&)(O8&:MA(*W,%LY$TK#B*
M-<9A=9$<K(@9P7@.79`%81,NSJ$VWA0N06Q,JU%UYD@QZ.@.P5)QP=*Q20$3
M6"@ZSC>WZ-$4AM$;L,C5!)`%57!/R1AYA.,K`^4K5R8>!+%C^.1IUL@0^L`Z
M_1498H`@6W#`GO.7+/`5[I!4>R9)AH8&GR-I3(%1H$$#A]:$^>B06#$`3./2
M%#`$"^G(D*P!`^`U0_<%OGK)`TD61%`"[X,@^<#&_B8MJ)>WW","J0Q5&.D"
M&./_RK`,DJ9&R^BD%;)V#6]S)28)%9LS!'$B?S)9?\7<:VP:;'A55Q%D;,DV
M"78ZE);0;$KI"8CE**_;NC7$NZ*U0K!""^',S<7`"RCDE32T@;;@@3RTW[W@
M0IZ2X/$,SR0XSR58S_;,!QB@#TWT+C(H1?40`7:P1/5A<-YH(8^!T$:1$C>!
M%/PFH060+([DGI\$AQ-!7W=1$040`"V&/[WE(-2:21@@F'$D(B#``B=2&@N!
MQ^THAR4B%F6P!251`B!`F7`@`P)&MGN)D(#4LP!`:41`!`P0U/ZKFP0A$FK!
M-(BA<PA1&191.]2E`EO'&8NC-VJA7@DF#RTL&66WPG#'_QO=V1LP9IW5).0-
MD2`+;"+ERGM*`6;]9NAR+=>B$Y!$.K>8'(_!"";I&3-WH7[XA'G(Z,50)A[7
M.`)^T`=5L#[XMCX'`A`0<%$]Z!%;@`?[U>3_Z!%`WCR`E!ML1"Y,4*L],03#
M4A55`WP4!]O`#)%-<1@-,$E.8.P.V>@:,#0F,``_4>C.-P-N0!804`/0F#Z]
MY&8B(&I16B,&0B%-E=R,C42(RY%%DE1)LA5QUB0'XDS7X$I<\CXQP`<6$,`,
MP-VW)LRZ5I/AG<S%K'\/I"?#)KH.\),"")2HFR@<0%@=E)2&98`YX("<T`JP
MZY251<X9""I3^0LV)"HZ!(*QD/^5C1J6V_99G++@*"_/#AYOU6UO/;(<&=!O
MPV+4^IOA!:!O$.H$;N:]&%('$Y`$'1$\3<LY%2,&,[Z_SME(I?D7#8->=\&L
MI0F=SXJ_L.$6(N`0Y;(3*=<`+%`5P+1>18$&-4T'%;`>\FL#(!$\/)$`-Z"0
M3-$75Y\A3[%>8V$%1.`&%)`6:I%@P=E)$_`&)#'ULI5@]]0$-%,1B[-U/,`;
MG%'O9W=V"79V,=-X7Q,NLB5BB5@:1BLM_N"@";(@S9.'8#%)/5%QA4GZ-97'
M-M6#/8')C?[H`K)CQ*'7/%:()D!00)(X6-8$FXY/XF$"L_SI?R#J,ILC7@83
M3YM%DVW_>F@@]H54`7^FZPF``PA1`C2=/'_FHEC!Z[2>$X!&`>3EQ,.N1*4D
M20U9UW8/`&P#&B%!>L'2!OX`/`"Q!#_R!Z5.+5TPCAQB([,,""(X&0,Q1H<N
M+H=&B49+(B-+DH\B44\CD&>&,2(B>21\?`2C!"0$.Q-B;P@L%`E>(2$MLRVQ
MMK<+N;J["R@HO+^^P@9!!L'$144&!F8.9D7-S@[3U#G6UAQ(2!P<UQP'W=\'
MX^0'*P(KXS[HYNL"[CXKZS[N`N_R]AT=Z.?Z^O;T[*&K!S#?.WCXW@E<2%#@
MOWSZ)$CP-]%?1(D4.^P@Q;&CQX\@0XH<9804"1*+FNS`40;"_Q`($#+@$&&A
M0`$P$2),P%$'@`8*`T0,&-II0(8&!7A@:""B@5,,8DR8R*,B@!T5*E[8M"'&
M@@VO7+U>(:'BR@0$/]+^V$"'#H(:#5@TP("!`9R[+$#4@#N``00`&2:8P,&`
MCEJV:"HD2/!%`PLQ(ACLA9,F384*%'R6:!`4!P2G`TIHF*'!BQL*&WCPP*J:
MZX2]-=YL0#`!3Q:LN'&?'-5EPFK!6;J8L-#%PH0)62;L2#Y\A.#B)L386(J!
MA?42%"A`8%"B1(42EL$SH%"9O/;*:2!08%"A\N4*=^&`B/^^,GCL7Q:_\J)A
M,8`!&)"P0Q<$=-&%"J?X88))39#0Q/^#'!T2TH--&-%'%7WTP<@BA\0P`$O]
M,08!#AA8,()=:+1%1V+X98?#!!X.T$`%7\R0``0:6.$%?PDP,$$7`\!4F1,W
M#.'%#"U8H4$&72@%``!#YJ?D!T1HX",&`XP00Q="!=5)%SN8L!,.(\011A1_
M<#+34T8Q,-<23SRQQ`B#X'#&(HDHPD@4BG0RR9P#G'$))!AT4445(PRP`PEY
M<,&%"X_R,1P>"+`APPT+V$++++=TR@LPON0BC*C+_$),J2@04TPR9K0*S31*
M4#/--=Z,8XT#UMB:0SGER!./.>:LD!!`OM(3D$#F+%300_LH*^PYR@IT[$'1
M2ENM``]!U`'_1MM6=)%$%6&TT4CDEFLN*2Z8A-(B.PQ01GXO94!(33:!48`%
M/)6AP1<,#$644!F($$`2?%C0E6H\7*%P50'@]D(``5SQQL2J<`65P08W4,,&
M:6U0`P@@PX%9!G39!3+':OQ00U\4?$&R"7W1L<$&(%1&60+]6<$`!I'-6,)=
M[7W1&`1""5*&FPW`,82-IE&`@!C'88!)EQ]F4`$=7V5QVTFF<"15%A9410*8
MS!%GP8#&(2<8`1A,8-Q7)6<`01D_IT?>79:Y1P%X$'0'`7J7B5R!7O/-!\>,
M\#'`0!I[=P>>=F7HMY@&E"=01I:GC$#`CRKP8(J#34184D<44MB1_X5]^(%A
M2:-3Z(<@=1#AA7Z?B4$G'&BDN`$::>@G-,E`RDCC%T[@:,7D,Y"X$]WM$9F?
M%U980023)&"001GO"OT%`-@?35=051S"QQDCC'")<.UF,(*@41CA!R8:@Z"Q
M:&7,=`:<Y->)@8:,--)_(GZ:!)T$]81._.A0B9J`HQ;(!4E9@`FLH,$00I"I
M36VJ4['XU*=^(:I0]0)5IUJ&`:"A#&BTZH31D!6N:)4#<>1@5N-`0@MY18YG
M/2M8!#&6/815#WJTHR'^8,@\GG4M:F5K'PUIB$/^L0Z+4(1;W0+71*0XKG-9
M\8H14A<BC&`"$?CD)3'!P0!J`H8RWLLH9?_X0`)*\"$Q%HTP-DB"":Y@DP($
MX"L*@U@`5A.Q5*CE!PA`P,2>1I<)+*4&=-B+_.;#`K]PKVW>V8`:)KF6&F!&
M/22R``8JD#L0M.<R+4N`DACP%N[`!PTB2X/0N-<)@#5@%7!(P!BLT`(8)"`-
M#,"!&/W5%)YE`$IM.\Z"1%&*W.@F"S$8@0EX<!SB#*=$8A+0HGJS.8,%J0P^
MT<#?WL.>]C#./"4PI<CBHY<:'&XREU&<XBRCN`HH3F2+FUOD\B.Y_D`@*%)1
M9A6$(SH+C8X`I3,=`3@D(5(4M$&C6\0?,(&#T1S)"T2SP4[@H*(>P($"I=F1
M!LH`":$TKSR22\#_].;"D[PY3Y1CJ)*=,#&"!G`GG(H#T'&"UX4HA&]\03F#
MU"(CD_O)*9DB``''/@8""'R@;X&:4_YT.8+P'2(,85!$GER`B3-$01)TBD0!
M17`&0QDA41AP%*1<(`H+X&$++%C#!#ME00QF4(-P]6`OAB%"504A",I@Q@E5
M&*MJS&J&X'BA`Y"@*W)\(QWJX.$]H"40Q>Y#6-@ZR+0BVT0D!H2'\8`L$AF[
MK&99EK+XV(<3@ZBM)WI+BJ@%5Q6QR%ISC<X")]E0242@KY?L38QB*$`$YF`O
M$HC@>A_X0`;Z192@?.@-][(!#VQ@@S?40#I7R$-7;-`YR-3@!RD#I%XV_[`*
MIAA21B#;6%I`P)TAM`0J;.386N[B25%^@0(-R`("&D`'\K(`;S<0&LY(68,2
M`&!PGJQ,?C0`@'X!S$U^&<T,QF"C-/!R!(5,A28SH`$1"#,+)S%FUP@@E0YC
MY3@JZ$T6,#"<+I`@FLV,&@Z>]"0192<[CJN,7=C+7I#-Z'`N[>;BN@F?PXU3
M9#XKP=Q@`@%Z+D:-A!!!F`QE@1C$`$.D>!#7(.21@D:Y="3!$T&-D,P!`$!V
M7AB"FR3*'IFA@04TP-E^-FIA#.#`.\VCIY2(0*(NG*@.[\V/?@D<L$ZL#Q6&
M=,I<-@(D,DGB$&+@F<9*1KF`W>\,@F``"-J"AO_Y?`$(`(A))-;G9IF(P!"(
MF&J>JGI5.,T$3IWH:OBZ,)/8CL(K;T#S$'(1BUK4FA9NI>`NA"'77>N"UZDJ
M1K#OBE=6[94:QV8A8&^UJP,@`5?`(JRPDI6.<R@V']5>B#S\$8_*-BL@#W$'
M9.^!K<<RMED0L183FUC:T3H1M=]*+15;2V\KFB"V434"'T0`@00,(5YB[$(`
M=AN!`JC@MQ0^*G%;B8D,(.!>8F"%C`#TAN9"S6U7$$,#$#"SCIMS/@R8EYOA
MH-[LTJ$","G!BRP@([;<^&-.$.5B&"`&<P(-:*H\'LXJ\-P&"!D\=ML>`.K@
M)08\*0-"3L""9YD&IQ#_*I@[F"XS[]D5V))"*NK""EEP8X+>J.`XP2&T!<2T
MN0E(-#)STY[0*.`$\/18/NQ-&M#2*<[X^.LN<K\Q'&#*1NZ$G(VJ9,SDU,C&
M$2QY`J$K!5DV;`(N&O3*35!!XK?,H<<#%$*<<!<1A':#]6QA"^S)'0MD$/,0
M*5T#`^B"]>#LA)A;X4D:^`!'_1"%&-2%R.$D3%/*9[XP+&$C)N"9GQE*"#E%
M(0PQ<,K&9E,#!L0^)@-8PAF,`A\0Y$YD%.`/]@9PB:X.H`Y$[P(B\BWJ`HZ@
MU$\("JJY6J@^G$&,HBC)5]!Z`UW?H@50N&"N?PWL7LNU_R!4!,1V5ZYR;,[0
M_RI_12N$U0VX0EC.MBN(-0Y$Q`[6!BU-Y`/)HBQ,M&VB]5FDQ0^-U0\@B&X&
M$2U'Y%GNEH+Q)F_RMEKU]H(@<6\H$08=,@+7\V]](T88P`,XD1,!0"?^101'
M,Q2\1SX9L`4!H'%L40%R(2-OD!;S!16O$4B&@5T_X$G^!0`X`#5'@5UJ0#,@
MPP+YT08E4").`4B7`3(THA\:4`);X'/>,7>!ER-EL`5BL1,I)R\J%Q128Q0$
MICA_002RDP`L4`-T,2XDD$<1DX0E<!3"I'BWL1JXD06CL""5N"!?IS8[8!S#
M(1@_PA5&`1/9H3V6\7:"XT[IE$YP,!3*IWQ\$12*\_]F;?0A#"`4H($E8I1@
MEI,``$!X##`"PF$@"V("&&("&6)EHQ!0B<=A_+,('O$@'!(^&K)0(B`:BT$!
M-$!*>-`70$,#3F!D&E`E@9(HHEAD.!-[&T4F=O8$9Z!33`$)$"85=@8)E^`<
MPC<72U$"94!TZR,HD2%4,U-?&'4C99`!2^`ADC9INY,&_[8OX90EY0,D^YAZ
MXQ=5HO8(D3`)0Q$G8`6,^Z1+FV@!%H``("!!M*8I^)=_N.8IH-)_'C0J<P5L
MQA!LRQ`$)Z0,**1"*V0-V^"`'`!#,21M$CB!%`B""K$L1QE$X*8M3$DL"%%N
MZ!!9"_&!Z48/)ZB"[L:"4A3_;RX(@UYY=:5@!#08!:K'$D/P!2.B@SR8$Q'P
M`IWV99<C`FW3CD;8``&P$PCPA3+#&1NG,K4(-2(@7I,T22<'8R\B!BVWA+@#
M!PR0']@C`HDF`C-3`Y46-+3S2@BP=W#6'D*F+U9R'*"Y%)^')7()FD+!`-C4
MB$A7!C,``3S'%1NA`HPG%083&1<CB2J`81OF$5N'%<'1!<GA-LK!B<&7:'W!
M'HRC/4[@'C(64P/@8TZ!8W`0&_,%($M!&$:A2SCPCG"A,?C8%$+A&3Z!EMC3
M'S(!C&-G*%6`=1PA9<OX3R31G@&59?Y$>=2(`X/H!-GX7-7X'M^X&`,F7!@0
M`U$P_P'7U!+=PT9.82#&USZ($A3ELU-%PWM+(525U``XDI:00'WQ`30R\`56
MT!AU<`8&2DH!R0)&\@H)L!X0"8SN$GYXHB=3%060\"="83Z)$I$?N7(CR0)M
MX&\G*0LIV5:XT)+#`&PQ>:2I`FQWM0RND@RO<H"RPD+:8%C3X(#;`"R)E8%&
M.6X:V`'Q`)4:6)7E9EFAM41H.I5()*9IBBW>,EIOJI5R.A%=^95V>A(N<%4D
MZB[_1C<&5A-L60`K40?A6#M1L0.(&@-B)%$X4`$_L`=ID3))@W*7HTF2885@
MZ$G:$4YFMP77Y4D\1P=[IST%A@'--VDDF4HX0CDT!S'34?\G@R`3,C$78K`E
M2_`')!``!9!QG4`7=,$EU0@!(B,C.'(W",`S!M(%,1`FI=`:UK,S8L";O6E,
M6L=A3D8`*M!U8^<V8#(=3"$CE-$RZK$WBQ,?<#&=RL>*_2)H?+&=2]$4$X"/
M#7`<\\H4BL8S'R((V40!;4`Y[X)TD&`"")*,5$:,&-('`\4@\VE0J%-YEI=E
MU$AA&O!O:&EA-CA<W)$?F89-EQ,G[#B/@N`E4LB@<,*.9\`931$7^C@B6:)Z
M(B`?B,06GC0T%$`($S`")4`#I[0[0T`D5G`#FE9H[T$!__8*I,$8,^%G(E`'
M]=-4_6.1HA9`6)4E^5.+AM(%BB/_2%M``QR4*;>VDOMGI'2%*J/B"V0;##1I
MDV:P*GN%@,S60K0B#@?P0LWF;$+9#M=&+6%Z+1Y($"BHID>9;B5XE>@6;M[6
M;EEI$7,JIQIAIX[;$23@`F%P"3M`6XQ!-T0!J&PY&,`EK'.A'$[V.F,D!MSQ
M`Q>0,I.$`-^A'@,@!AJW?*+:8RB'EFYH`WL!2(DT']^A/;73?#^#<^GA$QPE
M!CQ@,,)GJEB"CUV1!WS@!Y(0=6^0:`V@2_Z")1^R&>Z$FBOZ!6GP7&#2K+A)
M`F-'6V4H!AE6%1K&81W688J'O@-R8B:F'$K1%^'D.&['A#.B%S+"E_G*'8TD
M1F(T%TZA_PJ)UC:?*Y<\8TAM%C4W"B)MB)HM$1,!HR4&>RB'HB&0UR`.TD_U
MR2'*6"&49P3DXV6S<R.;P0.5>SW8PV)T(T;E\P1Q$`51X`??U:)TP5*7<`FF
M"AOS`0%5,I&8L#B7P0+P`4J40QH#<+,EH`-",#.)4;0ANC?.\5ME,(I?<);1
M,SL:4`<,1\7J$SZ)`+53A0E_DE7$5YHEN@4E.00<]+7ZYU9BRVLB9+;&T$$@
M),<UN;90VK;-H(!T>PWCT`UUBUC3]D/#(FZ<58)C*I4H2%IKZD1+](%4*<E!
MA)7?LH*+"V]U^K@P&+F6,`)]T`"18UYL%!1B$`!E-`=SD`4?@O\C4$*]K00D
M-,=R);`!>X"Z:J"ZV>%@JJ`QNS,?*4(9,(&6`[`7],4Q-),&0E9D!7G*B99+
MA!&+ND0(;:.L?I`'>:`PT84!9P`U<TD^ZP,_L,&8"V<4U],=M8@=JE0!%0<C
MDF(".]`'?-`'"Y(<.``'RI4;'\$UTZIU)]%U.Y"M)H:HB*F'ZE0!1+&N"MT9
MX=G0^TL8GLH9-6`#\[5H4!%,&+`#4C,@,=!UD)8H/?$3E"I/EZ,<ZED%`$6P
M6$:?R+C2)-&,#DN?D#8`X>AO-:MDY-,ENQ3`A1(G<6`FM:=3'S(4=5*+_?@(
M,K(7*P('3C!+O$@F0&@9\I$8-)!F_7'_.5+3J+I[`Y,#/;S(41/P6ZQW`_DE
M2M&C31W5<`5Y?GDBQJ.65%B5M*%!-"+P>6A&`VN`*;_@QF]<I/SGDJ4RDZDB
MV/TG;'),;%!J0@G(DS+$D]Q06!%(;1*86=("+<-"I@XAN,SBR(*KII3<R):L
MN.`BVIF<R9O,R?5&`H]R"7R``?UF.:5L8:B,$W.@`N;\`3_1!M0;%%Q2`A-P
M!0U``71`22E3,T5&`2]R!::Z%BNBNXQ39)MAB(EI3M]!`?KR&1;01Y$I:$^1
M"GE@C.%S$@J3!S?+2[UZ!EB`!9$!LR&SBDE+&/^A,0C@%S4"`340UI]&F^=;
M%3`C&<J1TJ.P_]\:QC4$0,\FH0+O:P(,U1=(%W+]TB^Z%!D3-Q>EV39PP3,(
M)AG.E=3=>:QFEPK!ER@B8&<CX`?*.C6$*GM^$<'0]PGM*3H6_$\?3&4#U<%6
MMM*+4$#N,K$$R21=<`:("FB&!&$_XK%R0N*^ZE)96#\M2HOL$1\?>CQ+TC;<
M8:$_0`<RL!AAU@9M`"`GDE]2<B,JRA^H9TA/G@9$4M;1HR3J(WQTLH\B4`5M
M+6J)D'YRL@11\'ZGJ8^=8-<_F@"]X+46!+9^G:0R.<=CZY*^8-C#4`PCA$)N
MZPW;P-A8F@-(4,CMP`YXRU@)D<A!=&X=^+=E2H)0R6ZC#KAEJBU0%/\1IA6G
M6QE%I3UOJ.VXJNT"E]`'$Y`!BU&0!N8;9903!Y<!=8#;+&I<G^9S&*`"UH,&
ME`1(X=HR1[$*XK5>Y5%D_V$#=Y2\2:-.L4H36N<;Q:L:ME,BKOL)`](;="'M
M<!%3A#&O.S!]LDL?#EZ-J`E3VBM2%%`#FF1BG;,:)Q$Z8B(W\YK=U"J;7;.^
M4E'PLKDE)R;6`".K$%X4U)%H;A./M`H@+O46H:J[^%L#;R&<73&A\U@^4<!2
MOT0$"?`=+*YR&5W!%KP@)1%0_PXZRUCC\(EEK+-EB3`G.!LBY+H1,\P'&OV.
M5$./<6)G&N,6<'%).9@E"(<=%=``GD1Z_9'_:<XQ`%<CLVE0UC;R$B3R?BOZ
MG]DQ!(NA)/^!"J&1G+Z#,X)(,CP#82S!Q3$0QF*,".F7D=)WG`S0!D-@'6BE
M5KO`UWW]5G\-@'DU#'EUMG1%QW1L;,T0Z8[-D\Y&#I9.0[Y2;>MPR/#@V1V@
M68VL$/IPN(/[R*%>N*-56MSBIMSRZO*&R;%^VK/.6K4^)\N*`[N^'7S(@S@!
M!LK.$Y1#`4P(GB/>``%S!?T%`I,TF<^.W!<-`APGLZO[%V6``;J5%&$=%'MA
MX1/=,`VRB:H1,04<-;X*)O$JWSQ\.`.0!CIX(N]Q%\'<B#-!&*GI%"60'T0`
M`2`@48;78:$`"$8$_R19)@,E-18V64U-!(^0@RJ3E)0DCI$[)CPD(F49`PPX
M`PTB#1,-&#4-"!@B8A,88B,C.R(BKF)B+'`5)6DEOPS#%7`@-1C)8B0C(EU=
M,5VW(U%/`R,X91\)#"5E$.`EH!@3,555!(V1ZX)&@I"-\?($[O7V[_8QS1E`
M7@DW%#)@V'&&EBM1#$*U@3!*Q(@NS1J`@-.+09HT%,"!VH$A0PDX:#8@`$$A
MP1`-%"H,P""-02\*7[[<N)'`R@P-&@3&$-$F#<TO,&M:L?(!P(`=.P8``%K3
MR]`91#Z4N78+UX`Z=09T,>(B3!@78%UP=;'$X9(G3\X,H,&6!@06+&BL6?]`
MEVZ(NRWRZFUQMV^(NG51"!X\V("!(D4,"#Z<^+!BPI!1&%9\V(QE,PXR8\[!
M&<D!)#DX'!A-6C3I%2L.K/`A(/4*`:U?=^@`N_9LV+-IK\Z-^[8`W[EI_Z;-
M>WCPX\B)!Y=P>[8$YAV>2Y\^W3GUZ]BE[UC'O;OW[^##0\I#@HN+*"/.)$V0
MX%O":Q;`@)D#AL2$`1G*)*``IY2(`<Z(`(H*8C``@AH_(%`#"!5@!-0`%@2`
M0`,-+%A1,!24T(`-=G1H1P`6Q!*A!22^8<,5?<000S(33"#&&V^(@<$6R-PB
MBQ@U\`+"1!11Q$(%%`#`0(LEN-3##TC^``<$9>#_T,`P3`ZP2@DU`:$!`S5.
M8$(6650R218#0("+)NF08*:7EI#P2!^1-&(F"9,8H@$`&3"`BXRR8)#*2A.(
M$,L()B1CP@@36)#,``EXH0%0%%#@Q$60&I,*H8,.!`U!Z46Q!`XBX%#'G`Q`
M```X$)2`PPAF$F!"%28\8D\?L+8YCSJNWN/.(_-`XLYYS91`A`9>>$%!&PV8
M`)$J(P%3005.9%B'DZX,T&`:%/E2`9-E3!4+#BP@L`$=(#C!G@9$)%"D"/ID
M4$<&$`#E1$Q#X53'""Z,4$))7SCQ+GLM$*6!"#MT$>87Y!+AQ0S^#,&I@*#@
M(N"S6W45%EAC16$66F6U_]$&`S2TP08+"80@F%TMS+!77GZ%$.Q?@1$VF6&2
M,?8RS(Y!-MEB,U^F\V8Y((&$:9R=1IIJHZ$V&FL^O`8;:L/5UIMQND'=6W+%
M(0<UU=`AE_5QU5%GG72Y92<V==N)9_;9:$="GGE&=''&3NRY-P"`8H`1000!
MJ&"!@/I1P$(I<SLDX``V%'C@#W2LT@U,)6`00`0%V(!!**10*%$--A1@API9
M\!!``5>T:$/A+[8X0C)ZLI*D@I93?B@#Q2QK#(,.7JF+1V@@N<%$:8@Z%0XX
M9`!`D3A`H,$,8VC`P@\V=&$"YS:H^8@)JXI@U#)HJI"JJJUR;T'VVJO)1Q<9
M?/^@@9@--,1``X=DPP`L(79!`$&QZ((#`!\0<=-^%SUZ48-P6`6%R.$0/SPC
M8&<X@Z8XA1\`"(D!WP!'0/RT@RK$8`GF0`>NFF`F>="J5N_0E0=U92NN&*$@
M`\")%X90`19@P`)=J-`;?K"[937(63@8B`@8P`(0A&0#-6B428HT@`D(S"7,
MBLD-AI"`&5A!`]S8P0CJ("2,-`I>3SP?!@B`@3(LJEE!$<H'()",48S@$!GP
M"`\;L(46X6",#I%B\$[%%:\8(0I1J,=Y+O8$]*RA#320`0WB$K*ZA*`%4(`!
M%/:2LKX`QF4SBZ1A$$.SQ$1&DI/<F64RTS.?D29HJ$G_3=%.(TH?1(TV26O:
M;%B3'!^8,CA7$TYRGD,UK&$-.K3\&BV]%AVPZ7)L8BM;VH9)3.]P@1Z:*@L$
M$O"%,K0A<#LH0`1X@`<]!&`$^0'`5/XS-P!UJ@0(>,,`X""2B51@&-UH``_`
M4(`73$)&8M">"2QPA2L$X)Z-F$0`K@`+$X7S#1.J$(G81X<-?,M"%/(%!4[1
M*6,4]`<(@@-,F(0#^V&I!G"@R:.^D```P&$`P1N>+!KP!2`H@`@40,8UD-*]
M1YQI`J!PD06VU,$W-:%+:`(/'U0U`/-E(!7L*H$$$W"\!+"@!B:0HJ9&$*(P
M>6$,8X`"%)A)@30,0UKGI%;B_P:8#&BHJ`^T4%$,`-3`X:5!FTR$0)T&PH=Z
M<%!Z]6BK/=81#^Z4,(3QV-4)=T@$*X0#`D7L@D/I4%`T+"M4#LQ`+3H%`H.B
M@05I2)0_JKH2:7CD74,`2**<:`4OO*\C97`4!682$Z+B)`,3X(.]LE5:?WVC
M!-P4P1G^X(=S1(-%6W@2N6!++[6L:P3NL&,4JF"$*OP!"Q8;`<;"@($U#&$-
M)U!"$`"#%T2>C"\I>V1A7H:8[LZL,8T)0A`$$X3';/=EXK5,$3"3&0=TD@,Y
M&`U\.;":I*G&:/<MVF\$P,I3!D<VR.EO+7NSM>@HQSIA2\[5MI;+7@*S.@Y^
M<#"+2?_A"@^B'G@<P3*'$-J$B"!"5YCGAS"0#6V^IYMS"Q[F4@>@_JBB!C5X
MPSWSIH("%`!$)'+1Z$;'B2Y=`0%)8@(3@(B`"<V-''/;$8]VQ((!I"$F'^X(
M.9-$0Q`\N9D"$<-_P`6DE#R9/2I)8QD8<*@$*&`,;A@"C'%!@,Y5XDT34.LI
M6M4$\&5A>]SIH)>8`8"<G`*"3&(F41%&+-.A901B&("B-&`%J":@`@R:'470
MF88*+*A"78U&%_Y`BS^HZ!8-/%^H(JBQ`2R#'GZH;??Z<"MXQ.,2F(C$/>CJ
M"%N!)0K2P,%-8I(1"%5!!`$D+!UZ$!>A:L1/(BA!#^'@(/;_U(0]8MH)!*K:
M*`HPD=%#X88;%R7:F!!L!E8"V!E3G($V9&`4;&P1B7'@(E>8`J38`H=^OL"I
M)[C`MV5`EQ&\\A4,1^$,#EEN%^:R!NE2]Y!Y6>3)_`*8!=B,N]V->&(FWAB8
MQ6R[.#-`>LT0A$TZ`#,<"#E\Y2N:4+H&OTECFF^:)N!5QK(#+5?P;WQI8-PT
M^&NV=`YQ&BSAGOO\.<*TL-#-1@(]NH!\"6`2!#P\@3S,<SX%F$`VBE("%(-T
M%$ZR`1Y<Y*(KV$`1)/I<WN`TXQC9P.RD(Y$)^-F`#:@!08@#086>))`^#6`B
M(='=DY9IE!#A8,H;>-*R2D+4,K`1_Z0,&N2/OGPE_.!@3J,(4[F$M8$`M$CM
M+9T>^2IZ!15LSA*8,`&;7*I/-$D/$EWX5`;\A!]V09$]P0+L0`J2%J7LIR8(
MJ\`&?H"&QG[+G#>$-!QPD0Q]C,`/">3#IP$DO/,!J0Q#&`*IG!$#/"[!#]V+
MAPIR)>M;U=75W;^K$<J"`R\0H5P9,G45G'R,&O3^6AS]0JG\A`&7\`XFWJZ)
M!O)=!0U#P(K65EKDH@%',58.U"C+]'H=50*G\Q_DT"(M@@<2B`=;$"T`$BK.
M-A1$H`!6(GW@<`U+0!9\@P-;P6\3$P6<=@UH$05A,`$R$`(WL`8HP#+5=5UZ
MX4C:=5Z,T?]=9L"#X"5>Y74S0@@S#E=>Z848[&49[Q4:0[,:H71?*1=*_34U
M_&4U4`,=+S=+NT1S$(9@4X-@O10V6?-S9`A,03=T:.@=Y3$61A`#]P,!TN=A
M`W$%!3`']+$#GN)`5==-P,,I3C)38O`X$:`&(*(+-N`Y^T0"`5`X,[0Z_X0,
MY"`C-;![0*1D%<$N#;`W$)!W;Z<&@<<`U<8`>&`(#4!85E95:;`O^]<`8M``
MI5)IO=!L&J`APS`J,?8&%6`POP('"-`,7:`).R4)DW`%M^`B\T1K<)(]=R8]
MU`,);X*'YX-L:60\2==$,T`!ZV,"`*</#F01SY8&>6=8N8,@@0?_*1_A"Y-B
M+"/0!V[C:?J08GTF)!2`$TG')`VP`W]`#T;@)B!D*[06:R140J[2!/>P!-B@
M`58R+B4P`>N7!L?0>\Q&$_$"`#FT0[S@$U?D;$0%`.@R`E[D*&#4+N0"!!S9
M?V?$+J1R;I5S*'[B(K"06RPP#*5&(2PPCV?F%#"0DV-@!4,`$W0R`$_P%0:9
M'ZL7!6#A%6%A!%CP'P^Q!"PX`4I`%RA@2`@G53:(@RVS71*G,SZ821SW,C$S
M&>(UE1K7<4B8A)L1<DS8A*XD2JL!&SZ@7U4#',?1-#/7'+4DAKC$A0Q&2S:W
MEV*(<Q%6AH0Y'6>8AHCY"#NE)B:T`PR@_TVO!2!,)4T1(!\6@!]E\).@!E+7
M`"`6``N>8P.+V")B\'6*P`.HB0H(\'9(@@!;X"VK<"<2H60U4%`;``="E2VF
MYHJYHSL[@IO>]CXV(`*3V`LVY!/C4@9;P`2N"`'5<A$P@1-O@0/>@`BH0`%`
MD)U>4`&M4`M[1@(60`#W@0N%8@+)"#Z7T!WGF29]H!2KAPK32%4)<'Y+IT,B
M@`5*P4/+]`45`"X^!`=.H'M(@B`@\`L9$BH+0SU=D")GD"+1@'5>)"14`D6D
M@@%%QP?#Q2JB1URME@X>!)#=]X]W13'2``&_PDQC-@%9D&P!A`81R5$UD3Q#
ML@6A`"0WT"PP.O\N'-D%)+84^E):?584.001ZI$,J;`%;:0+,M(I#C,,)<!1
M&GB-Q[`%%>`%4A4L5E`R5L!,4$J1U/`5Z)$-4Q$#1\EO[N`'`-(%3MD56Q"5
M!Y=P5GF#6"F5D#1)/,B52-@8ER%>93DS?+H816"6ZY6$[L49:UDTJ,$:;KE?
M<:D:QD&%=VF%!E9+?9E+OM2%8/.7O'2IA=FIV7&8B9F&.\4%N^("?.`)$=0P
MDUF9\J$"F*E-WK299\0`)J(+-4"<R'"+,2(&%L`#6;`%C:4[Y2013\)N-O`D
M;0=1;[<[5@1;%&@@_KDL$U$23T1&D@,"=`!`@Q=_[<$*-/H-E=8-HN+_0&("
M;\,3/##A!?W``C%"#DBQ`WZP`V*5:Q-P!9[S9J?7)F_B)1RT#FKB"?4I=1D0
M)`!0$N#V:#4R$*'0`)'%GW3@HC?T!1\!`D#FB<!)!*.R>GY"`-#`CGW@!P\*
M/!%J$02C`=*G`3D4`WZ0H:XV0NQ0#Q[ZH0%)#S'K""0J($`P`XRB(7C`HN:T
M+T,`I2C;(@)2`OKB(`)()V>`#O>1+?K1'BIY"BI2!3O`!Y]IJS#Y(S94`GUF
M,."F`&>VI?Z3HS-1MKR6$:<E`D'I%>B!F238%69J!"F8'DX9!G&``6Y*,GH1
MIR@SIP\'<44P!9K4@SUXENK5IQIG&'RJ<8;+_UXY\'&AT1E-F*A+,QI-0[E2
M4S4%9JECV+G+P9?8H4MZ"6&>6KIF&*JHZU)%%Q8$X`FCHE9V4@N".`<1H`)\
MXT"1!VJG<@BE"6.[TQ^F$$X_\`:BPP-;L'O>,J"WV0W:M`4\\"0U`%%5-JW,
M!%N%PP!T\`,@0`.09F4Y*GL-4`+%8$[-1E3@=(CBE"W!(`X>,0J3$SS.J2#7
M0@0Y2P%REZ8J4EM5P"9((0978`$[P)`M=2;HJ88$3`(80%'D$#Q<FW0GD;.6
MY@H)9`I+\@7@N#NW^0564"[KTP`4L2"]<UK>-`$<VP7CXP<,VH>?`@`7T6?^
ML$Q#4BOI0$*L-E>MEO\K=]4=]T`Q^[`-9]L`>/`D_=$@^\(>!/,!BM4GTP:2
M.:H!11%8SS"K"4$A22H&>%`%SP`1NKL01`4!W;LD'\!9P8(P5'4#I74#,J`#
MQKDLD$(!V<(`M+`$_-:V^<%N$D,Q;3@WT%"W=YNW57F5./BWW]5=4^`!.O-Q
MES&HA)L8'6>$0*BXZG7(CXL9/A,TI.2HE0M@K<$:7UB7DQJ8G\R7DWIS8O-+
M8%C*IIO*VI&ZJ<N87,%%PE,&\L=TLPL&+X`-F4F1Q$<+M`!2"'"L%0!1W[([
M=[<!;Y!;>&"\D[A[G:B]O8.-6V`#][',#")\^/(%[[,+(!!WYA1&LY@GQ5/_
M:>?$`-FD31\V4X$R#=&2"A,0,*TW%7L'`%9259@V$`;,`R1B`>OY9K)"".`3
M/H]`/I]P"O@A5*-R$O3+G0X!$11R+P[Y>VH``N<W`P!@:340*HVU)!G!*;Y(
M`%A,`"H+TK9P"U0T/*%"C\9347S0!Q9D#J)7PZ%J0L7%H?7PCJ9EP0RP!<\J
MOOT#HS$Q)UH!LGP3:$;<!IS"$ED,@4BZU$AJ.>R3'QQ5,.>W0I56$E#$*'"8
M$D3\/]+ZF\]I55.,U"P8!UZ!#:*"6G*;5.>0:R-P07S<`%-9@SFY<%A9IW8:
M<87L`7KM<8.;R$`(A&9`&4&P7H;;7CSC2?AE<G#I_QJ7^TH)IG,V][D%YF"!
M"9A[&;J#.9BA.S::K<JGR\JAZLJ"0#[:-,L`,@&"6)EV0&*Y3&:ZT,Y8@`4D
MA@%7$+YT<`%[P)H(,#?D7%%@(J`(XI_,-FWK\W5MM[QP\+!`XFT_=:O]25@N
M*HL$F#F6%RI+%SQII)(L\1`QD`>=ES=21"@L`7`A50>962HS\&A"Q0(5.`'Q
MVHS).&-CQR7=\<^@-ST#C(=T8A73."I>!&Z61GTC\-3%$!+9>IM4A24%\`,L
MX)QT(%'G=-0/X=%;H2(>K5HD?=XG?=5$8'C0P++@IX_N4,,A5+,$V8\PNX_S
M4--G-)])YQ8X@*00Y&7[PO]1^%,'&/`':]T,W43%","K\FI!L;`%.Z0Q3&02
MZ[,@#$`NS+3!"0.21YX2Q\!EL6-#/6(,%E(MPT"<8A#`.Z`FFE+6PB,5Z&("
ML,"CG=+6U<>"7B$""U"#@'P761F6.VBX>JW7#F#(AKTS'X<8?]UQ'"<9B:S(
M[O5QA7K)]P5@*3=SS/&%/+=SG3O9E"VZ$?9+GGWII@NJH&UA9@*S;@B92W?:
M*G`WJIUHK6VD`X$4]]$`M9T!<*`&%X`@<Z`&=,<0$V"\I4B)``2@,0%8)A*L
MO?=^2$MO*C6QU7((N0P!&\(#JC(YW@0@J.._(.T.6$`"]10B_]$IT`X\P],^
M);#_*$^F`17P!B2RSU\""=1#/?MJ>OE*5]EC")^P$IW"+J];)6E`Y$@QX!`T
MON#RH_('6T#V`Z[8GU;69.[[#'R`Q<45`VWH!]@0:A9L/+]B/&3$!WR@XZQ"
M#W)UPQ]:5S;LH>P@%B%4JFWK1>!P$FV@TUO`).SB13CQ#:"@(M!P#DFE"TR-
MI*;`/D)56O0+55;`GW`@`^^RI3+!:_Z3!C0P+&G00S"V(\<)*;`#(*G@;I9C
M([Q*(C:@`N/'@OL``.9"#C!&HZ-0?4Z)1^?!`&\.I]?EMSHH<8*+YYGA`>TU
M]XB\287;@V5I&4:(&81KZ(9:J)XQ2HC*2F20-*R42Y'Z_^B,?MF/3;I>TS68
M'OFIK.F;7F&D^LJ&4-JAC@MT>#>6.0"Y7'7!0Q7()@(\(`:_\`-S,*`"+U1U
M4@,%(`;8*MSOAZ-C5@.R/XDTE*TX&A2$(SE.&J[8'1`K$3"_.$\GPD^1*`L`
M#!%I,>"J@"/L`SS,IR[BFT;=8`Q,!`>FJ8;V/0EX%@GF#O[I^0BVX!Z'8M#?
M4!,P0`.Y90)V)SS%4"T:#`3F4B0U4&02Y9`3`0@L`R4X&#LQ?GU+?'TQ!#$Q
M70,B.&4`7VDE&C,:$%X:`UVB73%5)@0$3:JKJ*T$1K"QL:^NKBXNL`0F)K)&
M72(9&D-?"0E##%MB#6T9.#@9;?\,#343.R9\554Q$Q@-(@-M$&40)0,-W0QE
M&I]61$16"5].%6E?\DYI%?3Z<'#Z:?G@@$!#!T2_?_I8P&DPC9H8#"(:3)@(
M<0(/&V*V-!C1)4R8)R)^01#68`L(%@QPA,02I:6+*'Y&M`G1H@44&#!JZ@S!
M,\2"GRB"!C5`U$"1HT6FF/'`U$$.!TZ?0IWJP(P9J&:*6"UB($@0JV:^8M4*
M-<=3LSDX'#BP@NT!M2L$R"5#1D!<`1TD2.C0`:_>OWSU\LTK^&_AO80!&]Z[
MN+'CQY`C2YY,.?*.6I@S:][,N7-F$D9N&>$CHDR9+V7*B<!@H4"$"&#`!!`!
M`0``<B7_,DR:M&/$@"LV&#CY,4?-CQ\(&I2``(%!C0(6&M`I.-!@&@H4OC3'
M,*'!@!H_-ABL0`&"/0H8>`0P@0$#`P:31$0\)\8"'UA\"%P)`%Q9Q$GG8#!"
M#&<,4(%`T]$!!P,E2.-,!N0PL)"!%'@Q`P7GD)(?`22HX.&''I*0!0FM-$'"
MB2>"J"()37Q&8FG;88##<J:9IP$,%&RQA043##!`;0<.5`$Q,T!P70D@U``"
M"`D6)(@SK$'RB!]\G-&(*/)58EL)%&A`A`9?<#+`(=F@TJ*99[XR2XFKJ.)*
M+['@8D0ML9P!3#%XPM.&"!/U.8&.$XC!37OR#7#=#0D0`80"_PI804$%UD%0
MS##$W(,/`S2T00,(.J)AD$`'(=0/DTJ"4!(&6P0JQJH6M&H!)1C@80$>W4VS
M104T.('#`$\\,<((530@*88@5-#&GEU$$88+851AA`D])F#333!`45-///T$
ME%!%(974%%,PY4%94J$EU5160:755EI]!=95[Y9%KEILM;666G+-U9</<A'&
MEU^&!8988HWY2S!C`5>F\,(,-RS999Y%+/'$FG&AI@L$C%#'):E-,H(%8+@6
M6P`80`A`&3B\MYL(O0T@!@\L.+%!<>'54`&7Y;F<$1T;(+"!@@!EET`9#5C`
M@S(#F*K/>PPZ9X$*39BP0P`V6&!#'O\[J%I?'GXLL40,.YQ1`P)DUR`"@PVN
MMD,>,AZHC]LEQ"U?;@"4,"&$"7CAQ1`UV-#ABBBJ0H(%)EB0A8H@GJC9B4T@
MK@(&9=2ATC?/U&9>`C!\41*/@S"7!AQHH`&'$_8`]`62#8"@Q@47&%=L2@-@
M8$(DCS@R8!6B^(B#;9UT2807Q6C`P`X[9&,*+[V@V::;J.32F6ASG@*+:%WX
M1HP5V,^0``1M?(=`=P,PT(8S\(6?`0`::%!,.\`70\%UX^3S-CWYI('/_&B0
M_6D_#.3#T/];J,$;;$#`JKFJ@%93SQ7<LP4;O`$!/6`!#29(`QG(H`+R$<$(
MEF`$#$CJ!A/_'-^`_*`LCV1C`B(8`K5J8BUL96M;W"**M\(E+JJ8ZX9.P<I5
MJ@(OL+@K73S<8;DX@(2UU,M>;,%+O^JB+\'TA6"#<6)D\B*PA`'F8`[+HA:W
M:!B(4>R+8-R,$4@DBS.<#S6Z&<`(3!``D87,/;4I0_E69B<<U"``#9#9',)3
MD*`Q9P`3F<8&!BFZZY0G`1E`0`%"%AWXI(XA[4'`%:#6!-R1(`"85,$?SL`=
M;ISA#",X`Q;.P)`:#!(!-8`#0')3B![9C3SS,`AV=$,)!C`G`_#I'P7REH!D
M>+$5C'-<XA27"A:AR'&L<`4&ZH`R#0Y@1I8C!@R\4(&B]0A"[X-4_R&=@!V`
M0*H"-6"=<13TI-7,K@L$$`4?.**+&!3*-+U+0/KR1@0(<&0)9:H%\S"3O#=E
M)C1RV@7R8A&#$=#&2S/`WA<HD-#WE4`=C)H!)OQ1`F(4XP8WL,<-*'"#(6"'
M2]I<TI(:H)`C,:`""DF2DO[WOQK41U`3.$7C5&`''MA4/9BT`R;;:`/EL.`D
M%;"@$RQX@J*R8`LC>,(2PF"$"3#@"R"L9DRK4,(P1`$2+!A""W"2DYU@2UL+
M$`H*BF(4I-!P*C?D@%K-P@&T4`5=[PH+6'2(5JG0RX@KR*N]!$"&OO#U7U7<
M"\"D2-@I3@:+7$RL8BOSRS`Z]K%-D$4,2O]P">WXB$\!>`T8Y@"&'FG);I>=
M!$0*@<<T;&"<UL'.Z3!0-8B``)44S0`K62L;3-J`&Q,8H`6N`!P;\"`+)JA>
MH-XPP#S4X'\^XDX>V+:0D2[)'S<[60/$(((2'`@-&S@.'6X9.Q_5I@3G^-$F
M8#`#%DS$!"GZD!U6Y`H3H>AO@&/<\E9QHAB<#Y??8(#);#0&+["@;SN@1-P^
M)Q"#+`D@!Z$`'-2@!D\9Q#OFP("@N.,-#"274#ZR!)@DE3[L$2$#,37"\OS9
MF3:I"4YP:EXOHO`K''A)?0E`E!LXD3Y%`6%OC[J./8RD#V[B0\?O\P<<QD:=
M\52@?_"9SS3ZM*K_)A,0.*TZW$XQ*0<;,.'*5R8;V7I0@1LX@09K"',0E$!F
M)7A%!A+Q0VB,$).(2%AZ45A"2ZKPIP&HD*O6\NH+M15#&9JU*75MJUH'O58<
M4B6N<\VA$)]BAAS<"Z\^T&M<Z**O)T)QL(2%XF(WS>E.=_&QH`;CAEH4"S\P
MH++-F<0$,OL:SIK@F<P$K8\<28D&\``#%<CN!CRU("XU1PP%*``/4.@CAA1[
M-2IX`8@P:8'ZD,`%?,@#M/HD(`R8,KLUZT?XI"$H'X5JI/T;"0`:<(419*`"
M=#C.KN%`@9,5`M9E,,<@-*``G)2W:O%-48=(!%]DRI=-Z551$_RPN^9X_T._
MS+3'BUF``$%1XAG6!=T@LTN'"CC!'_*HCD%\!"`1'/<]<6/0^T[ZS`%H.![R
M](*'(<`=4QBA#_<Q0IGF--]]GK@7D15Q9&^.XCB#1!T:L((]JA5C"@Q!;PEX
M7QIH,*P@U2"5;S/DYUC`@FF@DB$'B;#6++`#"[P713B=LGHN@@<$:(3J5->!
MVM6.A!.4F<Q>,0"WO+(&9)B@"A[).U,!&H:OT?E/-,!<5W72@J^"=2C=FJ&X
MQA5H0A,:+6TURUNWDFC)U]4J]TK+`:C@@TCG=2Y,)(-@J_C$@B%V,:?WM.I7
M_YC&AOKUGB$U+/HP`%0G.3TBF\,<+#"`#&2@#O^@3<FNLC0`&[@'!!N`.LAQ
MF9[8!-OX#4```0=XA4L&0`4I"@`/KO`&,5PA#V+H_M,ES/74Z1J52H*#^5H9
MOGY@]P=J0("OA]8`MEG7.O;`QQ<TD`&#4@("N!0^7S`&,P`%8^`<$Q`#`G4*
M_:8B;"(X7]>`C),*:9(*!&!RNH$.OJ<=(S$#1(`D$B8CT$0!V*5KQX$&GV-D
M3`("3F!=[T$>#2(IVH$/)4!@WP`,Z),^Z:-R'@@*$Y`-SE-S-_>`-8=B*98+
ML;`$OO(C'P`F5C`#7B`/_R`__N!-D#(=3V<J%-4@`U!UI50V%,$=WL<#*F!3
M*I`%64"&U[=]!(1E3`#_03W0`VS``D$U06&V!C)05$7U=EYQ`RCP$S11$]AC
M!?R'`:&A=SXG"F"S"W_"`FTP`PH`!7FF9X<G5F3E+4500U'!5FIE1)Y(1&V%
M!&YU+HBVB3=T`F:Q%D_!`7<1:6S!+W315X(A%ZB7>I)ABZR7BZOG>K#7BZZP
M(624"Z6Q8\/'6B(3`7.0!93P>VD$.QGT'LUF#OEU6?)AC'8@9040`-WG6^&G
M'A^2(LUV'#]0`-SW0,=U#MP@`C]E*JEC*N8#`"#V*@P``L=A'#]0`SH6#RXS
M`3A`8/7P*-D!CP*"@])`4E\`!`4(!"60#$9#AL*$?>W5@(@C7V?B7OU&`*71
M_PS>\`S8Q&%$0`%C$XVRQ1P%EFX3MR33X0\$,22?<QT`43_8\6,MJ`_/1`GH
M\P%-F#X)Y05E(`(64('1,U"R4'-I8H1K0B>R@`5*.`(0$0SQ8`\Q1F#\\#;]
M(!!9^#_?$&%/%WX#5$!?YR&8I!XU]5M5(RAGAU)LD)9IJ78G0%1M269["'=Q
M!XB!R%5C,`:*`@`#$`/,DG<M`0DQ(`9X4'9;X(@)``612'@N!$.(=XG?0D/C
M8BZ$9D14\(EOD1:1YU9!Q$,Y((HWE`-%540'D(IQT0$^@%=X$8NS>#"!M3"X
MJ(NPN6F\Z(NT:28G1@"0$P\=LQJM`1LC(R,9,`YSI/\[NE,X8=APJT)<-K!(
M6=`$V*B-8H`1T2F=NT4"MP8>#*8&;T`'*[4@L6-A!R(0"'`<-K,<\-A`U85\
M/P`T01,\)5`#[O$H0J9*V:$!1+.,$#`-U;4)5@`%,Y`&TA>!J!!P#_DA%@F!
M,R5P_R8L&FEAN6$>'`8$7S`V`J0<<0,!%$`#UZ5K`S%(*@D'"]4/5O@/V2$/
MYP$0SF!0&C9/"8`]]BD"=P<)?I`(?7`*[35B1ND\K6"$?=`'*_:7U?,C>+)0
M\O."*K,0Y_!T2MH>8G@%V_<TRR9V-\4$5I9E/4!2:$=!++!V;*>'<>D50>"'
M&!44"Q"(+:`WGZ`^M]$,H9#_#?CT<GS@*EG`!#U0++LT`UREF(875I8H0V65
MB8MGBI.Y%E10F4:D%J)XF3@$1&4ABF5!1&9Q`DC0%O3"+WUA+Z6IFG[%FK'9
MJ9[*,+-9F["7'\&(,1ZDF[3T,6X$&]=T,@R0E<]$2S@P`1CA6YF5C38`'#C5
MG"H0`%E@-,=19;K%I#%E`=8FCLFW)"B5!LW1?2GS?@QVC[:$&PU@?-+P7*4C
M-/+TGCLP``LU#_[`3?O7DQ#1>RDS"1"04&,``PD@$5U@#0PHD1\RH!,HK\,T
M@>V%FQ""`^'UH%\P!'FC`!HP9--0+#68'4-`A:'3#RF)<0GP39GPDB5J40OE
M@LG5_P"FD8,ZF#XL5SRTH#S[E&*8T28YVD])Z#5+P!'4)0[,T2`5P''FL&1:
MDZN\13@$X'69!);75X9E^2<:L05Q&+1IB79;R@)YR'9M%Y=F8&9!`(@[`55A
M"K!#X%%,$V'<80VN@(998&405)@TH%4W07C7LJ=\VIA^=A2!&A6.1YF%6JB;
M9T1(@*ALI9E742Z.:A9%)(HGX!9KL0*6:A=Y9:ET045X\9J?>KB(JQ>A*JJ@
MQ@>D>C$$8$:W40:T!*-@\!J^V:W!B3(PZPRKH4;-UI#9V'U<V2H.F07M`7_B
M2#9O<%SR$4CM2`<^\S.8\J\,@`!X\![991R\5@_;@R&W)?\"RGID[U&B\C2K
M%Y@``4$/I"-/>@D1IY8!'E<#%$`$8X"0U%0?AW,XPN1>Q?20[V5B%AF^33`!
MP2F]#LH<*&<%!$@!5/<>+ZEC\B`_\_,V]@"Q$3M@7!(WY1$A\*$2&F.>ZT"(
M10*CJ&"CLW"4).8F)8MB)G9B7M,27[,-6#D?Q%H?-,M;O2IVVF<#'8Q`$X:E
M1S9!%;!V:JD#2)#"*1R72B`#<HE1>((G2`<!%,0`:*<C6S"8@ZD'/*P'<J`'
M.@Q!;*!V%M117B").U%X+N03?&:VB7<49T4NF-F)F]>V5*!7;GL`<:O%:7&W
M:'4"C\J)HIG"]=*W^2(`GI>:HN?_1(:;N&[<J8O+N(]%JJ`1&@2P`P4'@/$Q
M`:Z!N6#0K3@0:QSW<")0(#Z9G&(P?A+V0-]C-"I@K."!K`6A$247C4F3;MFY
M`=-:#CO2`.C6,\4B$/6@I@RP*B(0*O[``+ODGA.`FYY##W&S?^E3")00;\<E
M7HH"#RQ0'P+E"L=4H%#C(@GJ(1`H7Q/P4!EP#O^W?W@R!@+;(%P2O_*K=%$G
MKA``.@NB#]9U9/H@6P\*@"HC6KB4#ANKES%U"*10"KS0/#?*<T:93"`[8LWC
M$GN'.ZJ"G,O%*C<U9=FH?1=ACCBLI$]WEO6+4ES:I5YJ9F7J$T.`4=@QM4.@
M*4Q3=3I2_Q(3@`<]+`<:W<-8)L1T"&8WL-!BJ\0T\54O)%9C159G"\6`!GF#
M:L4P?<652<9OD<+F0BYUY6A:[(E^BYIGS"^I&3"M^<9$C;AQ+,>/U2&O@`M]
M<&HLN\>LIEDDX"._)T?4N"L%4GP/038,\0T8X#.M*V%'@P$3)X[W>&3MA@,$
ME#*[&Q[*"J'.P0.IY*%!,CK%0`P9D"J])Y7T("GR!`IBH`(]Q4RRY7L0(EN%
M;%#/P#24A9#;FBK%:J\&JD\LH@H3&3@MXEZ-HPHF$+VQ4\LM"CQ/Z`5*!Q#]
M4X/2+,W800X"P<VI_+(JDQ+A'!&K48VR94LP)KW5`*]S8IMO8O^4($N!\NS;
M"T@\AT`@,;`LN9`U31:=DQ0`&BT'!1#=%R&=W$!2N')202)22T*')Z`#;>F6
MX6U!8891&`6P[1/1)\4"&<0=.HP'6=##/+S1<N"&<J@#1FM!31N(2US2_+W$
ME=AG3_QGC*>V@UK%/E"HG7?%*\#@GK@6GGFW=ZMY#]ZWG=<6?ILO^U*X4#34
M1?WAL7G42!U&2KUF?&!R._:J(1'5L$$"WQ"<`"`-[6%0H>0C&#&/QE$VIVQ*
MQ\5:RL`SIY6=%>=KI<P#)#5QGGP0`(M(18,`<)!=O$8/JUP,W]$C99!-_\!A
MG<!:7F<"OC$?\@%)>5!0/Z*7J:0)%\+_;B6``&;X6QP2@96-?9B-V:P0O@I:
MV1=X&]]I2U]@!7H##YBP2B^)VC4X/R<UZ`U2M>]QKI<5($S:28-"&];5)<K+
M&B0B4,9C/'Y@/',2"_(LA!6("L3C)TS69`F("S'1'EN```.DG--G=C@<ZPPA
M"%17OT2+=D%E03+@!.?=T!M%09D2#>7#WB61PSH<W_$=W<J.97$XAT9+`^>]
MT#RA9TM,TOW=Q`(^X$FAB2Y-Q5;,+VTK%YZ75Q4NBGGK%$C0J*+)MQ8^[D#]
M+QR^Q@/3QB!>[XHEXB-.,7R@.$;`5!AY&MJAXEW``Y>K62KPXJ;!`)UT!CN`
M!>XT`,25`6GP_P-[D,G>H7[ET&S2`'_&L6NBTTT5(`8!<%SAH4J@`P)I,`S;
M$SNIA'P_4RS,JG!E<$<!(`8#4`RX@3/D8%YB<`A_P`<J4+,/01&'0#FZT0#/
MH`X75Q[)L`O$8Z.2S2*4+=F4A*\6*`*WH?#ND0%]#H5#VDW:_38@QS3PP3^Y
M43[&-LC=@`%GL-M9HRK$,P(A-PCHPP*G$*.`60I5H&:P0)1$B2(';-QO7^K$
M]0;U:!S:F`=S<@;.,",_Q=7>(`*X,D'6I1#M6)5P0(<79$$%+0.YX@3BN@[J
M0\,H=2IG(`JF0`!:FP5VT/JN;P?+3J=#:[1AZK0CW1/63NW]O6=EF__2B7>V
MX,+M:UO%5IPOA?K3Y(Y76DS&GBD5Z\Z*=M&W?AMIG6>I@\'AB1%%]K[]NHCO
M^2XQ=-SO<R(LDPO`K-''(R,)E2!'_\/V#"\)?3,`(%GQ'+\!-_-'T=@`V(8&
M^@`((!447Q`E-0%B#3\_((YP%4X07U]E`Q,8#"6/%14E$`"A)1,!*CP3##@,
M`P,B(@T--6\6)D:V)%=7-F(3K#@X(EU=(@,99749FAI#:0D)#6([!-,JU=;5
M)-E-!$U-)-?@*MXDW=OCW>`C`&49KS@0"58S7@E>0#-?:6D,JP-P#:P&\.,W
M`&"K!A@2)GR%X16O"3LB3IBHL.$`'!=QE"C_XX5!E8\?39B8-JV<R9/94I*@
M%6VBRXEBWMBPP4B-34:,-B"H@:'!A&DC,H#Z0(]"!18#]77J!*>ITTYIH-*@
M,(0"C:M8:;39VN87/Q8-MHC!0S9+%FMVTJ:5PY8M$R8]>K!AP4+&FALW%H38
MR[>OW[^`^RX83+@PBL.'#2A67*1QXRD>(DMVD",'A\L<#AR@PKFS@,^?5X#^
M[&.%Z0.G-:M&4IFRZ@.9!:Q`;=J'`-N@.^C>O5N";PFZ?PL?3KRX\>/(DRM?
MSKRY<^+22$J?3KVZ]>O8J_.9MCV;D3`NFF#(D*!2NQ$C3!2($`','#"]<)0I
M4R(5,%==_(C`$``#_P40>^SQPTUP4&!(`S;PL$4-&]"!!@MPT`%"&A000L$`
M8BA"QP8<3E@A(84T<(48Q1@R$`[&L"."&";L()(%,&9AP0X39&@!#P14$4,7
M,=`XP1N\-(`#`!I8,H((\F4@$#\04.!$>370,HU(61"04A/A9"D..26-HZ4W
MVY"`P7PX^#0`!!I804\"&K0)P3X#M>+**\00,T!#(M08D8MBN-++)9@DA-Z@
MKQSI2I*LT%?%26!VH])9V4Q#BT0OP10333CAI,8/'-)1`R=+\=/`-!C@0$$"
M"A!!A`8T=,)`!?K$&E532\$:*U5>$)$`!#2\2A=8"DU@@5E9Z*&''6P=J_\6
MLG+H\18><M%EUPU#)!`888'MU<*V?^G%5V'@+H""N(@AMMABCD$F660.4(99
M9IMQ-MJ\G^E&6FWXOJ89$OPB0=MLHI5FFFCU=B``;[P1U\%S##?L\,,01QQ=
M=A17;+%VVQ'`!Q^1NN`"`1.44)Z*Z*G'GGM@F'`1!$VFHB0Q(_"Q7P`APZ'&
M')O^0,<@+`]@00$[;8"&(R"@`0>%E$"P8B\1-@B))$-0,DHI?6K"0`-UPH(!
MBR94T0<?-@0@M@H3O*+U!#&D[0<&!=6`P-L-4-`F`Q9E4$(Q]5&8P`P:L+`%
M!C&T:,(W6JJ@TN'DH`-.XH9?6<X$&0``3$,0S##_@Q7.1)V`4?]H75%""&&-
MR0A[[N"'"7T6Q,#+!V6-D$+$_'(G!BPO:A*7TZ%.Z4L9ON$[IIDR\H9.GX)`
M*U2RZL,/'"-E,L0,8ZB9@!.UIN$$54VZ&BL#:92@BD89)(-0C3!:@(TI<C#;
MEEM,"!$7&VSH4!<-=PWA;;9[%8;__H(99FZYB3F7`1Q3!'5-IEV6P4R\/$,O
M,I#!7J-9@6WR-9O5]&M@`R/-;0AV,(35RS@+BY@(1TC"$C)G8A=+H0JMLS'N
M<(P$!/`8`<3```!4`@(#*%D`3M8>E;VC#!#@!T:.E)Y7\("&%5##'C8EH4%(
M#0,V0``(Z$#%#0A"'R""_\`$;/"&!C``#L:#RB<,@8$K&,X$%HBB3,20$#'D
M(1<P]%H,:I2A70B)94K"`!;R8`)B-``2$!+$%P!0@IX4@QU7&\`GK'"/`2``
M(C(B@#7,TCC$$4Y+EB1'.+`$.0T$D7+.P$L;!L("$-2@!BZ)2!XB$HT=-.0,
M1SK#&7;4A0EL`4D""6(J"N(*K9TR(F=(""9X`8H8;&-*(FG1'+L0S#9>"G@W
MP0GQ'/%'2"!O(-R+%5/`"(<!=*$*$\"!!F"`.7HXH9202,,7O#`/^L1I`'1Y
M'1W%<",>V%,M<A!;`-K"!++T8`MS8<$)E!"$@HZK6WK1GU\4^BW^76LP`!2@
M1/\9DZYUM8LR";S,`N5%+P$X$(+VDJ!L1`,PS<PF!_ZBC0]*@QO0^,!>"#/8
MP8!CPIK:]*8U1>$*=\I3Z:3$""XP`@%$L(Y"%&0$$U`!&)8ZAPADX2(9J$,0
M63&GK;6"B_RXB12/=KTOE,`G&)ABIZY8H4'BP`8%*(`-,N&].<$"J5<(0#;0
MJ,\`7`$3\^1%#*+PAPG$`@$<LN(DYO-53+!"$!0H004@82"E$2-R98(#`Q*+
MJAE4H`<8R,]'IG')PCG*45<J'#8BQ4D(?."3+$B&G!HP`@RX)$-NS(-L5YDA
M0V+D(ON!""8`$KX29."V^SE#1%Z4C6N<0@PUR(`&ML;_"[85I">PB(7;WA`\
M3DT3!-4,U4#J,Y"E-,41;N,0(VH0#)#AX`-`T(`S-)`/?GQ"`^N`P.2$,1$3
MX&%8W[AG``JP/CF\10@`AI\.D"`#)1`T"(CQUF``<[^',C0$"W8HA!?L/Q1,
M5*($-*`''"`%*51&@1NEPF@<2&(2RQ2"&YP@!BOXKY6NM&"YB6EO?!,<G-KX
MQCA.CDY[RN,5>L<6!!C!?"AQM09T@01@:`][>(`D'-2A#G)R14'^-!.!,`(!
MU:00(1B``#M6P)1A+$%B?\L?L17@%*++T!N+>X55UI*>]+0`&^W4MAT803]@
M))HC*`0/#7`YG&G(\X;04($$_P!1R@,@;"<^X04W*.`&;)C`$YX0`RN)MARA
M_1)H+=F-(V;@M%_%&E(C@H6-\:%%+D(U,$<`D-49(QEYU*U?F^P*U^Y`ML4E
M`0\:ATQ%B``.7]#``$[Y*:=(]HO@)7;QGN(J;,+I54YI@"G#NX%,1?,'713!
M#DB@,@VL:AU`Q,B<<@L1*W76#M<(``^:]9;WQ8\U#B#HN<KU8`GG+UP4SM_^
M\%UA"Y^K"!=.%V3:U>$/*[`S'/U,B1?NP(,]L(,O'BE+*RA!D8YF-QWL3<*$
M4^,<>_SC-MYQCT=>L6QXS`@D&$$=AGRU\J)LJ?VYR),90.=6.%<F`ZA`M8OM
M"9;A$/^M`>AB0+!&U4OPH!36L"LOW!@3/JYR(EU`*G5Q@H!$&^)N&.A#%U[E
M":4P%DU$H``"3*`1$`36:'+S9$$N,I\O%D@#7FAT`M!@`5A6VMR<+:YHK3$.
MDGP6'"91`=E/*]\MI+)TNW-),)$4OI6SK#YYS!`::3$1&-DSUY+*$$6$68,&
MO/<+7_Y4L;5,`:4TN[O8[*Y33$D'P-;$)K"/IN]V<DJ`8(`;!&`;05YA>!CI
M(D'5"(`=D`[X_-H@6C(H<$$7`T``1KC!$N8WN/2-/W#1.Z+_;LP`MU_1#7/8
MX`='^(@97N+=/!#C+K6-BV<SP986S&`(HW''00CR^MO_82+_)[G^I9,Q*W'!
M%D)U!BGB52RP'WSP<F!0`/$Q<P%Q$6MW"38@$%3D%)H@%(7$`PFH5F4##7(&
M6Q:`;BI`22H0`+N``&^``,(4*+30$P@@35CV"5]@:`-`(SG7"6*U`846;%X`
M`5NP`\5`*T[P!5%#`:&02%#%#WJC`3.@``D`!Q.`'EW0!R/16>%P.)6D#9IF
M$@2`<A8P`!]0!JL`#:,S**T5*)\3.[=5$*^S'Q9P!<5U>;I6/BW27)^#`:=D
M@F]0`\W`7HJ%/"!2(250`LJ#3=X%1C5019H2>["'$R=X2J!3AUNSA=N`.G64
M(*505V.C;M?`!9S(!00`(PBP!2RP_P8%%00"9(K.-WW49V_W)GVK2'WA$E'F
M@F$$5(N-(1F5D5'AQT`*1WX+%W_P)U.C(3#J9QLP%5/`$1PS!D(A='_.^(S(
MD7_[MW\9\T(`2``Q(!^3T`:M,`)]D&1+U1XD@B+(X`L.&!!EY%Q+P@]2!D7"
M-X(%0((V(F<V(()5<A:HDRD;`!#[(3HF`!!P,#3?E4Y?0`0?P``1H5@;@A,U
MP`"%X`Q?D"<BT"0)H"J;<ST`D`!T$SOLL`\EX&V6XP45@#;2X%F9=&FXPPTH
M\0U7(`(:\`'#MA!SLEH\$2R5,@&3EP79$$EF<4PBX2.06`-B\#9OXSM&N0$U
M4`$QR"9?D/]8@?B4@:@\B_5=U/9ZBGAM)_@VQ%81EF(#'=B&/!!XIE!764(L
M,#(2,>0"X$$`>""*,A`$!>08S'<8X?(MSP=]#B5]SV>7^-9\%C:+%&6+4S`%
M9C`%!<0N&(491Z`:O-B+Y->,'Y4PO!%C'2`PI/%2QYB,(31_-%8<R[@<S0B-
MHFE3TCB-)+<=&_,-30!D?6!U1L5:._`"/`0&78@BX6..&<$*9;16T45L"%!'
M8V,-ZW%$<D8^Y<,#WT`"$]""BU@#`K$D6R,DLP)&&P)L>T,$6B0&@H@&#@("
MW"-F,3@W90-$E$`)UG,JA(2&0(1%F5,M<"`&,-0U4W@X37`6GG7_#I8$>%Z2
M!PU0!AIP'T6'$0CAB+])3SJ97R,H-O9T!6<)=5T`B7:X$W;H.QRBE<3V"$BC
M7F\B*[629PQ2;5>)E5FI;*=D*1[H>V:T:R2P`UF`=&FA`B^0H/:$G)&"3`20
M3&BY,5A@`0@P%V\9EP"G&*F(+0ME;PREET<*47Y9+O.&+K980!K&+KFHF`B7
M<(ZY<!)`!L,1?YHI8[*!F>]78S/&F32E,*&9')]9IJ.YIOAGFFY*$JC9!ZH)
M9`20:)0`AB(P`C$@FTH&!BUIFU#VG%`U)[D`(Y;(`VF4"V.3!5@2@D=W=%RT
M$X%"/A/@-E1'3;`"`64@`A8P'FF`!M66_Q,Y&(,0L#6#P)X:4'J$$`\:4`$F
M,"8;6B'60PF[0G0B8($5,@GAF0880"-I4P665C@P-!V?Y0U9HA(DD0UYH`CB
MQA`*L70(``<9@"#V=`VZ`".:1Z(U"0O*II4(("%3A%W8E5W-)F:$\";&QA0@
M`%BANHB,2)0D:J(Q49QBD`MNF"6EL`,6``8Q&J/%)2-2`J<;(Z<DT$+(A$8]
MH`,#!9?:)Z3C0BX/>Y>LV#](RF\3!K%^*4`-.T!/&J63`7X<4*56ZHO(,:8R
M%E(=-%,;EZ9;RC!G:K+-^+*_<:9L6K,2L`.FEK,ZN[,\V[,^^[,]JS'5:&YT
M*@)#AJ<C<`8J</\R,#<"OW";-9=#1_(-;;A?ZI9&NT!/9G06G<J<-]%Y/`$0
MT-`3G5,T&P("3?D%'X`#;)0!.L<IQJ-E2UFJ%M``E.`DE.`$L^H,33@B:**J
M^M!5GL1:;`=$8L8FY9$`)8``,*)W5SBL>9<2^CFL]!FYB=.H'1AG]GITBH`!
M)4`$#)"U=/@Y=VB4.Y%L=PA8-<!L1[,]W,,/4QF[)0`''<(`/;.NWJIL$R&4
M\Y2Y,S$3/'`%1V<!2(6)+Q"<U9`%$9$2?)`V(Y%,J"FT.MJ)02429!&*`S4%
MICB7^':Q=JDM#$:Q>IE@%4LN\Q9`Z&*80<JQ@VF8&G91"/0N(99PY)?_I5I:
MLO(G?S&5<<K8<2RKIIY)?QP'LPOSO_]KLZ.)LT"[P`S<P`OL4R0`9$8PD7=Z
M'F?``^S1'F#0'T];!\#0@%([@RI0/K"U-78$#<)[5PW0@M*TNK"@"0B2"6#D
M>IP"![NBJ0R0(=S#3=UCKDM9!@A2`]DS"*775>$Y`'D`.1^P.;<2@T0``'GJ
M9`#@MH.P*[FZN+30-9ME;E2HG]U0'>/0Q>)0#NE&?-5@`W\"`4```6'[.HX(
M$W@(K\4F7<7S1]FT/=X%7@NI$V\S(1%"!W#P"7?3.=PJKUB;1I#*(D>G3VD5
MCQ,1CR-8K=R&EC>:HSO@O#<:M'S@`IQX<O8%_RUL4&!R:0!T2:03=F\3>['\
M5LKT5K'H*Z0:"Z6&J1CMZP&#N2X;EHO@-[_CQW!9"IK)J+\G*Z:A2:8`/+,%
M3+/!C,P:-\S^Z[^@J<PW9LP>I\`.?,W8W,#)2@)!90NT8T,D<P8DD,%+!09=
M\+1`9(Y(DJ<SV&:5VGD&(0ODM1_UB@GL*EY65`&V"P`#L%9E$JH2`@DTD#08
M8@$3J;<4$A5I<`.4T"8X4*GP@$74@S29,RJ=JEQ>!8,)L`XEP,X:\2JG4AX-
M_0PND4QBW)/'1!V*PW>-FB4M70T\X)78"A.E$CFI2DW2IJVG]`C_$+N+Q0K:
M,YU%PYU5%*HNJ!,-8/\W<6(VPM0[,V&OPHN)8@,C^U4`QQN/`?`"(M$XM#`I
MY38EJ-DC(M%_TJNS'G/6:`0M.O"CZ_NPJHS*<%U]XXNQ2UK*Y$(83,H83IIA
MD3$%`Z0NMVQ1\2N_5=K+OMP<FYF_P\QQ+<L<RNB9Q.S,S=R_SZPP`RS-)<29
MF)UCUIS-GOW9/&MRMM`$.S`D\X%#2?LS3`L?3[L.JT5$2'(&5Y`)"*`&M"<0
ML0`0.`!%/;&0`[(I$R)F9?#0O1`+A-8DL1*#7[#;LYT!45$A>AN$B0L`&^F?
MR`T5IP)?#/`3*Y$)J@!/KR"4;\`VL2,R,[`J$%D(6R#3?/<H9J&2*[UWH@7_
M0UY-$29*$PC``&50'D:AS]!F;,>C"0JM3:SP#\1&!]55H9[R*;!`57:8U$IB
M<[!51[E0K8Q<SDOU`B^PP8N<!<F4:O(I'2W2!=(PUM/@!VDC#3"4,4*ELP"(
M!2Y0:G(FBJ3(O=W;BM^+4-)7USP>L>0+F(_QI(<I!;9\F(*-0"![&>)GV`Y$
M0OVKOXX-S,?<I5VZV,+,I<O,L@<,V2Y+S??7`9T-VF+^V5;2S4W0A?.1S@UP
M!NH!CDMET,7@VJ^3$#$P`G<RVQ```C?1(?X@K9O*1@Q0`[_-*:L[1G?#"[]&
M>E'A1(70#JY4`M%=>EA$JQF``3!"5!R].O.Q#M,J_P8$X")RAK6_.Q-L)"=@
M1P3TT"0@@B&\H$Q\(%2$8Y_R+:P,6IR8<(<QX3O5Q2D[LY3\77K.ECRPRTV+
MM2$@>FV$SN`&H<Z]Q%RN]2(6D`V[-H(;GH$8#@;78)^3;`(/.A&I-B4D80([
M$@,<PP=^P#%]D.(YRN)&D+,B_LER81?,IXJJK)?B&XL]GN_-!U&Q/)CI4E&5
M8<OO2QF)F4"+N5'S<M@XY>66W=AFNJ7.+`22N9DRQLS"S,P,#_'/D?$Y]K)A
M/N8@[[,NU$*>"(`&709W2G.D$P!N#@8VP'AM9W/"M`/H<04(X-P;L$0#\@.!
MO!%_O@4#8';5%JU0X7,Y;/\##8`F32GI2),T^Y%H3"PKJTK=]7I$(N!;:6C@
M758*V8"U0%(#6P`0;=5:_4D$0(#J;<(FWM8&8@$150#KLYZ@UN"&<O@0K]4[
MNSY[#'X\>A,/^>"ZV^0(&W+/GH+@^BA%L-!-('P0KG6B-A!7WT"6"8KAD(P-
MD[(G:-0B+B$,)#XXU,$'.\`C(V%J!:LVE6P".=ON[DX2%G"]=8%@Y$OOK5B^
M_5;7%R9`&4O*_K;74/H8[0L9"63+B(E1(,O+H$&R-F;,\]?,^7OQSQQ3`!;]
M*RO9U(^,B-TPR\^F'Q_RW&]J`MM"A@.`)-"?-B0Y>3H!&/AR6<!XQJ`1S1HS
M9R#_`EQT)F@035:T.@?2^M5$18(`"!45:11?7Q`--C6&:8U.%(\W7PDE&#LB
M$%9?%(V%"1H:&0TF)CL[8J@VJCP!K5<V;V(3&#4-@R44`!\?&FD-(Q,-&D`S
M7E9>7@F&E`@\/`1\!$TJU-74K0'5)!;<J+(3$ZAOXS_EYC\;&W0U(`UP@O"#
MC0QI$`"@%()P<"`U-0AOSI7;@,`?"'X']U48P(#!`!$B,&#HXLT""1(J>%1K
M]:)C@1<!.K[0MLV4A1TF3H*;T*7+#FXJP7698,H$`1-\^-@L%6,'@8O0^/0Q
MU8>/!5(X<RI=RL>(43QX>K!8$P0%B@58LX;8FG7!UA!8_Z^&%=LUJ]6S:*T:
M6,NVK5NV:5$8"/*VB%V[4_(6F>*AKP<I.3@(]NO!08[#@A,?H<*XL8#'9")+
MEBRALN7+F#-KUMRA`V?/E3MWMBP:=&G1I$]W?NS#A^K7L&.KWLR9MNW0H"6,
MOLV[=^\=3(,+'TZ\N'&F!((JO6BD.0D,]KX`*"$"&`\P$<!H#X!A`(X,94HT
M?`AQQQD1>6P,@`!"C1IT("J4*`&A1"(+#5C0H0.BD2!"AV3`P!8#))#&._(\
M8L@7`^QP11X-0*`!!`TQ(%X%#=1@PQ7.K!*`*F)@T$`##)4X(AQI3)(`!%]H
M```$<$R4!P8:$)'`C4-\D6.+7_]L8<-1/VU$#0]9P&2"-^!X,TY``KV!0$$@
M)!1/!172TT@:#.@C7T,05``"&G2DLX$_2Q8T(D-94@G'B"/6X`TJ%O!P448:
M40-22"*-E(T*%_5)@BD[L+022H*RY!()*4TPPD0C=($4*3=%$T,,?BAE$P%^
M3-H'"3H]:EQ*44V%%E9?:?456%U9-59<8K'ZUEIW%?%J6VD98$9=>AF0UZZ%
M]0588CDXT)=A@27&P0&-,?:8`),UZ]NSF^6&V6ZZE5:M;*H)H>VVW';K[;;8
MRO:LM=7V=EIJTT*KKFT=`'?<N_#&^RY&1KC@`@$QX%"&(10\U`4)$00<<`$[
M##!`!M/_+?30""+$<)X85S2007OOU8`B(1!0B(`-(ZJ3QHLE-))Q&3BX.4!X
M\'0"0!D48J"*#02<!XPW-O!0#@^P/.F/+0T-X<4,,VCPA1,5[).B,A3,9R$#
M<(A0Q7-E`&'%,1HD8$R-"6S!@P5X9%&D!3_&(L:39"\I$#H$K2,EE59>.4^%
M^C30SS_I[*<.E5%FV(["!O=ML`@-8)`D"<D%:8T*'.5Y.$FDU/3H#C.!8XK@
MI;04`TW@[-1%HX*B%"E./%6:%#29NI2<4C=YR@476&#AE!%<2T476::>"A:J
M"["JNZNSQNK[K&K!JI=:001AQA1K\468`PY(81@'BQW!@12`_R%V[`'()@M9
MLY%)0,:ZX--&;;C8;MO#D][DH?XX9".PW[>G=8L:^+&9>RYNZ(9O;FWMRNO_
M__[#B+WNE2\`&`("#\$`";`3,#`4@`\B\,Z+%`81$9SA#`.`6(3:\X.#5,`)
M:7!"QG"0(1%XZ6*WH``%(%"&`;SA"F(0008V@:7YE&``#1!#S8C4IRL$X!7C
MJ,6(6)"E*#&@#!.2D-`.P8G_J#!I:;@%`G]A!!),``)`&`/0B$"$&5BA1AI@
MP09B,8$M2$0B_OC'V7Z@LW8@"!YMPQ(]X%8TA-!M`^5PCSG&Z*0*4,AO#,`!
M>3)4@W"\;(=[LI-(''B-D?#I(I=*SO].:-*%&"#E)SRI)$I,T))`N:0G-Z&)
M)SM)@!U<;B<VB8%+DI(33/6D4J=KI:=RP@47-"<:>-B"J,1BNU[B+G>ZHY5<
MXM*[6.U*+[*:%5OVXH%D%L%X4[@+7YA'/>HQ+S"+H<(!./`\P6`O6<IB%O>^
MYSW]F1,WN2'?:[:%!C3TX'RQL$`>^.`"H[S)20BHV[>$,#]S8@M_T_IG:J1U
M3FKI)C/I=!<`%\K0X/RD7O?RP\D.F$`",!`[!2``1/35I094,"+=F0!W,@"'
M#:!H$""L1PL!(K$,A*QH`&)A"33$@RM8,8(Y7$4!`N`,KN%A`CLC$0,H@,0/
M?"&*481#"<K_P+(G(E6%)2A:E!+"D`S4`0<8$(,)+B(&!E3M1LA8!M`HL*8(
MXI"03TI'078&AP&P36E9<EM#]&%'.N03CVMD7U!IT9T,X)`6;GJ3&%C!"FP$
MH``[=>3AY.2G4@`*.*DS@2HA9\E'2792-$$*.,[0*,>10I4N:<D$;!*HT=[$
ME)N,!C1,$0/5(N=1T&B=4XQB@2W0X`9EZ64+3F66LRCSMW7QW3'[@DR[*).9
MS;2+&8(@*V82JYJ'L5YCMIF8;SIF>^,\9_C4&:YOO?-\`,$#-PHG%,M"!2IC
M(]L&#*H_[HYF-K.YUD`)&E#[C8^^\^M?0_?;T*U"U"DBV-<A&!`1_Q,4`#L(
M)@'##M91\D2$1!B(&(7\B-1&T`<1/"@`QQ!&(0LEC0$9LH%A"\"#L3&)C378
MPA8\*@(CKK`,]U!&?2ILH0O!PV@0^#`(".+&0`I2<&)X9,$$;+4$W.`&"?#B
M4>$X)3A6Z<ERO#$__'%7O)Z#?6OUQQG],0N)H&(6.D0D-L!6@`@@=CN)?"3A
M4@>HQEEN)JBL'&L[A9-1.NJTI=V<)2!5RI9HT@03L.1-*BGG2/&!<*;LB6MS
M<DO8$L`(?^A#2BS0`QH,055>.54+-KU;K@`S>+#"2W'OLDS?2?.8>2&,!XI[
MW+\DURYT*<*PGA?=Z"J&"@+09G6SMRQQ<O]/N[XQC6?(MT]O]8`.X.V!V"H"
M6Q/TH0JR1`K7O`$5,3'AVDR`EGOC*]#=O&:^]V-7/\=]/_WR]]S^VRH![&4$
M`D3H@`3&@`GLH)UZJX"S,BQ#T?P601)R#,;U,5H:+ERR5FRM`0W)T),"(@?$
M&AQL;Q"B.^JQB2PA!`XKS#$4_^.?*1\$!/M)B'^H1$@6)S`<%K`IH@/\U:H9
MP@M$T,2"GDCSD;,M372-4@W"9&4]EN,-!%FK&<](BW"(X0VK^%&<1GQ@!R+X
M&JVH1A,B6S@V]V2RK.U)322)6E-:5K*5--UI1:NH$7B.<"P![58!O4G(D9*5
M?$!MI9!C+SKCY);_!.!&#2J`V]R1ZBM>L%UOVR+J5!,7U8A/O*H7S^K>N=K4
MTVQ>L8Q%>5SG&GO6]<&RQMD]8'\&?^HL=K>0C3Y4X,$F3.F#I+]>+^44);*D
M."]4TKH!?@Y[V[BO7[C`W4_QU>]:L%$HNH?_J:TVH5[MQL`,64A"#%1!!?7>
MSN9&H*\T`-)"96#`.%C`U(:4P*5*2\1.#_NA)_U`CV):*RT*,@`;\F@3\?`P
MEK!4QUN(IP%C3..30(`FA_RU!N,`5*G`#5&G%-#Q53F2`%9`!%)S(T(#56XC
M9?LP-W>U1C\71&DD$8$#9$<'-C5S6..'6$T7?20(!B.Q9K#W=9'4.#T!_W:L
MY3F0`CDO""F.U4D^P68SX7:!YA.!8@J!)CD\(6@QT"C)H5")!DO*D1-UURF,
MUF[=P`)]]W<AL&F]]&FAMA?#]1?4LWA<V(5>N&K19%RO,@75%(;)4QB21WEJ
MR`&6EVO@M'G.TGF>%U"A5VSNM!_?139PP@VD$`T#Q&Y.476&)ASDE1.6)0ZT
M)R9B(GKRDWON=1FP08?`YXBB(7S$=XD.91/'UQP$,`$E\`4P9A^6`'US4&\!
M,(34AS+]1U03(D8(D!\L,");0#<_4%@?`C8\$'&SF!\UEB4X5!!*E33S<2`2
MN`]K,E5YPQ!4@D,86`,BXE&!\P]A)F))\$/8D/\$)&8>9U`I&*`O99``.3(#
M,``T,X`T\Y!S_6!7Z6"!/U`F:>2,16=TX^`A3">"29`$]98=+[`=UI`%T!!+
M.S!WAAAGEX(472=:F\1UES,I!5E*DS(I-^AF+L$2P`$Y,M%F+GA:5_=G23$4
M.U`4K92$2Z@^C'83%B`&4-@5OE0JN5-J6>@7U123,ND\S,,\7UB3.`F&I.86
M>R$%T[,K!B!K->F3:WAKN!89CW%=OC89<Y@NDQ@;^Y2'[8,`8B![CM84S1$&
M6OF'[3:0?=@ZK<,I6-D<S?&'ED(*@J6(ZO`^\$-LW()[D/A[3TF)IV&)F'B7
MT9`2QV=+!"`&W@@`HN#_$M>1'?5&``R#`X!));@P!.#(F$-0`370<^[Q'DZ2
M8BM&2"B""Y]P"%]0`FM"(KC01/K@0?N0(6J%`.;P!OSG$"/B9>*P;$@'@O<X
MFTD@,`,3`"&"`6<0`WTP`?IB0%_@!6.@1<:0`&1UC+1X#C[7CA'WCFED=&+@
M@3YTC=@H@B(H,$VG.-0`%"H(DI82'*"#$T$1@RU(2IY#65NGD):S24C12109
M@Q-A2J9U$Y,U:);09RA!`GY02<91+SDQ3]%@!*#"`HRYDBSI6X7G*S.YH#)9
M:SD@DS49+#B9D]%DACRIA5*P:GB!AK]B+-(#/4>0/4<I&;VVE$S9E*`'E=SR
M_UVSJ(>F=WJ7)(A+85E-01RS-!QD698#!);"D1*"E5Y5E@Y"4'N,2)>\1XF,
M6&QVB9>7F#I-P&XW<3(PAE4F46;19Y@15`<N!0$.J`R,Z06/N6-X5)D@0$3C
MT0``L7<JU`E1=&/(.%7[L0X6XXL,(*8+!R5M`A#SN"$!0)O84&:V.9NN\`HA
M8E86%"@3935$,)QC8`7*D`;I:&4#<9K.*8U'AW0B1IWV>(^VV4#W"`;6X">%
MHX(W^BD]RH(],1-%J'4M^#B30FB/XW9:!X-NMTJ>HY&5LTH\$9"3(I!PIQ3^
MR0<`:HBU10,)8*!F$93"11@,&I-%J8;112S1.J'"4O^AT00KPO,7@I&A=H&&
MW:081Q"NX#2BDX%=E(&B1UH:QM8#:K4%5"E>1_$H59"C9#FC-/HN2-$'A4BO
MMY03K?.'`"N@C\(->'"I9-,#2:HM=+FPZIJP^X0&2\JDQ&<3)#!`[19@3(4#
M$Y`'9^`RA*D="K91"/-5R6`(2C8$Q_D.%Z9"FP`"[@,"#%`?66)Q\5%'^#>I
M>/0>/U`+#@:`8E!(7S8!+S2;B,6I`E.;MHE8-84SJO`&P<`F$-$F@C,!,M0B
MQ&`%7G0C7^`E5#:5[Y@D;\`-+\,*U;FIG0H&2=`1VM$1VD!>JT>J7\=?L`0Y
M?B"#<F9*=I=H$`E[HT0HFP3_#J#E$S':9RX1*((FJ]%P'+,UHUP#A;XT%LRE
M/+UB>$3YK#[ID^+ZH<]::QS@H!,:369@!LTUNGQ1N<EE!M0T>2`ZKHY!&9PG
MAYY'!N6SHN!5E04K;9<"K!!E+ZS3.O8*MY!RJE?)%'$+=_^:HZB3=_&*EMXP
ME?ET5TG*L+"1L`@+7J77O#H3L1*+;A1KL8;)0B0##A`A!E:Z'><100CS"<J`
M9%-C"%530QE3'X(0,@I11W/##OMQC"."FF@S$&O5`.[Z)!NB"E=PCZTPFX%J
M9@[W(ZB@?H$UC\V91NTP(NT@.!)3(U_4OBVB`9[))O]`)DM"CP50MM<9,/BX
M2(JE_V86,*HT.$M]:'<TVJ\+]1.N9`HV>#GL&82Z:I`^"&>00PH[R%JF0PI^
MX&8Q4(3@,&C\F83QDA*V)7AA,1?&(RPZ>1>^XJ'9U!CAJKE9O,5;O+D.*J&K
M1ERF)FO4,Q@;>DT>RKKA=*[>([O.0C_Y(QO=DH=6&:.JUX0`R[L\>I9(`:-?
MQ\0PC!3@"<CWJA1<N;BJ][:'J"13Z;!OB7L/JRUT(`3'%J=/<CY:!;>HH+W;
MRU_=NY4$T`4(DP$1(0*"-`$%,`>EJ!T%@P/?\8U:FP!08`5(1@0:D`_&6#0U
M@`;OX!]T<('G5PX(`*?^,*;7FPJ'A9W8B+01<(^(I<`\]?\R>O6,!A.+"N>.
M;E2_5((#9M>-NW`/N)PQ"0``)'1TJO`A8M"GT6R=T=Q`^Z@X0/$3*.B5AYRX
MT(!*,UQUQ4'#,EBKE=5VKRIVJ.I)/I%9%%D3?#!9?0AVJ$2?E21*E!(OIY-W
M*#D$J`(6<B$\QV.A05FZE6N4VI-KQL*Z6TQ=E!?&$HJZ#M#1HFO%VOJ3:6P]
MT/.&O1;';WRBZW)?<]D!*ZJ'4`%;.LH'?\`48`F6\Y2CR0&2P&L3WDF\31W5
M)E`%5,T'?6S50L$4](H%X)D')G!>#9Q/<0K)"1NGFOPF0:V"30B69FD*GXR7
M.%%+6AD&49I]&#`"?U,#/,#*]?;_RK`LRQH`-%Y@LD20#UZBB/"A$"4U$.<P
M)A/\#P!A#H5EG0(S!P_0J236M*B08FZR)'J55CK##O?+#B>RR[@``1I+)!(#
M`"O#,@X!.%M@`;*I8;+=J=AY8&RK9D"A$P$)=WU0Q(-[$XNL%,/]UDIAMV\G
MD7MKD#E(D7@F.:V*$O49=ZW*9SLP`F;G2H+V+A5=K(&7K,P5:E<(TI2GN6SX
MAF1P>=[$QHR!>9@'+)Z+AGT1NK%RQ9V[:L=3&#2=325JKK`+;-ZFHN;3`Z9G
M),Z&E0/T+DG=;I+DG:3:Q%+=U%A]'(`(:4]M=V!]=.K%<W4SUF/M77AH5U,9
MMN)ER)9U_^$!FQ-N;=R7&-<N,-=5U&48$$$)AP!R$'VO;#":R47(`%8W``>^
M#`+G]QX;$!]P0&47"`OX%)L@F+2`>ME.CEBOD#.6.<$4_`]+0A"B[4&C^:;U
MVPDLA$!X8`=V4&(S+@);@'0-Y\YE-@=;$P#1MU,D,<\Y\;:%*+S<>Z.$K!/'
M`9(.>5FTJDH0F9>Y*M$\N)YPECIC9\."V\*(2]V0-1P-;0(,+@8-@-$AX%O!
M-2S.^JS'8M/+HDW6Q<;NC=*=6VL3Z@'TG<:5V])FH-_6PVLW_;ISF%_3.^``
M04\6N[M<V12/-ELIJ-9:O83G=A-&L)4)[L=Q)LA"D<?PLJ/`_O\H09T3?E#M
MC_*CT0D32\WK[+;'`S378=`IR:'41>C)+`Y`+AX%81`%?T`"5W`%EU`=W@%B
M;W!8VF$"?R,"-28A@LT(+LL.>%7,;>6R!<$D&_+N/J0&#[#PEKWPF+W`(/*:
M35N9H=VUE>KE\N`0"-)6%<)O647FB-,*-C!8K!PP)=^I/+!5V[G"RYNOWCD4
MP#VCX'G/R<O/=PF2K]=*/=B#F?20?%#$](DY*%$3;F=*=]:0^-)),;\3#'E9
M*C[12\'LS>&C%7"LJX*@I1M=9UR4F,>ZFK<]E\?>TX4]T'H8J4[?H?OJS0,L
MJGY-TF5YKXO3VA7@V8+K""!>P7%+9.G_NZF7QXQ,\TQ:%!;[/_^X%-4ND,3!
M;K\+^)SL*>-.EHK?A-S^XEC@\D51W"M^[L1'`'^P!$L0!5&`$7Z`W3MP4P;C
M,O@(!EF`R@;S'?-A#\H`0EP;.`&!9>/P[JH`J+9M\@I,8DQ+Y999"^XJJ5K.
M#L;(#V"B-GFSRQD`O@+R$"IF1BCW@4WGSF"0\C8@,-K))ZKE>II_[CB_R*15
MN)<3=BA!9_()D8[EU7X6D(DK''9K^(/^\SU1%*CU_K%T=U,/%3T`"&L+@X0+
M*`9%'E*+C(L<CY"0!Y-4!U275#X^`IQDGF0"*Y,KEYR8IY,<DP>/.:ZO#@YF
ML[0>L:I4'!ZV_PZNCY94`I_#Q)\2Q\C)RLO*'<X2SM'10D(]/0AB8B;;)GS>
MW^#AXN/DY>;GZ.GJZ^SM[NX[.^_S].1^?GQ&2U%12W]\9T;LN$)BQP0,`P9@
MN!*A@`H1&3+@P!$Q`X02:1A4`%&CQILW-@JH&5G`1D@U$6R(X3&GY8.7#QKR
ML($`P<>;-VLBZ-B1SH:?.CLV:``"!!PX%9+":0`G(8.G#)Q&%;$%FXT`!0I$
MV,JUJU<P/.+9X,&#!(&S]=*J7<NGC]L^!/ATV]%E@HDN&&+$\$-@6]\870Q.
M.!O8Q(0N@.7)+9?X;%S$BN/RT0MW<HQNWL[V^6;$B`D+>-@(&A1BT/^A1(H:
M,8H4Z91K39V("?`A"I@IUY58K8+T"I8L6F9BY<"52TJL7JJ`42GF20(Q9M"C
M2YLN38@/--:P:>.&F:WW[^##BV<7;[SY;R8V_UG"?LF(,WYV7(YWY<J$!B(P
M!(CPL(S$A"(,,-$`(B#P`P]810#32P6(88%6*4T@1@0IO"33&SN!,%0-/_W@
M(5`\%<41'37186(-&A[%`@,EE`%`!E,U@,&,&'AD4D@0;M62@A9Z%0$8`:@@
M9%GQ<.?'6VZ=IZ1W<>W05Q>!T5687-O(I]<.)A04@T$C1(G/8O8DQH<?>GT)
M#IDQ\$&"'XAYLYED^73VF1@LW(!"(8=,D5K_:JM%<L2?1^!V"6S",`=**)3<
MYMHJC++6FP-*!'><+\`<(<4N#OR"2:'/1>?I,L]`0UT'G#A#3379X;'-9DNV
MZNJKL'I37JQ,$M#%"".PARL))`0T@04!!&O#0<#R@`&,#8PPP'L!#K#%#UEI
M]4"%+Z70H!A9I50#`@&HX2&&-84(`HDDEL@3BD8=5=100P7XE%,)L;"%&"9E
MRU5+^"[XP(Y;@?'""T*JP&M?53K)S:RT)LR.'R:<)=@$$TB)EGQ18MF78%`&
MQ@Y@@'71<%SW@-,F'_+M@,^;WG1F!`$6(%`G(:?IR:=JD``:J*"9<,*IH:2.
MHC-NM5&Q0FV.NG+<_]&4!I,+IL0%P^FG4#,SZG0"G&K--6*HNDT^?V"A\-=@
MAUT.PF*S@_(9(N3ZAUXD\-!%?A9<8<,5!22!8``V8"""1QC@D':S"(PTQ[0I
M%%YA!`%L,6^XVWZTP4[BBHC&B9$;54$:%%Q4`8$;=F2320AFE>_@"RHX1U=@
M`!FDD&81\)8WV]Q3I&-\H%7V[=[@0T#)4L93F)57-KS-80:U"7+M;9G#,5_D
M$(`F7VBRREEG+&\A`YY%3*']S'UR`"C..NMLZ##.B%)*^`)<,K30EZ2"A"H<
M/-I+#L(-9TGZ'`A'7&S-10UU!\>8&JE,=:IJ9$-K5>A#9[#`0*_A[H$0-/\/
MV2*8CAB\IVM[4<$5ND"@'<R$;EM)0MX2(H8KC"`#N!J0@3S$P@WDI`8;TM"(
MSM61HASEAG!8%[N:)96G-,!&/+"7CD:G+]2E[E\JR$(6S,*=V!U)>N:@75N@
M2,%77>QW$-N2E&(P`2T*SP2]@U+#OF&[<C2)>;`#4V;0)*LMF2E.M;/`%F@`
M,T1LCWLU^QYNT+<SGD4#43D+GP^$-DA-$*U1O'E4TDS1&PZ<;QC^^]2HR%"=
M`EX-`5I;53Y<P,G.5/&3H)S'!$,)CKB<Y1]FZ0,)P*`"$XQ`!!.(%H_4\(8!
MU*$,-2C`&7"`JP$\)2D5H``%2O!+=K%+1,A,9HK_DI(&C"3%F#*:D1A`0A:M
M#`Y?I'M)OKAR1"2R[BS<J,(VJB#./J3G37`*Q_%(&383Z`6,=ME=E*`4/.YP
M#$I8RHQDTOD-E)VI=I(9(V;8Z#R](&^3GI$C'0UAQUW,S$^!^M,>Q3<^\DW'
M!XE"GR8V:DA&K>)]11N.(X,!B@.\`A?\(T,DI3/):5CM&MHQ@2=5QLE.3I&=
M.,WI-T:I4S5Q@00"`VJT>/"9',&D00*:@!HL@"MW0>`+&B""`HB0@"%0H`(Y
M5&:ZCD(4IK"@`E"!"E40,!:R8,6:^#(<-GO4+W_9876\:MT4S6F"!"+I=3T-
MI4'B43+A\>XP=N'.81`C_\;N4"D\\JD=F12S2;G(41"GR1X>\R@H]%7T$\Z@
M)'5JLPD^;G0VM5F%*'B3G).BE!,K0(+]2@')E4I-@!UX:0_F)8;$>C(SWG"@
MFZB8U][BCJ?L9!4!@!JP%^0(##E2T%8*@#>(B0&P&&``!!)`A#',H*H4H$$:
M<F@BRP$3K$J!YE!L`I($[6M?AE/K6ML:K("9Q0(6&*.;[G$RZ;&*M[Z%X.ZT
M^,YNV'-+D!'>8*.TI;C@]SMEBLN5PO%8AF9/3XW(X\U.$;[+6E2`&#W`"OCH
M65'49F@'`.E'*64;3ICTM,9P;3.H4\!38:<'&W@N8M83A7^0HXGYS?'M@!M*
MM_^@A0`J0*)6DGNOF-A+##/ZE4I*H`$KC,$*"?@"!=(`S*S"@450&<"&R`LZ
M>U4+FVN-25O]!3"!T:Z)JWKB376L4\SP-S!H`:-<^GH&C[DS8_,I</+.X\XT
MN8Z+W?C#'SZSA38X&,*.>(0>76/9BG;`$["-!F=U]D=AZ(PV(`8QHT#LBE4X
MS1,KB-_]GJ;B9+"X@`B@0T<@IJK![D6+><C#F,")9C;;6F$\!B4ZCT2"%T3@
M7V#P45>8FY5AB>&L*6$`$68`Y2A?%:PX8(`(V%65SP4Q1]E,;^%<PDW5L6Y@
M990+P]!\S@/?6FQ)(D=?2P8F_W)#BWB6TC:VU(V[FCO_+6SJ`O0@A@^O*=3!
MN^B>1">:4N9D-M+2R/"&!9!9S)**$X9<P48W/30D(&$4"X>T234<FU*;FH`N
MM@8=G/M<B-4%GECBZQ?);=ASN_P\N0[E6>X!Y(:H(-@1R&9#\)8-DU@`6Z?;
M2@`:H`$@:$#*6-60C*9Y%;2V1-OI+=V/F.M>6N>.OE@'!V:V]G)=\_:*6C19
M/_U",))%["XCX"*<Z=*P)R)I/,Z#$EP,LI>566`"%;!3$1+A@$0K&GSBZ^.%
M-8OP#F"TLPV'M#1F\UG::'AHF@CQXS/NC`QO(L4K/34U+EF3"9QA!WD@P5T*
M:X$=8"!B$,-2K;O.>B7%'*=9__)U@G)N."//)%AGG4-6@HU49-DH6-:L%M35
MRE;DEAG<+!=''XZD)'O?N_7J2'<X^FPE)\FE+^*<&,/H@B4\-^R=?;&WDMYY
M=\2LS`1B`,$:$&$&6TC!3X!O=#$0?JK8"L$9H4"\-!S^<(T.#?*.-WF7)VD<
MAWG^HWFH4A/98'+Q1!>7L0UY4#P1HW+<D&ZW!7T8J!:O5T7FE!G;H`([!P9/
M9SA:(&8QD3K+E3HJ.!-R,$3"EU9@UA*I8P=5)T5GPAWNH#(J$PZO@U?CX'S2
MEX'N$(2RPE?<MW5DUX'=T!<0<QA<%%@:LRIW=1Y_$0-X@`=6PC!BT`,R$`22
MDBF*=O\$!S!A%,9'!A=I+59_AJ=_T0`-A#=`<&A(M+$)CO=_`PA`H;!A!A@U
M+D4-;,`&V9$U=:4738AZH!=K>H$%?T!.5<!%JH<9G<%)0CB)HL18.K494/2!
M29`MA*-M)XB"*HB"M#<'4$>*@\--04(660!??C%7RP=%S]<J20*$L4A*]\9/
M/+A;X$"$ZT9O>Y8>FL%U5'(7:6)0=&$FSK=G]7!@\1%/?K`$,=`'/\<&,J`$
MR"%AN$$H%28,4_.&E51`&V4=L"$-`30UI0):$E<UZ/A9H6)XZ1@J!V@J/8`J
MBC,O[X8858)/7,<QJL0'^*1R;K*+E#B0Z["!$61?=,47*I#_!`RI(*68+=>4
M<_I21"'T`G`E5["C2;9&BV_G6VAQ8'#A.H:U?/M$=T98;SR(D-)S,AJ36`96
MBVR1)(;1!9N!!?P@C7C``M4H4DWS&MH8/OU'?VG(43[08N0H*N4X->P(6NSX
M:"H%#9#7AIXR*D*P+0NH;Y[4,1&C8'#&E?@H3RVY%RE)D&2)#@8)0;Q5)5D2
M9$EP+_S2B9ZX%67F7N!&:[,3%Q58EASX@[&(B62'&:P"1E="/&4'#V*Y)0$)
MD]]A3H?1!US@`M!H`GC0`RQP`I:I*?''890V'6G8F9UI?Z.2E`($E(Q7*D<)
M#9IP?P`TE7TX6_.2>FB!)H(1'T72_T;5YX#5-S*NJ)>\*0YG"4K^-3M"!2$P
M47O]DA7!P@.KB&;T!83*V)L49&XA$V[]Y!9D-R:U8TZX23PMIP[XT&=CLA>N
MHYCAL0U0@@5<@`61.9ELH`-(<`(7EYF:J5&>69_4\!/X20W3(9JPM9F$LI_(
MP'CP"!T@EX!;<'H6,QF%@7[T%`]<Z21@N0.8V#&,U9'0V9N_^4`6FI%^T39W
M$RW,I9RK&%]-5"0FP'SW0)X7&ER\A23<<#$&97;\I7KO<#*(*1]\082O<C"(
M@04NT`];\G,UT)XZH`/_)W%$28>-EZ2:@`8O=C50JA-2.J4(\!-74W]JV)\,
MUW_B(Y70,/\;6[IBST!`J5)R8D`";=$[3*B/^=B54G)08E*=.KJB`YFAN..#
M`#6,8/2(++=Z=`I]Z,1N*=F!<V9R6W(E[T1&Z6&8WA"CSWD>1'@PB?BCT.@'
M))`'8H``5_.'?\BD0L"IG\JI\QBE4YH-!P1?>&"JW)&J5S@!BJ.IUF"E&W"?
M/U&?7$IIFH4,#X>&FW<-$F(8@=6H>G$ELPE0#HBH"QJ>B+F+>/JG=6J)EQB$
MW;$96\,-X\:G8Z2BT:>,.HJ)Y#"%TC>GW)INWCJ)&YH['`.MO]BF6T0QZMH.
M9Z$7?Y8FR".NBRFM__4'+K`>2R")IIJIL`JE`CNP,*43VG"%?2K_4]R@3[0&
MK!+B7*`A!EL@(1^1J;$ZJRW664!)2<AP*%3Y4M@@F/JHK!)Z9R<'3HUALC$0
MFV6B?,WJK)-HI[<SA8_*E[M%5]*9.V83D/VDBP?%L\RW9CS+K%`4M&ZB&<SW
MDF!CM$*[%O@5KXA!H<AC)N!T&+@2,1D3A3V[,+43EOC`%^.Y)'A:HEVD6.S!
M28&)?O^:#=JQMFZ['>1F;T80#CK8%@?3162B;[9";VLZ`3H!I4.Y"5X*<O8G
M6XKS*WG@!V<`'R`#&&?`!WD`1B?[%V($M?HV1NS&3^<*LT(HLQIJ7RY[LZXH
MKDVBL_I$#H*F3IE!L_N$G<JXJ.GV8ZY[_R2Q^49Y.IV']36X^[+A$7>!T3%P
M9K>.`488@"LC@`&^$[PCR;7^V`TQ2KOV>AZW5240\WWF5U.>1*T+JZ?;FS)S
M.[<T.SU&8&,-5+X<N@/[8)/L$04,Y`)8H!>#!JP3FZD;<*59BH!"\#@Z48AV
M,1E+@`5S:QDQ<`;1B');(R6_TQA5**&<ZZR>>Z?:N@[+AUMG(IU;%S*K@I<,
MG*=D!";W@!D@$SL9R3`A,R9?HCL@HY()(W8O&<'G`$Y?@IME<F<0>GV&4;PT
MDGI[5:^@2QYI<A>*P7S1.QZ;$<#<4')5XD;FQP<VIH,7.`Y.K*).',!I]`<$
M_+[P\0T=LS)K@_^/Z`<Q4PJE^,D$3*"_-N&V@B$?!!P#?S"WLMD'4M)%!N.N
M)$.A!WPE03O$#9R!#SRSO(MO7Y+"HLNS<48P)[HU>&EU;W2BXS:,&3DF'T-V
M'[P8#$,R59*C/B:2"I.B@RP>^7@9(YNW$)J/KV07)C<")B</>FP.&L,F)[RY
M8IL/'.JP.U!Z6:NWG%%3+K`8L*P.LJ:,._@6"YNW`%97B%$%YM</4>!);/*K
M_WJ%T!S-F=2=`%&,9]#&;L$Q!*.F\_:5_@@E8-L[1KO*>]QZ?5PVY/P.P0G.
MU8D>TF,"D6LQVWO(#5NM\N9N+`<8?UG/:NF/::<9V:F[7Y+.[$#/\L3_5^DJ
M/(DQ%WAQO!&#9#-2%_%`T.+`)IM!%]_@=BZ\C+O81#J,3P<Q`>5`5TTDS#W8
ME[Q+;M5;B%B215%`KVW1L@E;TJSBQ`R$)AW3J&R:QK$SK`^(FPH=&.%*T>5\
M;N?\-5)(175[TLZYM0`U/&GS,7W1L%1R%B0P`:ALR,(XO'C9,#N0-EKM&%.]
M.[A"H_5,,.#T-B,`%T*,U/>UT>=PP)"!CPZ(N11Z&$DF&'J#H`0#UXGE3A7:
MRZXBS-S!T_S+=20]TSB(I_:&@^/`<JD7TC_W7`2<T0;UD<C#0./00)VD,HJ(
M!230!W--8/`$6-97?;0YK.&<8$0+UT6=7T>M_S!;0X1++7[H4*)Z,QCP%&!^
M)=%YH-;T5AZB=QF[<P9=1-Q?+0)Z&KD4^B1I\E>C#!B!%6MZTP7.DZ-?0ZZN
M70[L6F=^<<]R(=U0TH2&8;P8\!G".`]]<*-B2;2Q@I`I`PX[0,#Q4&>+2\!I
M6X&V+0X--*C6V;W3EY=^\`=H8BM=4*B!-3Q3TA;_@(O>\`?20]4A.7<//2.U
M++FHO+"`\9VC)P_CEK*C2]2OS6:Q34'9N]_FP!T$,`%P4Q!O(P(P'E@6!.,B
M<"L`(A!=HB:W$AAZ0^,>LP.X4J(OGC;Q@`$>T^,P+A!W0>.H''I?/0)/%+8)
MH]T2C(GF]M\R/-Z6R_^G"(QZQ7NU@65@]+!\EZ&@WYHPPNC$:Q,#[RO2%G3?
MC.78Z&"^K9W8-U:!X]O&1H`8LDEO>!!?J:??M3A.-$W2)&?DGW'/;2J6\M8D
M"UUOR3CB!%GB.M;8+YK;HE?:+"X"V_!*=0$E/9YZ47W5^2$8SP7CM07C#6.=
M>UT\\1#5@/5*&&`!>WWJ(]`P5:`L$Y#IJUYN+B=/E_%.N(F/@$8PB9%ZM[)@
M;$&;@OFN%$0F]AW928:/9K/=+FM.22(E\9$7F%%]'&U&=4R(6Q+HW6PR^/25
M!>6+DOZGE)YCELX-K\2G>-U!+'[KW,#BY_WJMWYW<`,Q,X+J3[[JYM3C)U?_
M>D0.7_7^&0%R>@@A`JKW-A,0N87N6RNY4Y`1IULT9U^YIUVTX_AD[;!S=MQ7
MLP>IQGAQ>@?QZ9#!/+8[M"[/%N0&/",?/6)N'K))3^XF)F")F.EN,NZV[A?:
M[N[NHK`#Y)Q>):_45")PZKL>7P8_Z^AW\/AN`D@>XT`^`KM%O#2>[P=O]+]B
M`@&B]$IN*["$R(+.9C&<&+W##3@ON0O:S5DK=MX!Q/)T,I\TP>AZ\@B:\OAD
MNN*0NDX]][66;_"DVC\;'BL);QYS15&H[8X>&)6<NT#/FT*?7^]N]*J7\$SE
M\/C.*Y_1^09_ZZ1^>EJ6#7KSZISN/.847W2Q\`&/__DD&N-JZ1>Y7:WE]L>D
MU+IJ3ZS![?:N+J\$0T]Z]AU'N*P@;_,9??*H7#PX;\(O[.!K06ZR,MI^AIW0
M3_SS-!^_"V\6`^PT^LB33_G.7I;V1G-47_:&$=7)C?JH!S$PGG*RKRPSHA`&
M/P"IGOK?R9T(@;Q$#@@8(B,[A28C(A@F)A.&!!@#$P2+BWV6EWR9FIN<G9Z?
MH*&BFGZ9.UTQ.S&IBUU=.R:3,:X3)B2GL)2S.Y.COINK)GXQ?`2_Q\C(?GY]
MIA,8$UTCKZXQB\;-R=J?E-W7IS'1I7S+V=N@YINJA:ZOB[-=M<:J,7[&FI3G
M^OO\_?[_`)$5"DBPX*]+R_\F34@4:P(B$1`)Y9'VL(L)08-V8(0HXM5#CH5&
MC,A4BA''C#M&8$@Y@*,BC2=73H+(:Q&?2Y8,ZO24$YR)72;XF/`Y="BJH*=<
M=9M%+*`?5\.ZV-M)L`\S9^U0%6*U+M2P<55QDLS4!Y>FG#>K?O+I2BB?I$&%
M[>J$B:K=NWCS\ANHMZ\^L900V1J*`9JA1=$,DV"$P2)C:(T(/(-<ZZ>UJX@+
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M(;-,X.<S,`I#DH7@[+@-EDK2D]1W9:4"UI1Z1BKI3DE.&ER$Y.S`3):<XBA*
MIYQN4@H!JO!DZ2=6C8,F.TI]<U1QUMRW"SL65L(40/3$__)44WE.:E4?Q;$C
MTC36,#AA*F;E9-6I_30*VRO-.7HBL]16NT^EUMZU3(.@=@LEHJ#>Y&F$8YX%
M);,$8`H7A4`A!5NQR5'RHZ9P&1-54^<F4^=;J#13;K6I_+F#0\-V84R-'MY6
M#TF]9AM*-E85,EN-ACIL\<6:8(LQ/W_\@>=5O^HEWC[D>NPIQC[&VPJ)L2Q:
M6[P'0V6G19K$<`9W^MBT72F%8FJM5H4-/+!(C:QR'[^OO+GEQL=L9S.03$<=
MM<92;^,Q60V+G.\Q?SPW<K;,&!/;*1-PU4Z'[=HF[ZU1005?<S?WLR8X/*_R
M7\7IJ9C4&2HU0K`T:?)[FVUX;_\\:EJ#VEWUXA=3S3C7.=(U2N&:=(P.Y;\8
M@0V8UJ+UHV/)D>B=34EYIV@N/CHZUY/.[5-4NHJWSJSFY/#K$#3Q$#P-+*P&
M]:YWCZ,J;G=^D%![\,A+ZGCRH%C>R;9;\W$U,AU/3U?TF4O?=9386YK-TQU*
MPTN"CB&E,CQPSOQ=4GW8^]LYP"9$:K\SWBFI$49DDC]F&$PSV@YG:(<U4M*%
M8@SE#&=@%>8<]@>P7&5XRV*>!(VTO`E:,'EHB=8.LK$=UP0P0O-K2NF4X[M7
MS0LYQ)#1H4P!E?K%X![P$9>4@C/#C%%$)(TI&^^J@:QXQ*9L0LG'!8=(1/-4
ML(A(Q-C_=7;VEF*$+@;-D0HIO(,L5@@C6!+STZ)*M3E^;"<3MR+'5"#%&B*9
M`SY)$8D/8Q&.6&6E(232RA632,<Z4NH[=LSCQ:[#NCM9Y7WU^T[;-$6^#?VD
M'7;"@#6`=Q.?Z:-U;_)9#?WR+;"THF\2@X=;"`@+-F5G?0_4HRA'Z8LCDO*4
M10IE5)C!,_O1S0_T.@K2@#04N`1K-XT,I38N08]FA'%3D^Q+)>,7E':4S3-O
MF@T)D=G#8A5B@:B,YA!-*<UJEG%;9-E%JK;#(MB,`Q?K4-3:PJ'#,)Y%ER+*
M!MW>HCA$J0<3%8)-)F&QJUF,PR@[5%@NK,E//5*SGP`M2`8=_[D+55FH.T!R
M39KP"2>DI<)^X(%.?<K20O1Q3TOER8DL+#(?H@A.C(%4:.^F$[F`FC1X_SRI
M2O4A23PICH52$5L+2_$F#[D#:<H45=:0P4%_M3`I$_U:1BV1KE;928<>JLG$
MA#2OI'!KI5"M6DJC2M7)K2:"W1%2(^U6.EH*SBAF8I4\QS*\9I%$G3_M%PR?
MA$Z1U2="55`9OW:HJ"`"18":FI4K_%6.JOHU6U/]JV`?IDIO#NHWW)37V6RJ
M3U6EPWD29>?"P!$CQ&7T)E4`7L)"HS2AX**A70IBRO"%U<&:-DR!/:UJR\HP
M;9+%;?4CD5`LA,;DO!13:(%L0"A+@/]('HZ&6"O&KAH**_-)!2G*[.0LUH1%
M:`G7D:N-[GA2*]W3UH5%K5V8AO!XJT.6R%X0JYYN_Q&Q5#2#LL>S;%]@.946
MU?)=K$(;*DSWJH2%<Q7M"UEU]^L7ZO+WK^R)BJ;L@2:[#4,5G)UO'*$(ICZ(
M=WL`45=%:[13JO14IM]\W[Q,X5X-*?85>3#**FK$VO^:^(XG3G%X-L'6SBX*
MIB3$*2/U2Y8'6X\@%NTL#<UASE.,8$,O1BAMBG-/1'IV0G%3;XJ7?!X\,GFP
M5PTE5KGYS=B=;;8*[F1=?F7C&S?+2NML48K^`YL]D;,1/BJ)PII)0F7.RD_O
MNADTGTSGM3C_N<[651$(L]I7-%5C45"9"S9)P0P;SYFP@W8JTDH!W1.UM1^K
M^MY-::2IF\S"L]LU+DT%",8_X_G3Y_`OJ$T:,GMY!ZUGZ(QGDH9?2SPJ121!
MH"]OAJD'#O30HM"DI9/C/BE:Q:*Q5=6575@S0([ZV*,0-;+YZ:!EM+-1\G!S
M/3"J'LJ28%<]%2.<J,V/*-Z**096ZZYO52@RO:B`,^).;);-[E`HN]W,GJ+]
M_(!FVWZ(K:B]D]+,L:U-$>1>E#8N%`^KG-]E&$B#K++1E`QO=K^[X=%TD+?K
M,R^M;*K1&<WPM-]$8QI'F**K""#%6VCI:<2PQUV(F_&J40XT5:=[_Q!_\L-C
MKL?P0,EI/DT:;7()O7<>+HS'&KB]'DTR7VKE0P4N-F(M_B2\"HZ#[XL0S&F>
MXIE3O8X29TYL>*@=5W.PPL+$R<X.>>Z&]C4@R[K7"/LC%R!I2*MI_M'`R?&^
MJ5]]R5:_.Q)3=<X';L?>O-!VY<"NM0BV"!P>%D8G!4KWHW>A?4VWGW,8+;YQ
M`-+E0]>[PS?HK<Y[_O.@#[WH1T_ZTIO^]*C/(([:=FIQV3KUL)<T+:)!C<L\
M,_4,0VA.8UL/6%(X9B1V,8Q`]*G8&__XR$^^\I?/_-+?OOG0C[[TIT]]V%\I
M/'XW;"YE6/W.9X(6$SO;/G$/4M@Y/CE.6_]X/0JJ<W6WD.]6[;[\YT__^ML_
M.L^_O_[WS__^GXSX$65JFH(0P.1_XK$J:,8W_E,LUE=^C;=4E$=A=)=`F]86
M,A53\!=_!KB!'-B!_I=_'AB"(CB"H;<>#&,.KG9VER!>!CA+N1,-:A0/RD%^
M&>A"D:1H0M84Z!.!4W%V&DB"0!B$0DAZ(#B$1GB$'(@._5:`$+."U:-_/4(+
M07,*J=8%T,!]I8<U_28AVC%?WA&!6R%@AQ53Z<)M/(&$:)B&:%B$:MB&;AA]
M8M)OU]$Q3DB']]<C?D(1A@$H9H*%J+>$JZ(AH[(J+)1DC9<:5X%QU_.&C-B(
M_,>&CAB)DDAZ>(+_@JHA29;`@G>()Q)3&/V3:A,00/'P'WZ((YW25Y@0(=ZE
M2>8G1;$E;\20*L)`=(LXB;9XB\H'B;BXB[P(>CU7BAR8$)^S._TS`=JF*IS0
M,=4!,IE(A[AE1GIE#8"'2P#D:RU7#KV8C=J8?+JXC=[XC4<(4MZ6%;0'"Y=6
M.\O2!U7@,>R%33BAB9?H!U=S+X<T0&2W,"[$+>"XC_PH>MW8CP`9D/S7;\,(
M"[3'<F+$5UV33'?3C'88CU(7B$8%%S!5#.DHD!B9D3CQCQK9D1Z)?*Q4#QME
M3(LP&KP6D8TG3]P"CQ#)05MG$62C'$650L#XD3:IC1QYDSJYDYZWA(U4_R>T
M((-9X766,`L)A%XU^37P)V"J$`VUD"FP)8^_PI-4>8LY6958F96IPE>69!0K
M07O#`D6<-R&OL3!,2$8,<W%W)45$)D/+T#5:&9=M>)5R69<>22YX*2M:`99A
M693TPT.*<Y;1X7?R>#S@AG#SU4B9:'-VV9A!2)>.&9G\:#E]IHKM,`U.*0V-
M,5\#R'KH,Y52.9C_X8P&U87MP&CAL3V2N9HA")FL^9J\R()RR$(X=!P4`3BD
MB'@*UGO_$9J<TG/<=)H)"9O$R8&N69S(V8@VUG.-X@HJ,3!^4C"Q0C<BMC.J
M(IA2@HI+A4=PF9S>:7_'^9WB>82&AHVI,@NU&?\2`G1`QR4,(O$NN-6=X&*>
MW.1@F2"?XYF?T1>>^MF?(=AE6G@5SX!#*4>2G[,R7(>/#M8I7?.+%_>6_AFA
MS,>?$EJA^P>@VJ91?"F*S80<M/%V"[.@OZF,SYBA26FA*/IY%)JB+%I]74:B
MV"@QFNF4\].>*:$(0B&1#`8JF-)`K*0B^-FB0NHM*SJD1JI\+^JCJ5(%.Z1&
M.X1^+^:A(S9MU^B0#3H.2KI]-Q&D1]JE^,=Y7AJF\\=*<I@N@YA7NRDXI"**
M,>5L-6)OO5<(9/J$6\DI#RFF>%H68)JG?-I\9+J$*5B4M^5;.^AL-^,^M%8C
M`[$M=,JE??JH&[FGD#K_J;`'B-##7BDY#H*(4V,H191&6;-8#EU#IY1:JGIJ
MJJAJ>I::@B'I*+"T=2,F1:U4#[NY*',Q@P5XIZG:IT6ZJZ:ZJB&S2N9FEJ?)
M:.A35#\&ABT"/;Z*JKW:K)-JJ>YX@X+(>MM2K87Z%+O#<N8)K9/ZK-[:IX!*
MD-[DIN?F5!'R+`KFBEVUF]T:KKPJJ?`ZKZR*EVZZ0;-:@=KAIO7P.8(4*+`*
M,N]*KT8*K@3KI2W7F:NBJ07::;(Z2$+6;^C#6&_BJ`<KI`9[L48:-LTQ8((F
M..SWL$P!%4A9.E34?BQGL1J+HAF[LBU:@&W#:`*V#*4CLX*VJ2G9>-J!0O*(
M_YTN6Z$M^[,I>JG".2/38$-G8+-'VXJ,]B,1&"L.U;.^*;0L*Z]4^ZO;LE3]
MBE>Q8:Q9X7LDYF<U$DE1>Y\0>K46&K1HZY^7&AL:HK,B^R$T`C4O1B.]1V0]
M*H\JN[;>J;9\FY\)R4XZ]WC,D*U/8ZS3T%>A]7V)NRV(56AON;=_6YQ^.[GB
MR:B%>S/E"B.O>C9@*Z=B:ZX,VR_*V$"D:KGY6;FHFYS5$YKVY`>:2V**9K<\
M8QN(9XCPP(Z2N[I]:[6\*Z:ENY6Q@4!QVK#(*A7E@'Y@ZXI,\0?VLKN_2[F^
M&[U>*I^;@D`E$A4BQR7#1X7Z!A7,P#X$8+I32[WCJ?^ZYEN<;FDSMOL[ARM&
MAVD;(1EUC)J^^HF^]MN8<-D)E99RL2I"73(J`)2T-^%CO7>(8N2CT)N_D8F_
M#"R73_@QL54BP0:5[V-1?P0D#E:Z)_K`DJD*21K"(CS")%S")GS"*)S"*KS"
M+-S"+OS",!S#,AS#\>AFCC=@`.>N,);`=3K#/OS#0!S$0CS$1%S$1JS"JW#$
M2KS$3-S$3OS$4&S$E^B7#T5AG]NYM":Z_1;%7-S%7OS%8!S&79;$8ES&9GS&
M:)S&1;S!XK4J;;*\QOI!?MFFTZ;&=GS'>)S'4$S&>MS'?OS'@`S%I9!R\36W
MP_!!/'B,>AO(C-S(CNS'?/S_R)(\R92,QVS<QHOLHTXU0FU#/X/$5JQ4R:(\
MRJ1LQ)%<RJB<RJKLPY?LHY';,0/A5+KF8ZY88-O$J*N<R[J\R^)URKS\R\"\
MRU:*RZ1IKO)[4%&[JL&\S,S<R+[<S-`<S9.LMYE\C+_SM0XKLX`HS=S<S67\
MS$!LJ6(LSD5,SMXLR-OLR']ZK\!FE,1@NJU[SO)LQN:<RN#\P_7LQ?D<Q/L\
MST?<SWYLJ;;Q)KF;P/Y\T&4,T*)\SSZLT$_LT#(,T0B-S^G<R-):8/#P03PW
MT1S=Q1(MR0P]PQ^]Q"/MPB7=T29=T8Q\T8>,"B-P!AX#SYF,TC3]SRJ-RB$=
MT3?M_]$['<X]7=,B_=-]S-)4&$#*88>O#-1*+<0GS<@Y'<--7<Y"'=1+N-3\
M/-5Z3,Q%N4'VI&U6_=5#'-6`_-0P+*U@;-9$?-%@K=-B/<Y:_152V=9K/=</
MIM:J;&`LG==ZO==\W==^_=>`'=B"/=B$7=B&?=B(G=B*S==)NLBWO-B0'=F2
M/=F47=F6?=F&_:*4C=>8W=F>_=F@'=JB/=J@;<*D?=JHG=JJO=J3K=F3S=FL
M'=NR/=NT7=ND;=JVG=NZO=N\7=BN+=FPW=O"/=S$7=RGC=O&G=S*O=RB_=N1
M'=S,'=W2/=W4/=,B7-W8G=W:;=?+^=J\N=W@'=[BW=S(/?_>YGW>O.W<D`W=
MZ-W>[OW>>GW"\#W?]$W>W0W<WUW?^KW?YEW"XET]40!+H$O--"NGKEP.6)#@
M"N[*57#15=#@C'W@E_T'6-"Z#W[A$`Z($D/,6.#7&6[.TGW?^,W?)%[B)E[=
M'1,%4>`"`H[#!+[A+-@Q"C[C?H#AVU)+-?[@$8[)EDWA%H[A'[X,#2XQ`R;C
M'9[7#I;C/7WB>\W>3/[D4![EGLW@%Y[)'5[E25W5))SC6$[8=3WA/*[E,)K.
M"1[?8W[34BZM3I[F;-[F;A[8)&KCU5/F6"[B22U>*AX%/JKC%<WE0)[/F/WE
M6]QE@+[D8G[F;^YL^9WHC-[HCG[_YR`.X3LPXQ7>NBT^8*T,HQ`^YS,NX;K-
MZ93>Z5<ZZ"2<X.K=Z&O^Z*J^ZB8NZ*3>CI,NZHA^YY9>XZ\\XU%PY.E=X:%N
MY*)^Z"S,ZJG.ZL1>[.]-X:9^Z41.L[!DZEB@YY8.Y'RNX2Z.YPFNXKUNZ@\6
MY+1.V;ZN[3:6ZY6^Y^OX[>`>PL8^[,:^[NR^W76-.MT`+#;!9:2:/MT@*MIF
M"#F>Z>9.Z8+^X79^V#C\[3"*Y]!.HH60XN(^[I@<TP?.[3T>\)GMZL^]Z.U^
M\1B/W7\0!4:@R5[I"HWAB5:H2'U@!#5.49Z8\B(_`9;`I-#I;%:QZ:,:Z@GN
M`A6.[5?*_S"G#M!:WHXS;03J*.V$+N`4CNVFGN2`"/32[NW^K=@[G]CJGO%2
M/_6]S?%_\$*'@`,9``%<W_5<GP%UD`$BL$&Y@`$X4`=UP/5HG_9U4`89@`,B
M4`LI`1&$2^3+/O1?KK`VENR'K8Q%7M</'B<8CC^8G/#BWL94*L"+\.=,O^5.
M/_0C3O62/_G#W;I"(0(`0`0:4`9E\`6>_P6<#P!N+P)B,#!B(`8-D`$```"?
M[_FB7P8`\`$:P`!^,@`X,`#'<1BG?_KZ01_P$2=$7@\/MN"([?>+K.(-5`6,
M(`83(`9X4/HFT.`Q@/R:[.-A'B<FP/O8'_U5O=CEW?>07_&4/__^Y&_;;[$#
M>8`!94`$)=``6_#^\/_^GE@+>*#\%B`&GAC_\%\8`P`(&AH#&"(XA#L3(@V,
MC8Z/#1B2$V*5>7D[.WY^,7^>6*!8?YNDI::GFYZJHZE_45&>?B:*CEMB%CM5
M?:^JJ:*QG%5\F2:SCB(88B:9K:RHS]"DJ]/4T=;/U,#7VZ@Q,=S@X>+CY.7F
MY^CIZNOL[>[O\/'NPSMB.!\96Q/[^A-;_?NZ2!*(@1_`??PH,2`"84LA$1-,
M8(`@J*+%BQH2)/@"H0V#`0UVY"G&IX\?5:%$<<N639HK6)M,-("@46.;!A,T
MG>3%JD\O/U6"[C!A02(.00D$X<"P3.?_3W8L6[9C*8_3MZI8LVK=RK6KUZ]@
MPV:M(FM"F0\-:C`H`X$MA+<0.+XMXW:N1KIPZ98I4:-&&0T-FEJPT```$"`*
M$BN&P1B&XL<*@!`!@$.$2'HH76AV9FK4*CY\C(`>/7K524^\9(D9,.,Q$`@0
M2[[45BHHV:$[1&0@PCCQZV3,3KK@?-KTRJA4BY^:M@UY<=KGO(F=3KVZ]>O8
MLVM'-TH7@2Y_^U(@HL&*^1GH9YA?KT']#,1`QA!9/X,(D3(-$%#0P,($GV*$
M`4#$84!D5-.!![:'6&0?E$&("29]H@H?RWE"5DS%9*)A3L048T(IL_5A@A@L
M>*&8&PH0D0`#_TQ1^)QIMBV#P0`"CF'C&)*U,0$NK<!BFH9.20.-B$T-]:$L
MQ1#IH8N;D/54<"YETZ&'IIBDTVFID.,-<EQVZ:54QWTIYIADEFGFF6BFJ>::
M;+;IIG%AOBEGE^#$8@1X`&RAGQ6">)&`%X#Z&>B@7M0WQ@R$EE=&,AGP=]I0
M#21`(!`#3-#%I9AB>L9#C1(Q!F-$9(`!`49$@<4.&#2"02:B8.%"J568@(<8
M_S3`0@4,Y)IK!2PT\`\>>!3S3:DN@&*""":ZT5AB##4@!AZVN>*J"[S$*D8#
M0Q"A`&,S0,$8$#J:(.$?FK@:QA]=V*I#KUVXT$<5KCACDA%!30#)O?^^_H-`
MAB;8%D488?B1*B-,!752*-2J,@&P6SRR3T'[?&.2B\0U$]66<Z999\8<=^SQ
MQR"'+'*9<8Z<\4KS3O!%GF*TP:<&?FI$Z,R&(AJH1E8L*D:C+/0A2JR1$DB$
M"*0:8?311A/PGP43T/AI8H/X800H&&0`@"`#^'<P3,5LP4(;0[0WH-!$(#I$
M&X@4([4+89C*![*-(3IV@0PLW*\?45!KJA$B-IW`M@I`D<`0RL(`[@1\_.&J
M)^5JYL<`?P*J`0XQO!NO'YIH8@10(B25D>2>(Z71$!"4@`PET%;!M@MG9/!G
M`I7V"V]*473B!QY;B$!1`@`X.,(((@0OP@C_E?O1Q_&H>(FQR5QNS/SST$<O
M_?0<ETR]QLV-8H19>2+0!J(PPPQHV?799[Y];MCHAAM0()I`SHSRY_,H,DD:
M&1$-6(!\E?W&0-0$#-"`8H"0`<3U@0\C*,."<&`\XY&E&$W[B[8D@Y&Y2:8,
M#'!6OUZ"A;=IH#$K:H,&"*0!!MA"=J\PG@5H%4`">:$-+*"!MPRGH\0MCEQX
M<Q4&R@`9``1F!XISAN;H)0)M*<!&AQF0?29%0@SB!`^-2Z!B2A"1H'SB5.\*
MRA9:*!D`L&@'70C>`,9XAC_$8`<E25Z7EG<]Z$2CC7",HQSG:#+KT?%+QY$:
M]_3DLCY%KC[K(]``_X&0OC&L#P;N:U#\>J:2^BUH:&+8Q/&.IXHLGM$"$QD@
M!%:U`\(H$`9C&,`W8B0&W8VP0&7(``."UP@1#(`!5OM`$AT4D>(00`0?=$P"
M_L$``2D1`I4JRC<@.(!LS;)28I#AMVHH(<SYH8,3P($2QT8$*HIK.*P`8G>*
M>!@-4"!7.`@G.#.0@;\(;441R841$J@L(#!@*$'IPS>,Q+0!0,`+72R!!F?Q
M.U<2CQXF42.7V-A&Y]WQH`A-J$+!9(V%XC%[>BP#R_H(,YF]YS!N,!\A`ZD^
M]B529SP+HBR"=C\1B.$;*<'"*V`A%`),H`W;PM$FAT(823%&E%F<!>2.6?\0
M``%H,"ML0"_'5L()$,`G1KBE!CX%@UUFH900D"5B2FB+H="*!B9*S`Q@8P(7
MQ$"9-(Q(,S7Q!T<6:#_=-"D?PJ"29\;B6$9,0`-F50P"9"@1A6@#/AW#'V7$
M:H>,&<,[-6&;H!0#`PRP0A)ALZ-E#,,;$?M#&J_4F35V0HX&=:AF-\M9YMFQ
MLV[$AO;VV+*7":I0&$V/:HE02/*!#WX[XX](S2H9$6QPI?]J&[4D28(N0,`W
M0+!F,;`%!,;@8`<$&`H><+E89PVF*3&(5:R(PC01*+";`U"&\8R`2Q#.M2@-
M.`J!/@`!9UUK-[XI(5-.L@,:-.9PXA+I4+97@@G_4J`&]3U,`?E@*L]4$JY0
MRY^'3'")*4V@!#-X6D/J"EA0OC,/0#'L+'27X,DL11E'2B-)?+(_T0[TLG',
M+&A'3.(2G^FSH,WC]B3*1_"=]CUEFUFATF<S+UC!"XI:)"CH%S0WU%9V``LR
MP#0#BDO@,C(*F$'6/!2IQ,!@`%A8!NX@0*`O:#!6$2YLC([:71L-8;U&ZRYC
MY-JO8JQ&4O!)``L8\#??J#DB/G'!#A@P0S>$:ZP[:,(6VJP!$1`FJS-H0!^*
M-8THR$($8PAP)3!WO#0BB584>%I?3="$!H=R!WW(1:PPV4)0`K.*!G/C'WR2
MI0I]>(XB-K&J5\WJIS24_]4J)JW+K/"Z/Y7/?0<JE*=PK9$<QY8%.Q[IWQ"#
MOZ+T032@0?8!1U)*!=YODP38!`$:P,-M0=FJ`P!T!<20"^/IY'A5B.Z%_,"'
M":3!4X>J&P'^P-U<*B`!!=NT(NYY&`442C%>T&<Q@F($.=,95.%ZIDJ,M)#$
M0/NE*%*`CGY!25<<.M$*``PNG!2O[JBF1,RB(A\(L,/BNC,3_C,&1;I)@Y#L
MVXJ>L%+R/(P<@EXOU:V.N<PWB^+.QIK%I?V<H-!7XT'5;%`X`RE_=@RTOZ$H
MT,K(A9DK(09^"!7-0)A!!AH@-5APO-H*&`"Y:`6!A`]A"R:(@1%6X9.HF&#/
M@/_[\KK;#3AXW\VP+$3S8Q)0@0GD87/P&C4`9P"J`D8[B)FP`-J3/`!-R"2K
M7A`!N2/L"7H="^*`2:XNQKY2OF$.#T$[C,8)<`9G?[S,B#TE>5D`:ML<3!2D
M/DGV3HW9FL_\];`/\>I5??.)EL?6Z,EH1E6[VD.EA];O$SH+@ECTQK2``F-\
MI:XJ@"L&M($FK1$<,-?+BSQT/#$,'%&3$],&L%?AAEV:10;PW0"E<?<#BO$A
MA"P4*SQ,@`40,"(1AF#2/$SKK7OO>RU5<48Q%/PW[S(BOY48!90)*!<%L8)H
M`39QBJ,9/$$NN#,$251`6,`%G;<@#'`+\S8V5E`"&`#_+,M@,*<1"A7S:JPG
M>[,7>RJX@B^7@B56>WPD.6/#+#Z&(O4V*1V%2'X"6R$U',47-S/P`1_`>[F7
M<(&3`$Z`$X,1&IY@?<X&`]DW`16`3XB1@1"2-U\2%`.@&$KF'^<'..HG<'\P
M796``4>Q(F#'!Z#`5C]3!?D'`T00<*!`)$U6((4W=E5@`=D&-28E.SMQ0`H8
M<?G3;0@#$U&&><-631/@*A>8&!6``%N4``/B31"Q;Y1U1<$F@M>@/"`&1S#'
M@J`8BA_C>C0'42O6/12E1$F441;$BO%A2,KR48OT!\,A;(UA.$L$&;JX+7[R
M39%@`F/G!R30<3<U%'M'(-E5_P53\PMD5W9D5P4#4%PP``4,X(5B]F[K18)"
MD2&+$!&)HQEL.(;AQ@!\!X?A$@,JD5PEX!B_41+TP@<3X7&;5!1.`@MO8T02
MUVW2,C5F)`MXL(>$!T1&T(C!50'&1`1?,`!@UR^9<R6*0X(E^$:6A6JD*(H6
M>9'8LXFP9HI[Y#TWI@'V41^1(1GG4S9+I#Y0T#XXQH-#5XOUTQA04#HX4`+D
M5`(V>9,9T!;MH1CD,74-A$D\5(RS0([WDUWDMF/4,$G[PP=5(`+EZ`;O%!K7
MN$L?DA+=H0EVE0<4@AH/V1,Q0([Z%W9O-0()X!A$4'@1X@DF,``"9(<8AC?%
M<H\+J/]I7)ER_X$M[%@&WF<$Q.@&2>%"VV8!T7(J#GE%H261)^B)%8F1C-F8
M=.*")(8R$=4]%/"1-@8H/B89,C8#A=1SOL8SH2!L"K`^,T!Z$>,-9P1R#],`
M(E`"7N`8D5$&EI&'6S`$BI&!34>.2612FQ`&P]%P4L%N3AE8U1AFN=14@?%,
M038<E3-V`),W>`@4I.`S<U:.H5)+H,`',9!MC`$!9U`L.Q$&\-AU`[))RQ!G
M'51$`:8")D`JFO&>Q1(#NC-#7D!Z_<)Q$-`8$$`!@$8!SD(`5?`*YU*8S!$.
MG$B1D.F8"KJ@#&HFIV@++B,H-<%:47<S%K5K,6,>@B!T(K#_.']E=*.9/\F&
M;*0Q&A#4.:`D'^5%%#MTFQ%QC+452?_B`JA@>M/9E%;P*5#9GN?7&V069Z:B
M$L>6-[K%?N.F.-7I&_OE(C)1!MJB9#OP"YM@:#N0;0-2FK@@+66EGA%'>EO0
M!0CQ,#-B-;QQ*#2``,%2!5?7&PQ0`Q4@B9(!.V*%!><2):YF,6GB<M7C#A@Y
M%0W*4.KPIW$D"@/)8G@P:Y&3%`EV*!;Z)U:08+@&?!J@ERW39^R'B(HQ!@V0
M!VP5#9,T#&P)2HA4-UEP?5DG$OXW-T9I!`!C&T#RJ@8(C:V19-6H-,RE2P7#
MCZ7@$S[")48P9T9$0!.@&56`.S1@_X/FJ0FDEFD2$7\H`@&(DQIPE42#`Q<4
M<*U#,`0)D&"1H0$08)^R(Q%8AYLS085>0`,+R8PI5PJO^B)HHJ<GPZ<7Z:>"
M"B?K4*]M1*B=-U'FL:TV8SZ(TG.%\BE0@&.W]R>4*D)PX*&8ZALBP*G8U!)!
M]`?X*:H*`*T6D$`+`F7_P1H$@@.15`6^63'?H`W%R@!(Y@59`X@CE!ANIXRT
MP:M>\JL%%QD9L`-L4ZS;-PAB8`-$`1H$0``6\%2A&G$/&R\).""&LR"[Z&0)
MD`&$P&VQ>G7%I0`96!1F*'_E)09;Z0F)HWJFMB;P.B?OT*=0@:]WF@YH^W+;
MLS(0VJ_E,_]-2T1(&D5(X)-K":L!"\M6L3)XD4$T`)-2H;!2T^)2)1!3"O!E
M0"F-UT9;^1!NBA.D0:I2K_">4=`'+Z48<G54'K0@9#8[6+"K%>>KP*JD,<`V
MF/M_:O8/&$`0K5L0N=-FKS$!4YJTH#(X0X`7;P&26N4$&+!"VG4:?/E)[I03
M$,1FQ":G:G@23.BN;S*V<E*V\WJV:RNO:QL])N%2;KLG-V9!Z/8T&S4V&34H
MM.8%>=NA(UL_/&E;1@.?[SDMQ0(*!+`%,*48\]A@4&AX+S4V<D6/W[>&[_F<
MN14&]8,CBL@W'J2Y@>$3*N4,=4FZ-1LJI^L"9H5(=T$7`-`[>E'_!I)X1##@
M!1FH:4W)&S`P"/XP"?O0`&V@+6.0`+;%;>*2-SI$O.\48<DU$TD$PAB@E1%V
M>H7H)M#[)M)KD?2*MM9[O<^3O2J#BC?F!>:#(H7T-(_!&"H).@@+H7TV9&5%
M4BG"OOWFOL5"9--24\!50$#9&`/@!W:U&E183;?0+Z'@F^#HFY7K`A-``Z_8
M9Y@&&D>&(C\:N0Z,E!`L?QD@=EAP8`2R+"/)1(*T+8:3`*571(PA<45A9H.Q
M!526(K0DF*HS9-?W<=UA+5M``[/*$"+`!R00+0\)OT#<B1XSQ*)8Q/AZQ$A<
M1VJ,`5>C)_R)8^B!6E3\J/2Q'N81,P9B_[Y8W*&.XTB^(6"%-4FNBFE*@P'C
ML;2#(!(M>E.C]E=4AEV4$$FH@#QYP`6Y`6@X,`$,[$&]`0!,P<"Q<"%B\JOG
MQH[A(A-MZ05P`1?DE,\Y"0$9\'RES`)O`!3<1<(2)SM5T"'41B!J)@8`RJHN
M0+6)43=XPPO$A&:3$3M^Z,.]*K:NW#&P'(JR7*^T7,LB@SE7!P`UX#T5A6.V
M9B/`AR`X`]-)<;ZN$KKJFQANL$\#MM,>L@,C@&`I2@048'=.Z&1:!Q2RPI;4
M2GIOB20=(A*Y46U`,`0BZC93R10-V,YXBAPT2\)V-@$D,&?P865-YQ`0$Z:3
M@`"1`IOWM5V27/_"1&/05E(/U,:_(L!OIG)UMZD,+Q$%2Y?0]C$Y3&'0F-C*
M)3W2+!C2@HK8)/W*6+E#*-TR1!`HXD--%F&P?2(Y%G$?$)IXQN,--PT#5E`!
M_U#:IEW:ML(`-&%$FKS`XKI`6)!3,$H>^H0ZP'+;LU(#X24@D;&BZ)G`CJ'.
M\45HTGDP,[L#%?`T7TW&*6*%/<W3Q,`TY+@^7K!M>3#"D]P`_Q$:8\<W!WU>
MGV*'[5D2'#<$;$H):K@9Y')8NW$86^5<(7A`:<DF0>PF'PV*BOVGC-W8'4,A
M+G46*;W"@C`#?3)!1/`!&"$^"<[98G!/=VT;'"<IRM+"0_`%7R#3O0;_DC=(
MVX.]<:;*0$P9;A,6?]3J$:LD/*]4`A1!5#>A7="I5+ZQ*(DCPQ;GO"Q!LXYA
M2&U0"0N!(HMBT-8`*;(+K1`F`A_`&.J,"1("$[*0!S-Q4;+)P^7]-+@I''MS
MT$.!6!:-3OYKIVI2WVURWXE-O4:<W_S=,?ZS`_%G4BQ0`C20!B60*S30!G1>
M`C-IYS;)`',>YS9)`S3``#8Y`+HM"($1(]OG&DT+&:#D!4-0VQ_2"?#H;`IP
M7"%.AEJNX239R^@Q(+YA!<!T0O#R"J)AY+X!`",0PYFXU5%!LX^A(PT@0,T-
MC!N]"CR!@`0@!B4`'Q^0-20@`@L"&$H.OU&P_SGD=BWQ%QD`$#MZG1@T0`GP
M$K\JP6Y&0")P*AFB4GH4Q]&';>:QQ^T+NM]GGC&5LY8-XBP(<.[HCNZ5$*;[
M4`EO@`!B`._QC@#O_@;XQ1"E9P(C0!$*GN`8,3@4$.=IX5?C-@*-@C4-M`GT
M4(8#8#5BX[T$7@8TP`*V4`D[,#6I85T5`0$C\$RF`A/N_"5&\)7A(]AL"3.;
M9#2\T%\HL6/#7@77\A>"H'&XM*$C(!MY$[]C=T;:Q^\:``"6\1V-@F-U$\/0
M7AQ1$.\-</`_GP$C4%C/V]%[ZNVO1_6.">[A3K:S<!1[\1',MWRX\B#_04RY
M,D:Z\A&O1!%;NPR;,/_R`^,(;P\)DG#624>7](,JD=``7=`,/H)&RS`!;^]*
MR;<(=-\4M)@P??/VJ^(S$!GR>&0O!+,JDM`P6[`#0V:5+0\*+S\,<Q\)QCCW
M!0$:*J7YA&HE?Z4JJ[(YBN\?>L-6Y!)=>6,M@!\)&$`\G"#MAATR8KZ"5M^8
M6)_U;0(+WV!]1Z&*)'G\U4PA_R$"AL'(DG$8^+!/0#3L6#`2U%4,6LG3VH\;
M.]`)8[?>RT`EOC#ZV)1I1K+34P)=03'C>Q.`1,%T_2*@O^#X7S+V6JDXF0:"
M=-HV$`D(?GY_A%A8A'Y\?'\$>3N/529YBB8F?7U_6"Z&6%%_ESN$?)65ET;_
M1J,F.R9&+F&O88)553$Q?WQ5JWF3?(:>FH>$PL/$Q<6UQLG*R\."SL_0T=+.
MS-76U]C9R=/<W8/:X.'BX]O>YM#DZ>KK[.U_4:=^)F\U#0PE]VDE)?K[.".9
M/O'!,&"?P8/X1&`04^D1%EAA_D0B4,7/)DX8#1'RY*GBNRA1L*RB%<./D3Z#
M.,$".6N6HF*7_@B26,5(IY"'6C84(V96%%@Y9VJ+XH?`NS`N8DPPX><A4D.R
M6@H5=M.%Q!@M^VAJ6243QHX57V'ITS)3&)!&JF""&`9+2:EN_QA!.]?%1:#L
MD+G;R[>OW[^``PL>3+BPX70AC<C<U7#"TD<[)CR*_Q$*)Y\^D!])7J7*Q*A'
MWP9UE>F5D&).A82!S`02I$9"*/WL,.F"[&69KW'Y07G(UZ'0HM[)-)G:)69(
M-GTANB6\4Z%@IYKYL>4BRB9YLW]&F=TTF,S1G38)?QY].%8_JP]Y*CD<T0[V
MOSSYJ=CZH?,_E'<O:E936'+O[8FCUV$$6G/.@=]<<V"!V2S(X(,0NN.@@0B>
M@TU&&MEUR&F;X*(6>O9]HM5%=I%8'4[5[3;+=#^I5]%%L"7XW"LA"7-)2M:Y
M,%]#6*'4!Q\EC9@C3IDHAE(>?VQ"%BW=52?2;/>]YM6&K!&)VB">>`;268?4
M@MY/?N`!Y4/B]6?()I[PYO_4*Q*%`B!IBNUV'&1O#C)31F@%M-]R?.PP"VB7
MH$0:-<-5.)TM$2:*B*'=-&BAHLI,".FDE)9C#C:,>K,76DO.@I$@LQGS32V8
M=#)?)*$D1PA]-L8F(T;"0(/).Q4%2IIJOUBEVBVH$`+?*9#U85-U,GF&17FS
M#M)+(?])EPA*C_`Q5S"Y#.+*?'Z>2=1\,YTH$VB^A"1;J-/)Q0>WF,B&;1^3
M$'+B;XO\,LRLPG2UVF6SN)KJ=`EF*LB`E1+H[S2.7AJPLYH>K#"EDC(S,,'D
MS'0C>N=&8LEIO[UGIY>+_&MG)N_%4,ESW\JXF[HQ9;1HK;LA4M%,Y2U1WUBQ
M!7C_:U,L<6:O(2>1>XN@,]TVE2?+S8=2+LB()\^YZ,6RHK:S_:D55*J$BE&P
M^+%WX\O.T`+91_)^`\\I1G@LRWP?W8+O,U02.C#`"P_V<#0%)[QPPW'G+?"C
M%,[]##C/<+>;*C%$05E#GNW7!RFGSK:DNFJ9D"5G8BP"U>%R3=>0X_0&]-V?
M@E.C"+TWM7+(*N^U%,./G6.QHQA^IO1M*62!:O2XB<0J2,>'DE)U4^Z!EN0?
M?J;VAPD,H3Z3/)7,(M<AJ8"NRBR>39\OM&+#(TJ<B_ZX"@$FN%3DZ"Y=]@TJ
MBP3Y-J)Z"^;WWYCRK3#>[=<?&/V6OB^CP]%0,EGQ\G!,_V2Z\(T^+84LA]-)
MR"0C+1,XQC$QZ((M##B;RRRN:N_9`4J"]+D_B8QI+VG*N?`3$.L<PH$C65&?
M0H$>ER%O>KU`R0-71P!!]`$K3+IA!`D8FTLP33,"5(3K#@>:IJ@K;#R9@!@<
MTY+(I/`T?7C@GS9#F<A(IHF9^9%<%(,?Q]F0#[MPC`1KA0G(A$\S&DR6(O3B
M+[C9CR_ZFTK?[#8_^;WQCGW!GZCBN+]E0$,S(AC``'`P@"X08'$$(>0`1-`%
MM4P@D$LQ01<4XJ<JC$"0@A1!23`0R$$*<@0QX,,C1W`)23PRD(0$Y>B<\0@'
MBD`$$P`?*2XY`DGX802:I`EF&O\P``PT)!*CC!=^7BD&"XCAE5WXQ"0SV07(
M<%*"JW@D,\\C$Y2(TI.OG,!E8H#+"5A@![BT!9:@MP,1,(`!.,"!"'9`@($(
M<BDOP\(9!+D%$\1`!/_PTPX(4LA9/!*=Z52(&/)0B7]B(#8.Y&4Z,P!+SG1A
M``R`I0,A.H`)5&$"(U#ES3+E1CRR@X]U:U3<].C1DHJ#I,3@8Q\CQ4I)XB`#
MBWPE!C183@BH4P2@-`(!,``!``R`G2.`*3NK,(`ZQ'0$NY%F!LJP2%#N-`,,
M*-LU,W!3A93DCZL0`0#*T`!2/&(``,@`!AR13@)2;P(]90!#+&H"#,!4$2>)
M`0ZX:@'_M_XT*0.`*3)1551?JB*O,>V")8YV.)[BP!X0$,&/_"`"AK:5JF?X
MQ#L,(<HR$$$#7["I(0G0@*WZ<D5Y&(%G[8F##S"`G2;0:AU\28`N0(`(886`
M!@`@`M@Y$`(?&`!*)#F`,FP5`A!@0#-'(8(/$(&KJ35N&410!7QJ\C;IXBC[
M3/K1.(:4&WE#*76W6PWMZLZZ%$+=(^:*`0N8UY@36%P#N/H&V_+AJ0!(K`5$
M8%3.,*`.WN2)($Q@WKP:<D=H'0`E1,!4_FZ.<\Q;8CKQ$<DJB*&W92B!-_>A
MQ%4\&`(#@$!Y)?/8`>2!+#]R*PXPP(`,3(`$?.@"5<OKB,/U_]:O$Z!J?BLA
M,9&U%0(LL$$-@CL)!^(``KP4JQ"=@X7*FK8&-=B,"3I;AAI,3Q(8`(`&MF"!
M"3#`M!9`7@,T4`8,@`^M1&`!'B90`M@V``]C?JT(]CN`#V@`EF+`P$Q7@0<&
M$&$&7AA`G8&@@3?CP9S/%4BA#-51[H8#I/$SV-WL:.A&=Y?1+`7OHSDC2:;R
M!`,-:,!,98.!,L!TD;/I<&\UG5A2]%:1&"!$*_.*`:9)$L.7V4%>=^"(5C)E
M.A7A3%X;0%\1D$(,Z&R`3<DLX276%<-N5>LW]PG3%I<D#VZUZ5A9UUB8SAE\
M+VX(/F':`$#MKA*=AFD)(#""/*RNK?\,L&E7+8<14>(6`FF(:"NCW.3I^0':
MLZ4RF;&L"A%PV<L['8(&Q&R!+20@S&A&JQ5$8`02Q,"R#+!`#>[12S\!6P,4
M2`"0(9!9/V\!`\ED6G0956A')_I]UX78HA5M\I;G3Z1S1'EX=1'E`1@3L25`
M;6=+\$I0RL.N$PBH8RO1VT7VTE>KZ*N')`E3:,VZUAB412O)O%RPGG86P"Y!
M/9B*@V(7T]\1S8"&EVW77=R0$;+VJ6<>@1).OK266<YV0P@R;E\_0AB/Z'0)
M[%&"G^[.`NME@`E(4"J,W/:R9<!P8;=:@RS3H@\8Z#.5Q5!:P5>BN%TVP4XA
MX`4QX\'@,_#_/%KSW/`)0/P-6\B`F_UN92]4H`U>@,`0*D`#(MA\B<1Q&\FG
MZ_*4#\SW=!LII'OO<N\N2M+5V&`B8FQB8V+@I=I,+9"O0-`*VK6N<UVNKL5J
M7A.XAP`O)D!)7CV`LO6AUXPYUWM<MHH&U.'3&:A#+1V8[L;G-<)*1-Y<%\D`
MM:NB['E00_M%8%U5$D!R;U?0:3B`6G+W"&%D4]RQ$:O`4R)@`V_@7P?8832&
M&J)@>AK```^$'TL&``#0`$M419WV`2P09[(U`*2`>;XD2E\0>F*P!:7U!2:8
M9K87!7U26D"&`,*66Y,P`6T0>BPP`S-``5O``$`0<;##.X.V>\0'_SC(]V@L
M=S#&-X4FE84JA0T=$TJW1%6:U@`EL(#$508,(&<@UP=/97.I18*^%G=,I88A
M018FH'0J(F**P`=G\%(*,0(@ESLE05.LYGQ"10"RQGU!%U;Y%U3KI`HO%0/@
MHV(C)F<A1P`$R!29P$UR1E\_A6VKU1"`B&E]IT&98!>[P5-IV`#I%`-&,'[/
MMTZ"P(''XX$V-PFNTU8`\`%0I4ZT%G0?@(8EH`$:IFW_)BVN10004`$E0((#
M4$Q5]EH#4&30E@%<%F]EH`$>YFXST``&9WO`1@2G%3M!,G)2J(4GYS?`AP["
M=X7H:')<B&C7$">)X`</E4Z$U%7@\WSX6/](M_!0784\YC1_)C`"^*A.UD$3
MEW0&UG11BU0VRX=/BI137;0;]Q2'?R51X%11E?!0Z^0GE[0#)P%M_Z!Y]YA.
M`S`"+H"(E^1+IG%/^*A)U$,0@F5/$JE.DF$M2B)*Z,0`[U0QB%1QQ+$1WS$!
M@[1N?Q`+;?52&="4FF0$$S5NUK8YSU=1:U008J=.-8DZ^*22^_5(/V93O;0(
M1CEBQ]1+QZ1.*Q(TWT5HO/>.D29S"C)\DY*%</E&\5B%RT`TP_%>D8$!C@$[
MX_)`$R!!H!(9U+-$?F)15@28$Y"0H,,==E@#8D!.801R$\`>,3(?M9`+J+,9
MLU!%B5`+CE,+N,#_+D_2$@\$F"(YF*O@#$:P`UT`F'EP*N-22;30!0^D"CBS
M&K+A&%N@1"H"*@(D"%PT'OXD0#L`)KE`F)EY*L@S`8"I>2BD&6?`'1?U0!I$
M`&F!%8@H&2`Q'^8%G)&T"*I081@T&<C2,5HD77?)/W9IA>Y8*0CRGO9Y1S.Q
M`^^UAT"3"`303DRC'_RB'^=R'GO83IXC$/3R+(HC&WLH+4RSF8D0H!.J+HH@
M.GLB%T"C1?@QH0_J#!=*#3_RGX3'':M#H8KPGX3"$7TY"HL5&@8X0BG%+?[#
M/@^ZA_0XH;MPH=RQ2C3ZH()"&OPI#..G>0\*&Z.CGR"4H<T0E]Q0<MFE_U)Y
MJ3]1*H_519?%T(7W.2D<T1K#T*4.DZ6%P@Q$\S>0MCSJP)?'=WP08R?`X0PL
MF@Q>JJ9.N@T;X:7$L!I92@W/H*?%$`QT"C9X2I1WF@[F`*7M**5T!)]4FJB-
MV@[U.9=ZN:5X9)=:*B%6>J6+RJ@P5T?=@*@KIZB=RJGJZ*ARJ:F;ZJ2E2JE;
MB*5[.JF&FJGK8*FNFBB'^I;U(ZKS^7*KZJFP.@Z1&G.]RJJ56JL(<ZJH.JRS
M:JQM.:H!<ZLEI:NIRJMS4Z6_>E)3BJS$BI?,RJ;:J@Z7"JG=&H789:K1`*J^
M*JW!)ZS5:J[M*J[=&J[;RJV[2JT/`T>R"J[C&O^?>_.IN-H^ZEJN['JO[DJP
M\%JOK_JH\TJOTVJOO[<7\KJL")NPSDJ?WH"N6!BPTI".RFJQ^1HQV=JQ"VNM
M%:NJ[WJPWQJK$SNC*QLAT.I1&KNQDJJP&?NQP!JR)SNR`+NO-GNSUXJM+=NL
M`INNTH"QSQJS[#BP#QNJ-*NO\=JS.GNT0>NM(@NR/WMH/#NU#/*RQ8JTA**T
M_D*R*>NS4QNQ4<NT0RN?8TNV:PNT#;M'6EL@7(N?7ONU:ENUD"*E$(NS!GNV
M8JMR8)LI^'JU5*BU_'H8<\NP7LNQ.2NUA+N.27NWC>NW-?NV%(NW;MNV6&NX
MXRJW%_NO>E.W=DNJD\O_,%"[N9;+LDU+N8Y;L@X;MIAZNH6;NL>:MJU;M%<E
MLRBKN7\ANBOUNO`3N[0KM*4+MZL+O,$KN;X+N,JKKO>YO(S+O(5!JW&[#%XB
MO2K[N'DDNM&[KKN+O2;;MZ0KOG[$M\OKO<TKK<_KN]V+OM.;M<-K#=>KN\F*
MN8#!OC/KNFQKN^6KO6:+O*/;O^>KOY>KL>O+O?E+P+T+OPJ,#?/KOME[O'*#
MP($;P$X;O^1:O`5,ON%+O^,[P,F;OKIZP'7;OI%K&-2+P<SPP"=\P1+L/A0L
MPA8<P?S;P;!;P89BPB$LP"#LP1^LOO8)O0E<PS#,N=6K#"R\PS1LOPM<PD/L
M_\,N3,3&R[M4J\&J&[\]W,#$&[`DO+A/#,43;,0J;+VY"\%6J[V#Z\4X_+MG
MK,55S,$`7"$Z/,-3G,5*;,,C',3XN\9L?#\,+,7:D,1TG+E4O+U.O,9I[,89
M#,=U;,6U"\B/;,=]O,'.J\<Q_,,M3!@IK,@K7,:9W,:%G,@Q.\>3C+J*_+^-
MS,B4;,:I;,>0*ZI=C+2D7,I^L<F0[,">?,?[R\2U?,D\?,O:8,N.O,5+*\.#
M?,62+$?&K+>6?,C+3,N&C,&'FPR"K,Q1S,O1+,M?_,F@#+YQ'*S/;+ZLO,H]
M_,J*&LNCO,W<[,=BS,ED#,RS#,Z(Z\MX?,RF#,^+7/_,F,PHLQS/]%S/Y]S,
M:OS,6_O'W@P.U0S-_MRYPJO-B+RW[8S-J$S.NDS1`VS.S/R>0LS'!1W1!QW(
MN6S/P3S1[#S0^VS-UPS&WRS.@JO.%8W,R8S1)%U\>TS0GNO1*HW0H`O1#(W"
MQB?'-OV]'TVL\OS+^'S3+\RJ0-VO1RRQ32T81@O02QW._[S2:"R[+3?3Q+S.
M>7O57IW,+WV_TVS47.S2*'T,.VW64WW2YRO36/W&-ZS1;SW6[YO4,*W/;+W1
M3#W&5&W76QW669/2>"W5>MW7H?S6CJ;5<,W5BH+8C@W6@-W+/9W7<VVL46W5
M90O9(OW7L+S0[LQ=BIW/C&UPJU]]V)I]UF'\U(1=V2U[V:T<UY1=U:^=QVI-
MU]'*VGP]SW[-V6L=V\ZLVZJ-V87L73%P!K5PW,B=W,J]W,S=W,[]W-`=W=(]
JW=1=W=9]W=B=W=J]W=S=W=[]W>`=WN(]WN1=WN9]WNB=WNIMW6<0"``[
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
